<SEC-DOCUMENT>0001564590-21-027210.txt : 20210513
<SEC-HEADER>0001564590-21-027210.hdr.sgml : 20210513
<ACCEPTANCE-DATETIME>20210513073031
ACCESSION NUMBER:		0001564590-21-027210
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		84
CONFORMED PERIOD OF REPORT:	20210331
FILED AS OF DATE:		20210513
DATE AS OF CHANGE:		20210513

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			UroGen Pharma Ltd.
		CENTRAL INDEX KEY:			0001668243
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			L3
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38079
		FILM NUMBER:		21917201

	BUSINESS ADDRESS:	
		STREET 1:		9 HA'TA'ASIYA ST
		CITY:			RA'ANANA
		STATE:			L3
		ZIP:			4365007
		BUSINESS PHONE:		972 9 770 7601

	MAIL ADDRESS:	
		STREET 1:		9 HA'TA'ASIYA ST
		CITY:			RA'ANANA
		STATE:			L3
		ZIP:			4365007
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>urgn-10q_20210331.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml  version="1.0" encoding="utf-8"?>
<!-- DFIN ActiveDisclosure(SM) Inline XBRL Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2021-05-12T21:01:28.4376810+00:00 -->
<!-- Version            : 5.0.1.615 -->
<!-- Package ID         : 66acac3df2bb4a8e915da518ecfedb52 -->
<!-- Copyright (c) 2021 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<html xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:urgn="http://www.urogen.com/20210331" xmlns:us-types="http://fasb.org/us-types/2020-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2018-01-31" xmlns:srt-types="http://fasb.org/srt-types/2020-01-31" xmlns:srt="http://fasb.org/srt/2020-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2020-01-31" xmlns:naics="http://xbrl.sec.gov/naics/2017-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2020-01-31" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:dei-std="http://xbrl.sec.gov/dei-std/2020-01-31" xmlns:dei-ent-std="http://xbrl.sec.gov/dei-ent-std/2020-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2020-01-31" xmlns:country="http://xbrl.sec.gov/country/2020-01-31" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns="http://www.w3.org/1999/xhtml">
<head>
<meta http-equiv="Content-Type" content="text/html" />
<title>
urgn-10q_20210331.htm
</title>
</head>
<!-- NG Converter v5.0.2.50 -->
<body><div style="display:none">
	<ix:header>
		<ix:hidden>
			<ix:nonNumeric id="F_000001" name="dei:AmendmentFlag" contextRef="C_0001668243_20210101_20210331">false</ix:nonNumeric>
			<ix:nonNumeric id="F_000003" name="dei:DocumentFiscalYearFocus" contextRef="C_0001668243_20210101_20210331">2021</ix:nonNumeric>
			<ix:nonNumeric id="F_000004" name="dei:DocumentFiscalPeriodFocus" contextRef="C_0001668243_20210101_20210331">Q1</ix:nonNumeric>
			<ix:nonNumeric id="F_000009" name="dei:EntityCentralIndexKey" contextRef="C_0001668243_20210101_20210331">0001668243</ix:nonNumeric>
			<ix:nonNumeric id="F_000010" name="dei:CurrentFiscalYearEndDate" contextRef="C_0001668243_20210101_20210331">--12-31</ix:nonNumeric>
			<ix:nonNumeric id="F_000347" name="us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend" contextRef="C_0001668243_20210101_20210331">true</ix:nonNumeric>
			<ix:nonFraction unitRef="U_iso4217USD" id="F_000076" name="us-gaap:CommitmentsAndContingencies" contextRef="C_0001668243_20210331" xsi:nil="true"></ix:nonFraction>
			<ix:nonFraction unitRef="U_iso4217USD" id="F_000077" name="us-gaap:CommitmentsAndContingencies" contextRef="C_0001668243_20201231" xsi:nil="true"></ix:nonFraction>
			<ix:nonNumeric id="F_000251" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" contextRef="C_0001668243_us-gaapPropertyPlantAndEquipmentByTypeAxis_urgnComputersAndSoftwareMember_20210101_20210331">P3Y</ix:nonNumeric>
			<ix:nonNumeric id="F_000252" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" contextRef="C_0001668243_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapManufacturingFacilityMember_20210101_20210331">P2Y</ix:nonNumeric>
			<ix:nonNumeric id="F_000253" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" contextRef="C_0001668243_srtRangeAxis_srtMinimumMember_us-gaapPropertyPlantAndEquipmentByTypeAxis_urgnLaboratoryEquipmentMember_20210101_20210331">P3Y</ix:nonNumeric>
			<ix:nonNumeric id="F_000254" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" contextRef="C_0001668243_srtRangeAxis_srtMinimumMember_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapFurnitureAndFixturesMember_20210101_20210331">P5Y</ix:nonNumeric>
			<ix:nonNumeric id="F_000255" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" contextRef="C_0001668243_srtRangeAxis_srtMaximumMember_us-gaapPropertyPlantAndEquipmentByTypeAxis_urgnLaboratoryEquipmentMember_20210101_20210331">P6Y6M</ix:nonNumeric>
			<ix:nonNumeric id="F_000256" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" contextRef="C_0001668243_srtRangeAxis_srtMaximumMember_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapFurnitureAndFixturesMember_20210101_20210331">P16Y6M</ix:nonNumeric>
			<ix:nonNumeric id="F_000370" name="us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" contextRef="C_0001668243_20210331">us-gaap:OtherAssetsNoncurrent</ix:nonNumeric>
			<ix:nonNumeric id="F_000373" name="us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" contextRef="C_0001668243_20210331">us-gaap:OtherLiabilitiesCurrent</ix:nonNumeric>
			<ix:nonNumeric id="F_000386" name="us-gaap:RevenueFromContractWithCustomerProductAndServiceExtensibleList" contextRef="C_0001668243_20210101_20210331">urgn:JelmytoMember</ix:nonNumeric>
		</ix:hidden>
		<ix:references>
			<link:schemaRef xlink:type="simple" xlink:href="urgn-20210331.xsd" xlink:arcrole="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase"></link:schemaRef>
		</ix:references>
		<ix:resources>
			<xbrli:context id="C_0001668243_20210101_20210331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001668243</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:unit id="U_xbrlishares">
				<xbrli:measure>xbrli:shares</xbrli:measure>
			</xbrli:unit>
			<xbrli:context id="C_0001668243_20210331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001668243</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-03-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:unit id="U_iso4217ILS_xbrlishares">
				<xbrli:divide>
					<xbrli:unitNumerator>
						<xbrli:measure>iso4217:ILS</xbrli:measure>
					</xbrli:unitNumerator>
					<xbrli:unitDenominator>
						<xbrli:measure>xbrli:shares</xbrli:measure>
					</xbrli:unitDenominator>
				</xbrli:divide>
			</xbrli:unit>
			<xbrli:context id="C_0001668243_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001668243</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:unit id="U_iso4217USD">
				<xbrli:measure>iso4217:USD</xbrli:measure>
			</xbrli:unit>
			<xbrli:context id="C_0001668243_20200101_20200331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001668243</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:unit id="U_iso4217USD_xbrlishares">
				<xbrli:divide>
					<xbrli:unitNumerator>
						<xbrli:measure>iso4217:USD</xbrli:measure>
					</xbrli:unitNumerator>
					<xbrli:unitDenominator>
						<xbrli:measure>xbrli:shares</xbrli:measure>
					</xbrli:unitDenominator>
				</xbrli:divide>
			</xbrli:unit>
			<xbrli:context id="C_0001668243_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001668243</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001668243_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001668243</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001668243_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001668243</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001668243_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001668243</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001668243_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001668243</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001668243_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20200331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001668243</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001668243_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200101_20200331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001668243</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001668243_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20200101_20200331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001668243</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001668243_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20200101_20200331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001668243</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001668243_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001668243</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-03-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001668243_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001668243</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-03-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001668243_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20200331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001668243</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-03-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001668243_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20200331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001668243</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-03-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001668243_20200331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001668243</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-03-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001668243_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001668243</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001668243_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001668243</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001668243_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001668243</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001668243_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001668243</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001668243_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210101_20210331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001668243</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001668243_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20210101_20210331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001668243</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001668243_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20210101_20210331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001668243</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001668243_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20210101_20210331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001668243</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001668243_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001668243</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-03-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001668243_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20210331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001668243</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-03-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001668243_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20210331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001668243</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-03-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001668243_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20210331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001668243</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-03-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001668243_us-gaapPropertyPlantAndEquipmentByTypeAxis_urgnComputersAndSoftwareMember_20210101_20210331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001668243</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">urgn:ComputersAndSoftwareMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001668243_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapManufacturingFacilityMember_20210101_20210331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001668243</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ManufacturingFacilityMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001668243_srtRangeAxis_srtMinimumMember_us-gaapPropertyPlantAndEquipmentByTypeAxis_urgnLaboratoryEquipmentMember_20210101_20210331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001668243</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">urgn:LaboratoryEquipmentMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001668243_srtRangeAxis_srtMinimumMember_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapFurnitureAndFixturesMember_20210101_20210331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001668243</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001668243_srtRangeAxis_srtMaximumMember_us-gaapPropertyPlantAndEquipmentByTypeAxis_urgnLaboratoryEquipmentMember_20210101_20210331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001668243</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">urgn:LaboratoryEquipmentMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001668243_srtRangeAxis_srtMaximumMember_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapFurnitureAndFixturesMember_20210101_20210331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001668243</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001668243_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapFinancialInstrumentAxis_us-gaapUSGovernmentAgenciesDebtSecuritiesMember_20210331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001668243</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-03-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001668243_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapFinancialInstrumentAxis_us-gaapUSGovernmentAgenciesDebtSecuritiesMember_20210331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001668243</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-03-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001668243_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapFinancialInstrumentAxis_us-gaapCorporateBondSecuritiesMember_20210331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001668243</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-03-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001668243_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapFinancialInstrumentAxis_us-gaapCorporateBondSecuritiesMember_20210331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001668243</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-03-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001668243_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapFinancialInstrumentAxis_us-gaapMoneyMarketFundsMember_20210331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001668243</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-03-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001668243_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapFinancialInstrumentAxis_us-gaapMoneyMarketFundsMember_20210331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001668243</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-03-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001668243_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20210331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001668243</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-03-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001668243_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20210331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001668243</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-03-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001668243_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20210331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001668243</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-03-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001668243_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapFinancialInstrumentAxis_us-gaapUSGovernmentAgenciesDebtSecuritiesMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001668243</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001668243_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapFinancialInstrumentAxis_us-gaapUSGovernmentAgenciesDebtSecuritiesMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001668243</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001668243_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapFinancialInstrumentAxis_us-gaapCorporateBondSecuritiesMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001668243</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001668243_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapFinancialInstrumentAxis_us-gaapCorporateBondSecuritiesMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001668243</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001668243_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapFinancialInstrumentAxis_us-gaapMoneyMarketFundsMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001668243</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001668243_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapFinancialInstrumentAxis_us-gaapMoneyMarketFundsMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001668243</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001668243_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001668243</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001668243_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001668243</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001668243_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001668243</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001668243_us-gaapInvestmentTypeAxis_us-gaapUSTreasuryAndGovernmentMember_20210331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001668243</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-03-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001668243_us-gaapInvestmentTypeAxis_us-gaapCorporateDebtSecuritiesMember_20210331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001668243</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-03-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001668243_us-gaapInvestmentTypeAxis_us-gaapMoneyMarketFundsMember_20210331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001668243</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-03-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001668243_us-gaapPropertyPlantAndEquipmentByTypeAxis_urgnLaboratoryEquipmentMember_20210331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001668243</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">urgn:LaboratoryEquipmentMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-03-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001668243_us-gaapPropertyPlantAndEquipmentByTypeAxis_urgnLaboratoryEquipmentMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001668243</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">urgn:LaboratoryEquipmentMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001668243_us-gaapPropertyPlantAndEquipmentByTypeAxis_urgnComputersAndSoftwareMember_20210331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001668243</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">urgn:ComputersAndSoftwareMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-03-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001668243_us-gaapPropertyPlantAndEquipmentByTypeAxis_urgnComputersAndSoftwareMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001668243</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">urgn:ComputersAndSoftwareMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001668243_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapFurnitureAndFixturesMember_20210331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001668243</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-03-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001668243_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapFurnitureAndFixturesMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001668243</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001668243_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapLeaseholdImprovementsMember_20210331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001668243</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-03-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001668243_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapLeaseholdImprovementsMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001668243</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001668243_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapManufacturingFacilityMember_20210331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001668243</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ManufacturingFacilityMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-03-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001668243_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapManufacturingFacilityMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001668243</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ManufacturingFacilityMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001668243_srtConsolidatedEntitiesAxis_srtSubsidiariesMember_srtStatementGeographicalAxis_stprNY_20170901_20170930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001668243</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:SubsidiariesMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:NY</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2017-09-01</xbrli:startDate>
					<xbrli:endDate>2017-09-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001668243_srtConsolidatedEntitiesAxis_srtSubsidiariesMember_srtStatementGeographicalAxis_stprCA_20180401_20180430">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001668243</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:SubsidiariesMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2018-04-01</xbrli:startDate>
					<xbrli:endDate>2018-04-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001668243_srtConsolidatedEntitiesAxis_srtSubsidiariesMember_srtStatementGeographicalAxis_stprCA_20210331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001668243</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:SubsidiariesMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-03-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001668243_srtConsolidatedEntitiesAxis_srtSubsidiariesMember_srtStatementGeographicalAxis_stprCA_20191101_20191130">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001668243</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:SubsidiariesMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-11-01</xbrli:startDate>
					<xbrli:endDate>2019-11-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001668243_srtConsolidatedEntitiesAxis_srtSubsidiariesMember_srtStatementGeographicalAxis_stprCA_20210101_20210331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001668243</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:SubsidiariesMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001668243_srtConsolidatedEntitiesAxis_srtSubsidiariesMember_srtStatementGeographicalAxis_stprNJ_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapLeaseAgreementsMember_20191101_20191130">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001668243</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:SubsidiariesMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:NJ</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LeaseAgreementsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-11-01</xbrli:startDate>
					<xbrli:endDate>2019-11-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001668243_srtConsolidatedEntitiesAxis_srtSubsidiariesMember_srtStatementGeographicalAxis_stprNJ_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapLeaseAgreementsMember_20191130">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001668243</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:SubsidiariesMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:NJ</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LeaseAgreementsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-11-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001668243_srtConsolidatedEntitiesAxis_srtSubsidiariesMember_srtStatementGeographicalAxis_stprNJ_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapLeaseAgreementsMember_20210331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001668243</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:SubsidiariesMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:NJ</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LeaseAgreementsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-03-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001668243_srtRangeAxis_srtMinimumMember_20210101_20210331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001668243</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001668243_srtRangeAxis_srtMaximumMember_20210101_20210331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001668243</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:unit id="U_xbrlipure">
				<xbrli:measure>xbrli:pure</xbrli:measure>
			</xbrli:unit>
			<xbrli:context id="C_0001668243_srtCounterpartyNameAxis_urgnAllerganPharmaceuticalsInternationalLimitedAndAbbVieIncMember_srtRangeAxis_srtMaximumMember_us-gaapTypeOfArrangementAxis_urgnLicenseAgreementMember_20210331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001668243</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">urgn:AllerganPharmaceuticalsInternationalLimitedAndAbbVieIncMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">urgn:LicenseAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-03-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001668243_srtCounterpartyNameAxis_urgnAllerganPharmaceuticalsInternationalLimitedAndAbbVieIncMember_us-gaapTypeOfArrangementAxis_urgnLicenseAgreementMember_20210101_20210331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001668243</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">urgn:AllerganPharmaceuticalsInternationalLimitedAndAbbVieIncMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">urgn:LicenseAgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001668243_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_us-gaapLicenseAgreementTermsMember_20191101_20191130">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001668243</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-11-01</xbrli:startDate>
					<xbrli:endDate>2019-11-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001668243_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_us-gaapLicenseAgreementTermsMember_20191130">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001668243</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-11-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001668243_srtRangeAxis_srtMinimumMember_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_us-gaapLicenseAgreementTermsMember_20191101_20191130">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001668243</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-11-01</xbrli:startDate>
					<xbrli:endDate>2019-11-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001668243_srtRangeAxis_srtMaximumMember_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_us-gaapLicenseAgreementTermsMember_20191101_20191130">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001668243</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-11-01</xbrli:startDate>
					<xbrli:endDate>2019-11-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001668243_srtStatementScenarioAxis_urgnAfterFirstCommercialSaleOfLicensedProductMember_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_us-gaapLicenseAgreementTermsMember_20191101_20191130">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001668243</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:StatementScenarioAxis">urgn:AfterFirstCommercialSaleOfLicensedProductMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-11-01</xbrli:startDate>
					<xbrli:endDate>2019-11-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001668243_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_urgnMDAndersonMember_20210101_20210331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001668243</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">urgn:MDAndersonMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001668243_srtRangeAxis_srtMaximumMember_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapStatementEquityComponentsAxis_urgnPlanMember_20210101_20210331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001668243</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">urgn:PlanMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001668243_srtRangeAxis_srtMinimumMember_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapStatementEquityComponentsAxis_urgnPlanMember_20210101_20210331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001668243</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">urgn:PlanMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001668243_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapStatementEquityComponentsAxis_urgnPlanMember_20210101_20210331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001668243</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">urgn:PlanMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001668243_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_us-gaapVestingAxis_us-gaapShareBasedCompensationAwardTrancheOneMember_20210101_20210331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001668243</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001668243_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20210101_20210331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001668243</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001668243_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapVestingAxis_us-gaapShareBasedCompensationAwardTrancheOneMember_20210101_20210331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001668243</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001668243_us-gaapAwardTypeAxis_urgnTwoThousandSeventeenEquityIncentivePlanMember_20170301_20170331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001668243</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">urgn:TwoThousandSeventeenEquityIncentivePlanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2017-03-01</xbrli:startDate>
					<xbrli:endDate>2017-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001668243_us-gaapAwardTypeAxis_urgnTwoThousandSeventeenEquityIncentivePlanMember_20210101_20210331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001668243</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">urgn:TwoThousandSeventeenEquityIncentivePlanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001668243_us-gaapAwardTypeAxis_urgnTwoThousandSeventeenEquityIncentivePlanMember_20180101_20180101">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001668243</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">urgn:TwoThousandSeventeenEquityIncentivePlanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2018-01-01</xbrli:startDate>
					<xbrli:endDate>2018-01-01</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001668243_us-gaapAwardTypeAxis_urgnTwoThousandSeventeenEquityIncentivePlanMember_20181012_20181012">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001668243</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">urgn:TwoThousandSeventeenEquityIncentivePlanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2018-10-12</xbrli:startDate>
					<xbrli:endDate>2018-10-12</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001668243_us-gaapAwardTypeAxis_urgnTwoThousandSeventeenEquityIncentivePlanMember_20200608_20200608">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001668243</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">urgn:TwoThousandSeventeenEquityIncentivePlanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-06-08</xbrli:startDate>
					<xbrli:endDate>2020-06-08</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001668243_us-gaapAwardTypeAxis_urgnTwoThousandSeventeenEquityIncentivePlanMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20180101_20180101">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001668243</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">urgn:TwoThousandSeventeenEquityIncentivePlanMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2018-01-01</xbrli:startDate>
					<xbrli:endDate>2018-01-01</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001668243_us-gaapAwardTypeAxis_urgnTwoThousandSeventeenEquityIncentivePlanMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20181012_20181012">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001668243</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">urgn:TwoThousandSeventeenEquityIncentivePlanMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2018-10-12</xbrli:startDate>
					<xbrli:endDate>2018-10-12</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001668243_us-gaapAwardTypeAxis_urgnTwoThousandSeventeenEquityIncentivePlanMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200608_20200608">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001668243</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">urgn:TwoThousandSeventeenEquityIncentivePlanMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-06-08</xbrli:startDate>
					<xbrli:endDate>2020-06-08</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001668243_us-gaapAwardTypeAxis_urgnTwoThousandSeventeenEquityIncentivePlanMember_20210317_20210317">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001668243</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">urgn:TwoThousandSeventeenEquityIncentivePlanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-03-17</xbrli:startDate>
					<xbrli:endDate>2021-03-17</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001668243_us-gaapAwardTypeAxis_urgnTwoThousandSeventeenEquityIncentivePlanMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210317_20210317">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001668243</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">urgn:TwoThousandSeventeenEquityIncentivePlanMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-03-17</xbrli:startDate>
					<xbrli:endDate>2021-03-17</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001668243_us-gaapPlanNameAxis_urgnTwoThousandAndNineteenInducementPlanMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20190531">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001668243</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">urgn:TwoThousandAndNineteenInducementPlanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-05-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001668243_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20210101_20210331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001668243</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001668243_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20200101_20200331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001668243</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001668243_us-gaapIncomeStatementLocationAxis_us-gaapSellingGeneralAndAdministrativeExpensesMember_20210101_20210331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001668243</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001668243_us-gaapIncomeStatementLocationAxis_us-gaapSellingGeneralAndAdministrativeExpensesMember_20200101_20200331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001668243</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001668243_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_urgnIsraelInnovationAuthorityMember_20200331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001668243</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">urgn:IsraelInnovationAuthorityMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-03-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001668243_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_urgnIsraelInnovationAuthorityMember_20210101_20210331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001668243</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">urgn:IsraelInnovationAuthorityMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001668243_srtTitleOfIndividualAxis_srtChiefOperatingOfficerMember_20200331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001668243</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefOperatingOfficerMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-03-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001668243_srtTitleOfIndividualAxis_srtChiefFinancialOfficerMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001668243</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefFinancialOfficerMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001668243_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_urgnRTWInvestmentsMember_20210101_20210331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001668243</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">urgn:RTWInvestmentsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001668243_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_urgnRTWInvestmentsMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20210513_20210513">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001668243</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">urgn:RTWInvestmentsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-05-13</xbrli:startDate>
					<xbrli:endDate>2021-05-13</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
		</ix:resources>
	</ix:header>
</div>

<p style="border-bottom:Double 2.25pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:6pt;">&#160;</p>
<p style="text-align:center;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:18pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">UNITED STATES</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:18pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">SECURITIES AND EXCHANGE COMMISSION</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">WASHINGTON, DC 20549</p>
<p style="text-align:center;border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-left:40%;margin-right:40%;text-indent:0%;font-family:Times New Roman;font-size:6pt;">&#160;</p>
<p style="text-align:center;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:18pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">FORM <ix:nonNumeric id="F_000000" name="dei:DocumentType" contextRef="C_0001668243_20210101_20210331">10-Q</ix:nonNumeric></p>
<p style="text-align:center;border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-left:40%;margin-right:40%;text-indent:0%;font-family:Times New Roman;font-size:6pt;">&#160;</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">(Mark One)</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-family:Segoe UI Symbol;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Segoe UI Symbol;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000018" name="dei:DocumentQuarterlyReport" contextRef="C_0001668243_20210101_20210331" format="ixt-sec:boolballotbox">&#9746;</ix:nonNumeric></span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:10pt;">QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</p></td></tr></table></div>
<p style="text-align:center;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">For the quarterly period ended <ix:nonNumeric id="F_000002" name="dei:DocumentPeriodEndDate" contextRef="C_0001668243_20210101_20210331" format="ixt:datemonthdayyearen">March&#160;31, 2021</ix:nonNumeric><span style="font-size:10pt;font-weight:normal;">&#160;</span></p>
<p style="text-align:center;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">OR</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:bold;font-family:Segoe UI Symbol;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Segoe UI Symbol;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000019" name="dei:DocumentTransitionReport" contextRef="C_0001668243_20210101_20210331" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:10pt;">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:6pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">For the transition period from<span style="text-decoration:underline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span> to <span style="text-decoration:underline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></p>
<p style="text-align:center;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">Commission file number: <ix:nonNumeric id="F_000020" name="dei:EntityFileNumber" contextRef="C_0001668243_20210101_20210331">001-38079</ix:nonNumeric></p>
<p style="text-align:center;border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-left:40%;margin-right:40%;text-indent:0%;font-family:Times New Roman;font-size:6pt;">&#160;</p>
<p style="text-align:center;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:24pt;font-family:Calibri;text-transform:uppercase;font-style:normal;font-variant: normal;"><ix:nonNumeric id="F_000008" name="dei:EntityRegistrantName" contextRef="C_0001668243_20210101_20210331">UROGEN PHARMA LTD.</ix:nonNumeric></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(Exact Name of Registrant as Specified in its Charter)</p>
<p style="text-align:center;border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-left:40%;margin-right:40%;text-indent:0%;font-family:Times New Roman;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:6pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="width:50%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000021" name="dei:EntityIncorporationStateCountryCode" contextRef="C_0001668243_20210101_20210331" format="ixt-sec:edgarprovcountryen">Israel</ix:nonNumeric></p></td>
<td valign="bottom" style="width:50%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000022" name="dei:EntityTaxIdentificationNumber" contextRef="C_0001668243_20210101_20210331">98-1460746</ix:nonNumeric></p></td>
</tr>
<tr>
<td valign="bottom" style="width:50%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">(State or other jurisdiction of</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">incorporation or organization)</p></td>
<td valign="bottom" style="width:50%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">(I.R.S. Employer</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">Identification No.)</p></td>
</tr>
<tr>
<td valign="bottom" style="width:50%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000023" name="dei:EntityAddressAddressLine1" contextRef="C_0001668243_20210101_20210331">400 Alexander Park Drive</ix:nonNumeric>, <ix:nonNumeric id="F_000024" name="dei:EntityAddressCityOrTown" contextRef="C_0001668243_20210101_20210331">Princeton</ix:nonNumeric>, <ix:nonNumeric id="F_000025" name="dei:EntityAddressStateOrProvince" contextRef="C_0001668243_20210101_20210331" format="ixt-sec:stateprovnameen">New Jersey</ix:nonNumeric></p></td>
<td valign="bottom" style="width:50%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000026" name="dei:EntityAddressPostalZipCode" contextRef="C_0001668243_20210101_20210331">08540</ix:nonNumeric></p></td>
</tr>
<tr>
<td valign="bottom" style="width:50%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">(Address of principal executive offices)</p></td>
<td valign="bottom" style="width:50%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">(Zip Code)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:6pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonNumeric id="F_000027" name="dei:CityAreaCode" contextRef="C_0001668243_20210101_20210331">646</ix:nonNumeric>)<ix:nonNumeric id="F_000028" name="dei:LocalPhoneNumber" contextRef="C_0001668243_20210101_20210331"> 768-9780</ix:nonNumeric></p>
<p style="text-align:center;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">Registrant&#8217;s telephone number, including area code</p>
<p style="text-align:center;border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-left:40%;margin-right:40%;text-indent:0%;font-family:Times New Roman;font-size:6pt;">&#160;</p>
<p style="text-align:center;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">N/A</p>
<p style="text-align:center;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">(Former name, former address and former fiscal year, if changed since last report)</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:8pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Securities registered pursuant to Section 12(b) of the Act:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:6pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr style="height:14.5pt;">
<td valign="bottom" style="width:33.3%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="text-decoration:underline;">Title of each class</span></p></td>
<td valign="bottom" style="width:33.3%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="text-decoration:underline;">Trading Symbol</span></p></td>
<td valign="bottom" style="width:33.3%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="text-decoration:underline;">Name of exchange on which registered</span></p></td>
</tr>
<tr style="height:14.5pt;">
<td valign="bottom" style="width:33.3%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000006" name="dei:Security12bTitle" contextRef="C_0001668243_20210101_20210331">Ordinary Shares, par value NIS 0.01 per share</ix:nonNumeric></p></td>
<td valign="bottom" style="width:33.3%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000005" name="dei:TradingSymbol" contextRef="C_0001668243_20210101_20210331">URGN</ix:nonNumeric></p></td>
<td valign="bottom" style="width:33.3%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000007" name="dei:SecurityExchangeName" contextRef="C_0001668243_20210101_20210331" format="ixt-sec:exchnameen">The Nasdaq Stock Market LLC</ix:nonNumeric></p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:8pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. &#160;&#160;&#160;&#160;<ix:nonNumeric id="F_000016" name="dei:EntityCurrentReportingStatus" contextRef="C_0001668243_20210101_20210331">Yes</ix:nonNumeric>&#160;&#160;<span style="font-family:Segoe UI Symbol;">&#9746;</span>&#160;&#160;&#160;&#160;No&#160;&#160;<span style="font-family:Segoe UI Symbol;">&#9744;</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:8pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).&#160;&#160;&#160;&#160;<ix:nonNumeric id="F_000017" name="dei:EntityInteractiveDataCurrent" contextRef="C_0001668243_20210101_20210331">Yes</ix:nonNumeric>&#160;&#160;<span style="font-family:Segoe UI Symbol;">&#9746;</span>&#160;&#160;&#160;&#160;No&#160;&#160;<span style="font-family:Segoe UI Symbol;">&#9744;</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:8pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:6pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr style="height:10.8pt;">
<td valign="top" style="width:19.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Large&#160;accelerated&#160;filer</p></td>
<td valign="top" style="width:0.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:55.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Segoe UI Symbol;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9744;</p></td>
<td valign="top" style="width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top" style="width:20.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accelerated&#160;filer</p></td>
<td valign="top" style="width:0.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:2.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Segoe UI Symbol;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9744;</p></td>
</tr>
<tr style="height:3.75pt;">
<td valign="top" style="width:19.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="top" style="width:56.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="top" style="width:21.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="top" style="width:2.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:19.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000011" name="dei:EntityFilerCategory" contextRef="C_0001668243_20210101_20210331" format="ixt-sec:entityfilercategoryen">Non-accelerated filer</ix:nonNumeric></p></td>
<td valign="top" style="width:0.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:55.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Segoe UI Symbol;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9746;</p></td>
<td valign="top" style="width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top" style="width:20.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Smaller&#160;reporting&#160;company</p></td>
<td valign="top" style="width:0.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:2.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Segoe UI Symbol;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000012" name="dei:EntitySmallBusiness" contextRef="C_0001668243_20210101_20210331" format="ixt-sec:boolballotbox">&#9746;</ix:nonNumeric></p></td>
</tr>
<tr>
<td valign="top" style="width:19.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:55.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:20.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:2.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:19.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Emerging growth company</p></td>
<td valign="top" style="width:0.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:8pt;">&#160;</p></td>
<td valign="top" style="width:55.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Segoe UI Symbol;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000013" name="dei:EntityEmergingGrowthCompany" contextRef="C_0001668243_20210101_20210331" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></p></td>
<td valign="top" style="width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:8pt;">&#160;</p></td>
<td valign="top" style="width:20.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:8pt;">&#160;</p></td>
<td valign="top" style="width:0.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:8pt;">&#160;</p></td>
<td valign="top" style="width:2.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:8pt;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:8pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.&#160;<span style="font-family:Segoe UI Symbol;">&#9744;</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:8pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).&#160;&#160;&#160;&#160;Yes&#160;&#160;<span style="font-family:Segoe UI Symbol;"><ix:nonNumeric id="F_000015" name="dei:EntityShellCompany" contextRef="C_0001668243_20210101_20210331" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></span>&#160;&#160;&#160;&#160;No&#160;&#160;<span style="font-family:Segoe UI Symbol;">&#9746;</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:8pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of March 31, 2021, the registrant had <ix:nonFraction unitRef="U_xbrlishares" id="F_000014" name="dei:EntityCommonStockSharesOutstanding" contextRef="C_0001668243_20210331" decimals="INF" format="ixt:numdotdecimal">22,280,394</ix:nonFraction> ordinary shares, par value NIS 0.01 per share, outstanding. </p>
<p style="border-bottom:Double 2.25pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:1pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:2pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<hr style="page-break-after:always" />
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">UroGen Pharma Ltd</span><span style="font-weight:bold;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">.</span></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Index</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:82.82%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">Page</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">PART I.</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:82.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#PART_IFINANCIAL_INFORMATION"><span style="text-decoration:underline;">FINANCIAL INFORMATION</span></a></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item 1.</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:82.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_1_FINANCIAL_STATEMENTS"><span style="text-decoration:underline;">Financial Statements (Unaudited)</span></a></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:82.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#CONDENSED_CONSOLIDATED_BALANCE_SHEETS"><span style="text-decoration:underline;">Condensed Consolidated Balance Sheets</span></a></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:82.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#CONDENSED_CONSOLIDATED_STATEMENTS_OPERAT"><span style="text-decoration:underline;">Condensed Consolidated Statements of Operations</span></a></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-family:Times New Roman;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:82.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#CONDENSED_CONSOLIDATED_STATEMENTS_SHAREH"><span style="text-decoration:underline;">Condensed Consolidated Statements of Shareholders&#8217; Equity</span></a></p></td>
<td valign="bottom" style="width:7.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:82.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#CONDENSED_CONSOLIDATED_STATEMENTS_CASH_F"><span style="text-decoration:underline;">Condensed Consolidated Statements of Cash Flows</span></a></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:82.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#NOTES_TO_UNAUDITED_CONDENSED_CONSOLIDATE"><span style="text-decoration:underline;">Notes to Unaudited Condensed Consolidated Financial Statements</span></a></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item 2.</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:82.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_2_MANAGEMENTS_DISCUSSION_ANALYSIS_F"><span style="text-decoration:underline;">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></a></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item 3.</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:82.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_3_QUANTITATIVE_QUALITATIVE_DISCLOSU"><span style="text-decoration:underline;">Quantitative and Qualitative Disclosures About Market Risk</span></a></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item 4.</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:82.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_4_CONTROLS_PROCEDURES"><span style="text-decoration:underline;">Controls and Procedures</span></a></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">PART II.</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:82.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#PART_IIOR_INFORMATION"><span style="text-decoration:underline;">OTHER INFORMATION</span></a></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item 1.</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:82.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_1_LEGAL_PROCEEDINGS"><span style="text-decoration:underline;">Legal Proceedings</span></a></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item 1A.</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:82.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_1A_RISK_FACTORS"><span style="text-decoration:underline;">Risk Factors</span></a></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item 2.</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:82.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_2_UNREGISTERED_SALES_EQUITY_SECURIT"><span style="text-decoration:underline;">Unregistered Sales of Equity Securities and Use of Proceeds</span></a></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">81</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item 3.</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:82.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_3_DEFAULTS_UPON_SENIOR_SECURITIES"><span style="text-decoration:underline;">Defaults Upon Senior Securities</span></a></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">81</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item 4.</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:82.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_4_MINE_SAFETY_DISCLOSURES"><span style="text-decoration:underline;">Mine Safety Disclosures</span></a></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">82</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item 5.</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:82.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_5_OR_INFORMATION"><span style="text-decoration:underline;">Other Information</span></a></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">82</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item 6.</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:82.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_6_EXHIBITS"><span style="text-decoration:underline;">Exhibits</span></a></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">83</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:82.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#SIGNATURES"><span style="text-decoration:underline;">Signatures</span></a></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">84</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Trademarks and Trade Names</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unless the context requires otherwise, references in this Quarterly Report to the &#8220;Company&#8221;, &#8220;we,&#8221; &#8220;us&#8221; and &#8220;our&#8221; refer to UroGen Pharma Ltd. and its subsidiary, UroGen Pharma, Inc.<span style="font-style:italic;color:#000000;"> </span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">UroGen RTGel and Jelmyto are trademarks of ours that we use in this Quarterly Report. This Quarterly Report also includes trademarks, tradenames, and service marks that are the property of other organizations. Solely for convenience, our trademarks and tradenames referred to in this Quarterly Report appear without the &#174; or &#8482; symbols, but those references are not intended to indicate, in any way, that we will not assert, to the fullest extent under applicable law, our rights, or the right of the applicable licensor to our trademark and tradenames. We do not intend our use or display of other companies<span style="color:#000000;">&#8217;</span> trade names or trademarks to imply a relationship with, or endorsement or sponsorship of us by, any other companies.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">i</p>
<hr style="page-break-after:always" />
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="PART_IFINANCIAL_INFORMATION">Part I&#8212;Financial Information</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_1_FINANCIAL_STATEMENTS">Item 1. Financial Statements.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">UroGen Pharma Ltd.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="CONDENSED_CONSOLIDATED_BALANCE_SHEETS">Condensed Consolidated Balance Sheets</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(unaudited&#59; in thousands, except share amounts and par value)</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:12pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.2%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.76%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">March&#160;31, 2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.68%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31, 2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.2%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Assets</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.68%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current assets:</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.68%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash and cash equivalents</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000037" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="C_0001668243_20210331" decimals="-3" format="ixt:numdotdecimal" scale="3">40,492</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.68%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000038" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="C_0001668243_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">52,864</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Marketable securities</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000039" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" contextRef="C_0001668243_20210331" decimals="-3" format="ixt:numdotdecimal" scale="3">35,417</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.68%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000040" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" contextRef="C_0001668243_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">49,154</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restricted cash</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000041" name="us-gaap:RestrictedCashCurrent" contextRef="C_0001668243_20210331" decimals="-3" format="ixt:numdotdecimal" scale="3">1,225</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.68%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000042" name="us-gaap:RestrictedCashCurrent" contextRef="C_0001668243_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,226</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accounts receivable</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000043" name="us-gaap:AccountsReceivableNetCurrent" contextRef="C_0001668243_20210331" decimals="-3" format="ixt:numdotdecimal" scale="3">6,301</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.68%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000044" name="us-gaap:AccountsReceivableNetCurrent" contextRef="C_0001668243_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">7,047</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inventory</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000045" name="us-gaap:InventoryNet" contextRef="C_0001668243_20210331" decimals="-3" format="ixt:numdotdecimal" scale="3">3,331</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.68%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000046" name="us-gaap:InventoryNet" contextRef="C_0001668243_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,964</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepaid expenses and other current assets</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000047" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="C_0001668243_20210331" decimals="-3" format="ixt:numdotdecimal" scale="3">6,316</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.68%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000048" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="C_0001668243_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">3,364</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total current assets</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000049" name="us-gaap:AssetsCurrent" contextRef="C_0001668243_20210331" decimals="-3" format="ixt:numdotdecimal" scale="3">93,082</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000050" name="us-gaap:AssetsCurrent" contextRef="C_0001668243_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">115,619</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Non-current assets:</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.68%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment, net</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000051" name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="C_0001668243_20210331" decimals="-3" format="ixt:numdotdecimal" scale="3">2,142</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.68%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000052" name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="C_0001668243_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,046</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restricted deposit</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000053" name="us-gaap:RestrictedInvestmentsNoncurrent" contextRef="C_0001668243_20210331" decimals="-3" scale="3">223</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.68%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000054" name="us-gaap:RestrictedInvestmentsNoncurrent" contextRef="C_0001668243_20201231" decimals="-3" scale="3">223</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Right of use asset</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000055" name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="C_0001668243_20210331" decimals="-3" format="ixt:numdotdecimal" scale="3">1,901</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.68%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000056" name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="C_0001668243_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,158</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Marketable securities</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.68%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000057" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" contextRef="C_0001668243_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,893</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other non-current assets</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000058" name="us-gaap:OtherAssetsNoncurrent" contextRef="C_0001668243_20210331" decimals="-3" scale="3">66</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.68%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000059" name="us-gaap:OtherAssetsNoncurrent" contextRef="C_0001668243_20201231" decimals="-3" scale="3">66</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.2%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total Assets</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000060" name="us-gaap:Assets" contextRef="C_0001668243_20210331" decimals="-3" format="ixt:numdotdecimal" scale="3">97,414</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.68%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000061" name="us-gaap:Assets" contextRef="C_0001668243_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">122,005</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.2%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Liabilities and Shareholders' Equity</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.68%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current liabilities:</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.68%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accounts payable and accrued expenses</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000062" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" contextRef="C_0001668243_20210331" decimals="-3" format="ixt:numdotdecimal" scale="3">10,558</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.68%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000063" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" contextRef="C_0001668243_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">10,023</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Employee related accrued expenses</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000064" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" contextRef="C_0001668243_20210331" decimals="-3" format="ixt:numdotdecimal" scale="3">4,712</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.68%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000065" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" contextRef="C_0001668243_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">9,554</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other current liabilities</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000066" name="us-gaap:OtherLiabilitiesCurrent" contextRef="C_0001668243_20210331" decimals="-3" format="ixt:numdotdecimal" scale="3">1,735</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.68%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000067" name="us-gaap:OtherLiabilitiesCurrent" contextRef="C_0001668243_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,859</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total current liabilities:</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000068" name="us-gaap:LiabilitiesCurrent" contextRef="C_0001668243_20210331" decimals="-3" format="ixt:numdotdecimal" scale="3">17,005</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.68%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000069" name="us-gaap:LiabilitiesCurrent" contextRef="C_0001668243_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">21,436</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Non-current liabilities:</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.68%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Long-term lease liability</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000070" name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="C_0001668243_20210331" decimals="-3" format="ixt:numdotdecimal" scale="3">1,201</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.68%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000071" name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="C_0001668243_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,497</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Uncertain tax positions liability</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000072" name="us-gaap:LiabilityForUncertainTaxPositionsNoncurrent" contextRef="C_0001668243_20210331" decimals="-3" format="ixt:numdotdecimal" scale="3">2,717</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.68%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000073" name="us-gaap:LiabilityForUncertainTaxPositionsNoncurrent" contextRef="C_0001668243_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,717</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total Liabilities</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000074" name="us-gaap:Liabilities" contextRef="C_0001668243_20210331" decimals="-3" format="ixt:numdotdecimal" scale="3">20,923</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000075" name="us-gaap:Liabilities" contextRef="C_0001668243_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">25,650</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Commitments and contingencies (Note 14)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000076">&#160;</span></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.68%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000077">&#160;</span></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Shareholders' equity:</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.68%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Ordinary shares, NIS <ix:nonFraction unitRef="U_iso4217ILS_xbrlishares" id="F_000029" name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="C_0001668243_20210331" decimals="INF"><ix:nonFraction unitRef="U_iso4217ILS_xbrlishares" id="F_000030" name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="C_0001668243_20201231" decimals="INF">0.01</ix:nonFraction></ix:nonFraction> par value&#59; <ix:nonFraction unitRef="U_xbrlishares" id="F_000031" name="us-gaap:CommonStockSharesAuthorized" contextRef="C_0001668243_20210331" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction unitRef="U_xbrlishares" id="F_000032" name="us-gaap:CommonStockSharesAuthorized" contextRef="C_0001668243_20201231" decimals="INF" format="ixt:numdotdecimal">100,000,000</ix:nonFraction></ix:nonFraction> shares</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; authorized at March 31, 2021 and December 31, 2020&#59; <ix:nonFraction unitRef="U_xbrlishares" id="F_000033" name="us-gaap:CommonStockSharesIssued" contextRef="C_0001668243_20210331" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction unitRef="U_xbrlishares" id="F_000035" name="us-gaap:CommonStockSharesOutstanding" contextRef="C_0001668243_20210331" decimals="INF" format="ixt:numdotdecimal">22,280,394</ix:nonFraction></ix:nonFraction></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; and <ix:nonFraction unitRef="U_xbrlishares" id="F_000034" name="us-gaap:CommonStockSharesIssued" contextRef="C_0001668243_20201231" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction unitRef="U_xbrlishares" id="F_000036" name="us-gaap:CommonStockSharesOutstanding" contextRef="C_0001668243_20201231" decimals="INF" format="ixt:numdotdecimal">22,167,791</ix:nonFraction></ix:nonFraction> shares issued and outstanding as</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; of March 31, 2021 and December 31, 2020, respectively</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000078" name="us-gaap:CommonStockValue" contextRef="C_0001668243_20210331" decimals="-3" scale="3">61</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.68%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000079" name="us-gaap:CommonStockValue" contextRef="C_0001668243_20201231" decimals="-3" scale="3">60</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additional paid-in capital</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000080" name="us-gaap:AdditionalPaidInCapitalCommonStock" contextRef="C_0001668243_20210331" decimals="-3" format="ixt:numdotdecimal" scale="3">458,723</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.68%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000081" name="us-gaap:AdditionalPaidInCapitalCommonStock" contextRef="C_0001668243_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">452,525</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accumulated deficit</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000082" name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="C_0001668243_20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">382,436</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.68%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000083" name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="C_0001668243_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">356,501</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accumulated other comprehensive income</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000084" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="C_0001668243_20210331" decimals="-3" scale="3">143</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.68%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000085" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="C_0001668243_20201231" decimals="-3" scale="3">271</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total Shareholders' Equity</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000086" name="us-gaap:StockholdersEquity" contextRef="C_0001668243_20210331" decimals="-3" format="ixt:numdotdecimal" scale="3">76,491</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000087" name="us-gaap:StockholdersEquity" contextRef="C_0001668243_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">96,355</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.2%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total Liabilities and Shareholders' Equity</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000088" name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="C_0001668243_20210331" decimals="-3" format="ixt:numdotdecimal" scale="3">97,414</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.68%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000089" name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="C_0001668243_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">122,005</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:12pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The accompanying notes are an integral part of these condensed consolidated financial statements.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</p>
<hr style="page-break-after:always" />
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">UroGen Pharma Ltd.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="CONDENSED_CONSOLIDATED_STATEMENTS_OPERAT">Condensed Consolidated Statements of Operations and Comprehensive Loss</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">(unaudited&#59; in thousands, except share and per share amounts)</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59.64%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:37.6%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">For the Three Months Ended March&#160;31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59.64%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Revenues</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000090" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0001668243_20210101_20210331" decimals="-3" format="ixt:numdotdecimal" scale="3">7,485</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cost of revenues</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000091" name="us-gaap:CostOfRevenue" contextRef="C_0001668243_20210101_20210331" decimals="-3" scale="3">897</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Gross profit</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000092" name="us-gaap:GrossProfit" contextRef="C_0001668243_20210101_20210331" decimals="-3" format="ixt:numdotdecimal" scale="3">6,588</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating expenses:</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development expenses</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000093" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="C_0001668243_20210101_20210331" decimals="-3" format="ixt:numdotdecimal" scale="3">10,513</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000094" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="C_0001668243_20200101_20200331" decimals="-3" format="ixt:numdotdecimal" scale="3">16,588</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Selling, general and administrative expenses</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000095" name="us-gaap:SellingGeneralAndAdministrativeExpense" contextRef="C_0001668243_20210101_20210331" decimals="-3" format="ixt:numdotdecimal" scale="3">22,189</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000096" name="us-gaap:SellingGeneralAndAdministrativeExpense" contextRef="C_0001668243_20200101_20200331" decimals="-3" format="ixt:numdotdecimal" scale="3">21,973</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating loss</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000097" name="us-gaap:OperatingIncomeLoss" contextRef="C_0001668243_20210101_20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">26,114</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000098" name="us-gaap:OperatingIncomeLoss" contextRef="C_0001668243_20200101_20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">38,561</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest and other income, net</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000099" name="urgn:InterestAndOtherIncomeExpensesNet" contextRef="C_0001668243_20210101_20210331" decimals="-3" scale="3">179</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000100" name="urgn:InterestAndOtherIncomeExpensesNet" contextRef="C_0001668243_20200101_20200331" decimals="-3" scale="3">768</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59.64%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net Loss</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000101" name="us-gaap:NetIncomeLoss" contextRef="C_0001668243_20210101_20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">25,935</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000102" name="us-gaap:NetIncomeLoss" contextRef="C_0001668243_20200101_20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">37,793</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Statements of Comprehensive Loss</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000103" name="us-gaap:NetIncomeLoss" contextRef="C_0001668243_20210101_20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">25,935</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000104" name="us-gaap:NetIncomeLoss" contextRef="C_0001668243_20200101_20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">37,793</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other comprehensive income</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unrealized (loss) gain on marketable securities</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000105" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" contextRef="C_0001668243_20210101_20210331" decimals="-3" sign="-" scale="3">128</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000106" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" contextRef="C_0001668243_20200101_20200331" decimals="-3" scale="3">35</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59.64%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Comprehensive Loss</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000107" name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="C_0001668243_20210101_20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">26,063</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000108" name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="C_0001668243_20200101_20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">37,758</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59.64%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss per ordinary share basic and diluted</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000109" name="us-gaap:EarningsPerShareBasicAndDiluted" contextRef="C_0001668243_20210101_20210331" decimals="2" sign="-">1.17</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000110" name="us-gaap:EarningsPerShareBasicAndDiluted" contextRef="C_0001668243_20200101_20200331" decimals="2" sign="-">1.79</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59.64%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted average number of shares</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; outstanding used in computation</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; of basic and diluted loss per</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; ordinary share</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000111" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" contextRef="C_0001668243_20210101_20210331" decimals="0" format="ixt:numdotdecimal">22,242,375</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000112" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" contextRef="C_0001668243_20200101_20200331" decimals="0" format="ixt:numdotdecimal">21,158,161</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The accompanying notes are an integral part of these condensed consolidated financial statements.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br /></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</p>
<hr style="page-break-after:always" />
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">UroGen Pharma Ltd.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="CONDENSED_CONSOLIDATED_STATEMENTS_SHAREH">Condensed Consolidated Statements of Shareholders&#8217; Equity</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">(unaudited&#59; in thousands, except share amounts)</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:34.5%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.7%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Ordinary Shares</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:8.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Additional</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">paid-in</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:8.78%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Accumulated</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Other</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">comprehensive</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:6.54%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:34.5%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:8.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Number&#160;of</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.78%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">capital</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.78%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Deficit</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">income</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.54%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:34.5%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.78%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Shares</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.78%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Amount</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="14" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.52%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Amounts</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance as of January 1, 2020</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.78%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000113" name="us-gaap:SharesIssued" contextRef="C_0001668243_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20191231" decimals="INF" format="ixt:numdotdecimal">21,026,184</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.78%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000114" name="us-gaap:StockholdersEquity" contextRef="C_0001668243_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20191231" decimals="-3" scale="3">57</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.78%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000115" name="us-gaap:StockholdersEquity" contextRef="C_0001668243_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">407,986</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.78%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000116" name="us-gaap:StockholdersEquity" contextRef="C_0001668243_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">228,017</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000117" name="us-gaap:StockholdersEquity" contextRef="C_0001668243_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20191231" decimals="-3" scale="3">276</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000118" name="us-gaap:StockholdersEquity" contextRef="C_0001668243_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">180,302</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Changes During the Three</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; Months Ended March 31, 2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercise of options into ordinary shares</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000119" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="C_0001668243_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20200331" decimals="INF" format="ixt:numdotdecimal">186,756</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000120" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="C_0001668243_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20200331" decimals="-3" scale="3">1</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000121" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="C_0001668243_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200101_20200331" decimals="-3" scale="3">292</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.78%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000122" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="C_0001668243_20200101_20200331" decimals="-3" scale="3">293</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Share-based compensation</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.78%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.78%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000123" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="C_0001668243_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200101_20200331" decimals="-3" format="ixt:numdotdecimal" scale="3">7,617</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.78%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000124" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="C_0001668243_20200101_20200331" decimals="-3" format="ixt:numdotdecimal" scale="3">7,617</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other comprehensive income</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.78%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.78%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.78%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.78%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000125" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="C_0001668243_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20200101_20200331" decimals="-3" scale="3">35</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000126" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="C_0001668243_20200101_20200331" decimals="-3" scale="3">35</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:34.5%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000127" name="us-gaap:NetIncomeLoss" contextRef="C_0001668243_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20200101_20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">37,793</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000128" name="us-gaap:NetIncomeLoss" contextRef="C_0001668243_20200101_20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">37,793</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:34.5%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance as of March 31, 2020</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000129" name="us-gaap:SharesIssued" contextRef="C_0001668243_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200331" decimals="INF" format="ixt:numdotdecimal">21,212,940</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000130" name="us-gaap:StockholdersEquity" contextRef="C_0001668243_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200331" decimals="-3" scale="3">58</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000131" name="us-gaap:StockholdersEquity" contextRef="C_0001668243_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200331" decimals="-3" format="ixt:numdotdecimal" scale="3">415,895</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000132" name="us-gaap:StockholdersEquity" contextRef="C_0001668243_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">265,810</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000133" name="us-gaap:StockholdersEquity" contextRef="C_0001668243_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20200331" decimals="-3" scale="3">311</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000134" name="us-gaap:StockholdersEquity" contextRef="C_0001668243_20200331" decimals="-3" format="ixt:numdotdecimal" scale="3">150,454</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:34.5%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.78%; border-top:double 2.5pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.78%; border-top:double 2.5pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.78%; border-top:double 2.5pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.78%; border-top:double 2.5pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:double 2.5pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%; border-top:double 2.5pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance as of January 1, 2021</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.78%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000135" name="us-gaap:SharesIssued" contextRef="C_0001668243_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20201231" decimals="INF" format="ixt:numdotdecimal">22,167,791</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.78%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000136" name="us-gaap:StockholdersEquity" contextRef="C_0001668243_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20201231" decimals="-3" scale="3">60</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.78%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000137" name="us-gaap:StockholdersEquity" contextRef="C_0001668243_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">452,525</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.78%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000138" name="us-gaap:StockholdersEquity" contextRef="C_0001668243_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">356,501</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000139" name="us-gaap:StockholdersEquity" contextRef="C_0001668243_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20201231" decimals="-3" scale="3">271</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000140" name="us-gaap:StockholdersEquity" contextRef="C_0001668243_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">96,355</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Changes During the Three</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; Months Ended March 31, 2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercise of options into ordinary shares</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000141" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="C_0001668243_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210101_20210331" decimals="INF" format="ixt:numdotdecimal">112,603</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000142" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="C_0001668243_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210101_20210331" decimals="-3" scale="3">1</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000143" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="C_0001668243_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20210101_20210331" decimals="-3" scale="3">3</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.78%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000144" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="C_0001668243_20210101_20210331" decimals="-3" scale="3">4</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Share-based compensation</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.78%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.78%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000145" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="C_0001668243_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20210101_20210331" decimals="-3" format="ixt:numdotdecimal" scale="3">6,195</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.78%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000146" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="C_0001668243_20210101_20210331" decimals="-3" format="ixt:numdotdecimal" scale="3">6,195</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other comprehensive loss</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.78%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.78%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.78%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.78%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000147" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="C_0001668243_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20210101_20210331" decimals="-3" sign="-" scale="3">128</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000148" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="C_0001668243_20210101_20210331" decimals="-3" sign="-" scale="3">128</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:34.5%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000149" name="us-gaap:NetIncomeLoss" contextRef="C_0001668243_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20210101_20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">25,935</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000150" name="us-gaap:NetIncomeLoss" contextRef="C_0001668243_20210101_20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">25,935</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:34.5%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance as of March 31, 2021</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000151" name="us-gaap:SharesIssued" contextRef="C_0001668243_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210331" decimals="INF" format="ixt:numdotdecimal">22,280,394</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000152" name="us-gaap:StockholdersEquity" contextRef="C_0001668243_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210331" decimals="-3" scale="3">61</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000153" name="us-gaap:StockholdersEquity" contextRef="C_0001668243_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20210331" decimals="-3" format="ixt:numdotdecimal" scale="3">458,723</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000154" name="us-gaap:StockholdersEquity" contextRef="C_0001668243_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">382,436</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000155" name="us-gaap:StockholdersEquity" contextRef="C_0001668243_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20210331" decimals="-3" scale="3">143</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000156" name="us-gaap:StockholdersEquity" contextRef="C_0001668243_20210331" decimals="-3" format="ixt:numdotdecimal" scale="3">76,491</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:6pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The accompanying notes are an integral part of these condensed consolidated financial statements.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</p>
<hr style="page-break-after:always" />
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">UroGen Pharma Ltd.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="CONDENSED_CONSOLIDATED_STATEMENTS_CASH_F">Condensed Consolidated Statements of Cash Flow</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(unaudited&#59; in thousands)</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:63.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.26%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended March&#160;31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:63.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.8%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.8%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Cash Flows From Operating Activities</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000157" name="us-gaap:NetIncomeLoss" contextRef="C_0001668243_20210101_20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">25,935</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000158" name="us-gaap:NetIncomeLoss" contextRef="C_0001668243_20200101_20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">37,793</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Adjustment to reconcile net loss to net cash from operating activities:</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:41.05pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Depreciation and amortization</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000159" name="us-gaap:DepreciationAndAmortization" contextRef="C_0001668243_20210101_20210331" decimals="-3" scale="3">191</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000160" name="us-gaap:DepreciationAndAmortization" contextRef="C_0001668243_20200101_20200331" decimals="-3" scale="3">82</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:41.05pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amortization on marketable securities</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000161" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" contextRef="C_0001668243_20210101_20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">191</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000162" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" contextRef="C_0001668243_20200101_20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">98</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:41.05pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000163" name="us-gaap:ShareBasedCompensation" contextRef="C_0001668243_20210101_20210331" decimals="-3" format="ixt:numdotdecimal" scale="3">6,195</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000164" name="us-gaap:ShareBasedCompensation" contextRef="C_0001668243_20200101_20200331" decimals="-3" format="ixt:numdotdecimal" scale="3">7,617</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:41.05pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amortization of right of use asset</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000165" name="urgn:OperatingLeaseRightOfUseAssetAmortization" contextRef="C_0001668243_20210101_20210331" decimals="-3" scale="3">237</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000166" name="urgn:OperatingLeaseRightOfUseAssetAmortization" contextRef="C_0001668243_20200101_20200331" decimals="-3" scale="3">374</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:41.05pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lease liability</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000167" name="urgn:OperatingLeaseLiabilityAdjustments" contextRef="C_0001668243_20210101_20210331" decimals="-3" scale="3">400</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000168" name="urgn:OperatingLeaseLiabilityAdjustments" contextRef="C_0001668243_20200101_20200331" decimals="-3" scale="3">361</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Changes in operating assets and liabilities:</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:41.05pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inventory</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000169" name="us-gaap:IncreaseDecreaseInInventories" contextRef="C_0001668243_20210101_20210331" decimals="-3" format="ixt:numdotdecimal" scale="3">1,367</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:41.05pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accounts receivable</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000170" name="us-gaap:IncreaseDecreaseInAccountsReceivable" contextRef="C_0001668243_20210101_20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">746</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:41.05pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepaid expenses and other current assets</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000171" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="C_0001668243_20210101_20210331" decimals="-3" format="ixt:numdotdecimal" scale="3">2,952</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000172" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="C_0001668243_20200101_20200331" decimals="-3" scale="3">518</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:41.05pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accounts payable and accrued expenses</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000173" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" contextRef="C_0001668243_20210101_20210331" decimals="-3" scale="3">535</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000174" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" contextRef="C_0001668243_20200101_20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">2,498</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:63.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:41.05pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Employee related accrued expenses</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000175" name="us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities" contextRef="C_0001668243_20210101_20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">4,842</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000176" name="us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities" contextRef="C_0001668243_20200101_20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">2,636</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:63.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash used in operating activities</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000177" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="C_0001668243_20210101_20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">27,401</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000178" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="C_0001668243_20200101_20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">35,635</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Cash Flows From Investing Activities</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:41.05pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Purchase of marketable securities</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000179" name="us-gaap:PaymentsToAcquireMarketableSecurities" contextRef="C_0001668243_20200101_20200331" decimals="-3" format="ixt:numdotdecimal" scale="3">9,378</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:41.05pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Maturities of marketable securities</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000180" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" contextRef="C_0001668243_20210101_20210331" decimals="-3" format="ixt:numdotdecimal" scale="3">15,311</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000181" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" contextRef="C_0001668243_20200101_20200331" decimals="-3" format="ixt:numdotdecimal" scale="3">22,499</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:63.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:41.05pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Purchases of property and equipment</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000182" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="C_0001668243_20210101_20210331" decimals="-3" scale="3">287</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000183" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="C_0001668243_20200101_20200331" decimals="-3" scale="3">96</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:63.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash provided by investing activities</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000184" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="C_0001668243_20210101_20210331" decimals="-3" format="ixt:numdotdecimal" scale="3">15,024</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000185" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="C_0001668243_20200101_20200331" decimals="-3" format="ixt:numdotdecimal" scale="3">13,025</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Cash Flows From Financing Activities</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:41.05pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Proceeds from exercise of options into ordinary shares</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000186" name="us-gaap:ProceedsFromStockOptionsExercised" contextRef="C_0001668243_20210101_20210331" decimals="-3" scale="3">4</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000187" name="us-gaap:ProceedsFromStockOptionsExercised" contextRef="C_0001668243_20200101_20200331" decimals="-3" scale="3">293</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:63.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:41.05pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issuance cost related to at-the-market issuances</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000188" name="us-gaap:PaymentsOfStockIssuanceCosts" contextRef="C_0001668243_20200101_20200331" decimals="-3" scale="3">203</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:63.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash provided by financing activities</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000189" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="C_0001668243_20210101_20210331" decimals="-3" scale="3">4</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000190" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="C_0001668243_20200101_20200331" decimals="-3" scale="3">90</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Decrease in Cash and Cash Equivalents</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000191" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="C_0001668243_20210101_20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">12,373</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000192" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="C_0001668243_20200101_20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">22,520</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:63.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Cash, Cash Equivalents and Restricted Cash at Beginning of Period</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000193" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="C_0001668243_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">54,090</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000194" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="C_0001668243_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">50,211</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:63.08%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Cash, Cash Equivalents and Restricted Cash at End of Period</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000195" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="C_0001668243_20210331" decimals="-3" format="ixt:numdotdecimal" scale="3">41,717</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000196" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="C_0001668243_20200331" decimals="-3" format="ixt:numdotdecimal" scale="3">27,691</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Supplemental Disclosures of Non-Cash Activities</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:63.08%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:41.05pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Non-cash new lease liabilities</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000197" name="urgn:NonCashNewLeaseLiabilities" contextRef="C_0001668243_20210101_20210331" decimals="-3" sign="-" scale="3">20</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000198" name="urgn:NonCashNewLeaseLiabilities" contextRef="C_0001668243_20200101_20200331" decimals="-3" scale="3">72</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The accompanying notes are an integral part of these condensed consolidated financial statements.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">UroGen Pharma Ltd</span><span style="font-weight:bold;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">.</span></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="NOTES_TO_UNAUDITED_CONDENSED_CONSOLIDATE">Notes to the Unaudited Condensed Consolidated Financial Statements</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&#160;</p><ix:nonNumeric id="F_000199" name="us-gaap:NatureOfOperations" contextRef="C_0001668243_20210101_20210331" escape="true">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Note 1 &#8211; Business and Nature of Operations</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Calibri;font-size:10pt;text-transform:none;font-variant: normal;">Nature of Operations</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">UroGen<span style="letter-spacing:0.65pt;"> </span>Pharma<span style="letter-spacing:0.65pt;"> </span>Ltd.<span style="letter-spacing:0.4pt;"> </span>is<span style="letter-spacing:0.15pt;"> </span>an<span style="letter-spacing:0.25pt;"> </span>Israeli<span style="letter-spacing:0.5pt;"> </span>company<span style="letter-spacing:0.75pt;"> </span>incorporated<span style="letter-spacing:1pt;"> </span>in<span style="letter-spacing:0.2pt;"> </span><ix:nonNumeric id="F_000246" name="urgn:EntityIncorporationDateOfIncorporationMonthAndYear" contextRef="C_0001668243_20210101_20210331" format="ixt:datemonthyearen">April<span style="letter-spacing:0.4pt;"> </span>20<span style="letter-spacing:-0.1pt;">0</span>4</ix:nonNumeric><span style="letter-spacing:0.45pt;"> </span>(&#8220;UPL&#8221;). </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">UroGen<span style="letter-spacing:0.65pt;"> </span>Pharma<span style="letter-spacing:0.65pt;"> </span>Inc.,<span style="letter-spacing:0.35pt;"> </span>a<span style="letter-spacing:0.15pt;"> wholly owned </span>subsidiary<span style="letter-spacing:0.8pt;"> </span>of<span style="letter-spacing:0.2pt;"> </span>UPL,<span style="letter-spacing:0.45pt;"> </span>was<span style="letter-spacing:0.35pt;"> </span>incorporated<span style="letter-spacing:1pt;"> </span>in<span style="letter-spacing:0.2pt;"> </span>Del<span style="letter-spacing:-0.1pt;">a</span>ware<span style="letter-spacing:0.75pt;"> </span>in<span style="letter-spacing:0.2pt;"> </span>October<span style="letter-spacing:0.65pt;"> </span>2015<span style="letter-spacing:0.45pt;"> </span>and<span style="letter-spacing:0.35pt;"> </span>began<span style="letter-spacing:0.5pt;"> </span>operati<span style="letter-spacing:-0.1pt;">n</span>g<span style="letter-spacing:0.75pt;"> </span>in<span style="letter-spacing:0.2pt;"> </span><ix:nonNumeric id="F_000247" name="urgn:OperationsCommencedDateMonthAndYear" contextRef="C_0001668243_20210101_20210331" format="ixt:datemonthyearen">February<span style="letter-spacing:0.75pt;"> </span>2016</ix:nonNumeric><span style="letter-spacing:0.45pt;"> </span>(&#8220;UPI&#8221;). </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">UPL<span style="letter-spacing:0.4pt;"> </span>and<span style="letter-spacing:0.35pt;"> </span>UPI<span style="letter-spacing:0.35pt;"> </span>(together<span style="letter-spacing:0.75pt;"> </span>the<span style="letter-spacing:0.3pt;"> </span>&#8220;Company&#8221;)<span style="letter-spacing:0.95pt;"> </span>is<span style="letter-spacing:0.15pt;"> </span>a<span style="letter-spacing:0.45pt;"> </span>bi<span style="letter-spacing:-0.1pt;">o</span>pharmaceutical<span style="letter-spacing:1.45pt;"> </span>company<span style="letter-spacing:0.75pt;"> </span>focused<span style="letter-spacing:0.65pt;"> </span>on<span style="letter-spacing:0.25pt;"> </span>deve<span style="letter-spacing:-0.1pt;">l</span>oping and commercializing<span style="letter-spacing:0.85pt;"> </span>novel<span style="letter-spacing:0.45pt;"> </span>therapies<span style="letter-spacing:0.75pt;"> </span>desi<span style="letter-spacing:-0.1pt;">g</span>ned<span style="letter-spacing:0.75pt;"> </span>to change<span style="letter-spacing:0.65pt;"> </span>the<span style="letter-spacing:0.3pt;"> </span>standard<span style="letter-spacing:0.7pt;"> </span>of<span style="letter-spacing:0.2pt;"> </span>care<span style="letter-spacing:0.4pt;"> </span>for<span style="letter-spacing:0.25pt;"> </span>urological<span style="letter-spacing:0.8pt;"> </span>pathologies. Since commencing operations, the Company has devoted substantially all of its efforts to securing intellectual property rights, performing research and development activities, including conducting clinical trials and manufacturing activities, hiring personnel, launching the Company&#8217;s first commercial product, <span style="font-style:italic;">Jelmyto</span> (mitomycin) for pyelocalyceal solution, formerly known as UGN-101, and its product candidate UGN-102, and raising capital to support and expand these activities. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On April 15, 2020, the U.S. Food and Drug Administration (&#8220;FDA&#8221;) granted expedited approval for <span style="font-style:italic;">Jelmyto</span>, a first-in-class treatment indicated for adults with low-grade upper tract urothelial cancer (&#8220;low grade-UTUC&#8221;). <span style="font-style:italic;">Jelmyto</span> consists of mitomycin, an established chemotherapy, and sterile hydrogel, using our proprietary sustained release <span style="font-style:italic;">RTGel</span> technology. It has been designed to enable longer exposure of urinary tract tissue to mitomycin, thereby enabling the treatment of tumors by non-surgical means.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:6pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p><ix:nonNumeric id="F_000200" name="us-gaap:BasisOfAccounting" contextRef="C_0001668243_20210101_20210331" escape="true">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Note 2 &#8211; Basis of Presentation</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (&#8220;GAAP&#8221;) for interim financial information and in accordance with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all the information and footnotes required by GAAP for complete financial statements. In the opinion of the Company&#8217;s management, the accompanying condensed consolidated financial statements contain all adjustments (consisting of normal recurring accruals and adjustments) necessary for fair statement of its financial position, results of operations and cash flows of the Company at the dates and for the periods indicated. Interim results are not necessarily indicative of results for the full fiscal year. The year-end condensed consolidated balance sheet data was derived from audited financial statements but does not include all disclosures required by accounting principles generally accepted in the United States. The unaudited condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and the notes thereto contained in the Company&#8217;s Annual Report on Form 10-K for the year ended December&#160;31, 2020, as filed with the Securities and Exchange Commission (&#8220;SEC&#8221;) on March 18, 2021.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The consolidated financial statements include the accounts of UPL and its wholly owned subsidiary UPI. All material intercompany balances and transactions have been eliminated during consolidation.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has experienced net losses since its inception and has an accumulated deficit of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000248" name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="C_0001668243_20210331" decimals="-5" sign="-" scale="6">382.4</ix:nonFraction> million and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000249" name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="C_0001668243_20201231" decimals="-5" sign="-" scale="6">356.5</ix:nonFraction> million as of March&#160;31, 2021 and December&#160;31, 2020, respectively. The Company expects to incur losses and have negative net cash flows from operating activities as it executes on its strategy including engaging in further research and development activities, particularly conducting non-clinical studies and clinical trials.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The success of the Company depends on the ability to successfully commercialize its technologies to support its operations and strategic plan. Based on management&#8217;s cash flow projections the Company believes that its cash and cash equivalents and marketable securities after the closing of the transaction with RTW Investments (See Note 17 for further discussion) are sufficient to fund the Company&#8217;s planned operations for at least the next 12 months. The Company anticipates that it may need to raise additional capital in the future. There can be no assurances that the Company will be able to secure such additional financing if at all, or at terms that are satisfactory to the Company, and that it will be sufficient to meet its needs. In the event the Company is not successful in obtaining sufficient funding, this could force us to delay, limit, or reduce our product development, commercialization efforts or other operations.</p></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:nonNumeric id="F_000201" name="us-gaap:SignificantAccountingPoliciesTextBlock" contextRef="C_0001668243_20210101_20210331" escape="true" continuedAt="F_000201_dcnt_1624f546-2a85-45ab-9c3f-ee15bb83372b">
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Note 3 &#8211; Significant Accounting Policies</p><ix:nonNumeric id="F_000216" name="us-gaap:ConsolidationPolicyTextBlock" contextRef="C_0001668243_20210101_20210331" escape="true">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Calibri;font-size:10pt;text-transform:none;font-variant: normal;">Principles of Consolidation</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The condensed consolidated financial statements include the accounts of UPL and its subsidiary, UPI. Intercompany balances and transactions have been eliminated during consolidation.</p></ix:nonNumeric><ix:nonNumeric id="F_000217" name="us-gaap:UseOfEstimates" contextRef="C_0001668243_20210101_20210331" escape="true">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Calibri;font-size:10pt;text-transform:none;font-variant: normal;">Use of Estimates</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The<span style="letter-spacing:0.35pt;"> </span>preparation<span style="letter-spacing:0.9pt;"> </span>of<span style="letter-spacing:0.2pt;"> </span>financial<span style="letter-spacing:0.65pt;"> </span>statements<span style="letter-spacing:0.9pt;"> </span>in<span style="letter-spacing:0.2pt;"> </span>conformity<span style="letter-spacing:0.85pt;"> </span>with<span style="letter-spacing:0.35pt;"> U.S. </span>GAAP<span style="letter-spacing:0.5pt;"> </span>requires<span style="letter-spacing:0.65pt;"> </span>man<span style="letter-spacing:-0.1pt;">a</span>gement<span style="letter-spacing:1.05pt;"> </span>to<span style="letter-spacing:0.2pt;"> </span>make<span style="letter-spacing:0.45pt;"> </span>estimates<span style="letter-spacing:0.8pt;"> </span>and<span style="letter-spacing:0.35pt;"> </span>assumptions<span style="letter-spacing:1pt;"> </span>that<span style="letter-spacing:0.35pt;"> </span>affect the<span style="letter-spacing:0.05pt;"> </span>reported<span style="letter-spacing:0.7pt;"> </span>amounts<span style="letter-spacing:0.7pt;"> </span>of<span style="letter-spacing:0.2pt;"> </span>assets<span style="letter-spacing:0.6pt;"> </span>and<span style="letter-spacing:0.35pt;"> </span>liabilities,<span style="letter-spacing:0.75pt;"> </span>the<span style="letter-spacing:0.3pt;"> </span>disclosure<span style="letter-spacing:0.8pt;"> </span>of<span style="letter-spacing:0.2pt;"> </span>cont<span style="letter-spacing:-0.1pt;">i</span>ngent<span style="letter-spacing:0.85pt;"> </span>assets<span style="letter-spacing:0.55pt;"> </span>and<span style="letter-spacing:0.35pt;"> </span>liabilities<span style="letter-spacing:0.7pt;"> </span>at<span style="letter-spacing:0.2pt;"> </span>the<span style="letter-spacing:0.3pt;"> </span>date<span style="letter-spacing:0.4pt;"> </span>of<span style="letter-spacing:0.2pt;"> </span>the<span style="letter-spacing:0.3pt;"> </span>financ<span style="letter-spacing:-0.1pt;">i</span>al<span style="letter-spacing:0.65pt;"> </span>statements<span style="letter-spacing:0.9pt;"> </span>and<span style="letter-spacing:0.35pt;"> </span>the reported<span style="letter-spacing:0.7pt;"> </span>amounts<span style="letter-spacing:0.7pt;"> </span>of<span style="letter-spacing:0.2pt;"> </span>revenues<span style="letter-spacing:0.75pt;"> </span>and<span style="letter-spacing:0.35pt;"> </span>expenses<span style="letter-spacing:0.8pt;"> </span>duri<span style="letter-spacing:-0.1pt;">n</span>g<span style="letter-spacing:0.5pt;"> </span>the<span style="letter-spacing:0.3pt;"> </span>reporting<span style="letter-spacing:0.7pt;"> </span>period.<span style="letter-spacing:0.55pt;"> </span>Actual<span style="letter-spacing:0.5pt;"> </span>results<span style="letter-spacing:0.55pt;"> </span>may<span style="letter-spacing:0.35pt;"> </span>differ<span style="letter-spacing:0.45pt;"> </span>from<span style="letter-spacing:0.4pt;"> </span>those<span style="letter-spacing:0.45pt;"> </span>estimates.<span style="letter-spacing:0.8pt;"> </span>As<span style="letter-spacing:0.25pt;"> </span>applicable<span style="letter-spacing:0.9pt;"> </span>to the unaudited condensed<span style="letter-spacing:0.45pt;"> </span>consolidated<span style="letter-spacing:1pt;"> </span>financi<span style="letter-spacing:-0.1pt;">a</span>l<span style="letter-spacing:0.65pt;"> </span>statements,<span style="letter-spacing:0.95pt;"> </span>the<span style="letter-spacing:0.3pt;"> critical </span>accounting<span style="letter-spacing:0.35pt;"> estimates relate </span>to<span style="letter-spacing:0.2pt;"> </span>the<span style="letter-spacing:0.3pt;"> </span>fair<span style="letter-spacing:0.3pt;"> </span>value<span style="letter-spacing:0.45pt;"> </span>of<span style="letter-spacing:0.2pt;"> </span>share-based<span style="letter-spacing:1pt;"> </span>compensat<span style="letter-spacing:-0.1pt;">i</span>on,<span style="letter-spacing:0.55pt;"> </span>measurement<span style="letter-spacing:0.5pt;"> </span>of<span style="letter-spacing:0.2pt;"> </span>revenue and estimate of uncertain tax positions.</p></ix:nonNumeric><ix:nonNumeric id="F_000218" name="us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" contextRef="C_0001668243_20210101_20210331" escape="true">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Calibri;font-size:10pt;text-transform:none;font-variant: normal;">Functional<span style="letter-spacing:0.9pt;"> </span>Currency</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The<span style="letter-spacing:0.35pt;"> </span>U.S.<span style="letter-spacing:0.4pt;"> </span>dollar<span style="letter-spacing:0.45pt;"> </span>(&#8220;Dollar&#8221;)<span style="letter-spacing:0.7pt;"> </span>is<span style="letter-spacing:0.15pt;"> </span>the<span style="letter-spacing:0.35pt;"> </span>currency<span style="letter-spacing:0.7pt;"> </span>of<span style="letter-spacing:0.2pt;"> </span>the<span style="letter-spacing:0.3pt;"> </span>primary<span style="letter-spacing:0.6pt;"> </span>economic<span style="letter-spacing:0.8pt;"> </span>environment<span style="letter-spacing:1pt;"> </span>in<span style="letter-spacing:0.2pt;"> </span>which<span style="letter-spacing:0.5pt;"> </span>the<span style="letter-spacing:0.3pt;"> </span>operations<span style="letter-spacing:0.85pt;"> </span>of<span style="letter-spacing:0.2pt;"> </span>the<span style="letter-spacing:0.3pt;"> </span>Com<span style="letter-spacing:-0.1pt;">p</span>any<span style="letter-spacing:0.8pt;"> </span>are conducted.<span style="letter-spacing:0.9pt;"> </span>Therefore,<span style="letter-spacing:0.85pt;"> </span>the<span style="letter-spacing:0.3pt;"> </span>functional<span style="letter-spacing:0.8pt;"> </span>currency<span style="letter-spacing:0.7pt;"> </span>of<span style="letter-spacing:0.2pt;"> </span>the<span style="letter-spacing:0.3pt;"> </span>Company<span style="letter-spacing:0.8pt;"> </span>is<span style="letter-spacing:0.15pt;"> </span>the<span style="letter-spacing:0.3pt;"> </span>Dol<span style="letter-spacing:-0.1pt;">l</span>ar.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accordingly,<span style="letter-spacing:1pt;"> </span>transactions<span style="letter-spacing:0.95pt;"> </span>in<span style="letter-spacing:0.2pt;"> </span>currencies<span style="letter-spacing:0.85pt;"> </span>other<span style="letter-spacing:0.45pt;"> </span>than<span style="letter-spacing:0.4pt;"> </span>the<span style="letter-spacing:0.3pt;"> </span>Do<span style="letter-spacing:-0.1pt;">l</span>lar<span style="letter-spacing:0.5pt;"> </span>are<span style="letter-spacing:0.3pt;"> </span>measured<span style="letter-spacing:0.8pt;"> </span>and<span style="letter-spacing:0.35pt;"> </span>recorded<span style="letter-spacing:0.7pt;"> </span>in<span style="letter-spacing:0.2pt;"> </span>the<span style="letter-spacing:0.3pt;"> </span>functional<span style="letter-spacing:0.8pt;"> </span>currency<span style="letter-spacing:0.7pt;"> </span>usi<span style="letter-spacing:-0.1pt;">n</span>g<span style="letter-spacing:0.45pt;"> </span>the<span style="letter-spacing:0.3pt;"> </span>exchange<span style="letter-spacing:0.8pt;"> </span>rate<span style="letter-spacing:0.35pt;"> </span>in effect<span style="letter-spacing:0.45pt;"> </span>at<span style="letter-spacing:0.2pt;"> </span>the<span style="letter-spacing:0.3pt;"> </span>date<span style="letter-spacing:0.4pt;"> </span>of<span style="letter-spacing:0.2pt;"> </span>the<span style="letter-spacing:0.35pt;"> </span>transaction.<span style="letter-spacing:0.95pt;"> </span>At<span style="letter-spacing:0.2pt;"> </span>the<span style="letter-spacing:0.3pt;"> </span>balance<span style="letter-spacing:0.65pt;"> </span>sheet<span style="letter-spacing:0.45pt;"> </span>date,<span style="letter-spacing:0.45pt;"> </span>monetary<span style="letter-spacing:0.75pt;"> </span>assets<span style="letter-spacing:0.55pt;"> </span>and<span style="letter-spacing:0.35pt;"> </span>liab<span style="letter-spacing:-0.1pt;">i</span>lities<span style="letter-spacing:0.7pt;"> </span>that<span style="letter-spacing:0.35pt;"> </span>are<span style="letter-spacing:0.3pt;"> </span>denominated<span style="letter-spacing:1.05pt;"> </span>in<span style="letter-spacing:0.2pt;"> </span>currencies<span style="letter-spacing:0.85pt;"> </span>other<span style="letter-spacing:0.45pt;"> </span>than the<span style="letter-spacing:0.05pt;"> </span>Dollar<span style="letter-spacing:0.5pt;"> </span>are<span style="letter-spacing:0.3pt;"> </span>measured<span style="letter-spacing:0.8pt;"> </span>using<span style="letter-spacing:0.45pt;"> </span>the<span style="letter-spacing:0.3pt;"> </span>official<span style="letter-spacing:0.55pt;"> </span>exch<span style="letter-spacing:-0.1pt;">a</span>nge<span style="letter-spacing:0.8pt;"> </span>rate<span style="letter-spacing:0.35pt;"> </span>at<span style="letter-spacing:0.2pt;"> </span>the<span style="letter-spacing:0.3pt;"> </span>balance<span style="letter-spacing:0.65pt;"> </span>sheet<span style="letter-spacing:0.45pt;"> </span>date.<span style="letter-spacing:0.45pt;"> </span>The<span style="letter-spacing:0.35pt;"> </span>effects<span style="letter-spacing:0.55pt;"> </span>of<span style="letter-spacing:0.2pt;"> </span>foreign<span style="letter-spacing:0.55pt;"> </span>currency<span style="letter-spacing:0.8pt;"> </span>re-measurements<span style="letter-spacing:1.45pt;"> </span>are recorded<span style="letter-spacing:0.7pt;"> </span>in<span style="letter-spacing:0.2pt;"> </span>the<span style="letter-spacing:0.3pt;"> condensed </span>consolidated<span style="letter-spacing:1pt;"> </span>statements<span style="letter-spacing:0.9pt;"> </span>of<span style="letter-spacing:0.2pt;"> </span>operations<span style="letter-spacing:0.85pt;"> </span>as<span style="letter-spacing:0.25pt;"> </span>&#8220;Interest and other income, net.&#8221;</p></ix:nonNumeric><ix:nonNumeric id="F_000219" name="urgn:CashAndCashEquivalentsAndMarketableSecuritiesPolicyPolicyTextBlock" contextRef="C_0001668243_20210101_20210331" escape="true">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Calibri;font-size:10pt;text-transform:none;font-variant: normal;">Cash and Cash Equivalents&#59; <span style="color:#000000;">Marketable Securities</span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company considers all highly liquid investments with an original maturity of three months or less when purchased to be cash equivalents. Cash and cash equivalents consist primarily of money market funds and bank money market accounts and are stated at cost, which approximates fair value. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash and cash equivalents and marketable securities totaled $<ix:nonFraction unitRef="U_iso4217USD" id="F_000250" name="urgn:CashCashEquivalentsAndMarketableSecurities" contextRef="C_0001668243_20210331" decimals="-5" scale="6">75.9</ix:nonFraction> million as of March&#160;31, 2021. The Company classifies its marketable securities as available-for-sale in accordance with the <span style="letter-spacing:-0.2pt;">Financial Accounting Standards Board (&#8220;</span>FASB&#8221;) Accounting Standards Codification (&#8220;ASC&#8221;) Topic 320, &#8220;Investments &#8212; Debt and Equity Securities&#8221;. Available-for-sale debt securities are carried at fair value with unrealized gains and losses reported in other comprehensive income/loss within shareholders&#8217; equity. Realized gains and losses are recorded as a component of interest and other income (expense), net. The cost of securities sold is based on the specific-identification method. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Short-term investments are valued using models or other valuation methodologies that use Level 2 inputs. These models are primarily industry-standard models that consider various assumptions, including time value, yield curve, volatility factors, default rates, current market and contractual prices for the underlying financial instruments, as well as other relevant economic measures. The majority of these assumptions are observable in the marketplace, can be derived from observable data or are supported by observable levels at which transactions are executed in the marketplace.&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For individual debt securities classified as available-for-sale securities where there has been a decline in fair value below amortized cost, the Company determines whether the decline resulted from a credit loss or other factors. The Company records impairment relating to credit losses through an allowance for credit losses, limited by the amount that the fair value is less than the amortized cost basis. Impairment that has not been recorded through an allowance for credit losses is recorded through other comprehensive income, net of applicable taxes.</p></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p></ix:nonNumeric>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000201_dcnt_1624f546-2a85-45ab-9c3f-ee15bb83372b" continuedAt="F_000201_dcnt_d2fba547-bbc7-4bab-be86-fa35bdf75b54"><ix:nonNumeric id="F_000220" name="us-gaap:ConcentrationRiskCreditRisk" contextRef="C_0001668243_20210101_20210331" escape="true" continuedAt="F_000220_cnt_1">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Calibri;font-size:10pt;text-transform:none;font-variant: normal;">Concentration of Credit Risk</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial instruments, which potentially subject the Company to significant concentrations of credit risk, consist primarily of cash and cash equivalents and marketable securities. The primary objectives for the Company<span style="color:#000000;">&#8217;</span>s investment portfolio are the preservation of capital and the maintenance of liquidity. The Company does not enter into any investment transaction for trading or speculative purposes.</p></ix:nonNumeric><ix:continuation id="F_000220_cnt_1">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company<span style="color:#000000;">&#8217;</span>s investment policy limits investments to certain types of instruments such as certificates of deposit, money market instruments, obligations issued by the U.S. government and U.S. government agencies as well as corporate debt securities, and places restrictions on maturities and concentration by type and issuer. The Company maintains cash balances in excess of amounts insured by the Federal Deposit Insurance Corporation and concentrated within a limited number of financial institutions. The accounts are monitored by management to mitigate the risk.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s product sales are recognized through the Company's arrangement with a single customer, a third-party national specialty distributor. The Company assesses the need for an allowance for doubtful accounts primarily based on creditworthiness, historical payment experience and general economic conditions. The Company has not experienced any credit losses related to this customer and has not currently recognized any allowance for doubtful accounts.</p></ix:continuation><ix:nonNumeric id="F_000222" name="us-gaap:IncomeTaxPolicyTextBlock" contextRef="C_0001668243_20210101_20210331" escape="true">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Calibri;font-size:10pt;text-transform:none;font-variant: normal;">Income Taxes</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company provides for income taxes based on pretax income, if any, and applicable tax rates available in the various jurisdictions in which it operates, including Israel and the U.S. Deferred<span style="letter-spacing:0.6pt;"> </span>taxes<span style="letter-spacing:0.45pt;"> </span>are<span style="letter-spacing:0.3pt;"> </span>computed<span style="letter-spacing:0.8pt;"> </span>using<span style="letter-spacing:0.45pt;"> </span>the<span style="letter-spacing:0.3pt;"> </span>asset<span style="letter-spacing:0.45pt;"> </span>and<span style="letter-spacing:0.35pt;"> </span>liabi<span style="letter-spacing:-0.1pt;">l</span>ity<span style="letter-spacing:0.65pt;"> </span>method.<span style="letter-spacing:0.65pt;"> </span>Under<span style="letter-spacing:0.5pt;"> </span>the<span style="letter-spacing:0.3pt;"> </span>asset<span style="letter-spacing:0.45pt;"> </span>and<span style="letter-spacing:0.35pt;"> </span>liability<span style="letter-spacing:0.55pt;"> </span>method,<span style="letter-spacing:0.65pt;"> </span>deferred<span style="letter-spacing:0.7pt;"> </span>income<span style="letter-spacing:0.6pt;"> </span>tax<span style="letter-spacing:0.3pt;"> </span>assets<span style="letter-spacing:0.55pt;"> </span>and liabilities<span style="letter-spacing:0.7pt;"> </span>are<span style="letter-spacing:0.3pt;"> </span>determined<span style="letter-spacing:0.9pt;"> </span>bas<span style="letter-spacing:-0.1pt;">e</span>d<span style="letter-spacing:0.5pt;"> </span>on<span style="letter-spacing:0.25pt;"> </span>the<span style="letter-spacing:0.3pt;"> </span>differences<span style="letter-spacing:0.9pt;"> </span>between<span style="letter-spacing:0.7pt;"> </span>the<span style="letter-spacing:0.3pt;"> </span>financial<span style="letter-spacing:0.65pt;"> </span>reporti<span style="letter-spacing:-0.1pt;">n</span>g<span style="letter-spacing:0.7pt;"> </span>and<span style="letter-spacing:0.35pt;"> </span>tax bases<span style="letter-spacing:0.5pt;"> </span>of<span style="letter-spacing:0.2pt;"> </span>assets<span style="letter-spacing:0.55pt;"> </span>and<span style="letter-spacing:0.35pt;"> </span>liabilities<span style="letter-spacing:0.7pt;"> </span>and<span style="letter-spacing:0.35pt;"> </span>are<span style="letter-spacing:0.3pt;"> </span>mea<span style="letter-spacing:-0.1pt;">s</span>ured<span style="letter-spacing:0.8pt;"> </span>using<span style="letter-spacing:0.45pt;"> </span>the<span style="letter-spacing:0.3pt;"> </span>currently<span style="letter-spacing:0.7pt;"> </span>enacted<span style="letter-spacing:0.65pt;"> </span>tax<span style="letter-spacing:0.3pt;"> </span>rates<span style="letter-spacing:0.45pt;"> </span>and<span style="letter-spacing:0.35pt;"> </span>laws.<span style="letter-spacing:0.45pt;"> </span>A<span style="letter-spacing:0.15pt;"> </span>valuation<span style="letter-spacing:0.75pt;"> </span><span style="letter-spacing:-0.1pt;">a</span>llowance<span style="letter-spacing:0.8pt;"> </span>is<span style="letter-spacing:0.15pt;"> </span>recognized<span style="letter-spacing:0.9pt;"> </span>to<span style="letter-spacing:0.2pt;"> </span>the extent<span style="letter-spacing:0.5pt;"> </span>that<span style="letter-spacing:0.35pt;"> </span>it<span style="letter-spacing:0.15pt;"> </span>is<span style="letter-spacing:0.15pt;"> </span>more<span style="letter-spacing:0.45pt;"> </span>likely<span style="letter-spacing:0.45pt;"> </span>than<span style="letter-spacing:0.4pt;"> </span>not<span style="letter-spacing:0.3pt;"> </span>that<span style="letter-spacing:0.35pt;"> </span>the<span style="letter-spacing:0.35pt;"> </span>deferred<span style="letter-spacing:0.7pt;"> </span>taxes<span style="letter-spacing:0.45pt;"> </span>will<span style="letter-spacing:0.3pt;"> </span>not<span style="letter-spacing:0.3pt;"> </span>be<span style="letter-spacing:0.25pt;"> </span>realized<span style="letter-spacing:0.65pt;"> </span>in<span style="letter-spacing:0.2pt;"> </span>the<span style="letter-spacing:0.3pt;"> </span>foresee<span style="letter-spacing:-0.1pt;">a</span>ble<span style="letter-spacing:0.95pt;"> </span>future.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The<span style="letter-spacing:0.35pt;"> </span>Company<span style="letter-spacing:0.8pt;"> </span>follows<span style="letter-spacing:0.55pt;"> </span>a<span style="letter-spacing:0.3pt;"> </span>two-step<span style="letter-spacing:0.8pt;"> </span>approach<span style="letter-spacing:0.75pt;"> </span>in<span style="letter-spacing:0.2pt;"> </span>recognizing<span style="letter-spacing:0.9pt;"> </span>a<span style="letter-spacing:-0.1pt;">n</span>d<span style="letter-spacing:0.35pt;"> </span>measuring<span style="letter-spacing:0.85pt;"> </span>uncertain<span style="letter-spacing:0.75pt;"> </span>tax<span style="letter-spacing:0.3pt;"> </span>positions.<span style="letter-spacing:0.75pt;"> </span>After concluding that a particular filing position can be recognized (i.e., has a more-likely-than-not chance of being sustained), ASC 740-10-30-7 requires that the amount of benefit recognized be measured using a methodology based on the concept of cumulative probability. Under this methodology, the amount of benefit recorded represents the largest amount of tax benefit that is greater than 50% likely to be realized upon settlement with a taxing authority that has full knowledge of all relevant information. &#160;See Note 14 for further discussion related to income taxes.</p></ix:nonNumeric><ix:nonNumeric id="F_000223" name="us-gaap:InventoryPolicyTextBlock" contextRef="C_0001668243_20210101_20210331" escape="true">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Calibri;font-size:10pt;text-transform:none;font-variant: normal;">Inventory</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company capitalizes inventory costs related to products to be sold in the ordinary course of business. The Company makes a determination of capitalizing inventory costs for a product based on, among other factors, status of regulatory approval, information regarding safety, efficacy and expectations relating to commercial sales and recoverability of costs.&#160;For <span style="font-style:italic;">Jelmyto</span>, the Company commenced capitalization of inventory at the receipt of FDA approval.</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.67%;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company values its inventory at the lower of cost or net realizable value.&#160;The Company measures inventory approximating actual cost under a first-in, first-out basis. The Company assesses recoverability of inventory each reporting period to determine any write down to net realizable value resulting from excess or obsolete inventories<span style="font-style:italic;">.</span></p></ix:nonNumeric><ix:nonNumeric id="F_000224" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" contextRef="C_0001668243_20210101_20210331" escape="true" continuedAt="F_000224_dcnt_f49ae3d2-253b-4b28-a40f-fa45c624f826">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Calibri;font-size:10pt;text-transform:none;font-variant: normal;">Property and Equipment</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment are recorded at historical cost, net of accumulated depreciation, amortization and, if applicable, impairment charges. The Company reviews its property and equipment assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. </p></ix:nonNumeric></ix:continuation>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000201_dcnt_d2fba547-bbc7-4bab-be86-fa35bdf75b54" continuedAt="F_000201_dcnt_044a1985-6cd5-4b59-9bd1-db1355b5c403"><ix:continuation id="F_000224_dcnt_f49ae3d2-253b-4b28-a40f-fa45c624f826"><ix:nonNumeric id="F_000231" name="urgn:PropertyPlantAndEquipmentUsefulLifeTableTextBlock" contextRef="C_0001668243_20210101_20210331" escape="true">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment are depreciated over the following useful lives (in years):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:60%;">
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.02%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Useful Lives</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Computers and software</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000251">3</span></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Laboratory equipment</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3-6.5</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Furniture</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5-16.5</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Manufacturing equipment</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000252">2</span></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Leasehold improvements are amortized on a straight-line basis over the shorter of their estimated useful lives or lease terms. See Note 8 for further discussion regarding property and equipment.</p></ix:continuation><ix:nonNumeric id="F_000225" name="us-gaap:LesseeLeasesPolicyTextBlock" contextRef="C_0001668243_20210101_20210331" escape="true">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Calibri;font-size:10pt;text-transform:none;font-variant: normal;">Leases</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is a lessee in several noncancelable operating leases, primarily for office space, office equipment and vehicles. The Company currently has no finance leases.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company accounts for leases in accordance with ASC Topic 842, &#8220;Leases&#8221;<span style="font-style:italic;">.</span> The Company determines if an arrangement is a lease at inception. Right-of-use (&#8220;ROU&#8221;) assets and operating lease liabilities are recognized based on the present value of lease payments over the lease term as of the commencement date. Operating lease ROU assets are presented as operating lease right of use assets on the condensed consolidated balance sheets. The current portion of operating lease liabilities is included in other current liabilities and the long-term portion is presented separately as operating lease liabilities on the condensed consolidated balance sheets.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lease expense is recognized on a straight-line basis for operating leases. Variable lease payments associated with the Company&#8217;s leases are recognized when the event, activity, or circumstance in the lease agreement on which those payments are assessed occurs. Variable lease payments are presented as operating expense on the condensed consolidated statements of operations in the same line item as expense arising from fixed lease payments.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s lease terms may include options to extend the lease. The lease extensions are included in the measurement of the right of use asset and lease liability when it is reasonably certain that it will exercise that option.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Because most of the Company&#8217;s leases do not provide an implicit rate of return, an incremental borrowing rate is used based on the information available at the commencement date in determining the present value of lease payments on an individual lease basis. The Company&#8217;s incremental borrowing rate for a lease is the rate of interest it would have to pay on a collateralized basis to borrow an amount equal to the lease payments under similar terms. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ROU assets for operating leases are periodically reviewed for impairment losses under ASC 360-10, &#8220;Property, Plant, and Equipment&#8221;, to determine whether an ROU asset is impaired, and if so, the amount of the impairment loss to recognize.</p></ix:nonNumeric><ix:nonNumeric id="F_000226" name="us-gaap:RevenueRecognitionPolicyTextBlock" contextRef="C_0001668243_20210101_20210331" escape="true">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Calibri;font-size:10pt;text-transform:none;font-variant: normal;">Revenues</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Product sales from <span style="font-style:italic;">Jelmyto</span> are recognized as revenue under ASC 606 at the point in time that control of the product has been transferred to the customer, generally at the point the product has been delivered to the treating physician. All product sales of <span style="font-style:italic;">Jelmyto</span> are recognized through the Company's arrangement with a single customer, a third-party national specialty distributor. Net revenues recognized include management&#8217;s estimate of returns, consideration paid to the customer, chargebacks relating to differences between the wholesale acquisition cost and the contracted price offered to the end consumer, chargebacks relating to 340b drug pricing programs, Medicaid drug rebate programs, and the Company&#8217;s copay assistance program, which are estimated based on industry benchmarking studies as well as the Company&#8217;s historical experience.</p></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&#160;</p></ix:continuation>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000201_dcnt_044a1985-6cd5-4b59-9bd1-db1355b5c403"><ix:nonNumeric id="F_000227" name="us-gaap:ResearchAndDevelopmentExpensePolicy" contextRef="C_0001668243_20210101_20210331" escape="true">
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Calibri;font-size:10pt;text-transform:none;font-variant: normal;">Research and Development Expenses </p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development costs are expensed as incurred and consist primarily of the cost of salaries, share-based compensation expenses, payroll taxes and other employee benefits, subcontractors and materials used for research and development activities, including nonclinical studies, clinical trials, manufacturing costs and professional services. The costs of services performed by others in connection with the research and development activities of the Company, including research and development conducted by others on behalf of the Company, shall be included in research and development costs and expensed as the contracted work is performed. The Company accrues for costs incurred as the services are being provided by monitoring the status of the trial or project and the invoices received from its external service providers. The Company adjusts its accrual as actual costs become known. Where contingent milestone payments are due to third parties under research and development arrangements or license agreements, the milestone payment obligations are expensed when the milestone results are achieved.</p></ix:nonNumeric><ix:nonNumeric id="F_000228" name="us-gaap:SellingGeneralAndAdministrativeExpensesPolicyTextBlock" contextRef="C_0001668243_20210101_20210331" escape="true">
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Calibri;font-size:10pt;text-transform:none;font-variant: normal;">Selling<span style="font-weight:normal;font-style:normal;"> </span><span style="color:#000000;">General and Administrative Expenses</span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Selling, general and administrative expenses consist primarily of personnel costs (including share-based compensation related to directors, employees and consultants). Other significant costs include commercial, medical affairs, external professional service costs, facility costs, accounting and audit services, legal services, and other consulting fees. Selling, general and administrative costs are expensed as incurred, and the Company accrues for services provided by third parties related to the above expenses by monitoring the status of services provided and receiving estimates from its service providers and adjusting its accruals as actual costs become known.</p></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p><ix:nonNumeric id="F_000229" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansDirectorPolicy" contextRef="C_0001668243_20210101_20210331" escape="true">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Calibri;font-size:10pt;text-transform:none;font-variant: normal;">Share-Based Compensation</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Share-based compensation cost is measured at the grant date based on the fair value of the award and is recognized as expense over the required service period, which is equal to the vesting period. The fair value of options is determined using the Black-Scholes option-pricing model. The fair value of a restricted stock unit (&#8220;RSU&#8221;) equaled the closing price of the Company&#8217;s ordinary shares on the grant date. The Company accounts for forfeitures as they occur in accordance with ASC Topic 718, &#8220;Compensation&#8212;Stock Compensation&#8221;.<span style="letter-spacing:0.75pt;"> </span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The<span style="letter-spacing:0.35pt;"> </span>Company<span style="letter-spacing:0.8pt;"> </span>elected<span style="letter-spacing:0.6pt;"> </span>to<span style="letter-spacing:0.2pt;"> </span>recognize<span style="letter-spacing:0.8pt;"> </span>compen<span style="letter-spacing:-0.1pt;">s</span>ation<span style="letter-spacing:1.1pt;"> </span>costs<span style="letter-spacing:0.45pt;"> </span>for<span style="letter-spacing:0.25pt;"> </span>awards<span style="letter-spacing:0.6pt;"> </span>conditioned<span style="letter-spacing:0.9pt;"> </span>only<span style="letter-spacing:0.35pt;"> </span>on<span style="letter-spacing:0.25pt;"> </span>conti<span style="letter-spacing:-0.1pt;">n</span>ued<span style="letter-spacing:0.8pt;"> </span>service<span style="letter-spacing:0.6pt;"> </span>that<span style="letter-spacing:0.35pt;"> </span>have<span style="letter-spacing:0.4pt;"> </span>a<span style="letter-spacing:0.15pt;"> </span>graded<span style="letter-spacing:0.6pt;"> </span>vesting<span style="letter-spacing:0.6pt;"> </span>schedule<span style="letter-spacing:0.05pt;"> </span>using<span style="letter-spacing:0.45pt;"> </span>the<span style="letter-spacing:0.3pt;"> </span>straight-line<span style="letter-spacing:0.95pt;"> </span>method<span style="letter-spacing:0.55pt;"> </span>and<span style="letter-spacing:0.35pt;"> </span>to<span style="letter-spacing:0.2pt;"> </span>value<span style="letter-spacing:0.45pt;"> </span>the<span style="letter-spacing:0.3pt;"> </span>awards<span style="letter-spacing:0.6pt;"> </span>based<span style="letter-spacing:0.5pt;"> </span>on<span style="letter-spacing:0.25pt;"> </span>the<span style="letter-spacing:0.3pt;"> </span>sin<span style="letter-spacing:-0.1pt;">g</span>le-option<span style="letter-spacing:1pt;"> </span>award<span style="letter-spacing:0.5pt;"> </span>approach.<span style="letter-spacing:0.8pt;"> </span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&#160;</p></ix:nonNumeric><ix:nonNumeric id="F_000230" name="us-gaap:EarningsPerSharePolicyTextBlock" contextRef="C_0001668243_20210101_20210331" escape="true">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Calibri;font-size:10pt;text-transform:none;font-variant: normal;">Net Loss per Ordinary Share</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Basic net loss per share is computed by dividing the net loss attributable to ordinary shareholders by the weighted-average number of ordinary shares outstanding. Diluted net loss per share is computed similarly to basic net loss per share except that the denominator is increased to include the number of additional ordinary shares that would have been outstanding if the potential ordinary shares had been issued and if the additional ordinary shares were dilutive. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For all periods presented, potentially dilutive securities are excluded from the computation of fully diluted loss per share as their effect is anti-dilutive.</p></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></ix:continuation>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:nonNumeric id="F_000202" name="urgn:OtherFinancialInformationTextBlock" contextRef="C_0001668243_20210101_20210331" escape="true">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Note 4 &#8211; Other Financial Information</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Calibri;font-size:10pt;text-transform:none;font-variant: normal;">Accounts Payable and Accrued Expenses</p><ix:nonNumeric id="F_000232" name="us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" contextRef="C_0001668243_20210101_20210331" escape="true">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accounts payable and accrued expenses consist of the following as of March&#160;31, 2021 and December&#160;31, 2020 (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:70%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.74%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">March&#160;31, 2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.74%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31, 2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accounts payable</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.74%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000257" name="us-gaap:AccountsPayableCurrent" contextRef="C_0001668243_20210331" decimals="-3" format="ixt:numdotdecimal" scale="3">6,096</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.74%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000258" name="us-gaap:AccountsPayableCurrent" contextRef="C_0001668243_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">3,271</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued sales reserves</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.74%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000259" name="urgn:AccruedSalesReserves" contextRef="C_0001668243_20210331" decimals="-3" scale="3">449</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.74%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000260" name="urgn:AccruedSalesReserves" contextRef="C_0001668243_20201231" decimals="-3" scale="3">382</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued clinical expenses</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.74%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000261" name="urgn:AccruedClinicalExpensesCurrent" contextRef="C_0001668243_20210331" decimals="-3" scale="3">554</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.74%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000262" name="urgn:AccruedClinicalExpensesCurrent" contextRef="C_0001668243_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,359</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued research and development costs</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.74%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000263" name="urgn:AccruedResearchAndDevelopmentExpenseCurrent" contextRef="C_0001668243_20210331" decimals="-3" scale="3">862</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.74%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000264" name="urgn:AccruedResearchAndDevelopmentExpenseCurrent" contextRef="C_0001668243_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,356</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued selling, general and administrative expenses</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.74%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000265" name="urgn:AccruedSellingGeneralAndAdministrativeExpenseCurrent" contextRef="C_0001668243_20210331" decimals="-3" format="ixt:numdotdecimal" scale="3">1,309</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.74%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000266" name="urgn:AccruedSellingGeneralAndAdministrativeExpenseCurrent" contextRef="C_0001668243_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,440</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued other expense</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.74%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000267" name="us-gaap:OtherAccruedLiabilitiesCurrent" contextRef="C_0001668243_20210331" decimals="-3" format="ixt:numdotdecimal" scale="3">1,288</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.74%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000268" name="us-gaap:OtherAccruedLiabilitiesCurrent" contextRef="C_0001668243_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,215</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total accounts payable and accrued expenses</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.74%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000269" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" contextRef="C_0001668243_20210331" decimals="-3" format="ixt:numdotdecimal" scale="3">10,558</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.74%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000270" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" contextRef="C_0001668243_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">10,023</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Calibri;font-size:10pt;text-transform:none;font-variant: normal;">Interest and Other Income (Expenses), Net</p><ix:nonNumeric id="F_000233" name="us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock" contextRef="C_0001668243_20210101_20210331" escape="true">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest and other income (expenses) consisted of the following as of March&#160;31, 2021 and 2020 (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:70%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.12%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended March&#160;31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest income</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.74%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000271" name="us-gaap:InvestmentIncomeInterest" contextRef="C_0001668243_20210101_20210331" decimals="-3" scale="3">167</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.74%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000272" name="us-gaap:InvestmentIncomeInterest" contextRef="C_0001668243_20200101_20200331" decimals="-3" scale="3">811</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other finance income(expenses)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.74%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000273" name="urgn:OtherFinanceExpensesIncome" contextRef="C_0001668243_20210101_20210331" decimals="-3" scale="3">12</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.74%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000274" name="urgn:OtherFinanceExpensesIncome" contextRef="C_0001668243_20200101_20200331" decimals="-3" sign="-" scale="3">43</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total interest and other income</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.74%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000275" name="urgn:FinanceIncomeExpenseNet" contextRef="C_0001668243_20210101_20210331" decimals="-3" scale="3">179</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.74%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000276" name="urgn:FinanceIncomeExpenseNet" contextRef="C_0001668243_20200101_20200331" decimals="-3" scale="3">768</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div></ix:nonNumeric></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p><ix:nonNumeric id="F_000203" name="us-gaap:InventoryDisclosureTextBlock" contextRef="C_0001668243_20210101_20210331" escape="true">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:4pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Note 5 &#8211; Inventories</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:12pt;">&#160;</p><ix:nonNumeric id="F_000234" name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock" contextRef="C_0001668243_20210101_20210331" escape="true">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inventories consist of the following as of March&#160;31, 2021 and December&#160;31, 2020 (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:70%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:65.18%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.76%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.62%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">March&#160;31, 2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.76%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.62%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31, 2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Raw materials</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.62%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000277" name="us-gaap:InventoryRawMaterials" contextRef="C_0001668243_20210331" decimals="-3" format="ixt:numdotdecimal" scale="3">2,443</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.62%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000278" name="us-gaap:InventoryRawMaterials" contextRef="C_0001668243_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,051</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:65.18%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Finished goods</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.76%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.62%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000279" name="us-gaap:InventoryFinishedGoods" contextRef="C_0001668243_20210331" decimals="-3" scale="3">888</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.76%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.62%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000280" name="us-gaap:InventoryFinishedGoods" contextRef="C_0001668243_20201231" decimals="-3" scale="3">913</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:65.18%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total inventories</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.76%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.62%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000281" name="us-gaap:InventoryNet" contextRef="C_0001668243_20210331" decimals="-3" format="ixt:numdotdecimal" scale="3">3,331</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.76%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.62%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000282" name="us-gaap:InventoryNet" contextRef="C_0001668243_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,964</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p></ix:nonNumeric><ix:nonNumeric id="F_000204" name="us-gaap:FairValueDisclosuresTextBlock" contextRef="C_0001668243_20210101_20210331" escape="true" continuedAt="F_000204_dcnt_71218850-7569-4241-9a3e-6600e99d399e">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Note 6 &#8211; Fair Value Measurements</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company follows authoritative accounting guidance, which among other things, defines fair value, establishes a consistent framework for measuring fair value and expands disclosure for each major asset and liability category measured at fair value on either a recurring or nonrecurring basis. Fair value is an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As a basis for considering such assumptions, a three-tier fair value hierarchy has been established, which prioritizes the inputs used in measuring fair value as follows:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level 1:</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:10pt;">Observable inputs such as quoted prices (unadjusted) in active markets for identical assets or liabilities.</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level 2:</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:10pt;">Inputs other than quoted prices that are observable for the asset or liability, either directly or indirectly. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active.</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level 3:</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:10pt;">Unobservable inputs that reflect the reporting entity<span style="color:#000000;">&#8217;</span>s own assumptions.</p></td></tr></table></div></ix:nonNumeric>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000204_dcnt_71218850-7569-4241-9a3e-6600e99d399e">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The carrying amounts of the Company<span style="color:#000000;">&#8217;</span>s other current assets, accounts payable and accrued liabilities are generally considered to be representative of their fair value because of the short-term nature of these instruments. <ix:nonFraction unitRef="U_iso4217USD" id="F_000283" name="us-gaap:FairValueAssetsLevel1ToLevel2TransfersAmount" contextRef="C_0001668243_20210331" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction unitRef="U_iso4217USD" id="F_000284" name="us-gaap:FairValueAssetsLevel2ToLevel1TransfersAmount" contextRef="C_0001668243_20210331" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction unitRef="U_iso4217USD" id="F_000286" name="us-gaap:FairValueLiabilitiesLevel2ToLevel1TransfersAmount" contextRef="C_0001668243_20210331" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction unitRef="U_iso4217USD" id="F_000287" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3" contextRef="C_0001668243_20210101_20210331" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction unitRef="U_iso4217USD" id="F_000288" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3" contextRef="C_0001668243_20210101_20210331" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction unitRef="U_iso4217USD" id="F_000289" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3" contextRef="C_0001668243_20210101_20210331" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction unitRef="U_iso4217USD" id="F_000290" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3" contextRef="C_0001668243_20210101_20210331" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction unitRef="U_iso4217USD" id="F_000285" name="us-gaap:FairValueLiabilitiesLevel1ToLevel2TransfersAmount" contextRef="C_0001668243_20210331" decimals="INF" format="ixt-sec:numwordsen">No</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> transfers between levels have occurred during the periods presented.</p><ix:nonNumeric id="F_000235" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" contextRef="C_0001668243_20210101_20210331" escape="true">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Assets and liabilities measured at fair value on a recurring basis based on Level 1 and Level 2 fair value measurement criteria as of March&#160;31, 2021 are as follows (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.78%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.04%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Fair Value Measurements Using</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Quoted&#160;Prices</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Significant</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">in Active</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Balance&#160;as&#160;of</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Markets for</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Observable</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">March&#160;31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Identical&#160;Assets</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Inputs</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(Level 1)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(Level 2)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Marketable securities:</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US government</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000291" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="C_0001668243_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapFinancialInstrumentAxis_us-gaapUSGovernmentAgenciesDebtSecuritiesMember_20210331" decimals="-3" format="ixt:numdotdecimal" scale="3">20,572</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000292" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="C_0001668243_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapFinancialInstrumentAxis_us-gaapUSGovernmentAgenciesDebtSecuritiesMember_20210331" decimals="-3" format="ixt:numdotdecimal" scale="3">20,572</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate bonds</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000293" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="C_0001668243_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapFinancialInstrumentAxis_us-gaapCorporateBondSecuritiesMember_20210331" decimals="-3" format="ixt:numdotdecimal" scale="3">14,845</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000294" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="C_0001668243_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapFinancialInstrumentAxis_us-gaapCorporateBondSecuritiesMember_20210331" decimals="-3" format="ixt:numdotdecimal" scale="3">14,845</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money market funds<sup style="font-size:85%;line-height:120%;vertical-align:top">(1)</sup></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000295" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="C_0001668243_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapFinancialInstrumentAxis_us-gaapMoneyMarketFundsMember_20210331" decimals="-3" format="ixt:numdotdecimal" scale="3">30,413</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000296" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="C_0001668243_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapFinancialInstrumentAxis_us-gaapMoneyMarketFundsMember_20210331" decimals="-3" format="ixt:numdotdecimal" scale="3">30,413</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total marketable securities</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000297" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="C_0001668243_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20210331" decimals="-3" format="ixt:numdotdecimal" scale="3">65,830</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000298" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="C_0001668243_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20210331" decimals="-3" format="ixt:numdotdecimal" scale="3">50,985</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000299" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="C_0001668243_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20210331" decimals="-3" format="ixt:numdotdecimal" scale="3">14,845</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:3.33%;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160; </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.8%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%;line-height:120%;vertical-align:top">(1)</sup></span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:10pt;"><span style="color:#000000;">Included within cash and cash equivalents on the condensed consolidated balance sheets.</span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.13%;text-indent:0%;font-family:Times New Roman;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:2pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Assets and liabilities measured at fair value on a recurring basis based on Level 1 and Level 2 fair value measurement criteria as of December&#160;31, 2020 are as follows (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.78%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.04%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Fair&#160;Value&#160;Measurements&#160;Using</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Quoted&#160;Prices</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Significant</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">in Active</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Balance&#160;as&#160;of</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Markets for</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Observable</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Identical&#160;Assets</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Inputs</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(Level 1)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(Level 2)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Marketable securities:</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US government</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000300" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="C_0001668243_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapFinancialInstrumentAxis_us-gaapUSGovernmentAgenciesDebtSecuritiesMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">29,186</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000301" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="C_0001668243_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapFinancialInstrumentAxis_us-gaapUSGovernmentAgenciesDebtSecuritiesMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">29,186</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate bonds</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000302" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="C_0001668243_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapFinancialInstrumentAxis_us-gaapCorporateBondSecuritiesMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">21,861</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000303" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="C_0001668243_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapFinancialInstrumentAxis_us-gaapCorporateBondSecuritiesMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">21,861</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money market funds<sup style="font-size:85%;line-height:120%;vertical-align:top">(1)</sup></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000304" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="C_0001668243_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapFinancialInstrumentAxis_us-gaapMoneyMarketFundsMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">39,744</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000305" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="C_0001668243_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapFinancialInstrumentAxis_us-gaapMoneyMarketFundsMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">39,744</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total marketable securities</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000306" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="C_0001668243_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">90,791</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000307" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="C_0001668243_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">68,930</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000308" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="C_0001668243_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">21,861</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.8%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%;line-height:120%;vertical-align:top">(1)</sup></span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:10pt;"><span style="color:#000000;">Included within cash and cash equivalents on the condensed consolidated balance sheets.</span></p></td></tr></table></div></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company<span style="color:#000000;">&#8217;</span>s in money market funds are valued based on publicly available quoted market prices for identical securities as of March&#160;31, 2021 and December&#160;31, 2020. </p></ix:continuation>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:6pt;">&#160;</p><ix:nonNumeric id="F_000205" name="urgn:MarketableSecuritiesDisclosureTextBlock" contextRef="C_0001668243_20210101_20210331" escape="true" continuedAt="F_000205_dcnt_224db7b5-7f9a-4544-8f36-f6f9fc9114c9">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Note 7 &#8211; Marketable Securities</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p><ix:nonNumeric id="F_000236" name="us-gaap:MarketableSecuritiesTextBlock" contextRef="C_0001668243_20210101_20210331" escape="true" continuedAt="F_000236_cnt_1">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes the Company&#8217;s marketable securities as of March&#160;31, 2021 (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:39.4%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.58%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Amortized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Cost Basis</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.58%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Gains</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.58%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Losses</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.58%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Fair Value</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Marketable securities:</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.58%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.58%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.58%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.58%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US government</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.58%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000309" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="C_0001668243_us-gaapInvestmentTypeAxis_us-gaapUSTreasuryAndGovernmentMember_20210331" decimals="-3" format="ixt:numdotdecimal" scale="3">20,448</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.58%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000313" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="C_0001668243_us-gaapInvestmentTypeAxis_us-gaapUSTreasuryAndGovernmentMember_20210331" decimals="-3" scale="3">124</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.58%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.58%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000316" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="C_0001668243_us-gaapInvestmentTypeAxis_us-gaapUSTreasuryAndGovernmentMember_20210331" decimals="-3" format="ixt:numdotdecimal" scale="3">20,572</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate bonds</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.58%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000310" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="C_0001668243_us-gaapInvestmentTypeAxis_us-gaapCorporateDebtSecuritiesMember_20210331" decimals="-3" format="ixt:numdotdecimal" scale="3">14,826</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.58%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000314" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="C_0001668243_us-gaapInvestmentTypeAxis_us-gaapCorporateDebtSecuritiesMember_20210331" decimals="-3" scale="3">19</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.58%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.58%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000317" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="C_0001668243_us-gaapInvestmentTypeAxis_us-gaapCorporateDebtSecuritiesMember_20210331" decimals="-3" format="ixt:numdotdecimal" scale="3">14,845</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:39.4%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money market funds<sup style="font-size:85%;line-height:120%;vertical-align:top">(1)</sup></p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.58%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000311" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="C_0001668243_us-gaapInvestmentTypeAxis_us-gaapMoneyMarketFundsMember_20210331" decimals="-3" format="ixt:numdotdecimal" scale="3">30,413</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.58%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.58%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.58%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000318" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="C_0001668243_us-gaapInvestmentTypeAxis_us-gaapMoneyMarketFundsMember_20210331" decimals="-3" format="ixt:numdotdecimal" scale="3">30,413</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:39.4%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total marketable securities</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.58%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000312" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="C_0001668243_20210331" decimals="-3" format="ixt:numdotdecimal" scale="3">65,687</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.58%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000315" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="C_0001668243_20210331" decimals="-3" scale="3">143</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.58%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.58%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000319" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="C_0001668243_20210331" decimals="-3" format="ixt:numdotdecimal" scale="3">65,830</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div></ix:nonNumeric></ix:nonNumeric>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000205_dcnt_224db7b5-7f9a-4544-8f36-f6f9fc9114c9"><ix:continuation id="F_000236_cnt_1">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:3.8%;text-indent:-3.8%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.8%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%;line-height:120%;vertical-align:top">(1)</sup></span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:10pt;"><span style="color:#000000;">Included within cash and cash equivalents on the condensed consolidated balance sheets.</span></p></td></tr></table></div></ix:continuation>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company classifies its marketable securities as available-for-sale and they consist of all debt securities. The amortized cost basis as of March&#160;31, 2021 includes $<ix:nonFraction unitRef="U_iso4217USD" id="F_000320" name="us-gaap:InterestReceivable" contextRef="C_0001668243_20210331" decimals="-5" scale="6">0.1</ix:nonFraction> million of accrued interest receivable<span style="color:#000000;">. </span>As of March&#160;31, 2021, marketable securities were in a net unrealized gain position of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000321" name="urgn:DebtSecuritiesAvailableForSaleUnrealizedGainPosition" contextRef="C_0001668243_20210331" decimals="-5" scale="6">0.1</ix:nonFraction> million.&#160;<span style="color:#000000;">Unrealized gains and losses on available-for-sale debt securities are included as a component of comprehensive loss.&#160;&#160;</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of <span style="color:#000000;">March&#160;31, 2021</span>, the Company did <ix:nonFraction unitRef="U_iso4217USD" id="F_000322" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" contextRef="C_0001668243_20210331" decimals="INF" format="ixt-sec:numwordsen" scale="3">no</ix:nonFraction>t hold any marketable securities in an unrealized loss position. Per the Company&#8217;s general investment strategy, the Company does not intend to sell the investments before maturity. <span style="color:#000000;">As of&#160;March&#160;31, 2021, the Company believes the cost basis for its marketable securities were recoverable in all material aspects and <ix:nonFraction unitRef="U_iso4217USD" id="F_000323" name="us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesPortionRecognizedInEarnings" contextRef="C_0001668243_20210101_20210331" decimals="INF" format="ixt-sec:numwordsen" scale="3">no</ix:nonFraction> credit impairments were recognized in the period.</span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s marketable securities as of March&#160;31, 2021 mature at various dates through February 2022. <ix:nonNumeric id="F_000237" name="urgn:SummaryOfFairValuesOfMarketableSecuritiesByContractualMaturityTableTextBlock" contextRef="C_0001668243_20210101_20210331" escape="true" continuedAt="F_000237_cnt_1">The fair values of marketable securities by contractual maturity consist of the following (in thousands)</ix:nonNumeric>:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p><ix:continuation id="F_000237_cnt_1">
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59.6%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.76%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.42%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">March&#160;31, 2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.76%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.42%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31, 2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Maturities within one year</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000324" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" contextRef="C_0001668243_20210331" decimals="-3" format="ixt:numdotdecimal" scale="3">65,830</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000325" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" contextRef="C_0001668243_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">88,898</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59.6%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Maturities after one year through three years</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.76%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.76%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000326" name="urgn:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughThreeYearsFairValue" contextRef="C_0001668243_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,893</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59.6%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total marketable securities</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.76%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000327" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="C_0001668243_20210331" decimals="-3" format="ixt:numdotdecimal" scale="3">65,830</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.76%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000328" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="C_0001668243_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">90,791</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p></ix:continuation></ix:continuation><ix:nonNumeric id="F_000206" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" contextRef="C_0001668243_20210101_20210331" escape="true">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Note 8 &#8211; Property and Equipment</p><ix:nonNumeric id="F_000238" name="us-gaap:PropertyPlantAndEquipmentTextBlock" contextRef="C_0001668243_20210101_20210331" escape="true">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment, consists of the following as of March&#160;31, 2021 and December&#160;31, 2020 (in thousands):</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59.54%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.42%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">March&#160;31, 2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.42%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31, 2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Laboratory equipment</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000329" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_0001668243_us-gaapPropertyPlantAndEquipmentByTypeAxis_urgnLaboratoryEquipmentMember_20210331" decimals="-3" scale="3">337</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000330" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_0001668243_us-gaapPropertyPlantAndEquipmentByTypeAxis_urgnLaboratoryEquipmentMember_20201231" decimals="-3" scale="3">333</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Computer equipment and software</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000331" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_0001668243_us-gaapPropertyPlantAndEquipmentByTypeAxis_urgnComputersAndSoftwareMember_20210331" decimals="-3" format="ixt:numdotdecimal" scale="3">1,970</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000332" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_0001668243_us-gaapPropertyPlantAndEquipmentByTypeAxis_urgnComputersAndSoftwareMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,676</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Furniture</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000333" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_0001668243_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapFurnitureAndFixturesMember_20210331" decimals="-3" scale="3">586</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000334" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_0001668243_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapFurnitureAndFixturesMember_20201231" decimals="-3" scale="3">597</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Leasehold improvements</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000335" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_0001668243_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapLeaseholdImprovementsMember_20210331" decimals="-3" scale="3">609</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000336" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_0001668243_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapLeaseholdImprovementsMember_20201231" decimals="-3" scale="3">609</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59.54%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Manufacturing equipment</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000337" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_0001668243_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapManufacturingFacilityMember_20210331" decimals="-3" scale="3">226</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000338" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_0001668243_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapManufacturingFacilityMember_20201231" decimals="-3" scale="3">226</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000339" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_0001668243_20210331" decimals="-3" format="ixt:numdotdecimal" scale="3">3,728</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000340" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_0001668243_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">3,441</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59.54%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less: accumulated depreciation and amortization</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000341" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="C_0001668243_20210331" decimals="-3" format="ixt:numdotdecimal" scale="3">1,586</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000342" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="C_0001668243_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,395</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59.54%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment, net</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000343" name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="C_0001668243_20210331" decimals="-3" format="ixt:numdotdecimal" scale="3">2,142</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000344" name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="C_0001668243_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,046</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&#160;</p></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Depreciation and amortization expenses were $<ix:nonFraction unitRef="U_iso4217USD" id="F_000345" name="us-gaap:DepreciationDepletionAndAmortization" contextRef="C_0001668243_20210101_20210331" decimals="-5" scale="6">0.2</ix:nonFraction> million and&#160;$<ix:nonFraction unitRef="U_iso4217USD" id="F_000346" name="us-gaap:DepreciationDepletionAndAmortization" contextRef="C_0001668243_20200101_20200331" decimals="-5" scale="6">0.1</ix:nonFraction> million&#160;for the three months ended March&#160;31, 2021 and 2020, respectively. </p></ix:nonNumeric><ix:nonNumeric id="F_000207" name="us-gaap:LesseeOperatingLeasesTextBlock" contextRef="C_0001668243_20210101_20210331" escape="true" continuedAt="F_000207_dcnt_3a3d11bd-298c-4ae1-90a3-e010d96c2b70">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Note 9 - Leases </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Calibri;font-size:10pt;text-transform:none;font-variant: normal;">Operating Leases</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has the following office and laboratory facility leases:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:6pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Calibri;">In April 2016, <ix:nonNumeric id="F_000348" name="us-gaap:LesseeOperatingLeaseOptionToExtend" contextRef="C_0001668243_20210101_20210331">UPL signed an addendum to its November 2014 lease agreement for the Company&#8217;s executive offices located in Israel, in order to increase the office space rented and to extend the rent period until 2019. In March 2019, UPL utilized the agreement extension option and extended the rent period for additional <ix:nonNumeric id="F_000349" name="us-gaap:LesseeOperatingLeaseRenewalTerm" contextRef="C_0001668243_20210331" format="ixt-sec:durwordsen">three years</ix:nonNumeric> until <ix:nonNumeric id="F_000350" name="urgn:LesseeOperatingLeaseExtendedLeaseExpirationDateMonthAndYear" contextRef="C_0001668243_20210101_20210331" format="ixt:datemonthyearen">August 2022</ix:nonNumeric>.</ix:nonNumeric></span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Calibri;">In September 2017, UPI entered into a new lease agreement for its office space in New York, which the Company previously used as its headquarters. The lease agreement commenced in <ix:nonNumeric id="F_000351" name="urgn:LeaseCommencementDateMonthAndYear" contextRef="C_0001668243_srtConsolidatedEntitiesAxis_srtSubsidiariesMember_srtStatementGeographicalAxis_stprNY_20170901_20170930" format="ixt:datemonthyearen">October 2017</ix:nonNumeric> and terminated in <ix:nonNumeric id="F_000352" name="urgn:LeaseTerminationDateMonthAndYear" contextRef="C_0001668243_srtConsolidatedEntitiesAxis_srtSubsidiariesMember_srtStatementGeographicalAxis_stprNY_20170901_20170930" format="ixt:datemonthyearen">February 2021</ix:nonNumeric>.</span><span style="font-family:Times New Roman;">&#160;&#160;</span></p></td></tr></table></div></ix:nonNumeric>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000207_dcnt_3a3d11bd-298c-4ae1-90a3-e010d96c2b70" continuedAt="F_000207_dcnt_3d85e26f-e15a-4ccd-b97c-a564796c1389">
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Calibri;">In April 2018, UPI entered into a new lease agreement for an office in Los Angeles, California. The lease commencement date was <ix:nonNumeric id="F_000353" name="urgn:LeaseCommencementDate" contextRef="C_0001668243_srtConsolidatedEntitiesAxis_srtSubsidiariesMember_srtStatementGeographicalAxis_stprCA_20180401_20180430" format="ixt:datemonthdayyearen">July 10, 2018</ix:nonNumeric> and terminates in <ix:nonNumeric id="F_000354" name="urgn:LeaseTerminationDateMonthAndYear" contextRef="C_0001668243_srtConsolidatedEntitiesAxis_srtSubsidiariesMember_srtStatementGeographicalAxis_stprCA_20180401_20180430" format="ixt:datemonthyearen">March 2024</ix:nonNumeric>. The landlord provided a tenant allowance for leasehold improvements of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000355" name="urgn:ProceedsFromTenantAllowance" contextRef="C_0001668243_srtConsolidatedEntitiesAxis_srtSubsidiariesMember_srtStatementGeographicalAxis_stprCA_20180401_20180430" decimals="-5" scale="6">0.2</ix:nonFraction> million that was accounted for as a lease incentive. The Company&#8217;s remaining contractual obligation under this lease is approximately $<ix:nonFraction unitRef="U_iso4217USD" id="F_000356" name="us-gaap:ContractualObligation" contextRef="C_0001668243_srtConsolidatedEntitiesAxis_srtSubsidiariesMember_srtStatementGeographicalAxis_stprCA_20210331" decimals="-5" scale="6">0.8</ix:nonFraction> million as of March&#160;31, 2021.</span><span style="color:#212529;font-family:Calibri;"> In November 2019, UPI entered into a sublease for this office space, with a lease commencement date of&#160;<ix:nonNumeric id="F_000357" name="urgn:LesseeOperatingSubleaseCommencementDate" contextRef="C_0001668243_srtConsolidatedEntitiesAxis_srtSubsidiariesMember_srtStatementGeographicalAxis_stprCA_20191101_20191130" format="ixt:datemonthdayyearen">January 1, 2020</ix:nonNumeric> and continuing until the end of the lease term in <ix:nonNumeric id="F_000358" name="urgn:LesseeOperatingSubleaseTerminationDateMonthAndYear" contextRef="C_0001668243_srtConsolidatedEntitiesAxis_srtSubsidiariesMember_srtStatementGeographicalAxis_stprCA_20191101_20191130" format="ixt:datemonthyearen">March 2024</ix:nonNumeric>. The subtenants exercised their early access clause and moved into the premises the end of November 2019.&#160;The remaining rental payments to be received over the lease term is approximately $<ix:nonFraction unitRef="U_iso4217USD" id="F_000359" name="us-gaap:SubleaseIncome" contextRef="C_0001668243_srtConsolidatedEntitiesAxis_srtSubsidiariesMember_srtStatementGeographicalAxis_stprCA_20210101_20210331" decimals="-5" scale="6">0.7</ix:nonFraction>&#160;million </span><span style="font-family:Calibri;">as of March&#160;31, 2021</span><span style="color:#212529;font-family:Calibri;">. The Company accounts for the sublease as on operating lease in accordance with ASC 842-10-25-2 and ASC 842-10-25-3. The main lease was considered for impairment and the amount was determined to be immaterial.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Calibri;">In November 2019, UPI entered into a new lease agreement for an office in Princeton, New Jersey, which the Company now uses as its headquarters. The lease commencement date was <ix:nonNumeric id="F_000360" name="urgn:LeaseCommencementDate" contextRef="C_0001668243_srtConsolidatedEntitiesAxis_srtSubsidiariesMember_srtStatementGeographicalAxis_stprNJ_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapLeaseAgreementsMember_20191101_20191130" format="ixt:datemonthdayyearen">November 29, 2019</ix:nonNumeric> and the lease term is <ix:nonNumeric id="F_000361" name="us-gaap:LesseeOperatingLeaseTermOfContract" contextRef="C_0001668243_srtConsolidatedEntitiesAxis_srtSubsidiariesMember_srtStatementGeographicalAxis_stprNJ_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapLeaseAgreementsMember_20191130" format="ixt-sec:durmonth">38</ix:nonNumeric> months. The Company&#8217;s remaining contractual obligation under this lease is approximately $<ix:nonFraction unitRef="U_iso4217USD" id="F_000362" name="us-gaap:ContractualObligation" contextRef="C_0001668243_srtConsolidatedEntitiesAxis_srtSubsidiariesMember_srtStatementGeographicalAxis_stprNJ_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapLeaseAgreementsMember_20210331" decimals="-5" scale="6">1.0</ix:nonFraction> million as of March&#160;31, 2021.</span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, the Company has other operating office equipment and vehicle leases. The Company&#8217;s operating leases may require minimum rent payments, contingent rent payments adjusted periodically for inflation, or rent payments equal to the greater of a minimum rent or contingent rent. The Company&#8217;s leases do not contain any residual value guarantees or material restrictive covenants. The Company&#8217;s leases expire at various dates from <ix:nonNumeric id="F_000363" name="urgn:LeaseExpirationYear" contextRef="C_0001668243_srtRangeAxis_srtMinimumMember_20210101_20210331">2021</ix:nonNumeric> through <ix:nonNumeric id="F_000364" name="urgn:LeaseExpirationYear" contextRef="C_0001668243_srtRangeAxis_srtMaximumMember_20210101_20210331">2024</ix:nonNumeric>, with varying renewal and termination options. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&#160;</p><ix:nonNumeric id="F_000239" name="us-gaap:LeaseCostTableTextBlock" contextRef="C_0001668243_20210101_20210331" escape="true">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The components of lease cost for the three months ended March&#160;31, 2021 were as follows <span style="color:#000000;">(in thousands)</span>:</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:77.4%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.58%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended March&#160;31, 2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:77.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease cost</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.58%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000365" name="us-gaap:OperatingLeaseCost" contextRef="C_0001668243_20210101_20210331" decimals="-3" scale="3">267</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:77.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sublease income</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.58%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000366" name="us-gaap:SubleaseIncome" contextRef="C_0001668243_20210101_20210331" decimals="-3" scale="3">56</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:77.4%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Variable lease cost</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.58%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000367" name="us-gaap:VariableLeaseCost" contextRef="C_0001668243_20210101_20210331" decimals="-3" scale="3">22</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:77.4%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.58%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000368" name="us-gaap:LeaseCost" contextRef="C_0001668243_20210101_20210331" decimals="-3" scale="3">233</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div></ix:nonNumeric>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&#160;</p><ix:nonNumeric id="F_000240" name="urgn:ScheduleOfOperatingLeaseAmountsRecognizedUponAdoptionTableTextBlock" contextRef="C_0001668243_20210101_20210331" escape="true">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The amounts recognized as of March&#160;31, 2021 were as follows <span style="color:#000000;">(in thousands):</span> </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.02%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">March&#160;31, 2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Right of use asset</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000369" name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="C_0001668243_20210331" decimals="-3" format="ixt:numdotdecimal" scale="3">1,901</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Long-term lease liability</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000371" name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="C_0001668243_20210331" decimals="-3" format="ixt:numdotdecimal" scale="3">1,201</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other current liabilities</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000372" name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="C_0001668243_20210331" decimals="-3" format="ixt:numdotdecimal" scale="3">1,077</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div></ix:nonNumeric>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of March&#160;31, 2021, <ix:nonFraction unitRef="U_iso4217USD" id="F_000374" name="us-gaap:OperatingLeaseImpairmentLoss" contextRef="C_0001668243_20210101_20210331" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction> impairment losses have been recognized to date.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&#160;</p><ix:nonNumeric id="F_000241" name="urgn:ScheduleOfSupplementalInformationRelatedToLeasesTableTextBlock" contextRef="C_0001668243_20210101_20210331" escape="true">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Supplemental information related to leases for the periods reported is as follows (in thousands):</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:77.26%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.72%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended March&#160;31, 2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:77.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash paid for amounts included in the measurement of lease liabilities:</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.72%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:77.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating cash flows from operating leases</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.72%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000375" name="us-gaap:OperatingLeasePayments" contextRef="C_0001668243_20210101_20210331" decimals="-3" format="ixt:numdotdecimal" scale="3">2,157</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:77.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Right-of-use assets obtained in exchange for new operating lease liabilities</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.72%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000376" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" contextRef="C_0001668243_20210101_20210331" decimals="-3" scale="3">135</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:77.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted-average remaining lease term of operating leases</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.72%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000377" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" contextRef="C_0001668243_20210331" format="ixt-sec:duryear">2.13</ix:nonNumeric> years</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:77.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted-average discount rate of operating leases</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.72%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000378" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" contextRef="C_0001668243_20210331" decimals="4" scale="-2">5.36</ix:nonFraction>%</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&#160;</p></ix:continuation>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000207_dcnt_3d85e26f-e15a-4ccd-b97c-a564796c1389">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Calibri;font-size:10pt;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;color:#000000;font-family:Calibri;font-size:10pt;text-transform:none;font-variant: normal;">Subleases</span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&#160;</p><ix:nonNumeric id="F_000242" name="urgn:LesseeOperatingSubLeasePaymentsToBeReceivedMaturityTableTextBlock" contextRef="C_0001668243_20210101_20210331" escape="true">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of March&#160;31, 2021 undiscounted cash flows to be received under the Company&#8217;s operating sublease on an annual basis was as follows (in thousands):</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:77.54%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.42%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Operating Leases</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:77.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Years ending December 31,</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.42%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:77.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Remainder of 2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000379" name="urgn:LesseeOperatingSubLeasePaymentsToBeReceivedRemainderOfFiscalYear" contextRef="C_0001668243_20210331" decimals="-3" scale="3">176</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:77.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000380" name="urgn:LesseeOperatingSubLeasePaymentsToBeReceivedNextTwelveMonths" contextRef="C_0001668243_20210331" decimals="-3" scale="3">243</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:77.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2023</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000381" name="urgn:LesseeOperatingSubLeasePaymentsToBeReceivedTwoYears" contextRef="C_0001668243_20210331" decimals="-3" scale="3">251</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:77.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2024</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000382" name="urgn:LesseeOperatingSubLeasePaymentsToBeReceivedThreeYears" contextRef="C_0001668243_20210331" decimals="-3" scale="3">49</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:77.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2025</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:77.54%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2026 and thereafter</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.42%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:77.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.42%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000383" name="urgn:LesseeOperatingSubLeasePaymentsToBeReceived" contextRef="C_0001668243_20210331" decimals="-3" scale="3">719</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&#160;</p><ix:nonNumeric id="F_000243" name="urgn:LesseeOperatingSubLeaseIncomeRecognizedNetInOperatingExpensesTableTextBlock" contextRef="C_0001668243_20210101_20210331" escape="true">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sublease income is recognized net within operating expenses. Sublease income for the three months ended March&#160;31, 2021 was as follows (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:77.54%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.42%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended March&#160;31, 2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:77.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sublease income from fixed lease payments</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.42%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000384" name="urgn:LesseeOperatingSubLeaseIncomeFromFixedLeasePayments" contextRef="C_0001668243_20210101_20210331" decimals="-3" scale="3">56</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:77.54%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sublease income from variable payments</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.42%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:77.54%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.42%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000385" name="us-gaap:SubleaseIncome" contextRef="C_0001668243_20210101_20210331" decimals="-3" scale="3">56</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&#160;</p></ix:continuation><ix:nonNumeric id="F_000208" name="us-gaap:RevenueFromContractWithCustomerTextBlock" contextRef="C_0001668243_20210101_20210331" escape="true">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Note 10 &#8211; Revenue From Product Sales</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:12pt;">&#160;</p><ix:nonNumeric id="F_000244" name="us-gaap:DisaggregationOfRevenueTableTextBlock" contextRef="C_0001668243_20210101_20210331" escape="true">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net product sales consist of the following for the three months ended March&#160;31, 2021 (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:77.68%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.28%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended March&#160;31, 2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:77.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Jelmyto</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.28%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000387" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0001668243_20210101_20210331" decimals="-3" format="ixt:numdotdecimal" scale="3">7,485</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&#160;</p></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:nonNumeric id="F_000209" name="urgn:LicenseAndCollaborationAgreementsDisclosureTextBlock" contextRef="C_0001668243_20210101_20210331" escape="true" continuedAt="F_000209_dcnt_cd2a3968-081e-4c54-9c48-1c9f24fc7604">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Note 11 &#8211; License and Collaboration Agreements</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Calibri;font-size:10pt;text-transform:none;font-variant: normal;">Allergan/AbbVie Agreement</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In October 2016, the Company entered into the Allergan/AbbVie Agreement and granted Allergan (now part of AbbVie) an exclusive worldwide license to research, develop, manufacture and commercialize pharmaceutical products that contain <span style="font-style:italic;">RTGel</span> and clostridial toxins (including BOTOX<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup>), alone or in combination with certain other active ingredients, referred to as the Licensed Products, which are approved for the treatment of adults with overactive bladder who cannot use or do not adequately respond to anticholinergics. Additionally, the Company granted Allergan a non-exclusive, worldwide license to use certain of the Company&#8217;s trademarks as required for Allergan to practice its exclusive license with respect to the Licensed Products.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the Allergan/AbbVie Agreement, Allergan is solely responsible for costs and development of the Licensed Products and obtaining all regulatory approvals for Licensed Products worldwide, as well as worldwide commercialization of the Licensed Products after receiving the regulatory approval to do so. Allergan is required to use commercially reasonable efforts to develop and commercialize the Licensed Products for overactive bladder in certain major market countries.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p></ix:nonNumeric>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000209_dcnt_cd2a3968-081e-4c54-9c48-1c9f24fc7604" continuedAt="F_000209_dcnt_db3251fb-9a2c-4bd1-a9a2-5007d00c97cf">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Further, the Company is eligible to receive additional material milestone payments of up to an aggregate of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000388" name="urgn:ContractWithCustomerAdditionalMilestonePaymentEligibleToReceive" contextRef="C_0001668243_srtCounterpartyNameAxis_urgnAllerganPharmaceuticalsInternationalLimitedAndAbbVieIncMember_srtRangeAxis_srtMaximumMember_us-gaapTypeOfArrangementAxis_urgnLicenseAgreementMember_20210331" decimals="-5" scale="6">200.0</ix:nonFraction> million upon the successful completion of certain development, regulatory and commercial milestones. As of March&#160;31, 2021, since inception of the Allergan/AbbVie Agreement the Company has received a total of&#160;$<ix:nonFraction unitRef="U_iso4217USD" id="F_000389" name="urgn:MilestonePaymentsReceivedForLicensingAgreement" contextRef="C_0001668243_srtCounterpartyNameAxis_urgnAllerganPharmaceuticalsInternationalLimitedAndAbbVieIncMember_us-gaapTypeOfArrangementAxis_urgnLicenseAgreementMember_20210101_20210331" decimals="-5" scale="6">25.0</ix:nonFraction> million in milestone payments from Allergan. Allergan will pay the Company a tiered royalty in the low single digits based on worldwide annual net sales of Licensed Products, subject to certain reductions for the market entry of competing products and/or loss of the Company&#8217;s patent coverage of Licensed Products. The Company is responsible for payments to any third party for certain <span style="font-style:italic;">RTGel</span>-related third-party intellectual properties.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the Allergan/AbbVie Agreement, Allergan granted the Company a non-exclusive, sublicensable, fully paid-up, perpetual, worldwide license under any improvements Allergan makes to the composition, formulation, or manufacture of <span style="font-style:italic;">RTGel</span> for the research, development, manufacture and commercialization of any product containing <span style="font-style:italic;">RTGel</span> and any active ingredient (other than a clostridial toxin) for all indications other than indications covered by the agreement and an exclusive, sublicensable, royalty-bearing (in low single digits), perpetual worldwide license under such improvements for use in the prevention or treatment of oncology indications.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In August 2020, the Company announced that the Phase 2 APOLLO trial did not meet the primary endpoint, it is believed to be the result of BOTOX not effectively permeating the urothelium. The Company is continuing to explore the potential use of <span style="font-style:italic;">RTGel</span> in combination with other products in AbbVie&#8217;s portfolio. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Calibri;font-size:10pt;text-transform:none;font-variant: normal;">Agenus Agreement<span style="font-weight:normal;font-style:normal;"> </span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In November 2019, the Company entered into a license agreement with Agenus Inc, pursuant to which Agenus granted to the Company an exclusive, worldwide (not including Argentina, Brazil, Chile, Colombia, Peru, Venezuela and their respective territories and possessions), royalty-bearing, sublicensable license under Agenus&#8217;s intellectual property rights to develop, make, use, sell, import, and otherwise commercialize products incorporating a proprietary antibody of Agenus known as AGEN1884 for the treatment of cancers of the urinary tract via intravesical delivery. AGEN1884 is an anti-CTLA-4 antagonist that is currently being evaluated by Agenus as a monotherapy in PD-1 refractory patients and in combination with Agenus&#8217; anti-PD-1 antibody in solid tumors. Initially, the Company plans to develop AGEN1884 in combination with UGN-201 for the treatment of high-grade NMIBC. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to the license agreement, the Company paid Agenus an upfront fee of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000390" name="urgn:UpfrontFee" contextRef="C_0001668243_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_us-gaapLicenseAgreementTermsMember_20191101_20191130" decimals="-5" scale="6">10.0</ix:nonFraction> million and has agreed to pay Agenus up to $<ix:nonFraction unitRef="U_iso4217USD" id="F_000391" name="urgn:MaximumAmountPayableUponAchievingCertainClinicalDevelopmentAndRegulatoryMilestones" contextRef="C_0001668243_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_us-gaapLicenseAgreementTermsMember_20191130" decimals="INF" scale="6">115.0</ix:nonFraction> million upon achieving certain clinical development and regulatory milestones, up to $<ix:nonFraction unitRef="U_iso4217USD" id="F_000392" name="urgn:MaximumAmountPayableUponAchievingCertainCommercialMilestones" contextRef="C_0001668243_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_us-gaapLicenseAgreementTermsMember_20191130" decimals="INF" scale="6">85.0</ix:nonFraction> million upon achieving certain commercial milestones, and royalties on net sales of licensed products in the <ix:nonFraction unitRef="U_xbrlipure" id="F_000393" name="urgn:RoyaltyRangingOnNetSalesOfLicensedProducts" contextRef="C_0001668243_srtRangeAxis_srtMinimumMember_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_us-gaapLicenseAgreementTermsMember_20191101_20191130" decimals="INF" scale="-2">14</ix:nonFraction>%-<ix:nonFraction unitRef="U_xbrlipure" id="F_000394" name="urgn:RoyaltyRangingOnNetSalesOfLicensedProducts" contextRef="C_0001668243_srtRangeAxis_srtMaximumMember_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_us-gaapLicenseAgreementTermsMember_20191101_20191130" decimals="INF" scale="-2">20</ix:nonFraction>% range. The Company will be responsible for all development and commercialization activities. Under the terms of the license agreement, Agenus has agreed to use commercially reasonable efforts to supply AGEN1884 to the Company for use in preclinical studies or clinical trials.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unless earlier terminated in accordance with the terms of the license agreement, the license agreement will expire on a product-by-product and country-by-country basis at the later of (a) the expiration of the last to expire valid claim of a licensed patent right that covers the licensed product in such country or (b) <ix:nonNumeric id="F_000395" name="urgn:LicenseAgreementExpirationTerm" contextRef="C_0001668243_srtStatementScenarioAxis_urgnAfterFirstCommercialSaleOfLicensedProductMember_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_us-gaapLicenseAgreementTermsMember_20191101_20191130" format="ixt-sec:duryear">15</ix:nonNumeric> years after the first commercial sale of the licensed product in such country. The Company may terminate the license agreement for convenience upon 180 days&#8217; written notice to Agenus. Either party may terminate the license agreement upon 60 days&#8217; notice to the other party if, prior to the first commercial sale of a licensed product, the Company substantially ceases to conduct development activities of the licensed products for nine consecutive months (and during such period, Agenus has complied with its obligations under the license agreement) other than in response to a requirement of an applicable regulatory authority or an event outside of the Company&#8217;s control. In addition, either party may terminate the license agreement in the event of an uncured material breach of the other party. </p></ix:continuation>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000209_dcnt_db3251fb-9a2c-4bd1-a9a2-5007d00c97cf">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Calibri;font-size:10pt;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-family:Calibri;font-size:10pt;text-transform:none;font-variant: normal;">MD Anderson Agreement</span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">In January 2021, the Company announced that it entered into a three-year strategic research collaboration agreement with MD Anderson focusing on UGN-302 as an investigational treatment for high-grade NMIBC. Under the agreement, MD Anderson and the Company will collaborate on the design and conduct of non-clinical and clinical studies with oversight from a joint steering committee. The Company will provide funding, developmental candidates, and other support. Pursuant to the agreement, the Company makes bi-annual payments to MD Anderson fund the collaboration. As of March 31, 2021, the Company has made payments to MD Anderson of $</span><ix:nonFraction unitRef="U_iso4217USD" id="F_000396" name="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross" contextRef="C_0001668243_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_urgnMDAndersonMember_20210101_20210331" decimals="0" format="ixt:numdotdecimal">500,000</ix:nonFraction> recognized evenly over the associated six-month period through research and development expenses<span style="Background-color:#FFFFFF;">.</span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></ix:continuation><ix:nonNumeric id="F_000210" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" contextRef="C_0001668243_20210101_20210331" escape="true">
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Note 12 &#8211; Shareholders&#8217; Equity </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company had <ix:nonFraction unitRef="U_xbrlishares" id="F_000397" name="us-gaap:CommonStockSharesAuthorized" contextRef="C_0001668243_20210331" decimals="-5" scale="6"><ix:nonFraction unitRef="U_xbrlishares" id="F_000398" name="us-gaap:CommonStockSharesAuthorized" contextRef="C_0001668243_20201231" decimals="-5" scale="6">100.0</ix:nonFraction></ix:nonFraction> million ordinary shares authorized for issuance as of March&#160;31, 2021 and December&#160;31, 2020, respectively. The Company had <ix:nonFraction unitRef="U_xbrlishares" id="F_000399" name="us-gaap:CommonStockSharesIssued" contextRef="C_0001668243_20210331" decimals="-5" scale="6"><ix:nonFraction unitRef="U_xbrlishares" id="F_000401" name="us-gaap:CommonStockSharesOutstanding" contextRef="C_0001668243_20210331" decimals="-5" scale="6">22.3</ix:nonFraction></ix:nonFraction> million and <ix:nonFraction unitRef="U_xbrlishares" id="F_000400" name="us-gaap:CommonStockSharesIssued" contextRef="C_0001668243_20201231" decimals="-5" scale="6"><ix:nonFraction unitRef="U_xbrlishares" id="F_000402" name="us-gaap:CommonStockSharesOutstanding" contextRef="C_0001668243_20201231" decimals="-5" scale="6">22.2</ix:nonFraction></ix:nonFraction> million ordinary shares issued and outstanding as of March&#160;31, 2021 and December&#160;31, 2020, respectively. Each<span style="letter-spacing:0.45pt;"> </span>ordinary<span style="letter-spacing:0.65pt;"> </span>share<span style="letter-spacing:0.45pt;"> </span>is<span style="letter-spacing:0.15pt;"> </span>entitled<span style="letter-spacing:0.6pt;"> </span>to<span style="letter-spacing:0.2pt;"> </span>one<span style="letter-spacing:0.35pt;"> </span>vote.<span style="letter-spacing:0.4pt;"> </span>The<span style="letter-spacing:0.35pt;"> </span>hol<span style="letter-spacing:-0.1pt;">d</span>ers<span style="letter-spacing:0.6pt;"> </span>of<span style="letter-spacing:0.2pt;"> </span>ordinary<span style="letter-spacing:0.65pt;"> </span>shares<span style="letter-spacing:0.55pt;"> </span>are<span style="letter-spacing:0.3pt;"> </span>also<span style="letter-spacing:0.35pt;"> </span>entitled<span style="letter-spacing:0.6pt;"> </span>to<span style="letter-spacing:0.2pt;"> </span>receive<span style="letter-spacing:0.6pt;"> </span>dividends<span style="letter-spacing:0.75pt;"> </span><span style="letter-spacing:-0.1pt;">w</span>henever<span style="letter-spacing:0.8pt;"> </span>funds<span style="letter-spacing:0.45pt;"> </span>are<span style="letter-spacing:0.3pt;"> </span>legally available,<span style="letter-spacing:0.75pt;"> </span>when<span style="letter-spacing:0.45pt;"> </span>and<span style="letter-spacing:0.35pt;"> </span>if<span style="letter-spacing:0.3pt;"> </span>declared<span style="letter-spacing:0.7pt;"> </span>by<span style="letter-spacing:0.25pt;"> </span>the<span style="letter-spacing:0.3pt;"> </span>Board<span style="letter-spacing:0.5pt;"> </span>of<span style="letter-spacing:0.2pt;"> </span>Directors <span style="Background-color:#FFFFFF;color:#000000;">(the &#8220;Board&#8221;)</span>.<span style="letter-spacing:0.8pt;"> </span>Since<span style="letter-spacing:0.45pt;"> </span>its<span style="letter-spacing:0.2pt;"> </span>inception,<span style="letter-spacing:0.8pt;"> </span>the<span style="letter-spacing:0.3pt;"> </span>Board<span style="letter-spacing:0.8pt;"> </span>has<span style="letter-spacing:0.3pt;"> </span>not<span style="letter-spacing:0.3pt;"> </span>declared<span style="letter-spacing:0.7pt;"> </span>any<span style="letter-spacing:0.3pt;"> </span>dividends.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;&#160;&#160;&#160;</p></ix:nonNumeric><ix:nonNumeric id="F_000211" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" contextRef="C_0001668243_20210101_20210331" escape="true" continuedAt="F_000211_dcnt_15f85c08-26fa-4bbd-a581-c70f3a5069a9">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Note 13 &#8211; Share-Based Compensation</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In<span style="letter-spacing:0.2pt;"> </span>October<span style="letter-spacing:0.65pt;"> </span>2010,<span style="letter-spacing:0.45pt;"> </span>the<span style="letter-spacing:0.9pt;"> </span>Board<span style="letter-spacing:0.7pt;"> </span>approved<span style="letter-spacing:0.75pt;"> </span>a<span style="letter-spacing:0.15pt;"> </span>share<span style="letter-spacing:0.45pt;"> </span>option<span style="letter-spacing:0.5pt;"> </span>plan<span style="letter-spacing:0.35pt;"> </span>(the<span style="letter-spacing:0.35pt;"> </span>&#8220;Pl<span style="letter-spacing:-0.1pt;">a</span>n&#8221;)<span style="letter-spacing:0.55pt;"> </span>for<span style="letter-spacing:0.25pt;"> </span>grants<span style="letter-spacing:0.5pt;"> </span>to<span style="letter-spacing:0.2pt;"> </span>Company<span style="letter-spacing:0.8pt;"> </span>employees,<span style="letter-spacing:0.9pt;"> </span>consultants, directors,<span style="letter-spacing:0.75pt;"> </span>and<span style="letter-spacing:0.35pt;"> </span>other<span style="letter-spacing:0.45pt;"> </span>service<span style="letter-spacing:0.6pt;"> </span>providers.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The<span style="letter-spacing:0.4pt;"> </span>grant<span style="letter-spacing:0.45pt;"> </span>of<span style="letter-spacing:0.2pt;"> </span>options<span style="letter-spacing:0.6pt;"> </span>to<span style="letter-spacing:0.2pt;"> </span>Israeli<span style="letter-spacing:0.5pt;"> </span>employees<span style="letter-spacing:0.85pt;"> </span>under<span style="letter-spacing:0.5pt;"> </span>the<span style="letter-spacing:0.3pt;"> </span>Plan<span style="letter-spacing:0.4pt;"> </span>is<span style="letter-spacing:0.15pt;"> </span>su<span style="letter-spacing:-0.1pt;">b</span>ject<span style="letter-spacing:0.6pt;"> </span>to<span style="letter-spacing:0.2pt;"> </span>the<span style="letter-spacing:0.3pt;"> </span>terms<span style="letter-spacing:0.45pt;"> </span>stipulated<span style="letter-spacing:0.8pt;"> </span>by<span style="letter-spacing:0.25pt;"> </span>Section<span style="letter-spacing:0.6pt;"> </span>102<span style="letter-spacing:0.35pt;"> </span>of<span style="letter-spacing:0.2pt;"> </span>the<span style="letter-spacing:0.3pt;"> </span>Israeli<span style="letter-spacing:0.5pt;"> </span>Income<span style="letter-spacing:0.6pt;"> </span>Tax<span style="letter-spacing:0.35pt;"> </span>Ordinance (&#8220;Section<span style="letter-spacing:0.75pt;"> </span>102&#8221;).<span style="letter-spacing:0.5pt;"> </span>The<span style="letter-spacing:0.35pt;"> </span>option<span style="letter-spacing:0.5pt;"> </span>grants<span style="letter-spacing:0.5pt;"> </span>are<span style="letter-spacing:0.3pt;"> </span>subject<span style="letter-spacing:0.6pt;"> </span>to<span style="letter-spacing:0.2pt;"> </span>the<span style="letter-spacing:0.3pt;"> </span>track<span style="letter-spacing:0.4pt;"> </span>chosen<span style="letter-spacing:0.6pt;"> </span>by<span style="letter-spacing:0.25pt;"> </span>the<span style="letter-spacing:0.3pt;"> </span>Company,<span style="letter-spacing:0.8pt;"> </span>either<span style="letter-spacing:0.45pt;"> </span>the<span style="letter-spacing:0.3pt;"> </span>&#8220;regular<span style="letter-spacing:0.65pt;"> </span>income&#8221;<span style="letter-spacing:0.65pt;"> </span>track<span style="letter-spacing:0.4pt;"> </span>or<span style="letter-spacing:0.2pt;"> </span>the<span style="letter-spacing:0.3pt;"> </span>&#8220;capital<span style="letter-spacing:0.6pt;"> </span>gains&#8221;<span style="letter-spacing:0.5pt;"> </span>track,<span style="letter-spacing:0.05pt;"> </span>as<span style="letter-spacing:0.25pt;"> </span>set<span style="letter-spacing:0.3pt;"> </span>out<span style="letter-spacing:0.3pt;"> </span>in<span style="letter-spacing:0.2pt;"> </span>Section<span style="letter-spacing:0.6pt;"> </span>102.<span style="letter-spacing:0.4pt;"> </span>The<span style="letter-spacing:0.35pt;"> </span>Company<span style="letter-spacing:0.8pt;"> </span>registered<span style="letter-spacing:0.8pt;"> </span>the<span style="letter-spacing:0.3pt;"> </span>Plan<span style="letter-spacing:0.4pt;"> </span>un<span style="letter-spacing:-0.1pt;">d</span>er<span style="letter-spacing:0.5pt;"> </span>the<span style="letter-spacing:0.3pt;"> </span>capital<span style="letter-spacing:0.55pt;"> </span>gains<span style="letter-spacing:0.45pt;"> </span>track,<span style="letter-spacing:0.45pt;"> </span>which<span style="letter-spacing:0.5pt;"> </span>offers<span style="letter-spacing:0.45pt;"> </span>more<span style="letter-spacing:0.45pt;"> </span>favorable<span style="letter-spacing:0.75pt;"> </span>tax<span style="letter-spacing:0.3pt;"> </span>rates<span style="letter-spacing:0.45pt;"> </span>to<span style="letter-spacing:0.2pt;"> </span>the employees.<span style="letter-spacing:0.9pt;"> </span>As<span style="letter-spacing:0.25pt;"> </span>a<span style="letter-spacing:0.15pt;"> </span>result,<span style="letter-spacing:0.5pt;"> </span>and<span style="letter-spacing:0.35pt;"> </span>pursuant<span style="letter-spacing:0.7pt;"> </span>to<span style="letter-spacing:0.2pt;"> </span>the<span style="letter-spacing:0.3pt;"> </span>terms<span style="letter-spacing:0.45pt;"> </span>of<span style="letter-spacing:0.2pt;"> </span>Section<span style="letter-spacing:0.6pt;"> </span>102,<span style="letter-spacing:0.4pt;"> </span>the<span style="letter-spacing:0.3pt;"> </span>Company<span style="letter-spacing:0.8pt;"> </span>is<span style="letter-spacing:0.15pt;"> </span>not<span style="letter-spacing:0.3pt;"> </span>allowed<span style="letter-spacing:0.65pt;"> </span>to<span style="letter-spacing:0.2pt;"> </span>claim<span style="letter-spacing:0.45pt;"> </span>as<span style="letter-spacing:0.25pt;"> </span>an<span style="letter-spacing:0.25pt;"> </span>ex<span style="letter-spacing:-0.1pt;">p</span>ense<span style="letter-spacing:0.7pt;"> </span>for<span style="letter-spacing:0.25pt;"> </span>tax<span style="letter-spacing:0.3pt;"> </span>purposes<span style="letter-spacing:0.75pt;"> </span>the amounts<span style="letter-spacing:0.7pt;"> </span>credited<span style="letter-spacing:0.65pt;"> </span>to<span style="letter-spacing:0.2pt;"> </span>the<span style="letter-spacing:0.3pt;"> </span>employees<span style="letter-spacing:0.85pt;"> </span>in<span style="letter-spacing:0.2pt;"> </span>respect<span style="letter-spacing:0.6pt;"> </span>of<span style="letter-spacing:0.2pt;"> </span>options<span style="letter-spacing:0.6pt;"> </span>granted<span style="letter-spacing:0.65pt;"> </span>to<span style="letter-spacing:0.2pt;"> </span>them<span style="letter-spacing:0.45pt;"> </span>under<span style="letter-spacing:0.5pt;"> </span>the<span style="letter-spacing:0.3pt;"> </span>P<span style="letter-spacing:-0.1pt;">l</span>an,<span style="letter-spacing:0.45pt;"> </span>including<span style="letter-spacing:0.7pt;"> </span>amounts<span style="letter-spacing:0.7pt;"> </span>recorded<span style="letter-spacing:0.7pt;"> </span>as<span style="letter-spacing:0.25pt;"> </span>salary<span style="letter-spacing:0.5pt;"> </span>be<span style="letter-spacing:-0.1pt;">n</span>efits<span style="letter-spacing:0.8pt;"> </span>in<span style="letter-spacing:0.2pt;"> </span>the Company&#8217;s<span style="letter-spacing:0.9pt;"> </span>accounts,<span style="letter-spacing:0.8pt;"> </span>with<span style="letter-spacing:0.35pt;"> </span>the<span style="letter-spacing:0.3pt;"> </span>exception<span style="letter-spacing:0.8pt;"> </span>of<span style="letter-spacing:0.2pt;"> </span>the<span style="letter-spacing:0.3pt;"> </span>work-income<span style="letter-spacing:1pt;"> </span>b<span style="letter-spacing:-0.1pt;">e</span>nefit<span style="letter-spacing:0.55pt;"> </span>component,<span style="letter-spacing:0.95pt;"> </span>if<span style="letter-spacing:0.15pt;"> </span>any,<span style="letter-spacing:0.35pt;"> </span>determined<span style="letter-spacing:0.9pt;"> </span>on<span style="letter-spacing:0.25pt;"> </span>grant<span style="letter-spacing:0.45pt;"> </span>date.<span style="letter-spacing:0.45pt;"> </span>For<span style="letter-spacing:0.4pt;"> </span>non-employees<span style="letter-spacing:1.3pt;"> </span>and<span style="letter-spacing:0.35pt;"> </span>for non-Israeli<span style="letter-spacing:0.95pt;"> </span>employees,<span style="letter-spacing:0.9pt;"> </span>the<span style="letter-spacing:0.3pt;"> </span>Plan<span style="letter-spacing:0.4pt;"> </span>is<span style="letter-spacing:0.15pt;"> </span>subject<span style="letter-spacing:0.6pt;"> </span>to<span style="letter-spacing:0.2pt;"> </span>Section<span style="letter-spacing:0.6pt;"> </span>3(i)<span style="letter-spacing:0.3pt;"> </span>of<span style="letter-spacing:0.2pt;"> </span>the<span style="letter-spacing:0.3pt;"> </span>Israeli<span style="letter-spacing:0.5pt;"> </span>Income<span style="letter-spacing:0.6pt;"> </span>Tax<span style="letter-spacing:0.35pt;"> </span>Ordinance.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Employees are typically granted stock options and/or restricted stock units, or RSUs, upon commencement of employment. Also, eligible employees may receive an annual grant of options or RSUs. Non-employee members of the Board typically receive a grant of RSUs and/or stock options annually. The term of any option granted under the Plan cannot exceed <ix:nonNumeric id="F_000403" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" contextRef="C_0001668243_srtRangeAxis_srtMaximumMember_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapStatementEquityComponentsAxis_urgnPlanMember_20210101_20210331" format="ixt-sec:duryear">10</ix:nonNumeric> years. Options shall not have an exercise price less than <ix:nonFraction unitRef="U_xbrlipure" id="F_000404" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" contextRef="C_0001668243_srtRangeAxis_srtMinimumMember_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapStatementEquityComponentsAxis_urgnPlanMember_20210101_20210331" decimals="2" scale="-2">100</ix:nonFraction>% of the fair market value of the Company&#8217;s ordinary shares on the grant date, and generally vest over a period of <ix:nonNumeric id="F_000405" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" contextRef="C_0001668243_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapStatementEquityComponentsAxis_urgnPlanMember_20210101_20210331" format="ixt-sec:durwordsen">three years</ix:nonNumeric>. If the individual possesses more than <ix:nonFraction unitRef="U_xbrlipure" id="F_000406" name="urgn:ShareBasedCompensationArrangementByShareBasedPaymentAwardIndividualVotingPowersPercentage" contextRef="C_0001668243_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapStatementEquityComponentsAxis_urgnPlanMember_20210101_20210331" decimals="2" scale="-2">10</ix:nonFraction>% of the combined voting power of all classes of equity of the Company, the exercise price shall not be less than <ix:nonFraction unitRef="U_xbrlipure" id="F_000407" name="urgn:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfPurchasePriceForIndividualsHavingMoreThanTenPercentOfCombinedVotingPower" contextRef="C_0001668243_srtRangeAxis_srtMinimumMember_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapStatementEquityComponentsAxis_urgnPlanMember_20210101_20210331" decimals="2" scale="-2">110</ix:nonFraction>% of the fair market value of an ordinary share of stock on the date of grant.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s RSU and option grants provide for accelerated or continued vesting in certain circumstances as defined in the plans and related grant agreements, including a termination in connection with a change in control. RSUs generally vest in a <ix:nonFraction unitRef="U_xbrlipure" id="F_000408" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" contextRef="C_0001668243_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_us-gaapVestingAxis_us-gaapShareBasedCompensationAwardTrancheOneMember_20210101_20210331" decimals="2" scale="-2">33</ix:nonFraction>% increment upon the first anniversary of grant, and in either equal quarterly or annual amounts for the <ix:nonNumeric id="F_000409" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" contextRef="C_0001668243_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20210101_20210331" format="ixt-sec:durwordsen">two years</ix:nonNumeric> following the one-year anniversary of the grant date. Options generally vest in a <ix:nonFraction unitRef="U_xbrlipure" id="F_000410" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" contextRef="C_0001668243_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapVestingAxis_us-gaapShareBasedCompensationAwardTrancheOneMember_20210101_20210331" decimals="2" scale="-2">33</ix:nonFraction>% increment upon the first anniversary of the grant date, and in either equal quarterly or annual amounts for the two years following the one-year anniversary of the grant date.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The<span style="letter-spacing:0.35pt;"> </span>expected<span style="letter-spacing:0.75pt;"> </span>volatility<span style="letter-spacing:0.65pt;"> </span>is<span style="letter-spacing:0.15pt;"> </span>based<span style="letter-spacing:0.5pt;"> </span>on<span style="letter-spacing:0.25pt;"> a mix of the Company&#8217;s historical volatility, and </span>the<span style="letter-spacing:0.3pt;"> </span>histori<span style="letter-spacing:-0.1pt;">c</span>al<span style="letter-spacing:0.7pt;"> </span>volatility<span style="letter-spacing:0.65pt;"> </span>of<span style="letter-spacing:0.2pt;"> </span>comparable<span style="letter-spacing:1pt;"> </span>companies with similar attributes to the Company, including industry, stage of life cycle, size and financial leverage.<span style="letter-spacing:0.9pt;"> </span>The<span style="letter-spacing:0.35pt;"> </span>risk-free<span style="letter-spacing:0.65pt;"> </span>interest<span style="letter-spacing:0.6pt;"> </span>rate<span style="letter-spacing:0.35pt;"> </span>assumption<span style="letter-spacing:0.9pt;"> </span>is<span style="letter-spacing:0.15pt;"> </span>based<span style="letter-spacing:0.5pt;"> </span>on observed<span style="letter-spacing:0.75pt;"> </span>interest<span style="letter-spacing:0.6pt;"> </span>rates<span style="letter-spacing:0.45pt;"> </span>appropriate<span style="letter-spacing:0.9pt;"> </span>for<span style="letter-spacing:0.25pt;"> </span>the<span style="letter-spacing:0.3pt;"> </span>expected<span style="letter-spacing:0.75pt;"> </span>term<span style="letter-spacing:0.4pt;"> </span>of<span style="letter-spacing:0.2pt;"> </span>the<span style="letter-spacing:0.3pt;"> </span>options<span style="letter-spacing:0.6pt;"> </span>granted.<span style="letter-spacing:0.5pt;"> </span>The<span style="letter-spacing:0.35pt;"> </span>expected<span style="letter-spacing:0.75pt;"> </span>term<span style="letter-spacing:0.4pt;"> </span>is<span style="letter-spacing:0.15pt;"> </span>the<span style="letter-spacing:0.3pt;"> </span>length<span style="letter-spacing:0.5pt;"> </span>of<span style="letter-spacing:0.2pt;"> </span>time<span style="letter-spacing:0.35pt;"> </span>until the<span style="letter-spacing:0.05pt;"> </span>expected<span style="letter-spacing:0.75pt;"> </span>dates<span style="letter-spacing:0.45pt;"> </span>of<span style="letter-spacing:0.2pt;"> </span>exercising<span style="letter-spacing:0.8pt;"> </span>the<span style="letter-spacing:0.3pt;"> </span>options and<span style="letter-spacing:0.35pt;"> </span>is<span style="letter-spacing:0.15pt;"> </span>estimated<span style="letter-spacing:0.8pt;"> </span>for<span style="letter-spacing:0.25pt;"> </span>employees<span style="letter-spacing:0.85pt;"> </span>using<span style="letter-spacing:0.45pt;"> </span>the<span style="letter-spacing:0.3pt;"> </span>simplified<span style="letter-spacing:0.75pt;"> </span>method<span style="letter-spacing:0.6pt;"> </span>due<span style="letter-spacing:0.35pt;"> </span>to insufficient<span style="letter-spacing:0.85pt;"> </span>specific<span style="letter-spacing:0.6pt;"> </span>historical<span style="letter-spacing:0.7pt;"> </span>information<span style="letter-spacing:0.9pt;"> </span>of<span style="letter-spacing:0.2pt;"> </span>employ<span style="letter-spacing:-0.1pt;">e</span>es&#8217;<span style="letter-spacing:0.9pt;"> </span>exercise<span style="letter-spacing:0.7pt;"> </span>behavior,<span style="letter-spacing:0.75pt;"> </span>and<span style="letter-spacing:0.35pt;"> </span>for<span style="letter-spacing:0.3pt;"> </span>non-employees,<span style="letter-spacing:1.35pt;"> </span>and directors<span style="letter-spacing:0.7pt;"> </span>using<span style="letter-spacing:0.45pt;"> </span>the<span style="letter-spacing:0.05pt;"> </span>contractual<span style="letter-spacing:0.9pt;"> </span>term.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In March 2017, the Board adopted the 2017 Equity Incentive Plan (the "2017 Plan"), which was approved by the shareholders in April 2017. The 2017 Plan provides for the grant of incentive stock options to the Company's employees and for the grant of </p></ix:nonNumeric>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000211_dcnt_15f85c08-26fa-4bbd-a581-c70f3a5069a9">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">nonstatutory stock options, stock appreciation rights, restricted stock awards, </span><span style="font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">RSU</span><span style="font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> awards, performance </span><span style="font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">share </span><span style="font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">awards, performance cash awards, and other forms of </span><span style="font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">share </span><span style="font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">awards to the Company's employees, directors and consultants.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The maximum number of ordinary shares that may initially be issued under the 2017 Plan is <ix:nonFraction unitRef="U_xbrlishares" id="F_000411" name="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionSharesApprovedForIssuance" contextRef="C_0001668243_us-gaapAwardTypeAxis_urgnTwoThousandSeventeenEquityIncentivePlanMember_20170301_20170331" decimals="INF" format="ixt:numdotdecimal">1,400,000</ix:nonFraction>. In addition, the number of ordinary shares reserved for issuance under the 2017 Plan will automatically increase on January 1st of each calendar year, from January 1, 2018 through January 1, 2026, so that the number of such shares reserved for issuance will equal <ix:nonFraction unitRef="U_xbrlipure" id="F_000412" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" contextRef="C_0001668243_us-gaapAwardTypeAxis_urgnTwoThousandSeventeenEquityIncentivePlanMember_20210101_20210331" decimals="INF" scale="-2">12</ix:nonFraction>% of the total number of ordinary shares outstanding on the last day of the calendar month prior to the date of each automatic increase, or a lesser number of shares determined by the Board. The maximum number of ordinary shares that may be issued upon the exercise of stock options under the 2017 Plan is <ix:nonFraction unitRef="U_xbrlishares" id="F_000413" name="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionSharesApprovedForIssuance" contextRef="C_0001668243_us-gaapAwardTypeAxis_urgnTwoThousandSeventeenEquityIncentivePlanMember_20210101_20210331" decimals="INF" format="ixt:numdotdecimal">5,600,000</ix:nonFraction>. On January 1, 2018, the share reserve increased by <ix:nonFraction unitRef="U_xbrlishares" id="F_000414" name="urgn:ShareBasedGoodsAndNonEmployeeServicesTransactionSharesReserveIncreaseForIssuance" contextRef="C_0001668243_us-gaapAwardTypeAxis_urgnTwoThousandSeventeenEquityIncentivePlanMember_20180101_20180101" decimals="INF" format="ixt:numdotdecimal">250,167</ix:nonFraction> to <ix:nonFraction unitRef="U_xbrlishares" id="F_000417" name="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionSharesApprovedForIssuance" contextRef="C_0001668243_us-gaapAwardTypeAxis_urgnTwoThousandSeventeenEquityIncentivePlanMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20180101_20180101" decimals="INF" format="ixt:numdotdecimal">1,650,167</ix:nonFraction>. On October 12, 2018, the Company increased the amount of registered ordinary shares of the Company&#8217;s 2017 Plan by <ix:nonFraction unitRef="U_xbrlishares" id="F_000415" name="urgn:ShareBasedGoodsAndNonEmployeeServicesTransactionSharesReserveIncreaseForIssuance" contextRef="C_0001668243_us-gaapAwardTypeAxis_urgnTwoThousandSeventeenEquityIncentivePlanMember_20181012_20181012" decimals="INF" format="ixt:numdotdecimal">1,900,000</ix:nonFraction> to <ix:nonFraction unitRef="U_xbrlishares" id="F_000418" name="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionSharesApprovedForIssuance" contextRef="C_0001668243_us-gaapAwardTypeAxis_urgnTwoThousandSeventeenEquityIncentivePlanMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20181012_20181012" decimals="INF" format="ixt:numdotdecimal">3,550,167</ix:nonFraction>. On June 8, 2020 the Company increased the amount of registered ordinary shares of the Company&#8217;s 2017 Plan by <ix:nonFraction unitRef="U_xbrlishares" id="F_000416" name="urgn:ShareBasedGoodsAndNonEmployeeServicesTransactionSharesReserveIncreaseForIssuance" contextRef="C_0001668243_us-gaapAwardTypeAxis_urgnTwoThousandSeventeenEquityIncentivePlanMember_20200608_20200608" decimals="INF" format="ixt:numdotdecimal">400,000</ix:nonFraction> to <ix:nonFraction unitRef="U_xbrlishares" id="F_000419" name="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionSharesApprovedForIssuance" contextRef="C_0001668243_us-gaapAwardTypeAxis_urgnTwoThousandSeventeenEquityIncentivePlanMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200608_20200608" decimals="INF" format="ixt:numdotdecimal">3,950,167</ix:nonFraction>. On March 17, 2021, the Board approved an increase to the amount of registered ordinary shares of the Company&#8217;s 2017 Plan by <ix:nonFraction unitRef="U_xbrlishares" id="F_000420" name="urgn:ShareBasedGoodsAndNonEmployeeServicesTransactionSharesReserveIncreaseForIssuance" contextRef="C_0001668243_us-gaapAwardTypeAxis_urgnTwoThousandSeventeenEquityIncentivePlanMember_20210317_20210317" decimals="INF" format="ixt:numdotdecimal">400,000</ix:nonFraction> to <ix:nonFraction unitRef="U_xbrlishares" id="F_000421" name="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionSharesApprovedForIssuance" contextRef="C_0001668243_us-gaapAwardTypeAxis_urgnTwoThousandSeventeenEquityIncentivePlanMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210317_20210317" decimals="INF" format="ixt:numdotdecimal">4,350,167</ix:nonFraction>, subject to approval by the Company&#8217;s shareholders.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;&#160;&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In May 2019, the Company adopted the UroGen Pharma Ltd. 2019 Inducement Plan (the &#8220;Inducement Plan&#8221;). Under the Inducement Plan, the Company is authorized to issue up to <ix:nonFraction unitRef="U_xbrlishares" id="F_000422" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" contextRef="C_0001668243_us-gaapPlanNameAxis_urgnTwoThousandAndNineteenInducementPlanMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20190531" decimals="INF" format="ixt:numdotdecimal">900,000</ix:nonFraction> ordinary shares pursuant to awards issued under the Inducement Plan. <span style="Background-color:#FFFFFF;color:#000000;">The only persons eligible to receive grants of Awards (as defined below) under the Inducement Plan are individuals who satisfy the standards for inducement grants under Nasdaq Marketplace Rule 5635(c)(4) or 5635(c)(3) and the related guidance under Nasdaq IM&#160;5635-1,&#160;including individuals who were not previously an employee or director of the Company or are following a bona fide period of&#160;non-employment,&#160;in each case as an inducement material to such individual&#8217;s agreement to enter into employment with the Company.&#160;Under the Inducement Plan, an &#8220;Award&#8221; is a nonstatutory stock option, restricted stock unit or other right to receive ordinary shares pursuant to the Inducement Plan.</span> &#160;&#160;&#160;&#160;&#160;&#160;&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</p><ix:nonNumeric id="F_000245" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" contextRef="C_0001668243_20210101_20210331" escape="true">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The<span style="letter-spacing:0.35pt;"> </span>following<span style="letter-spacing:0.7pt;"> </span>table<span style="letter-spacing:0.4pt;"> </span>illustrates<span style="letter-spacing:0.75pt;"> </span>the<span style="letter-spacing:0.3pt;"> </span>effect<span style="letter-spacing:0.45pt;"> </span>of<span style="letter-spacing:0.2pt;"> </span>share-based<span style="letter-spacing:1pt;"> </span>com<span style="letter-spacing:-0.1pt;">p</span>ensation<span style="letter-spacing:1.1pt;"> </span>on<span style="letter-spacing:0.25pt;"> </span>the<span style="letter-spacing:0.3pt;"> condensed consolidated </span>statements<span style="letter-spacing:0.9pt;"> </span>of<span style="letter-spacing:0.2pt;"> </span>operations (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:70%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.54%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended March&#160;31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development expenses</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000423" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_0001668243_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20210101_20210331" decimals="-3" format="ixt:numdotdecimal" scale="3">1,107</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000424" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_0001668243_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20200101_20200331" decimals="-3" format="ixt:numdotdecimal" scale="3">1,943</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Selling, general and administrative expenses</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000425" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_0001668243_us-gaapIncomeStatementLocationAxis_us-gaapSellingGeneralAndAdministrativeExpensesMember_20210101_20210331" decimals="-3" format="ixt:numdotdecimal" scale="3">5,088</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000426" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_0001668243_us-gaapIncomeStatementLocationAxis_us-gaapSellingGeneralAndAdministrativeExpensesMember_20200101_20200331" decimals="-3" format="ixt:numdotdecimal" scale="3">5,674</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000427" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_0001668243_20210101_20210331" decimals="-3" format="ixt:numdotdecimal" scale="3">6,195</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000428" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_0001668243_20200101_20200331" decimals="-3" format="ixt:numdotdecimal" scale="3">7,617</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The total unrecognized compensation cost of options and RSUs at March&#160;31, 2021 is&#160;$<ix:nonFraction unitRef="U_iso4217USD" id="F_000429" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" contextRef="C_0001668243_20210331" decimals="-5" scale="6">33.6</ix:nonFraction> million with a weighted average recognition period of <ix:nonNumeric id="F_000430" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" contextRef="C_0001668243_20210101_20210331" format="ixt-sec:duryear">1.86</ix:nonNumeric> years. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&#160;</p></ix:continuation><ix:nonNumeric id="F_000212" name="us-gaap:IncomeTaxDisclosureTextBlock" contextRef="C_0001668243_20210101_20210331" escape="true" continuedAt="F_000212_dcnt_cbe13ce6-36dc-47e1-b58a-56a190252e14">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Note 14 &#8211; Income Taxes </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">UroGen Pharma Ltd.<span style="letter-spacing:0.8pt;"> </span>is<span style="letter-spacing:0.15pt;"> </span>taxed<span style="letter-spacing:0.45pt;"> </span>under<span style="letter-spacing:0.5pt;"> </span>Israeli<span style="letter-spacing:0.5pt;"> </span>tax<span style="letter-spacing:0.3pt;"> </span>laws. As of March&#160;31, 2021, the Company continues to maintain a full valuation allowance against deferred tax assets for all jurisdictions. In evaluating the need for a valuation allowance, the Company considers all sources of taxable income available to realize the deferred tax asset, including the future reversal of existing temporary differences, forecasts of future taxable income, and tax planning strategies. The Company has cumulative global pretax accounting losses for the years ended 2020, 2019 and 2018, and for the three months ended March&#160;31, 2021. The Company will continue to assess the extent to which its deferred tax assets may be realized in the future and will adjust the valuation allowance as needed.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has a liability for uncertain tax positions of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000431" name="us-gaap:UnrecognizedTaxBenefits" contextRef="C_0001668243_20210331" decimals="-5" scale="6">2.7</ix:nonFraction> million as of March 31, 2021 for tax positions relating to transfer pricing between affiliated entities. The Company recognizes interest accrued and penalties related to uncertain tax positions as a component of income tax expense. As of March 31, 2021, the Company&#8217;s liability for uncertain tax positions includes  $<ix:nonFraction unitRef="U_iso4217USD" id="F_000432" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" contextRef="C_0001668243_20210331" decimals="-5" scale="6">0.7</ix:nonFraction> million of interest and penalties accrued during 2020.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company operates on a global basis and is subject to tax laws and regulations in the U.S. and Israel. The estimate of the Company&#8217;s tax liabilities relating to uncertain tax positions requires management to assess uncertainties and to make judgments about the application of complex tax laws and regulations, expectations regarding the outcome of tax authority examinations, as well as the ultimate measurement of potential liabilities. </p></ix:nonNumeric>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000212_dcnt_cbe13ce6-36dc-47e1-b58a-56a190252e14">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The uncertain tax positions are reviewed quarterly and adjusted as events occur that could affect potential liabilities for additional taxes, including lapsing of applicable statutes of limitations, correspondence with tax authorities, proposed assessments by tax authorities, identification of new issues, and issuance of new legislation or regulations. </span><span style="font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company believes that adequate amounts of tax have been provided in income tax expense for any adjustments that may result from its uncertain tax positions. Based upon the information currently available, the Company does not reasonably expect changes in its existing uncertain tax positions in the next 12 months and have recorded the gross uncertain tax positions as a long-term liability.</span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&#160;</p></ix:continuation><ix:nonNumeric id="F_000213" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" contextRef="C_0001668243_20210101_20210331" escape="true">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Note 15 &#8211; Related Parties</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There were no related party transactions for the three months ended March&#160;31, 2021 or the three months ended March&#160;31, 2020. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:12pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></ix:nonNumeric><ix:nonNumeric id="F_000214" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" contextRef="C_0001668243_20210101_20210331" escape="true" continuedAt="F_000214_dcnt_6c42849a-4af1-4fda-b717-e1200ad62d2f">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Note 16 &#8211; Commitments and Contingencies </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the normal course of business, the Company enters into contracts that contain a variety of indemnifications with its employees, licensors, suppliers and service providers. Further, the Company indemnifies its directors and officers who are, or were, serving at the Company<span style="color:#000000;">&#8217;</span>s request in such capacities. The Company<span style="color:#000000;">&#8217;</span>s maximum exposure under these arrangements is unknown as of March&#160;31, 2021 and December&#160;31, 2020. The Company does not anticipate recognizing any significant losses relating to these arrangements.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Calibri;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Grants from the Israeli Innovation Authority in Israel (&#8220;IIA&#8221;)</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has received grants from the IIA for research and development funding. Up until 2007, the IIA participation in the funding of the Company&#8217;s operations was by grants provided to Granot Ventures, a government supported technology incubator, as part of the Israeli Ministry of Industry and Commerce Director General Directive 8.2. Since 2008, the funding was provided directly to Company.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On January 12, 2020, the IIA Office of Chief Scientist approved the Company's request to unwind its obligation to the IIA regarding grants that were loaned to the Company between January 2004 and September 2016. The total payment under the IIA approval, net of the royalties already paid, $<ix:nonFraction unitRef="U_iso4217USD" id="F_000433" name="us-gaap:AccruedRoyaltiesCurrentAndNoncurrent" contextRef="C_0001668243_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_urgnIsraelInnovationAuthorityMember_20200331" decimals="-5" scale="6">6.6</ix:nonFraction> million, was fully paid during the first quarter of 2020 and recognized as research and development expense. Based on this payment, the Company will have full freedom to transfer IIA-funded technology or manufacture products developed with IIA-funded technology outside of the State of Israel. Other than the commitment to continue at least <ix:nonFraction unitRef="U_xbrlipure" id="F_000434" name="urgn:MaximumPercentageOfCommitmentToContinueEmploymentOfResearchAndDevelopmentJobs" contextRef="C_0001668243_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_urgnIsraelInnovationAuthorityMember_20210101_20210331" decimals="2" scale="-2">75</ix:nonFraction>% of its based R&#38;D jobs in Israel (at the time of settlement) for a period of at least <ix:nonNumeric id="F_000435" name="urgn:MaximumTermForCommitmentToContinueEmploymentOfResearchAndDevelopmentJobs" contextRef="C_0001668243_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_urgnIsraelInnovationAuthorityMember_20210101_20210331" format="ixt-sec:durwordsen">three years</ix:nonNumeric>, all other obligations with the IIA ceased to exist as per the agreement.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Calibri;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Separation Agreement</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On March 20, 2020, the Company entered into a Separation Agreement with Stephen Mullennix, the Company&#8217;s Chief Operating Officer, which sets forth the terms of Mr. Mullennix&#8217;s termination of employment with the Company, effective as of April 30, 2020, or Separation Date. The arrangement includes cash severance, as well as a pro rata portion of the target annual bonus for calendar year 2020, contingent on certain performance conditions. The Company accrued $<ix:nonFraction unitRef="U_iso4217USD" id="F_000436" name="us-gaap:AccruedBonusesCurrentAndNoncurrent" contextRef="C_0001668243_srtTitleOfIndividualAxis_srtChiefOperatingOfficerMember_20200331" decimals="-5" scale="6">0.4</ix:nonFraction> million during the quarter ended March 31, 2020 in relation to this arrangement.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On September 7, 2020, the Company entered into a Separation Agreement with Peter Pfreundschuh, the Company&#8217;s Chief Financial Officer, which sets forth the terms of Mr. Pfreundschuh&#8217;s termination of employment with the Company, effective as of October 15, 2020. The arrangement includes cash severance, a pro rata portion of the target annual bonus for calendar year 2020 contingent on certain performance conditions, and partial acceleration of share-based compensation. The Company recognized $<ix:nonFraction unitRef="U_iso4217USD" id="F_000437" name="us-gaap:SeveranceCosts1" contextRef="C_0001668243_srtTitleOfIndividualAxis_srtChiefFinancialOfficerMember_20200101_20201231" decimals="-5" scale="6">0.7</ix:nonFraction> million during the year ended December 31, 2020 in relation to this arrangement, which was paid during March and April 2021.<span style="font-family:Times New Roman;">&#160;&#160;&#160;&#160; </span>&#160;&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Calibri;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Leases</p></ix:nonNumeric>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000214_dcnt_6c42849a-4af1-4fda-b717-e1200ad62d2f">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">See N</span><span style="font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ote </span><span style="font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9</span><span style="font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> for further discussion regarding lease commitments.</span></p></ix:continuation><ix:nonNumeric id="F_000215" name="us-gaap:SubsequentEventsTextBlock" contextRef="C_0001668243_20210101_20210331" escape="true">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Note 17 &#8211; Subsequent Events</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In March 2021, the Company announced a transaction with RTW Investments (&#8220;RTW&#8221;) totaling $75.0 million in funding for the Company to support the launch of Jelmyto and the development of UGN-102. RTW will provide the Company with an upfront cash payment of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000438" name="urgn:UpfrontFee" contextRef="C_0001668243_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_urgnRTWInvestmentsMember_20210101_20210331" decimals="-5" scale="6">75.0</ix:nonFraction> million and will receive tiered future payments based on global annual net product sales of Jelmyto and UGN-102, if approved. The Company received the $<ix:nonFraction unitRef="U_iso4217USD" id="F_000439" name="urgn:UpfrontCashPaymentReceivedNetOfCosts" contextRef="C_0001668243_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_urgnRTWInvestmentsMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20210513_20210513" decimals="-5" scale="6">75.0</ix:nonFraction> million of cash, net of costs in May 2021 following the receipt of necessary regulatory approvals, and recognized an associated long term liability.&#160;&#160;</p></ix:nonNumeric>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_2_MANAGEMENTS_DISCUSSION_ANALYSIS_F">Item 2. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Calibri;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our unaudited condensed consolidated financial statements and related notes included in this Quarterly Report <span style="color:#000000;">and&#160;the audited financial statements and notes thereto as of and for the year ended December&#160;31, 2020 and the related Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations, both of which are contained in our Annual Report on Form 10-K for the year ended December 31, 2020 (&#8220;Annual Report&#8221;), which was filed with the U.S. Securities and Exchange Commission (&#8220;SEC&#8221;) on March 18, 2021</span>. The information in this discussion contains forward-looking statements and information within the meaning of Section 27A of the Securities Act of 1933, as amended (&#8220;Securities Act&#8221;), and Section 21E of the Securities Exchange Act of 1934, as amended, (&#8220;Exchange Act&#8221;), which are subject to the &#8220;safe harbor&#8221; created by those sections. These forward-looking statements include, but are not limited to, statements concerning our strategy, future operations, future financial position, future revenues, projected costs, prospects and plans and objectives of management. The words &#8220;anticipates,&#8221; &#8220;believes,&#8221; &#8220;estimates,&#8221; &#8220;expects,&#8221; &#8220;intends,&#8221; &#8220;may,&#8221; &#8220;plans,&#8221; &#8220;projects,&#8221; &#8220;will,&#8221; &#8220;would&#8221; and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements and you should not place undue reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements that we make. These forward-looking statements involve risks and uncertainties that could cause our actual results to differ materially from those in the forward-looking statements, including, without limitation, the risks set forth in Part II, Item 1A, &#8220;Risk Factors&#8221; in this Quarterly Report. The forward-looking statements are applicable only as of the date on which they are made, and we do not assume any obligation to update any forward-looking statements.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Overview</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;letter-spacing:-0.1pt;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are a biopharmaceutical company dedicated to building and commercializing novel solutions that treat specialty cancers and urologic diseases. We have developed <span style="font-style:italic;">RTGel</span>&#8482; reverse-thermal hydrogel, a proprietary sustained release, hydrogel-based technology that has the potential to improve therapeutic profiles of existing drugs. Our technology is designed to enable longer exposure of the urinary tract tissue to medications, making local therapy a potentially effective treatment option. Our approved product <span style="font-style:italic;">Jelmyto</span> (mitomycin) for pyelocalyceal solution, and our investigational candidate UGN-102 (mitomycin) for intravesical solution, are designed to ablate tumors by non-surgical means and to treat several forms of non-muscle invasive urothelial cancer, including low-grade upper tract urothelial cancer (&#8220;low-grade UTUC&#8221;) and low-grade intermediate risk non-muscle invasive bladder cancer (&#8220;low-grade intermediate risk NMIBC&#8221;), respectively. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We estimate that the annual treatable patient population of low-grade UTUC in the United States is approximately 6,000 to 7,000&#59; the estimated annual treatable population of<span style="letter-spacing:-0.2pt;"> </span>low-grade intermediate risk NMIBC is approximately 80,000. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;font-family:Calibri;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">RTGel<span style="font-style:normal;"> is a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel, which, unlike the general characteristics of most forms of matter, is liquid at lower temperatures and converts into gel form when warmed to body temperature. We believe that these characteristics promote ease of delivery into and retention of drugs in body cavities, including the bladder and the upper urinary tract, forming a transient reservoir of drug that disintegrates over time while preventing rapid excretion, providing for increased dwell time. </span>RTGel<span style="font-style:normal;"> leverages the physiologic flow of urine to provide a natural exit from the body. </span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We believe that <span style="font-style:italic;">RTGel</span>, when formulated with an active drug, may allow for the improved efficacy of treatment of various types of specialty cancers and urologic diseases without compromising the safety of the patient or interfering with the natural flow of fluids in the urinary tract. <span style="font-style:italic;">RTGel</span> achieves this by:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Calibri;">increasing the exposure of active drugs in the bladder and upper urinary tract by significantly extending the dwell time of the active drug while conforming to the anatomy of the bladder and the upper urinary tract, which allows for enhanced drug tissue coverage. For example, the average dwell time of the standard mitomycin water formulation, currently used as adjuvant treatment, in the upper urinary tract is approximately five minutes, compared to approximately six hours when mitomycin is formulated with </span><span style="font-style:italic;font-family:Calibri;">RTGel</span><span style="font-family:Calibri;">&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Calibri;">administering higher doses of an active drug than would otherwise be possible using standard water-based formulations. For instance, it is only possible to dissolve 0.5 mg of mitomycin in 1 mL of water while it is possible to formulate up to 8 mg of mitomycin with 1 mL of </span><span style="font-style:italic;font-family:Calibri;">RTGel</span><span style="font-family:Calibri;">&#59; and </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Calibri;">maintaining the active drug&#8217;s molecular structure and mode of action. </span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">These characteristics of </span><span style="font-style:italic;">RTGel</span><span style="font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> enable sustained release of mitomycin in the urinary tract for both </span><span style="font-style:italic;">Jelmyto</span><span style="font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> and UGN-102. Further, </span><span style="font-style:italic;">RTGel</span><span style="font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> may be particularly effective in the bladder and upper urinary tract where tumor visibility and access are challenging, and where there exists a significant amount of urine flow and voiding. We believe that these characteristics of </span><span style="font-style:italic;">RTGel</span><span style="font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> may prove useful for the local delivery of active drugs to other bodily cavities in addition to the bladder and upper urinary tract.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Calibri;font-size:10pt;text-transform:none;font-variant: normal;">Jelmyto</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On April 15, 2020, the FDA approved our new drug application (&#8220;NDA&#8221;) for <span style="font-style:italic;">Jelmyto</span> (mitomycin) for pyelocalyceal solution, formerly known as UGN-101, for the treatment of adult patients with low-grade UTUC. <span style="font-style:italic;">Jelmyto</span> consists of mitomycin, an established chemotherapy, and sterile hydrogel, using our proprietary sustained release <span style="font-style:italic;">RTGel</span> technology. It has been designed to prolong exposure of urinary tract tissue to mitomycin, thereby enabling the treatment of tumors by non-surgical means. New product exclusivity for <span style="font-style:italic;">Jelmyto</span> exists through April 15, 2023, Orphan Drug exclusivity through April 15, 2027 as well as a composition of matter patent through 2031.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Low-grade UTUC is a rare cancer that develops in the lining of the upper urinary tract, ureters and kidneys. In the United States, there are approximately 6,000 - 7,000 new or recurrent low-grade UTUC patients annually. It is a challenging condition to treat due to the complex anatomy of the urinary tract system. The current standard of care includes multiple surgeries, and most patients require a radical nephroureterectomy, which includes the removal of the renal pelvis, kidney, ureter and bladder cuff. Treatment is further complicated by the fact that low-grade UTUC is most commonly diagnosed in patients over 70 years of age, who may already have compromised kidney function and may suffer further complications as a result of a major surgery.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The FDA approval is based on results from our Phase 3 OLYMPUS trial showing <span style="font-style:italic;">Jelmyto</span> achieved clinically significant disease eradication in adults with low-grade UTUC. Findings from the final study results include:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:10pt;">Complete response (&#8220;CR&#8221;) (primary endpoint) of 58% (41/71) in the intent-to-treat population and in the sub-population of patients who were deemed not capable of surgical removal at diagnosis.</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:10pt;">At the 12-month time point for assessment of durability, 23 patients remained in CR of a total of 41 patients, eight had experienced recurrence of disease and ten patients were unable to be evaluated. </p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:10pt;">Durability of response was estimated to be 81.8% at 12 months by Kaplan-Meier analysis. The median duration of response was not reached. </p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:3pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:3pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:10pt;">The most commonly reported adverse events (&#8805; 20%) were ureteric obstruction, flank pain, urinary tract infection, hematuria, abdominal pain, fatigue, renal dysfunction, nausea, dysuria and vomiting. Most adverse events were mild to moderate and manageable using well established treatments. No treatment-related deaths occurred.</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-right:0.56%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In June 2020, we initiated our commercial launch of <span style="font-style:italic;">Jelmyto</span> in the United States. We have staffed, trained and prepared a commercial team comprising a field force of approximately 48 representatives with deep experience in both urology and oncology. The sales representatives are led by seven regional business managers. Each region is supported by a Clinical Nurse Educator to provide education and training around instillation, as well as a Field Reimbursement manager to help ensure access and reimbursement for appropriate patients. In addition, we have a team of seven medical science liaisons who appropriately engage with physicians interested in learning more about UroGen, <span style="font-style:italic;">Jelmyto</span> and our technology, including through virtual meetings.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are committed to helping patients access <span style="font-style:italic;">Jelmyto</span>. Our market access teams have laid the foundation for coverage and reimbursement, meeting multiple times with payers. The majority of large commercial plans have policies in place, covering over 150 million lives. In addition to reimbursement and access, we have also been focused on ensuring seamless integration into physician practices. We have implemented processes to help make <span style="font-style:italic;">Jelmyto</span> preparation and administration safe and seamless for practitioners and patients, including entering into an agreement with a major national pharmacy under which the pharmacy, following receipt of a patient prescription, prepares and dispenses the <span style="font-style:italic;">Jelmyto</span> admixture on our behalf. <span style="Background-color:#FFFFFF;color:#000000;">In October 2020, a Medicare C-Code was issued for </span><span style="font-style:italic;Background-color:#FFFFFF;color:#000000;">Jelmyto</span><span style="Background-color:#FFFFFF;color:#000000;">. Centers for Medicare &#38; Medicaid Services established a permanent and product-specific J-code for </span><span style="font-style:italic;Background-color:#FFFFFF;color:#000000;">Jelmyto</span><span style="Background-color:#FFFFFF;color:#000000;"> that took effect on January 1, 2021 and replaced the C-Code.</span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Calibri;font-size:10pt;text-transform:none;font-variant: normal;">UGN-102</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are evaluating the safety and efficacy of UGN-102, our novel sustained-release high dose formulation of mitomycin, for the treatment of low-grade intermediate risk NMIBC. </span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have shared final topline data from the Phase 2b OPTIMA II trial for our lead product candidate, UGN-102, in patients with low-grade intermediate risk NMIBC, defined as those with one or two of the following criteria: multifocal disease, large tumors and rapid rates of recurrence. The single-arm, open label trial completed enrollment of 63 patients at clinical sites across the United States and Israel in September 2019. Patients were treated with six weekly instillations of UGN-102 and underwent assessment of complete response, or CR (the primary endpoint) four to six weeks following the last instillation. The interim data were also published as a supplement to the April 2020 issue of The Journal of Urology, and we anticipate publishing the final data in a peer-reviewed journal in 2021. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In November 2020, we reported final topline data consistent with our previous reports showing that 65%, or 41 out of 63 patients, treated with UGN-102 achieved a complete response three months after the start of therapy. <span style="Background-color:#FFFFFF;color:#000000;">In this subset of patients, duration of response at nine months (12-months from initiation of therapy) was estimated by Kaplan-Meier (KM) analysis to be 72.5%. Median duration of response was not reached.</span> The most common adverse events, greater than 10%, were most often reported as mild to moderate in severity and include dysuria, hematuria, urinary frequency, fatigue, urgency and urinary tract infection.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We believe that UGN-102 has the potential to be a new therapeutic option for the treatment of low-grade intermediate risk NMIBC patients. We initiated the Phase 3 ATLAS trial in December 2020 and are currently enrolling patients in this trial assessing UGN-102 with or without trans-urethral resection of bladder tumor (TURBT) compared to standard of care, TURBT.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Urothelial cancer, which is comprised of bladder cancer and UTUC, affects a large, and what we believe to be, an underserved patient population. Annual expenditures for Medicare alone in the United States for the treatment of urothelial cancer were estimated to be at least $5.0 billion in 2020. The majority of the expenditures are spent on tumor resection surgeries such as transurethral resection of bladder tumor, or TURBT. In 2017, the estimated prevalence of urothelial cancer in the United States was 748,000 and in 2020 the annual incidence of urothelial cancer was approximately 85,000. The prevalence in 2017 of&#160;&#160;low-grade intermediate risk NMIBC was approximately 340,000. We estimate based upon a review of peer-reviewed literature and publicly available data that there are approximately 80,000 low-grade intermediate risk NMIBC patients in the U.S. annually.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">UGN-102 is administered locally using the standard practice of intravesical instillation directly into the bladder via a catheter. The instillation into the bladder is expected to take place in a physician&#8217;s office as a same-day treatment, in comparison with TURBT or similar surgical procedures, which are operations conducted under general anesthesia and may require an overnight stay. Surgical tumor removal often has limited success due to the inability to properly identify, reach and resect all tumors. We believe that an effective chemoablation agent can potentially provide better eradication of tumors irrespective of the detectability and location of the tumors. In addition, by removing the need for surgery, patients may avoid potential complications associated with surgery.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Calibri;font-size:10pt;text-transform:none;font-variant: normal;">UGN-302</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our immuno-uro-oncology pipeline includes UGN-302, the sequential use of UGN-201, a TLR 7/8 agonist and UGN-301, an anti-CTLA-4 antibody, being studied as an investigational treatment for high-grade non-muscle invasive bladder cancer (high-grade NMIBC). UroGen&#8217;s approach involves the local delivery of these potent immunomodulators. UGN-301, an immune checkpoint inhibitor, is delivered using UroGen&#8217;s proprietary <span style="font-style:italic;">RTGel</span> platform to increase dwell time, which has been shown to significantly improve the effectiveness of intravesical therapy. UGN-201 is a proprietary novel, liquid formulation of imiquimod, a generic toll-like receptor 7/8, or TLR 7/8 agonist, which has been evaluated for the treatment of high-grade NMIBC, which may include carcinoma in situ, or CIS. Toll-like receptor agonists play a key role in initiating the innate immune response system. We believe that the combination of UGN-201 with UGN-301 could represent a valid alternative to the current standard of care for the post-TURBT adjuvant treatment of high-grade NMIBC. In November 2019, we entered into a worldwide license agreement with Agenus Inc. to develop and commercialize zalifrelimab, an anti-CTLA-4 antibody, via intravesical delivery in combination with UGN-201 (together referred to as UGN-302) for the treatment of urinary tract cancers, initially<span style="letter-spacing:-0.1pt;"> in </span>high-grade NMIBC. We believe that the combination treatment makes local therapy a potentially more effective treatment option while minimizing systemic exposure and potential side effects.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Our Research and Development and License Agreements</span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Calibri;font-size:10pt;text-transform:none;font-variant: normal;">Allergan/AbbVie Agreement</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In October 2016, we entered into the Allergan/AbbVie Agreement and granted Allergan an exclusive worldwide license to research, develop, manufacture and commercialize pharmaceutical products that contain <span style="font-style:italic;">RTGel</span> and clostridial toxins including BOTOX. The license grants the exclusivity for the <span style="font-style:italic;">RTGel</span> and clostridial toxins including BOTOX alone or in combination with certain other active ingredients, referred to as the Licensed Products, which are approved for the treatment of adults with overactive bladder who cannot use or do not adequately respond to anticholinergics. Additionally, we granted Allergan a non-exclusive, worldwide license to use certain of our trademarks as required for Allergan to practice its exclusive license with respect to the Licensed Products.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the Allergan/AbbVie Agreement, Allergan is solely responsible, at its expense, for developing, obtaining regulatory approvals for and commercializing, on a worldwide basis, pharmaceutical products that contain <span style="font-style:italic;">RTGel</span> and clostridial toxins (including BOTOX), alone or in combination with certain other active ingredients, collectively, the Licensed Products. Allergan is obligated to pay us a tiered royalty in the low single digits based on worldwide annual net sales of Licensed Products, subject to certain reductions for the market entry of competing products and/or loss of our patent coverage of Licensed Products. We are responsible for payments to any third party for certain <span style="font-style:italic;">RTGel</span>-related third-party intellectual properties. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In August 2017, we announced that Allergan had submitted an IND to the FDA in order to be able to commence clinical trials in the United States using an <span style="font-style:italic;">RTGel</span> formulation in combination with BOTOX. In October 2017, Allergan commenced a Phase 2 clinical trial of BOTOX/<span style="font-style:italic;">RTGel</span> for the treatment of OAB, with the potential to evolve from multiple injections of BOTOX into the bladder to a single instillation of the novel formulation.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In August 2020, we announced that the Phase 2 APOLLO trial did not meet the primary endpoint, it is believed to be the result of BOTOX not effectively permeating the urothelium. We are continuing to explore the potential use of <span style="font-style:italic;">RTGel</span> in combination with other products in AbbVie&#8217;s portfolio.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Calibri;text-transform:none;font-variant: normal;">Agenus Agreement</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In November 2019, we entered into a license agreement with Agenus Inc. (&#8220;Agenus&#8221;). Pursuant to the agreement, Agenus granted us an exclusive, worldwide license (not including Argentina, Brazil, Chile, Colombia, Peru, Venezuela and their respective territories and possessions), royalty-bearing, sublicensable license under Agenus&#8217;s intellectual property rights to develop, make, use, sell, import and otherwise commercialize products incorporating a proprietary antibody of Agenus known as AGEN1884 for the treatment of cancers of the urinary tract via intravesical delivery. AGEN1884 is an anti-CTLA-4 antagonist that is currently being evaluated by Agenus as a monotherapy in PD-1 refractory patients and in combination with Agenus&#8217; anti-PD-1 antibody (AGEN2034) in solid tumors. <span style="color:#000000;">UGN-301 is a formulation of </span><span style="font-style:italic;color:#000000;">RTGel</span><span style="color:#000000;"> and zalifrelimab that is in early-stage development for high-grade NMIBC.</span></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Calibri;font-size:10pt;text-transform:none;font-variant: normal;">MD Anderson Agreement</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Based on nonclinical studies conducted by us, UGN-201 in combination with anti-CTLA-4 antagonists have shown encouraging results for the potential treatment of high-grade NMIBC. <span style="color:#000000;">In January 2021, we announced that we entered into a three-year strategic research collaboration agreement with MD Anderson focusing on UGN-302 as an investigational treatment for high-grade NMIBC. Under the agreement, MD Anderson and UroGen will collaborate on the design and conduct of non-clinical and clinical studies with oversight from a joint steering committee. UroGen will provide funding, developmental candidates, and other support</span>. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For additional information regarding our research and development and license agreements, see Note 11 to our financial statements appearing elsewhere in this Quarterly Report.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Impact of COVID-19 Pandemic</p>
<p style="margin-top:12pt;margin-bottom:6pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the event of a prolonged disruption related to COVID-19, there could be detrimental impact to our ongoing and future clinical trials, our ongoing commercial launch and future commercialization activities for Jelmyto, and our ability to access capital markets. Specifically, we have experienced a delay in site initiation activities in certain countries outside the U.S. within our UGN-102 clinical trial as well as a softening of our first quarter 2021 Jelmyto revenues.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:6pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Recently, the U.S. has mounted a comprehensive COVID-19 vaccination campaign. </span><span style="font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the first quarter 2021, t</span><span style="font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">he staged vaccination rollout prioritize</span><span style="font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">d</span><span style="font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> health-care workers, certain other essential workers and high-risk populations, which generally include</span><span style="font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">d</span><span style="font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> individuals in their 60s and 70s, and individuals with certain underlying medical conditions. </span><span style="font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We believe t</span><span style="font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">he vaccination effort in the U.S. </span><span style="font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">impacted</span><span style="font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> our ongoing commercialization of </span><span style="font-style:italic;">Jelmyto</span><span style="font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> in </span><span style="font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">three</span><span style="font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> main aspects. </span><span style="font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">First, current or potentially eligible patients chose to delay their procedures until after they have been vaccinated for COVID-19. Second, the p</span><span style="font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">rioritization of hospital and clinic resources towards the vaccination effort may </span><span style="font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">have </span><span style="font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">hinder</span><span style="font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ed</span><span style="font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> the ability of patients who are currently using </span><span style="font-style:italic;">Jelmyto</span><span style="font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> or who are eligible to use </span><span style="font-style:italic;">Jelmyto</span><span style="font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> to schedule </span><span style="font-style:italic;">Jelmyto</span><span style="font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> instillation procedures. </span><span style="font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lastly, our commercial team was limited in their ability to visit hospitals and clinics due to many facilities restricting access. </span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of the end of April 2021, the majority of people over age 65 in the U.S. have received vaccinations to protect against COVID-19, we believe this is correlated with the increasing amount of new patient starts we observed in both March and April. It is difficult to predict how COVID-19, and any associated variants, will impact the healthcare industry for the remainder of 2021, as such we continue to monitor the evolving COVID-19 situation, and the potential further impacts that the pandemic and related government response may have on our business throughout 2021.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Components of Operating Results</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Calibri;font-size:10pt;text-transform:none;font-variant: normal;">Revenues</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#auto;font-size:10pt;font-family:Calibri;letter-spacing:0.25pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the three months ended March&#160;31, 2021 we recognized $7.5 million, of revenues from sales of our product, <span style="font-style:italic;">Jelmyto</span>. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Calibri;font-size:10pt;text-transform:none;font-variant: normal;">Cost of Revenues</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cost of revenues consist primarily of inventory and related costs associated with the manufacturing, distribution, warehousing and preparation of <span style="font-style:italic;">Jelmyto</span>. In periods prior to receiving FDA approval for <span style="font-style:italic;">Jelmyto</span>, we recognized inventory and related costs associated with the manufacture of <span style="font-style:italic;">Jelmyto</span> as research and development expenses.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Calibri;font-size:10pt;text-transform:none;font-variant: normal;">Research and Development Expenses</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development expenses, net consist primarily of:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Calibri;">salaries and related costs, including share-based compensation expense, for our personnel in research and development functions&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Calibri;">expenses incurred under agreements with third parties, including clinical research organizations (&#8220;CROs&#8221;), subcontractors, suppliers and consultants, nonclinical studies and clinical trials&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Calibri;">expenses incurred to acquire, develop and manufacture nonclinical study and clinical trial materials&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Calibri;">expenses incurred to purchase active pharmaceutical ingredient (&#8220;API&#8221;) and other related manufacturing costs&#59; and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Calibri;">facility and equipment costs, including depreciation expense, maintenance and allocated direct and indirect overhead costs. </span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We expense all research and development costs as incurred. We estimate nonclinical study and clinical trial expenses based on the services performed pursuant to contracts with research institutions and contract research organizations that conduct and manage nonclinical studies and clinical trials on our behalf based on actual time and expenses incurred by them.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We accrue for costs incurred as the services are being provided by monitoring the status of the trial or project and the invoices received from our external service providers. We adjust our accrual as actual costs become known. Where at risk contingent milestone payments are due to third parties under research and development and collaboration agreements, the milestone payment obligations are expensed when the milestone results are achieved.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have received grants under the Israeli Law for the Encouragement of Industrial Research, Development and Technological Innovation, 5754-1984 (the &#8220;R&#38;D Law&#8221;), from the Israel Innovation Authority in Israel (the &#8220;IIA&#8221;), formerly known as the Office of the Chief Scientist of the Ministry of Economy and Industry, an independent and impartial public entity, for some of our development programs. Through March&#160;31, 2021, we had received grants in the aggregate amount of $2.1&#160;million. On January 12, 2020, the IIA Office of Chief Scientist approved the Company&#8217;s request to unwind its obligation to the IIA regarding grants that were loaned to the Company between January 2004 and September 2016. The total payment under the IIA approval, net of the royalties already paid, amounts to $6.6 million, which was fully paid during the first quarter of 2020. See Note 16 to the Consolidated Financial Statements included in this report for additional information.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are currently focused on advancing our product candidates, and our future research and development expenses will depend on their clinical success. Research and development expenses will continue to be significant and will increase over at least the next several years as we continue to develop our product candidates and conduct </span><span style="font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">nonclinical</span><span style="font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> studies and clinical trials of our product candidates.</span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development activities are central to our business model. Product candidates in later stages of clinical development generally have higher development costs than those in earlier stages of clinical development, primarily due to the increased size and duration of later-stage clinical trials. We do not believe that it is possible at this time to accurately project total expenses required for us to reach commercialization of our product candidates. Due to the inherently unpredictable nature of nonclinical and clinical development, we are unable to estimate with certainty the costs we will incur and the timelines that will be required in the continued development and approval of our product candidates. Clinical and nonclinical development timelines, the probability of success and development costs can differ materially from expectations. In addition, we cannot forecast which product candidates may be subject to future collaborations, if and when such arrangements will be entered into, if at all, and to what degree such arrangements would affect our development plans and capital requirements. We expect our research and development expenses to increase over the next several years as our clinical programs progress and as we seek to initiate clinical trials of additional product candidates. We also expect to incur increased research and development expenses as we selectively identify and develop additional product candidates. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The duration, costs and timing of clinical trials and development of our product candidates will depend on a variety of factors that include, but are not limited to, the following:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Calibri;color:#000000;">per patient trial costs&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Calibri;color:#000000;">the number of patients that participate in the trials&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Calibri;color:#000000;">the number of sites included in the trials&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Calibri;color:#000000;">the countries in which the trials are conducted&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Calibri;color:#000000;">the length of time required to enroll eligible patients&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Calibri;color:#000000;">delays or operational challenges resulting from the ongoing COVID-19 pandemic&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Calibri;color:#000000;">the number of doses that patients receive&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Calibri;color:#000000;">the drop-out or discontinuation rates of patients&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Calibri;color:#000000;">potential additional safety monitoring or other studies requested by regulatory agencies&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Calibri;color:#000000;">the duration of patient follow-up&#59; and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Calibri;color:#000000;">the efficacy and safety profile of the product candidates.</span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, the probability of success for each product candidate will depend on numerous factors, including competition, manufacturing capability and commercial viability. We will determine which programs to pursue and how much to fund each program in response to the scientific and clinical success of each product candidate, as well as an assessment of each product candidate<span style="color:#000000;">&#8217;</span>s commercial potential.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other than <span style="font-style:italic;">Jelmyto</span>, which was approved by the FDA in April 2020, we have not received approval of any of our product candidates. UGN-102 is still in clinical development and our other product candidates are in nonclinical development, and the outcome of these efforts is uncertain. As such, we cannot estimate the actual amounts necessary to successfully complete the development and commercialization of our product candidates or whether, or when, we may achieve profitability. Until such time, if ever, as we can generate substantial product revenue, we expect to finance our cash needs through a combination of equity or debt financings and collaboration arrangements. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">License fees and development milestone payments related to in-licensed products and technology are expensed as incurred if it is determined at that point that they have no established alternative future use. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Calibri;font-size:10pt;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;color:#000000;font-family:Calibri;font-size:10pt;text-transform:none;font-variant: normal;">Selling</span><span style="font-weight:bold;font-style:italic;color:#000000;font-family:Calibri;font-size:10pt;text-transform:none;font-variant: normal;"> and Marketing Expenses</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To date, selling and marketing expenses consist primarily of commercial personnel costs (including share-based compensation) along with pre-commercialization and initial commercialization activities related to <span style="font-style:italic;">Jelmyto</span>, formerly known as UGN-101<span style="color:#000000;">. We anticipate that our selling and marketing expenses will increase in 2021 as we continue the commercialization of </span><span style="font-style:italic;color:#000000;">Jelmyto</span><span style="color:#000000;">.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Calibri;font-size:10pt;text-transform:none;font-variant: normal;">General and Administrative Expenses</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative expenses consist primarily of personnel costs (including share-based compensation related to directors, executives, finance, medical affairs, business development, investor relations, and human resource functions). Other significant costs include medical affairs services, external professional service costs, facility costs, accounting and audit services, legal services, and other consulting fees.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We anticipate that our general and administrative expenses will increase in the future as we increase our administrative headcount and infrastructure to support the potential approval and commercialization of our product candidates and our continued research and development programs. These increases will likely include increased costs related to the hiring of additional personnel and fees to outside consultants, lawyers and accountants, among other expenses. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Calibri;font-size:10pt;text-transform:none;font-variant: normal;">Interest and Other Income (Expenses), Net</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest and other income (expenses), net, consisted primarily of interest income.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Calibri;font-size:10pt;text-transform:none;font-variant: normal;">Income Taxes</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have yet to generate taxable income in Israel. We have historically incurred operating losses resulting in carry forward tax losses totaling approximately $250.2 million as of December 31, 2020. We anticipate that we will continue to generate tax losses for the foreseeable future and that we will be able to carry forward these tax losses indefinitely to future taxable years. Accordingly, we do not expect to pay taxes in Israel until we have taxable income after the full utilization of our carry forward tax losses. We have provided a full valuation allowance with respect to the deferred tax assets related to these carry forward losses. Income tax expense also consists of our estimate of uncertain tax positions, and related interest and penalties. <span style="color:#000000;">See Note 14 to the Consolidated Financial Statements for further information.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Critical Accounting Policies and Significant Judgments and Estimates</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of our unaudited condensed consolidated financial statements requires us to make estimates, judgments and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities, and the revenues and expenses incurred during the reported periods. In accordance with GAAP, we base our estimates on historical experience and on various other factors that we believe are reasonable under the circumstances at the time such estimates are made. Actual results may differ from these estimates under different assumptions or conditions. We discussed the critical accounting policies used in the preparation of our financial statements in <span style="font-style:italic;">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span> included in the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2020 as filed with the SEC on March 18, 2021 (&#8220;Annual Report&#8221;) as well as in the Note 3 <span style="color:#000000;">to the Consolidated Financial Statements included in this report</span>.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Results of Operations</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Calibri;font-size:10pt;text-transform:none;font-variant: normal;">Comparison of the three months ended March&#160;31, 2021 and 2020</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table sets forth our results of operations for the three months ended March&#160;31, 2021 and 2020.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="10" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.3%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended March&#160;31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Change</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="10" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.3%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Revenues</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,485</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,485</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cost of revenues</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">897</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">897</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Gross profit</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,588</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,588</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating expenses:</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,513</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16,588</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(6,075</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Selling and marketing</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,435</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,651</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">784</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,754</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,322</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(568</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total operating expenses</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32,702</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">38,561</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5,859</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating loss</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(26,114</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(38,561</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,447</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest and other income, net</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">179</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">768</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(589</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(25,935</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(37,793</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,858</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;font-family:Calibri;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Revenues</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Revenues were $7.5 million and $0 for the three months ended March&#160;31, 2021 and 2020, respectively. The increase in revenues of $7.5 million reflects sales of our product <span style="font-style:italic;">Jelmyto</span> following its approval by the FDA in April 2020. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;font-family:Calibri;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Cost of Revenues</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cost of revenues were $0.9 million and $0 for the three months ended March&#160;31, 2021 and 2020, respectively. In periods prior to receiving FDA approval for <span style="font-style:italic;">Jelmyto</span>, we recognized inventory and related costs associated with the manufacture of <span style="font-style:italic;">Jelmyto</span> as research and development expenses. We expect this to continue to impact cost of revenues through the second quarter of 2022 as we produce <span style="font-style:italic;">Jelmyto</span> at costs reflecting the full costs of manufacturing and as we deplete inventories that we had expensed prior to receiving FDA approval. Gross margin would have been approximately 85.6% versus 88.0% for the three months ended March 31, 2021 if we had not sold <span style="font-style:italic;">Jelmyto</span> units that were expensed prior to regulatory approval.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;font-family:Calibri;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Research and Development Expenses</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development (R&#38;D) expenses were $10.5 million and $16.6 million for the three months ended March&#160;31, 2021 and 2020, respectively. The overall decrease of $6.1 million is primarily attributable to the one-time payment in the prior year of $6.6 million to unwind our obligation to the IIA. Excluding the impact of the payment to the IIA, R&#38;D expenses remained largely consistent, however, for the three months ended March 31, 2021 primarily related to the development of UGN-102, as compared to the March 31, 2020 where R&#38;D expenses primarily related to <span style="font-style:italic;">Jelmyto.</span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-style:italic;font-family:Calibri;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Selling and Marketing Expenses</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Selling and marketing expenses were $11.4 million and $10.7 million for the three months ended March&#160;31, 2021 and 2020, respectively. The increase in selling and marketing expenses of $0.7 million is primarily attributable to salaries and benefits of the commercial and marketing team members who joined subsequent to March 31, 2020, partially offset by higher brand marketing expenses in the first quarter of 2020 in preparation for the commercialization of <span style="font-style:italic;">Jelmyto</span>. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-style:italic;font-family:Calibri;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">General and Administrative Expenses</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative expenses were $10.8 million and $11.3 million for the three months ended March&#160;31, 2021 and 2020, respectively. The decrease in general and administrative expenses of $0.5 million resulted primarily from a decrease in share-based compensation. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-style:italic;font-family:Calibri;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"><span style="font-style:italic;font-family:Calibri;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Interest and Other</span><span style="font-style:italic;font-family:Calibri;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"> Income</span><span style="font-style:italic;font-family:Calibri;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"> </span><span style="font-style:italic;font-family:Calibri;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">(</span><span style="font-style:italic;font-family:Calibri;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Expense</span><span style="font-style:italic;font-family:Calibri;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">s</span><span style="font-style:italic;font-family:Calibri;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">)</span><span style="font-style:italic;font-family:Calibri;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">, Net</span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest and other income (expenses), net, was $0.2 million and $0.8 million for the three months ended March&#160;31, 2021 and 2020, respectively. The decrease in interest and other income (expenses), net of $0.6 million was <span style="Background-color:#FFFFFF;color:#000000;">primarily due to a decrease in our cash and cash equivalents and marketable securities.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Liquidity and Capital Resources</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of March&#160;31, 2021, we had $75.9 million in cash and cash equivalents and marketable securities. Cash in excess of immediate requirements is invested in accordance with our investment policy, primarily with a view to liquidity and capital preservation, and is held primarily in U.S. dollars. Based on our cash flow projections, we believe that our current cash and cash equivalents and marketable securities are sufficient to fund our planned operations for at least the next 12 months.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Through March&#160;31, 2021, we funded our operations primarily through public equity offerings and private placements of equity securities. </p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In December 2019, we entered into a sales agreement (the &#8220;ATM Sales Agreement&#8221;) with Cowen and Company, LLC (&#8220;Cowen&#8221;)<span style="font-size:12pt;"> </span>pursuant to which we may from time to time offer and sell our ordinary shares having an aggregate offering price of up to $100.0 million. The shares are offered and will be sold pursuant to a shelf registration statement on Form S-3 which was declared effective by the SEC on January 2, 2020. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the second quarter of 2020, we sold 700,000 ordinary shares under the ATM Sales Agreement, for gross proceeds of approximately $16.6 million. The net proceeds to us after deducting sales commissions to Cowen and other issuance expenses were approximately $15.8 million. The remaining capacity under the ATM Sales Agreement is approximately $83.4 million.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In March 2021, UroGen and RTW Investments (&#8220;RTW&#8221;) announced a transaction totaling $75.0 million in funding for us to support the launch of Jelmyto and the development of UGN-102. RTW will provide us with an upfront cash payment of $75.0 million and will receive tiered future payments based on global annual net product sales of Jelmyto and UGN-102, if approved. We received the $75.0 million of cash in May 2021 following the receipt of necessary regulatory approvals. </p>
<p style="margin-top:12pt;margin-bottom:6pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have incurred losses since our inception and negative cash flows from our operations, and as of March&#160;31, 2021 we had an accumulated deficit of $382.4 million. We anticipate that we will continue to incur losses for at least the next two years. Our primary uses of capital are, and we expect will continue to be, commercialization activities, research and development expenses, including third-party clinical research and development services, laboratory and related supplies, clinical costs, including manufacturing costs, legal and other regulatory expenses and general and administrative costs, partially offset by proceeds from sales of Jelmyto.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We cannot estimate the actual amounts necessary to successfully commercialize any approved products, including Jelmyto, or whether, or when, we may achieve profitability. Until such time, if ever, as we can generate substantial product revenue, we expect to finance our cash needs through a combination of equity or debt financings and collaboration arrangements.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Calibri;font-size:10pt;text-transform:none;font-variant: normal;">Cash Flows</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table sets forth the significant sources and uses of cash for the periods set forth below:&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:70%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.54%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended March&#160;31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash (used in) provided by:</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating activities</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(27,401</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(35,635</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Investing activities</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,024</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,025</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financing activities</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">90</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net change in cash and cash equivalents</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(12,373</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(22,520</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"><span style="font-style:italic;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Operating Activities</span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash used in operating activities was $27.4 million during the three months ended March&#160;31, 2021, compared to $35.6 million during the three months ended March&#160;31, 2020. The $8.2 million decrease was attributable primarily to the decrease of $11.9 million in the net loss driven by revenue from sales of our product <span style="font-style:italic;">Jelmyto</span> during the three months ended March 31, 2021, as well as the payment to the IIA during the three months ended March 31, 2020, partially offset by inventory build and sales commission payments during the three months ended March 31, 2021.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Investing Activities</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash provided by investing activities was $15.0 million during the three months ended March&#160;31, 2021, compared to $13.0 million provided by investing activities during the three months ended March&#160;31, 2020. The increase of $2.0 million is primarily related to a decrease in purchases of marketable securities as compared to the prior year.  </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Financing Activities</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash provided by financing activities was $4,000 during the three months ended March&#160;31, 2021, compared to $0.1 million during the three months ended March&#160;31, 2020. The decrease of $0.1 million is primarily related a decrease in proceeds from exercise of options, partially offset by reduction in issuance costs.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Off&#8209;Balance Sheet Arrangements</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the periods presented, we did not have, nor do we currently have, any off&#8209;balance sheet arrangements as defined under SEC rules.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_3_QUANTITATIVE_QUALITATIVE_DISCLOSU">Item 3. Quantitative and Qualitative Disclosures About Market Risk.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Calibri;font-size:10pt;text-transform:none;font-variant: normal;">Interest Rate Fluctuation Risk</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Some of the securities in which we invest have market risk in that a change in prevailing interest rates may cause the principal amount of the marketable securities to fluctuate. Financial instruments that potentially subject us to significant concentrations of credit risk consist primarily of cash and cash equivalents and marketable securities. <span style="Background-color:#FFFFFF;color:#000000;">As of March&#160;31, 2021 </span>we had $75.9 million of cash and cash equivalents and marketable securities.<span style="Background-color:#FFFFFF;color:#000000;"> </span>We invest our cash primarily in money market accounts, but also invest in commercial paper and debt instruments of financial institutions, corporations, U.S. government-sponsored agencies and the U.S. Treasury. The primary objectives of our investment activities are to ensure liquidity and to preserve principal while at the same time maximizing the income we receive from our marketable securities without significantly increasing risk. We have established guidelines regarding approved investments and maturities of investments, which are designed to maintain safety and liquidity. If a 10% change in interest rates were to have occurred on March&#160;31, 2021, this change would not have had a material effect on the fair value of our cash and cash equivalents and marketable securities as of that date.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Calibri;font-size:10pt;text-transform:none;font-variant: normal;">Inflation Risk</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inflation generally may affect us by increasing our cost of labor and clinical trial costs. Inflation has not had a material effect on our business, financial condition or results of operations during the three months ended March&#160;31, 2021 and 2020.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Calibri;font-size:10pt;text-transform:none;font-variant: normal;">Foreign Currency Exchange Risk</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The U.S. dollar is our functional and reporting currency. However, a significant portion of our operating expenses are incurred in NIS. As a result, we are exposed to the risk that the NIS may appreciate relative to the dollar, or, if the NIS instead devalues relative to the dollar, that the inflation rate in Israel may exceed such rate of devaluation of the NIS, or that the timing of such devaluation may lag behind inflation in Israel. In any such event, the dollar cost of our operations in Israel would increase and our dollar-denominated results of operations would be adversely affected. We cannot predict any future trends in the rate of inflation in Israel or the rate of devaluation, if any, of the NIS against the dollar. For example, although the dollar appreciated against the NIS in 2018 by 8.1%, the dollar depreciated against the NIS during 2019 and 2020 by a total of 14.2%. If the dollar cost of our operations in Israel increases, our dollar-measured results of operations will be adversely affected. Our operations also could be adversely affected if we are unable to effectively hedge against currency fluctuations in the future.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We do not currently engage in currency hedging activities in order to reduce this currency exposure, but we may begin to do so in the future. Instruments that may be used to hedge future risks may include foreign currency forward and swap contracts. These instruments may be used to selectively manage risks, but there can be no assurance that we will be fully protected against material foreign currency fluctuations.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_4_CONTROLS_PROCEDURES">Item 4. Controls and Procedures.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Calibri;font-size:10pt;text-transform:none;font-variant: normal;">Evaluation of Disclosure Controls and Procedures</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our management, with the participation of our chief executive and financial officers (our principal executive officer and principal financial officer, respectively), evaluated the effectiveness of our disclosures controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act, as of March&#160;31, 2021. The term &#8220;disclosure controls and procedures,&#8221; as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act, means controls and other procedures of a company that are designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC&#8217;s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the company&#8217;s management, including its principal executive and principal financial officers, as appropriate, to allow timely decisions regarding required disclosure. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Based on the evaluation of our disclosure controls and procedures as of March&#160;31, 2021, our principal executive officer and principal financial officer concluded that, as of such date, our disclosure controls and procedures were effective at a reasonable assurance level<span style="color:#000000;">.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Calibri;font-size:10pt;text-transform:none;font-variant: normal;">Changes in Internal Control over Financial Reporting</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We regularly review our system of internal control over financial reporting and make changes to our processes and systems to improve controls and increase efficiency, while ensuring that we maintain an effective internal control environment. Changes may include such activities as implementing new, more efficient systems, consolidating activities, and migrating processes. During the quarter ended March 31, 2021, we implemented a new enterprise resource planning (&#8220;ERP&#8221;) system which is expected to improve the efficiency of certain financial and related transactional processes. This implementation affects the processes that constitute our internal control over financial reporting and requires testing for effectiveness. We expect to continue to enhance our finance systems and processes for automation and efficiency, and strengthen internal control over financial reporting.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There were no further changes in our internal control over financial reporting during the quarter ended March 31, 2021 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting<span style="color:#000000;">.</span></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="PART_IIOR_INFORMATION">Part II&#8212;Other Information</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_1_LEGAL_PROCEEDINGS">Item 1. Legal Proceedings.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">From time to time, we may be involved in various claims and legal proceedings relating to claims arising out of our operations. We are not currently a party to any legal proceedings that, in the opinion of our management, are likely to have a material adverse effect on our business. Regardless of outcome, litigation can have an adverse impact on us because of defense and settlement costs, diversion of management resources and other factors.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_1A_RISK_FACTORS">Item 1A. Risk Factors.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Risk Factor Summary</p>
<p style="margin-bottom:12pt;margin-top:6pt;text-indent:0%;font-style:italic;font-family:Calibri;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Below is a summary of the principal factors that make an investment in our ordinary shares speculative or risky. This summary does not address all of the risks that we face. Additional discussion of the risks summarized in this risk factor summary, and other risks that we face, can be found below under the heading &#8220;Risk Factors&#8221; and should be carefully considered, together with other information in this Quarterly Report on Form 10-Q and our other filings with the SEC before making investment decisions regarding our ordinary shares.</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Calibri;">We are highly dependent on the successful commercialization of our only approved product, </span><span style="font-style:italic;font-family:Calibri;">Jelmyto</span><span style="font-family:Calibri;">.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Calibri;">We have limited experience as an organization in marketing and distributing products and are therefore subject to certain risks in relation to the commercialization of </span><span style="font-style:italic;font-family:Calibri;">Jelmyto</span><span style="font-family:Calibri;"> and any of our other product candidates that receives regulatory approval.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Calibri;">The market opportunities for </span><span style="font-style:italic;font-family:Calibri;">Jelmyto</span><span style="font-family:Calibri;"> and our product candidates may be limited to those patients who are ineligible for established therapies or for whom prior therapies have failed and may be small.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-style:italic;font-family:Calibri;">Jelmyto</span><span style="font-family:Calibri;"> and any our product candidates that receive regulatory approval may fail to achieve the broad degree of physician adoption and use and market acceptance necessary for commercial success.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-style:italic;font-family:Calibri;">Jelmyto</span><span style="font-family:Calibri;"> and our product candidates, if approved, will face significant competition with competing technologies and our failure to compete effectively may prevent us from achieving significant market penetration.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Calibri;">In addition to </span><span style="font-style:italic;font-family:Calibri;">Jelmyto</span><span style="font-family:Calibri;">, we are dependent on the success of our lead product candidate, UGN-102, and our other product candidates, including obtaining regulatory approval to market our product candidates in the United States.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Calibri;">Clinical drug development involves a lengthy and expensive process with an uncertain outcome, results of earlier studies and trials may not be predictive of future trial results, and our clinical trials may fail to adequately demonstrate the safety and efficacy of our product candidates.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Calibri;">We have entered into a licensing agreement and in the future may enter into collaborations with other third parties for the development or commercialization of our product candidates. If our collaborations are not successful, we may not be able to capitalize on the market potential of these product candidates. </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Calibri;">We currently contract with third-party subcontractors and single-source suppliers for certain raw materials, compounds and components necessary to produce </span><span style="font-style:italic;font-family:Calibri;">Jelmyto</span><span style="font-family:Calibri;"> for commercial use, and to produce UGN-102 and UGN-201 for nonclinical studies and clinical trials, and expect to continue to do so to support commercial scale production of UGN-102 and UGN-201, if approved. There are significant risks associated with the manufacture of pharmaceutical products and contracting with contract manufacturers, including single-source suppliers. Furthermore, our existing third-party subcontractors and single-source suppliers may not be able to meet the increased need for certain raw materials, compounds and components that may result from our commercialization efforts. This increases the risk that we will not have sufficient quantities of </span><span style="font-style:italic;font-family:Calibri;">Jelmyto</span><span style="font-family:Calibri;">, UGN-102 or UGN-201 or be able to obtain such quantities at an acceptable cost, which could delay, prevent or impair our development or commercialization efforts.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Calibri;">If product liability lawsuits are brought against us, we may incur substantial liabilities and may be required to limit commercialization of any of our other products we develop.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Calibri;">If we fail to attract and keep senior management and key personnel, we may be unable to successfully develop our product candidates, conduct our clinical trials and commercialize any of the products we develop. </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Calibri;">Our business could be adversely affected by the effects of health pandemics or epidemics, including the COVID-19 pandemic.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Calibri;">We have a limited operating history and have incurred significant losses and negative cash flows since our inception, and we anticipate that we will continue to incur significant losses and negative cash flows for the foreseeable future, which makes it difficult to assess our future viability.</span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span><span style="font-family:Calibri;">We will require substantial additional financing to achieve our goals, and a failure to obtain this capital when needed and on acceptable terms, or at all, could force us to delay, limit, reduce or terminate our product development, commercialization efforts or other operations.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Calibri;">If our efforts to obtain, protect or enforce our patents and other intellectual property rights related to our product candidates and technologies are not adequate, we may not be able to compete effectively, and we otherwise may be harmed.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Calibri;">If the FDA does not conclude that UGN-102 satisfies the requirements under Section 505(b)(2) of the Federal Food Drug and Cosmetic Act, or Section 505(b)(2), or if the requirements for our product candidates are not as we expect, the approval pathway for these product candidates will likely take significantly longer, cost significantly more and entail significantly greater complications and risks than anticipated, and in either case may not be successful.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-style:italic;font-family:Calibri;">Jelmyto</span><span style="font-family:Calibri;"> and any of product candidates that receives regulatory approval will be subject to ongoing regulatory obligations and continued regulatory review, which may result in significant additional expenses, limit or withdraw regulatory approval and subject us to penalties if we fail to comply with applicable regulatory requirements.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Calibri;color:#000000;">It may be difficult for us to profitably sell our product candidates if coverage and reimbursement for these products is limited by government authorities and/or third-party payor policies.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:0pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Calibri;">Our research and development and other significant operations are located in Israel and, therefore, our results may be adversely affected by political, economic and military instability in Israel.</span></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Risk Factors</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Calibri;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">You should carefully consider the following risk factors, as well as the other information in this report, before deciding whether to purchase, hold or sell shares of our ordinary shares. The occurrence of any of the following risks could harm our business, financial condition, results of operations and/or growth prospects or cause our actual results to differ materially from those contained in forward-looking statements we have made in this report and those we may make from time to time. When evaluating our business, you should consider all of the factors described as well as the other information in our Annual Report, including our financial statements and the related notes, &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operation&#8221; and&#160;&#160;Item 1A, &#8220;Risk Factors&#8221; of our Form 10-K for the year ended December&#160;31, 2020, as filed with the Securities and Exchange Commission (&#8220;SEC&#8221;) on March 18, 2021. The risk factors set forth below did not appear as risk factors in, or contain changes to the similarly titled risk factors included in, Item 1A of our Annual Report. If any of the following risks actually occurs, our business, financial condition, results of operations and future growth prospects would likely be materially and adversely affected. In these circumstances, the market price of our ordinary shares would likely decline and you may lose all or part of your investment. Additional risks and uncertainties not presently known to us or that we currently deem immaterial also may impair our business operations.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">Risks Related to Our Business and Strategy </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Calibri;text-transform:none;font-variant: normal;">We are highly dependent on the successful commercialization of our only approved product, Jelmyto. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">Other than </span><span style="font-style:italic;Background-color:#FFFFFF;">Jelmyto</span><span style="Background-color:#FFFFFF;">, which we commercially launched in the United States in June 2020, we have not commercialized any other product candidates. </span><span style="color:#000000;">We have invested significant efforts and financial resources in the research and development of </span><span style="font-style:italic;color:#000000;">Jelmyto</span><span style="color:#000000;">, our first and only product approved for commercial sale. </span>We are focusing a significant portion of our activities and resources on <span style="font-style:italic;">Jelmyto</span>, and we believe our prospects are highly dependent on, and a significant portion of the value of our company relates to, our ability to successfully commercialize <span style="font-style:italic;">Jelmyto</span> in the United States. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Successful commercialization of <span style="font-style:italic;">Jelmyto</span> is subject to many risks. We have only recently initiated our commercial launch of <span style="font-style:italic;">Jelmyto</span>, and prior to that, we have never, as an organization, launched or commercialized any product. There is no guarantee that our ongoing commercial launch of <span style="font-style:italic;">Jelmyto</span> or our future commercialization efforts will be successful, or that we will be able to successfully launch and commercialize any other product candidate that receives regulatory approval. There are numerous examples of unsuccessful product launches and failures to meet high expectations of market potential, including by pharmaceutical companies with more experience and resources than us. While we have established our commercial team and have hired our U.S. sales force, we will need to maintain, further train and develop our team in order to be prepared to successfully coordinate the ongoing launch and commercialization of <span style="font-style:italic;">Jelmyto</span>. Even if we are successful in maintaining and further developing our commercial team, there are many factors that could cause the ongoing launch and commercialization of <span style="font-style:italic;">Jelmyto</span> to be unsuccessful, including a number of factors that are outside our control. <span style="color:#000000;">We must also properly train physicians and nurses for the skillful preparation and administration of </span><span style="font-style:italic;color:#000000;">Jelmyto</span><span style="color:#000000;">, and develop a broad experiential knowledge base of aggregated clinician feedback from which we can refine appropriate procedures for product administration, without which there could be a risk of adverse events. </span></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Because no drug has previously been approved by the FDA for the treatment of low-grade UTUC, it is especially difficult to estimate </span><span style="font-style:italic;">Jelmyto</span><span style="color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8217;s market potential. The commercial success of </span><span style="font-style:italic;">Jelmyto</span><span style="color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> depends on the extent to which patients and physicians accept and adopt </span><span style="font-style:italic;">Jelmyto</span><span style="color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> as a treatment for low-grade UTUC, and we do not know whether our or others&#8217; estimates in this regard will be accurate. For example, if the patient population suffering from low-grade UTUC is smaller than we estimate or if physicians are unwilling to prescribe or patients are unwilling to be treated with </span><span style="font-style:italic;">Jelmyto</span><span style="color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> due to label warnings, adverse events associated with product administration or other reasons, the commercial potential of </span><span style="font-style:italic;">Jelmyto</span><span style="color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> will be limited. At this time, we have only limited information regarding how physicians, patients and payors will respond to the pricing of </span><span style="font-style:italic;">Jelmyto</span><span style="color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. Physicians may not prescribe </span><span style="font-style:italic;">Jelmyto</span><span style="color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> and patients may be unwilling to be treated with </span><span style="font-style:italic;">Jelmyto</span><span style="color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> if coverage is not provided or reimbursement is inadequate to cover a significant portion of the cost.</span><span style="font-weight:bold;font-style:italic;">&#160;</span><span style="color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additionally, any negative development for </span><span style="font-style:italic;">Jelmyto</span><span style="color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> in our post-marketing commitments, or in regulatory processes in other jurisdictions, may adversely impact the commercial results and potential of </span><span style="font-style:italic;">Jelmyto</span><span style="color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. Thus, significant uncertainty remains regarding the commercial potential of </span><span style="font-style:italic;">Jelmyto</span><span style="color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;color:#212529;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">In addition, our ongoing commercial launch of </span><span style="font-style:italic;Background-color:#FFFFFF;">Jelmyto</span><span style="Background-color:#FFFFFF;"> and subsequent commercialization efforts could be hindered by the&#160;COVID-19&#160;pandemic, although we are currently not able to predict or quantify any such potential impact with any degree of certainty.</span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If the launch or commercialization of <span style="font-style:italic;">Jelmyto</span> is unsuccessful or perceived as disappointing, our stock price could decline significantly and the long-term success of the product and our company could be harmed.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Calibri;text-transform:none;font-variant: normal;">Jelmyto has only been studied in a limited number of patients and in limited populations. Following the initiation of our commercial launch in June 2020, Jelmyto is now available to a much larger number of patients and in broader populations, and we do not know whether the results of Jelmyto use in such larger number of patients and broader populations will be consistent with the results from our clinical studies.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;text-transform:none;font-variant: normal;">Jelmyto<span style="font-style:normal;"> has been administered only to a limited number of patients and in limited populations in clinical studies, including our successful </span><span style="Background-color:#FFFFFF;color:#212529;font-style:normal;">pivotal Phase 3 OLYMPUS clinical trial for the treatment of adult patients with low-grade UTUC</span><span style="font-style:normal;">. While the FDA granted approval of </span>Jelmyto<span style="font-style:normal;"> based on the data included in the NDA, including data from the OLYMPUS clinical trial, we do not know whether the results when a large number of patients and broader populations are exposed to </span>Jelmyto<span style="font-style:normal;">, including results related to safety and efficacy, will be consistent with the results from earlier clinical studies of </span>Jelmyto<span style="font-style:normal;"> that served as the basis for the approval of </span>Jelmyto<span style="font-style:normal;">. New data relating to </span>Jelmyto<span style="font-style:normal;">, including from adverse event reports and post-marketing studies in the United States, and from other ongoing clinical studies, may result in changes to the product label and may adversely affect sales, or result in withdrawal of </span>Jelmyto<span style="font-style:normal;"> from the market. The FDA and regulatory authorities in other jurisdictions may also consider the new data in reviewing potential marketing applications in other jurisdictions, or imposing post&#8209;approval requirements. If any of these actions were to occur, it could result in significant expense and delay or limit our ability to generate sales revenues.</span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Calibri;text-transform:none;font-variant: normal;">We have limited experience as an organization in marketing and distributing products and are therefore subject to certain risks in relation to the commercialization of Jelmyto and any of our other product candidates that receives regulatory approval. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our strategy is to build and maintain a fully integrated biopharmaceutical company to successfully execute the commercial launch of <span style="font-style:italic;">Jelmyto</span> in the United States. <span style="font-style:italic;">Jelmyto</span> is our only product that has been approved for sale by any regulatory body, and it became available in the United States in June 2020. While we have established a commercial management team and have also established a field-based organization comprised of approximately 70 individuals, including a sales team, reimbursement support team, clinical nurse educators, national account managers and medical liaisons, we only recently commenced the commercial launch of <span style="font-style:italic;">Jelmyto</span> in the United States and currently have very limited experience commercializing pharmaceutical products as an organization. In order to successfully commercialize <span style="font-style:italic;">Jelmyto</span>, we must continue to develop our sales, marketing, managerial, compliance and related capabilities or make arrangements with third parties to perform these services. This involves many challenges, such as recruiting and retaining talented personnel, training employees, setting the appropriate system of incentives, managing additional headcount and integrating new business units into an existing corporate infrastructure. These efforts will continue to be expensive and time-consuming, and we cannot be certain that we will be able to successfully further develop these capabilities. Additionally, we will need to maintain and further develop our sales force, and we will be competing with other pharmaceutical and biotechnology companies to recruit, hire, train and retain marketing and sales personnel. In the event we are unable to effectively develop and maintain our commercial team, including our sales force, our ability to effectively commercialize <span style="font-style:italic;">Jelmyto</span> would be limited, and we would not be able to generate product revenues successfully. If we fail to establish and maintain an effective sales and marketing infrastructure, we will be unable to successfully commercialize our product candidates, which in turn would have an adverse effect on our business, financial condition and results of operations. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">33</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Calibri;font-size:10pt;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-family:Calibri;font-size:10pt;text-transform:none;font-variant: normal;">If we are unable to effectively train and equip our sales force, our ability to successfully commercialize Jelmyto will be harmed.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Calibri;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Jelmyto<span style="font-style:normal;"> is a newly-marketed drug and, therefore, none of the members of our sales force had ever promoted </span>Jelmyto<span style="font-style:normal;"> prior to its launch. In addition, </span>Jelmyto<span style="font-style:normal;"> is the first drug approved by the FDA for the treatment of</span><span style="color:#000000;font-style:normal;"> low-grade UTUC</span><span style="font-style:normal;">. As a result, we are and will continue to be required to expend significant time and resources to train our sales force to be credible, persuasive, and compliant with applicable laws in marketing </span>Jelmyto<span style="font-style:normal;"> for the treatment of </span><span style="color:#000000;font-style:normal;">low-grade UTUC </span><span style="font-style:normal;">to physicians and nurses. In addition, we must train our sales force to ensure that a consistent and appropriate message about </span>Jelmyto<span style="font-style:normal;"> is being delivered to our potential customers. If we are unable to effectively train our sales force and equip them with effective materials, including medical and sales literature to help them inform and educate potential customers about the benefits and risks of </span>Jelmyto<span style="font-style:normal;"> and its proper administration, our efforts to successfully commercialize </span>Jelmyto<span style="font-style:normal;"> could be put in jeopardy, which would negatively impact our ability to generate product revenues.</span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additionally, our work-at-home policy due to COVID-19 includes our sales representatives, who would normally conduct in-person office visits with healthcare providers. Although we have developed digital materials and programs for our sales force to use in order to continue to engage virtually with their target physicians, there can be no assurance that these new tools and approaches will be effective at sustaining prescription levels of <span style="font-style:italic;">Jelmyto</span>. Disruptions in the prescription volume of <span style="font-style:italic;">Jelmyto</span> could also occur:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Calibri;">if patients are physically quarantined or are unable or unwilling to visit healthcare providers&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Calibri;">if physicians restrict access to their facilities for a material period of time&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Calibri;">if healthcare providers prioritize treatment of acute or communicable illnesses over treatment of low-grade UTUC&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Calibri;">if pharmacies are closed or suffering supply chain disruptions&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Calibri;">if patients lose access to employer-sponsored health insurance due to period of high unemployment&#59; or</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Calibri;">as a result of general disruptions in the operations of payors, distributors, logistics providers and other third parties that are necessary for </span><span style="font-style:italic;font-family:Calibri;">Jelmyto</span><span style="font-family:Calibri;"> to be prescribed and reimbursed.</span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Calibri;text-transform:none;font-variant: normal;">The market opportunities for Jelmyto and our product candidates may be limited to those patients who are ineligible for established therapies or for whom prior therapies have failed and may be small. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cancer therapies are sometimes characterized as first-line, second-line or third-line. When cancer is detected early enough, first-line therapy, often chemotherapy, hormone therapy, surgery, radiotherapy or a combination of these, is sometimes adequate to cure the cancer or prolong life. Second- and third-line therapies are administered to patients when prior therapy is not or is no longer effective. For urothelial cancers, the current first-line standard of care is surgery designed to remove one or more tumors. Chemotherapy is currently used in treating urothelial cancer only as an adjuvant, or supplemental therapy, after tumor resection. We are designing our lead product candidates with the goal of replacing surgery as the standard of care for certain urothelial cancers. However, there is no guarantee that our product candidates, if approved, would be approved for first-line or even later lines of therapy, and that prior to any such approvals, we will not have to conduct additional clinical trials. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our projections of both the number of people who have the cancers we are targeting, as well as the subset of people with these cancers who have previously failed prior treatments, and who have the potential to benefit from treatment with our product candidates, are based on our beliefs and estimates. These estimates have been derived from a variety of sources, including scientific literature, surveys of clinics, patient foundations or third-party market research, and may prove to be incorrect. Further, new studies may change the estimated incidence or prevalence of these cancers and the number of patients may turn out to be lower than expected. Additionally, the potentially addressable patient population for our product candidates may be limited or may not be amenable to treatment with our product candidates. For instance, our pivotal Phase 3 OLYMPUS clinical trial for <span style="font-style:italic;">Jelmyto</span> was designed to evaluate the use of <span style="font-style:italic;">Jelmyto</span> for the treatment of tumors in the renal pelvis (the funnel-like dilated part of the ureter in the kidney) and was not designed to evaluate the use of <span style="font-style:italic;">Jelmyto</span> for the treatment of tumors in the ureter (the tube that connects the kidneys to the bladder). Even though <span style="font-style:italic;">Jelmyto</span> is approved for the treatment of low-grade UTUC, physicians may choose to only use it to treat tumors in the renal pelvis and not tumors in the ureter, which would limit the degree of physician adoption and market acceptance of <span style="font-style:italic;">Jelmyto</span>. Even if we obtain significant market share, because the potential target populations are small, we may never achieve profitability without obtaining regulatory approval for additional indications, including the use of the products as first- or second-line therapy. For example, low-grade UTUC is a rare malignant tumor of the cells lining the urinary tract and there is limited scientific literature or other research on the incidence and prevalence of low-grade UTUC. If our estimates of the incidence </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">34</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and prevalence of low-grade UTUC are incorrect, </span><span style="font-style:italic;">Jelmyto</span><span style="font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8217;s commercial viability may prove to be limited, which may negatively affect our financial results. </span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Calibri;text-transform:none;font-variant: normal;">Jelmyto and any of our product candidates that receives regulatory approval may fail to achieve the broad degree of physician adoption and use and market acceptance necessary for commercial success. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The commercial success of <span style="font-style:italic;">Jelmyto</span> and any other product candidate that receives regulatory approval will depend significantly on their broad adoption and use by physicians, for approved indications, including, in the case of <span style="font-style:italic;">Jelmyto</span>, for the treatment of low-grade UTUC, and in the case of UGN-102, for the treatment of low-grade intermediate risk NMIBC, and for other therapeutic indications that we may seek to pursue with any of our product candidates. Physicians treating low-grade UTUC and low-grade intermediate risk NMIBC have never had to consider treatments other than surgery. The degree and rate of physician and patient adoption of <span style="font-style:italic;">Jelmyto</span>, UGN-102 or any of our other product candidates, if approved, will depend on a number of factors, including: </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Calibri;">the clinical indications for which the product is approved&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Calibri;">the safety and efficacy data from the clinical trial(s) supporting the approved clinical indications&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Calibri;">the approved labeling and packaging for our products, including the degree of product preparation and administration convenience and ease of use that is afforded to physicians by the approved labeling and product packaging&#59;&#160;&#160;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Calibri;">the prevalence and severity of adverse side effects and the level of benefit/risk observed in our clinical trials&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Calibri;">sufficient patient satisfaction with the results and administration of our products and overall treatment experience, including relative convenience, ease of use and avoidance of, or reduction in, adverse side effects&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Calibri;">the extent to which physicians recommend our products to patients&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Calibri;">physicians&#8217; and patients&#8217; willingness to adopt new therapies in lieu of other products or treatments, including willingness to adopt </span><span style="font-style:italic;font-family:Calibri;">Jelmyto</span><span style="font-family:Calibri;">, and our lead product candidate UGN-102 as locally-administered drug replacements to current surgical standards of care&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Calibri;">the cost of treatment, safety and efficacy of our products in relation to alternative treatments, including the recurrence rate of our treatments&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Calibri;">the extent to which the costs of our products are covered and reimbursed by third-party payors, including the availability of a physician reimbursement code for our treatments, and patients&#8217; willingness to pay for our products&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Calibri;">whether treatment with our products, including the treatment of low-grade UTUC with </span><span style="font-style:italic;font-family:Calibri;">Jelmyto</span><span style="font-family:Calibri;"> and the treatment of low-grade intermediate risk NMIBC with UGN-102, if approved, will be deemed to be an elective procedure by third- party payors&#59; if so, the cost of treatment would be borne by the patient and would be less likely to be broadly adopted&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Calibri;">proper training of physicians or nurses for the skillful administration of our approved product, </span><span style="font-style:italic;font-family:Calibri;">Jelmyto</span><span style="font-family:Calibri;">, and UGN-102, if approved, and development of a broad experiential knowledge base of aggregated clinician feedback from which we can refine appropriate procedures for product administration, without which there could be a risk of adverse events&#59; and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Calibri;">the effectiveness of our sales and marketing efforts, especially the success of any targeted marketing efforts directed toward physicians and clinics and any direct-to-consumer marketing efforts we may initiate. </span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If <span style="font-style:italic;">Jelmyto</span>, UGN-102 or any of our other product candidates is approved for use but fails to achieve the broad degree of physician adoption and market acceptance necessary for commercial success, our operating results and financial condition would be adversely affected. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">35</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Calibri;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Calibri;text-transform:none;font-variant: normal;">Jelmyto and our product candidates, if approved, will face significant competition with competing technologies and our failure to compete effectively may prevent us from achieving significant market penetration. </span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The biopharmaceutical industry is intensely competitive and subject to rapid and significant technological change. Our potential competitors include large and experienced companies that enjoy significant competitive advantages over us, such as greater financial, research and development, manufacturing, personnel and marketing resources, greater brand recognition and more experience and expertise in obtaining marketing approvals from the FDA and foreign regulatory authorities. These companies may develop new drugs to treat the indications that we target or seek to have existing drugs approved for use for the treatment of the indications that we target. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The FDA has approved five immunotherapy drugs known as checkpoint inhibitors&#59; Tecentriq (atezolizumab), Bavenico (avelumab), Imfinzi (durvalumab), Opdivo (nivolumab) and Keytruda (pembrolizumab) for the treatment of locally advanced or metastatic bladder cancer, a form of muscle invasive bladder cancer. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are aware of several pharmaceutical companies that are developing drugs in the fields of urology and uro-oncology, such as Roche, Vyriad, GSK, Celgene, Lipac Oncology, Samyang biopharma, Merck Sharp&#160;&#38; Dohme Corp., Eleven biotherapeutics, Viralytics Limited, AADi, LLC, Biocancell Ltd., ImmunityBio, Seagen Inc., Steba Biotech Ltd., FKD Therapies Oy and Janssen. We do not know whether these potential competitors are already developing, or plan to develop, low-grade UTUC or high-grade UTUC treatments or other indications that we are pursuing. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are also aware that other companies, such as Janssen and Lipac are conducting, or have recently conducted clinical trials for product candidates for the treatment of low-grade intermediate risk NMIBC. Outside of these indications where we are developing products, we are aware of other companies doing work in both bladder and upper tract cancers, but these are with agents or on targets in high-grade, metastatic, or muscle invasive cancers. Competition may increase further as a result of advances in the commercial applicability of technologies and greater availability of capital for investment in this industry. Our competitors may succeed in developing, acquiring or licensing products that are more effective, easier to administer or less costly than our product candidates. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, we face competition from existing standards of treatment, TURBT surgery for bladder cancer. If we are not able to demonstrate that our product candidates are at least as safe and effective as such courses of treatment, medical professionals may not adopt our product candidates in replacement of the existing standard of care, which is first-line tumor surgical procedures. Generic mitomycin injectable drug products, while approved by FDA for gastric and pancreatic cancers, are neither approved for low-grade UTUC nor reconstituted with hydrogel as <span style="font-style:italic;">Jelmyto</span> is, although they may be used off-label by physicians for the treatment of low-grade UTUC, as they have been prior to the approval of <span style="font-style:italic;">Jelmyto</span>.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Calibri;text-transform:none;font-variant: normal;">Our ability to market Jelmyto and any of our product candidates that receive marketing approval is and will be limited to certain indications. If we want to expand the indications for which we may market our products, we will need to obtain additional regulatory approvals, which may not be granted. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Calibri;font-weight:normal;text-transform:none;font-variant: normal;">Jelmyto<span style="font-style:normal;"> is indicated for adult patients with low-grade upper tract urothelial cancer. We are currently developing UGN-102 and UGN-201 for the treatment of various forms of bladder cancer. The FDA and other applicable regulatory agencies will restrict our ability to market or advertise our products to the scope of the approved label for the applicable product and for no other indications, which could limit physician and patient adoption. We may attempt to develop and, if approved, promote and commercialize new treatment indications for our products in the future, but we cannot predict when or if we will receive the regulatory approvals required to do so. Failure to receive such approvals will prevent us from promoting or commercializing new treatment indications. In addition, we would be required to conduct additional clinical trials or studies to support approvals for additional indications, which would be time consuming and expensive, and may produce results that do not support regulatory approvals. If we do not obtain additional regulatory approvals, our ability to expand our business will be limited. </span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:2pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Calibri;text-transform:none;font-variant: normal;">If we are found to have improperly promoted off-label uses of Jelmyto or any other product candidate that receives regulatory approval, or if physicians misuse our products, we may become subject to prohibitions on the sale or marketing of our products, significant sanctions, and product liability claims, and our image and reputation within the industry and marketplace could be harmed. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The FDA and other regulatory agencies strictly regulate the marketing and promotional claims that are made about drug products. In particular, a product may not be promoted for uses or indications that are not approved by the FDA or such other regulatory agencies as reflected in the product&#8217;s approved labeling and may not be promoted based on overstated efficacy or omission of </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">36</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">important safety information. For example, we cannot promote the use of our product </span><span style="font-style:italic;">Jelmyto</span><span style="font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> in a manner that is inconsistent with the approved label, but we are permitted to share truthful and non-misleading information that is otherwise consistent with the product&#8217;s FDA approved labeling. However, physicians are able, in their independent medical judgment, to use </span><span style="font-style:italic;">Jelmyto</span><span style="font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> on their patients in an off-label manner, such as for the treatment of other urology indications. If we are found to have promoted such off-label uses, we may receive warning letters and become subject to significant liability, which would harm our business. The federal government has levied large administrative, civil and criminal fines against companies for alleged improper promotion and has enjoined several companies from engaging in off-label promotion. If we become the target of such an investigation or prosecution based on our marketing and promotional practices, we could face similar sanctions, which would harm our business. In addition, management&#8217;s attention could be diverted from our business operations, significant legal expenses could be incurred, and our reputation could be damaged. The FDA has also requested that companies enter into consent decrees or permanent injunctions under which specified promotional conduct is changed or curtailed. If we are deemed by the FDA to have engaged in the promotion of our products for off-label use, we could be subject to prohibitions on the sale or marketing of our products or significant fines and penalties, and the imposition of these sanctions could also affect our reputation with physicians, patients and caregivers, and our position within the industry. </span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Physicians may also misuse our products or use improper techniques, potentially leading to adverse results, side effects or injury, which may lead to product liability claims. If our products are misused or used with improper technique, we may become subject to costly litigation. Product liability claims could divert management&#8217;s attention from our core business, be expensive to defend, and result in sizable damage awards against us that may not be covered by insurance. We currently carry product liability insurance covering our clinical trials with policy limits that we believe are customary for similarly situated companies and adequate to provide us with coverage for foreseeable risks. Although we maintain such insurance, any claim that may be brought against us could result in a court judgment or settlement in an amount that is not covered, in whole or in part, by our insurance or that is in excess of the limits of our insurance coverage. In addition, while we have established product liability insurance relating to our commercialization of <span style="font-style:italic;">Jelmyto</span>, there can be no assurance that we will be able to maintain this insurance on commercially reasonable terms or that this insurance will be sufficient. Furthermore, the use of our products for conditions other than those approved by the FDA may not effectively treat such conditions, which could harm our reputation in the marketplace among physicians and patients. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Calibri;text-transform:none;font-variant: normal;">In addition to Jelmyto, we are dependent on the success of our lead product candidate, UGN-102, and our other product candidates, including obtaining regulatory approval to market our product candidates in the United States. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The research, development, testing, manufacturing, labeling, packaging, approval, promotion, advertising, storage, recordkeeping, marketing, distribution, post-approval monitoring and reporting, and export and import of drug products are subject to extensive regulation by the FDA and by foreign regulatory authorities. These regulations differ from country to country. To gain approval to market our product candidates, we must provide clinical data that adequately demonstrate the safety and efficacy of the product for the intended indication. Other than <span style="font-style:italic;">Jelmyto</span>, all of our product candidates, including <span style="color:#000000;">our lead product candidate, </span>UGN-102, remain in clinical development and have not yet received regulatory approval from the FDA or any other regulatory agency in the United States or any other country. Our business depends upon obtaining these regulatory approvals. There are no drugs that have been approved by the FDA for the primary treatment of low-grade NMIBC, <span style="letter-spacing:-0.1pt;">and </span>only four drugs have been approved by the FDA as adjuvant treatment for high-grade NMIBC. The FDA can delay, limit or deny approval of our product candidates for many reasons. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The success of our product candidates is subject to significant risks, including risks associated with successfully completing current and future clinical trials, such as: </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Calibri;">the FDA&#8217;s acceptance of our parameters for regulatory approval relating to UGN-102 and our other product candidates, including our proposed indications, primary and secondary endpoint assessments and measurements, safety evaluations and regulatory pathways, and proposed labeling and packaging&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Calibri;">our ability to successfully complete the FDA requirements related to chemistry, manufacturing and controls, or CMC, for UGN-102 and our other product candidates, and if completed, their sufficiency to support an NDA&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Calibri;">the FDA&#8217;s timely acceptance of our Investigational New Drug applications, or INDs, for our product candidates. Without such IND acceptances, we will be unable to commence clinical trials in the United States&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Calibri;">the FDA&#8217;s acceptance of the number, design, size, conduct and implementation of our clinical trials, our trial protocols and the interpretation of data from nonclinical studies or clinical trials&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Calibri;">the FDA&#8217;s acceptance of the population studied in our clinical trials being sufficiently large, broad and representative to assess efficacy and safety in the patient population for which we seek approval&#59;</span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">37</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span><span style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span><span style="font-family:Calibri;">our ability to successfully complete the clinical trials of our product candidates, including timely patient enrollment and acceptable safety and efficacy data and our ability to demonstrate the safety and efficacy of the product candidates undergoing such clinical trials&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Calibri;">our ability to demonstrate that clinical or other benefits of our product candidates outweigh any safety or other perceived risks&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Calibri;">the FDA&#8217;s need to schedule an advisory committee meeting, and to conduct such meeting, in a timely manner to evaluate and decide on the approval of our potential future NDA for UGN-102&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Calibri;">if applicable, the recommendation of the FDA&#8217;s advisory committee to approve our applications to market UGN-102 and our other product candidates in the United States, without limiting the approved labeling, specifications, distribution or use of the products, or imposing other restrictions&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Calibri;">the FDA&#8217;s determination of safety and efficacy of our product candidates&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Calibri;">the FDA&#8217;s determination that the 505(b)(2) regulatory pathway is available for our product candidates&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Calibri;">the prevalence and severity of adverse events associated with our product candidates, including UGN-102, as there are no drugs and related drug administration procedures approved for the primary treatment of low-grade NMIBC, that are based on </span><span style="font-style:italic;font-family:Calibri;">RTGel</span><span style="font-family:Calibri;"> technology&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Calibri;">the timely and satisfactory performance by third-party contractors of their obligations in relation to our clinical trials&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Calibri;">our success in educating physicians and patients about the benefits, administration and use of our product candidates, if approved, particularly in light of the fact that there are currently no drugs approved by the FDA for the treatment of UTUC, and there are no drugs that have been approved by the FDA for the primary treatment of low-grade NMIBC, </span><span style="font-family:Calibri;letter-spacing:-0.1pt;">and </span><span style="font-family:Calibri;">only four drugs have been approved by the FDA as adjuvant treatment for high-grade NMIBC&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Calibri;">the availability, perceived advantages, relative cost, safety and efficacy of alternative and competing treatments for the indications addressed by our product candidates&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Calibri;">the effectiveness of our marketing, sales and distribution strategy, and operations, as well as that of any current and future licensees&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Calibri;">the FDA&#8217;s acceptance of the quality of our drug substance or drug product, formulation, labeling, packaging, or the specifications of our product candidates is sufficient for approval&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Calibri;">our ability to develop, validate and maintain a commercially viable manufacturing process that is compliant with current good manufacturing practices, or cGMP&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Calibri;">the FDA&#8217;s acceptance of the manufacturing processes or facilities of third-party manufacturers with which we contract&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Calibri;">our ability to secure supply of the raw materials from TAPI (Teva Active Pharmaceutical Ingredients) or other suppliers for our product candidates to support clinical trials and commercial use&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Calibri;">Our ability to manufacture or secure finished product from third-party suppliers for product candidates, including UGN-102, if approved.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Calibri;">our ability to obtain, protect and enforce our intellectual property rights with respect to our product candidates&#59; and </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Calibri;">our ability to properly train physicians or nurses for the skillful preparation and administration of any of our product candidates that receive approval, including UGN-102, and our ability to develop a broad experiential knowledge base of aggregated clinician feedback from which we can refine appropriate procedures for product administration, without which there could be a risk of adverse events. </span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Many of these clinical, regulatory and commercial risks are beyond our control. Further, these risks and uncertainties impact all of&#160;our clinical programs that we pursue and have been amplified by the recent COVID-19 pandemic, as described below. Accordingly, we cannot assure you that we will be able to advance any more of our product candidates through clinical development, or to obtain additional regulatory approval of any of our product candidates. To the extent we seek regulatory approval in foreign countries, we may face challenges similar to those described above with regulatory authorities in applicable jurisdictions. Any delay in obtaining, or inability to obtain, applicable regulatory approval for any of our product candidates would delay or prevent commercialization of our product candidates and would thus negatively impact our business, results of operations and prospects. Even if we receive </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">38</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">approval of any of the product candidates in our pipeline or future product candidates, there is no assurance that we will be able to successful commercialize any of them. </span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Calibri;text-transform:none;font-variant: normal;">To date we have only generated limited clinical data for our investigational product candidates. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Positive results in nonclinical testing and early clinical trials do not ensure that later clinical trials will be successful. A number of pharmaceutical companies have suffered significant setbacks in clinical trials, including in Phase 3 clinical trials, after promising results in nonclinical testing and early clinical trials. These setbacks have included negative safety and efficacy observations in later clinical trials, including previously unreported adverse effects. To date, our clinical trials and other programs have involved small patient populations and because of the small sample size, the results of these clinical trials may be subject to substantial variability and may not be indicative of future results. We initiated the Phase 3 ATLAS trial in December 2020 and are currently enrolling patients in this trial assessing UGN-102 with or without trans-urethral resection of bladder tumor (TURBT) compared to standard of care, TURBT. If our clinical trials do not ultimately indicate that our product candidates are safe and effective for their intended use, the FDA may not approve any NDA that we may submit to market such product candidates, and our business would not be able to generate revenue from the sale of any such product candidates. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Calibri;text-transform:none;font-variant: normal;">Interim, topline and preliminary data from our clinical trials that we announce or publish from time to time may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">From time to time, we may publicly disclose preliminary, interim or topline data from our clinical trials. These interim updates are based on a preliminary analysis of then-available data, and the results and related findings and conclusions are subject to change as patient data become available and following a more comprehensive review of the data related to the particular study or trial. We also make assumptions, estimations, calculations and conclusions as part of our analyses of data, and we may not have received or had the opportunity to fully and carefully evaluate all data. As a result, the topline results that we report may differ from future results of the same studies, or different conclusions or considerations may qualify such results, once additional data have been received and fully evaluated. Topline data also remain subject to audit and verification procedures that may result in the final data being materially different from the preliminary data we previously published. As a result, topline data should be viewed with caution until the final data are available. In addition, we may report interim analyses of only certain endpoints rather than all endpoints. Interim data from clinical trials that we may complete are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and more patient data become available. In particular, interim data may reflect small sample sizes, be subject to substantial variability and may not be indicative of either future interim results or final results. Publications based on interim data may differ from FDA approved product labeling. Adverse changes between interim data and final data could significantly harm our business and prospects. Further, additional disclosure of interim data by us or by our competitors in the future could result in volatility in the price of our ordinary shares. See the description of risks under the heading &#8220;Risks Related to Ownership of our Ordinary Shares&#8221; for additional disclosures related to the risk of volatility in the price of our ordinary shares. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Further, others, including regulatory agencies, may not accept or agree with our assumptions, estimates, calculations, conclusions or analyses or may interpret or weigh the importance of data differently, which could impact the value of the particular program, the approvability or commercialization of the particular product candidate or product and our company in general. In addition, the information we choose to publicly disclose regarding a particular study or clinical trial is typically selected from a more extensive amount of available information. Furthermore, we may report interim analyses of only certain endpoints rather than all endpoints. You or others may not agree with what we determine is the material or otherwise appropriate information to include in our disclosure, and any information we determine not to disclose may ultimately be deemed significant with respect to future decisions, conclusions, views, activities or otherwise regarding a particular product, product candidate or our business. If the preliminary or topline data that we report differ from late, final or actual results, or if others, including regulatory authorities, disagree with the conclusions reached, our ability to obtain approval for, and commercialize, UGN-102 or any other investigational product candidate may be harmed, which could harm our business, financial condition, results of operations and prospects. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Calibri;text-transform:none;font-variant: normal;">We have limited experience in conducting clinical trials and obtaining approval for product candidates and may be unable to do so successfully. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As a company, we have limited experience in conducting clinical trials and have progressed only one product candidate through to regulatory approval. In part because of this lack of experience, our clinical trials may require more time and incur greater costs than we anticipate. We cannot be certain that the planned clinical trials will begin or conclude on time, if at all. Large-scale trials will require significant additional financial and management resources. Third-party clinical investigators do not operate under our control. Any performance failure on the part of such third parties could delay the clinical development of our product candidates or </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">39</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">delay or prevent us from obtaining regulatory approval or commercializing our current or future product candidates, depriving us of potential product revenue and resulting in additional losses. </span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Calibri;text-transform:none;font-variant: normal;">We have not yet applied for regulatory approvals to market UGN-102 or the other product candidates in our pipeline, and we may be delayed in obtaining or failing to obtain such regulatory approvals and to commercialize our product candidates. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The process of developing, obtaining regulatory approval for and commercializing our product candidates is long, complex, costly and uncertain, and delays or failure can occur at any stage. The research, testing, manufacturing, labeling, marketing, sale and distribution of drugs are subject to extensive and rigorous regulation by the FDA and foreign regulatory agencies, as applicable. These regulations are agency-specific and differ by jurisdiction. We are not permitted to market any product candidate in the United States until we receive approval of an NDA from the FDA, or in any foreign countries until we receive the requisite approval from the respective regulatory agencies in such countries. To gain approval of an NDA or other equivalent regulatory approval, we must provide the FDA or relevant foreign regulatory authority with nonclinical and clinical data that demonstrates the safety and efficacy of the product for the intended indication. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Before we can submit an NDA to the FDA or comparable similar applications to foreign regulatory authorities, we must conduct Phase 3 clinical trials, or a pivotal/registration trial equivalent, for each product candidate. After submission of an NDA, the FDA may raise additional questions on any data contained in the application. These questions may come in the form of information requests or in the NDA 74-day letter as review issues. We must address these questions during the review, but we do not know whether our responses will be acceptable to the FDA. We cannot assure you that the FDA will not decide to require us to perform additional clinical trials, including potentially requiring us to perform an additional pivotal study with a control arm, before approving, or as a condition of approving, NDA&#8217;s for our product candidates. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Phase 3 clinical trials often produce unsatisfactory results even though prior clinical trials were successful. Moreover, the results of clinical trials may be unsatisfactory to the FDA or foreign regulatory authorities even if we believe those clinical trials to be successful. The FDA or applicable foreign regulatory agencies may suspend one or all of our clinical trials or require that we conduct additional clinical, nonclinical, manufacturing, validation or drug product quality studies and submit that data before considering or reconsidering any NDA or comparable foreign regulatory application that we may submit. Depending on the extent of these additional studies, approval of any applications that we submit may be significantly delayed or may cause the termination of such programs or may require us to expend more resources than we have available. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If any of these outcomes occur, we may not receive regulatory approval for the corresponding product candidates, and our business would not be able to generate revenue from the sale of any such product candidates. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Calibri;text-transform:none;font-variant: normal;">Changes in funding for the&#160;FDA, the SEC&#160;and other government agencies could hinder their ability to hire and retain key leadership and other personnel, prevent new products and services from being developed or commercialized in a timely manner or otherwise prevent those agencies from performing normal functions on which the operation of our business may rely, which could negatively impact our business. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The ability of the&#160;FDA&#160;to review and approve new products can be affected by a variety of factors, including government budget and funding levels, ability to hire and retain key personnel and accept payment of user fees, and statutory, regulatory, and policy changes. Average review times at the agency have fluctuated in recent years as a result. In addition, government funding of the SEC and other government agencies on which our operations may rely, including those that fund research and development activities is subject to the political process, which is inherently fluid and unpredictable. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Disruptions at the&#160;FDA&#160;and other agencies may also slow the time necessary for new drugs to be reviewed and/or approved by necessary government agencies, which would adversely affect our business. For example, over the last several years, the U.S. government has shut down several times and certain regulatory agencies, such as the&#160;FDA and the SEC, have had to furlough critical&#160;FDA, SEC and other government&#160;employees and stop critical activities. If a prolonged&#160;government&#160;shutdown&#160;occurs, it could significantly impact the ability of the FDA to timely review and process our regulatory submissions, which could have a material adverse effect on our business. Further, future government shutdowns could impact our ability to access the public markets and obtain necessary capital in order to properly capitalize and continue our operations. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">40</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Calibri;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Calibri;text-transform:none;font-variant: normal;">We may not be able to advance our nonclinical product candidates into clinical development and through regulatory approval and commercialization. </span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Certain of our product candidates are currently in nonclinical development and are therefore currently subject to the risks associated with nonclinical development, including the risks associated with: </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Calibri;">generating adequate and sufficient nonclinical safety and efficacy data in a timely fashion to support the initiation of clinical trials&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Calibri;">obtaining regulatory approval to commence clinical trials in any jurisdiction, including the submission and acceptance of INDs&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Calibri;">contracting with the necessary parties to conduct a clinical trial&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Calibri;">enrolling sufficient numbers of patients in clinical trials in timely fashion, if at all&#59; and </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Calibri;">timely manufacture of sufficient quantities of the product candidate for use in clinical trials. </span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">These risks and uncertainties impact all of&#160;our nonclinical programs that we pursue and have been amplified by the recent COVID-19 pandemic, as described below. If we are unsuccessful in advancing our nonclinical product candidates into clinical trials in a timely fashion, our business may be harmed. Even if we are successful in advancing our nonclinical product candidates into clinical development, their success will be subject to all of the clinical, regulatory and commercial risks described elsewhere in this report and our other filings with the SEC. Accordingly, we cannot assure you that we will be able to develop, obtain regulatory approval for, commercialize or generate significant revenue from our product candidates. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Calibri;text-transform:none;font-variant: normal;">Clinical drug development involves a lengthy and expensive process with an uncertain outcome, results of earlier studies and trials may not be predictive of future trial results, and our clinical trials may fail to adequately demonstrate the safety and efficacy of our product candidates. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Clinical testing is expensive and can take many years to complete, and its outcome is inherently uncertain. A failure of one or more of our clinical trials can occur at any time during the clinical trial process. We do not know whether our ongoing and future clinical trials, if any, will begin on time, need to be redesigned, enroll an adequate number of patients on time or be completed on schedule, if at all. Clinical trials can be delayed, suspended or terminated for a variety of reasons, including failure to: </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Calibri;">generate sufficient nonclinical, toxicology, or other in vivo or in vitro data to support the initiation or continuation of clinical trials&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Calibri;">obtain regulatory approval or feedback on trial design, in order to commence a trial&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Calibri;">identify, recruit and train suitable clinical investigators&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Calibri;">reach agreement on acceptable terms with prospective CROs and clinical trial sites, and have such CROs and sites effect the proper and timely conduct of our clinical trials&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Calibri;">obtain and maintain institutional review board, or IRB, approval at each clinical trial site&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Calibri;">identify, recruit, enroll and retain suitable patients to participate in a trial&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Calibri;">have a sufficient number of patients enrolled, complete a trial or return for post-treatment follow-up&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Calibri;">ensure clinical investigators and clinical trial sites observe trial protocol or continue to participate in a trial&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Calibri;">address any patient safety concerns that arise during the course of a trial&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Calibri;">address any conflicts with new or existing laws or regulations&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Calibri;">add a sufficient number of clinical trial sites&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Calibri;">manufacture sufficient quantities at the required quality of product candidate for use in clinical trials&#59; or </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Calibri;">raise sufficient capital to fund a trial. </span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Patient enrollment is a significant factor in the timing and success of clinical trials and is affected by many factors, including the size and nature of the patient population, the proximity of patients to clinical sites, the eligibility criteria for the trial, the design of the clinical trial, competing clinical trials and clinicians&#8217; and patients&#8217; or caregivers&#8217; perceptions as to the potential advantages of the </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">41</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">drug candidate being studied in relation to other available therapies, including any new drugs or treatments that may be developed or approved for the indications we are investigating. </span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may also encounter delays if a clinical trial is suspended or terminated by us, by the IRBs of the institutions in which such trials are being conducted, by the trial&#8217;s data safety monitoring board, by the FDA or by the applicable foreign regulatory authorities. Such authorities may suspend or terminate one or more of our clinical trials due to a number of factors, including our failure to conduct the clinical trial in accordance with relevant regulatory requirements or clinical protocols, inspection of the clinical trial operations or trial site by the FDA or foreign regulatory authorities resulting in the imposition of a clinical hold, unforeseen safety issues or adverse side effects, failure to demonstrate a benefit from using a drug, changes in governmental regulations or administrative actions or lack of adequate funding to continue the clinical trial. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If we experience delays in carrying out or completing any clinical trial of our product candidates, the commercial prospects of our product candidates may be harmed, and our ability to generate product revenues from any of these product candidates will be delayed. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, any delays in completing our clinical trials will increase our costs, slow down our product candidate development and approval process and jeopardize our ability to commence product sales and generate revenues. Any of these occurrences may significantly harm our business and financial condition. In addition, many of the factors that cause, or lead to, a delay in the commencement or completion of clinical trials may also ultimately lead to the denial of regulatory approval of our product candidates. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Calibri;text-transform:none;font-variant: normal;">Jelmyto or any of our product candidates may produce undesirable side effects that we may not have detected in our previous nonclinical studies and clinical trials or that are not expected with mitomycin treatment or inconsistent with catheter administration procedures. This could prevent us from gaining marketing approval or market acceptance for these product candidates, or from maintaining such approval and acceptance, and could substantially increase commercialization costs and even force us to cease operations. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As with most pharmaceutical products, <span style="font-style:italic;">Jelmyto</span> and our product candidates may be associated with side effects or adverse events that can vary in severity and frequency. Side effects or adverse events associated with the use of <span style="font-style:italic;">Jelmyto</span> or any of our product candidates, including UGN-102, may be observed at any time, including in clinical trials or once a product is commercialized, and any such side effects or adverse events may negatively affect our ability to obtain regulatory approval or market our product candidates. To date, in our nonclinical testing, completed Compassionate Use Program for <span style="font-style:italic;">Jelmyto</span> clinical trials and post-marketing experience, we have observed several adverse events and serious adverse events, including ureteric obstruction, ureteral stenosis, inhibition of urine flow, rash, flank pain, kidney swelling, kidney infection, renal dysfunction, hematuria, fatigue, nausea, abdominal pain, dysuria, vomiting, urinary tract infection, urgency in urination and pain during urination. In addition, we have observed transient perturbation of laboratory measures of renal and hematopoietic function. These adverse events are known mitomycin or procedure-related adverse events and many are indicated as potential side effects of mitomycin usage on the mitomycin label. However, we cannot assure you that we will not observe additional drug or procedure-related serious adverse events in the future or that the FDA will not determine them as such. Side effects such as toxicity or other safety issues associated with the use of <span style="font-style:italic;">Jelmyto</span> or our product candidates could require us to perform additional studies or halt development or sale of <span style="font-style:italic;">Jelmyto</span> or our product candidates or expose us to product liability lawsuits, which will harm our business. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Furthermore, our Phase 2b clinical trial for UGN-102 involved larger patient bases than in our prior studies of these candidates, and the commercial marketing of <span style="font-style:italic;">Jelmyto</span> and, if approved, UGN-102, will further expand the clinical exposure of the drugs to a wider and more diverse group of patients than those participating in the clinical trials, which may identify undesirable side effects caused by these products that were not previously observed or reported. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The FDA and foreign regulatory agency regulations require that we report certain information about adverse medical events if our products may have caused or contributed to those adverse events. The timing of our obligation to report would be triggered by the date upon which we become aware of the adverse event as well as the nature and severity of the event. We may fail to report adverse events of which we become aware within the prescribed timeframe. We may also fail to appreciate that we have become aware of a reportable adverse event, especially if it is not reported to us as an adverse event or if it is an adverse event that is unexpected or removed in time from the use of our products. If we fail to comply with our reporting obligations, the FDA or a foreign regulatory agency could take action including enforcing a hold on or cessation of clinical trials, withdrawal of approved drugs from the market, criminal prosecution, the imposition of civil monetary penalties or seizure of our products. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">42</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additionally, in the event we discover the existence of adverse medical events or side effects caused by one of our products or product candidates, a number of other potentially significant negative consequences could result, including: </span></p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Calibri;">our inability to submit an NDA or similar application for our product candidates because of insufficient risk-reward, or the denial of such application by the FDA or foreign regulatory authorities&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Calibri;">the FDA or foreign regulatory authorities suspending or terminating our clinical trials or suspending or withdrawing their approval of the product&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Calibri;">the FDA or foreign regulatory authorities requiring the addition of labeling statements, such as boxed or other warnings or contraindications or distribution and use restrictions&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Calibri;">the FDA or foreign regulatory authorities requiring us to issue specific communications to healthcare professionals, such as letters alerting them to new safety information about our product, changes in dosage or other important information&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Calibri;">the FDA or foreign regulatory authorities issuing negative publicity regarding the affected product, including safety communications&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Calibri;">our being limited with respect to the safety-related claims that we can make in our marketing or promotional materials&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Calibri;">our being required to change the way the product is administered, conduct additional nonclinical studies or clinical trials or restrict or cease the distribution or use of the product&#59; and </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Calibri;">our being sued and held liable for harm caused to patients. </span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any of these events could prevent us from achieving market acceptance or approval of the affected product or product candidate and could substantially increase development or commercialization costs, force us to withdraw from the market any approved product, or even force us to cease operations. We cannot assure you that we will resolve any issues related to any product-related adverse events to the satisfaction of the FDA or any regulatory agency in a timely manner or ever, which could harm our business, prospects and financial condition. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Calibri;text-transform:none;font-variant: normal;">We may continue to face future developmental and regulatory difficulties related to Jelmyto and any other product candidates that receive marketing approval. In addition, we are subject to government regulations and we may experience delays in obtaining required regulatory approvals to market our proposed product candidates. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are subject to certain postmarketing commitments related to <span style="font-style:italic;">Jelmyto</span>, including a requirement for a period of five years to provide annual updates for the duration of response for all patients with ongoing complete responses enrolled in the OLYMPUS trial. With respect to our current and future candidates, even if we complete clinical testing and receive approval of any regulatory filing for our product candidates, the FDA or applicable foreign regulatory agency may grant approval contingent on the performance of additional costly post-approval clinical trials, risk mitigation requirements and surveillance requirements to monitor the safety or efficacy of the product, which could negatively impact us by reducing revenues or increasing expenses, and cause the approved product candidate not to be commercially viable. Absence of long-term safety data may further limit the approved uses of our products, if any. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The FDA or applicable foreign regulatory agency also may approve our product candidates for a more limited indication or a narrower patient population than we originally requested or may not approve the labeling that we believe is necessary or desirable for the successful commercialization of our product candidates. Furthermore, any such approved product will remain subject to extensive regulatory requirements, including requirements relating to manufacturing, labeling, packaging, adverse event reporting, storage, advertising, promotion, distribution and recordkeeping. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If we fail to comply with the regulatory requirements of the FDA or other applicable foreign regulatory authorities, or previously unknown problems with any approved commercial products, manufacturers or manufacturing processes are discovered, we could be subject to administrative or judicially imposed sanctions or other setbacks, including the following: </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Calibri;">suspension or imposition of restrictions on operations, including costly new manufacturing requirements&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Calibri;">regulatory agency refusal to approve pending applications or supplements to applications&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Calibri;">suspension of any ongoing clinical trials&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Calibri;">suspension or withdrawal of marketing approval&#59; </span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">43</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span><span style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span><span style="font-family:Calibri;">an injunction or imposition of civil or criminal penalties or monetary fines&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Calibri;">seizure or detention of products&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Calibri;">bans or restrictions on imports and exports&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Calibri;">issuance of warning letters or untitled letters&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Calibri;">suspension or imposition of restrictions on operations, including costly new manufacturing requirements&#59; or </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Calibri;">refusal of regulatory authorities to approve pending applications or supplements to applications. </span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, various aspects of our operations are subject to federal, state or local laws, rules and regulations, any of which may change from time to time. Costs arising out of any regulatory developments could be time-consuming and expensive and could divert management resources and attention and, consequently, could adversely affect our business, financial condition, cash flows and results of operations. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Calibri;text-transform:none;font-variant: normal;">If we are not successful in developing, receiving regulatory approval for and commercializing our nonclinical and clinical product candidates, our ability to expand our business and achieve our strategic objectives could be impaired. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Although we have received FDA approval of <span style="font-style:italic;">Jelmyto</span> for pyelocalyceal solution, for the treatment of adult patients with low-grade UTUC, and we plan to devote a substantial portion of our resources to the continued clinical testing and potential approval UGN-102 for the treatment of low-grade intermediate risk NMIBC, another key element of our strategy is to discover, develop and commercialize a portfolio of products to serve additional therapeutic markets. We are seeking to do so through our internal research programs, but our resources are limited, and those that we have are geared towards clinical testing and seeking regulatory approval of UGN-102 and our other existing product candidates. We may also explore strategic collaborations for the development or acquisition of new products, but we may not be successful in entering into such relationships. Research programs to identify product candidates require substantial technical, financial and human resources, regardless of whether any product candidates are ultimately identified. Our research programs may initially show promise in identifying potential product candidates, yet fail to yield product candidates for clinical development for many reasons, including: </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Calibri;">the research methodology used may not be successful in identifying potential product candidates&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Calibri;">competitors may develop alternatives that render our product candidates obsolete or less attractive&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Calibri;">a product candidate may in a subsequent trial be shown to have harmful side effects or other characteristics that indicate it is unlikely to be effective or otherwise does not meet applicable regulatory criteria&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Calibri;">a product candidate may not be capable of being produced in commercial quantities at an acceptable cost, or at all&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Calibri;">a product candidate may not be accepted as safe and effective by patients, the medical community or third-party payors, if applicable&#59; and </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Calibri;">intellectual property or other proprietary rights of third parties for product candidates we develop may potentially block our entry into certain markets or make such entry economically impracticable. </span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If we fail to develop and successfully commercialize other product candidates, our business and future prospects may be harmed, and our business will be more vulnerable to any problems that we encounter in developing and commercializing our product candidates. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">44</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Calibri;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Calibri;text-transform:none;font-variant: normal;">We have entered into a licensing agreement and in the future may enter into collaborations with other third parties for the development or commercialization of our product candidates. If our collaborations are not successful, we may not be able to capitalize on the market potential of these product candidates. </span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In October 2016, we entered into the Allergan/AbbVie Agreement. Under the Allergan/AbbVie Agreement, we granted Allergan an exclusive worldwide license to research, develop, manufacture and commercialize pharmaceutical products that contain a proprietary <span style="font-style:italic;">RTGel</span> formulation and clostridial toxins (including BOTOX), alone or in combination with certain other active ingredients, which we refer to collectively as the Licensed Products. Either party may terminate the Allergan/AbbVie Agreement for uncured material breach by the other party and for the insolvency of the other party. We may terminate the Allergan/AbbVie Agreement if Allergan or its affiliates challenges any of our patents licensed to Allergan and such patent challenge is not required under a court order or subpoena and is not a defense against a claim, action or proceeding asserted by us, our affiliates or licensees against Allergan, its affiliates or sublicensees. In addition, Allergan may unilaterally terminate the Allergan/AbbVie Agreement for any reason upon advance notice. If Allergan has the right to terminate the Allergan/AbbVie Agreement due to our uncured material breach, Allergan may elect to continue the agreement and reduce all future milestone and royalty payment obligations to us by a specified percentage. In the event of any termination of the Allergan/AbbVie Agreement, Allergan will assign or grant a right of reference to any regulatory documentation related to <span style="font-style:italic;">RTGel</span> to us, all rights and licenses to Allergan will terminate, and the license Allergan granted to us under their improvements to <span style="font-style:italic;">RTGel</span> will continue. If any of these events occurs, we will not be able to obtain, or may be delayed in obtaining, marketing approvals for the Licensed Products and will not be able to, or may be delayed in our efforts to, successfully commercialize the Licensed Products, and our business will be harmed. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In August 2020, we announced that the Phase 2 APOLLO trial did not meet the primary endpoint, it is believed to be the result of BOTOX not effectively permeating the urothelium. We are continuing to explore the potential use of <span style="font-style:italic;">RTGel</span> in combination with other products in AbbVie&#8217;s portfolio.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may utilize a variety of types of collaboration, distribution and other marketing arrangements with third parties to develop our product candidates and commercialize our approved product candidates, if any. We are not currently party to any such arrangement. Our ability to generate revenues from these arrangements will depend on our collaborators&#8217; abilities and efforts to successfully perform the functions assigned to them in these arrangements. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our existing collaboration with AbbVie and any future collaborations that we enter into, may pose a number of risks, including the following: </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Calibri;">collaborators have significant discretion in determining the amount and timing of efforts and resources that they will apply to these collaborations&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Calibri;">collaborators may not perform their obligations as expected&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Calibri;">product candidates developed by collaborators may not perform sufficiently in clinical trials to be determined to be safe and effective, thereby delaying or terminating the drug approval process and reducing or eliminating milestone payments to which we would otherwise be entitled if the product candidates had successfully met their endpoints and/or received FDA approval&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Calibri;">clinical trials conducted by collaborators could give rise to new safety concerns&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Calibri;">collaborators may not pursue development and commercialization of our product candidates that receive marketing approval or may elect not to continue or renew development or commercialization programs based on clinical trial results, changes in the collaborators&#8217; strategic focus or available funding, or external factors, such as an acquisition, that divert resources or create competing priorities&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Calibri;">collaborators may delay clinical trials, provide insufficient funding for a clinical trial program, stop a clinical trial or abandon a product candidate, repeat or conduct new clinical trials or require a new formulation of a product candidate for clinical testing&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Calibri;">collaborators could independently develop, or develop with third parties, products that compete directly or indirectly with our products or product candidates if the collaborators believe that competitive products are more likely to be successfully developed or can be commercialized under terms that are more economically attractive than ours&#59; </span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">45</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span><span style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span><span style="font-family:Calibri;">product candidates discovered in collaboration with us may be viewed by our collaborators as competitive with their own product candidates or products, which may cause collaborators to cease to devote resources to the commercialization of our product candidates&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Calibri;">a collaborator with marketing and distribution rights to one or more of our product candidates that achieve regulatory approval may not commit sufficient resources to the marketing and distribution of such product or products&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Calibri;">disagreements with collaborators, including disagreements over proprietary rights, contract interpretation or the preferred course of development, might cause delays or termination of the research, development or commercialization of product candidates, might lead to additional responsibilities for us with respect to product candidates, or might result in litigation or arbitration, any of which would divert management attention and resources, be time-consuming and expensive&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Calibri;">collaborators may not properly maintain or defend our intellectual property rights or may use our proprietary information in such a way as to invite litigation that could jeopardize or invalidate our intellectual property or proprietary information or expose us to potential litigation&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Calibri;">collaborators may infringe the intellectual property rights of third parties, which may expose us to litigation and potential liability&#59; and </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Calibri;">collaborations may be terminated for the convenience of the collaborator and, if terminated, we could be required to raise additional capital to pursue further development or commercialization of the applicable product candidates. </span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Collaborations may not lead to development or commercialization of product candidates in the most efficient manner, or at all, and may otherwise experience challenges. For example, in August 2020, we announced that the Phase 2 APOLLO trial did not meet the primary endpoint, it is believed to be the result of BOTOX not effectively permeating the urothelium. While we are continuing to explore the potential use of <span style="font-style:italic;">RTGel</span> in combination with other products in AbbVie&#8217;s portfolio, there can be no assurance that the collaboration will result in the successful development of a product candidate. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If the Allergan/AbbVie Agreement, and any future collaborations that we enter into, do not result in the successful development and commercialization of products or if one of our collaborators terminates its agreement with us, we may not receive any future research funding or milestone or royalty payments under the collaboration. If we do not receive the funding we expect under these agreements, our development of our product candidates could be delayed, and we may need additional resources to develop our product candidates. All the risks relating to product development, regulatory approval and commercialization described in this report also apply to the activities of our collaborators. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additionally, subject to its contractual obligations to us, if a collaborator of ours were to be involved in a business combination, it might deemphasize or terminate the development or commercialization of any product candidate licensed to it by us. If one of our collaborators terminates its agreement with us, we may find it more difficult to attract new collaborators and perception of us in the business and financial communities could be harmed. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">46</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Calibri;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Calibri;text-transform:none;font-variant: normal;">We currently contract with third-party subcontractors and single-source suppliers for certain raw materials, compounds and components necessary to produce Jelmyto for commercial use, and to produce UGN-102 and UGN-201 for nonclinical studies and clinical trials, and expect to continue to do so to support commercial scale production of UGN-102 and UGN-201, if approved. There are significant risks associated with the manufacture of pharmaceutical products and contracting with contract manufacturers and with single-source suppliers. Furthermore, our existing third-party subcontractors and single-source suppliers may not be able to meet the increased need for certain raw materials, compounds and components that may result from our commercialization efforts. This increases the risk that we will not have sufficient quantities of Jelmyto, UGN-102 or UGN-201 or be able to obtain such quantities at an acceptable cost, which could delay, prevent or impair our development or commercialization efforts. </span><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Calibri;text-transform:none;font-variant: normal;">*</span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We currently rely on third party subcontractors and suppliers for certain compounds and components necessary to produce <span style="font-style:italic;">Jelmyto</span> for commercial use and UGN-102 and UGN-201 for our nonclinical studies, clinical trials and commercial use, should our drug candidates receive regulatory approval. We currently depend on Teva Pharmaceuticals Industries Ltd., or Teva, as our single-source supplier of mitomycin active pharmaceutical ingredient, or API, for <span style="font-style:italic;">Jelmyto</span> and UGN-102. We rely on Cenexi-Laboratoires Thissen s.a., and Isotopia Molecular Imaging Ltd. as our sole suppliers for the mitomycin and gel contained in <span style="font-style:italic;">Jelmyto</span> and UGN-102, respectively. We also currently depend on a single source supplier for imiquimod for UGN-201. Because there are a limited number of suppliers for the raw materials that we use to manufacture our product candidates, we may need to engage alternate suppliers to prevent a possible disruption of the manufacture of the materials necessary to produce <span style="font-style:italic;">Jelmyto</span> for commercial sale and our product candidates for our clinical trials and their subsequent commercial sale, if approved. Even if we are able to engage alternate suppliers on reasonable terms, we may face delays or increased costs in our supply chain that could jeopardize the commercialization of <span style="font-style:italic;">Jelmyto</span>. We do not have any control over the availability of raw materials. If we or our suppliers and manufacturers are unable to purchase these raw materials on acceptable terms, at sufficient quality levels, or in adequate quantities, if at all, the development and commercialization of our product candidates or any future product candidates, would be delayed or there would be a shortage in supply, which would impair our ability to meet our development objectives for our product candidates or generate revenues from the sale of <span style="font-style:italic;">Jelmyto</span> or any other approved products. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We expect to continue to rely on these or other subcontractors and suppliers to support our commercial requirements for <span style="font-style:italic;">Jelmyto</span>, as well as UGN-102 or any of our other product candidates if approved for marketing by the FDA or foreign regulatory authorities. We also rely on a single third-party manufacturer to produce our proprietary drug product, or final mitomycin formulation, necessary for our clinical trial and commercial requirements. We plan to continue to rely on third parties for the production of mitomycin API, the gel contained in <span style="font-style:italic;">Jelmyto</span> and UGN-102, and for imiquimod for UGN-201, as well as for the raw materials, compounds and components necessary to produce our product candidates and for nonclinical studies and clinical trials. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Even though we are approved as a commercial supplier of <span style="font-style:italic;">Jelmyto</span>, we have limited experience as a company in the commercial supply of drugs and may never be successful as a commercial supplier of drug products containing mitomycin. In addition, cost-overruns, unexpected delays, equipment failures, logistics breakdowns, labor shortages, natural disasters, power failures, production failures or product recalls, and numerous other factors could prevent us from realizing the intended benefits of our sales strategy and have a material adverse effect on our business. Further, although we commercially supply <span style="font-style:italic;">Jelmyto</span>, further build-out is required and establishing such commercial-scale supply capabilities requires additional investment, is time-consuming and may be subject to delays, including because of shortage of labor, compliance with regulatory requirements or receipt of necessary regulatory approvals. In addition, building out our <span style="font-style:italic;">Jelmyto</span> commercial supply capabilities may cost more than we currently anticipate, and delays or problems may adversely impact our ability to provide sufficient quantities of <span style="font-style:italic;">Jelmyto</span> to support our ongoing commercial launch and commercialization of <span style="font-style:italic;">Jelmyto</span> as well as our financial condition. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">While we currently have over 12 months of mitomycin API and <span style="font-style:italic;">Jelmyto</span> finished product on hand to continue our commercial and clinical operations as planned, depending on the duration of the COVID-19 pandemic and whether further disruptions occur, we may face such delays or costs in future years. Although we believe we have sufficient quantities of mitomycin API for planned manufacturing operations during 2021, a prolonged supply interruption of certain components could adversely affect our ability to conduct commercialization activities and planned clinical trials. If any third party in our supply or distribution chain for materials or finished product is adversely impacted by restrictions resulting from the ongoing COVID-19 pandemic, including staffing shortages, production slowdowns and disruptions in delivery systems, our supply chain may be disrupted, limiting our ability to manufacture and distribute <span style="font-style:italic;">Jelmyto</span> for commercial sales and our product candidates for our clinical trials and research and development operations. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, before we can begin to commercially manufacture any product candidate that receives regulatory approval in the future other than <span style="font-style:italic;">Jelmyto</span>, whether in a third-party facility or in our own facility, once established, we must obtain regulatory approval from </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">47</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the FDA for our manufacturing process and facility in order to sell such products in the United States. A manufacturing authorization would also have to be obtained from the appropriate European Union regulatory authorities in order sell such products in the European Union. In order to obtain approval, we will need to ensure that all of the processes, methods and equipment of such manufacturing facilities are compliant with cGMP, and perform extensive audits of vendors, contract laboratories and suppliers. If any vendors, contract laboratories or suppliers is found to be out of compliance with cGMP, we may experience delays or disruptions in manufacturing while we work with these third parties to remedy the violation or while we work to identify suitable replacement vendors. The cGMP requirements govern quality control of the manufacturing process and documentation policies and procedures. In complying with cGMP, we will be obligated to expend time, money and effort in production, record keeping and quality control to assure that the product meets applicable specifications and other requirements. If we fail to comply with these requirements, we would be subject to possible regulatory action and may not be permitted to sell any product candidate that we may develop. </span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our continuing reliance on third party subcontractors and suppliers entails a number of risks, including reliance on the third party for regulatory compliance and quality assurance, the possible breach of the manufacturing or supply agreement by the third party, and the possible termination or nonrenewal of the agreement by the third party at a time that is costly or inconvenient for us. In addition, third party subcontractors and suppliers may not be able to comply with cGMP or quality system regulation, also called QSR, or similar regulatory requirements outside the United States. If any of these risks transpire, we may be unable to timely retain alternate subcontractors or suppliers on acceptable terms and with sufficient quality standards and production capacity, which may disrupt and delay our clinical trials or the manufacture and commercial sale of our in-line or investigational product candidates, if approved. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our failure or the failure of our third-party subcontractors and suppliers to comply with applicable regulations could result in sanctions being imposed on us, including fines, injunctions, civil penalties, delays, suspension or withdrawal of approvals, license revocation, seizures or recalls of products, operating restrictions and criminal prosecutions, any of which could significantly and adversely affect supplies of <span style="font-style:italic;">Jelmyto</span>, UGN-102 or any of our other product candidates that we may develop. Any failure or refusal to supply or any interruption in supply of the components for <span style="font-style:italic;">Jelmyto</span>, UGN-102 or any other product candidates that we may develop could delay, prevent or impair our clinical development or commercialization efforts. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We currently use single source suppliers relative to production of the <span style="font-style:italic;">RTGel</span> products, the ureteral catheter and injector which are required to be used with <span style="font-style:italic;">Jelmyto</span>. Both the ureteral catheter and injector are used as part of the delivery of <span style="font-style:italic;">Jelmyto</span>. We are assessing second source suppliers regarding certain components of <span style="font-style:italic;">Jelmyto</span> and are advancing these conversations as a means to ensure both a second source and potential future reductions in cost of revenues. However, there can be no assurance that we will be able to secure any second-source suppliers for these key components on a timely basis, on favorable terms, or at all.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We rely on third party transportation to deliver materials to our facilities and ship products to our customers. Transport operators are exposed to various risks, such as extreme weather conditions, natural disasters, work stoppages, personnel shortages, and operating hazards, as well as interstate and international transportation requirements. If we experience transportation problems, or if there are other significant changes in the cost of these services, we may not be able to arrange efficient alternatives and timely means to obtain materials or ship products to our customers. Our failure to obtain such materials, ship products or maintain sufficient buffer inventory could materially and adversely impact our business, financial condition and results of operations.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may need to enter into agreements with additional distributors or suppliers, and there is no guarantee that we will be able to do so on commercially reasonable terms or at all. If we are unable to maintain and, if needed, expand, our network of specialty distributors or suppliers, this would expose us to substantial risk in our clinical development or commercialization efforts. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Calibri;text-transform:none;font-variant: normal;">Failure to obtain marketing approval in international jurisdictions would prevent our approved product, Jelmyto, and our product candidates from being marketed abroad. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In order to market and sell our products in the European Union and other jurisdictions, we or our third-party collaborators must obtain separate marketing approvals and comply with numerous and varying regulatory requirements. The approval procedure varies among countries and can involve additional testing. The time required to obtain approval may differ substantially from that required to obtain FDA approval. Regulatory approval processes outside the United States generally include all of the risks associated with obtaining FDA approval. In addition, in many countries outside the United States, it is required that the product be approved for reimbursement before the product can be commercialized in that country. We may not obtain approvals from regulatory authorities outside the United States on a timely basis, if at all. Approval by the FDA does not ensure approval by regulatory authorities in other countries or jurisdictions, and approval by one regulatory authority outside the United States does </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">48</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">not ensure approval by regulatory authorities in other countries or jurisdictions or by the FDA. We may not be able to submit for marketing approvals and may not receive the necessary approvals to commercialize our product candidates in any particular market. </span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Calibri;text-transform:none;font-variant: normal;">We rely on third parties and consultants to assist us in conducting our clinical trials for our product candidates. If these third parties or consultants do not successfully carry out their contractual duties or meet expected deadlines, we may be unable to obtain regulatory approval for or commercialize UGN-102 or any of our other product candidates. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We do not have the ability to independently conduct many of our nonclinical studies or our clinical trials. We rely on medical institutions, clinical investigators, contract laboratories, and other third parties, such as CROs to conduct clinical trials on our product candidates. Third parties play a significant role in the conduct of our clinical trials and the subsequent collection and analysis of data. These third parties are not our employees, and except for remedies available to us under our agreements, we have limited ability to control the amount or timing of resources that any such third party will devote to our clinical trials. Due to the limited drug development for non-muscle invasive urothelial cancers over the past 15 years, neither we nor any third-party clinical investigators, CROs and/or consultants are likely to have extensive experience conducting clinical trials for the indications we are targeting. If our CROs or any other third parties upon which we rely for administration and conduct of our clinical trials do not successfully carry out their contractual duties or obligations or meet expected deadlines, if they need to be replaced or if the quality or accuracy of the clinical data they obtain is compromised due to the failure to adhere to our clinical protocols, regulatory requirements, or for other reasons, or if they otherwise perform in a substandard manner, our clinical trials may be extended, delayed, suspended or terminated, and we may not be able to complete development of, obtain regulatory approval for, or successfully commercialize our product candidates. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We and the third parties upon whom we rely are required to comply with Good Clinical Practice, or GCP, regulations, which are regulations and guidelines enforced by regulatory authorities around the world for products in clinical development. Regulatory authorities enforce these GCP regulations through periodic inspections of clinical trial sponsors, principal investigators and clinical trial sites. If we or our third parties fail to comply with applicable GCP regulations, the clinical data generated in our clinical trials may be deemed unreliable and our submission of marketing applications may be delayed, or the regulatory authorities may require us to perform additional clinical trials before approving our marketing applications. We cannot assure you that, upon inspection, a regulatory authority will determine that any of our clinical trials comply or complied with applicable GCP regulations. In addition, our clinical trials must be conducted with material produced under current GMP regulations, which are enforced by regulatory authorities. Our failure to comply with these regulations may require us to repeat clinical trials, which would delay the regulatory approval process. Moreover, our business may be impacted if our CROs, clinical investigators or other third parties violate federal or state fraud and abuse or false claims laws and regulations or healthcare privacy and security laws. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In order for our clinical trials to be carried out effectively and efficiently, it is imperative that our CROs and other third parties communicate and coordinate with one another. Moreover, our CROs and other third parties may also have relationships with other commercial entities, some of which may compete with us. Our CROs and other third parties may terminate their agreements with us upon as few as 30 days&#8217; notice under certain circumstances. If our CROs or other third parties conducting our clinical trials do not perform their contractual duties or obligations, experience work stoppages, do not meet expected deadlines, terminate their agreements with us or need to be replaced, or if the quality or accuracy of the clinical data they obtain is compromised due to the failure to adhere to our clinical trial protocols or GCPs, or for any other reason, we may need to conduct additional clinical trials or enter into new arrangements with alternative CROs, clinical investigators or other third parties. We may be unable to enter into arrangements with alternative CROs on commercially reasonable terms, or at all. Switching or adding CROs, clinical investigators or other third parties can involve substantial cost and require extensive management time and focus. In addition, there is a natural transition period when a new CRO commences work. As a result, delays may occur, which can impact our ability to meet our desired clinical development timelines. Although we carefully manage our relationship with our CROs, clinical investigators and other third parties, there can be no assurance that we will not encounter such challenges or delays in the future or that these delays or challenges will not have a negative impact on our business, prospects, financial condition or results of operations. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">49</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Calibri;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Calibri;text-transform:none;font-variant: normal;">If in the future we acquire or in-license technologies or product candidates, we may incur various costs, may have integration difficulties and may experience other risks that could harm our business and results of operations. </span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the future, we may acquire or in-license additional product candidates and technologies. Any product candidate or technologies we in-license or acquire will likely require additional development efforts prior to commercial sale, including extensive nonclinical or clinical testing, or both, and approval by the FDA and applicable foreign regulatory authorities, if any. All product candidates are prone to risks of failure inherent in pharmaceutical product development, including the possibility that the product candidate, or product developed based on in-licensed technology, will not be shown to be sufficiently safe and effective for approval by regulatory authorities. If intellectual property related to product candidates or technologies we in-license is not adequate, we may not be able to commercialize the affected products even after expending resources on their development. In addition, we may not be able to economically manufacture or successfully commercialize any product candidate that we develop based on acquired or in-licensed technology that is granted regulatory approval, and such products may not gain wide acceptance or be competitive in the marketplace. Moreover, integrating any newly acquired or in-licensed product candidates could be expensive and time-consuming. If we cannot effectively manage these aspects of our business strategy, our business may be materially harmed. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Calibri;text-transform:none;font-variant: normal;">We have recently increased the size of our organization and will need to continue to increase the size of our organization. If we fail to manage our growth effectively, our business could be disrupted. *</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of March 31, 2021, we had 190 employees, of whom 43 are based in Israel and 147 are based in the United States. We will need to continue to expand our development, quality, managerial, operational, finance, marketing, sales and other resources to manage our operations and clinical trials, continue our development activities and commercialize our product candidates, if approved. Our management, personnel, systems and facilities currently in place may not be adequate to support this future growth. Our need to effectively execute our expansion strategy requires that we: </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Calibri;">manage our clinical trials effectively&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Calibri;">identify, recruit, retain, incentivize and integrate additional employees&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Calibri;">manage our internal development efforts effectively while carrying out our contractual obligations to third parties&#59; and </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Calibri;">continue to improve our operational, financial and management controls, reporting systems and procedures. </span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As we continue to grow as an organization, including by expanding our development efforts and building out and developing our commercial capabilities to support our ongoing commercial launch of <span style="font-style:italic;">Jelmyto</span>, we will evaluate, and may implement, changes to our organization that may be appropriate in order to properly manage and direct our growth and transformation into a commercial-stage company. Due to our limited financial resources and our limited experience in managing a larger company, we may not be able to effectively manage the expansion of our operations or recruit and train additional qualified personnel. In addition, the ongoing COVID-19 pandemic could make recruiting and training more difficult. The physical expansion of our operations may lead to significant costs and may divert our management and business development resources. Any inability to manage expansion or other significant changes to our organization could delay the execution of our development, commercialization and strategic objectives or disrupt our operations&#59; and if we are not successful in commercializing our approved product or any of our product candidates that may receive regulatory approval, either on our own or through collaborations with one or more third parties, our revenues will suffer, and we would incur significant additional losses. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">50</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Calibri;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Calibri;text-transform:none;font-variant: normal;">If product liability lawsuits are brought against us, we may incur substantial liabilities and may be required to limit commercialization of any of our other products we develop. </span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We face an inherent risk of product liability as a result of the clinical testing of our product candidates and will face an even greater risk with the commercialization of <span style="font-style:italic;">Jelmyto</span> or any other investigational product candidate that receives marketing approval. For example, we may be sued if any product we develop allegedly causes injury or is found to be otherwise unsuitable during product testing, manufacturing, marketing or sale. Any such product liability claims may include allegations of defects in manufacturing, defects in design, a failure to warn of dangers inherent in the product, negligence, strict liability and a breach of warranties. Claims could also be asserted under state consumer protection acts. If we cannot successfully defend ourselves against product liability claims, we may incur substantial liabilities or be required to limit commercialization of our products. Even a successful defense would require significant financial and management resources. Regardless of the merits or eventual outcome, liability claims may result in: </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Calibri;">decreased demand for </span><span style="font-style:italic;font-family:Calibri;">Jelmyto</span><span style="font-family:Calibri;"> and our investigational product candidates we develop&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Calibri;">injury to our reputation and significant negative media attention&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Calibri;">withdrawal of clinical trial participants or cancellation of clinical trials&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Calibri;">costs to defend the related litigation, which may be only partially recoverable even in the event of successful defenses&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Calibri;">a diversion of management&#8217;s time and our resources&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Calibri;">substantial monetary awards to trial participants or patients&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Calibri;">regulatory investigations, product recalls, withdrawals or labeling, marketing or promotional restrictions&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Calibri;">loss of revenues&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Calibri;">exhaustion of any available insurance and our capital resources&#59; and </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Calibri;">the inability to commercialize any product we develop. </span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our inability to obtain and maintain sufficient product liability insurance at an acceptable cost and scope of coverage to protect against potential product liability claims could prevent or inhibit the commercialization of products we may develop. We currently carry general clinical trial product liability insurance in an amount that we believe is adequate to cover the scope of our ongoing clinical programs. Although we maintain such insurance, any claim that may be brought against us could result in a court judgment or settlement in an amount that is not covered, in whole or in part, by our insurance or that is in excess of the limits of our insurance coverage. Our insurance policies also have various exclusions and deductibles, and we may be subject to a product liability claim for which we have no coverage. We will have to pay any amounts awarded by a court or negotiated in a settlement that exceed our coverage limitations or that are not covered by our insurance, and we may not have, or be able to obtain, sufficient capital to pay such amounts. Moreover, in the future, we may not be able to maintain insurance coverage at a reasonable cost or in sufficient amounts to protect us against losses. As a result of receiving marketing approval of <span style="font-style:italic;">Jelmyto</span>, have expanded our insurance coverage to include the commercialization of <span style="font-style:italic;">Jelmyto</span>&#59; however, we may be unable to continue to obtain this liability insurance on commercially reasonable terms. In addition, if and when we obtain approval for marketing UGN-102 or any other product candidate, we intend to further expand our insurance coverage to include the commercialization of UGN-102 or nay other approved product&#59; however, we may be unable to obtain this additional liability insurance on commercially reasonable terms. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Calibri;text-transform:none;font-variant: normal;">If we fail to attract and keep senior management and key personnel, we may be unable to successfully develop our product candidates, conduct our clinical trials and commercialize any of the products we develop. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our success depends in part on our continued ability to attract, retain and motivate highly qualified management, clinical, scientific and other personnel. We believe that our future success is highly dependent upon the contributions of members of our senior management, as well as our senior scientists and other members of our management team. The loss of services of any of these individuals could delay or prevent the successful development of our product pipeline, completion of our planned clinical trials or the commercialization of our product candidates. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Although we have not historically experienced unique difficulties in attracting and retaining qualified employees, we could experience such problems in the future. For example, competition for qualified personnel in the pharmaceutical field is intense due to the limited number of individuals who possess the skills and experience required by our industry. We will need to hire additional </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">51</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">personnel as we expand our clinical development and commercial activities. We may not be able to attract and retain quality personnel on acceptable terms, or at all. In addition, to the extent we hire personnel from competitors, we may be subject to allegations that they have been improperly solicited or that they have divulged proprietary or other confidential information, or that their former employers own their research output. </span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Calibri;text-transform:none;font-variant: normal;">If our security measures are compromised, or our information technology systems or those of our vendors, and other relevant third parties fail or suffer security breaches, loss or leakage of data, and other disruptions, this could result in a material disruption of our drug development program, compromise sensitive information related to our business, harm our reputation, trigger our breach notification obligations, prevent us from accessing critical information, and expose us to liability or other adverse effects to our business.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the ordinary course of our business, we may collect, process and store proprietary, confidential and sensitive information, including personal information (including health information), intellectual property, trade secrets, and proprietary business information owned or controlled by ourselves or other parties. We face several risks relative to protecting the security, confidentiality, integrity and availability of this critical information, including loss of access risk, inappropriate use or disclosure, inappropriate modification, and the risk of being unable to adequately monitor, audit and modify our controls over our critical information. This risk extends to the third-party service providers who handle elements of our operations and data processing.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We, our CROs and other contractors, consultants, and other third parties on which we rely, depend on information technology, telecommunication systems and data processing for significant elements of our operations, including, for example, systems handling human resources, financial reporting and controls, regulatory compliance and other infrastructure operations. Notwithstanding the implementation of security measures, these information technology systems are potentially vulnerable to breakdown, service interruptions, system malfunction, natural disasters, fire, terrorism, war and telecommunication and electrical failures, as well as security breaches from inadvertent or intentional actions by our personnel, third-party vendors, contractors, consultants, business partners, or third parties, or from cyber-attacks by malicious third parties (including the deployment of malware, ransomware, denial-of-service attacks, social engineering, and other means to affect service reliability and threaten the confidentiality, integrity, and availability of information), which may compromise our information technology, telecommunication systems and data, or that of our third-party vendors and other contractors and consultants, or lead to data leakage. The risk of a security breach or disruption, particularly through accidental actions or omissions by trusted insiders, cyber-attacks or cyber intrusions has generally increased as the number, intensity, and sophistication of attempted attacks and intrusions from around the world have increased. We may not be able to anticipate all types of security threats, and we may not be able to implement preventative measures effective against all such security threats. Any such breach or interruption could compromise our networks and the information stored there could be accessed by parties, manipulated, publicly disclosed, lost, or stolen. Any event that leads to unauthorized access, use or disclosure of personal information could harm our reputation directly, compel us to comply with federal and/or state breach notification laws and foreign equivalents, subject us to mandatory corrective action, which could result in significant costs and reputational damage or otherwise have an adverse effect on our business. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Failures or significant downtime of our information technology or telecommunication systems or those used by our third-party service providers could cause significant interruptions in our operations and adversely impact the confidentiality, integrity and availability of sensitive or confidential information, including preventing us from conducting clinical trials, tests or research and development activities and preventing us from managing the administrative aspects of our business. For example, the loss of clinical trial data from completed, ongoing or planned clinical trials could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. To the extent that any disruption or security breach results in a loss of or damage to our data or applications, or inappropriate disclosure of confidential or proprietary information, we could incur liability and the further development of our product candidates could be delayed. If the information technology systems of our third-party vendors and other contractors become subject to disruptions or security breaches, we may have insufficient recourse against such third parties and may have to expend significant resources to mitigate the impact of such an event, and to develop and implement protections to prevent future events of this nature from occurring.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">52</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Calibri;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Calibri;text-transform:none;font-variant: normal;">Under applicable employment laws, we may not be able to enforce covenants not to compete. </span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We generally enter into non-competition agreements as part of our employment agreements with our employees. These agreements generally prohibit our employees, if they cease working for us, from competing directly with us or working for our competitors or clients for a limited period. We may be unable to enforce these agreements under the laws of the jurisdictions in which our employees work, and it may be difficult for us to restrict our competitors from benefitting from the expertise our former employees or consultants developed while working for us. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For example, Israeli labor courts have required employers seeking to enforce non-compete undertakings of a former employee to demonstrate that the competitive activities of the former employee will harm one of a limited number of material interests of the employer which have been recognized by the courts as justification for the enforcement of non-compete undertakings, such as the protection of a company&#8217;s trade secrets or other intellectual property. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Calibri;text-transform:none;font-variant: normal;">Our employees, independent contractors, clinical investigators, CROs, consultants and vendors may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements and insider trading. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are exposed to the risk that our employees, independent contractors, clinical investigators, CROs, consultants and vendors may engage in fraudulent conduct or other illegal activity. Misconduct by these parties could include intentional, reckless and/or negligent conduct, breach of contract or other unauthorized activities that violate: FDA regulations, including those laws requiring the reporting of true, complete and accurate information to the FDA&#59; manufacturing standards&#59; federal, state and foreign healthcare fraud and abuse laws&#59; buying or selling of our stock while in possession of material non-public information&#59; or laws that require the reporting of financial information or data accurately. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Specifically, research, sales, marketing, education and other business arrangements in the healthcare industry are subject to extensive laws intended to prevent fraud, misconduct, kickbacks, self-dealing and other abusive practices. These laws may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive and other business arrangements. Activities subject to these laws also include the improper use of information obtained in the course of clinical trials, which could result in regulatory sanctions and serious harm to our reputation. We have adopted a Corporate Code of Ethics and Conduct and a Compliance Program, but it is not always possible to identify and deter misconduct by employees and other third parties, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to be in compliance with such laws. If any such actions are instituted against us, even if we are successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business. Violations of such laws subject us to numerous penalties, including, but not limited to, the imposition of significant civil, criminal and administrative penalties, damages, monetary fines, disgorgement, imprisonment, additional reporting requirements and oversight if we become subject to a corporate integrity agreement or similar agreement to resolve allegations of non-compliance with these laws, possible exclusion from participation in Medicare, Medicaid and other federal healthcare programs, contractual damages, reputational harm, diminished profits and future earnings, and curtailment of our operations, any of which could adversely affect our ability to operate our business and our results of operations. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Most states also have statutes or regulations similar to these federal laws, which may apply to items such as pharmaceutical products and services reimbursed by private insurers. We and/or our future partners may be subject to administrative, civil and criminal sanctions for violations of any of these federal and state laws. Pharmaceutical and other healthcare companies have been prosecuted under these laws for a variety of promotional and marketing activities, such as: providing free trips, free goods, improper consulting fees and grants and other monetary benefits to prescribers&#59; reporting to pricing services inflated average wholesale prices that were then used by federal programs to set reimbursement rates&#59; engaging in&#160;off-label&#160;promotion&#59; and submitting inflated best price information to the Medicaid Rebate Program to reduce liability for Medicaid rebates. Ensuring that our internal operations and future business arrangements with third parties comply with applicable healthcare laws and regulations will involve substantial costs. It is possible that governmental authorities will conclude that our business practices do not comply with current or future statutes, regulations, agency guidance or case law involving applicable fraud and abuse or other healthcare laws and regulations, which could have a significant impact on the conduct of our business.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">53</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Calibri;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Calibri;text-transform:none;font-variant: normal;">Our business involves the use of hazardous materials and we and our third-party manufacturers and suppliers must comply with environmental laws and regulations, which can be expensive and restrict how we do business. </span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our research and development activities and our third-party subcontractors&#8217; and suppliers&#8217; activities involve the controlled storage, use, transportation and disposal of hazardous materials owned by us, including mitomycin, key components of our product candidates, and other hazardous compounds. We and our manufacturers and suppliers are subject to laws and regulations governing the use, manufacture, storage, handling and disposal of these hazardous materials. Despite our efforts, we cannot eliminate the risk of contamination. This could cause an interruption of our commercialization efforts and business operations, environmental damage resulting in costly clean-up and liabilities under applicable laws and regulations governing the use, storage, handling and disposal of these materials and specified waste products. Although we believe that the safety procedures utilized by us and our subcontractors and suppliers for handling and disposing of these materials generally comply with the standards prescribed by these laws and regulations, we cannot guarantee that this is the case or eliminate the risk of accidental contamination or injury from these materials. In such an event, we may be held liable for any resulting damages and such liability could exceed our resources and state or federal or other applicable authorities may curtail our use of certain materials and interrupt our business operations. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Furthermore, environmental laws and regulations are complex, change frequently and have tended to become more stringent. We cannot predict the impact of such changes and cannot be certain of our future compliance. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Calibri;text-transform:none;font-variant: normal;">Exchange rate fluctuations between the U.S.&#160;Dollar and the New Israeli Shekel may negatively affect our earnings. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The U.S. dollar is our functional and reporting currency. However, a significant portion of our operating expenses are incurred in New Israeli Shekels, or NIS, which is the lawful currency of the State of Israel. As a result, we are exposed to the risks that the NIS may appreciate relative to the dollar, or, if the NIS instead devalues relative to the dollar, that the inflation rate in Israel may exceed such rate of devaluation of the NIS, or that the timing of such devaluation may lag behind inflation in Israel. In any such event, the dollar cost of our operations in Israel would increase and our dollar-denominated results of operations would be adversely affected. We cannot predict any future trends in the rate of inflation in Israel or the rate of devaluation (if any) of the NIS against the dollar. For example, <span style="color:#000000;">although the dollar appreciated against the NIS in 2018 by 8.1%, the dollar depreciated against the NIS during 2019 and 2020 by 14.2%.</span> If the dollar cost of our operations in Israel increase, our dollar-measured results of operations will be adversely affected. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#212529;font-family:Calibri;font-size:10pt;text-transform:none;font-variant: normal;">Our business could be adversely affected by the effects of health pandemics or epidemics, including the COVID-19 pandemic. *</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The recent outbreak of the novel strain of coronavirus, SARS-CoV-2, causing COVID-19 disease, which has been declared by the World Health Organization to be a pandemic, has spread across the globe and is impacting worldwide economic activity. A pandemic, including COVID-19 or other public health epidemic, poses the risk that we or our employees, contractors, suppliers, customers, and other partners may be prevented from conducting certain business activities for an indefinite period of time, including due to spread of the disease within these groups or due to shutdowns that may be requested or mandated by governmental authorities. While it is not possible at this time to estimate the impact that COVID-19 could have on our business, the COVID-19 pandemic and mitigation measures have had and may continue to have an adverse impact on global economic conditions which could have an adverse effect on our business and financial condition, including impairing our ability to raise capital when needed. The continued spread of COVID-19 and the measures taken by various governments could disrupt the supply chain of material needed for our product candidates and our approved product, <span style="font-style:italic;">Jelmyto</span>, interrupt healthcare services, delay coverage decisions from Medicare and third party payors, delay ongoing and planned clinical trials involving our product candidates and have a material adverse effect on our business, financial condition and results of operations. In addition, we and many of our potential customers and partners worldwide have in the past and may in the future be subject to stay-at-home orders as a result of the COVID-19 pandemic. In addition, our ongoing commercial launch of <span style="font-style:italic;">Jelmyto</span> and subsequent commercialization activities could be hindered by the COVID-19 pandemic, although we are currently not able to predict or quantify any such potential impact with any degree of certainty. However, the worldwide spread of the COVID-19 virus has resulted and may continue to result in a global slowdown of economic activity which is likely to decrease demand for a broad variety of goods and services, including potentially for <span style="font-style:italic;">Jelmyto</span>, while also disrupting sales channels and marketing activities for an unknown period of time until the disease is contained. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&#160;</p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The timelines and conduct of our ongoing clinical trials may be affected by the COVID-19 pandemic. Clinical site initiation and patient enrollment may be delayed due to prioritization of hospital resources toward the COVID-19 pandemic and patients&#8217; ability or willingness to participate in clinical trials. For those patients who are enrolled and desire to continue in the clinical trials, some patients may not be able or willing to comply with clinical trial protocols if quarantines or governmental orders impede patient movement or interrupt healthcare services. Similarly, we may face increased challenges with the ability to recruit and retain patients </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">54</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:0pt;margin-bottom:0pt;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and principal investigators and site staff who, as healthcare providers, may have heightened exposure to COVID-19, which could adversely impact our clinical trial operations, timelines and outcomes. While we remain in close contact with our clinical research organizations, clinical sites and suppliers to attempt to assess the impacts that COVID-19 may have on our clinical trials and projected timelines and we are in the process of implementing appropriate mitigating measures in accordance with recent FDA guidance in an effort to ensure the ongoing safety of the patients in our clinical trials and the continued collection of high quality data, there is no guarantee that such efforts will be successful. As challenging as conducting clinical trials is during normal times, the risks, operational challenges and costs of conducting clinical trials has increased substantially during the pandemic.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additionally, during the COVID-19 pandemic, our sales force has had physical access to hospitals, clinics, healthcare providers and pharmacies curtailed, which we believe have affected our sales to date and may in the future have a material adverse effect on our future sales. While digital tools are available to our field employees to facilitate remote meetings with physicians and other healthcare providers, we cannot ensure that these methods will be effective. Additionally, patients who are currently using <span style="font-style:italic;">Jelmyto</span> or who are eligible to use <span style="font-style:italic;">Jelmyto</span>, may be unable to meet with their healthcare providers in person, which may reduce the number of prescription refills or new patient starts, affecting our revenues both in our currently approved indication and potentially impacting our anticipated launches in other indications, if approved. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Moreover, the global outbreak of the COVID-19 coronavirus continues to evolve, and the extent to which the COVID-19 coronavirus may impact our business, results of operations and financial position will depend on future developments, which are highly uncertain and cannot be predicted with confidence, such as the ultimate geographic spread of the disease, the duration of the outbreak, travel restrictions and social distancing in the United States and other countries, business closures or business disruptions, and the effectiveness of actions taken in the United States and other countries to contain and treat the disease.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To the extent the COVID-19 pandemic adversely affects our business and financial results, it may also have the effect of heightening many of the other risks described in the &#8220;Risk Factors&#8221; section of this report.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Calibri;text-transform:none;font-variant: normal;">Certain of our clinical trials and other significant operations are located outside of the U.S. and, therefore, our results may be adversely affected by geopolitical, economic and military instability. *</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Certain of our clinical trials are operated outside of the U.S. and if any of these current or future trials or the related facilities were to be damaged, destroyed or otherwise unable to operate, whether due to war, acts of hostility, earthquakes, fire, floods, hurricanes, storms, tornadoes, other natural disasters, employee malfeasance, terrorist acts, pandemic, power outages or otherwise, or if performance of our clinical trials are disrupted for any other reason, such an event could cause significant development and product delays. If we experience delays in achieving our development objectives within a timeframe that meets our prospective customers&#8217; expectations, our business, prospects, financial results and reputation could be harmed. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Geopolitical, economic and military conditions around the world may directly affect our business. Any hostilities involving any of the countries in which we operate, including terrorist activities, political instability or violence in the region or the interruption or curtailment of trade or transport between such country and its trading partners could adversely affect our operations and results of operations and adversely affect the market price of our ordinary shares. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Calibri;text-transform:none;font-variant: normal;">Our business activities may be subject to the U.S. Foreign Corrupt Practices Act (<span style="font-style:normal;">FCPA</span>) and similar anti-bribery and anti-corruption laws of other countries in which we operate, as well as U.S. and certain foreign export controls, trade sanctions, and import laws and regulations. Compliance with these legal requirements could limit our ability to compete in foreign markets and subject us to liability if we violate them. *</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We currently dedicate certain resources to comply with numerous laws and regulations in each jurisdiction in which we operate outside of the U.S. Our business activities in these foreign countries may be subject to the&#160;FCPA&#160;and similar anti-bribery or anti-corruption laws, regulations or rules of other countries in which we operate. The&#160;FCPA&#160;generally prohibits companies and their employees and third party intermediaries from offering, promising, giving or authorizing the provision of anything of value, either directly or indirectly, to a&#160;non-U.S.&#160;government official in order to influence official action or otherwise obtain or retain business. The&#160;FCPA&#160;also requires public companies to make and keep books and records that accurately and fairly reflect the transactions of the corporation and to devise and maintain an adequate system of internal accounting controls. Our business is heavily regulated and therefore involves significant interaction with public officials, including officials of&#160;non-U.S.&#160;governments. Additionally, in many other countries, hospitals owned and operated by the government, and doctors and other hospital employees would be considered foreign officials under the&#160;FCPA. Recently the SEC and U.S. Department of Justice have increased their&#160;FCPA&#160;enforcement activities with respect to biotechnology and pharmaceutical companies. There is no certainty that all of our employees, agents or contractors, or those of our affiliates, will comply with all applicable laws and regulations, particularly given the high level of complexity of these laws. Violations of these laws and regulations could result in fines, criminal sanctions against us, our officers or our employees, </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">55</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">disgorgement, and other sanctions and remedial measures, and prohibitions on the conduct of our</span><span style="font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">business. Any such violations could include prohibitions on our ability to offer our product in one or more countries and could materially damage our reputation, our brand, our international activities, our ability to attract and retain employees and our business.</span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, our product and activities may be subject to U.S. and foreign export controls, trade sanctions and import laws and regulations. Governmental regulation of the import or export of our product, or our failure to obtain any required import or export authorization for our product, when applicable, could harm our international sales and adversely affect our revenue. Compliance with applicable regulatory requirements regarding the export of our product may create delays in the introduction of our product in international markets or, in some cases, prevent the export of our product to some countries altogether. Furthermore, U.S. export control laws and economic sanctions prohibit the shipment of certain products and services to countries, governments, and persons targeted by U.S. sanctions. If we fail to comply with export and import regulations and such economic sanctions, penalties could be imposed, including fines and/or denial of certain export privileges. Moreover, any new export or import restrictions, new legislation or shifting approaches in the enforcement or scope of existing regulations, or in the countries, persons, or product targeted by such regulations, could result in decreased use of our product by, or in our decreased ability to export our product to existing or potential customers with international operations. Any decreased use of our product or limitation on our ability to export or sell access to our product would likely significantly harm our business, financial condition, results of operations and prospects.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">Risks Related to Our Limited Operating History, Financial Condition and Capital Requirements </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Calibri;text-transform:none;font-variant: normal;">We have a limited operating history and have incurred significant losses and negative cash flows since our inception, and we anticipate that we will continue to incur significant losses and negative cash flows for the foreseeable future, which makes it difficult to assess our future viability. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are a biopharmaceutical company with a limited operating history upon which you can evaluate our business and prospects. We are not profitable and have incurred net losses in each period since we commenced operations in 2004, including net losses of $128.5&#160;million and $105.1&#160;million for the years ended December 31, 2020 and 2019, respectively.<span style="color:#000000;">&#160;For the three months ended March 31, 2021 and 2020, we reported net losses of $25.9 and $37.8 million, respectively. As of March 31, 2021, we had an accumulated deficit of&#160;$382.4 million.&#160;</span>We expect to continue to incur significant expenses and increasing operating losses for the foreseeable future. Our ability to ultimately achieve recurring revenues and profitability is dependent upon our ability to successfully complete the development of our product candidates and obtain necessary regulatory approvals for and successfully manufacture, market and commercialize our products. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We believe that we will continue to expend substantial resources in the foreseeable future for the clinical development of our current product candidates or any additional product candidates and indications that we may choose to pursue in the future. These expenditures will include costs associated with research and development, conducting nonclinical studies and clinical trials, and payments for third-party manufacturing and supply, as well as sales and marketing of any of our product candidates that are approved for sale by regulatory agencies. Because the outcome of any clinical trial is highly uncertain, we cannot reasonably estimate the actual amounts necessary to successfully complete the development and commercialization of our clinical stage and nonclinical drug candidates and any other drug candidates that we may develop in the future. Other unanticipated costs may also arise. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our future capital requirements depend on many factors, including: </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Calibri;">the timing of, and the costs involved in, clinical development and obtaining regulatory approvals for our product candidates&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Calibri;">changes in regulatory requirements during the development phase that can delay or force us to stop our activities related to any of our product candidates&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Calibri;">the cost of commercialization activities for </span><span style="font-style:italic;font-family:Calibri;">Jelmyto</span><span style="font-family:Calibri;"> and any other products approved for sale, including marketing, sales and distribution costs&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Calibri;">our degree of success in commercializing </span><span style="font-style:italic;font-family:Calibri;">Jelmyto</span><span style="font-family:Calibri;">&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Calibri;">the cost of third-party manufacturing of our products candidates and any approved products&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Calibri;">the number and characteristics of any other product candidates we develop or acquire&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Calibri;">our ability to establish and maintain strategic collaborations, licensing or other commercialization arrangements, and the terms and timing of such arrangements&#59; </span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">56</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span><span style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span><span style="font-family:Calibri;">the extent and rate of market acceptance of any approved products&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Calibri;">the expenses needed to attract and retain skilled personnel&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Calibri;">the costs associated with being a public company&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Calibri;">the costs involved in preparing, filing, prosecuting, maintaining, defending and enforcing patent and other intellectual property claims, including potential litigation costs, and the outcome of such litigation&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Calibri;">the timing, receipt and amount of sales of, or royalties on, future approved products, if any&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Calibri;">any product liability or other lawsuits related to our products or business arrangements&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Calibri;">scientific breakthroughs in the field of urothelial cancer treatment and diagnosis that could significantly diminish the need for our product candidates or make them obsolete&#59; and </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Calibri;">changes in reimbursement or other regulatory policies that could have a negative impact on our future revenue stream. </span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, we have limited experience and have not yet demonstrated an ability to successfully overcome many of the risks and uncertainties frequently encountered by companies in new and rapidly evolving fields, particularly in the biopharmaceutical industry. Drug development is a highly speculative undertaking and involves a substantial degree of risk. To date, we have not obtained regulatory approval for any product except <span style="font-style:italic;">Jelmyto</span> and we have not commercialized any of our products or generated any revenue from product sales. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Calibri;text-transform:none;font-variant: normal;">We will require substantial additional financing to achieve our goals, and a failure to obtain this capital when needed and on acceptable terms, or at all, could force us to delay, limit, reduce or terminate our product development, commercialization efforts or other operations. *</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Since our inception, almost all our resources have been dedicated to the nonclinical and clinical development of our first commercial product, <span style="font-style:italic;">Jelmyto</span>, and our lead product candidate UGN-102. As of March 31, 2021, we had cash and cash equivalents and marketable securities of $75.9 million. In January 2019, we completed an underwritten public offering in which we received net proceeds of approximately $161.4 million, after deducting the underwriting discounts and commissions and payment of other offering expenses. During the second quarter of 2020, we sold 700,000 ordinary shares under the ATM Sales Agreement, for gross proceeds of approximately $16.6 million. The net proceeds to us after deducting sales commissions to Cowen and other issuance expenses were approximately $15.8 million. The remaining capacity under the ATM Sales Agreement is approximately $83.4 million. In March 2021, the Company announced a transaction with RTW Investments (&#8220;RTW&#8221;) totaling $75.0 million in funding for the Company to support the launch of Jelmyto and the development of UGN-102. RTW will provide the Company with an upfront cash payment of $75.0 million and will receive tiered future payments based on global annual net product sales of Jelmyto and UGN-102, if approved. The Company received the $75.0 million of cash, net of costs in May 2021.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Based on our cash flow projections, we believe that our current cash and cash equivalents and marketable securities are sufficient to fund our planned operations for at least the next 12 months. We expect that we will require additional capital to complete clinical trials, obtain regulatory approval for and commercialize our product candidates. However, our operating plan may change as a result of many factors currently unknown to us, and we may need to seek additional funds sooner than planned, through public or private equity financings, convertible debt or debt financings, third-party funding, marketing and distribution arrangements, as well as other collaborations, strategic alliances and licensing arrangements, or a combination of these approaches. In any event, we will require additional capital to pursue nonclinical and clinical activities, and pursue regulatory approval for, and to commercialize, our pipeline product candidates. Even if we believe that we have sufficient funds for our current or future operating plans, we may seek additional capital if market conditions are favorable or if we have specific strategic considerations. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any additional fundraising efforts may divert the attention of our management from day-to-day activities, which may adversely affect our ability to develop and commercialize our product candidates. In addition, we cannot guarantee that future financing will be available in sufficient amounts or on terms acceptable to us, if at all. Moreover, the terms of any financing may negatively impact the holdings or the rights of our shareholders, and the issuance of additional securities, whether equity or debt, by us or the possibility of such issuance may cause the market price of our shares to decline. The incurrence of indebtedness could result in increased fixed payment obligations and we may be required to agree to certain restrictive covenants, such as limitations on our ability to incur additional debt, limitations on our ability to acquire, sell or license intellectual property rights and other operating restrictions that could adversely impact our ability to conduct our business. We could also be required to seek funds through arrangements with collaborative partners or otherwise at an earlier stage than would be desirable and we may be required to </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">57</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">relinquish rights to some of our technologies, intellectual property or product candidates or otherwise agree to terms unfavorable to us, any of which may harm our business, financial condition, cash flows, operating results and prospects. </span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If adequate funds are not available to us on a timely basis, we may be required or choose to: </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Calibri;">delay, limit, reduce or terminate nonclinical studies, clinical trials or other development activities for our product candidates or any of our future product candidates&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Calibri;">delay, limit, reduce or terminate our other research and development activities&#59; or </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Calibri;">delay, limit, reduce or terminate our establishment or expansion of manufacturing, sales and marketing or distribution capabilities or other activities that may be necessary to commercialize </span><span style="font-style:italic;font-family:Calibri;">Jelmyto</span><span style="font-family:Calibri;"> or any of our product candidates that obtain marketing approval. </span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may also be unable to expand our operations or otherwise capitalize on our business opportunities, as desired, which could harm our business, financial condition, cash flows and results of operations. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Calibri;text-transform:none;font-variant: normal;">Raising additional capital may cause dilution to our shareholders, restrict our operations or require us to relinquish rights to our technologies or product candidates. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Until such time, if ever, as we can generate substantial product revenues, we expect to finance our cash needs through equity, convertible debt or debt financings, as well as selectively continuing to enter into collaborations, strategic alliances and licensing arrangements. We do not currently have any committed external source of funds other than funding under the existing exclusive license agreement we entered into with Allergan Pharmaceuticals International Limited, or Allergan, a wholly owned subsidiary of Allergan plc, which is now a part of AbbVie Inc., in October 2016, or the Allergan/AbbVie Agreement. Under the Allergan/AbbVie Agreement, we may receive additional material milestone payments upon the successful completion of certain development, regulatory and commercial milestones and royalties with respect to future sales of collaboration products by Allergan. Allergan may unilaterally terminate our existing collaboration for any reason upon advance notice. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To the extent that we raise additional capital through the sale of equity or convertible debt securities, your ownership interest will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect your rights as an ordinary shareholder. Debt financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring and distributing dividends, and may be secured by all or a portion of our assets. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If we raise funds by selectively continuing to enter into additional collaborations, strategic alliances or licensing arrangements with third parties, we may have to relinquish additional valuable rights to our technologies, future revenue streams, research programs or product candidates or to grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds through equity, convertible debt or debt financings when needed, we may be required to delay, limit, reduce or terminate our product development or future commercialization efforts or grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves. If we are unable to raise additional funds through other collaborations, strategic alliances or licensing arrangements, we may be required to terminate product development or future commercialization efforts or to cease operations altogether. </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">Risks Related to Our Intellectual Property </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Calibri;text-transform:none;font-variant: normal;">If our efforts to obtain, protect or enforce our patents and other intellectual property rights related to our product candidates and technologies are not adequate, we may not be able to compete effectively, and we otherwise may be harmed. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our commercial success depends in part upon our ability to obtain and maintain patent protection and utilize trade secret protection for our intellectual property and proprietary technologies, our products and their uses, as well as our ability to operate without infringing upon the proprietary rights of others. We rely upon a combination of patents, trade secret protection and confidentiality agreements, assignment of invention agreements and other contractual arrangements to protect the intellectual property related to hydrogel-based pharmaceutical compositions for optimal delivery of a drug in internal cavities such as the bladder, the method for treating urothelial cancer using hydrogel-based compositions, the method for treating overactive bladder topically without the need for injections, an in-dwelling ureter catheter system for optimal delivery of a drug into the renal cavity, and pharmaceutical compositions comprising an imidazoquinolin (amine) and lactic acid for use in a method for the treatment of bladder diseases, as well as other intellectual property advancements. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">58</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We seek patent protection for our product candidates, and we have established several patent families comprised of issued patents and pending patent applications covering our proprietary </span><span style="font-style:italic;">RTGel</span><span style="font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> technology, the pharmaceutical compositions, methods of use and manufacturing aspects of our product candidates. In the United States, we currently have 16 granted patents that are directed to protect our approved product, </span><span style="font-style:italic;">Jelmyto</span><span style="font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> and our lead product candidate, UGN-102, a proprietary </span><span style="font-style:italic;">RTGel</span><span style="font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> technology, various local compositions comprising different active ingredients, inter alia compositions comprising a Botulinum Toxin, UGN-201, UGN-302 and our future product candidates that are under company research. These patents claim methods, combination products and novel compositions for treating different diseases, especially cancer in internal cavities, in particular urinary tract cancer. These issued patents are set to expire between 2024 and 2037. In total, our IP portfolio includes 38 granted patents worldwide, and more than 40 pending patent applications filed in the US, Europe, Israel and Japan that are directed to cover various methods, systems and compositions for treating cancer locally, by intravesical means, utilize various active ingredients and the combinations thereof. These patent applications, if issued, are set to expire between 2031 and 2037. </span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Limitations on the scope of our intellectual property rights may limit our ability to prevent third parties from designing around such rights and competing against us. For example, our patents do not claim a new compound. Rather, the active pharmaceutical ingredients of our products are known compounds and our granted patents and pending patent applications are directed inter alia to novel formulations of these known compounds with our proprietary <span style="font-style:italic;">RTGel</span> technology. Accordingly, other parties may compete with us, for example, by independently developing or obtaining competing topical formulations that design around our patent claims, but which may contain the same active ingredients, or by seeking to invalidate our patents. Any disclosure to or misappropriation by third parties of our confidential proprietary information could enable competitors to quickly duplicate or surpass our technological achievements, eroding our competitive position in the market. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We will not necessarily seek to protect our intellectual property rights in all jurisdictions throughout the world and we may not be able to adequately enforce our intellectual property rights even in the jurisdictions where we seek protection.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">One or more of the patent applications that we filed or license may fail to result in granted patents in the United States or foreign jurisdictions, or if granted may fail to prevent a potential infringer from marketing its product or be deemed invalid and unenforceable by a court. Competitors in the field of reverse thermal gel therapies have created a substantial amount of scientific publications, patents and patent applications and other materials relating to their technologies. Our ability to obtain and maintain valid and enforceable patents depends on various factors, including interpretation of our technology and the prior art and whether the differences between them allow our technology to be patentable. Patent applications and granted patents are complex, lengthy and highly technical documents that are often prepared under limited time constraints and may not be free from errors that make their interpretation uncertain. The existence of errors in a patent may have an adverse effect on the patent, its scope and its enforceability. Our pending patent applications may not issue, and the scope of the claims of patent applications that do issue may be too narrow to adequately protect our competitive advantage. Also, our granted patents may be subject to challenges or narrowly construed and may not provide adequate protection. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Calibri;text-transform:none;font-variant: normal;">We may be subject to claims that we infringe, misappropriate or otherwise violate the intellectual property rights of third parties. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Even if our patents do successfully issue, third parties may challenge the validity, enforceability or scope of such granted patents or any other granted patents we own or license, which may result in such patents being narrowed, invalidated or held unenforceable. For example, patents granted by the European Patent Office may be opposed by any person within nine months from the publication of their grant. Also, patents granted by the United States Patent and Trademark Office, or USPTO, may be subject to reexamination and other challenges. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pharmaceutical patents and patent applications involve highly complex legal and factual questions, which, if determined adversely to us, could negatively impact our patent position. There is significant litigation activity in the pharmaceutical industry regarding patent and other intellectual property rights. Such litigation could result in substantial costs and be a distraction to management and other employees.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The patent positions of biotechnology and pharmaceutical companies can be highly uncertain and involve complex legal and factual questions. The interpretation and breadth of claims allowed in some patents covering pharmaceutical compositions may be uncertain and difficult to determine and are often affected materially by the facts and circumstances that pertain to the patented compositions and the related patent claims. Furthermore, even if they are not challenged, our patents and patent applications may not adequately protect our intellectual property or prevent others from designing around our claims. To meet such challenges, which are part of the risks and uncertainties of developing and marketing product candidates, we may need to evaluate third party intellectual property rights and, if appropriate, to seek licenses for such third party intellectual property or to challenge such third </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">59</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">party intellectual property, which may be costly and may or may not be successful, which could also have an adverse effect on the commercial potential for </span><span style="font-style:italic;">Jelmyto</span><span style="font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, UGN-102 and any of our product candidates. </span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Calibri;text-transform:none;font-variant: normal;">We may receive only limited protection, or no protection, from our issued patents and patent applications. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">There can be no assurance that the patent applications will be granted. The term of individual patents depends upon the legal term of the patents in the countries in which they are obtained.</span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The patent application process, also known as patent prosecution, is expensive and time consuming, and we or any future licensors and licensees may not be able to prepare, file and prosecute all necessary or desirable patent applications at a reasonable cost or in a timely manner. It is also possible that we or any future licensors or licensees will fail to identify patentable aspects of inventions made in the course of development and commercialization activities before it is too late to obtain patent protection on them. Therefore, these and any of our patents and applications may not be prosecuted and enforced in a manner consistent with the best interests of our business. It is possible that defects of form in the preparation or filing of our patents or patent applications may exist, or may arise in the future, for example with respect to proper priority claims, inventorship, etc., although we are unaware of any such defects that we believe are of material import. If we or any future licensors or licensees fail to establish, maintain or protect such patents and other intellectual property rights, such rights may be reduced or eliminated. If any future licensors or licensees are not fully cooperative or disagree with us as to the prosecution, maintenance or enforcement of any patent rights, such patent rights could be compromised. If there are material defects in the form or preparation of our patents or patent applications, such patents or applications may be invalid and unenforceable. Any of these outcomes could impair our ability to prevent competition from third parties, which may have an adverse impact on our business. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The strength of patents in the pharmaceutical field involves complex legal and scientific questions and can be uncertain. This uncertainty includes changes to the patent laws through either legislative action to change statutory patent law or court action that may reinterpret existing law in ways affecting the scope or validity of issued patents. The patent applications that we own or in-license may fail to result in issued patents in the United States or foreign countries with claims that cover our product candidates. Even if patents do successfully issue from the patent applications that we own or in-license, third parties may challenge the validity, enforceability or scope of such patents, which may result in such patents being narrowed, invalidated or held unenforceable. For example, patents granted by the European Patent Office may be challenged, also known as opposed, by any person within nine months from the publication of their grant. Any successful challenge to our patents could deprive us of exclusive rights necessary for the successful commercialization of our product candidates. Furthermore, even if they are unchallenged, our patents may not adequately protect our product candidates, provide exclusivity for our product candidates, or prevent others from designing around our claims. If the breadth or strength of protection provided by the patents we hold or pursue with respect to our product candidates is challenged, it could dissuade companies from collaborating with us to develop or threaten our ability to commercialize our product candidates. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Patents have a limited lifespan. In the United States, the natural expiration of a patent is generally 20 years after it is filed. Various extensions may be available&#59; however, the life of a patent, and the protection it affords, is limited. Without patent protection for our product candidates, we may be open to competition from generic versions of our product candidates. Further, if we encounter delays in our development efforts, including our clinical trials, the period of time during which we could market our product candidates under patent protection would be reduced. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A considerable number of our patents and patent applications are entitled to effective filing dates prior to March&#160;16, 2013. For U.S. patent applications in which patent claims are entitled to a priority date before March&#160;16, 2013, an interference proceeding can be provoked by a third party, for example a competitor, or instituted by the USPTO to determine who was the first to invent any of the subject matter covered by those patent claims. An unfavorable outcome could require us to cease using the related technology or to attempt to license rights from the prevailing party. Our business could be harmed if the prevailing party does not offer us a license on commercially reasonable terms. Our participation in an interference proceeding may fail and, even if successful, may result in substantial costs and distract our management. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">60</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Calibri;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Calibri;text-transform:none;font-variant: normal;">Our trade secrets may not have sufficient intellectual property protection. </span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition to the protection afforded by patents, we also rely on trade secret protection to protect proprietary know-how that may not be patentable or that we elect not to patent, processes for which patents may be difficult to obtain or enforce, and any other elements of our product candidates, and our product development processes (such as manufacturing and formulation technologies) that involve proprietary know-how, information or technology that is not covered by patents. However, trade secrets can be difficult to protect. If the steps taken to maintain our trade secrets are deemed inadequate, we may have insufficient recourse against third parties for misappropriating any trade secrets. Misappropriation or unauthorized disclosure of our trade secrets could significantly affect our competitive position and may have an adverse effect on our business. Furthermore, trade secret protection does not prevent competitors from independently developing substantially equivalent information and techniques and we cannot guarantee that our competitors will not independently develop substantially equivalent information and techniques. The FDA, as part of its Transparency Initiative, is currently considering whether to make additional information publicly available on a routine basis, including information that we may consider to be trade secrets or other proprietary information, and it is not clear at the present time how the FDA&#8217;s disclosure policies may change in the future, if at all. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In an effort to protect our trade secrets and other confidential information, we require our employees, consultants, advisors, and any other third parties that have access to our proprietary know-how, information or technology, for example, third parties involved in the formulation and manufacture of our product candidates, and third parties involved in our clinical trials to execute confidentiality agreements upon the commencement of their relationships with us. These agreements require that all confidential information developed by the individual or made known to the individual by us during the course of the individual&#8217;s relationship with us is kept confidential and not disclosed to third parties. However, we cannot be certain that our trade secrets and other confidential proprietary information will not be disclosed despite having such confidentiality agreements. Adequate remedies may not exist in the event of unauthorized use or disclosure of our trade secrets. In addition, in some situations, these confidentiality agreements may conflict with, or be subject to, the rights of third parties with whom our employees, consultants, or advisors have previous employment or consulting relationships. To the extent that our employees, consultants or contractors use any intellectual property owned by third parties in their work for us, disputes may arise as to the rights in any related or resulting know-how and inventions. If we are unable to prevent unauthorized material disclosure of our trade secrets to third parties, we may not be able to establish or maintain a competitive advantage in our market, which could harm our business, operating results and financial condition. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Calibri;text-transform:none;font-variant: normal;">Changes in U.S. patent law could diminish the value of patents in general, thereby impairing our ability to protect our products. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As is the case with other pharmaceutical companies, our success is heavily dependent on intellectual property, particularly on obtaining and enforcing patents. Obtaining and enforcing patents in the pharmaceutical industry involves both technological and legal complexity, and therefore, is costly, time-consuming and inherently uncertain. In addition, the United States has recently enacted and is currently implementing wide-ranging patent reform legislation. Further, recent U.S. Supreme Court rulings have either narrowed the scope of patent protection available in certain circumstances or weakened the rights of patent owners in certain situations. In addition to increasing uncertainty with regard to our ability to obtain patents in the future, this combination of events has created uncertainty with respect to the value of patents, once obtained. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For our U.S. patent applications containing a claim not entitled to priority before March&#160;16, 2013, there is a greater level of uncertainty in the patent law. In September 2011, the Leahy-Smith America Invents Act, or the America Invents Act, or AIA, was signed into law. The AIA includes a number of significant changes to U.S. patent law, including provisions that affect the way patent applications will be prosecuted and may also affect patent litigation. The USPTO is currently developing regulations and procedures to govern administration of the AIA, and many of the substantive changes to patent law associated with the AIA. It is not clear what other, if any, impact the AIA will have on the operation of our business. Moreover, the AIA and its implementation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents, all of which could harm our business and financial condition. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">61</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">An important change introduced by the AIA is that, as of March&#160;16, 2013, the United States transitioned to a &#8220;first-to-file&#8221; system for deciding which party should be granted a patent when two or more patent applications are filed by different parties claiming the same invention. A third party that files a patent application in the USPTO after that date but before us could therefore be awarded a patent covering an invention of ours even, if we had made the invention before it was made by the third party. This will require us to be cognizant going forward of the time from invention to filing of a patent application. Furthermore, our ability to obtain and maintain valid and enforceable patents depends on whether the differences between our technology and the prior art allow our technology to be patentable over the prior art. Since patent applications in the United States and most other countries are confidential for a period of time after filing, we cannot be certain that we were the first to either (i)&#160;file any patent application related to our product candidates or (ii)&#160;invent any of the inventions claimed in our patents or patent applications. </span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Among some of the other changes introduced by the AIA are changes that limit where a patentee may file a patent infringement suit and provide opportunities for third parties to challenge any issued patent in the USPTO. This applies to all of our U.S. patents, even those issued before March&#160;16, 2013. Because of a lower evidentiary standard in USPTO proceedings compared to the evidentiary standard in a United States federal court necessary to invalidate a patent claim, a third party could potentially provide evidence in a USPTO proceeding sufficient for the USPTO to hold a claim invalid even though the same evidence would be insufficient to invalidate the claim if first presented in a district court action. Accordingly, a third party may attempt to use the USPTO procedures to invalidate our patent claims that would not have been invalidated if first challenged by the third party as a defendant in a district court action. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Depending on decisions by the U.S. Congress, the federal courts, and the USPTO, the laws and regulations governing patents could change in unpredictable ways that would weaken our ability to obtain new patents or to enforce our existing patents and patents that we might obtain in the future. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Calibri;text-transform:none;font-variant: normal;">Obtaining and maintaining our patent protection depends on compliance with various procedural, documentary, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The USPTO and various foreign governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other similar provisions during the patent prosecution process. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Periodic maintenance fees and various other governmental fees on any issued patent and/or pending patent applications are due to be paid to the USPTO and foreign patent agencies in several stages over the lifetime of a patent or patent application. We have systems in place to remind us to pay these fees, and we employ an outside firm and rely on our outside counsel to pay these fees. While an inadvertent lapse may sometimes be cured by payment of a late fee or by other means in accordance with the applicable rules, there are many situations in which noncompliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. If we fail to maintain the patents and patent applications directed to our product candidates, our competitors might be able to enter the market earlier than should otherwise have been the case, which could harm our business. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Calibri;text-transform:none;font-variant: normal;">We may not be able to protect our intellectual property rights throughout the world. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Filing, prosecuting and defending patents on our product candidates in all countries throughout the world would be prohibitively expensive. The requirements for patentability may differ in certain countries, particularly developing countries. For example, unlike other countries, China has a heightened requirement for patentability, and specifically requires a detailed description of medical uses of a claimed drug. In addition, the laws of some foreign countries do not protect intellectual property rights to the same extent as laws in the United States. Consequently, we may not be able to prevent third parties from practicing our inventions in all countries outside the United States. Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop their own products and further, may export otherwise infringing products to territories where we have patent protection, but enforcement on infringing activities is inadequate. These products may compete with our products, and our patents or other intellectual property rights may not be effective or sufficient to prevent them from competing. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents and other intellectual property protection, particularly those relating to pharmaceuticals, which could make it difficult for us to stop the infringement of our patents or marketing of competing products in violation of our proprietary rights generally. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">62</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Proceedings to enforce our patent rights in foreign jurisdictions could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly and our patent applications at risk of not issuing, and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate, and the damages or other remedies awarded, if any, may not be commercially meaningful. In addition, certain countries in Europe and certain developing countries, including India and China, have compulsory licensing laws under which a patent owner may be compelled to grant licenses to third parties. In those countries, we may have limited remedies if our patents are infringed or if we are compelled to grant a license to our patents to a third party, which could materially diminish the value of those patents. This could limit our potential revenue opportunities. Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we own or license. Finally, our ability to protect and enforce our intellectual property rights may be adversely affected by unforeseen changes in foreign intellectual property laws. </span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Calibri;text-transform:none;font-variant: normal;">If we are unable to protect our trademarks from infringement, our business prospects may be harmed. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We filed applications for trademarks (<span style="font-style:italic;">Jelmyto</span> <sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup>, <span style="font-style:italic;">RTGel</span>&#8482;, UroGen<sup style="font-size:85%;line-height:120%;vertical-align:top"> &#174;</sup> and Cystoject &#8482;) that identify our branding elements, such as <span style="font-style:italic;">Jelmyto</span> and our unique technology in the United States, Europe and Japan. Although we take steps to monitor the possible infringement or misuse of our trademarks, it is possible that third parties may infringe, dilute or otherwise violate our trademark rights. Any unauthorized use of our trademarks could harm our reputation or commercial interests. In addition, our enforcement against third-party infringers or violators may be unduly expensive and time-consuming, and the outcome may be an inadequate remedy. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Calibri;text-transform:none;font-variant: normal;">We may become involved in lawsuits to protect or enforce our patents or other intellectual property or the patents of our licensors, which could be expensive and time consuming. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Third parties may infringe or misappropriate our intellectual property, including our existing patents, patents that may issue to us in the future, or the patents of our licensors to which we have a license. As a result, we may be required to file infringement claims to stop third-party infringement or unauthorized use. Further, we may not be able to prevent, alone or with our licensors, misappropriation of our intellectual property rights, particularly in countries where the laws may not protect those rights as fully as in the United States. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Drug manufacturers may develop, seek approval for, and launch generic versions of our products. If we file an infringement action against such a generic drug manufacturer, that company may challenge the scope, validity or enforceability of our or our licensors&#8217; patents, requiring us and/or our licensors to engage in complex, lengthy and costly litigation or other proceedings. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For example, if we or one of our licensors initiated legal proceedings against a third party to enforce a patent covering our product candidates, the defendant could counterclaim that the patent covering our product candidates is invalid and/or unenforceable. In patent litigation in the United States, defendant counterclaims alleging invalidity and/or unenforceability are commonplace, and there are numerous grounds upon which a third party can assert invalidity or unenforceability of a patent. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, within and outside of the United States, there has been a substantial amount of litigation and administrative proceedings, including interference and reexamination proceedings before the USPTO or oppositions and other comparable proceedings in various foreign jurisdictions, regarding patent and other intellectual property rights in the pharmaceutical industry. Recently, the AIA introduced new procedures including inter partes review and post grant review. The implementation of these procedures brings uncertainty to the possibility of challenges to our patents in the future, including challenges by competitors who perceive our patents as blocking entry into the market for their products, and the outcome of such challenges. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Such litigation and administrative proceedings could result in revocation of our patents or amendment of our patents such that they do not cover our product candidates. They may also put our pending patent applications at risk of not issuing or issuing with limited and potentially inadequate scope to cover our product candidates. The outcome following legal assertions of invalidity and unenforceability is unpredictable. With respect to the validity question, for example, we cannot be certain that there is no invalidating prior art, of which we and the patent examiner were unaware during prosecution. Additionally, it is also possible that prior art of which we are aware, but which we do not believe affects the validity or enforceability of a claim, may, nonetheless, ultimately be found by a court of law or an administrative panel to affect the validity or enforceability of a claim. If a defendant were to prevail on a legal assertion of invalidity and/or unenforceability, we would lose at least part, and perhaps all, of the patent protection on our product candidates. Such a loss of patent protection could have a negative impact on our business. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">63</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Enforcing our or our licensors&#8217; intellectual property rights through litigation is very expensive, particularly for a company of our size, and time-consuming. Some of our competitors may be able to sustain the costs of litigation more effectively than we can because of greater financial resources. Patent litigation and other proceedings may also absorb significant management time. </span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could impair our ability to compete in the marketplace. The occurrence of any of the foregoing could harm our business, financial condition or results of operations. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation or administrative proceedings, there is a risk that some of our confidential information could be compromised by disclosure. In addition, during the course of litigation or administrative proceedings, there could be public announcements of the results of hearings, motions or other interim proceedings or developments or public access to related documents. If investors perceive these results to be negative, the market price for our ordinary shares could be significantly harmed. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Calibri;text-transform:none;font-variant: normal;">We may become subject to claims for remuneration or royalties for assigned service invention rights by our employees, which could result in litigation and adversely affect our business. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A significant portion of our intellectual property has been developed by our employees during their employment. Under the Israeli Patent Law, 5727-1967, or the Patent Law, inventions conceived by an employee during the scope of his or her employment with a company are regarded as &#8220;service inventions.&#8221; The Israeli Compensation and Royalties Committee, or the Committee, a body constituted under the Patent Law, has previously held, in certain cases, that employees may be entitled to remuneration for service inventions that they develop during their service for a company despite their explicit waiver of such right. Therefore, although we enter into agreements with our employees pursuant to which they waive their right to special remuneration for service inventions created in the scope of their employment or engagement and agree that any such inventions are owned exclusively by us, we may face claims by employees demanding remuneration beyond their regular salary and benefits. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Calibri;text-transform:none;font-variant: normal;">Third-party claims alleging intellectual property infringement may adversely affect our business. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our commercial success depends in part on our avoiding infringement of the patents and proprietary rights of third parties, for example, the intellectual property rights of competitors. Our research, development and commercialization activities may be subject to claims that we infringe or otherwise violate patents owned or controlled by third parties. Numerous U.S. and foreign issued patents and pending patent applications, which are owned by third parties, exist in the fields in which we are developing our product candidates. As the biotechnology and pharmaceutical industries expand and more patents are issued, the risk increases that our activities related to our product candidates may give rise to claims of infringement of the patent rights of others. We cannot assure you that our product candidates will not infringe existing or future patents. We may not be aware of patents that have already issued that a third party might assert are infringed by our product candidates. It is also possible that patents of which we are aware, but which we do not believe are relevant to our product candidates, could nevertheless be found to be infringed by our product candidates. Nevertheless, we are not aware of any issued patents that we believe would prevent us from marketing our product candidates, if approved. There may also be patent applications that have been filed but not published that, when issued as patents, could be asserted against us. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Third parties making claims against us for infringement or misappropriation of their intellectual property rights may seek and obtain injunctive or other equitable relief, which could effectively block our ability to further develop and commercialize our product candidates. Further, if a patent infringement suit were brought against us, we could be forced to stop or delay research, development, manufacturing or sales of the product or product candidate that is the subject of the suit. Defense of these claims, regardless of their merit, would cause us to incur substantial expenses, and would be a substantial diversion of management time and employee resources from our business. In the event of a successful claim of infringement against us by a third party, we may have to (i)&#160;pay substantial damages, including treble damages and attorneys&#8217; fees if we are found to have willfully infringed the third party&#8217;s patents&#59; (ii)&#160;obtain one or more licenses from the third party&#59; (iii)&#160;pay royalties to the third party&#59; and/or (iv)&#160;redesign any infringing products. Redesigning any infringing products may be impossible or require substantial time and monetary expenditures. Further, we cannot predict whether any required license would be available at all or whether it would be available on commercially reasonable terms. In the event that we could not obtain a license, we may be unable to further develop and commercialize our product candidates, which could harm our business significantly. Even if we are able to obtain a license, the license would likely obligate us to pay license fees or royalties or both, and the rights granted to us might be nonexclusive, which could result in our competitors gaining access to the same intellectual property. Ultimately, we could be prevented from commercializing a product, or </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">64</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">be forced to cease some aspect of our business operations, if, as a result of actual or threatened patent infringement claims, we are unable to enter into licenses on acceptable terms. </span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Defending ourselves or our licensors in litigation is very expensive, particularly for a company of our size, and time-consuming. Some of our competitors may be able to sustain the costs of litigation or administrative proceedings more effectively than we can because of greater financial resources. Patent litigation and other proceedings may also absorb significant management time. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could impair our ability to compete in the marketplace. The occurrence of any of the foregoing could harm our business, financial condition or results of operations. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Calibri;text-transform:none;font-variant: normal;">We may be subject to claims that our employees, consultants or independent contractors have wrongfully used or disclosed confidential information of third parties. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We employ individuals who were previously employed at other biotechnology or pharmaceutical companies. We may be subject to claims that we or our employees, consultants or independent contractors have inadvertently or otherwise improperly used or disclosed confidential information of these third parties or our employees&#8217; former employers. Further, we may be subject to ownership disputes in the future arising, for example, from conflicting obligations of consultants or others who are involved in developing our product candidates. We may also be subject to claims that former employees, consultants, independent contractors, collaborators or other third parties have an ownership interest in our patents or other intellectual property. Litigation may be necessary to defend against these and other claims challenging our right to and use of confidential and proprietary information. If we fail in defending any such claims, in addition to paying monetary damages, we may lose our rights therein. Such an outcome could have a negative impact on our business. Even if we are successful in defending against these claims, litigation could result in substantial cost and be a distraction to our management and employees. </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">Risks Related to Government Regulation </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Calibri;text-transform:none;font-variant: normal;">If the FDA does not conclude that UGN-102 satisfies the requirements under Section&#160;505(b)(2) of the Federal Food Drug and Cosmetic Act, or Section&#160;505(b)(2), or if the requirements for such product candidates are not as we expect, the approval pathway for these product candidates will likely take significantly longer, cost significantly more and entail significantly greater complications and risks than anticipated, and in either case may not be successful.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Drug Price Competition and Patent Term Restoration Act of 1984, also known as the Hatch-Waxman Act, added Section&#160;505(b)(2) to the Federal Food, Drug and Cosmetic Act. Section&#160;505(b)(2) permits the filing of an NDA where at least some of the information required for approval comes from studies that were not conducted by or for the applicant, and for which the applicant has not received a right of reference, which could expedite the development program for UGN-102 and our other product candidates by potentially decreasing the amount of nonclinical and clinical data that we would need to generate in order to obtain FDA approval. However, while we believe that our product candidates are reformulations of existing drugs and, therefore, will not be treated as new chemical entities, or NCEs, the submission of an NDA under the Section&#160;505(b)(2) pathway does not preclude the FDA from determining that the product candidate that is the subject of such submission is an NCE and therefore not eligible for review under such regulatory pathway. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If the FDA does not allow us to pursue the Section&#160;505(b)(2) pathway as anticipated, we may need to conduct additional nonclinical experiments and clinical trials, provide additional data and information, and meet additional standards for regulatory approval. If this were to occur, the time and financial resources required to obtain FDA approval for these product candidates, and complications and risks associated with these product candidates, would likely increase significantly. Moreover, inability to pursue the Section&#160;505(b)(2) pathway could result in new competitive products reaching the market more quickly than our product candidates, which would likely harm our competitive position and prospects. Even if we are allowed to pursue the Section&#160;505(b)(2) pathway, our product candidates may not receive the requisite approvals for commercialization. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, notwithstanding the approval of a number of products by the FDA under Section&#160;505(b)(2) certain competitors and others have objected to the FDA&#8217;s interpretation of Section&#160;505(b)(2). If the FDA&#8217;s interpretation of Section&#160;505(b)(2) is successfully challenged, the FDA may be required to change its 505(b)(2) policies and practices, which could delay or even prevent the FDA from approving any NDA that we submit under Section&#160;505(b)(2). In addition, the pharmaceutical industry is highly competitive, and Section&#160;505(b)(2) NDAs are subject to special requirements designed to protect the patent rights of sponsors of previously approved drugs that are referenced in a Section&#160;505(b)(2) NDA. These requirements may give rise to patent litigation and mandatory delays in approval of our potential future NDAs for up to 30 months depending on the outcome of any litigation. It is not uncommon for a </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">65</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">manufacturer of an approved product to file a citizen petition with the FDA seeking to delay approval of, or impose additional approval requirements for, pending competing products. If successful, such petitions can significantly delay, or even prevent, the approval of the new product. However, even if the FDA ultimately denies such a petition, the FDA may substantially delay approval while it considers and responds to the petition. In addition, even if we are able to utilize the Section&#160;505(b)(2) regulatory pathway for our product candidates, there is no guarantee this would ultimately lead to faster product development or earlier approval. </span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Moreover, even if these product candidates are approved under the Section&#160;505(b)(2) pathway, as the case may be, the approval may be subject to limitations on the indicated uses for which the products may be marketed or to other conditions of approval or may contain requirements for costly post-marketing testing and surveillance to monitor the safety or efficacy of the products. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Calibri;text-transform:none;font-variant: normal;">We expect current and future legislation affecting the healthcare industry, including healthcare reform, to impact our business generally and to increase limitations on reimbursement, rebates and other payments, which could adversely affect third-party coverage of our products, our operations, and/or how much or under what circumstances healthcare providers will prescribe or administer our products, if approved. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The United States and some foreign jurisdictions are considering or have enacted a number of legislative and regulatory proposals to change the healthcare system in ways that could affect our ability to sell our products profitably. Among policy makers and payors in the United States and elsewhere, there is significant interest in promoting changes in healthcare systems with the stated goals of containing healthcare costs, improving quality or expanding access. In the United States, the pharmaceutical industry has been a particular focus of these efforts and has been significantly affected by major legislative initiatives. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For example, in March 2010, President Obama signed into law the Patient Protection and Affordable Care Act and the Health Care and Education Reconciliation Act of 2010, or collectively, the ACA, laws intended, among other things, to broaden access to health insurance, improve quality of care, and reduce or constrain the growth of healthcare spending. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Provisions of the ACA relevant to the pharmaceutical industry included the following: </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Calibri;">an annual, nondeductible fee on any entity that manufactures or imports certain branded prescription drugs and biologic agents, apportioned among these entities according to their market share in certain government healthcare programs, not including orphan drug sales&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Calibri;">an increase in the statutory minimum rebates a manufacturer must pay under the Medicaid Drug Rebate Program to 23.1% and 13% of the average manufacturer price for most branded and generic drugs, respectively&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Calibri;">a new Medicare Part D coverage gap discount program, in which manufacturers must now agree to offer 70% point-of-sale discounts on negotiated prices of applicable brand drugs to eligible beneficiaries during their coverage gap period, as a condition for the manufacturer&#8217;s outpatient drugs to be covered under Medicare Part D&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Calibri;">extension of manufacturers&#8217; Medicaid rebate liability to covered drugs dispensed to individuals who are enrolled in Medicaid managed care organizations&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Calibri;">expansion of eligibility criteria for Medicaid programs by, among other things, allowing states to offer Medicaid coverage to additional individuals and by adding new mandatory eligibility categories for certain individuals with income at or below 133% of the Federal Poverty Level, thereby potentially increasing manufacturers&#8217; Medicaid rebate liability&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Calibri;">expansion of the entities eligible for discounts under the Public Health Service pharmaceutical pricing program&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Calibri;">new requirements to report annually certain financial arrangements with physicians and teaching hospitals&#59; as defined in the ACA and its implementing regulations, including reporting any payment or &#8220;transfer of value&#8221; provided to physicians, as defined by such law, and teaching hospitals and any ownership and investment interests held by such physicians and their immediate family members during the preceding calendar year, which will be expanded beginning in 2022 to include reporting obligations with respect to financial relationships with certain additional healthcare providers&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Calibri;">expansion of healthcare fraud and abuse laws, including the federal civil False Claims Act and the federal Anti-Kickback Statute, new government investigative powers and enhanced penalties for noncompliance&#59; and </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Calibri;">a new Patient-Centered Outcomes Research Institute to oversee, identify priorities in and conduct comparative clinical effectiveness research, along with funding for such research. </span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">66</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There have been judicial, Congressional and executive branch challenges to certain aspects of the ACA. Concurrently, Congress has considered legislation that would repeal or repeal and replace all or part of the ACA. While Congress has not passed comprehensive repeal legislation, several bills affecting the implementation of certain taxes under the ACA have been signed into law. For example, the </span><span style="font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tax Cuts and Jobs Act of 2017 (</span><span style="font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;</span><span style="font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tax Act</span><span style="font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8221;</span><span style="font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</span><span style="font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">included a provision that repealed, effective January&#160;1, 2019, the tax-based shared responsibility payment imposed by the ACA on certain individuals who fail to maintain qualifying health coverage for all or part of a year that is commonly referred to as the &#8220;individual mandate.&#8221; </span><span style="font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Further</span><span style="font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, the 2020 federal spending package permanently eliminated, effective January&#160;1, 2020, the ACA-mandated &#8220;Cadillac&#8221; tax on high cost employer-sponsored health coverage and medical device tax and, effective January 1, 2021, also eliminated the health insurer tax. The Bipartisan Budget Act of 2018, or the BBA, among other things, amended the ACA, effective January&#160;1, 2019, to close the coverage gap in most Medicare drug plans, commonly referred to as the &#8220;donut hole.&#8221; On December&#160;14, 2018, a U.S. District Court judge in the Northern District of Texas, or the Texas District Court Judge, ruled that the individual mandate is a critical and inseverable feature of the ACA, and therefore, because it was repealed as part of the Tax Act, the remaining provisions of the ACA are invalid as well. Additionally, on December 18, 2019, the U.S. Court of Appeals for the 5</span><span style="font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%;line-height:120%;vertical-align:top">th</sup></span><span style="font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> Circuit upheld the District Court ruling that the individual mandate was unconstitutional and remanded the case back to the District Court to determine whether the remaining provisions of the ACA are invalid as well. The United States Supreme Court is currently reviewing this case, but it is unknown when a decision will be reached. Although the U.S. Supreme Court has </span><span style="font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">not </span><span style="font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">yet ruled on the constitutionality of the ACA, on January 28, 2021, President Biden issued an executive order </span><span style="font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">that initiated</span><span style="font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> a special enrollment period for purposes of obtaining health insurance coverage through the ACA marketplace</span><span style="font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, </span><span style="font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">which began on February 15, 2021 and will remain open through August 15, 2021</span><span style="font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. The executive order also instructs certain governmental agencies to review and reconsider their existing policies and rules that limit access to healthcare, including among others, reexamining Medicaid demonstration projects and waiver programs that include work requirements, and policies that create unnecessary barriers to obtaining access to health insurance coverage through Medicaid or the ACA. </span><span style="font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additionally, on February 10, 2021, the Biden administration withdrew the federal government&#8217;s support for overturning the ACA.</span><span style="font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">It is unclear how the Supreme Court ruling, other such litigation and the healthcare reform measures of the Biden administration will impact the ACA and our business. </span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, other legislative changes have been proposed and adopted since the ACA was enacted. For example, in August 2011, President Obama signed into law the Budget Control Act of 2011, which, among other things, created the Joint Select Committee on Deficit Reduction, or a Joint Selection Committee, to recommend to Congress proposals in spending reductions. The Joint Select Committee did not achieve a targeted deficit reduction of an amount greater than $1.2 trillion for the years 2013 through 2021, triggering the legislation&#8217;s automatic reduction to several government programs. This includes aggregate reductions to Medicare payments to healthcare providers of up to 2.0% per fiscal year, which started in 2013 and, due to subsequent legislative amendments to the statute, including the BBA, will stay in effect through 2030, except for a temporary suspension from May 1, 2020 through December 31, 2021 due to the COVID-19 pandemic, unless additional Congressional action is taken. In January 2013, President Obama signed into law the American Taxpayer Relief Act of 2012, which, among other things, reduced Medicare payments to several categories of healthcare providers and increased the statute of limitations period for the government to recover overpayments to providers from three to five years. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additionally, there have been several recent U.S. Congressional inquiries and proposed and enacted legislation at the federal and state levels designed to, among other things, bring more transparency to drug pricing, review the relationship between pricing and manufacturer patient programs, reduce the cost of drugs under Medicare, and reform government program reimbursement methodologies for drugs. At the federal level, the former Trump Administration&#160;&#160;used several means to propose or implement drug pricing reform, including through federal budget proposals, executive orders and policy initiatives. For example, on July 24, 2020 and September 13, 2020, the Trump Administration announced several executive orders related to prescription drug pricing that attempted to implement several of the Administration&#8217;s proposals. The FDA also released a final rule, effective November 30, 2020, implementing a portion of President Trump&#8217;s importation executive order announced in July 2020, providing guidance for states to build and submit importation plans for drugs from Canada. Further, on November&#160;20, 2020, the U.S. Department of Health &#38; Human Services (&#8220;HHS&#8221;) finalized a regulation removing safe harbor protection for price reductions from pharmaceutical manufacturers to plan sponsors under Part&#160;D, either directly or through pharmacy benefit managers, unless the price reduction is required by law. The implementation of the rule has been delayed by the Biden administration from January 1, 2022 to January 1, 2023 in response to ongoing litigation. The rule also creates a new safe harbor for price reductions reflected at the point-of-sale, as well as a new safe harbor for certain fixed fee arrangements between pharmacy benefit managers and manufacturers, the implementation of which have also been delayed by the Biden administration until January 1, 2023. On November 20, 2020, the Centers for Medicare &#38; Medicaid Services (&#8220;CMS&#8221;) issued an interim final rule implementing President Trump&#8217;s Most Favored Nation executive order, which would tie Medicare Part B payments for certain physician-administered drugs to the lowest price paid in other economically advanced countries. The Most Favored Nation regulations mandate participation by identified Medicare Part B providers and will apply in all U.S. states and territories for a seven-year period beginning January 1, 2021, and ending December 31, 2027. On December 28, 2020, the United States District Court in Northern California issued a nationwide preliminary injunction against implementation of the interim final rule. However, it is unclear whether the Biden administration will work to reverse these measures or pursue similar policy initiatives. At the state level, legislatures have increasingly passed legislation and implemented </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">67</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. If healthcare policies or reforms intended to curb healthcare costs are adopted, or if we experience negative publicity with respect to the pricing of our products or the pricing of pharmaceutical drugs generally, the prices that we charge for any approved products may be limited, our commercial opportunity may be limited and/or our revenues from sales of our products may be negatively impacted. In addition, it is possible that additional governmental action will be taken in response to the COVID-19 pandemic. </span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If we obtain regulatory approval and commercialization of UGN-102 or any of our other product candidates, these laws may result in additional reductions in healthcare funding, which could have an adverse effect on our customers and accordingly, our financial operations. Legislative and regulatory proposals have been made to expand post-approval requirements and restrict sales and promotional activities for pharmaceutical products. We cannot be sure whether additional legislative changes will be enacted, or whether regulations, guidance or interpretations will be changed, or what the impact of such changes on the marketing approvals of UGN-102 or our other product candidates may be. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Although we cannot predict the full effect on our business of the implementation of existing legislation or the enactment of additional legislation pursuant to healthcare and other legislative reform, we believe that legislation or regulations that would reduce reimbursement for, or restrict coverage of, our products could adversely affect how much or under what circumstances healthcare providers will prescribe or administer our products. This could adversely affect our business by reducing our ability to generate revenues, raise capital, obtain additional licensees and market our products. In addition, we believe the increasing emphasis on managed care in the United States has and will continue to put pressure on the price and usage of pharmaceutical products, which may adversely impact product sales. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Calibri;text-transform:none;font-variant: normal;">We may be unable to obtain Orphan Drug Designation or exclusivity for future product candidates we may develop. If our competitors are able to obtain orphan drug exclusivity for their products that are for the same indication as our product candidates, we may not be able to have competing products approved by the applicable regulatory authority for a significant period of time.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the Orphan Drug Act of 1983, or the Orphan Drug Act, the FDA may designate a product as an orphan drug if it is intended to treat an orphan disease or condition, defined as a patient population of fewer than 200,000 in the United States, or a patient population greater than 200,000 in the United States where there is no reasonable expectation that the cost of developing the drug will be recovered from sales in the United States. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the United States, Orphan Drug Designation entitles a party to financial incentives, such as opportunities for grant funding towards clinical trial costs, tax advantages and user-fee waivers. In addition, if a product receives the first FDA approval for the indication for which it has Orphan Drug Designation, the product is entitled to orphan drug exclusivity, which means the FDA may not approve any other application to market the same drug for the same indication for a period of seven years, except in limited circumstances, such as a showing of clinical superiority over the product with orphan exclusivity or where the manufacturer is unable to assure sufficient product quantity. Although the FDA has granted new product exclusivity to <span style="font-style:italic;">Jelmyto</span> for the treatment of UTUC, we may not receive new product exclusivity for any of our other product candidates.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Although the FDA has granted Orphan Drug Designation to <span style="font-style:italic;">Jelmyto</span> and UGN-201 for treatment of UTUC and CIS, we may not receive Orphan Drug Designation for any of our other product candidates. If our competitors are able to obtain orphan drug exclusivity for their products that are the same or similar to our product candidates before our drug candidates are approved, we may not be able to have competing product candidates approved by the FDA for a significant period of time. Any delay in our ability to bring our product candidates to market would negatively impact our business, revenue, cash flows and operations. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Calibri;text-transform:none;font-variant: normal;">Orphan Drug Designation may not ensure that we will enjoy market exclusivity in a particular market, and if we fail to obtain or maintain orphan drug exclusivity for our product candidates, we may be subject to earlier competition and our potential revenue will be reduced. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Orphan Drug Designation entitles a party to financial incentives, such as opportunities for grant funding towards clinical trial costs, tax advantages, user-fee waivers and market exclusivity for certain periods of time. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Calibri;font-weight:normal;text-transform:none;font-variant: normal;">Jelmyto<span style="font-style:normal;"> and UGN-201 have been granted Orphan Drug Designation for the treatment of UTUC and CIS, respectively, in the United States. Even if we obtain Orphan Drug Designation for our other product candidates, we may not be the first to obtain regulatory </span></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">68</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:12pt;font-style:italic;font-size:10pt;font-family:Calibri;font-weight:normal;text-transform:none;font-variant: normal;"><span style="font-style:normal;">approval for any particular orphan indication due to the uncertainties associated with developing biopharmaceutical products. Further, even if we obtain Orphan Drug Designation for a product candidate, that exclusivity may not effectively protect the product from competition because different drugs with different active moieties can be approved for the same condition. In addition, if a competitor obtains approval and marketing exclusivity for a drug product with an active moiety that is the same as that in a product candidate we are pursuing for the same indication, approval of our product candidate would be blocked during the period of marketing exclusivity unless we could demonstrate that our product candidate is clinically superior to the approved product. Conversely, even if we are granted orphan exclusivity, a competitor that demonstrates clinical superiority with the same active moiety may obtain approval prior to expiration of our exclusivity. In addition, if a competitor obtains approval and marketing exclusivity for a drug product with an active moiety that is the same as that in a product candidate, we are pursuing for a different orphan indication, this may negatively impact the market opportunity for our product candidate. There have been legal challenges to aspects of the FDA&#8217;s regulations and policies concerning the exclusivity provisions of the Orphan Drug Act, and future challenges could lead to changes that affect the protections afforded our product candidates in ways that are difficult to predict. </span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Calibri;text-transform:none;font-variant: normal;">Jelmyto and any of product candidates that receives regulatory approval will be subject to ongoing regulatory obligations and continued regulatory review, which may result in significant additional expenses, limit or withdraw regulatory approval and subject us to penalties if we fail to comply with applicable regulatory requirements. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Calibri;font-weight:normal;text-transform:none;font-variant: normal;">Jelmyto<span style="font-style:normal;"> and any of our product candidates that receives regulatory approval will be subject to continual regulatory review by the FDA and/or foreign regulatory authorities. Additionally, </span>Jelmyto<span style="font-style:normal;"> and any product candidates that receive regulatory approval will be subject to extensive and ongoing regulatory requirements, including labeling and other restrictions and market withdrawal and we may be subject to penalties if we fail to comply with regulatory requirements or experience unanticipated problems with our products. </span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The FDA approval of <span style="font-style:italic;">Jelmyto</span> is, and any regulatory approvals that we receive for our product candidates may be, subject to limitations on the approved indications for which the product may be marketed or to the conditions of approval. In addition, any regulatory approvals that we receive for our current or future product candidates may contain requirements for potentially costly post-marketing testing, including Phase 4 clinical trials, and surveillance to monitor the safety and efficacy of the product. In addition, the manufacturing processes, labeling, packaging, distribution, adverse event reporting, storage, advertising, promotion and recordkeeping for <span style="font-style:italic;">Jelmyto</span> is, and any of our other product candidates that receives regulatory approval will be, subject to extensive and ongoing regulatory requirements. These requirements include submissions of safety and other post-marketing information and reports, registration, as well as continued compliance with cGMP and GCP for any clinical trials that we conduct post-approval. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Later discovery of previously unknown problems with our products or product candidates, including adverse events of unanticipated severity or frequency, or problems with our third-party manufacturers&#8217; processes, or failure to comply with regulatory requirements, may result in, among other things: </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Calibri;">restrictions on the marketing or manufacturing of the product, withdrawal of the product from the market, or voluntary or mandatory product recalls&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Calibri;">fines, warning letters or holds on clinical trials&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Calibri;">refusal by the FDA to approve pending applications or supplements to approved applications submitted by us, or suspension or revocation of product license approvals&#59; and </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Calibri;">product seizure or detention, or refusal to permit the import or export of products&#59; and injunctions or the imposition of civil or criminal penalties. </span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our ongoing regulatory requirements may also change from time to time, potentially harming or making costlier our commercialization efforts. We cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative action, either in the United States or other countries. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval that we may have obtained, and we may not achieve or sustain profitability, which would adversely affect our business. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">69</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Calibri;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Calibri;text-transform:none;font-variant: normal;">Our relationships with healthcare professionals, independent contractors, clinical investigators, CROs, consultants and vendors in connection with our current and future business activities may be subject to federal and state healthcare fraud and abuse laws, false claims laws, transparency laws, government price reporting, and health information privacy and security laws. If we are unable to comply, or have not fully complied, with such laws, we could face penalties.</span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may currently be or may become subject to various U.S. federal, state and foreign health care laws, including those intended to prevent health care fraud and abuse. These laws may impact, among other things, our clinical research, sales and marketing activities, and constrain the business or financial arrangements with healthcare providers, physicians, and other parties that have the ability to directly or indirectly influence the prescribing, ordering, marketing, or distribution of products for which we obtain marketing approval. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The federal Anti-Kickback Statute prohibits, among other things, persons or entities from knowingly and willfully soliciting, offering, receiving or paying any remuneration (including any kickback, bribe or rebate), directly or indirectly, overtly or covertly, in cash or in kind, to induce or reward, or in return for, either the referral of an individual for, or the purchase, lease, order or recommendation of, any good, facility, item or service, for which payment may be made, in whole or in part, by a federal healthcare program such as Medicare and Medicaid. Remuneration has been broadly defined to include anything of value, including, but not limited to, cash, improper discounts, and free or reduced-price items and services. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Federal false claims laws, including the federal civil False Claims Act, or the FCA, and civil monetary penalties law impose penalties against individuals or entities for, among other things, knowingly presenting, or causing to be presented, to the federal government, claims for payment or approval that are false or fraudulent or making a false record or statement to avoid, decrease or conceal an obligation to pay money to the federal government. The FCA has been used to, among other things, prosecute persons and entities submitting claims for payment that are inaccurate or fraudulent, that are for services not provided as claimed, or for services that are not medically necessary. The FCA includes a whistleblower provision that allows individuals to bring actions on behalf of the federal government and share a portion of the recovery of successful claims. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Many states have similar fraud and abuse statutes and regulations that may be broader in scope and may apply regardless of payor, in addition to items and services reimbursed under Medicaid and other state programs. State and federal authorities have aggressively targeted pharmaceutical companies for, among other things, alleged violations of these anti-fraud statutes, based on among other things, unlawful financial inducements paid to prescribers and beneficiaries, as well as impermissible promotional practices, including certain marketing arrangements that rely on volume-based pricing and off-label promotion of FDA-approved products. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, among other things, imposes civil and criminal liability for knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program, including public and private payors, or knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false statement in connection with the delivery of or payment for healthcare benefits, items or services. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additionally, HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act, or HITECH, and their implementing regulations, impose, among other things, specified requirements on covered entities, including certain healthcare providers, health plans, and healthcare clearinghouses, and their business associates as well as their covered subcontractors relating to the privacy, security and transmission of individually identifiable health information, including mandatory contractual terms and required implementation of certain safeguards of such information. Among other things, HITECH makes HIPAA&#8217;s security standards directly applicable to business associates, independent contractors or agents of covered entities that receive or obtain protected health information in connection with providing a service on behalf of a covered entity. HITECH also created four new tiers of civil monetary penalties, amended HIPAA to make civil and criminal penalties directly applicable to business associates, and gave state attorneys general new authority to file civil actions for damages or injunctions in federal courts to enforce HIPAA and seek attorneys&#8217; fees and costs associated with pursuing federal civil actions. In addition, state laws govern the privacy and security of health information in some circumstances, many of which differ from each other in significant ways, may not have the same effect and may not be preempted by HIPAA, thus complicating compliance efforts. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our operations will also be subject to the federal Open Payments program pursuant to the Physician Payments Sunshine Act, created under Section&#160;6002 of the ACA and its implementing regulations, which requires certain manufacturers of drugs, devices, biologicals and medical supplies for which payment is available under Medicare, Medicaid, or the Children&#8217;s Health Insurance Program, with specific exceptions, to annually report to CMS information related to payments and other transfers of value provided to physicians, (defined to include doctors, dentists, optometrists, podiatrists and chiropractors), and teaching hospitals and certain </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">70</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ownership and investment interests held by physicians and their immediate family members to CMS, which will be expanded beginning in 2022, to require applicable manufacturers to report such information regarding its payments and other transfers of value to physician assistants, nurse practitioners, clinical nurse specialists, anesthesiologist assistants, certified registered nurse anesthetists and certified nurse midwives</span><span style="font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> made</span><span style="font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> during the previous year. We may also be subject to state laws that require drug manufacturers to report information related to payments and other transfers of value to physicians and other healthcare providers or marketing expenditures, drug pricing, and/or state laws that require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance guidelines promulgated by the federal government. Certain state and local laws also require the registration of pharmaceutical sales representatives.</span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Many states have also adopted laws similar to each of the above federal laws, which may be broader in scope and apply to items or services reimbursed by any payor, including commercial insurers. In addition, we may be subject to certain foreign healthcare laws that are analogous to the U.S. healthcare laws described above. If any of our business activities, including but not limited to our relationships with healthcare providers, are found to violate any of the aforementioned laws, we may be subject to significant administrative, civil and criminal penalties, damages, monetary fines, disgorgement, imprisonment, possible exclusion from participation in Medicare, Medicaid and other federal healthcare programs, contractual damages, reputational harm, additional reporting requirements and oversight if we become subject to a corporate integrity agreement or similar agreement to resolve allegations of non-compliance with these laws, diminished profits and future earnings and curtailment or restructuring of our operations. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Also, the U.S. Foreign Corrupt Practices Act and similar worldwide anti-bribery laws generally prohibit companies and their intermediaries from making improper payments to non-U.S. officials for the purpose of obtaining or retaining business. We cannot assure you that our internal control policies and procedures will protect us from reckless or negligent acts committed by our employees, future distributors, partners, collaborators or agents. Violations of these laws, or allegations of such violations, could result in fines, penalties or prosecution and have a negative impact on our business, results of operations and reputation. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Calibri;text-transform:none;font-variant: normal;">Legislative or regulatory healthcare reforms in the United States or abroad may make it more difficult and costly for us to obtain regulatory clearance or approval of our product candidates or any future product candidates and to produce, market, and distribute our products after clearance or approval is obtained. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">From time to time, legislation is drafted and introduced in Congress in the United States or by governments in foreign jurisdictions that could significantly change the statutory provisions governing the regulatory clearance or approval, manufacture, and marketing of regulated products or the reimbursement thereof. In addition, FDA or foreign regulatory agency regulations and guidance are often revised or reinterpreted by the FDA or the applicable foreign regulatory agency in ways that may significantly affect our business and our products. Any new regulations or revisions or reinterpretations of existing regulations may impose additional costs or lengthen review times of our product candidates or any future product candidates. We cannot determine what effect changes in regulations, statutes, legal interpretation or policies, when and if promulgated, enacted or adopted may have on our business in the future. Such changes could, among other things, require: </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Calibri;">changes to manufacturing methods&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Calibri;">recall, replacement, or discontinuance of one or more of our products&#59; and </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Calibri;">additional recordkeeping. </span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Each of these would likely entail substantial time and cost and could harm our business and our financial results. In addition, delays in receipt of or failure to receive regulatory clearances or approvals for any future products would harm our business, financial condition, and results of operations. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Calibri;text-transform:none;font-variant: normal;">We are subject to stringent and changing privacy and data security laws, contractual obligations, self-regulatory schemes, government regulation, and standards related to data privacy and security. The actual or perceived failure by us, our customers, partners or vendors to comply with such obligations could harm our reputation, subject us to significant fines and liability, or otherwise adversely affect our business. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are or may become subject to numerous domestic and foreign laws and regulations regarding privacy, data protection, and data security, the scope of which is changing, subject to differing applications and interpretations and may be inconsistent among countries, or conflict with other rules. We are also subject to the terms of our contractual obligations to customers and third parties related to privacy, data protection and data security. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">71</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For example, the European Union, or EU, has established its own data security and privacy legal framework, including but not limited to the European General Data Protection Regulation, or GDPR, which imposes onerous and comprehensive privacy, data protection, and data security obligations onto data controllers and processors, and contains provisions specifically directed at the processing of health information, higher sanctions and extra-territoriality measures intended to bring non-EU companies under the regulation. </span><span style="font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our upcoming clinical trial will include sites in the EU, which will increase our exposure to potential liability under the GDPR. </span><span style="font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Penalties for non-compliance with the GDPR can be significant and include fines in the amount greater of </span><span style="color:#000000;">&#8364;20 million or 4% of global turnover and restrictions or prohibitions on data processing, which could impair our ability to do business in the EU, </span><span style="color:#000000;">interrupt our clinical trials,</span><span style="color:#000000;"> </span><span style="color:#000000;">reduce demand for our services and adversely impact our business and results of operations.</span><span style="font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> We anticipate that over time we may expand our business to include additional operations outside of the United States and Israel. With such expansion, we would be subject to increased governmental regulation in other countries in which we might operate, including the GDPR. Assisting our customers, partners, and vendors in complying with the GDPR or other foreign laws, or complying with such laws ourselves, may cause us to incur substantial operational costs or require us to change our business practices. </span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Moreover, many foreign laws, including the GDPR and data protection laws in the United Kingdom and Switzerland, impose restrictions on the transfer of personal information to the United States and most other countries unless the parties to the transfer have implemented specific safeguards to protect the transferred personal information. A recent decision by the Court of Justice of the European Union (the &#8220;Schrems II&#8221; ruling), however, has invalidated the EU-U.S. Privacy Shield Framework, which was one of the primary mechanisms used by U.S. Companies to import personal information from Europe, and raised questions about whether the European Commission&#8217;s Standard Contractual Clauses (&#8220;SCCs&#8221;), one of the primary alternatives to the Privacy Shield, can lawfully be used for personal information transfers from Europe to the United States or most other countries. Similarly, the Swiss Federal Data Protection and Information Commissioner recently opined that the Swiss-U.S. Privacy Shield is inadequate for transfers of data from Switzerland to the U.S. The United Kingdom, whose data protection laws are similar to those of the European Union, may similarly determine that the EU-U.S. Privacy Shield is not a valid mechanism for lawfully transferring personal information from the UK to the U.S.&#160;&#160;The European Commission recently proposed updates to the SCCs, and additional regulatory guidance has been released that seeks to impose additional obligations on companies seeking to rely on the SCCs. Given that, at present, there are few, if any, viable alternatives to the EU-U.S. Privacy Shield and the SCCs, any transfers by us or our vendors of personal data from Europe may not comply with European data protection law, which may increase our exposure to the GDPR&#8217;s heightened sanctions for violations of its cross-border data transfer restrictions and may prohibit our transfer of EU personal data outside of the EU (including clinical trial data), and may adversely impact our operations, product development and ability to provide our products. There is currently uncertainty surrounding how to implement such safeguards and how to conduct such transfers.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Regulation of privacy, data protection and data security has also become more stringent in the United States. For example, California recently enacted legislation that has been dubbed the first &#8220;GDPR-like&#8221; law in the United States. Known as the California Consumer Privacy Act, or CCPA, it creates new individual privacy rights for consumers (as that word is broadly defined in the law) and places increased privacy and security obligations on entities handling personal data of consumers or households. Effective January 1, 2020, the CCPA requires covered companies to provide new disclosures to California consumers, provides such consumers new ways to opt-out of certain sales of personal information, and allows for a new cause of action for data breaches. The CCPA will be expanded substantially on January 1, 2023, when the California Privacy Rights Act of 2020 (&#8220;CPRA&#8221;) becomes fully operative. The CPRA will, among other things, give California residents the ability to limit use of certain sensitive personal information, establish restrictions on the retention of personal information, and expand the types of data breaches subject to the CCPA&#8217;s private right of action. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Complying with these various laws could require us to incur substantial costs, take on more onerous obligations in our contracts, restrict our ability to collect, use and disclose data, require us to change our business practices and compliance procedures in a manner adverse to our business, or, in some cases, impact our ability to operate in certain jurisdictions. The actual or perceived failure by us, our customers, our vendors, or other relevant third parties to address or comply with these laws, regulations, and obligations could increase our compliance and operational costs, expose us to regulatory scrutiny, actions, fines, civil or criminal penalties, private litigation, cause regulators to reject, limit or disrupt our clinical trial activities, harm our reputation, and otherwise cause a material effect on our business, financial condition, and results of our operations. Moreover, inability to import personal information from Europe to the United States or other countries may disrupt or require us to change our business practices, interrupt our business operations, including clinical trials, and otherwise have a material financial impact on our business.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Calibri;text-transform:none;font-variant: normal;">If we fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could negatively impact our business. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are subject to numerous environmental, health and safety laws and regulations, including those governing laboratory procedures and the handling, use, storage, treatment and disposal of hazardous materials and wastes. Our operations involve the </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">72</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">use of hazardous and flammable materials, including chemicals and biological materials. Our operations also produce hazardous waste products. We generally contract with third parties for the disposal of these materials and wastes. We cannot eliminate the risk of contamination or injury from these materials. In the event of contamination or injury resulting from our use of hazardous materials, we could be held liable for any resulting damages, and any liability could exceed our resources. We also could incur significant costs associated with civil or criminal fines and penalties. </span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We maintain workers compensation insurance to cover us for costs and expenses we may incur due to injuries to our employees resulting from the use of hazardous materials or other work-related injuries with policy limits that we believe are customary for similarly situated companies and adequate to provide us with coverage for foreseeable risks. Although we maintain such insurance, this insurance may not provide adequate coverage against potential liabilities. In addition, we may incur substantial costs in order to comply with current or future environmental, health and safety laws and regulations. These current or future laws and regulations may impair our research, development or production efforts. Failure to comply with these laws and regulations also may result in substantial fines, penalties or other sanctions. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Calibri;text-transform:none;font-variant: normal;">It may be difficult for us to profitably sell our product candidates if coverage and reimbursement for these products is limited by government authorities and/or third-party payor policies. </p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&#160;</p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition to any healthcare reform measures which may affect reimbursement, market acceptance and sales of <span style="font-style:italic;">Jelmyto</span>, UGN-102 and our other product candidates, if approved, will depend on the coverage and reimbursement policies of third-party payors, like government authorities, private health insurers, and managed care organizations. Third-party payors decide which medications they will cover and separately establish reimbursement levels. In October 2020, a Medicare C-Code was issued for <span style="font-style:italic;">Jelmyto</span> and we have obtained pass-through status for two years, no more than three. CMS has established a permanent and product-specific J-code for <span style="font-style:italic;">Jelmyto</span> that took effect on January 1, 2021.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A primary trend in the U.S. healthcare industry and elsewhere is cost containment. Government and other third-party payors are increasingly challenging the prices charged for health care products, examining the cost effectiveness of drugs in addition to their safety and efficacy, and limiting or attempting to limit both coverage and the level of reimbursement for prescription drugs. Although our experience to date has demonstrated coverage for <span style="font-style:italic;">Jelmyto</span>, we cannot be sure that adequate coverage will be available for UGN-102 or our other product candidates, if approved, or, if coverage is available, the level of reimbursement will be adequate to make our products affordable for patients or profitable for us. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There is significant uncertainty related to the insurance coverage and reimbursement of newly approved products. In the United States, decisions about reimbursement for new medicines under Medicare are made by CMS, as the administrator for the Medicare program. Private third-party payors often use CMS as a model for their coverage and reimbursement decisions, but also have their own methods and approval process apart from CMS&#8217;s determinations. Our experience to date has demonstrated coverage with CMS and commercial payors for <span style="font-style:italic;">Jelmyto</span>, and we have established written policies with certain commercial providers. However, it is difficult to predict what CMS as well as other third-party payors will decide with respect to reimbursement for fundamentally novel products such as ours, as there is no body of established practices and precedents for these new products. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Reimbursement may impact the demand for, and/or the price of, any product for which we obtain marketing approval. Assuming we obtain coverage for a given product by a third-party payor, the resulting reimbursement payment rates may not be adequate or may require co-payments that patients find unacceptably high. Patients who are prescribed medications for the treatment of their conditions, and their prescribing physicians, generally rely on third-party payors to reimburse all or part of the costs associated with their prescription drugs. Patients are unlikely to use our products unless coverage is provided, and reimbursement is adequate to cover all or a significant portion of the cost of our products. Moreover, f<span style="Background-color:#FFFFFF;color:#212121;">or products administered under the supervision of a physician, obtaining and maintaining coverage and adequate reimbursement may be particularly difficult because of the higher prices often associated with such drugs. Additionally, separate reimbursement for the product itself or the treatment or procedure in which the product is used may not be available, which may impact physician utilization. </span>Therefore, coverage and adequate reimbursement is critical to new product acceptance. Coverage decisions may depend upon clinical and economic standards that disfavor new drug products when more established or lower cost therapeutic alternatives are already available or subsequently become available. There may be significant delays in obtaining coverage and reimbursement for newly approved drugs, and coverage may be more limited than the purposes for which the drug is approved by the FDA or applicable foreign regulatory authorities. Moreover, eligibility for coverage and reimbursement does not imply that a drug will be paid for in all cases or at a rate that covers our costs, including research, development, manufacture, sale and distribution. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">73</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Reimbursement by a third-party payor may depend upon a number of factors including the third-party payor&#8217;s determination that use of a product is: </span></p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Calibri;">a covered benefit under its health plan&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Calibri;">safe, effective and medically necessary&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Calibri;">appropriate for the specific patient&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Calibri;">cost-effective&#59; and </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Calibri;">neither experimental nor investigational. </span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Obtaining and maintaining coverage and reimbursement approval for a product from a government or other third-party payor is a time-consuming and costly process that could require us to provide supporting scientific, clinical and cost effectiveness data for the use of our products to the payor. Further, no uniform policy requirement for coverage and reimbursement for drug products exists among third-party payors in the United States. Therefore, coverage and reimbursement for drug products can differ significantly from payor to payor. As a result, the coverage determination process may require us to provide scientific and clinical support for the use of our products to each payor separately, with no assurance that coverage and adequate reimbursement will be applied consistently or obtained in the first instance. We may not be able to provide data sufficient to gain acceptance with respect to coverage and/or sufficient reimbursement levels. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Although we have observed written policy coverage in commercial plans as well as coverage for government plans for <span style="font-style:italic;">Jelmyto</span> to date, we cannot be sure that adequate coverage or reimbursement will continue to be available for <span style="font-style:italic;">Jelmyto</span>, or be available for UGN-102 or any of our other product candidates, if approved. Also, we cannot be sure that reimbursement amounts will not reduce the demand for, or the price of, our future products. If reimbursement is not available, or is available only to limited levels, we may not be able to successfully commercialize <span style="font-style:italic;">Jelmyto</span>, UGN-102 or our other product candidates, or achieve profitably at all, even if approved. Additionally, coverage policies and reimbursement rates may change at any time. Even if favorable coverage and reimbursement status is attained for any of our products or product candidates that receive regulatory approval, less favorable coverage policies and reimbursement rates may be implemented in the future. If we are unable to obtain and maintain sufficient third&#8209;party coverage and adequate reimbursement for our products, the commercial success of our products may be greatly hindered and our financial condition and results of operations may be materially and adversely affected.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Calibri;text-transform:none;font-variant: normal;">Legislative or regulatory healthcare reforms in the United States may make it more difficult and costly for us to obtain regulatory clearance or approval of UGN-102 or any of our other product candidates and to produce, market, and distribute Jelmyto or any of our product candidates that receives clearance or approval. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">From time to time, legislation is drafted and introduced in Congress that could significantly change the statutory provisions governing the regulatory clearance or approval, manufacture, and marketing of regulated products or the reimbursement thereof. In addition, FDA regulations and guidance are often revised or reinterpreted by the FDA in ways that may significantly affect our business and our products. Any new regulations or revisions or reinterpretations of existing regulations may impose additional costs or lengthen review times of UGN-102 or any of our other product candidates. We cannot determine what effect changes in regulations, statutes, legal interpretation or policies, when and if promulgated, enacted or adopted may have on our business in the future. Such changes could, among other things, require: </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Calibri;">changes to manufacturing methods&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Calibri;">change in protocol design&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Calibri;">additional treatment arm (control)&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Calibri;">recall, replacement, or discontinuance of one or more of our products&#59; and </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Calibri;">additional recordkeeping. </span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Each of these would likely entail substantial time and cost and could harm our business and our financial results. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">74</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-size:10pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">Risks Related to Ownership of Our Ordinary Shares </span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Calibri;text-transform:none;font-variant: normal;">The market price of our ordinary shares has been and may continue to be subject to fluctuation and you could lose all or part of your investment. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The stock market in general has been, and the market price of our ordinary shares in particular has been and may continue to be, subject to fluctuation, whether due to, or irrespective of, our operating results and financial condition. The market price of our ordinary shares on the Nasdaq Global Market may fluctuate as a result of a number of factors, some of which are beyond our control, including, but not limited to: </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Calibri;">the success of our launch and commercialization of </span><span style="font-style:italic;font-family:Calibri;">Jelmyto</span><span style="font-family:Calibri;">&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Calibri;">actual or anticipated variations in our and our competitors&#8217; results of operations and financial condition&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Calibri;">physician and market acceptance of </span><span style="font-style:italic;font-family:Calibri;">Jelmyto</span><span style="font-family:Calibri;"> or any other approved product&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Calibri;">the mix of products that we sell&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Calibri;">any voluntary or mandatory recall of </span><span style="font-style:italic;font-family:Calibri;">Jelmyto</span><span style="font-family:Calibri;"> or any other approved product, or the imposition of any additional labeling, marketing or promotional restrictions&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Calibri;">our success or failure to obtain approval for and commercialize our product candidates&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Calibri;">changes in the structure of healthcare payment systems&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Calibri;">changes in earnings estimates or recommendations by securities analysts, if our ordinary shares are covered by analysts&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Calibri;">development of technological innovations or new competitive products by others&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Calibri;">announcements of technological innovations or new products by us&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Calibri;">publication of the results of nonclinical or clinical trials for </span><span style="font-style:italic;font-family:Calibri;">Jelmyto</span><span style="font-family:Calibri;">, UGN-102 or our other product candidates&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Calibri;">failure by us to achieve a publicly announced milestone&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Calibri;">delays between our expenditures to develop and market new or enhanced product candidates and the generation of sales from those products&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Calibri;">developments concerning intellectual property rights&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Calibri;">the announcement of, or developments in, any litigation matters, including any product liability claims related to </span><span style="font-style:italic;font-family:Calibri;">Jelmyto</span><span style="font-family:Calibri;"> or any of our product candidates&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Calibri;">regulatory developments and the decisions of regulatory authorities as to the approval or rejection of new or modified products&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Calibri;">changes in the amounts that we spend to develop, acquire or license new products, technologies or businesses&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Calibri;">changes in our expenditures to promote our products&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Calibri;">our sale or proposed sale, or the sale by our significant shareholders, of our ordinary shares or other securities in the future&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Calibri;">changes in key personnel&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Calibri;">success or failure of our research and development projects or those of our competitors&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Calibri;">the trading volume of our ordinary shares&#59; and </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Calibri;">general economic and market conditions and other factors, such as the COVID-19 pandemic, including factors unrelated to our operating performance. </span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">These factors and any corresponding price fluctuations may negatively impact the market price of our ordinary shares and result in substantial losses being incurred by our investors. In the past, following periods of market volatility, public company shareholders have often instituted securities class action litigation. If we were to become involved in securities litigation, it could impose a substantial cost upon us and divert the resources and attention of our management from our business. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Calibri;text-transform:none;font-variant: normal;">Future sales of our ordinary shares could reduce the market price of our ordinary shares. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">75</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If our existing shareholders, particularly our directors, their affiliates, or our executive officers, sell a substantial number of our ordinary shares in the public market, the market price of our ordinary shares could decrease significantly. The perception in the public market that our shareholders might sell our ordinary shares could also depress the market price of our ordinary shares and could impair our future ability to obtain capital, especially through an offering of equity securities. </span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of the date of this Annual Report, the holders of up to approximately 4.5 million ordinary shares are entitled to registration rights. In addition, our sale of additional ordinary shares or similar securities in order to raise capital might have a similar negative impact on the share price of our ordinary shares. A decline in the price of our ordinary shares might impede our ability to raise capital through the issuance of additional ordinary shares or other equity securities and may cause you to lose part or all of your investment in our ordinary shares. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Calibri;text-transform:none;font-variant: normal;">Future equity offerings could result in future dilution and could cause the price of our ordinary shares to decline. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In order to raise additional capital, we may in the future offer additional ordinary shares or other securities convertible into or exchangeable for our ordinary shares at prices that we determine from time to time, and investors purchasing shares or other securities in the future could have rights superior to existing shareholders. We may choose to raise additional capital due to market conditions or strategic considerations, even if we believe we have sufficient funds for our current or future operating plans. On December 20, 2019, we entered into a sales agreement with Cowen and Company, LLC pursuant to which we may from time to time offer and sell our ordinary shares, having an aggregate offering price of up to $100.0 million, to or through Cowen, acting as sales agent or principal, in any manner deemed to be an &#8220;at-the market offering&#8221;. The shares will be offered and sold pursuant to our shelf registration statement on Form S-3 filed with the SEC on December 20, 2019, which was declared effective on January 2, 2020. As of March 31, 2021, we had sold 700,000 shares under the sales agreement for total gross proceeds of $16.6 million, leaving up to $83.4 million available for sale under the sales agreement. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Calibri;text-transform:none;font-variant: normal;">The significant share ownership position of our officers, directors and entities affiliated with certain of our directors may limit your ability to influence corporate matters. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our officers, directors and entities affiliated with certain of our directors beneficially own a significant portion of our outstanding ordinary shares. Accordingly, these persons are able to significantly influence, though not independently determine, the outcome of matters required to be submitted to our shareholders for approval, including decisions relating to the election of our board of directors, and the outcome of any proposed merger or consolidation of our company. These interests may not be consistent with those of our other shareholders. In addition, these persons&#8217; significant interest in us may discourage third parties from seeking to acquire control of us, which may adversely affect the market price of our ordinary shares. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Calibri;text-transform:none;font-variant: normal;">We have never paid cash dividends on our share capital, and we do not anticipate paying any cash dividends in the foreseeable future. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have never declared or paid cash dividends on our share capital, nor do we anticipate paying any cash dividends on our share capital in the foreseeable future. We currently intend to retain all available funds and any future earnings to fund the development and growth of our business. As a result, capital appreciation, if any, of our ordinary shares will be investors&#8217; sole source of gain for the foreseeable future. In addition, Israeli law limits our ability to declare and pay dividends and may subject our dividends to Israeli withholding taxes. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Calibri;text-transform:none;font-variant: normal;">If we are classified as a passive foreign investment company, or PFIC, our U.S. shareholders may suffer adverse tax consequences. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Generally, for any taxable year, if at least 75% of our gross income is passive income, or at least 50% of the value of our assets is attributable to assets that produce passive income or are held for the production of passive income, including cash, we would be characterized as a PFIC for U.S. federal income tax purposes.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">76</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The determination of whether we are a PFIC is a fact-intensive determination made on an annual basis and the applicable law is subject to varying interpretation. In particular, the characterization of our assets as active or passive may depend in part on our current and intended future business plans, which are subject to change. In addition, for our current and future taxable years, the total value of our assets for PFIC testing purposes may be determined in part by reference to the market price of our ordinary shares from time to time, which may fluctuate considerably. Under the income test, our status as a PFIC depends on the composition of our income which will depend on the transactions we enter into in the future and our corporate structure. The composition of our income and assets is also affected by how, and how quickly, we spend the cash we raise in any offering.</span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We do not believe we were a PFIC for the year ending December 31, 2020. We have not yet made a determination as to our expected PFIC status for the current taxable year. We cannot provide any assurances regarding our PFIC status for the current or future taxable years, and our U.S. tax counsel has not provided any opinion regarding our PFIC status.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If we are characterized as a PFIC, our U.S. Holders (as defined below) may suffer adverse tax consequences, including having gains realized on the sale of our ordinary shares treated as ordinary income, rather than capital gain, the loss of the preferential rate applicable to dividends received on our ordinary shares by individuals who are U.S. Holders, having interest charges apply to distributions by us and gains from the sales of our shares, and additional reporting requirements under U.S. federal income tax laws and regulations. A U.S. Holder that (i) owns our ordinary shares at any point during a year in which we are characterized as a PFIC and (ii) does not timely make a QEF Election (as described below) will treat such ordinary shares as stock in a PFIC for all subsequent tax years, even if we no longer qualify as a PFIC under the relevant tests in such subsequent tax years. A U.S. Holder may be able to elect out of such treatment if we are no longer characterized as a PFIC by making a &#8220;purging election.&#8221; For purposes of this discussion, a &#8220;U.S. Holder&#8221; is a beneficial owner of our ordinary shares that, for U.S. federal income tax purposes, is or is treated as any of the following: (a) an individual who is a citizen or resident of the United States&#59; (b) a corporation, or entity treated as a corporation for U.S. federal income tax purposes, created or organized under the laws of the United States, any state thereof, or the District of Columbia&#59; (c) an estate, the income of which is subject to U.S. federal income tax regardless of its source&#59; or (d) a trust that (1) is subject to the supervision of a U.S. court and the control of one or more &#8220;United States persons&#8221; (within the meaning of Section 7701(a)(30) of the Code), or (2) has a valid election in effect to be treated as a United States person for U.S. federal income tax purposes.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Calibri;text-transform:none;font-variant: normal;">Future changes to tax laws could have a material adverse effect on us and reduce net returns to our shareholders. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our tax treatment is subject to changes in tax laws, regulations and treaties, or the interpretation thereof, tax policy initiatives and reforms under consideration and the practices of tax authorities in jurisdictions in which we operate, as well as tax policy initiatives and reforms related to the Organisation for Economic Co-Operation and Development&#8217;s, or OECD, Base Erosion and Profit Shifting, or BEPS Project, the European Commission&#8217;s state aid investigations and other initiatives. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Such changes may include (but are not limited to) the taxation of operating income, investment income, dividends received or, in the specific context of withholding tax dividends paid. We are unable to predict what tax reform may be proposed or enacted in the future or what effect such changes would have on our business, but such changes, to the extent they are brought into tax legislation, regulations, policies or practices, could affect our financial position and overall or effective tax rates in the future in countries where we have operations, reduce post-tax returns to our shareholders, and increase the complexity, burden and cost of tax compliance. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;letter-spacing:-0.15pt;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">New income, sales, use or other tax laws, statutes, rules, regulations or ordinances could be enacted at any time, which could affect the tax treatment of our domestic and foreign earnings. Any new taxes could adversely affect our domestic and international business operations, and our business and financial performance. Further, existing tax laws, statutes, rules, regulations or ordinances could be interpreted, changed, modified or applied adversely to us. For example, the Tax Act made many significant changes to the U.S. Internal Revenue Code of 1986, as amended, or the Code. Future guidance from the Internal Revenue Service and other tax authorities with respect to the Tax Act may affect us, and certain aspects of the Tax Act could be repealed or modified in future legislation. For example, the CARES Act modified certain provisions of the Tax Act. In addition, it is uncertain if and to what extent various states will conform to the Tax Act, the CARES Act, or any newly enacted federal tax legislation. Changes in corporate tax rates, the realization of net deferred tax assets relating to our operations, the taxation of foreign earnings, and the deductibility of expenses under the Tax Act or future reform legislation could have a material impact on the value of our deferred tax assets, could result in significant one-time charges, and could increase our future U.S. tax expense.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">77</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Calibri;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Calibri;text-transform:none;font-variant: normal;">Tax authorities may disagree with our positions and conclusions regarding certain tax positions, resulting in unanticipated costs, taxes or non-realization of expected benefits. </span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A tax authority may disagree with tax positions that we have taken, which could result in increased tax liabilities. For example, the U.S. Internal Revenue Service or another tax authority could challenge our allocation of income by tax jurisdiction and the amounts paid between our affiliated companies pursuant to our intercompany arrangements and transfer pricing policies, including amounts paid with respect to our intellectual property development. Similarly, a tax authority could assert that we are subject to tax in a jurisdiction where we believe we have not established a taxable nexus, often referred to as a &#8220;permanent establishment&#8221; under international tax treaties, and such an assertion, if successful, could increase our expected tax liability in one or more jurisdictions. A tax authority may take the position that material income tax liabilities, interest and penalties are payable by us, in which case, we expect that we might contest such assessment. Contesting such an assessment may be lengthy and costly and if we were unsuccessful in disputing the assessment, the implications could increase our anticipated effective tax rate, where applicable. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Calibri;text-transform:none;font-variant: normal;">If a United States person is treated as owning at least 10% of our ordinary shares, such holder may be subject to adverse U.S. federal income tax consequences. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If a U.S. Holder is treated as owning (directly, indirectly or constructively) at least 10% of the value or voting power of our ordinary shares, such U.S. Holder may be treated as a &#8220;United States shareholder&#8221; with respect to each &#8220;controlled foreign corporation&#8221; in our group (if any). Because our group includes at least one U.S. subsidiary (Urogen Pharma, Inc.), if we were to form or acquire any non-U.S. subsidiaries in the future, they may be treated as controlled foreign corporations of any U.S. Holder owning (directly, indirectly or constructively) at least 10% of the value or voting power of our ordinary shares. A United States shareholder of a controlled foreign corporation may be required to annually report and include in its U.S. taxable income its pro rata share of &#8220;Subpart F income,&#8221; &#8220;global intangible low-taxed income&#8221; and investments in U.S. property by controlled foreign corporations, regardless of whether we make any distributions. An individual that is a United States shareholder with respect to a controlled foreign corporation generally would not be allowed certain tax deductions or foreign tax credits that would be allowed to a United States shareholder that is a U.S. corporation. We cannot provide any assurances that we will assist investors in determining whether any non-U.S. subsidiaries that we may form or acquire in the future would be treated as a controlled foreign corporation or whether such investor would be treated as a United States shareholder with respect to any of such controlled foreign corporations. Further, we cannot provide any assurances that we will furnish to any U.S. shareholder information that may be necessary to comply with the reporting and tax paying obligations discussed above. Failure to comply with these reporting obligations may subject you to significant monetary penalties and may prevent the statute of limitations with respect to your U.S. federal income tax return for the year for which reporting was due from starting. U.S. Holders should consult their tax advisors regarding the potential application of these rules to their investment in our ordinary shares. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Calibri;text-transform:none;font-variant: normal;">Our ability to use our U.S. net operating loss carryforwards and certain other tax attributes to offset future taxable income and taxes may be limited.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under U.S. federal income tax law, federal net operating losses, or NOLs, incurred in tax years beginning after December 31, 2017, may be carried forward indefinitely, but the deductibility of such federal net operating losses in tax years beginning after December 31, 2020, is limited to 80% of taxable income. In addition, under Sections 382 and 383 of the Code, and corresponding provisions of state law, if a corporation undergoes an &#8220;ownership change,&#8221; which is generally defined as a greater than 50% change, by value, in its equity ownership over a three-year period, the corporation&#8217;s ability to utilize its pre-change NOL carryforwards and other pre-change tax attributes to offset future its post-change income or taxes may be limited. We have not performed a detailed analysis to determine whether an ownership change under Section 382 of the Code has occurred for UroGen Pharma, Inc. If we undergo an ownership change, our ability to utilize NOLs and other tax attributes could be limited by Sections 382 and 383 of the Code. Future changes in our share ownership, some of which are outside of our control, could result in an ownership change under Section 382 of the Code. As a result, even if we attain profitability, we may be unable to use a material portion of our NOLs and other tax attributes, which could negatively impact our future cash flows. In addition, at the state level, there may be periods during which the use of net operating loss carryforwards is suspended or otherwise limited, which could accelerate or permanently increase state taxes owed.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">78</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-size:10pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">Risks Related to our Operations in Israel </span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Calibri;text-transform:none;font-variant: normal;">Our research and development and other significant operations are located in Israel and, therefore, our results may be adversely affected by political, economic and military instability in Israel. *</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our research and development facilities are located in Ra&#8217;anana, Israel. If these or any future facilities in Israel were to be damaged, destroyed or otherwise unable to operate, whether due to war, acts of hostility, earthquakes, fire, floods, hurricanes, storms, tornadoes, other natural disasters, employee malfeasance, terrorist acts, pandemic, power outages or otherwise, or if performance of our research and development is disrupted for any other reason, such an event could delay our clinical trials or, if our product candidates are approved and we choose to manufacture all or any part of them internally, jeopardize our ability to manufacture our products as promptly as our prospective customers will likely expect, or possibly at all. If we experience delays in achieving our development objectives, or if we are unable to manufacture an approved product within a timeframe that meets our prospective customers&#8217; expectations, our business, prospects, financial results and reputation could be harmed. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Political, economic and military conditions in Israel may directly affect our business. Since the establishment of the State of Israel in 1948, a number of armed conflicts have taken place between Israel and its neighboring countries, Hamas (an Islamist militia and political group that controls the Gaza Strip) and Hezbollah (an Islamist militia and political group based in Lebanon). In addition, several countries, principally in the Middle East, restrict doing business with Israel, and additional countries may impose restrictions on doing business with Israel and Israeli companies whether as a result of hostilities in the region or otherwise. Any hostilities involving Israel, terrorist activities, political instability or violence in the region or the interruption or curtailment of trade or transport between Israel and its trading partners could adversely affect our operations and results of operations and adversely affect the market price of our ordinary shares. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our commercial insurance does not cover losses that may occur as a result of an event associated with the security situation in the Middle East. Although the Israeli government is currently committed to covering the reinstatement value of direct damages that are caused by terrorist attacks or acts of war, there can be no assurance that this government coverage will be maintained, or if maintained, will be sufficient to compensate us fully for damages incurred. Any losses or damages incurred by us could have a material adverse effect on our business, financial condition and results of operations. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Further, our operations could be disrupted by the obligations of our employees to perform military service. As of March 31, 2021, we had 43 employees based in Israel. Of these employees, some may be military reservists, and may be called upon to perform military reserve duty of up to 36 days per year (and in some cases more) until they reach the age of 40 (and in some cases, up to the age of 45 or older). Additionally, they may be called to active duty at any time under emergency circumstances. In response to increased tension and hostilities in the region, there have been, at times, call-ups of military reservists, and it is possible that there will be additional call-ups in the future. Our operations could be disrupted by the absence of these employees due to military service. Such disruption could harm our business and operating results. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Calibri;text-transform:none;font-variant: normal;">Provisions of Israeli law and our articles of association may delay, prevent or otherwise impede a merger with, or an acquisition of, us, even when the terms of such a transaction are favorable to us and our shareholders. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Israeli corporate law regulates mergers, requires tender offers for acquisitions of shares above specified thresholds, requires special approvals for transactions involving directors, officers or significant shareholders and regulates other matters that may be relevant to such types of transactions. For example, a tender offer for all of a company&#8217;s issued and outstanding shares can only be completed if shareholders not accepting the tender offer hold less than 5% of the issued share capital. Completion of the tender offer also requires approval of a majority of the offerees that do not have a personal interest in the tender offer, unless shareholders not accepting the tender offer hold less than 2% of the company&#8217;s outstanding shares. Furthermore, the shareholders, including those who indicated their acceptance of the tender offer, may, at any time within six months following the completion of the tender offer, petition an Israeli court to alter the consideration for the acquisition, unless the acquirer stipulated in its tender offer that a shareholder that accepts the offer may not seek such appraisal rights. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">79</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Furthermore, Israeli tax considerations may make potential transactions unappealing to us or to our shareholders whose country of residence does not have a tax treaty with Israel exempting such shareholders from Israeli tax. For example, Israeli tax law does not recognize tax-free share exchanges to the same extent as U.S. tax law. With respect to mergers, Israeli tax law allows for tax deferral in certain circumstances but makes the deferral contingent on the fulfillment of a number of conditions, including, in some cases, a holding period of two years from the date of the transaction during which sales and dispositions of shares of the participating companies are subject to certain restrictions. Moreover, with respect to certain share swap transactions, the tax deferral is limited in time, and when such time expires, the tax becomes payable even if no disposition of the shares has occurred. These provisions could delay, prevent or impede an acquisition of us or our merger with another company, even if such an acquisition or merger would be beneficial to us or to our shareholders. </span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Calibri;text-transform:none;font-variant: normal;">It may be difficult to enforce a judgment of a U.S. court against us, our officers and directors or the Israeli experts named in our reports filed with the SEC in Israel or the United States, to assert U.S. securities laws claims in Israel or to serve process on our officers and directors and these experts. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are incorporated in Israel. One of our directors resides outside of the United States, and most of our assets and most of the assets of this director are located outside of the United States. Therefore, a judgment obtained against us, or this director, including a judgment based on the civil liability provisions of the U.S. federal securities laws, may not be collectible in the United States and may not be enforced by an Israeli court. It may also be difficult for you to effect service of process on this director in the United States or to assert U.S. securities law claims in original actions instituted in Israel. Israeli courts may refuse to hear a claim based on an alleged violation of U.S. securities laws reasoning that Israel is not the most appropriate forum in which to bring such a claim. In addition, even if an Israeli court agrees to hear a claim, it may determine that Israeli law and not U.S. law is applicable to the claim. If U.S. law is found to be applicable, the content of applicable U.S. law must be proven as a fact by expert witnesses, which can be a time consuming and costly process. Certain matters of procedure will also be governed by Israeli law. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There is little binding case law in Israel that addresses the matters described above. As a result of the difficulty associated with enforcing a judgment against us in Israel, you may not be able to collect any damages awarded by either a U.S. or foreign court. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Calibri;text-transform:none;font-variant: normal;">Your rights and responsibilities as a shareholder will be governed by Israeli law, which differs in some material respects from the rights and responsibilities of shareholders of U.S. companies. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The rights and responsibilities of the holders of our ordinary shares are governed by our articles of association and by Israeli law. These rights and responsibilities differ in some material respects from the rights and responsibilities of shareholders in U.S. companies. In particular, a shareholder of an Israeli company has a duty to act in good faith and in a customary manner in exercising its rights and performing its obligations towards the company and other shareholders, and to refrain from abusing its power in the company, including, among other things, in voting at a general meeting of shareholders on matters such as amendments to a company&#8217;s articles of association, increases in a company&#8217;s authorized share capital, mergers and acquisitions and related party transactions requiring shareholder approval, as well as a general duty to refrain from discriminating against other shareholders. In addition, a shareholder who is aware that it possesses the power to determine the outcome of a vote at a meeting of the shareholders or to appoint or prevent the appointment of a director or executive officer in the company has a duty of fairness toward the company. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There is limited case law available to assist us in understanding the nature of these duties or the implications of these provisions. These provisions may be interpreted to impose additional obligations and liabilities on holders of our ordinary shares that are not typically imposed on shareholders of U.S. companies. </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">Risks Related to Our Management and Employees </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Calibri;text-transform:none;font-variant: normal;">We depend on our executive officers and key clinical, technical and commercial personnel to operate our business effectively, and we must attract and retain highly skilled employees in order to succeed. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our success depends upon the continued service and performance of our executive officers who are essential to our growth and development. The loss of one or more of our executive officers could delay or prevent the continued successful implementation of our growth strategy, could affect our ability to manage our company effectively and to carry out our business plan, or could otherwise be detrimental to us. As of January 31, 2021, we had 187 employees. Therefore, knowledge of our product candidates and clinical trials is concentrated among a small number of individuals. Members of our executive team as well as key clinical, scientific, </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">80</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">technical and commercial personnel may resign at any time and there can be no assurance that we will be able to continue to retain such personnel. If we cannot recruit suitable replacements in a timely manner, our business will be adversely impacted. </span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our growth and continued success will also depend on our ability to attract and retain additional highly qualified and skilled research and development, operational, managerial and finance personnel. However, we face significant competition for experienced personnel in the pharmaceutical field. Many of the other pharmaceutical companies that we compete against for qualified personnel have greater financial and other resources, different risk profiles and a longer history in the industry than we do. They also may provide more diverse opportunities and better chances for career advancement. Some of these characteristics may be more appealing to quality candidates than what we have to offer. If we cannot retain our existing skilled scientific and operational personnel and attract and retain sufficiently skilled additional scientific and operational personnel, as required, for our research and development and manufacturing operations on acceptable terms, we may not be able to continue to develop and commercialize our existing product candidates or new products. Further, any failure to effectively integrate new personnel could prevent us from successfully growing our company. </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">General Risk Factors </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Calibri;text-transform:none;font-variant: normal;">If equity research analysts do not publish research or reports about our business or if they issue unfavorable commentary or downgrade our ordinary shares, the price of our ordinary shares could decline. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The trading market for our ordinary shares relies in part on the research and reports that equity research analysts publish about us and our business, if at all. We do not have control over these analysts, and we do not have commitments from them to write research reports about us. The price of our ordinary shares could decline if no research reports are published about us or our business, or if one or more equity research analysts downgrade our ordinary shares or if those analysts issue other unfavorable commentary or cease publishing reports about us or our business. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Calibri;text-transform:none;font-variant: normal;">Our business could be negatively affected as a result of actions of activist shareholders, and such activism could impact the trading value of our securities.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Shareholders may, from time to time, engage in proxy solicitations or advance stockholder proposals, or otherwise attempt to effect changes and assert influence on our board of directors and management. Activist campaigns that contest or conflict with our strategic direction or seek changes in the composition of our board of directors could have an adverse effect on our operating results and financial condition. A proxy contest would require us to incur significant legal and advisory fees, proxy solicitation expenses and administrative and associated costs and require significant time and attention by our board of directors and management, diverting their attention from the pursuit of our business strategy. Any perceived uncertainties as to our future direction and control, our ability to execute on our strategy, or changes to the composition of our board of directors or senior management team arising from a proxy contest could lead to the perception of a change in the direction of our business or instability which may result in the loss of potential business opportunities, make it more difficult to pursue our strategic initiatives, or limit our ability to attract and retain qualified personnel and business partners, any of which could adversely affect our business and operating results. If individuals are ultimately elected to our board of directors with a specific agenda, it may adversely affect our ability to effectively implement our business strategy and create additional value for our stockholders. We may choose to initiate, or may become subject to, litigation as a result of the proxy contest or matters arising from the proxy contest, which would serve as a further distraction to our board of directors and management and would require us to incur significant additional costs. In addition, actions such as those described above could cause significant fluctuations in our stock price based upon temporary or speculative market perceptions or other factors that do not necessarily reflect the underlying fundamentals and prospects of our business.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_2_UNREGISTERED_SALES_EQUITY_SECURIT">Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">None.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_3_DEFAULTS_UPON_SENIOR_SECURITIES">Item 3. Defaults Upon Senior Securities.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">None.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">81</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_4_MINE_SAFETY_DISCLOSURES"><span style="font-weight:bold;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Item 4. Mine Saf</span><span style="font-weight:bold;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">ety Disclosures.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">None.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_5_OR_INFORMATION">Item 5. Other Information.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">None.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">82</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_6_EXHIBITS">Item 6. Exhibits.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following exhibits are filed as part of this report:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">Exhibit</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">Number</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.96%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:91.96%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">Description</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:91.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">&#160;&#160;&#160;&#160;3.1</span></p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:91.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001668243/000119312517175069/d401998dex31.htm"><span style="text-decoration:underline;">Articles of Association of the Registrant (incorporated by reference to Exhibit 3.1 to the Form 6-K filed on May 18, 2017).</span></a></p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:91.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">&#160;&#160;10.1</span></p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:91.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="urgn-ex101_102.htm"><span style="text-decoration:underline;">Omnibus Amendment to Equity Awards between the Company and Elizabeth Barrett, dated January 19, 2021</span></a></p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:91.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">&#160;&#160;10.2</span></p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:91.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="urgn-ex102_101.htm"><span style="text-decoration:underline;">Amendment 1 to Employment Agreement between the Company and Elizabeth Barrett, dated January 26, 2021</span></a></p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:91.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">&#160;&#160;10.3</span></p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:91.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="urgn-ex103_100.htm"><span style="text-decoration:underline;">Amendment 1 to Employment Agreement between the Company and Mark Schoenberg, dated January 26, 2021</span></a></p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:91.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">&#160;&#160;10.4</span></p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:91.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="urgn-ex104_98.htm"><span style="text-decoration:underline;">Amendment 1 to Employment Agreement between the Company and Jason Smith, dated January 26, 2021</span></a></p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:91.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">&#160;&#160;10.5</span></p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:91.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="urgn-ex105_99.htm"><span style="text-decoration:underline;">Amendment 2 to Employment Agreement between the Company and Mark Schoenberg, dated March 15, 2021</span></a></p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:91.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">&#160;&#160;10.6</span></p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:91.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="urgn-ex106_433.htm"><span style="text-decoration:underline;">Pre-Paid Forward Contract by and among the Registrant and RTW Investments ICAV for and on behalf of RTW Fund 2, dated as of March 18, 2021, as amended.</span></a></p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:91.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">&#160;&#160;31.1</span></p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:91.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="urgn-ex311_11.htm"><span style="text-decoration:underline;">Certification of Principal Executive Officer pursuant to Rules 13a-14(a) or 15d-14(a) under the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</span></a></p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:91.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">&#160;&#160;31.2</span></p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:91.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="urgn-ex312_6.htm"><span style="text-decoration:underline;">Certification of Principal Financial Officer pursuant to Rules 13a-14(a) or 15d-14(a) under the Securities Exchange Act of 1934, as amended, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</span></a></p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:91.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">&#160;&#160;32.1#</span></p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:91.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="urgn-ex321_7.htm"><span style="text-decoration:underline;">Certification of Principal Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</span></a></p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:91.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">&#160;&#160;32.2#</span></p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:91.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="urgn-ex322_9.htm"><span style="text-decoration:underline;">Certification of Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</span></a></p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:91.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">101.INS</span></p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:91.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inline XBRL Instance Document &#8211; The instance document does not appear in the interactive data file because its XBRL tags are embedded within the Inline XBRL document</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:91.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">101.SCH</span></p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:91.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inline XBRL Taxonomy Extension Schema Document</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:91.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">101.CAL</span></p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:91.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inline XBRL Taxonomy Extension Calculation Linkbase Document</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:91.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">101.DEF</span></p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:91.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inline XBRL Taxonomy Extension Definition Linkbase Document</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:91.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">101.LAB</span></p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:91.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inline XBRL Taxonomy Extension Label Linkbase Document</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:91.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">101.PRE</span></p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:91.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">Inline XBRL Taxonomy Extension Presentation Linkbase Document</span></p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:91.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">104</span></p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:91.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">The cover page from the Company&#8217;s Quarterly Report on Form 10-Q has been formatted in Inline XBRL</span></p></td>
</tr>
</table></div>
<p style="border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-right:86.67%;text-indent:0%;font-family:Times New Roman;font-size:6pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.8%;white-space:nowrap">
<p style="margin-top:2pt;margin-bottom:0pt;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">#</span></p></td>
<td valign="top">
<p style="margin-top:2pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:10pt;">The information in Exhibits 32.1 and 32.2 shall not be deemed &#8220;filed&#8221; for purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act or the Exchange Act (including this Quarterly Report), unless the Registrant specifically incorporates the foregoing information into those documents by reference.</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:-4.54%;font-family:Times New Roman;font-size:12pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">83</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="SIGNATURES">Signatures</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">UroGen Pharma Ltd.</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:45.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">May 13, 2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.46%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/&#160;Elizabeth Barrett</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.46%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Elizabeth Barrett</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Chief Executive Officer</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(Principal Executive Officer)</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:45.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">May 13, 2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.46%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/&#160;Molly Henderson</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.46%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Molly Henderson</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Chief Financial Officer</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(Principal Financial and Accounting Officer)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">84</p></body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>urgn-ex101_102.htm
<DESCRIPTION>EX-10.1
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
urgn-ex101_102.htm
</title>
</head>
<!-- NG Converter v5.0.2.50 -->
<body>

<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 10.1</p>
<p style="margin-top:4pt;text-align:center;margin-bottom:0pt;margin-left:23.78%;margin-right:27.31%;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">UROGEN<font style="letter-spacing:-0.1pt;"> </font>PHARMA<font style="letter-spacing:-0.1pt;"> </font>LTD.</p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;;font-size:15.5pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:23.78%;margin-right:27.5%;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">OMNIBUS<font style="letter-spacing:-0.15pt;"> </font>AMENDMENT<font style="letter-spacing:-0.15pt;"> </font>TO<font style="letter-spacing:-0.05pt;"> </font>EQUITY<font style="letter-spacing:-0.1pt;"> </font>AWARDS</p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;;font-size:15.5pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:0pt;margin-bottom:0pt;margin-left:2.16%;margin-right:5.7%;text-indent:7.06%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This<font style="letter-spacing:0.05pt;"> </font>Omnibus<font style="letter-spacing:0.05pt;"> </font>Amendment<font style="letter-spacing:0.05pt;"> </font>to<font style="letter-spacing:0.05pt;"> </font>those<font style="letter-spacing:0.05pt;"> </font>certain<font style="letter-spacing:0.05pt;"> </font>Stock<font style="letter-spacing:0.05pt;"> </font>Option<font style="letter-spacing:0.05pt;"> </font>Agreements<font style="letter-spacing:0.05pt;"> </font>and<font style="letter-spacing:0.05pt;"> </font>RSU<font style="letter-spacing:0.05pt;"> </font>Award<font style="letter-spacing:0.05pt;"> </font>Agreements (each as defined below) (this &#8220;<font style="font-weight:bold;font-style:italic;">Amendment</font>&#8221;) is entered into by and between <font style="font-weight:bold;">E</font><font style="font-weight:bold;font-size:9pt;">LIZABETH</font><font style="font-weight:bold;font-size:9pt;letter-spacing:0.05pt;"> </font><font style="font-weight:bold;">B</font><font style="font-weight:bold;font-size:9pt;">ARRETT</font><font style="font-weight:bold;font-size:9pt;letter-spacing:0.05pt;"> </font>and<font style="letter-spacing:0.05pt;"> </font><font style="font-weight:bold;">U</font><font style="font-weight:bold;font-size:9pt;">RO</font><font style="font-weight:bold;">G</font><font style="font-weight:bold;font-size:9pt;">EN</font><font style="font-weight:bold;font-size:9pt;letter-spacing:0.05pt;"> </font><font style="font-weight:bold;">P</font><font style="font-weight:bold;font-size:9pt;">HARMA</font><font style="font-weight:bold;font-size:9pt;letter-spacing:0.05pt;"> </font><font style="font-weight:bold;">L</font><font style="font-weight:bold;font-size:9pt;">TD</font>.<font style="letter-spacing:0.05pt;"> </font>(the<font style="letter-spacing:0.05pt;"> </font>&#8220;<font style="font-weight:bold;font-style:italic;">Company</font>&#8221;),<font style="letter-spacing:0.05pt;"> </font>effective<font style="letter-spacing:0.05pt;"> </font>as<font style="letter-spacing:0.05pt;"> </font>of<font style="letter-spacing:0.05pt;"> </font>January<font style="letter-spacing:0.05pt;"> </font>19,<font style="letter-spacing:2.8pt;"> </font>2021<font style="letter-spacing:0.05pt;"> </font>(&#8220;<font style="font-weight:bold;font-style:italic;">Amendment Effective Date</font>&#8221;). Capitalized terms used but not defined herein will have the meanings<font style="letter-spacing:0.05pt;"> </font>given<font style="letter-spacing:-0.2pt;"> </font>to<font style="letter-spacing:-0.15pt;"> </font>them<font style="letter-spacing:0.05pt;"> </font>in the respective<font style="letter-spacing:-0.05pt;"> </font>Equity Awards (as defined below).</p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:2.15%;margin-right:5.7%;text-indent:7.07%;font-weight:bold;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">W<font style="font-size:9pt;">HEREAS</font><font style="font-weight:normal;">,</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">the</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">Company</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">granted</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">to</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">Ms.</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">Barrett</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">certain</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">options</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">to</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">purchase</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">shares</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">of</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">the</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">Company&#8217;s Ordinary Shares pursuant to the Company&#8217;s 2017 Equity Incentive Plan, as amended (the</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">&#8220;</font><font style="font-style:italic;">Plan</font><font style="font-weight:normal;">&#8221;), and those certain Notices of Stock Option Grant (the &#8220;</font><font style="font-style:italic;">Stock Option Grant Notices</font><font style="font-weight:normal;">&#8221;) and Stock</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">Option Agreements and the exhibits and attachments attached thereto (the &#8220;</font><font style="font-style:italic;">Stock Option Agreements</font><font style="font-weight:normal;">&#8221;),</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">with</font><font style="letter-spacing:-0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">details as set forth on</font><font style="letter-spacing:-0.15pt;font-weight:normal;"> </font>Exhibit A<font style="letter-spacing:-0.05pt;"> </font><font style="font-weight:normal;">(collectively,</font><font style="letter-spacing:-0.15pt;font-weight:normal;"> </font><font style="font-weight:normal;">the</font><font style="letter-spacing:-0.1pt;font-weight:normal;"> </font><font style="font-weight:normal;">&#8220;</font><font style="font-style:italic;">Option</font><font style="font-style:italic;letter-spacing:-0.1pt;"> </font><font style="font-style:italic;">Grants</font><font style="font-weight:normal;">&#8221;);</font></p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:10.5pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:2.16%;margin-right:5.7%;text-indent:7.06%;font-weight:bold;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">W<font style="font-size:9pt;">HEREAS</font><font style="font-weight:normal;">, the Company awarded to Ms. Barrett certain Restricted Stock Unit (&#8220;</font><font style="font-style:italic;">RSU</font><font style="font-weight:normal;">&#8221;) Awards</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">to receive shares the Company&#8217;s Ordinary Shares pursuant to the Plan and those certain Notices of RSU</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">Grant (the &#8220;</font><font style="font-style:italic;">Restricted Stock Unit Grant Notices</font><font style="font-weight:normal;">&#8221;), and the RSU Award Agreements and the exhibits and</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">attachments attached thereto (the &#8220;</font><font style="font-style:italic;">RSU Award Agreements</font><font style="font-weight:normal;">&#8221;), with details as set forth on </font>Exhibit A <font style="font-weight:normal;">(the</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">&#8220;</font><font style="font-style:italic;">Award</font><font style="font-style:italic;letter-spacing:-0.05pt;"> </font><font style="font-style:italic;">Agreements</font><font style="font-weight:normal;">&#8221; and</font><font style="letter-spacing:-0.2pt;font-weight:normal;"> </font><font style="font-weight:normal;">with</font><font style="letter-spacing:-0.15pt;font-weight:normal;"> </font><font style="font-weight:normal;">the Option</font><font style="letter-spacing:-0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">Grants,</font><font style="letter-spacing:-0.15pt;font-weight:normal;"> </font><font style="font-weight:normal;">collectively</font><font style="letter-spacing:-0.15pt;font-weight:normal;"> </font><font style="font-weight:normal;">the</font><font style="letter-spacing:-0.15pt;font-weight:normal;"> </font><font style="font-weight:normal;">&#8220;</font><font style="font-style:italic;">Equity Awards</font><font style="font-weight:normal;">&#8221;);</font></p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:2.15%;margin-right:5.7%;text-indent:7.07%;font-weight:bold;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">W<font style="font-size:9pt;">HEREAS</font><font style="font-weight:normal;">, the Company and Ms. Barrett desire to amend the &#8220;Vesting Schedule&#8221; of the Equity</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">Awards;</font></p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:0pt;margin-bottom:0pt;margin-left:2.15%;margin-right:5.7%;text-indent:7.07%;font-weight:bold;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">W<font style="font-size:9pt;">HEREAS</font><font style="font-weight:normal;">, the Board of Directors of the Company has approved this Amendment to modify the</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">&#8220;Vesting</font><font style="letter-spacing:-0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">Schedule&#8221;</font><font style="letter-spacing:-0.1pt;font-weight:normal;"> </font><font style="font-weight:normal;">of</font><font style="letter-spacing:-0.1pt;font-weight:normal;"> </font><font style="font-weight:normal;">the</font><font style="letter-spacing:-0.1pt;font-weight:normal;"> </font><font style="font-weight:normal;">Equity Awards;</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">and</font></p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:0pt;margin-bottom:0pt;margin-left:2.15%;margin-right:5.7%;text-indent:7.07%;font-weight:bold;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">W<font style="font-size:9pt;">HEREAS</font><font style="font-weight:normal;">, Ms. Barrett acknowledges that he or she has been advised to seek personal tax advice</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">prior to entering</font><font style="letter-spacing:-0.15pt;font-weight:normal;"> </font><font style="font-weight:normal;">into this Amendment.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:2.16%;margin-right:5.7%;text-indent:7.06%;font-weight:bold;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">N<font style="font-size:9pt;">OW</font><font style="font-weight:normal;">,</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font>T<font style="font-size:9pt;">HEREFORE</font><font style="font-weight:normal;">,</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">in</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">consideration</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">of</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">the</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">mutual</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">promises,</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">covenants</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">and</font><font style="letter-spacing:2.75pt;font-weight:normal;"> </font><font style="font-weight:normal;">conditions</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">hereinafter set forth, and for other good and valuable consideration, receipt and sufficiency of which are</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">hereby</font><font style="letter-spacing:-0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">acknowledged,</font><font style="letter-spacing:-0.15pt;font-weight:normal;"> </font><font style="font-weight:normal;">the</font><font style="letter-spacing:-0.1pt;font-weight:normal;"> </font><font style="font-weight:normal;">parties hereto mutually agree as</font><font style="letter-spacing:-0.15pt;font-weight:normal;"> </font><font style="font-weight:normal;">follows:</font></p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:94.3%;">
<tr>
<td valign="top" style="width:7.07%;white-space:nowrap">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;text-indent:7.07%;font-weight:bold;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">1.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;text-indent:7.07%;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="text-decoration:underline;">Amendment to Vesting Schedule</font><font style="font-weight:normal;">:</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">The &#8220;Vesting Schedule&#8221; set forth in each Equity</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">Award is hereby amended and restated and shall read in its entirety as set forth on </font>E<font style="font-size:9pt;">XHIBIT </font>A <font style="font-weight:normal;">hereto. For</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">the avoidance of doubt, Ms. Barrett acknowledges and agrees that the vesting provisions of the Equity</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">Awards set forth in Section 4.1 of her Executive Employment Agreement, dated January 3, 2019, with</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">UroGen Pharma, Inc., a wholly owned subsidiary of the Company (the &#8220;</font><font style="font-style:italic;">Employment Agreement</font><font style="font-weight:normal;">&#8221;), are</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">superseded</font><font style="letter-spacing:-0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">by</font><font style="letter-spacing:-0.15pt;font-weight:normal;"> </font><font style="font-weight:normal;">the vesting</font><font style="letter-spacing:-0.15pt;font-weight:normal;"> </font><font style="font-weight:normal;">provisions set</font><font style="letter-spacing:-0.1pt;font-weight:normal;"> </font><font style="font-weight:normal;">forth</font><font style="letter-spacing:-0.15pt;font-weight:normal;"> </font><font style="font-weight:normal;">in this Amendment.</font></p></td>
<td valign="top" style="width:5.7%;white-space:nowrap">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;text-indent:7.07%;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td></tr></table></div>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:94.3%;">
<tr>
<td valign="top" style="width:7.07%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:7.07%;font-weight:bold;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">2.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:7.07%;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="text-decoration:underline;">Entire Agreement; Counterparts</font><font style="font-weight:normal;">.</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">Except as explicitly modified herein, each Equity</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">Award shall remain in full force and effect.</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">In the event of any conflict between this Amendment and the</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">Equity Awards, this Amendment shall govern.</font><font style="letter-spacing:2.8pt;font-weight:normal;"> </font><font style="font-weight:normal;">This Amendment and each Equity Award, with the</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">exhibits attached thereto, and, except as specified in Section 1 hereof, the Employment Agreement,</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">constitute the entire agreement between Ms. Barrett and the Company regarding the terms and conditions</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">of the respective Equity Awards.</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">This Amendment supersedes all prior negotiations, representations or</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">agreements between Ms. Barrett and the Company, whether written or oral, concerning the modifications</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">of</font><font style="letter-spacing:0.65pt;font-weight:normal;"> </font><font style="font-weight:normal;">each</font><font style="letter-spacing:0.65pt;font-weight:normal;"> </font><font style="font-weight:normal;">Equity</font><font style="letter-spacing:0.65pt;font-weight:normal;"> </font><font style="font-weight:normal;">Award</font><font style="letter-spacing:0.6pt;font-weight:normal;"> </font><font style="font-weight:normal;">set</font><font style="letter-spacing:0.6pt;font-weight:normal;"> </font><font style="font-weight:normal;">forth</font><font style="letter-spacing:0.55pt;font-weight:normal;"> </font><font style="font-weight:normal;">herein.</font><font style="letter-spacing:1.35pt;font-weight:normal;"> </font><font style="font-weight:normal;">This</font><font style="letter-spacing:0.55pt;font-weight:normal;"> </font><font style="font-weight:normal;">Amendment</font><font style="letter-spacing:0.55pt;font-weight:normal;"> </font><font style="font-weight:normal;">may</font><font style="letter-spacing:0.65pt;font-weight:normal;"> </font><font style="font-weight:normal;">be</font><font style="letter-spacing:0.55pt;font-weight:normal;"> </font><font style="font-weight:normal;">executed</font><font style="letter-spacing:0.55pt;font-weight:normal;"> </font><font style="font-weight:normal;">in</font><font style="letter-spacing:0.5pt;font-weight:normal;"> </font><font style="font-weight:normal;">counterparts,</font><font style="letter-spacing:0.65pt;font-weight:normal;"> </font><font style="font-weight:normal;">including</font><font style="letter-spacing:0.65pt;font-weight:normal;"> </font><font style="font-weight:normal;">by</font></p></td>
<td valign="top" style="width:5.7%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:7.07%;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 10.1</p>
<p style="margin-top:4pt;margin-bottom:0pt;margin-left:2.16%;margin-right:2.55%;text-indent:0%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU2"></a><font style="font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">facsimile</font><font style="letter-spacing:2.05pt;"> </font><font style="font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or</font><font style="letter-spacing:2.15pt;"> </font><font style="font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">portable</font><font style="letter-spacing:2.1pt;"> </font><font style="font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">document</font><font style="letter-spacing:2.1pt;"> </font><font style="font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">format</font><font style="letter-spacing:2.15pt;"> </font><font style="font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(.PDF),</font><font style="letter-spacing:2.1pt;"> </font><font style="font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">each</font><font style="letter-spacing:2.05pt;"> </font><font style="font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of</font><font style="letter-spacing:2.15pt;"> </font><font style="font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">which</font><font style="letter-spacing:2.2pt;"> </font><font style="font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">shall</font><font style="letter-spacing:2.1pt;"> </font><font style="font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">constitute</font><font style="letter-spacing:2.1pt;"> </font><font style="font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">an</font><font style="letter-spacing:2.1pt;"> </font><font style="font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">original</font><font style="letter-spacing:2.1pt;"> </font><font style="font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and</font><font style="letter-spacing:2.2pt;"> </font><font style="font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">which</font><font style="letter-spacing:-2.6pt;"> </font><font style="font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">together shall</font><font style="letter-spacing:0.05pt;"> </font><font style="font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">constitute one and</font><font style="letter-spacing:-0.15pt;"> </font><font style="font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the</font><font style="letter-spacing:-0.1pt;"> </font><font style="font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">same instrument.</font></p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:10.5pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:23.78%;margin-right:27.31%;text-indent:0%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[Signature<font style="letter-spacing:-0.1pt;"> </font>Page<font style="letter-spacing:-0.05pt;"> </font>Follows]</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:8.5pt;">&nbsp;</p>
<p style="text-align:center;margin-top:4pt;margin-bottom:0pt;margin-left:23.78%;margin-right:27.31%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">- 2<font style="letter-spacing:0.05pt;"> </font>-</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 10.1</p>
<p style="margin-top:4pt;margin-bottom:0pt;margin-left:2.16%;margin-right:2.55%;text-indent:7.06%;font-weight:bold;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU3"></a><font style="font-weight:bold;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">I</font><font style="font-size:9pt;">N</font><font style="font-size:9pt;letter-spacing:0.35pt;"> </font><font style="font-weight:bold;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">W</font><font style="font-size:9pt;">ITNESS</font><font style="font-size:9pt;letter-spacing:0.35pt;"> </font><font style="font-weight:bold;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">W</font><font style="font-size:9pt;">HEREOF</font><font style="font-weight:normal;">,</font><font style="letter-spacing:0.4pt;font-weight:normal;"> </font><font style="font-weight:normal;">the</font><font style="letter-spacing:0.4pt;font-weight:normal;"> </font><font style="font-weight:normal;">parties</font><font style="letter-spacing:0.45pt;font-weight:normal;"> </font><font style="font-weight:normal;">hereto</font><font style="letter-spacing:0.35pt;font-weight:normal;"> </font><font style="font-weight:normal;">have</font><font style="letter-spacing:0.3pt;font-weight:normal;"> </font><font style="font-weight:normal;">caused</font><font style="letter-spacing:0.4pt;font-weight:normal;"> </font><font style="font-weight:normal;">this</font><font style="letter-spacing:0.4pt;font-weight:normal;"> </font><font style="font-weight:normal;">Amendment</font><font style="letter-spacing:0.45pt;font-weight:normal;"> </font><font style="font-weight:normal;">to</font><font style="letter-spacing:0.2pt;font-weight:normal;"> </font><font style="font-weight:normal;">Equity</font><font style="letter-spacing:0.4pt;font-weight:normal;"> </font><font style="font-weight:normal;">Awards</font><font style="letter-spacing:0.25pt;font-weight:normal;"> </font><font style="font-weight:normal;">to</font><font style="letter-spacing:0.4pt;font-weight:normal;"> </font><font style="font-weight:normal;">be</font><font style="letter-spacing:-2.6pt;font-weight:normal;"> </font><font style="font-weight:normal;">duly</font><font style="letter-spacing:-0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">executed</font><font style="letter-spacing:-0.15pt;font-weight:normal;"> </font><font style="font-weight:normal;">as of</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">the Amendment</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">Effective Date.</font></p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:15.5pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:44.6%;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">U<font style="font-size:9pt;">RO</font>G<font style="font-size:9pt;">EN</font><font style="font-size:9pt;letter-spacing:-0.1pt;"> </font>P<font style="font-size:9pt;">HARMA</font><font style="font-size:9pt;letter-spacing:-0.05pt;"> </font>L<font style="font-size:9pt;">TD</font>.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:12pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:44.59%;white-space:nowrap">
<p style="margin-top:10pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="margin-top:10pt;margin-bottom:0pt;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</font></p></td>
<td valign="top">
<p style="margin-top:10pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="text-decoration:underline;">/s/ Molly Henderson</font> Molly<font style="letter-spacing:-0.05pt;"> </font>Henderson</p></td>
<td valign="top" style="width:6.68%;white-space:nowrap">
<p style="margin-top:10pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td></tr></table></div>
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:49.03%;text-indent:0%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Chief<font style="letter-spacing:-0.05pt;"> </font>Financial Officer</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="margin-top:7pt;margin-bottom:0pt;margin-left:44.59%;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">E<font style="font-size:9pt;">LIZABETH</font><font style="font-size:9pt;letter-spacing:-0.15pt;"> </font>B<font style="font-size:9pt;">ARRETT</font><font style="font-weight:normal;">:</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="margin-top:10pt;margin-bottom:0pt;margin-left:44.59%;text-indent:0%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By: <font style="letter-spacing:-0.3pt;"> </font><font style="text-decoration:underline;"> /s/ Elizabeth Barrett</font><font style="text-decoration:underline;margin-left:474pt;"></font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;">&nbsp;</p>
<p style="text-align:center;margin-top:4pt;margin-bottom:0pt;margin-left:23.78%;margin-right:20.43%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">- 3<font style="letter-spacing:0.05pt;"> </font>-</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 10.1</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:1pt;margin-top:4pt;margin-left:40.21%;margin-right:43.81%;text-indent:0.02%;font-weight:bold;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">E<font style="font-size:9pt;">XHIBIT </font>A<font style="letter-spacing:0.05pt;"> </font><font style="letter-spacing:-0.05pt;">E</font><font style="font-size:9pt;letter-spacing:-0.05pt;">QUITY</font><font style="font-size:9pt;letter-spacing:-0.55pt;"> </font>A<font style="font-size:9pt;">WARDS</font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse;  margin-left:1.15%;width:497.5pt;;">
<tr>
<td style="width:43.2pt;"></td>
<td style="width:55.55pt;"></td>
<td style="width:82.55pt;"></td>
<td style="width:143.65pt;"></td>
<td style="width:172.55pt;"></td>
</tr>
<tr style="height:37.85pt;">
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.35pt;;margin-right:0.59%;text-indent:0.2pt;;font-weight:bold;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Equity<font style="letter-spacing:-2.6pt;"> </font>Award</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:16.65pt;;margin-right:2.36%;text-indent:-3.4pt;;font-weight:bold;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Grant<font style="letter-spacing:-0.15pt;"> </font>Date</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:19.15pt;;margin-right:1.18%;text-indent:-11.65pt;;font-weight:bold;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Total Number<font style="letter-spacing:-2.6pt;"> </font>of Shares</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:5.85pt;;margin-right:0.98%;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Number of Unvested Shares<font style="letter-spacing:-2.6pt;"> </font>(as<font style="letter-spacing:-0.05pt;"> </font>of the Amendment</p>
<p style="text-align:center;line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:5.7pt;;margin-right:0.98%;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Effective<font style="letter-spacing:-0.05pt;"> </font>Date)</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:45.95pt;;margin-right:5.89%;text-indent:-14.55pt;;font-weight:bold;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Amended and Restated<font style="letter-spacing:-2.6pt;"> </font>Vesting<font style="letter-spacing:-0.05pt;"> </font>Schedule</p></td>
</tr>
<tr style="height:25.3pt;">
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-top:6pt;margin-bottom:0pt;margin-left:5.25pt;;margin-right:0.79%;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Option</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-top:6pt;margin-bottom:0pt;margin-left:4.4pt;;margin-right:0.59%;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1/3/2019</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-top:6pt;margin-bottom:0pt;margin-left:22.3pt;;margin-right:4.13%;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">277,432</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:right;margin-top:5pt;margin-bottom:0pt;margin-left:0pt;;margin-right:11%;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">92,478</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:33.95pt;;margin-right:2.36%;text-indent:-20.05pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The unvested shares shall vest in<font style="letter-spacing:-2.6pt;"> </font>full<font style="letter-spacing:0.05pt;"> </font>on<font style="letter-spacing:-0.15pt;"> </font>January 3,<font style="letter-spacing:-0.15pt;"> </font>2022.</p></td>
</tr>
<tr style="height:63.1pt;">
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:12pt;">&nbsp;</p>
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:9.5pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:5.25pt;;margin-right:0.79%;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Option</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:12pt;">&nbsp;</p>
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:9.5pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:4.4pt;;margin-right:0.59%;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1/31/2020</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:12pt;">&nbsp;</p>
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:9.5pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:22.3pt;;margin-right:4.13%;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">45,000</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:12pt;">&nbsp;</p>
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:9.5pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:11%;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">45,000</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:8.1pt;;margin-right:1.18%;text-indent:-1.2pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1/3 of the unvested shares shall vest<font style="letter-spacing:-2.6pt;"> </font>on January 31, 2021, and 1/3 of the<font style="letter-spacing:-2.6pt;"> </font>unvested<font style="letter-spacing:-0.2pt;"> </font>shares<font style="letter-spacing:-0.1pt;"> </font>shall<font style="letter-spacing:0.05pt;"> </font>vest<font style="letter-spacing:-0.15pt;"> </font>annually</p>
<p style="text-align:justify;line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:73.15pt;;margin-right:1.38%;text-indent:-65.1pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">thereafter for the remaining two (2)<font style="letter-spacing:-2.6pt;"> </font>years.</p></td>
</tr>
<tr style="height:25.2pt;">
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-top:6pt;margin-bottom:0pt;margin-left:5.25pt;;margin-right:0.79%;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">RSU</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-top:6pt;margin-bottom:0pt;margin-left:4.4pt;;margin-right:0.59%;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1/3/2019</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-top:6pt;margin-bottom:0pt;margin-left:22.3pt;;margin-right:4.13%;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">317,065</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;margin-right:10.41%;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">105,689</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:33.95pt;;margin-right:2.36%;text-indent:-20.05pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The unvested shares shall vest in<font style="letter-spacing:-2.6pt;"> </font>full<font style="letter-spacing:0.05pt;"> </font>on<font style="letter-spacing:-0.15pt;"> </font>January 3,<font style="letter-spacing:-0.15pt;"> </font>2022.</p></td>
</tr>
<tr style="height:50.6pt;">
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:16.5pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:5.25pt;;margin-right:0.79%;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">RSU</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:16.5pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:4.4pt;;margin-right:0.59%;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1/31/2020</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:16.5pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:22.3pt;;margin-right:4.13%;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,000</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:12pt;">&nbsp;</p>
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:9.5pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:11%;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,000</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-top:0pt;margin-bottom:0pt;margin-left:7.55pt;;margin-right:1.18%;text-indent:-0.65pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1/3 of the unvested shares shall vest<font style="letter-spacing:-2.6pt;"> </font>on January 31, 2021, and 1/3 of the<font style="letter-spacing:-2.6pt;"> </font>shares<font style="letter-spacing:-0.1pt;"> </font>shall<font style="letter-spacing:-0.05pt;"> </font>vest<font style="letter-spacing:-0.2pt;"> </font>annually<font style="letter-spacing:-0.1pt;"> </font>thereafter</p>
<p style="text-align:justify;line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:16.15pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">for<font style="letter-spacing:-0.1pt;"> </font>the<font style="letter-spacing:-0.1pt;"> </font>remaining two<font style="letter-spacing:-0.15pt;"> </font>(2)<font style="letter-spacing:-0.05pt;"> </font>years.</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-top:9pt;margin-bottom:0pt;margin-left:23.78%;margin-right:27.31%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">- 4<font style="letter-spacing:0.05pt;"> </font>-</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.2
<SEQUENCE>3
<FILENAME>urgn-ex102_101.htm
<DESCRIPTION>EX-10.2
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
urgn-ex102_101.htm
</title>
</head>
<!-- NG Converter v5.0.2.50 -->
<body>

<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 10.2</p>
<p style="margin-top:4pt;margin-bottom:0pt;margin-left:22.36%;text-indent:0%;font-family:Times New Roman;font-size:11pt;"><a name="AMENDMENT_NO._1_TO_EXECUTIVE_EMPLOYMENT_"></a>&nbsp;</p>
<p style="margin-top:4pt;margin-bottom:0pt;margin-left:22.36%;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">AMENDMENT<font style="letter-spacing:-0.25pt;"> </font>NO.<font style="letter-spacing:-0.2pt;"> </font>1<font style="letter-spacing:-0.2pt;"> </font>TO<font style="letter-spacing:-0.15pt;"> </font>EXECUTIVE<font style="letter-spacing:-0.2pt;"> </font>EMPLOYMENT<font style="letter-spacing:-0.25pt;"> </font>AGREEMENT</p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:10.32%;margin-right:0.92%;text-indent:6.64%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This<font style="letter-spacing:0.05pt;"> </font>Amendment<font style="letter-spacing:0.05pt;"> </font>No.<font style="letter-spacing:0.05pt;"> </font>1<font style="letter-spacing:0.05pt;"> </font>(this<font style="letter-spacing:0.05pt;"> </font>&#8220;Amendment&#8221;)<font style="letter-spacing:0.05pt;"> </font>to<font style="letter-spacing:0.05pt;"> </font>that<font style="letter-spacing:0.05pt;"> </font>certain<font style="letter-spacing:0.05pt;"> </font>Executive<font style="letter-spacing:0.05pt;"> </font>Employment<font style="letter-spacing:0.05pt;"> </font>Agreement, effective January 3, 2019, by and between Elizabeth Barrett (the &#8220;<font style="text-decoration:underline;">Executive</font>&#8221;) and<font style="letter-spacing:0.05pt;"> </font>UroGen Pharma, Inc., a wholly owned subsidiary (the &#8220;<font style="text-decoration:underline;">Subsidiary</font>&#8221;) of UroGen Pharma, Ltd. (the<font style="letter-spacing:0.05pt;"> </font>&#8220;<font style="text-decoration:underline;">Parent</font>&#8221;)<font style="letter-spacing:0.1pt;"> </font>(the<font style="letter-spacing:1.25pt;"> </font>Subsidiary<font style="letter-spacing:1.25pt;"> </font>and<font style="letter-spacing:1.3pt;"> </font>the<font style="letter-spacing:1.05pt;"> </font>Parent<font style="letter-spacing:1.3pt;"> </font>together,<font style="letter-spacing:1.15pt;"> </font>the<font style="letter-spacing:1.3pt;"> </font>&#8220;<font style="text-decoration:underline;">Company</font>&#8221;)<font style="letter-spacing:1.2pt;"> </font>is<font style="letter-spacing:1.3pt;"> </font>entered<font style="letter-spacing:1.2pt;"> </font>into<font style="letter-spacing:1.3pt;"> </font>as<font style="letter-spacing:1.25pt;"> </font>of<font style="letter-spacing:1.25pt;"> </font>this<font style="letter-spacing:1.25pt;"> </font>26th<font style="letter-spacing:-2.9pt;"> </font>day<font style="letter-spacing:0.05pt;"> </font>of<font style="letter-spacing:0.05pt;"> </font>January 2021. The Subsidiary, Parent and Executive are collectively referred to in this<font style="letter-spacing:0.05pt;"> </font>Amendment<font style="letter-spacing:-0.8pt;"> </font>as &#8220;<font style="text-decoration:underline;">the</font><font style="text-decoration:underline;letter-spacing:-0.05pt;"> </font><font style="text-decoration:underline;">Parties</font>.&#8221;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;margin-top:0pt;margin-bottom:0pt;margin-left:10.33%;margin-right:0.92%;text-indent:6.64%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">W<font style="font-size:9.5pt;">HEREAS</font><font style="font-weight:normal;">,</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">the</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">Parent</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">and</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">Executive</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">are</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">Parties</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">to</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">a</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">certain</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">Executive</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">Employment</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">Agreement</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">effective</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">January</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">3,</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">2019</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">(the</font><font style="letter-spacing:3pt;font-weight:normal;"> </font><font style="font-weight:normal;">&#8220;Agreement)</font><font style="letter-spacing:3pt;font-weight:normal;"> </font><font style="font-weight:normal;">(capitalized</font><font style="letter-spacing:3pt;font-weight:normal;"> </font><font style="font-weight:normal;">terms</font><font style="letter-spacing:3pt;font-weight:normal;"> </font><font style="font-weight:normal;">used</font><font style="letter-spacing:3pt;font-weight:normal;"> </font><font style="font-weight:normal;">and</font><font style="letter-spacing:3pt;font-weight:normal;"> </font><font style="font-weight:normal;">not</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">otherwise</font><font style="letter-spacing:1.25pt;font-weight:normal;"> </font><font style="font-weight:normal;">defined</font><font style="letter-spacing:-0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">herein</font><font style="letter-spacing:-0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">shall</font><font style="letter-spacing:-0.1pt;font-weight:normal;"> </font><font style="font-weight:normal;">have</font><font style="letter-spacing:-0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">the</font><font style="letter-spacing:-0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">meanings</font><font style="letter-spacing:-0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">given</font><font style="letter-spacing:-0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">to</font><font style="letter-spacing:-0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">such</font><font style="letter-spacing:-0.1pt;font-weight:normal;"> </font><font style="font-weight:normal;">terms</font><font style="letter-spacing:-0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">in</font><font style="letter-spacing:-0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">the</font><font style="letter-spacing:-0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">Agreement);</font><font style="letter-spacing:-0.1pt;font-weight:normal;"> </font><font style="font-weight:normal;">and</font></p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:11.5pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:16.97%;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">W<font style="font-size:9.5pt;">HEREAS</font><font style="font-weight:normal;">,</font><font style="letter-spacing:-0.15pt;font-weight:normal;"> </font><font style="font-weight:normal;">the</font><font style="letter-spacing:-0.25pt;font-weight:normal;"> </font><font style="font-weight:normal;">Parties</font><font style="letter-spacing:-0.1pt;font-weight:normal;"> </font><font style="font-weight:normal;">wish</font><font style="letter-spacing:-0.15pt;font-weight:normal;"> </font><font style="font-weight:normal;">to</font><font style="letter-spacing:-0.1pt;font-weight:normal;"> </font><font style="font-weight:normal;">amend</font><font style="letter-spacing:-0.15pt;font-weight:normal;"> </font><font style="font-weight:normal;">the</font><font style="letter-spacing:-0.25pt;font-weight:normal;"> </font><font style="font-weight:normal;">Agreement</font><font style="letter-spacing:-0.1pt;font-weight:normal;"> </font><font style="font-weight:normal;">as</font><font style="letter-spacing:-0.15pt;font-weight:normal;"> </font><font style="font-weight:normal;">set</font><font style="letter-spacing:-0.1pt;font-weight:normal;"> </font><font style="font-weight:normal;">forth</font><font style="letter-spacing:-0.15pt;font-weight:normal;"> </font><font style="font-weight:normal;">herein.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:10.33%;margin-right:0.92%;text-indent:6.64%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">N<font style="font-size:9.5pt;">OW</font><font style="font-size:9.5pt;letter-spacing:0.05pt;"> </font>T<font style="font-size:9.5pt;">HEREFORE</font><font style="font-weight:normal;">, in consideration and in furtherance of Executive&#8217;s continued at-will</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">employment with the Company, and for other good and valuable consideration, the receipt and</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">sufficiency</font><font style="letter-spacing:-0.2pt;font-weight:normal;"> </font><font style="font-weight:normal;">of</font><font style="letter-spacing:-0.15pt;font-weight:normal;"> </font><font style="font-weight:normal;">which</font><font style="letter-spacing:-0.2pt;font-weight:normal;"> </font><font style="font-weight:normal;">is</font><font style="letter-spacing:-0.1pt;font-weight:normal;"> </font><font style="font-weight:normal;">hereby</font><font style="letter-spacing:-0.15pt;font-weight:normal;"> </font><font style="font-weight:normal;">acknowledged,</font><font style="letter-spacing:-0.15pt;font-weight:normal;"> </font><font style="font-weight:normal;">the</font><font style="letter-spacing:-0.15pt;font-weight:normal;"> </font><font style="font-weight:normal;">Parties</font><font style="letter-spacing:-0.1pt;font-weight:normal;"> </font><font style="font-weight:normal;">hereto</font><font style="letter-spacing:-0.15pt;font-weight:normal;"> </font><font style="font-weight:normal;">agree</font><font style="letter-spacing:-0.15pt;font-weight:normal;"> </font><font style="font-weight:normal;">as</font><font style="letter-spacing:-0.1pt;font-weight:normal;"> </font><font style="font-weight:normal;">follows:</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:10.33%;margin-right:0.92%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.<font style="margin-left:92pt;"></font>Section<font style="letter-spacing:0.65pt;"> </font>7.2<font style="letter-spacing:0.65pt;"> </font>of<font style="letter-spacing:0.7pt;"> </font>the<font style="letter-spacing:0.7pt;"> </font>Agreement<font style="letter-spacing:0.7pt;"> </font>is<font style="letter-spacing:0.6pt;"> </font>hereby<font style="letter-spacing:0.75pt;"> </font>amended<font style="letter-spacing:0.8pt;"> </font>by<font style="letter-spacing:0.65pt;"> </font>deleting<font style="letter-spacing:0.65pt;"> </font>the<font style="letter-spacing:0.7pt;"> </font>entire<font style="letter-spacing:0.7pt;"> </font>section<font style="letter-spacing:0.65pt;"> </font>thereof<font style="letter-spacing:0.7pt;"> </font>and<font style="letter-spacing:-2.85pt;"> </font>replacing<font style="letter-spacing:-0.05pt;"> </font>it with<font style="letter-spacing:-0.05pt;"> </font>the<font style="letter-spacing:-0.1pt;"> </font>following:</p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:12.5pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:17.71%;margin-right:9.04%;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#8220;7.2<font style="letter-spacing:0.05pt;"> </font>Acceleration of<font style="letter-spacing:0.05pt;"> </font>Equity<font style="letter-spacing:0.05pt;"> </font>Awards;<font style="letter-spacing:0.05pt;"> </font>Change<font style="letter-spacing:0.05pt;"> </font>of<font style="letter-spacing:0.05pt;"> </font>Control.<font style="letter-spacing:0.05pt;"> </font><font style="font-weight:normal;">If</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">the</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">Company</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">terminates</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">Executive&#8217;s</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">employment</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">with</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">the</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">Company</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">without</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">Cause,</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">or</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">Executive</font><font style="letter-spacing:-0.15pt;font-weight:normal;"> </font><font style="font-weight:normal;">resigns</font><font style="letter-spacing:-0.15pt;font-weight:normal;"> </font><font style="font-weight:normal;">for</font><font style="letter-spacing:-0.15pt;font-weight:normal;"> </font><font style="font-weight:normal;">Good</font><font style="letter-spacing:-0.15pt;font-weight:normal;"> </font><font style="font-weight:normal;">Reason,</font><font style="letter-spacing:-0.15pt;font-weight:normal;"> </font><font style="font-weight:normal;">in</font><font style="letter-spacing:-0.1pt;font-weight:normal;"> </font><font style="font-weight:normal;">either</font><font style="letter-spacing:-0.15pt;font-weight:normal;"> </font><font style="font-weight:normal;">case</font><font style="letter-spacing:-0.15pt;font-weight:normal;"> </font><font style="font-weight:normal;">within</font><font style="letter-spacing:-0.15pt;font-weight:normal;"> </font><font style="font-weight:normal;">three</font><font style="letter-spacing:-0.15pt;font-weight:normal;"> </font><font style="font-weight:normal;">(3)</font><font style="letter-spacing:-0.1pt;font-weight:normal;"> </font><font style="font-weight:normal;">months</font><font style="letter-spacing:-0.15pt;font-weight:normal;"> </font><font style="font-weight:normal;">prior</font><font style="letter-spacing:-0.15pt;font-weight:normal;"> </font><font style="font-weight:normal;">to,</font><font style="letter-spacing:-2.9pt;font-weight:normal;"> </font><font style="font-weight:normal;">or</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">twenty-four</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">(24)</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">months</font><font style="letter-spacing:3pt;font-weight:normal;"> </font><font style="font-weight:normal;">following</font><font style="letter-spacing:3pt;font-weight:normal;"> </font><font style="font-weight:normal;">the</font><font style="letter-spacing:3pt;font-weight:normal;"> </font><font style="font-weight:normal;">closing</font><font style="letter-spacing:3pt;font-weight:normal;"> </font><font style="font-weight:normal;">of</font><font style="letter-spacing:3pt;font-weight:normal;"> </font><font style="font-weight:normal;">a</font><font style="letter-spacing:3pt;font-weight:normal;"> </font><font style="font-weight:normal;">Change</font><font style="letter-spacing:3pt;font-weight:normal;"> </font><font style="font-weight:normal;">of</font><font style="letter-spacing:3pt;font-weight:normal;"> </font><font style="font-weight:normal;">Control,</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">then</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">in</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">addition</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">to</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">the</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">benefits</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">set</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">forth</font><font style="letter-spacing:3pt;font-weight:normal;"> </font><font style="font-weight:normal;">in</font><font style="letter-spacing:3pt;font-weight:normal;"> </font><font style="font-weight:normal;">Section</font><font style="letter-spacing:3pt;font-weight:normal;"> </font><font style="font-weight:normal;">7.1</font><font style="letter-spacing:3pt;font-weight:normal;"> </font><font style="font-weight:normal;">and pursuant</font><font style="letter-spacing:3pt;font-weight:normal;"> </font><font style="font-weight:normal;">to</font><font style="letter-spacing:3pt;font-weight:normal;"> </font><font style="font-weight:normal;">the</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">terms</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">of</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">Section</font><font style="letter-spacing:3pt;font-weight:normal;"> </font><font style="font-weight:normal;">6,</font><font style="letter-spacing:3pt;font-weight:normal;"> </font><font style="font-weight:normal;">the</font><font style="letter-spacing:3pt;font-weight:normal;"> </font><font style="font-weight:normal;">Company</font><font style="letter-spacing:3pt;font-weight:normal;"> </font><font style="font-weight:normal;">will</font><font style="letter-spacing:3pt;font-weight:normal;"> </font><font style="font-weight:normal;">fully</font><font style="letter-spacing:3pt;font-weight:normal;"> </font><font style="font-weight:normal;">accelerate</font><font style="letter-spacing:3pt;font-weight:normal;"> </font><font style="font-weight:normal;">the vesting of the</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">Option and the RSU, as well as any other equity interests granted to Executive,</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">such</font><font style="letter-spacing:0.75pt;font-weight:normal;"> </font><font style="font-weight:normal;">that</font><font style="letter-spacing:0.8pt;font-weight:normal;"> </font><font style="font-weight:normal;">100%</font><font style="letter-spacing:1.65pt;font-weight:normal;"> </font><font style="font-weight:normal;">of</font><font style="letter-spacing:1.6pt;font-weight:normal;"> </font><font style="font-weight:normal;">the</font><font style="letter-spacing:1.65pt;font-weight:normal;"> </font><font style="font-weight:normal;">then-unvested</font><font style="letter-spacing:1.6pt;font-weight:normal;"> </font><font style="font-weight:normal;">shares</font><font style="letter-spacing:1.65pt;font-weight:normal;"> </font><font style="font-weight:normal;">subject</font><font style="letter-spacing:1.55pt;font-weight:normal;"> </font><font style="font-weight:normal;">to</font><font style="letter-spacing:1.65pt;font-weight:normal;"> </font><font style="font-weight:normal;">the</font><font style="letter-spacing:1.6pt;font-weight:normal;"> </font><font style="font-weight:normal;">Option</font><font style="letter-spacing:1.65pt;font-weight:normal;"> </font><font style="font-weight:normal;">and</font><font style="letter-spacing:1.6pt;font-weight:normal;"> </font><font style="font-weight:normal;">the</font><font style="letter-spacing:1.65pt;font-weight:normal;"> </font><font style="font-weight:normal;">RSU</font><font style="letter-spacing:-2.9pt;font-weight:normal;"> </font><font style="font-weight:normal;">(or</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">other</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">equity</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">interests)</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">will</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">be</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">deemed</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">vested</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">and</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">exercisable</font><font style="letter-spacing:3pt;font-weight:normal;"> </font><font style="font-weight:normal;">as</font><font style="letter-spacing:3pt;font-weight:normal;"> </font><font style="font-weight:normal;">of</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">Executive&#8217;s</font><font style="letter-spacing:0.35pt;font-weight:normal;"> </font><font style="font-weight:normal;">last</font><font style="letter-spacing:0.4pt;font-weight:normal;"> </font><font style="font-weight:normal;">day</font><font style="letter-spacing:0.35pt;font-weight:normal;"> </font><font style="font-weight:normal;">of employment.&#8221;</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:11.07%;margin-right:2.4%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.<font style="margin-left:96pt;"></font>This<font style="letter-spacing:-0.7pt;"> </font>Amendment<font style="letter-spacing:-0.65pt;"> </font>may<font style="letter-spacing:-0.6pt;"> </font>be<font style="letter-spacing:-0.6pt;"> </font>executed<font style="letter-spacing:-0.55pt;"> </font>in<font style="letter-spacing:-0.7pt;"> </font>several<font style="letter-spacing:-0.55pt;"> </font>counterparts,<font style="letter-spacing:-0.55pt;"> </font>all<font style="letter-spacing:-0.7pt;"> </font>of<font style="letter-spacing:-0.6pt;"> </font>which<font style="letter-spacing:-0.65pt;"> </font>taken<font style="letter-spacing:-0.6pt;"> </font>together<font style="letter-spacing:-0.7pt;"> </font>shall<font style="letter-spacing:-2.9pt;"> </font>constitute one single agreement between the parties. Except as amended hereby, all of the other<font style="letter-spacing:0.05pt;"> </font>terms<font style="letter-spacing:-0.05pt;"> </font>and<font style="letter-spacing:-0.05pt;"> </font>conditions of<font style="letter-spacing:-0.1pt;"> </font>the<font style="letter-spacing:-0.1pt;"> </font>Agreement shall<font style="letter-spacing:-0.05pt;"> </font>remain and<font style="letter-spacing:-0.05pt;"> </font>continue<font style="letter-spacing:-0.1pt;"> </font>in full<font style="letter-spacing:-0.05pt;"> </font>force<font style="letter-spacing:-0.05pt;"> </font>and<font style="letter-spacing:0.05pt;"> </font>effect.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;">&nbsp;</p>
<p style="margin-top:4pt;margin-bottom:0pt;margin-left:17.71%;text-indent:0%;font-weight:bold;font-size:12pt;letter-spacing:-0.15pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">I<font style="font-size:9.5pt;">N</font><font style="font-size:9.5pt;letter-spacing:-0.5pt;"> </font>W<font style="font-size:9.5pt;">ITNESS</font><font style="font-size:9.5pt;letter-spacing:-0.6pt;"> </font>W<font style="font-size:9.5pt;">HEREOF</font><font style="font-weight:normal;">,</font><font style="letter-spacing:-0.85pt;font-weight:normal;"> </font><font style="font-weight:normal;">the</font><font style="letter-spacing:-0.4pt;font-weight:normal;"> </font><font style="font-weight:normal;">Parties</font><font style="letter-spacing:-0.85pt;font-weight:normal;"> </font><font style="font-weight:normal;">have</font><font style="letter-spacing:-0.55pt;font-weight:normal;"> </font><font style="font-weight:normal;">executed</font><font style="letter-spacing:-0.7pt;font-weight:normal;"> </font><font style="font-weight:normal;">this</font><font style="letter-spacing:-0.6pt;font-weight:normal;"> </font><font style="font-weight:normal;">Amendment</font><font style="letter-spacing:-0.7pt;font-weight:normal;"> </font><font style="font-weight:normal;">as</font><font style="letter-spacing:-0.55pt;font-weight:normal;"> </font><font style="font-weight:normal;">of</font><font style="letter-spacing:-0.4pt;font-weight:normal;"> </font><font style="font-weight:normal;">the</font><font style="letter-spacing:-0.6pt;font-weight:normal;"> </font><font style="font-weight:normal;">date</font><font style="letter-spacing:-0.65pt;font-weight:normal;"> </font><font style="font-weight:normal;">first</font><font style="letter-spacing:-0.6pt;font-weight:normal;"> </font><font style="font-weight:normal;">written</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:11.07%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">above.</p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;">&nbsp;</p>
<p style="margin-top:4pt;margin-bottom:0pt;margin-left:11.26%;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">U<font style="font-size:9.5pt;">RO</font>G<font style="font-size:9.5pt;">EN</font><font style="font-size:9.5pt;letter-spacing:-0.1pt;"> </font>P<font style="font-size:9.5pt;">HARMA</font>,<font style="letter-spacing:-0.7pt;"> </font>L<font style="font-size:9.5pt;">TD</font>.<font style="margin-left:294pt;">E</font><font style="font-size:9.5pt;">XECUTIVE</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="margin-top:4pt;margin-bottom:0pt;margin-left:11.26%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:<font style="text-decoration:underline;"> /s/ Molly Henderson</font><font style="text-decoration:underline;margin-left:231pt;"></font><font style="margin-left:294pt;"></font><font style="text-decoration:underline;"> /s/ Elizabeth Barrett</font><font style="text-decoration:underline;margin-left:231pt;"></font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.62%;text-indent:6.64%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU2"></a>Name:<font style="letter-spacing:2.35pt;"> </font>Molly<font style="letter-spacing:-0.25pt;"> </font>Henderson<font style="margin-left:36pt;"> Name:</font><font style="letter-spacing:-0.25pt;"> </font>Elizabeth<font style="letter-spacing:-0.2pt;"> </font>Barrett<font style="margin-left:36pt;"></font></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:11.26%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Title:<font style="margin-left:101pt;">Chief</font><font style="letter-spacing:-0.45pt;"> </font>Financial<font style="letter-spacing:-0.4pt;"> </font>Officer</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br /></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 10.2</p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.3
<SEQUENCE>4
<FILENAME>urgn-ex103_100.htm
<DESCRIPTION>EX-10.3
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
urgn-ex103_100.htm
</title>
</head>
<!-- NG Converter v5.0.2.50 -->
<body>

<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 10.3</p>
<p style="text-align:center;margin-top:4pt;margin-bottom:0pt;margin-left:13.65%;margin-right:13.12%;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="AMENDMENT_NO._1_TO_EXECUTIVE_EMPLOYMENT_"></a>AMENDMENT<font style="letter-spacing:-0.25pt;"> </font>NO.<font style="letter-spacing:-0.15pt;"> </font>1<font style="letter-spacing:-0.15pt;"> </font>TO<font style="letter-spacing:-0.15pt;"> </font>EXECUTIVE<font style="letter-spacing:-0.2pt;"> </font>EMPLOYMENT<font style="letter-spacing:-0.2pt;"> </font>AGREEMENT</p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:1.25%;margin-right:1.04%;text-indent:7.5%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This<font style="letter-spacing:0.05pt;"> </font>Amendment<font style="letter-spacing:0.05pt;"> </font>No.<font style="letter-spacing:0.05pt;"> </font>1<font style="letter-spacing:0.05pt;"> </font>(this<font style="letter-spacing:0.05pt;"> </font>&#8220;<font style="text-decoration:underline;">Amendment</font>&#8221;)<font style="letter-spacing:0.05pt;"> </font>to<font style="letter-spacing:0.05pt;"> </font>that<font style="letter-spacing:0.05pt;"> </font>certain<font style="letter-spacing:0.05pt;"> </font>Executive<font style="letter-spacing:0.05pt;"> </font>Employment<font style="letter-spacing:-2.85pt;"> </font>Agreement, dated January 23, 2020 by and between Mark P. Schoenberg, MD (&#8220;<font style="text-decoration:underline;">Executive</font>&#8221;) and<font style="letter-spacing:-2.85pt;"> </font>UroGen Pharma, Inc. and UroGen Pharma, Ltd. (collectively, &#8220;<font style="text-decoration:underline;">Company</font>&#8221;) is entered into as of<font style="letter-spacing:0.05pt;"> </font>this 26<sup style="font-size:85%;line-height:120%;vertical-align:top">th</sup> day of January 2021. The Company and Executive are collectively referred to in this<font style="letter-spacing:0.05pt;"> </font>Amendment<font style="letter-spacing:-0.05pt;"> </font>as &#8220;<font style="text-decoration:underline;">the</font><font style="text-decoration:underline;letter-spacing:-0.05pt;"> </font><font style="text-decoration:underline;">Parties</font>.&#8221;</p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:4pt;margin-bottom:0pt;margin-left:1.25%;margin-right:1.04%;text-indent:7.5%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">W<font style="font-size:9.5pt;">HEREAS</font><font style="font-weight:normal;">,</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">the</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">Subsidiary,</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">Parent</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">and</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">Executive</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">are</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">Parties</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">to</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">a</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">certain</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">Executive</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">Employment Agreement dated January 23, 2020 (the &#8220;Agreement&#8221;) (capitalized terms used and</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">not</font><font style="letter-spacing:-0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">otherwise</font><font style="letter-spacing:-0.1pt;font-weight:normal;"> </font><font style="font-weight:normal;">defined</font><font style="letter-spacing:-0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">herein</font><font style="letter-spacing:-0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">shall</font><font style="letter-spacing:-0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">have</font><font style="letter-spacing:-0.1pt;font-weight:normal;"> </font><font style="font-weight:normal;">the</font><font style="letter-spacing:-0.1pt;font-weight:normal;"> </font><font style="font-weight:normal;">meanings</font><font style="letter-spacing:-0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">given</font><font style="letter-spacing:-0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">to</font><font style="letter-spacing:-0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">such</font><font style="letter-spacing:-0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">terms</font><font style="letter-spacing:-0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">in</font><font style="letter-spacing:-0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">the</font><font style="letter-spacing:-0.1pt;font-weight:normal;"> </font><font style="font-weight:normal;">Agreement);</font><font style="letter-spacing:-0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">and</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:8.75%;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">W<font style="font-size:9.5pt;">HEREAS</font><font style="font-weight:normal;">,</font><font style="letter-spacing:-0.1pt;font-weight:normal;"> </font><font style="font-weight:normal;">the</font><font style="letter-spacing:-0.1pt;font-weight:normal;"> </font><font style="font-weight:normal;">Parties</font><font style="letter-spacing:-0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">wish</font><font style="letter-spacing:-0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">to</font><font style="letter-spacing:-0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">amend</font><font style="letter-spacing:-0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">the</font><font style="letter-spacing:-0.1pt;font-weight:normal;"> </font><font style="font-weight:normal;">Agreement</font><font style="letter-spacing:-0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">as</font><font style="letter-spacing:-0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">set</font><font style="letter-spacing:-0.1pt;font-weight:normal;"> </font><font style="font-weight:normal;">forth</font><font style="letter-spacing:-0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">herein.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:1.25%;margin-right:1.04%;text-indent:7.5%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">N<font style="font-size:9.5pt;">OW </font>T<font style="font-size:9.5pt;">HEREFORE</font><font style="font-weight:normal;">, in consideration and in furtherance of Executive&#8217;s continued at-will</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">employment with the Company, and for other good and valuable consideration, the receipt and</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">sufficiency</font><font style="letter-spacing:-0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">of</font><font style="letter-spacing:-0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">which</font><font style="letter-spacing:-0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">is hereby acknowledged,</font><font style="letter-spacing:-0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">the</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">Parties hereto</font><font style="letter-spacing:-0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">agree</font><font style="letter-spacing:-0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">as follows:</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:1.24%;margin-right:1.04%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.<font style="margin-left:42pt;"></font>Section<font style="letter-spacing:-0.2pt;"> </font>4.3<font style="letter-spacing:-0.2pt;"> </font>of<font style="letter-spacing:-0.1pt;"> </font>the<font style="letter-spacing:-0.1pt;"> </font>Agreement<font style="letter-spacing:-0.15pt;"> </font>is<font style="letter-spacing:-0.2pt;"> </font>hereby<font style="letter-spacing:-0.05pt;"> </font>amended<font style="letter-spacing:0.05pt;"> </font>by<font style="letter-spacing:-0.2pt;"> </font>deleting<font style="letter-spacing:-0.2pt;"> </font>the<font style="letter-spacing:-0.05pt;"> </font>entire<font style="letter-spacing:-0.1pt;"> </font>section<font style="letter-spacing:-0.2pt;"> </font>thereof<font style="letter-spacing:-0.1pt;"> </font>and<font style="letter-spacing:-2.9pt;"> </font>replacing<font style="letter-spacing:-0.05pt;"> </font>it with the<font style="letter-spacing:-0.05pt;"> </font>following:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:8.75%;margin-right:8.54%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="font-weight:bold;">4.3</font><font style="font-weight:bold;letter-spacing:0.05pt;"> </font><font style="font-weight:bold;">Acceleration</font><font style="font-weight:bold;letter-spacing:0.05pt;"> </font><font style="font-weight:bold;">of</font><font style="font-weight:bold;letter-spacing:0.05pt;"> </font><font style="font-weight:bold;">Equity</font><font style="font-weight:bold;letter-spacing:0.05pt;"> </font><font style="font-weight:bold;">Awards;</font><font style="font-weight:bold;letter-spacing:0.05pt;"> </font><font style="font-weight:bold;">Change</font><font style="font-weight:bold;letter-spacing:0.05pt;"> </font><font style="font-weight:bold;">of</font><font style="font-weight:bold;letter-spacing:0.05pt;"> </font><font style="font-weight:bold;">Control</font>.<font style="letter-spacing:0.05pt;"> </font>If<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>Company<font style="letter-spacing:-2.85pt;"> </font>terminates<font style="letter-spacing:0.05pt;"> </font>Executive&#8217;s<font style="letter-spacing:0.05pt;"> </font>employment<font style="letter-spacing:0.05pt;"> </font>with<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>Company<font style="letter-spacing:0.05pt;"> </font>without<font style="letter-spacing:0.05pt;"> </font>Cause,<font style="letter-spacing:0.05pt;"> </font>or<font style="letter-spacing:0.05pt;"> </font>Executive<font style="letter-spacing:-0.1pt;"> </font>resigns<font style="letter-spacing:-0.2pt;"> </font>for<font style="letter-spacing:-0.25pt;"> </font>Good<font style="letter-spacing:-0.15pt;"> </font>Reason,<font style="letter-spacing:-0.2pt;"> </font>in<font style="letter-spacing:-0.05pt;"> </font>either<font style="letter-spacing:-0.1pt;"> </font>case<font style="letter-spacing:-0.05pt;"> </font>within<font style="letter-spacing:-0.2pt;"> </font>three<font style="letter-spacing:-0.1pt;"> </font>(3)<font style="letter-spacing:-0.25pt;"> </font>months<font style="letter-spacing:-0.15pt;"> </font>prior<font style="letter-spacing:-0.25pt;"> </font>to,<font style="letter-spacing:-2.9pt;"> </font>or twenty-four (24) months following the closing of a Change of Control, then the<font style="letter-spacing:-2.85pt;"> </font>Company will fully accelerate the vesting of the unvested options, warrants and<font style="letter-spacing:0.05pt;"> </font>restricted stock units (as well as any other equity interests granted to Executive),<font style="letter-spacing:0.05pt;"> </font>such that 100% of the then-unvested shares subject to the options, warrants and<font style="letter-spacing:0.05pt;"> </font>restricted<font style="letter-spacing:0.05pt;"> </font>stock<font style="letter-spacing:0.05pt;"> </font>units<font style="letter-spacing:0.05pt;"> </font>(or<font style="letter-spacing:0.05pt;"> </font>other<font style="letter-spacing:0.05pt;"> </font>equity<font style="letter-spacing:0.05pt;"> </font>interests)<font style="letter-spacing:0.05pt;"> </font>will<font style="letter-spacing:0.05pt;"> </font>be<font style="letter-spacing:0.05pt;"> </font>deemed<font style="letter-spacing:0.05pt;"> </font>vested<font style="letter-spacing:0.05pt;"> </font>and<font style="letter-spacing:0.05pt;"> </font>exercisable<font style="letter-spacing:-0.1pt;"> </font>as of<font style="letter-spacing:-0.05pt;"> </font>Executive&#8217;s last day<font style="letter-spacing:-0.05pt;"> </font>of<font style="letter-spacing:0.05pt;"> </font>employment.&#8221;</p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:1.25%;margin-right:1.04%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.<font style="margin-left:42pt;"></font>This<font style="letter-spacing:-0.7pt;"> </font>Amendment<font style="letter-spacing:-0.65pt;"> </font>may<font style="letter-spacing:-0.6pt;"> </font>be<font style="letter-spacing:-0.6pt;"> </font>executed<font style="letter-spacing:-0.55pt;"> </font>in<font style="letter-spacing:-0.75pt;"> </font>several<font style="letter-spacing:-0.55pt;"> </font>counterparts,<font style="letter-spacing:-0.55pt;"> </font>all<font style="letter-spacing:-0.7pt;"> </font>of<font style="letter-spacing:-0.6pt;"> </font>which<font style="letter-spacing:-0.65pt;"> </font>taken<font style="letter-spacing:-0.6pt;"> </font>together<font style="letter-spacing:-0.7pt;"> </font>shall<font style="letter-spacing:-2.9pt;"> </font>constitute one single agreement between the parties. Except as amended hereby, all of the other<font style="letter-spacing:0.05pt;"> </font>terms<font style="letter-spacing:-0.05pt;"> </font>and<font style="letter-spacing:-0.05pt;"> </font>conditions of<font style="letter-spacing:-0.1pt;"> </font>the<font style="letter-spacing:-0.1pt;"> </font>Agreement shall<font style="letter-spacing:-0.05pt;"> </font>remain and<font style="letter-spacing:-0.05pt;"> </font>continue<font style="letter-spacing:-0.1pt;"> </font>in full<font style="letter-spacing:-0.05pt;"> </font>force<font style="letter-spacing:-0.05pt;"> </font>and<font style="letter-spacing:0.05pt;"> </font>effect.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:13pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:13pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:13pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:13pt;">&nbsp;</p>
<p style="margin-top:8pt;margin-bottom:0pt;margin-left:10.95%;text-indent:0%;font-style:italic;font-size:12pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">[Remainder<font style="letter-spacing:-0.1pt;"> </font>of<font style="letter-spacing:-0.05pt;"> </font>Page<font style="letter-spacing:-0.1pt;"> </font>Intentionally<font style="letter-spacing:-0.1pt;"> </font>Blank;<font style="letter-spacing:-0.1pt;"> </font>Signature<font style="letter-spacing:-0.1pt;"> </font>Lines<font style="letter-spacing:-0.1pt;"> </font>on<font style="letter-spacing:-0.05pt;"> </font>Following<font style="letter-spacing:-0.05pt;"> </font>Page]</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></a>
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:0.62%;text-indent:0%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:9pt;">1</font></p>&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 10.3</p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:11.5pt;">&nbsp;</p>
<p style="margin-top:4pt;margin-bottom:0pt;margin-left:8.75%;text-indent:0%;font-weight:bold;font-size:12pt;letter-spacing:-0.15pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">I<font style="font-size:9.5pt;">N</font><font style="font-size:9.5pt;letter-spacing:-0.5pt;"> </font>W<font style="font-size:9.5pt;">ITNESS</font><font style="font-size:9.5pt;letter-spacing:-0.6pt;"> </font>W<font style="font-size:9.5pt;">HEREOF</font><font style="font-weight:normal;">,</font><font style="letter-spacing:-0.85pt;font-weight:normal;"> </font><font style="font-weight:normal;">the</font><font style="letter-spacing:-0.4pt;font-weight:normal;"> </font><font style="font-weight:normal;">Parties</font><font style="letter-spacing:-0.85pt;font-weight:normal;"> </font><font style="font-weight:normal;">have</font><font style="letter-spacing:-0.5pt;font-weight:normal;"> </font><font style="font-weight:normal;">executed</font><font style="letter-spacing:-0.75pt;font-weight:normal;"> </font><font style="font-weight:normal;">this</font><font style="letter-spacing:-0.6pt;font-weight:normal;"> </font><font style="font-weight:normal;">Amendment</font><font style="letter-spacing:-0.65pt;font-weight:normal;"> </font><font style="font-weight:normal;">as</font><font style="letter-spacing:-0.6pt;font-weight:normal;"> </font><font style="font-weight:normal;">of</font><font style="letter-spacing:-0.35pt;font-weight:normal;"> </font><font style="font-weight:normal;">the</font><font style="letter-spacing:-0.65pt;font-weight:normal;"> </font><font style="font-weight:normal;">date</font><font style="letter-spacing:-0.65pt;font-weight:normal;"> </font><font style="font-weight:normal;">first</font><font style="letter-spacing:-0.55pt;font-weight:normal;"> </font><font style="font-weight:normal;">written</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:1.25%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">above.</p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;">&nbsp;</p>
<p style="margin-top:4pt;margin-bottom:0pt;margin-left:1.47%;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">U<font style="font-size:9.5pt;">RO</font>G<font style="font-size:9.5pt;">EN</font><font style="font-size:9.5pt;letter-spacing:-0.15pt;"> </font>P<font style="font-size:9.5pt;">HARMA</font>,<font style="letter-spacing:-0.7pt;"> </font>I<font style="font-size:9.5pt;">NC</font>.<font style="margin-left:240pt;">E</font><font style="font-size:9.5pt;">XECUTIVE</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="margin-top:4pt;margin-bottom:0pt;margin-left:1.47%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:<font style="text-decoration:underline;"> /s/ Elizabeth Barrett</font><font style="text-decoration:underline;margin-left:174pt;"></font><font style="margin-left:240pt;"></font><font style="text-decoration:underline;"> /s/ Mark</font><font style="text-decoration:underline;letter-spacing:-0.1pt;"> </font><font style="text-decoration:underline;">Schoenberg</font><font style="text-decoration:underline;margin-left:174pt;"></font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:1.47%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU2"></a>Name:<font style="letter-spacing:2.55pt;"> </font>Elizabeth<font style="letter-spacing:-0.15pt;"> </font>Barrett<font style="margin-left:36pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Name:</font><font style="letter-spacing:-0.1pt;"> </font>Mark<font style="letter-spacing:-0.1pt;"> </font>P.<font style="letter-spacing:-0.1pt;"> </font>Schoenberg,<font style="letter-spacing:-0.05pt;"> </font>MD</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:1.47%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Title:<font style="margin-left:47pt;">Chief</font><font style="letter-spacing:-0.15pt;"> </font>Executive<font style="letter-spacing:-0.15pt;"> </font>Officer</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-top:4pt;margin-bottom:0pt;margin-left:1.47%;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">U<font style="font-size:9.5pt;">RO</font>G<font style="font-size:9.5pt;">EN</font><font style="font-size:9.5pt;letter-spacing:-0.25pt;"> </font>P<font style="font-size:9.5pt;">HARMA</font><font style="font-size:9.5pt;letter-spacing:-0.2pt;"> </font>L<font style="font-size:9.5pt;">TD</font>.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:13pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:1.47%;margin-right:63.54%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By: <font style="text-decoration:underline;">/s/ Elizabeth Barrett</font><font style="text-decoration:underline;margin-left:174pt;"></font> Name:<font style="letter-spacing:2.65pt;"> </font>Elizabeth<font style="letter-spacing:-0.1pt;"> </font>Barrett</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br /></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></a>
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:0.62%;text-indent:0%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:9pt;">2</font></p>&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 10.3</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:1.47%;margin-right:63.54%;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></a>
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:0.62%;text-indent:0%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:9pt;">3</font></p>&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.4
<SEQUENCE>5
<FILENAME>urgn-ex104_98.htm
<DESCRIPTION>EX-10.4
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
urgn-ex104_98.htm
</title>
</head>
<!-- NG Converter v5.0.2.50 -->
<body>

<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 10.4</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:4pt;margin-bottom:0pt;margin-left:22.28%;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="AMENDMENT_NO._1_TO_EXECUTIVE_EMPLOYMENT_"></a>AMENDMENT<font style="letter-spacing:-0.25pt;"> </font>NO.<font style="letter-spacing:-0.2pt;"> </font>1<font style="letter-spacing:-0.2pt;"> </font>TO<font style="letter-spacing:-0.15pt;"> </font>EXECUTIVE<font style="letter-spacing:-0.2pt;"> </font>EMPLOYMENT<font style="letter-spacing:-0.25pt;"> </font>AGREEMENT</p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:10.85%;margin-right:0.93%;text-indent:6.72%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This<font style="letter-spacing:0.05pt;"> </font>Amendment<font style="letter-spacing:0.05pt;"> </font>No.<font style="letter-spacing:0.05pt;"> </font>1<font style="letter-spacing:0.05pt;"> </font>(this<font style="letter-spacing:0.05pt;"> </font>&#8220;<font style="text-decoration:underline;">Amendment</font>&#8221;)<font style="letter-spacing:0.05pt;"> </font>to<font style="letter-spacing:0.05pt;"> </font>that<font style="letter-spacing:0.05pt;"> </font>certain<font style="letter-spacing:0.05pt;"> </font>Executive<font style="letter-spacing:0.05pt;"> </font>Employment<font style="letter-spacing:0.05pt;"> </font>Agreement, dated August 12, 2020, by and between Jason Smith (&#8220;Executive&#8221;) and UroGen<font style="letter-spacing:0.05pt;"> </font>Pharma,<font style="letter-spacing:-0.55pt;"> </font>Inc.,<font style="letter-spacing:-0.45pt;"> </font>a<font style="letter-spacing:-0.45pt;"> </font>wholly<font style="letter-spacing:-0.45pt;"> </font>owned<font style="letter-spacing:-0.45pt;"> </font>subsidiary<font style="letter-spacing:-0.45pt;"> </font>(the<font style="letter-spacing:-0.45pt;"> </font>&#8220;<font style="text-decoration:underline;">Subsidiary</font>&#8221;)<font style="letter-spacing:-0.45pt;"> </font>of<font style="letter-spacing:-0.45pt;"> </font>UroGen<font style="letter-spacing:-0.5pt;"> </font>Pharma,<font style="letter-spacing:-0.45pt;"> </font>Ltd.<font style="letter-spacing:-0.45pt;"> </font>(the<font style="letter-spacing:-0.45pt;"> </font>&#8220;<font style="text-decoration:underline;">Parent</font>&#8221;)<font style="letter-spacing:-2.9pt;"> </font>(the Subsidiary and the Parent together, the &#8220;<font style="text-decoration:underline;">Company</font>&#8221;) is entered into as of this 26th day of<font style="letter-spacing:0.05pt;"> </font>January<font style="letter-spacing:-0.5pt;"> </font>2021.<font style="letter-spacing:0.15pt;"> </font>The<font style="letter-spacing:-0.45pt;"> </font>Subsidiary,<font style="letter-spacing:-0.5pt;"> </font>Parent<font style="letter-spacing:-0.45pt;"> </font>and<font style="letter-spacing:-0.45pt;"> </font>Executive<font style="letter-spacing:-0.45pt;"> </font>are<font style="letter-spacing:-0.45pt;"> </font>collectively<font style="letter-spacing:-0.45pt;"> </font>referred<font style="letter-spacing:-0.45pt;"> </font>to<font style="letter-spacing:-0.5pt;"> </font>in<font style="letter-spacing:-0.45pt;"> </font>this<font style="letter-spacing:-0.45pt;"> </font>Amendment<font style="letter-spacing:-2.85pt;"> </font>as<font style="letter-spacing:-0.1pt;"> </font>&#8220;<font style="text-decoration:underline;">the</font><font style="text-decoration:underline;letter-spacing:-0.05pt;"> </font><font style="text-decoration:underline;">Parties</font>.&#8221;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:10.85%;margin-right:0.93%;text-indent:6.72%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">W<font style="font-size:9.5pt;">HEREAS</font><font style="font-weight:normal;">, the Subsidiary and Executive are Parties to a certain Executive Employment</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">Agreement dated August 12, 2020 (the &#8220;Agreement&#8221;) (capitalized terms used and not otherwise</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">defined</font><font style="letter-spacing:-0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">herein shall</font><font style="letter-spacing:-0.1pt;font-weight:normal;"> </font><font style="font-weight:normal;">have the</font><font style="letter-spacing:-0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">meanings given</font><font style="letter-spacing:-0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">to such</font><font style="letter-spacing:-0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">terms</font><font style="letter-spacing:-0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">in the</font><font style="letter-spacing:-0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">Agreement);</font><font style="letter-spacing:-0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">and</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:22.72%;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">W<font style="font-size:9.5pt;">HEREAS</font><font style="font-weight:normal;">,</font><font style="letter-spacing:-0.15pt;font-weight:normal;"> </font><font style="font-weight:normal;">the</font><font style="letter-spacing:-0.2pt;font-weight:normal;"> </font><font style="font-weight:normal;">Parties</font><font style="letter-spacing:-0.15pt;font-weight:normal;"> </font><font style="font-weight:normal;">wish</font><font style="letter-spacing:-0.1pt;font-weight:normal;"> </font><font style="font-weight:normal;">to</font><font style="letter-spacing:-0.15pt;font-weight:normal;"> </font><font style="font-weight:normal;">amend</font><font style="letter-spacing:-0.15pt;font-weight:normal;"> </font><font style="font-weight:normal;">the</font><font style="letter-spacing:-0.25pt;font-weight:normal;"> </font><font style="font-weight:normal;">Agreement</font><font style="letter-spacing:-0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">as</font><font style="letter-spacing:-0.15pt;font-weight:normal;"> </font><font style="font-weight:normal;">set</font><font style="letter-spacing:-0.15pt;font-weight:normal;"> </font><font style="font-weight:normal;">forth</font><font style="letter-spacing:-0.1pt;font-weight:normal;"> </font><font style="font-weight:normal;">herein.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:10.85%;margin-right:0.93%;text-indent:6.72%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">N<font style="font-size:9.5pt;">OW </font>T<font style="font-size:9.5pt;">HEREFORE</font><font style="font-weight:normal;">, in consideration and in furtherance of Executive&#8217;s continued at-will</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">employment with the Company, and for other good and valuable consideration, the receipt and</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">sufficiency</font><font style="letter-spacing:-0.2pt;font-weight:normal;"> </font><font style="font-weight:normal;">of</font><font style="letter-spacing:-0.15pt;font-weight:normal;"> </font><font style="font-weight:normal;">which</font><font style="letter-spacing:-0.2pt;font-weight:normal;"> </font><font style="font-weight:normal;">is</font><font style="letter-spacing:-0.15pt;font-weight:normal;"> </font><font style="font-weight:normal;">hereby</font><font style="letter-spacing:-0.15pt;font-weight:normal;"> </font><font style="font-weight:normal;">acknowledged,</font><font style="letter-spacing:-0.15pt;font-weight:normal;"> </font><font style="font-weight:normal;">the</font><font style="letter-spacing:-0.1pt;font-weight:normal;"> </font><font style="font-weight:normal;">Parties</font><font style="letter-spacing:-0.15pt;font-weight:normal;"> </font><font style="font-weight:normal;">hereto</font><font style="letter-spacing:-0.15pt;font-weight:normal;"> </font><font style="font-weight:normal;">agree</font><font style="letter-spacing:-0.15pt;font-weight:normal;"> </font><font style="font-weight:normal;">as</font><font style="letter-spacing:-0.15pt;font-weight:normal;"> </font><font style="font-weight:normal;">follows:</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:10.85%;margin-right:1.87%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.<font style="margin-left:94pt;"></font>Section<font style="letter-spacing:-0.25pt;"> </font>7.2<font style="letter-spacing:-0.2pt;"> </font>of<font style="letter-spacing:-0.15pt;"> </font>the<font style="letter-spacing:-0.15pt;"> </font>Agreement<font style="letter-spacing:-0.15pt;"> </font>is<font style="letter-spacing:-0.25pt;"> </font>hereby<font style="letter-spacing:-0.2pt;"> </font>amended<font style="letter-spacing:0.1pt;"> </font>by<font style="letter-spacing:-0.2pt;"> </font>deleting<font style="letter-spacing:-0.2pt;"> </font>the<font style="letter-spacing:-0.15pt;"> </font>entire<font style="letter-spacing:-0.15pt;"> </font>section<font style="letter-spacing:-0.2pt;"> </font>thereof<font style="letter-spacing:-0.2pt;"> </font>and<font style="letter-spacing:-2.85pt;"> </font>replacing it with<font style="letter-spacing:-0.05pt;"> </font>the<font style="letter-spacing:-0.05pt;"> </font>following:</p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:14pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:17.9%;margin-right:8.02%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="font-weight:bold;">7.2</font><font style="font-weight:bold;letter-spacing:0.05pt;"> </font><font style="font-weight:bold;">Acceleration</font><font style="font-weight:bold;letter-spacing:0.05pt;"> </font><font style="font-weight:bold;">of</font><font style="font-weight:bold;letter-spacing:0.05pt;"> </font><font style="font-weight:bold;">Equity</font><font style="font-weight:bold;letter-spacing:0.05pt;"> </font><font style="font-weight:bold;">Awards;</font><font style="font-weight:bold;letter-spacing:0.05pt;"> </font><font style="font-weight:bold;">Change</font><font style="font-weight:bold;letter-spacing:0.05pt;"> </font><font style="font-weight:bold;">of</font><font style="font-weight:bold;letter-spacing:0.05pt;"> </font><font style="font-weight:bold;">Control.</font><font style="font-weight:bold;letter-spacing:0.05pt;"> </font>If<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>Company<font style="letter-spacing:-2.85pt;"> </font>terminates<font style="letter-spacing:0.05pt;"> </font>Executive&#8217;s<font style="letter-spacing:0.05pt;"> </font>employment<font style="letter-spacing:0.05pt;"> </font>with<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>Company<font style="letter-spacing:0.05pt;"> </font>without<font style="letter-spacing:0.05pt;"> </font>Cause,<font style="letter-spacing:0.05pt;"> </font>or<font style="letter-spacing:0.05pt;"> </font>Executive<font style="letter-spacing:-0.15pt;"> </font>resigns<font style="letter-spacing:-0.15pt;"> </font>for<font style="letter-spacing:0.05pt;"> </font>Good<font style="letter-spacing:-0.15pt;"> </font>Reason,<font style="letter-spacing:-0.15pt;"> </font>in<font style="letter-spacing:-0.1pt;"> </font>either<font style="letter-spacing:-0.15pt;"> </font>case<font style="letter-spacing:-0.1pt;"> </font>within<font style="letter-spacing:-0.15pt;"> </font>three<font style="letter-spacing:-0.1pt;"> </font>(3)<font style="letter-spacing:-0.15pt;"> </font>months<font style="letter-spacing:-0.15pt;"> </font>prior<font style="letter-spacing:-0.1pt;"> </font>to,<font style="letter-spacing:-2.9pt;"> </font>or twenty-four (24) months following the closing of a Change of Control, then in<font style="letter-spacing:0.05pt;"> </font>addition to the benefits set forth in Section 7.1 and pursuant to the terms<font style="letter-spacing:3pt;"> </font>of<font style="letter-spacing:0.05pt;"> </font>Section 6, the Company will fully accelerate the vesting of the Option and the<font style="letter-spacing:0.05pt;"> </font>RSU,<font style="letter-spacing:1pt;"> </font>as<font style="letter-spacing:1.05pt;"> </font>well<font style="letter-spacing:1pt;"> </font>as<font style="letter-spacing:1.05pt;"> </font>any<font style="letter-spacing:1pt;"> </font>other<font style="letter-spacing:1.05pt;"> </font>equity<font style="letter-spacing:1pt;"> </font>interests<font style="letter-spacing:1.05pt;"> </font>granted<font style="letter-spacing:1pt;"> </font>to<font style="letter-spacing:1.05pt;"> </font>Executive,<font style="letter-spacing:1.05pt;"> </font>such<font style="letter-spacing:1pt;"> </font>that<font style="letter-spacing:0.95pt;"> </font>100%<font style="letter-spacing:-2.9pt;"> </font>of the then-unvested shares subject to the Option and the RSU (or other equity<font style="letter-spacing:0.05pt;"> </font>interests) will be deemed vested and exercisable as of Executive&#8217;s last day of<font style="letter-spacing:0.05pt;"> </font>employment.&#8221;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:11.19%;margin-right:1.31%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.<font style="margin-left:96pt;"></font>This<font style="letter-spacing:-0.7pt;"> </font>Amendment<font style="letter-spacing:-0.65pt;"> </font>may<font style="letter-spacing:-0.6pt;"> </font>be<font style="letter-spacing:-0.6pt;"> </font>executed<font style="letter-spacing:-0.55pt;"> </font>in<font style="letter-spacing:-0.7pt;"> </font>several<font style="letter-spacing:-0.55pt;"> </font>counterparts,<font style="letter-spacing:-0.55pt;"> </font>all<font style="letter-spacing:-0.7pt;"> </font>of<font style="letter-spacing:-0.6pt;"> </font>which<font style="letter-spacing:-0.65pt;"> </font>taken<font style="letter-spacing:-0.6pt;"> </font>together<font style="letter-spacing:-0.7pt;"> </font>shall<font style="letter-spacing:-2.9pt;"> </font>constitute one single agreement between the parties. Except as amended hereby, all of the other<font style="letter-spacing:0.05pt;"> </font>terms<font style="letter-spacing:-0.05pt;"> </font>and<font style="letter-spacing:-0.05pt;"> </font>conditions of<font style="letter-spacing:-0.1pt;"> </font>the<font style="letter-spacing:-0.1pt;"> </font>Agreement shall<font style="letter-spacing:-0.05pt;"> </font>remain and<font style="letter-spacing:-0.05pt;"> </font>continue<font style="letter-spacing:-0.1pt;"> </font>in full<font style="letter-spacing:-0.05pt;"> </font>force<font style="letter-spacing:-0.05pt;"> </font>and<font style="letter-spacing:0.05pt;"> </font>effect.</p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:11.5pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:11.19%;margin-right:1.31%;text-indent:6.72%;font-weight:bold;letter-spacing:-0.15pt;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">I<font style="font-size:9.5pt;">N </font>W<font style="font-size:9.5pt;">ITNESS </font>W<font style="font-size:9.5pt;">HEREOF</font><font style="font-weight:normal;">,</font><font style="letter-spacing:-0.6pt;font-weight:normal;"> </font><font style="font-weight:normal;">the Parties</font><font style="letter-spacing:-0.6pt;font-weight:normal;"> </font><font style="font-weight:normal;">hereto</font><font style="letter-spacing:-0.6pt;font-weight:normal;"> </font><font style="font-weight:normal;">have</font><font style="letter-spacing:-0.4pt;font-weight:normal;"> </font><font style="font-weight:normal;">executed</font><font style="letter-spacing:-0.6pt;font-weight:normal;"> </font><font style="letter-spacing:-0.1pt;font-weight:normal;">this</font><font style="letter-spacing:-0.35pt;font-weight:normal;"> </font><font style="letter-spacing:-0.1pt;font-weight:normal;">Amendment</font><font style="letter-spacing:-0.6pt;font-weight:normal;"> </font><font style="letter-spacing:-0.1pt;font-weight:normal;">as</font><font style="letter-spacing:-0.35pt;font-weight:normal;"> </font><font style="letter-spacing:-0.1pt;font-weight:normal;">of</font><font style="font-weight:normal;"> </font><font style="letter-spacing:-0.1pt;font-weight:normal;">the</font><font style="letter-spacing:-0.45pt;font-weight:normal;"> </font><font style="letter-spacing:-0.1pt;font-weight:normal;">date</font><font style="letter-spacing:-0.4pt;font-weight:normal;"> </font><font style="letter-spacing:-0.1pt;font-weight:normal;">first</font><font style="letter-spacing:-2.85pt;font-weight:normal;"> </font><font style="font-weight:normal;">written</font><font style="letter-spacing:-0.45pt;font-weight:normal;"> </font><font style="font-weight:normal;">above.</font></p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;">&nbsp;</p>
<p style="margin-top:4pt;margin-bottom:0pt;margin-left:11.39%;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">U<font style="font-size:9.5pt;">RO</font>G<font style="font-size:9.5pt;">EN</font><font style="font-size:9.5pt;letter-spacing:-0.15pt;"> </font>P<font style="font-size:9.5pt;">HARMA</font>,<font style="letter-spacing:-0.7pt;"> </font>I<font style="font-size:9.5pt;">NC</font>.<font style="margin-left:294pt;">E</font><font style="font-size:9.5pt;">XECUTIVE</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="margin-top:4pt;margin-bottom:0pt;margin-left:11.39%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:<font style="text-decoration:underline;"> /s/ Elizabeth Barrett</font><font style="text-decoration:underline;margin-left:228pt;"></font><font style="margin-left:294pt;"></font><font style="text-decoration:underline;"> /s/ Jason Smith</font><font style="text-decoration:underline;margin-left:228pt;"></font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.67%;text-indent:6.72%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU2"></a>Name:<font style="letter-spacing:2.55pt;"> </font>Elizabeth<font style="letter-spacing:-0.15pt;"> </font>Barrett<font style="margin-left:36pt;">&nbsp;&nbsp;Name:</font><font style="letter-spacing:-0.1pt;"> </font>Jason<font style="letter-spacing:-0.1pt;"> </font>D.<font style="letter-spacing:-0.05pt;"> </font>Smith</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:11.39%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Title:<font style="margin-left:101pt;">Chief</font><font style="letter-spacing:-0.15pt;"> </font>Executive<font style="letter-spacing:-0.15pt;"> </font>Officer</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br /></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 10.4</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:11.39%;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.5
<SEQUENCE>6
<FILENAME>urgn-ex105_99.htm
<DESCRIPTION>EX-10.5
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
urgn-ex105_99.htm
</title>
</head>
<!-- NG Converter v5.0.2.50 -->
<body>

<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-size:11pt;font-weight:bold;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;text-indent:0%;">Exhibit 10.5</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-weight:bold;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-weight:bold;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">AMENDMENT NO. 2 TO EXECUTIVE EMPLOYMENT AGREEMENT</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This Amendment No. 2 (this &#8220;<font style="text-decoration:underline;">Second Amendment</font>&#8221;) to that <font style="Background-color:#FFFFFF;color:#000000;">certain Executive Employment Agreement, made as of January 23, 2020, as amended, by and between </font>UroGen Pharma Inc., a wholly owned subsidiary (the &#8220;<font style="text-decoration:underline;">Subsidiary</font>&#8221;) of UroGen Pharma Ltd. (the &#8220;<font style="text-decoration:underline;">Parent</font>&#8221;) (the Subsidiary and the Parent together, the &#8220;<font style="text-decoration:underline;">Company</font>&#8221;) and Mark P. Schoenberg, MD (the &#8220;<font style="text-decoration:underline;">Executive</font>&#8221;). The Subsidiary, Parent and Executive are collectively referred to in this Second Amendment as the &#8220;<font style="text-decoration:underline;">Parties</font>.&#8221;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-variant: small-caps;font-style:normal;text-transform:none;">Whereas<font style="font-weight:normal;font-variant: normal;">, the Company and Executive are Parties to a certain Executive Employment Agreement </font><font style="Background-color:#FFFFFF;color:#000000;font-weight:normal;font-variant: normal;">effective as of January 23, 2020, as amended </font><font style="font-weight:normal;font-variant: normal;">(the &#8220;</font><font style="text-decoration:underline;font-weight:normal;font-variant: normal;">Agreement</font><font style="font-weight:normal;font-variant: normal;">&#8221;) (capitalized terms used and not otherwise defined herein shall have the meanings given to such terms in the Agreement);  </font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-variant: small-caps;font-style:normal;text-transform:none;">Whereas<font style="font-weight:normal;font-variant: normal;">, on March 15, 2021, the Parent&#8217;s Compensation, Nominating and Corporate Governance Committee approved an increase in the reduced-time capacity under the Agreement from a 50% full-time equivalent role to a 75% full-time equivalent role as of January 1, 2021 (&#8220;</font><font style="text-decoration:underline;font-weight:normal;font-variant: normal;">Reduced Time Employment</font><font style="font-weight:normal;font-variant: normal;">&#8221;); and </font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> <font style="font-weight:bold;font-variant: small-caps;">Whereas</font>, on March 17, 2021, the Parent&#8217;s Board of Directors endorsed and approved the Reduced Time Employment. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-variant: small-caps;font-style:normal;text-transform:none;">Now Therefore<font style="font-weight:normal;font-variant: normal;">, in consideration and in furtherance of Executive&#8217;s continued at-will employment with the Company, and for other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the Parties hereto agree as follows: </font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.<font style="margin-left:36pt;"></font>Section 2.1 of the Agreement is hereby amended by deleting the entire section thereof and replacing it with the following: </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;margin-right:7.69%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> &#8220;<font style="font-weight:bold;">2.1 Salary</font>. For services to be rendered hereunder during Executive&#8217;s 75% full-time equivalent employment with the Company (the &#8220;<font style="font-weight:bold;">reduced-time employment</font>&#8221;), Executive shall receive an annual base salary of $307,500 effective January 1, 2021 through February 28, 2021, and beginning on March 1, 2021 and thereafter an annual base salary of $316,725 (the &#8220;<font style="font-weight:bold;">Base Salary</font>&#8221;), to be reviewed annually by the Board of Directors for increase only; not subject to decrease at any time or for any reason. The Base Salary will be subject to standard payroll deductions and withholding and payable in accordance with the Company&#8217;s regular payroll schedule.&#8221;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.<font style="margin-left:36pt;"></font>Section 3 of the Agreement is hereby amended by deleting the entire section thereof and replacing it with the following:</p>
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;margin-right:7.69%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_92"></a><a name="_cp_text_1_92"></a>&#8220;<font style="font-weight:bold;">3. Standard Company Benefits</font>. Executive shall be entitled to participate in all employee benefit programs for which Executive is eligible under the terms and conditions of the benefit plans that may be in effect from time to time and provided </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;margin-left:7.69%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-1</a>-</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;margin-right:7.69%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU2"></a><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">by the Company to its employees, except that under the PTO plan for senior executives effective January 1, 202</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> (i) Executive&#8217;s PTO shall be prorated at </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">75</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%; and (ii) Executive&#8217;s accrual of paid-time off shall be prorated at </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">75</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%. The Company reserves the right to</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">cancel or change the benefit plans or programs it offers to its employees at any time</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8221;</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.<font style="margin-left:36pt;"></font>This Second Amendment may be executed in several counterparts, all of which taken together shall constitute one single agreement between the parties. Except as amended hereby, all of the other terms and conditions of the Agreement shall remain and continue in full force and effect.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-variant: small-caps;letter-spacing:-0.15pt;font-style:normal;text-transform:none;">In Witness Whereof<font style="letter-spacing:-0.2pt;font-weight:normal;font-variant: normal;">, </font><font style="font-weight:normal;font-variant: normal;">the </font><font style="letter-spacing:-0.2pt;font-weight:normal;font-variant: normal;">Parties </font><font style="font-weight:normal;font-variant: normal;">have </font><font style="letter-spacing:-0.2pt;font-weight:normal;font-variant: normal;">executed </font><font style="font-weight:normal;font-variant: normal;">this </font><font style="letter-spacing:-0.2pt;font-weight:normal;font-variant: normal;">Second Amendment </font><font style="font-weight:normal;font-variant: normal;">as </font><font style="font-weight:normal;font-variant: normal;">of </font><font style="font-weight:normal;font-variant: normal;">April 13, 2021.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:99.89%;">
<tr>
<td style="width:49.95%;"></td>
<td style="width:49.95%;"></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:-4.5pt;;text-indent:0pt;;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-variant: small-caps;font-style:normal;text-transform:none;">UroGen Pharma Inc.</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:-4.5pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:-4.5pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:-4.5pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:<font style="text-decoration:underline;">/s/ Elizabeth Barrett&nbsp;&nbsp; </font></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:-4.5pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Name:Elizabeth Barrett</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:-4.5pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Title:Chief Executive Officer</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:-4.5pt;;text-indent:0pt;;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-variant: small-caps;font-style:normal;text-transform:none;">Executive</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:-4.5pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:-4.5pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:-4.5pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">/s/ Mark Schoenberg</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:-4.5pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">Name: Mark S. Schoenberg</font></p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-variant: small-caps;font-style:normal;text-transform:none;">UroGen Pharma Ltd.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By: <font style="text-decoration:underline;">/s/ Elizabeth Barrett</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Name:<font style="margin-left:36pt;"></font>Elizabeth Barrett</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Title:<font style="margin-left:36pt;">Chief Executive Officer</font></p>
<p style="margin-bottom:8pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br /></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;margin-left:7.69%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-2</a>-</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;margin-left:7.69%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-3</a>-</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.6
<SEQUENCE>7
<FILENAME>urgn-ex106_433.htm
<DESCRIPTION>EX-10.6
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
urgn-ex106_433.htm
</title>
</head>
<!-- NG Converter v5.0.2.50 -->
<body>

<p style="text-align:right;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 10.6</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT UROGEN PHARMA LTD. TREATS AS PRIVATE OR CONFIDENTIAL</p>
<p style="Background-color:#auto;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"><a name="_Hlk55152212"></a><a name="_Hlk54855729"></a><a name="_Hlk55153632"></a><a name="_Hlk66040733"></a>&nbsp;</p>
<p style="Background-color:#auto;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:left;Background-color:#auto;margin-bottom:24pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-weight:bold;text-transform:uppercase;">&nbsp;</p>
<p style="Background-color:#auto;text-align:center;margin-bottom:24pt;margin-top:0pt;text-indent:0%;font-weight:normal;font-variant: small-caps;text-transform:uppercase;font-size:12pt;font-family:Times New Roman;font-style:normal;">PRE-PAID FORWARD CONTRACT</p>
<p style="Background-color:#auto;text-align:center;margin-bottom:24pt;margin-top:0pt;text-indent:0%;font-weight:normal;text-transform:none;font-variant: small-caps;font-size:12pt;font-family:Times New Roman;font-style:normal;">By and Between</p>
<p style="text-align:center;Background-color:#auto;margin-bottom:15pt;margin-top:0pt;text-indent:0%;font-weight:normal;font-variant: small-caps;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;">UroGen Pharma Ltd.</p>
<p style="Background-color:#auto;text-align:center;margin-bottom:24pt;margin-top:0pt;text-indent:0%;font-weight:normal;text-transform:none;font-variant: small-caps;font-size:12pt;font-family:Times New Roman;font-style:normal;">and</p>
<p style="Background-color:#auto;text-align:center;margin-bottom:24pt;margin-top:0pt;text-indent:0%;font-weight:normal;text-transform:none;font-variant: small-caps;font-size:12pt;font-family:Times New Roman;font-style:normal;">RTW Investments ICAV for RTW Fund 2</p>
<p style="Background-color:#auto;text-align:center;margin-bottom:24pt;margin-top:0pt;text-indent:0%;font-weight:normal;text-transform:none;font-variant: small-caps;font-size:12pt;font-family:Times New Roman;font-style:normal;">Dated as of March 18, 2021</p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:bold;">&nbsp;</p>
<p style="Background-color:#auto;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;Background-color:#FFFFFF;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
<p style="margin-top:12pt;line-height:10pt;Background-color:#FFFFFF;margin-bottom:0pt;text-indent:0%;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">250212926 v1</p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:7pt;font-family:Times New Roman;">&nbsp;</p>&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;Background-color:#auto;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> <font style="font-weight:bold;">Exhibit 10.6</font></p>
<p style="text-align:center;Background-color:#auto;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU2"></a><font style="font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">TABLE OF CONTENTS</font></p>
<p style="Background-color:#auto;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Page</font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.15%;white-space:nowrap">
<p style="margin-top:6pt;Background-color:#FFFFFF;margin-bottom:0pt;color:#010000;text-transform:uppercase;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;font-variant: normal;"><font style="color:#010000;text-transform:uppercase;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;font-variant: normal;">ARTICLE 1</font><font style="text-transform:uppercase;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;font-variant: normal;"> DEFINITIONS</font></p></td>
<td valign="top">
<p style="margin-top:6pt;Background-color:#FFFFFF;margin-bottom:0pt;color:#010000;text-transform:uppercase;font-weight:normal;font-style:normal;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><font style="color:#000000;">1</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.15%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:18.85%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;color:#010000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#010000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Section 1.1</font></p></td>
<td valign="top">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;"><font style="color:#auto;"></font><font style="text-decoration:underline;font-family:Times New Roman;font-size:10pt;">Definitions</font><font style="font-family:Times New Roman;font-size:10pt;">1</font></p></td>
<td valign="top" style="width:1.92%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.15%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:18.85%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;color:#010000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#010000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Section 1.2</font></p></td>
<td valign="top">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;"><font style="color:#auto;"></font><font style="text-decoration:underline;font-family:Times New Roman;font-size:10pt;">Certain Interpretations</font><font style="font-family:Times New Roman;font-size:10pt;">20</font></p></td>
<td valign="top" style="width:1.92%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.15%;white-space:nowrap">
<p style="margin-top:6pt;Background-color:#FFFFFF;margin-bottom:0pt;color:#010000;text-transform:uppercase;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;font-variant: normal;"><font style="color:#010000;text-transform:uppercase;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;font-variant: normal;">ARTICLE 2</font><font style="text-transform:uppercase;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;font-variant: normal;"> GRANT OF THE REVENUE PARTICIPATION RIGHT</font></p></td>
<td valign="top">
<p style="margin-top:6pt;Background-color:#FFFFFF;margin-bottom:0pt;color:#010000;text-transform:uppercase;font-weight:normal;font-style:normal;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><font style="color:#000000;">21</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.15%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:18.85%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;color:#010000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#010000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Section 2.1</font></p></td>
<td valign="top">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;"><font style="color:#auto;"></font><font style="text-decoration:underline;font-family:Times New Roman;font-size:10pt;">Grant</font><font style="font-family:Times New Roman;font-size:10pt;">21</font></p></td>
<td valign="top" style="width:1.92%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.15%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:18.85%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;color:#010000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#010000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Section 2.2</font></p></td>
<td valign="top">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;"><font style="color:#auto;"></font><font style="text-decoration:underline;font-family:Times New Roman;font-size:10pt;">Pre-Paid Forward Price</font><font style="font-family:Times New Roman;font-size:10pt;">21</font></p></td>
<td valign="top" style="width:1.92%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.15%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:18.85%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;color:#010000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#010000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Section 2.3</font></p></td>
<td valign="top">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;"><font style="color:#auto;"></font><font style="text-decoration:underline;font-family:Times New Roman;font-size:10pt;">No Assumed Obligations, Etc.</font><font style="font-family:Times New Roman;font-size:10pt;">21</font></p></td>
<td valign="top" style="width:1.92%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.15%;white-space:nowrap">
<p style="margin-top:6pt;Background-color:#FFFFFF;margin-bottom:0pt;color:#010000;text-transform:uppercase;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;font-variant: normal;"><font style="color:#010000;text-transform:uppercase;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;font-variant: normal;">ARTICLE 3</font><font style="text-transform:uppercase;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;font-variant: normal;"> CLOSING</font></p></td>
<td valign="top">
<p style="margin-top:6pt;Background-color:#FFFFFF;margin-bottom:0pt;color:#010000;text-transform:uppercase;font-weight:normal;font-style:normal;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><font style="color:#000000;">22</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.15%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:18.85%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;color:#010000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#010000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Section 3.1</font></p></td>
<td valign="top">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;"><font style="color:#auto;"></font><font style="text-decoration:underline;font-family:Times New Roman;font-size:10pt;">Closing</font><font style="font-family:Times New Roman;font-size:10pt;">22</font></p></td>
<td valign="top" style="width:1.92%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.15%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:18.85%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;color:#010000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#010000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Section 3.2</font></p></td>
<td valign="top">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;"><font style="color:#auto;"></font><font style="text-decoration:underline;font-family:Times New Roman;font-size:10pt;">Payment of Pre-Paid Forward Price</font><font style="font-family:Times New Roman;font-size:10pt;">22</font></p></td>
<td valign="top" style="width:1.92%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.15%;white-space:nowrap">
<p style="margin-top:6pt;Background-color:#FFFFFF;margin-bottom:0pt;color:#010000;text-transform:uppercase;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;font-variant: normal;"><font style="color:#010000;text-transform:uppercase;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;font-variant: normal;">ARTICLE 4</font><font style="text-transform:uppercase;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;font-variant: normal;"> REPRESENTATIONS AND WARRANTIES</font></p></td>
<td valign="top">
<p style="margin-top:6pt;Background-color:#FFFFFF;margin-bottom:0pt;color:#010000;text-transform:uppercase;font-weight:normal;font-style:normal;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><font style="color:#000000;">22</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.15%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:18.85%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;color:#010000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#010000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Section 4.1</font></p></td>
<td valign="top">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;"><font style="color:#auto;"></font><font style="text-decoration:underline;font-family:Times New Roman;font-size:10pt;">Company&#8217;s Representations and Warranties</font><font style="font-family:Times New Roman;font-size:10pt;">22</font></p></td>
<td valign="top" style="width:1.92%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.15%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:18.85%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;color:#010000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#010000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Section 4.2</font></p></td>
<td valign="top">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;"><font style="color:#auto;"></font><font style="text-decoration:underline;font-family:Times New Roman;font-size:10pt;">Payer&#8217;s Representations and Warranties</font><font style="font-family:Times New Roman;font-size:10pt;">26</font></p></td>
<td valign="top" style="width:1.92%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.15%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:18.85%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;color:#010000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#010000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Section 4.3</font></p></td>
<td valign="top">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;"><font style="color:#auto;"></font><font style="text-decoration:underline;font-family:Times New Roman;font-size:10pt;">No Implied Representations and Warranties</font><font style="font-family:Times New Roman;font-size:10pt;">27</font></p></td>
<td valign="top" style="width:1.92%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.15%;white-space:nowrap">
<p style="margin-top:6pt;Background-color:#FFFFFF;margin-bottom:0pt;color:#010000;text-transform:uppercase;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;font-variant: normal;"><font style="color:#010000;text-transform:uppercase;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;font-variant: normal;">ARTICLE 5</font><font style="text-transform:uppercase;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;font-variant: normal;"> CONDITIONS TO CLOSING</font></p></td>
<td valign="top">
<p style="margin-top:6pt;Background-color:#FFFFFF;margin-bottom:0pt;color:#010000;text-transform:uppercase;font-weight:normal;font-style:normal;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><font style="color:#000000;">28</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.15%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:18.85%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;color:#010000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#010000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Section 5.1</font></p></td>
<td valign="top">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;"><font style="color:#auto;"></font><font style="text-decoration:underline;font-family:Times New Roman;font-size:10pt;">Conditions to the Payer&#8217;s Obligations</font><font style="font-family:Times New Roman;font-size:10pt;">28</font></p></td>
<td valign="top" style="width:1.92%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.15%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:18.85%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;color:#010000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#010000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Section 5.2</font></p></td>
<td valign="top">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;"><font style="color:#auto;"></font><font style="text-decoration:underline;font-family:Times New Roman;font-size:10pt;">Conditions to the Company&#8217;s Obligations</font><font style="font-family:Times New Roman;font-size:10pt;">29</font></p></td>
<td valign="top" style="width:1.92%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.15%;white-space:nowrap">
<p style="margin-top:6pt;Background-color:#FFFFFF;margin-bottom:0pt;color:#010000;text-transform:uppercase;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;font-variant: normal;"><font style="color:#010000;text-transform:uppercase;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;font-variant: normal;">ARTICLE 6</font><font style="text-transform:uppercase;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;font-variant: normal;"> COVENANTS</font></p></td>
<td valign="top">
<p style="margin-top:6pt;Background-color:#FFFFFF;margin-bottom:0pt;color:#010000;text-transform:uppercase;font-weight:normal;font-style:normal;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><font style="color:#000000;">31</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.15%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:18.85%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;color:#010000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#010000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Section 6.1</font></p></td>
<td valign="top">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;"><font style="color:#auto;"></font><font style="text-decoration:underline;font-family:Times New Roman;font-size:10pt;">Reporting</font><font style="font-family:Times New Roman;font-size:10pt;">31</font></p></td>
<td valign="top" style="width:1.92%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.15%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:18.85%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;color:#010000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#010000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Section 6.2</font></p></td>
<td valign="top">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;"><font style="color:#auto;"></font><font style="text-decoration:underline;font-family:Times New Roman;font-size:10pt;">Revenue Payments; Revenue Participation and Revenue Payment Details</font><font style="font-family:Times New Roman;font-size:10pt;">31</font></p></td>
<td valign="top" style="width:1.92%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.15%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:18.85%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;color:#010000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#010000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Section 6.3</font></p></td>
<td valign="top">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;"><font style="color:#auto;"></font><font style="text-decoration:underline;font-family:Times New Roman;font-size:10pt;">Disclosures</font><font style="font-family:Times New Roman;font-size:10pt;">32</font></p></td>
<td valign="top" style="width:1.92%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.15%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:18.85%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;color:#010000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#010000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Section 6.4</font></p></td>
<td valign="top">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;"><font style="color:#auto;"></font><font style="text-decoration:underline;font-family:Times New Roman;font-size:10pt;">Inspections and Audits of the Company</font><font style="font-family:Times New Roman;font-size:10pt;">33</font></p></td>
<td valign="top" style="width:1.92%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.15%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:18.85%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;color:#010000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#010000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Section 6.5</font></p></td>
<td valign="top">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;"><font style="color:#auto;"></font><font style="text-decoration:underline;font-family:Times New Roman;font-size:10pt;">Intellectual Property Matters</font><font style="font-family:Times New Roman;font-size:10pt;">.33</font></p></td>
<td valign="top" style="width:1.92%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.15%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:18.85%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;color:#010000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#010000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Section 6.6</font></p></td>
<td valign="top">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;"><font style="color:#auto;"></font><font style="text-decoration:underline;font-family:Times New Roman;font-size:10pt;">In-Licenses</font><font style="font-family:Times New Roman;font-size:10pt;">34</font></p></td>
<td valign="top" style="width:1.92%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.15%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:18.85%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;color:#010000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#010000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Section 6.7</font></p></td>
<td valign="top">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;"><font style="color:#auto;"></font><font style="text-decoration:underline;font-family:Times New Roman;font-size:10pt;">Out-Licenses</font><font style="font-family:Times New Roman;font-size:10pt;">.35</font></p></td>
<td valign="top" style="width:1.92%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.15%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:18.85%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;color:#010000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#010000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Section 6.8</font></p></td>
<td valign="top">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;"><font style="color:#auto;"></font><font style="text-decoration:underline;font-family:Times New Roman;font-size:10pt;">Negative Pledge and Intercreditor Agreement</font><font style="font-family:Times New Roman;font-size:10pt;">36</font></p></td>
<td valign="top" style="width:1.92%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.15%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:18.85%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;color:#010000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#010000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Section 6.9</font></p></td>
<td valign="top">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;"><font style="color:#auto;"></font><font style="text-decoration:underline;font-family:Times New Roman;font-size:10pt;">Insolvency Event</font><font style="font-family:Times New Roman;font-size:10pt;">36</font></p></td>
<td valign="top" style="width:1.92%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.15%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:18.85%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;color:#010000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#010000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Section 6.10</font></p></td>
<td valign="top">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;"><font style="color:#auto;"></font><font style="text-decoration:underline;font-family:Times New Roman;font-size:10pt;">Use of Proceeds; Diligence</font><font style="font-family:Times New Roman;font-size:10pt;">.36</font></p></td>
<td valign="top" style="width:1.92%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.15%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:18.85%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;color:#010000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#010000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Section 6.11</font></p></td>
<td valign="top">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;"><font style="color:#auto;"></font><font style="text-decoration:underline;font-family:Times New Roman;font-size:10pt;">IIA</font><font style="font-family:Times New Roman;font-size:10pt;">37</font></p></td>
<td valign="top" style="width:1.92%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.15%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:18.85%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;color:#010000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#010000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Section 6.12</font></p></td>
<td valign="top">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;"><font style="color:#auto;"></font><font style="text-decoration:underline;font-family:Times New Roman;font-size:10pt;">Efforts to Consummate Transactions</font><font style="font-family:Times New Roman;font-size:10pt;">37</font></p></td>
<td valign="top" style="width:1.92%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.15%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:18.85%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;color:#010000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#010000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Section 6.13</font></p></td>
<td valign="top">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;"><font style="color:#auto;"></font><font style="text-decoration:underline;font-family:Times New Roman;font-size:10pt;">Further Assurances</font><font style="font-family:Times New Roman;font-size:10pt;">37</font></p></td>
<td valign="top" style="width:1.92%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.15%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:18.85%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;color:#010000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#010000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Section 6.14</font></p></td>
<td valign="top">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;"><font style="color:#auto;"></font><font style="text-decoration:underline;font-family:Times New Roman;font-size:10pt;">Product Collateral</font><font style="font-family:Times New Roman;font-size:10pt;">37</font></p></td>
<td valign="top" style="width:1.92%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.15%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:18.85%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;color:#010000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#010000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Section 6.15</font></p></td>
<td valign="top">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;"><font style="color:#auto;"></font><font style="text-decoration:underline;font-family:Times New Roman;font-size:10pt;">Escrow</font><font style="font-family:Times New Roman;font-size:10pt;">37</font></p></td>
<td valign="top" style="width:1.92%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.15%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:18.85%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;color:#010000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#010000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Section 6.16</font></p></td>
<td valign="top">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;"><font style="color:#auto;"></font><font style="text-decoration:underline;font-family:Times New Roman;font-size:10pt;">Certain Tax Matters</font><font style="font-family:Times New Roman;font-size:10pt;">.38</font></p></td>
<td valign="top" style="width:1.92%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.15%;white-space:nowrap">
<p style="margin-top:6pt;Background-color:#FFFFFF;margin-bottom:0pt;color:#010000;text-transform:uppercase;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;font-variant: normal;"><font style="color:#010000;text-transform:uppercase;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;font-variant: normal;">ARTICLE 7</font><font style="text-transform:uppercase;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;font-variant: normal;"> INDEMNIFICATION</font></p></td>
<td valign="top">
<p style="margin-top:6pt;Background-color:#FFFFFF;margin-bottom:0pt;color:#010000;text-transform:uppercase;font-weight:normal;font-style:normal;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><font style="color:#000000;">39</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.15%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:18.85%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;color:#010000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#010000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Section 7.1</font></p></td>
<td valign="top">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;"><font style="color:#auto;"></font><font style="text-decoration:underline;font-family:Times New Roman;font-size:10pt;">General Indemnity</font><font style="font-family:Times New Roman;font-size:10pt;">39</font></p></td>
<td valign="top" style="width:1.92%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.15%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:18.85%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;color:#010000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#010000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Section 7.2</font></p></td>
<td valign="top">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;"><font style="color:#auto;"></font><font style="text-decoration:underline;font-family:Times New Roman;font-size:10pt;">Notice of Claims</font><font style="font-family:Times New Roman;font-size:10pt;">39</font></p></td>
<td valign="top" style="width:1.92%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.15%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:18.85%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;color:#010000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#010000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Section 7.3</font></p></td>
<td valign="top">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;"><font style="color:#auto;"></font><font style="text-decoration:underline;font-family:Times New Roman;font-size:10pt;">Limitations on Liability</font><font style="font-family:Times New Roman;font-size:10pt;">39</font></p></td>
<td valign="top" style="width:1.92%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.15%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:18.85%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;color:#010000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#010000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Section 7.4</font></p></td>
<td valign="top">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;"><font style="color:#auto;"></font><font style="text-decoration:underline;font-family:Times New Roman;font-size:10pt;">Exclusive Remedy</font><font style="font-family:Times New Roman;font-size:10pt;">40</font></p></td>
<td valign="top" style="width:1.92%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.15%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:18.85%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;color:#010000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#010000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Section 7.5</font></p></td>
<td valign="top">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;"><font style="color:#auto;"></font><font style="text-decoration:underline;font-family:Times New Roman;font-size:10pt;">Tax Treatment of Indemnification Payments</font><font style="font-family:Times New Roman;font-size:10pt;">40</font></p></td>
<td valign="top" style="width:1.92%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.15%;white-space:nowrap">
<p style="margin-top:6pt;Background-color:#FFFFFF;margin-bottom:0pt;color:#010000;text-transform:uppercase;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;font-variant: normal;"><font style="color:#010000;text-transform:uppercase;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;font-variant: normal;">ARTICLE 8</font><font style="text-transform:uppercase;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;font-variant: normal;"> CONFIDENTIALITY</font></p></td>
<td valign="top">
<p style="margin-top:6pt;Background-color:#FFFFFF;margin-bottom:0pt;color:#010000;text-transform:uppercase;font-weight:normal;font-style:normal;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><font style="color:#000000;">40</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.15%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:18.85%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;color:#010000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#010000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Section 8.1</font></p></td>
<td valign="top">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;"><font style="color:#auto;"></font><font style="text-decoration:underline;font-family:Times New Roman;font-size:10pt;">Confidentiality</font><font style="font-family:Times New Roman;font-size:10pt;">40</font></p></td>
<td valign="top" style="width:1.92%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.15%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:18.85%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;color:#010000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#010000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Section 8.2</font></p></td>
<td valign="top">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;"><font style="color:#auto;"></font><font style="text-decoration:underline;font-family:Times New Roman;font-size:10pt;">Authorized Disclosure</font><font style="font-family:Times New Roman;font-size:10pt;">41</font></p></td>
<td valign="top" style="width:1.92%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.15%;white-space:nowrap">
<p style="margin-top:6pt;Background-color:#FFFFFF;margin-bottom:0pt;color:#010000;text-transform:uppercase;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;font-variant: normal;"><font style="color:#010000;text-transform:uppercase;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;font-variant: normal;">ARTICLE 9</font><font style="text-transform:uppercase;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;font-variant: normal;"> TERMINATION</font></p></td>
<td valign="top">
<p style="margin-top:6pt;Background-color:#FFFFFF;margin-bottom:0pt;color:#010000;text-transform:uppercase;font-weight:normal;font-style:normal;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><font style="color:#000000;">42</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.15%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:18.85%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;color:#010000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#010000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Section 9.1</font></p></td>
<td valign="top">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;"><font style="color:#auto;"></font><font style="text-decoration:underline;font-family:Times New Roman;font-size:10pt;">Mutual Termination</font><font style="font-family:Times New Roman;font-size:10pt;">42</font></p></td>
<td valign="top" style="width:1.92%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.15%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:18.85%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;color:#010000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#010000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Section 9.2</font></p></td>
<td valign="top">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;"><font style="color:#auto;"></font><font style="text-decoration:underline;font-family:Times New Roman;font-size:10pt;">Automatic Termination</font><font style="font-family:Times New Roman;font-size:10pt;">42</font></p></td>
<td valign="top" style="width:1.92%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td></tr></table></div>
<p style="text-align:center;Background-color:#auto;margin-top:12pt;line-height:10pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(i</a>)</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
<p style="line-height:10pt;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">250212926 v1</p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:7pt;font-family:Times New Roman;">&nbsp;</p>&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;Background-color:#auto;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> <font style="font-weight:bold;">Exhibit 10.6</font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.15%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:18.85%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;color:#010000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#010000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Section 9.3</font></p></td>
<td valign="top">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;"><a name="_AEIOULastRenderedPageBreakAEIOU3"></a><font style="font-family:Times New Roman;font-size:10pt;"></font><font style="color:#auto;"></font><font style="text-decoration:underline;font-family:Times New Roman;font-size:10pt;">Survival</font><font style="font-family:Times New Roman;font-size:10pt;">42</font></p></td>
<td valign="top" style="width:1.92%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.15%;white-space:nowrap">
<p style="margin-top:6pt;Background-color:#FFFFFF;margin-bottom:0pt;color:#010000;text-transform:uppercase;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;font-variant: normal;"><font style="color:#010000;text-transform:uppercase;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;font-variant: normal;">ARTICLE 10</font><font style="text-transform:uppercase;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;font-variant: normal;"> MISCELLANEOUS</font></p></td>
<td valign="top">
<p style="margin-top:6pt;Background-color:#FFFFFF;margin-bottom:0pt;color:#010000;text-transform:uppercase;font-weight:normal;font-style:normal;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><font style="color:#000000;">42</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.15%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:18.85%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;color:#010000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#010000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Section 10.1</font></p></td>
<td valign="top">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;"><font style="color:#auto;"></font><font style="text-decoration:underline;font-family:Times New Roman;font-size:10pt;">Headings</font><font style="font-family:Times New Roman;font-size:10pt;">42</font></p></td>
<td valign="top" style="width:1.92%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.15%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:18.85%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;color:#010000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#010000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Section 10.2</font></p></td>
<td valign="top">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;"><font style="color:#auto;"></font><font style="text-decoration:underline;font-family:Times New Roman;font-size:10pt;">Notices</font><font style="font-family:Times New Roman;font-size:10pt;">42</font></p></td>
<td valign="top" style="width:1.92%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.15%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:18.85%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;color:#010000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#010000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Section 10.3</font></p></td>
<td valign="top">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;"><font style="color:#auto;"></font><font style="text-decoration:underline;font-family:Times New Roman;font-size:10pt;">Expenses</font><font style="font-family:Times New Roman;font-size:10pt;">43</font></p></td>
<td valign="top" style="width:1.92%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.15%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:18.85%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;color:#010000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#010000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Section 10.4</font></p></td>
<td valign="top">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;"><font style="color:#auto;"></font><font style="text-decoration:underline;font-family:Times New Roman;font-size:10pt;">Assignment</font><font style="font-family:Times New Roman;font-size:10pt;">43</font></p></td>
<td valign="top" style="width:1.92%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.15%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:18.85%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;color:#010000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#010000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Section 10.5</font></p></td>
<td valign="top">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;"><font style="color:#auto;"></font><font style="text-decoration:underline;font-family:Times New Roman;font-size:10pt;">Amendment and Waiver</font><font style="font-family:Times New Roman;font-size:10pt;">.44</font></p></td>
<td valign="top" style="width:1.92%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.15%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:18.85%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;color:#010000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#010000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Section 10.6</font></p></td>
<td valign="top">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;"><font style="color:#auto;"></font><font style="text-decoration:underline;font-family:Times New Roman;font-size:10pt;">Entire Agreement</font><font style="font-family:Times New Roman;font-size:10pt;">44</font></p></td>
<td valign="top" style="width:1.92%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.15%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:18.85%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;color:#010000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#010000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Section 10.7</font></p></td>
<td valign="top">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;"><font style="color:#auto;"></font><font style="text-decoration:underline;font-family:Times New Roman;font-size:10pt;">No Third-Party Beneficiaries</font><font style="font-family:Times New Roman;font-size:10pt;">44</font></p></td>
<td valign="top" style="width:1.92%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.15%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:18.85%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;color:#010000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#010000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Section 10.8</font></p></td>
<td valign="top">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;"><font style="color:#auto;"></font><font style="text-decoration:underline;font-family:Times New Roman;font-size:10pt;">Governing Law</font><font style="font-family:Times New Roman;font-size:10pt;">45</font></p></td>
<td valign="top" style="width:1.92%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.15%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:18.85%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;color:#010000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#010000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Section 10.9</font></p></td>
<td valign="top">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;"><font style="color:#auto;"></font><font style="text-decoration:underline;font-family:Times New Roman;font-size:10pt;">Jurisdiction; Venue</font><font style="font-family:Times New Roman;font-size:10pt;">.45</font></p></td>
<td valign="top" style="width:1.92%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.15%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:18.85%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;color:#010000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#010000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Section 10.10</font></p></td>
<td valign="top">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;"><font style="color:#auto;"></font><font style="text-decoration:underline;font-family:Times New Roman;font-size:10pt;">Severability</font><font style="font-family:Times New Roman;font-size:10pt;">46</font></p></td>
<td valign="top" style="width:1.92%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.15%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:18.85%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;color:#010000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#010000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Section 10.11</font></p></td>
<td valign="top">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;"><font style="color:#auto;"></font><font style="text-decoration:underline;font-family:Times New Roman;font-size:10pt;">Specific Performance</font><font style="font-family:Times New Roman;font-size:10pt;">46</font></p></td>
<td valign="top" style="width:1.92%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.15%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:18.85%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;color:#010000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#010000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Section 10.12</font></p></td>
<td valign="top">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;"><font style="color:#auto;"></font><font style="text-decoration:underline;font-family:Times New Roman;font-size:10pt;">Counterparts</font><font style="font-family:Times New Roman;font-size:10pt;">46</font></p></td>
<td valign="top" style="width:1.92%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.15%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:18.85%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;color:#010000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#010000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Section 10.13</font></p></td>
<td valign="top">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;"><font style="color:#auto;"></font><font style="text-decoration:underline;font-family:Times New Roman;font-size:10pt;">Relationship of the Parties</font><font style="font-family:Times New Roman;font-size:10pt;">46</font></p></td>
<td valign="top" style="width:1.92%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;color:#010000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td></tr></table></div>
<p style="Background-color:#auto;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="Background-color:#auto;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU4"></a><br /></p>
<p style="text-align:center;Background-color:#auto;margin-top:12pt;line-height:10pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(ii)</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
<p style="line-height:10pt;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">250212926 v1</p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:7pt;font-family:Times New Roman;">&nbsp;</p>&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;Background-color:#auto;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> <font style="font-weight:bold;">Exhibit 10.6</font></p>
<p style="Background-color:#auto;margin-bottom:0pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;text-decoration:underline;">Index of Exhibits, Schedules and Annexes</font></p>
<p style="Background-color:#auto;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="Background-color:#auto;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk65621469"></a>Exhibit A:<font style="margin-left:63pt;">Form of Company Opinions</font></p>
<p style="Background-color:#auto;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exhibit B:<font style="margin-left:63pt;">Valuation Procedures</font></p>
<p style="Background-color:#auto;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="Background-color:#auto;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:70.3%;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:70.3%;">&nbsp;</p>
<p style="text-align:center;Background-color:#auto;margin-top:12pt;line-height:10pt; clear:both;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(iii</a>)</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
<p style="line-height:10pt;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">250212926 v1</p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:7pt;font-family:Times New Roman;">&nbsp;</p>&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;Background-color:#auto;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 10.6</p>
<p style="text-align:center;Background-color:#auto;margin-bottom:12pt;margin-top:0pt;text-indent:0%;text-transform:uppercase;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU5"></a><font style="text-transform:uppercase;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;font-variant: normal;">PRE-PAID FORWARD CONTRACT</font></p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_9kR3WTr26648CSOvxxIK0ysk07A7NWL8AJ134y3"></a><a name="_9kR3WTr26649Ec9F2R6q6"></a>This <font style="text-transform:uppercase;">PRE-PAID FORWARD CONTRACT</font>, dated as of March 18, 2021 (this &#8220;<font style="text-decoration:underline;">Agreement</font>&#8221;), is made and entered into by and between <font style="font-variant: small-caps;">RTW Investments ICAV</font><a name="_9kR3WTr26648CSOvxxIK0ysk07A7NWL8AJ134y3"></a>, an Irish Collective Asset-management Vehicle registered in Ireland as an umbrella fund with segregated liability between sub-funds (the &#8220;<font style="text-decoration:underline;">Payer</font><a name="_9kR3WTr26649Ec9F2R6q6"></a>&#8221;), for and on behalf of its sub-fund, RTW Fund 2, and <font style="font-variant: small-caps;">UroGen Pharma Ltd.</font>, an Israel corporation with company registration number 513537621 (the &#8220;<font style="text-decoration:underline;">Company</font>&#8221;).</p>
<p style="Background-color:#auto;text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;text-transform:uppercase;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;font-variant: normal;"><font style="text-decoration:underline;">W I T N E S S E T H</font><font style="text-decoration:none;">:</font></p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">WHEREAS, the Company is in the business of, among other things, developing and commercializing the Products (as defined below); and</p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">WHEREAS, the Company and the Payer desire to enter into a pre-paid forward contract providing for the Company&#8217;s grant to the Payer of the right to receive cash payments as a participation in future revenues of the Company through the Revenue Participation Right (as defined below) in exchange for payment of the Pre-Paid Forward Price (as defined below), and the Company desires to grant the Revenue Participation Right to the Payer in exchange for the Payer&#8217;s payment of the Pre-Paid Forward Price, in each case on the terms and conditions set forth in this Agreement.</p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">NOW THEREFORE, in consideration of the representations, warranties, covenants and agreements set forth herein and for good and valuable consideration, the receipt and adequacy of which are hereby acknowledged, the Company and the Payer hereby agree as follows:</p>
<p style="Background-color:#auto;text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#010000;text-transform:uppercase;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;font-variant: normal;"><a name="_Toc56700552"></a><a name="_Toc56006779"></a><a name="_Toc56700553"></a><a name="_Toc65621581"></a><a name="_Toc65623743"></a><a name="_Toc66905130"></a>ARTICLE 1<font style="text-transform:none;color:#000000;"><br /><a name="_Toc56006779"></a><a name="_Toc56700553"></a><a name="_Toc65621581"></a><a name="_Toc65623743"></a><a name="_Toc66905130"></a>DEFINITIONS</font></p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;color:#010000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc56006778"></a><a name="_Toc56006780"></a><a name="_Toc56700554"></a><a name="_Toc65621582"></a><a name="_Toc65623744"></a><a name="_Toc66905131"></a><a name="_Ref276305883"></a><font style="text-decoration:underline;">Definitions</font></p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;text-indent:2.31%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. The following terms, as used herein, shall have the following meanings:</p>
<p style="margin-bottom:12pt;Background-color:#FFFFFF;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk66476506"></a><a name="_AEIOULastRenderedPageBreakAEIOU6"></a><a name="_Hlk66476506"></a>&#8220;<font style="text-decoration:underline;">Acceptable Intercreditor Agreement</font>&#8221; means (a) a first-lien/second lien intercreditor agreement between the Payer and Senior Debt Provider providing [***]<br /></p>
<p style="text-align:center;Background-color:#auto;margin-top:12pt;line-height:10pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
<p style="line-height:10pt;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">250212926 v1</p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:7pt;font-family:Times New Roman;">&nbsp;</p>&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;Background-color:#auto;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 10.6</p>
<p style="margin-bottom:12pt;Background-color:#FFFFFF;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> and (b) any other intercreditor agreement between Payer and a Senior Debt Provider in form and substance reasonably satisfactory to Payer, such Senior Debt Provider and the Company. As used in this definition of &#8220;Acceptable Intercreditor Agreement,&#8221; &#8220;Payer Disposition Proceeds Amount&#8221; means, with respect to any disposition, sale or other transfer of Product Collateral, the lesser of (x) </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> of the proceeds from such disposition (or sale or transfer, as applicable), after payment of all fees, costs and expenses (including attorneys&#8217; fees and costs) in connection with such disposition and any other costs or expenses incurred in connection with the enforcement of any right or remedy thereunder and (y) the Remaining Obligations. For the avoidance of doubt, for purposes of any waterfall referenced above,</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the Payer Disposition Proceeds Amount shall have the same priority of payment as any principal and interest obligations due to the Senior Debt Provider and shall not be subordinated in right of payment to such obligations.</font></p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU7"></a>&#8220;<font style="text-decoration:underline;">Affiliate</font>&#8221; means, with respect to any particular Person, any other Person directly or indirectly controlling, controlled by or under common control with such particular Person. For purposes of the foregoing sentence, the term &#8220;control&#8221; means direct or indirect ownership of (x) fifty percent (50%) or more, including ownership by trusts with substantially the same beneficial <br /></p>
<p style="text-align:center;Background-color:#auto;margin-top:12pt;line-height:10pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
<p style="line-height:10pt;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">250212926 v1</p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:7pt;font-family:Times New Roman;">&nbsp;</p>&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;Background-color:#auto;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 10.6</p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">interests, of the voting and equity rights of such Person, firm, trust, corporation, partnership or other entity or combination thereof, or (y) the power to direct the management of such Person, firm, trust, corporation, partnership or other entity or combination thereof, by contract or otherwise. </font></p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="text-decoration:underline;">Agreement</font>&#8221; is defined in the preamble.</p>
<p style="margin-bottom:12pt;Background-color:#FFFFFF;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="text-decoration:underline;">Bankruptcy Court</font>&#8221; is defined in Exhibit B hereto.</p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="text-decoration:underline;">Bankruptcy Laws</font>&#8221; means, collectively, bankruptcy, insolvency, reorganization, moratorium, fraudulent conveyance, fraudulent transfer or other similar laws or regulations affecting the enforcement of creditors&#8217; rights generally, including any proceedings under the Israeli Insolvency Law.</p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="text-decoration:underline;">Board</font>&#8221; means the board of directors of the Company.</p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="text-decoration:underline;">Business Day</font>&#8221; means any day other than (a)&#160;a Saturday or Sunday or (b)&#160;a day on which banking institutions located in New York are permitted or required by applicable law or regulation to remain closed.</p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="text-decoration:underline;">Capital Lease</font>&#8221; means, as applied to any Person, any lease of any property by that Person as lessee which, in accordance with GAAP, is required to be accounted for as a capital lease on the balance sheet of that Person; provided that, for the avoidance of doubt, any lease that was (or would have been) accounted for by such Person as an operating lease prior to the issuance of the Accounting Standards Update No. 2016-02 by the Financial Accounting Standards Board and any similar lease entered into thereafter by such Person shall be accounted for as an operating lease and not as a Capital Lease.</p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="text-decoration:underline;">Clinical Trial</font>&#8221; means a clinical trial intended to support the Marketing Approval or Commercialization of a Product.</p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="text-decoration:underline;">Clinical Updates</font>&#8221; means [***].</p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="text-decoration:underline;">Closing</font>&#8221; means the closing of the grant of the Revenue Participation Right hereunder.</p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="text-decoration:underline;">Closing Date</font>&#8221; means the date on which the Closing occurs pursuant to &#8206;Section 3.1.</p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="text-decoration:underline;">CMC</font>&#8221; means chemistry, manufacturing and controls with respect to a Product.</p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Ref441868512"></a><a name="_Ref441870311"></a><a name="_Ref441948433"></a><a name="_Toc442238514"></a><a name="_Toc442266160"></a><a name="_Toc445389994"></a><a name="_Toc445651790"></a>&#8220;<font style="text-decoration:underline;">Combination Product</font><a name="_Ref441868512"></a><a name="_Ref441870311"></a><a name="_Ref441948433"></a><a name="_Toc442238514"></a><a name="_Toc442266160"></a><a name="_Toc445389994"></a><a name="_Toc445651790"></a>&#8221; means:</p>
<p style="Background-color:#auto;margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Ref442259377"></a>(a)<font style="margin-left:36pt;"></font>a single pharmaceutical formulation (whether co-formulated or administered together via the same administration route) containing as its active ingredients both a Product and one or more other therapeutically or prophylactically active pharmaceutical or biologic ingredients (each an &#8220;<font style="text-decoration:underline;">Other Component</font>&#8221;), or<br /></p>
<p style="text-align:center;Background-color:#auto;margin-top:12pt;line-height:10pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</a></p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
<p style="line-height:10pt;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">250212926 v1</p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:7pt;font-family:Times New Roman;">&nbsp;</p>&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;Background-color:#auto;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 10.6</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="Background-color:#auto;margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)<font style="margin-left:36pt;"></font>a combination therapy comprised of a Product and one or more Other Component(s), whether priced and sold in a single package containing such multiple products, packaged separately but sold together for a single price, or sold under separate price points but labeled for use together,</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:3.85%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_9kR3WTr26647GSJ7x"></a><a name="_9kR3WTr26647GSJ7x"></a>in each case, including all dosage forms, formulations, presentations, and package configurations. Drug delivery vehicles, adjuvants and excipients will not be deemed to be &#8220;active ingredients&#8221;, except in the case where such delivery vehicle, adjuvant or excipient is recognized by the FDA as an active ingredient in accordance with 21 C.F.R. 210.3(b)(7). All references to Products in this Agreement shall be deemed to include Combination Products.</p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="text-decoration:underline;">Commercial Updates</font>&#8221; means [***]. </p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_9kR3WTr26649Awy28dFr2q050zNRDGGL8z"></a><a name="_9kMHG5YVt4886BCy04AfHt4s2721PTFIINA1"></a>&#8220;<font style="text-decoration:underline;">Commercialization</font><a name="_9kR3WTr26649Awy28dFr2q050zNRDGGL8z"></a>&#8221; means any and all activities directed to the distribution, marketing, detailing, promotion, selling and securing of reimbursement of a Product (including the using, importing, selling and offering for sale of such Product), and shall include post-Marketing Approval<a name="_9kMHG5YVt4886BCy04AfHt4s2721PTFIINA1"></a> studies to the extent required by a Regulatory Authority, post-launch marketing, promoting, detailing, distributing, selling such Product, importing, exporting or transporting such Product for sale, and regulatory compliance with respect to the foregoing. When used as a verb, &#8220;Commercialize&#8221; shall mean to engage in Commercialization. Except with respect to post-Marketing Approval studies required by a Regulatory Authority, Commercialization shall not include any activities directed to the research or development (including pre-clinical and clinical development) or manufacture of a Product.</p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="text-decoration:underline;">Commercialization License</font>&#8221; means any Out-License, or any other agreement between the Company or any of its Affiliates and any Third Party, pursuant to which rights are granted to a Third Party (other than any Distributor) to market, detail, promote, sell or secure reimbursement of any Product, whether through a license, sublicense, covenant not to sue, or similar arrangement under any Intellectual Property Right or the transfer, assignment or other conveyance of ownership rights in or to any Intellectual Property Right.</p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="text-decoration:underline;">Commercially Reasonable Efforts</font>&#8221; means the level of efforts and resources (measured as of the time that such efforts and resources are required to be used under this Agreement) that are commonly used by a commercial-stage public biotechnology company of similar size and resources to Company (provided that such size and resources shall not decrease below the size and resources of the Company as of the Closing Date), to develop, manufacture or commercialize, as the case may be, a comparable product for a comparable clinical indication (with respect to market size and commercial opportunity) at a similar stage in its development or product life and of a similar market and potential to the Product, but without regard to the Company&#8217;s financial obligations under this Agreement. </p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="text-decoration:underline;">Company</font>&#8221; is defined in the preamble. References to the Company herein shall be deemed to include any assignee of the Company pursuant to &#8206;Section 10.4.<br /></p>
<p style="text-align:center;Background-color:#auto;margin-top:12pt;line-height:10pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</a></p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
<p style="line-height:10pt;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">250212926 v1</p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:7pt;font-family:Times New Roman;">&nbsp;</p>&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;Background-color:#auto;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 10.6</p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU8"></a><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;</font><font style="text-decoration:underline;">Company Certificate</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8221; is defined in </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8206;</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Section 5.1(g)</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</font></p>
<p style="margin-bottom:12pt;Background-color:#FFFFFF;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="text-decoration:underline;">Company Indemnified Parties</font>&#8221; is defined in &#8206;Section 7.1(b).<font style="font-weight:bold;"> </font></p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="text-decoration:underline;">Confidential Information</font>&#8221; is defined in &#8206;Section 8.1.</p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="text-decoration:underline;">Consensus Value of Net Sales</font>&#8221; is defined in Exhibit B hereto.</p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="text-decoration:underline;">Covered Jurisdiction</font>&#8221; means [***].</p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="text-decoration:underline;">Disclosing Party</font>&#8221; is defined in &#8206;Section 8.1.</p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="text-decoration:underline;">Disclosure Schedule</font>&#8221; means the Disclosure Schedule, dated as of the date hereof, delivered to the Payer by the Company concurrently with the execution of this Agreement. </p>
<p style="margin-bottom:6pt;Background-color:#FFFFFF;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="text-decoration:underline;">Distributor</font>&#8221; means a Third Party that (a) (i) purchases or has the option to purchase any Product in finished form from or at the direction of the Company or any of its Affiliates, (ii) has the right, option or obligation to distribute, market and sell such Product (with or without packaging rights) in one or more regions, and (iii) does not otherwise make any royalty, milestone, profit share or other similar payment to the Company or its Affiliate based on such Third Party&#8217;s sale of the Product or (b) (i)&#160;does not take title to such Product, (ii)&#160;does not invoice sales of such Product to Third Party customers and (iii)&#160;is responsible only for inventory management and distribution with respect to such Product on behalf of the Company or its Affiliate. The term &#8220;packaging rights&#8221; in this definition will mean the right for the Distributor to package or have packaged Product supplied in unpackaged bulk form into individual ready-for-sale packs.</p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="text-decoration:underline;">EMA</font>&#8221; means the European Medicines Agency, or any successor agency thereto.</p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="text-decoration:underline;">ERISA</font>&#8221; means the Employee Retirement Income Security Act of 1974.</p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="text-decoration:underline;">Escrow Account</font>&#8221; means that certain bank account established pursuant to the Escrow Agreement and controlled by the Escrow Agent.</p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="text-decoration:underline;">Escrow Agent</font>&#8221; means an escrow agent to be mutually agreed upon by the Company and the Payer.</p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="text-decoration:underline;">European Countries</font>&#8221; means, collectively, each member within the European Union, each member of the European Economic Area (to the extent such member is not a member of the European Union), Switzerland and the United Kingdom </p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU9"></a>&#8220;<font style="text-decoration:underline;">Excluded Collateral</font>&#8221; means, each of (i) any &#8220;intent to use&#8221; trademark applications for which a statement of use has not been filed (but only until such statement is filed), (ii) equipment, (iii) cash, cash equivalents, investment property and securities and bank accounts (except, in each case with respect to identifiable proceeds from the disposition of the Product Collateral in connection with any enforcement of the security interests granted pursuant to the Security Documents (which, for the avoidance of doubt, shall not include proceeds of inventory sold in the ordinary course of business or payments under any Permitted License)), and (iv) any <br /></p>
<p style="text-align:center;Background-color:#auto;margin-top:12pt;line-height:10pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
<p style="line-height:10pt;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">250212926 v1</p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:7pt;font-family:Times New Roman;">&nbsp;</p>&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;Background-color:#auto;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 10.6</p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">permit, license or agreement entered into by the Company (A) to the extent that any such permit, license or agreement or any law applicable thereto prohibits the creation of a Lien thereon, but only to the extent, and for as long as, such prohibition is not terminated or rendered unenforceable or otherwise deemed ineffective by the Uniform Commercial Code or any other applicable law or (B) to the extent that the creation of a Lien in favor of the Payer would result in a breach or termination pursuant to the terms of or a default under any such permit, license or agreement (other than to the extent that any such term would be rendered ineffective pursuant to the Sections 9-406, 9-407, 9-408 or 9-409 of the Uniform Commercial Code or any other applicable law (including the Bankruptcy Code) or principles of equity).</font></p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="text-decoration:underline;">Excluded Out-License</font>&#8221; means any Out-License other than any Commercialization License.</p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="text-decoration:underline;">Existing Patent Rights</font>&#8221; is defined in &#8206;Section 4.1(k)(i).</p>
<p style="margin-bottom:6pt;Background-color:#FFFFFF;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="text-decoration:underline;">FD&amp;C Act</font>&#8221; means the United States Federal Food, Drug, and Cosmetic Act.</p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="text-decoration:underline;">FDA</font>&#8221; means the U.S. Food and Drug Administration, or any successor agency thereto.</p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="text-decoration:underline;">GAAP</font>&#8221; means generally accepted accounting principles in the United States in effect from time to time.</p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="text-decoration:underline;">Governmental Entity</font>&#8221; means any: (a)&#160;nation, principality, republic, state, commonwealth, province, territory, county, municipality, district or other jurisdiction of any nature; (b)&#160;federal, state, local, municipal, foreign or other government; (c)&#160;governmental or quasi-governmental authority of any nature (including any governmental division, subdivision, department, agency, bureau, branch, office, commission, council, board, instrumentality, officer, official, representative, organization, unit, body or other entity and any court, arbitrator or other tribunal); (d)&#160;multi-national organization or body; or (e)&#160;individual, body or other entity exercising, or entitled to exercise, any executive, legislative, judicial, administrative, regulatory, police, military or taxing authority or power of any nature.</p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_9kR3WTr1AB458OCv69UK10tzyqptmWw1"></a><a name="_9kR3WTr1AB458OCv69UK10tzyqptmWw1"></a>&#8220;<font style="text-decoration:underline;">Gross Sales</font>&#8221; is defined in the definition of &#8220;Net Sales&#8221;.</p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="text-decoration:underline;">Improvements</font>&#8221; means any improvement, invention or discovery relating to a Product (other than with respect to a new composition of matter), including the formulation, or the method of manufacture of a Product.</p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="text-decoration:underline;">IIA</font>&#8221; is defined in &#8206;Section 4.1(k)(ix).</p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="text-decoration:underline;">In-License</font>&#8221; means any license, settlement agreement or other agreement or arrangement between the Company or any of its Affiliates and any Third Party pursuant to which the Company or any of its Affiliates obtains a license or a covenant not to sue or similar grant of rights to any Patents or other intellectual property rights of such Third Party that is necessary for the research, development, manufacture, use or Commercialization of a Product.</p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU10"></a>&#8220;<font style="text-decoration:underline;">Indebtedness</font>&#8221; of any Person means any indebtedness for borrowed money, any obligation evidenced by a note, bond, debenture or similar instrument, or any guarantee of any of <br /></p>
<p style="text-align:center;Background-color:#auto;margin-top:12pt;line-height:10pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
<p style="line-height:10pt;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">250212926 v1</p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:7pt;font-family:Times New Roman;">&nbsp;</p>&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;Background-color:#auto;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 10.6</p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the foregoing.</font></p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="text-decoration:underline;">Indemnified Party</font>&#8221; is defined in &#8206;Section 7.2.</p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="text-decoration:underline;">Indemnifying Party</font>&#8221; is defined in &#8206;Section 7.2.</p>
<p style="margin-bottom:12pt;Background-color:#FFFFFF;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="text-decoration:underline;">Insolvency Event</font>&#8221; means in relation to each of the Company or its Affiliates: (a) any voluntary or involuntary filing for it of a petition under any Bankruptcy Laws; (b) it institutes or has instituted against it a proceeding seeking the grant of an initiation of proceedings order (&#8220;tsav le-ptichat halichim&#8221;) pursuant to the Israeli Insolvency Law, a judgment of insolvency or bankruptcy or any other relief under any Bankruptcy Laws or rehabilitation proceedings as defined under the Israeli Insolvency Law or other Bankruptcy Laws, or a petition is presented for its winding-up or liquidation by it or any other person; (c) it has a resolution passed for its winding-up, dissolution, rehabilitation, official management or liquidation; (d) it seeks or becomes subject to the appointment of a liquidator, administrator, provisional liquidator, conservator, receiver, administrative receiver, compulsory manager, special manager, trustee, supervisor custodian or other similar official for it or relating to all or substantially all its assets (whether temporary or permanent); (e) (i) it is dissolved; (ii) it is or becomes unable or admits inability to pay its debts as they fall due or it obligations (including future and contingent obligations) exceed the value of its assets; (iii) it is otherwise deemed insolvent under any applicable Bankruptcy Law; (iv) it has a secured party take possession of all or substantially all its assets or has a distress, execution, attachment, sequestration or other legal process levied, enforced or sued on or against all or substantially all its assets and such party maintains possession, or any such process is not dismissed, discharged, stayed or restrained, in each case within 10 days thereafter; or (v) it makes a general assignment, arrangement or composition with or for the benefit of its creditors; (f) a moratorium or stay of proceedings (&#8220;ikuv halichim&#8221;) is declared in respect of any of its Indebtedness or a petition is presented whether by the Company (including by virtue of section 319c of the Israeli Insolvency Law) or any other person, for such moratorium or stay of proceedings; (g) a notification is made to any of its creditors of the commencement of protected negotiations (&#8220;masa u-matan mugan&#8221;) pursuant to the Israeli Insolvency Law; (h) any other corporate action or legal proceedings in relation to the events specified in the foregoing clauses (a) to (g) (inclusive); or (i) it causes or is subject to any event with respect to it which, under the applicable laws of any jurisdiction, has an analogous effect to any of the events specified in the foregoing clauses (a) to (h) (inclusive).</p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="text-decoration:underline;">Intellectual Property Product Rights</font>&#8221; means any and all of the following as they exist throughout the world at any time: (a) the Intellectual Property Rights; (b) rights in registered and unregistered trademarks, service marks, trade names, trade dress, logos, packaging design, slogans and Internet domain names, and registrations and applications for registration of any of the foregoing, in each case, with respect to any Product that are owned or in-licensed by Company or any of its Affiliates; and (c) any and all other intellectual property rights and/or proprietary rights, whether or not patentable, specifically relating to any of the foregoing, as necessary for the development, manufacture or Commercialization of a Product that are owned or in-licensed by Company or any of its Affiliates.</p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="text-decoration:underline;">Intellectual Property Rights</font>&#8221; means any and all of the following as they exist throughout the world at any time: (a) the Patent Rights and (b) the Know-How Rights.<br /></p>
<p style="text-align:center;Background-color:#auto;margin-top:12pt;line-height:10pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7</a></p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
<p style="line-height:10pt;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">250212926 v1</p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:7pt;font-family:Times New Roman;">&nbsp;</p>&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;Background-color:#auto;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 10.6</p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU11"></a><a name="_Hlk66891478"></a><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;</font><font style="text-decoration:underline;">Intellectual Property Updates</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk66891478"></a>&#8221; </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">means </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">***</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">]</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</font></p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">&#8220;Israeli Companies Law</font>&#8221; means the Israeli Companies Law, 1999, as amended from time to time and any regulations promulgated thereunder.</p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">&#8220;Israeli Insolvency Law</font>&#8221; means the Israeli Insolvency and Rehabilitation Law, 2018 as amended from time to time and any regulations promulgated thereunder;</p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="text-decoration:underline;">Israeli Security Agreement</font>&#8221; means the security agreement to be governed by Israeli law and granted by the Company in favor of the Payer pursuant to which the Company grants the Payer a first ranking fixed charge over the Product Collateral and Payer Priority Collateral and a floating charge over the inventory and all future Product Collateral.</p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="text-decoration:underline;">Jelmyto</font>&#8221; means (a) the pharmaceutical product known as JELMYTO<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup> (mitomycin) (and foreign-named equivalents) for pyelocalyceal solution,<font style="text-decoration:none;"> </font>(b) any pharmaceutical product for the treatment of upper tract urothelial cancer in a hydrogel formulation that contains any radioisomer, stereoisomer, racemates, solvates, salt forms, bases, anhydrides, hydrates, polymorphs, metabolites, ester forms, deuterated forms or pro-drugs of mitomycin, and (c) any pharmaceutical product that contains any of the foregoing, in each case of (a)&#8211;(c), in any dosage form, dosing regimen, strength, or route of administration.</p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="text-decoration:underline;">Jelmyto Launch Sales Threshold</font>&#8221; means the threshold amount for each corresponding Jelmyto Launch Year as set forth in the chart below:</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:64.24%;">
<tr>
<td style="width:26.1%;"></td>
<td style="width:38.14%;"></td>
</tr>
<tr>
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="Background-color:#auto;margin-top:6pt;margin-bottom:6pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Jelmyto Launch Year</p></td>
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="Background-color:#auto;margin-top:6pt;margin-bottom:6pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Jelmyto Launch Sales Threshold <br />(Annual Jelmyto Net Sales)</p></td>
</tr>
<tr>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="Background-color:#auto;margin-top:6pt;margin-bottom:6pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A. [***]</p></td>
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="Background-color:#auto;margin-top:6pt;margin-bottom:6pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$[***]</p></td>
</tr>
<tr>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="Background-color:#auto;margin-top:6pt;margin-bottom:6pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">B. [***]</p></td>
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="Background-color:#auto;margin-top:6pt;margin-bottom:6pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$[***]</p></td>
</tr>
<tr>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="Background-color:#auto;margin-top:6pt;margin-bottom:6pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">C. [***]</p></td>
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="Background-color:#auto;margin-top:6pt;margin-bottom:6pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$[***]</p></td>
</tr>
</table></div>
<p style="Background-color:#auto;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="text-decoration:underline;">Jelmyto Launch Year</font>&#8221; is defined in the definition of &#8220;[***]&#8221;.</p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="text-decoration:underline;">Jelmyto Net Sales</font>&#8221; means the Net Sales of Jelmyto.</p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU12"></a>&#8220;<font style="text-decoration:underline;">Jelmyto Net Sales Revenue Rate</font>&#8221; means the applicable percentage based on the portion of the corresponding level of annual Jelmyto Net Sales in a calendar year as set forth in the chart below; provided, however, that in the event that the Company does not receive Marketing Approval from the FDA on or before [***] for UGN-102 to treat low-grade intermediate <br /></p>
<p style="text-align:center;Background-color:#auto;margin-top:12pt;line-height:10pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
<p style="line-height:10pt;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">250212926 v1</p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:7pt;font-family:Times New Roman;">&nbsp;</p>&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;Background-color:#auto;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 10.6</p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">risk non-muscle invasive bladder cancer, the Jelmyto Net Sales Revenue Rate will increase </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">by 1.5%</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> (applicable to all tiers) on worldwide annual Jelmyto Net Sales from and after </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">***</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">]</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> (the &#8220;</font><font style="text-decoration:underline;">UGN-102 Delay Payment</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8221;), which for clarity will be in addition to any rate increase pursuant to the definition of &#8220;</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">***</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">]</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8221; below</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">:</font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:99.89%;">
<tr>
<td style="width:56.15%;"></td>
<td style="width:43.74%;"></td>
</tr>
<tr>
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="Background-color:#auto;margin-top:6pt;margin-bottom:6pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_9kR3WTr26649HhQis7"></a><a name="_9kR3WTr266479ICw4skUIr0EMDiT6vXx2A"></a><a name="_9kR3WTr26649HhQis7"></a>Payment Tiers<a name="_9kR3WTr266479ICw4skUIr0EMDiT6vXx2A"></a> based on Annual Jelmyto<font style="font-weight:normal;"> </font>Net Sales</p></td>
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="Background-color:#auto;margin-top:6pt;margin-bottom:6pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Jelmyto Net Sales Revenue Rate Applicable to Each Net Sales Tier</p></td>
</tr>
<tr>
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="Background-color:#auto;margin-top:6pt;margin-bottom:6pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_9kR3WTr26645CNCw4skUIr0EMDePy7LTKpaD2e4"></a><a name="_9kR3WTr26645CNCw4skUIr0EMDePy7LTKpaD2e4"></a>A. Annual Jelmyto Net Sales of up to $200,000,000</p></td>
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="Background-color:#auto;margin-top:6pt;margin-bottom:6pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Jelmyto Tier 1 Rate</p></td>
</tr>
<tr>
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="Background-color:#auto;margin-top:6pt;margin-bottom:6pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_9kMHG5YVt48869BKEy6umWKt2GOFkV8xZz4C"></a><a name="_9kMHG5YVt48869BKEy6umWKt2GOFkV8xZz4C"></a>B. Annual Jelmyto Net Sales exceeding $200,000,000 and less than or equal to $300,000,000</p></td>
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="Background-color:#auto;margin-top:6pt;margin-bottom:6pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.0%</p></td>
</tr>
<tr>
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="Background-color:#auto;margin-top:6pt;margin-bottom:6pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_9kMHG5YVt48867EPEy6umWKt2GOFgR09NVMrcF4"></a><a name="_9kMHG5YVt48867EPEy6umWKt2GOFgR09NVMrcF4"></a>C. Annual Jelmyto Net Sales in excess of $300,000,000</p></td>
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="Background-color:#auto;margin-top:6pt;margin-bottom:6pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.0%</p></td>
</tr>
</table></div>
<p style="Background-color:#auto;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_9kMIH5YVt48867EPEy6umWKt2GOFgR09NVMrcF4"></a>&#8220;<font style="text-decoration:underline;"><a name="_9kMIH5YVt48867EPEy6umWKt2GOFgR09NVMrcF4"></a>Jelmyto Revenue Payments</font>&#8221; means, for each calendar quarter, an amount payable to the Payer equal to the amount of Jelmyto Net Sales during such calendar quarter multiplied by the Jelmyto Net Sales Revenue Rate. For clarity, the Jelmyto Net Sales Revenue Rate used to calculate the Jelmyto Revenue Payments for a given date in a calendar quarter (a) will be based on the worldwide aggregate annual Jelmyto Net Sales billed or invoiced for the calendar year through and including such date, and (b) may be different for different periods during such calendar quarter depending on the specific date the worldwide aggregate Jelmyto Net Sales crosses over to the next payment tier. By way of example, if worldwide aggregate Jelmyto Net Sales invoiced as of (i) April 12 for the calendar year equal $185,000,000, (ii) April 13 for the calendar year equal $210,000,000, and (c) June 30 for the calendar year equal $295,000,000, then the Jelmyto Net Sales Revenue Rate for such [calendar quarter] shall be equal to the Jelmyto Tier 1 Rate with respect to Jelmyto Net Sales through and including April 12, and 3.0% with respect to Jelmyto Net Sales from April 13 through and including June 30, in each case subject to further adjustment by the UGN-102 Delay Payment.</p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU13"></a>&#8220;<font style="text-decoration:underline;">Jelmyto Tier 1 Rate</font>&#8221; means 9.5% (subject to potential upward adjustment based on any UGN-102 Delay Payments as set forth in the definition of <font style="text-decoration:underline;">Jelmyto Net Sales Revenue Rate</font>); provided, however, that if in any of [***] [***], [***] or [***] (each, a &#8220;<font style="text-decoration:underline;">Jelmyto Launch Year</font>&#8221;) worldwide annual Jelmyto Net Sales are below the applicable Jelmyto Launch Sales Threshold, then the Jelmyto Tier 1 Rate will increase by 3.5% starting the following [***]. For clarity, the aggregate maximum increase pursuant to the foregoing is 3.5%, regardless of the number of years the worldwide annual Jelmyto Net Sales are below the applicable Jelmyto Launch Sales Threshold. If annual Jelmyto Net Sales subsequently exceed the applicable Jelmyto Launch Sales Threshold in the following [***], then the Jelmyto Tier 1 Rate will decrease by 3.5% (which decrease would take effect with respect to the calendar year following the Jelmyto Launch Year in which the Jelmyto Launch Sales Threshold is achieved). If, at the end of [***], the Jelmyto Tier 1 Rate has been increased by 3.5% for the [***] calendar year because the annual Jelmyto Net Sales in [***] have not exceeded the Jelmyto Launch Sales Threshold applicable to [***], then the Jelmyto Tier 1 Rate will remain increased by 3.5%; <br /></p>
<p style="text-align:center;Background-color:#auto;margin-top:12pt;line-height:10pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
<p style="line-height:10pt;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">250212926 v1</p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:7pt;font-family:Times New Roman;">&nbsp;</p>&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;Background-color:#auto;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 10.6</p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">provided, however, that if worldwide annual Jelmyto Net Sales exceeds $</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">***</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">]</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> in any of the </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">***</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">]</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> through </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">***</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">]</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> calendar years, then the Jelmyto Tier 1 Rate will decrease </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">by </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.5</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> (which decrease would take effect with respect to the </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">***</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">] </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">following the </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">***</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">] </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">in which such $</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">***</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">] </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">threshold is first achieved) and remain at such rate thereafter.</font></p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="text-decoration:underline;">Judgment</font>&#8221; means any judgment, order, writ, injunction, citation, award or decree of any nature.</p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="text-decoration:underline;">Know-How</font>&#8221; means any and all proprietary or confidential information, know-how and trade secrets, including processes, formulae, models and techniques (but excluding rights in research in progress, algorithms, data, databases, data collections, chemical and biological materials and the results of experimentation and testing).</p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="text-decoration:underline;">Know-How Rights</font>&#8221; means any and all Know-How owned or in-licensed by the Company or any of its Affiliates or under which the Company or any of its Affiliates is or may become empowered to grant licenses necessary for the development, manufacture, or Commercialization of a Product<font style="Background-color:#FFFFFF;">.</font></p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="text-decoration:underline;">Knowledge of the Company</font>&#8221; means the actual knowledge of the individuals listed on <font style="text-decoration:underline;">Schedule 1.1</font> of the Disclosure Schedule,<font style="Background-color:#FFFFFF;color:#000000;"> </font>after reasonable due inquiry. </p>
<p style="margin-bottom:12pt;Background-color:#FFFFFF;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="text-decoration:underline;">Licensee</font>&#8221; means, with respect to any Product, a Third Party to whom the Company or any Affiliate of the Company has granted a Commercialization License. For clarity, a Distributor shall not be deemed to be a &#8220;Licensee.&#8221;</p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="text-decoration:underline;">Lien</font>&#8221; means any mortgage, lien, pledge, participation interest, charge, adverse claim, security interest, encumbrance or restriction of any kind, including any restriction on use, transfer or exercise of any other attribute of ownership of any kind; provided that, for the avoidance of doubt, Permitted Licenses shall not be deemed to be a &#8220;Lien&#8221;.</p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="text-decoration:underline;">Loss</font>&#8221; means any and all Judgments, damages, losses, claims, costs, liabilities and expenses, including reasonable and documented fees and out-of-pocket expenses of counsel.</p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_9kR3WTr26649BXV1ovvvv1qeAx444"></a>&#8220;<font style="text-decoration:underline;">Loss of Market Exclusivity</font><a name="_9kR3WTr26649BXV1ovvvv1qeAx444"></a>&#8221; shall mean, on a Product-by-Product and country-by-country basis, the later to occur of: (a) the expiration of the last-to-expire Valid Claim of a Patent Right covering such Product in such country; and (b) the expiry of all Regulatory Exclusivity Periods for such Product in such country.</p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_9kR3WTr26648GaBnymw1wvJSI62D8HA5EAGdaMJ"></a>&#8220;<font style="text-decoration:underline;">Marketing Approval</font><a name="_9kR3WTr26648GaBnymw1wvJSI62D8HA5EAGdaMJ"></a>&#8221; means, an NDA approved by the FDA, a Marketing Authorization Application approved by the EMA under the centralized European procedure, or any corresponding non-U.S. or non-EMA application, registration or certification, necessary or reasonably useful to market a Product approved by the corresponding Regulatory Authority, including pricing and reimbursement approvals where required. For clarity, notwithstanding the foregoing, solely with respect to &#8206;Section 6.2, &#8220;Marketing Approval&#8221; shall not include pricing and reimbursement approvals.</p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU14"></a>&#8220;<font style="text-decoration:underline;">Material Adverse Effect</font>&#8221; means (a) an adverse effect in any material respect on the timing, duration or amount of the Revenue Payments, (b) a material adverse effect on (i) a <br /></p>
<p style="text-align:center;Background-color:#auto;margin-top:12pt;line-height:10pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
<p style="line-height:10pt;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">250212926 v1</p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:7pt;font-family:Times New Roman;">&nbsp;</p>&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;Background-color:#auto;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 10.6</p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Product, (ii) any of the Intellectual Property Rights, including the Company&#8217;s rights in or to any Intellectual Property Rights, (iii) any Marketing Approval of a Product or the timing thereof, (iv) the legality, validity or enforceability of any provision of this Agreement or any other Transaction Document, (v) the ability of the Company to perform any of its obligations under this Agreement or any other Transaction Document, (vi) the rights or remedies of the Payer under this Agreement or any other Transaction Document, or (vii) the business of the Company or its Affiliates or (c) an adverse effect in any material respect on the Revenue Participation Rights, the Product Collateral, or the Security Documents.</font></p>
<p style="margin-bottom:12pt;Background-color:#FFFFFF;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="text-decoration:underline;">Minimum Return Date</font>&#8221; means [***].</p>
<p style="margin-bottom:12pt;Background-color:#FFFFFF;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_9kR3WTr26648HcGwWMA0HL74yqj1A6C"></a>&#8220;<font style="text-decoration:underline;">NDA</font><a name="_9kR3WTr26648HcGwWMA0HL74yqj1A6C"></a>&#8221; means a New Drug Application submitted to the FDA in the United States in accordance with the FD&amp;C Act with respect to a pharmaceutical product or any analogous application or submission with any Regulatory Authority outside of the United States.</p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="text-decoration:underline;">Net Sales</font>&#8221; means, with respect to a Product, the gross amount invoiced, billed or otherwise recorded for sales of such Product anywhere in the world by or on behalf of the Company, its Affiliates, or any Licensee of the Company or any of the Company&#8217;s Affiliates (each of the foregoing Persons, for purposes of this definition, shall be considered a &#8220;<font style="text-decoration:underline;">Related Party</font>&#8221;) to a Third Party in an arms-length transaction (&#8220;<font style="text-decoration:underline;">Gross Sales</font>&#8221;) less the following amounts, to the extent actually incurred or accrued, and not reimbursed by such Third Party, provided, that any given amount may be taken as a permitted deduction only once:</p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;margin-left:7.69%;text-indent:7.69%;color:#010000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)<font style="margin-left:36pt;"></font><font style="color:#000000;">reasonable and customary rebates, chargebacks, quantity, trade and similar discounts, credits and allowances and other price reductions reasonably granted, allowed, incurred or paid in so far as they are applied to sales of a Product;</font></p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;margin-left:7.69%;text-indent:7.69%;color:#010000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_9kR3WTr26646CNBvzymfwz"></a><a name="_9kR3WTr266478HCw4skQEkmxAYTzw0stfew7K4v"></a>(b)<font style="margin-left:36pt;"></font><font style="color:#000000;"><a name="_9kR3WTr26646CNBvzymfwz"></a>discounts (including cash, quantity, trade, governmental, and similar discounts), coupons, retroactive price reductions, charge back payments and rebates granted to<a name="_9kR3WTr266478HCw4skQEkmxAYTzw0stfew7K4v"></a> managed care organizations or to federal, state and local governments, or to their agencies (including payments made under the new &#8220;Medicare Part D Coverage Gap Discount Program&#8221; and the &#8220;Annual Fee for Branded Pharmaceutical Manufacturers&#8221; specific to the Product), in each case, as applied to sales of the Product and actually given to customers;</font></p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;margin-left:7.69%;text-indent:7.69%;color:#010000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c)<font style="margin-left:36pt;"></font><font style="color:#000000;">reasonable and customary credits, adjustments, and allowances, including those granted on account of price adjustments, billing errors, and damage, Product otherwise not in saleable condition, and rejection, return or recall of a Product;</font></p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;margin-left:7.69%;text-indent:7.69%;color:#010000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(d)<font style="margin-left:36pt;"></font><font style="color:#000000;">reasonable and customary freight and insurance costs incurred with respect to the shipment of a Product to customers, in each case if charged separately and invoiced to the customer;<br /></font></p>
<p style="text-align:center;Background-color:#auto;margin-top:12pt;line-height:10pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11</a></p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
<p style="line-height:10pt;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">250212926 v1</p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:7pt;font-family:Times New Roman;">&nbsp;</p>&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;Background-color:#auto;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 10.6</p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;margin-left:7.69%;text-indent:7.69%;color:#010000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU15"></a><font style="color:#010000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(e)</font><font style="margin-left:36pt;"></font><font style="color:#000000;">customs duties, surcharges and other similar governmental charges incurred in connection with the exportation or importation of a Product to the extent included in the gross amount invoiced;</font></p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;margin-left:7.69%;text-indent:7.69%;color:#010000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_9kR3WTr26645BMCw4skQEkmxAYTzw0stfew7K4v"></a>(f)<font style="margin-left:36pt;"></font><font style="color:#000000;"><a name="_9kR3WTr26645BMCw4skQEkmxAYTzw0stfew7K4v"></a>sales, use, value-added, excise, turnover, inventory and other similar Taxes (excluding income Taxes), and that portion of annual fees due under Section 9008 of the United States Patient Protection and Affordable Care Act of 2010 (Pub. L. No. 111-48) and any other fee imposed by any equivalent applicable law, in each of the foregoing cases, that Company allocates to sales of a Product in accordance with Company&#8217;s standard policies and procedures consistently applied across its products, as adjusted for offsets, rebates and refunds, imposed in connection with the sales of the Product to any Third Party, to the extent such Taxes are not paid by the Third Party;</font></p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;margin-left:7.69%;text-indent:7.69%;color:#010000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(g)<font style="margin-left:36pt;"></font><font style="color:#000000;">actual copayment waiver amounts uncollected or uncollectible debt amounts with respect to sales of a Product, provided that if the debt is thereafter paid, the corresponding amount shall be added to the Net Sales of the period during which it is paid;</font></p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;margin-left:7.69%;text-indent:7.69%;color:#010000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(h)<font style="margin-left:36pt;"></font><font style="color:#000000;">reasonable, customary and documented out of pocket amounts directly relating to co-pay programs, bridging programs or other similar patient assistance programs which may be implemented from time to time by the Company; and</font></p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;margin-left:7.69%;text-indent:7.69%;color:#010000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(i)<font style="margin-left:36pt;"></font><font style="color:#000000;">other similar or customary deductions taken in the ordinary course of business as permitted in calculating net sales or net revenue (as applicable).</font></p>
<p style="Background-color:#auto;margin-bottom:6pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Each of the amounts set forth shall be determined consistent with a Related Party&#8217;s customary practices and in accordance with GAAP or International Financial Reporting Standards.</p>
<p style="Background-color:#auto;margin-bottom:6pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_9kR3WTr26648I3wxbNoluzkWOxHP"></a><a name="_9kMHG5YVt4886AK5yzdPqnw1mYQzJR"></a><a name="_9kMIH5YVt4886AK5yzdPqnw1mYQzJR"></a><a name="_9kR3WTr26648I3wxbNoluzkWOxHP"></a>For clarity, &#8220;Net Sales&#8221; will not include (i) sales or dispositions for charitable, promotional, pre-clinical, clinical, regulatory, compassionate use, named patient use or indigent or other similar programs, reasonable quantities of Products used as samples, and Products used in the development of Products, (ii) sales or dispositions between any of the Related Parties (unless a Related Party is the final end-user of such Product), but will include subsequent sales or dispositions of Products to a non-Related Party<a name="_9kMHG5YVt4886AK5yzdPqnw1mYQzJR"></a>, or (iii) any amounts or other consideration received by a Related Party from a Licensee, Distributor, or a non-Related Party<a name="_9kMIH5YVt4886AK5yzdPqnw1mYQzJR"></a> in consideration of the grant of a (sub)license or co-promotion or distribution right to such non-Related Party, including any upfront or milestone payments (whether or not such milestones are based on net sales of a Product).</p>
<p style="Background-color:#auto;margin-bottom:6pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">With respect to sales of a Product invoiced in U.S. dollars, Net Sales shall be determined in U.S. dollars. With respect to sales of a Product invoiced in a currency other than U.S. dollars, Net Sales shall be determined by converting the currencies at which the sales are made into U.S. dollars, at rates of exchange determined in a manner consistent with the Company&#8217;s or a Licensee&#8217;s, as applicable, method for calculating rates of exchange in the preparation of the Company&#8217;s or such Licensee&#8217;s annual financial statements in accordance with GAAP or International Financial Reporting Standards.</p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU16"></a>Net Sales for any Combination Product shall be calculated on a country-by-country basis <br /></p>
<p style="text-align:center;Background-color:#auto;margin-top:12pt;line-height:10pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
<p style="line-height:10pt;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">250212926 v1</p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:7pt;font-family:Times New Roman;">&nbsp;</p>&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;Background-color:#auto;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 10.6</p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">by multiplying actual Net Sales of such Combination Product by the fraction </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A/(A+B) where &#8220;A&#8221; is the </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">weighted average invoice price</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> of the Product </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">contained in such Combination Product when sold separately in such country during the applicable accounting period in which the sales of the Combination Product were made</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, and &#8220;B&#8221; is the combined </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">weighted average invoice</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> prices of all of the Other Components</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">contained in such Combination Product sold separately in such country during such same accounting period</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. If a Product contained in such Combination Product is not sold separately in finished form in such country, the Company and the Payer shall determine Net Sales for such Product by mutual agreement based on the relative contribution of such Product and each such other active ingredient in such Combination Product in accordance with the above formula, and shall take into account in good faith any applicable allocations and calculations that may have been made for the same period in other countries.</font></p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Notwithstanding the foregoing, in the event that the Related Party is any party other than Company or its Affiliates, then Net Sales (including Combination Product allocations in connection with such Net Sales) will be calculated based on the corresponding definition of net sales in the applicable Permitted License permitting such sales, provided that such definition is commercially reasonable.</p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="text-decoration:underline;">Non-Exclusive Patent Rights</font>&#8221; means any Patent Rights non-exclusively in-licensed or otherwise held on a non-exclusive basis by Company or any of its Affiliates pursuant to rights granted by customers, suppliers, or service providers in the ordinary course of business.</p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="text-decoration:underline;">Order</font>&#8221; means any order, judgment, injunction, award, decree, ruling, stipulation, determination, or writ of any Governmental Entity.</p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="text-decoration:underline;">Other Component</font>&#8221; is defined in the definition of &#8220;Combination Products&#8221;.</p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="text-decoration:underline;">Out-License</font>&#8221; means each license or other agreement between the Company or any of its Affiliates and any Third Party pursuant to which the Company or any of its Affiliates (a) grants a license or sublicense of any Intellectual Property Right, or (b) transfers, assigns or otherwise conveys or grants any access or rights in or to any Intellectual Property Right.</p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="text-decoration:underline;">Patent Rights</font>&#8221; means (a) those Patents listed in <font style="text-decoration:underline;">Schedule 4.1(k)(i)(A); (b) </font>any continuation, continuation-in-part, division, provisional or any substitute applications of the foregoing; (c) any patent issued with respect to any of the foregoing; (d) any certificate, reissue, reexamination, renewal or patent term extension or adjustment (including any supplementary protection certificate) of any of the foregoing or other governmental actions which extend any of the subject matter of any of the foregoing; (e) any substitution patent, confirmation patent or registration patent or patent of addition based on any of the foregoing; (f) foreign counterparts of any of the foregoing; and (g) existing or future Patents covering any Improvements<font style="Background-color:#FFFFFF;">.</font></p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU17"></a>&#8220;<font style="text-decoration:underline;">Patents</font>&#8221; means any and all patents and patent applications existing as of the date of this Agreement and all patent applications filed hereafter, including any continuation, continuation-in-part, division, provisional or any substitute applications, any patent issued with respect to any of the foregoing patent applications, any certificate, reissue, reexamination, renewal or patent term extension or adjustment (including any supplementary protection certificate) of any such patent or other governmental actions which extend any of the subject matter of a patent, and any <br /></p>
<p style="text-align:center;Background-color:#auto;margin-top:12pt;line-height:10pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
<p style="line-height:10pt;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">250212926 v1</p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:7pt;font-family:Times New Roman;">&nbsp;</p>&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;Background-color:#auto;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 10.6</p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">substitution patent, confirmation patent or registration patent or patent of addition based on any such patent, and all foreign counterparts of any of the foregoing.</font></p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="text-decoration:underline;">Payer</font>&#8221; is defined in the preamble.</p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="text-decoration:underline;">Payer Indemnified Parties</font>&#8221; is defined in &#8206;Section 7.1(a).</p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="text-decoration:underline;">Payer Priority Collateral</font>&#8221; means, the Revenue Participation Right and the Revenue Payments, and any proceeds thereof. For the further avoidance of doubt, the Payer Priority Collateral is part of the Product Collateral.</p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">"<font style="text-decoration:underline;">Payment Obligations</font>" means the Remaining Obligations plus expenses, default interest, penalties, and enforcement costs.</p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="text-decoration:underline;">Permitted License</font>&#8221; is defined in &#8206;Section 6.7(a).</p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="text-decoration:underline;">Permitted Liens</font>&#8221; means the following:</p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)<font style="margin-left:36pt;"></font><font style="font-size:12pt;color:#000000;">Liens for Taxes, assessments or governmental charges or levies not yet due or which are being contested in good faith and by appropriate proceedings diligently conducted, if adequate reserves with respect thereto are maintained on the books of the applicable Person in accordance with GAAP or International Financial Reporting Standards;</font></p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)<font style="margin-left:36pt;"></font><font style="font-size:12pt;color:#000000;">statutory Liens of landlords and Liens of carriers, warehousemen, mechanics, materialmen and suppliers and other Liens imposed by law or pursuant to customary reservations or retentions of title arising in the ordinary course of business, </font><font style="text-decoration:underline;font-size:12pt;color:#000000;">provided</font><font style="font-size:12pt;color:#000000;">, </font><font style="text-decoration:underline;font-size:12pt;color:#000000;">that</font><font style="font-size:12pt;color:#000000;">, such Liens secure only amounts not yet due and payable or, if due and payable, are unfiled and no other action has been taken to enforce the same or are being contested in good faith by appropriate proceedings for which adequate reserves determined in accordance with GAAP or International Financial Reporting Standards have been established;</font></p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c)<font style="margin-left:36pt;"></font><font style="font-size:12pt;color:#000000;"> Liens on property existing at the time of acquisition of such property provided that such liens were in existence prior to such acquisition and not incurred in contemplation thereof;</font></p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(d)<font style="margin-left:36pt;"></font><font style="font-size:12pt;color:#000000;">Permitted Licenses, including any interest or title of a licensee under a Permitted License;</font></p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(e)<font style="margin-left:36pt;"></font><font style="font-size:12pt;color:#000000;">Any interest of a licensor or sublicensor under any In-License entered into by Company;</font></p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(f)<font style="margin-left:36pt;"></font><font style="font-size:12pt;color:#000000;">pledges or deposits in the ordinary course of business in connection with workers&#8217; compensation, unemployment insurance and other social security legislation, other than any Lien imposed by ERISA;</font></p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU18"></a>(g)<font style="margin-left:36pt;"></font><font style="font-size:12pt;color:#000000;">deposits to secure the performance of bids, trade contracts and leases (other than Indebtedness), statutory obligations, surety and appeal bonds, indemnity and <br /></font></p>
<p style="text-align:center;Background-color:#auto;margin-top:12pt;line-height:10pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
<p style="line-height:10pt;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">250212926 v1</p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:7pt;font-family:Times New Roman;">&nbsp;</p>&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;Background-color:#auto;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 10.6</p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;color:#000000;">performance bonds and other obligations of a like nature incurred in the ordinary course of business;</font></p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(h)<font style="margin-left:36pt;"></font><font style="font-size:12pt;color:#000000;">easements, rights-of-way, restrictions and other similar encumbrances affecting real property which, in the aggregate, are not substantial in amount, and which do not materially interfere with the ordinary conduct of the business of the applicable Person;</font></p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(i)<font style="margin-left:36pt;"></font><font style="font-size:12pt;color:#000000;">leases or subleases granted to others in the ordinary course of business and as permitted under this Agreement, and not interfering in any material respect with the Revenue Participation Right, the Product Rights, the Product Collateral, or the Security Documents;</font></p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(j)<font style="margin-left:36pt;"></font><font style="font-size:12pt;color:#000000;">any interest of title of a lessor under, and Liens arising from UCC financing statements (or equivalent filings, registrations or agreements in foreign jurisdictions) relating to, leases permitted by this Agreement;</font></p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(k)<font style="margin-left:36pt;"></font><font style="font-size:12pt;color:#000000;">normal and customary Liens and rights of setoff upon deposits of cash and securities in favor of banks or other depository institutions;</font></p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(l)<font style="margin-left:36pt;"></font><font style="font-size:12pt;color:#000000;">normal and customary Liens on cash and cash equivalents incurred to secure treasury, depository, overdraft, cash pooling, netting, credit card processing services, foreign exchange swap obligations, electronic funds transfer (including automated clearing house funds transfers), and other cash management arrangements; </font></p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(m)<font style="margin-left:36pt;"></font><font style="font-size:12pt;color:#000000;">Liens on specific items of inventory or other goods (and the proceeds thereof) of the Company securing such Person&#8217;s obligations in respect of bankers&#8217; acceptances issued or created for the account of such Person to facilitate the purchase, shipment or storage of such inventory or other goods;</font></p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(n)<font style="margin-left:36pt;"></font><font style="font-size:12pt;color:#000000;">Liens arising out of conditional sale, title retention, consignment or similar arrangements for the sale of goods entered into in the ordinary course of business;</font></p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(o)<font style="margin-left:36pt;"></font><font style="font-size:12pt;color:#000000;">Liens in favor of customs and revenue authorities arising as a matter of law to secure payment of customs duties in connection with the importation of goods in the ordinary course of business;</font></p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(p)<font style="margin-left:36pt;"></font><font style="font-size:12pt;color:#000000;">Liens in the nature of right of setoff in favor of counterparties to contractual agreements with the Company in the ordinary course of business; and</font></p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(q)<font style="margin-left:36pt;"></font><font style="font-size:12pt;color:#000000;">Liens securing Permitted Secured Debt.</font></p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="text-decoration:underline;">Permitted Secured Debt</font>&#8221; means: (a) obligations under Capital Leases and purchase money financings, (b) Indebtedness related to insurance premium financing arrangements, (c) reimbursement obligations in respect of letters of credit and banker&#8217;s acceptances (other than letters of credit securing Indebtedness for borrowed money or obligations in respect of any royalty or revenue interest sale or financing) and (d) other Indebtedness, in each case of (a), (b), (c) and (d) to the extent the Permitted Secured Debt is secured by Lien(s) on any of the Product Collateral and subject to an Acceptable Intercreditor Agreement executed and delivered by the Payer, the Company, and the applicable Senior Debt Provider.<br /></p>
<p style="text-align:center;Background-color:#auto;margin-top:12pt;line-height:10pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15</a></p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
<p style="line-height:10pt;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">250212926 v1</p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:7pt;font-family:Times New Roman;">&nbsp;</p>&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;Background-color:#auto;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 10.6</p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU19"></a><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;</font><font style="text-decoration:underline;">Person</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8221; means any individual, firm, corporation, company, partnership, limited liability company, trust, joint venture, association, estate, trust, Governmental Entity or other entity, enterprise, association or organization.</font></p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="text-decoration:underline;">Pre-Paid Forward Price</font>&#8221; is defined in &#8206;Section 2.2.</p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="text-decoration:underline;">Prime Rate</font>&#8221; means the prime rate published by The Wall Street Journal, from time to time, as the prime&#160;rate.</p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="text-decoration:underline;">Product</font>&#8221; and &#8220;<font style="text-decoration:underline;">Products</font>&#8221; means, individually and collectively, Jelmyto and UGN-102.</p>
<p style="margin-bottom:12pt;Background-color:#FFFFFF;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="text-decoration:underline;">Product Collateral</font>&#8221; means the Company&#8217;s rights, title and interests in (a) the Products (including all inventory of the Products), (b) the Product Rights owned, licensed or otherwise held by the Company, (c) Payer Priority Collateral and (d) any proceeds in addition to those described in clause (c) from either (a) or (b) above, including all accounts receivable and general intangibles resulting from the sale, license or other disposition of Products by the Company or its Licensees. Notwithstanding the foregoing, &#8220;Product Collateral&#8221; shall not include any Excluded Collateral.</p>
<p style="margin-bottom:12pt;Background-color:#FFFFFF;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_223"></a><a name="_cp_text_1_225"></a><a name="_cp_text_1_227"></a><a name="_cp_text_1_228"></a><a name="_cp_text_1_230"></a>&#8220;<font style="text-decoration:underline;">Product Rights</font><a name="_cp_text_1_223"></a>&#8221; means any and all of the following, as they exist throughout the world: (a<a name="_cp_text_1_225"></a>) Intellectual Property Product Rights, <a name="_cp_text_1_227"></a>(b<a name="_cp_text_1_228"></a>) regulatory filings, submissions and approvals, including Marketing Approvals, with or from any Regulatory Authorities <a name="_cp_text_1_230"></a>with respect to any of the Products, (c) In-Licenses, (d) Commercialization Licenses, and (e) agreements necessary for, or otherwise material to, the development, manufacture, use, marketing, promotion, sale or distribution of any of the Products.</p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="text-decoration:underline;">Quarterly Deadline</font>&#8221; is defined in &#8206;Section 6.1(a).</p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="text-decoration:underline;">Receiving Party</font>&#8221; is defined in &#8206;Section 8.1.</p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="text-decoration:underline;">Regulatory Authority</font>&#8221; means any national or supranational governmental authority, including the FDA, the EMA or such equivalent regulatory authority, or any successor agency thereto, that has responsibility in granting a Marketing Approval.</p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="text-decoration:underline;">Regulatory Exclusivity Period</font>&#8221; shall mean, with respect to each Product in any country, any period of data, market or other regulatory exclusivity (other than Patent exclusivity) granted or afforded by law or by a Regulatory Authority in such country that confers exclusive marketing rights with respect to such Product in such country or prevents another party from using or otherwise relying on any data supporting the Marketing Approval for such Product.</p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="text-decoration:underline;">Regulatory Updates</font>&#8221; means [***].</p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="text-decoration:underline;">Related Party</font>&#8221; is defined in the definition of &#8220;Net Sales&#8221;.</p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU20"></a>&#8220;<font style="text-decoration:underline;">Remaining Obligations</font>&#8221; means the lesser of (x) the Revenue <br /></p>
<p style="text-align:center;Background-color:#auto;margin-top:12pt;line-height:10pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
<p style="line-height:10pt;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">250212926 v1</p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:7pt;font-family:Times New Roman;">&nbsp;</p>&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;Background-color:#auto;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 10.6</p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Payment Cap less Revenue Payments actually received by the Payer at such time and (y) the </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">***</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">]</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> to be payable through </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">***</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">]</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> (without regard to any bankruptcy or insolvency of the Company, any of its Affiliates or any Third Party) (which shall be determined in accordance with </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exhibit B</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">).</font></p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="text-decoration:underline;">Report</font>&#8221; is defined in &#8206;Section 6.1.</p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="text-decoration:underline;">Representative</font>&#8221; means, with respect to any Person, (a)&#160;any direct or indirect member or partner of such Person and (b)&#160;any manager, director, trustee, officer, employee, agent, advisor or other representative (including attorneys, accountants, consultants, contractors, actual and potential lenders, investors, co-investors and assignees, bankers and financial advisers) of such Person.</p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="text-decoration:underline;">Revenue Participation Right</font>&#8221; means the right to receive the Revenue Payments on account of Net Sales of Products on or after the Effective Date and prior to the Revenue Payment Termination Date.</p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="text-decoration:underline;">Revenue Payment Cap</font>&#8221; means if the aggregate payments of the Revenue Payments received by the Payer are equal to or greater than $300,000,000.</p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="text-decoration:underline;">Revenue Payments</font>&#8221; means the Jelmyto Revenue Payments and UGN-102 Revenue Payments.</p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="text-decoration:underline;">Revenue Payment Termination Date</font>&#8221; means the date at the end of the calendar quarter in which aggregate payments of the Revenue Payments actually received by the Payer equal the Revenue Payment Cap.</p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="text-decoration:underline;">RTGel</font>&#8221; means the Company&#8217;s proprietary hydrogel polymer reverse-thermal composition known as &#8220;RTGel&#8482;&#8221;.</p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="text-decoration:underline;">RTGel Improvement</font>&#8221; means any improvement, invention or discovery relating to (a) the composition or formulation of RTGel or (b) the method of manufacturing or administration of RTGel, including in each cases of (a) and (b), as such improvement, invention, or discovery relates to RTGel by itself or in combination with one or more additional therapeutically or prophylactically active pharmaceutical or biologic ingredients other than any [***].</p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="text-decoration:underline;">Safety Notices</font>&#8221; means any recalls, field notifications, market withdrawals, warnings, &#8220;dear doctor&#8221; letters, investigator notices, safety alerts or other notices of action issued or instigated by the Company, any of its Affiliates or any Regulatory Authority relating to an alleged lack of safety or regulatory compliance of any Product. </p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="text-decoration:underline;">Securities Act</font>&#8221; means the Securities Act of 1933, as amended.</p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="text-decoration:underline;">Security Documents</font>&#8221; means the U.S. Security Documents and the Israeli Security Agreement.<br /></p>
<p style="text-align:center;Background-color:#auto;margin-top:12pt;line-height:10pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17</a></p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
<p style="line-height:10pt;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">250212926 v1</p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:7pt;font-family:Times New Roman;">&nbsp;</p>&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;Background-color:#auto;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 10.6</p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU21"></a><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;</font><font style="text-decoration:underline;">Senior Debt Provider</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8221; means, collectively, the lenders or providers (or its or their agents or representatives, as applicable) of Indebtedness secured by Lien(s) on any of the Product Collateral that enter into an Acceptable Intercreditor Agreement executed and delivered by the Payer, the Company, and the applicable Senior Debt Provider.</font></p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="text-decoration:underline;">Solvent</font>&#8221; means it is able (and has not admitted its inability) to pay its debts as they fall due, its obligations (including known future and contingent obligations) do not exceed the value of its assets or it is otherwise not deemed insolvent under applicable law (including under the Israeli Insolvency Law).</p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="text-decoration:underline;">Subsidiary</font>&#8221; means any and all corporations, partnerships, limited liability companies, joint ventures, associations and other entities controlled (by contract or otherwise) by the Company directly or indirectly through one or more intermediaries. For purposes hereof, the Company shall be deemed to control a partnership, limited liability company, association or other business entity if the Company, directly or indirectly through one or more intermediaries, shall be allocated a majority of partnership, limited liability company, association or other business entity gains or losses or shall be or control the managing director or general partner of such partnership, limited liability company, association or other business entity. </p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="text-decoration:underline;">Tax</font>&#8221; or &#8220;<font style="text-decoration:underline;">Taxes</font>&#8221; means any income, gross receipts, license, payroll, employment, excise, severance, occupation, premium, windfall profits, environmental, customs duties, capital stock, franchise, profits, withholding, social security, unemployment, disability, real property, personal property, abandoned property, value added, alternative or add-on minimum, estimated or other tax of any kind whatsoever, including any interest, penalty or addition thereto, whether disputed or not.</p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="text-decoration:underline;">Territory</font>&#8221; means all countries of the world.</p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="text-decoration:underline;">Third Party</font>&#8221; means any Person that is not the Company or the Company&#8217;s Affiliates.</p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">"<font style="text-decoration:underline;">Transaction Documents</font>" means this Agreement, the Security Documents, any closing certificate, and any other documents or agreements to be delivered pursuant to this Agreement and the Security Documents.</p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk66891662"></a>&#8220;<font style="text-decoration:underline;">Transaction Expenses</font>&#8221; means the aggregate amount of any and all documented fees and expenses reasonably incurred by or on behalf of, or paid or to be paid directly by, the Payer in connection with the diligence of the transactions contemplated hereby or thereby, and the negotiation, preparation or execution of the Transaction Documents and any ancillary documents, the filing, registration and perfection of the Transaction Documents, or the performance or consummation of the transactions contemplated hereby or thereby [***].</p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU22"></a>&#8220;<font style="text-decoration:underline;">UCC</font>&#8221; means the Uniform Commercial Code as in effect from time to time in the State of New York; provided, that, if, with respect to any financing statement or by reason of any provisions of applicable law, the perfection or the effect of perfection or non-perfection of the security interest or any portion thereof granted pursuant to &#8206;Section 2.1(b) is governed by the Uniform Commercial Code as in effect in a jurisdiction of the United States other than the State of New York, then &#8220;UCC&#8221; means the Uniform Commercial Code as in effect from time to time <br /></p>
<p style="text-align:center;Background-color:#auto;margin-top:12pt;line-height:10pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
<p style="line-height:10pt;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">250212926 v1</p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:7pt;font-family:Times New Roman;">&nbsp;</p>&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;Background-color:#auto;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 10.6</p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">in such other jurisdiction for purposes of the provisions of this Agreement and any financing statement relating to such perfection or effect of perfection or non-perfection.</font></p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk66782907"></a>&#8220;<font style="text-decoration:underline;">UGN-102</font>&#8221; means (a) the pharmaceutical product known as UGN-102 (mitomycin) for intravesical solution, (b) any pharmaceutical product for the treatment of bladder cancer in a hydrogel formulation that contains any radioisomer, stereoisomer, racemates, solvates, salt forms, bases, anhydrides, hydrates, polymorphs, metabolites, ester forms, deuterated forms or pro-drugs of mitomycin, and (c) any pharmaceutical product that contains any of the foregoing, in each case of (a)&#8211;(c), in any dosage form, dosing regimen, strength, or route of administration.</p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk57618664"></a>&#8220;<font style="text-decoration:underline;">UGN-102 Delay Payment</font>&#8221; is defined in the definition of &#8220;Jelmyto Net Sales Revenue Rate&#8221;.</p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="text-decoration:underline;">UGN-102 Net Sale</font>s&#8221; means Net Sales of UGN-102.</p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="text-decoration:underline;">UGN-102 Net Sales Revenue Rate</font>&#8221; means the applicable percentage based on the portion of the corresponding level of worldwide annual UGN-102 Net Sales in a calendar year as set forth in the chart below:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:99.89%;">
<tr>
<td style="width:56.11%;"></td>
<td style="width:43.78%;"></td>
</tr>
<tr>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="Background-color:#auto;margin-top:6pt;margin-bottom:6pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_9kMHG5YVt4886BJjSku9"></a><a name="_9kMHG5YVt4886BJjSku9"></a>Payment Tiers based on Annual UGN-102 Net Sales</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="Background-color:#auto;margin-top:6pt;margin-bottom:6pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">UGN-102 Net Sales Revenue Rate Applicable to Each Net Sales Tier</p></td>
</tr>
<tr>
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="Background-color:#auto;margin-top:6pt;margin-bottom:6pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A. Annual UGN-102 Net Sales of up to $200,000,000</p></td>
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="Background-color:#auto;margin-top:6pt;margin-bottom:6pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.5%</p></td>
</tr>
<tr>
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="Background-color:#auto;margin-top:6pt;margin-bottom:6pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">B. Annual UGN-102 Net Sales exceeding $200,000,000 and less than or equal to $300,000,000</p></td>
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="Background-color:#auto;margin-top:6pt;margin-bottom:6pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.0%</p></td>
</tr>
<tr>
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="Background-color:#auto;margin-top:6pt;margin-bottom:6pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">C. Annual UGN-102 Net Sales in excess of $300,000,000</p></td>
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="Background-color:#auto;margin-top:6pt;margin-bottom:6pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.5%</p></td>
</tr>
</table></div>
<p style="Background-color:#auto;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="text-decoration:underline;">UGN-102 Revenue Payments</font>&#8221; means, for each calendar quarter, an amount payable to the Payer equal to the amount of worldwide aggregate annual UGN-102 Net Sales during such calendar quarter multiplied by the UGN-102 Net Sales Revenue Rate. For clarity, the UGN-102 Net Sales Revenue Rate used to calculate the UGN-102 Revenue Payments for a given date in a calendar quarter (a) will be based on the worldwide aggregate annual UGN-102 Net Sales billed or invoiced for the calendar year through and including such date, and (b) may be different for different periods during such calendar quarter depending on the specific date the worldwide aggregate UGN-102 Net Sales crosses over to the next payment tier. By way of example, if worldwide aggregate UGN-102 Net Sales invoiced as of (i) April 12 for the calendar year equal $185,000,000, (ii) April 13 for the calendar year equal $210,000,000, and (c) June 30 for the calendar year equal $295,000,000, then the UGN-102 Net Sales Revenue Rate for such calendar quarter shall be equal to 2.5% with respect to UGN-102 Net Sales through and including April 12, and 1.0% with respect to UGN-102 Net Sales from April 13 through and including June 30.<br /></p>
<p style="text-align:center;Background-color:#auto;margin-top:12pt;line-height:10pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19</a></p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
<p style="line-height:10pt;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">250212926 v1</p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:7pt;font-family:Times New Roman;">&nbsp;</p>&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;Background-color:#auto;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 10.6</p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU23"></a><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;</font><font style="text-decoration:underline;">U.S. Security Documents</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8221; means </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the security agreements to be governed by U.S. law and granted by the Company in favor of the Payer pursuant to which the Company grants the Payer a security interest over the Product Collateral and </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the Patent Rights</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</font></p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="text-decoration:underline;">Valid Claim</font>&#8221; shall mean: (a) any claim of an issued and unexpired Patent included within the Patent Rights, that shall not have been withdrawn, lapsed, abandoned, revoked, canceled or disclaimed, or held invalid or unenforceable by a court, Governmental Entity, national or regional patent office or other appropriate body that has competent jurisdiction in a decision being final and unappealable or unappealed within the time allowed for appeal; and (b) a claim of a pending Patent application included within the Patent Rights that is filed and being prosecuted in good faith and that has not been finally abandoned or finally rejected and which has been pending for no more than seven years from the date of filing of the earliest Patent application to which such pending Patent application claims priority.</p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="text-decoration:underline;">Withholding Action</font>&#8221; is defined in &#8206;Section 6.16(b).</p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;color:#010000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc55233510"></a><a name="_Toc56006781"></a><a name="_Toc56700555"></a><a name="_Toc65621583"></a><a name="_Toc65623745"></a><a name="_Toc66905132"></a><font style="text-decoration:underline;">Certain Interpretations</font></p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. Except where expressly stated otherwise in this Agreement, the following rules of interpretation apply to this Agreement:</p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;color:#010000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)<font style="margin-left:36pt;"></font><font style="color:#000000;">&#8220;either&#8221; and &#8220;or&#8221; are disjunctive but not necessarily exclusive and &#8220;include,&#8221; &#8220;includes&#8221; and &#8220;including&#8221; are not limiting and shall be deemed to be followed by the words &#8220;without limitation&#8221;;</font></p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;color:#010000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)<font style="margin-left:36pt;"></font><font style="color:#000000;">&#8220;extent&#8221; in the phrase &#8220;to the extent&#8221; means the degree to which a subject or other thing extends, and such phrase does not mean simply &#8220;if&#8221;;</font></p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;color:#010000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c)<font style="margin-left:36pt;"></font><font style="color:#000000;">&#8220;hereof,&#8221; &#8220;hereto,&#8221; &#8220;herein&#8221; and &#8220;hereunder&#8221; and words of similar import when used in this Agreement refer to this Agreement as a whole and not to any particular provision of this Agreement;</font></p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;color:#010000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(d)<font style="margin-left:36pt;"></font><font style="color:#000000;">references to a Person are also to its permitted successors and assigns;</font></p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;color:#010000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(e)<font style="margin-left:36pt;"></font><font style="color:#000000;">definitions are applicable to the singular as well as the plural forms of such terms;</font></p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;color:#010000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(f)<font style="margin-left:36pt;"></font><font style="color:#000000;">references to an &#8220;Article&#8221;, &#8220;Section&#8221; or &#8220;Exhibit&#8221; refer to an Article&#160;or Section of, or an Exhibit to, this Agreement, and references to a &#8220;Schedule&#8221; refer to the corresponding part of the Disclosure Schedule;</font></p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;color:#010000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(g)<font style="margin-left:36pt;"></font><font style="color:#000000;">references to &#8220;$&#8221; or otherwise to dollar amounts refer to the lawful currency of the United States; and</font></p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;color:#010000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(h)<font style="margin-left:36pt;"></font><font style="color:#000000;">references to a law include any amendment or modification to such law and any rules and regulations issued thereunder, whether such amendment or modification is made, or issuance of such rules and regulations occurs, before or after the date of this Agreement.<br /></font></p>
<p style="text-align:center;Background-color:#auto;margin-top:12pt;line-height:10pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20</a></p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
<p style="line-height:10pt;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">250212926 v1</p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:7pt;font-family:Times New Roman;">&nbsp;</p>&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;Background-color:#auto;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 10.6</p>
<p style="Background-color:#auto;text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#010000;text-transform:uppercase;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU24"></a><a name="_Ref277710162"></a><a name="_Ref277771285"></a><a name="_Toc55233511"></a><a name="_Toc56006782"></a><a name="_Toc56700556"></a><a name="_Toc65621584"></a><a name="_Toc65623746"></a><a name="_Toc66905133"></a><font style="color:#010000;text-transform:uppercase;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;font-variant: normal;">ARTICLE 2</font><font style="text-transform:none;color:#000000;"><br /><a name="_Ref277710162"></a><a name="_Ref277771285"></a><a name="_Toc55233511"></a><a name="_Toc56006782"></a><a name="_Toc56700556"></a><a name="_Toc65621584"></a><a name="_Toc65623746"></a><a name="_Toc66905133"></a></font><font style="text-transform:none;color:#000000;">GRANT OF THE REVENUE PARTICIPATION RIGHT</font></p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;color:#010000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc55233512"></a><a name="_Toc56006783"></a><a name="_Toc56700557"></a><a name="_Toc65621585"></a><a name="_Toc65623747"></a><a name="_Ref65757511"></a><a name="_Toc66905134"></a><font style="text-decoration:underline;">Grant</font></p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. </p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;color:#010000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)<font style="margin-left:36pt;"></font><font style="color:#000000;">At the Closing and upon the terms and subject to the conditions of this Agreement, the Company shall grant to the Payer, and the Payer shall receive and accept from the Company, the Revenue Participation Right, free and clear of all Liens, except for any Liens in favor of, or granted by or otherwise applicable to, the Payer and Liens for Taxes, assessments or governmental charges or levies not yet due. Immediately upon the grant to the Payer by the Company of the Revenue Participation Right pursuant to this &#8206;Section 2.1, all of the Company&#8217;s right, title and interest in and to the Revenue Participation Right shall terminate, and all such right, title and interest shall vest in the Payer.</font></p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;color:#010000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Ref56498532"></a><a name="_Hlk66890974"></a>(b)<font style="margin-left:36pt;"></font><font style="color:#000000;">As security for the payment and fulfilment of the Payment Obligations, until the Minimum Return Date, (i) the Company does hereby grant to the Payer a <a name="_Hlk66890974"></a>first priority security interest in and to all right, title and interest in, to and under the Product Collateral, and (ii) the Company does hereby grant to the Payer a security interest in and to all right, title and interest in, to and under the Revenue Participation Right and the Revenue Payments, in each case, pursuant to the terms of the Security Documents. The Company hereby authorizes the Payer, from and after the Closing, to file financing statements (and continuation statements with respect to such financing statements when applicable) naming the Company as the debtor and the Payer as the secured party, and in such manner and such jurisdictions as are necessary or appropriate to perfect the Security Documents (including, without limitation, in Israel and the United States), including updating such financing statements when and if there are any new Intellectual Property Product Rights; provided that, notwithstanding the foregoing, the Security Documents (and the collateral thereunder) shall not include, and shall not extend to any Excluded Collateral.</font></p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;color:#010000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c)<font style="margin-left:36pt;"></font><font style="color:#000000;">Upon the receipt of Marketing Approval in any Covered Jurisdiction outside of Israel and the United States, and until the Minimum Return Date, the Company shall take such actions as reasonably requested by the Payer (including the filing of any financing statements, and any continuation statements with respect to such financing statements when applicable) to grant and perfect the security interest granted hereby and by the Security Documents with respect to any Patent Rights and Marketing Approvals constituting Product Collateral and any other material Product Collateral located in such jurisdiction (to the extent reasonably practicable).</font></p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;color:#010000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Ref66447975"></a><a name="_Toc66905135"></a><font style="text-decoration:underline;">Pre-Paid Forward Price</font></p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. At the Closing and upon the terms and subject to the conditions of this Agreement, the price to be paid as consideration to the Company for the grant of the Revenue Participation Right to the Payer is Seventy-Five Million Dollars ($75,000,000) in cash (the &#8220;<font style="text-decoration:underline;">Pre-Paid Forward Price</font>&#8221;).</p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;color:#010000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc55233514"></a><a name="_Toc56006785"></a><a name="_Toc56700559"></a><a name="_Toc65621587"></a><a name="_Toc65623749"></a><a name="_Toc66905136"></a><font style="text-decoration:underline;">No Assumed Obligations, Etc.</font></p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU25"></a> Notwithstanding any provision in this Agreement to the contrary, the Payer is only agreeing, on the terms and conditions set forth in this Agreement, to receive and accept the Revenue Participation Right and is not assuming any <br /></p>
<p style="text-align:center;Background-color:#auto;margin-top:12pt;line-height:10pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
<p style="line-height:10pt;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">250212926 v1</p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:7pt;font-family:Times New Roman;">&nbsp;</p>&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;Background-color:#auto;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 10.6</p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">liability or obligation of the Company of whatever nature, whether presently in existence or arising or asserted hereafter. </font></p>
<p style="Background-color:#auto;text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#010000;text-transform:uppercase;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;font-variant: normal;"><a name="_Ref276307547"></a><a name="_Toc55233515"></a><a name="_Toc56006786"></a><a name="_Toc56700560"></a><a name="_Toc65621588"></a><a name="_Toc65623750"></a><a name="_Toc66905137"></a>ARTICLE 3<font style="text-transform:none;color:#000000;"><br /><a name="_Ref276307547"></a><a name="_Toc55233515"></a><a name="_Toc56006786"></a><a name="_Toc56700560"></a><a name="_Toc65621588"></a><a name="_Toc65623750"></a><a name="_Toc66905137"></a>CLOSING</font></p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;color:#010000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Ref370725266"></a><a name="_Toc55233516"></a><a name="_Toc56006787"></a><a name="_Toc56700561"></a><a name="_Toc65621589"></a><a name="_Toc65623751"></a><a name="_Toc66905138"></a><a name="_Ref276307559"></a><font style="text-decoration:underline;">Closing</font></p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;color:#010000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)<font style="margin-left:36pt;"></font><font style="color:#000000;">. The</font><font style="font-weight:bold;color:#000000;"> </font><font style="color:#000000;">Closing shall take place remotely via the exchange of documents and signatures on the date that is two Business Days after the satisfaction or waiver of the conditions set forth in &#8206;ARTICLE 5 (other than those conditions that by their nature are to be satisfied at the Closing), or as otherwise mutually agreed by the Payer and the Company.</font></p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;color:#010000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc55233517"></a><a name="_Toc56006788"></a><a name="_Toc56700562"></a><a name="_Toc65621590"></a><a name="_Toc65623752"></a><a name="_Toc66905139"></a><font style="text-decoration:underline;">Payment of Pre-Paid Forward Price</font></p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;color:#010000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)<font style="margin-left:36pt;"></font><font style="color:#000000;">. The Escrow Agent shall be instructed to automatically release the payment of the Pre-Paid Forward Price to the Company at the Closing by electronic funds transfer or wire transfer of immediately available funds to one or more accounts specified by the Company pursuant to &#8206;Section 6.15.</font></p>
<p style="Background-color:#auto;text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#010000;text-transform:uppercase;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;font-variant: normal;"><a name="_Ref525246891"></a><a name="_Ref525246898"></a><a name="_Ref525251376"></a><a name="_Toc55233518"></a><a name="_Toc56006789"></a><a name="_Toc56700563"></a><a name="_Toc65621592"></a><a name="_Toc65623754"></a><a name="_Toc66905140"></a>ARTICLE 4<font style="text-transform:none;color:#000000;"><br /><a name="_Ref525246891"></a><a name="_Ref525246898"></a><a name="_Ref525251376"></a><a name="_Toc55233518"></a><a name="_Toc56006789"></a><a name="_Toc56700563"></a><a name="_Toc65621592"></a><a name="_Toc65623754"></a><a name="_Toc66905140"></a>REPRESENTATIONS AND WARRANTIES</font></p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;color:#010000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Ref525246923"></a><a name="_Toc55233519"></a><a name="_Toc56006790"></a><a name="_Toc56700564"></a><a name="_Toc65621593"></a><a name="_Toc65623755"></a><a name="_Toc66905141"></a><a name="_Ref276315247"></a><a name="_Ref276316115"></a><font style="text-decoration:underline;">Company&#8217;s Representations and Warranties</font></p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. Except as set forth on the Disclosure Schedules attached hereto, the Company hereby represents and warrants to the Payer that as of the date hereof and as of the Closing Date:</p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;color:#010000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Ref55802486"></a><font style="text-decoration:underline;">Existence; Good Standing</font></p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. The Company is a corporation duly incorporated, validly existing and in good standing under the laws of Israel. The Company is duly licensed or qualified to do business and is in corporate good standing in each jurisdiction in which the nature of the business conducted by it or the character or location of the properties and assets owned, leased or operated by it makes such licensing or qualification necessary, except where the failure to be so licensed or qualified and in corporate good standing has not and would not reasonably be expected to have, either individually or in the aggregate, a Material Adverse Effect. The Company is not a &#8220;company in violation&#8221; (&#8220;hevrah meferah&#8221;) as defined in Section 362A of the Israeli Companies Law and it has not received notice that it is expected to be registered as such.</p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;color:#010000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Ref55802487"></a><font style="text-decoration:underline;">Authorization</font></p>
<p style="margin-bottom:12pt;Background-color:#FFFFFF;margin-top:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk66890600"></a><a name="_Hlk66890600"></a>. The Company has all requisite corporate power and authority to execute, deliver and perform its obligations under the Transaction Documents. The execution, delivery and performance of the Transaction Documents, and the consummation of the transactions contemplated hereby, have been duly authorized by all necessary corporate action on the part of the Company.</p>
<p style="margin-bottom:12pt;Background-color:#FFFFFF;margin-top:0pt;text-indent:15.38%;color:#010000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Ref55802488"></a><font style="text-decoration:underline;">Enforceability</font></p>
<p style="margin-bottom:12pt;Background-color:#FFFFFF;margin-top:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk66890748"></a><a name="_Hlk66890748"></a>. The Transaction Documents have been duly executed and delivered by an authorized officer of the Company and constitute the valid and binding obligation of the Company, enforceable against the Company in accordance with its terms, except as may be limited by applicable Bankruptcy Laws or by general principles of equity (whether considered in a proceeding in equity or at law).<br /></p>
<p style="text-align:center;Background-color:#auto;margin-top:12pt;line-height:10pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22</a></p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
<p style="line-height:10pt;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">250212926 v1</p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:7pt;font-family:Times New Roman;">&nbsp;</p>&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;Background-color:#auto;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 10.6</p>
<p style="margin-bottom:12pt;Background-color:#FFFFFF;margin-top:0pt;text-indent:15.38%;color:#010000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU26"></a><font style="text-decoration:underline;color:#000000;">No Conflicts</font></p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk66890505"></a><a name="_Hlk66890505"></a>. The execution, delivery and performance by the Company of the Transaction Documents and the consummation of the transactions contemplated hereby and thereby do not and will not (i)&#160;contravene or conflict with the Articles of Association of the Company, (ii)&#160;contravene or conflict with or constitute a material default under any law binding upon or applicable to the Company or the Revenue Participation Right or (iii)&#160;contravene or conflict with or constitute a material default under any material agreement or Judgment binding upon or applicable to the Company or the Revenue Participation Right.</p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;color:#010000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Consents</font></p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk66890777"></a><a name="_Hlk66890777"></a>. Except for the consents that have been obtained on or prior to the Closing, the UCC financing statements contemplated by &#8206;Section 2.1(b), or any filings required by the federal securities laws or stock exchange rules, or any filings and registrations of the Security Documents at the Israeli Registrar of Companies and to the extent applicable, at the Israeli Patent Office, no consent, approval, license, order, authorization, registration, declaration or filing with or of any Governmental Entity or other Person is required to be done or obtained by the Company in connection with (i)&#160;the execution and delivery by the Company of the Transaction Documents, (ii)&#160;the performance by the Company of its obligations under the Transaction Documents or (iii)&#160;the consummation by the Company of any of the transactions contemplated by the Transaction Documents.</p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;color:#010000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">No Litigation</font></p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. Neither the Company nor any of its Subsidiaries is a party to, and has not received any written notice of, any action, suit, investigation or proceeding pending before any Governmental Entity and, to the Knowledge of the Company, no such action, suit, investigation or proceeding has been threatened against the Company, that, individually or in the aggregate, has had or would, if determined adversely, reasonably be expected to have a Material Adverse Effect. </p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;color:#010000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Compliance</font></p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;text-indent:25%;color:#010000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(i)<font style="margin-left:36pt;"></font><font style="color:#000000;">All applications, submissions, information and data related to a Product submitted or utilized as the basis for any request to any Regulatory Authority by or on behalf of the Company were true and correct in all material respects as of the date of such submission or request, and, to the Knowledge of the Company any material updates, changes, corrections or modification to such applications, submissions, information or data required under applicable laws or regulations have been submitted to the necessary Regulatory Authorities.</font></p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;text-indent:25%;color:#010000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_9kR3WTr266489MLnrv"></a><a name="_9kR3WTr26649JkW279xWgvw1vwyEKG4dT7CBG04"></a><a name="_9kR3WTr26647CMHvgduF"></a><a name="_9kR3WTr26648AQIsmiflSTuxI889v6"></a>(ii)<font style="margin-left:36pt;"></font><font style="color:#000000;"><a name="_9kR3WTr266489MLnrv"></a>Neither the Company nor any of its Subsidiaries has committed any act, made any statement or failed to make any statement that would reasonably be expected to provide a basis for the FDA or EMA to invoke its policy with respect to &#8220;Fraud<a name="_9kR3WTr26649JkW279xWgvw1vwyEKG4dT7CBG04"></a>, Untrue Statements of Material Facts<a name="_9kR3WTr26647CMHvgduF"></a>, Bribery<a name="_9kR3WTr26648AQIsmiflSTuxI889v6"></a>, and Illegal Gratuities&#8221;, or similar policies, set forth in any applicable laws or regulations.</font></p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;text-indent:25%;color:#010000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Ref502777807"></a>(iii)<font style="margin-left:36pt;"></font><font style="color:#000000;">The Company has provided to the Payer prior to the date hereof in a data room available to the Payer true and correct copies or summaries of all material written communications sent or received by the Company and any of its Affiliates to or from any Regulatory Authorities that relate to each Product since [***].<br /></font></p>
<p style="text-align:center;Background-color:#auto;margin-top:12pt;line-height:10pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23</a></p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
<p style="line-height:10pt;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">250212926 v1</p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:7pt;font-family:Times New Roman;">&nbsp;</p>&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;Background-color:#auto;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 10.6</p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;text-indent:25%;color:#010000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU27"></a><a name="_9kR3WTr2664ADfLn1tutSL0G21"></a><a name="_9kR3WTr26647HVI10Plh"></a><a name="_9kR3WTr26649IjW2yz3piQM1H32"></a><font style="color:#010000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(iv)</font><font style="margin-left:36pt;"></font><font style="color:#000000;"><a name="_9kR3WTr2664ADfLn1tutSL0G21"></a>None of the Company, any of its Subsidiaries and, to the Knowledge of the Company, any Third Party manufacturer of any Product, has received from the FDA a &#8220;</font><font style="color:#000000;">Warning Letter</font><font style="color:#000000;"><a name="_9kR3WTr26647HVI10Plh"></a>&#8221;, </font><font style="color:#000000;">Form FDA</font><font style="color:#000000;"><a name="_9kR3WTr26649IjW2yz3piQM1H32"></a>-483, &#8220;</font><font style="color:#000000;">Untitled Letter</font><font style="color:#000000;">,&#8221; or similar material written correspondence or notice alleging violations of applicable laws and regulations enforced by the FDA, or any comparable material written correspondence from any other Regulatory Authority with regard to either Product or the manufacture, processing, packaging or holding thereof, the subject of which communication is unresolved and if determined adversely to the Company or such Subsidiary would, individually or in the aggregate, reasonably be expected to result in a Material Adverse Effect.</font></p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;text-indent:25%;color:#010000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(v)<font style="margin-left:36pt;"></font><font style="color:#000000;">Since [***], (A) there have been no Safety Notices, (B) to the Knowledge of the Company, there are no unresolved material product complaints with respect to any Product, which would result in a Material Adverse Effect, and (C) to the Knowledge of the Company, there are no facts currently in existence that would, individually or in the aggregate, reasonably be expected to result in (1) a material Safety Notice with respect to any Product, or (2) a material change in the labeling of any Product. Since [***], neither the Company nor any of its Subsidiaries has experienced any significant failures in the manufacturing of any Product for clinical use or commercial sale that, individually or in the aggregate, have had or would reasonably be expected to result in, if such failure occurred again, a Material Adverse Effect.</font></p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;color:#010000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Licenses</font></p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;text-indent:25.96%;color:#010000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Ref502777822"></a><a name="_Ref370725308"></a>(i)<font style="margin-left:36pt;"></font><font style="text-decoration:underline;color:#000000;">In-Licenses</font><font style="color:#000000;">. There are no In-Licenses. </font></p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;text-indent:25.96%;color:#010000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Ref55287287"></a><a name="_9kR3WTr26646BQI10Plh"></a>(ii)<font style="margin-left:36pt;"></font><font style="text-decoration:underline;color:#000000;">Out-Licenses</font><font style="color:#000000;"><a name="_9kR3WTr26646BQI10Plh"></a>. There are no Out-Licenses other than Excluded Out-Licenses.</font></p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;color:#010000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk66890401"></a>(i)<font style="margin-left:36pt;"></font><font style="text-decoration:underline;color:#000000;">No Liens; Title to Revenue Participation Right</font><font style="color:#000000;"><a name="_Hlk66890401"></a>. Neither the Product Collateral nor any of the property or assets, in each case, that specifically relate to the Products, including Intellectual Property Rights, of the Company or any of its Subsidiaries is subject to any Lien, except for any Permitted Lien or any non-exclusive license or rights to use granted to customers, suppliers, manufacturers or service providers in the ordinary course of business.</font></p>
<p style="margin-bottom:12pt;Background-color:#FFFFFF;margin-top:0pt;text-indent:15.38%;color:#010000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(j)<font style="margin-left:126pt;"></font><font style="text-decoration:underline;color:#000000;">Manufacturing; Supply</font><font style="color:#000000;">. All Products have, since [***], been manufactured, transported, stored and handled in all material respects in accordance with applicable law and with good manufacturing practices. Since [***], neither the Company nor any Affiliate of the Company has experienced any significant failures in the manufacturing or supply of any Product that, individually or in the aggregate, have had or would reasonably be expected to result in, if such failure occurred again, a Material Adverse Effect. The Company has on hand or has made adequate provisions to secure sufficient clinical quantities of Products to complete all clinical trials and all activities required for Marketing Approvals, in each case, that are ongoing or planned as of the date hereof. The Company has on hand or has made adequate provisions to secure sufficient quantities of Jelmyto to support the commercial launch of Jelmyto in the Territory.</font></p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;color:#010000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(k)<font style="margin-left:36pt;"></font><font style="text-decoration:underline;color:#000000;">Intellectual Property</font><font style="color:#000000;">.<br /></font></p>
<p style="text-align:center;Background-color:#auto;margin-top:12pt;line-height:10pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24</a></p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
<p style="line-height:10pt;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">250212926 v1</p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:7pt;font-family:Times New Roman;">&nbsp;</p>&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;Background-color:#auto;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 10.6</p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;text-indent:25.96%;color:#010000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Ref306701751"></a><a name="_Ref56345737"></a><a name="_AEIOULastRenderedPageBreakAEIOU28"></a><a name="_Hlk56346078"></a><font style="color:#010000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(i)</font><font style="margin-left:36pt;"></font><font style="text-decoration:underline;color:#000000;">Schedule 4.1(k)(i)(A)</font><font style="color:#000000;"> of the Disclosure Schedule </font><font style="color:#000000;">lists all of the currently existing Patents included within the Patent Rights (other than the Non-Exclusive Patent Rights) (the &#8220;</font><font style="text-decoration:underline;color:#000000;">Existing Patent Rights</font><font style="color:#000000;">&#8221;). Except as set forth on </font><font style="text-decoration:underline;color:#000000;">Schedule 4.1(k)(i)(A)</font><font style="color:#000000;"><a name="_Hlk56346078"></a> of the Disclosure Schedule, the Company is the sole and exclusive registered owner of all of the </font><font style="color:#000000;">Existing </font><font style="color:#000000;">Patent Rights. </font><font style="text-decoration:underline;color:#000000;">Schedule 4.1(k)(i)(A)</font><font style="color:#000000;"> of the Disclosure Schedule specifies as to each listed patent or patent application the jurisdictions by or in which each such patent has issued as a patent or such patent application has been filed, including the respective patent or application numbers. The Existing Patent Rights comprise all the Patent Rights (other than the Non-Exclusive Patent Rights) that are owned or in-licensed by the Company or any of its Affiliates or under which the Company or any of its Affiliates is or may become empowered to grant licenses that are necessary for, or used in, the development, manufacture, use, marketing, promotion, sale or distribution of a Product as of the date hereof and the Closing Date.</font></p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;text-indent:25.96%;color:#010000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(ii)<font style="margin-left:36pt;"></font><font style="color:#000000;">Neither Company nor any of its Subsidiaries is a party to any pending and, to the Knowledge of the Company, there is no threatened, litigation, interference, reexamination, opposition or like procedure involving any of the Existing Patent Rights.</font></p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;text-indent:25.96%;color:#010000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(iii)<font style="margin-left:36pt;"></font><font style="color:#000000;">All of the issued patents within the Existing Patent Rights are (A) to the Knowledge of the Company, valid and enforceable, and (B) in full force and effect. None of the issued patents within the Existing Patent Rights have lapsed, expired or otherwise terminated. Neither Company nor any of its Subsidiaries has received any written notice relating to the lapse, expiration or other termination of any of the issued patents within the Existing Patent Rights, and neither Company nor its Subsidiaries has received any written legal opinion that alleges that, an issued patent within any of the Existing Patent Rights is invalid or unenforceable.</font></p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;text-indent:25.96%;color:#010000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(iv)<font style="margin-left:36pt;"></font><font style="color:#000000;">Neither Company nor any of its Subsidiaries has received any written notice that there is any, and, to the Knowledge of the Company, there is no, Person who is or claims to be an inventor under any of the Existing Patent Rights who is not a named inventor thereof.</font></p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;text-indent:25.96%;color:#010000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(v)<font style="margin-left:36pt;"></font><font style="color:#000000;">Neither the Company not its Affiliates has received any written notice of any claim by any Person challenging the inventorship or ownership of, the rights of the Company in and to, or the patentability, validity or enforceability of, any of the Existing Patent Rights, or asserting that the development, manufacture, importation, sale, offer for sale or use of the Product infringes, misappropriates or otherwise violates or will infringe, misappropriate or otherwise violate such Person&#8217;s Patents or other intellectual property rights.</font></p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;text-indent:25.96%;color:#010000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(vi)<font style="margin-left:36pt;"></font><font style="color:#000000;">To the Knowledge of the Company, the discovery, development manufacture, importation, sale, offer for sale or use of each Product, in each case in the form such Product exists as of the date hereof and as such activity is currently contemplated by the Company, has not and will not, infringe, misappropriate or otherwise violate any Patents or other intellectual property rights owned by any Third Party.</font></p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;text-indent:25.96%;color:#010000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(vii)<font style="margin-left:36pt;"></font><font style="color:#000000;">To the Knowledge of the Company, no Person has infringed, misappropriated or otherwise violated, or is infringing, misappropriating or otherwise violating, any of the Intellectual Property Rights.<br /></font></p>
<p style="text-align:center;Background-color:#auto;margin-top:12pt;line-height:10pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25</a></p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
<p style="line-height:10pt;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">250212926 v1</p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:7pt;font-family:Times New Roman;">&nbsp;</p>&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;Background-color:#auto;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 10.6</p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;text-indent:25.96%;color:#010000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU29"></a><font style="color:#010000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(viii)</font><font style="margin-left:36pt;"></font><font style="color:#000000;">The Company has paid all maintenance fees, annuities and like payments required as of the date hereof with respect to each of the Existing Patent Rights.</font></p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;text-indent:25.96%;color:#010000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Ref65781156"></a><a name="_9kR3WTr26648BRKwy7ut2y4RTJ73E9CT"></a>(ix)<font style="margin-left:36pt;"></font><font style="color:#000000;"><a name="_9kR3WTr26648BRKwy7ut2y4RTJ73E9CT"></a>The Company does not have any obligations to the Innovation Authority in Israel (&#8220;</font><font style="text-decoration:underline;color:#000000;">IIA</font><font style="color:#000000;">&#8221;) (including any payments or royalties) nor has it applied for any grant from the IIA which has not been repaid in full or terminated, other than the commitment to continue to employ at least 75% of its research and development jobs in Israel (at the time of the settlement between the Company and the IIA regarding unwinding the Company&#8217;s obligations to the IIA regarding grants that were loaned by the IIA to the Company between January 2004 and September 2016) for a period of at least [***], until [***], which such commitment the Company is in full compliance with. There are no restrictions on transferring or pledging the Product Collateral and the Payer Priority Collateral or manufacturing the Products outside of the State of Israel, nor is any approval required from the IIA for the transactions contemplated by this Agreement and the other Transaction Documents (including the grant of the Security Documents).</font></p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;color:#010000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(l)<font style="margin-left:36pt;"></font><font style="text-decoration:underline;color:#000000;">Indebtedness</font><font style="color:#000000;">. </font><font style="text-decoration:underline;color:#000000;">T</font><font style="color:#000000;">he Company does not have any outstanding Indebtedness in excess of $[***] in the aggregate principal amount.</font></p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;color:#010000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(m)<font style="margin-left:36pt;"></font><font style="text-decoration:underline;color:#000000;">Solvency</font><font style="color:#000000;">. No Insolvency Event has occurred in respect of the Company. The Company has no plan or intention of, and the Company has not received any notice that any other Person has any plan or intention of, filing, making, or obtaining any petition, notice, Order, or resolution as specified in the definition of Insolvency Event or of seeking the appointment of a receiver, trustee, custodian, or similar fiduciary as specified in clause (e) of the definition of Insolvency Event.&nbsp;&nbsp;The Company is Solvent and has sufficient assets and capital to carry on its business as currently conducted and to perform its obligations hereunder.</font></p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;color:#010000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk66890319"></a>(n)<font style="margin-left:36pt;"></font><font style="text-decoration:underline;color:#000000;">Security</font><font style="color:#000000;"><a name="_Hlk66890319"></a>. At the Closing, and upon filing, registration and perfection of the Security Documents within the time periods required by applicable law, the Payer will have a valid first priority security interest in and to all right, title and interest in, to and under the Product Collateral.</font></p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;color:#010000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(o)<font style="margin-left:36pt;"></font><font style="text-decoration:underline;color:#000000;">Lien Related Representation and Warranties</font><font style="color:#000000;">. The Company&#8217;s exact legal name is, and for the immediately preceding five years has been, &#8220;UroGen Pharma Ltd.&#8221; The Company is, and for the prior five years has been, incorporated in Israel.</font></p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;color:#010000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Ref525248995"></a><a name="_9kR3WTr26647EPF6xpmnrHN46vuJ"></a>(p)<font style="margin-left:36pt;"></font><font style="text-decoration:underline;color:#000000;">Brokers&#8217; Fees</font><font style="color:#000000;"><a name="_9kR3WTr26647EPF6xpmnrHN46vuJ"></a>. Except for Cowen and Company, there is no investment banker, broker, finder, financial advisor or other intermediary who has been retained by or is authorized to act on behalf of the Company who might be entitled to any fee or commission in connection with the transactions contemplated by the Transaction Documents.</font></p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;color:#010000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Ref276323437"></a><a name="_Toc56006791"></a><a name="_Toc56700565"></a><a name="_Toc65621594"></a><a name="_Toc65623756"></a><a name="_Toc66905142"></a><font style="text-decoration:underline;">Payer&#8217;s Representations and Warranties</font></p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_9kR3WTr26646FXKwy7ut2y4RTJ73E9CT"></a><a name="_9kR3WTr26646FXKwy7ut2y4RTJ73E9CT"></a>. The Payer hereby represents and warrants to the Company that as of the date hereof and as of the Closing Date:</p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;color:#010000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_9kMHG5YVt4886AEUQxzzKM20um29C9PYNACL356"></a><a name="_9kR3WTr26649Db9F2R6q"></a>(a)<font style="margin-left:36pt;"></font><font style="text-decoration:underline;color:#000000;">Existence; Good Standing</font><font style="color:#000000;"><a name="_9kMHG5YVt4886AEUQxzzKM20um29C9PYNACL356"></a>. The Payer is an Irish Collective Asset-management Vehicle<a name="_9kR3WTr26649Db9F2R6q"></a> registered in Ireland as an umbrella fund with segregated liability between sub-funds, for and on behalf of its sub-fund, RTW Fund 2.<br /></font></p>
<p style="text-align:center;Background-color:#auto;margin-top:12pt;line-height:10pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26</a></p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
<p style="line-height:10pt;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">250212926 v1</p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:7pt;font-family:Times New Roman;">&nbsp;</p>&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;Background-color:#auto;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 10.6</p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;color:#010000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU30"></a><a name="_9kR3WTr266468KF6xpmnrHN46vuJ"></a><font style="color:#010000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)</font><font style="margin-left:36pt;"></font><font style="text-decoration:underline;color:#000000;">Authorization</font><font style="color:#000000;"><a name="_9kR3WTr266468KF6xpmnrHN46vuJ"></a>. The Payer h</font><font style="color:#000000;">as the requisite </font><font style="color:#000000;">trust right, power and authority to execute, deliver and perform its obligations under this Agreement. The execution, delivery and performance of this Agreement, and the consummation of the transactions contemplated hereby, have been duly authorized by all necessary action on the part of the Payer. </font></p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;color:#010000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c)<font style="margin-left:36pt;"></font><font style="text-decoration:underline;color:#000000;">Enforceability</font><font style="color:#000000;">. This Agreement has been duly executed and delivered by an authorized person of the owner trustee of the Payer and constitutes the valid and binding obligation of the Payer, enforceable against the Payer in accordance with its terms, except as may be limited by applicable Bankruptcy Laws or by general principles of equity (whether considered in a proceeding in equity or at law).</font></p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;color:#010000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(d)<font style="margin-left:36pt;"></font><font style="text-decoration:underline;color:#000000;">No Conflicts</font><font style="color:#000000;">. The execution, delivery and performance by the Payer of this Agreement do not and will not (i)&#160;contravene or conflict with the organizational documents of the Payer, (ii)&#160;contravene or conflict with or constitute a default under any material provision of any law binding upon or applicable to the Payer or (iii)&#160;contravene or conflict with or constitute a default under any material contract or other material agreement or Judgment binding upon or applicable to the Payer.</font></p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;color:#010000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(e)<font style="margin-left:36pt;"></font><font style="text-decoration:underline;color:#000000;">Consents</font><font style="color:#000000;">. Except for any filings required by the federal securities laws or stock exchange rules, no consent, approval, license, order, authorization, registration, declaration or filing with or of any Governmental Entity or other Person is required to be done or obtained by the Payer in connection with (i)&#160;the execution and delivery by the Payer of this Agreement, (ii)&#160;the performance by the Payer of its obligations under this Agreement or (iii)&#160;the consummation by the Payer of any of the transactions contemplated by this Agreement.</font></p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;color:#010000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(f)<font style="margin-left:36pt;"></font><font style="text-decoration:underline;color:#000000;">No Litigation</font><font style="color:#000000;">. There is no action, suit, investigation or proceeding pending or, to the knowledge of the Payer, threatened before any Governmental Entity to which the Payer is a party that would, if determined adversely, reasonably be expected to prevent or materially and adversely affect the ability of the Payer to perform its obligations under this Agreement.</font></p>
<p style="margin-bottom:12pt;Background-color:#FFFFFF;margin-top:0pt;text-indent:15.38%;color:#010000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(g)<font style="margin-left:108pt;"></font><font style="text-decoration:underline;color:#000000;">Financing</font><font style="color:#000000;">. The Payer has sufficient cash to pay the Pre-Paid Forward Price at the Closing. The Payer acknowledges that its obligations under this Agreement are not contingent on obtaining financing. </font></p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;color:#010000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc468783565"></a>(h)<font style="margin-left:36pt;"></font><font style="text-decoration:underline;color:#000000;">Brokers&#8217; Fees</font><font style="color:#000000;"><a name="_Toc468783565"></a>. There is no investment banker, broker, finder, financial advisor or other intermediary who has been retained by or is authorized to act on behalf of the Payer who might be entitled to any fee or commission in connection with the transactions contemplated by this Agreement.</font></p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;color:#010000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Ref66442279"></a><a name="_Ref525251270"></a><a name="_Toc56006792"></a><a name="_Toc56700566"></a><a name="_Toc65621595"></a><a name="_Toc65623757"></a><a name="_Hlk66440530"></a>(i)<font style="margin-left:36pt;"></font><font style="text-decoration:underline;color:#000000;">Tax Residency</font><font style="color:#000000;"><a name="_Hlk66440530"></a>. The Payer is a resident of Ireland for Irish tax purposes and, as of the date hereof and as a matter of Irish law, is treated as eligible to claim the benefit </font><font style="color:#000000;">of </font><font style="color:#000000;">the double tax treaty concluded (a) between Ireland and the State of Israel and (b) between Ireland and the United States.</font></p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;color:#010000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Ref66893256"></a><a name="_Toc66905143"></a><font style="text-decoration:underline;">No Implied Representations and Warranties</font></p>
<p style="margin-bottom:12pt;Background-color:#FFFFFF;margin-top:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU31"></a>. The Payer acknowledges and agrees that, other than the express representations and warranties of the Company specifically contained in &#8206;ARTICLE 4 and the other Transaction Documents, (a) there are no representations or warranties of the Company either expressed or implied with respect to the Patent Rights or <br /></p>
<p style="text-align:center;Background-color:#auto;margin-top:12pt;line-height:10pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
<p style="line-height:10pt;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">250212926 v1</p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:7pt;font-family:Times New Roman;">&nbsp;</p>&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;Background-color:#auto;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 10.6</p>
<p style="margin-bottom:12pt;Background-color:#FFFFFF;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Revenue Payment and that the Payer does not rely on, and shall have no remedies in respect of, any representation or warranty not specifically set forth in </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8206;</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ARTICLE 4</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> and the other Transaction Documents, and all other representations and warranties are hereby expressly disclaimed, and (b) nothing contained herein guarantees that sales of the Products or the aggregate Revenue Payments due to the Payer will achieve any specific amounts (it being understood and agreed that nothing in this</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8206;</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Section 4.3</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> shall limit in any way the Company&#8217;s obligations under </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8206;</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ARTICLE 8</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">). Notwithstanding the foregoing, claims for fraud, gross negligence, or willful misconduct shall not be waived or limited in any way by this</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8206;</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Section 4.3</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. Except for the Revenue Participation Right, the Security Documents and the Payer&#8217;s rights under </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8206;</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Section 6.5(d)</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, the Payer further acknowledges and agrees that no licenses or assignments under any assets (including the Patent Rights or any other intellectual property) of the Company and its Affiliates are granted pursuant to this Agreement, including by implication, estoppel, exhaustion or otherwise.</font></p>
<p style="Background-color:#auto;text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#010000;text-transform:uppercase;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;font-variant: normal;"><a name="_Ref276307513"></a><a name="_Ref288147333"></a><a name="_Toc56006793"></a><a name="_Toc56700567"></a><a name="_Toc65621596"></a><a name="_Toc65623758"></a><a name="_Toc66905144"></a>ARTICLE 5<font style="text-transform:none;color:#000000;"><br /><a name="_Ref276307513"></a><a name="_Ref288147333"></a><a name="_Toc56006793"></a><a name="_Toc56700567"></a><a name="_Toc65621596"></a><a name="_Toc65623758"></a><a name="_Toc66905144"></a>CONDITIONS TO CLOSING</font></p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;color:#010000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Ref54806032"></a><a name="_Toc56006794"></a><a name="_Toc56700568"></a><a name="_Toc65621597"></a><a name="_Toc65623759"></a><a name="_Toc66905145"></a><font style="text-decoration:underline;">Conditions to the Payer&#8217;s Obligations</font></p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Ref276308185"></a><a name="_Ref276308185"></a>. The obligations of the Payer to consummate the transactions contemplated hereunder on the Closing Date are subject to the satisfaction or waiver, at or prior to the Closing Date, of each of the following conditions precedent:</p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;color:#010000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Ref57024686"></a>(a)<font style="margin-left:36pt;"></font><font style="color:#000000;">The Company shall have performed and complied in all material respects with all agreements, covenants, obligations and conditions required to be performed and complied with by it under this Agreement at or prior to the Closing Date, and the Payer shall have received a certificate executed by a duly authorized officer of the Company on the Closing Date certifying on behalf of the Company to the effect of the foregoing.</font></p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;color:#010000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Ref276308187"></a>(b)<font style="margin-left:36pt;"></font><font style="color:#000000;">The representations and warranties of the Company contained in &#8206;Section 4.1 shall have been true and correct in all material respects as of the date hereof and shall be true and correct in all material respects as of the Closing Date as though made at and as of the date hereof and as of the Closing Date, respectively, except to the extent any such representation or warranty expressly speaks as of a particular date, in which case it shall be true and correct in all material respects as of such date; </font><font style="text-decoration:underline;color:#000000;">provided</font><font style="color:#000000;"> that, to the extent that any such representation or warranty is qualified by the term &#8220;material&#8221; or &#8220;Material Adverse Effect,&#8221; such representation or warranty (as so written, including the term &#8220;material&#8221; or &#8220;Material Adverse Effect&#8221;) shall have been true and correct in all respects as of the date hereof and shall be true and correct in all respects as of the Closing Date or such other date, as applicable. The Payer shall have received a certificate executed by an authorized officer of the Company on the Closing Date certifying on behalf of the Company to the effect of the foregoing.</font></p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;color:#010000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c)<font style="margin-left:36pt;"></font><font style="color:#000000;">No event or events shall have occurred, or be reasonably likely to occur, that, individually or in the aggregate, have had or would reasonably be expected to result in (or, with the giving of notice, the passage of time or otherwise, would result in) a Material Adverse Effect. The Payer shall have received a certificate executed by a duly authorized officer of the Company on the Closing Date certifying on behalf of the Company to the effect of the foregoing. <br /></font></p>
<p style="text-align:center;Background-color:#auto;margin-top:12pt;line-height:10pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28</a></p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
<p style="line-height:10pt;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">250212926 v1</p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:7pt;font-family:Times New Roman;">&nbsp;</p>&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;Background-color:#auto;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 10.6</p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;color:#010000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU32"></a><font style="color:#010000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(d)</font><font style="margin-left:36pt;"></font><font style="color:#000000;">There shall not have been issued and be in effect any Judgment of any Governmental Entity enjoining, preventing or restricting the consummation of the transactions contemplated by this Agreement.</font></p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;color:#010000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(e)<font style="margin-left:36pt;"></font><font style="color:#000000;">There shall not have been instituted or be pending any action or proceeding by any Governmental Entity or any other Person (i)&#160;challenging or seeking to make illegal, to delay materially or otherwise directly or indirectly to restrain or prohibit the consummation of the transactions contemplated hereby, (ii)&#160;seeking to obtain material damages in connection with the transactions contemplated hereby or (iii)&#160;seeking to restrain or prohibit the Payer&#8217;s receipt and acceptance of the Revenue Participation Right. </font></p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;color:#010000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(f)<font style="margin-left:36pt;"></font><font style="color:#000000;">The Company shall have delivered to the Payer the legal opinions of Cooley LLP and Hamburger Evron &amp; Co., each as counsel to the Company, in substantially the forms attached hereto as Exhibit A.</font></p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;color:#010000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Ref502778182"></a>(g)<font style="margin-left:36pt;"></font><font style="color:#000000;">The Payer shall have received a certificate of an officer of the Company, dated the Closing Date, certifying as to (i)&#160;the incumbency of each officer of the Company executing this Agreement and (ii)&#160;the attached thereto copies of (A) the Company&#8217;s Articles of Association, and (B) resolutions adopted by the Company&#8217;s Board authorizing the execution and delivery by the Company of this Agreement and the consummation by the Company of the transactions contemplated hereby (the &#8220;</font><font style="text-decoration:underline;color:#000000;">Company Certificate</font><font style="color:#000000;">&#8221;). </font></p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;color:#010000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk58195502"></a><a name="_9kR3WTr26647FR2pqqz1y"></a>(h)<font style="margin-left:36pt;"></font><font style="color:#000000;"><a name="_9kR3WTr26647FR2pqqz1y"></a>The Company shall have confirmed it has scheduled delivery to Payer of a CD or USB containing copies of all documents uploaded to the Datasite data room related to the transactions contemplated by this Agreement, as of the date hereof, maintained by the Company and made available to the Payer, including all documents referred to in &#8206;Section 4.1(g)(iii) and &#8206;Section 4.1(h)(ii).</font></p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;color:#010000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Ref66434204"></a>(i)<font style="margin-left:36pt;"></font><font style="color:#000000;">The Company shall have executed and delivered the Security Documents in form and substance reasonably acceptable to the Payer, and all deliverables required in connection with the Security Documents and their registration or perfection, including: (i) an original notice of charge (Form 10) with respect to each of the Security Documents, as required for the registration of each of the Security Documents at the Israeli Registrar of Companies and (ii) a power of attorney duly completed and signed by an authorized representative(s) of the Company in favor of the Payer's Israeli legal counsel, with respect to the registration of the Liens over the Israeli Patents at the Israeli Patent Office.</font></p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;color:#010000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(j)<font style="margin-left:36pt;"></font><font style="color:#000000;">The Security Documents, including any deliverables required, shall have been filed at all applicable registries (including the Israeli Registrar of Companies and in respect of any Israeli Patents, at the Israeli Patent Office) in each applicable jurisdiction and the actual completed registration of such Security Documents at such registries shall have been obtained.</font></p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;color:#010000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc56006795"></a><a name="_Toc56700569"></a><a name="_Toc65621598"></a><a name="_Toc65623760"></a><a name="_Toc66905146"></a><font style="text-decoration:underline;">Conditions to the Company&#8217;s Obligations</font></p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. The obligations of the Company to consummate the transactions contemplated hereunder on the Closing Date are subject to the satisfaction or waiver, at or prior to the Closing Date, of each of the following conditions precedent:<br /></p>
<p style="text-align:center;Background-color:#auto;margin-top:12pt;line-height:10pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29</a></p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
<p style="line-height:10pt;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">250212926 v1</p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:7pt;font-family:Times New Roman;">&nbsp;</p>&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;Background-color:#auto;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 10.6</p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;color:#010000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU33"></a><font style="color:#010000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)</font><font style="margin-left:36pt;"></font><font style="color:#000000;">The Payer shall have performed and complied in all material respects with all agreements, covenants, obligations and conditions required to be performed and complied with by it under this Agreement at or prior to the Closing Date, and the Company shall have received a certificate executed by a duly authorized representative of the Payer on the Closing Date certifying on behalf of the Payer to the effect of the foregoing.</font></p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;color:#010000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Ref57129324"></a><a name="_9kR3WTr266469M2pqqz1y"></a>(b)<font style="margin-left:36pt;"></font><font style="color:#000000;">The representations and warranties of the Payer contained in &#8206;Section 4.2<a name="_9kR3WTr266469M2pqqz1y"></a> shall have been true and correct in all material respects as of the date hereof and shall be true and correct in all material respects as of the Closing Date as though made at and as of the date hereof and Closing Date, respectively, except to the extent any such representation or warranty expressly speaks as of a particular date, in which case it shall be true and correct in all material respects as of such date; </font><font style="text-decoration:underline;color:#000000;">provided</font><font style="color:#000000;">, that to the extent that any such representation or warranty is qualified by the term &#8220;material,&#8221; or &#8220;Material Adverse Effect&#8221; such representation or warranty (as so written, including the term &#8220;material&#8221; or &#8220;Material Adverse Effect&#8221;) shall have been true and correct in all respects as of the date hereof and shall be true and correct in all respects as of the Closing Date or such other date, as applicable. The Company shall have received a certificate executed by a duly authorized officer of the Payer on the Closing Date certifying on behalf of the Payer to the effect of the foregoing.</font></p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;color:#010000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c)<font style="margin-left:36pt;"></font><font style="color:#000000;">There shall not have been issued and be in effect any Judgment of any Governmental Entity enjoining, preventing or restricting the consummation of the transactions contemplated by this Agreement.</font></p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;color:#010000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(d)<font style="margin-left:36pt;"></font><font style="color:#000000;">There shall not have been instituted or be pending any action or proceeding by any Governmental Entity or any other Person (i)&#160;challenging or seeking to make illegal, to delay materially or otherwise directly or indirectly to restrain or prohibit the consummation of the transactions contemplated hereby, (ii)&#160;seeking to obtain material damages in connection with the transactions contemplated hereby or (iii)&#160;seeking to restrain or prohibit the Payer&#8217;s receipt and acceptance of the Revenue Participation Right.</font></p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;color:#010000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Ref370725043"></a>(e)<font style="margin-left:36pt;"></font><font style="color:#000000;">The Payer shall have delivered to the Company standard existence and authority opinions in respect of the Payer, enforceability opinions on this Agreement, and an opinion that this Agreement does not conflict with the organizational documents of the Payer or applicable law, each such opinion in a form previously agreed upon by the Company and the Payer.</font></p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;color:#010000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(f)<font style="margin-left:36pt;"></font><font style="color:#000000;">The Company shall have received a certificate of an authorized person of the owner trustee of the Payer, dated the Closing Date, certifying as to the incumbency of the officers executing this Agreement on behalf of the Payer.</font></p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;color:#010000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(g)<font style="margin-left:36pt;"></font><font style="color:#000000;">The Payer shall have executed and delivered the Security Documents in form and substance reasonably acceptable to the Payer, and all deliverables required thereunder.</font></p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;color:#010000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU34"></a>(h)<font style="margin-left:36pt;"></font><font style="color:#000000;">The Payer shall complete, sign and deliver a United States Internal Revenue Service Form W-8BEN-E certifying that it is exempt from U.S. federal withholding Tax under a United States income Tax treaty with respect to </font><font style="color:#000000;">each of &#8220;royalties,&#8221; &#8220;interest&#8221; and </font><font style="color:#000000;"><br /></font></p>
<p style="text-align:center;Background-color:#auto;margin-top:12pt;line-height:10pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
<p style="line-height:10pt;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">250212926 v1</p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:7pt;font-family:Times New Roman;">&nbsp;</p>&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;Background-color:#auto;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 10.6</p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;color:#010000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;">&#8220;other income&#8221;</font><font style="color:#000000;"> and shall, to the extent permitted under applicable law, update such form upon the expiration, obsolescence or other invalidity of such form.</font></p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;color:#010000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(i)<font style="margin-left:36pt;"></font><font style="color:#000000;">The Payer shall complete, sign and deliver, to the extent applicable, an official tax residency certificate for the purpose of applying benefits under the double tax treaty between the state of Israel and Ireland, issued by the Irish revenue commissioners and shall, to the extent permitted under applicable law, update such form upon the expiration, obsolescence or other invalidity of such forms. </font></p>
<p style="Background-color:#auto;text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#010000;text-transform:uppercase;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;font-variant: normal;"><a name="_Toc56006796"></a><a name="_Toc56700570"></a><a name="_Toc65621599"></a><a name="_Toc65623761"></a><a name="_Toc66905147"></a>ARTICLE 6<font style="text-transform:none;color:#000000;"><br /><a name="_Toc56006796"></a><a name="_Toc56700570"></a><a name="_Toc65621599"></a><a name="_Toc65623761"></a><a name="_Toc66905147"></a>COVENANTS</font></p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;color:#010000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Ref370794626"></a><a name="_Toc56006797"></a><a name="_Toc56700571"></a><a name="_Toc65621600"></a><a name="_Toc65623762"></a><a name="_Toc66905148"></a><a name="_Ref370725249"></a><a name="_Ref306405604"></a><font style="text-decoration:underline;">Reporting</font></p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. From and after the date hereof and until the Revenue Payment Termination Date, the Company shall provide the Payer:</p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;color:#010000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Ref56959720"></a><a name="_Ref65929122"></a><a name="_Hlk66891434"></a><a name="_Ref56959746"></a>(a)<font style="margin-left:36pt;"></font><font style="color:#000000;">concurrently with, and in any case no later than the [***] after, the earlier of the following dates (the &#8220;</font><font style="text-decoration:underline;color:#000000;">Quarterly Deadline</font><font style="color:#000000;">&#8221;): (i) the filing of the Quarterly Report on Form 10-Q or Annual Report on Form 10-K, as applicable, for the immediately preceding quarter and (ii) the applicable due date for such reports (but in no event later than [***] following the end of the first three fiscal quarters and [***] following the end of the fourth fiscal quarter), a reasonably detailed quarterly report setting forth, with respect to such same period, (A) the [***], (B) the [<a name="_Ref56959746"></a>***], (C) the [***], and (D) the [***] (collectively the &#8220;</font><font style="text-decoration:underline;color:#000000;">Reports</font><font style="color:#000000;">&#8221;); provided that for any such updates made by a Licensee or other Third Party for which the Company receives such update fewer than [***] prior to the Quarterly Deadline, such update will be included in the following calendar quarter&#8217;s Reports;</font></p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;color:#010000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)<font style="margin-left:36pt;"></font><font style="color:#000000;">the Company shall include in each Report any (i) material [***] updates and (ii) reasonable details as to the achievement of any [***] set forth in each Commercialization License; and</font></p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;color:#010000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c)<font style="margin-left:36pt;"></font><font style="color:#000000;">the Company shall also provide the Payer with such additional information regarding the updates included in each Report as the Payer may reasonably request from time to time. The Company shall meet [***] (or as otherwise requested by the Payer) with the Payer to review such Reports and any other material updates. The Company shall prepare and maintain and shall cause its Affiliates and use commercially reasonable efforts to cause Licensees to prepare and maintain reasonably complete and accurate records of the information to be disclosed in each Report. All Reports, and the Confidential Information contained therein, shall be the Confidential Information of Company and subject to the obligations of confidentiality set forth in &#8206;ARTICLE 8.</font></p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;color:#010000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Ref55237719"></a><a name="_Toc55233527"></a><a name="_Toc56006798"></a><a name="_Toc56700572"></a><a name="_Toc65621601"></a><a name="_Toc65623763"></a><a name="_Toc66905149"></a><font style="text-decoration:underline;">Revenue Payments; Revenue Participation and Revenue Payment Details</font></p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. </p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;color:#010000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Ref401932580"></a><a name="_AEIOULastRenderedPageBreakAEIOU35"></a>(a)<font style="margin-left:36pt;"></font><font style="color:#000000;">From and after the Closing Date and until the Revenue Payment Termination Date, the Company shall pay to the Payer, without any setoff or offset (subject, in each case, to &#8206;Section 6.16), the Revenue Payment for each calendar quarter on the [***], <br /></font></p>
<p style="text-align:center;Background-color:#auto;margin-top:12pt;line-height:10pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
<p style="line-height:10pt;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">250212926 v1</p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:7pt;font-family:Times New Roman;">&nbsp;</p>&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;Background-color:#auto;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 10.6</p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;color:#010000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;">provided that for any Net Sales made by a Licensee for which payment is received by the Company fewer than </font><font style="color:#000000;">[</font><font style="color:#000000;">***</font><font style="color:#000000;">]</font><font style="color:#000000;"> prior to the </font><font style="color:#000000;">[</font><font style="color:#000000;">***</font><font style="color:#000000;">]</font><font style="color:#000000;">, such payment to the Payer will be paid with the </font><font style="color:#000000;">following calendar quarter&#8217;s Revenue Payment. The Revenue Payment payable for the </font><font style="color:#000000;">calendar quarter </font><font style="color:#000000;">during which the Closing occurs shall be prorated from the Effective Date through the end of such </font><font style="color:#000000;">calendar quarter</font><font style="color:#000000;">.</font><font style="color:#000000;"> A late fee of </font><font style="color:#000000;">[</font><font style="color:#000000;">***</font><font style="color:#000000;">]</font><font style="color:#000000;">% over the Prime Rate (calculated on a per annum basis) will accrue on all unpaid amounts with respect to any Revenue Payment from the date such obligation was due. The imposition and payment of a late fee shall not constitute a waiver of the Payer&#8217;s rights with respect to such payment default.</font></p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;color:#010000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Ref525248889"></a><a name="_Ref370834462"></a>(b)<font style="margin-left:36pt;"></font><font style="color:#000000;">From and after the Closing Date and until the Revenue Payment Termination Date, the Company shall deliver to Payer a report for each [***] concurrently with, and in any case no later than the [***] after, the [***], in a form to be mutually agreed to by the parties, setting forth in reasonable detail with respect to each Product, (i) Gross Sales and Net Sales for the applicable [***] and [***], on a country-by-country basis (including a reasonably detailed break-down of all permitted deductions from Gross Sales used to determine Net Sales and any proceeds treated as Net Sales pursuant to &#8206;Section 6.5(d)), and (ii) (A) the calculation of the Revenue Payment payable to the Payer for the applicable [***], identifying, on a country-by-country basis, the number of units of each Product sold by the Company, its Affiliates and each Licensee and (B) foreign currency exchange rates used (which shall be rates of exchange determined in a manner consistent with the Company&#8217;s method for calculating rates of exchange in the preparation of the Company&#8217;s annual financial statements in accordance with GAAP); provided that, for any reports received by the Company with respect to Net Sales by Licensees fewer than [***] prior to the [***], the Company shall deliver to the Payer the relevant information from such reports in the following [***]&#8217;s report. </font></p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;color:#010000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c)<font style="margin-left:36pt;"></font><font style="color:#000000;">Any payments required to be made by either party under this Agreement shall be made in United States Dollars via electronic funds transfer or wire transfer of immediately available funds to such bank account as the other party shall designate in writing prior to the date of such payment.</font></p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;color:#010000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Ref370802214"></a><a name="_Toc56006799"></a><a name="_Toc56700573"></a><a name="_Toc65621602"></a><a name="_Toc65623764"></a><a name="_Toc66905150"></a><a name="_Ref276325316"></a><a name="_Ref316947888"></a><a name="_Ref277718599"></a><font style="text-decoration:underline;">Disclosures</font></p>
<p style="margin-bottom:12pt;Background-color:#FFFFFF;margin-top:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU36"></a>. Except for a press release and the Company&#8217;s Current Report on Form 8-K describing the material terms of this Agreement and the transactions contemplated by this Agreement, in each case previously approved in form and substance by the Company and the Payer, or any other public announcement using substantially the same disclosure as such press release or Form 8-K, neither the Payer nor the Company shall, and each party hereto shall cause its respective Representatives, Affiliates and Affiliates&#8217; Representatives not to, issue a press release or other public announcement or otherwise make any public disclosure with respect to this Agreement or the subject matter hereof without the prior written consent of the other party hereto (which consent shall not be unreasonably withheld or delayed), except as may be required by applicable law, regulation or stock exchange rule (in which case the party hereto required to make the press release or other public announcement or disclosure shall allow the other party hereto reasonable time to comment on, and, if applicable, reasonably direct the disclosing party to seek confidential treatment in respect of portions of, such press release or other public announcement or disclosure in advance of such issuance); provided that (a) no review or consent shall be required with respect to disclosures by either party hereto otherwise previously approved pursuant to this Section 6.3 and (b) notwithstanding anything herein to the contrary, each party <br /></p>
<p style="text-align:center;Background-color:#auto;margin-top:12pt;line-height:10pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
<p style="line-height:10pt;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">250212926 v1</p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:7pt;font-family:Times New Roman;">&nbsp;</p>&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;Background-color:#auto;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 10.6</p>
<p style="margin-bottom:12pt;Background-color:#FFFFFF;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">hereto may, without the review or consent of the other party hereto, disclose (and nothing herein shall be construed to restrict either party hereto from disclosing) the Pre-Paid Forward Price and the amount and nature of the Revenue Participation Right (and related accounting disclosures of the transactions contemplated hereby) in such party&#8217;s periodic reports and financial statements. </font></p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;color:#010000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Ref370802118"></a><a name="_Toc55233529"></a><a name="_Toc56006800"></a><a name="_Toc56700574"></a><a name="_Toc65621603"></a><a name="_Toc65623765"></a><a name="_Toc66905151"></a><font style="text-decoration:underline;">Inspections and Audits of the Company</font></p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. Following the Closing and until [***] after the Revenue Payment Termination Date, upon at least [***] written notice and during normal business hours, no more frequently than [***] per [***], the Payer may cause an inspection and/or audit by an independent public accounting firm reasonably acceptable to the Company to be made of the Company&#8217;s books of account for the [***] prior to the audit for the purpose of determining the correctness of Revenue Payments made under this Agreement. Upon the Payer&#8217;s reasonable request, no more frequently than [***] per [***] while any Commercialization License remains in effect, the Company shall use Commercially Reasonable Efforts to exercise any rights it may have under any Commercialization License relating to a Product to cause an inspection and/or audit by an independent public accounting firm to be made of the books of account of any counterparty thereto for the purpose of determining the correctness of Revenue Payments made under this Agreement. All of the out-of-pocket expenses of any inspection or audit requested by the Payer hereunder (including the fees and expenses of such independent public accounting firm designated for such purpose) shall be borne solely by the Payer, unless the independent public accounting firm determines that Revenue Payments previously paid during the period of the audit were underpaid by an amount greater than [***]% of the Revenue Payments actually paid during such period, in which case such expenses shall be borne by the Company. Any such accounting firm shall not disclose the confidential information of the Company or any such Licensee relating to a Product to the Payer, except to the extent such disclosure is necessary to determine the correctness of Revenue Payments or otherwise would be included in a Report. All information obtained by the Payer as a result of any such inspection or audit shall be Confidential Information subject to &#8206;ARTICLE 8. If any audit discloses any underpayments by the Company to the Payer, then such underpayment, shall be paid by the Company to the Payer within [***] of it being so disclosed. If any audit discloses any overpayments by the Company to the Payer, then the Company shall have the right to credit the amount of the overpayment against each subsequent quarterly Revenue Payment due to the Payer until the overpayment has been fully applied. If the overpayment is not fully applied prior to the final quarterly Revenue Payment due hereunder, the Payer shall promptly refund an amount equal to any such remaining overpayment.</p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;color:#010000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc56006801"></a><a name="_Toc56700575"></a><a name="_Toc65621604"></a><a name="_Toc65623766"></a><a name="_Toc66905152"></a>Section 6.5<font style="margin-left:36pt;"></font><font style="text-decoration:underline;color:#000000;">Intellectual Property Matters</font><font style="color:#000000;">.&nbsp;&nbsp;During the term of the Revenue Participation Right:</font></p>
<p style="margin-bottom:12pt;Background-color:#FFFFFF;margin-top:0pt;text-indent:15.38%;color:#010000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)<font style="margin-left:36pt;"></font><font style="color:#000000;">The Company shall provide to the Payer a copy of any written notice received by the Company from a Third Party alleging or claiming that the making, having made, using, importing, offering for sale or selling of a Product infringes or misappropriates any Patents or other intellectual property rights of such Third Party, together with copies of material correspondence sent or received by the Company related thereto, as soon as practicable and in any event not more than [***] following such delivery or receipt.<br /></font></p>
<p style="text-align:center;Background-color:#auto;margin-top:12pt;line-height:10pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">33</a></p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
<p style="line-height:10pt;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">250212926 v1</p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:7pt;font-family:Times New Roman;">&nbsp;</p>&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;Background-color:#auto;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 10.6</p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;color:#010000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU37"></a><font style="color:#010000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)</font><font style="margin-left:36pt;"></font><font style="color:#000000;">The Company shall promptly inform the Payer of any infringement by a Third Party of any Patent Right of which any of the individuals named in the definition of &#8220;Knowledge of the Company&#8221; (or the successors of such Person at the Company) becomes aware. Without limiting the foregoing, the Company shall provide to the Payer a copy of any written notice of any suspected infringement of any Patent Rights delivered or received by the Company, as well as copies of material correspondence related thereto, as soon as practicable and in any event not more than </font><font style="color:#000000;">[</font><font style="color:#000000;">***</font><font style="color:#000000;">] </font><font style="color:#000000;">following such delivery or receipt. The Company shall use Commercially Reasonable Efforts to diligently enforce and defend the Patent Rights (other than Patent Rights non-exclusively in-licensed or otherwise held on a non-exclusive basis by Company or any of its Affiliates), including Commercially Reasonable Efforts to bring any legal action for infringement or defend any counterclaim of invalidity or unenforceability or action of a Third Party for declaratory judgment of non-infringement or non-interference.</font></p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;color:#010000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c)<font style="margin-left:36pt;"></font><font style="color:#000000;">From and after the date hereof and until the Revenue Payment Termination Date, within [***] of initiating, or permitting a Licensee to initiate, an enforcement action regarding any suspected infringement by a Third Party of any Patent Right or defending any counterclaim of invalidity or unenforceability or action of a Third Party for declaratory judgment of non-infringement or non-interference, the Company shall provide the Payer with written notice of such action.</font></p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;color:#010000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Ref55892352"></a>(d)<font style="margin-left:36pt;"></font><font style="color:#000000;">If the Company recovers monetary damages from a Third Party in an action brought for such Third Party&#8217;s infringement of any Patent Rights relating to a Product, where such damages, whether in the form of judgment or settlement, are awarded for such infringement of such Patent Rights, (i) such recovery will be allocated first to the reimbursement of any expenses incurred by the Company (or any party to an In-License or Permitted License of such Patent Rights entitled to such reimbursement under any such In-License or Permitted License) in bringing such action (including all reasonable attorney&#8217;s fees), (ii) any remaining amounts will be reduced, if applicable, to comply with allocation of recovered damages with licensors of such Patent Rights required under any In-Licenses or Permitted License of such Patent Rights under any such In-License or Permitted License, if any, and (iii) any residual amount of such damages after application of (i) and (ii) will be treated as Net Sales with respect to the applicable Product for purposes of the Transaction Documents.</font></p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;color:#010000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc56006802"></a><a name="_Toc56700576"></a><a name="_Toc65621605"></a><a name="_Toc65623767"></a><a name="_Toc66905153"></a><font style="text-decoration:underline;">In-Licenses</font></p>
<p style="Background-color:#auto;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.&nbsp;&nbsp;During the term of the Revenue Participation Right:</p>
<p style="Background-color:#auto;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;color:#010000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk66891359"></a>(a)<font style="margin-left:36pt;"></font><font style="color:#000000;">The Company shall promptly (and in any event within [***]) provide the Payer with (i) executed copies of any In-License entered into by the Company or its Affiliates after the date hereof, and (ii) executed copies of each amendment, supplement, modification or written waiver of any provision of any In-License.</font></p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;color:#010000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU38"></a>(b)<font style="margin-left:36pt;"></font><font style="color:#000000;">The Company shall use Commercially Reasonable Efforts to comply in all material respects with its obligations under any In-Licenses it enters into and shall not take any action or forego any action that would reasonably be expected to result in a material breach thereof. Promptly, and in any event within [***], after receipt of any (written or oral) notice from a counterparty to any In-License or its Affiliates of an alleged material breach under any In-License, the Company shall provide the Payer a copy thereof (or if restricted by <br /></font></p>
<p style="text-align:center;Background-color:#auto;margin-top:12pt;line-height:10pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">34</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
<p style="line-height:10pt;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">250212926 v1</p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:7pt;font-family:Times New Roman;">&nbsp;</p>&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;Background-color:#auto;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 10.6</p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;color:#010000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;">applicable confidentiality obligations under such In-License, notice thereof and a summary of such material breach). The Company shall use its Commercially Reasonable Efforts to cure any material breaches by it under any In-License and shall give written notice to the Payer upon curing any such breach. The Company shall provide the Payer with written notice following becoming aware of a counterparty&#8217;s material breach of its obligations under any In-License. The Company shall not terminate any In-License without providing the Payer prior written notice. Promptly, and in any event within </font><font style="color:#000000;">[</font><font style="color:#000000;">***</font><font style="color:#000000;">] </font><font style="color:#000000;">following the Company&#8217;s notice to a counterparty to any In-License of an alleged breach by such counterparty under any such In-License, the Company shall provide the Payer a copy thereof.</font></p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;color:#010000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Ref316951115"></a><a name="_Toc56006803"></a><a name="_Toc56700577"></a><a name="_Toc65621606"></a><a name="_Toc65623768"></a><a name="_Toc66905154"></a><a name="_Ref316945931"></a>Section 6.7<font style="margin-left:36pt;"></font><font style="text-decoration:underline;color:#000000;">Out-Licenses</font><font style="color:#000000;">.&nbsp;&nbsp;During the term of the Revenue Participation Right:</font></p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;color:#010000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Ref316947302"></a><a name="_Ref525248760"></a><a name="_Ref400054099"></a>(a)<font style="margin-left:36pt;"></font><font style="color:#000000;">Subject to compliance with this &#8206;Section 6.7, the Company, or any of its Affiliates, may enter into a new Out-License with a Third Party (each such Out-License that complies with this &#8206;Section 6.7, a &#8220;</font><font style="text-decoration:underline;color:#000000;">Permitted License</font><font style="color:#000000;">&#8221;), </font><font style="text-decoration:underline;color:#000000;">provided</font><font style="color:#000000;">, that any such Out-License that is a Commercialization License and grants, transfers or otherwise conveys rights to Commercialize a Product within [***] shall be subject to Payer&#8217;s prior written consent (not to be unreasonably, withheld, conditioned, or delayed), unless the Licensee is [***] of at least (i) $[***] or (ii) $[***] with at least $[***] in [***] in the [***] prior to enter into such new Commercialization License.</font></p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;color:#010000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)<font style="margin-left:36pt;"></font><font style="color:#000000;">The Company shall promptly (and in any event within [***]) provide the Payer with (i) executed copies of each Commercialization License, and (ii) executed copies of each amendment, supplement, modification or written waiver of any material provision of any Commercialization License.</font></p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;color:#010000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c)<font style="margin-left:36pt;"></font><font style="color:#000000;">The Company shall include in all Commercialization Licenses provisions permitting the Company to audit such Licensee and shall use commercially reasonable efforts to include terms and conditions consistent in all material respects with the Payer&#8217;s rights to audit the Company set forth in &#8206;Section 6.4.</font></p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;color:#010000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(d)<font style="margin-left:36pt;"></font><font style="color:#000000;">The Company shall provide the Payer prompt (and in any event within [***]) written notice of a Licensee&#8217;s material breach of its obligations under any Commercialization License of which any of the individuals named in the definition of &#8220;Knowledge of the Company&#8221; (or the successors of such Person at the Company) becomes aware.</font></p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;color:#010000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(e)<font style="margin-left:36pt;"></font><font style="color:#000000;">The Company shall provide the Payer with written notice promptly (and in any event within [***]) following the termination of any Commercialization License.</font></p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;color:#010000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU39"></a>(f)<font style="margin-left:36pt;"></font><font style="color:#000000;">The Payer acknowledges and agrees that in the event that Company enters into (or plans to enter into) any Permitted License, the Payer shall, at the reasonable request of the Company, enter into non-disturbance and similar agreements in a form reasonably acceptable <br /></font></p>
<p style="text-align:center;Background-color:#auto;margin-top:12pt;line-height:10pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">35</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
<p style="line-height:10pt;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">250212926 v1</p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:7pt;font-family:Times New Roman;">&nbsp;</p>&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;Background-color:#auto;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 10.6</p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;color:#010000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;">to the Payer in connection with such&nbsp;&nbsp;Permitted License to the extent reasonably requested by the counter-party to such (or prospective counter-party) thereto.</font></p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;color:#010000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc66905155"></a><font style="text-decoration:underline;">Negative Pledge and Intercreditor Agreement</font></p>
<p style="margin-bottom:12pt;Background-color:#FFFFFF;margin-top:0pt;text-indent:19.23%;color:#010000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk66891226"></a>(a)<font style="margin-left:126pt;"></font><font style="color:#000000;"><a name="_Hlk66891226"></a>. At any time prior to the Minimum Return Date, the Company shall not, without the prior written consent of the Payer, create, incur, assume or suffer to exist any Lien upon or with respect to the Product Collateral, except for Permitted Liens. For the avoidance of doubt, nothing herein shall restrict the Company from incurring unsecured Indebtedness or Indebtedness secured by assets that are not Product Collateral or Revenue Participation Rights.</font></p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;color:#010000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Ref66797722"></a><a name="_Toc66905156"></a><font style="text-decoration:underline;">Insolvency Event</font></p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. Upon an Insolvency Event, the Company agrees that the amounts comprising the Payment Obligations shall automatically and immediately accelerate and become immediately due and payable, in each case, without any action or notice by any party or Person and the Payer may take such other steps as it sees fit including enforcing the Liens pursuant to the Security Documents subject to any applicable Acceptable Intercreditor Agreement entered into prior to such date. The parties hereto acknowledge and agree that (a)&#160;this Agreement is a non-executory contract, (b)&#160;the Payer will have fully and completely performed all of its obligations and duties due hereunder as of the Closing, including having paid in cash the entire Pre-Paid Forward Price, which is adequate and proper consideration for the Remaining Obligations outstanding to the Payer under this Agreement, (c)&#160;the Company&#8217;s Remaining Obligations to the Payer are fully-earned, irrevocable and unconditional, including in an Insolvency Event, (d)&#160;in light of the impracticality and difficulty of ascertaining actual damages, the Remaining Obligations are intended to be a reasonable calculation of the actual damages that would be suffered by the Payer as a result of any such Insolvency Event and are not intended to act as a penalty, (e)&#160;the process by which the Remaining Obligations are to be determined shall not be considered an action that may be blocked by the automatic stay or any other provision of Bankruptcy Law in an Insolvency Event but rather a fair and rational approach for establishing the value of such amount and (f)&#160;it would be inequitable and unjust for all parties hereto and all other interested parties or Persons for any bankruptcy court, other court, Governmental Entity or other Person to not honor or carry out the process for establishing the Remaining Obligations as set forth in this Agreement.</p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;color:#010000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc56700579"></a><a name="_Toc56006805"></a><a name="_Toc65621608"></a><a name="_Toc65623770"></a><a name="_Toc66905157"></a>Section 6.10<font style="margin-left:36pt;"></font><font style="text-decoration:underline;color:#000000;">Use of Proceeds; Diligence</font><font style="color:#000000;">.</font></p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;color:#010000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Ref57359519"></a>(a)<font style="margin-left:36pt;"></font><font style="color:#000000;">All amounts paid by the Payer to the Company under this Agreement will be solely used by the Company to [***], [***], and [***]. </font></p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;color:#010000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Ref65764960"></a>(b)<font style="margin-left:36pt;"></font><font style="color:#000000;">The Company shall use Commercially Reasonable Efforts to (i) complete clinical development, (ii) prepare, execute, deliver and file any and all agreements, documents or instruments that are necessary or desirable to secure and maintain all Marketing Approval required to Commercialize the Products in the Territory, (iii) not withdraw or abandon, or fail to take any action necessary to prevent the withdrawal or abandonment of, any such Marketing Approvals, and (iv) Commercialize (either directly or through Licensees) the Products in the Territory. <br /></font></p>
<p style="text-align:center;Background-color:#auto;margin-top:12pt;line-height:10pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">36</a></p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
<p style="line-height:10pt;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">250212926 v1</p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:7pt;font-family:Times New Roman;">&nbsp;</p>&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;Background-color:#auto;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 10.6</p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;color:#010000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU40"></a><font style="color:#010000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c)</font><font style="margin-left:36pt;"></font><font style="color:#000000;">On a country-by-country and Product-by-Product basis, if a Loss of Market Exclusivity has occurred in such country for such Product, the Company&#8217;s obligations under </font><font style="color:#000000;">&#8206;</font><font style="color:#000000;">Section 6.10(b)</font><font style="color:#000000;"> shall no longer apply in such country for such Product.</font><font style="color:#000000;"> </font></p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;color:#010000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc66905158"></a><font style="text-decoration:underline;">IIA</font></p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;color:#010000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)<font style="margin-left:36pt;"></font><font style="color:#000000;">. The Company agrees (a) to not apply for or take further grants or funding from the IIA, and (b) to comply with its current obligations to the IIA regarding the commitment to continue to employ at least 75% of its research and development jobs in Israel for a period of at least [***], until [***].</font></p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;color:#010000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc55233535"></a><a name="_Toc56006806"></a><a name="_Toc56700580"></a><a name="_Toc65621609"></a><a name="_Toc65623771"></a><a name="_Toc66905159"></a><font style="text-decoration:underline;">Efforts to Consummate Transactions</font></p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. Subject to the terms and conditions of this Agreement, each of the Company and the Payer will use its commercially reasonable efforts prior to the Closing to take, or cause to be taken, all actions and to do, or cause to be done, all things reasonably necessary under applicable law to consummate the transactions contemplated by the Transaction Documents. Each of the Payer and the Company agrees to execute and deliver such other documents, certificates, agreements and other writings and to take such other actions as may be reasonably necessary in order to consummate or implement expeditiously the transactions contemplated by the Transaction Documents.</p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;color:#010000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc55233536"></a><a name="_Toc56700581"></a><a name="_Toc56006807"></a><a name="_Toc65621610"></a><a name="_Toc65623772"></a><a name="_Toc66449854"></a><a name="_Toc66905160"></a><font style="text-decoration:underline;">Further Assurances</font></p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk66890903"></a><a name="_Hlk66890903"></a>. After the Closing, the Company and the Payer agree to execute and deliver such other documents, certificates, agreements and other writings and to take such other actions as may be reasonably necessary in order to give effect to the transactions contemplated by the Transaction Documents. During the term of the Revenue Participation Right, the Company shall not, and shall cause its Affiliates not to, develop, commercialize or Out-License any pharmaceutical product (that is not a Product) incorporating (a) [***] or (b) [***], in each case of (a) or (b) without the prior written consent of the Payer.</p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;margin-left:1.92%;text-indent:7.69%;color:#010000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc66905161"></a><font style="text-decoration:underline;">Product Collateral</font></p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk66890923"></a><a name="_Hlk66890923"></a>. To the extent additional Product Collateral is created, obtained or acquired by the Company, the Company shall promptly take all such steps to ensure that such additional Product Collateral are subject to the Liens conferred by the Security Documents including by way of entering into any amendments or supplements to the Security Documents or any additional Security Documents to the satisfaction of the Payer and promptly making all such necessary filings and registrations as are required including at the Israeli Registrar of Companies and if in respect of Israeli Patents, with the Israeli Patent Office within the required timeframe and in each case to the satisfaction of the Payer. For the avoidance of doubt, the Company shall not be required to take any action to grant or perfect the security interests granted hereby and the Security Documents in any jurisdiction outside of the Covered Jurisdictions.</p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;margin-left:1.92%;text-indent:7.69%;color:#010000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Ref66820478"></a><a name="_Toc66905162"></a><font style="text-decoration:underline;">Escrow</font></p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU41"></a>. As promptly as practicable after the date hereof the Company and the Payer shall enter into a mutually acceptable Escrow Agreement, at the sole cost of the Company, and the Payer will deposit the Pre-Paid Forward Price into the Escrow Account. If the satisfaction or waiver of all conditions set forth in &#8206;ARTICLE 5 occurs, such that the Closing would occur upon release of the Pre-Paid Forward Price, then the parties shall provide joint written instructions to the Escrow Agent directing the Escrow Agent to promptly release <br /></p>
<p style="text-align:center;Background-color:#auto;margin-top:12pt;line-height:10pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">37</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
<p style="line-height:10pt;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">250212926 v1</p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:7pt;font-family:Times New Roman;">&nbsp;</p>&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;Background-color:#auto;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 10.6</p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the Pre-Paid Forward Price to the Company. If this Agreement is terminated prior to the Closing Date pursuant to </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8206;</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ARTICLE 9</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, then the Payer shall provide written instructions to the Escrow Agent directing the Escrow Agent to promptly return the Pre-Paid Forward Price to the Payer.</font></p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;margin-left:1.92%;text-indent:7.69%;color:#010000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Ref58062736"></a><a name="_Toc65621612"></a><a name="_Toc65623774"></a><a name="_Toc66905163"></a>Section 6.16<font style="margin-left:36pt;"></font><font style="text-decoration:underline;color:#000000;">Certain Tax Matters</font><font style="color:#000000;">.</font></p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;color:#010000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Ref58065030"></a>(a)<font style="margin-left:36pt;"></font><font style="color:#000000;">If there is an inquiry by any Governmental Entity of the Payer or the Company related to the treatment of the transactions contemplated by this Agreement, the parties hereto shall cooperate with each other in responding to such inquiry in a reasonable manner.</font></p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;color:#010000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Ref66442306"></a>(b)<font style="margin-left:36pt;"></font><font style="color:#000000;">The parties acknowledge and agree that, as of the date hereof, all payments by the Company to the Payer and by the Payer to the Company shall be made without deduction or withholding for any Taxes. If any change in applicable law requires the deduction or withholding of any Tax from any payment by the Company, then the Company shall be entitled to withhold and deduct (or cause to be withheld and deducted) from any amount payable under this Agreement to the Payer any Tax that it is required to withhold and deduct under applicable law. The Company shall timely pay the full amount deducted or withheld to the relevant governmental authority in accordance with applicable law. For the avoidance of doubt and notwithstanding anything to the contrary in this Agreement, any amount payable by the Company to the Payer shall be increased as necessary so that after deduction or withholding of any Tax has been made (including such deductions and withholdings applicable to additional sums payable under this Paragraph) (whether as a result of a change in applicable law or otherwise), the Payer receives an amount equal to the sum it would have received had no such deduction or withholding been made; provided, however, that if as a result of a Withholding Action by the Payer (including any assignee or successor), the amount of any tax withheld or deducted exceeds the amount of such withholding or deduction that would have been required in the absence of such Withholding Action, the Company shall be required to pay an additional amount only to the extent that the Company would be required to pay any additional amount to the Payer pursuant to this &#8206;Section 6.16(b) if the Payer had not committed such Withholding Action (except to the extent such excess additional amounts results from a change in applicable law that occurs after the date of such Withholding Action). For purposes of this &#8206;Section 6.16(b), &#8220;</font><font style="text-decoration:underline;color:#000000;">Withholding Action</font><font style="color:#000000;">&#8221; means (i) a permitted assignment of this Agreement (in whole or in part) by the Payer to an Affiliate or a Third Party resident in a different jurisdiction; (ii) a redomiciliation of such party, an assignee or a successor to a jurisdiction other than Ireland or Israel; and (iii) any action taken after the date of this Agreement by the Payer (other than at the request of the Company and other than actions required by applicable law) that causes the representation in &#8206;Section 4.2(i) to be inaccurate (disregarding for this purpose the reference to &#8220;as of the date hereof&#8221;).</font></p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;color:#010000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c)<font style="margin-left:36pt;"></font><font style="color:#000000;">The parties hereto shall use commercially reasonable efforts to give or cause to be given to the other party hereto such assistance and such information concerning the reasons for withholding or deduction (including, in reasonable detail, the method of calculation for the deduction or withholding thereof) as may be reasonably necessary to claim exemption therefrom, or credit therefor, or relief (whether at source or by reclaim) therefrom, and, in each case, shall furnish the other party with proper evidence of the taxes withheld and deducted and remitted to the relevant taxing authority.<br /></font></p>
<p style="text-align:center;Background-color:#auto;margin-top:12pt;line-height:10pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">38</a></p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
<p style="line-height:10pt;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">250212926 v1</p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:7pt;font-family:Times New Roman;">&nbsp;</p>&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;Background-color:#auto;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 10.6</p>
<p style="Background-color:#auto;text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#010000;text-transform:uppercase;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU42"></a><a name="_Ref276335384"></a><a name="_Toc55233537"></a><a name="_Toc56006808"></a><a name="_Toc56700582"></a><a name="_Toc65621613"></a><a name="_Toc65623775"></a><a name="_Toc66905164"></a><font style="color:#010000;text-transform:uppercase;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;font-variant: normal;">ARTICLE 7</font><font style="text-transform:none;color:#000000;"><br /><a name="_Ref276335384"></a><a name="_Toc55233537"></a><a name="_Toc56006808"></a><a name="_Toc56700582"></a><a name="_Toc65621613"></a><a name="_Toc65623775"></a><a name="_Toc66905164"></a></font><font style="text-transform:none;color:#000000;">INDEMNIFICATION</font></p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;color:#010000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Ref288083709"></a><a name="_Ref288083944"></a><a name="_Toc55233538"></a><a name="_Toc56006809"></a><a name="_Toc56700583"></a><a name="_Toc65621614"></a><a name="_Toc65623776"></a><a name="_Toc66905165"></a><font style="text-decoration:underline;">General Indemnity</font></p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. From and after the Closing:</p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;color:#010000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Ref276335804"></a><a name="_Ref288083735"></a><a name="_Ref288084038"></a>(a)<font style="margin-left:36pt;"></font><font style="color:#000000;">the Company hereby agrees to indemnify, defend and hold harmless the Payer and its Affiliates and its and their directors, managers, trustees, officers, agents and employees (the &#8220;</font><font style="text-decoration:underline;color:#000000;">Payer Indemnified Parties</font><font style="color:#000000;">&#8221;) from, against and in respect of all Losses suffered or incurred by the Payer Indemnified Parties to the extent arising out of or resulting from (i)&#160;any breach of any of the representations or warranties of the Company in the Transaction Documents, and (ii)&#160;any breach of any of the covenants or agreements of the Company in the Transaction Documents; and</font></p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;color:#010000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Ref288083812"></a><a name="_Ref288084040"></a>(b)<font style="margin-left:36pt;"></font><font style="color:#000000;">the Payer hereby agrees to indemnify, defend and hold harmless the Company and its Affiliates and its and their directors, officers, agents and employees (the &#8220;</font><font style="text-decoration:underline;color:#000000;">Company Indemnified Parties</font><font style="color:#000000;">&#8221;) from, against and in respect of all Losses suffered or incurred by the Company Indemnified Parties to the extent arising out of or resulting from (i)&#160;any breach of any of the representations or warranties of the Payer in the Transaction Documents, and (ii)&#160;any breach of any of the covenants or agreements of the Payer in the Transaction Documents.</font></p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;color:#010000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Ref525247550"></a><a name="_Toc55233539"></a><a name="_Toc56006810"></a><a name="_Toc56700584"></a><a name="_Toc65621615"></a><a name="_Toc65623777"></a><a name="_Toc66905166"></a><font style="text-decoration:underline;">Notice of Claims</font></p>
<p style="margin-bottom:12pt;Background-color:#FFFFFF;margin-top:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. If either a Payer Indemnified Party, on the one hand, or a Company Indemnified Party, on the other hand (such Payer Indemnified Party on the one hand and such Company Indemnified Party on the other hand being hereinafter referred to as an &#8220;<font style="text-decoration:underline;">Indemnified Party</font>&#8221;), has suffered or incurred any Losses for which indemnification may be sought under this &#8206;ARTICLE 7, the Indemnified Party shall so notify the other party from whom indemnification is sought under this &#8206;ARTICLE 7 (the &#8220;<font style="text-decoration:underline;">Indemnifying Party</font>&#8221;) promptly in writing describing such Loss, the amount or estimated amount thereof, if known or reasonably capable of estimation, and the method of computation of such Loss, all with reasonable particularity and containing a reference to the provisions of this Agreement in respect of which such Loss shall have occurred. If any claim, action, suit or proceeding is asserted or instituted by or against a Third Party with respect to which an Indemnified Party intends to claim any Loss under this &#8206;ARTICLE 7, such Indemnified Party shall promptly notify the Indemnifying Party of such claim, action, suit or proceeding and tender to the Indemnifying Party the defense of such claim, action, suit or proceeding. A failure by an Indemnified Party to give notice and to tender the defense of such claim, action, suit or proceeding in a timely manner pursuant to this &#8206;Section 7.2 shall not limit the obligation of the Indemnifying Party under this &#8206;ARTICLE 7, except to the extent such Indemnifying Party is actually prejudiced thereby. </p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;color:#010000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Ref288169455"></a><a name="_Ref288216881"></a><a name="_Ref288216956"></a><a name="_Toc55233540"></a><a name="_Toc56006811"></a><a name="_Toc56700585"></a><a name="_Toc65621616"></a><a name="_Toc65623778"></a><a name="_Toc66905167"></a><font style="text-decoration:underline;">Limitations on Liability</font></p>
<p style="margin-bottom:12pt;Background-color:#FFFFFF;margin-top:0pt;text-indent:15.38%;color:#010000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU43"></a>(a)<font style="margin-left:72pt;"></font><font style="color:#000000;">. Except for claims arising from a breach of confidentiality obligations under &#8206;ARTICLE 8 or in cases of fraud, gross negligence, or willful misconduct, no party hereto shall be liable for any lost profits or revenue, lost opportunity, consequential, punitive, special or incidental damages under this &#8206;ARTICLE 7 (and no claim for indemnification hereunder shall be asserted) as a result of any breach or violation of any covenant or agreement of such party (including under this &#8206;ARTICLE 7) in or pursuant to this Agreement. In connection with the foregoing, the parties hereto acknowledge and agree that (i) the Payer&#8217;s damages, if any, for any such action or claim will typically include Losses for <br /></font></p>
<p style="text-align:center;Background-color:#auto;margin-top:12pt;line-height:10pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">39</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
<p style="line-height:10pt;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">250212926 v1</p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:7pt;font-family:Times New Roman;">&nbsp;</p>&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;Background-color:#auto;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 10.6</p>
<p style="margin-bottom:12pt;Background-color:#FFFFFF;margin-top:0pt;color:#010000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;">Revenue Payments that the Payer was entitled to receive but did not receive timely or at all due to such indemnifiable event and (ii) the Payer shall be entitled to make claims for all such missing or delayed Revenue Payments as Losses hereunder, and such missing or Revenue Payments shall not be deemed consequential, punitive, special, indirect or incidental damages.</font></p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;color:#010000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc55233541"></a><a name="_Toc56006812"></a><a name="_Toc56700586"></a><a name="_Toc65621617"></a><a name="_Toc65623779"></a><a name="_Toc66905168"></a><a name="_Toc163638420"></a><a name="_Toc163638494"></a><a name="_Toc164000422"></a><a name="_Toc164621468"></a><a name="_Ref276334543"></a><a name="_Ref276336116"></a><a name="_Toc277686262"></a><a name="_Toc473650678"></a><font style="text-decoration:underline;">Exclusive Remedy</font></p>
<p style="margin-bottom:12pt;Background-color:#FFFFFF;margin-top:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. Except as set forth in &#8206;Section 6.9, &#8206;Section 10.11, and Exhibit B, and except for any event of default or the enforcement of any remedies under the Security Documents, from and after Closing, the rights of the parties hereto pursuant to (and subject to the conditions of) this &#8206;ARTICLE 7 shall be the sole and exclusive remedy of the parties hereto and their respective Affiliates with respect to any Losses (whether based in contract, tort or otherwise) resulting from or relating to any breach of the representations and warranties made under this Agreement or any certificate, document or instrument delivered hereunder, and each party hereto hereby waives, to the fullest extent permitted under applicable law, and agrees not to assert after Closing, any other claim or action in respect of any such breach. Notwithstanding the foregoing, claims for fraud, gross negligence, or willful misconduct shall not be waived or limited in any way by this &#8206;ARTICLE 7.</p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;color:#010000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc65621618"></a><a name="_Toc65623780"></a><a name="_Toc66905169"></a><font style="text-decoration:underline;">Tax Treatment of Indemnification Payments</font></p>
<p style="margin-bottom:12pt;Background-color:#FFFFFF;margin-top:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. For all purposes hereunder, any indemnification payments made pursuant to this &#8206;ARTICLE 7 will be treated as an adjustment to the Pre-Paid Forward Price for tax purposes to the fullest extent permitted by applicable law.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="Background-color:#auto;text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#010000;text-transform:uppercase;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;font-variant: normal;"><a name="_Ref370725185"></a><a name="_Ref370725493"></a><a name="_Toc55233542"></a><a name="_Toc56006813"></a><a name="_Toc56700587"></a><a name="_Toc65621619"></a><a name="_Toc65623781"></a><a name="_Toc66905170"></a>ARTICLE 8<font style="text-transform:none;color:#000000;"><br /><a name="_Ref370725185"></a><a name="_Ref370725493"></a><a name="_Toc55233542"></a><a name="_Toc56006813"></a><a name="_Toc56700587"></a><a name="_Toc65621619"></a><a name="_Toc65623781"></a><a name="_Toc66905170"></a>CONFIDENTIALITY</font></p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;color:#010000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Ref370725281"></a><a name="_Toc55233543"></a><a name="_Toc56006814"></a><a name="_Toc56700588"></a><a name="_Toc65621620"></a><a name="_Toc65623782"></a><a name="_Toc66905171"></a><font style="text-decoration:underline;">Confidentiality</font></p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. Except as provided in this &#8206;ARTICLE 8, &#8206;Section 10.4 or otherwise agreed in writing by the parties, the parties hereto agree that, during the term of this Agreement and for [***] thereafter, each party (the &#8220;<font style="text-decoration:underline;">Receiving Party</font>&#8221;) shall keep confidential and shall not publish or otherwise disclose and shall not use for any purpose other than as provided for in this Agreement (which includes the exercise of any rights or the performance of any obligations hereunder) any information furnished to it by or on behalf of the other party (the &#8220;<font style="text-decoration:underline;">Disclosing Party</font>&#8221;) pursuant to this Agreement (such information, &#8220;<font style="text-decoration:underline;">Confidential Information</font>&#8221; of the Disclosing Party), except for that portion of such information that:</p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;color:#010000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)<font style="margin-left:36pt;"></font><font style="color:#000000;">was already known to the Receiving Party, other than under an obligation of confidentiality, at the time of disclosure by the Disclosing Party;</font></p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;color:#010000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)<font style="margin-left:36pt;"></font><font style="color:#000000;">was generally available to the public or otherwise part of the public domain at the time of its disclosure to the Receiving Party;</font></p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;color:#010000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c)<font style="margin-left:36pt;"></font><font style="color:#000000;">became generally available to the public or otherwise part of the public domain after its disclosure and other than through any act or omission of the Receiving Party in breach of this Agreement or any other agreement; <br /></font></p>
<p style="text-align:center;Background-color:#auto;margin-top:12pt;line-height:10pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">40</a></p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
<p style="line-height:10pt;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">250212926 v1</p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:7pt;font-family:Times New Roman;">&nbsp;</p>&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;Background-color:#auto;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 10.6</p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;color:#010000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU44"></a><font style="color:#010000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(d)</font><font style="margin-left:36pt;"></font><font style="color:#000000;">is independently developed by the Receiving Party or any of its Affiliates, as evidenced by written records, without the use of or reference of the Confidential Information; or</font></p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;color:#010000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(e)<font style="margin-left:36pt;"></font><font style="color:#000000;">is subsequently disclosed to the Receiving Party on a non-confidential basis by a Third Party without obligations of confidentiality with respect thereto.</font></p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;color:#010000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Ref525247779"></a><a name="_Toc55233544"></a><a name="_Toc56006815"></a><a name="_Toc56700589"></a><a name="_Toc65621621"></a><a name="_Toc65623783"></a><a name="_Toc66905172"></a><font style="text-decoration:underline;">Authorized Disclosure</font></p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;color:#010000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)<font style="margin-left:36pt;"></font><font style="color:#000000;">Either party may disclose Confidential Information to the extent such disclosure is reasonably necessary in the following situations:</font></p>
<p style="margin-bottom:12pt;Background-color:#FFFFFF;margin-top:0pt;text-indent:26.92%;color:#010000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Ref370725148"></a>(i)<font style="margin-left:36pt;"></font><font style="color:#000000;">prosecuting or defending litigation;</font></p>
<p style="margin-bottom:12pt;Background-color:#FFFFFF;margin-top:0pt;text-indent:26.92%;color:#010000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Ref370725154"></a>(ii)<font style="margin-left:36pt;"></font><font style="color:#000000;">complying with applicable laws and regulations, including regulations promulgated by securities exchanges; </font></p>
<p style="margin-bottom:12pt;Background-color:#FFFFFF;margin-top:0pt;text-indent:26.92%;color:#010000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Ref370725161"></a>(iii)<font style="margin-left:36pt;"></font><font style="color:#000000;">complying with a valid order of a court of competent jurisdiction or other Governmental Entity; </font></p>
<p style="margin-bottom:12pt;Background-color:#FFFFFF;margin-top:0pt;text-indent:26.92%;color:#010000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Ref370725169"></a>(iv)<font style="margin-left:36pt;"></font><font style="color:#000000;">for regulatory, Tax or customs purposes;</font></p>
<p style="margin-bottom:12pt;Background-color:#FFFFFF;margin-top:0pt;text-indent:26.92%;color:#010000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(v)<font style="margin-left:36pt;"></font><font style="color:#000000;">for audit purposes, provided that each recipient of Confidential Information must be bound by customary and reasonable obligations of confidentiality and non-use prior to any such disclosure;</font></p>
<p style="margin-bottom:12pt;Background-color:#FFFFFF;margin-top:0pt;text-indent:26.92%;color:#010000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(vi)<font style="margin-left:36pt;"></font><font style="color:#000000;">disclosure to its Affiliates and Representatives on a need-to-know basis, provided that each such recipient of Confidential Information must be bound by contractual or professional obligations of confidentiality and non-use at least as stringent as those imposed upon the parties hereunder prior to any such disclosure; </font></p>
<p style="margin-bottom:12pt;Background-color:#FFFFFF;margin-top:0pt;text-indent:26.92%;color:#010000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(vii)<font style="margin-left:36pt;"></font><font style="color:#000000;">upon the prior written consent of the Disclosing Party; </font></p>
<p style="margin-bottom:12pt;Background-color:#FFFFFF;margin-top:0pt;text-indent:26.92%;color:#010000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(viii)<font style="margin-left:36pt;"></font><font style="color:#000000;">disclosure to its potential investors, and other sources of funding, including debt financing, or potential partners, collaborators or acquirers, and their respective accountants, financial advisors and other professional representatives, provided, that such disclosure shall be made only to the extent customarily required to consummate such investment, financing transaction partnership, collaboration or acquisition and that each recipient of Confidential Information must be bound by customary obligations of confidentiality and non-use prior to any such disclosure;</font></p>
<p style="margin-bottom:12pt;Background-color:#FFFFFF;margin-top:0pt;text-indent:26.92%;color:#010000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(ix)<font style="margin-left:36pt;"></font><font style="color:#000000;">as is necessary in connection with a permitted assignment pursuant to &#8206;Section 10.4.</font></p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;color:#010000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU45"></a>(b)<font style="margin-left:36pt;"></font><font style="color:#000000;">Notwithstanding the foregoing, in the event the Receiving Party is required to make a disclosure of the Disclosing Party&#8217;s Confidential Information pursuant to &#8206;Section 8.2(a)(i), &#8206;(ii), &#8206;(iii) or &#8206;(iv), it will, except where impracticable, give reasonable advance notice to the Disclosing Party of such disclosure and use reasonable efforts to secure confidential <br /></font></p>
<p style="text-align:center;Background-color:#auto;margin-top:12pt;line-height:10pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">41</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
<p style="line-height:10pt;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">250212926 v1</p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:7pt;font-family:Times New Roman;">&nbsp;</p>&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;Background-color:#auto;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 10.6</p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;color:#010000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;">treatment of such information. In any event, the Payer shall not file any patent application based upon or using the Confidential Information of Company provided hereunder.</font></p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;color:#010000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c)<font style="margin-left:36pt;"></font><font style="color:#000000;">Notwithstanding anything set forth in this Agreement, materials and documentation relating to the Company&#8217;s Intellectual Property Rights may be only disclosed to or accessed by the Payer and its attorneys and auditors, without further disclosure to any other Representative of the Payer.</font></p>
<p style="Background-color:#auto;text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#010000;text-transform:uppercase;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;font-variant: normal;"><a name="_Ref276307534"></a><a name="_Ref276323593"></a><a name="_Ref276336080"></a><a name="_Toc55233545"></a><a name="_Toc56006816"></a><a name="_Toc56700590"></a><a name="_Toc65621622"></a><a name="_Toc65623784"></a><a name="_Toc66905173"></a>ARTICLE 9<font style="text-transform:none;color:#000000;"><br /><a name="_Ref276307534"></a><a name="_Ref276323593"></a><a name="_Ref276336080"></a><a name="_Toc55233545"></a><a name="_Toc56006816"></a><a name="_Toc56700590"></a><a name="_Toc65621622"></a><a name="_Toc65623784"></a><a name="_Toc66905173"></a>TERMINATION</font></p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;color:#010000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Ref276336048"></a><a name="_Toc55233546"></a><a name="_Toc56006817"></a><a name="_Toc56700591"></a><a name="_Toc65621623"></a><a name="_Toc65623785"></a><a name="_Toc66905174"></a><font style="text-decoration:underline;">Mutual Termination</font></p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. This Agreement may be terminated by mutual written agreement of the Payer and the Company.</p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;color:#010000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Ref55152190"></a><a name="_Toc55233548"></a><a name="_Toc56006819"></a><a name="_Toc56700593"></a><a name="_Toc65621624"></a><a name="_Toc65623786"></a><a name="_Toc66905175"></a><font style="text-decoration:underline;">Automatic Termination</font></p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Ref319389981"></a>. Unless earlier terminated as provided in &#8206;Section 9.1, this Agreement shall continue in full force and effect until: (a) if the Closing has not occurred, [***] after the date hereof, or (b) following the Closing, [***] after the Revenue Payment Termination Date, at which point this Agreement shall automatically terminate, except with respect to any rights that shall have accrued prior to such termination.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;color:#010000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc54856677"></a><a name="_Toc54856678"></a><a name="_Toc54856679"></a><a name="_Ref400034852"></a><a name="_Ref525247992"></a><a name="_Toc55233549"></a><a name="_Toc56006820"></a><a name="_Toc56700594"></a><a name="_Toc65621625"></a><a name="_Toc65623787"></a><a name="_Toc66905176"></a><font style="text-decoration:underline;">Survival</font></p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. Notwithstanding anything to the contrary in this &#8206;ARTICLE 9, the following provisions shall survive termination of this Agreement: &#8206;Section 6.3 (Disclosures), &#8206;Section 6.4 (Inspections and Audits of the Company) (for the time period stated therein) &#8206;ARTICLE 7 (Indemnification), &#8206;ARTICLE 8 (Confidentiality) (for the time period stated therein), this &#8206;Section 9.3 (Survival) and &#8206;ARTICLE 10 (Miscellaneous). Termination of the Agreement shall not relieve any party of liability in respect of breaches under this Agreement by any party on or prior to termination. </p>
<p style="Background-color:#auto;text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#010000;text-transform:uppercase;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;font-variant: normal;"><a name="_Ref276336118"></a><a name="_Toc55233550"></a><a name="_Toc56006821"></a><a name="_Toc56700595"></a><a name="_Toc65621626"></a><a name="_Toc65623788"></a><a name="_Toc66905177"></a>ARTICLE 10<font style="text-transform:none;color:#000000;"><br /><a name="_Ref276336118"></a><a name="_Toc55233550"></a><a name="_Toc56006821"></a><a name="_Toc56700595"></a><a name="_Toc65621626"></a><a name="_Toc65623788"></a><a name="_Toc66905177"></a>MISCELLANEOUS</font></p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;color:#010000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc55233551"></a><a name="_Toc56006822"></a><a name="_Toc56700596"></a><a name="_Toc65621627"></a><a name="_Toc65623789"></a><a name="_Toc66905178"></a><font style="text-decoration:underline;">Headings</font></p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. The table of contents and the descriptive headings of the several Articles and Sections of this Agreement and the Exhibits and Schedules are for convenience only, do not constitute a part of this Agreement and shall not control or affect, in any way, the meaning or interpretation of this Agreement.</p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;color:#010000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Ref525251315"></a><a name="_Ref525251326"></a><a name="_Toc55233552"></a><a name="_Toc56006823"></a><a name="_Toc56700597"></a><a name="_Toc65621628"></a><a name="_Toc65623790"></a><a name="_Toc66905179"></a><a name="_Ref276322454"></a><font style="text-decoration:underline;">Notices</font></p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. All notices and other communications under this Agreement shall be in writing and shall be by email with PDF attachment, facsimile, courier service or personal delivery to the following addresses, or to such other addresses as shall be designated from time to time by a party hereto in accordance with this &#8206;Section 10.2:</p>
<p style="Background-color:#auto;margin-bottom:6pt;margin-top:0pt;margin-left:15.38%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If to the Company, to it at:</p>
<p style="Background-color:#auto;margin-bottom:0pt;margin-top:0pt;margin-left:19.23%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">UroGen Pharma Ltd.</p>
<p style="Background-color:#auto;margin-bottom:0pt;margin-top:0pt;margin-left:19.23%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">400 Alexander Park Drive</p>
<p style="Background-color:#auto;margin-bottom:0pt;margin-top:0pt;margin-left:19.23%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Princeton, NJ 08540<br /></p>
<p style="text-align:center;Background-color:#auto;margin-top:12pt;line-height:10pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">42</a></p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
<p style="line-height:10pt;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">250212926 v1</p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:7pt;font-family:Times New Roman;">&nbsp;</p>&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;Background-color:#auto;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 10.6</p>
<p style="Background-color:#auto;margin-bottom:0pt;margin-top:0pt;margin-left:19.23%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU46"></a><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Attn: </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">***</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">]</font></p>
<p style="Background-color:#auto;margin-bottom:0pt;margin-top:0pt;margin-left:19.23%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Email: [***]</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;"><font style="margin-left:36pt;">&nbsp;</font>&nbsp;</p>
<p style="Background-color:#auto;margin-bottom:6pt;margin-top:0pt;margin-left:15.38%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">with a copy to:</p>
<p style="Background-color:#auto;margin-bottom:0pt;margin-top:0pt;margin-left:19.23%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cooley LLP</p>
<p style="Background-color:#auto;margin-bottom:0pt;margin-top:0pt;margin-left:19.23%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4401 Eastgate Mall</p>
<p style="Background-color:#auto;margin-bottom:0pt;margin-top:0pt;margin-left:19.23%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">San Diego, CA 92121-1909</p>
<p style="Background-color:#auto;margin-bottom:0pt;margin-top:0pt;margin-left:19.23%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Attn: Charles J. Bair</p>
<p style="Background-color:#auto;margin-bottom:0pt;margin-top:0pt;margin-left:19.23%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Email: cbair@cooley.com</p>
<p style="Background-color:#auto;margin-bottom:6pt;margin-top:0pt;margin-left:15.38%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="Background-color:#auto;margin-bottom:6pt;margin-top:0pt;margin-left:15.38%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If to the Payer, to it at:</p>
<p style="Background-color:#auto;margin-top:12pt;margin-bottom:0pt;margin-left:19.23%;margin-right:7.69%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">RTW Investments, LP</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:19.23%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">40 10th Avenue, Floor 7</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:19.23%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">New York, NY 10014</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:19.23%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Attn: [***] and Bradley Sitko</p>
<p style="Background-color:#auto;margin-bottom:0pt;margin-top:0pt;margin-left:19.23%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Email: [***] bs@rtwfunds.com and [***]</p>
<p style="Background-color:#auto;margin-bottom:0pt;margin-top:0pt;margin-left:19.23%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="Background-color:#auto;margin-bottom:6pt;margin-top:0pt;margin-left:15.38%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">with a copy to:</p>
<p style="Background-color:#auto;margin-bottom:0pt;margin-top:0pt;margin-left:19.23%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Gibson, Dunn &amp; Crutcher LLP</p>
<p style="Background-color:#auto;margin-bottom:0pt;margin-top:0pt;margin-left:19.23%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">555 Mission Street</p>
<p style="Background-color:#auto;margin-bottom:0pt;margin-top:0pt;margin-left:19.23%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">San Francisco, CA 94105</p>
<p style="Background-color:#auto;margin-bottom:0pt;margin-top:0pt;margin-left:19.23%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Attention: Ryan Murr &amp; Todd Trattner</p>
<p style="Background-color:#auto;margin-bottom:0pt;margin-top:0pt;margin-left:19.23%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">E-mail: rmurr@gibsondunn.com; ttrattner@gibsondunn.com</p>
<p style="Background-color:#auto;margin-bottom:0pt;margin-top:0pt;margin-left:15.38%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">All notices and communications under this Agreement shall be deemed to have been duly given (i)&#160;when delivered by hand, if personally delivered, (ii)&#160;when sent, if sent by facsimile, with an acknowledgement of sending being produced by the sending facsimile machine, (iii) when sent, if by email with PDF attachment, with an acknowledgement of receipt being produced by the recipient&#8217;s email account, or (iv)&#160;one Business Day following sending within the United States by overnight delivery via commercial one-day overnight courier service.</p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;color:#010000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc55233553"></a><a name="_Toc56006824"></a><a name="_Toc56700598"></a><a name="_Toc65621629"></a><a name="_Toc65623791"></a><a name="_Toc66905180"></a><a name="_Hlk66891698"></a><font style="text-decoration:underline;">Expenses</font></p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk66891712"></a><a name="_Hlk66891712"></a>. The Company shall promptly reimburse the Payer for all Transaction Expenses. Except as otherwise provided herein, all fees, costs and expenses (including any legal, accounting and banking fees) incurred in connection with the preparation, negotiation, execution and delivery of this Agreement and to consummate the transactions contemplated hereby shall be paid by the party hereto incurring such fees, costs and expenses; provided however that the Company shall reimburse the Payer for all costs related to perfection and enforcement of the Transaction Documents.</p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;color:#010000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Ref370725421"></a><a name="_Toc55233554"></a><a name="_Toc56006825"></a><a name="_Toc56700599"></a><a name="_Toc65621630"></a><a name="_Toc65623792"></a><a name="_Toc66905181"></a><font style="text-decoration:underline;">Assignment</font></p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU47"></a><a name="_9kR3WTr26647DOFwvoutlkoxCD21"></a>. The Company may not assign in whole or in part this Agreement, any of its rights or obligations hereunder, or any Product Rights, without the Payer&#8217;s prior written consent, except to a Third Party in connection with the sale or transfer of all or substantially all of the Company&#8217;s business or assets related to a Product, whether by merger, sale of assets, reorganization, or other conveyance of title and only if upon closing any such transaction, the Company causes such Affiliate or Third Party, as applicable, (a) to deliver a <br /></p>
<p style="text-align:center;Background-color:#auto;margin-top:12pt;line-height:10pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">43</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
<p style="line-height:10pt;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">250212926 v1</p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:7pt;font-family:Times New Roman;">&nbsp;</p>&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;Background-color:#auto;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 10.6</p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">writing to the Payer in which it assumes all of the obligations of the Company to the Payer under this Agreement and other Transaction Documents, (b) such Affiliate or Third Party shall be deemed an assignee of Company under this Agreement, and (c) concurrent with such assignment, the effectiveness of which shall be conditional upon, to deliver to the Payer of the same or equivalent Liens on the Product Collateral under the Security Documents and perfect and register such Liens at all applicable registries in all applicable jurisdictions to the Payer's satisfaction; provided that (i) such assignment does not result in any adverse Tax consequences to the Payer as determined at the time of such assignment and (ii) for the avoidance of doubt, nothing in this </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8206;</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Section 10.4</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> shall restrict the Company from incurring any Permitted Liens, entering into any Permitted License, from transferring the Marketing Approvals for any jurisdiction to any subsidiary or a Licensee (or an affiliate of a Licensee) in connection with a Permitted License, or incurring any Indebtedness. Following the Closing, the Payer may assign this Agreement in whole or in part to any Person, provided that such assignment (i) does not result in any adverse Tax consequences to the Company </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_9kR3WTr26647DOFwvoutlkoxCD21"></a>and (ii) is not made to a pharmaceutical company developing or </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Commercializing</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> therapies for the treatment of urologic diseases, in each case </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">as determined at the time of such assignment. This Agreement shall be binding upon, inure to the benefit of and be enforceable by, the parties hereto and their respective permitted successors and assigns. Any purported assignment of this Agreement in violation of this </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8206;</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Section 10.4</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> shall be null and void.</font></p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;color:#010000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc55233555"></a><a name="_Toc56006826"></a><a name="_Toc56700600"></a><a name="_Toc65621631"></a><a name="_Toc65623793"></a><a name="_Toc66905182"></a>Section 10.5<font style="margin-left:36pt;"></font><font style="text-decoration:underline;color:#000000;">Amendment and Waiver</font><font style="color:#000000;">.</font></p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;color:#010000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)<font style="margin-left:36pt;"></font><font style="color:#000000;">This Agreement may be amended, modified or supplemented only in a writing signed by each of the parties hereto. Any provision of this Agreement may be waived only in a writing signed by the party hereto granting such waiver.</font></p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;color:#010000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)<font style="margin-left:36pt;"></font><font style="color:#000000;">No failure or delay on the part of any party hereto in exercising any right, power or remedy hereunder shall operate as a waiver thereof, nor shall any single or partial exercise of any such right, power or remedy preclude any other or further exercise thereof or the exercise of any other right, power or remedy. No course of dealing between the parties hereto shall be effective to amend, modify, supplement or waive any provision of this Agreement.</font></p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;color:#010000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc55233556"></a><a name="_Toc56006827"></a><a name="_Toc56700601"></a><a name="_Toc65621632"></a><a name="_Toc65623794"></a><a name="_Toc66905183"></a><font style="text-decoration:underline;">Entire Agreement</font></p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. This Agreement, the Exhibits annexed hereto and the Disclosure Schedule constitute the entire understanding between the parties hereto with respect to the subject matter hereof and supersede all other understandings and negotiations with respect thereto. As of the date hereof, the Confidentiality Agreement between the Payer and the Company, dated as of [***] is hereby terminated without further force and effect, superseded by &#8206;ARTICLE 8 of this Agreement and all obligations between the parties relating to confidentiality shall be governed by &#8206;ARTICLE 8 of this Agreement.</p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;color:#010000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc55233557"></a><a name="_Toc56006828"></a><a name="_Toc56700602"></a><a name="_Toc65621633"></a><a name="_Toc65623795"></a><a name="_Toc66905184"></a><font style="text-decoration:underline;">No Third-Party Beneficiaries</font></p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU48"></a>. This Agreement is for the sole benefit of the Company and the Payer and their permitted successors and assigns and nothing herein expressed or implied shall give or be construed to give to any Person, other than the parties hereto and such <br /></p>
<p style="text-align:center;Background-color:#auto;margin-top:12pt;line-height:10pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">44</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
<p style="line-height:10pt;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">250212926 v1</p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:7pt;font-family:Times New Roman;">&nbsp;</p>&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;Background-color:#auto;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 10.6</p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">successors and assigns, any legal or equitable rights hereunder, except that the Indemnified Parties shall be third-party beneficiaries of the benefits provided for in </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8206;</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Section 7.1</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</font></p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;color:#010000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc55233558"></a><a name="_Toc56006829"></a><a name="_Toc56700603"></a><a name="_Toc65621634"></a><a name="_Toc65623796"></a><a name="_Toc66905185"></a><font style="text-decoration:underline;">Governing Law</font></p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. This Agreement shall be exclusively governed by, and construed in accordance with, the laws of the State of New York without giving effect to any choice or conflict of law provision or rule that would cause the application of the laws of any other jurisdiction.</p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;color:#010000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc55233559"></a><a name="_Toc56006830"></a><a name="_Toc56700604"></a><a name="_Toc65621635"></a><a name="_Toc65623797"></a><a name="_Toc66905186"></a>Section 10.9<font style="margin-left:36pt;"></font><font style="text-decoration:underline;color:#000000;">Jurisdiction; Venue</font><font style="color:#000000;">.</font></p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;color:#010000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_9kR3WTr266467JFwvoutlkoxCD21"></a>(a)<font style="margin-left:36pt;"></font><font style="color:#000000;"><a name="_9kR3WTr266467JFwvoutlkoxCD21"></a>EACH OF THE PARTIES HERETO HEREBY IRREVOCABLY AND UNCONDITIONALLY SUBMITS, FOR ITSELF AND ITS RESPECTIVE PROPERTY AND ASSETS, TO THE EXCLUSIVE JURISDICTION OF ANY NEW YORK STATE COURT OR FEDERAL COURT OF THE UNITED STATES OF AMERICA SITTING IN NEW YORK COUNTY, NEW YORK, AND ANY APPELLATE COURT THEREOF, IN ANY ACTION OR PROCEEDING ARISING OUT OF OR RELATING TO THIS AGREEMENT (INCLUDING IN RELATION TO ITS VALIDITY, ENFORCEMENT AND TERMINATION), OR FOR RECOGNITION OR ENFORCEMENT OF ANY JUDGMENT IN RESPECT THEREOF, AND THE PAYER AND THE COMPANY HEREBY IRREVOCABLY AND UNCONDITIONALLY AGREE THAT ALL CLAIMS IN RESPECT OF ANY SUCH ACTION OR PROCEEDING MAY BE HEARD AND DETERMINED IN ANY SUCH NEW YORK STATE COURT OR, TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW, IN SUCH FEDERAL COURT. THE PAYER AND THE COMPANY HEREBY AGREE THAT A FINAL JUDGMENT IN ANY SUCH ACTION OR PROCEEDING SHALL BE CONCLUSIVE AND MAY BE ENFORCED IN OTHER JURISDICTIONS BY SUIT ON THE JUDGMENT OR IN ANY OTHER MANNER PROVIDED BY APPLICABLE LAW. EACH OF THE PAYER AND THE COMPANY HEREBY SUBMITS TO THE EXCLUSIVE PERSONAL JURISDICTION AND VENUE OF SUCH NEW YORK STATE AND FEDERAL COURTS. THE PAYER AND THE COMPANY AGREE, TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW, THAT PROCESS MAY BE SERVED ON THE PAYER OR THE COMPANY IN THE SAME MANNER THAT NOTICES MAY BE GIVEN PURSUANT TO SECTION&#160;&#8206;10.2 HEREOF.</font></p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;color:#010000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)<font style="margin-left:36pt;"></font><font style="color:#000000;">EACH OF THE PARTIES HERETO HEREBY IRREVOCABLY AND UNCONDITIONALLY WAIVES, TO THE FULLEST EXTENT IT MAY LEGALLY AND EFFECTIVELY DO SO, ANY OBJECTION THAT IT MAY NOW OR HEREAFTER HAVE TO THE LAYING OF VENUE OF ANY ACTION OR PROCEEDING ARISING OUT OF OR RELATING TO THIS AGREEMENT IN ANY NEW YORK STATE OR FEDERAL COURT. EACH OF THE PAYER AND THE COMPANY HEREBY IRREVOCABLY WAIVES, TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW, THE DEFENSE OF AN INCONVENIENT FORUM TO THE MAINTENANCE OF SUCH ACTION OR PROCEEDING IN ANY SUCH COURT.</font></p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;color:#010000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU49"></a>(c)<font style="margin-left:36pt;"></font><font style="text-transform:uppercase;color:#000000;">Each Party hereby jointly and severally waives any and all right to trial by jury in any action or proceeding relating to this Agreement or any other document delivered hereunder or in connection herewith, or any transaction arising from or connected </font><font style="color:#000000;"><br /></font></p>
<p style="text-align:center;Background-color:#auto;margin-top:12pt;line-height:10pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">45</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
<p style="line-height:10pt;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">250212926 v1</p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:7pt;font-family:Times New Roman;">&nbsp;</p>&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;Background-color:#auto;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 10.6</p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;color:#010000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-transform:uppercase;color:#000000;">to any of the foregoing. Each of the Parties represents that this waiver is knowingly, willingly, and voluntarily given</font><font style="color:#000000;">.</font></p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;color:#010000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(d)<font style="margin-left:36pt;"></font><font style="color:#000000;">NOTHING IN THIS AGREEMENT SHALL AFFECT ANY RIGHT OF THE PAYER TO BRING ANY ACTION, LITIGATION OR PROCEEDING (INCLUDING ENFORCEMENT OF ANY LIEN) RELATED TO THE ISRAELI SECURITY AGREEMENT IN THE COURTS SPECIFIED IN THE ISRAELI SECURITY AGREEMENT.</font></p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;color:#010000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc55233560"></a><a name="_Toc56006831"></a><a name="_Toc56700605"></a><a name="_Toc65621636"></a><a name="_Toc65623798"></a><a name="_Toc66905187"></a><font style="text-decoration:underline;">Severability</font></p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. If any term or provision of this Agreement shall for any reason be held to be invalid, illegal or unenforceable in any situation in any jurisdiction, then, to the extent that the economic and legal substance of the transactions contemplated hereby is not affected in a manner that is materially adverse to either party hereto, all other terms and provisions of this Agreement shall nevertheless remain in full force and effect and the enforceability and validity of the offending term or provision shall not be affected in any other situation or jurisdiction. </p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;color:#010000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Ref276335952"></a><a name="_Toc55233561"></a><a name="_Toc56006832"></a><a name="_Toc56700606"></a><a name="_Toc65621637"></a><a name="_Toc65623799"></a><a name="_Toc66905188"></a><font style="text-decoration:underline;">Specific Performance</font></p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. Each of the parties acknowledges and agrees that the other party would be damaged irreparably in the event any of the provisions of this Agreement are not performed in accordance with their specific terms or otherwise are breached or violated. Accordingly, each of the parties agrees that, without posting bond or other undertaking, the other party will be entitled to seek an injunction or injunctions to prevent breaches or violations of the provisions of this Agreement and to seek to enforce specifically this Agreement and the terms and provisions hereof in any action, suit or other proceeding instituted in any court of the United States or any state thereof having jurisdiction over the parties and the matter in addition to any other remedy to which it may be entitled, at law or in equity. Each of the parties further agrees that, in the event of any action for specific performance in respect of such breach of violation, it will not assert the defense that a remedy at law would be adequate.</p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;color:#010000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc55233562"></a><a name="_Toc56006833"></a><a name="_Toc56700607"></a><a name="_Toc65621638"></a><a name="_Toc65623800"></a><a name="_Toc66905189"></a><font style="text-decoration:underline;">Counterparts</font></p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. This Agreement may be executed in any number of counterparts and by the parties hereto in separate counterparts, each of which when so executed shall be deemed to be an original and all of which taken together shall constitute one and the same agreement. Copies of executed counterparts transmitted by telecopy, facsimile or other similar means of electronic transmission, including &#8220;PDF,&#8221; shall be considered original executed counterparts, provided receipt of such counterparts is confirmed.</p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;color:#010000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc55233563"></a><a name="_Toc56006834"></a><a name="_Toc56700608"></a><a name="_Toc65621639"></a><a name="_Toc65623801"></a><a name="_Toc66905190"></a><font style="text-decoration:underline;">Relationship of the Parties</font></p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. The relationship between the Payer and the Company is solely that of recipient and grantor, and neither the Payer nor the Company has any fiduciary or other special relationship with the other party or any of its Affiliates. This Agreement is not a partnership, investment or similar agreement, and nothing contained herein shall be deemed to constitute the Payer and the Company as a partnership, an association, a joint venture or any other kind of entity or legal form for any purposes, including any Tax purposes, or to constitute the Payer as an investor in the Company. The Payer and the Company agree that they shall not take any inconsistent position with respect to such treatment in a filing with any Governmental Entity.</p>
<p style="Background-color:#auto;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;Background-color:#auto;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;font-size:12pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">[Signature Page Follows]</p>
<p style="Background-color:#auto;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;Background-color:#auto;margin-top:12pt;line-height:10pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">46</a></p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
<p style="line-height:10pt;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">250212926 v1</p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:7pt;font-family:Times New Roman;">&nbsp;</p>&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;Background-color:#auto;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 10.6<font style="font-weight:normal;"> </font></p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU50"></a><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be executed and delivered by their respective representatives thereunto duly authorized as of the date first above written.</font></p>
<div align="right">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:47.94%;">
<tr>
<td style="width:6.01%;"></td>
<td style="width:41.92%;"></td>
</tr>
<tr>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;">
<p style="Background-color:#auto;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;text-align:left;">&nbsp;</p></td>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;">
<p style="Background-color:#auto;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;text-align:left;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;">
<p style="Background-color:#auto;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;text-align:left;">&nbsp;</p></td>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;">
<p style="Background-color:#auto;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;text-align:left;">&nbsp;</p></td>
</tr>
<tr>
<td colspan="2" valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;">
<p style="Background-color:#auto;margin-bottom:0pt;margin-top:0pt;margin-left:6.55pt;;text-indent:-6.55pt;;text-align:left;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">COMPANY</p>
<p style="Background-color:#auto;margin-bottom:0pt;margin-top:0pt;margin-left:6.55pt;;text-indent:-6.55pt;;font-family:Times New Roman;font-size:10pt;text-align:left;">&nbsp;</p></td>
</tr>
<tr>
<td colspan="2" valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;">
<p style="Background-color:#auto;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-variant: small-caps;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;">UroGen Pharma Ltd.</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;">
<p style="Background-color:#auto;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;text-align:left;">&nbsp;</p></td>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;">
<p style="Background-color:#auto;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;text-align:left;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;">
<p style="Background-color:#auto;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;text-align:left;">&nbsp;</p></td>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;">
<p style="Background-color:#auto;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;text-align:left;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;">
<p style="Background-color:#auto;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;">
<p style="Background-color:#auto;border-bottom:Solid 0.75pt;padding-bottom:0pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Molly Henderson</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;">
<p style="Background-color:#auto;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;text-align:left;">&nbsp;</p></td>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;">
<p style="Background-color:#auto;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Name: Molly Henderson</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;">
<p style="Background-color:#auto;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;text-align:left;">&nbsp;</p></td>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;">
<p style="Background-color:#auto;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Title: Chief Financial Officer</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;">
<p style="Background-color:#auto;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;text-align:left;">&nbsp;</p></td>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;">
<p style="Background-color:#auto;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;text-align:left;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;">
<p style="Background-color:#auto;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;text-align:left;">&nbsp;</p></td>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;">
<p style="Background-color:#auto;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;text-align:left;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;">
<p style="Background-color:#auto;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;text-align:left;">&nbsp;</p></td>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;">
<p style="Background-color:#auto;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;text-align:left;">&nbsp;</p></td>
</tr>
<tr>
<td colspan="2" valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;">
<p style="Background-color:#auto;margin-bottom:0pt;margin-top:0pt;margin-left:6.55pt;;text-indent:-6.55pt;;text-align:left;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">PAYER</p>
<p style="Background-color:#auto;margin-bottom:0pt;margin-top:0pt;margin-left:6.55pt;;text-indent:-6.55pt;;font-family:Times New Roman;font-size:10pt;text-align:left;">&nbsp;</p></td>
</tr>
<tr>
<td colspan="2" valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;">
<p style="Background-color:#auto;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-variant: small-caps;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;">RTW Investments ICAV for and on behalf of RTW Fund 2</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;">
<p style="Background-color:#auto;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;text-align:left;">&nbsp;</p></td>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;">
<p style="Background-color:#auto;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;text-align:left;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;">
<p style="Background-color:#auto;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;text-align:left;">&nbsp;</p></td>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;">
<p style="Background-color:#auto;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;text-align:left;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;">
<p style="Background-color:#auto;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;text-align:left;">&nbsp;</p></td>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;">
<p style="Background-color:#auto;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;text-align:left;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;">
<p style="Background-color:#auto;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;">
<p style="Background-color:#auto;border-bottom:Solid 0.75pt;padding-bottom:0pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Dermot Hanley</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;">
<p style="Background-color:#auto;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;text-align:left;">&nbsp;</p></td>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;">
<p style="Background-color:#auto;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Name: Dermot Hanley</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;">
<p style="Background-color:#auto;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;text-align:left;">&nbsp;</p></td>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;">
<p style="Background-color:#auto;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Title: Chairman</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;">
<p style="Background-color:#auto;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;text-align:left;">&nbsp;</p></td>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;">
<p style="Background-color:#auto;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;text-align:left;">&nbsp;</p></td>
</tr>
</table></div>
<p style="Background-color:#auto;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="Background-color:#auto;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="Background-color:#auto;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;Background-color:#auto;margin-top:12pt;line-height:10pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[Signature Page to Pre-Paid Forward Contract]</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
<p style="line-height:10pt;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">250212926 v1</p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:7pt;font-family:Times New Roman;">&nbsp;</p>&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;Background-color:#auto;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU51"></a><font style="font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit A</font></p>
<p style="text-align:center;Background-color:#auto;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;Background-color:#auto;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Form of Company Opinions</p>
<p style="text-align:center;Background-color:#auto;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br /></p>
<p style="margin-top:12pt;Background-color:#FFFFFF;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
<p style="margin-top:12pt;line-height:10pt;Background-color:#FFFFFF;margin-bottom:0pt;text-indent:0%;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">250212926 v1</p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:7pt;font-family:Times New Roman;">&nbsp;</p>&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="Background-color:#auto;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<p style="text-align:center;Background-color:#auto;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU52"></a><font style="font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit B</font></p>
<p style="text-align:center;Background-color:#auto;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Valuation Procedures</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:6pt;Background-color:#FFFFFF;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***] </p>
<p style="Background-color:#auto;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><br /></p>
<p style="margin-top:12pt;Background-color:#FFFFFF;margin-bottom:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
<p style="line-height:10pt;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">250212926 v1</p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:7pt;font-family:Times New Roman;">&nbsp;</p>&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="Background-color:#auto;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-align:center;Background-color:#FFFFFF;text-indent:0%;font-weight:normal;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU53"></a><font style="font-weight:normal;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">AMENDMENT NO. 1 TO</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-align:center;Background-color:#FFFFFF;text-indent:0%;font-weight:normal;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">PRE-PAID FORWARD CONTRACT</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This Amendment No. 1 to Pre-Paid Forward Contract&nbsp;&nbsp;(&#8220;<font style="text-decoration:underline;">Amendment</font>&#8221;), dated April 30, 2021 (the &#8220;<font style="text-decoration:underline;">Amendment Date</font>&#8221;), is between RTW Investments ICAV, an Irish Collective Asset-management Vehicle registered in Ireland as an umbrella fund with segregated liability between sub-funds (the &#8220;<font style="text-decoration:underline;">Payer</font>&#8221;), for and on behalf of its sub-fund, RTW Fund 2, and UroGen Pharma Ltd., an Israel corporation with company registration number 513537621 (the &#8220;<font style="text-decoration:underline;">Company</font>&#8221;), and amends that certain Pre-Paid Forward Contract, dated as of March 18, 2021 (the &#8220;<font style="text-decoration:underline;">Agreement</font>&#8221;), by and between the Payer and the Company. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">WHEREAS, the parties mutually wish to amend the Agreement to, among other things, extend the automatic termination date; and</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">WHEREAS, Section 10.5 of the Agreement provides that the Agreement may be amended by a writing signed by each of the parties to the Agreement.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">NOW THEREFORE, in consideration of the covenants and agreements set forth herein and for good and valuable consideration, the receipt and adequacy of which are hereby acknowledged, the Company and the Payer hereby agree as follows: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;Background-color:#auto;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;Background-color:#auto;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="text-decoration:underline;font-size:12pt;">Defined Terms</font><font style="font-size:12pt;">.&nbsp;&nbsp;Capitalized terms that are used in this Amendment have the meaning set forth in the Agreement, unless otherwise defined in this Amendment.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;Background-color:#auto;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;Background-color:#auto;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="text-decoration:underline;font-size:12pt;">Amendment</font><font style="font-size:12pt;">. Effective as of the Amendment Date, Section 9.2 of the Agreement is amended to read in its entirety as follows:</font></p></td></tr></table></div>
<p style="margin-bottom:6pt;Background-color:#FFFFFF;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:6pt;Background-color:#FFFFFF;margin-top:0pt;margin-left:15.38%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Automatic Termination</font>.&nbsp;&nbsp;Unless earlier terminated as provided in Section 9.1, this Agreement shall continue in full force and effect until: (a) if the Closing has not occurred, [***] after the date hereof, or (b) following the Closing, [***] after the Revenue Payment Termination Date, at which point this Agreement shall automatically terminate, except with respect to any rights that shall have accrued prior to such termination.</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;Background-color:#auto;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;Background-color:#auto;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="text-decoration:underline;font-size:12pt;">Entire Agreement</font><font style="font-size:12pt;">.&nbsp;&nbsp;The provisions of this Amendment supersede all provisions of the Agreement that are inconsistent with the provisions of this Amendment.&nbsp;&nbsp;The Agreement, as modified by this Amendment, remains in full force and effect and, with the Exhibits annexed thereto and the Disclosure Schedule constitute the entire understanding between the parties hereto with respect to the subject matter hereof and thereof and supersede all other understandings and negotiations with respect hereto and thereto.&nbsp;&nbsp;Unless the context otherwise requires, the term &#8220;Agreement&#8221; as used in the Agreement shall be deemed to refer to the Agreement as amended hereby.&nbsp;&nbsp;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;Background-color:#auto;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;Background-color:#auto;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="text-decoration:underline;font-size:12pt;">Governing Law</font><font style="font-size:12pt;">.&nbsp;&nbsp;This Amendment shall be exclusively governed by, and construed in accordance with, the laws of the State of New York without giving effect to any choice or conflict of law provision or rule that would cause the application of the laws of any other jurisdiction.<br /></font></p></td></tr></table></div>
<p style="margin-top:12pt;Background-color:#FFFFFF;margin-bottom:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
<p style="line-height:10pt;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">250212926 v1</p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:7pt;font-family:Times New Roman;">&nbsp;</p>&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="Background-color:#auto;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;Background-color:#auto;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;Background-color:#auto;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><a name="_AEIOULastRenderedPageBreakAEIOU54"></a><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="text-decoration:underline;font-size:12pt;">Waiver</font><font style="font-size:12pt;">.&nbsp;&nbsp;</font><font style="font-size:12pt;">This Amendment shall not be deemed a waiver by </font><font style="font-size:12pt;">any</font><font style="font-size:12pt;"> </font><font style="font-size:12pt;">p</font><font style="font-size:12pt;">arty of any of its rights or remedies under the Agreement, except to the extent expressly set forth in this Amendment.&nbsp;&nbsp;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;Background-color:#auto;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;Background-color:#auto;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="text-decoration:underline;font-size:12pt;">Counterparts</font><font style="font-size:12pt;">.&nbsp;&nbsp;This Amendment may be executed in any number of counterparts and by the parties hereto in separate counterparts, each of which when so executed shall be deemed to be an original and all of which taken together shall constitute one and the same agreement. Copies of executed counterparts transmitted by telecopy, facsimile or other similar means of electronic transmission, including &#8220;PDF,&#8221; shall be considered original executed counterparts, provided receipt of such counterparts is confirmed.</font></p></td></tr></table></div>
<p style="margin-bottom:6pt;Background-color:#FFFFFF;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:6pt;Background-color:#FFFFFF;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:6pt;Background-color:#FFFFFF;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[<font style="font-style:italic;">Signature Page Follows</font>]</p>
<p style="text-align:center;margin-bottom:6pt;Background-color:#FFFFFF;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:6pt;Background-color:#FFFFFF;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;Background-color:#FFFFFF;margin-bottom:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
<p style="line-height:10pt;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">250212926 v1</p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:7pt;font-family:Times New Roman;">&nbsp;</p>&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:6pt;Background-color:#FFFFFF;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU55"></a><font style="font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">IN WITNESS WHEREOF</font><font style="font-weight:normal;">, the </font><font style="font-weight:normal;">parties hereto have caused this Amendment to be executed and delivered by their respective representatives thereunto duly authorized as of the date first above written</font><font style="font-weight:normal;">.</font></p>
<p style="margin-bottom:6pt;Background-color:#FFFFFF;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:46.15%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">COMPANY</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:46.15%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:46.15%;text-indent:0%;font-variant: small-caps;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;">UroGen Pharma Ltd.<font style="font-variant: normal;"><br /></font></p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:46.15%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br /><br />By: <font style="text-decoration:underline;">/s/ Molly Henderson</font><br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Name: Molly Henderson<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Title:&nbsp;&nbsp; Chief Financial Officer</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:46.15%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:46.15%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:46.15%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:46.15%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">PAYER</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:46.15%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:46.15%;text-indent:0%;font-variant: small-caps;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;">RTW Investments ICAV for and on behalf of RTW Fund 2<font style="font-variant: normal;"><br /></font></p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:46.15%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br /><br />By: <font style="text-decoration:underline;">/s/ Dermot Hanley</font><br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Name: Dermot Hanley<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Title:&nbsp;&nbsp; Chairman</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:46.15%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="Background-color:#auto;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;Background-color:#FFFFFF;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
<p style="margin-top:12pt;line-height:10pt;Background-color:#FFFFFF;margin-bottom:0pt;text-indent:0%;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">250212926 v1</p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:7pt;font-family:Times New Roman;">&nbsp;</p>&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>8
<FILENAME>urgn-ex311_11.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
urgn-ex311_11.htm
</title>
</head>
<!-- NG Converter v5.0.2.50 -->
<body>

<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 31.1</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">CERTIFICATION PURSUANT TO</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">I, Elizabeth Barrett, certify that:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.43%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:10pt;">I have reviewed this quarterly report on Form 10-Q of UroGen Pharma, Ltd.;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.43%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:10pt;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.43%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:10pt;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.43%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:10pt;">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.43%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.43%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:10pt;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.43%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.43%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:10pt;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.43%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.43%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c)</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:10pt;">Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.43%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.43%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(d)</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:10pt;">Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.43%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:10pt;">The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.43%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.43%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:10pt;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.43%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.43%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:10pt;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.43%;text-indent:-5.43%;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;width:5.3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date: </p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;width:45%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">May 13, 2021</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;width:4%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:46%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/&#160;Elizabeth Barrett</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:45%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:46%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Elizabeth Barrett</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:45%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Chief Executive Officer</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(Principal Executive Officer)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>9
<FILENAME>urgn-ex312_6.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
urgn-ex312_6.htm
</title>
</head>
<!-- NG Converter v5.0.2.50 -->
<body>

<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 31.2</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">CERTIFICATION PURSUANT TO</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">I, Molly Henderson, certify that:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.43%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:10pt;">I have reviewed this quarterly report on Form 10-Q of UroGen Pharma, Ltd.;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.43%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:10pt;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.43%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:10pt;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.43%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:10pt;">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.43%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.43%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:10pt;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.43%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.43%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:10pt;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.43%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.43%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c)</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:10pt;">Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.43%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.43%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(d)</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:10pt;">Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.43%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:10pt;">The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.43%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.43%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:10pt;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.43%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.43%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:10pt;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.43%;text-indent:-5.43%;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;width:5.32%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date: </p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;width:44.96%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">May 13, 2021</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;width:4%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:46.36%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/&#160;Molly Henderson</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:44.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:46.36%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Molly Henderson</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:44.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:46.36%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Chief Financial Officer</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(Principal Financial and Accounting Officer)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>10
<FILENAME>urgn-ex321_7.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
urgn-ex321_7.htm
</title>
</head>
<!-- NG Converter v5.0.2.50 -->
<body>

<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 32.1</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">CERTIFICATION PURSUANT TO</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In connection with the Quarterly Report of UroGen Pharma, Ltd. (the &#8220;Company&#8221;) on Form 10-Q for the period ended March 31, 2021 as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I, Elizabeth Barrett, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. &#167; 1350, as adopted pursuant to &#167; 906 of the Sarbanes-Oxley Act of 2002, that:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1)</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:10pt;">The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2)</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:10pt;">The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:-4.54%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:45.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date: May 13, 2021</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.46%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/&#160;Elizabeth Barrett</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.46%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Elizabeth Barrett</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Chief Executive Officer</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(Principal Executive Officer)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>11
<FILENAME>urgn-ex322_9.htm
<DESCRIPTION>EX-32.2
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
urgn-ex322_9.htm
</title>
</head>
<!-- NG Converter v5.0.2.50 -->
<body>

<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 32.2</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">CERTIFICATION PURSUANT TO</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In connection with the Quarterly Report of UroGen Pharma, Ltd. (the &#8220;Company&#8221;) on Form 10-Q for the period ended March 31, 2021 as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I, Molly Henderson, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. &#167; 1350, as adopted pursuant to &#167; 906 of the Sarbanes-Oxley Act of 2002, that:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1)</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:10pt;">The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2)</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:10pt;">The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:-4.54%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:45.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date: May 13, 2021</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.46%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/&#160;Molly Henderson</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.46%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Molly Henderson</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Chief Financial Officer</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(Principal Financial and Accounting Officer)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>12
<FILENAME>urgn-20210331.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN ActiveDisclosure(SM) XBRL Schema Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2021-05-12T21:01:28.4366810+00:00 -->
<!-- Version            : 5.0.1.615 -->
<!-- Package ID         : 66acac3df2bb4a8e915da518ecfedb52 -->
<!-- Copyright (c) 2021 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:us-types="http://fasb.org/us-types/2020-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2018-01-31" xmlns:srt-types="http://fasb.org/srt-types/2020-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2020-01-31" xmlns:urgn="http://www.urogen.com/20210331" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:srt="http://fasb.org/srt/2020-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xmlns:naics="http://xbrl.sec.gov/naics/2017-01-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:country="http://xbrl.sec.gov/country/2020-01-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:currency="http://xbrl.sec.gov/currency/2020-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2020-01-31" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.urogen.com/20210331" xmlns:xsd="http://www.w3.org/2001/XMLSchema">
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance" />
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase" />
  <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd" namespace="http://xbrl.sec.gov/country/2020-01-31" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd" namespace="http://xbrl.sec.gov/currency/2020-01-31" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd" namespace="http://xbrl.sec.gov/dei/2020-01-31" />
  <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/non-numeric" />
  <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/numeric" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/exch/2020/exch-2020-01-31.xsd" namespace="http://xbrl.sec.gov/exch/2020-01-31" />
  <xsd:import schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd" namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" />
  <xsd:import schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" namespace="http://www.xbrl.org/2009/role/negated" />
  <xsd:import schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" namespace="http://www.xbrl.org/2009/role/net" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd" namespace="http://xbrl.sec.gov/naics/2017-01-31" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/sic/2020/sic-2020-01-31.xsd" namespace="http://xbrl.sec.gov/sic/2020-01-31" />
  <xsd:import schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd" namespace="http://fasb.org/srt/2020-01-31" />
  <xsd:import schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd" namespace="http://fasb.org/srt-roles/2020-01-31" />
  <xsd:import schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd" namespace="http://fasb.org/srt-types/2020-01-31" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd" namespace="http://xbrl.sec.gov/stpr/2018-01-31" />
  <xsd:import schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd" namespace="http://fasb.org/us-gaap/2020-01-31" />
  <xsd:import schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd" namespace="http://fasb.org/us-roles/2020-01-31" />
  <xsd:import schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd" namespace="http://fasb.org/us-types/2020-01-31" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType id="TemplateLink" roleURI="http://www.urogen.com/20210331/role/TemplateLink" xmlns:link="http://www.xbrl.org/2003/linkbase">
        <link:definition>00000 - Document - Template Link</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="urgn-20210331_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:title="Calculation Links, all" xlink:type="simple" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="urgn-20210331_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:title="Definition Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="urgn-20210331_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:title="Label Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="urgn-20210331_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:title="Presentation Links, all" xlink:type="simple" />
      <link:roleType roleURI="http://www.urogen.com/20210331/taxonomy/role/DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.urogen.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParentheticalUnaudited" id="Role_StatementCondensedConsolidatedBalanceSheetsParentheticalUnaudited">
        <link:definition>100010 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) (unaudited)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.urogen.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" id="Role_StatementCondensedConsolidatedBalanceSheetsUnaudited">
        <link:definition>100020 - Statement - Condensed Consolidated Balance Sheets (unaudited)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.urogen.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited" id="Role_StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited">
        <link:definition>100030 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (unaudited)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.urogen.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfShareholdersEquityUnaudited" id="Role_StatementCondensedConsolidatedStatementsOfShareholdersEquityUnaudited">
        <link:definition>100040 - Statement - Condensed Consolidated Statements of Shareholders&apos; Equity (unaudited)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.urogen.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowUnaudited" id="Role_StatementCondensedConsolidatedStatementsOfCashFlowUnaudited">
        <link:definition>100050 - Statement - Condensed Consolidated Statements of Cash Flow (Unaudited)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.urogen.com/20210331/taxonomy/role/DisclosureBusinessAndNatureOfOperations" id="Role_DisclosureBusinessAndNatureOfOperations">
        <link:definition>100060 - Disclosure - Business and Nature of Operations</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.urogen.com/20210331/taxonomy/role/DisclosureBasisOfPresentation" id="Role_DisclosureBasisOfPresentation">
        <link:definition>100070 - Disclosure - Basis of Presentation</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.urogen.com/20210331/taxonomy/role/DisclosureSignificantAccountingPolicies" id="Role_DisclosureSignificantAccountingPolicies">
        <link:definition>100080 - Disclosure - Significant Accounting Policies</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.urogen.com/20210331/taxonomy/role/DisclosureOtherFinancialInformation" id="Role_DisclosureOtherFinancialInformation">
        <link:definition>100090 - Disclosure - Other Financial Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.urogen.com/20210331/taxonomy/role/DisclosureInventories" id="Role_DisclosureInventories">
        <link:definition>100100 - Disclosure - Inventories</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.urogen.com/20210331/taxonomy/role/DisclosureFairValueMeasurements" id="Role_DisclosureFairValueMeasurements">
        <link:definition>100110 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.urogen.com/20210331/taxonomy/role/DisclosureMarketableSecurities" id="Role_DisclosureMarketableSecurities">
        <link:definition>100120 - Disclosure - Marketable Securities</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.urogen.com/20210331/taxonomy/role/DisclosurePropertyAndEquipment" id="Role_DisclosurePropertyAndEquipment">
        <link:definition>100130 - Disclosure - Property and Equipment</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.urogen.com/20210331/taxonomy/role/DisclosureLeases" id="Role_DisclosureLeases">
        <link:definition>100140 - Disclosure - Leases</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.urogen.com/20210331/taxonomy/role/DisclosureRevenueFromProductSales" id="Role_DisclosureRevenueFromProductSales">
        <link:definition>100150 - Disclosure - Revenue from Product Sales</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.urogen.com/20210331/taxonomy/role/DisclosureLicenseAndCollaborationAgreements" id="Role_DisclosureLicenseAndCollaborationAgreements">
        <link:definition>100160 - Disclosure - License and Collaboration Agreements</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.urogen.com/20210331/taxonomy/role/DisclosureShareholdersEquity" id="Role_DisclosureShareholdersEquity">
        <link:definition>100170 - Disclosure - Shareholders&apos; Equity</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.urogen.com/20210331/taxonomy/role/DisclosureShareBasedCompensation" id="Role_DisclosureShareBasedCompensation">
        <link:definition>100180 - Disclosure - Share-Based Compensation</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.urogen.com/20210331/taxonomy/role/DisclosureIncomeTaxes" id="Role_DisclosureIncomeTaxes">
        <link:definition>100190 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.urogen.com/20210331/taxonomy/role/DisclosureRelatedParties" id="Role_DisclosureRelatedParties">
        <link:definition>100200 - Disclosure - Related Parties</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.urogen.com/20210331/taxonomy/role/DisclosureCommitmentsAndContingencies" id="Role_DisclosureCommitmentsAndContingencies">
        <link:definition>100210 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.urogen.com/20210331/taxonomy/role/DisclosureSubsequentEvents" id="Role_DisclosureSubsequentEvents">
        <link:definition>100220 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.urogen.com/20210331/taxonomy/role/DisclosureSignificantAccountingPoliciesPolicies" id="Role_DisclosureSignificantAccountingPoliciesPolicies">
        <link:definition>100230 - Disclosure - Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.urogen.com/20210331/taxonomy/role/DisclosureSignificantAccountingPoliciesTables" id="Role_DisclosureSignificantAccountingPoliciesTables">
        <link:definition>100240 - Disclosure - Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.urogen.com/20210331/taxonomy/role/DisclosureOtherFinancialInformationTables" id="Role_DisclosureOtherFinancialInformationTables">
        <link:definition>100250 - Disclosure - Other Financial Information (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.urogen.com/20210331/taxonomy/role/DisclosureInventoriesTables" id="Role_DisclosureInventoriesTables">
        <link:definition>100260 - Disclosure - Inventories (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.urogen.com/20210331/taxonomy/role/DisclosureFairValueMeasurementsTables" id="Role_DisclosureFairValueMeasurementsTables">
        <link:definition>100270 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.urogen.com/20210331/taxonomy/role/DisclosureMarketableSecuritiesTables" id="Role_DisclosureMarketableSecuritiesTables">
        <link:definition>100280 - Disclosure - Marketable Securities (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.urogen.com/20210331/taxonomy/role/DisclosurePropertyAndEquipmentTables" id="Role_DisclosurePropertyAndEquipmentTables">
        <link:definition>100290 - Disclosure - Property and Equipment (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.urogen.com/20210331/taxonomy/role/DisclosureLeasesTables" id="Role_DisclosureLeasesTables">
        <link:definition>100300 - Disclosure - Leases (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.urogen.com/20210331/taxonomy/role/DisclosureRevenueFromProductSalesTables" id="Role_DisclosureRevenueFromProductSalesTables">
        <link:definition>100310 - Disclosure - Revenue from Product Sales (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.urogen.com/20210331/taxonomy/role/DisclosureShareBasedCompensationTables" id="Role_DisclosureShareBasedCompensationTables">
        <link:definition>100320 - Disclosure - Share-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.urogen.com/20210331/taxonomy/role/DisclosureBusinessAndNatureOfOperationsAdditionalInformationDetails" id="Role_DisclosureBusinessAndNatureOfOperationsAdditionalInformationDetails">
        <link:definition>100330 - Disclosure - Business and Nature of Operations - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.urogen.com/20210331/taxonomy/role/DisclosureBasisOfPresentationAddititonalInformationDetails" id="Role_DisclosureBasisOfPresentationAddititonalInformationDetails">
        <link:definition>100340 - Disclosure - Basis of Presentation - Addititonal Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.urogen.com/20210331/taxonomy/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails" id="Role_DisclosureSignificantAccountingPoliciesAdditionalInformationDetails">
        <link:definition>100350 - Disclosure - Significant Accounting Policies - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.urogen.com/20210331/taxonomy/role/DisclosureSignificantAccountingPoliciesPropertyAndEquipmentUsefulLivesDetails" id="Role_DisclosureSignificantAccountingPoliciesPropertyAndEquipmentUsefulLivesDetails">
        <link:definition>100360 - Disclosure - Significant Accounting Policies - Property and Equipment Useful Lives (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.urogen.com/20210331/taxonomy/role/DisclosureOtherFinancialInformationScheduleOfAccountsPayableAndAccruedExpensesDetails" id="Role_DisclosureOtherFinancialInformationScheduleOfAccountsPayableAndAccruedExpensesDetails">
        <link:definition>100370 - Disclosure - Other Financial Information - Schedule of Accounts Payable and Accrued Expenses (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.urogen.com/20210331/taxonomy/role/DisclosureOtherFinancialInformationScheduleOfInterestAndOtherIncomeExpensesDetails" id="Role_DisclosureOtherFinancialInformationScheduleOfInterestAndOtherIncomeExpensesDetails">
        <link:definition>100380 - Disclosure - Other Financial Information - Schedule of Interest and Other Income (Expenses) (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.urogen.com/20210331/taxonomy/role/DisclosureInventoriesScheduleOfInventoriesDetails" id="Role_DisclosureInventoriesScheduleOfInventoriesDetails">
        <link:definition>100390 - Disclosure - Inventories - Schedule of Inventories (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.urogen.com/20210331/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails" id="Role_DisclosureFairValueMeasurementsAdditionalInformationDetails">
        <link:definition>100400 - Disclosure - Fair Value Measurements - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.urogen.com/20210331/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" id="Role_DisclosureFairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails">
        <link:definition>100410 - Disclosure - Fair Value Measurements - Summary of Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.urogen.com/20210331/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfMarketableSecuritiesDetails" id="Role_DisclosureMarketableSecuritiesSummaryOfMarketableSecuritiesDetails">
        <link:definition>100420 - Disclosure - Marketable Securities - Summary of Marketable Securities (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.urogen.com/20210331/taxonomy/role/DisclosureMarketableSecuritiesAdditionalInformationDetails" id="Role_DisclosureMarketableSecuritiesAdditionalInformationDetails">
        <link:definition>100430 - Disclosure - Marketable Securities - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.urogen.com/20210331/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfFairValuesOfMarketableSecuritiesByContractualMaturityDetails" id="Role_DisclosureMarketableSecuritiesSummaryOfFairValuesOfMarketableSecuritiesByContractualMaturityDetails">
        <link:definition>100440 - Disclosure - Marketable Securities - Summary of Fair Values of Marketable Securities by Contractual Maturity (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.urogen.com/20210331/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails" id="Role_DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails">
        <link:definition>100450 - Disclosure - Property and Equipment - Schedule of Property and Equipment (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.urogen.com/20210331/taxonomy/role/DisclosurePropertyAndEquipmentAdditionalInformationDetails" id="Role_DisclosurePropertyAndEquipmentAdditionalInformationDetails">
        <link:definition>100460 - Disclosure - Property and Equipment - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.urogen.com/20210331/taxonomy/role/DisclosureLeasesAdditionalInformationDetails" id="Role_DisclosureLeasesAdditionalInformationDetails">
        <link:definition>100470 - Disclosure - Leases - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.urogen.com/20210331/taxonomy/role/DisclosureLeasesComponentsOfLeaseCostDetails" id="Role_DisclosureLeasesComponentsOfLeaseCostDetails">
        <link:definition>100480 - Disclosure - Leases - Components of Lease Cost (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.urogen.com/20210331/taxonomy/role/DisclosureLeasesScheduleOfAmountsRecognizedDetails" id="Role_DisclosureLeasesScheduleOfAmountsRecognizedDetails">
        <link:definition>100490 - Disclosure - Leases - Schedule of Amounts Recognized (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.urogen.com/20210331/taxonomy/role/DisclosureLeasesScheduleOfSupplementalInformationRelatedToLeasesDetails" id="Role_DisclosureLeasesScheduleOfSupplementalInformationRelatedToLeasesDetails">
        <link:definition>100500 - Disclosure - Leases - Schedule of Supplemental Information Related to Leases (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.urogen.com/20210331/taxonomy/role/DisclosureLeasesScheduleOfUndiscountedCashFlowsToBeReceivedUnderOperatingSubleaseOnAnnualBasisDetails" id="Role_DisclosureLeasesScheduleOfUndiscountedCashFlowsToBeReceivedUnderOperatingSubleaseOnAnnualBasisDetails">
        <link:definition>100510 - Disclosure - Leases - Schedule of Undiscounted Cash Flows to be Received Under Operating Sublease on an Annual Basis (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.urogen.com/20210331/taxonomy/role/DisclosureLeasesScheduleOfSubleaseIncomeRecognizedNetWithinOperatingExpensesDetails" id="Role_DisclosureLeasesScheduleOfSubleaseIncomeRecognizedNetWithinOperatingExpensesDetails">
        <link:definition>100520 - Disclosure - Leases - Schedule of Sublease Income Recognized Net within Operating Expenses (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.urogen.com/20210331/taxonomy/role/DisclosureRevenueFromProductSalesScheduleOfNetProductSalesDetails" id="Role_DisclosureRevenueFromProductSalesScheduleOfNetProductSalesDetails">
        <link:definition>100530 - Disclosure - Revenue from Product Sales - Schedule of Net Product Sales (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.urogen.com/20210331/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails" id="Role_DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails">
        <link:definition>100540 - Disclosure - License and Collaboration Agreements - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.urogen.com/20210331/taxonomy/role/DisclosureShareholdersEquityAdditionalInformationDetails" id="Role_DisclosureShareholdersEquityAdditionalInformationDetails">
        <link:definition>100550 - Disclosure - Shareholders&apos; Equity - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.urogen.com/20210331/taxonomy/role/DisclosureShareBasedCompensationAdditionalInformationDetails" id="Role_DisclosureShareBasedCompensationAdditionalInformationDetails">
        <link:definition>100560 - Disclosure - Share-Based Compensation - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.urogen.com/20210331/taxonomy/role/DisclosureShareBasedCompensationScheduleOfEffectOfShareBasedCompensationOnCondensedConsolidatedStatementsOfOperationsDetails" id="Role_DisclosureShareBasedCompensationScheduleOfEffectOfShareBasedCompensationOnCondensedConsolidatedStatementsOfOperationsDetails">
        <link:definition>100570 - Disclosure - Share Based Compensation - Schedule of Effect of Share-Based Compensation on Condensed Consolidated Statements of Operations (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.urogen.com/20210331/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" id="Role_DisclosureIncomeTaxesAdditionalInformationDetails">
        <link:definition>100580 - Disclosure - Income Taxes - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.urogen.com/20210331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" id="Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails">
        <link:definition>100590 - Disclosure - Commitments and Contingencies - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.urogen.com/20210331/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" id="Role_DisclosureSubsequentEventsAdditionalInformationDetails">
        <link:definition>100600 - Disclosure - Subsequent Events - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:element id="urgn_InterestAndOtherIncomeExpensesNet" name="InterestAndOtherIncomeExpensesNet" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="urgn_OperatingLeaseRightOfUseAssetAmortization" name="OperatingLeaseRightOfUseAssetAmortization" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="urgn_OperatingLeaseLiabilityAdjustments" name="OperatingLeaseLiabilityAdjustments" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="urgn_NonCashNewLeaseLiabilities" name="NonCashNewLeaseLiabilities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="urgn_OtherFinancialInformationTextBlock" name="OtherFinancialInformationTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="urgn_OtherFinancialInformationAbstract" name="OtherFinancialInformationAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="urgn_MarketableSecuritiesDisclosureTextBlock" name="MarketableSecuritiesDisclosureTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="urgn_LicenseAndCollaborationAgreementsDisclosureTextBlock" name="LicenseAndCollaborationAgreementsDisclosureTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="urgn_LiscenseAgreementAbstract" name="LiscenseAgreementAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="urgn_CashAndCashEquivalentsAndMarketableSecuritiesPolicyPolicyTextBlock" name="CashAndCashEquivalentsAndMarketableSecuritiesPolicyPolicyTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="urgn_PropertyPlantAndEquipmentUsefulLifeTableTextBlock" name="PropertyPlantAndEquipmentUsefulLifeTableTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="urgn_SummaryOfFairValuesOfMarketableSecuritiesByContractualMaturityTableTextBlock" name="SummaryOfFairValuesOfMarketableSecuritiesByContractualMaturityTableTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="urgn_ScheduleOfOperatingLeaseAmountsRecognizedUponAdoptionTableTextBlock" name="ScheduleOfOperatingLeaseAmountsRecognizedUponAdoptionTableTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="urgn_ScheduleOfSupplementalInformationRelatedToLeasesTableTextBlock" name="ScheduleOfSupplementalInformationRelatedToLeasesTableTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="urgn_LesseeOperatingSubLeasePaymentsToBeReceivedMaturityTableTextBlock" name="LesseeOperatingSubLeasePaymentsToBeReceivedMaturityTableTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="urgn_LesseeOperatingSubLeaseIncomeRecognizedNetInOperatingExpensesTableTextBlock" name="LesseeOperatingSubLeaseIncomeRecognizedNetInOperatingExpensesTableTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="urgn_EntityIncorporationDateOfIncorporationMonthAndYear" name="EntityIncorporationDateOfIncorporationMonthAndYear" type="xbrli:gYearMonthItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="urgn_OperationsCommencedDateMonthAndYear" name="OperationsCommencedDateMonthAndYear" type="xbrli:gYearMonthItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="urgn_CashCashEquivalentsAndMarketableSecurities" name="CashCashEquivalentsAndMarketableSecurities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="urgn_ComputersAndSoftwareMember" name="ComputersAndSoftwareMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="urgn_LaboratoryEquipmentMember" name="LaboratoryEquipmentMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="urgn_AccruedSalesReserves" name="AccruedSalesReserves" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="urgn_AccruedClinicalExpensesCurrent" name="AccruedClinicalExpensesCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="urgn_AccruedResearchAndDevelopmentExpenseCurrent" name="AccruedResearchAndDevelopmentExpenseCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="urgn_AccruedSellingGeneralAndAdministrativeExpenseCurrent" name="AccruedSellingGeneralAndAdministrativeExpenseCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="urgn_OtherFinanceExpensesIncome" name="OtherFinanceExpensesIncome" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="urgn_FinanceIncomeExpenseNet" name="FinanceIncomeExpenseNet" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="urgn_DebtSecuritiesAvailableForSaleUnrealizedGainPosition" name="DebtSecuritiesAvailableForSaleUnrealizedGainPosition" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="urgn_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughThreeYearsFairValue" name="AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughThreeYearsFairValue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="urgn_LesseeOperatingLeaseExtendedLeaseExpirationDateMonthAndYear" name="LesseeOperatingLeaseExtendedLeaseExpirationDateMonthAndYear" type="xbrli:gYearMonthItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="urgn_LeaseCommencementDateMonthAndYear" name="LeaseCommencementDateMonthAndYear" type="xbrli:gYearMonthItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="urgn_LeaseTerminationDateMonthAndYear" name="LeaseTerminationDateMonthAndYear" type="xbrli:gYearMonthItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="urgn_LeaseCommencementDate" name="LeaseCommencementDate" type="xbrli:dateItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="urgn_ProceedsFromTenantAllowance" name="ProceedsFromTenantAllowance" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="urgn_LesseeOperatingSubleaseCommencementDate" name="LesseeOperatingSubleaseCommencementDate" type="xbrli:dateItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="urgn_LesseeOperatingSubleaseTerminationDateMonthAndYear" name="LesseeOperatingSubleaseTerminationDateMonthAndYear" type="xbrli:gYearMonthItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="urgn_LeaseExpirationYear" name="LeaseExpirationYear" type="xbrli:gYearItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="urgn_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract" name="CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="urgn_LesseeOperatingSubLeasePaymentsToBeReceivedRemainderOfFiscalYear" name="LesseeOperatingSubLeasePaymentsToBeReceivedRemainderOfFiscalYear" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="urgn_LesseeOperatingSubLeasePaymentsToBeReceivedNextTwelveMonths" name="LesseeOperatingSubLeasePaymentsToBeReceivedNextTwelveMonths" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="urgn_LesseeOperatingSubLeasePaymentsToBeReceivedTwoYears" name="LesseeOperatingSubLeasePaymentsToBeReceivedTwoYears" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="urgn_LesseeOperatingSubLeasePaymentsToBeReceivedThreeYears" name="LesseeOperatingSubLeasePaymentsToBeReceivedThreeYears" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="urgn_LesseeOperatingSubLeasePaymentsToBeReceivedFourYears" name="LesseeOperatingSubLeasePaymentsToBeReceivedFourYears" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="urgn_LesseeOperatingSubLeasePaymentsToBeReceivedFourYearsAndThereafter" name="LesseeOperatingSubLeasePaymentsToBeReceivedFourYearsAndThereafter" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="urgn_LesseeOperatingSubLeasePaymentsToBeReceived" name="LesseeOperatingSubLeasePaymentsToBeReceived" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="urgn_LesseeOperatingSubLeaseIncomeFromFixedLeasePayments" name="LesseeOperatingSubLeaseIncomeFromFixedLeasePayments" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="urgn_LesseeOperatingSubLeaseIncomeFromVariablePayments" name="LesseeOperatingSubLeaseIncomeFromVariablePayments" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="urgn_ContractWithCustomerAdditionalMilestonePaymentEligibleToReceive" name="ContractWithCustomerAdditionalMilestonePaymentEligibleToReceive" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="urgn_MilestonePaymentsReceivedForLicensingAgreement" name="MilestonePaymentsReceivedForLicensingAgreement" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="urgn_AllerganPharmaceuticalsInternationalLimitedAndAbbVieIncMember" name="AllerganPharmaceuticalsInternationalLimitedAndAbbVieIncMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="urgn_LicenseAgreementMember" name="LicenseAgreementMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="urgn_AfterFirstCommercialSaleOfLicensedProductMember" name="AfterFirstCommercialSaleOfLicensedProductMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="urgn_MDAndersonMember" name="MDAndersonMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="urgn_UpfrontFee" name="UpfrontFee" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="urgn_MaximumAmountPayableUponAchievingCertainClinicalDevelopmentAndRegulatoryMilestones" name="MaximumAmountPayableUponAchievingCertainClinicalDevelopmentAndRegulatoryMilestones" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="urgn_MaximumAmountPayableUponAchievingCertainCommercialMilestones" name="MaximumAmountPayableUponAchievingCertainCommercialMilestones" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="urgn_RoyaltyRangingOnNetSalesOfLicensedProducts" name="RoyaltyRangingOnNetSalesOfLicensedProducts" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="urgn_LicenseAgreementExpirationTerm" name="LicenseAgreementExpirationTerm" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="urgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardIndividualVotingPowersPercentage" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardIndividualVotingPowersPercentage" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="urgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfPurchasePriceForIndividualsHavingMoreThanTenPercentOfCombinedVotingPower" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfPurchasePriceForIndividualsHavingMoreThanTenPercentOfCombinedVotingPower" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="urgn_PlanMember" name="PlanMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="urgn_TwoThousandSeventeenEquityIncentivePlanMember" name="TwoThousandSeventeenEquityIncentivePlanMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="urgn_TwoThousandAndNineteenInducementPlanMember" name="TwoThousandAndNineteenInducementPlanMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="urgn_ShareBasedGoodsAndNonEmployeeServicesTransactionSharesReserveIncreaseForIssuance" name="ShareBasedGoodsAndNonEmployeeServicesTransactionSharesReserveIncreaseForIssuance" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="urgn_MaximumPercentageOfCommitmentToContinueEmploymentOfResearchAndDevelopmentJobs" name="MaximumPercentageOfCommitmentToContinueEmploymentOfResearchAndDevelopmentJobs" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="urgn_MaximumTermForCommitmentToContinueEmploymentOfResearchAndDevelopmentJobs" name="MaximumTermForCommitmentToContinueEmploymentOfResearchAndDevelopmentJobs" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="urgn_CommitmentsAndContingentLiabilitiesLineItems" name="CommitmentsAndContingentLiabilitiesLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="urgn_CommitmentsAndContingentLiabilitiesTable" name="CommitmentsAndContingentLiabilitiesTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="urgn_IsraelInnovationAuthorityMember" name="IsraelInnovationAuthorityMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="urgn_UpfrontCashPaymentReceivedNetOfCosts" name="UpfrontCashPaymentReceivedNetOfCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="urgn_RTWInvestmentsMember" name="RTWInvestmentsMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>13
<FILENAME>urgn-20210331_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN ActiveDisclosure(SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2021-05-12T21:01:28.4366810+00:00 -->
<!-- Version            : 5.0.1.615 -->
<!-- Package ID         : 66acac3df2bb4a8e915da518ecfedb52 -->
<!-- Copyright (c) 2021 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef xlink:type="simple" xlink:href="urgn-20210331.xsd#TemplateLink" roleURI="http://www.urogen.com/20210331/role/TemplateLink" />
  <link:roleRef roleURI="http://www.urogen.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" xlink:href="urgn-20210331.xsd#Role_StatementCondensedConsolidatedBalanceSheetsUnaudited" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.urogen.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNet" xlink:type="locator" xlink:label="us-gaap_InventoryNet" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:type="locator" xlink:label="us-gaap_AccountsReceivableNetCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashCurrent" xlink:type="locator" xlink:label="us-gaap_RestrictedCashCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:type="locator" xlink:label="us-gaap_OtherAssetsNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedInvestmentsNoncurrent" xlink:type="locator" xlink:label="us-gaap_RestrictedInvestmentsNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent" xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets" xlink:type="locator" xlink:label="us-gaap_Assets" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_OtherLiabilitiesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilityForUncertainTaxPositionsNoncurrent" xlink:type="locator" xlink:label="us-gaap_LiabilityForUncertainTaxPositionsNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue" xlink:type="locator" xlink:label="us-gaap_CommonStockValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities" xlink:type="locator" xlink:label="us-gaap_Liabilities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_CommitmentsAndContingencies" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_CommonStockValue" order="10040.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" order="10050.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="10060.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="10070.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LiabilitiesCurrent" order="10080.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="10090.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LiabilityForUncertainTaxPositionsNoncurrent" order="10100.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" order="10110.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" order="10120.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_OtherLiabilitiesCurrent" order="10130.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent" order="10140.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="10150.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_RestrictedInvestmentsNoncurrent" order="10160.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="10170.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" order="10180.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OtherAssetsNoncurrent" order="10190.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="10200.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" order="10210.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_RestrictedCashCurrent" order="10220.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent" order="10230.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_InventoryNet" order="10240.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="10250.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.urogen.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited" xlink:href="urgn-20210331.xsd#Role_StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.urogen.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfRevenue" xlink:type="locator" xlink:label="us-gaap_CostOfRevenue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="locator" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GrossProfit" xlink:type="locator" xlink:label="us-gaap_GrossProfit" />
    <link:loc xlink:href="urgn-20210331.xsd#urgn_InterestAndOtherIncomeExpensesNet" xlink:type="locator" xlink:label="urgn_InterestAndOtherIncomeExpensesNet" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_NetIncomeLoss" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="urgn_InterestAndOtherIncomeExpensesNet" order="10040.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_GrossProfit" order="10050.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="10060.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense" order="10070.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_GrossProfit" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="10080.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_GrossProfit" xlink:to="us-gaap_CostOfRevenue" order="10090.00" priority="2" use="optional" weight="-1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.urogen.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowUnaudited" xlink:href="urgn-20210331.xsd#Role_StatementCondensedConsolidatedStatementsOfCashFlowUnaudited" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.urogen.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowUnaudited">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInInventories" />
    <link:loc xlink:href="urgn-20210331.xsd#urgn_OperatingLeaseLiabilityAdjustments" xlink:type="locator" xlink:label="urgn_OperatingLeaseLiabilityAdjustments" />
    <link:loc xlink:href="urgn-20210331.xsd#urgn_OperatingLeaseRightOfUseAssetAmortization" xlink:type="locator" xlink:label="urgn_OperatingLeaseRightOfUseAssetAmortization" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:type="locator" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationAndAmortization" xlink:type="locator" xlink:label="us-gaap_DepreciationAndAmortization" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:type="locator" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:type="locator" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="10040.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" order="10050.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquireMarketableSecurities" order="10060.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" order="10070.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="10080.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetIncomeLoss" order="10090.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_DepreciationAndAmortization" order="10100.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" order="10110.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ShareBasedCompensation" order="10120.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="urgn_OperatingLeaseRightOfUseAssetAmortization" order="10130.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="urgn_OperatingLeaseLiabilityAdjustments" order="10140.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInInventories" order="10150.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable" order="10160.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="10170.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" order="10180.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" order="10190.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.urogen.com/20210331/taxonomy/role/DisclosureOtherFinancialInformationScheduleOfAccountsPayableAndAccruedExpensesDetails" xlink:href="urgn-20210331.xsd#Role_DisclosureOtherFinancialInformationScheduleOfAccountsPayableAndAccruedExpensesDetails" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.urogen.com/20210331/taxonomy/role/DisclosureOtherFinancialInformationScheduleOfAccountsPayableAndAccruedExpensesDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" />
    <link:loc xlink:href="urgn-20210331.xsd#urgn_AccruedSellingGeneralAndAdministrativeExpenseCurrent" xlink:type="locator" xlink:label="urgn_AccruedSellingGeneralAndAdministrativeExpenseCurrent" />
    <link:loc xlink:href="urgn-20210331.xsd#urgn_AccruedResearchAndDevelopmentExpenseCurrent" xlink:type="locator" xlink:label="urgn_AccruedResearchAndDevelopmentExpenseCurrent" />
    <link:loc xlink:href="urgn-20210331.xsd#urgn_AccruedClinicalExpensesCurrent" xlink:type="locator" xlink:label="urgn_AccruedClinicalExpensesCurrent" />
    <link:loc xlink:href="urgn-20210331.xsd#urgn_AccruedSalesReserves" xlink:type="locator" xlink:label="urgn_AccruedSalesReserves" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableCurrent" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="urgn_AccruedSalesReserves" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="urgn_AccruedClinicalExpensesCurrent" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="urgn_AccruedResearchAndDevelopmentExpenseCurrent" order="10040.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="urgn_AccruedSellingGeneralAndAdministrativeExpenseCurrent" order="10050.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="10060.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.urogen.com/20210331/taxonomy/role/DisclosureOtherFinancialInformationScheduleOfInterestAndOtherIncomeExpensesDetails" xlink:href="urgn-20210331.xsd#Role_DisclosureOtherFinancialInformationScheduleOfInterestAndOtherIncomeExpensesDetails" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.urogen.com/20210331/taxonomy/role/DisclosureOtherFinancialInformationScheduleOfInterestAndOtherIncomeExpensesDetails">
    <link:loc xlink:href="urgn-20210331.xsd#urgn_OtherFinanceExpensesIncome" xlink:type="locator" xlink:label="urgn_OtherFinanceExpensesIncome" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:type="locator" xlink:label="us-gaap_InvestmentIncomeInterest" />
    <link:loc xlink:href="urgn-20210331.xsd#urgn_FinanceIncomeExpenseNet" xlink:type="locator" xlink:label="urgn_FinanceIncomeExpenseNet" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="urgn_FinanceIncomeExpenseNet" xlink:to="us-gaap_InvestmentIncomeInterest" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="urgn_FinanceIncomeExpenseNet" xlink:to="urgn_OtherFinanceExpensesIncome" order="10020.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.urogen.com/20210331/taxonomy/role/DisclosureInventoriesScheduleOfInventoriesDetails" xlink:href="urgn-20210331.xsd#Role_DisclosureInventoriesScheduleOfInventoriesDetails" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.urogen.com/20210331/taxonomy/role/DisclosureInventoriesScheduleOfInventoriesDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryFinishedGoods" xlink:type="locator" xlink:label="us-gaap_InventoryFinishedGoods" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryRawMaterials" xlink:type="locator" xlink:label="us-gaap_InventoryRawMaterials" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNet" xlink:type="locator" xlink:label="us-gaap_InventoryNet" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryRawMaterials" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryFinishedGoods" order="10020.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.urogen.com/20210331/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfMarketableSecuritiesDetails" xlink:href="urgn-20210331.xsd#Role_DisclosureMarketableSecuritiesSummaryOfMarketableSecuritiesDetails" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.urogen.com/20210331/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfMarketableSecuritiesDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" order="10010.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" order="10030.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.urogen.com/20210331/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfFairValuesOfMarketableSecuritiesByContractualMaturityDetails" xlink:href="urgn-20210331.xsd#Role_DisclosureMarketableSecuritiesSummaryOfFairValuesOfMarketableSecuritiesByContractualMaturityDetails" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.urogen.com/20210331/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfFairValuesOfMarketableSecuritiesByContractualMaturityDetails">
    <link:loc xlink:href="urgn-20210331.xsd#urgn_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughThreeYearsFairValue" xlink:type="locator" xlink:label="urgn_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughThreeYearsFairValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="urgn_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughThreeYearsFairValue" order="10020.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.urogen.com/20210331/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails" xlink:href="urgn-20210331.xsd#Role_DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.urogen.com/20210331/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="10020.00" priority="2" use="optional" weight="-1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.urogen.com/20210331/taxonomy/role/DisclosureLeasesComponentsOfLeaseCostDetails" xlink:href="urgn-20210331.xsd#Role_DisclosureLeasesComponentsOfLeaseCostDetails" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.urogen.com/20210331/taxonomy/role/DisclosureLeasesComponentsOfLeaseCostDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableLeaseCost" xlink:type="locator" xlink:label="us-gaap_VariableLeaseCost" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubleaseIncome" xlink:type="locator" xlink:label="us-gaap_SubleaseIncome" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseCost" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseCost" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseCost" xlink:type="locator" xlink:label="us-gaap_LeaseCost" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_OperatingLeaseCost" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_SubleaseIncome" order="10020.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_VariableLeaseCost" order="10030.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.urogen.com/20210331/taxonomy/role/DisclosureLeasesScheduleOfUndiscountedCashFlowsToBeReceivedUnderOperatingSubleaseOnAnnualBasisDetails" xlink:href="urgn-20210331.xsd#Role_DisclosureLeasesScheduleOfUndiscountedCashFlowsToBeReceivedUnderOperatingSubleaseOnAnnualBasisDetails" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.urogen.com/20210331/taxonomy/role/DisclosureLeasesScheduleOfUndiscountedCashFlowsToBeReceivedUnderOperatingSubleaseOnAnnualBasisDetails">
    <link:loc xlink:href="urgn-20210331.xsd#urgn_LesseeOperatingSubLeasePaymentsToBeReceivedFourYearsAndThereafter" xlink:type="locator" xlink:label="urgn_LesseeOperatingSubLeasePaymentsToBeReceivedFourYearsAndThereafter" />
    <link:loc xlink:href="urgn-20210331.xsd#urgn_LesseeOperatingSubLeasePaymentsToBeReceivedFourYears" xlink:type="locator" xlink:label="urgn_LesseeOperatingSubLeasePaymentsToBeReceivedFourYears" />
    <link:loc xlink:href="urgn-20210331.xsd#urgn_LesseeOperatingSubLeasePaymentsToBeReceivedThreeYears" xlink:type="locator" xlink:label="urgn_LesseeOperatingSubLeasePaymentsToBeReceivedThreeYears" />
    <link:loc xlink:href="urgn-20210331.xsd#urgn_LesseeOperatingSubLeasePaymentsToBeReceivedTwoYears" xlink:type="locator" xlink:label="urgn_LesseeOperatingSubLeasePaymentsToBeReceivedTwoYears" />
    <link:loc xlink:href="urgn-20210331.xsd#urgn_LesseeOperatingSubLeasePaymentsToBeReceivedNextTwelveMonths" xlink:type="locator" xlink:label="urgn_LesseeOperatingSubLeasePaymentsToBeReceivedNextTwelveMonths" />
    <link:loc xlink:href="urgn-20210331.xsd#urgn_LesseeOperatingSubLeasePaymentsToBeReceivedRemainderOfFiscalYear" xlink:type="locator" xlink:label="urgn_LesseeOperatingSubLeasePaymentsToBeReceivedRemainderOfFiscalYear" />
    <link:loc xlink:href="urgn-20210331.xsd#urgn_LesseeOperatingSubLeasePaymentsToBeReceived" xlink:type="locator" xlink:label="urgn_LesseeOperatingSubLeasePaymentsToBeReceived" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="urgn_LesseeOperatingSubLeasePaymentsToBeReceived" xlink:to="urgn_LesseeOperatingSubLeasePaymentsToBeReceivedRemainderOfFiscalYear" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="urgn_LesseeOperatingSubLeasePaymentsToBeReceived" xlink:to="urgn_LesseeOperatingSubLeasePaymentsToBeReceivedNextTwelveMonths" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="urgn_LesseeOperatingSubLeasePaymentsToBeReceived" xlink:to="urgn_LesseeOperatingSubLeasePaymentsToBeReceivedTwoYears" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="urgn_LesseeOperatingSubLeasePaymentsToBeReceived" xlink:to="urgn_LesseeOperatingSubLeasePaymentsToBeReceivedThreeYears" order="10040.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="urgn_LesseeOperatingSubLeasePaymentsToBeReceived" xlink:to="urgn_LesseeOperatingSubLeasePaymentsToBeReceivedFourYears" order="10050.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="urgn_LesseeOperatingSubLeasePaymentsToBeReceived" xlink:to="urgn_LesseeOperatingSubLeasePaymentsToBeReceivedFourYearsAndThereafter" order="10060.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.urogen.com/20210331/taxonomy/role/DisclosureLeasesScheduleOfSubleaseIncomeRecognizedNetWithinOperatingExpensesDetails" xlink:href="urgn-20210331.xsd#Role_DisclosureLeasesScheduleOfSubleaseIncomeRecognizedNetWithinOperatingExpensesDetails" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.urogen.com/20210331/taxonomy/role/DisclosureLeasesScheduleOfSubleaseIncomeRecognizedNetWithinOperatingExpensesDetails">
    <link:loc xlink:href="urgn-20210331.xsd#urgn_LesseeOperatingSubLeaseIncomeFromVariablePayments" xlink:type="locator" xlink:label="urgn_LesseeOperatingSubLeaseIncomeFromVariablePayments" />
    <link:loc xlink:href="urgn-20210331.xsd#urgn_LesseeOperatingSubLeaseIncomeFromFixedLeasePayments" xlink:type="locator" xlink:label="urgn_LesseeOperatingSubLeaseIncomeFromFixedLeasePayments" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubleaseIncome" xlink:type="locator" xlink:label="us-gaap_SubleaseIncome" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_SubleaseIncome" xlink:to="urgn_LesseeOperatingSubLeaseIncomeFromFixedLeasePayments" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_SubleaseIncome" xlink:to="urgn_LesseeOperatingSubLeaseIncomeFromVariablePayments" order="10020.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>14
<FILENAME>urgn-20210331_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN ActiveDisclosure(SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2021-05-12T21:01:28.4366810+00:00 -->
<!-- Version            : 5.0.1.615 -->
<!-- Package ID         : 66acac3df2bb4a8e915da518ecfedb52 -->
<!-- Copyright (c) 2021 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" />
  <link:roleRef xlink:type="simple" xlink:href="urgn-20210331.xsd#TemplateLink" roleURI="http://www.urogen.com/20210331/role/TemplateLink" />
  <link:roleRef roleURI="http://www.urogen.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfShareholdersEquityUnaudited" xlink:href="urgn-20210331.xsd#Role_StatementCondensedConsolidatedStatementsOfShareholdersEquityUnaudited" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.urogen.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfShareholdersEquityUnaudited">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssued" xlink:type="locator" xlink:label="us-gaap_SharesIssued" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="10200.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesIssued" order="10220.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" order="10340.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="10360.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" order="10480.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTax" order="10620.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="10760.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.urogen.com/20210331/taxonomy/role/DisclosureSignificantAccountingPoliciesPropertyAndEquipmentUsefulLivesDetails" xlink:href="urgn-20210331.xsd#Role_DisclosureSignificantAccountingPoliciesPropertyAndEquipmentUsefulLivesDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.urogen.com/20210331/taxonomy/role/DisclosureSignificantAccountingPoliciesPropertyAndEquipmentUsefulLivesDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ManufacturingFacilityMember" xlink:type="locator" xlink:label="us-gaap_ManufacturingFacilityMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:type="locator" xlink:label="us-gaap_FurnitureAndFixturesMember" />
    <link:loc xlink:href="urgn-20210331.xsd#urgn_LaboratoryEquipmentMember" xlink:type="locator" xlink:label="urgn_LaboratoryEquipmentMember" />
    <link:loc xlink:href="urgn-20210331.xsd#urgn_ComputersAndSoftwareMember" xlink:type="locator" xlink:label="urgn_ComputersAndSoftwareMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="urgn_ComputersAndSoftwareMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="urgn_LaboratoryEquipmentMember" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ManufacturingFacilityMember" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="srt_RangeAxis" order="10160.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_2" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" order="10260.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.urogen.com/20210331/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" xlink:href="urgn-20210331.xsd#Role_DisclosureFairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.urogen.com/20210331/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel2Member" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel1Member" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:type="locator" xlink:label="us-gaap_MoneyMarketFundsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateBondSecuritiesMember" xlink:type="locator" xlink:label="us-gaap_CorporateBondSecuritiesMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:type="locator" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="locator" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="locator" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:type="locator" xlink:label="us-gaap_FinancialInstrumentAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTable" xlink:type="locator" xlink:label="us-gaap_FairValueByBalanceSheetGroupingTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:type="locator" xlink:label="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_FairValueByBalanceSheetGroupingTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_FinancialInstrumentAxis" order="10100.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CorporateBondSecuritiesMember" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_MoneyMarketFundsMember" order="10190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="10200.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2" order="10210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="10230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" order="10250.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" order="10270.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" order="10540.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.urogen.com/20210331/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfMarketableSecuritiesDetails" xlink:href="urgn-20210331.xsd#Role_DisclosureMarketableSecuritiesSummaryOfMarketableSecuritiesDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.urogen.com/20210331/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfMarketableSecuritiesDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesAbstract" xlink:type="locator" xlink:label="us-gaap_MarketableSecuritiesAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:type="locator" xlink:label="us-gaap_MoneyMarketFundsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:type="locator" xlink:label="us-gaap_CorporateDebtSecuritiesMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USTreasuryAndGovernmentMember" xlink:type="locator" xlink:label="us-gaap_USTreasuryAndGovernmentMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:type="locator" xlink:label="us-gaap_InvestmentTypeCategorizationMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:type="locator" xlink:label="us-gaap_InvestmentTypeCategorizationMember_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:type="locator" xlink:label="us-gaap_InvestmentTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesTable" xlink:type="locator" xlink:label="us-gaap_MarketableSecuritiesTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesLineItems" xlink:type="locator" xlink:label="us-gaap_MarketableSecuritiesLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_MarketableSecuritiesLineItems" xlink:to="us-gaap_MarketableSecuritiesTable" order="10040.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_MarketableSecuritiesTable" xlink:to="us-gaap_InvestmentTypeAxis" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember_2" order="10080.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember" order="10100.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_USTreasuryAndGovernmentMember" order="10120.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_CorporateDebtSecuritiesMember" order="10140.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_MoneyMarketFundsMember" order="10160.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MarketableSecuritiesLineItems" xlink:to="us-gaap_MarketableSecuritiesAbstract" order="10190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MarketableSecuritiesAbstract" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" order="10430.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MarketableSecuritiesAbstract" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" order="10550.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MarketableSecuritiesAbstract" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" order="10670.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MarketableSecuritiesAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" order="10790.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.urogen.com/20210331/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails" xlink:href="urgn-20210331.xsd#Role_DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.urogen.com/20210331/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ManufacturingFacilityMember" xlink:type="locator" xlink:label="us-gaap_ManufacturingFacilityMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:type="locator" xlink:label="us-gaap_LeaseholdImprovementsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:type="locator" xlink:label="us-gaap_FurnitureAndFixturesMember" />
    <link:loc xlink:href="urgn-20210331.xsd#urgn_ComputersAndSoftwareMember" xlink:type="locator" xlink:label="urgn_ComputersAndSoftwareMember" />
    <link:loc xlink:href="urgn-20210331.xsd#urgn_LaboratoryEquipmentMember" xlink:type="locator" xlink:label="urgn_LaboratoryEquipmentMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="10030.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="10060.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="urgn_LaboratoryEquipmentMember" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="urgn_ComputersAndSoftwareMember" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ManufacturingFacilityMember" order="10190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="10220.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="10460.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="10500.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.urogen.com/20210331/taxonomy/role/DisclosureLeasesAdditionalInformationDetails" xlink:href="urgn-20210331.xsd#Role_DisclosureLeasesAdditionalInformationDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.urogen.com/20210331/taxonomy/role/DisclosureLeasesAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseImpairmentLoss" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseImpairmentLoss" />
    <link:loc xlink:href="urgn-20210331.xsd#urgn_LeaseExpirationYear" xlink:type="locator" xlink:label="urgn_LeaseExpirationYear" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubleaseIncome" xlink:type="locator" xlink:label="us-gaap_SubleaseIncome" />
    <link:loc xlink:href="urgn-20210331.xsd#urgn_LesseeOperatingSubleaseTerminationDateMonthAndYear" xlink:type="locator" xlink:label="urgn_LesseeOperatingSubleaseTerminationDateMonthAndYear" />
    <link:loc xlink:href="urgn-20210331.xsd#urgn_LesseeOperatingSubleaseCommencementDate" xlink:type="locator" xlink:label="urgn_LesseeOperatingSubleaseCommencementDate" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractualObligation" xlink:type="locator" xlink:label="us-gaap_ContractualObligation" />
    <link:loc xlink:href="urgn-20210331.xsd#urgn_ProceedsFromTenantAllowance" xlink:type="locator" xlink:label="urgn_ProceedsFromTenantAllowance" />
    <link:loc xlink:href="urgn-20210331.xsd#urgn_LeaseCommencementDate" xlink:type="locator" xlink:label="urgn_LeaseCommencementDate" />
    <link:loc xlink:href="urgn-20210331.xsd#urgn_LeaseTerminationDateMonthAndYear" xlink:type="locator" xlink:label="urgn_LeaseTerminationDateMonthAndYear" />
    <link:loc xlink:href="urgn-20210331.xsd#urgn_LeaseCommencementDateMonthAndYear" xlink:type="locator" xlink:label="urgn_LeaseCommencementDateMonthAndYear" />
    <link:loc xlink:href="urgn-20210331.xsd#urgn_LesseeOperatingLeaseExtendedLeaseExpirationDateMonthAndYear" xlink:type="locator" xlink:label="urgn_LesseeOperatingLeaseExtendedLeaseExpirationDateMonthAndYear" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseAgreementsMember" xlink:type="locator" xlink:label="us-gaap_LeaseAgreementsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" />
    <link:loc xlink:href="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd#stpr_NJ" xlink:type="locator" xlink:label="stpr_NJ" />
    <link:loc xlink:href="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd#stpr_CA" xlink:type="locator" xlink:label="stpr_CA" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SubsidiariesMember" xlink:type="locator" xlink:label="srt_SubsidiariesMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidatedEntitiesDomain" xlink:type="locator" xlink:label="srt_ConsolidatedEntitiesDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidatedEntitiesDomain" xlink:type="locator" xlink:label="srt_ConsolidatedEntitiesDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidatedEntitiesAxis" xlink:type="locator" xlink:label="srt_ConsolidatedEntitiesAxis" />
    <link:loc xlink:href="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd#stpr_NY" xlink:type="locator" xlink:label="stpr_NY" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain" xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain" xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis" xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:type="locator" xlink:label="us-gaap_LesseeLeaseDescriptionTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:type="locator" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeLeaseDescriptionTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="srt_StatementGeographicalAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="stpr_NY" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="srt_ConsolidatedEntitiesAxis" order="10100.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_ConsolidatedEntitiesAxis" xlink:to="srt_ConsolidatedEntitiesDomain_2" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ConsolidatedEntitiesAxis" xlink:to="srt_ConsolidatedEntitiesDomain" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ConsolidatedEntitiesDomain" xlink:to="srt_SubsidiariesMember" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="stpr_CA" order="10210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="stpr_NJ" order="10330.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" order="10400.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2" order="10410.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" order="10430.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_LeaseAgreementsMember" order="10450.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="srt_RangeAxis" order="10460.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10490.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10510.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10530.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" order="10560.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseOptionToExtend" order="10580.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm" order="10600.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="urgn_LesseeOperatingLeaseExtendedLeaseExpirationDateMonthAndYear" order="10620.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="urgn_LeaseCommencementDateMonthAndYear" order="10670.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="urgn_LeaseTerminationDateMonthAndYear" order="10690.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="urgn_LeaseCommencementDate" order="10740.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="urgn_ProceedsFromTenantAllowance" order="10820.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_ContractualObligation" order="10860.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="urgn_LesseeOperatingSubleaseCommencementDate" order="10900.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="urgn_LesseeOperatingSubleaseTerminationDateMonthAndYear" order="10940.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_SubleaseIncome" order="10980.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract" order="11070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="urgn_LeaseExpirationYear" order="11140.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseImpairmentLoss" order="11210.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.urogen.com/20210331/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails" xlink:href="urgn-20210331.xsd#Role_DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.urogen.com/20210331/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross" />
    <link:loc xlink:href="urgn-20210331.xsd#urgn_LicenseAgreementExpirationTerm" xlink:type="locator" xlink:label="urgn_LicenseAgreementExpirationTerm" />
    <link:loc xlink:href="urgn-20210331.xsd#urgn_RoyaltyRangingOnNetSalesOfLicensedProducts" xlink:type="locator" xlink:label="urgn_RoyaltyRangingOnNetSalesOfLicensedProducts" />
    <link:loc xlink:href="urgn-20210331.xsd#urgn_MaximumAmountPayableUponAchievingCertainCommercialMilestones" xlink:type="locator" xlink:label="urgn_MaximumAmountPayableUponAchievingCertainCommercialMilestones" />
    <link:loc xlink:href="urgn-20210331.xsd#urgn_MaximumAmountPayableUponAchievingCertainClinicalDevelopmentAndRegulatoryMilestones" xlink:type="locator" xlink:label="urgn_MaximumAmountPayableUponAchievingCertainClinicalDevelopmentAndRegulatoryMilestones" />
    <link:loc xlink:href="urgn-20210331.xsd#urgn_UpfrontFee" xlink:type="locator" xlink:label="urgn_UpfrontFee" />
    <link:loc xlink:href="urgn-20210331.xsd#urgn_MilestonePaymentsReceivedForLicensingAgreement" xlink:type="locator" xlink:label="urgn_MilestonePaymentsReceivedForLicensingAgreement" />
    <link:loc xlink:href="urgn-20210331.xsd#urgn_ContractWithCustomerAdditionalMilestonePaymentEligibleToReceive" xlink:type="locator" xlink:label="urgn_ContractWithCustomerAdditionalMilestonePaymentEligibleToReceive" />
    <link:loc xlink:href="urgn-20210331.xsd#urgn_MDAndersonMember" xlink:type="locator" xlink:label="urgn_MDAndersonMember" />
    <link:loc xlink:href="urgn-20210331.xsd#urgn_AfterFirstCommercialSaleOfLicensedProductMember" xlink:type="locator" xlink:label="urgn_AfterFirstCommercialSaleOfLicensedProductMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:type="locator" xlink:label="srt_ScenarioUnspecifiedDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:type="locator" xlink:label="srt_ScenarioUnspecifiedDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementScenarioAxis" xlink:type="locator" xlink:label="srt_StatementScenarioAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LicenseAgreementTermsMember" xlink:type="locator" xlink:label="us-gaap_LicenseAgreementTermsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="urgn-20210331.xsd#urgn_LicenseAgreementMember" xlink:type="locator" xlink:label="urgn_LicenseAgreementMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:loc xlink:href="urgn-20210331.xsd#urgn_AllerganPharmaceuticalsInternationalLimitedAndAbbVieIncMember" xlink:type="locator" xlink:label="urgn_AllerganPharmaceuticalsInternationalLimitedAndAbbVieIncMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis" xlink:type="locator" xlink:label="srt_CounterpartyNameAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="srt_CounterpartyNameAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="urgn_AllerganPharmaceuticalsInternationalLimitedAndAbbVieIncMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="10120.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_2" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="urgn_LicenseAgreementMember" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="srt_RangeAxis" order="10200.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10250.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10270.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" order="10360.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_2" order="10370.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" order="10390.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="us-gaap_LicenseAgreementTermsMember" order="10410.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="srt_StatementScenarioAxis" order="10560.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain_2" order="10570.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" order="10590.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="urgn_AfterFirstCommercialSaleOfLicensedProductMember" order="10610.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="urgn_MDAndersonMember" order="10670.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="urgn_ContractWithCustomerAdditionalMilestonePaymentEligibleToReceive" order="10700.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="urgn_MilestonePaymentsReceivedForLicensingAgreement" order="10720.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="urgn_UpfrontFee" order="10770.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="urgn_MaximumAmountPayableUponAchievingCertainClinicalDevelopmentAndRegulatoryMilestones" order="10790.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="urgn_MaximumAmountPayableUponAchievingCertainCommercialMilestones" order="10810.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="urgn_RoyaltyRangingOnNetSalesOfLicensedProducts" order="10830.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="urgn_LicenseAgreementExpirationTerm" order="10900.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross" order="10950.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.urogen.com/20210331/taxonomy/role/DisclosureShareBasedCompensationAdditionalInformationDetails" xlink:href="urgn-20210331.xsd#Role_DisclosureShareBasedCompensationAdditionalInformationDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.urogen.com/20210331/taxonomy/role/DisclosureShareBasedCompensationAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
    <link:loc xlink:href="urgn-20210331.xsd#urgn_ShareBasedGoodsAndNonEmployeeServicesTransactionSharesReserveIncreaseForIssuance" xlink:type="locator" xlink:label="urgn_ShareBasedGoodsAndNonEmployeeServicesTransactionSharesReserveIncreaseForIssuance" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSharesApprovedForIssuance" xlink:type="locator" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSharesApprovedForIssuance" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" />
    <link:loc xlink:href="urgn-20210331.xsd#urgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfPurchasePriceForIndividualsHavingMoreThanTenPercentOfCombinedVotingPower" xlink:type="locator" xlink:label="urgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfPurchasePriceForIndividualsHavingMoreThanTenPercentOfCombinedVotingPower" />
    <link:loc xlink:href="urgn-20210331.xsd#urgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardIndividualVotingPowersPercentage" xlink:type="locator" xlink:label="urgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardIndividualVotingPowersPercentage" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
    <link:loc xlink:href="urgn-20210331.xsd#urgn_TwoThousandAndNineteenInducementPlanMember" xlink:type="locator" xlink:label="urgn_TwoThousandAndNineteenInducementPlanMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:type="locator" xlink:label="us-gaap_PlanNameDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <link:loc xlink:href="urgn-20210331.xsd#urgn_TwoThousandSeventeenEquityIncentivePlanMember" xlink:type="locator" xlink:label="urgn_TwoThousandSeventeenEquityIncentivePlanMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VestingDomain" xlink:type="locator" xlink:label="us-gaap_VestingDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VestingDomain" xlink:type="locator" xlink:label="us-gaap_VestingDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VestingAxis" xlink:type="locator" xlink:label="us-gaap_VestingAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:type="locator" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" />
    <link:loc xlink:href="urgn-20210331.xsd#urgn_PlanMember" xlink:type="locator" xlink:label="urgn_PlanMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10140.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="urgn_PlanMember" order="10190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="10280.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2" order="10290.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="10310.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="10330.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="10470.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_VestingAxis" order="10520.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain_2" order="10530.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain" order="10550.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember" order="10570.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="urgn_TwoThousandSeventeenEquityIncentivePlanMember" order="10650.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="10830.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="10920.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain_2" order="10930.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="10950.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="urgn_TwoThousandAndNineteenInducementPlanMember" order="10970.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" order="11000.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" order="11020.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" order="11040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="urgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardIndividualVotingPowersPercentage" order="11060.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="urgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfPurchasePriceForIndividualsHavingMoreThanTenPercentOfCombinedVotingPower" order="11080.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" order="11130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSharesApprovedForIssuance" order="11220.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" order="11260.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="urgn_ShareBasedGoodsAndNonEmployeeServicesTransactionSharesReserveIncreaseForIssuance" order="11340.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" order="11570.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" order="11620.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" order="11640.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.urogen.com/20210331/taxonomy/role/DisclosureShareBasedCompensationScheduleOfEffectOfShareBasedCompensationOnCondensedConsolidatedStatementsOfOperationsDetails" xlink:href="urgn-20210331.xsd#Role_DisclosureShareBasedCompensationScheduleOfEffectOfShareBasedCompensationOnCondensedConsolidatedStatementsOfOperationsDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.urogen.com/20210331/taxonomy/role/DisclosureShareBasedCompensationScheduleOfEffectOfShareBasedCompensationOnCondensedConsolidatedStatementsOfOperationsDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:type="locator" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesMember" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="10140.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.urogen.com/20210331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" xlink:href="urgn-20210331.xsd#Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.urogen.com/20210331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeveranceCosts1" xlink:type="locator" xlink:label="us-gaap_SeveranceCosts1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedBonusesCurrentAndNoncurrent" xlink:type="locator" xlink:label="us-gaap_AccruedBonusesCurrentAndNoncurrent" />
    <link:loc xlink:href="urgn-20210331.xsd#urgn_MaximumTermForCommitmentToContinueEmploymentOfResearchAndDevelopmentJobs" xlink:type="locator" xlink:label="urgn_MaximumTermForCommitmentToContinueEmploymentOfResearchAndDevelopmentJobs" />
    <link:loc xlink:href="urgn-20210331.xsd#urgn_MaximumPercentageOfCommitmentToContinueEmploymentOfResearchAndDevelopmentJobs" xlink:type="locator" xlink:label="urgn_MaximumPercentageOfCommitmentToContinueEmploymentOfResearchAndDevelopmentJobs" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedRoyaltiesCurrentAndNoncurrent" xlink:type="locator" xlink:label="us-gaap_AccruedRoyaltiesCurrentAndNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ChiefFinancialOfficerMember" xlink:type="locator" xlink:label="srt_ChiefFinancialOfficerMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ChiefOperatingOfficerMember" xlink:type="locator" xlink:label="srt_ChiefOperatingOfficerMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualAxis" xlink:type="locator" xlink:label="srt_TitleOfIndividualAxis" />
    <link:loc xlink:href="urgn-20210331.xsd#urgn_IsraelInnovationAuthorityMember" xlink:type="locator" xlink:label="urgn_IsraelInnovationAuthorityMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" />
    <link:loc xlink:href="urgn-20210331.xsd#urgn_CommitmentsAndContingentLiabilitiesTable" xlink:type="locator" xlink:label="urgn_CommitmentsAndContingentLiabilitiesTable" />
    <link:loc xlink:href="urgn-20210331.xsd#urgn_CommitmentsAndContingentLiabilitiesLineItems" xlink:type="locator" xlink:label="urgn_CommitmentsAndContingentLiabilitiesLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="urgn_CommitmentsAndContingentLiabilitiesLineItems" xlink:to="urgn_CommitmentsAndContingentLiabilitiesTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="urgn_CommitmentsAndContingentLiabilitiesTable" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="urgn_IsraelInnovationAuthorityMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="urgn_CommitmentsAndContingentLiabilitiesTable" xlink:to="srt_TitleOfIndividualAxis" order="10100.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_2" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_ChiefOperatingOfficerMember" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_ChiefFinancialOfficerMember" order="10210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="urgn_CommitmentsAndContingentLiabilitiesLineItems" xlink:to="us-gaap_AccruedRoyaltiesCurrentAndNoncurrent" order="10240.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="urgn_CommitmentsAndContingentLiabilitiesLineItems" xlink:to="urgn_MaximumPercentageOfCommitmentToContinueEmploymentOfResearchAndDevelopmentJobs" order="10260.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="urgn_CommitmentsAndContingentLiabilitiesLineItems" xlink:to="urgn_MaximumTermForCommitmentToContinueEmploymentOfResearchAndDevelopmentJobs" order="10280.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="urgn_CommitmentsAndContingentLiabilitiesLineItems" xlink:to="us-gaap_AccruedBonusesCurrentAndNoncurrent" order="10330.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="urgn_CommitmentsAndContingentLiabilitiesLineItems" xlink:to="us-gaap_SeveranceCosts1" order="10380.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.urogen.com/20210331/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" xlink:href="urgn-20210331.xsd#Role_DisclosureSubsequentEventsAdditionalInformationDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.urogen.com/20210331/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails">
    <link:loc xlink:href="urgn-20210331.xsd#urgn_UpfrontCashPaymentReceivedNetOfCosts" xlink:type="locator" xlink:label="urgn_UpfrontCashPaymentReceivedNetOfCosts" />
    <link:loc xlink:href="urgn-20210331.xsd#urgn_UpfrontFee" xlink:type="locator" xlink:label="urgn_UpfrontFee" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember" xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" />
    <link:loc xlink:href="urgn-20210331.xsd#urgn_RTWInvestmentsMember" xlink:type="locator" xlink:label="urgn_RTWInvestmentsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTable" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:type="locator" xlink:label="us-gaap_SubsequentEventLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="urgn_RTWInvestmentsMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="10120.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain_2" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="urgn_UpfrontFee" order="10200.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="urgn_UpfrontCashPaymentReceivedNetOfCosts" order="10220.00" priority="2" use="optional" />
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>15
<FILENAME>urgn-20210331_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN ActiveDisclosure(SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2021-05-12T21:01:28.4376810+00:00 -->
<!-- Version            : 5.0.1.615 -->
<!-- Package ID         : 66acac3df2bb4a8e915da518ecfedb52 -->
<!-- Copyright (c) 2021 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://fasb.org/us-gaap/role/label/axisDefault" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd#axisDefault" xlink:type="simple" />
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Document Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:type="locator" xlink:label="dei_DocumentFiscalYearFocus" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Fiscal Year Focus</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Year Focus</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:type="locator" xlink:label="dei_DocumentFiscalPeriodFocus" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Fiscal Period Focus</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Period Focus</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Title of 12(b) Security</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security12b Title</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security Exchange Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:type="locator" xlink:label="dei_CurrentFiscalYearEndDate" />
    <link:label xml:lang="en-US" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current Fiscal Year End Date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Current Fiscal Year End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory" xlink:type="locator" xlink:label="dei_EntityFilerCategory" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFilerCategory_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Filer Category</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFilerCategory_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Filer Category</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitySmallBusiness" xlink:type="locator" xlink:label="dei_EntitySmallBusiness" />
    <link:label xml:lang="en-US" xlink:label="dei_EntitySmallBusiness_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Small Business</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntitySmallBusiness_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Small Business</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:type="locator" xlink:label="dei_EntityCommonStockSharesOutstanding" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Common Stock, Ordinary Shares Outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Common Stock Shares Outstanding</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany" xlink:type="locator" xlink:label="dei_EntityShellCompany" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityShellCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Shell Company</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityShellCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Shell Company</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:type="locator" xlink:label="dei_EntityCurrentReportingStatus" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCurrentReportingStatus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Current Reporting Status</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCurrentReportingStatus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Current Reporting Status</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:type="locator" xlink:label="dei_EntityInteractiveDataCurrent" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Interactive Data Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Interactive Data Current</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentQuarterlyReport" xlink:type="locator" xlink:label="dei_DocumentQuarterlyReport" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentQuarterlyReport_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Quarterly Report</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentQuarterlyReport_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Quarterly Report</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentTransitionReport" xlink:type="locator" xlink:label="dei_DocumentTransitionReport" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentTransitionReport_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Transition Report</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentTransitionReport_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Transition Report</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation, State or Country Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation State Country Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line One</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address Address Line1</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, City or Town</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address City Or Town</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, State or Province</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address State Or Province</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Postal Zip Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address Postal Zip Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Of Financial Position [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Ordinary shares, par value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Par Or Stated Value Per Share</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Ordinary shares, shares authorized</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Shares Authorized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Ordinary shares, issued</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Shares Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Ordinary shares, outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Shares Outstanding</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract" xlink:type="locator" xlink:label="us-gaap_AssetsAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Assets [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:type="locator" xlink:label="us-gaap_AssetsCurrentAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current assets:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Assets Current [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and cash equivalents</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash And Cash Equivalents At Carrying Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Marketable securities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Available For Sale Securities Debt Securities Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashCurrent" xlink:type="locator" xlink:label="us-gaap_RestrictedCashCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RestrictedCashCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted cash</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashCurrent" xlink:to="us-gaap_RestrictedCashCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RestrictedCashCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Cash Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:type="locator" xlink:label="us-gaap_AccountsReceivableNetCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Accounts receivable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNetCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Receivable Net Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNet" xlink:type="locator" xlink:label="us-gaap_InventoryNet" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InventoryNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Inventory</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryNet_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InventoryNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Inventory Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid expenses and other current assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Expense And Other Assets Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent" xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Assets Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsNoncurrentAbstract" xlink:type="locator" xlink:label="us-gaap_AssetsNoncurrentAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsNoncurrentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-current assets:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_AssetsNoncurrentAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsNoncurrentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Assets Noncurrent [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment, net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedInvestmentsNoncurrent" xlink:type="locator" xlink:label="us-gaap_RestrictedInvestmentsNoncurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RestrictedInvestmentsNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted deposit</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedInvestmentsNoncurrent" xlink:to="us-gaap_RestrictedInvestmentsNoncurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RestrictedInvestmentsNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Investments Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Right of use asset</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Right Of Use Asset</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Marketable securities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Available For Sale Securities Debt Securities Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:type="locator" xlink:label="us-gaap_OtherAssetsNoncurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other non-current assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Assets Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets" xlink:type="locator" xlink:label="us-gaap_Assets" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_Assets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total Assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_Assets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Liabilities and Shareholders&apos; Equity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities And Stockholders Equity [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current liabilities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities Current [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable and accrued expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Payable And Accrued Liabilities Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employee related accrued expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Employee Related Liabilities Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_OtherLiabilitiesCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other current liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesCurrent" xlink:to="us-gaap_OtherLiabilitiesCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Liabilities Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current liabilities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:type="locator" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-current liabilities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_LiabilitiesNoncurrentAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities Noncurrent [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-term lease liability</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Liability Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilityForUncertainTaxPositionsNoncurrent" xlink:type="locator" xlink:label="us-gaap_LiabilityForUncertainTaxPositionsNoncurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilityForUncertainTaxPositionsNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Uncertain tax positions liability</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilityForUncertainTaxPositionsNoncurrent" xlink:to="us-gaap_LiabilityForUncertainTaxPositionsNoncurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilityForUncertainTaxPositionsNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liability For Uncertain Tax Positions Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities" xlink:type="locator" xlink:label="us-gaap_Liabilities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_Liabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total Liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_Liabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments and contingencies (Note 14)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Commitments And Contingencies</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shareholders&apos; equity:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders Equity [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue" xlink:type="locator" xlink:label="us-gaap_CommonStockValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Ordinary shares, NIS 0.01 par value; 100,000,000 shares authorized at March 31, 2021 and December 31, 2020; 22,280,394 and 22,167,791 shares issued and outstanding as of March 31, 2021 and December 31, 2020, respectively</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional paid-in capital</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid In Capital Common Stock</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated deficit</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings Accumulated Deficit</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated other comprehensive income</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accumulated Other Comprehensive Income Loss Net Of Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total Shareholders&apos; Equity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders Equity</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total Liabilities and Shareholders&apos; Equity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities And Stockholders Equity</link:label>
    <link:loc xlink:href="urgn-20210331.xsd#urgn_InterestAndOtherIncomeExpensesNet" xlink:type="locator" xlink:label="urgn_InterestAndOtherIncomeExpensesNet" />
    <link:label xml:lang="en-US" xlink:label="urgn_InterestAndOtherIncomeExpensesNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Interest and other Income (expenses) net.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="urgn_InterestAndOtherIncomeExpensesNet" xlink:to="urgn_InterestAndOtherIncomeExpensesNet_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeStatementAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenues</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Revenue From Contract With Customer Excluding Assessed Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfRevenue" xlink:type="locator" xlink:label="us-gaap_CostOfRevenue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CostOfRevenue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cost of revenues</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfRevenue" xlink:to="us-gaap_CostOfRevenue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CostOfRevenue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cost Of Revenue</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GrossProfit" xlink:type="locator" xlink:label="us-gaap_GrossProfit" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_GrossProfit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Gross profit</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GrossProfit" xlink:to="us-gaap_GrossProfit_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_GrossProfit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Gross Profit</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:type="locator" xlink:label="us-gaap_OperatingExpensesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating expenses:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="locator" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Selling, general and administrative expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Selling General And Administrative Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Operating loss</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Income Loss</link:label>
    <link:label xml:lang="en-US" xlink:label="urgn_InterestAndOtherIncomeExpensesNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest and other income, net</link:label>
    <link:label xml:lang="en-US" xlink:label="urgn_InterestAndOtherIncomeExpensesNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Interest And Other Income Expenses Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net Loss</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Income Loss</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statements of Comprehensive Loss</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTaxAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Comprehensive Income Net Of Tax [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other comprehensive income</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrealized (loss) gain on marketable securities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Comprehensive Loss</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Comprehensive Income Net Of Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss per ordinary share basic and diluted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share Basic And Diluted</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average number of shares outstanding used in computation of basic and diluted loss per ordinary share</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number Of Share Outstanding Basic And Diluted</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Of Stockholders Equity [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statement [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Components</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Equity Components [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EquityComponentDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Component</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EquityComponentDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Equity Component [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Ordinary Shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional Paid-In Capital</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid In Capital [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated Deficit</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other Comprehensive Income</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accumulated Other Comprehensive Income [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statement [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Balance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssued" xlink:type="locator" xlink:label="us-gaap_SharesIssued" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharesIssued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Balance,Share</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssued" xlink:to="us-gaap_SharesIssued_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharesIssued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Shares Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercise of options into ordinary shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Value Stock Options Exercised</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercise of options into ordinary shares, shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares Stock Options Exercised</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-based compensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other comprehensive income (loss)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTax_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Comprehensive Income Loss Net Of Tax</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Net loss</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Balance</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharesIssued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Balance,Share</link:label>
    <link:loc xlink:href="urgn-20210331.xsd#urgn_OperatingLeaseRightOfUseAssetAmortization" xlink:type="locator" xlink:label="urgn_OperatingLeaseRightOfUseAssetAmortization" />
    <link:label xml:lang="en-US" xlink:label="urgn_OperatingLeaseRightOfUseAssetAmortization_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating lease, right-of-use asset, amortization.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="urgn_OperatingLeaseRightOfUseAssetAmortization" xlink:to="urgn_OperatingLeaseRightOfUseAssetAmortization_lbl" />
    <link:loc xlink:href="urgn-20210331.xsd#urgn_OperatingLeaseLiabilityAdjustments" xlink:type="locator" xlink:label="urgn_OperatingLeaseLiabilityAdjustments" />
    <link:label xml:lang="en-US" xlink:label="urgn_OperatingLeaseLiabilityAdjustments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating lease liability, adjustments.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="urgn_OperatingLeaseLiabilityAdjustments" xlink:to="urgn_OperatingLeaseLiabilityAdjustments_lbl" />
    <link:loc xlink:href="urgn-20210331.xsd#urgn_NonCashNewLeaseLiabilities" xlink:type="locator" xlink:label="urgn_NonCashNewLeaseLiabilities" />
    <link:label xml:lang="en-US" xlink:label="urgn_NonCashNewLeaseLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Non-cash new lease liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="urgn_NonCashNewLeaseLiabilities" xlink:to="urgn_NonCashNewLeaseLiabilities_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Of Cash Flows [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash Flows From Operating Activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Operating Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Adjustment to reconcile net loss to net cash from operating activities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationAndAmortization" xlink:type="locator" xlink:label="us-gaap_DepreciationAndAmortization" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DepreciationAndAmortization_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Depreciation and amortization</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationAndAmortization" xlink:to="us-gaap_DepreciationAndAmortization_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DepreciationAndAmortization_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Depreciation And Amortization</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:type="locator" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Amortization on marketable securities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:to="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accretion Amortization Of Discounts And Premiums Investments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation</link:label>
    <link:label xml:lang="en-US" xlink:label="urgn_OperatingLeaseRightOfUseAssetAmortization_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amortization of right of use asset</link:label>
    <link:label xml:lang="en-US" xlink:label="urgn_OperatingLeaseRightOfUseAssetAmortization_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Right Of Use Asset Amortization</link:label>
    <link:label xml:lang="en-US" xlink:label="urgn_OperatingLeaseLiabilityAdjustments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Lease liability</link:label>
    <link:label xml:lang="en-US" xlink:label="urgn_OperatingLeaseLiabilityAdjustments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Liability Adjustments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Changes in operating assets and liabilities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Operating Capital [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInInventories" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInInventories_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Inventory</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInInventories" xlink:to="us-gaap_IncreaseDecreaseInInventories_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInInventories_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Inventories</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Accounts receivable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Accounts Receivable</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Prepaid expenses and other current assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Prepaid Deferred Expense And Other Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable and accrued expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Accounts Payable And Accrued Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employee related accrued expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Employee Related Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash used in operating activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Operating Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash Flows From Investing Activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Investing Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Purchase of marketable securities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireMarketableSecurities" xlink:to="us-gaap_PaymentsToAcquireMarketableSecurities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Payments To Acquire Marketable Securities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:type="locator" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maturities of marketable securities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Sale And Maturity Of Marketable Securities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Purchases of property and equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Payments To Acquire Property Plant And Equipment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash provided by investing activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Investing Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash Flows From Financing Activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Financing Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from exercise of options into ordinary shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Stock Options Exercised</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:type="locator" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Issuance cost related to at-the-market issuances</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Payments Of Stock Issuance Costs</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash provided by financing activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Financing Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Decrease in Cash and Cash Equivalents</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Cash, Cash Equivalents and Restricted Cash at Beginning of Period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Cash, Cash Equivalents and Restricted Cash at End of Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Supplemental Disclosures of Non-Cash Activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash Flow Noncash Investing And Financing Activities Disclosure [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:label="urgn_NonCashNewLeaseLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-cash new lease liabilities</link:label>
    <link:label xml:lang="en-US" xlink:label="urgn_NonCashNewLeaseLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Non Cash New Lease Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Organization Consolidation And Presentation Of Financial Statements [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NatureOfOperations" xlink:type="locator" xlink:label="us-gaap_NatureOfOperations" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NatureOfOperations_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Business and Nature of Operations</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NatureOfOperations" xlink:to="us-gaap_NatureOfOperations_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NatureOfOperations_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Nature Of Operations</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BasisOfAccounting" xlink:type="locator" xlink:label="us-gaap_BasisOfAccounting" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_BasisOfAccounting_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Basis of Presentation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccounting" xlink:to="us-gaap_BasisOfAccounting_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_BasisOfAccounting_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Basis Of Accounting</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Policies [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="locator" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Significant Accounting Policies</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:href="urgn-20210331.xsd#urgn_OtherFinancialInformationTextBlock" xlink:type="locator" xlink:label="urgn_OtherFinancialInformationTextBlock" />
    <link:label xml:lang="en-US" xlink:label="urgn_OtherFinancialInformationTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Other financial information.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="urgn_OtherFinancialInformationTextBlock" xlink:to="urgn_OtherFinancialInformationTextBlock_lbl" />
    <link:loc xlink:href="urgn-20210331.xsd#urgn_OtherFinancialInformationAbstract" xlink:type="locator" xlink:label="urgn_OtherFinancialInformationAbstract" />
    <link:label xml:lang="en-US" xlink:label="urgn_OtherFinancialInformationAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Other financial information.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="urgn_OtherFinancialInformationAbstract" xlink:to="urgn_OtherFinancialInformationAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="urgn_OtherFinancialInformationAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Financial Information [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:label="urgn_OtherFinancialInformationTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other Financial Information</link:label>
    <link:label xml:lang="en-US" xlink:label="urgn_OtherFinancialInformationTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Financial Information [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_InventoryDisclosureAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InventoryDisclosureAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Inventory Disclosure [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryDisclosureAbstract" xlink:to="us-gaap_InventoryDisclosureAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_InventoryDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InventoryDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Inventories</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryDisclosureTextBlock" xlink:to="us-gaap_InventoryDisclosureTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InventoryDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Inventory Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Disclosures [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Measurements</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:href="urgn-20210331.xsd#urgn_MarketableSecuritiesDisclosureTextBlock" xlink:type="locator" xlink:label="urgn_MarketableSecuritiesDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="urgn_MarketableSecuritiesDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Marketable securities.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="urgn_MarketableSecuritiesDisclosureTextBlock" xlink:to="urgn_MarketableSecuritiesDisclosureTextBlock_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:type="locator" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Investments Debt And Equity Securities [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="urgn_MarketableSecuritiesDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Marketable Securities</link:label>
    <link:label xml:lang="en-US" xlink:label="urgn_MarketableSecuritiesDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Marketable Securities Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and Equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract" xlink:type="locator" xlink:label="us-gaap_LeasesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LeasesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Leases [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeasesAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Leases</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Leases [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Revenue From Contract With Customer [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RevenueFromContractWithCustomerTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue from Product Sales</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:to="us-gaap_RevenueFromContractWithCustomerTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RevenueFromContractWithCustomerTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Revenue From Contract With Customer [Text Block]</link:label>
    <link:loc xlink:href="urgn-20210331.xsd#urgn_LicenseAndCollaborationAgreementsDisclosureTextBlock" xlink:type="locator" xlink:label="urgn_LicenseAndCollaborationAgreementsDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="urgn_LicenseAndCollaborationAgreementsDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">License and collaboration agreements.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="urgn_LicenseAndCollaborationAgreementsDisclosureTextBlock" xlink:to="urgn_LicenseAndCollaborationAgreementsDisclosureTextBlock_lbl" />
    <link:loc xlink:href="urgn-20210331.xsd#urgn_LiscenseAgreementAbstract" xlink:type="locator" xlink:label="urgn_LiscenseAgreementAbstract" />
    <link:label xml:lang="en-US" xlink:label="urgn_LiscenseAgreementAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">liscense agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="urgn_LiscenseAgreementAbstract" xlink:to="urgn_LiscenseAgreementAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="urgn_LiscenseAgreementAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liscense Agreement [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:label="urgn_LicenseAndCollaborationAgreementsDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">License and Collaboration Agreements</link:label>
    <link:label xml:lang="en-US" xlink:label="urgn_LicenseAndCollaborationAgreementsDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">License And Collaboration Agreements Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract" xlink:type="locator" xlink:label="us-gaap_EquityAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EquityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Equity [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shareholders&apos; Equity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-Based Compensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure Of Compensation Related Costs Share Based Payments [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Taxes</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transactions [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Parties</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transactions Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Commitments And Contingencies Disclosure [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments and Contingencies</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Commitments And Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:type="locator" xlink:label="us-gaap_SubsequentEventsAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Events [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:type="locator" xlink:label="us-gaap_SubsequentEventsTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Events</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Events [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_ConsolidationPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Principles of Consolidation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConsolidationPolicyTextBlock" xlink:to="us-gaap_ConsolidationPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Consolidation Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UseOfEstimates" xlink:type="locator" xlink:label="us-gaap_UseOfEstimates" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_UseOfEstimates_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Use of Estimates</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_UseOfEstimates_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Use Of Estimates</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Functional Currency</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:to="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Foreign Currency Transactions And Translations Policy [Text Block]</link:label>
    <link:loc xlink:href="urgn-20210331.xsd#urgn_CashAndCashEquivalentsAndMarketableSecuritiesPolicyPolicyTextBlock" xlink:type="locator" xlink:label="urgn_CashAndCashEquivalentsAndMarketableSecuritiesPolicyPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="urgn_CashAndCashEquivalentsAndMarketableSecuritiesPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Cash and cash equivalents and marketable securities policy.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="urgn_CashAndCashEquivalentsAndMarketableSecuritiesPolicyPolicyTextBlock" xlink:to="urgn_CashAndCashEquivalentsAndMarketableSecuritiesPolicyPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="urgn_CashAndCashEquivalentsAndMarketableSecuritiesPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and Cash Equivalents; Marketable Securities</link:label>
    <link:label xml:lang="en-US" xlink:label="urgn_CashAndCashEquivalentsAndMarketableSecuritiesPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash And Cash Equivalents And Marketable Securities Policy Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskCreditRisk" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Concentration of Credit Risk</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Concentration Risk Credit Risk</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Taxes</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_InventoryPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InventoryPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Inventory</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryPolicyTextBlock" xlink:to="us-gaap_InventoryPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InventoryPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Inventory Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and Equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Leases</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Leases Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenues</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Revenue Recognition Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development Expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development Expense Policy</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Selling General and Administrative Expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Selling General And Administrative Expenses Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansDirectorPolicy" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansDirectorPolicy" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansDirectorPolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-Based Compensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansDirectorPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansDirectorPolicy_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansDirectorPolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Option And Incentive Plans Director Policy</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net Loss per Ordinary Share</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share Policy [Text Block]</link:label>
    <link:loc xlink:href="urgn-20210331.xsd#urgn_PropertyPlantAndEquipmentUsefulLifeTableTextBlock" xlink:type="locator" xlink:label="urgn_PropertyPlantAndEquipmentUsefulLifeTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="urgn_PropertyPlantAndEquipmentUsefulLifeTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Property, plant and equipment, useful life.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="urgn_PropertyPlantAndEquipmentUsefulLifeTableTextBlock" xlink:to="urgn_PropertyPlantAndEquipmentUsefulLifeTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="urgn_PropertyPlantAndEquipmentUsefulLifeTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and Equipment Useful Lives</link:label>
    <link:label xml:lang="en-US" xlink:label="urgn_PropertyPlantAndEquipmentUsefulLifeTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Useful Life Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Accounts Payable and Accrued Expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Accounts Payable And Accrued Liabilities Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock" xlink:type="locator" xlink:label="us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Interest and Other Income (Expenses)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock" xlink:to="us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Interest Income And Interest Expense Disclosure Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Inventories</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Inventory Current Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Assets and Liabilities Measured at Fair Value on a Recurring Basis</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Fair Value Assets And Liabilities Measured On Recurring Basis Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesTextBlock" xlink:type="locator" xlink:label="us-gaap_MarketableSecuritiesTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_MarketableSecuritiesTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Marketable Securities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesTextBlock" xlink:to="us-gaap_MarketableSecuritiesTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_MarketableSecuritiesTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Marketable Securities [Text Block]</link:label>
    <link:loc xlink:href="urgn-20210331.xsd#urgn_SummaryOfFairValuesOfMarketableSecuritiesByContractualMaturityTableTextBlock" xlink:type="locator" xlink:label="urgn_SummaryOfFairValuesOfMarketableSecuritiesByContractualMaturityTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="urgn_SummaryOfFairValuesOfMarketableSecuritiesByContractualMaturityTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Fair values of marketable securities by contractual maturity.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="urgn_SummaryOfFairValuesOfMarketableSecuritiesByContractualMaturityTableTextBlock" xlink:to="urgn_SummaryOfFairValuesOfMarketableSecuritiesByContractualMaturityTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="urgn_SummaryOfFairValuesOfMarketableSecuritiesByContractualMaturityTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Fair Values of Marketable Securities by Contractual Maturity</link:label>
    <link:label xml:lang="en-US" xlink:label="urgn_SummaryOfFairValuesOfMarketableSecuritiesByContractualMaturityTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Summary Of Fair Values Of Marketable Securities By Contractual Maturity Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Property and Equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseCostTableTextBlock" xlink:type="locator" xlink:label="us-gaap_LeaseCostTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Components of Lease Cost</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCostTableTextBlock" xlink:to="us-gaap_LeaseCostTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lease Cost Table [Text Block]</link:label>
    <link:loc xlink:href="urgn-20210331.xsd#urgn_ScheduleOfOperatingLeaseAmountsRecognizedUponAdoptionTableTextBlock" xlink:type="locator" xlink:label="urgn_ScheduleOfOperatingLeaseAmountsRecognizedUponAdoptionTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="urgn_ScheduleOfOperatingLeaseAmountsRecognizedUponAdoptionTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Schedule of operating lease amounts recognized upon adoption.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="urgn_ScheduleOfOperatingLeaseAmountsRecognizedUponAdoptionTableTextBlock" xlink:to="urgn_ScheduleOfOperatingLeaseAmountsRecognizedUponAdoptionTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="urgn_ScheduleOfOperatingLeaseAmountsRecognizedUponAdoptionTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Amounts Recognized</link:label>
    <link:label xml:lang="en-US" xlink:label="urgn_ScheduleOfOperatingLeaseAmountsRecognizedUponAdoptionTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Operating Lease Amounts Recognized Upon Adoption Table [Text Block]</link:label>
    <link:loc xlink:href="urgn-20210331.xsd#urgn_ScheduleOfSupplementalInformationRelatedToLeasesTableTextBlock" xlink:type="locator" xlink:label="urgn_ScheduleOfSupplementalInformationRelatedToLeasesTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="urgn_ScheduleOfSupplementalInformationRelatedToLeasesTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Schedule of supplemental information related to leases.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="urgn_ScheduleOfSupplementalInformationRelatedToLeasesTableTextBlock" xlink:to="urgn_ScheduleOfSupplementalInformationRelatedToLeasesTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="urgn_ScheduleOfSupplementalInformationRelatedToLeasesTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Supplemental Information Related to Leases</link:label>
    <link:label xml:lang="en-US" xlink:label="urgn_ScheduleOfSupplementalInformationRelatedToLeasesTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Supplemental Information Related To Leases Table [Text Block]</link:label>
    <link:loc xlink:href="urgn-20210331.xsd#urgn_LesseeOperatingSubLeasePaymentsToBeReceivedMaturityTableTextBlock" xlink:type="locator" xlink:label="urgn_LesseeOperatingSubLeasePaymentsToBeReceivedMaturityTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="urgn_LesseeOperatingSubLeasePaymentsToBeReceivedMaturityTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Lessee operating sub lease payments to be received maturity.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="urgn_LesseeOperatingSubLeasePaymentsToBeReceivedMaturityTableTextBlock" xlink:to="urgn_LesseeOperatingSubLeasePaymentsToBeReceivedMaturityTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="urgn_LesseeOperatingSubLeasePaymentsToBeReceivedMaturityTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Undiscounted Cash Flows to be Received Under Operating Sublease on an Annual Basis</link:label>
    <link:label xml:lang="en-US" xlink:label="urgn_LesseeOperatingSubLeasePaymentsToBeReceivedMaturityTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Sub Lease Payments To Be Received Maturity Table [Text Block]</link:label>
    <link:loc xlink:href="urgn-20210331.xsd#urgn_LesseeOperatingSubLeaseIncomeRecognizedNetInOperatingExpensesTableTextBlock" xlink:type="locator" xlink:label="urgn_LesseeOperatingSubLeaseIncomeRecognizedNetInOperatingExpensesTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="urgn_LesseeOperatingSubLeaseIncomeRecognizedNetInOperatingExpensesTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Lessee operating sub lease income recognized net in operating expenses.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="urgn_LesseeOperatingSubLeaseIncomeRecognizedNetInOperatingExpensesTableTextBlock" xlink:to="urgn_LesseeOperatingSubLeaseIncomeRecognizedNetInOperatingExpensesTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="urgn_LesseeOperatingSubLeaseIncomeRecognizedNetInOperatingExpensesTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Sublease Income Recognized Net within Operating Expenses</link:label>
    <link:label xml:lang="en-US" xlink:label="urgn_LesseeOperatingSubLeaseIncomeRecognizedNetInOperatingExpensesTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Sub Lease Income Recognized Net In Operating Expenses Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:type="locator" xlink:label="us-gaap_DisaggregationOfRevenueTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DisaggregationOfRevenueTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Net Product Sales</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:to="us-gaap_DisaggregationOfRevenueTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DisaggregationOfRevenueTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disaggregation Of Revenue Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Effect of Share-Based Compensation on Statements of Operations</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Text Block]</link:label>
    <link:loc xlink:href="urgn-20210331.xsd#urgn_EntityIncorporationDateOfIncorporationMonthAndYear" xlink:type="locator" xlink:label="urgn_EntityIncorporationDateOfIncorporationMonthAndYear" />
    <link:label xml:lang="en-US" xlink:label="urgn_EntityIncorporationDateOfIncorporationMonthAndYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Entity incorporation date of incorporation month and year.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="urgn_EntityIncorporationDateOfIncorporationMonthAndYear" xlink:to="urgn_EntityIncorporationDateOfIncorporationMonthAndYear_lbl" />
    <link:label xml:lang="en-US" xlink:label="urgn_EntityIncorporationDateOfIncorporationMonthAndYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Date of incorporation</link:label>
    <link:label xml:lang="en-US" xlink:label="urgn_EntityIncorporationDateOfIncorporationMonthAndYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation Date Of Incorporation Month And Year</link:label>
    <link:loc xlink:href="urgn-20210331.xsd#urgn_OperationsCommencedDateMonthAndYear" xlink:type="locator" xlink:label="urgn_OperationsCommencedDateMonthAndYear" />
    <link:label xml:lang="en-US" xlink:label="urgn_OperationsCommencedDateMonthAndYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Operations commenced date month and year.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="urgn_OperationsCommencedDateMonthAndYear" xlink:to="urgn_OperationsCommencedDateMonthAndYear_lbl" />
    <link:label xml:lang="en-US" xlink:label="urgn_OperationsCommencedDateMonthAndYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Date of operating commencement</link:label>
    <link:label xml:lang="en-US" xlink:label="urgn_OperationsCommencedDateMonthAndYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operations Commenced Date Month And Year</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Accumulated deficit</link:label>
    <link:loc xlink:href="urgn-20210331.xsd#urgn_CashCashEquivalentsAndMarketableSecurities" xlink:type="locator" xlink:label="urgn_CashCashEquivalentsAndMarketableSecurities" />
    <link:label xml:lang="en-US" xlink:label="urgn_CashCashEquivalentsAndMarketableSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Cash, cash equivalents and marketable securities.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="urgn_CashCashEquivalentsAndMarketableSecurities" xlink:to="urgn_CashCashEquivalentsAndMarketableSecurities_lbl" />
    <link:label xml:lang="en-US" xlink:label="urgn_CashCashEquivalentsAndMarketableSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total cash and cash equivalents and marketable securities</link:label>
    <link:label xml:lang="en-US" xlink:label="urgn_CashCashEquivalentsAndMarketableSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash Cash Equivalents And Marketable Securities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Property Plant And Equipment [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Property Plant And Equipment [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-Lived Tangible Asset</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment By Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-Lived Tangible Asset</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Type [Domain]</link:label>
    <link:loc xlink:href="urgn-20210331.xsd#urgn_ComputersAndSoftwareMember" xlink:type="locator" xlink:label="urgn_ComputersAndSoftwareMember" />
    <link:label xml:lang="en-US" xlink:label="urgn_ComputersAndSoftwareMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Computers and software.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="urgn_ComputersAndSoftwareMember" xlink:to="urgn_ComputersAndSoftwareMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="urgn_ComputersAndSoftwareMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Computers and Software</link:label>
    <link:label xml:lang="en-US" xlink:label="urgn_ComputersAndSoftwareMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Computers And Software [Member]</link:label>
    <link:loc xlink:href="urgn-20210331.xsd#urgn_LaboratoryEquipmentMember" xlink:type="locator" xlink:label="urgn_LaboratoryEquipmentMember" />
    <link:label xml:lang="en-US" xlink:label="urgn_LaboratoryEquipmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Laboratory equipment.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="urgn_LaboratoryEquipmentMember" xlink:to="urgn_LaboratoryEquipmentMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="urgn_LaboratoryEquipmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Laboratory Equipment</link:label>
    <link:label xml:lang="en-US" xlink:label="urgn_LaboratoryEquipmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Laboratory Equipment [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:type="locator" xlink:label="us-gaap_FurnitureAndFixturesMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Furniture</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FurnitureAndFixturesMember" xlink:to="us-gaap_FurnitureAndFixturesMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Furniture And Fixtures [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ManufacturingFacilityMember" xlink:type="locator" xlink:label="us-gaap_ManufacturingFacilityMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ManufacturingFacilityMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Manufacturing Equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ManufacturingFacilityMember" xlink:to="us-gaap_ManufacturingFacilityMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ManufacturingFacilityMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Manufacturing Facility [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:label xml:lang="en-US" xlink:label="srt_RangeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statistical Measurement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_RangeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Range [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:label xml:lang="en-US" xlink:label="srt_RangeMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statistical Measurement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_RangeMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Range [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:label xml:lang="en-US" xlink:label="srt_MinimumMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Minimum</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_MinimumMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Minimum [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:label xml:lang="en-US" xlink:label="srt_MaximumMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_MaximumMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Maximum [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property Plant And Equipment [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and Equipment, Useful Lives</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Useful Life</link:label>
    <link:loc xlink:href="urgn-20210331.xsd#urgn_AccruedSalesReserves" xlink:type="locator" xlink:label="urgn_AccruedSalesReserves" />
    <link:label xml:lang="en-US" xlink:label="urgn_AccruedSalesReserves_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued sales reserves.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="urgn_AccruedSalesReserves" xlink:to="urgn_AccruedSalesReserves_lbl" />
    <link:loc xlink:href="urgn-20210331.xsd#urgn_AccruedClinicalExpensesCurrent" xlink:type="locator" xlink:label="urgn_AccruedClinicalExpensesCurrent" />
    <link:label xml:lang="en-US" xlink:label="urgn_AccruedClinicalExpensesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued clinical expenses current.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="urgn_AccruedClinicalExpensesCurrent" xlink:to="urgn_AccruedClinicalExpensesCurrent_lbl" />
    <link:loc xlink:href="urgn-20210331.xsd#urgn_AccruedResearchAndDevelopmentExpenseCurrent" xlink:type="locator" xlink:label="urgn_AccruedResearchAndDevelopmentExpenseCurrent" />
    <link:label xml:lang="en-US" xlink:label="urgn_AccruedResearchAndDevelopmentExpenseCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued Research and Development Expense, Current.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="urgn_AccruedResearchAndDevelopmentExpenseCurrent" xlink:to="urgn_AccruedResearchAndDevelopmentExpenseCurrent_lbl" />
    <link:loc xlink:href="urgn-20210331.xsd#urgn_AccruedSellingGeneralAndAdministrativeExpenseCurrent" xlink:type="locator" xlink:label="urgn_AccruedSellingGeneralAndAdministrativeExpenseCurrent" />
    <link:label xml:lang="en-US" xlink:label="urgn_AccruedSellingGeneralAndAdministrativeExpenseCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued selling general and administrative expense current.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="urgn_AccruedSellingGeneralAndAdministrativeExpenseCurrent" xlink:to="urgn_AccruedSellingGeneralAndAdministrativeExpenseCurrent_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Payable Current</link:label>
    <link:label xml:lang="en-US" xlink:label="urgn_AccruedSalesReserves_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued sales reserves</link:label>
    <link:label xml:lang="en-US" xlink:label="urgn_AccruedSalesReserves_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Sales Reserves</link:label>
    <link:label xml:lang="en-US" xlink:label="urgn_AccruedClinicalExpensesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued clinical expenses</link:label>
    <link:label xml:lang="en-US" xlink:label="urgn_AccruedClinicalExpensesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Clinical Expenses Current</link:label>
    <link:label xml:lang="en-US" xlink:label="urgn_AccruedResearchAndDevelopmentExpenseCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued research and development costs</link:label>
    <link:label xml:lang="en-US" xlink:label="urgn_AccruedResearchAndDevelopmentExpenseCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Research And Development Expense Current</link:label>
    <link:label xml:lang="en-US" xlink:label="urgn_AccruedSellingGeneralAndAdministrativeExpenseCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued selling, general and administrative expenses</link:label>
    <link:label xml:lang="en-US" xlink:label="urgn_AccruedSellingGeneralAndAdministrativeExpenseCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Selling General And Administrative Expense Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued other expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Accrued Liabilities Current</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total accounts payable and accrued expenses</link:label>
    <link:loc xlink:href="urgn-20210331.xsd#urgn_OtherFinanceExpensesIncome" xlink:type="locator" xlink:label="urgn_OtherFinanceExpensesIncome" />
    <link:label xml:lang="en-US" xlink:label="urgn_OtherFinanceExpensesIncome_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Other finance expenses (income).</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="urgn_OtherFinanceExpensesIncome" xlink:to="urgn_OtherFinanceExpensesIncome_lbl" />
    <link:loc xlink:href="urgn-20210331.xsd#urgn_FinanceIncomeExpenseNet" xlink:type="locator" xlink:label="urgn_FinanceIncomeExpenseNet" />
    <link:label xml:lang="en-US" xlink:label="urgn_FinanceIncomeExpenseNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Finance income expense net.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="urgn_FinanceIncomeExpenseNet" xlink:to="urgn_FinanceIncomeExpenseNet_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:type="locator" xlink:label="us-gaap_InvestmentIncomeInterest" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InvestmentIncomeInterest_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest income</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeInterest" xlink:to="us-gaap_InvestmentIncomeInterest_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InvestmentIncomeInterest_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Investment Income Interest</link:label>
    <link:label xml:lang="en-US" xlink:label="urgn_OtherFinanceExpensesIncome_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other finance income(expenses)</link:label>
    <link:label xml:lang="en-US" xlink:label="urgn_OtherFinanceExpensesIncome_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Finance Expenses Income</link:label>
    <link:label xml:lang="en-US" xlink:label="urgn_FinanceIncomeExpenseNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total interest and other income</link:label>
    <link:label xml:lang="en-US" xlink:label="urgn_FinanceIncomeExpenseNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Finance Income Expense Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryRawMaterials" xlink:type="locator" xlink:label="us-gaap_InventoryRawMaterials" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InventoryRawMaterials_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Raw materials</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryRawMaterials" xlink:to="us-gaap_InventoryRawMaterials_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InventoryRawMaterials_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Inventory Raw Materials</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryFinishedGoods" xlink:type="locator" xlink:label="us-gaap_InventoryFinishedGoods" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InventoryFinishedGoods_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Finished goods</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryFinishedGoods" xlink:to="us-gaap_InventoryFinishedGoods_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InventoryFinishedGoods_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Inventory Finished Goods</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_InventoryNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total inventories</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair value assets, transfers between level 1 to level 2</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount" xlink:to="us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Assets Level1 To Level2 Transfers Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair value assets, transfers between level 2 to level 1</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount" xlink:to="us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Assets Level2 To Level1 Transfers Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesLevel1ToLevel2TransfersAmount" xlink:type="locator" xlink:label="us-gaap_FairValueLiabilitiesLevel1ToLevel2TransfersAmount" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueLiabilitiesLevel1ToLevel2TransfersAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair value liabilities, transfers between level 1 to level 2</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesLevel1ToLevel2TransfersAmount" xlink:to="us-gaap_FairValueLiabilitiesLevel1ToLevel2TransfersAmount_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueLiabilitiesLevel1ToLevel2TransfersAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Liabilities Level1 To Level2 Transfers Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesLevel2ToLevel1TransfersAmount" xlink:type="locator" xlink:label="us-gaap_FairValueLiabilitiesLevel2ToLevel1TransfersAmount" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueLiabilitiesLevel2ToLevel1TransfersAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair value liabilities, transfers between level 2 to level 1</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesLevel2ToLevel1TransfersAmount" xlink:to="us-gaap_FairValueLiabilitiesLevel2ToLevel1TransfersAmount_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueLiabilitiesLevel2ToLevel1TransfersAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Liabilities Level2 To Level1 Transfers Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair value assets, transfers into level 3</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Into Level3</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair value assets, transfers out of level 3</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Out Of Level3</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair value liabilities, transfers into level 3</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Into Level3</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair value liabilities, transfers out of level 3</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Out Of Level3</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTable" xlink:type="locator" xlink:label="us-gaap_FairValueByBalanceSheetGroupingTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueByBalanceSheetGroupingTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value By Balance Sheet Grouping [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_FairValueByBalanceSheetGroupingTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueByBalanceSheetGroupingTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value By Balance Sheet Grouping [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Measurement Frequency</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value By Measurement Frequency [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Measurement Frequency</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurement Frequency [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value, Measurements, Recurring</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsRecurringMember" xlink:to="us-gaap_FairValueMeasurementsRecurringMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurements Recurring [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:type="locator" xlink:label="us-gaap_FinancialInstrumentAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FinancialInstrumentAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Financial Instrument</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_FinancialInstrumentAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FinancialInstrumentAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Financial Instrument [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="locator" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Financial Instruments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Transfers And Servicing Of Financial Instruments Types Of Financial Instruments [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:type="locator" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">US Government</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:to="us-gaap_USGovernmentAgenciesDebtSecuritiesMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">U S Government Agencies Debt Securities [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateBondSecuritiesMember" xlink:type="locator" xlink:label="us-gaap_CorporateBondSecuritiesMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CorporateBondSecuritiesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Corporate Bonds</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CorporateBondSecuritiesMember" xlink:to="us-gaap_CorporateBondSecuritiesMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CorporateBondSecuritiesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Corporate Bond Securities [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:type="locator" xlink:label="us-gaap_MoneyMarketFundsMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Money Market Funds</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MoneyMarketFundsMember" xlink:to="us-gaap_MoneyMarketFundsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Money Market Funds [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Hierarchy and NAV</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value By Fair Value Hierarchy Level [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Hierarchy and NAV</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurements Fair Value Hierarchy [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel1Member" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Quoted Prices in Active Markets for Identical Assets (Level 1)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Inputs Level1 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel2Member" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Significant Other Observable Inputs (Level 2)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Inputs Level2 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:type="locator" xlink:label="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Marketable securities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Available For Sale Securities Debt Securities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesTable" xlink:type="locator" xlink:label="us-gaap_MarketableSecuritiesTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_MarketableSecuritiesTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Marketable Securities [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesTable" xlink:to="us-gaap_MarketableSecuritiesTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_MarketableSecuritiesTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Marketable Securities [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:type="locator" xlink:label="us-gaap_InvestmentTypeAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InvestmentTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Investment Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InvestmentTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Investment Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:type="locator" xlink:label="us-gaap_InvestmentTypeCategorizationMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InvestmentTypeCategorizationMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Investments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_InvestmentTypeCategorizationMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InvestmentTypeCategorizationMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Investment Type Categorization [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USTreasuryAndGovernmentMember" xlink:type="locator" xlink:label="us-gaap_USTreasuryAndGovernmentMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_USTreasuryAndGovernmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">US Government</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_USTreasuryAndGovernmentMember" xlink:to="us-gaap_USTreasuryAndGovernmentMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_USTreasuryAndGovernmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">U S Treasury And Government [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:type="locator" xlink:label="us-gaap_CorporateDebtSecuritiesMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CorporateDebtSecuritiesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Corporate Bonds</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CorporateDebtSecuritiesMember" xlink:to="us-gaap_CorporateDebtSecuritiesMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CorporateDebtSecuritiesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Corporate Debt Securities [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesLineItems" xlink:type="locator" xlink:label="us-gaap_MarketableSecuritiesLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_MarketableSecuritiesLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Marketable Securities [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesLineItems" xlink:to="us-gaap_MarketableSecuritiesLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_MarketableSecuritiesLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Marketable Securities [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesAbstract" xlink:type="locator" xlink:label="us-gaap_MarketableSecuritiesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_MarketableSecuritiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Marketable securities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesAbstract" xlink:to="us-gaap_MarketableSecuritiesAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_MarketableSecuritiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Marketable Securities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Amortized Cost Basis</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Available For Sale Debt Securities Amortized Cost Basis</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrealized Gains</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Unrealized Losses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Fair Value</link:label>
    <link:loc xlink:href="urgn-20210331.xsd#urgn_DebtSecuritiesAvailableForSaleUnrealizedGainPosition" xlink:type="locator" xlink:label="urgn_DebtSecuritiesAvailableForSaleUnrealizedGainPosition" />
    <link:label xml:lang="en-US" xlink:label="urgn_DebtSecuritiesAvailableForSaleUnrealizedGainPosition_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Debt securities available for sale unrealized gain position.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="urgn_DebtSecuritiesAvailableForSaleUnrealizedGainPosition" xlink:to="urgn_DebtSecuritiesAvailableForSaleUnrealizedGainPosition_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestReceivable" xlink:type="locator" xlink:label="us-gaap_InterestReceivable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InterestReceivable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued interest receivable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestReceivable" xlink:to="us-gaap_InterestReceivable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InterestReceivable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Interest Receivable</link:label>
    <link:label xml:lang="en-US" xlink:label="urgn_DebtSecuritiesAvailableForSaleUnrealizedGainPosition_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Available-for-sale debt securities, unrealized gain position</link:label>
    <link:label xml:lang="en-US" xlink:label="urgn_DebtSecuritiesAvailableForSaleUnrealizedGainPosition_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities Available For Sale Unrealized Gain Position</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:type="locator" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Available-for-sale debt securities, unrealized loss position</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities Available For Sale Unrealized Loss Position</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesPortionRecognizedInEarnings" xlink:type="locator" xlink:label="us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesPortionRecognizedInEarnings" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesPortionRecognizedInEarnings_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other-than-temporary impairment Loss, debt securities, portion recognized in earnings</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesPortionRecognizedInEarnings" xlink:to="us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesPortionRecognizedInEarnings_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesPortionRecognizedInEarnings_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Than Temporary Impairment Loss Debt Securities Portion Recognized In Earnings</link:label>
    <link:loc xlink:href="urgn-20210331.xsd#urgn_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughThreeYearsFairValue" xlink:type="locator" xlink:label="urgn_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughThreeYearsFairValue" />
    <link:label xml:lang="en-US" xlink:label="urgn_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughThreeYearsFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Available for sale securities debt maturities after one through three years fair value.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="urgn_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughThreeYearsFairValue" xlink:to="urgn_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughThreeYearsFairValue_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Available For Sale Securities Debt Maturities Fair Value [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maturities within one year</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Available For Sale Securities Debt Maturities Within One Year Fair Value</link:label>
    <link:label xml:lang="en-US" xlink:label="urgn_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughThreeYearsFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maturities after one year through three years</link:label>
    <link:label xml:lang="en-US" xlink:label="urgn_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughThreeYearsFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Available For Sale Securities Debt Maturities After One Through Three Years Fair Value</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total marketable securities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:type="locator" xlink:label="us-gaap_LeaseholdImprovementsMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Leasehold Improvements</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdImprovementsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Leasehold Improvements [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less: accumulated depreciation and amortization</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accumulated Depreciation Depletion And Amortization Property Plant And Equipment</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Property and equipment, net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:type="locator" xlink:label="us-gaap_DepreciationDepletionAndAmortization" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Depreciation and amortization expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationDepletionAndAmortization" xlink:to="us-gaap_DepreciationDepletionAndAmortization_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Depreciation Depletion And Amortization</link:label>
    <link:loc xlink:href="urgn-20210331.xsd#urgn_LesseeOperatingLeaseExtendedLeaseExpirationDateMonthAndYear" xlink:type="locator" xlink:label="urgn_LesseeOperatingLeaseExtendedLeaseExpirationDateMonthAndYear" />
    <link:label xml:lang="en-US" xlink:label="urgn_LesseeOperatingLeaseExtendedLeaseExpirationDateMonthAndYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Lessee operating lease extended lease expiration date, month and year.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="urgn_LesseeOperatingLeaseExtendedLeaseExpirationDateMonthAndYear" xlink:to="urgn_LesseeOperatingLeaseExtendedLeaseExpirationDateMonthAndYear_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:type="locator" xlink:label="us-gaap_LesseeLeaseDescriptionTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeLeaseDescriptionTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lessee Lease Description [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_LesseeLeaseDescriptionTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeLeaseDescriptionTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Lease Description [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis" xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" />
    <link:label xml:lang="en-US" xlink:label="srt_StatementGeographicalAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Geographical</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_StatementGeographicalAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_StatementGeographicalAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Geographical [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain" xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" />
    <link:label xml:lang="en-US" xlink:label="srt_SegmentGeographicalDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Geographical</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_SegmentGeographicalDomain" xlink:to="srt_SegmentGeographicalDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_SegmentGeographicalDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Segment Geographical [Domain]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd#stpr_NY" xlink:type="locator" xlink:label="stpr_NY" />
    <link:label xml:lang="en-US" xlink:label="stpr_NY_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">New York</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="stpr_NY" xlink:to="stpr_NY_lbl" />
    <link:label xml:lang="en-US" xlink:label="stpr_NY_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">NEW YORK</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidatedEntitiesAxis" xlink:type="locator" xlink:label="srt_ConsolidatedEntitiesAxis" />
    <link:label xml:lang="en-US" xlink:label="srt_ConsolidatedEntitiesAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Consolidated Entities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ConsolidatedEntitiesAxis" xlink:to="srt_ConsolidatedEntitiesAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_ConsolidatedEntitiesAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Consolidated Entities [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidatedEntitiesDomain" xlink:type="locator" xlink:label="srt_ConsolidatedEntitiesDomain" />
    <link:label xml:lang="en-US" xlink:label="srt_ConsolidatedEntitiesDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Consolidated Entities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ConsolidatedEntitiesDomain" xlink:to="srt_ConsolidatedEntitiesDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_ConsolidatedEntitiesDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Consolidated Entities [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SubsidiariesMember" xlink:type="locator" xlink:label="srt_SubsidiariesMember" />
    <link:label xml:lang="en-US" xlink:label="srt_SubsidiariesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">UroGen Pharma Inc.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_SubsidiariesMember" xlink:to="srt_SubsidiariesMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_SubsidiariesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Subsidiaries [Member]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd#stpr_CA" xlink:type="locator" xlink:label="stpr_CA" />
    <link:label xml:lang="en-US" xlink:label="stpr_CA_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Los Angeles, California</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="stpr_CA" xlink:to="stpr_CA_lbl" />
    <link:label xml:lang="en-US" xlink:label="stpr_CA_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">CALIFORNIA</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd#stpr_NJ" xlink:type="locator" xlink:label="stpr_NJ" />
    <link:label xml:lang="en-US" xlink:label="stpr_NJ_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Princeton, NJ</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="stpr_NJ" xlink:to="stpr_NJ_lbl" />
    <link:label xml:lang="en-US" xlink:label="stpr_NJ_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">NEW JERSEY</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Finite-Lived Intangible Assets by Major Class</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Finite Lived Intangible Assets By Major Class [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Finite-Lived Intangible Assets, Major Class Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Finite Lived Intangible Assets Major Class Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseAgreementsMember" xlink:type="locator" xlink:label="us-gaap_LeaseAgreementsMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LeaseAgreementsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease Agreement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseAgreementsMember" xlink:to="us-gaap_LeaseAgreementsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LeaseAgreementsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lease Agreements [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:type="locator" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lessee Lease Description [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeLeaseDescriptionLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Lease Description [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating leases, existence of option to extend</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xlink:to="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Existence Of Option To Extend</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating leases, options to extend lease term, description</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:to="us-gaap_LesseeOperatingLeaseOptionToExtend_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Option To Extend</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating leases, options to extend lease term</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Renewal Term</link:label>
    <link:label xml:lang="en-US" xlink:label="urgn_LesseeOperatingLeaseExtendedLeaseExpirationDateMonthAndYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease extended lease expiration, month and year</link:label>
    <link:label xml:lang="en-US" xlink:label="urgn_LesseeOperatingLeaseExtendedLeaseExpirationDateMonthAndYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Extended Lease Expiration Date Month And Year</link:label>
    <link:loc xlink:href="urgn-20210331.xsd#urgn_LeaseCommencementDateMonthAndYear" xlink:type="locator" xlink:label="urgn_LeaseCommencementDateMonthAndYear" />
    <link:label xml:lang="en-US" xlink:label="urgn_LeaseCommencementDateMonthAndYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Lease commencement date month and year.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="urgn_LeaseCommencementDateMonthAndYear" xlink:to="urgn_LeaseCommencementDateMonthAndYear_lbl" />
    <link:loc xlink:href="urgn-20210331.xsd#urgn_LeaseTerminationDateMonthAndYear" xlink:type="locator" xlink:label="urgn_LeaseTerminationDateMonthAndYear" />
    <link:label xml:lang="en-US" xlink:label="urgn_LeaseTerminationDateMonthAndYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Lease termination date month and year.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="urgn_LeaseTerminationDateMonthAndYear" xlink:to="urgn_LeaseTerminationDateMonthAndYear_lbl" />
    <link:label xml:lang="en-US" xlink:label="urgn_LeaseCommencementDateMonthAndYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease commencement period, month and year</link:label>
    <link:label xml:lang="en-US" xlink:label="urgn_LeaseCommencementDateMonthAndYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lease Commencement Date Month And Year</link:label>
    <link:label xml:lang="en-US" xlink:label="urgn_LeaseTerminationDateMonthAndYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease termination period, month and year</link:label>
    <link:label xml:lang="en-US" xlink:label="urgn_LeaseTerminationDateMonthAndYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lease Termination Date Month And Year</link:label>
    <link:loc xlink:href="urgn-20210331.xsd#urgn_LeaseCommencementDate" xlink:type="locator" xlink:label="urgn_LeaseCommencementDate" />
    <link:label xml:lang="en-US" xlink:label="urgn_LeaseCommencementDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Lease commencement date.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="urgn_LeaseCommencementDate" xlink:to="urgn_LeaseCommencementDate_lbl" />
    <link:loc xlink:href="urgn-20210331.xsd#urgn_ProceedsFromTenantAllowance" xlink:type="locator" xlink:label="urgn_ProceedsFromTenantAllowance" />
    <link:label xml:lang="en-US" xlink:label="urgn_ProceedsFromTenantAllowance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Proceeds from tenant allowance.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="urgn_ProceedsFromTenantAllowance" xlink:to="urgn_ProceedsFromTenantAllowance_lbl" />
    <link:loc xlink:href="urgn-20210331.xsd#urgn_LesseeOperatingSubleaseCommencementDate" xlink:type="locator" xlink:label="urgn_LesseeOperatingSubleaseCommencementDate" />
    <link:label xml:lang="en-US" xlink:label="urgn_LesseeOperatingSubleaseCommencementDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Lessee operating sublease commencement date.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="urgn_LesseeOperatingSubleaseCommencementDate" xlink:to="urgn_LesseeOperatingSubleaseCommencementDate_lbl" />
    <link:loc xlink:href="urgn-20210331.xsd#urgn_LesseeOperatingSubleaseTerminationDateMonthAndYear" xlink:type="locator" xlink:label="urgn_LesseeOperatingSubleaseTerminationDateMonthAndYear" />
    <link:label xml:lang="en-US" xlink:label="urgn_LesseeOperatingSubleaseTerminationDateMonthAndYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Lessee operating sublease termination date month and year.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="urgn_LesseeOperatingSubleaseTerminationDateMonthAndYear" xlink:to="urgn_LesseeOperatingSubleaseTerminationDateMonthAndYear_lbl" />
    <link:label xml:lang="en-US" xlink:label="urgn_LeaseCommencementDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease commencement date</link:label>
    <link:label xml:lang="en-US" xlink:label="urgn_LeaseCommencementDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lease Commencement Date</link:label>
    <link:label xml:lang="en-US" xlink:label="urgn_ProceedsFromTenantAllowance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from tenant allowance</link:label>
    <link:label xml:lang="en-US" xlink:label="urgn_ProceedsFromTenantAllowance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Tenant Allowance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractualObligation" xlink:type="locator" xlink:label="us-gaap_ContractualObligation" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ContractualObligation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Remaining contractual obligation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractualObligation" xlink:to="us-gaap_ContractualObligation_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ContractualObligation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Contractual Obligation</link:label>
    <link:label xml:lang="en-US" xlink:label="urgn_LesseeOperatingSubleaseCommencementDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lessee operating sublease commencement date</link:label>
    <link:label xml:lang="en-US" xlink:label="urgn_LesseeOperatingSubleaseCommencementDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Sublease Commencement Date</link:label>
    <link:label xml:lang="en-US" xlink:label="urgn_LesseeOperatingSubleaseTerminationDateMonthAndYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lessee operating sublease termination period, month and year</link:label>
    <link:label xml:lang="en-US" xlink:label="urgn_LesseeOperatingSubleaseTerminationDateMonthAndYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Sublease Termination Date Month And Year</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubleaseIncome" xlink:type="locator" xlink:label="us-gaap_SubleaseIncome" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubleaseIncome_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Remaining rental payments to be received over the lease term</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubleaseIncome" xlink:to="us-gaap_SubleaseIncome_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubleaseIncome_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sublease Income</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease term</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Term Of Contract</link:label>
    <link:loc xlink:href="urgn-20210331.xsd#urgn_LeaseExpirationYear" xlink:type="locator" xlink:label="urgn_LeaseExpirationYear" />
    <link:label xml:lang="en-US" xlink:label="urgn_LeaseExpirationYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Lease expiration year.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="urgn_LeaseExpirationYear" xlink:to="urgn_LeaseExpirationYear_lbl" />
    <link:label xml:lang="en-US" xlink:label="urgn_LeaseExpirationYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease expiration year</link:label>
    <link:label xml:lang="en-US" xlink:label="urgn_LeaseExpirationYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lease Expiration Year</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseCost" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseCost" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease cost</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseCost" xlink:to="us-gaap_OperatingLeaseCost_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Cost</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubleaseIncome_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Sublease income</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableLeaseCost" xlink:type="locator" xlink:label="us-gaap_VariableLeaseCost" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_VariableLeaseCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Variable lease cost</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VariableLeaseCost" xlink:to="us-gaap_VariableLeaseCost_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_VariableLeaseCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Variable Lease Cost</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseCost" xlink:type="locator" xlink:label="us-gaap_LeaseCost" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LeaseCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Lease, Cost</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_LeaseCost_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LeaseCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lease Cost</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible List]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Right Of Use Asset Statement Of Financial Position Extensible List</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other current liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Liability Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating Lease, Liability, Current, Statement of Financial Position [Extensible List]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:to="us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Liability Current Statement Of Financial Position Extensible List</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseImpairmentLoss" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseImpairmentLoss" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseImpairmentLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Impairment losses on operating leases</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseImpairmentLoss" xlink:to="us-gaap_OperatingLeaseImpairmentLoss_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseImpairmentLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Impairment Loss</link:label>
    <link:loc xlink:href="urgn-20210331.xsd#urgn_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract" xlink:type="locator" xlink:label="urgn_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract" />
    <link:label xml:lang="en-US" xlink:label="urgn_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Cash paid for amounts included in measurement of lease liabilities.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="urgn_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract" xlink:to="urgn_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="urgn_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash paid for amounts included in the measurement of lease liabilities:</link:label>
    <link:label xml:lang="en-US" xlink:label="urgn_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash Paid For Amounts Included In Measurement Of Lease Liabilities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasePayments" xlink:type="locator" xlink:label="us-gaap_OperatingLeasePayments" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeasePayments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating cash flows from operating leases</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasePayments" xlink:to="us-gaap_OperatingLeasePayments_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeasePayments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Payments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="locator" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Right-of-use assets obtained in exchange for new operating lease liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Right Of Use Asset Obtained In Exchange For Operating Lease Liability</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average remaining lease term of operating leases</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Weighted Average Remaining Lease Term1</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average discount rate of operating leases</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Weighted Average Discount Rate Percent</link:label>
    <link:loc xlink:href="urgn-20210331.xsd#urgn_LesseeOperatingSubLeasePaymentsToBeReceivedRemainderOfFiscalYear" xlink:type="locator" xlink:label="urgn_LesseeOperatingSubLeasePaymentsToBeReceivedRemainderOfFiscalYear" />
    <link:label xml:lang="en-US" xlink:label="urgn_LesseeOperatingSubLeasePaymentsToBeReceivedRemainderOfFiscalYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Lessee operating sub lease payments to be received remainder of fiscal year.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="urgn_LesseeOperatingSubLeasePaymentsToBeReceivedRemainderOfFiscalYear" xlink:to="urgn_LesseeOperatingSubLeasePaymentsToBeReceivedRemainderOfFiscalYear_lbl" />
    <link:loc xlink:href="urgn-20210331.xsd#urgn_LesseeOperatingSubLeasePaymentsToBeReceivedNextTwelveMonths" xlink:type="locator" xlink:label="urgn_LesseeOperatingSubLeasePaymentsToBeReceivedNextTwelveMonths" />
    <link:label xml:lang="en-US" xlink:label="urgn_LesseeOperatingSubLeasePaymentsToBeReceivedNextTwelveMonths_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Lessee operating sublease payments to be received next twelve months.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="urgn_LesseeOperatingSubLeasePaymentsToBeReceivedNextTwelveMonths" xlink:to="urgn_LesseeOperatingSubLeasePaymentsToBeReceivedNextTwelveMonths_lbl" />
    <link:loc xlink:href="urgn-20210331.xsd#urgn_LesseeOperatingSubLeasePaymentsToBeReceivedTwoYears" xlink:type="locator" xlink:label="urgn_LesseeOperatingSubLeasePaymentsToBeReceivedTwoYears" />
    <link:label xml:lang="en-US" xlink:label="urgn_LesseeOperatingSubLeasePaymentsToBeReceivedTwoYears_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Lessee operating sub lease payments to be received two years.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="urgn_LesseeOperatingSubLeasePaymentsToBeReceivedTwoYears" xlink:to="urgn_LesseeOperatingSubLeasePaymentsToBeReceivedTwoYears_lbl" />
    <link:loc xlink:href="urgn-20210331.xsd#urgn_LesseeOperatingSubLeasePaymentsToBeReceivedThreeYears" xlink:type="locator" xlink:label="urgn_LesseeOperatingSubLeasePaymentsToBeReceivedThreeYears" />
    <link:label xml:lang="en-US" xlink:label="urgn_LesseeOperatingSubLeasePaymentsToBeReceivedThreeYears_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Lessee operating sub lease payments to be received three years.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="urgn_LesseeOperatingSubLeasePaymentsToBeReceivedThreeYears" xlink:to="urgn_LesseeOperatingSubLeasePaymentsToBeReceivedThreeYears_lbl" />
    <link:loc xlink:href="urgn-20210331.xsd#urgn_LesseeOperatingSubLeasePaymentsToBeReceivedFourYears" xlink:type="locator" xlink:label="urgn_LesseeOperatingSubLeasePaymentsToBeReceivedFourYears" />
    <link:label xml:lang="en-US" xlink:label="urgn_LesseeOperatingSubLeasePaymentsToBeReceivedFourYears_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Lessee operating sub lease payments to be received four years.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="urgn_LesseeOperatingSubLeasePaymentsToBeReceivedFourYears" xlink:to="urgn_LesseeOperatingSubLeasePaymentsToBeReceivedFourYears_lbl" />
    <link:loc xlink:href="urgn-20210331.xsd#urgn_LesseeOperatingSubLeasePaymentsToBeReceivedFourYearsAndThereafter" xlink:type="locator" xlink:label="urgn_LesseeOperatingSubLeasePaymentsToBeReceivedFourYearsAndThereafter" />
    <link:label xml:lang="en-US" xlink:label="urgn_LesseeOperatingSubLeasePaymentsToBeReceivedFourYearsAndThereafter_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Lessee operating sublease payments to be received four years and thereafter.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="urgn_LesseeOperatingSubLeasePaymentsToBeReceivedFourYearsAndThereafter" xlink:to="urgn_LesseeOperatingSubLeasePaymentsToBeReceivedFourYearsAndThereafter_lbl" />
    <link:loc xlink:href="urgn-20210331.xsd#urgn_LesseeOperatingSubLeasePaymentsToBeReceived" xlink:type="locator" xlink:label="urgn_LesseeOperatingSubLeasePaymentsToBeReceived" />
    <link:label xml:lang="en-US" xlink:label="urgn_LesseeOperatingSubLeasePaymentsToBeReceived_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Lessee operating sub lease payments to be received.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="urgn_LesseeOperatingSubLeasePaymentsToBeReceived" xlink:to="urgn_LesseeOperatingSubLeasePaymentsToBeReceived_lbl" />
    <link:label xml:lang="en-US" xlink:label="urgn_LesseeOperatingSubLeasePaymentsToBeReceivedRemainderOfFiscalYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Remainder of 2021</link:label>
    <link:label xml:lang="en-US" xlink:label="urgn_LesseeOperatingSubLeasePaymentsToBeReceivedRemainderOfFiscalYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Sub Lease Payments To Be Received Remainder Of Fiscal Year</link:label>
    <link:label xml:lang="en-US" xlink:label="urgn_LesseeOperatingSubLeasePaymentsToBeReceivedNextTwelveMonths_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2022</link:label>
    <link:label xml:lang="en-US" xlink:label="urgn_LesseeOperatingSubLeasePaymentsToBeReceivedNextTwelveMonths_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Sub Lease Payments To Be Received Next Twelve Months</link:label>
    <link:label xml:lang="en-US" xlink:label="urgn_LesseeOperatingSubLeasePaymentsToBeReceivedTwoYears_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2023</link:label>
    <link:label xml:lang="en-US" xlink:label="urgn_LesseeOperatingSubLeasePaymentsToBeReceivedTwoYears_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Sub Lease Payments To Be Received Two Years</link:label>
    <link:label xml:lang="en-US" xlink:label="urgn_LesseeOperatingSubLeasePaymentsToBeReceivedThreeYears_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2024</link:label>
    <link:label xml:lang="en-US" xlink:label="urgn_LesseeOperatingSubLeasePaymentsToBeReceivedThreeYears_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Sub Lease Payments To Be Received Three Years</link:label>
    <link:label xml:lang="en-US" xlink:label="urgn_LesseeOperatingSubLeasePaymentsToBeReceivedFourYears_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2025</link:label>
    <link:label xml:lang="en-US" xlink:label="urgn_LesseeOperatingSubLeasePaymentsToBeReceivedFourYears_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Sub Lease Payments To Be Received Four Years</link:label>
    <link:label xml:lang="en-US" xlink:label="urgn_LesseeOperatingSubLeasePaymentsToBeReceivedFourYearsAndThereafter_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2026 and thereafter</link:label>
    <link:label xml:lang="en-US" xlink:label="urgn_LesseeOperatingSubLeasePaymentsToBeReceivedFourYearsAndThereafter_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Sub Lease Payments To Be Received Four Years And Thereafter</link:label>
    <link:label xml:lang="en-US" xlink:label="urgn_LesseeOperatingSubLeasePaymentsToBeReceived_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Lessee operating sublease payments to be received</link:label>
    <link:label xml:lang="en-US" xlink:label="urgn_LesseeOperatingSubLeasePaymentsToBeReceived_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Sub Lease Payments To Be Received</link:label>
    <link:loc xlink:href="urgn-20210331.xsd#urgn_LesseeOperatingSubLeaseIncomeFromFixedLeasePayments" xlink:type="locator" xlink:label="urgn_LesseeOperatingSubLeaseIncomeFromFixedLeasePayments" />
    <link:label xml:lang="en-US" xlink:label="urgn_LesseeOperatingSubLeaseIncomeFromFixedLeasePayments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Lessee operating sub lease income from fixed lease payments.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="urgn_LesseeOperatingSubLeaseIncomeFromFixedLeasePayments" xlink:to="urgn_LesseeOperatingSubLeaseIncomeFromFixedLeasePayments_lbl" />
    <link:loc xlink:href="urgn-20210331.xsd#urgn_LesseeOperatingSubLeaseIncomeFromVariablePayments" xlink:type="locator" xlink:label="urgn_LesseeOperatingSubLeaseIncomeFromVariablePayments" />
    <link:label xml:lang="en-US" xlink:label="urgn_LesseeOperatingSubLeaseIncomeFromVariablePayments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Lessee operating sub lease income from variable payments.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="urgn_LesseeOperatingSubLeaseIncomeFromVariablePayments" xlink:to="urgn_LesseeOperatingSubLeaseIncomeFromVariablePayments_lbl" />
    <link:label xml:lang="en-US" xlink:label="urgn_LesseeOperatingSubLeaseIncomeFromFixedLeasePayments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sublease income from fixed lease payments</link:label>
    <link:label xml:lang="en-US" xlink:label="urgn_LesseeOperatingSubLeaseIncomeFromFixedLeasePayments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Sub Lease Income From Fixed Lease Payments</link:label>
    <link:label xml:lang="en-US" xlink:label="urgn_LesseeOperatingSubLeaseIncomeFromVariablePayments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sublease income from variable payments</link:label>
    <link:label xml:lang="en-US" xlink:label="urgn_LesseeOperatingSubLeaseIncomeFromVariablePayments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Sub Lease Income From Variable Payments</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubleaseIncome_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Sublease income</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList" xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue from Contract with Customer Product and Service [Extensible List]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList" xlink:to="us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Revenue From Contract With Customer Product And Service Extensible List</link:label>
    <link:loc xlink:href="urgn-20210331.xsd#urgn_ContractWithCustomerAdditionalMilestonePaymentEligibleToReceive" xlink:type="locator" xlink:label="urgn_ContractWithCustomerAdditionalMilestonePaymentEligibleToReceive" />
    <link:label xml:lang="en-US" xlink:label="urgn_ContractWithCustomerAdditionalMilestonePaymentEligibleToReceive_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Contract with customer additional milestone payment eligible to receive.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="urgn_ContractWithCustomerAdditionalMilestonePaymentEligibleToReceive" xlink:to="urgn_ContractWithCustomerAdditionalMilestonePaymentEligibleToReceive_lbl" />
    <link:loc xlink:href="urgn-20210331.xsd#urgn_MilestonePaymentsReceivedForLicensingAgreement" xlink:type="locator" xlink:label="urgn_MilestonePaymentsReceivedForLicensingAgreement" />
    <link:label xml:lang="en-US" xlink:label="urgn_MilestonePaymentsReceivedForLicensingAgreement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Milestone payment received for licensing agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="urgn_MilestonePaymentsReceivedForLicensingAgreement" xlink:to="urgn_MilestonePaymentsReceivedForLicensingAgreement_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Research And Development Arrangement Contract To Perform For Others [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Research And Development Arrangement Contract To Perform For Others [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis" xlink:type="locator" xlink:label="srt_CounterpartyNameAxis" />
    <link:label xml:lang="en-US" xlink:label="srt_CounterpartyNameAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Counterparty Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_CounterpartyNameAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_CounterpartyNameAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Counterparty Name [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <link:label xml:lang="en-US" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Counterparty Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Repurchase Agreement Counterparty Name [Domain]</link:label>
    <link:loc xlink:href="urgn-20210331.xsd#urgn_AllerganPharmaceuticalsInternationalLimitedAndAbbVieIncMember" xlink:type="locator" xlink:label="urgn_AllerganPharmaceuticalsInternationalLimitedAndAbbVieIncMember" />
    <link:label xml:lang="en-US" xlink:label="urgn_AllerganPharmaceuticalsInternationalLimitedAndAbbVieIncMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Allergan Pharmaceuticals International Limited and AbbVie Inc..</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="urgn_AllerganPharmaceuticalsInternationalLimitedAndAbbVieIncMember" xlink:to="urgn_AllerganPharmaceuticalsInternationalLimitedAndAbbVieIncMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="urgn_AllerganPharmaceuticalsInternationalLimitedAndAbbVieIncMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Allergan/AbbVie</link:label>
    <link:label xml:lang="en-US" xlink:label="urgn_AllerganPharmaceuticalsInternationalLimitedAndAbbVieIncMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Allergan Pharmaceuticals International Limited And Abb Vie Inc [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaborative Arrangement and Arrangement Other than Collaborative</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Type Of Arrangement [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaborative Arrangement and Arrangement Other than Collaborative</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Arrangements And Nonarrangement Transactions [Member]</link:label>
    <link:loc xlink:href="urgn-20210331.xsd#urgn_LicenseAgreementMember" xlink:type="locator" xlink:label="urgn_LicenseAgreementMember" />
    <link:label xml:lang="en-US" xlink:label="urgn_LicenseAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">License agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="urgn_LicenseAgreementMember" xlink:to="urgn_LicenseAgreementMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="urgn_LicenseAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">License Agreement</link:label>
    <link:label xml:lang="en-US" xlink:label="urgn_LicenseAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">License Agreement [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development Arrangement, Contract to Perform for Others, Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development Arrangement Contract To Perform For Others By Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development Arrangement, Contract to Perform for Others, Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development Arrangement Contract To Perform For Others Type [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LicenseAgreementTermsMember" xlink:type="locator" xlink:label="us-gaap_LicenseAgreementTermsMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LicenseAgreementTermsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Agenus Agreement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LicenseAgreementTermsMember" xlink:to="us-gaap_LicenseAgreementTermsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LicenseAgreementTermsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">License Agreement Terms [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementScenarioAxis" xlink:type="locator" xlink:label="srt_StatementScenarioAxis" />
    <link:label xml:lang="en-US" xlink:label="srt_StatementScenarioAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Scenario</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_StatementScenarioAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_StatementScenarioAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Scenario [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:type="locator" xlink:label="srt_ScenarioUnspecifiedDomain" />
    <link:label xml:lang="en-US" xlink:label="srt_ScenarioUnspecifiedDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Scenario</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="srt_ScenarioUnspecifiedDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_ScenarioUnspecifiedDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Scenario Unspecified [Domain]</link:label>
    <link:loc xlink:href="urgn-20210331.xsd#urgn_AfterFirstCommercialSaleOfLicensedProductMember" xlink:type="locator" xlink:label="urgn_AfterFirstCommercialSaleOfLicensedProductMember" />
    <link:label xml:lang="en-US" xlink:label="urgn_AfterFirstCommercialSaleOfLicensedProductMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">After first commercial sale of licensed product.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="urgn_AfterFirstCommercialSaleOfLicensedProductMember" xlink:to="urgn_AfterFirstCommercialSaleOfLicensedProductMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="urgn_AfterFirstCommercialSaleOfLicensedProductMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">After First Commercial Sale of Licensed Product</link:label>
    <link:label xml:lang="en-US" xlink:label="urgn_AfterFirstCommercialSaleOfLicensedProductMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">After First Commercial Sale Of Licensed Product [Member]</link:label>
    <link:loc xlink:href="urgn-20210331.xsd#urgn_MDAndersonMember" xlink:type="locator" xlink:label="urgn_MDAndersonMember" />
    <link:label xml:lang="en-US" xlink:label="urgn_MDAndersonMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">MD Anderson.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="urgn_MDAndersonMember" xlink:to="urgn_MDAndersonMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="urgn_MDAndersonMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">MD Anderson</link:label>
    <link:label xml:lang="en-US" xlink:label="urgn_MDAndersonMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">M D Anderson [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research And Development Arrangement Contract To Perform For Others [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development Arrangement Contract To Perform For Others [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="urgn_ContractWithCustomerAdditionalMilestonePaymentEligibleToReceive_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">License agreement additional milestone payments eligible to receive</link:label>
    <link:label xml:lang="en-US" xlink:label="urgn_ContractWithCustomerAdditionalMilestonePaymentEligibleToReceive_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Contract With Customer Additional Milestone Payment Eligible To Receive</link:label>
    <link:label xml:lang="en-US" xlink:label="urgn_MilestonePaymentsReceivedForLicensingAgreement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Milestone payments received for licensing agreement</link:label>
    <link:label xml:lang="en-US" xlink:label="urgn_MilestonePaymentsReceivedForLicensingAgreement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Milestone Payments Received For Licensing Agreement</link:label>
    <link:loc xlink:href="urgn-20210331.xsd#urgn_UpfrontFee" xlink:type="locator" xlink:label="urgn_UpfrontFee" />
    <link:label xml:lang="en-US" xlink:label="urgn_UpfrontFee_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Upfront fee.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="urgn_UpfrontFee" xlink:to="urgn_UpfrontFee_lbl" />
    <link:loc xlink:href="urgn-20210331.xsd#urgn_MaximumAmountPayableUponAchievingCertainClinicalDevelopmentAndRegulatoryMilestones" xlink:type="locator" xlink:label="urgn_MaximumAmountPayableUponAchievingCertainClinicalDevelopmentAndRegulatoryMilestones" />
    <link:label xml:lang="en-US" xlink:label="urgn_MaximumAmountPayableUponAchievingCertainClinicalDevelopmentAndRegulatoryMilestones_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Maximum amount payable upon achieving certain clinical development and regulatory milestones.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="urgn_MaximumAmountPayableUponAchievingCertainClinicalDevelopmentAndRegulatoryMilestones" xlink:to="urgn_MaximumAmountPayableUponAchievingCertainClinicalDevelopmentAndRegulatoryMilestones_lbl" />
    <link:loc xlink:href="urgn-20210331.xsd#urgn_MaximumAmountPayableUponAchievingCertainCommercialMilestones" xlink:type="locator" xlink:label="urgn_MaximumAmountPayableUponAchievingCertainCommercialMilestones" />
    <link:label xml:lang="en-US" xlink:label="urgn_MaximumAmountPayableUponAchievingCertainCommercialMilestones_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Maximum amount payable upon achieving certain commercial milestones.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="urgn_MaximumAmountPayableUponAchievingCertainCommercialMilestones" xlink:to="urgn_MaximumAmountPayableUponAchievingCertainCommercialMilestones_lbl" />
    <link:loc xlink:href="urgn-20210331.xsd#urgn_RoyaltyRangingOnNetSalesOfLicensedProducts" xlink:type="locator" xlink:label="urgn_RoyaltyRangingOnNetSalesOfLicensedProducts" />
    <link:label xml:lang="en-US" xlink:label="urgn_RoyaltyRangingOnNetSalesOfLicensedProducts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Royalty ranging on net sales of licensed products.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="urgn_RoyaltyRangingOnNetSalesOfLicensedProducts" xlink:to="urgn_RoyaltyRangingOnNetSalesOfLicensedProducts_lbl" />
    <link:label xml:lang="en-US" xlink:label="urgn_UpfrontFee_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Upfront fee</link:label>
    <link:label xml:lang="en-US" xlink:label="urgn_UpfrontFee_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Upfront Fee</link:label>
    <link:label xml:lang="en-US" xlink:label="urgn_MaximumAmountPayableUponAchievingCertainClinicalDevelopmentAndRegulatoryMilestones_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum amount payable upon achieving certain clinical development and regulatory milestones</link:label>
    <link:label xml:lang="en-US" xlink:label="urgn_MaximumAmountPayableUponAchievingCertainClinicalDevelopmentAndRegulatoryMilestones_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Maximum Amount Payable Upon Achieving Certain Clinical Development And Regulatory Milestones</link:label>
    <link:label xml:lang="en-US" xlink:label="urgn_MaximumAmountPayableUponAchievingCertainCommercialMilestones_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum amount payable upon achieving certain commercial milestones</link:label>
    <link:label xml:lang="en-US" xlink:label="urgn_MaximumAmountPayableUponAchievingCertainCommercialMilestones_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Maximum Amount Payable Upon Achieving Certain Commercial Milestones</link:label>
    <link:label xml:lang="en-US" xlink:label="urgn_RoyaltyRangingOnNetSalesOfLicensedProducts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Royalty ranging on net sales of licensed products</link:label>
    <link:label xml:lang="en-US" xlink:label="urgn_RoyaltyRangingOnNetSalesOfLicensedProducts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Royalty Ranging On Net Sales Of Licensed Products</link:label>
    <link:loc xlink:href="urgn-20210331.xsd#urgn_LicenseAgreementExpirationTerm" xlink:type="locator" xlink:label="urgn_LicenseAgreementExpirationTerm" />
    <link:label xml:lang="en-US" xlink:label="urgn_LicenseAgreementExpirationTerm_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">License agreement expiration term.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="urgn_LicenseAgreementExpirationTerm" xlink:to="urgn_LicenseAgreementExpirationTerm_lbl" />
    <link:label xml:lang="en-US" xlink:label="urgn_LicenseAgreementExpirationTerm_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">License agreement expiration term</link:label>
    <link:label xml:lang="en-US" xlink:label="urgn_LicenseAgreementExpirationTerm_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">License Agreement Expiration Term</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Payments recognized through research and development expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development Arrangement Contract To Perform For Others Costs Incurred Gross</link:label>
    <link:loc xlink:href="urgn-20210331.xsd#urgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardIndividualVotingPowersPercentage" xlink:type="locator" xlink:label="urgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardIndividualVotingPowersPercentage" />
    <link:label xml:lang="en-US" xlink:label="urgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardIndividualVotingPowersPercentage_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangement by share based payment award individual voting power percentage.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="urgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardIndividualVotingPowersPercentage" xlink:to="urgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardIndividualVotingPowersPercentage_lbl" />
    <link:loc xlink:href="urgn-20210331.xsd#urgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfPurchasePriceForIndividualsHavingMoreThanTenPercentOfCombinedVotingPower" xlink:type="locator" xlink:label="urgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfPurchasePriceForIndividualsHavingMoreThanTenPercentOfCombinedVotingPower" />
    <link:label xml:lang="en-US" xlink:label="urgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfPurchasePriceForIndividualsHavingMoreThanTenPercentOfCombinedVotingPower_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangement by share based payment award percentage of purchase price for individuals having more than ten percent of combined voting power.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="urgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfPurchasePriceForIndividualsHavingMoreThanTenPercentOfCombinedVotingPower" xlink:to="urgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfPurchasePriceForIndividualsHavingMoreThanTenPercentOfCombinedVotingPower_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]</link:label>
    <link:loc xlink:href="urgn-20210331.xsd#urgn_PlanMember" xlink:type="locator" xlink:label="urgn_PlanMember" />
    <link:label xml:lang="en-US" xlink:label="urgn_PlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Plan</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="urgn_PlanMember" xlink:to="urgn_PlanMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="urgn_PlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Plan</link:label>
    <link:label xml:lang="en-US" xlink:label="urgn_PlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Plan [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AwardTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Award Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AwardTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Award Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Award Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangements By Share Based Payment Award Award Type And Plan Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Employee Stock Option [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:type="locator" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted Stock Units (RSUs)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockUnitsRSUMember" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Stock Units R S U [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VestingAxis" xlink:type="locator" xlink:label="us-gaap_VestingAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_VestingAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vesting</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_VestingAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Vesting [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VestingDomain" xlink:type="locator" xlink:label="us-gaap_VestingDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_VestingDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vesting</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_VestingDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_VestingDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Vesting [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tranche One</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Award Tranche One [Member]</link:label>
    <link:loc xlink:href="urgn-20210331.xsd#urgn_TwoThousandSeventeenEquityIncentivePlanMember" xlink:type="locator" xlink:label="urgn_TwoThousandSeventeenEquityIncentivePlanMember" />
    <link:label xml:lang="en-US" xlink:label="urgn_TwoThousandSeventeenEquityIncentivePlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">2017 equity incentive plan.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="urgn_TwoThousandSeventeenEquityIncentivePlanMember" xlink:to="urgn_TwoThousandSeventeenEquityIncentivePlanMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="urgn_TwoThousandSeventeenEquityIncentivePlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2017 Equity Incentive Plan</link:label>
    <link:label xml:lang="en-US" xlink:label="urgn_TwoThousandSeventeenEquityIncentivePlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Seventeen Equity Incentive Plan [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PlanNameAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Plan Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PlanNameAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Plan Name [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PlanNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Plan Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PlanNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Plan Name [Domain]</link:label>
    <link:loc xlink:href="urgn-20210331.xsd#urgn_TwoThousandAndNineteenInducementPlanMember" xlink:type="locator" xlink:label="urgn_TwoThousandAndNineteenInducementPlanMember" />
    <link:label xml:lang="en-US" xlink:label="urgn_TwoThousandAndNineteenInducementPlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand and nineteen inducement plan.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="urgn_TwoThousandAndNineteenInducementPlanMember" xlink:to="urgn_TwoThousandAndNineteenInducementPlanMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="urgn_TwoThousandAndNineteenInducementPlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2019 Inducement Plan</link:label>
    <link:label xml:lang="en-US" xlink:label="urgn_TwoThousandAndNineteenInducementPlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand And Nineteen Inducement Plan [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options granted, expected term</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercise price of stock options as percentage of fair market value of shares on grant date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Purchase Price Of Common Stock Percent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Awards vesting period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1</link:label>
    <link:label xml:lang="en-US" xlink:label="urgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardIndividualVotingPowersPercentage_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Combined voting power percentage</link:label>
    <link:label xml:lang="en-US" xlink:label="urgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardIndividualVotingPowersPercentage_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Individual Voting Powers Percentage</link:label>
    <link:label xml:lang="en-US" xlink:label="urgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfPurchasePriceForIndividualsHavingMoreThanTenPercentOfCombinedVotingPower_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock options exercise price percentage for individuals possesses more than 10% of the combined voter power</link:label>
    <link:label xml:lang="en-US" xlink:label="urgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfPurchasePriceForIndividualsHavingMoreThanTenPercentOfCombinedVotingPower_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Percentage Of Purchase Price For Individuals Having More Than Ten Percent Of Combined Voting Power</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vesting percentage</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Award Vesting Rights Percentage</link:label>
    <link:loc xlink:href="urgn-20210331.xsd#urgn_ShareBasedGoodsAndNonEmployeeServicesTransactionSharesReserveIncreaseForIssuance" xlink:type="locator" xlink:label="urgn_ShareBasedGoodsAndNonEmployeeServicesTransactionSharesReserveIncreaseForIssuance" />
    <link:label xml:lang="en-US" xlink:label="urgn_ShareBasedGoodsAndNonEmployeeServicesTransactionSharesReserveIncreaseForIssuance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based goods and non-employee services transaction shares reserve increase for issuance.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="urgn_ShareBasedGoodsAndNonEmployeeServicesTransactionSharesReserveIncreaseForIssuance" xlink:to="urgn_ShareBasedGoodsAndNonEmployeeServicesTransactionSharesReserveIncreaseForIssuance_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSharesApprovedForIssuance" xlink:type="locator" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSharesApprovedForIssuance" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSharesApprovedForIssuance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum number of ordinary share issuable under the 2017 incentive plan</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSharesApprovedForIssuance" xlink:to="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSharesApprovedForIssuance_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSharesApprovedForIssuance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Goods And Nonemployee Services Transaction Shares Approved For Issuance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of ordinary shares reserved for issuance, percentage</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Percentage Of Outstanding Stock Maximum</link:label>
    <link:label xml:lang="en-US" xlink:label="urgn_ShareBasedGoodsAndNonEmployeeServicesTransactionSharesReserveIncreaseForIssuance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Increase in number of ordinary share issuable under the 2017 incentive plan</link:label>
    <link:label xml:lang="en-US" xlink:label="urgn_ShareBasedGoodsAndNonEmployeeServicesTransactionSharesReserveIncreaseForIssuance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Goods And Non Employee Services Transaction Shares Reserve Increase For Issuance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of stock options approved for grants</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Statement Location</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement Location [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Statement Location</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement Location [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development Expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development Expense [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:type="locator" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Selling, General and Administrative Expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Selling General And Administrative Expenses [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-based compensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Allocated Share Based Compensation Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrecognized compensation cost of options and RSUs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected to be recognized over a weighted average period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:type="locator" xlink:label="us-gaap_UnrecognizedTaxBenefits" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Liability for uncertain tax positions</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefits" xlink:to="us-gaap_UnrecognizedTaxBenefits_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:type="locator" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued interest and penalties included in liability for uncertain tax positions</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued</link:label>
    <link:loc xlink:href="urgn-20210331.xsd#urgn_MaximumPercentageOfCommitmentToContinueEmploymentOfResearchAndDevelopmentJobs" xlink:type="locator" xlink:label="urgn_MaximumPercentageOfCommitmentToContinueEmploymentOfResearchAndDevelopmentJobs" />
    <link:label xml:lang="en-US" xlink:label="urgn_MaximumPercentageOfCommitmentToContinueEmploymentOfResearchAndDevelopmentJobs_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Maximum percentage of commitment to continue employment of research and development jobs.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="urgn_MaximumPercentageOfCommitmentToContinueEmploymentOfResearchAndDevelopmentJobs" xlink:to="urgn_MaximumPercentageOfCommitmentToContinueEmploymentOfResearchAndDevelopmentJobs_lbl" />
    <link:loc xlink:href="urgn-20210331.xsd#urgn_MaximumTermForCommitmentToContinueEmploymentOfResearchAndDevelopmentJobs" xlink:type="locator" xlink:label="urgn_MaximumTermForCommitmentToContinueEmploymentOfResearchAndDevelopmentJobs" />
    <link:label xml:lang="en-US" xlink:label="urgn_MaximumTermForCommitmentToContinueEmploymentOfResearchAndDevelopmentJobs_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Maximum term for commitment to continue employment of research and development jobs.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="urgn_MaximumTermForCommitmentToContinueEmploymentOfResearchAndDevelopmentJobs" xlink:to="urgn_MaximumTermForCommitmentToContinueEmploymentOfResearchAndDevelopmentJobs_lbl" />
    <link:loc xlink:href="urgn-20210331.xsd#urgn_CommitmentsAndContingentLiabilitiesLineItems" xlink:type="locator" xlink:label="urgn_CommitmentsAndContingentLiabilitiesLineItems" />
    <link:label xml:lang="en-US" xlink:label="urgn_CommitmentsAndContingentLiabilitiesLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Commitments and contingent liabilities.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="urgn_CommitmentsAndContingentLiabilitiesLineItems" xlink:to="urgn_CommitmentsAndContingentLiabilitiesLineItems_lbl" />
    <link:loc xlink:href="urgn-20210331.xsd#urgn_CommitmentsAndContingentLiabilitiesTable" xlink:type="locator" xlink:label="urgn_CommitmentsAndContingentLiabilitiesTable" />
    <link:label xml:lang="en-US" xlink:label="urgn_CommitmentsAndContingentLiabilitiesTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Commitments and contingent liabilities.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="urgn_CommitmentsAndContingentLiabilitiesTable" xlink:to="urgn_CommitmentsAndContingentLiabilitiesTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="urgn_CommitmentsAndContingentLiabilitiesTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments And Contingent Liabilities [Table]</link:label>
    <link:label xml:lang="en-US" xlink:label="urgn_CommitmentsAndContingentLiabilitiesTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Commitments And Contingent Liabilities [Table]</link:label>
    <link:loc xlink:href="urgn-20210331.xsd#urgn_IsraelInnovationAuthorityMember" xlink:type="locator" xlink:label="urgn_IsraelInnovationAuthorityMember" />
    <link:label xml:lang="en-US" xlink:label="urgn_IsraelInnovationAuthorityMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Israel Innovation Authority.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="urgn_IsraelInnovationAuthorityMember" xlink:to="urgn_IsraelInnovationAuthorityMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="urgn_IsraelInnovationAuthorityMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">IIA</link:label>
    <link:label xml:lang="en-US" xlink:label="urgn_IsraelInnovationAuthorityMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Israel Innovation Authority [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualAxis" xlink:type="locator" xlink:label="srt_TitleOfIndividualAxis" />
    <link:label xml:lang="en-US" xlink:label="srt_TitleOfIndividualAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Title of Individual</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_TitleOfIndividualAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Title Of Individual [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" />
    <link:label xml:lang="en-US" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Title of Individual</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Title Of Individual With Relationship To Entity [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ChiefOperatingOfficerMember" xlink:type="locator" xlink:label="srt_ChiefOperatingOfficerMember" />
    <link:label xml:lang="en-US" xlink:label="srt_ChiefOperatingOfficerMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stephen Mullennix</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ChiefOperatingOfficerMember" xlink:to="srt_ChiefOperatingOfficerMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_ChiefOperatingOfficerMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Chief Operating Officer [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ChiefFinancialOfficerMember" xlink:type="locator" xlink:label="srt_ChiefFinancialOfficerMember" />
    <link:label xml:lang="en-US" xlink:label="srt_ChiefFinancialOfficerMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Peter Pfreundschuh</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ChiefFinancialOfficerMember" xlink:to="srt_ChiefFinancialOfficerMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_ChiefFinancialOfficerMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Chief Financial Officer [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="urgn_CommitmentsAndContingentLiabilitiesLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments And Contingent Liabilities [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="urgn_CommitmentsAndContingentLiabilitiesLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Commitments And Contingent Liabilities [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedRoyaltiesCurrentAndNoncurrent" xlink:type="locator" xlink:label="us-gaap_AccruedRoyaltiesCurrentAndNoncurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccruedRoyaltiesCurrentAndNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Royalty amount payable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedRoyaltiesCurrentAndNoncurrent" xlink:to="us-gaap_AccruedRoyaltiesCurrentAndNoncurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccruedRoyaltiesCurrentAndNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Royalties Current And Noncurrent</link:label>
    <link:label xml:lang="en-US" xlink:label="urgn_MaximumPercentageOfCommitmentToContinueEmploymentOfResearchAndDevelopmentJobs_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum percentage of commitment to continue employment of research and development jobs</link:label>
    <link:label xml:lang="en-US" xlink:label="urgn_MaximumPercentageOfCommitmentToContinueEmploymentOfResearchAndDevelopmentJobs_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Maximum Percentage Of Commitment To Continue Employment Of Research And Development Jobs</link:label>
    <link:label xml:lang="en-US" xlink:label="urgn_MaximumTermForCommitmentToContinueEmploymentOfResearchAndDevelopmentJobs_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum term for commitment to continue employment of research and development jobs</link:label>
    <link:label xml:lang="en-US" xlink:label="urgn_MaximumTermForCommitmentToContinueEmploymentOfResearchAndDevelopmentJobs_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Maximum Term For Commitment To Continue Employment Of Research And Development Jobs</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedBonusesCurrentAndNoncurrent" xlink:type="locator" xlink:label="us-gaap_AccruedBonusesCurrentAndNoncurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccruedBonusesCurrentAndNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued bonus payable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedBonusesCurrentAndNoncurrent" xlink:to="us-gaap_AccruedBonusesCurrentAndNoncurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccruedBonusesCurrentAndNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Bonuses Current And Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeveranceCosts1" xlink:type="locator" xlink:label="us-gaap_SeveranceCosts1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SeveranceCosts1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employee termination cost</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeveranceCosts1" xlink:to="us-gaap_SeveranceCosts1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SeveranceCosts1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Severance Costs1</link:label>
    <link:loc xlink:href="urgn-20210331.xsd#urgn_UpfrontCashPaymentReceivedNetOfCosts" xlink:type="locator" xlink:label="urgn_UpfrontCashPaymentReceivedNetOfCosts" />
    <link:label xml:lang="en-US" xlink:label="urgn_UpfrontCashPaymentReceivedNetOfCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Upfront cash payment received net of costs.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="urgn_UpfrontCashPaymentReceivedNetOfCosts" xlink:to="urgn_UpfrontCashPaymentReceivedNetOfCosts_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTable" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event [Table]</link:label>
    <link:loc xlink:href="urgn-20210331.xsd#urgn_RTWInvestmentsMember" xlink:type="locator" xlink:label="urgn_RTWInvestmentsMember" />
    <link:label xml:lang="en-US" xlink:label="urgn_RTWInvestmentsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">RTW Investments.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="urgn_RTWInvestmentsMember" xlink:to="urgn_RTWInvestmentsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="urgn_RTWInvestmentsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">RTW Investments</link:label>
    <link:label xml:lang="en-US" xlink:label="urgn_RTWInvestmentsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">R T W Investments [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventTypeDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember" xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Events</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:type="locator" xlink:label="us-gaap_SubsequentEventLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="urgn_UpfrontCashPaymentReceivedNetOfCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Upfront cash payment received net of costs</link:label>
    <link:label xml:lang="en-US" xlink:label="urgn_UpfrontCashPaymentReceivedNetOfCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Upfront Cash Payment Received Net Of Costs</link:label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>16
<FILENAME>urgn-20210331_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN ActiveDisclosure(SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2021-05-12T21:01:28.4376810+00:00 -->
<!-- Version            : 5.0.1.615 -->
<!-- Package ID         : 66acac3df2bb4a8e915da518ecfedb52 -->
<!-- Copyright (c) 2021 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.urogen.com/20210331/role/TemplateLink" xlink:href="urgn-20210331.xsd#TemplateLink" xlink:type="simple" />
  <link:roleRef roleURI="http://www.urogen.com/20210331/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="urgn-20210331.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.urogen.com/20210331/taxonomy/role/DocumentDocumentAndEntityInformation">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentTransitionReport" xlink:type="locator" xlink:label="dei_DocumentTransitionReport" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentQuarterlyReport" xlink:type="locator" xlink:label="dei_DocumentQuarterlyReport" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:type="locator" xlink:label="dei_EntityInteractiveDataCurrent" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:type="locator" xlink:label="dei_EntityCurrentReportingStatus" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany" xlink:type="locator" xlink:label="dei_EntityShellCompany" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:type="locator" xlink:label="dei_EntityCommonStockSharesOutstanding" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitySmallBusiness" xlink:type="locator" xlink:label="dei_EntitySmallBusiness" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory" xlink:type="locator" xlink:label="dei_EntityFilerCategory" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:type="locator" xlink:label="dei_CurrentFiscalYearEndDate" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:type="locator" xlink:label="dei_DocumentFiscalPeriodFocus" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:type="locator" xlink:label="dei_DocumentFiscalYearFocus" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalYearFocus" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalPeriodFocus" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CurrentFiscalYearEndDate" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFilerCategory" order="10230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntitySmallBusiness" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="10270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCommonStockSharesOutstanding" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityShellCompany" order="10310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCurrentReportingStatus" order="10330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityInteractiveDataCurrent" order="10350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentQuarterlyReport" order="10370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentTransitionReport" order="10390.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="10410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="10430.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="10450.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="10470.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="10490.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="10510.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="10530.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="10550.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="10570.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.urogen.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParentheticalUnaudited" xlink:href="urgn-20210331.xsd#Role_StatementCondensedConsolidatedBalanceSheetsParentheticalUnaudited" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.urogen.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParentheticalUnaudited">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesAuthorized" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesIssued" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesOutstanding" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.urogen.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" xlink:href="urgn-20210331.xsd#Role_StatementCondensedConsolidatedBalanceSheetsUnaudited" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.urogen.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue" xlink:type="locator" xlink:label="us-gaap_CommonStockValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities" xlink:type="locator" xlink:label="us-gaap_Liabilities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilityForUncertainTaxPositionsNoncurrent" xlink:type="locator" xlink:label="us-gaap_LiabilityForUncertainTaxPositionsNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:type="locator" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_OtherLiabilitiesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets" xlink:type="locator" xlink:label="us-gaap_Assets" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:type="locator" xlink:label="us-gaap_OtherAssetsNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedInvestmentsNoncurrent" xlink:type="locator" xlink:label="us-gaap_RestrictedInvestmentsNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsNoncurrentAbstract" xlink:type="locator" xlink:label="us-gaap_AssetsNoncurrentAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent" xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNet" xlink:type="locator" xlink:label="us-gaap_InventoryNet" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:type="locator" xlink:label="us-gaap_AccountsReceivableNetCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashCurrent" xlink:type="locator" xlink:label="us-gaap_RestrictedCashCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:type="locator" xlink:label="us-gaap_AssetsCurrentAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract" xlink:type="locator" xlink:label="us-gaap_AssetsAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AssetsAbstract" order="10260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" order="10340.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="10420.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" order="10460.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_RestrictedCashCurrent" order="10500.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AccountsReceivableNetCurrent" order="10540.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_InventoryNet" order="10580.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="10620.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" order="10660.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsNoncurrentAbstract" order="10700.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="10780.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_RestrictedInvestmentsNoncurrent" order="10820.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="10860.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" order="10900.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_OtherAssetsNoncurrent" order="10940.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Assets" order="10980.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" order="11020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="11100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" order="11180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" order="11220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OtherLiabilitiesCurrent" order="11260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" order="11300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesNoncurrentAbstract" order="11340.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="11420.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_LiabilityForUncertainTaxPositionsNoncurrent" order="11460.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_Liabilities" order="11500.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" order="11540.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" order="11580.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" order="11660.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" order="11700.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="11740.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="11780.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" order="11820.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="11860.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.urogen.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited" xlink:href="urgn-20210331.xsd#Role_StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.urogen.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <link:loc xlink:href="urgn-20210331.xsd#urgn_InterestAndOtherIncomeExpensesNet" xlink:type="locator" xlink:label="urgn_InterestAndOtherIncomeExpensesNet" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="locator" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:type="locator" xlink:label="us-gaap_OperatingExpensesAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GrossProfit" xlink:type="locator" xlink:label="us-gaap_GrossProfit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfRevenue" xlink:type="locator" xlink:label="us-gaap_CostOfRevenue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeStatementAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_CostOfRevenue" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_GrossProfit" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingExpensesAbstract" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="10300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense" order="10340.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingIncomeLoss" order="10380.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="urgn_InterestAndOtherIncomeExpensesNet" order="10420.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_NetIncomeLoss" order="10460.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" order="10500.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:to="us-gaap_NetIncomeLoss" order="10580.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" order="10620.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" order="10700.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax" order="10740.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted" order="10780.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" order="10820.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.urogen.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfShareholdersEquityUnaudited" xlink:href="urgn-20210331.xsd#Role_StatementCondensedConsolidatedStatementsOfShareholdersEquityUnaudited" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.urogen.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfShareholdersEquityUnaudited">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssued" xlink:type="locator" xlink:label="us-gaap_SharesIssued_li0l2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" xlink:label="us-gaap_StockholdersEquity_li0l2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssued" xlink:type="locator" xlink:label="us-gaap_SharesIssued" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesIssued" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" order="10330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="10350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" order="10470.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTax" order="10610.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="10750.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity_li0l2" order="10890.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesIssued_li0l2" order="10910.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.urogen.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowUnaudited" xlink:href="urgn-20210331.xsd#Role_StatementCondensedConsolidatedStatementsOfCashFlowUnaudited" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.urogen.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowUnaudited">
    <link:loc xlink:href="urgn-20210331.xsd#urgn_NonCashNewLeaseLiabilities" xlink:type="locator" xlink:label="urgn_NonCashNewLeaseLiabilities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_li0l2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:type="locator" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:type="locator" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInInventories" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
    <link:loc xlink:href="urgn-20210331.xsd#urgn_OperatingLeaseLiabilityAdjustments" xlink:type="locator" xlink:label="urgn_OperatingLeaseLiabilityAdjustments" />
    <link:loc xlink:href="urgn-20210331.xsd#urgn_OperatingLeaseRightOfUseAssetAmortization" xlink:type="locator" xlink:label="urgn_OperatingLeaseRightOfUseAssetAmortization" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:type="locator" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationAndAmortization" xlink:type="locator" xlink:label="us-gaap_DepreciationAndAmortization" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetIncomeLoss" order="10280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="10320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DepreciationAndAmortization" order="10400.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" order="10440.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" order="10480.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="urgn_OperatingLeaseRightOfUseAssetAmortization" order="10520.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="urgn_OperatingLeaseLiabilityAdjustments" order="10560.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" order="10600.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInInventories" order="10680.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable" order="10720.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="10760.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" order="10800.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" order="10840.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="10880.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" order="10920.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireMarketableSecurities" order="11000.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" order="11040.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="11080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="11120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="11160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="11240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" order="11280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="11320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" order="11360.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" order="11400.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_li0l2" order="11440.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" order="11480.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="urgn_NonCashNewLeaseLiabilities" order="11560.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.urogen.com/20210331/taxonomy/role/DisclosureBusinessAndNatureOfOperations" xlink:href="urgn-20210331.xsd#Role_DisclosureBusinessAndNatureOfOperations" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.urogen.com/20210331/taxonomy/role/DisclosureBusinessAndNatureOfOperations">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NatureOfOperations" xlink:type="locator" xlink:label="us-gaap_NatureOfOperations" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_NatureOfOperations" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.urogen.com/20210331/taxonomy/role/DisclosureBasisOfPresentation" xlink:href="urgn-20210331.xsd#Role_DisclosureBasisOfPresentation" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.urogen.com/20210331/taxonomy/role/DisclosureBasisOfPresentation">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BasisOfAccounting" xlink:type="locator" xlink:label="us-gaap_BasisOfAccounting" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_BasisOfAccounting" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.urogen.com/20210331/taxonomy/role/DisclosureSignificantAccountingPolicies" xlink:href="urgn-20210331.xsd#Role_DisclosureSignificantAccountingPolicies" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.urogen.com/20210331/taxonomy/role/DisclosureSignificantAccountingPolicies">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="locator" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.urogen.com/20210331/taxonomy/role/DisclosureOtherFinancialInformation" xlink:href="urgn-20210331.xsd#Role_DisclosureOtherFinancialInformation" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.urogen.com/20210331/taxonomy/role/DisclosureOtherFinancialInformation">
    <link:loc xlink:href="urgn-20210331.xsd#urgn_OtherFinancialInformationTextBlock" xlink:type="locator" xlink:label="urgn_OtherFinancialInformationTextBlock" />
    <link:loc xlink:href="urgn-20210331.xsd#urgn_OtherFinancialInformationAbstract" xlink:type="locator" xlink:label="urgn_OtherFinancialInformationAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="urgn_OtherFinancialInformationAbstract" xlink:to="urgn_OtherFinancialInformationTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.urogen.com/20210331/taxonomy/role/DisclosureInventories" xlink:href="urgn-20210331.xsd#Role_DisclosureInventories" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.urogen.com/20210331/taxonomy/role/DisclosureInventories">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_InventoryDisclosureTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_InventoryDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryDisclosureAbstract" xlink:to="us-gaap_InventoryDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.urogen.com/20210331/taxonomy/role/DisclosureFairValueMeasurements" xlink:href="urgn-20210331.xsd#Role_DisclosureFairValueMeasurements" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.urogen.com/20210331/taxonomy/role/DisclosureFairValueMeasurements">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.urogen.com/20210331/taxonomy/role/DisclosureMarketableSecurities" xlink:href="urgn-20210331.xsd#Role_DisclosureMarketableSecurities" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.urogen.com/20210331/taxonomy/role/DisclosureMarketableSecurities">
    <link:loc xlink:href="urgn-20210331.xsd#urgn_MarketableSecuritiesDisclosureTextBlock" xlink:type="locator" xlink:label="urgn_MarketableSecuritiesDisclosureTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:type="locator" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="urgn_MarketableSecuritiesDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.urogen.com/20210331/taxonomy/role/DisclosurePropertyAndEquipment" xlink:href="urgn-20210331.xsd#Role_DisclosurePropertyAndEquipment" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.urogen.com/20210331/taxonomy/role/DisclosurePropertyAndEquipment">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.urogen.com/20210331/taxonomy/role/DisclosureLeases" xlink:href="urgn-20210331.xsd#Role_DisclosureLeases" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.urogen.com/20210331/taxonomy/role/DisclosureLeases">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract" xlink:type="locator" xlink:label="us-gaap_LeasesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.urogen.com/20210331/taxonomy/role/DisclosureRevenueFromProductSales" xlink:href="urgn-20210331.xsd#Role_DisclosureRevenueFromProductSales" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.urogen.com/20210331/taxonomy/role/DisclosureRevenueFromProductSales">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.urogen.com/20210331/taxonomy/role/DisclosureLicenseAndCollaborationAgreements" xlink:href="urgn-20210331.xsd#Role_DisclosureLicenseAndCollaborationAgreements" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.urogen.com/20210331/taxonomy/role/DisclosureLicenseAndCollaborationAgreements">
    <link:loc xlink:href="urgn-20210331.xsd#urgn_LicenseAndCollaborationAgreementsDisclosureTextBlock" xlink:type="locator" xlink:label="urgn_LicenseAndCollaborationAgreementsDisclosureTextBlock" />
    <link:loc xlink:href="urgn-20210331.xsd#urgn_LiscenseAgreementAbstract" xlink:type="locator" xlink:label="urgn_LiscenseAgreementAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="urgn_LiscenseAgreementAbstract" xlink:to="urgn_LicenseAndCollaborationAgreementsDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.urogen.com/20210331/taxonomy/role/DisclosureShareholdersEquity" xlink:href="urgn-20210331.xsd#Role_DisclosureShareholdersEquity" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.urogen.com/20210331/taxonomy/role/DisclosureShareholdersEquity">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract" xlink:type="locator" xlink:label="us-gaap_EquityAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.urogen.com/20210331/taxonomy/role/DisclosureShareBasedCompensation" xlink:href="urgn-20210331.xsd#Role_DisclosureShareBasedCompensation" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.urogen.com/20210331/taxonomy/role/DisclosureShareBasedCompensation">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.urogen.com/20210331/taxonomy/role/DisclosureIncomeTaxes" xlink:href="urgn-20210331.xsd#Role_DisclosureIncomeTaxes" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.urogen.com/20210331/taxonomy/role/DisclosureIncomeTaxes">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.urogen.com/20210331/taxonomy/role/DisclosureRelatedParties" xlink:href="urgn-20210331.xsd#Role_DisclosureRelatedParties" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.urogen.com/20210331/taxonomy/role/DisclosureRelatedParties">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.urogen.com/20210331/taxonomy/role/DisclosureCommitmentsAndContingencies" xlink:href="urgn-20210331.xsd#Role_DisclosureCommitmentsAndContingencies" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.urogen.com/20210331/taxonomy/role/DisclosureCommitmentsAndContingencies">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.urogen.com/20210331/taxonomy/role/DisclosureSubsequentEvents" xlink:href="urgn-20210331.xsd#Role_DisclosureSubsequentEvents" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.urogen.com/20210331/taxonomy/role/DisclosureSubsequentEvents">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:type="locator" xlink:label="us-gaap_SubsequentEventsTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:type="locator" xlink:label="us-gaap_SubsequentEventsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.urogen.com/20210331/taxonomy/role/DisclosureSignificantAccountingPoliciesPolicies" xlink:href="urgn-20210331.xsd#Role_DisclosureSignificantAccountingPoliciesPolicies" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.urogen.com/20210331/taxonomy/role/DisclosureSignificantAccountingPoliciesPolicies">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansDirectorPolicy" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansDirectorPolicy" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_InventoryPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskCreditRisk" />
    <link:loc xlink:href="urgn-20210331.xsd#urgn_CashAndCashEquivalentsAndMarketableSecuritiesPolicyPolicyTextBlock" xlink:type="locator" xlink:label="urgn_CashAndCashEquivalentsAndMarketableSecuritiesPolicyPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UseOfEstimates" xlink:type="locator" xlink:label="us-gaap_UseOfEstimates" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_ConsolidationPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConsolidationPolicyTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="urgn_CashAndCashEquivalentsAndMarketableSecuritiesPolicyPolicyTextBlock" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConcentrationRiskCreditRisk" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_InventoryPolicyTextBlock" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" order="10230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansDirectorPolicy" order="10270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.urogen.com/20210331/taxonomy/role/DisclosureSignificantAccountingPoliciesTables" xlink:href="urgn-20210331.xsd#Role_DisclosureSignificantAccountingPoliciesTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.urogen.com/20210331/taxonomy/role/DisclosureSignificantAccountingPoliciesTables">
    <link:loc xlink:href="urgn-20210331.xsd#urgn_PropertyPlantAndEquipmentUsefulLifeTableTextBlock" xlink:type="locator" xlink:label="urgn_PropertyPlantAndEquipmentUsefulLifeTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="urgn_PropertyPlantAndEquipmentUsefulLifeTableTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.urogen.com/20210331/taxonomy/role/DisclosureOtherFinancialInformationTables" xlink:href="urgn-20210331.xsd#Role_DisclosureOtherFinancialInformationTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.urogen.com/20210331/taxonomy/role/DisclosureOtherFinancialInformationTables">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock" xlink:type="locator" xlink:label="us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" />
    <link:loc xlink:href="urgn-20210331.xsd#urgn_OtherFinancialInformationAbstract" xlink:type="locator" xlink:label="urgn_OtherFinancialInformationAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="urgn_OtherFinancialInformationAbstract" xlink:to="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="urgn_OtherFinancialInformationAbstract" xlink:to="us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.urogen.com/20210331/taxonomy/role/DisclosureInventoriesTables" xlink:href="urgn-20210331.xsd#Role_DisclosureInventoriesTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.urogen.com/20210331/taxonomy/role/DisclosureInventoriesTables">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_InventoryDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryDisclosureAbstract" xlink:to="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.urogen.com/20210331/taxonomy/role/DisclosureFairValueMeasurementsTables" xlink:href="urgn-20210331.xsd#Role_DisclosureFairValueMeasurementsTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.urogen.com/20210331/taxonomy/role/DisclosureFairValueMeasurementsTables">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.urogen.com/20210331/taxonomy/role/DisclosureMarketableSecuritiesTables" xlink:href="urgn-20210331.xsd#Role_DisclosureMarketableSecuritiesTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.urogen.com/20210331/taxonomy/role/DisclosureMarketableSecuritiesTables">
    <link:loc xlink:href="urgn-20210331.xsd#urgn_SummaryOfFairValuesOfMarketableSecuritiesByContractualMaturityTableTextBlock" xlink:type="locator" xlink:label="urgn_SummaryOfFairValuesOfMarketableSecuritiesByContractualMaturityTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesTextBlock" xlink:type="locator" xlink:label="us-gaap_MarketableSecuritiesTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:type="locator" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_MarketableSecuritiesTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="urgn_SummaryOfFairValuesOfMarketableSecuritiesByContractualMaturityTableTextBlock" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.urogen.com/20210331/taxonomy/role/DisclosurePropertyAndEquipmentTables" xlink:href="urgn-20210331.xsd#Role_DisclosurePropertyAndEquipmentTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.urogen.com/20210331/taxonomy/role/DisclosurePropertyAndEquipmentTables">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.urogen.com/20210331/taxonomy/role/DisclosureLeasesTables" xlink:href="urgn-20210331.xsd#Role_DisclosureLeasesTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.urogen.com/20210331/taxonomy/role/DisclosureLeasesTables">
    <link:loc xlink:href="urgn-20210331.xsd#urgn_LesseeOperatingSubLeaseIncomeRecognizedNetInOperatingExpensesTableTextBlock" xlink:type="locator" xlink:label="urgn_LesseeOperatingSubLeaseIncomeRecognizedNetInOperatingExpensesTableTextBlock" />
    <link:loc xlink:href="urgn-20210331.xsd#urgn_LesseeOperatingSubLeasePaymentsToBeReceivedMaturityTableTextBlock" xlink:type="locator" xlink:label="urgn_LesseeOperatingSubLeasePaymentsToBeReceivedMaturityTableTextBlock" />
    <link:loc xlink:href="urgn-20210331.xsd#urgn_ScheduleOfSupplementalInformationRelatedToLeasesTableTextBlock" xlink:type="locator" xlink:label="urgn_ScheduleOfSupplementalInformationRelatedToLeasesTableTextBlock" />
    <link:loc xlink:href="urgn-20210331.xsd#urgn_ScheduleOfOperatingLeaseAmountsRecognizedUponAdoptionTableTextBlock" xlink:type="locator" xlink:label="urgn_ScheduleOfOperatingLeaseAmountsRecognizedUponAdoptionTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseCostTableTextBlock" xlink:type="locator" xlink:label="us-gaap_LeaseCostTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract" xlink:type="locator" xlink:label="us-gaap_LeasesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeaseCostTableTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="urgn_ScheduleOfOperatingLeaseAmountsRecognizedUponAdoptionTableTextBlock" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="urgn_ScheduleOfSupplementalInformationRelatedToLeasesTableTextBlock" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="urgn_LesseeOperatingSubLeasePaymentsToBeReceivedMaturityTableTextBlock" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="urgn_LesseeOperatingSubLeaseIncomeRecognizedNetInOperatingExpensesTableTextBlock" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.urogen.com/20210331/taxonomy/role/DisclosureRevenueFromProductSalesTables" xlink:href="urgn-20210331.xsd#Role_DisclosureRevenueFromProductSalesTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.urogen.com/20210331/taxonomy/role/DisclosureRevenueFromProductSalesTables">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:type="locator" xlink:label="us-gaap_DisaggregationOfRevenueTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="us-gaap_DisaggregationOfRevenueTableTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.urogen.com/20210331/taxonomy/role/DisclosureShareBasedCompensationTables" xlink:href="urgn-20210331.xsd#Role_DisclosureShareBasedCompensationTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.urogen.com/20210331/taxonomy/role/DisclosureShareBasedCompensationTables">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.urogen.com/20210331/taxonomy/role/DisclosureBusinessAndNatureOfOperationsAdditionalInformationDetails" xlink:href="urgn-20210331.xsd#Role_DisclosureBusinessAndNatureOfOperationsAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.urogen.com/20210331/taxonomy/role/DisclosureBusinessAndNatureOfOperationsAdditionalInformationDetails">
    <link:loc xlink:href="urgn-20210331.xsd#urgn_OperationsCommencedDateMonthAndYear" xlink:type="locator" xlink:label="urgn_OperationsCommencedDateMonthAndYear" />
    <link:loc xlink:href="urgn-20210331.xsd#urgn_EntityIncorporationDateOfIncorporationMonthAndYear" xlink:type="locator" xlink:label="urgn_EntityIncorporationDateOfIncorporationMonthAndYear" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="urgn_EntityIncorporationDateOfIncorporationMonthAndYear" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="urgn_OperationsCommencedDateMonthAndYear" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.urogen.com/20210331/taxonomy/role/DisclosureBasisOfPresentationAddititonalInformationDetails" xlink:href="urgn-20210331.xsd#Role_DisclosureBasisOfPresentationAddititonalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.urogen.com/20210331/taxonomy/role/DisclosureBasisOfPresentationAddititonalInformationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.urogen.com/20210331/taxonomy/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails" xlink:href="urgn-20210331.xsd#Role_DisclosureSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.urogen.com/20210331/taxonomy/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails">
    <link:loc xlink:href="urgn-20210331.xsd#urgn_CashCashEquivalentsAndMarketableSecurities" xlink:type="locator" xlink:label="urgn_CashCashEquivalentsAndMarketableSecurities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="urgn_CashCashEquivalentsAndMarketableSecurities" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.urogen.com/20210331/taxonomy/role/DisclosureSignificantAccountingPoliciesPropertyAndEquipmentUsefulLivesDetails" xlink:href="urgn-20210331.xsd#Role_DisclosureSignificantAccountingPoliciesPropertyAndEquipmentUsefulLivesDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.urogen.com/20210331/taxonomy/role/DisclosureSignificantAccountingPoliciesPropertyAndEquipmentUsefulLivesDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ManufacturingFacilityMember" xlink:type="locator" xlink:label="us-gaap_ManufacturingFacilityMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:type="locator" xlink:label="us-gaap_FurnitureAndFixturesMember" />
    <link:loc xlink:href="urgn-20210331.xsd#urgn_LaboratoryEquipmentMember" xlink:type="locator" xlink:label="urgn_LaboratoryEquipmentMember" />
    <link:loc xlink:href="urgn-20210331.xsd#urgn_ComputersAndSoftwareMember" xlink:type="locator" xlink:label="urgn_ComputersAndSoftwareMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="urgn_ComputersAndSoftwareMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="urgn_LaboratoryEquipmentMember" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ManufacturingFacilityMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="srt_RangeAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.urogen.com/20210331/taxonomy/role/DisclosureOtherFinancialInformationScheduleOfAccountsPayableAndAccruedExpensesDetails" xlink:href="urgn-20210331.xsd#Role_DisclosureOtherFinancialInformationScheduleOfAccountsPayableAndAccruedExpensesDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.urogen.com/20210331/taxonomy/role/DisclosureOtherFinancialInformationScheduleOfAccountsPayableAndAccruedExpensesDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" />
    <link:loc xlink:href="urgn-20210331.xsd#urgn_AccruedSellingGeneralAndAdministrativeExpenseCurrent" xlink:type="locator" xlink:label="urgn_AccruedSellingGeneralAndAdministrativeExpenseCurrent" />
    <link:loc xlink:href="urgn-20210331.xsd#urgn_AccruedResearchAndDevelopmentExpenseCurrent" xlink:type="locator" xlink:label="urgn_AccruedResearchAndDevelopmentExpenseCurrent" />
    <link:loc xlink:href="urgn-20210331.xsd#urgn_AccruedClinicalExpensesCurrent" xlink:type="locator" xlink:label="urgn_AccruedClinicalExpensesCurrent" />
    <link:loc xlink:href="urgn-20210331.xsd#urgn_AccruedSalesReserves" xlink:type="locator" xlink:label="urgn_AccruedSalesReserves" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" />
    <link:loc xlink:href="urgn-20210331.xsd#urgn_OtherFinancialInformationAbstract" xlink:type="locator" xlink:label="urgn_OtherFinancialInformationAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="urgn_OtherFinancialInformationAbstract" xlink:to="us-gaap_AccountsPayableCurrent" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="urgn_OtherFinancialInformationAbstract" xlink:to="urgn_AccruedSalesReserves" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="urgn_OtherFinancialInformationAbstract" xlink:to="urgn_AccruedClinicalExpensesCurrent" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="urgn_OtherFinancialInformationAbstract" xlink:to="urgn_AccruedResearchAndDevelopmentExpenseCurrent" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="urgn_OtherFinancialInformationAbstract" xlink:to="urgn_AccruedSellingGeneralAndAdministrativeExpenseCurrent" order="10230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="urgn_OtherFinancialInformationAbstract" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="10270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="urgn_OtherFinancialInformationAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" order="10310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.urogen.com/20210331/taxonomy/role/DisclosureOtherFinancialInformationScheduleOfInterestAndOtherIncomeExpensesDetails" xlink:href="urgn-20210331.xsd#Role_DisclosureOtherFinancialInformationScheduleOfInterestAndOtherIncomeExpensesDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.urogen.com/20210331/taxonomy/role/DisclosureOtherFinancialInformationScheduleOfInterestAndOtherIncomeExpensesDetails">
    <link:loc xlink:href="urgn-20210331.xsd#urgn_FinanceIncomeExpenseNet" xlink:type="locator" xlink:label="urgn_FinanceIncomeExpenseNet" />
    <link:loc xlink:href="urgn-20210331.xsd#urgn_OtherFinanceExpensesIncome" xlink:type="locator" xlink:label="urgn_OtherFinanceExpensesIncome" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:type="locator" xlink:label="us-gaap_InvestmentIncomeInterest" />
    <link:loc xlink:href="urgn-20210331.xsd#urgn_OtherFinancialInformationAbstract" xlink:type="locator" xlink:label="urgn_OtherFinancialInformationAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="urgn_OtherFinancialInformationAbstract" xlink:to="us-gaap_InvestmentIncomeInterest" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="urgn_OtherFinancialInformationAbstract" xlink:to="urgn_OtherFinanceExpensesIncome" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="urgn_OtherFinancialInformationAbstract" xlink:to="urgn_FinanceIncomeExpenseNet" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.urogen.com/20210331/taxonomy/role/DisclosureInventoriesScheduleOfInventoriesDetails" xlink:href="urgn-20210331.xsd#Role_DisclosureInventoriesScheduleOfInventoriesDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.urogen.com/20210331/taxonomy/role/DisclosureInventoriesScheduleOfInventoriesDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNet" xlink:type="locator" xlink:label="us-gaap_InventoryNet" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryFinishedGoods" xlink:type="locator" xlink:label="us-gaap_InventoryFinishedGoods" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryRawMaterials" xlink:type="locator" xlink:label="us-gaap_InventoryRawMaterials" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_InventoryDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryDisclosureAbstract" xlink:to="us-gaap_InventoryRawMaterials" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryDisclosureAbstract" xlink:to="us-gaap_InventoryFinishedGoods" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryDisclosureAbstract" xlink:to="us-gaap_InventoryNet" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.urogen.com/20210331/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails" xlink:href="urgn-20210331.xsd#Role_DisclosureFairValueMeasurementsAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.urogen.com/20210331/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesLevel2ToLevel1TransfersAmount" xlink:type="locator" xlink:label="us-gaap_FairValueLiabilitiesLevel2ToLevel1TransfersAmount" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesLevel1ToLevel2TransfersAmount" xlink:type="locator" xlink:label="us-gaap_FairValueLiabilitiesLevel1ToLevel2TransfersAmount" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueLiabilitiesLevel1ToLevel2TransfersAmount" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueLiabilitiesLevel2ToLevel1TransfersAmount" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.urogen.com/20210331/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" xlink:href="urgn-20210331.xsd#Role_DisclosureFairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.urogen.com/20210331/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:type="locator" xlink:label="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel2Member" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel1Member" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:type="locator" xlink:label="us-gaap_MoneyMarketFundsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateBondSecuritiesMember" xlink:type="locator" xlink:label="us-gaap_CorporateBondSecuritiesMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:type="locator" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="locator" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:type="locator" xlink:label="us-gaap_FinancialInstrumentAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTable" xlink:type="locator" xlink:label="us-gaap_FairValueByBalanceSheetGroupingTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueByBalanceSheetGroupingTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_FinancialInstrumentAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CorporateBondSecuritiesMember" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_MoneyMarketFundsMember" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" order="10260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" order="10520.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" order="10530.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.urogen.com/20210331/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfMarketableSecuritiesDetails" xlink:href="urgn-20210331.xsd#Role_DisclosureMarketableSecuritiesSummaryOfMarketableSecuritiesDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.urogen.com/20210331/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfMarketableSecuritiesDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesAbstract" xlink:type="locator" xlink:label="us-gaap_MarketableSecuritiesAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesLineItems" xlink:type="locator" xlink:label="us-gaap_MarketableSecuritiesLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:type="locator" xlink:label="us-gaap_MoneyMarketFundsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:type="locator" xlink:label="us-gaap_CorporateDebtSecuritiesMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USTreasuryAndGovernmentMember" xlink:type="locator" xlink:label="us-gaap_USTreasuryAndGovernmentMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:type="locator" xlink:label="us-gaap_InvestmentTypeCategorizationMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:type="locator" xlink:label="us-gaap_InvestmentTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesTable" xlink:type="locator" xlink:label="us-gaap_MarketableSecuritiesTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:type="locator" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_MarketableSecuritiesTable" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MarketableSecuritiesTable" xlink:to="us-gaap_InvestmentTypeAxis" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_USTreasuryAndGovernmentMember" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_CorporateDebtSecuritiesMember" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_MoneyMarketFundsMember" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MarketableSecuritiesTable" xlink:to="us-gaap_MarketableSecuritiesLineItems" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MarketableSecuritiesLineItems" xlink:to="us-gaap_MarketableSecuritiesAbstract" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MarketableSecuritiesAbstract" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" order="10420.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MarketableSecuritiesAbstract" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" order="10540.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MarketableSecuritiesAbstract" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" order="10660.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MarketableSecuritiesAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" order="10780.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.urogen.com/20210331/taxonomy/role/DisclosureMarketableSecuritiesAdditionalInformationDetails" xlink:href="urgn-20210331.xsd#Role_DisclosureMarketableSecuritiesAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.urogen.com/20210331/taxonomy/role/DisclosureMarketableSecuritiesAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesPortionRecognizedInEarnings" xlink:type="locator" xlink:label="us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesPortionRecognizedInEarnings" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:type="locator" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" />
    <link:loc xlink:href="urgn-20210331.xsd#urgn_DebtSecuritiesAvailableForSaleUnrealizedGainPosition" xlink:type="locator" xlink:label="urgn_DebtSecuritiesAvailableForSaleUnrealizedGainPosition" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestReceivable" xlink:type="locator" xlink:label="us-gaap_InterestReceivable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:type="locator" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_InterestReceivable" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="urgn_DebtSecuritiesAvailableForSaleUnrealizedGainPosition" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesPortionRecognizedInEarnings" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.urogen.com/20210331/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfFairValuesOfMarketableSecuritiesByContractualMaturityDetails" xlink:href="urgn-20210331.xsd#Role_DisclosureMarketableSecuritiesSummaryOfFairValuesOfMarketableSecuritiesByContractualMaturityDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.urogen.com/20210331/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfFairValuesOfMarketableSecuritiesByContractualMaturityDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities" />
    <link:loc xlink:href="urgn-20210331.xsd#urgn_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughThreeYearsFairValue" xlink:type="locator" xlink:label="urgn_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughThreeYearsFairValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract" xlink:to="urgn_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughThreeYearsFairValue" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.urogen.com/20210331/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails" xlink:href="urgn-20210331.xsd#Role_DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.urogen.com/20210331/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ManufacturingFacilityMember" xlink:type="locator" xlink:label="us-gaap_ManufacturingFacilityMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:type="locator" xlink:label="us-gaap_LeaseholdImprovementsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:type="locator" xlink:label="us-gaap_FurnitureAndFixturesMember" />
    <link:loc xlink:href="urgn-20210331.xsd#urgn_ComputersAndSoftwareMember" xlink:type="locator" xlink:label="urgn_ComputersAndSoftwareMember" />
    <link:loc xlink:href="urgn-20210331.xsd#urgn_LaboratoryEquipmentMember" xlink:type="locator" xlink:label="urgn_LaboratoryEquipmentMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="10040.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="urgn_LaboratoryEquipmentMember" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="urgn_ComputersAndSoftwareMember" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ManufacturingFacilityMember" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="10450.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="10490.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.urogen.com/20210331/taxonomy/role/DisclosurePropertyAndEquipmentAdditionalInformationDetails" xlink:href="urgn-20210331.xsd#Role_DisclosurePropertyAndEquipmentAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.urogen.com/20210331/taxonomy/role/DisclosurePropertyAndEquipmentAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:type="locator" xlink:label="us-gaap_DepreciationDepletionAndAmortization" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_DepreciationDepletionAndAmortization" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.urogen.com/20210331/taxonomy/role/DisclosureLeasesAdditionalInformationDetails" xlink:href="urgn-20210331.xsd#Role_DisclosureLeasesAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.urogen.com/20210331/taxonomy/role/DisclosureLeasesAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseImpairmentLoss" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseImpairmentLoss" />
    <link:loc xlink:href="urgn-20210331.xsd#urgn_LeaseExpirationYear" xlink:type="locator" xlink:label="urgn_LeaseExpirationYear" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubleaseIncome" xlink:type="locator" xlink:label="us-gaap_SubleaseIncome" />
    <link:loc xlink:href="urgn-20210331.xsd#urgn_LesseeOperatingSubleaseTerminationDateMonthAndYear" xlink:type="locator" xlink:label="urgn_LesseeOperatingSubleaseTerminationDateMonthAndYear" />
    <link:loc xlink:href="urgn-20210331.xsd#urgn_LesseeOperatingSubleaseCommencementDate" xlink:type="locator" xlink:label="urgn_LesseeOperatingSubleaseCommencementDate" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractualObligation" xlink:type="locator" xlink:label="us-gaap_ContractualObligation" />
    <link:loc xlink:href="urgn-20210331.xsd#urgn_ProceedsFromTenantAllowance" xlink:type="locator" xlink:label="urgn_ProceedsFromTenantAllowance" />
    <link:loc xlink:href="urgn-20210331.xsd#urgn_LeaseCommencementDate" xlink:type="locator" xlink:label="urgn_LeaseCommencementDate" />
    <link:loc xlink:href="urgn-20210331.xsd#urgn_LeaseTerminationDateMonthAndYear" xlink:type="locator" xlink:label="urgn_LeaseTerminationDateMonthAndYear" />
    <link:loc xlink:href="urgn-20210331.xsd#urgn_LeaseCommencementDateMonthAndYear" xlink:type="locator" xlink:label="urgn_LeaseCommencementDateMonthAndYear" />
    <link:loc xlink:href="urgn-20210331.xsd#urgn_LesseeOperatingLeaseExtendedLeaseExpirationDateMonthAndYear" xlink:type="locator" xlink:label="urgn_LesseeOperatingLeaseExtendedLeaseExpirationDateMonthAndYear" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:type="locator" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseAgreementsMember" xlink:type="locator" xlink:label="us-gaap_LeaseAgreementsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" />
    <link:loc xlink:href="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd#stpr_NJ" xlink:type="locator" xlink:label="stpr_NJ" />
    <link:loc xlink:href="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd#stpr_CA" xlink:type="locator" xlink:label="stpr_CA" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SubsidiariesMember" xlink:type="locator" xlink:label="srt_SubsidiariesMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidatedEntitiesDomain" xlink:type="locator" xlink:label="srt_ConsolidatedEntitiesDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidatedEntitiesAxis" xlink:type="locator" xlink:label="srt_ConsolidatedEntitiesAxis" />
    <link:loc xlink:href="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd#stpr_NY" xlink:type="locator" xlink:label="stpr_NY" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain" xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis" xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:type="locator" xlink:label="us-gaap_LesseeLeaseDescriptionTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract" xlink:type="locator" xlink:label="us-gaap_LeasesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeLeaseDescriptionTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="srt_StatementGeographicalAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="stpr_NY" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="srt_ConsolidatedEntitiesAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ConsolidatedEntitiesAxis" xlink:to="srt_ConsolidatedEntitiesDomain" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ConsolidatedEntitiesDomain" xlink:to="srt_SubsidiariesMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="stpr_CA" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="stpr_NJ" order="10320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" order="10420.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_LeaseAgreementsMember" order="10440.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="srt_RangeAxis" order="10030.06" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10480.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10500.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10520.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_LesseeLeaseDescriptionLineItems" order="10540.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" order="10550.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseOptionToExtend" order="10570.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm" order="10590.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="urgn_LesseeOperatingLeaseExtendedLeaseExpirationDateMonthAndYear" order="10610.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="urgn_LeaseCommencementDateMonthAndYear" order="10660.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="urgn_LeaseTerminationDateMonthAndYear" order="10680.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="urgn_LeaseCommencementDate" order="10730.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="urgn_ProceedsFromTenantAllowance" order="10810.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_ContractualObligation" order="10850.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="urgn_LesseeOperatingSubleaseCommencementDate" order="10890.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="urgn_LesseeOperatingSubleaseTerminationDateMonthAndYear" order="10930.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_SubleaseIncome" order="10970.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract" order="11060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="urgn_LeaseExpirationYear" order="11130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseImpairmentLoss" order="11200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.urogen.com/20210331/taxonomy/role/DisclosureLeasesComponentsOfLeaseCostDetails" xlink:href="urgn-20210331.xsd#Role_DisclosureLeasesComponentsOfLeaseCostDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.urogen.com/20210331/taxonomy/role/DisclosureLeasesComponentsOfLeaseCostDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseCost" xlink:type="locator" xlink:label="us-gaap_LeaseCost" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableLeaseCost" xlink:type="locator" xlink:label="us-gaap_VariableLeaseCost" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubleaseIncome" xlink:type="locator" xlink:label="us-gaap_SubleaseIncome" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseCost" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseCost" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract" xlink:type="locator" xlink:label="us-gaap_LeasesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeaseCost" order="10040.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_SubleaseIncome" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_VariableLeaseCost" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeaseCost" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.urogen.com/20210331/taxonomy/role/DisclosureLeasesScheduleOfAmountsRecognizedDetails" xlink:href="urgn-20210331.xsd#Role_DisclosureLeasesScheduleOfAmountsRecognizedDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.urogen.com/20210331/taxonomy/role/DisclosureLeasesScheduleOfAmountsRecognizedDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract" xlink:type="locator" xlink:label="us-gaap_LeasesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.urogen.com/20210331/taxonomy/role/DisclosureLeasesScheduleOfSupplementalInformationRelatedToLeasesDetails" xlink:href="urgn-20210331.xsd#Role_DisclosureLeasesScheduleOfSupplementalInformationRelatedToLeasesDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.urogen.com/20210331/taxonomy/role/DisclosureLeasesScheduleOfSupplementalInformationRelatedToLeasesDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="locator" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasePayments" xlink:type="locator" xlink:label="us-gaap_OperatingLeasePayments" />
    <link:loc xlink:href="urgn-20210331.xsd#urgn_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract" xlink:type="locator" xlink:label="urgn_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract" xlink:type="locator" xlink:label="us-gaap_LeasesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="urgn_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="urgn_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract" xlink:to="us-gaap_OperatingLeasePayments" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.urogen.com/20210331/taxonomy/role/DisclosureLeasesScheduleOfUndiscountedCashFlowsToBeReceivedUnderOperatingSubleaseOnAnnualBasisDetails" xlink:href="urgn-20210331.xsd#Role_DisclosureLeasesScheduleOfUndiscountedCashFlowsToBeReceivedUnderOperatingSubleaseOnAnnualBasisDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.urogen.com/20210331/taxonomy/role/DisclosureLeasesScheduleOfUndiscountedCashFlowsToBeReceivedUnderOperatingSubleaseOnAnnualBasisDetails">
    <link:loc xlink:href="urgn-20210331.xsd#urgn_LesseeOperatingSubLeasePaymentsToBeReceived" xlink:type="locator" xlink:label="urgn_LesseeOperatingSubLeasePaymentsToBeReceived" />
    <link:loc xlink:href="urgn-20210331.xsd#urgn_LesseeOperatingSubLeasePaymentsToBeReceivedFourYearsAndThereafter" xlink:type="locator" xlink:label="urgn_LesseeOperatingSubLeasePaymentsToBeReceivedFourYearsAndThereafter" />
    <link:loc xlink:href="urgn-20210331.xsd#urgn_LesseeOperatingSubLeasePaymentsToBeReceivedFourYears" xlink:type="locator" xlink:label="urgn_LesseeOperatingSubLeasePaymentsToBeReceivedFourYears" />
    <link:loc xlink:href="urgn-20210331.xsd#urgn_LesseeOperatingSubLeasePaymentsToBeReceivedThreeYears" xlink:type="locator" xlink:label="urgn_LesseeOperatingSubLeasePaymentsToBeReceivedThreeYears" />
    <link:loc xlink:href="urgn-20210331.xsd#urgn_LesseeOperatingSubLeasePaymentsToBeReceivedTwoYears" xlink:type="locator" xlink:label="urgn_LesseeOperatingSubLeasePaymentsToBeReceivedTwoYears" />
    <link:loc xlink:href="urgn-20210331.xsd#urgn_LesseeOperatingSubLeasePaymentsToBeReceivedNextTwelveMonths" xlink:type="locator" xlink:label="urgn_LesseeOperatingSubLeasePaymentsToBeReceivedNextTwelveMonths" />
    <link:loc xlink:href="urgn-20210331.xsd#urgn_LesseeOperatingSubLeasePaymentsToBeReceivedRemainderOfFiscalYear" xlink:type="locator" xlink:label="urgn_LesseeOperatingSubLeasePaymentsToBeReceivedRemainderOfFiscalYear" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract" xlink:type="locator" xlink:label="us-gaap_LeasesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="urgn_LesseeOperatingSubLeasePaymentsToBeReceivedRemainderOfFiscalYear" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="urgn_LesseeOperatingSubLeasePaymentsToBeReceivedNextTwelveMonths" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="urgn_LesseeOperatingSubLeasePaymentsToBeReceivedTwoYears" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="urgn_LesseeOperatingSubLeasePaymentsToBeReceivedThreeYears" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="urgn_LesseeOperatingSubLeasePaymentsToBeReceivedFourYears" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="urgn_LesseeOperatingSubLeasePaymentsToBeReceivedFourYearsAndThereafter" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="urgn_LesseeOperatingSubLeasePaymentsToBeReceived" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.urogen.com/20210331/taxonomy/role/DisclosureLeasesScheduleOfSubleaseIncomeRecognizedNetWithinOperatingExpensesDetails" xlink:href="urgn-20210331.xsd#Role_DisclosureLeasesScheduleOfSubleaseIncomeRecognizedNetWithinOperatingExpensesDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.urogen.com/20210331/taxonomy/role/DisclosureLeasesScheduleOfSubleaseIncomeRecognizedNetWithinOperatingExpensesDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubleaseIncome" xlink:type="locator" xlink:label="us-gaap_SubleaseIncome" />
    <link:loc xlink:href="urgn-20210331.xsd#urgn_LesseeOperatingSubLeaseIncomeFromVariablePayments" xlink:type="locator" xlink:label="urgn_LesseeOperatingSubLeaseIncomeFromVariablePayments" />
    <link:loc xlink:href="urgn-20210331.xsd#urgn_LesseeOperatingSubLeaseIncomeFromFixedLeasePayments" xlink:type="locator" xlink:label="urgn_LesseeOperatingSubLeaseIncomeFromFixedLeasePayments" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract" xlink:type="locator" xlink:label="us-gaap_LeasesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="urgn_LesseeOperatingSubLeaseIncomeFromFixedLeasePayments" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="urgn_LesseeOperatingSubLeaseIncomeFromVariablePayments" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_SubleaseIncome" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.urogen.com/20210331/taxonomy/role/DisclosureRevenueFromProductSalesScheduleOfNetProductSalesDetails" xlink:href="urgn-20210331.xsd#Role_DisclosureRevenueFromProductSalesScheduleOfNetProductSalesDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.urogen.com/20210331/taxonomy/role/DisclosureRevenueFromProductSalesScheduleOfNetProductSalesDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList" xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.urogen.com/20210331/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails" xlink:href="urgn-20210331.xsd#Role_DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.urogen.com/20210331/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross" />
    <link:loc xlink:href="urgn-20210331.xsd#urgn_LicenseAgreementExpirationTerm" xlink:type="locator" xlink:label="urgn_LicenseAgreementExpirationTerm" />
    <link:loc xlink:href="urgn-20210331.xsd#urgn_RoyaltyRangingOnNetSalesOfLicensedProducts" xlink:type="locator" xlink:label="urgn_RoyaltyRangingOnNetSalesOfLicensedProducts" />
    <link:loc xlink:href="urgn-20210331.xsd#urgn_MaximumAmountPayableUponAchievingCertainCommercialMilestones" xlink:type="locator" xlink:label="urgn_MaximumAmountPayableUponAchievingCertainCommercialMilestones" />
    <link:loc xlink:href="urgn-20210331.xsd#urgn_MaximumAmountPayableUponAchievingCertainClinicalDevelopmentAndRegulatoryMilestones" xlink:type="locator" xlink:label="urgn_MaximumAmountPayableUponAchievingCertainClinicalDevelopmentAndRegulatoryMilestones" />
    <link:loc xlink:href="urgn-20210331.xsd#urgn_UpfrontFee" xlink:type="locator" xlink:label="urgn_UpfrontFee" />
    <link:loc xlink:href="urgn-20210331.xsd#urgn_MilestonePaymentsReceivedForLicensingAgreement" xlink:type="locator" xlink:label="urgn_MilestonePaymentsReceivedForLicensingAgreement" />
    <link:loc xlink:href="urgn-20210331.xsd#urgn_ContractWithCustomerAdditionalMilestonePaymentEligibleToReceive" xlink:type="locator" xlink:label="urgn_ContractWithCustomerAdditionalMilestonePaymentEligibleToReceive" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" />
    <link:loc xlink:href="urgn-20210331.xsd#urgn_MDAndersonMember" xlink:type="locator" xlink:label="urgn_MDAndersonMember" />
    <link:loc xlink:href="urgn-20210331.xsd#urgn_AfterFirstCommercialSaleOfLicensedProductMember" xlink:type="locator" xlink:label="urgn_AfterFirstCommercialSaleOfLicensedProductMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:type="locator" xlink:label="srt_ScenarioUnspecifiedDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementScenarioAxis" xlink:type="locator" xlink:label="srt_StatementScenarioAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LicenseAgreementTermsMember" xlink:type="locator" xlink:label="us-gaap_LicenseAgreementTermsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="urgn-20210331.xsd#urgn_LicenseAgreementMember" xlink:type="locator" xlink:label="urgn_LicenseAgreementMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:loc xlink:href="urgn-20210331.xsd#urgn_AllerganPharmaceuticalsInternationalLimitedAndAbbVieIncMember" xlink:type="locator" xlink:label="urgn_AllerganPharmaceuticalsInternationalLimitedAndAbbVieIncMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis" xlink:type="locator" xlink:label="srt_CounterpartyNameAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" />
    <link:loc xlink:href="urgn-20210331.xsd#urgn_LiscenseAgreementAbstract" xlink:type="locator" xlink:label="urgn_LiscenseAgreementAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="urgn_LiscenseAgreementAbstract" xlink:to="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="srt_CounterpartyNameAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="urgn_AllerganPharmaceuticalsInternationalLimitedAndAbbVieIncMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="urgn_LicenseAgreementMember" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="srt_RangeAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" order="10030.06" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" order="10380.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="us-gaap_LicenseAgreementTermsMember" order="10400.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="srt_StatementScenarioAxis" order="10030.08" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" order="10580.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="urgn_AfterFirstCommercialSaleOfLicensedProductMember" order="10600.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="urgn_MDAndersonMember" order="10660.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" order="10680.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="urgn_ContractWithCustomerAdditionalMilestonePaymentEligibleToReceive" order="10690.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="urgn_MilestonePaymentsReceivedForLicensingAgreement" order="10710.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="urgn_UpfrontFee" order="10760.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="urgn_MaximumAmountPayableUponAchievingCertainClinicalDevelopmentAndRegulatoryMilestones" order="10780.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="urgn_MaximumAmountPayableUponAchievingCertainCommercialMilestones" order="10800.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="urgn_RoyaltyRangingOnNetSalesOfLicensedProducts" order="10820.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="urgn_LicenseAgreementExpirationTerm" order="10890.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross" order="10940.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.urogen.com/20210331/taxonomy/role/DisclosureShareholdersEquityAdditionalInformationDetails" xlink:href="urgn-20210331.xsd#Role_DisclosureShareholdersEquityAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.urogen.com/20210331/taxonomy/role/DisclosureShareholdersEquityAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract" xlink:type="locator" xlink:label="us-gaap_EquityAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_CommonStockSharesAuthorized" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_CommonStockSharesIssued" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_CommonStockSharesOutstanding" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.urogen.com/20210331/taxonomy/role/DisclosureShareBasedCompensationAdditionalInformationDetails" xlink:href="urgn-20210331.xsd#Role_DisclosureShareBasedCompensationAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.urogen.com/20210331/taxonomy/role/DisclosureShareBasedCompensationAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
    <link:loc xlink:href="urgn-20210331.xsd#urgn_ShareBasedGoodsAndNonEmployeeServicesTransactionSharesReserveIncreaseForIssuance" xlink:type="locator" xlink:label="urgn_ShareBasedGoodsAndNonEmployeeServicesTransactionSharesReserveIncreaseForIssuance" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSharesApprovedForIssuance" xlink:type="locator" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSharesApprovedForIssuance" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" />
    <link:loc xlink:href="urgn-20210331.xsd#urgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfPurchasePriceForIndividualsHavingMoreThanTenPercentOfCombinedVotingPower" xlink:type="locator" xlink:label="urgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfPurchasePriceForIndividualsHavingMoreThanTenPercentOfCombinedVotingPower" />
    <link:loc xlink:href="urgn-20210331.xsd#urgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardIndividualVotingPowersPercentage" xlink:type="locator" xlink:label="urgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardIndividualVotingPowersPercentage" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:loc xlink:href="urgn-20210331.xsd#urgn_TwoThousandAndNineteenInducementPlanMember" xlink:type="locator" xlink:label="urgn_TwoThousandAndNineteenInducementPlanMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <link:loc xlink:href="urgn-20210331.xsd#urgn_TwoThousandSeventeenEquityIncentivePlanMember" xlink:type="locator" xlink:label="urgn_TwoThousandSeventeenEquityIncentivePlanMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VestingDomain" xlink:type="locator" xlink:label="us-gaap_VestingDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VestingAxis" xlink:type="locator" xlink:label="us-gaap_VestingAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:type="locator" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" />
    <link:loc xlink:href="urgn-20210331.xsd#urgn_PlanMember" xlink:type="locator" xlink:label="urgn_PlanMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="urgn_PlanMember" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="10300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="10320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="10460.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_VestingAxis" order="10030.06" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain" order="10540.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember" order="10560.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="urgn_TwoThousandSeventeenEquityIncentivePlanMember" order="10640.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="10820.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="10030.08" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="10940.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="urgn_TwoThousandAndNineteenInducementPlanMember" order="10960.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="10980.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" order="10990.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" order="11010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" order="11030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="urgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardIndividualVotingPowersPercentage" order="11050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="urgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfPurchasePriceForIndividualsHavingMoreThanTenPercentOfCombinedVotingPower" order="11070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" order="11120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSharesApprovedForIssuance" order="11210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" order="11250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="urgn_ShareBasedGoodsAndNonEmployeeServicesTransactionSharesReserveIncreaseForIssuance" order="11330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" order="11560.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" order="11610.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" order="11630.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.urogen.com/20210331/taxonomy/role/DisclosureShareBasedCompensationScheduleOfEffectOfShareBasedCompensationOnCondensedConsolidatedStatementsOfOperationsDetails" xlink:href="urgn-20210331.xsd#Role_DisclosureShareBasedCompensationScheduleOfEffectOfShareBasedCompensationOnCondensedConsolidatedStatementsOfOperationsDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.urogen.com/20210331/taxonomy/role/DisclosureShareBasedCompensationScheduleOfEffectOfShareBasedCompensationOnCondensedConsolidatedStatementsOfOperationsDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:type="locator" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesMember" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.urogen.com/20210331/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" xlink:href="urgn-20210331.xsd#Role_DisclosureIncomeTaxesAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.urogen.com/20210331/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:type="locator" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:type="locator" xlink:label="us-gaap_UnrecognizedTaxBenefits" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_UnrecognizedTaxBenefits" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.urogen.com/20210331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" xlink:href="urgn-20210331.xsd#Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.urogen.com/20210331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeveranceCosts1" xlink:type="locator" xlink:label="us-gaap_SeveranceCosts1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedBonusesCurrentAndNoncurrent" xlink:type="locator" xlink:label="us-gaap_AccruedBonusesCurrentAndNoncurrent" />
    <link:loc xlink:href="urgn-20210331.xsd#urgn_MaximumTermForCommitmentToContinueEmploymentOfResearchAndDevelopmentJobs" xlink:type="locator" xlink:label="urgn_MaximumTermForCommitmentToContinueEmploymentOfResearchAndDevelopmentJobs" />
    <link:loc xlink:href="urgn-20210331.xsd#urgn_MaximumPercentageOfCommitmentToContinueEmploymentOfResearchAndDevelopmentJobs" xlink:type="locator" xlink:label="urgn_MaximumPercentageOfCommitmentToContinueEmploymentOfResearchAndDevelopmentJobs" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedRoyaltiesCurrentAndNoncurrent" xlink:type="locator" xlink:label="us-gaap_AccruedRoyaltiesCurrentAndNoncurrent" />
    <link:loc xlink:href="urgn-20210331.xsd#urgn_CommitmentsAndContingentLiabilitiesLineItems" xlink:type="locator" xlink:label="urgn_CommitmentsAndContingentLiabilitiesLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ChiefFinancialOfficerMember" xlink:type="locator" xlink:label="srt_ChiefFinancialOfficerMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ChiefOperatingOfficerMember" xlink:type="locator" xlink:label="srt_ChiefOperatingOfficerMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualAxis" xlink:type="locator" xlink:label="srt_TitleOfIndividualAxis" />
    <link:loc xlink:href="urgn-20210331.xsd#urgn_IsraelInnovationAuthorityMember" xlink:type="locator" xlink:label="urgn_IsraelInnovationAuthorityMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" />
    <link:loc xlink:href="urgn-20210331.xsd#urgn_CommitmentsAndContingentLiabilitiesTable" xlink:type="locator" xlink:label="urgn_CommitmentsAndContingentLiabilitiesTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="urgn_CommitmentsAndContingentLiabilitiesTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="urgn_CommitmentsAndContingentLiabilitiesTable" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="urgn_IsraelInnovationAuthorityMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="urgn_CommitmentsAndContingentLiabilitiesTable" xlink:to="srt_TitleOfIndividualAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_ChiefOperatingOfficerMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_ChiefFinancialOfficerMember" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="urgn_CommitmentsAndContingentLiabilitiesTable" xlink:to="urgn_CommitmentsAndContingentLiabilitiesLineItems" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="urgn_CommitmentsAndContingentLiabilitiesLineItems" xlink:to="us-gaap_AccruedRoyaltiesCurrentAndNoncurrent" order="10230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="urgn_CommitmentsAndContingentLiabilitiesLineItems" xlink:to="urgn_MaximumPercentageOfCommitmentToContinueEmploymentOfResearchAndDevelopmentJobs" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="urgn_CommitmentsAndContingentLiabilitiesLineItems" xlink:to="urgn_MaximumTermForCommitmentToContinueEmploymentOfResearchAndDevelopmentJobs" order="10270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="urgn_CommitmentsAndContingentLiabilitiesLineItems" xlink:to="us-gaap_AccruedBonusesCurrentAndNoncurrent" order="10320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="urgn_CommitmentsAndContingentLiabilitiesLineItems" xlink:to="us-gaap_SeveranceCosts1" order="10370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.urogen.com/20210331/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" xlink:href="urgn-20210331.xsd#Role_DisclosureSubsequentEventsAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.urogen.com/20210331/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails">
    <link:loc xlink:href="urgn-20210331.xsd#urgn_UpfrontCashPaymentReceivedNetOfCosts" xlink:type="locator" xlink:label="urgn_UpfrontCashPaymentReceivedNetOfCosts" />
    <link:loc xlink:href="urgn-20210331.xsd#urgn_UpfrontFee" xlink:type="locator" xlink:label="urgn_UpfrontFee" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:type="locator" xlink:label="us-gaap_SubsequentEventLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember" xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" />
    <link:loc xlink:href="urgn-20210331.xsd#urgn_RTWInvestmentsMember" xlink:type="locator" xlink:label="urgn_RTWInvestmentsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTable" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:type="locator" xlink:label="us-gaap_SubsequentEventsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="urgn_RTWInvestmentsMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventLineItems" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="urgn_UpfrontFee" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="urgn_UpfrontCashPaymentReceivedNetOfCosts" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>urgn-10q_20210331_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2020-01-31"
  xmlns:stpr="http://xbrl.sec.gov/stpr/2018-01-31"
  xmlns:urgn="http://www.urogen.com/20210331"
  xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="urgn-20210331.xsd" xlink:type="simple"/>
    <context id="C_0001668243_20210101_20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="C_0001668243_20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="C_0001668243_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001668243_20200101_20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="C_0001668243_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001668243_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001668243_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001668243_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001668243_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001668243_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="C_0001668243_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200101_20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="C_0001668243_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20200101_20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="C_0001668243_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20200101_20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="C_0001668243_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="C_0001668243_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="C_0001668243_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="C_0001668243_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="C_0001668243_20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="C_0001668243_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001668243_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001668243_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001668243_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001668243_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210101_20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="C_0001668243_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20210101_20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="C_0001668243_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20210101_20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="C_0001668243_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20210101_20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="C_0001668243_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="C_0001668243_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="C_0001668243_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="C_0001668243_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="C_0001668243_us-gaapPropertyPlantAndEquipmentByTypeAxis_urgnComputersAndSoftwareMember_20210101_20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">urgn:ComputersAndSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="C_0001668243_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapManufacturingFacilityMember_20210101_20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ManufacturingFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="C_0001668243_srtRangeAxis_srtMinimumMember_us-gaapPropertyPlantAndEquipmentByTypeAxis_urgnLaboratoryEquipmentMember_20210101_20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">urgn:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="C_0001668243_srtRangeAxis_srtMinimumMember_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapFurnitureAndFixturesMember_20210101_20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="C_0001668243_srtRangeAxis_srtMaximumMember_us-gaapPropertyPlantAndEquipmentByTypeAxis_urgnLaboratoryEquipmentMember_20210101_20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">urgn:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="C_0001668243_srtRangeAxis_srtMaximumMember_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapFurnitureAndFixturesMember_20210101_20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="C_0001668243_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapFinancialInstrumentAxis_us-gaapUSGovernmentAgenciesDebtSecuritiesMember_20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="C_0001668243_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapFinancialInstrumentAxis_us-gaapUSGovernmentAgenciesDebtSecuritiesMember_20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="C_0001668243_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapFinancialInstrumentAxis_us-gaapCorporateBondSecuritiesMember_20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="C_0001668243_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapFinancialInstrumentAxis_us-gaapCorporateBondSecuritiesMember_20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="C_0001668243_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapFinancialInstrumentAxis_us-gaapMoneyMarketFundsMember_20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="C_0001668243_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapFinancialInstrumentAxis_us-gaapMoneyMarketFundsMember_20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="C_0001668243_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="C_0001668243_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="C_0001668243_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="C_0001668243_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapFinancialInstrumentAxis_us-gaapUSGovernmentAgenciesDebtSecuritiesMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001668243_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapFinancialInstrumentAxis_us-gaapUSGovernmentAgenciesDebtSecuritiesMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001668243_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapFinancialInstrumentAxis_us-gaapCorporateBondSecuritiesMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001668243_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapFinancialInstrumentAxis_us-gaapCorporateBondSecuritiesMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001668243_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapFinancialInstrumentAxis_us-gaapMoneyMarketFundsMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001668243_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapFinancialInstrumentAxis_us-gaapMoneyMarketFundsMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001668243_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001668243_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001668243_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001668243_us-gaapInvestmentTypeAxis_us-gaapUSTreasuryAndGovernmentMember_20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="C_0001668243_us-gaapInvestmentTypeAxis_us-gaapCorporateDebtSecuritiesMember_20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="C_0001668243_us-gaapInvestmentTypeAxis_us-gaapMoneyMarketFundsMember_20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="C_0001668243_us-gaapPropertyPlantAndEquipmentByTypeAxis_urgnLaboratoryEquipmentMember_20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">urgn:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="C_0001668243_us-gaapPropertyPlantAndEquipmentByTypeAxis_urgnLaboratoryEquipmentMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">urgn:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001668243_us-gaapPropertyPlantAndEquipmentByTypeAxis_urgnComputersAndSoftwareMember_20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">urgn:ComputersAndSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="C_0001668243_us-gaapPropertyPlantAndEquipmentByTypeAxis_urgnComputersAndSoftwareMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">urgn:ComputersAndSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001668243_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapFurnitureAndFixturesMember_20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="C_0001668243_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapFurnitureAndFixturesMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001668243_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapLeaseholdImprovementsMember_20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="C_0001668243_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapLeaseholdImprovementsMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001668243_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapManufacturingFacilityMember_20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ManufacturingFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="C_0001668243_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapManufacturingFacilityMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ManufacturingFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001668243_srtConsolidatedEntitiesAxis_srtSubsidiariesMember_srtStatementGeographicalAxis_stprNY_20170901_20170930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:NY</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-09-01</startDate>
            <endDate>2017-09-30</endDate>
        </period>
    </context>
    <context id="C_0001668243_srtConsolidatedEntitiesAxis_srtSubsidiariesMember_srtStatementGeographicalAxis_stprCA_20180401_20180430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-04-30</endDate>
        </period>
    </context>
    <context id="C_0001668243_srtConsolidatedEntitiesAxis_srtSubsidiariesMember_srtStatementGeographicalAxis_stprCA_20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="C_0001668243_srtConsolidatedEntitiesAxis_srtSubsidiariesMember_srtStatementGeographicalAxis_stprCA_20191101_20191130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-11-01</startDate>
            <endDate>2019-11-30</endDate>
        </period>
    </context>
    <context id="C_0001668243_srtConsolidatedEntitiesAxis_srtSubsidiariesMember_srtStatementGeographicalAxis_stprCA_20210101_20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="C_0001668243_srtConsolidatedEntitiesAxis_srtSubsidiariesMember_srtStatementGeographicalAxis_stprNJ_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapLeaseAgreementsMember_20191101_20191130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:NJ</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LeaseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-11-01</startDate>
            <endDate>2019-11-30</endDate>
        </period>
    </context>
    <context id="C_0001668243_srtConsolidatedEntitiesAxis_srtSubsidiariesMember_srtStatementGeographicalAxis_stprNJ_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapLeaseAgreementsMember_20191130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:NJ</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LeaseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-11-30</instant>
        </period>
    </context>
    <context id="C_0001668243_srtConsolidatedEntitiesAxis_srtSubsidiariesMember_srtStatementGeographicalAxis_stprNJ_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapLeaseAgreementsMember_20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:NJ</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LeaseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="C_0001668243_srtRangeAxis_srtMinimumMember_20210101_20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="C_0001668243_srtRangeAxis_srtMaximumMember_20210101_20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="C_0001668243_srtCounterpartyNameAxis_urgnAllerganPharmaceuticalsInternationalLimitedAndAbbVieIncMember_srtRangeAxis_srtMaximumMember_us-gaapTypeOfArrangementAxis_urgnLicenseAgreementMember_20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">urgn:AllerganPharmaceuticalsInternationalLimitedAndAbbVieIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">urgn:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="C_0001668243_srtCounterpartyNameAxis_urgnAllerganPharmaceuticalsInternationalLimitedAndAbbVieIncMember_us-gaapTypeOfArrangementAxis_urgnLicenseAgreementMember_20210101_20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">urgn:AllerganPharmaceuticalsInternationalLimitedAndAbbVieIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">urgn:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="C_0001668243_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_us-gaapLicenseAgreementTermsMember_20191101_20191130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-11-01</startDate>
            <endDate>2019-11-30</endDate>
        </period>
    </context>
    <context id="C_0001668243_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_us-gaapLicenseAgreementTermsMember_20191130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-11-30</instant>
        </period>
    </context>
    <context id="C_0001668243_srtRangeAxis_srtMinimumMember_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_us-gaapLicenseAgreementTermsMember_20191101_20191130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-11-01</startDate>
            <endDate>2019-11-30</endDate>
        </period>
    </context>
    <context id="C_0001668243_srtRangeAxis_srtMaximumMember_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_us-gaapLicenseAgreementTermsMember_20191101_20191130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-11-01</startDate>
            <endDate>2019-11-30</endDate>
        </period>
    </context>
    <context id="C_0001668243_srtStatementScenarioAxis_urgnAfterFirstCommercialSaleOfLicensedProductMember_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_us-gaapLicenseAgreementTermsMember_20191101_20191130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">urgn:AfterFirstCommercialSaleOfLicensedProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-11-01</startDate>
            <endDate>2019-11-30</endDate>
        </period>
    </context>
    <context id="C_0001668243_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_urgnMDAndersonMember_20210101_20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">urgn:MDAndersonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="C_0001668243_srtRangeAxis_srtMaximumMember_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapStatementEquityComponentsAxis_urgnPlanMember_20210101_20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">urgn:PlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="C_0001668243_srtRangeAxis_srtMinimumMember_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapStatementEquityComponentsAxis_urgnPlanMember_20210101_20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">urgn:PlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="C_0001668243_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapStatementEquityComponentsAxis_urgnPlanMember_20210101_20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">urgn:PlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="C_0001668243_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_us-gaapVestingAxis_us-gaapShareBasedCompensationAwardTrancheOneMember_20210101_20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="C_0001668243_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20210101_20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="C_0001668243_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapVestingAxis_us-gaapShareBasedCompensationAwardTrancheOneMember_20210101_20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="C_0001668243_us-gaapAwardTypeAxis_urgnTwoThousandSeventeenEquityIncentivePlanMember_20170301_20170331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">urgn:TwoThousandSeventeenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-03-01</startDate>
            <endDate>2017-03-31</endDate>
        </period>
    </context>
    <context id="C_0001668243_us-gaapAwardTypeAxis_urgnTwoThousandSeventeenEquityIncentivePlanMember_20210101_20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">urgn:TwoThousandSeventeenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="C_0001668243_us-gaapAwardTypeAxis_urgnTwoThousandSeventeenEquityIncentivePlanMember_20180101_20180101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">urgn:TwoThousandSeventeenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-01-01</endDate>
        </period>
    </context>
    <context id="C_0001668243_us-gaapAwardTypeAxis_urgnTwoThousandSeventeenEquityIncentivePlanMember_20181012_20181012">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">urgn:TwoThousandSeventeenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-10-12</startDate>
            <endDate>2018-10-12</endDate>
        </period>
    </context>
    <context id="C_0001668243_us-gaapAwardTypeAxis_urgnTwoThousandSeventeenEquityIncentivePlanMember_20200608_20200608">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">urgn:TwoThousandSeventeenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-08</startDate>
            <endDate>2020-06-08</endDate>
        </period>
    </context>
    <context id="C_0001668243_us-gaapAwardTypeAxis_urgnTwoThousandSeventeenEquityIncentivePlanMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20180101_20180101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">urgn:TwoThousandSeventeenEquityIncentivePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-01-01</endDate>
        </period>
    </context>
    <context id="C_0001668243_us-gaapAwardTypeAxis_urgnTwoThousandSeventeenEquityIncentivePlanMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20181012_20181012">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">urgn:TwoThousandSeventeenEquityIncentivePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-10-12</startDate>
            <endDate>2018-10-12</endDate>
        </period>
    </context>
    <context id="C_0001668243_us-gaapAwardTypeAxis_urgnTwoThousandSeventeenEquityIncentivePlanMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200608_20200608">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">urgn:TwoThousandSeventeenEquityIncentivePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-08</startDate>
            <endDate>2020-06-08</endDate>
        </period>
    </context>
    <context id="C_0001668243_us-gaapAwardTypeAxis_urgnTwoThousandSeventeenEquityIncentivePlanMember_20210317_20210317">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">urgn:TwoThousandSeventeenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-17</startDate>
            <endDate>2021-03-17</endDate>
        </period>
    </context>
    <context id="C_0001668243_us-gaapAwardTypeAxis_urgnTwoThousandSeventeenEquityIncentivePlanMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210317_20210317">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">urgn:TwoThousandSeventeenEquityIncentivePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-17</startDate>
            <endDate>2021-03-17</endDate>
        </period>
    </context>
    <context id="C_0001668243_us-gaapPlanNameAxis_urgnTwoThousandAndNineteenInducementPlanMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20190531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">urgn:TwoThousandAndNineteenInducementPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-05-31</instant>
        </period>
    </context>
    <context id="C_0001668243_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20210101_20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="C_0001668243_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20200101_20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="C_0001668243_us-gaapIncomeStatementLocationAxis_us-gaapSellingGeneralAndAdministrativeExpensesMember_20210101_20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="C_0001668243_us-gaapIncomeStatementLocationAxis_us-gaapSellingGeneralAndAdministrativeExpensesMember_20200101_20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="C_0001668243_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_urgnIsraelInnovationAuthorityMember_20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">urgn:IsraelInnovationAuthorityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="C_0001668243_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_urgnIsraelInnovationAuthorityMember_20210101_20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">urgn:IsraelInnovationAuthorityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="C_0001668243_srtTitleOfIndividualAxis_srtChiefOperatingOfficerMember_20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefOperatingOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="C_0001668243_srtTitleOfIndividualAxis_srtChiefFinancialOfficerMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefFinancialOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001668243_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_urgnRTWInvestmentsMember_20210101_20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">urgn:RTWInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="C_0001668243_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_urgnRTWInvestmentsMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20210513_20210513">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">urgn:RTWInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-13</startDate>
            <endDate>2021-05-13</endDate>
        </period>
    </context>
    <unit id="U_xbrlishares">
        <measure>shares</measure>
    </unit>
    <unit id="U_iso4217ILS_xbrlishares">
        <divide>
            <unitNumerator>
                <measure>iso4217:ILS</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="U_iso4217USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="U_iso4217USD_xbrlishares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="U_xbrlipure">
        <measure>pure</measure>
    </unit>
    <dei:AmendmentFlag contextRef="C_0001668243_20210101_20210331" id="F_000001">false</dei:AmendmentFlag>
    <dei:DocumentFiscalYearFocus contextRef="C_0001668243_20210101_20210331" id="F_000003">2021</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus contextRef="C_0001668243_20210101_20210331" id="F_000004">Q1</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey contextRef="C_0001668243_20210101_20210331" id="F_000009">0001668243</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate contextRef="C_0001668243_20210101_20210331" id="F_000010">--12-31</dei:CurrentFiscalYearEndDate>
    <us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend contextRef="C_0001668243_20210101_20210331" id="F_000347">true</us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend>
    <us-gaap:CommitmentsAndContingencies
      contextRef="C_0001668243_20210331"
      id="F_000076"
      unitRef="U_iso4217USD"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="C_0001668243_20201231"
      id="F_000077"
      unitRef="U_iso4217USD"
      xsi:nil="true"/>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="C_0001668243_us-gaapPropertyPlantAndEquipmentByTypeAxis_urgnComputersAndSoftwareMember_20210101_20210331"
      id="F_000251">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="C_0001668243_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapManufacturingFacilityMember_20210101_20210331"
      id="F_000252">P2Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="C_0001668243_srtRangeAxis_srtMinimumMember_us-gaapPropertyPlantAndEquipmentByTypeAxis_urgnLaboratoryEquipmentMember_20210101_20210331"
      id="F_000253">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="C_0001668243_srtRangeAxis_srtMinimumMember_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapFurnitureAndFixturesMember_20210101_20210331"
      id="F_000254">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="C_0001668243_srtRangeAxis_srtMaximumMember_us-gaapPropertyPlantAndEquipmentByTypeAxis_urgnLaboratoryEquipmentMember_20210101_20210331"
      id="F_000255">P6Y6M</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="C_0001668243_srtRangeAxis_srtMaximumMember_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapFurnitureAndFixturesMember_20210101_20210331"
      id="F_000256">P16Y6M</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList contextRef="C_0001668243_20210331" id="F_000370">us-gaap:OtherAssetsNoncurrent</us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList contextRef="C_0001668243_20210331" id="F_000373">us-gaap:OtherLiabilitiesCurrent</us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:RevenueFromContractWithCustomerProductAndServiceExtensibleList contextRef="C_0001668243_20210101_20210331" id="F_000386">urgn:JelmytoMember</us-gaap:RevenueFromContractWithCustomerProductAndServiceExtensibleList>
    <dei:DocumentType contextRef="C_0001668243_20210101_20210331" id="F_000000">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport contextRef="C_0001668243_20210101_20210331" id="F_000018">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate contextRef="C_0001668243_20210101_20210331" id="F_000002">2021-03-31</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport contextRef="C_0001668243_20210101_20210331" id="F_000019">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="C_0001668243_20210101_20210331" id="F_000020">001-38079</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="C_0001668243_20210101_20210331" id="F_000008">UROGEN PHARMA LTD.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="C_0001668243_20210101_20210331" id="F_000021">L3</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="C_0001668243_20210101_20210331" id="F_000022">98-1460746</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="C_0001668243_20210101_20210331" id="F_000023">400 Alexander Park Drive</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="C_0001668243_20210101_20210331" id="F_000024">Princeton</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="C_0001668243_20210101_20210331" id="F_000025">NJ</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="C_0001668243_20210101_20210331" id="F_000026">08540</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="C_0001668243_20210101_20210331" id="F_000027">646</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="C_0001668243_20210101_20210331" id="F_000028"> 768-9780</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="C_0001668243_20210101_20210331" id="F_000006">Ordinary Shares, par value NIS 0.01 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="C_0001668243_20210101_20210331" id="F_000005">URGN</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="C_0001668243_20210101_20210331" id="F_000007">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus contextRef="C_0001668243_20210101_20210331" id="F_000016">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="C_0001668243_20210101_20210331" id="F_000017">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="C_0001668243_20210101_20210331" id="F_000011">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="C_0001668243_20210101_20210331" id="F_000012">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="C_0001668243_20210101_20210331" id="F_000013">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany contextRef="C_0001668243_20210101_20210331" id="F_000015">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="C_0001668243_20210331"
      decimals="INF"
      id="F_000014"
      unitRef="U_xbrlishares">22280394</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_0001668243_20210331"
      decimals="-3"
      id="F_000037"
      unitRef="U_iso4217USD">40492000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_0001668243_20201231"
      decimals="-3"
      id="F_000038"
      unitRef="U_iso4217USD">52864000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="C_0001668243_20210331"
      decimals="-3"
      id="F_000039"
      unitRef="U_iso4217USD">35417000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="C_0001668243_20201231"
      decimals="-3"
      id="F_000040"
      unitRef="U_iso4217USD">49154000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:RestrictedCashCurrent
      contextRef="C_0001668243_20210331"
      decimals="-3"
      id="F_000041"
      unitRef="U_iso4217USD">1225000</us-gaap:RestrictedCashCurrent>
    <us-gaap:RestrictedCashCurrent
      contextRef="C_0001668243_20201231"
      decimals="-3"
      id="F_000042"
      unitRef="U_iso4217USD">1226000</us-gaap:RestrictedCashCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="C_0001668243_20210331"
      decimals="-3"
      id="F_000043"
      unitRef="U_iso4217USD">6301000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="C_0001668243_20201231"
      decimals="-3"
      id="F_000044"
      unitRef="U_iso4217USD">7047000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:InventoryNet
      contextRef="C_0001668243_20210331"
      decimals="-3"
      id="F_000045"
      unitRef="U_iso4217USD">3331000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="C_0001668243_20201231"
      decimals="-3"
      id="F_000046"
      unitRef="U_iso4217USD">1964000</us-gaap:InventoryNet>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_0001668243_20210331"
      decimals="-3"
      id="F_000047"
      unitRef="U_iso4217USD">6316000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_0001668243_20201231"
      decimals="-3"
      id="F_000048"
      unitRef="U_iso4217USD">3364000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="C_0001668243_20210331"
      decimals="-3"
      id="F_000049"
      unitRef="U_iso4217USD">93082000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="C_0001668243_20201231"
      decimals="-3"
      id="F_000050"
      unitRef="U_iso4217USD">115619000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_0001668243_20210331"
      decimals="-3"
      id="F_000051"
      unitRef="U_iso4217USD">2142000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_0001668243_20201231"
      decimals="-3"
      id="F_000052"
      unitRef="U_iso4217USD">2046000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:RestrictedInvestmentsNoncurrent
      contextRef="C_0001668243_20210331"
      decimals="-3"
      id="F_000053"
      unitRef="U_iso4217USD">223000</us-gaap:RestrictedInvestmentsNoncurrent>
    <us-gaap:RestrictedInvestmentsNoncurrent
      contextRef="C_0001668243_20201231"
      decimals="-3"
      id="F_000054"
      unitRef="U_iso4217USD">223000</us-gaap:RestrictedInvestmentsNoncurrent>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_0001668243_20210331"
      decimals="-3"
      id="F_000055"
      unitRef="U_iso4217USD">1901000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_0001668243_20201231"
      decimals="-3"
      id="F_000056"
      unitRef="U_iso4217USD">2158000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="C_0001668243_20201231"
      decimals="-3"
      id="F_000057"
      unitRef="U_iso4217USD">1893000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="C_0001668243_20210331"
      decimals="-3"
      id="F_000058"
      unitRef="U_iso4217USD">66000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="C_0001668243_20201231"
      decimals="-3"
      id="F_000059"
      unitRef="U_iso4217USD">66000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="C_0001668243_20210331"
      decimals="-3"
      id="F_000060"
      unitRef="U_iso4217USD">97414000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="C_0001668243_20201231"
      decimals="-3"
      id="F_000061"
      unitRef="U_iso4217USD">122005000</us-gaap:Assets>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="C_0001668243_20210331"
      decimals="-3"
      id="F_000062"
      unitRef="U_iso4217USD">10558000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="C_0001668243_20201231"
      decimals="-3"
      id="F_000063"
      unitRef="U_iso4217USD">10023000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="C_0001668243_20210331"
      decimals="-3"
      id="F_000064"
      unitRef="U_iso4217USD">4712000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="C_0001668243_20201231"
      decimals="-3"
      id="F_000065"
      unitRef="U_iso4217USD">9554000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="C_0001668243_20210331"
      decimals="-3"
      id="F_000066"
      unitRef="U_iso4217USD">1735000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="C_0001668243_20201231"
      decimals="-3"
      id="F_000067"
      unitRef="U_iso4217USD">1859000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_0001668243_20210331"
      decimals="-3"
      id="F_000068"
      unitRef="U_iso4217USD">17005000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_0001668243_20201231"
      decimals="-3"
      id="F_000069"
      unitRef="U_iso4217USD">21436000</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_0001668243_20210331"
      decimals="-3"
      id="F_000070"
      unitRef="U_iso4217USD">1201000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_0001668243_20201231"
      decimals="-3"
      id="F_000071"
      unitRef="U_iso4217USD">1497000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:LiabilityForUncertainTaxPositionsNoncurrent
      contextRef="C_0001668243_20210331"
      decimals="-3"
      id="F_000072"
      unitRef="U_iso4217USD">2717000</us-gaap:LiabilityForUncertainTaxPositionsNoncurrent>
    <us-gaap:LiabilityForUncertainTaxPositionsNoncurrent
      contextRef="C_0001668243_20201231"
      decimals="-3"
      id="F_000073"
      unitRef="U_iso4217USD">2717000</us-gaap:LiabilityForUncertainTaxPositionsNoncurrent>
    <us-gaap:Liabilities
      contextRef="C_0001668243_20210331"
      decimals="-3"
      id="F_000074"
      unitRef="U_iso4217USD">20923000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="C_0001668243_20201231"
      decimals="-3"
      id="F_000075"
      unitRef="U_iso4217USD">25650000</us-gaap:Liabilities>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_0001668243_20210331"
      decimals="INF"
      id="F_000029"
      unitRef="U_iso4217ILS_xbrlishares">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_0001668243_20201231"
      decimals="INF"
      id="F_000030"
      unitRef="U_iso4217ILS_xbrlishares">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_0001668243_20210331"
      decimals="INF"
      id="F_000031"
      unitRef="U_xbrlishares">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_0001668243_20201231"
      decimals="INF"
      id="F_000032"
      unitRef="U_xbrlishares">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_0001668243_20210331"
      decimals="INF"
      id="F_000033"
      unitRef="U_xbrlishares">22280394</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_0001668243_20210331"
      decimals="INF"
      id="F_000035"
      unitRef="U_xbrlishares">22280394</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_0001668243_20201231"
      decimals="INF"
      id="F_000034"
      unitRef="U_xbrlishares">22167791</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_0001668243_20201231"
      decimals="INF"
      id="F_000036"
      unitRef="U_xbrlishares">22167791</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="C_0001668243_20210331"
      decimals="-3"
      id="F_000078"
      unitRef="U_iso4217USD">61000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="C_0001668243_20201231"
      decimals="-3"
      id="F_000079"
      unitRef="U_iso4217USD">60000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="C_0001668243_20210331"
      decimals="-3"
      id="F_000080"
      unitRef="U_iso4217USD">458723000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="C_0001668243_20201231"
      decimals="-3"
      id="F_000081"
      unitRef="U_iso4217USD">452525000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_0001668243_20210331"
      decimals="-3"
      id="F_000082"
      unitRef="U_iso4217USD">-382436000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_0001668243_20201231"
      decimals="-3"
      id="F_000083"
      unitRef="U_iso4217USD">-356501000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="C_0001668243_20210331"
      decimals="-3"
      id="F_000084"
      unitRef="U_iso4217USD">143000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="C_0001668243_20201231"
      decimals="-3"
      id="F_000085"
      unitRef="U_iso4217USD">271000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquity
      contextRef="C_0001668243_20210331"
      decimals="-3"
      id="F_000086"
      unitRef="U_iso4217USD">76491000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001668243_20201231"
      decimals="-3"
      id="F_000087"
      unitRef="U_iso4217USD">96355000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="C_0001668243_20210331"
      decimals="-3"
      id="F_000088"
      unitRef="U_iso4217USD">97414000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="C_0001668243_20201231"
      decimals="-3"
      id="F_000089"
      unitRef="U_iso4217USD">122005000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0001668243_20210101_20210331"
      decimals="-3"
      id="F_000090"
      unitRef="U_iso4217USD">7485000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfRevenue
      contextRef="C_0001668243_20210101_20210331"
      decimals="-3"
      id="F_000091"
      unitRef="U_iso4217USD">897000</us-gaap:CostOfRevenue>
    <us-gaap:GrossProfit
      contextRef="C_0001668243_20210101_20210331"
      decimals="-3"
      id="F_000092"
      unitRef="U_iso4217USD">6588000</us-gaap:GrossProfit>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_0001668243_20210101_20210331"
      decimals="-3"
      id="F_000093"
      unitRef="U_iso4217USD">10513000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_0001668243_20200101_20200331"
      decimals="-3"
      id="F_000094"
      unitRef="U_iso4217USD">16588000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="C_0001668243_20210101_20210331"
      decimals="-3"
      id="F_000095"
      unitRef="U_iso4217USD">22189000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="C_0001668243_20200101_20200331"
      decimals="-3"
      id="F_000096"
      unitRef="U_iso4217USD">21973000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_0001668243_20210101_20210331"
      decimals="-3"
      id="F_000097"
      unitRef="U_iso4217USD">-26114000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_0001668243_20200101_20200331"
      decimals="-3"
      id="F_000098"
      unitRef="U_iso4217USD">-38561000</us-gaap:OperatingIncomeLoss>
    <urgn:InterestAndOtherIncomeExpensesNet
      contextRef="C_0001668243_20210101_20210331"
      decimals="-3"
      id="F_000099"
      unitRef="U_iso4217USD">179000</urgn:InterestAndOtherIncomeExpensesNet>
    <urgn:InterestAndOtherIncomeExpensesNet
      contextRef="C_0001668243_20200101_20200331"
      decimals="-3"
      id="F_000100"
      unitRef="U_iso4217USD">768000</urgn:InterestAndOtherIncomeExpensesNet>
    <us-gaap:NetIncomeLoss
      contextRef="C_0001668243_20210101_20210331"
      decimals="-3"
      id="F_000101"
      unitRef="U_iso4217USD">-25935000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_0001668243_20200101_20200331"
      decimals="-3"
      id="F_000102"
      unitRef="U_iso4217USD">-37793000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_0001668243_20210101_20210331"
      decimals="-3"
      id="F_000103"
      unitRef="U_iso4217USD">-25935000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_0001668243_20200101_20200331"
      decimals="-3"
      id="F_000104"
      unitRef="U_iso4217USD">-37793000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="C_0001668243_20210101_20210331"
      decimals="-3"
      id="F_000105"
      unitRef="U_iso4217USD">-128000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="C_0001668243_20200101_20200331"
      decimals="-3"
      id="F_000106"
      unitRef="U_iso4217USD">35000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="C_0001668243_20210101_20210331"
      decimals="-3"
      id="F_000107"
      unitRef="U_iso4217USD">-26063000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="C_0001668243_20200101_20200331"
      decimals="-3"
      id="F_000108"
      unitRef="U_iso4217USD">-37758000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="C_0001668243_20210101_20210331"
      decimals="2"
      id="F_000109"
      unitRef="U_iso4217USD_xbrlishares">-1.17</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="C_0001668243_20200101_20200331"
      decimals="2"
      id="F_000110"
      unitRef="U_iso4217USD_xbrlishares">-1.79</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="C_0001668243_20210101_20210331"
      decimals="0"
      id="F_000111"
      unitRef="U_xbrlishares">22242375</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="C_0001668243_20200101_20200331"
      decimals="0"
      id="F_000112"
      unitRef="U_xbrlishares">21158161</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:SharesIssued
      contextRef="C_0001668243_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20191231"
      decimals="INF"
      id="F_000113"
      unitRef="U_xbrlishares">21026184</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="C_0001668243_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20191231"
      decimals="-3"
      id="F_000114"
      unitRef="U_iso4217USD">57000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001668243_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20191231"
      decimals="-3"
      id="F_000115"
      unitRef="U_iso4217USD">407986000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001668243_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20191231"
      decimals="-3"
      id="F_000116"
      unitRef="U_iso4217USD">-228017000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001668243_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20191231"
      decimals="-3"
      id="F_000117"
      unitRef="U_iso4217USD">276000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001668243_20191231"
      decimals="-3"
      id="F_000118"
      unitRef="U_iso4217USD">180302000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_0001668243_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20200331"
      decimals="INF"
      id="F_000119"
      unitRef="U_xbrlishares">186756</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_0001668243_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20200331"
      decimals="-3"
      id="F_000120"
      unitRef="U_iso4217USD">1000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_0001668243_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200101_20200331"
      decimals="-3"
      id="F_000121"
      unitRef="U_iso4217USD">292000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_0001668243_20200101_20200331"
      decimals="-3"
      id="F_000122"
      unitRef="U_iso4217USD">293000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_0001668243_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200101_20200331"
      decimals="-3"
      id="F_000123"
      unitRef="U_iso4217USD">7617000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_0001668243_20200101_20200331"
      decimals="-3"
      id="F_000124"
      unitRef="U_iso4217USD">7617000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="C_0001668243_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20200101_20200331"
      decimals="-3"
      id="F_000125"
      unitRef="U_iso4217USD">35000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="C_0001668243_20200101_20200331"
      decimals="-3"
      id="F_000126"
      unitRef="U_iso4217USD">35000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="C_0001668243_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20200101_20200331"
      decimals="-3"
      id="F_000127"
      unitRef="U_iso4217USD">-37793000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_0001668243_20200101_20200331"
      decimals="-3"
      id="F_000128"
      unitRef="U_iso4217USD">-37793000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesIssued
      contextRef="C_0001668243_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200331"
      decimals="INF"
      id="F_000129"
      unitRef="U_xbrlishares">21212940</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="C_0001668243_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200331"
      decimals="-3"
      id="F_000130"
      unitRef="U_iso4217USD">58000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001668243_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200331"
      decimals="-3"
      id="F_000131"
      unitRef="U_iso4217USD">415895000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001668243_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20200331"
      decimals="-3"
      id="F_000132"
      unitRef="U_iso4217USD">-265810000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001668243_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20200331"
      decimals="-3"
      id="F_000133"
      unitRef="U_iso4217USD">311000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001668243_20200331"
      decimals="-3"
      id="F_000134"
      unitRef="U_iso4217USD">150454000</us-gaap:StockholdersEquity>
    <us-gaap:SharesIssued
      contextRef="C_0001668243_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20201231"
      decimals="INF"
      id="F_000135"
      unitRef="U_xbrlishares">22167791</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="C_0001668243_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20201231"
      decimals="-3"
      id="F_000136"
      unitRef="U_iso4217USD">60000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001668243_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20201231"
      decimals="-3"
      id="F_000137"
      unitRef="U_iso4217USD">452525000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001668243_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20201231"
      decimals="-3"
      id="F_000138"
      unitRef="U_iso4217USD">-356501000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001668243_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20201231"
      decimals="-3"
      id="F_000139"
      unitRef="U_iso4217USD">271000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001668243_20201231"
      decimals="-3"
      id="F_000140"
      unitRef="U_iso4217USD">96355000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_0001668243_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210101_20210331"
      decimals="INF"
      id="F_000141"
      unitRef="U_xbrlishares">112603</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_0001668243_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210101_20210331"
      decimals="-3"
      id="F_000142"
      unitRef="U_iso4217USD">1000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_0001668243_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20210101_20210331"
      decimals="-3"
      id="F_000143"
      unitRef="U_iso4217USD">3000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_0001668243_20210101_20210331"
      decimals="-3"
      id="F_000144"
      unitRef="U_iso4217USD">4000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_0001668243_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20210101_20210331"
      decimals="-3"
      id="F_000145"
      unitRef="U_iso4217USD">6195000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_0001668243_20210101_20210331"
      decimals="-3"
      id="F_000146"
      unitRef="U_iso4217USD">6195000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="C_0001668243_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20210101_20210331"
      decimals="-3"
      id="F_000147"
      unitRef="U_iso4217USD">-128000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="C_0001668243_20210101_20210331"
      decimals="-3"
      id="F_000148"
      unitRef="U_iso4217USD">-128000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="C_0001668243_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20210101_20210331"
      decimals="-3"
      id="F_000149"
      unitRef="U_iso4217USD">-25935000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_0001668243_20210101_20210331"
      decimals="-3"
      id="F_000150"
      unitRef="U_iso4217USD">-25935000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesIssued
      contextRef="C_0001668243_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210331"
      decimals="INF"
      id="F_000151"
      unitRef="U_xbrlishares">22280394</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="C_0001668243_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210331"
      decimals="-3"
      id="F_000152"
      unitRef="U_iso4217USD">61000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001668243_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20210331"
      decimals="-3"
      id="F_000153"
      unitRef="U_iso4217USD">458723000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001668243_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20210331"
      decimals="-3"
      id="F_000154"
      unitRef="U_iso4217USD">-382436000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001668243_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20210331"
      decimals="-3"
      id="F_000155"
      unitRef="U_iso4217USD">143000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001668243_20210331"
      decimals="-3"
      id="F_000156"
      unitRef="U_iso4217USD">76491000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="C_0001668243_20210101_20210331"
      decimals="-3"
      id="F_000157"
      unitRef="U_iso4217USD">-25935000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_0001668243_20200101_20200331"
      decimals="-3"
      id="F_000158"
      unitRef="U_iso4217USD">-37793000</us-gaap:NetIncomeLoss>
    <us-gaap:DepreciationAndAmortization
      contextRef="C_0001668243_20210101_20210331"
      decimals="-3"
      id="F_000159"
      unitRef="U_iso4217USD">191000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="C_0001668243_20200101_20200331"
      decimals="-3"
      id="F_000160"
      unitRef="U_iso4217USD">82000</us-gaap:DepreciationAndAmortization>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="C_0001668243_20210101_20210331"
      decimals="-3"
      id="F_000161"
      unitRef="U_iso4217USD">-191000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="C_0001668243_20200101_20200331"
      decimals="-3"
      id="F_000162"
      unitRef="U_iso4217USD">-98000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:ShareBasedCompensation
      contextRef="C_0001668243_20210101_20210331"
      decimals="-3"
      id="F_000163"
      unitRef="U_iso4217USD">6195000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="C_0001668243_20200101_20200331"
      decimals="-3"
      id="F_000164"
      unitRef="U_iso4217USD">7617000</us-gaap:ShareBasedCompensation>
    <urgn:OperatingLeaseRightOfUseAssetAmortization
      contextRef="C_0001668243_20210101_20210331"
      decimals="-3"
      id="F_000165"
      unitRef="U_iso4217USD">237000</urgn:OperatingLeaseRightOfUseAssetAmortization>
    <urgn:OperatingLeaseRightOfUseAssetAmortization
      contextRef="C_0001668243_20200101_20200331"
      decimals="-3"
      id="F_000166"
      unitRef="U_iso4217USD">374000</urgn:OperatingLeaseRightOfUseAssetAmortization>
    <urgn:OperatingLeaseLiabilityAdjustments
      contextRef="C_0001668243_20210101_20210331"
      decimals="-3"
      id="F_000167"
      unitRef="U_iso4217USD">400000</urgn:OperatingLeaseLiabilityAdjustments>
    <urgn:OperatingLeaseLiabilityAdjustments
      contextRef="C_0001668243_20200101_20200331"
      decimals="-3"
      id="F_000168"
      unitRef="U_iso4217USD">361000</urgn:OperatingLeaseLiabilityAdjustments>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="C_0001668243_20210101_20210331"
      decimals="-3"
      id="F_000169"
      unitRef="U_iso4217USD">1367000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="C_0001668243_20210101_20210331"
      decimals="-3"
      id="F_000170"
      unitRef="U_iso4217USD">-746000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="C_0001668243_20210101_20210331"
      decimals="-3"
      id="F_000171"
      unitRef="U_iso4217USD">2952000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="C_0001668243_20200101_20200331"
      decimals="-3"
      id="F_000172"
      unitRef="U_iso4217USD">518000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="C_0001668243_20210101_20210331"
      decimals="-3"
      id="F_000173"
      unitRef="U_iso4217USD">535000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="C_0001668243_20200101_20200331"
      decimals="-3"
      id="F_000174"
      unitRef="U_iso4217USD">-2498000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities
      contextRef="C_0001668243_20210101_20210331"
      decimals="-3"
      id="F_000175"
      unitRef="U_iso4217USD">-4842000</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
    <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities
      contextRef="C_0001668243_20200101_20200331"
      decimals="-3"
      id="F_000176"
      unitRef="U_iso4217USD">-2636000</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_0001668243_20210101_20210331"
      decimals="-3"
      id="F_000177"
      unitRef="U_iso4217USD">-27401000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_0001668243_20200101_20200331"
      decimals="-3"
      id="F_000178"
      unitRef="U_iso4217USD">-35635000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="C_0001668243_20200101_20200331"
      decimals="-3"
      id="F_000179"
      unitRef="U_iso4217USD">9378000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="C_0001668243_20210101_20210331"
      decimals="-3"
      id="F_000180"
      unitRef="U_iso4217USD">15311000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="C_0001668243_20200101_20200331"
      decimals="-3"
      id="F_000181"
      unitRef="U_iso4217USD">22499000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="C_0001668243_20210101_20210331"
      decimals="-3"
      id="F_000182"
      unitRef="U_iso4217USD">287000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="C_0001668243_20200101_20200331"
      decimals="-3"
      id="F_000183"
      unitRef="U_iso4217USD">96000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_0001668243_20210101_20210331"
      decimals="-3"
      id="F_000184"
      unitRef="U_iso4217USD">15024000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_0001668243_20200101_20200331"
      decimals="-3"
      id="F_000185"
      unitRef="U_iso4217USD">13025000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="C_0001668243_20210101_20210331"
      decimals="-3"
      id="F_000186"
      unitRef="U_iso4217USD">4000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="C_0001668243_20200101_20200331"
      decimals="-3"
      id="F_000187"
      unitRef="U_iso4217USD">293000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="C_0001668243_20200101_20200331"
      decimals="-3"
      id="F_000188"
      unitRef="U_iso4217USD">203000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_0001668243_20210101_20210331"
      decimals="-3"
      id="F_000189"
      unitRef="U_iso4217USD">4000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_0001668243_20200101_20200331"
      decimals="-3"
      id="F_000190"
      unitRef="U_iso4217USD">90000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="C_0001668243_20210101_20210331"
      decimals="-3"
      id="F_000191"
      unitRef="U_iso4217USD">-12373000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="C_0001668243_20200101_20200331"
      decimals="-3"
      id="F_000192"
      unitRef="U_iso4217USD">-22520000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_0001668243_20201231"
      decimals="-3"
      id="F_000193"
      unitRef="U_iso4217USD">54090000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_0001668243_20191231"
      decimals="-3"
      id="F_000194"
      unitRef="U_iso4217USD">50211000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_0001668243_20210331"
      decimals="-3"
      id="F_000195"
      unitRef="U_iso4217USD">41717000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_0001668243_20200331"
      decimals="-3"
      id="F_000196"
      unitRef="U_iso4217USD">27691000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <urgn:NonCashNewLeaseLiabilities
      contextRef="C_0001668243_20210101_20210331"
      decimals="-3"
      id="F_000197"
      unitRef="U_iso4217USD">-20000</urgn:NonCashNewLeaseLiabilities>
    <urgn:NonCashNewLeaseLiabilities
      contextRef="C_0001668243_20200101_20200331"
      decimals="-3"
      id="F_000198"
      unitRef="U_iso4217USD">72000</urgn:NonCashNewLeaseLiabilities>
    <us-gaap:NatureOfOperations contextRef="C_0001668243_20210101_20210331" id="F_000199">
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Note 1 &#x2013; Business and Nature of Operations&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Calibri;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Nature of Operations&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;UroGen&lt;span style="letter-spacing:0.65pt;"&gt; &lt;/span&gt;Pharma&lt;span style="letter-spacing:0.65pt;"&gt; &lt;/span&gt;Ltd.&lt;span style="letter-spacing:0.4pt;"&gt; &lt;/span&gt;is&lt;span style="letter-spacing:0.15pt;"&gt; &lt;/span&gt;an&lt;span style="letter-spacing:0.25pt;"&gt; &lt;/span&gt;Israeli&lt;span style="letter-spacing:0.5pt;"&gt; &lt;/span&gt;company&lt;span style="letter-spacing:0.75pt;"&gt; &lt;/span&gt;incorporated&lt;span style="letter-spacing:1pt;"&gt; &lt;/span&gt;in&lt;span style="letter-spacing:0.2pt;"&gt; &lt;/span&gt;April&lt;span style="letter-spacing:0.4pt;"&gt; &lt;/span&gt;20&lt;span style="letter-spacing:-0.1pt;"&gt;0&lt;/span&gt;4&lt;span style="letter-spacing:0.45pt;"&gt; &lt;/span&gt;(&#x201c;UPL&#x201d;). &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;UroGen&lt;span style="letter-spacing:0.65pt;"&gt; &lt;/span&gt;Pharma&lt;span style="letter-spacing:0.65pt;"&gt; &lt;/span&gt;Inc.,&lt;span style="letter-spacing:0.35pt;"&gt; &lt;/span&gt;a&lt;span style="letter-spacing:0.15pt;"&gt; wholly owned &lt;/span&gt;subsidiary&lt;span style="letter-spacing:0.8pt;"&gt; &lt;/span&gt;of&lt;span style="letter-spacing:0.2pt;"&gt; &lt;/span&gt;UPL,&lt;span style="letter-spacing:0.45pt;"&gt; &lt;/span&gt;was&lt;span style="letter-spacing:0.35pt;"&gt; &lt;/span&gt;incorporated&lt;span style="letter-spacing:1pt;"&gt; &lt;/span&gt;in&lt;span style="letter-spacing:0.2pt;"&gt; &lt;/span&gt;Del&lt;span style="letter-spacing:-0.1pt;"&gt;a&lt;/span&gt;ware&lt;span style="letter-spacing:0.75pt;"&gt; &lt;/span&gt;in&lt;span style="letter-spacing:0.2pt;"&gt; &lt;/span&gt;October&lt;span style="letter-spacing:0.65pt;"&gt; &lt;/span&gt;2015&lt;span style="letter-spacing:0.45pt;"&gt; &lt;/span&gt;and&lt;span style="letter-spacing:0.35pt;"&gt; &lt;/span&gt;began&lt;span style="letter-spacing:0.5pt;"&gt; &lt;/span&gt;operati&lt;span style="letter-spacing:-0.1pt;"&gt;n&lt;/span&gt;g&lt;span style="letter-spacing:0.75pt;"&gt; &lt;/span&gt;in&lt;span style="letter-spacing:0.2pt;"&gt; &lt;/span&gt;February&lt;span style="letter-spacing:0.75pt;"&gt; &lt;/span&gt;2016&lt;span style="letter-spacing:0.45pt;"&gt; &lt;/span&gt;(&#x201c;UPI&#x201d;). &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;UPL&lt;span style="letter-spacing:0.4pt;"&gt; &lt;/span&gt;and&lt;span style="letter-spacing:0.35pt;"&gt; &lt;/span&gt;UPI&lt;span style="letter-spacing:0.35pt;"&gt; &lt;/span&gt;(together&lt;span style="letter-spacing:0.75pt;"&gt; &lt;/span&gt;the&lt;span style="letter-spacing:0.3pt;"&gt; &lt;/span&gt;&#x201c;Company&#x201d;)&lt;span style="letter-spacing:0.95pt;"&gt; &lt;/span&gt;is&lt;span style="letter-spacing:0.15pt;"&gt; &lt;/span&gt;a&lt;span style="letter-spacing:0.45pt;"&gt; &lt;/span&gt;bi&lt;span style="letter-spacing:-0.1pt;"&gt;o&lt;/span&gt;pharmaceutical&lt;span style="letter-spacing:1.45pt;"&gt; &lt;/span&gt;company&lt;span style="letter-spacing:0.75pt;"&gt; &lt;/span&gt;focused&lt;span style="letter-spacing:0.65pt;"&gt; &lt;/span&gt;on&lt;span style="letter-spacing:0.25pt;"&gt; &lt;/span&gt;deve&lt;span style="letter-spacing:-0.1pt;"&gt;l&lt;/span&gt;oping and commercializing&lt;span style="letter-spacing:0.85pt;"&gt; &lt;/span&gt;novel&lt;span style="letter-spacing:0.45pt;"&gt; &lt;/span&gt;therapies&lt;span style="letter-spacing:0.75pt;"&gt; &lt;/span&gt;desi&lt;span style="letter-spacing:-0.1pt;"&gt;g&lt;/span&gt;ned&lt;span style="letter-spacing:0.75pt;"&gt; &lt;/span&gt;to change&lt;span style="letter-spacing:0.65pt;"&gt; &lt;/span&gt;the&lt;span style="letter-spacing:0.3pt;"&gt; &lt;/span&gt;standard&lt;span style="letter-spacing:0.7pt;"&gt; &lt;/span&gt;of&lt;span style="letter-spacing:0.2pt;"&gt; &lt;/span&gt;care&lt;span style="letter-spacing:0.4pt;"&gt; &lt;/span&gt;for&lt;span style="letter-spacing:0.25pt;"&gt; &lt;/span&gt;urological&lt;span style="letter-spacing:0.8pt;"&gt; &lt;/span&gt;pathologies. Since commencing operations, the Company has devoted substantially all of its efforts to securing intellectual property rights, performing research and development activities, including conducting clinical trials and manufacturing activities, hiring personnel, launching the Company&#x2019;s first commercial product, &lt;span style="font-style:italic;"&gt;Jelmyto&lt;/span&gt; (mitomycin) for pyelocalyceal solution, formerly known as UGN-101, and its product candidate UGN-102, and raising capital to support and expand these activities. &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On April 15, 2020, the U.S. Food and Drug Administration (&#x201c;FDA&#x201d;) granted expedited approval for &lt;span style="font-style:italic;"&gt;Jelmyto&lt;/span&gt;, a first-in-class treatment indicated for adults with low-grade upper tract urothelial cancer (&#x201c;low grade-UTUC&#x201d;). &lt;span style="font-style:italic;"&gt;Jelmyto&lt;/span&gt; consists of mitomycin, an established chemotherapy, and sterile hydrogel, using our proprietary sustained release &lt;span style="font-style:italic;"&gt;RTGel&lt;/span&gt; technology. It has been designed to enable longer exposure of urinary tract tissue to mitomycin, thereby enabling the treatment of tumors by non-surgical means.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:6pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;</us-gaap:NatureOfOperations>
    <urgn:EntityIncorporationDateOfIncorporationMonthAndYear contextRef="C_0001668243_20210101_20210331" id="F_000246">2004-04</urgn:EntityIncorporationDateOfIncorporationMonthAndYear>
    <urgn:OperationsCommencedDateMonthAndYear contextRef="C_0001668243_20210101_20210331" id="F_000247">2016-02</urgn:OperationsCommencedDateMonthAndYear>
    <us-gaap:BasisOfAccounting contextRef="C_0001668243_20210101_20210331" id="F_000200">
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Note 2 &#x2013; Basis of Presentation&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (&#x201c;GAAP&#x201d;) for interim financial information and in accordance with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all the information and footnotes required by GAAP for complete financial statements. In the opinion of the Company&#x2019;s management, the accompanying condensed consolidated financial statements contain all adjustments (consisting of normal recurring accruals and adjustments) necessary for fair statement of its financial position, results of operations and cash flows of the Company at the dates and for the periods indicated. Interim results are not necessarily indicative of results for the full fiscal year. The year-end condensed consolidated balance sheet data was derived from audited financial statements but does not include all disclosures required by accounting principles generally accepted in the United States. The unaudited condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and the notes thereto contained in the Company&#x2019;s Annual Report on Form 10-K for the year ended December&#160;31, 2020, as filed with the Securities and Exchange Commission (&#x201c;SEC&#x201d;) on March 18, 2021.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The consolidated financial statements include the accounts of UPL and its wholly owned subsidiary UPI. All material intercompany balances and transactions have been eliminated during consolidation.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company has experienced net losses since its inception and has an accumulated deficit of $382.4 million and $356.5 million as of March&#160;31, 2021 and December&#160;31, 2020, respectively. The Company expects to incur losses and have negative net cash flows from operating activities as it executes on its strategy including engaging in further research and development activities, particularly conducting non-clinical studies and clinical trials.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The success of the Company depends on the ability to successfully commercialize its technologies to support its operations and strategic plan. Based on management&#x2019;s cash flow projections the Company believes that its cash and cash equivalents and marketable securities after the closing of the transaction with RTW Investments (See Note 17 for further discussion) are sufficient to fund the Company&#x2019;s planned operations for at least the next 12 months. The Company anticipates that it may need to raise additional capital in the future. There can be no assurances that the Company will be able to secure such additional financing if at all, or at terms that are satisfactory to the Company, and that it will be sufficient to meet its needs. In the event the Company is not successful in obtaining sufficient funding, this could force us to delay, limit, or reduce our product development, commercialization efforts or other operations.&lt;/p&gt;</us-gaap:BasisOfAccounting>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_0001668243_20210331"
      decimals="-5"
      id="F_000248"
      unitRef="U_iso4217USD">-382400000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_0001668243_20201231"
      decimals="-5"
      id="F_000249"
      unitRef="U_iso4217USD">-356500000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="C_0001668243_20210101_20210331" id="F_000201">
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Note 3 &#x2013; Significant Accounting Policies&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Calibri;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Principles of Consolidation&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The condensed consolidated financial statements include the accounts of UPL and its subsidiary, UPI. Intercompany balances and transactions have been eliminated during consolidation.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Calibri;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Use of Estimates&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The&lt;span style="letter-spacing:0.35pt;"&gt; &lt;/span&gt;preparation&lt;span style="letter-spacing:0.9pt;"&gt; &lt;/span&gt;of&lt;span style="letter-spacing:0.2pt;"&gt; &lt;/span&gt;financial&lt;span style="letter-spacing:0.65pt;"&gt; &lt;/span&gt;statements&lt;span style="letter-spacing:0.9pt;"&gt; &lt;/span&gt;in&lt;span style="letter-spacing:0.2pt;"&gt; &lt;/span&gt;conformity&lt;span style="letter-spacing:0.85pt;"&gt; &lt;/span&gt;with&lt;span style="letter-spacing:0.35pt;"&gt; U.S. &lt;/span&gt;GAAP&lt;span style="letter-spacing:0.5pt;"&gt; &lt;/span&gt;requires&lt;span style="letter-spacing:0.65pt;"&gt; &lt;/span&gt;man&lt;span style="letter-spacing:-0.1pt;"&gt;a&lt;/span&gt;gement&lt;span style="letter-spacing:1.05pt;"&gt; &lt;/span&gt;to&lt;span style="letter-spacing:0.2pt;"&gt; &lt;/span&gt;make&lt;span style="letter-spacing:0.45pt;"&gt; &lt;/span&gt;estimates&lt;span style="letter-spacing:0.8pt;"&gt; &lt;/span&gt;and&lt;span style="letter-spacing:0.35pt;"&gt; &lt;/span&gt;assumptions&lt;span style="letter-spacing:1pt;"&gt; &lt;/span&gt;that&lt;span style="letter-spacing:0.35pt;"&gt; &lt;/span&gt;affect the&lt;span style="letter-spacing:0.05pt;"&gt; &lt;/span&gt;reported&lt;span style="letter-spacing:0.7pt;"&gt; &lt;/span&gt;amounts&lt;span style="letter-spacing:0.7pt;"&gt; &lt;/span&gt;of&lt;span style="letter-spacing:0.2pt;"&gt; &lt;/span&gt;assets&lt;span style="letter-spacing:0.6pt;"&gt; &lt;/span&gt;and&lt;span style="letter-spacing:0.35pt;"&gt; &lt;/span&gt;liabilities,&lt;span style="letter-spacing:0.75pt;"&gt; &lt;/span&gt;the&lt;span style="letter-spacing:0.3pt;"&gt; &lt;/span&gt;disclosure&lt;span style="letter-spacing:0.8pt;"&gt; &lt;/span&gt;of&lt;span style="letter-spacing:0.2pt;"&gt; &lt;/span&gt;cont&lt;span style="letter-spacing:-0.1pt;"&gt;i&lt;/span&gt;ngent&lt;span style="letter-spacing:0.85pt;"&gt; &lt;/span&gt;assets&lt;span style="letter-spacing:0.55pt;"&gt; &lt;/span&gt;and&lt;span style="letter-spacing:0.35pt;"&gt; &lt;/span&gt;liabilities&lt;span style="letter-spacing:0.7pt;"&gt; &lt;/span&gt;at&lt;span style="letter-spacing:0.2pt;"&gt; &lt;/span&gt;the&lt;span style="letter-spacing:0.3pt;"&gt; &lt;/span&gt;date&lt;span style="letter-spacing:0.4pt;"&gt; &lt;/span&gt;of&lt;span style="letter-spacing:0.2pt;"&gt; &lt;/span&gt;the&lt;span style="letter-spacing:0.3pt;"&gt; &lt;/span&gt;financ&lt;span style="letter-spacing:-0.1pt;"&gt;i&lt;/span&gt;al&lt;span style="letter-spacing:0.65pt;"&gt; &lt;/span&gt;statements&lt;span style="letter-spacing:0.9pt;"&gt; &lt;/span&gt;and&lt;span style="letter-spacing:0.35pt;"&gt; &lt;/span&gt;the reported&lt;span style="letter-spacing:0.7pt;"&gt; &lt;/span&gt;amounts&lt;span style="letter-spacing:0.7pt;"&gt; &lt;/span&gt;of&lt;span style="letter-spacing:0.2pt;"&gt; &lt;/span&gt;revenues&lt;span style="letter-spacing:0.75pt;"&gt; &lt;/span&gt;and&lt;span style="letter-spacing:0.35pt;"&gt; &lt;/span&gt;expenses&lt;span style="letter-spacing:0.8pt;"&gt; &lt;/span&gt;duri&lt;span style="letter-spacing:-0.1pt;"&gt;n&lt;/span&gt;g&lt;span style="letter-spacing:0.5pt;"&gt; &lt;/span&gt;the&lt;span style="letter-spacing:0.3pt;"&gt; &lt;/span&gt;reporting&lt;span style="letter-spacing:0.7pt;"&gt; &lt;/span&gt;period.&lt;span style="letter-spacing:0.55pt;"&gt; &lt;/span&gt;Actual&lt;span style="letter-spacing:0.5pt;"&gt; &lt;/span&gt;results&lt;span style="letter-spacing:0.55pt;"&gt; &lt;/span&gt;may&lt;span style="letter-spacing:0.35pt;"&gt; &lt;/span&gt;differ&lt;span style="letter-spacing:0.45pt;"&gt; &lt;/span&gt;from&lt;span style="letter-spacing:0.4pt;"&gt; &lt;/span&gt;those&lt;span style="letter-spacing:0.45pt;"&gt; &lt;/span&gt;estimates.&lt;span style="letter-spacing:0.8pt;"&gt; &lt;/span&gt;As&lt;span style="letter-spacing:0.25pt;"&gt; &lt;/span&gt;applicable&lt;span style="letter-spacing:0.9pt;"&gt; &lt;/span&gt;to the unaudited condensed&lt;span style="letter-spacing:0.45pt;"&gt; &lt;/span&gt;consolidated&lt;span style="letter-spacing:1pt;"&gt; &lt;/span&gt;financi&lt;span style="letter-spacing:-0.1pt;"&gt;a&lt;/span&gt;l&lt;span style="letter-spacing:0.65pt;"&gt; &lt;/span&gt;statements,&lt;span style="letter-spacing:0.95pt;"&gt; &lt;/span&gt;the&lt;span style="letter-spacing:0.3pt;"&gt; critical &lt;/span&gt;accounting&lt;span style="letter-spacing:0.35pt;"&gt; estimates relate &lt;/span&gt;to&lt;span style="letter-spacing:0.2pt;"&gt; &lt;/span&gt;the&lt;span style="letter-spacing:0.3pt;"&gt; &lt;/span&gt;fair&lt;span style="letter-spacing:0.3pt;"&gt; &lt;/span&gt;value&lt;span style="letter-spacing:0.45pt;"&gt; &lt;/span&gt;of&lt;span style="letter-spacing:0.2pt;"&gt; &lt;/span&gt;share-based&lt;span style="letter-spacing:1pt;"&gt; &lt;/span&gt;compensat&lt;span style="letter-spacing:-0.1pt;"&gt;i&lt;/span&gt;on,&lt;span style="letter-spacing:0.55pt;"&gt; &lt;/span&gt;measurement&lt;span style="letter-spacing:0.5pt;"&gt; &lt;/span&gt;of&lt;span style="letter-spacing:0.2pt;"&gt; &lt;/span&gt;revenue and estimate of uncertain tax positions.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Calibri;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Functional&lt;span style="letter-spacing:0.9pt;"&gt; &lt;/span&gt;Currency&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The&lt;span style="letter-spacing:0.35pt;"&gt; &lt;/span&gt;U.S.&lt;span style="letter-spacing:0.4pt;"&gt; &lt;/span&gt;dollar&lt;span style="letter-spacing:0.45pt;"&gt; &lt;/span&gt;(&#x201c;Dollar&#x201d;)&lt;span style="letter-spacing:0.7pt;"&gt; &lt;/span&gt;is&lt;span style="letter-spacing:0.15pt;"&gt; &lt;/span&gt;the&lt;span style="letter-spacing:0.35pt;"&gt; &lt;/span&gt;currency&lt;span style="letter-spacing:0.7pt;"&gt; &lt;/span&gt;of&lt;span style="letter-spacing:0.2pt;"&gt; &lt;/span&gt;the&lt;span style="letter-spacing:0.3pt;"&gt; &lt;/span&gt;primary&lt;span style="letter-spacing:0.6pt;"&gt; &lt;/span&gt;economic&lt;span style="letter-spacing:0.8pt;"&gt; &lt;/span&gt;environment&lt;span style="letter-spacing:1pt;"&gt; &lt;/span&gt;in&lt;span style="letter-spacing:0.2pt;"&gt; &lt;/span&gt;which&lt;span style="letter-spacing:0.5pt;"&gt; &lt;/span&gt;the&lt;span style="letter-spacing:0.3pt;"&gt; &lt;/span&gt;operations&lt;span style="letter-spacing:0.85pt;"&gt; &lt;/span&gt;of&lt;span style="letter-spacing:0.2pt;"&gt; &lt;/span&gt;the&lt;span style="letter-spacing:0.3pt;"&gt; &lt;/span&gt;Com&lt;span style="letter-spacing:-0.1pt;"&gt;p&lt;/span&gt;any&lt;span style="letter-spacing:0.8pt;"&gt; &lt;/span&gt;are conducted.&lt;span style="letter-spacing:0.9pt;"&gt; &lt;/span&gt;Therefore,&lt;span style="letter-spacing:0.85pt;"&gt; &lt;/span&gt;the&lt;span style="letter-spacing:0.3pt;"&gt; &lt;/span&gt;functional&lt;span style="letter-spacing:0.8pt;"&gt; &lt;/span&gt;currency&lt;span style="letter-spacing:0.7pt;"&gt; &lt;/span&gt;of&lt;span style="letter-spacing:0.2pt;"&gt; &lt;/span&gt;the&lt;span style="letter-spacing:0.3pt;"&gt; &lt;/span&gt;Company&lt;span style="letter-spacing:0.8pt;"&gt; &lt;/span&gt;is&lt;span style="letter-spacing:0.15pt;"&gt; &lt;/span&gt;the&lt;span style="letter-spacing:0.3pt;"&gt; &lt;/span&gt;Dol&lt;span style="letter-spacing:-0.1pt;"&gt;l&lt;/span&gt;ar.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accordingly,&lt;span style="letter-spacing:1pt;"&gt; &lt;/span&gt;transactions&lt;span style="letter-spacing:0.95pt;"&gt; &lt;/span&gt;in&lt;span style="letter-spacing:0.2pt;"&gt; &lt;/span&gt;currencies&lt;span style="letter-spacing:0.85pt;"&gt; &lt;/span&gt;other&lt;span style="letter-spacing:0.45pt;"&gt; &lt;/span&gt;than&lt;span style="letter-spacing:0.4pt;"&gt; &lt;/span&gt;the&lt;span style="letter-spacing:0.3pt;"&gt; &lt;/span&gt;Do&lt;span style="letter-spacing:-0.1pt;"&gt;l&lt;/span&gt;lar&lt;span style="letter-spacing:0.5pt;"&gt; &lt;/span&gt;are&lt;span style="letter-spacing:0.3pt;"&gt; &lt;/span&gt;measured&lt;span style="letter-spacing:0.8pt;"&gt; &lt;/span&gt;and&lt;span style="letter-spacing:0.35pt;"&gt; &lt;/span&gt;recorded&lt;span style="letter-spacing:0.7pt;"&gt; &lt;/span&gt;in&lt;span style="letter-spacing:0.2pt;"&gt; &lt;/span&gt;the&lt;span style="letter-spacing:0.3pt;"&gt; &lt;/span&gt;functional&lt;span style="letter-spacing:0.8pt;"&gt; &lt;/span&gt;currency&lt;span style="letter-spacing:0.7pt;"&gt; &lt;/span&gt;usi&lt;span style="letter-spacing:-0.1pt;"&gt;n&lt;/span&gt;g&lt;span style="letter-spacing:0.45pt;"&gt; &lt;/span&gt;the&lt;span style="letter-spacing:0.3pt;"&gt; &lt;/span&gt;exchange&lt;span style="letter-spacing:0.8pt;"&gt; &lt;/span&gt;rate&lt;span style="letter-spacing:0.35pt;"&gt; &lt;/span&gt;in effect&lt;span style="letter-spacing:0.45pt;"&gt; &lt;/span&gt;at&lt;span style="letter-spacing:0.2pt;"&gt; &lt;/span&gt;the&lt;span style="letter-spacing:0.3pt;"&gt; &lt;/span&gt;date&lt;span style="letter-spacing:0.4pt;"&gt; &lt;/span&gt;of&lt;span style="letter-spacing:0.2pt;"&gt; &lt;/span&gt;the&lt;span style="letter-spacing:0.35pt;"&gt; &lt;/span&gt;transaction.&lt;span style="letter-spacing:0.95pt;"&gt; &lt;/span&gt;At&lt;span style="letter-spacing:0.2pt;"&gt; &lt;/span&gt;the&lt;span style="letter-spacing:0.3pt;"&gt; &lt;/span&gt;balance&lt;span style="letter-spacing:0.65pt;"&gt; &lt;/span&gt;sheet&lt;span style="letter-spacing:0.45pt;"&gt; &lt;/span&gt;date,&lt;span style="letter-spacing:0.45pt;"&gt; &lt;/span&gt;monetary&lt;span style="letter-spacing:0.75pt;"&gt; &lt;/span&gt;assets&lt;span style="letter-spacing:0.55pt;"&gt; &lt;/span&gt;and&lt;span style="letter-spacing:0.35pt;"&gt; &lt;/span&gt;liab&lt;span style="letter-spacing:-0.1pt;"&gt;i&lt;/span&gt;lities&lt;span style="letter-spacing:0.7pt;"&gt; &lt;/span&gt;that&lt;span style="letter-spacing:0.35pt;"&gt; &lt;/span&gt;are&lt;span style="letter-spacing:0.3pt;"&gt; &lt;/span&gt;denominated&lt;span style="letter-spacing:1.05pt;"&gt; &lt;/span&gt;in&lt;span style="letter-spacing:0.2pt;"&gt; &lt;/span&gt;currencies&lt;span style="letter-spacing:0.85pt;"&gt; &lt;/span&gt;other&lt;span style="letter-spacing:0.45pt;"&gt; &lt;/span&gt;than the&lt;span style="letter-spacing:0.05pt;"&gt; &lt;/span&gt;Dollar&lt;span style="letter-spacing:0.5pt;"&gt; &lt;/span&gt;are&lt;span style="letter-spacing:0.3pt;"&gt; &lt;/span&gt;measured&lt;span style="letter-spacing:0.8pt;"&gt; &lt;/span&gt;using&lt;span style="letter-spacing:0.45pt;"&gt; &lt;/span&gt;the&lt;span style="letter-spacing:0.3pt;"&gt; &lt;/span&gt;official&lt;span style="letter-spacing:0.55pt;"&gt; &lt;/span&gt;exch&lt;span style="letter-spacing:-0.1pt;"&gt;a&lt;/span&gt;nge&lt;span style="letter-spacing:0.8pt;"&gt; &lt;/span&gt;rate&lt;span style="letter-spacing:0.35pt;"&gt; &lt;/span&gt;at&lt;span style="letter-spacing:0.2pt;"&gt; &lt;/span&gt;the&lt;span style="letter-spacing:0.3pt;"&gt; &lt;/span&gt;balance&lt;span style="letter-spacing:0.65pt;"&gt; &lt;/span&gt;sheet&lt;span style="letter-spacing:0.45pt;"&gt; &lt;/span&gt;date.&lt;span style="letter-spacing:0.45pt;"&gt; &lt;/span&gt;The&lt;span style="letter-spacing:0.35pt;"&gt; &lt;/span&gt;effects&lt;span style="letter-spacing:0.55pt;"&gt; &lt;/span&gt;of&lt;span style="letter-spacing:0.2pt;"&gt; &lt;/span&gt;foreign&lt;span style="letter-spacing:0.55pt;"&gt; &lt;/span&gt;currency&lt;span style="letter-spacing:0.8pt;"&gt; &lt;/span&gt;re-measurements&lt;span style="letter-spacing:1.45pt;"&gt; &lt;/span&gt;are recorded&lt;span style="letter-spacing:0.7pt;"&gt; &lt;/span&gt;in&lt;span style="letter-spacing:0.2pt;"&gt; &lt;/span&gt;the&lt;span style="letter-spacing:0.3pt;"&gt; condensed &lt;/span&gt;consolidated&lt;span style="letter-spacing:1pt;"&gt; &lt;/span&gt;statements&lt;span style="letter-spacing:0.9pt;"&gt; &lt;/span&gt;of&lt;span style="letter-spacing:0.2pt;"&gt; &lt;/span&gt;operations&lt;span style="letter-spacing:0.85pt;"&gt; &lt;/span&gt;as&lt;span style="letter-spacing:0.25pt;"&gt; &lt;/span&gt;&#x201c;Interest and other income, net.&#x201d;&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Calibri;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Cash and Cash Equivalents; &lt;span style="color:#000000;"&gt;Marketable Securities&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company considers all highly liquid investments with an original maturity of three months or less when purchased to be cash equivalents. Cash and cash equivalents consist primarily of money market funds and bank money market accounts and are stated at cost, which approximates fair value. &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cash and cash equivalents and marketable securities totaled $75.9 million as of March&#160;31, 2021. The Company classifies its marketable securities as available-for-sale in accordance with the &lt;span style="letter-spacing:-0.2pt;"&gt;Financial Accounting Standards Board (&#x201c;&lt;/span&gt;FASB&#x201d;) Accounting Standards Codification (&#x201c;ASC&#x201d;) Topic 320, &#x201c;Investments &#x2014; Debt and Equity Securities&#x201d;. Available-for-sale debt securities are carried at fair value with unrealized gains and losses reported in other comprehensive income/loss within shareholders&#x2019; equity. Realized gains and losses are recorded as a component of interest and other income (expense), net. The cost of securities sold is based on the specific-identification method. &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Short-term investments are valued using models or other valuation methodologies that use Level 2 inputs. These models are primarily industry-standard models that consider various assumptions, including time value, yield curve, volatility factors, default rates, current market and contractual prices for the underlying financial instruments, as well as other relevant economic measures. The majority of these assumptions are observable in the marketplace, can be derived from observable data or are supported by observable levels at which transactions are executed in the marketplace.&#160;&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;For individual debt securities classified as available-for-sale securities where there has been a decline in fair value below amortized cost, the Company determines whether the decline resulted from a credit loss or other factors. The Company records impairment relating to credit losses through an allowance for credit losses, limited by the amount that the fair value is less than the amortized cost basis. Impairment that has not been recorded through an allowance for credit losses is recorded through other comprehensive income, net of applicable taxes.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Calibri;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Concentration of Credit Risk&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Financial instruments, which potentially subject the Company to significant concentrations of credit risk, consist primarily of cash and cash equivalents and marketable securities. The primary objectives for the Company&lt;span style="color:#000000;"&gt;&#x2019;&lt;/span&gt;s investment portfolio are the preservation of capital and the maintenance of liquidity. The Company does not enter into any investment transaction for trading or speculative purposes.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company&lt;span style="color:#000000;"&gt;&#x2019;&lt;/span&gt;s investment policy limits investments to certain types of instruments such as certificates of deposit, money market instruments, obligations issued by the U.S. government and U.S. government agencies as well as corporate debt securities, and places restrictions on maturities and concentration by type and issuer. The Company maintains cash balances in excess of amounts insured by the Federal Deposit Insurance Corporation and concentrated within a limited number of financial institutions. The accounts are monitored by management to mitigate the risk.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company&#x2019;s product sales are recognized through the Company's arrangement with a single customer, a third-party national specialty distributor. The Company assesses the need for an allowance for doubtful accounts primarily based on creditworthiness, historical payment experience and general economic conditions. The Company has not experienced any credit losses related to this customer and has not currently recognized any allowance for doubtful accounts.&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Calibri;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Income Taxes&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company provides for income taxes based on pretax income, if any, and applicable tax rates available in the various jurisdictions in which it operates, including Israel and the U.S. Deferred&lt;span style="letter-spacing:0.6pt;"&gt; &lt;/span&gt;taxes&lt;span style="letter-spacing:0.45pt;"&gt; &lt;/span&gt;are&lt;span style="letter-spacing:0.3pt;"&gt; &lt;/span&gt;computed&lt;span style="letter-spacing:0.8pt;"&gt; &lt;/span&gt;using&lt;span style="letter-spacing:0.45pt;"&gt; &lt;/span&gt;the&lt;span style="letter-spacing:0.3pt;"&gt; &lt;/span&gt;asset&lt;span style="letter-spacing:0.45pt;"&gt; &lt;/span&gt;and&lt;span style="letter-spacing:0.35pt;"&gt; &lt;/span&gt;liabi&lt;span style="letter-spacing:-0.1pt;"&gt;l&lt;/span&gt;ity&lt;span style="letter-spacing:0.65pt;"&gt; &lt;/span&gt;method.&lt;span style="letter-spacing:0.65pt;"&gt; &lt;/span&gt;Under&lt;span style="letter-spacing:0.5pt;"&gt; &lt;/span&gt;the&lt;span style="letter-spacing:0.3pt;"&gt; &lt;/span&gt;asset&lt;span style="letter-spacing:0.45pt;"&gt; &lt;/span&gt;and&lt;span style="letter-spacing:0.35pt;"&gt; &lt;/span&gt;liability&lt;span style="letter-spacing:0.55pt;"&gt; &lt;/span&gt;method,&lt;span style="letter-spacing:0.65pt;"&gt; &lt;/span&gt;deferred&lt;span style="letter-spacing:0.7pt;"&gt; &lt;/span&gt;income&lt;span style="letter-spacing:0.6pt;"&gt; &lt;/span&gt;tax&lt;span style="letter-spacing:0.3pt;"&gt; &lt;/span&gt;assets&lt;span style="letter-spacing:0.55pt;"&gt; &lt;/span&gt;and liabilities&lt;span style="letter-spacing:0.7pt;"&gt; &lt;/span&gt;are&lt;span style="letter-spacing:0.3pt;"&gt; &lt;/span&gt;determined&lt;span style="letter-spacing:0.9pt;"&gt; &lt;/span&gt;bas&lt;span style="letter-spacing:-0.1pt;"&gt;e&lt;/span&gt;d&lt;span style="letter-spacing:0.5pt;"&gt; &lt;/span&gt;on&lt;span style="letter-spacing:0.25pt;"&gt; &lt;/span&gt;the&lt;span style="letter-spacing:0.3pt;"&gt; &lt;/span&gt;differences&lt;span style="letter-spacing:0.9pt;"&gt; &lt;/span&gt;between&lt;span style="letter-spacing:0.7pt;"&gt; &lt;/span&gt;the&lt;span style="letter-spacing:0.3pt;"&gt; &lt;/span&gt;financial&lt;span style="letter-spacing:0.65pt;"&gt; &lt;/span&gt;reporti&lt;span style="letter-spacing:-0.1pt;"&gt;n&lt;/span&gt;g&lt;span style="letter-spacing:0.7pt;"&gt; &lt;/span&gt;and&lt;span style="letter-spacing:0.35pt;"&gt; &lt;/span&gt;tax bases&lt;span style="letter-spacing:0.5pt;"&gt; &lt;/span&gt;of&lt;span style="letter-spacing:0.2pt;"&gt; &lt;/span&gt;assets&lt;span style="letter-spacing:0.55pt;"&gt; &lt;/span&gt;and&lt;span style="letter-spacing:0.35pt;"&gt; &lt;/span&gt;liabilities&lt;span style="letter-spacing:0.7pt;"&gt; &lt;/span&gt;and&lt;span style="letter-spacing:0.35pt;"&gt; &lt;/span&gt;are&lt;span style="letter-spacing:0.3pt;"&gt; &lt;/span&gt;mea&lt;span style="letter-spacing:-0.1pt;"&gt;s&lt;/span&gt;ured&lt;span style="letter-spacing:0.8pt;"&gt; &lt;/span&gt;using&lt;span style="letter-spacing:0.45pt;"&gt; &lt;/span&gt;the&lt;span style="letter-spacing:0.3pt;"&gt; &lt;/span&gt;currently&lt;span style="letter-spacing:0.7pt;"&gt; &lt;/span&gt;enacted&lt;span style="letter-spacing:0.65pt;"&gt; &lt;/span&gt;tax&lt;span style="letter-spacing:0.3pt;"&gt; &lt;/span&gt;rates&lt;span style="letter-spacing:0.45pt;"&gt; &lt;/span&gt;and&lt;span style="letter-spacing:0.35pt;"&gt; &lt;/span&gt;laws.&lt;span style="letter-spacing:0.45pt;"&gt; &lt;/span&gt;A&lt;span style="letter-spacing:0.15pt;"&gt; &lt;/span&gt;valuation&lt;span style="letter-spacing:0.75pt;"&gt; &lt;/span&gt;&lt;span style="letter-spacing:-0.1pt;"&gt;a&lt;/span&gt;llowance&lt;span style="letter-spacing:0.8pt;"&gt; &lt;/span&gt;is&lt;span style="letter-spacing:0.15pt;"&gt; &lt;/span&gt;recognized&lt;span style="letter-spacing:0.9pt;"&gt; &lt;/span&gt;to&lt;span style="letter-spacing:0.2pt;"&gt; &lt;/span&gt;the extent&lt;span style="letter-spacing:0.5pt;"&gt; &lt;/span&gt;that&lt;span style="letter-spacing:0.35pt;"&gt; &lt;/span&gt;it&lt;span style="letter-spacing:0.15pt;"&gt; &lt;/span&gt;is&lt;span style="letter-spacing:0.15pt;"&gt; &lt;/span&gt;more&lt;span style="letter-spacing:0.45pt;"&gt; &lt;/span&gt;likely&lt;span style="letter-spacing:0.45pt;"&gt; &lt;/span&gt;than&lt;span style="letter-spacing:0.4pt;"&gt; &lt;/span&gt;not&lt;span style="letter-spacing:0.3pt;"&gt; &lt;/span&gt;that&lt;span style="letter-spacing:0.35pt;"&gt; &lt;/span&gt;the&lt;span style="letter-spacing:0.35pt;"&gt; &lt;/span&gt;deferred&lt;span style="letter-spacing:0.7pt;"&gt; &lt;/span&gt;taxes&lt;span style="letter-spacing:0.45pt;"&gt; &lt;/span&gt;will&lt;span style="letter-spacing:0.3pt;"&gt; &lt;/span&gt;not&lt;span style="letter-spacing:0.3pt;"&gt; &lt;/span&gt;be&lt;span style="letter-spacing:0.25pt;"&gt; &lt;/span&gt;realized&lt;span style="letter-spacing:0.65pt;"&gt; &lt;/span&gt;in&lt;span style="letter-spacing:0.2pt;"&gt; &lt;/span&gt;the&lt;span style="letter-spacing:0.3pt;"&gt; &lt;/span&gt;foresee&lt;span style="letter-spacing:-0.1pt;"&gt;a&lt;/span&gt;ble&lt;span style="letter-spacing:0.95pt;"&gt; &lt;/span&gt;future.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The&lt;span style="letter-spacing:0.35pt;"&gt; &lt;/span&gt;Company&lt;span style="letter-spacing:0.8pt;"&gt; &lt;/span&gt;follows&lt;span style="letter-spacing:0.55pt;"&gt; &lt;/span&gt;a&lt;span style="letter-spacing:0.3pt;"&gt; &lt;/span&gt;two-step&lt;span style="letter-spacing:0.8pt;"&gt; &lt;/span&gt;approach&lt;span style="letter-spacing:0.75pt;"&gt; &lt;/span&gt;in&lt;span style="letter-spacing:0.2pt;"&gt; &lt;/span&gt;recognizing&lt;span style="letter-spacing:0.9pt;"&gt; &lt;/span&gt;a&lt;span style="letter-spacing:-0.1pt;"&gt;n&lt;/span&gt;d&lt;span style="letter-spacing:0.35pt;"&gt; &lt;/span&gt;measuring&lt;span style="letter-spacing:0.85pt;"&gt; &lt;/span&gt;uncertain&lt;span style="letter-spacing:0.75pt;"&gt; &lt;/span&gt;tax&lt;span style="letter-spacing:0.3pt;"&gt; &lt;/span&gt;positions.&lt;span style="letter-spacing:0.75pt;"&gt; &lt;/span&gt;After concluding that a particular filing position can be recognized (i.e., has a more-likely-than-not chance of being sustained), ASC 740-10-30-7 requires that the amount of benefit recognized be measured using a methodology based on the concept of cumulative probability. Under this methodology, the amount of benefit recorded represents the largest amount of tax benefit that is greater than 50% likely to be realized upon settlement with a taxing authority that has full knowledge of all relevant information. &#160;See Note 14 for further discussion related to income taxes.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Calibri;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Inventory&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company capitalizes inventory costs related to products to be sold in the ordinary course of business. The Company makes a determination of capitalizing inventory costs for a product based on, among other factors, status of regulatory approval, information regarding safety, efficacy and expectations relating to commercial sales and recoverability of costs.&#160;For &lt;span style="font-style:italic;"&gt;Jelmyto&lt;/span&gt;, the Company commenced capitalization of inventory at the receipt of FDA approval.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.67%;text-indent:0%;font-family:Times New Roman;font-size:12pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company values its inventory at the lower of cost or net realizable value.&#160;The Company measures inventory approximating actual cost under a first-in, first-out basis. The Company assesses recoverability of inventory each reporting period to determine any write down to net realizable value resulting from excess or obsolete inventories&lt;span style="font-style:italic;"&gt;.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Calibri;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Property and Equipment&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Property and equipment are recorded at historical cost, net of accumulated depreciation, amortization and, if applicable, impairment charges. The Company reviews its property and equipment assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Property and equipment are depreciated over the following useful lives (in years):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:60%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.02%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.88%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Useful Lives&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.02%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Computers and software&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000251"&gt;3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.02%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Laboratory equipment&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.88%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3-6.5&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.02%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Furniture&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.88%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5-16.5&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.02%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Manufacturing equipment&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000252"&gt;2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Leasehold improvements are amortized on a straight-line basis over the shorter of their estimated useful lives or lease terms. See Note 8 for further discussion regarding property and equipment.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Calibri;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Leases&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company is a lessee in several noncancelable operating leases, primarily for office space, office equipment and vehicles. The Company currently has no finance leases.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company accounts for leases in accordance with ASC Topic 842, &#x201c;Leases&#x201d;&lt;span style="font-style:italic;"&gt;.&lt;/span&gt; The Company determines if an arrangement is a lease at inception. Right-of-use (&#x201c;ROU&#x201d;) assets and operating lease liabilities are recognized based on the present value of lease payments over the lease term as of the commencement date. Operating lease ROU assets are presented as operating lease right of use assets on the condensed consolidated balance sheets. The current portion of operating lease liabilities is included in other current liabilities and the long-term portion is presented separately as operating lease liabilities on the condensed consolidated balance sheets.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Lease expense is recognized on a straight-line basis for operating leases. Variable lease payments associated with the Company&#x2019;s leases are recognized when the event, activity, or circumstance in the lease agreement on which those payments are assessed occurs. Variable lease payments are presented as operating expense on the condensed consolidated statements of operations in the same line item as expense arising from fixed lease payments.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company&#x2019;s lease terms may include options to extend the lease. The lease extensions are included in the measurement of the right of use asset and lease liability when it is reasonably certain that it will exercise that option.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Because most of the Company&#x2019;s leases do not provide an implicit rate of return, an incremental borrowing rate is used based on the information available at the commencement date in determining the present value of lease payments on an individual lease basis. The Company&#x2019;s incremental borrowing rate for a lease is the rate of interest it would have to pay on a collateralized basis to borrow an amount equal to the lease payments under similar terms. &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;ROU assets for operating leases are periodically reviewed for impairment losses under ASC 360-10, &#x201c;Property, Plant, and Equipment&#x201d;, to determine whether an ROU asset is impaired, and if so, the amount of the impairment loss to recognize.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Calibri;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Revenues&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Product sales from &lt;span style="font-style:italic;"&gt;Jelmyto&lt;/span&gt; are recognized as revenue under ASC 606 at the point in time that control of the product has been transferred to the customer, generally at the point the product has been delivered to the treating physician. All product sales of &lt;span style="font-style:italic;"&gt;Jelmyto&lt;/span&gt; are recognized through the Company's arrangement with a single customer, a third-party national specialty distributor. Net revenues recognized include management&#x2019;s estimate of returns, consideration paid to the customer, chargebacks relating to differences between the wholesale acquisition cost and the contracted price offered to the end consumer, chargebacks relating to 340b drug pricing programs, Medicaid drug rebate programs, and the Company&#x2019;s copay assistance program, which are estimated based on industry benchmarking studies as well as the Company&#x2019;s historical experience.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;"&gt;&#160;&lt;/p&gt;
&lt;p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Calibri;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Research and Development Expenses &lt;/p&gt;
&lt;p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research and development costs are expensed as incurred and consist primarily of the cost of salaries, share-based compensation expenses, payroll taxes and other employee benefits, subcontractors and materials used for research and development activities, including nonclinical studies, clinical trials, manufacturing costs and professional services. The costs of services performed by others in connection with the research and development activities of the Company, including research and development conducted by others on behalf of the Company, shall be included in research and development costs and expensed as the contracted work is performed. The Company accrues for costs incurred as the services are being provided by monitoring the status of the trial or project and the invoices received from its external service providers. The Company adjusts its accrual as actual costs become known. Where contingent milestone payments are due to third parties under research and development arrangements or license agreements, the milestone payment obligations are expensed when the milestone results are achieved.&lt;/p&gt;
&lt;p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Calibri;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Selling&lt;span style="font-weight:normal;font-style:normal;"&gt; &lt;/span&gt;&lt;span style="color:#000000;"&gt;General and Administrative Expenses&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Selling, general and administrative expenses consist primarily of personnel costs (including share-based compensation related to directors, employees and consultants). Other significant costs include commercial, medical affairs, external professional service costs, facility costs, accounting and audit services, legal services, and other consulting fees. Selling, general and administrative costs are expensed as incurred, and the Company accrues for services provided by third parties related to the above expenses by monitoring the status of services provided and receiving estimates from its service providers and adjusting its accruals as actual costs become known.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Calibri;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Share-Based Compensation&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Share-based compensation cost is measured at the grant date based on the fair value of the award and is recognized as expense over the required service period, which is equal to the vesting period. The fair value of options is determined using the Black-Scholes option-pricing model. The fair value of a restricted stock unit (&#x201c;RSU&#x201d;) equaled the closing price of the Company&#x2019;s ordinary shares on the grant date. The Company accounts for forfeitures as they occur in accordance with ASC Topic 718, &#x201c;Compensation&#x2014;Stock Compensation&#x201d;.&lt;span style="letter-spacing:0.75pt;"&gt; &lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The&lt;span style="letter-spacing:0.35pt;"&gt; &lt;/span&gt;Company&lt;span style="letter-spacing:0.8pt;"&gt; &lt;/span&gt;elected&lt;span style="letter-spacing:0.6pt;"&gt; &lt;/span&gt;to&lt;span style="letter-spacing:0.2pt;"&gt; &lt;/span&gt;recognize&lt;span style="letter-spacing:0.8pt;"&gt; &lt;/span&gt;compen&lt;span style="letter-spacing:-0.1pt;"&gt;s&lt;/span&gt;ation&lt;span style="letter-spacing:1.1pt;"&gt; &lt;/span&gt;costs&lt;span style="letter-spacing:0.45pt;"&gt; &lt;/span&gt;for&lt;span style="letter-spacing:0.25pt;"&gt; &lt;/span&gt;awards&lt;span style="letter-spacing:0.6pt;"&gt; &lt;/span&gt;conditioned&lt;span style="letter-spacing:0.9pt;"&gt; &lt;/span&gt;only&lt;span style="letter-spacing:0.35pt;"&gt; &lt;/span&gt;on&lt;span style="letter-spacing:0.25pt;"&gt; &lt;/span&gt;conti&lt;span style="letter-spacing:-0.1pt;"&gt;n&lt;/span&gt;ued&lt;span style="letter-spacing:0.8pt;"&gt; &lt;/span&gt;service&lt;span style="letter-spacing:0.6pt;"&gt; &lt;/span&gt;that&lt;span style="letter-spacing:0.35pt;"&gt; &lt;/span&gt;have&lt;span style="letter-spacing:0.4pt;"&gt; &lt;/span&gt;a&lt;span style="letter-spacing:0.15pt;"&gt; &lt;/span&gt;graded&lt;span style="letter-spacing:0.6pt;"&gt; &lt;/span&gt;vesting&lt;span style="letter-spacing:0.6pt;"&gt; &lt;/span&gt;schedule&lt;span style="letter-spacing:0.05pt;"&gt; &lt;/span&gt;using&lt;span style="letter-spacing:0.45pt;"&gt; &lt;/span&gt;the&lt;span style="letter-spacing:0.3pt;"&gt; &lt;/span&gt;straight-line&lt;span style="letter-spacing:0.95pt;"&gt; &lt;/span&gt;method&lt;span style="letter-spacing:0.55pt;"&gt; &lt;/span&gt;and&lt;span style="letter-spacing:0.35pt;"&gt; &lt;/span&gt;to&lt;span style="letter-spacing:0.2pt;"&gt; &lt;/span&gt;value&lt;span style="letter-spacing:0.45pt;"&gt; &lt;/span&gt;the&lt;span style="letter-spacing:0.3pt;"&gt; &lt;/span&gt;awards&lt;span style="letter-spacing:0.6pt;"&gt; &lt;/span&gt;based&lt;span style="letter-spacing:0.5pt;"&gt; &lt;/span&gt;on&lt;span style="letter-spacing:0.25pt;"&gt; &lt;/span&gt;the&lt;span style="letter-spacing:0.3pt;"&gt; &lt;/span&gt;sin&lt;span style="letter-spacing:-0.1pt;"&gt;g&lt;/span&gt;le-option&lt;span style="letter-spacing:1pt;"&gt; &lt;/span&gt;award&lt;span style="letter-spacing:0.5pt;"&gt; &lt;/span&gt;approach.&lt;span style="letter-spacing:0.8pt;"&gt; &lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Calibri;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Net Loss per Ordinary Share&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Basic net loss per share is computed by dividing the net loss attributable to ordinary shareholders by the weighted-average number of ordinary shares outstanding. Diluted net loss per share is computed similarly to basic net loss per share except that the denominator is increased to include the number of additional ordinary shares that would have been outstanding if the potential ordinary shares had been issued and if the additional ordinary shares were dilutive. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;For all periods presented, potentially dilutive securities are excluded from the computation of fully diluted loss per share as their effect is anti-dilutive.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock contextRef="C_0001668243_20210101_20210331" id="F_000216">
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Calibri;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Principles of Consolidation&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The condensed consolidated financial statements include the accounts of UPL and its subsidiary, UPI. Intercompany balances and transactions have been eliminated during consolidation.&lt;/p&gt;</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:UseOfEstimates contextRef="C_0001668243_20210101_20210331" id="F_000217">
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Calibri;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Use of Estimates&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The&lt;span style="letter-spacing:0.35pt;"&gt; &lt;/span&gt;preparation&lt;span style="letter-spacing:0.9pt;"&gt; &lt;/span&gt;of&lt;span style="letter-spacing:0.2pt;"&gt; &lt;/span&gt;financial&lt;span style="letter-spacing:0.65pt;"&gt; &lt;/span&gt;statements&lt;span style="letter-spacing:0.9pt;"&gt; &lt;/span&gt;in&lt;span style="letter-spacing:0.2pt;"&gt; &lt;/span&gt;conformity&lt;span style="letter-spacing:0.85pt;"&gt; &lt;/span&gt;with&lt;span style="letter-spacing:0.35pt;"&gt; U.S. &lt;/span&gt;GAAP&lt;span style="letter-spacing:0.5pt;"&gt; &lt;/span&gt;requires&lt;span style="letter-spacing:0.65pt;"&gt; &lt;/span&gt;man&lt;span style="letter-spacing:-0.1pt;"&gt;a&lt;/span&gt;gement&lt;span style="letter-spacing:1.05pt;"&gt; &lt;/span&gt;to&lt;span style="letter-spacing:0.2pt;"&gt; &lt;/span&gt;make&lt;span style="letter-spacing:0.45pt;"&gt; &lt;/span&gt;estimates&lt;span style="letter-spacing:0.8pt;"&gt; &lt;/span&gt;and&lt;span style="letter-spacing:0.35pt;"&gt; &lt;/span&gt;assumptions&lt;span style="letter-spacing:1pt;"&gt; &lt;/span&gt;that&lt;span style="letter-spacing:0.35pt;"&gt; &lt;/span&gt;affect the&lt;span style="letter-spacing:0.05pt;"&gt; &lt;/span&gt;reported&lt;span style="letter-spacing:0.7pt;"&gt; &lt;/span&gt;amounts&lt;span style="letter-spacing:0.7pt;"&gt; &lt;/span&gt;of&lt;span style="letter-spacing:0.2pt;"&gt; &lt;/span&gt;assets&lt;span style="letter-spacing:0.6pt;"&gt; &lt;/span&gt;and&lt;span style="letter-spacing:0.35pt;"&gt; &lt;/span&gt;liabilities,&lt;span style="letter-spacing:0.75pt;"&gt; &lt;/span&gt;the&lt;span style="letter-spacing:0.3pt;"&gt; &lt;/span&gt;disclosure&lt;span style="letter-spacing:0.8pt;"&gt; &lt;/span&gt;of&lt;span style="letter-spacing:0.2pt;"&gt; &lt;/span&gt;cont&lt;span style="letter-spacing:-0.1pt;"&gt;i&lt;/span&gt;ngent&lt;span style="letter-spacing:0.85pt;"&gt; &lt;/span&gt;assets&lt;span style="letter-spacing:0.55pt;"&gt; &lt;/span&gt;and&lt;span style="letter-spacing:0.35pt;"&gt; &lt;/span&gt;liabilities&lt;span style="letter-spacing:0.7pt;"&gt; &lt;/span&gt;at&lt;span style="letter-spacing:0.2pt;"&gt; &lt;/span&gt;the&lt;span style="letter-spacing:0.3pt;"&gt; &lt;/span&gt;date&lt;span style="letter-spacing:0.4pt;"&gt; &lt;/span&gt;of&lt;span style="letter-spacing:0.2pt;"&gt; &lt;/span&gt;the&lt;span style="letter-spacing:0.3pt;"&gt; &lt;/span&gt;financ&lt;span style="letter-spacing:-0.1pt;"&gt;i&lt;/span&gt;al&lt;span style="letter-spacing:0.65pt;"&gt; &lt;/span&gt;statements&lt;span style="letter-spacing:0.9pt;"&gt; &lt;/span&gt;and&lt;span style="letter-spacing:0.35pt;"&gt; &lt;/span&gt;the reported&lt;span style="letter-spacing:0.7pt;"&gt; &lt;/span&gt;amounts&lt;span style="letter-spacing:0.7pt;"&gt; &lt;/span&gt;of&lt;span style="letter-spacing:0.2pt;"&gt; &lt;/span&gt;revenues&lt;span style="letter-spacing:0.75pt;"&gt; &lt;/span&gt;and&lt;span style="letter-spacing:0.35pt;"&gt; &lt;/span&gt;expenses&lt;span style="letter-spacing:0.8pt;"&gt; &lt;/span&gt;duri&lt;span style="letter-spacing:-0.1pt;"&gt;n&lt;/span&gt;g&lt;span style="letter-spacing:0.5pt;"&gt; &lt;/span&gt;the&lt;span style="letter-spacing:0.3pt;"&gt; &lt;/span&gt;reporting&lt;span style="letter-spacing:0.7pt;"&gt; &lt;/span&gt;period.&lt;span style="letter-spacing:0.55pt;"&gt; &lt;/span&gt;Actual&lt;span style="letter-spacing:0.5pt;"&gt; &lt;/span&gt;results&lt;span style="letter-spacing:0.55pt;"&gt; &lt;/span&gt;may&lt;span style="letter-spacing:0.35pt;"&gt; &lt;/span&gt;differ&lt;span style="letter-spacing:0.45pt;"&gt; &lt;/span&gt;from&lt;span style="letter-spacing:0.4pt;"&gt; &lt;/span&gt;those&lt;span style="letter-spacing:0.45pt;"&gt; &lt;/span&gt;estimates.&lt;span style="letter-spacing:0.8pt;"&gt; &lt;/span&gt;As&lt;span style="letter-spacing:0.25pt;"&gt; &lt;/span&gt;applicable&lt;span style="letter-spacing:0.9pt;"&gt; &lt;/span&gt;to the unaudited condensed&lt;span style="letter-spacing:0.45pt;"&gt; &lt;/span&gt;consolidated&lt;span style="letter-spacing:1pt;"&gt; &lt;/span&gt;financi&lt;span style="letter-spacing:-0.1pt;"&gt;a&lt;/span&gt;l&lt;span style="letter-spacing:0.65pt;"&gt; &lt;/span&gt;statements,&lt;span style="letter-spacing:0.95pt;"&gt; &lt;/span&gt;the&lt;span style="letter-spacing:0.3pt;"&gt; critical &lt;/span&gt;accounting&lt;span style="letter-spacing:0.35pt;"&gt; estimates relate &lt;/span&gt;to&lt;span style="letter-spacing:0.2pt;"&gt; &lt;/span&gt;the&lt;span style="letter-spacing:0.3pt;"&gt; &lt;/span&gt;fair&lt;span style="letter-spacing:0.3pt;"&gt; &lt;/span&gt;value&lt;span style="letter-spacing:0.45pt;"&gt; &lt;/span&gt;of&lt;span style="letter-spacing:0.2pt;"&gt; &lt;/span&gt;share-based&lt;span style="letter-spacing:1pt;"&gt; &lt;/span&gt;compensat&lt;span style="letter-spacing:-0.1pt;"&gt;i&lt;/span&gt;on,&lt;span style="letter-spacing:0.55pt;"&gt; &lt;/span&gt;measurement&lt;span style="letter-spacing:0.5pt;"&gt; &lt;/span&gt;of&lt;span style="letter-spacing:0.2pt;"&gt; &lt;/span&gt;revenue and estimate of uncertain tax positions.&lt;/p&gt;</us-gaap:UseOfEstimates>
    <us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock contextRef="C_0001668243_20210101_20210331" id="F_000218">
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Calibri;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Functional&lt;span style="letter-spacing:0.9pt;"&gt; &lt;/span&gt;Currency&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The&lt;span style="letter-spacing:0.35pt;"&gt; &lt;/span&gt;U.S.&lt;span style="letter-spacing:0.4pt;"&gt; &lt;/span&gt;dollar&lt;span style="letter-spacing:0.45pt;"&gt; &lt;/span&gt;(&#x201c;Dollar&#x201d;)&lt;span style="letter-spacing:0.7pt;"&gt; &lt;/span&gt;is&lt;span style="letter-spacing:0.15pt;"&gt; &lt;/span&gt;the&lt;span style="letter-spacing:0.35pt;"&gt; &lt;/span&gt;currency&lt;span style="letter-spacing:0.7pt;"&gt; &lt;/span&gt;of&lt;span style="letter-spacing:0.2pt;"&gt; &lt;/span&gt;the&lt;span style="letter-spacing:0.3pt;"&gt; &lt;/span&gt;primary&lt;span style="letter-spacing:0.6pt;"&gt; &lt;/span&gt;economic&lt;span style="letter-spacing:0.8pt;"&gt; &lt;/span&gt;environment&lt;span style="letter-spacing:1pt;"&gt; &lt;/span&gt;in&lt;span style="letter-spacing:0.2pt;"&gt; &lt;/span&gt;which&lt;span style="letter-spacing:0.5pt;"&gt; &lt;/span&gt;the&lt;span style="letter-spacing:0.3pt;"&gt; &lt;/span&gt;operations&lt;span style="letter-spacing:0.85pt;"&gt; &lt;/span&gt;of&lt;span style="letter-spacing:0.2pt;"&gt; &lt;/span&gt;the&lt;span style="letter-spacing:0.3pt;"&gt; &lt;/span&gt;Com&lt;span style="letter-spacing:-0.1pt;"&gt;p&lt;/span&gt;any&lt;span style="letter-spacing:0.8pt;"&gt; &lt;/span&gt;are conducted.&lt;span style="letter-spacing:0.9pt;"&gt; &lt;/span&gt;Therefore,&lt;span style="letter-spacing:0.85pt;"&gt; &lt;/span&gt;the&lt;span style="letter-spacing:0.3pt;"&gt; &lt;/span&gt;functional&lt;span style="letter-spacing:0.8pt;"&gt; &lt;/span&gt;currency&lt;span style="letter-spacing:0.7pt;"&gt; &lt;/span&gt;of&lt;span style="letter-spacing:0.2pt;"&gt; &lt;/span&gt;the&lt;span style="letter-spacing:0.3pt;"&gt; &lt;/span&gt;Company&lt;span style="letter-spacing:0.8pt;"&gt; &lt;/span&gt;is&lt;span style="letter-spacing:0.15pt;"&gt; &lt;/span&gt;the&lt;span style="letter-spacing:0.3pt;"&gt; &lt;/span&gt;Dol&lt;span style="letter-spacing:-0.1pt;"&gt;l&lt;/span&gt;ar.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accordingly,&lt;span style="letter-spacing:1pt;"&gt; &lt;/span&gt;transactions&lt;span style="letter-spacing:0.95pt;"&gt; &lt;/span&gt;in&lt;span style="letter-spacing:0.2pt;"&gt; &lt;/span&gt;currencies&lt;span style="letter-spacing:0.85pt;"&gt; &lt;/span&gt;other&lt;span style="letter-spacing:0.45pt;"&gt; &lt;/span&gt;than&lt;span style="letter-spacing:0.4pt;"&gt; &lt;/span&gt;the&lt;span style="letter-spacing:0.3pt;"&gt; &lt;/span&gt;Do&lt;span style="letter-spacing:-0.1pt;"&gt;l&lt;/span&gt;lar&lt;span style="letter-spacing:0.5pt;"&gt; &lt;/span&gt;are&lt;span style="letter-spacing:0.3pt;"&gt; &lt;/span&gt;measured&lt;span style="letter-spacing:0.8pt;"&gt; &lt;/span&gt;and&lt;span style="letter-spacing:0.35pt;"&gt; &lt;/span&gt;recorded&lt;span style="letter-spacing:0.7pt;"&gt; &lt;/span&gt;in&lt;span style="letter-spacing:0.2pt;"&gt; &lt;/span&gt;the&lt;span style="letter-spacing:0.3pt;"&gt; &lt;/span&gt;functional&lt;span style="letter-spacing:0.8pt;"&gt; &lt;/span&gt;currency&lt;span style="letter-spacing:0.7pt;"&gt; &lt;/span&gt;usi&lt;span style="letter-spacing:-0.1pt;"&gt;n&lt;/span&gt;g&lt;span style="letter-spacing:0.45pt;"&gt; &lt;/span&gt;the&lt;span style="letter-spacing:0.3pt;"&gt; &lt;/span&gt;exchange&lt;span style="letter-spacing:0.8pt;"&gt; &lt;/span&gt;rate&lt;span style="letter-spacing:0.35pt;"&gt; &lt;/span&gt;in effect&lt;span style="letter-spacing:0.45pt;"&gt; &lt;/span&gt;at&lt;span style="letter-spacing:0.2pt;"&gt; &lt;/span&gt;the&lt;span style="letter-spacing:0.3pt;"&gt; &lt;/span&gt;date&lt;span style="letter-spacing:0.4pt;"&gt; &lt;/span&gt;of&lt;span style="letter-spacing:0.2pt;"&gt; &lt;/span&gt;the&lt;span style="letter-spacing:0.35pt;"&gt; &lt;/span&gt;transaction.&lt;span style="letter-spacing:0.95pt;"&gt; &lt;/span&gt;At&lt;span style="letter-spacing:0.2pt;"&gt; &lt;/span&gt;the&lt;span style="letter-spacing:0.3pt;"&gt; &lt;/span&gt;balance&lt;span style="letter-spacing:0.65pt;"&gt; &lt;/span&gt;sheet&lt;span style="letter-spacing:0.45pt;"&gt; &lt;/span&gt;date,&lt;span style="letter-spacing:0.45pt;"&gt; &lt;/span&gt;monetary&lt;span style="letter-spacing:0.75pt;"&gt; &lt;/span&gt;assets&lt;span style="letter-spacing:0.55pt;"&gt; &lt;/span&gt;and&lt;span style="letter-spacing:0.35pt;"&gt; &lt;/span&gt;liab&lt;span style="letter-spacing:-0.1pt;"&gt;i&lt;/span&gt;lities&lt;span style="letter-spacing:0.7pt;"&gt; &lt;/span&gt;that&lt;span style="letter-spacing:0.35pt;"&gt; &lt;/span&gt;are&lt;span style="letter-spacing:0.3pt;"&gt; &lt;/span&gt;denominated&lt;span style="letter-spacing:1.05pt;"&gt; &lt;/span&gt;in&lt;span style="letter-spacing:0.2pt;"&gt; &lt;/span&gt;currencies&lt;span style="letter-spacing:0.85pt;"&gt; &lt;/span&gt;other&lt;span style="letter-spacing:0.45pt;"&gt; &lt;/span&gt;than the&lt;span style="letter-spacing:0.05pt;"&gt; &lt;/span&gt;Dollar&lt;span style="letter-spacing:0.5pt;"&gt; &lt;/span&gt;are&lt;span style="letter-spacing:0.3pt;"&gt; &lt;/span&gt;measured&lt;span style="letter-spacing:0.8pt;"&gt; &lt;/span&gt;using&lt;span style="letter-spacing:0.45pt;"&gt; &lt;/span&gt;the&lt;span style="letter-spacing:0.3pt;"&gt; &lt;/span&gt;official&lt;span style="letter-spacing:0.55pt;"&gt; &lt;/span&gt;exch&lt;span style="letter-spacing:-0.1pt;"&gt;a&lt;/span&gt;nge&lt;span style="letter-spacing:0.8pt;"&gt; &lt;/span&gt;rate&lt;span style="letter-spacing:0.35pt;"&gt; &lt;/span&gt;at&lt;span style="letter-spacing:0.2pt;"&gt; &lt;/span&gt;the&lt;span style="letter-spacing:0.3pt;"&gt; &lt;/span&gt;balance&lt;span style="letter-spacing:0.65pt;"&gt; &lt;/span&gt;sheet&lt;span style="letter-spacing:0.45pt;"&gt; &lt;/span&gt;date.&lt;span style="letter-spacing:0.45pt;"&gt; &lt;/span&gt;The&lt;span style="letter-spacing:0.35pt;"&gt; &lt;/span&gt;effects&lt;span style="letter-spacing:0.55pt;"&gt; &lt;/span&gt;of&lt;span style="letter-spacing:0.2pt;"&gt; &lt;/span&gt;foreign&lt;span style="letter-spacing:0.55pt;"&gt; &lt;/span&gt;currency&lt;span style="letter-spacing:0.8pt;"&gt; &lt;/span&gt;re-measurements&lt;span style="letter-spacing:1.45pt;"&gt; &lt;/span&gt;are recorded&lt;span style="letter-spacing:0.7pt;"&gt; &lt;/span&gt;in&lt;span style="letter-spacing:0.2pt;"&gt; &lt;/span&gt;the&lt;span style="letter-spacing:0.3pt;"&gt; condensed &lt;/span&gt;consolidated&lt;span style="letter-spacing:1pt;"&gt; &lt;/span&gt;statements&lt;span style="letter-spacing:0.9pt;"&gt; &lt;/span&gt;of&lt;span style="letter-spacing:0.2pt;"&gt; &lt;/span&gt;operations&lt;span style="letter-spacing:0.85pt;"&gt; &lt;/span&gt;as&lt;span style="letter-spacing:0.25pt;"&gt; &lt;/span&gt;&#x201c;Interest and other income, net.&#x201d;&lt;/p&gt;</us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
    <urgn:CashAndCashEquivalentsAndMarketableSecuritiesPolicyPolicyTextBlock contextRef="C_0001668243_20210101_20210331" id="F_000219">
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Calibri;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Cash and Cash Equivalents; &lt;span style="color:#000000;"&gt;Marketable Securities&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company considers all highly liquid investments with an original maturity of three months or less when purchased to be cash equivalents. Cash and cash equivalents consist primarily of money market funds and bank money market accounts and are stated at cost, which approximates fair value. &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cash and cash equivalents and marketable securities totaled $75.9 million as of March&#160;31, 2021. The Company classifies its marketable securities as available-for-sale in accordance with the &lt;span style="letter-spacing:-0.2pt;"&gt;Financial Accounting Standards Board (&#x201c;&lt;/span&gt;FASB&#x201d;) Accounting Standards Codification (&#x201c;ASC&#x201d;) Topic 320, &#x201c;Investments &#x2014; Debt and Equity Securities&#x201d;. Available-for-sale debt securities are carried at fair value with unrealized gains and losses reported in other comprehensive income/loss within shareholders&#x2019; equity. Realized gains and losses are recorded as a component of interest and other income (expense), net. The cost of securities sold is based on the specific-identification method. &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Short-term investments are valued using models or other valuation methodologies that use Level 2 inputs. These models are primarily industry-standard models that consider various assumptions, including time value, yield curve, volatility factors, default rates, current market and contractual prices for the underlying financial instruments, as well as other relevant economic measures. The majority of these assumptions are observable in the marketplace, can be derived from observable data or are supported by observable levels at which transactions are executed in the marketplace.&#160;&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;For individual debt securities classified as available-for-sale securities where there has been a decline in fair value below amortized cost, the Company determines whether the decline resulted from a credit loss or other factors. The Company records impairment relating to credit losses through an allowance for credit losses, limited by the amount that the fair value is less than the amortized cost basis. Impairment that has not been recorded through an allowance for credit losses is recorded through other comprehensive income, net of applicable taxes.&lt;/p&gt;</urgn:CashAndCashEquivalentsAndMarketableSecuritiesPolicyPolicyTextBlock>
    <urgn:CashCashEquivalentsAndMarketableSecurities
      contextRef="C_0001668243_20210331"
      decimals="-5"
      id="F_000250"
      unitRef="U_iso4217USD">75900000</urgn:CashCashEquivalentsAndMarketableSecurities>
    <us-gaap:ConcentrationRiskCreditRisk contextRef="C_0001668243_20210101_20210331" id="F_000220">
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Calibri;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Concentration of Credit Risk&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Financial instruments, which potentially subject the Company to significant concentrations of credit risk, consist primarily of cash and cash equivalents and marketable securities. The primary objectives for the Company&lt;span style="color:#000000;"&gt;&#x2019;&lt;/span&gt;s investment portfolio are the preservation of capital and the maintenance of liquidity. The Company does not enter into any investment transaction for trading or speculative purposes.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company&lt;span style="color:#000000;"&gt;&#x2019;&lt;/span&gt;s investment policy limits investments to certain types of instruments such as certificates of deposit, money market instruments, obligations issued by the U.S. government and U.S. government agencies as well as corporate debt securities, and places restrictions on maturities and concentration by type and issuer. The Company maintains cash balances in excess of amounts insured by the Federal Deposit Insurance Corporation and concentrated within a limited number of financial institutions. The accounts are monitored by management to mitigate the risk.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company&#x2019;s product sales are recognized through the Company's arrangement with a single customer, a third-party national specialty distributor. The Company assesses the need for an allowance for doubtful accounts primarily based on creditworthiness, historical payment experience and general economic conditions. The Company has not experienced any credit losses related to this customer and has not currently recognized any allowance for doubtful accounts.&lt;/p&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="C_0001668243_20210101_20210331" id="F_000222">
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Calibri;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Income Taxes&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company provides for income taxes based on pretax income, if any, and applicable tax rates available in the various jurisdictions in which it operates, including Israel and the U.S. Deferred&lt;span style="letter-spacing:0.6pt;"&gt; &lt;/span&gt;taxes&lt;span style="letter-spacing:0.45pt;"&gt; &lt;/span&gt;are&lt;span style="letter-spacing:0.3pt;"&gt; &lt;/span&gt;computed&lt;span style="letter-spacing:0.8pt;"&gt; &lt;/span&gt;using&lt;span style="letter-spacing:0.45pt;"&gt; &lt;/span&gt;the&lt;span style="letter-spacing:0.3pt;"&gt; &lt;/span&gt;asset&lt;span style="letter-spacing:0.45pt;"&gt; &lt;/span&gt;and&lt;span style="letter-spacing:0.35pt;"&gt; &lt;/span&gt;liabi&lt;span style="letter-spacing:-0.1pt;"&gt;l&lt;/span&gt;ity&lt;span style="letter-spacing:0.65pt;"&gt; &lt;/span&gt;method.&lt;span style="letter-spacing:0.65pt;"&gt; &lt;/span&gt;Under&lt;span style="letter-spacing:0.5pt;"&gt; &lt;/span&gt;the&lt;span style="letter-spacing:0.3pt;"&gt; &lt;/span&gt;asset&lt;span style="letter-spacing:0.45pt;"&gt; &lt;/span&gt;and&lt;span style="letter-spacing:0.35pt;"&gt; &lt;/span&gt;liability&lt;span style="letter-spacing:0.55pt;"&gt; &lt;/span&gt;method,&lt;span style="letter-spacing:0.65pt;"&gt; &lt;/span&gt;deferred&lt;span style="letter-spacing:0.7pt;"&gt; &lt;/span&gt;income&lt;span style="letter-spacing:0.6pt;"&gt; &lt;/span&gt;tax&lt;span style="letter-spacing:0.3pt;"&gt; &lt;/span&gt;assets&lt;span style="letter-spacing:0.55pt;"&gt; &lt;/span&gt;and liabilities&lt;span style="letter-spacing:0.7pt;"&gt; &lt;/span&gt;are&lt;span style="letter-spacing:0.3pt;"&gt; &lt;/span&gt;determined&lt;span style="letter-spacing:0.9pt;"&gt; &lt;/span&gt;bas&lt;span style="letter-spacing:-0.1pt;"&gt;e&lt;/span&gt;d&lt;span style="letter-spacing:0.5pt;"&gt; &lt;/span&gt;on&lt;span style="letter-spacing:0.25pt;"&gt; &lt;/span&gt;the&lt;span style="letter-spacing:0.3pt;"&gt; &lt;/span&gt;differences&lt;span style="letter-spacing:0.9pt;"&gt; &lt;/span&gt;between&lt;span style="letter-spacing:0.7pt;"&gt; &lt;/span&gt;the&lt;span style="letter-spacing:0.3pt;"&gt; &lt;/span&gt;financial&lt;span style="letter-spacing:0.65pt;"&gt; &lt;/span&gt;reporti&lt;span style="letter-spacing:-0.1pt;"&gt;n&lt;/span&gt;g&lt;span style="letter-spacing:0.7pt;"&gt; &lt;/span&gt;and&lt;span style="letter-spacing:0.35pt;"&gt; &lt;/span&gt;tax bases&lt;span style="letter-spacing:0.5pt;"&gt; &lt;/span&gt;of&lt;span style="letter-spacing:0.2pt;"&gt; &lt;/span&gt;assets&lt;span style="letter-spacing:0.55pt;"&gt; &lt;/span&gt;and&lt;span style="letter-spacing:0.35pt;"&gt; &lt;/span&gt;liabilities&lt;span style="letter-spacing:0.7pt;"&gt; &lt;/span&gt;and&lt;span style="letter-spacing:0.35pt;"&gt; &lt;/span&gt;are&lt;span style="letter-spacing:0.3pt;"&gt; &lt;/span&gt;mea&lt;span style="letter-spacing:-0.1pt;"&gt;s&lt;/span&gt;ured&lt;span style="letter-spacing:0.8pt;"&gt; &lt;/span&gt;using&lt;span style="letter-spacing:0.45pt;"&gt; &lt;/span&gt;the&lt;span style="letter-spacing:0.3pt;"&gt; &lt;/span&gt;currently&lt;span style="letter-spacing:0.7pt;"&gt; &lt;/span&gt;enacted&lt;span style="letter-spacing:0.65pt;"&gt; &lt;/span&gt;tax&lt;span style="letter-spacing:0.3pt;"&gt; &lt;/span&gt;rates&lt;span style="letter-spacing:0.45pt;"&gt; &lt;/span&gt;and&lt;span style="letter-spacing:0.35pt;"&gt; &lt;/span&gt;laws.&lt;span style="letter-spacing:0.45pt;"&gt; &lt;/span&gt;A&lt;span style="letter-spacing:0.15pt;"&gt; &lt;/span&gt;valuation&lt;span style="letter-spacing:0.75pt;"&gt; &lt;/span&gt;&lt;span style="letter-spacing:-0.1pt;"&gt;a&lt;/span&gt;llowance&lt;span style="letter-spacing:0.8pt;"&gt; &lt;/span&gt;is&lt;span style="letter-spacing:0.15pt;"&gt; &lt;/span&gt;recognized&lt;span style="letter-spacing:0.9pt;"&gt; &lt;/span&gt;to&lt;span style="letter-spacing:0.2pt;"&gt; &lt;/span&gt;the extent&lt;span style="letter-spacing:0.5pt;"&gt; &lt;/span&gt;that&lt;span style="letter-spacing:0.35pt;"&gt; &lt;/span&gt;it&lt;span style="letter-spacing:0.15pt;"&gt; &lt;/span&gt;is&lt;span style="letter-spacing:0.15pt;"&gt; &lt;/span&gt;more&lt;span style="letter-spacing:0.45pt;"&gt; &lt;/span&gt;likely&lt;span style="letter-spacing:0.45pt;"&gt; &lt;/span&gt;than&lt;span style="letter-spacing:0.4pt;"&gt; &lt;/span&gt;not&lt;span style="letter-spacing:0.3pt;"&gt; &lt;/span&gt;that&lt;span style="letter-spacing:0.35pt;"&gt; &lt;/span&gt;the&lt;span style="letter-spacing:0.35pt;"&gt; &lt;/span&gt;deferred&lt;span style="letter-spacing:0.7pt;"&gt; &lt;/span&gt;taxes&lt;span style="letter-spacing:0.45pt;"&gt; &lt;/span&gt;will&lt;span style="letter-spacing:0.3pt;"&gt; &lt;/span&gt;not&lt;span style="letter-spacing:0.3pt;"&gt; &lt;/span&gt;be&lt;span style="letter-spacing:0.25pt;"&gt; &lt;/span&gt;realized&lt;span style="letter-spacing:0.65pt;"&gt; &lt;/span&gt;in&lt;span style="letter-spacing:0.2pt;"&gt; &lt;/span&gt;the&lt;span style="letter-spacing:0.3pt;"&gt; &lt;/span&gt;foresee&lt;span style="letter-spacing:-0.1pt;"&gt;a&lt;/span&gt;ble&lt;span style="letter-spacing:0.95pt;"&gt; &lt;/span&gt;future.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The&lt;span style="letter-spacing:0.35pt;"&gt; &lt;/span&gt;Company&lt;span style="letter-spacing:0.8pt;"&gt; &lt;/span&gt;follows&lt;span style="letter-spacing:0.55pt;"&gt; &lt;/span&gt;a&lt;span style="letter-spacing:0.3pt;"&gt; &lt;/span&gt;two-step&lt;span style="letter-spacing:0.8pt;"&gt; &lt;/span&gt;approach&lt;span style="letter-spacing:0.75pt;"&gt; &lt;/span&gt;in&lt;span style="letter-spacing:0.2pt;"&gt; &lt;/span&gt;recognizing&lt;span style="letter-spacing:0.9pt;"&gt; &lt;/span&gt;a&lt;span style="letter-spacing:-0.1pt;"&gt;n&lt;/span&gt;d&lt;span style="letter-spacing:0.35pt;"&gt; &lt;/span&gt;measuring&lt;span style="letter-spacing:0.85pt;"&gt; &lt;/span&gt;uncertain&lt;span style="letter-spacing:0.75pt;"&gt; &lt;/span&gt;tax&lt;span style="letter-spacing:0.3pt;"&gt; &lt;/span&gt;positions.&lt;span style="letter-spacing:0.75pt;"&gt; &lt;/span&gt;After concluding that a particular filing position can be recognized (i.e., has a more-likely-than-not chance of being sustained), ASC 740-10-30-7 requires that the amount of benefit recognized be measured using a methodology based on the concept of cumulative probability. Under this methodology, the amount of benefit recorded represents the largest amount of tax benefit that is greater than 50% likely to be realized upon settlement with a taxing authority that has full knowledge of all relevant information. &#160;See Note 14 for further discussion related to income taxes.&lt;/p&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:InventoryPolicyTextBlock contextRef="C_0001668243_20210101_20210331" id="F_000223">
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Calibri;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Inventory&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company capitalizes inventory costs related to products to be sold in the ordinary course of business. The Company makes a determination of capitalizing inventory costs for a product based on, among other factors, status of regulatory approval, information regarding safety, efficacy and expectations relating to commercial sales and recoverability of costs.&#160;For &lt;span style="font-style:italic;"&gt;Jelmyto&lt;/span&gt;, the Company commenced capitalization of inventory at the receipt of FDA approval.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.67%;text-indent:0%;font-family:Times New Roman;font-size:12pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company values its inventory at the lower of cost or net realizable value.&#160;The Company measures inventory approximating actual cost under a first-in, first-out basis. The Company assesses recoverability of inventory each reporting period to determine any write down to net realizable value resulting from excess or obsolete inventories&lt;span style="font-style:italic;"&gt;.&lt;/span&gt;&lt;/p&gt;</us-gaap:InventoryPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="C_0001668243_20210101_20210331" id="F_000224">
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Calibri;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Property and Equipment&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Property and equipment are recorded at historical cost, net of accumulated depreciation, amortization and, if applicable, impairment charges. The Company reviews its property and equipment assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Property and equipment are depreciated over the following useful lives (in years):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:60%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.02%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.88%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Useful Lives&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.02%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Computers and software&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000251"&gt;3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.02%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Laboratory equipment&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.88%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3-6.5&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.02%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Furniture&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.88%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5-16.5&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.02%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Manufacturing equipment&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000252"&gt;2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Leasehold improvements are amortized on a straight-line basis over the shorter of their estimated useful lives or lease terms. See Note 8 for further discussion regarding property and equipment.&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <urgn:PropertyPlantAndEquipmentUsefulLifeTableTextBlock contextRef="C_0001668243_20210101_20210331" id="F_000231">
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Property and equipment are depreciated over the following useful lives (in years):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:60%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.02%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.88%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Useful Lives&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.02%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Computers and software&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000251"&gt;3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.02%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Laboratory equipment&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.88%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3-6.5&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.02%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Furniture&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.88%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5-16.5&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.02%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Manufacturing equipment&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000252"&gt;2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</urgn:PropertyPlantAndEquipmentUsefulLifeTableTextBlock>
    <us-gaap:LesseeLeasesPolicyTextBlock contextRef="C_0001668243_20210101_20210331" id="F_000225">
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Calibri;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Leases&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company is a lessee in several noncancelable operating leases, primarily for office space, office equipment and vehicles. The Company currently has no finance leases.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company accounts for leases in accordance with ASC Topic 842, &#x201c;Leases&#x201d;&lt;span style="font-style:italic;"&gt;.&lt;/span&gt; The Company determines if an arrangement is a lease at inception. Right-of-use (&#x201c;ROU&#x201d;) assets and operating lease liabilities are recognized based on the present value of lease payments over the lease term as of the commencement date. Operating lease ROU assets are presented as operating lease right of use assets on the condensed consolidated balance sheets. The current portion of operating lease liabilities is included in other current liabilities and the long-term portion is presented separately as operating lease liabilities on the condensed consolidated balance sheets.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Lease expense is recognized on a straight-line basis for operating leases. Variable lease payments associated with the Company&#x2019;s leases are recognized when the event, activity, or circumstance in the lease agreement on which those payments are assessed occurs. Variable lease payments are presented as operating expense on the condensed consolidated statements of operations in the same line item as expense arising from fixed lease payments.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company&#x2019;s lease terms may include options to extend the lease. The lease extensions are included in the measurement of the right of use asset and lease liability when it is reasonably certain that it will exercise that option.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Because most of the Company&#x2019;s leases do not provide an implicit rate of return, an incremental borrowing rate is used based on the information available at the commencement date in determining the present value of lease payments on an individual lease basis. The Company&#x2019;s incremental borrowing rate for a lease is the rate of interest it would have to pay on a collateralized basis to borrow an amount equal to the lease payments under similar terms. &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;ROU assets for operating leases are periodically reviewed for impairment losses under ASC 360-10, &#x201c;Property, Plant, and Equipment&#x201d;, to determine whether an ROU asset is impaired, and if so, the amount of the impairment loss to recognize.&lt;/p&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:RevenueRecognitionPolicyTextBlock contextRef="C_0001668243_20210101_20210331" id="F_000226">
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Calibri;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Revenues&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Product sales from &lt;span style="font-style:italic;"&gt;Jelmyto&lt;/span&gt; are recognized as revenue under ASC 606 at the point in time that control of the product has been transferred to the customer, generally at the point the product has been delivered to the treating physician. All product sales of &lt;span style="font-style:italic;"&gt;Jelmyto&lt;/span&gt; are recognized through the Company's arrangement with a single customer, a third-party national specialty distributor. Net revenues recognized include management&#x2019;s estimate of returns, consideration paid to the customer, chargebacks relating to differences between the wholesale acquisition cost and the contracted price offered to the end consumer, chargebacks relating to 340b drug pricing programs, Medicaid drug rebate programs, and the Company&#x2019;s copay assistance program, which are estimated based on industry benchmarking studies as well as the Company&#x2019;s historical experience.&lt;/p&gt;</us-gaap:RevenueRecognitionPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="C_0001668243_20210101_20210331" id="F_000227">
&lt;p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Calibri;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Research and Development Expenses &lt;/p&gt;
&lt;p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research and development costs are expensed as incurred and consist primarily of the cost of salaries, share-based compensation expenses, payroll taxes and other employee benefits, subcontractors and materials used for research and development activities, including nonclinical studies, clinical trials, manufacturing costs and professional services. The costs of services performed by others in connection with the research and development activities of the Company, including research and development conducted by others on behalf of the Company, shall be included in research and development costs and expensed as the contracted work is performed. The Company accrues for costs incurred as the services are being provided by monitoring the status of the trial or project and the invoices received from its external service providers. The Company adjusts its accrual as actual costs become known. Where contingent milestone payments are due to third parties under research and development arrangements or license agreements, the milestone payment obligations are expensed when the milestone results are achieved.&lt;/p&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:SellingGeneralAndAdministrativeExpensesPolicyTextBlock contextRef="C_0001668243_20210101_20210331" id="F_000228">
&lt;p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Calibri;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Selling&lt;span style="font-weight:normal;font-style:normal;"&gt; &lt;/span&gt;&lt;span style="color:#000000;"&gt;General and Administrative Expenses&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Selling, general and administrative expenses consist primarily of personnel costs (including share-based compensation related to directors, employees and consultants). Other significant costs include commercial, medical affairs, external professional service costs, facility costs, accounting and audit services, legal services, and other consulting fees. Selling, general and administrative costs are expensed as incurred, and the Company accrues for services provided by third parties related to the above expenses by monitoring the status of services provided and receiving estimates from its service providers and adjusting its accruals as actual costs become known.&lt;/p&gt;</us-gaap:SellingGeneralAndAdministrativeExpensesPolicyTextBlock>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansDirectorPolicy contextRef="C_0001668243_20210101_20210331" id="F_000229">
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Calibri;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Share-Based Compensation&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Share-based compensation cost is measured at the grant date based on the fair value of the award and is recognized as expense over the required service period, which is equal to the vesting period. The fair value of options is determined using the Black-Scholes option-pricing model. The fair value of a restricted stock unit (&#x201c;RSU&#x201d;) equaled the closing price of the Company&#x2019;s ordinary shares on the grant date. The Company accounts for forfeitures as they occur in accordance with ASC Topic 718, &#x201c;Compensation&#x2014;Stock Compensation&#x201d;.&lt;span style="letter-spacing:0.75pt;"&gt; &lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The&lt;span style="letter-spacing:0.35pt;"&gt; &lt;/span&gt;Company&lt;span style="letter-spacing:0.8pt;"&gt; &lt;/span&gt;elected&lt;span style="letter-spacing:0.6pt;"&gt; &lt;/span&gt;to&lt;span style="letter-spacing:0.2pt;"&gt; &lt;/span&gt;recognize&lt;span style="letter-spacing:0.8pt;"&gt; &lt;/span&gt;compen&lt;span style="letter-spacing:-0.1pt;"&gt;s&lt;/span&gt;ation&lt;span style="letter-spacing:1.1pt;"&gt; &lt;/span&gt;costs&lt;span style="letter-spacing:0.45pt;"&gt; &lt;/span&gt;for&lt;span style="letter-spacing:0.25pt;"&gt; &lt;/span&gt;awards&lt;span style="letter-spacing:0.6pt;"&gt; &lt;/span&gt;conditioned&lt;span style="letter-spacing:0.9pt;"&gt; &lt;/span&gt;only&lt;span style="letter-spacing:0.35pt;"&gt; &lt;/span&gt;on&lt;span style="letter-spacing:0.25pt;"&gt; &lt;/span&gt;conti&lt;span style="letter-spacing:-0.1pt;"&gt;n&lt;/span&gt;ued&lt;span style="letter-spacing:0.8pt;"&gt; &lt;/span&gt;service&lt;span style="letter-spacing:0.6pt;"&gt; &lt;/span&gt;that&lt;span style="letter-spacing:0.35pt;"&gt; &lt;/span&gt;have&lt;span style="letter-spacing:0.4pt;"&gt; &lt;/span&gt;a&lt;span style="letter-spacing:0.15pt;"&gt; &lt;/span&gt;graded&lt;span style="letter-spacing:0.6pt;"&gt; &lt;/span&gt;vesting&lt;span style="letter-spacing:0.6pt;"&gt; &lt;/span&gt;schedule&lt;span style="letter-spacing:0.05pt;"&gt; &lt;/span&gt;using&lt;span style="letter-spacing:0.45pt;"&gt; &lt;/span&gt;the&lt;span style="letter-spacing:0.3pt;"&gt; &lt;/span&gt;straight-line&lt;span style="letter-spacing:0.95pt;"&gt; &lt;/span&gt;method&lt;span style="letter-spacing:0.55pt;"&gt; &lt;/span&gt;and&lt;span style="letter-spacing:0.35pt;"&gt; &lt;/span&gt;to&lt;span style="letter-spacing:0.2pt;"&gt; &lt;/span&gt;value&lt;span style="letter-spacing:0.45pt;"&gt; &lt;/span&gt;the&lt;span style="letter-spacing:0.3pt;"&gt; &lt;/span&gt;awards&lt;span style="letter-spacing:0.6pt;"&gt; &lt;/span&gt;based&lt;span style="letter-spacing:0.5pt;"&gt; &lt;/span&gt;on&lt;span style="letter-spacing:0.25pt;"&gt; &lt;/span&gt;the&lt;span style="letter-spacing:0.3pt;"&gt; &lt;/span&gt;sin&lt;span style="letter-spacing:-0.1pt;"&gt;g&lt;/span&gt;le-option&lt;span style="letter-spacing:1pt;"&gt; &lt;/span&gt;award&lt;span style="letter-spacing:0.5pt;"&gt; &lt;/span&gt;approach.&lt;span style="letter-spacing:0.8pt;"&gt; &lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;"&gt;&#160;&lt;/p&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansDirectorPolicy>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="C_0001668243_20210101_20210331" id="F_000230">
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Calibri;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Net Loss per Ordinary Share&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Basic net loss per share is computed by dividing the net loss attributable to ordinary shareholders by the weighted-average number of ordinary shares outstanding. Diluted net loss per share is computed similarly to basic net loss per share except that the denominator is increased to include the number of additional ordinary shares that would have been outstanding if the potential ordinary shares had been issued and if the additional ordinary shares were dilutive. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;For all periods presented, potentially dilutive securities are excluded from the computation of fully diluted loss per share as their effect is anti-dilutive.&lt;/p&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <urgn:OtherFinancialInformationTextBlock contextRef="C_0001668243_20210101_20210331" id="F_000202">
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Note 4 &#x2013; Other Financial Information&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Calibri;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Accounts Payable and Accrued Expenses&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accounts payable and accrued expenses consist of the following as of March&#160;31, 2021 and December&#160;31, 2020 (in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.74%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;March&#160;31, 2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.74%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&#160;31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accounts payable&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.74%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,096&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.74%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,271&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accrued sales reserves&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.74%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;449&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.74%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;382&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accrued clinical expenses&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.74%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;554&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.74%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,359&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accrued research and development costs&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.74%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;862&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.74%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,356&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accrued selling, general and administrative expenses&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.74%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,309&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.74%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,440&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59.22%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accrued other expense&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.74%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,288&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.74%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,215&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59.22%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total accounts payable and accrued expenses&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.74%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10,558&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.74%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10,023&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:12pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Calibri;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Interest and Other Income (Expenses), Net&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Interest and other income (expenses) consisted of the following as of March&#160;31, 2021 and 2020 (in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.12%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Three Months Ended March&#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Interest income&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.74%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;167&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.74%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;811&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59.22%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other finance income(expenses)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.74%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;12&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.74%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(43&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59.22%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total interest and other income&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.74%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;179&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.74%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;768&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</urgn:OtherFinancialInformationTextBlock>
    <us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock contextRef="C_0001668243_20210101_20210331" id="F_000232">
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accounts payable and accrued expenses consist of the following as of March&#160;31, 2021 and December&#160;31, 2020 (in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.74%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;March&#160;31, 2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.74%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&#160;31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accounts payable&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.74%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,096&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.74%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,271&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accrued sales reserves&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.74%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;449&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.74%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;382&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accrued clinical expenses&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.74%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;554&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.74%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,359&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accrued research and development costs&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.74%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;862&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.74%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,356&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accrued selling, general and administrative expenses&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.74%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,309&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.74%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,440&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59.22%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accrued other expense&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.74%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,288&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.74%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,215&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59.22%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total accounts payable and accrued expenses&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.74%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10,558&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.74%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10,023&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock>
    <us-gaap:AccountsPayableCurrent
      contextRef="C_0001668243_20210331"
      decimals="-3"
      id="F_000257"
      unitRef="U_iso4217USD">6096000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="C_0001668243_20201231"
      decimals="-3"
      id="F_000258"
      unitRef="U_iso4217USD">3271000</us-gaap:AccountsPayableCurrent>
    <urgn:AccruedSalesReserves
      contextRef="C_0001668243_20210331"
      decimals="-3"
      id="F_000259"
      unitRef="U_iso4217USD">449000</urgn:AccruedSalesReserves>
    <urgn:AccruedSalesReserves
      contextRef="C_0001668243_20201231"
      decimals="-3"
      id="F_000260"
      unitRef="U_iso4217USD">382000</urgn:AccruedSalesReserves>
    <urgn:AccruedClinicalExpensesCurrent
      contextRef="C_0001668243_20210331"
      decimals="-3"
      id="F_000261"
      unitRef="U_iso4217USD">554000</urgn:AccruedClinicalExpensesCurrent>
    <urgn:AccruedClinicalExpensesCurrent
      contextRef="C_0001668243_20201231"
      decimals="-3"
      id="F_000262"
      unitRef="U_iso4217USD">1359000</urgn:AccruedClinicalExpensesCurrent>
    <urgn:AccruedResearchAndDevelopmentExpenseCurrent
      contextRef="C_0001668243_20210331"
      decimals="-3"
      id="F_000263"
      unitRef="U_iso4217USD">862000</urgn:AccruedResearchAndDevelopmentExpenseCurrent>
    <urgn:AccruedResearchAndDevelopmentExpenseCurrent
      contextRef="C_0001668243_20201231"
      decimals="-3"
      id="F_000264"
      unitRef="U_iso4217USD">1356000</urgn:AccruedResearchAndDevelopmentExpenseCurrent>
    <urgn:AccruedSellingGeneralAndAdministrativeExpenseCurrent
      contextRef="C_0001668243_20210331"
      decimals="-3"
      id="F_000265"
      unitRef="U_iso4217USD">1309000</urgn:AccruedSellingGeneralAndAdministrativeExpenseCurrent>
    <urgn:AccruedSellingGeneralAndAdministrativeExpenseCurrent
      contextRef="C_0001668243_20201231"
      decimals="-3"
      id="F_000266"
      unitRef="U_iso4217USD">2440000</urgn:AccruedSellingGeneralAndAdministrativeExpenseCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="C_0001668243_20210331"
      decimals="-3"
      id="F_000267"
      unitRef="U_iso4217USD">1288000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="C_0001668243_20201231"
      decimals="-3"
      id="F_000268"
      unitRef="U_iso4217USD">1215000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="C_0001668243_20210331"
      decimals="-3"
      id="F_000269"
      unitRef="U_iso4217USD">10558000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="C_0001668243_20201231"
      decimals="-3"
      id="F_000270"
      unitRef="U_iso4217USD">10023000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock contextRef="C_0001668243_20210101_20210331" id="F_000233">
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Interest and other income (expenses) consisted of the following as of March&#160;31, 2021 and 2020 (in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.12%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Three Months Ended March&#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Interest income&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.74%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;167&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.74%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;811&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59.22%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other finance income(expenses)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.74%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;12&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.74%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(43&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59.22%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total interest and other income&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.74%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;179&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.74%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;768&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock>
    <us-gaap:InvestmentIncomeInterest
      contextRef="C_0001668243_20210101_20210331"
      decimals="-3"
      id="F_000271"
      unitRef="U_iso4217USD">167000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="C_0001668243_20200101_20200331"
      decimals="-3"
      id="F_000272"
      unitRef="U_iso4217USD">811000</us-gaap:InvestmentIncomeInterest>
    <urgn:OtherFinanceExpensesIncome
      contextRef="C_0001668243_20210101_20210331"
      decimals="-3"
      id="F_000273"
      unitRef="U_iso4217USD">12000</urgn:OtherFinanceExpensesIncome>
    <urgn:OtherFinanceExpensesIncome
      contextRef="C_0001668243_20200101_20200331"
      decimals="-3"
      id="F_000274"
      unitRef="U_iso4217USD">-43000</urgn:OtherFinanceExpensesIncome>
    <urgn:FinanceIncomeExpenseNet
      contextRef="C_0001668243_20210101_20210331"
      decimals="-3"
      id="F_000275"
      unitRef="U_iso4217USD">179000</urgn:FinanceIncomeExpenseNet>
    <urgn:FinanceIncomeExpenseNet
      contextRef="C_0001668243_20200101_20200331"
      decimals="-3"
      id="F_000276"
      unitRef="U_iso4217USD">768000</urgn:FinanceIncomeExpenseNet>
    <us-gaap:InventoryDisclosureTextBlock contextRef="C_0001668243_20210101_20210331" id="F_000203">
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:4pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Note 5 &#x2013; Inventories&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:12pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Inventories consist of the following as of March&#160;31, 2021 and December&#160;31, 2020 (in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:65.18%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.76%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.62%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;March&#160;31, 2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.76%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.62%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&#160;31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.18%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Raw materials&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.62%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,443&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.62%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,051&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:65.18%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Finished goods&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.76%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.62%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;888&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.76%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.62%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;913&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:65.18%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total inventories&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.76%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.62%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,331&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.76%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.62%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,964&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;"&gt;&#160;&lt;/p&gt;</us-gaap:InventoryDisclosureTextBlock>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock contextRef="C_0001668243_20210101_20210331" id="F_000234">
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Inventories consist of the following as of March&#160;31, 2021 and December&#160;31, 2020 (in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:65.18%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.76%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.62%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;March&#160;31, 2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.76%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.62%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&#160;31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.18%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Raw materials&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.62%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,443&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.62%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,051&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:65.18%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Finished goods&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.76%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.62%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;888&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.76%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.62%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;913&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:65.18%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total inventories&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.76%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.62%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,331&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.76%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.62%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,964&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryRawMaterials
      contextRef="C_0001668243_20210331"
      decimals="-3"
      id="F_000277"
      unitRef="U_iso4217USD">2443000</us-gaap:InventoryRawMaterials>
    <us-gaap:InventoryRawMaterials
      contextRef="C_0001668243_20201231"
      decimals="-3"
      id="F_000278"
      unitRef="U_iso4217USD">1051000</us-gaap:InventoryRawMaterials>
    <us-gaap:InventoryFinishedGoods
      contextRef="C_0001668243_20210331"
      decimals="-3"
      id="F_000279"
      unitRef="U_iso4217USD">888000</us-gaap:InventoryFinishedGoods>
    <us-gaap:InventoryFinishedGoods
      contextRef="C_0001668243_20201231"
      decimals="-3"
      id="F_000280"
      unitRef="U_iso4217USD">913000</us-gaap:InventoryFinishedGoods>
    <us-gaap:InventoryNet
      contextRef="C_0001668243_20210331"
      decimals="-3"
      id="F_000281"
      unitRef="U_iso4217USD">3331000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="C_0001668243_20201231"
      decimals="-3"
      id="F_000282"
      unitRef="U_iso4217USD">1964000</us-gaap:InventoryNet>
    <us-gaap:FairValueDisclosuresTextBlock contextRef="C_0001668243_20210101_20210331" id="F_000204">
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Note 6 &#x2013; Fair Value Measurements&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company follows authoritative accounting guidance, which among other things, defines fair value, establishes a consistent framework for measuring fair value and expands disclosure for each major asset and liability category measured at fair value on either a recurring or nonrecurring basis. Fair value is an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As a basis for considering such assumptions, a three-tier fair value hierarchy has been established, which prioritizes the inputs used in measuring fair value as follows:&lt;/p&gt;
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:2.27%;white-space:nowrap" valign="top"&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="width:6.67%;white-space:nowrap" valign="top"&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 1:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:10pt;"&gt;Observable inputs such as quoted prices (unadjusted) in active markets for identical assets or liabilities.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:2.27%;white-space:nowrap" valign="top"&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="width:6.67%;white-space:nowrap" valign="top"&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 2:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:10pt;"&gt;Inputs other than quoted prices that are observable for the asset or liability, either directly or indirectly. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:2.27%;white-space:nowrap" valign="top"&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="width:6.67%;white-space:nowrap" valign="top"&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 3:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:10pt;"&gt;Unobservable inputs that reflect the reporting entity&lt;span style="color:#000000;"&gt;&#x2019;&lt;/span&gt;s own assumptions.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The carrying amounts of the Company&lt;span style="color:#000000;"&gt;&#x2019;&lt;/span&gt;s other current assets, accounts payable and accrued liabilities are generally considered to be representative of their fair value because of the short-term nature of these instruments. No transfers between levels have occurred during the periods presented.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Assets and liabilities measured at fair value on a recurring basis based on Level 1 and Level 2 fair value measurement criteria as of March&#160;31, 2021 are as follows (in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.78%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.04%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair Value Measurements Using&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Quoted&#160;Prices&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Significant&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;in Active&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance&#160;as&#160;of&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Markets for&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Observable&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;March&#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Identical&#160;Assets&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Inputs&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;(Level 1)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;(Level 2)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Marketable securities:&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;US government&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;20,572&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;20,572&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Corporate bonds&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;14,845&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;14,845&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Money market funds&lt;sup style="font-size:85%;line-height:120%;vertical-align:top"&gt;(1)&lt;/sup&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;30,413&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;30,413&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total marketable securities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;65,830&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;50,985&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;14,845&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:3.33%;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160; &lt;/p&gt;
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:3.8%;white-space:nowrap" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;sup style="font-size:85%;line-height:120%;vertical-align:top"&gt;(1)&lt;/sup&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:10pt;"&gt;&lt;span style="color:#000000;"&gt;Included within cash and cash equivalents on the condensed consolidated balance sheets.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.13%;text-indent:0%;font-family:Times New Roman;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:2pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Assets and liabilities measured at fair value on a recurring basis based on Level 1 and Level 2 fair value measurement criteria as of December&#160;31, 2020 are as follows (in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.78%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.04%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair&#160;Value&#160;Measurements&#160;Using&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Quoted&#160;Prices&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Significant&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;in Active&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance&#160;as&#160;of&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Markets for&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Observable&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Identical&#160;Assets&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Inputs&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;(Level 1)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;(Level 2)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Marketable securities:&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;US government&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;29,186&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;29,186&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Corporate bonds&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;21,861&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;21,861&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Money market funds&lt;sup style="font-size:85%;line-height:120%;vertical-align:top"&gt;(1)&lt;/sup&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;39,744&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;39,744&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total marketable securities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;90,791&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;68,930&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;21,861&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;"&gt;&#160;&lt;/p&gt;
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:3.8%;white-space:nowrap" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;sup style="font-size:85%;line-height:120%;vertical-align:top"&gt;(1)&lt;/sup&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:10pt;"&gt;&lt;span style="color:#000000;"&gt;Included within cash and cash equivalents on the condensed consolidated balance sheets.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company&lt;span style="color:#000000;"&gt;&#x2019;&lt;/span&gt;s in money market funds are valued based on publicly available quoted market prices for identical securities as of March&#160;31, 2021 and December&#160;31, 2020. &lt;/p&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:FairValueAssetsLevel1ToLevel2TransfersAmount
      contextRef="C_0001668243_20210331"
      decimals="INF"
      id="F_000283"
      unitRef="U_iso4217USD">0</us-gaap:FairValueAssetsLevel1ToLevel2TransfersAmount>
    <us-gaap:FairValueAssetsLevel2ToLevel1TransfersAmount
      contextRef="C_0001668243_20210331"
      decimals="INF"
      id="F_000284"
      unitRef="U_iso4217USD">0</us-gaap:FairValueAssetsLevel2ToLevel1TransfersAmount>
    <us-gaap:FairValueLiabilitiesLevel2ToLevel1TransfersAmount
      contextRef="C_0001668243_20210331"
      decimals="INF"
      id="F_000286"
      unitRef="U_iso4217USD">0</us-gaap:FairValueLiabilitiesLevel2ToLevel1TransfersAmount>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3
      contextRef="C_0001668243_20210101_20210331"
      decimals="INF"
      id="F_000287"
      unitRef="U_iso4217USD">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3
      contextRef="C_0001668243_20210101_20210331"
      decimals="INF"
      id="F_000288"
      unitRef="U_iso4217USD">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3
      contextRef="C_0001668243_20210101_20210331"
      decimals="INF"
      id="F_000289"
      unitRef="U_iso4217USD">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3
      contextRef="C_0001668243_20210101_20210331"
      decimals="INF"
      id="F_000290"
      unitRef="U_iso4217USD">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3>
    <us-gaap:FairValueLiabilitiesLevel1ToLevel2TransfersAmount
      contextRef="C_0001668243_20210331"
      decimals="INF"
      id="F_000285"
      unitRef="U_iso4217USD">0</us-gaap:FairValueLiabilitiesLevel1ToLevel2TransfersAmount>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock contextRef="C_0001668243_20210101_20210331" id="F_000235">
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Assets and liabilities measured at fair value on a recurring basis based on Level 1 and Level 2 fair value measurement criteria as of March&#160;31, 2021 are as follows (in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.78%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.04%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair Value Measurements Using&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Quoted&#160;Prices&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Significant&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;in Active&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance&#160;as&#160;of&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Markets for&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Observable&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;March&#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Identical&#160;Assets&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Inputs&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;(Level 1)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;(Level 2)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Marketable securities:&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;US government&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;20,572&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;20,572&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Corporate bonds&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;14,845&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;14,845&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Money market funds&lt;sup style="font-size:85%;line-height:120%;vertical-align:top"&gt;(1)&lt;/sup&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;30,413&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;30,413&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total marketable securities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;65,830&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;50,985&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;14,845&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:3.33%;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160; &lt;/p&gt;
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:3.8%;white-space:nowrap" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;sup style="font-size:85%;line-height:120%;vertical-align:top"&gt;(1)&lt;/sup&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:10pt;"&gt;&lt;span style="color:#000000;"&gt;Included within cash and cash equivalents on the condensed consolidated balance sheets.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.13%;text-indent:0%;font-family:Times New Roman;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:2pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Assets and liabilities measured at fair value on a recurring basis based on Level 1 and Level 2 fair value measurement criteria as of December&#160;31, 2020 are as follows (in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.78%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.04%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair&#160;Value&#160;Measurements&#160;Using&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Quoted&#160;Prices&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Significant&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;in Active&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance&#160;as&#160;of&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Markets for&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Observable&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Identical&#160;Assets&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Inputs&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;(Level 1)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;(Level 2)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Marketable securities:&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;US government&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;29,186&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;29,186&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Corporate bonds&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;21,861&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;21,861&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Money market funds&lt;sup style="font-size:85%;line-height:120%;vertical-align:top"&gt;(1)&lt;/sup&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;39,744&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;39,744&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total marketable securities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;90,791&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;68,930&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;21,861&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;"&gt;&#160;&lt;/p&gt;
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:3.8%;white-space:nowrap" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;sup style="font-size:85%;line-height:120%;vertical-align:top"&gt;(1)&lt;/sup&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:10pt;"&gt;&lt;span style="color:#000000;"&gt;Included within cash and cash equivalents on the condensed consolidated balance sheets.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_0001668243_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapFinancialInstrumentAxis_us-gaapUSGovernmentAgenciesDebtSecuritiesMember_20210331"
      decimals="-3"
      id="F_000291"
      unitRef="U_iso4217USD">20572000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_0001668243_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapFinancialInstrumentAxis_us-gaapUSGovernmentAgenciesDebtSecuritiesMember_20210331"
      decimals="-3"
      id="F_000292"
      unitRef="U_iso4217USD">20572000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_0001668243_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapFinancialInstrumentAxis_us-gaapCorporateBondSecuritiesMember_20210331"
      decimals="-3"
      id="F_000293"
      unitRef="U_iso4217USD">14845000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_0001668243_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapFinancialInstrumentAxis_us-gaapCorporateBondSecuritiesMember_20210331"
      decimals="-3"
      id="F_000294"
      unitRef="U_iso4217USD">14845000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_0001668243_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapFinancialInstrumentAxis_us-gaapMoneyMarketFundsMember_20210331"
      decimals="-3"
      id="F_000295"
      unitRef="U_iso4217USD">30413000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_0001668243_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapFinancialInstrumentAxis_us-gaapMoneyMarketFundsMember_20210331"
      decimals="-3"
      id="F_000296"
      unitRef="U_iso4217USD">30413000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_0001668243_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20210331"
      decimals="-3"
      id="F_000297"
      unitRef="U_iso4217USD">65830000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_0001668243_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20210331"
      decimals="-3"
      id="F_000298"
      unitRef="U_iso4217USD">50985000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_0001668243_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20210331"
      decimals="-3"
      id="F_000299"
      unitRef="U_iso4217USD">14845000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_0001668243_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapFinancialInstrumentAxis_us-gaapUSGovernmentAgenciesDebtSecuritiesMember_20201231"
      decimals="-3"
      id="F_000300"
      unitRef="U_iso4217USD">29186000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_0001668243_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapFinancialInstrumentAxis_us-gaapUSGovernmentAgenciesDebtSecuritiesMember_20201231"
      decimals="-3"
      id="F_000301"
      unitRef="U_iso4217USD">29186000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_0001668243_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapFinancialInstrumentAxis_us-gaapCorporateBondSecuritiesMember_20201231"
      decimals="-3"
      id="F_000302"
      unitRef="U_iso4217USD">21861000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_0001668243_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapFinancialInstrumentAxis_us-gaapCorporateBondSecuritiesMember_20201231"
      decimals="-3"
      id="F_000303"
      unitRef="U_iso4217USD">21861000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_0001668243_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapFinancialInstrumentAxis_us-gaapMoneyMarketFundsMember_20201231"
      decimals="-3"
      id="F_000304"
      unitRef="U_iso4217USD">39744000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_0001668243_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapFinancialInstrumentAxis_us-gaapMoneyMarketFundsMember_20201231"
      decimals="-3"
      id="F_000305"
      unitRef="U_iso4217USD">39744000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_0001668243_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231"
      decimals="-3"
      id="F_000306"
      unitRef="U_iso4217USD">90791000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_0001668243_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231"
      decimals="-3"
      id="F_000307"
      unitRef="U_iso4217USD">68930000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_0001668243_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231"
      decimals="-3"
      id="F_000308"
      unitRef="U_iso4217USD">21861000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <urgn:MarketableSecuritiesDisclosureTextBlock contextRef="C_0001668243_20210101_20210331" id="F_000205">
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Note 7 &#x2013; Marketable Securities&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following table summarizes the Company&#x2019;s marketable securities as of March&#160;31, 2021 (in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:39.4%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.58%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Amortized&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cost Basis&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.58%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unrealized&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gains&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.58%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unrealized&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Losses&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.58%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair Value&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.4%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Marketable securities:&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.58%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.58%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.58%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.58%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.4%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;US government&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.58%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;20,448&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.58%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;124&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.58%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.58%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;20,572&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.4%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Corporate bonds&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.58%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;14,826&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.58%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;19&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.58%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.58%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;14,845&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:39.4%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Money market funds&lt;sup style="font-size:85%;line-height:120%;vertical-align:top"&gt;(1)&lt;/sup&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.58%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;30,413&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.58%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.58%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.58%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;30,413&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:39.4%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total marketable securities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.58%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;65,687&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.58%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;143&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.58%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.58%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;65,830&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:3.8%;text-indent:-3.8%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:3.8%;white-space:nowrap" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;sup style="font-size:85%;line-height:120%;vertical-align:top"&gt;(1)&lt;/sup&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:10pt;"&gt;&lt;span style="color:#000000;"&gt;Included within cash and cash equivalents on the condensed consolidated balance sheets.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company classifies its marketable securities as available-for-sale and they consist of all debt securities. The amortized cost basis as of March&#160;31, 2021 includes $0.1 million of accrued interest receivable&lt;span style="color:#000000;"&gt;. &lt;/span&gt;As of March&#160;31, 2021, marketable securities were in a net unrealized gain position of $0.1 million.&#160;&lt;span style="color:#000000;"&gt;Unrealized gains and losses on available-for-sale debt securities are included as a component of comprehensive loss.&#160;&#160;&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of &lt;span style="color:#000000;"&gt;March&#160;31, 2021&lt;/span&gt;, the Company did not hold any marketable securities in an unrealized loss position. Per the Company&#x2019;s general investment strategy, the Company does not intend to sell the investments before maturity. &lt;span style="color:#000000;"&gt;As of&#160;March&#160;31, 2021, the Company believes the cost basis for its marketable securities were recoverable in all material aspects and no credit impairments were recognized in the period.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company&#x2019;s marketable securities as of March&#160;31, 2021 mature at various dates through February 2022. The fair values of marketable securities by contractual maturity consist of the following (in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59.6%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.76%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.42%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;March&#160;31, 2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.76%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.42%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&#160;31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.6%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Maturities within one year&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;65,830&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;88,898&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59.6%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Maturities after one year through three years&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.76%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.76%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,893&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59.6%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total marketable securities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.76%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;65,830&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.76%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;90,791&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;"&gt;&#160;&lt;/p&gt;</urgn:MarketableSecuritiesDisclosureTextBlock>
    <us-gaap:MarketableSecuritiesTextBlock contextRef="C_0001668243_20210101_20210331" id="F_000236">
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following table summarizes the Company&#x2019;s marketable securities as of March&#160;31, 2021 (in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:39.4%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.58%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Amortized&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cost Basis&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.58%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unrealized&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gains&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.58%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unrealized&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Losses&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.58%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair Value&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.4%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Marketable securities:&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.58%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.58%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.58%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.58%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.4%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;US government&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.58%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;20,448&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.58%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;124&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.58%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.58%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;20,572&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.4%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Corporate bonds&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.58%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;14,826&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.58%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;19&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.58%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.58%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;14,845&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:39.4%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Money market funds&lt;sup style="font-size:85%;line-height:120%;vertical-align:top"&gt;(1)&lt;/sup&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.58%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;30,413&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.58%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.58%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.58%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;30,413&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:39.4%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total marketable securities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.58%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;65,687&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.58%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;143&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.58%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.58%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;65,830&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:3.8%;text-indent:-3.8%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:3.8%;white-space:nowrap" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;sup style="font-size:85%;line-height:120%;vertical-align:top"&gt;(1)&lt;/sup&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:10pt;"&gt;&lt;span style="color:#000000;"&gt;Included within cash and cash equivalents on the condensed consolidated balance sheets.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:MarketableSecuritiesTextBlock>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_0001668243_us-gaapInvestmentTypeAxis_us-gaapUSTreasuryAndGovernmentMember_20210331"
      decimals="-3"
      id="F_000309"
      unitRef="U_iso4217USD">20448000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_0001668243_us-gaapInvestmentTypeAxis_us-gaapUSTreasuryAndGovernmentMember_20210331"
      decimals="-3"
      id="F_000313"
      unitRef="U_iso4217USD">124000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_0001668243_us-gaapInvestmentTypeAxis_us-gaapUSTreasuryAndGovernmentMember_20210331"
      decimals="-3"
      id="F_000316"
      unitRef="U_iso4217USD">20572000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_0001668243_us-gaapInvestmentTypeAxis_us-gaapCorporateDebtSecuritiesMember_20210331"
      decimals="-3"
      id="F_000310"
      unitRef="U_iso4217USD">14826000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_0001668243_us-gaapInvestmentTypeAxis_us-gaapCorporateDebtSecuritiesMember_20210331"
      decimals="-3"
      id="F_000314"
      unitRef="U_iso4217USD">19000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_0001668243_us-gaapInvestmentTypeAxis_us-gaapCorporateDebtSecuritiesMember_20210331"
      decimals="-3"
      id="F_000317"
      unitRef="U_iso4217USD">14845000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_0001668243_us-gaapInvestmentTypeAxis_us-gaapMoneyMarketFundsMember_20210331"
      decimals="-3"
      id="F_000311"
      unitRef="U_iso4217USD">30413000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_0001668243_us-gaapInvestmentTypeAxis_us-gaapMoneyMarketFundsMember_20210331"
      decimals="-3"
      id="F_000318"
      unitRef="U_iso4217USD">30413000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_0001668243_20210331"
      decimals="-3"
      id="F_000312"
      unitRef="U_iso4217USD">65687000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_0001668243_20210331"
      decimals="-3"
      id="F_000315"
      unitRef="U_iso4217USD">143000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_0001668243_20210331"
      decimals="-3"
      id="F_000319"
      unitRef="U_iso4217USD">65830000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:InterestReceivable
      contextRef="C_0001668243_20210331"
      decimals="-5"
      id="F_000320"
      unitRef="U_iso4217USD">100000</us-gaap:InterestReceivable>
    <urgn:DebtSecuritiesAvailableForSaleUnrealizedGainPosition
      contextRef="C_0001668243_20210331"
      decimals="-5"
      id="F_000321"
      unitRef="U_iso4217USD">100000</urgn:DebtSecuritiesAvailableForSaleUnrealizedGainPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="C_0001668243_20210331"
      decimals="INF"
      id="F_000322"
      unitRef="U_iso4217USD">0</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesPortionRecognizedInEarnings
      contextRef="C_0001668243_20210101_20210331"
      decimals="INF"
      id="F_000323"
      unitRef="U_iso4217USD">0</us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesPortionRecognizedInEarnings>
    <urgn:SummaryOfFairValuesOfMarketableSecuritiesByContractualMaturityTableTextBlock contextRef="C_0001668243_20210101_20210331" id="F_000237">The fair values of marketable securities by contractual maturity consist of the following (in thousands)
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59.6%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.76%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.42%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;March&#160;31, 2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.76%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.42%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&#160;31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.6%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Maturities within one year&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;65,830&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;88,898&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59.6%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Maturities after one year through three years&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.76%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.76%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,893&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59.6%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total marketable securities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.76%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;65,830&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.76%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;90,791&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;"&gt;&#160;&lt;/p&gt;</urgn:SummaryOfFairValuesOfMarketableSecuritiesByContractualMaturityTableTextBlock>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
      contextRef="C_0001668243_20210331"
      decimals="-3"
      id="F_000324"
      unitRef="U_iso4217USD">65830000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
      contextRef="C_0001668243_20201231"
      decimals="-3"
      id="F_000325"
      unitRef="U_iso4217USD">88898000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
    <urgn:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughThreeYearsFairValue
      contextRef="C_0001668243_20201231"
      decimals="-3"
      id="F_000326"
      unitRef="U_iso4217USD">1893000</urgn:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughThreeYearsFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_0001668243_20210331"
      decimals="-3"
      id="F_000327"
      unitRef="U_iso4217USD">65830000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_0001668243_20201231"
      decimals="-3"
      id="F_000328"
      unitRef="U_iso4217USD">90791000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="C_0001668243_20210101_20210331" id="F_000206">
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Note 8 &#x2013; Property and Equipment&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Property and equipment, consists of the following as of March&#160;31, 2021 and December&#160;31, 2020 (in thousands):&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59.54%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.42%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;March&#160;31, 2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.42%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&#160;31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.54%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Laboratory equipment&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;337&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;333&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.54%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Computer equipment and software&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,970&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,676&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.54%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Furniture&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;586&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;597&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.54%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Leasehold improvements&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;609&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;609&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59.54%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Manufacturing equipment&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;226&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;226&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.54%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,728&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,441&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59.54%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Less: accumulated depreciation and amortization&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(1,586&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(1,395&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59.54%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Property and equipment, net&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,142&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,046&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Depreciation and amortization expenses were $0.2 million and&#160;$0.1 million&#160;for the three months ended March&#160;31, 2021 and 2020, respectively. &lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="C_0001668243_20210101_20210331" id="F_000238">
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Property and equipment, consists of the following as of March&#160;31, 2021 and December&#160;31, 2020 (in thousands):&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59.54%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.42%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;March&#160;31, 2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.42%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&#160;31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.54%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Laboratory equipment&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;337&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;333&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.54%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Computer equipment and software&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,970&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,676&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.54%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Furniture&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;586&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;597&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.54%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Leasehold improvements&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;609&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;609&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59.54%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Manufacturing equipment&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;226&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;226&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.54%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,728&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,441&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59.54%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Less: accumulated depreciation and amortization&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(1,586&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(1,395&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59.54%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Property and equipment, net&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,142&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,046&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;"&gt;&#160;&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_0001668243_us-gaapPropertyPlantAndEquipmentByTypeAxis_urgnLaboratoryEquipmentMember_20210331"
      decimals="-3"
      id="F_000329"
      unitRef="U_iso4217USD">337000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_0001668243_us-gaapPropertyPlantAndEquipmentByTypeAxis_urgnLaboratoryEquipmentMember_20201231"
      decimals="-3"
      id="F_000330"
      unitRef="U_iso4217USD">333000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_0001668243_us-gaapPropertyPlantAndEquipmentByTypeAxis_urgnComputersAndSoftwareMember_20210331"
      decimals="-3"
      id="F_000331"
      unitRef="U_iso4217USD">1970000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_0001668243_us-gaapPropertyPlantAndEquipmentByTypeAxis_urgnComputersAndSoftwareMember_20201231"
      decimals="-3"
      id="F_000332"
      unitRef="U_iso4217USD">1676000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_0001668243_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapFurnitureAndFixturesMember_20210331"
      decimals="-3"
      id="F_000333"
      unitRef="U_iso4217USD">586000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_0001668243_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapFurnitureAndFixturesMember_20201231"
      decimals="-3"
      id="F_000334"
      unitRef="U_iso4217USD">597000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_0001668243_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapLeaseholdImprovementsMember_20210331"
      decimals="-3"
      id="F_000335"
      unitRef="U_iso4217USD">609000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_0001668243_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapLeaseholdImprovementsMember_20201231"
      decimals="-3"
      id="F_000336"
      unitRef="U_iso4217USD">609000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_0001668243_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapManufacturingFacilityMember_20210331"
      decimals="-3"
      id="F_000337"
      unitRef="U_iso4217USD">226000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_0001668243_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapManufacturingFacilityMember_20201231"
      decimals="-3"
      id="F_000338"
      unitRef="U_iso4217USD">226000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_0001668243_20210331"
      decimals="-3"
      id="F_000339"
      unitRef="U_iso4217USD">3728000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_0001668243_20201231"
      decimals="-3"
      id="F_000340"
      unitRef="U_iso4217USD">3441000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="C_0001668243_20210331"
      decimals="-3"
      id="F_000341"
      unitRef="U_iso4217USD">1586000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="C_0001668243_20201231"
      decimals="-3"
      id="F_000342"
      unitRef="U_iso4217USD">1395000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_0001668243_20210331"
      decimals="-3"
      id="F_000343"
      unitRef="U_iso4217USD">2142000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_0001668243_20201231"
      decimals="-3"
      id="F_000344"
      unitRef="U_iso4217USD">2046000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="C_0001668243_20210101_20210331"
      decimals="-5"
      id="F_000345"
      unitRef="U_iso4217USD">200000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="C_0001668243_20200101_20200331"
      decimals="-5"
      id="F_000346"
      unitRef="U_iso4217USD">100000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:LesseeOperatingLeasesTextBlock contextRef="C_0001668243_20210101_20210331" id="F_000207">
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Note 9 - Leases &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Calibri;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Operating Leases&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company has the following office and laboratory facility leases:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:6pt;"&gt;&#160;&lt;/p&gt;
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:3.33%;white-space:nowrap" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="width:2.27%;white-space:nowrap" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2022;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"&gt;&lt;span style="font-family:Calibri;"&gt;In April 2016, UPL signed an addendum to its November 2014 lease agreement for the Company&#x2019;s executive offices located in Israel, in order to increase the office space rented and to extend the rent period until 2019. In March 2019, UPL utilized the agreement extension option and extended the rent period for additional three years until August 2022.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:3.33%;white-space:nowrap" valign="top"&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="width:2.27%;white-space:nowrap" valign="top"&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2022;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"&gt;&lt;span style="font-family:Calibri;"&gt;In September 2017, UPI entered into a new lease agreement for its office space in New York, which the Company previously used as its headquarters. The lease agreement commenced in October 2017 and terminated in February 2021.&lt;/span&gt;&lt;span style="font-family:Times New Roman;"&gt;&#160;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:3.33%;white-space:nowrap" valign="top"&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="width:2.27%;white-space:nowrap" valign="top"&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2022;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"&gt;&lt;span style="font-family:Calibri;"&gt;In April 2018, UPI entered into a new lease agreement for an office in Los Angeles, California. The lease commencement date was July 10, 2018 and terminates in March 2024. The landlord provided a tenant allowance for leasehold improvements of $0.2 million that was accounted for as a lease incentive. The Company&#x2019;s remaining contractual obligation under this lease is approximately $0.8 million as of March&#160;31, 2021.&lt;/span&gt;&lt;span style="color:#212529;font-family:Calibri;"&gt; In November 2019, UPI entered into a sublease for this office space, with a lease commencement date of&#160;January 1, 2020 and continuing until the end of the lease term in March 2024. The subtenants exercised their early access clause and moved into the premises the end of November 2019.&#160;The remaining rental payments to be received over the lease term is approximately $0.7&#160;million &lt;/span&gt;&lt;span style="font-family:Calibri;"&gt;as of March&#160;31, 2021&lt;/span&gt;&lt;span style="color:#212529;font-family:Calibri;"&gt;. The Company accounts for the sublease as on operating lease in accordance with ASC 842-10-25-2 and ASC 842-10-25-3. The main lease was considered for impairment and the amount was determined to be immaterial.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:3.33%;white-space:nowrap" valign="top"&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="width:2.27%;white-space:nowrap" valign="top"&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2022;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"&gt;&lt;span style="font-family:Calibri;"&gt;In November 2019, UPI entered into a new lease agreement for an office in Princeton, New Jersey, which the Company now uses as its headquarters. The lease commencement date was November 29, 2019 and the lease term is 38 months. The Company&#x2019;s remaining contractual obligation under this lease is approximately $1.0 million as of March&#160;31, 2021.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In addition, the Company has other operating office equipment and vehicle leases. The Company&#x2019;s operating leases may require minimum rent payments, contingent rent payments adjusted periodically for inflation, or rent payments equal to the greater of a minimum rent or contingent rent. The Company&#x2019;s leases do not contain any residual value guarantees or material restrictive covenants. The Company&#x2019;s leases expire at various dates from 2021 through 2024, with varying renewal and termination options. &lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The components of lease cost for the three months ended March&#160;31, 2021 were as follows &lt;span style="color:#000000;"&gt;(in thousands)&lt;/span&gt;:&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:77.4%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.58%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Three Months Ended March&#160;31, 2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:77.4%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Operating lease cost&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.58%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;267&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:77.4%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Sublease income&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.58%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(56&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:77.4%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Variable lease cost&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.58%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;22&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:77.4%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.58%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;233&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The amounts recognized as of March&#160;31, 2021 were as follows &lt;span style="color:#000000;"&gt;(in thousands):&lt;/span&gt; &lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.02%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.88%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;March&#160;31, 2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.02%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Right of use asset&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,901&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.02%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Long-term lease liability&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,201&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.02%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other current liabilities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,077&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of March&#160;31, 2021, no impairment losses have been recognized to date.&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Supplemental information related to leases for the periods reported is as follows (in thousands):&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:77.26%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.72%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Three Months Ended March&#160;31, 2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:77.26%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cash paid for amounts included in the measurement of lease liabilities:&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.72%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:77.26%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Operating cash flows from operating leases&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.72%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,157&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:77.26%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Right-of-use assets obtained in exchange for new operating lease liabilities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.72%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;135&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:77.26%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted-average remaining lease term of operating leases&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.72%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2.13 years&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:77.26%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted-average discount rate of operating leases&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.72%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5.36%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Calibri;font-size:10pt;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-weight:bold;font-style:italic;color:#000000;font-family:Calibri;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Subleases&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of March&#160;31, 2021 undiscounted cash flows to be received under the Company&#x2019;s operating sublease on an annual basis was as follows (in thousands):&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:77.54%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.42%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Operating Leases&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:77.54%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Years ending December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.42%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:77.54%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Remainder of 2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.42%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;176&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:77.54%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2022&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.42%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;243&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:77.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2023&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.42%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;251&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:77.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2024&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.42%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;49&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:77.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2025&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.42%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:77.54%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2026 and thereafter&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.42%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:77.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.42%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;719&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Sublease income is recognized net within operating expenses. Sublease income for the three months ended March&#160;31, 2021 was as follows (in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:77.54%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.42%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Three Months Ended March&#160;31, 2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:77.54%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Sublease income from fixed lease payments&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.42%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;56&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:77.54%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Sublease income from variable payments&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.42%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:77.54%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.42%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;56&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;"&gt;&#160;&lt;/p&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:LesseeOperatingLeaseOptionToExtend contextRef="C_0001668243_20210101_20210331" id="F_000348">UPL signed an addendum to its November 2014 lease agreement for the Company&#x2019;s executive offices located in Israel, in order to increase the office space rented and to extend the rent period until 2019. In March 2019, UPL utilized the agreement extension option and extended the rent period for additional three years until August 2022.</us-gaap:LesseeOperatingLeaseOptionToExtend>
    <us-gaap:LesseeOperatingLeaseRenewalTerm contextRef="C_0001668243_20210331" id="F_000349">P3Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <urgn:LesseeOperatingLeaseExtendedLeaseExpirationDateMonthAndYear contextRef="C_0001668243_20210101_20210331" id="F_000350">2022-08</urgn:LesseeOperatingLeaseExtendedLeaseExpirationDateMonthAndYear>
    <urgn:LeaseCommencementDateMonthAndYear
      contextRef="C_0001668243_srtConsolidatedEntitiesAxis_srtSubsidiariesMember_srtStatementGeographicalAxis_stprNY_20170901_20170930"
      id="F_000351">2017-10</urgn:LeaseCommencementDateMonthAndYear>
    <urgn:LeaseTerminationDateMonthAndYear
      contextRef="C_0001668243_srtConsolidatedEntitiesAxis_srtSubsidiariesMember_srtStatementGeographicalAxis_stprNY_20170901_20170930"
      id="F_000352">2021-02</urgn:LeaseTerminationDateMonthAndYear>
    <urgn:LeaseCommencementDate
      contextRef="C_0001668243_srtConsolidatedEntitiesAxis_srtSubsidiariesMember_srtStatementGeographicalAxis_stprCA_20180401_20180430"
      id="F_000353">2018-07-10</urgn:LeaseCommencementDate>
    <urgn:LeaseTerminationDateMonthAndYear
      contextRef="C_0001668243_srtConsolidatedEntitiesAxis_srtSubsidiariesMember_srtStatementGeographicalAxis_stprCA_20180401_20180430"
      id="F_000354">2024-03</urgn:LeaseTerminationDateMonthAndYear>
    <urgn:ProceedsFromTenantAllowance
      contextRef="C_0001668243_srtConsolidatedEntitiesAxis_srtSubsidiariesMember_srtStatementGeographicalAxis_stprCA_20180401_20180430"
      decimals="-5"
      id="F_000355"
      unitRef="U_iso4217USD">200000</urgn:ProceedsFromTenantAllowance>
    <us-gaap:ContractualObligation
      contextRef="C_0001668243_srtConsolidatedEntitiesAxis_srtSubsidiariesMember_srtStatementGeographicalAxis_stprCA_20210331"
      decimals="-5"
      id="F_000356"
      unitRef="U_iso4217USD">800000</us-gaap:ContractualObligation>
    <urgn:LesseeOperatingSubleaseCommencementDate
      contextRef="C_0001668243_srtConsolidatedEntitiesAxis_srtSubsidiariesMember_srtStatementGeographicalAxis_stprCA_20191101_20191130"
      id="F_000357">2020-01-01</urgn:LesseeOperatingSubleaseCommencementDate>
    <urgn:LesseeOperatingSubleaseTerminationDateMonthAndYear
      contextRef="C_0001668243_srtConsolidatedEntitiesAxis_srtSubsidiariesMember_srtStatementGeographicalAxis_stprCA_20191101_20191130"
      id="F_000358">2024-03</urgn:LesseeOperatingSubleaseTerminationDateMonthAndYear>
    <us-gaap:SubleaseIncome
      contextRef="C_0001668243_srtConsolidatedEntitiesAxis_srtSubsidiariesMember_srtStatementGeographicalAxis_stprCA_20210101_20210331"
      decimals="-5"
      id="F_000359"
      unitRef="U_iso4217USD">700000</us-gaap:SubleaseIncome>
    <urgn:LeaseCommencementDate
      contextRef="C_0001668243_srtConsolidatedEntitiesAxis_srtSubsidiariesMember_srtStatementGeographicalAxis_stprNJ_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapLeaseAgreementsMember_20191101_20191130"
      id="F_000360">2019-11-29</urgn:LeaseCommencementDate>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="C_0001668243_srtConsolidatedEntitiesAxis_srtSubsidiariesMember_srtStatementGeographicalAxis_stprNJ_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapLeaseAgreementsMember_20191130"
      id="F_000361">P38M</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:ContractualObligation
      contextRef="C_0001668243_srtConsolidatedEntitiesAxis_srtSubsidiariesMember_srtStatementGeographicalAxis_stprNJ_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapLeaseAgreementsMember_20210331"
      decimals="-5"
      id="F_000362"
      unitRef="U_iso4217USD">1000000.0</us-gaap:ContractualObligation>
    <urgn:LeaseExpirationYear
      contextRef="C_0001668243_srtRangeAxis_srtMinimumMember_20210101_20210331"
      id="F_000363">2021</urgn:LeaseExpirationYear>
    <urgn:LeaseExpirationYear
      contextRef="C_0001668243_srtRangeAxis_srtMaximumMember_20210101_20210331"
      id="F_000364">2024</urgn:LeaseExpirationYear>
    <us-gaap:LeaseCostTableTextBlock contextRef="C_0001668243_20210101_20210331" id="F_000239">
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The components of lease cost for the three months ended March&#160;31, 2021 were as follows &lt;span style="color:#000000;"&gt;(in thousands)&lt;/span&gt;:&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:77.4%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.58%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Three Months Ended March&#160;31, 2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:77.4%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Operating lease cost&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.58%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;267&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:77.4%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Sublease income&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.58%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(56&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:77.4%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Variable lease cost&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.58%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;22&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:77.4%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.58%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;233&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseCost
      contextRef="C_0001668243_20210101_20210331"
      decimals="-3"
      id="F_000365"
      unitRef="U_iso4217USD">267000</us-gaap:OperatingLeaseCost>
    <us-gaap:SubleaseIncome
      contextRef="C_0001668243_20210101_20210331"
      decimals="-3"
      id="F_000366"
      unitRef="U_iso4217USD">56000</us-gaap:SubleaseIncome>
    <us-gaap:VariableLeaseCost
      contextRef="C_0001668243_20210101_20210331"
      decimals="-3"
      id="F_000367"
      unitRef="U_iso4217USD">22000</us-gaap:VariableLeaseCost>
    <us-gaap:LeaseCost
      contextRef="C_0001668243_20210101_20210331"
      decimals="-3"
      id="F_000368"
      unitRef="U_iso4217USD">233000</us-gaap:LeaseCost>
    <urgn:ScheduleOfOperatingLeaseAmountsRecognizedUponAdoptionTableTextBlock contextRef="C_0001668243_20210101_20210331" id="F_000240">
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The amounts recognized as of March&#160;31, 2021 were as follows &lt;span style="color:#000000;"&gt;(in thousands):&lt;/span&gt; &lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.02%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.88%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;March&#160;31, 2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.02%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Right of use asset&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,901&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.02%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Long-term lease liability&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,201&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.02%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other current liabilities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,077&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</urgn:ScheduleOfOperatingLeaseAmountsRecognizedUponAdoptionTableTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_0001668243_20210331"
      decimals="-3"
      id="F_000369"
      unitRef="U_iso4217USD">1901000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_0001668243_20210331"
      decimals="-3"
      id="F_000371"
      unitRef="U_iso4217USD">1201000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_0001668243_20210331"
      decimals="-3"
      id="F_000372"
      unitRef="U_iso4217USD">1077000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseImpairmentLoss
      contextRef="C_0001668243_20210101_20210331"
      decimals="INF"
      id="F_000374"
      unitRef="U_iso4217USD">0</us-gaap:OperatingLeaseImpairmentLoss>
    <urgn:ScheduleOfSupplementalInformationRelatedToLeasesTableTextBlock contextRef="C_0001668243_20210101_20210331" id="F_000241">
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Supplemental information related to leases for the periods reported is as follows (in thousands):&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:77.26%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.72%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Three Months Ended March&#160;31, 2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:77.26%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cash paid for amounts included in the measurement of lease liabilities:&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.72%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:77.26%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Operating cash flows from operating leases&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.72%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,157&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:77.26%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Right-of-use assets obtained in exchange for new operating lease liabilities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.72%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;135&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:77.26%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted-average remaining lease term of operating leases&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.72%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2.13 years&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:77.26%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted-average discount rate of operating leases&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.72%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5.36%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</urgn:ScheduleOfSupplementalInformationRelatedToLeasesTableTextBlock>
    <us-gaap:OperatingLeasePayments
      contextRef="C_0001668243_20210101_20210331"
      decimals="-3"
      id="F_000375"
      unitRef="U_iso4217USD">2157000</us-gaap:OperatingLeasePayments>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="C_0001668243_20210101_20210331"
      decimals="-3"
      id="F_000376"
      unitRef="U_iso4217USD">135000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="C_0001668243_20210331" id="F_000377">P2Y1M17D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="C_0001668243_20210331"
      decimals="4"
      id="F_000378"
      unitRef="U_xbrlipure">0.0536</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <urgn:LesseeOperatingSubLeasePaymentsToBeReceivedMaturityTableTextBlock contextRef="C_0001668243_20210101_20210331" id="F_000242">
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of March&#160;31, 2021 undiscounted cash flows to be received under the Company&#x2019;s operating sublease on an annual basis was as follows (in thousands):&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:77.54%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.42%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Operating Leases&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:77.54%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Years ending December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.42%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:77.54%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Remainder of 2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.42%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;176&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:77.54%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2022&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.42%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;243&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:77.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2023&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.42%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;251&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:77.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2024&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.42%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;49&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:77.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2025&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.42%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:77.54%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2026 and thereafter&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.42%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:77.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.42%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;719&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</urgn:LesseeOperatingSubLeasePaymentsToBeReceivedMaturityTableTextBlock>
    <urgn:LesseeOperatingSubLeasePaymentsToBeReceivedRemainderOfFiscalYear
      contextRef="C_0001668243_20210331"
      decimals="-3"
      id="F_000379"
      unitRef="U_iso4217USD">176000</urgn:LesseeOperatingSubLeasePaymentsToBeReceivedRemainderOfFiscalYear>
    <urgn:LesseeOperatingSubLeasePaymentsToBeReceivedNextTwelveMonths
      contextRef="C_0001668243_20210331"
      decimals="-3"
      id="F_000380"
      unitRef="U_iso4217USD">243000</urgn:LesseeOperatingSubLeasePaymentsToBeReceivedNextTwelveMonths>
    <urgn:LesseeOperatingSubLeasePaymentsToBeReceivedTwoYears
      contextRef="C_0001668243_20210331"
      decimals="-3"
      id="F_000381"
      unitRef="U_iso4217USD">251000</urgn:LesseeOperatingSubLeasePaymentsToBeReceivedTwoYears>
    <urgn:LesseeOperatingSubLeasePaymentsToBeReceivedThreeYears
      contextRef="C_0001668243_20210331"
      decimals="-3"
      id="F_000382"
      unitRef="U_iso4217USD">49000</urgn:LesseeOperatingSubLeasePaymentsToBeReceivedThreeYears>
    <urgn:LesseeOperatingSubLeasePaymentsToBeReceived
      contextRef="C_0001668243_20210331"
      decimals="-3"
      id="F_000383"
      unitRef="U_iso4217USD">719000</urgn:LesseeOperatingSubLeasePaymentsToBeReceived>
    <urgn:LesseeOperatingSubLeaseIncomeRecognizedNetInOperatingExpensesTableTextBlock contextRef="C_0001668243_20210101_20210331" id="F_000243">
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Sublease income is recognized net within operating expenses. Sublease income for the three months ended March&#160;31, 2021 was as follows (in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:77.54%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.42%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Three Months Ended March&#160;31, 2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:77.54%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Sublease income from fixed lease payments&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.42%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;56&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:77.54%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Sublease income from variable payments&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.42%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:77.54%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.42%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;56&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</urgn:LesseeOperatingSubLeaseIncomeRecognizedNetInOperatingExpensesTableTextBlock>
    <urgn:LesseeOperatingSubLeaseIncomeFromFixedLeasePayments
      contextRef="C_0001668243_20210101_20210331"
      decimals="-3"
      id="F_000384"
      unitRef="U_iso4217USD">56000</urgn:LesseeOperatingSubLeaseIncomeFromFixedLeasePayments>
    <us-gaap:SubleaseIncome
      contextRef="C_0001668243_20210101_20210331"
      decimals="-3"
      id="F_000385"
      unitRef="U_iso4217USD">56000</us-gaap:SubleaseIncome>
    <us-gaap:RevenueFromContractWithCustomerTextBlock contextRef="C_0001668243_20210101_20210331" id="F_000208">
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Note 10 &#x2013; Revenue From Product Sales&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:12pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net product sales consist of the following for the three months ended March&#160;31, 2021 (in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:77.68%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.28%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Three Months Ended March&#160;31, 2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:77.68%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Jelmyto&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.28%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7,485&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;"&gt;&#160;&lt;/p&gt;</us-gaap:RevenueFromContractWithCustomerTextBlock>
    <us-gaap:DisaggregationOfRevenueTableTextBlock contextRef="C_0001668243_20210101_20210331" id="F_000244">
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net product sales consist of the following for the three months ended March&#160;31, 2021 (in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:77.68%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.28%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Three Months Ended March&#160;31, 2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:77.68%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Jelmyto&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.28%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7,485&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:DisaggregationOfRevenueTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0001668243_20210101_20210331"
      decimals="-3"
      id="F_000387"
      unitRef="U_iso4217USD">7485000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <urgn:LicenseAndCollaborationAgreementsDisclosureTextBlock contextRef="C_0001668243_20210101_20210331" id="F_000209">
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Note 11 &#x2013; License and Collaboration Agreements&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Calibri;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Allergan/AbbVie Agreement&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In October 2016, the Company entered into the Allergan/AbbVie Agreement and granted Allergan (now part of AbbVie) an exclusive worldwide license to research, develop, manufacture and commercialize pharmaceutical products that contain &lt;span style="font-style:italic;"&gt;RTGel&lt;/span&gt; and clostridial toxins (including BOTOX&lt;sup style="font-size:85%;line-height:120%;vertical-align:top"&gt;&#xae;&lt;/sup&gt;), alone or in combination with certain other active ingredients, referred to as the Licensed Products, which are approved for the treatment of adults with overactive bladder who cannot use or do not adequately respond to anticholinergics. Additionally, the Company granted Allergan a non-exclusive, worldwide license to use certain of the Company&#x2019;s trademarks as required for Allergan to practice its exclusive license with respect to the Licensed Products.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Under the Allergan/AbbVie Agreement, Allergan is solely responsible for costs and development of the Licensed Products and obtaining all regulatory approvals for Licensed Products worldwide, as well as worldwide commercialization of the Licensed Products after receiving the regulatory approval to do so. Allergan is required to use commercially reasonable efforts to develop and commercialize the Licensed Products for overactive bladder in certain major market countries.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Further, the Company is eligible to receive additional material milestone payments of up to an aggregate of $200.0 million upon the successful completion of certain development, regulatory and commercial milestones. As of March&#160;31, 2021, since inception of the Allergan/AbbVie Agreement the Company has received a total of&#160;$25.0 million in milestone payments from Allergan. Allergan will pay the Company a tiered royalty in the low single digits based on worldwide annual net sales of Licensed Products, subject to certain reductions for the market entry of competing products and/or loss of the Company&#x2019;s patent coverage of Licensed Products. The Company is responsible for payments to any third party for certain &lt;span style="font-style:italic;"&gt;RTGel&lt;/span&gt;-related third-party intellectual properties.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Under the Allergan/AbbVie Agreement, Allergan granted the Company a non-exclusive, sublicensable, fully paid-up, perpetual, worldwide license under any improvements Allergan makes to the composition, formulation, or manufacture of &lt;span style="font-style:italic;"&gt;RTGel&lt;/span&gt; for the research, development, manufacture and commercialization of any product containing &lt;span style="font-style:italic;"&gt;RTGel&lt;/span&gt; and any active ingredient (other than a clostridial toxin) for all indications other than indications covered by the agreement and an exclusive, sublicensable, royalty-bearing (in low single digits), perpetual worldwide license under such improvements for use in the prevention or treatment of oncology indications.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In August 2020, the Company announced that the Phase 2 APOLLO trial did not meet the primary endpoint, it is believed to be the result of BOTOX not effectively permeating the urothelium. The Company is continuing to explore the potential use of &lt;span style="font-style:italic;"&gt;RTGel&lt;/span&gt; in combination with other products in AbbVie&#x2019;s portfolio. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Calibri;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Agenus Agreement&lt;span style="font-weight:normal;font-style:normal;"&gt; &lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In November 2019, the Company entered into a license agreement with Agenus Inc, pursuant to which Agenus granted to the Company an exclusive, worldwide (not including Argentina, Brazil, Chile, Colombia, Peru, Venezuela and their respective territories and possessions), royalty-bearing, sublicensable license under Agenus&#x2019;s intellectual property rights to develop, make, use, sell, import, and otherwise commercialize products incorporating a proprietary antibody of Agenus known as AGEN1884 for the treatment of cancers of the urinary tract via intravesical delivery. AGEN1884 is an anti-CTLA-4 antagonist that is currently being evaluated by Agenus as a monotherapy in PD-1 refractory patients and in combination with Agenus&#x2019; anti-PD-1 antibody in solid tumors. Initially, the Company plans to develop AGEN1884 in combination with UGN-201 for the treatment of high-grade NMIBC. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Pursuant to the license agreement, the Company paid Agenus an upfront fee of $10.0 million and has agreed to pay Agenus up to $115.0 million upon achieving certain clinical development and regulatory milestones, up to $85.0 million upon achieving certain commercial milestones, and royalties on net sales of licensed products in the 14%-20% range. The Company will be responsible for all development and commercialization activities. Under the terms of the license agreement, Agenus has agreed to use commercially reasonable efforts to supply AGEN1884 to the Company for use in preclinical studies or clinical trials.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unless earlier terminated in accordance with the terms of the license agreement, the license agreement will expire on a product-by-product and country-by-country basis at the later of (a) the expiration of the last to expire valid claim of a licensed patent right that covers the licensed product in such country or (b) 15 years after the first commercial sale of the licensed product in such country. The Company may terminate the license agreement for convenience upon 180 days&#x2019; written notice to Agenus. Either party may terminate the license agreement upon 60 days&#x2019; notice to the other party if, prior to the first commercial sale of a licensed product, the Company substantially ceases to conduct development activities of the licensed products for nine consecutive months (and during such period, Agenus has complied with its obligations under the license agreement) other than in response to a requirement of an applicable regulatory authority or an event outside of the Company&#x2019;s control. In addition, either party may terminate the license agreement in the event of an uncured material breach of the other party. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Calibri;font-size:10pt;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-weight:bold;font-style:italic;font-family:Calibri;font-size:10pt;text-transform:none;font-variant: normal;"&gt;MD Anderson Agreement&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="Background-color:#FFFFFF;"&gt;In January 2021, the Company announced that it entered into a three-year strategic research collaboration agreement with MD Anderson focusing on UGN-302 as an investigational treatment for high-grade NMIBC. Under the agreement, MD Anderson and the Company will collaborate on the design and conduct of non-clinical and clinical studies with oversight from a joint steering committee. The Company will provide funding, developmental candidates, and other support. Pursuant to the agreement, the Company makes bi-annual payments to MD Anderson fund the collaboration. As of March 31, 2021, the Company has made payments to MD Anderson of $&lt;/span&gt;500,000 recognized evenly over the associated six-month period through research and development expenses&lt;span style="Background-color:#FFFFFF;"&gt;.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;</urgn:LicenseAndCollaborationAgreementsDisclosureTextBlock>
    <urgn:ContractWithCustomerAdditionalMilestonePaymentEligibleToReceive
      contextRef="C_0001668243_srtCounterpartyNameAxis_urgnAllerganPharmaceuticalsInternationalLimitedAndAbbVieIncMember_srtRangeAxis_srtMaximumMember_us-gaapTypeOfArrangementAxis_urgnLicenseAgreementMember_20210331"
      decimals="-5"
      id="F_000388"
      unitRef="U_iso4217USD">200000000.0</urgn:ContractWithCustomerAdditionalMilestonePaymentEligibleToReceive>
    <urgn:MilestonePaymentsReceivedForLicensingAgreement
      contextRef="C_0001668243_srtCounterpartyNameAxis_urgnAllerganPharmaceuticalsInternationalLimitedAndAbbVieIncMember_us-gaapTypeOfArrangementAxis_urgnLicenseAgreementMember_20210101_20210331"
      decimals="-5"
      id="F_000389"
      unitRef="U_iso4217USD">25000000.0</urgn:MilestonePaymentsReceivedForLicensingAgreement>
    <urgn:UpfrontFee
      contextRef="C_0001668243_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_us-gaapLicenseAgreementTermsMember_20191101_20191130"
      decimals="-5"
      id="F_000390"
      unitRef="U_iso4217USD">10000000.0</urgn:UpfrontFee>
    <urgn:MaximumAmountPayableUponAchievingCertainClinicalDevelopmentAndRegulatoryMilestones
      contextRef="C_0001668243_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_us-gaapLicenseAgreementTermsMember_20191130"
      decimals="INF"
      id="F_000391"
      unitRef="U_iso4217USD">115000000.0</urgn:MaximumAmountPayableUponAchievingCertainClinicalDevelopmentAndRegulatoryMilestones>
    <urgn:MaximumAmountPayableUponAchievingCertainCommercialMilestones
      contextRef="C_0001668243_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_us-gaapLicenseAgreementTermsMember_20191130"
      decimals="INF"
      id="F_000392"
      unitRef="U_iso4217USD">85000000.0</urgn:MaximumAmountPayableUponAchievingCertainCommercialMilestones>
    <urgn:RoyaltyRangingOnNetSalesOfLicensedProducts
      contextRef="C_0001668243_srtRangeAxis_srtMinimumMember_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_us-gaapLicenseAgreementTermsMember_20191101_20191130"
      decimals="INF"
      id="F_000393"
      unitRef="U_xbrlipure">0.14</urgn:RoyaltyRangingOnNetSalesOfLicensedProducts>
    <urgn:RoyaltyRangingOnNetSalesOfLicensedProducts
      contextRef="C_0001668243_srtRangeAxis_srtMaximumMember_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_us-gaapLicenseAgreementTermsMember_20191101_20191130"
      decimals="INF"
      id="F_000394"
      unitRef="U_xbrlipure">0.20</urgn:RoyaltyRangingOnNetSalesOfLicensedProducts>
    <urgn:LicenseAgreementExpirationTerm
      contextRef="C_0001668243_srtStatementScenarioAxis_urgnAfterFirstCommercialSaleOfLicensedProductMember_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_us-gaapLicenseAgreementTermsMember_20191101_20191130"
      id="F_000395">P15Y</urgn:LicenseAgreementExpirationTerm>
    <us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross
      contextRef="C_0001668243_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_urgnMDAndersonMember_20210101_20210331"
      decimals="0"
      id="F_000396"
      unitRef="U_iso4217USD">500000</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="C_0001668243_20210101_20210331" id="F_000210">
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Note 12 &#x2013; Shareholders&#x2019; Equity &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company had 100.0 million ordinary shares authorized for issuance as of March&#160;31, 2021 and December&#160;31, 2020, respectively. The Company had 22.3 million and 22.2 million ordinary shares issued and outstanding as of March&#160;31, 2021 and December&#160;31, 2020, respectively. Each&lt;span style="letter-spacing:0.45pt;"&gt; &lt;/span&gt;ordinary&lt;span style="letter-spacing:0.65pt;"&gt; &lt;/span&gt;share&lt;span style="letter-spacing:0.45pt;"&gt; &lt;/span&gt;is&lt;span style="letter-spacing:0.15pt;"&gt; &lt;/span&gt;entitled&lt;span style="letter-spacing:0.6pt;"&gt; &lt;/span&gt;to&lt;span style="letter-spacing:0.2pt;"&gt; &lt;/span&gt;one&lt;span style="letter-spacing:0.35pt;"&gt; &lt;/span&gt;vote.&lt;span style="letter-spacing:0.4pt;"&gt; &lt;/span&gt;The&lt;span style="letter-spacing:0.35pt;"&gt; &lt;/span&gt;hol&lt;span style="letter-spacing:-0.1pt;"&gt;d&lt;/span&gt;ers&lt;span style="letter-spacing:0.6pt;"&gt; &lt;/span&gt;of&lt;span style="letter-spacing:0.2pt;"&gt; &lt;/span&gt;ordinary&lt;span style="letter-spacing:0.65pt;"&gt; &lt;/span&gt;shares&lt;span style="letter-spacing:0.55pt;"&gt; &lt;/span&gt;are&lt;span style="letter-spacing:0.3pt;"&gt; &lt;/span&gt;also&lt;span style="letter-spacing:0.35pt;"&gt; &lt;/span&gt;entitled&lt;span style="letter-spacing:0.6pt;"&gt; &lt;/span&gt;to&lt;span style="letter-spacing:0.2pt;"&gt; &lt;/span&gt;receive&lt;span style="letter-spacing:0.6pt;"&gt; &lt;/span&gt;dividends&lt;span style="letter-spacing:0.75pt;"&gt; &lt;/span&gt;&lt;span style="letter-spacing:-0.1pt;"&gt;w&lt;/span&gt;henever&lt;span style="letter-spacing:0.8pt;"&gt; &lt;/span&gt;funds&lt;span style="letter-spacing:0.45pt;"&gt; &lt;/span&gt;are&lt;span style="letter-spacing:0.3pt;"&gt; &lt;/span&gt;legally available,&lt;span style="letter-spacing:0.75pt;"&gt; &lt;/span&gt;when&lt;span style="letter-spacing:0.45pt;"&gt; &lt;/span&gt;and&lt;span style="letter-spacing:0.35pt;"&gt; &lt;/span&gt;if&lt;span style="letter-spacing:0.3pt;"&gt; &lt;/span&gt;declared&lt;span style="letter-spacing:0.7pt;"&gt; &lt;/span&gt;by&lt;span style="letter-spacing:0.25pt;"&gt; &lt;/span&gt;the&lt;span style="letter-spacing:0.3pt;"&gt; &lt;/span&gt;Board&lt;span style="letter-spacing:0.5pt;"&gt; &lt;/span&gt;of&lt;span style="letter-spacing:0.2pt;"&gt; &lt;/span&gt;Directors &lt;span style="Background-color:#FFFFFF;color:#000000;"&gt;(the &#x201c;Board&#x201d;)&lt;/span&gt;.&lt;span style="letter-spacing:0.8pt;"&gt; &lt;/span&gt;Since&lt;span style="letter-spacing:0.45pt;"&gt; &lt;/span&gt;its&lt;span style="letter-spacing:0.2pt;"&gt; &lt;/span&gt;inception,&lt;span style="letter-spacing:0.8pt;"&gt; &lt;/span&gt;the&lt;span style="letter-spacing:0.3pt;"&gt; &lt;/span&gt;Board&lt;span style="letter-spacing:0.8pt;"&gt; &lt;/span&gt;has&lt;span style="letter-spacing:0.3pt;"&gt; &lt;/span&gt;not&lt;span style="letter-spacing:0.3pt;"&gt; &lt;/span&gt;declared&lt;span style="letter-spacing:0.7pt;"&gt; &lt;/span&gt;any&lt;span style="letter-spacing:0.3pt;"&gt; &lt;/span&gt;dividends.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/p&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_0001668243_20210331"
      decimals="-5"
      id="F_000397"
      unitRef="U_xbrlishares">100000000.0</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_0001668243_20201231"
      decimals="-5"
      id="F_000398"
      unitRef="U_xbrlishares">100000000.0</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_0001668243_20210331"
      decimals="-5"
      id="F_000399"
      unitRef="U_xbrlishares">22300000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_0001668243_20210331"
      decimals="-5"
      id="F_000401"
      unitRef="U_xbrlishares">22300000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_0001668243_20201231"
      decimals="-5"
      id="F_000400"
      unitRef="U_xbrlishares">22200000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_0001668243_20201231"
      decimals="-5"
      id="F_000402"
      unitRef="U_xbrlishares">22200000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="C_0001668243_20210101_20210331" id="F_000211">
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Note 13 &#x2013; Share-Based Compensation&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In&lt;span style="letter-spacing:0.2pt;"&gt; &lt;/span&gt;October&lt;span style="letter-spacing:0.65pt;"&gt; &lt;/span&gt;2010,&lt;span style="letter-spacing:0.45pt;"&gt; &lt;/span&gt;the&lt;span style="letter-spacing:0.9pt;"&gt; &lt;/span&gt;Board&lt;span style="letter-spacing:0.7pt;"&gt; &lt;/span&gt;approved&lt;span style="letter-spacing:0.75pt;"&gt; &lt;/span&gt;a&lt;span style="letter-spacing:0.15pt;"&gt; &lt;/span&gt;share&lt;span style="letter-spacing:0.45pt;"&gt; &lt;/span&gt;option&lt;span style="letter-spacing:0.5pt;"&gt; &lt;/span&gt;plan&lt;span style="letter-spacing:0.35pt;"&gt; &lt;/span&gt;(the&lt;span style="letter-spacing:0.35pt;"&gt; &lt;/span&gt;&#x201c;Pl&lt;span style="letter-spacing:-0.1pt;"&gt;a&lt;/span&gt;n&#x201d;)&lt;span style="letter-spacing:0.55pt;"&gt; &lt;/span&gt;for&lt;span style="letter-spacing:0.25pt;"&gt; &lt;/span&gt;grants&lt;span style="letter-spacing:0.5pt;"&gt; &lt;/span&gt;to&lt;span style="letter-spacing:0.2pt;"&gt; &lt;/span&gt;Company&lt;span style="letter-spacing:0.8pt;"&gt; &lt;/span&gt;employees,&lt;span style="letter-spacing:0.9pt;"&gt; &lt;/span&gt;consultants, directors,&lt;span style="letter-spacing:0.75pt;"&gt; &lt;/span&gt;and&lt;span style="letter-spacing:0.35pt;"&gt; &lt;/span&gt;other&lt;span style="letter-spacing:0.45pt;"&gt; &lt;/span&gt;service&lt;span style="letter-spacing:0.6pt;"&gt; &lt;/span&gt;providers.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The&lt;span style="letter-spacing:0.4pt;"&gt; &lt;/span&gt;grant&lt;span style="letter-spacing:0.45pt;"&gt; &lt;/span&gt;of&lt;span style="letter-spacing:0.2pt;"&gt; &lt;/span&gt;options&lt;span style="letter-spacing:0.6pt;"&gt; &lt;/span&gt;to&lt;span style="letter-spacing:0.2pt;"&gt; &lt;/span&gt;Israeli&lt;span style="letter-spacing:0.5pt;"&gt; &lt;/span&gt;employees&lt;span style="letter-spacing:0.85pt;"&gt; &lt;/span&gt;under&lt;span style="letter-spacing:0.5pt;"&gt; &lt;/span&gt;the&lt;span style="letter-spacing:0.3pt;"&gt; &lt;/span&gt;Plan&lt;span style="letter-spacing:0.4pt;"&gt; &lt;/span&gt;is&lt;span style="letter-spacing:0.15pt;"&gt; &lt;/span&gt;su&lt;span style="letter-spacing:-0.1pt;"&gt;b&lt;/span&gt;ject&lt;span style="letter-spacing:0.6pt;"&gt; &lt;/span&gt;to&lt;span style="letter-spacing:0.2pt;"&gt; &lt;/span&gt;the&lt;span style="letter-spacing:0.3pt;"&gt; &lt;/span&gt;terms&lt;span style="letter-spacing:0.45pt;"&gt; &lt;/span&gt;stipulated&lt;span style="letter-spacing:0.8pt;"&gt; &lt;/span&gt;by&lt;span style="letter-spacing:0.25pt;"&gt; &lt;/span&gt;Section&lt;span style="letter-spacing:0.6pt;"&gt; &lt;/span&gt;102&lt;span style="letter-spacing:0.35pt;"&gt; &lt;/span&gt;of&lt;span style="letter-spacing:0.2pt;"&gt; &lt;/span&gt;the&lt;span style="letter-spacing:0.3pt;"&gt; &lt;/span&gt;Israeli&lt;span style="letter-spacing:0.5pt;"&gt; &lt;/span&gt;Income&lt;span style="letter-spacing:0.6pt;"&gt; &lt;/span&gt;Tax&lt;span style="letter-spacing:0.35pt;"&gt; &lt;/span&gt;Ordinance (&#x201c;Section&lt;span style="letter-spacing:0.75pt;"&gt; &lt;/span&gt;102&#x201d;).&lt;span style="letter-spacing:0.5pt;"&gt; &lt;/span&gt;The&lt;span style="letter-spacing:0.35pt;"&gt; &lt;/span&gt;option&lt;span style="letter-spacing:0.5pt;"&gt; &lt;/span&gt;grants&lt;span style="letter-spacing:0.5pt;"&gt; &lt;/span&gt;are&lt;span style="letter-spacing:0.3pt;"&gt; &lt;/span&gt;subject&lt;span style="letter-spacing:0.6pt;"&gt; &lt;/span&gt;to&lt;span style="letter-spacing:0.2pt;"&gt; &lt;/span&gt;the&lt;span style="letter-spacing:0.3pt;"&gt; &lt;/span&gt;track&lt;span style="letter-spacing:0.4pt;"&gt; &lt;/span&gt;chosen&lt;span style="letter-spacing:0.6pt;"&gt; &lt;/span&gt;by&lt;span style="letter-spacing:0.25pt;"&gt; &lt;/span&gt;the&lt;span style="letter-spacing:0.3pt;"&gt; &lt;/span&gt;Company,&lt;span style="letter-spacing:0.8pt;"&gt; &lt;/span&gt;either&lt;span style="letter-spacing:0.45pt;"&gt; &lt;/span&gt;the&lt;span style="letter-spacing:0.3pt;"&gt; &lt;/span&gt;&#x201c;regular&lt;span style="letter-spacing:0.65pt;"&gt; &lt;/span&gt;income&#x201d;&lt;span style="letter-spacing:0.65pt;"&gt; &lt;/span&gt;track&lt;span style="letter-spacing:0.4pt;"&gt; &lt;/span&gt;or&lt;span style="letter-spacing:0.2pt;"&gt; &lt;/span&gt;the&lt;span style="letter-spacing:0.3pt;"&gt; &lt;/span&gt;&#x201c;capital&lt;span style="letter-spacing:0.6pt;"&gt; &lt;/span&gt;gains&#x201d;&lt;span style="letter-spacing:0.5pt;"&gt; &lt;/span&gt;track,&lt;span style="letter-spacing:0.05pt;"&gt; &lt;/span&gt;as&lt;span style="letter-spacing:0.25pt;"&gt; &lt;/span&gt;set&lt;span style="letter-spacing:0.3pt;"&gt; &lt;/span&gt;out&lt;span style="letter-spacing:0.3pt;"&gt; &lt;/span&gt;in&lt;span style="letter-spacing:0.2pt;"&gt; &lt;/span&gt;Section&lt;span style="letter-spacing:0.6pt;"&gt; &lt;/span&gt;102.&lt;span style="letter-spacing:0.4pt;"&gt; &lt;/span&gt;The&lt;span style="letter-spacing:0.35pt;"&gt; &lt;/span&gt;Company&lt;span style="letter-spacing:0.8pt;"&gt; &lt;/span&gt;registered&lt;span style="letter-spacing:0.8pt;"&gt; &lt;/span&gt;the&lt;span style="letter-spacing:0.3pt;"&gt; &lt;/span&gt;Plan&lt;span style="letter-spacing:0.4pt;"&gt; &lt;/span&gt;un&lt;span style="letter-spacing:-0.1pt;"&gt;d&lt;/span&gt;er&lt;span style="letter-spacing:0.5pt;"&gt; &lt;/span&gt;the&lt;span style="letter-spacing:0.3pt;"&gt; &lt;/span&gt;capital&lt;span style="letter-spacing:0.55pt;"&gt; &lt;/span&gt;gains&lt;span style="letter-spacing:0.45pt;"&gt; &lt;/span&gt;track,&lt;span style="letter-spacing:0.45pt;"&gt; &lt;/span&gt;which&lt;span style="letter-spacing:0.5pt;"&gt; &lt;/span&gt;offers&lt;span style="letter-spacing:0.45pt;"&gt; &lt;/span&gt;more&lt;span style="letter-spacing:0.45pt;"&gt; &lt;/span&gt;favorable&lt;span style="letter-spacing:0.75pt;"&gt; &lt;/span&gt;tax&lt;span style="letter-spacing:0.3pt;"&gt; &lt;/span&gt;rates&lt;span style="letter-spacing:0.45pt;"&gt; &lt;/span&gt;to&lt;span style="letter-spacing:0.2pt;"&gt; &lt;/span&gt;the employees.&lt;span style="letter-spacing:0.9pt;"&gt; &lt;/span&gt;As&lt;span style="letter-spacing:0.25pt;"&gt; &lt;/span&gt;a&lt;span style="letter-spacing:0.15pt;"&gt; &lt;/span&gt;result,&lt;span style="letter-spacing:0.5pt;"&gt; &lt;/span&gt;and&lt;span style="letter-spacing:0.35pt;"&gt; &lt;/span&gt;pursuant&lt;span style="letter-spacing:0.7pt;"&gt; &lt;/span&gt;to&lt;span style="letter-spacing:0.2pt;"&gt; &lt;/span&gt;the&lt;span style="letter-spacing:0.3pt;"&gt; &lt;/span&gt;terms&lt;span style="letter-spacing:0.45pt;"&gt; &lt;/span&gt;of&lt;span style="letter-spacing:0.2pt;"&gt; &lt;/span&gt;Section&lt;span style="letter-spacing:0.6pt;"&gt; &lt;/span&gt;102,&lt;span style="letter-spacing:0.4pt;"&gt; &lt;/span&gt;the&lt;span style="letter-spacing:0.3pt;"&gt; &lt;/span&gt;Company&lt;span style="letter-spacing:0.8pt;"&gt; &lt;/span&gt;is&lt;span style="letter-spacing:0.15pt;"&gt; &lt;/span&gt;not&lt;span style="letter-spacing:0.3pt;"&gt; &lt;/span&gt;allowed&lt;span style="letter-spacing:0.65pt;"&gt; &lt;/span&gt;to&lt;span style="letter-spacing:0.2pt;"&gt; &lt;/span&gt;claim&lt;span style="letter-spacing:0.45pt;"&gt; &lt;/span&gt;as&lt;span style="letter-spacing:0.25pt;"&gt; &lt;/span&gt;an&lt;span style="letter-spacing:0.25pt;"&gt; &lt;/span&gt;ex&lt;span style="letter-spacing:-0.1pt;"&gt;p&lt;/span&gt;ense&lt;span style="letter-spacing:0.7pt;"&gt; &lt;/span&gt;for&lt;span style="letter-spacing:0.25pt;"&gt; &lt;/span&gt;tax&lt;span style="letter-spacing:0.3pt;"&gt; &lt;/span&gt;purposes&lt;span style="letter-spacing:0.75pt;"&gt; &lt;/span&gt;the amounts&lt;span style="letter-spacing:0.7pt;"&gt; &lt;/span&gt;credited&lt;span style="letter-spacing:0.65pt;"&gt; &lt;/span&gt;to&lt;span style="letter-spacing:0.2pt;"&gt; &lt;/span&gt;the&lt;span style="letter-spacing:0.3pt;"&gt; &lt;/span&gt;employees&lt;span style="letter-spacing:0.85pt;"&gt; &lt;/span&gt;in&lt;span style="letter-spacing:0.2pt;"&gt; &lt;/span&gt;respect&lt;span style="letter-spacing:0.6pt;"&gt; &lt;/span&gt;of&lt;span style="letter-spacing:0.2pt;"&gt; &lt;/span&gt;options&lt;span style="letter-spacing:0.6pt;"&gt; &lt;/span&gt;granted&lt;span style="letter-spacing:0.65pt;"&gt; &lt;/span&gt;to&lt;span style="letter-spacing:0.2pt;"&gt; &lt;/span&gt;them&lt;span style="letter-spacing:0.45pt;"&gt; &lt;/span&gt;under&lt;span style="letter-spacing:0.5pt;"&gt; &lt;/span&gt;the&lt;span style="letter-spacing:0.3pt;"&gt; &lt;/span&gt;P&lt;span style="letter-spacing:-0.1pt;"&gt;l&lt;/span&gt;an,&lt;span style="letter-spacing:0.45pt;"&gt; &lt;/span&gt;including&lt;span style="letter-spacing:0.7pt;"&gt; &lt;/span&gt;amounts&lt;span style="letter-spacing:0.7pt;"&gt; &lt;/span&gt;recorded&lt;span style="letter-spacing:0.7pt;"&gt; &lt;/span&gt;as&lt;span style="letter-spacing:0.25pt;"&gt; &lt;/span&gt;salary&lt;span style="letter-spacing:0.5pt;"&gt; &lt;/span&gt;be&lt;span style="letter-spacing:-0.1pt;"&gt;n&lt;/span&gt;efits&lt;span style="letter-spacing:0.8pt;"&gt; &lt;/span&gt;in&lt;span style="letter-spacing:0.2pt;"&gt; &lt;/span&gt;the Company&#x2019;s&lt;span style="letter-spacing:0.9pt;"&gt; &lt;/span&gt;accounts,&lt;span style="letter-spacing:0.8pt;"&gt; &lt;/span&gt;with&lt;span style="letter-spacing:0.35pt;"&gt; &lt;/span&gt;the&lt;span style="letter-spacing:0.3pt;"&gt; &lt;/span&gt;exception&lt;span style="letter-spacing:0.8pt;"&gt; &lt;/span&gt;of&lt;span style="letter-spacing:0.2pt;"&gt; &lt;/span&gt;the&lt;span style="letter-spacing:0.3pt;"&gt; &lt;/span&gt;work-income&lt;span style="letter-spacing:1pt;"&gt; &lt;/span&gt;b&lt;span style="letter-spacing:-0.1pt;"&gt;e&lt;/span&gt;nefit&lt;span style="letter-spacing:0.55pt;"&gt; &lt;/span&gt;component,&lt;span style="letter-spacing:0.95pt;"&gt; &lt;/span&gt;if&lt;span style="letter-spacing:0.15pt;"&gt; &lt;/span&gt;any,&lt;span style="letter-spacing:0.35pt;"&gt; &lt;/span&gt;determined&lt;span style="letter-spacing:0.9pt;"&gt; &lt;/span&gt;on&lt;span style="letter-spacing:0.25pt;"&gt; &lt;/span&gt;grant&lt;span style="letter-spacing:0.45pt;"&gt; &lt;/span&gt;date.&lt;span style="letter-spacing:0.45pt;"&gt; &lt;/span&gt;For&lt;span style="letter-spacing:0.4pt;"&gt; &lt;/span&gt;non-employees&lt;span style="letter-spacing:1.3pt;"&gt; &lt;/span&gt;and&lt;span style="letter-spacing:0.35pt;"&gt; &lt;/span&gt;for non-Israeli&lt;span style="letter-spacing:0.95pt;"&gt; &lt;/span&gt;employees,&lt;span style="letter-spacing:0.9pt;"&gt; &lt;/span&gt;the&lt;span style="letter-spacing:0.3pt;"&gt; &lt;/span&gt;Plan&lt;span style="letter-spacing:0.4pt;"&gt; &lt;/span&gt;is&lt;span style="letter-spacing:0.15pt;"&gt; &lt;/span&gt;subject&lt;span style="letter-spacing:0.6pt;"&gt; &lt;/span&gt;to&lt;span style="letter-spacing:0.2pt;"&gt; &lt;/span&gt;Section&lt;span style="letter-spacing:0.6pt;"&gt; &lt;/span&gt;3(i)&lt;span style="letter-spacing:0.3pt;"&gt; &lt;/span&gt;of&lt;span style="letter-spacing:0.2pt;"&gt; &lt;/span&gt;the&lt;span style="letter-spacing:0.3pt;"&gt; &lt;/span&gt;Israeli&lt;span style="letter-spacing:0.5pt;"&gt; &lt;/span&gt;Income&lt;span style="letter-spacing:0.6pt;"&gt; &lt;/span&gt;Tax&lt;span style="letter-spacing:0.35pt;"&gt; &lt;/span&gt;Ordinance.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Employees are typically granted stock options and/or restricted stock units, or RSUs, upon commencement of employment. Also, eligible employees may receive an annual grant of options or RSUs. Non-employee members of the Board typically receive a grant of RSUs and/or stock options annually. The term of any option granted under the Plan cannot exceed 10 years. Options shall not have an exercise price less than 100% of the fair market value of the Company&#x2019;s ordinary shares on the grant date, and generally vest over a period of three years. If the individual possesses more than 10% of the combined voting power of all classes of equity of the Company, the exercise price shall not be less than 110% of the fair market value of an ordinary share of stock on the date of grant.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company&#x2019;s RSU and option grants provide for accelerated or continued vesting in certain circumstances as defined in the plans and related grant agreements, including a termination in connection with a change in control. RSUs generally vest in a 33% increment upon the first anniversary of grant, and in either equal quarterly or annual amounts for the two years following the one-year anniversary of the grant date. Options generally vest in a 33% increment upon the first anniversary of the grant date, and in either equal quarterly or annual amounts for the two years following the one-year anniversary of the grant date.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The&lt;span style="letter-spacing:0.35pt;"&gt; &lt;/span&gt;expected&lt;span style="letter-spacing:0.75pt;"&gt; &lt;/span&gt;volatility&lt;span style="letter-spacing:0.65pt;"&gt; &lt;/span&gt;is&lt;span style="letter-spacing:0.15pt;"&gt; &lt;/span&gt;based&lt;span style="letter-spacing:0.5pt;"&gt; &lt;/span&gt;on&lt;span style="letter-spacing:0.25pt;"&gt; a mix of the Company&#x2019;s historical volatility, and &lt;/span&gt;the&lt;span style="letter-spacing:0.3pt;"&gt; &lt;/span&gt;histori&lt;span style="letter-spacing:-0.1pt;"&gt;c&lt;/span&gt;al&lt;span style="letter-spacing:0.7pt;"&gt; &lt;/span&gt;volatility&lt;span style="letter-spacing:0.65pt;"&gt; &lt;/span&gt;of&lt;span style="letter-spacing:0.2pt;"&gt; &lt;/span&gt;comparable&lt;span style="letter-spacing:1pt;"&gt; &lt;/span&gt;companies with similar attributes to the Company, including industry, stage of life cycle, size and financial leverage.&lt;span style="letter-spacing:0.9pt;"&gt; &lt;/span&gt;The&lt;span style="letter-spacing:0.35pt;"&gt; &lt;/span&gt;risk-free&lt;span style="letter-spacing:0.65pt;"&gt; &lt;/span&gt;interest&lt;span style="letter-spacing:0.6pt;"&gt; &lt;/span&gt;rate&lt;span style="letter-spacing:0.35pt;"&gt; &lt;/span&gt;assumption&lt;span style="letter-spacing:0.9pt;"&gt; &lt;/span&gt;is&lt;span style="letter-spacing:0.15pt;"&gt; &lt;/span&gt;based&lt;span style="letter-spacing:0.5pt;"&gt; &lt;/span&gt;on observed&lt;span style="letter-spacing:0.75pt;"&gt; &lt;/span&gt;interest&lt;span style="letter-spacing:0.6pt;"&gt; &lt;/span&gt;rates&lt;span style="letter-spacing:0.45pt;"&gt; &lt;/span&gt;appropriate&lt;span style="letter-spacing:0.9pt;"&gt; &lt;/span&gt;for&lt;span style="letter-spacing:0.25pt;"&gt; &lt;/span&gt;the&lt;span style="letter-spacing:0.3pt;"&gt; &lt;/span&gt;expected&lt;span style="letter-spacing:0.75pt;"&gt; &lt;/span&gt;term&lt;span style="letter-spacing:0.4pt;"&gt; &lt;/span&gt;of&lt;span style="letter-spacing:0.2pt;"&gt; &lt;/span&gt;the&lt;span style="letter-spacing:0.3pt;"&gt; &lt;/span&gt;options&lt;span style="letter-spacing:0.6pt;"&gt; &lt;/span&gt;granted.&lt;span style="letter-spacing:0.5pt;"&gt; &lt;/span&gt;The&lt;span style="letter-spacing:0.35pt;"&gt; &lt;/span&gt;expected&lt;span style="letter-spacing:0.75pt;"&gt; &lt;/span&gt;term&lt;span style="letter-spacing:0.4pt;"&gt; &lt;/span&gt;is&lt;span style="letter-spacing:0.15pt;"&gt; &lt;/span&gt;the&lt;span style="letter-spacing:0.3pt;"&gt; &lt;/span&gt;length&lt;span style="letter-spacing:0.5pt;"&gt; &lt;/span&gt;of&lt;span style="letter-spacing:0.2pt;"&gt; &lt;/span&gt;time&lt;span style="letter-spacing:0.35pt;"&gt; &lt;/span&gt;until the&lt;span style="letter-spacing:0.05pt;"&gt; &lt;/span&gt;expected&lt;span style="letter-spacing:0.75pt;"&gt; &lt;/span&gt;dates&lt;span style="letter-spacing:0.45pt;"&gt; &lt;/span&gt;of&lt;span style="letter-spacing:0.2pt;"&gt; &lt;/span&gt;exercising&lt;span style="letter-spacing:0.8pt;"&gt; &lt;/span&gt;the&lt;span style="letter-spacing:0.3pt;"&gt; &lt;/span&gt;options and&lt;span style="letter-spacing:0.35pt;"&gt; &lt;/span&gt;is&lt;span style="letter-spacing:0.15pt;"&gt; &lt;/span&gt;estimated&lt;span style="letter-spacing:0.8pt;"&gt; &lt;/span&gt;for&lt;span style="letter-spacing:0.25pt;"&gt; &lt;/span&gt;employees&lt;span style="letter-spacing:0.85pt;"&gt; &lt;/span&gt;using&lt;span style="letter-spacing:0.45pt;"&gt; &lt;/span&gt;the&lt;span style="letter-spacing:0.3pt;"&gt; &lt;/span&gt;simplified&lt;span style="letter-spacing:0.75pt;"&gt; &lt;/span&gt;method&lt;span style="letter-spacing:0.6pt;"&gt; &lt;/span&gt;due&lt;span style="letter-spacing:0.35pt;"&gt; &lt;/span&gt;to insufficient&lt;span style="letter-spacing:0.85pt;"&gt; &lt;/span&gt;specific&lt;span style="letter-spacing:0.6pt;"&gt; &lt;/span&gt;historical&lt;span style="letter-spacing:0.7pt;"&gt; &lt;/span&gt;information&lt;span style="letter-spacing:0.9pt;"&gt; &lt;/span&gt;of&lt;span style="letter-spacing:0.2pt;"&gt; &lt;/span&gt;employ&lt;span style="letter-spacing:-0.1pt;"&gt;e&lt;/span&gt;es&#x2019;&lt;span style="letter-spacing:0.9pt;"&gt; &lt;/span&gt;exercise&lt;span style="letter-spacing:0.7pt;"&gt; &lt;/span&gt;behavior,&lt;span style="letter-spacing:0.75pt;"&gt; &lt;/span&gt;and&lt;span style="letter-spacing:0.35pt;"&gt; &lt;/span&gt;for&lt;span style="letter-spacing:0.3pt;"&gt; &lt;/span&gt;non-employees,&lt;span style="letter-spacing:1.35pt;"&gt; &lt;/span&gt;and directors&lt;span style="letter-spacing:0.7pt;"&gt; &lt;/span&gt;using&lt;span style="letter-spacing:0.45pt;"&gt; &lt;/span&gt;the&lt;span style="letter-spacing:0.05pt;"&gt; &lt;/span&gt;contractual&lt;span style="letter-spacing:0.9pt;"&gt; &lt;/span&gt;term.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In March 2017, the Board adopted the 2017 Equity Incentive Plan (the "2017 Plan"), which was approved by the shareholders in April 2017. The 2017 Plan provides for the grant of incentive stock options to the Company's employees and for the grant of &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;nonstatutory stock options, stock appreciation rights, restricted stock awards, &lt;/span&gt;&lt;span style="font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;RSU&lt;/span&gt;&lt;span style="font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; awards, performance &lt;/span&gt;&lt;span style="font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;share &lt;/span&gt;&lt;span style="font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;awards, performance cash awards, and other forms of &lt;/span&gt;&lt;span style="font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;share &lt;/span&gt;&lt;span style="font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;awards to the Company's employees, directors and consultants.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The maximum number of ordinary shares that may initially be issued under the 2017 Plan is 1,400,000. In addition, the number of ordinary shares reserved for issuance under the 2017 Plan will automatically increase on January 1st of each calendar year, from January 1, 2018 through January 1, 2026, so that the number of such shares reserved for issuance will equal 12% of the total number of ordinary shares outstanding on the last day of the calendar month prior to the date of each automatic increase, or a lesser number of shares determined by the Board. The maximum number of ordinary shares that may be issued upon the exercise of stock options under the 2017 Plan is 5,600,000. On January 1, 2018, the share reserve increased by 250,167 to 1,650,167. On October 12, 2018, the Company increased the amount of registered ordinary shares of the Company&#x2019;s 2017 Plan by 1,900,000 to 3,550,167. On June 8, 2020 the Company increased the amount of registered ordinary shares of the Company&#x2019;s 2017 Plan by 400,000 to 3,950,167. On March 17, 2021, the Board approved an increase to the amount of registered ordinary shares of the Company&#x2019;s 2017 Plan by 400,000 to 4,350,167, subject to approval by the Company&#x2019;s shareholders.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In May 2019, the Company adopted the UroGen Pharma Ltd. 2019 Inducement Plan (the &#x201c;Inducement Plan&#x201d;). Under the Inducement Plan, the Company is authorized to issue up to 900,000 ordinary shares pursuant to awards issued under the Inducement Plan. &lt;span style="Background-color:#FFFFFF;color:#000000;"&gt;The only persons eligible to receive grants of Awards (as defined below) under the Inducement Plan are individuals who satisfy the standards for inducement grants under Nasdaq Marketplace Rule 5635(c)(4) or 5635(c)(3) and the related guidance under Nasdaq IM&#160;5635-1,&#160;including individuals who were not previously an employee or director of the Company or are following a bona fide period of&#160;non-employment,&#160;in each case as an inducement material to such individual&#x2019;s agreement to enter into employment with the Company.&#160;Under the Inducement Plan, an &#x201c;Award&#x201d; is a nonstatutory stock option, restricted stock unit or other right to receive ordinary shares pursuant to the Inducement Plan.&lt;/span&gt; &#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The&lt;span style="letter-spacing:0.35pt;"&gt; &lt;/span&gt;following&lt;span style="letter-spacing:0.7pt;"&gt; &lt;/span&gt;table&lt;span style="letter-spacing:0.4pt;"&gt; &lt;/span&gt;illustrates&lt;span style="letter-spacing:0.75pt;"&gt; &lt;/span&gt;the&lt;span style="letter-spacing:0.3pt;"&gt; &lt;/span&gt;effect&lt;span style="letter-spacing:0.45pt;"&gt; &lt;/span&gt;of&lt;span style="letter-spacing:0.2pt;"&gt; &lt;/span&gt;share-based&lt;span style="letter-spacing:1pt;"&gt; &lt;/span&gt;com&lt;span style="letter-spacing:-0.1pt;"&gt;p&lt;/span&gt;ensation&lt;span style="letter-spacing:1.1pt;"&gt; &lt;/span&gt;on&lt;span style="letter-spacing:0.25pt;"&gt; &lt;/span&gt;the&lt;span style="letter-spacing:0.3pt;"&gt; condensed consolidated &lt;/span&gt;statements&lt;span style="letter-spacing:0.9pt;"&gt; &lt;/span&gt;of&lt;span style="letter-spacing:0.2pt;"&gt; &lt;/span&gt;operations (in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.54%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Three Months Ended March&#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research and development expenses&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,107&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,943&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Selling, general and administrative expenses&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,088&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,674&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,195&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7,617&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The total unrecognized compensation cost of options and RSUs at March&#160;31, 2021 is&#160;$33.6 million with a weighted average recognition period of 1.86 years. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;"&gt;&#160;&lt;/p&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="C_0001668243_srtRangeAxis_srtMaximumMember_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapStatementEquityComponentsAxis_urgnPlanMember_20210101_20210331"
      id="F_000403">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent
      contextRef="C_0001668243_srtRangeAxis_srtMinimumMember_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapStatementEquityComponentsAxis_urgnPlanMember_20210101_20210331"
      decimals="2"
      id="F_000404"
      unitRef="U_xbrlipure">1</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="C_0001668243_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapStatementEquityComponentsAxis_urgnPlanMember_20210101_20210331"
      id="F_000405">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <urgn:ShareBasedCompensationArrangementByShareBasedPaymentAwardIndividualVotingPowersPercentage
      contextRef="C_0001668243_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapStatementEquityComponentsAxis_urgnPlanMember_20210101_20210331"
      decimals="2"
      id="F_000406"
      unitRef="U_xbrlipure">0.10</urgn:ShareBasedCompensationArrangementByShareBasedPaymentAwardIndividualVotingPowersPercentage>
    <urgn:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfPurchasePriceForIndividualsHavingMoreThanTenPercentOfCombinedVotingPower
      contextRef="C_0001668243_srtRangeAxis_srtMinimumMember_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapStatementEquityComponentsAxis_urgnPlanMember_20210101_20210331"
      decimals="2"
      id="F_000407"
      unitRef="U_xbrlipure">1.10</urgn:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfPurchasePriceForIndividualsHavingMoreThanTenPercentOfCombinedVotingPower>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="C_0001668243_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_us-gaapVestingAxis_us-gaapShareBasedCompensationAwardTrancheOneMember_20210101_20210331"
      decimals="2"
      id="F_000408"
      unitRef="U_xbrlipure">0.33</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="C_0001668243_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20210101_20210331"
      id="F_000409">P2Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="C_0001668243_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapVestingAxis_us-gaapShareBasedCompensationAwardTrancheOneMember_20210101_20210331"
      decimals="2"
      id="F_000410"
      unitRef="U_xbrlipure">0.33</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionSharesApprovedForIssuance
      contextRef="C_0001668243_us-gaapAwardTypeAxis_urgnTwoThousandSeventeenEquityIncentivePlanMember_20170301_20170331"
      decimals="INF"
      id="F_000411"
      unitRef="U_xbrlishares">1400000</us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionSharesApprovedForIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum
      contextRef="C_0001668243_us-gaapAwardTypeAxis_urgnTwoThousandSeventeenEquityIncentivePlanMember_20210101_20210331"
      decimals="INF"
      id="F_000412"
      unitRef="U_xbrlipure">0.12</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum>
    <us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionSharesApprovedForIssuance
      contextRef="C_0001668243_us-gaapAwardTypeAxis_urgnTwoThousandSeventeenEquityIncentivePlanMember_20210101_20210331"
      decimals="INF"
      id="F_000413"
      unitRef="U_xbrlishares">5600000</us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionSharesApprovedForIssuance>
    <urgn:ShareBasedGoodsAndNonEmployeeServicesTransactionSharesReserveIncreaseForIssuance
      contextRef="C_0001668243_us-gaapAwardTypeAxis_urgnTwoThousandSeventeenEquityIncentivePlanMember_20180101_20180101"
      decimals="INF"
      id="F_000414"
      unitRef="U_xbrlishares">250167</urgn:ShareBasedGoodsAndNonEmployeeServicesTransactionSharesReserveIncreaseForIssuance>
    <us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionSharesApprovedForIssuance
      contextRef="C_0001668243_us-gaapAwardTypeAxis_urgnTwoThousandSeventeenEquityIncentivePlanMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20180101_20180101"
      decimals="INF"
      id="F_000417"
      unitRef="U_xbrlishares">1650167</us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionSharesApprovedForIssuance>
    <urgn:ShareBasedGoodsAndNonEmployeeServicesTransactionSharesReserveIncreaseForIssuance
      contextRef="C_0001668243_us-gaapAwardTypeAxis_urgnTwoThousandSeventeenEquityIncentivePlanMember_20181012_20181012"
      decimals="INF"
      id="F_000415"
      unitRef="U_xbrlishares">1900000</urgn:ShareBasedGoodsAndNonEmployeeServicesTransactionSharesReserveIncreaseForIssuance>
    <us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionSharesApprovedForIssuance
      contextRef="C_0001668243_us-gaapAwardTypeAxis_urgnTwoThousandSeventeenEquityIncentivePlanMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20181012_20181012"
      decimals="INF"
      id="F_000418"
      unitRef="U_xbrlishares">3550167</us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionSharesApprovedForIssuance>
    <urgn:ShareBasedGoodsAndNonEmployeeServicesTransactionSharesReserveIncreaseForIssuance
      contextRef="C_0001668243_us-gaapAwardTypeAxis_urgnTwoThousandSeventeenEquityIncentivePlanMember_20200608_20200608"
      decimals="INF"
      id="F_000416"
      unitRef="U_xbrlishares">400000</urgn:ShareBasedGoodsAndNonEmployeeServicesTransactionSharesReserveIncreaseForIssuance>
    <us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionSharesApprovedForIssuance
      contextRef="C_0001668243_us-gaapAwardTypeAxis_urgnTwoThousandSeventeenEquityIncentivePlanMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200608_20200608"
      decimals="INF"
      id="F_000419"
      unitRef="U_xbrlishares">3950167</us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionSharesApprovedForIssuance>
    <urgn:ShareBasedGoodsAndNonEmployeeServicesTransactionSharesReserveIncreaseForIssuance
      contextRef="C_0001668243_us-gaapAwardTypeAxis_urgnTwoThousandSeventeenEquityIncentivePlanMember_20210317_20210317"
      decimals="INF"
      id="F_000420"
      unitRef="U_xbrlishares">400000</urgn:ShareBasedGoodsAndNonEmployeeServicesTransactionSharesReserveIncreaseForIssuance>
    <us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionSharesApprovedForIssuance
      contextRef="C_0001668243_us-gaapAwardTypeAxis_urgnTwoThousandSeventeenEquityIncentivePlanMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210317_20210317"
      decimals="INF"
      id="F_000421"
      unitRef="U_xbrlishares">4350167</us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionSharesApprovedForIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="C_0001668243_us-gaapPlanNameAxis_urgnTwoThousandAndNineteenInducementPlanMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20190531"
      decimals="INF"
      id="F_000422"
      unitRef="U_xbrlishares">900000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock contextRef="C_0001668243_20210101_20210331" id="F_000245">
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The&lt;span style="letter-spacing:0.35pt;"&gt; &lt;/span&gt;following&lt;span style="letter-spacing:0.7pt;"&gt; &lt;/span&gt;table&lt;span style="letter-spacing:0.4pt;"&gt; &lt;/span&gt;illustrates&lt;span style="letter-spacing:0.75pt;"&gt; &lt;/span&gt;the&lt;span style="letter-spacing:0.3pt;"&gt; &lt;/span&gt;effect&lt;span style="letter-spacing:0.45pt;"&gt; &lt;/span&gt;of&lt;span style="letter-spacing:0.2pt;"&gt; &lt;/span&gt;share-based&lt;span style="letter-spacing:1pt;"&gt; &lt;/span&gt;com&lt;span style="letter-spacing:-0.1pt;"&gt;p&lt;/span&gt;ensation&lt;span style="letter-spacing:1.1pt;"&gt; &lt;/span&gt;on&lt;span style="letter-spacing:0.25pt;"&gt; &lt;/span&gt;the&lt;span style="letter-spacing:0.3pt;"&gt; condensed consolidated &lt;/span&gt;statements&lt;span style="letter-spacing:0.9pt;"&gt; &lt;/span&gt;of&lt;span style="letter-spacing:0.2pt;"&gt; &lt;/span&gt;operations (in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.54%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Three Months Ended March&#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research and development expenses&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,107&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,943&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Selling, general and administrative expenses&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,088&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,674&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,195&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7,617&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_0001668243_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20210101_20210331"
      decimals="-3"
      id="F_000423"
      unitRef="U_iso4217USD">1107000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_0001668243_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20200101_20200331"
      decimals="-3"
      id="F_000424"
      unitRef="U_iso4217USD">1943000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_0001668243_us-gaapIncomeStatementLocationAxis_us-gaapSellingGeneralAndAdministrativeExpensesMember_20210101_20210331"
      decimals="-3"
      id="F_000425"
      unitRef="U_iso4217USD">5088000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_0001668243_us-gaapIncomeStatementLocationAxis_us-gaapSellingGeneralAndAdministrativeExpensesMember_20200101_20200331"
      decimals="-3"
      id="F_000426"
      unitRef="U_iso4217USD">5674000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_0001668243_20210101_20210331"
      decimals="-3"
      id="F_000427"
      unitRef="U_iso4217USD">6195000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_0001668243_20200101_20200331"
      decimals="-3"
      id="F_000428"
      unitRef="U_iso4217USD">7617000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="C_0001668243_20210331"
      decimals="-5"
      id="F_000429"
      unitRef="U_iso4217USD">33600000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="C_0001668243_20210101_20210331" id="F_000430">P1Y10M9D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="C_0001668243_20210101_20210331" id="F_000212">
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Note 14 &#x2013; Income Taxes &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;UroGen Pharma Ltd.&lt;span style="letter-spacing:0.8pt;"&gt; &lt;/span&gt;is&lt;span style="letter-spacing:0.15pt;"&gt; &lt;/span&gt;taxed&lt;span style="letter-spacing:0.45pt;"&gt; &lt;/span&gt;under&lt;span style="letter-spacing:0.5pt;"&gt; &lt;/span&gt;Israeli&lt;span style="letter-spacing:0.5pt;"&gt; &lt;/span&gt;tax&lt;span style="letter-spacing:0.3pt;"&gt; &lt;/span&gt;laws. As of March&#160;31, 2021, the Company continues to maintain a full valuation allowance against deferred tax assets for all jurisdictions. In evaluating the need for a valuation allowance, the Company considers all sources of taxable income available to realize the deferred tax asset, including the future reversal of existing temporary differences, forecasts of future taxable income, and tax planning strategies. The Company has cumulative global pretax accounting losses for the years ended 2020, 2019 and 2018, and for the three months ended March&#160;31, 2021. The Company will continue to assess the extent to which its deferred tax assets may be realized in the future and will adjust the valuation allowance as needed.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company has a liability for uncertain tax positions of $2.7 million as of March 31, 2021 for tax positions relating to transfer pricing between affiliated entities. The Company recognizes interest accrued and penalties related to uncertain tax positions as a component of income tax expense. As of March 31, 2021, the Company&#x2019;s liability for uncertain tax positions includes  $0.7 million of interest and penalties accrued during 2020.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company operates on a global basis and is subject to tax laws and regulations in the U.S. and Israel. The estimate of the Company&#x2019;s tax liabilities relating to uncertain tax positions requires management to assess uncertainties and to make judgments about the application of complex tax laws and regulations, expectations regarding the outcome of tax authority examinations, as well as the ultimate measurement of potential liabilities. &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The uncertain tax positions are reviewed quarterly and adjusted as events occur that could affect potential liabilities for additional taxes, including lapsing of applicable statutes of limitations, correspondence with tax authorities, proposed assessments by tax authorities, identification of new issues, and issuance of new legislation or regulations. &lt;/span&gt;&lt;span style="font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company believes that adequate amounts of tax have been provided in income tax expense for any adjustments that may result from its uncertain tax positions. Based upon the information currently available, the Company does not reasonably expect changes in its existing uncertain tax positions in the next 12 months and have recorded the gross uncertain tax positions as a long-term liability.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;"&gt;&#160;&lt;/p&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="C_0001668243_20210331"
      decimals="-5"
      id="F_000431"
      unitRef="U_iso4217USD">2700000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
      contextRef="C_0001668243_20210331"
      decimals="-5"
      id="F_000432"
      unitRef="U_iso4217USD">700000</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="C_0001668243_20210101_20210331" id="F_000213">
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Note 15 &#x2013; Related Parties&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;There were no related party transactions for the three months ended March&#160;31, 2021 or the three months ended March&#160;31, 2020. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:12pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="C_0001668243_20210101_20210331" id="F_000214">
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Note 16 &#x2013; Commitments and Contingencies &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In the normal course of business, the Company enters into contracts that contain a variety of indemnifications with its employees, licensors, suppliers and service providers. Further, the Company indemnifies its directors and officers who are, or were, serving at the Company&lt;span style="color:#000000;"&gt;&#x2019;&lt;/span&gt;s request in such capacities. The Company&lt;span style="color:#000000;"&gt;&#x2019;&lt;/span&gt;s maximum exposure under these arrangements is unknown as of March&#160;31, 2021 and December&#160;31, 2020. The Company does not anticipate recognizing any significant losses relating to these arrangements.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Calibri;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Grants from the Israeli Innovation Authority in Israel (&#x201c;IIA&#x201d;)&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company has received grants from the IIA for research and development funding. Up until 2007, the IIA participation in the funding of the Company&#x2019;s operations was by grants provided to Granot Ventures, a government supported technology incubator, as part of the Israeli Ministry of Industry and Commerce Director General Directive 8.2. Since 2008, the funding was provided directly to Company.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On January 12, 2020, the IIA Office of Chief Scientist approved the Company's request to unwind its obligation to the IIA regarding grants that were loaned to the Company between January 2004 and September 2016. The total payment under the IIA approval, net of the royalties already paid, $6.6 million, was fully paid during the first quarter of 2020 and recognized as research and development expense. Based on this payment, the Company will have full freedom to transfer IIA-funded technology or manufacture products developed with IIA-funded technology outside of the State of Israel. Other than the commitment to continue at least 75% of its based R&amp;amp;D jobs in Israel (at the time of settlement) for a period of at least three years, all other obligations with the IIA ceased to exist as per the agreement.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Calibri;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Separation Agreement&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On March 20, 2020, the Company entered into a Separation Agreement with Stephen Mullennix, the Company&#x2019;s Chief Operating Officer, which sets forth the terms of Mr. Mullennix&#x2019;s termination of employment with the Company, effective as of April 30, 2020, or Separation Date. The arrangement includes cash severance, as well as a pro rata portion of the target annual bonus for calendar year 2020, contingent on certain performance conditions. The Company accrued $0.4 million during the quarter ended March 31, 2020 in relation to this arrangement.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On September 7, 2020, the Company entered into a Separation Agreement with Peter Pfreundschuh, the Company&#x2019;s Chief Financial Officer, which sets forth the terms of Mr. Pfreundschuh&#x2019;s termination of employment with the Company, effective as of October 15, 2020. The arrangement includes cash severance, a pro rata portion of the target annual bonus for calendar year 2020 contingent on certain performance conditions, and partial acceleration of share-based compensation. The Company recognized $0.7 million during the year ended December 31, 2020 in relation to this arrangement, which was paid during March and April 2021.&lt;span style="font-family:Times New Roman;"&gt;&#160;&#160;&#160;&#160; &lt;/span&gt;&#160;&#160;&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Calibri;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Leases&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;See N&lt;/span&gt;&lt;span style="font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;ote &lt;/span&gt;&lt;span style="font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9&lt;/span&gt;&lt;span style="font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; for further discussion regarding lease commitments.&lt;/span&gt;&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:AccruedRoyaltiesCurrentAndNoncurrent
      contextRef="C_0001668243_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_urgnIsraelInnovationAuthorityMember_20200331"
      decimals="-5"
      id="F_000433"
      unitRef="U_iso4217USD">6600000</us-gaap:AccruedRoyaltiesCurrentAndNoncurrent>
    <urgn:MaximumPercentageOfCommitmentToContinueEmploymentOfResearchAndDevelopmentJobs
      contextRef="C_0001668243_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_urgnIsraelInnovationAuthorityMember_20210101_20210331"
      decimals="2"
      id="F_000434"
      unitRef="U_xbrlipure">0.75</urgn:MaximumPercentageOfCommitmentToContinueEmploymentOfResearchAndDevelopmentJobs>
    <urgn:MaximumTermForCommitmentToContinueEmploymentOfResearchAndDevelopmentJobs
      contextRef="C_0001668243_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_urgnIsraelInnovationAuthorityMember_20210101_20210331"
      id="F_000435">P3Y</urgn:MaximumTermForCommitmentToContinueEmploymentOfResearchAndDevelopmentJobs>
    <us-gaap:AccruedBonusesCurrentAndNoncurrent
      contextRef="C_0001668243_srtTitleOfIndividualAxis_srtChiefOperatingOfficerMember_20200331"
      decimals="-5"
      id="F_000436"
      unitRef="U_iso4217USD">400000</us-gaap:AccruedBonusesCurrentAndNoncurrent>
    <us-gaap:SeveranceCosts1
      contextRef="C_0001668243_srtTitleOfIndividualAxis_srtChiefFinancialOfficerMember_20200101_20201231"
      decimals="-5"
      id="F_000437"
      unitRef="U_iso4217USD">700000</us-gaap:SeveranceCosts1>
    <us-gaap:SubsequentEventsTextBlock contextRef="C_0001668243_20210101_20210331" id="F_000215">
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Note 17 &#x2013; Subsequent Events&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In March 2021, the Company announced a transaction with RTW Investments (&#x201c;RTW&#x201d;) totaling $75.0 million in funding for the Company to support the launch of Jelmyto and the development of UGN-102. RTW will provide the Company with an upfront cash payment of $75.0 million and will receive tiered future payments based on global annual net product sales of Jelmyto and UGN-102, if approved. The Company received the $75.0 million of cash, net of costs in May 2021 following the receipt of necessary regulatory approvals, and recognized an associated long term liability.&#160;&#160;&lt;/p&gt;</us-gaap:SubsequentEventsTextBlock>
    <urgn:UpfrontFee
      contextRef="C_0001668243_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_urgnRTWInvestmentsMember_20210101_20210331"
      decimals="-5"
      id="F_000438"
      unitRef="U_iso4217USD">75000000.0</urgn:UpfrontFee>
    <urgn:UpfrontCashPaymentReceivedNetOfCosts
      contextRef="C_0001668243_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_urgnRTWInvestmentsMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20210513_20210513"
      decimals="-5"
      id="F_000439"
      unitRef="U_iso4217USD">75000000.0</urgn:UpfrontCashPaymentReceivedNetOfCosts>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140482550918872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2021 </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar. 31,  2021<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2021<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">URGN<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Ordinary Shares, par value NIS 0.01 per share<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">UROGEN PHARMA LTD.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001668243<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Ordinary Shares Outstanding</a></td>
<td class="nump">22,280,394<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-38079<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">L3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">98-1460746<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">400 Alexander Park Drive<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Princeton<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">NJ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">08540<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">646<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text"> 768-9780<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140482549160792">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Parenthetical) (unaudited) - &#8362; / shares<br></strong></div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement Of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Ordinary shares, par value</a></td>
<td class="nump">&#8362; 0.01<span></span>
</td>
<td class="nump">&#8362; 0.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Ordinary shares, shares authorized</a></td>
<td class="nump">100,000,000<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Ordinary shares, issued</a></td>
<td class="nump">22,280,394<span></span>
</td>
<td class="nump">22,167,791<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ordinary shares, outstanding</a></td>
<td class="nump">22,280,394<span></span>
</td>
<td class="nump">22,167,791<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140482551268152">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 40,492<span></span>
</td>
<td class="nump">$ 52,864<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Marketable securities</a></td>
<td class="nump">35,417<span></span>
</td>
<td class="nump">49,154<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashCurrent', window );">Restricted cash</a></td>
<td class="nump">1,225<span></span>
</td>
<td class="nump">1,226<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="nump">6,301<span></span>
</td>
<td class="nump">7,047<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory</a></td>
<td class="nump">3,331<span></span>
</td>
<td class="nump">1,964<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">6,316<span></span>
</td>
<td class="nump">3,364<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">93,082<span></span>
</td>
<td class="nump">115,619<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsNoncurrentAbstract', window );"><strong>Non-current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">2,142<span></span>
</td>
<td class="nump">2,046<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedInvestmentsNoncurrent', window );">Restricted deposit</a></td>
<td class="nump">223<span></span>
</td>
<td class="nump">223<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right of use asset</a></td>
<td class="nump">1,901<span></span>
</td>
<td class="nump">2,158<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,893<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other non-current assets</a></td>
<td class="nump">66<span></span>
</td>
<td class="nump">66<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total Assets</a></td>
<td class="nump">97,414<span></span>
</td>
<td class="nump">122,005<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Accounts payable and accrued expenses</a></td>
<td class="nump">10,558<span></span>
</td>
<td class="nump">10,023<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Employee related accrued expenses</a></td>
<td class="nump">4,712<span></span>
</td>
<td class="nump">9,554<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="nump">1,735<span></span>
</td>
<td class="nump">1,859<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities:</a></td>
<td class="nump">17,005<span></span>
</td>
<td class="nump">21,436<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>Non-current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Long-term lease liability</a></td>
<td class="nump">1,201<span></span>
</td>
<td class="nump">1,497<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilityForUncertainTaxPositionsNoncurrent', window );">Uncertain tax positions liability</a></td>
<td class="nump">2,717<span></span>
</td>
<td class="nump">2,717<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total Liabilities</a></td>
<td class="nump">20,923<span></span>
</td>
<td class="nump">25,650<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 14)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Shareholders' equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Ordinary shares, NIS 0.01 par value; 100,000,000 shares authorized at March 31, 2021 and December 31, 2020; 22,280,394 and 22,167,791 shares issued and outstanding as of March 31, 2021 and December 31, 2020, respectively</a></td>
<td class="nump">61<span></span>
</td>
<td class="nump">60<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">458,723<span></span>
</td>
<td class="nump">452,525<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(382,436)<span></span>
</td>
<td class="num">(356,501)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income</a></td>
<td class="nump">143<span></span>
</td>
<td class="nump">271<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total Shareholders' Equity</a></td>
<td class="nump">76,491<span></span>
</td>
<td class="nump">96,355<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total Liabilities and Shareholders' Equity</a></td>
<td class="nump">$ 97,414<span></span>
</td>
<td class="nump">$ 122,005<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121593590&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121593590&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121558606&amp;loc=SL82898722-210454<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121558606&amp;loc=SL82898722-210454<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForUncertainTaxPositionsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount recognized for uncertainty in income taxes classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityForUncertainTaxPositionsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6904-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedInvestmentsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents the noncurrent portion of investments which are not defined as or included in marketable (debt, equity, or other) securities that are pledged or subject to withdrawal restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedInvestmentsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140482554614632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Operations and Comprehensive Loss (unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">$ 7,485<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfRevenue', window );">Cost of revenues</a></td>
<td class="nump">897<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross profit</a></td>
<td class="nump">6,588<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expenses</a></td>
<td class="nump">10,513<span></span>
</td>
<td class="nump">$ 16,588<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative expenses</a></td>
<td class="nump">22,189<span></span>
</td>
<td class="nump">21,973<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating loss</a></td>
<td class="num">(26,114)<span></span>
</td>
<td class="num">(38,561)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_urgn_InterestAndOtherIncomeExpensesNet', window );">Interest and other income, net</a></td>
<td class="nump">179<span></span>
</td>
<td class="nump">768<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Loss</a></td>
<td class="num">(25,935)<span></span>
</td>
<td class="num">(37,793)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxAbstract', window );"><strong>Statements of Comprehensive Loss</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(25,935)<span></span>
</td>
<td class="num">(37,793)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract', window );"><strong>Other comprehensive income</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized (loss) gain on marketable securities</a></td>
<td class="num">(128)<span></span>
</td>
<td class="nump">35<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive Loss</a></td>
<td class="num">$ (26,063)<span></span>
</td>
<td class="num">$ (37,758)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Net loss per ordinary share basic and diluted</a></td>
<td class="num">$ (1.17)<span></span>
</td>
<td class="num">$ (1.79)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted average number of shares outstanding used in computation of basic and diluted loss per ordinary share</a></td>
<td class="nump">22,242,375<span></span>
</td>
<td class="nump">21,158,161<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_urgn_InterestAndOtherIncomeExpensesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Interest and other Income (expenses) net.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">urgn_InterestAndOtherIncomeExpensesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>urgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate cost of goods produced and sold and services rendered during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrossProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1,2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrossProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140482551217432">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Shareholders' Equity (unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Ordinary Shares</div></th>
<th class="th"><div>Additional Paid-In Capital</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th"><div>Other Comprehensive Income</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2019</a></td>
<td class="nump">$ 180,302<span></span>
</td>
<td class="nump">$ 57<span></span>
</td>
<td class="nump">$ 407,986<span></span>
</td>
<td class="num">$ (228,017)<span></span>
</td>
<td class="nump">$ 276<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance,Share at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,026,184<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of options into ordinary shares</a></td>
<td class="nump">293<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">292<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of options into ordinary shares, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">186,756<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation</a></td>
<td class="nump">7,617<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,617<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss)</a></td>
<td class="nump">35<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(37,793)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(37,793)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Mar. 31, 2020</a></td>
<td class="nump">150,454<span></span>
</td>
<td class="nump">$ 58<span></span>
</td>
<td class="nump">415,895<span></span>
</td>
<td class="num">(265,810)<span></span>
</td>
<td class="nump">311<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance,Share at Mar. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,212,940<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2020</a></td>
<td class="nump">96,355<span></span>
</td>
<td class="nump">$ 60<span></span>
</td>
<td class="nump">452,525<span></span>
</td>
<td class="num">(356,501)<span></span>
</td>
<td class="nump">271<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance,Share at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,167,791<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of options into ordinary shares</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of options into ordinary shares, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">112,603<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation</a></td>
<td class="nump">6,195<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,195<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss)</a></td>
<td class="num">(128)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(128)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(25,935)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(25,935)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Mar. 31, 2021</a></td>
<td class="nump">$ 76,491<span></span>
</td>
<td class="nump">$ 61<span></span>
</td>
<td class="nump">$ 458,723<span></span>
</td>
<td class="num">$ (382,436)<span></span>
</td>
<td class="nump">$ 143<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance,Share at Mar. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,280,394<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=120383193&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=120383193&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326096&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=121640130&amp;loc=d3e1436-108581<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140482551262264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Cash Flow (Unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash Flows From Operating Activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (25,935)<span></span>
</td>
<td class="num">$ (37,793)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustment to reconcile net loss to net cash from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">191<span></span>
</td>
<td class="nump">82<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments', window );">Amortization on marketable securities</a></td>
<td class="nump">191<span></span>
</td>
<td class="nump">98<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">6,195<span></span>
</td>
<td class="nump">7,617<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_urgn_OperatingLeaseRightOfUseAssetAmortization', window );">Amortization of right of use asset</a></td>
<td class="nump">237<span></span>
</td>
<td class="nump">374<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_urgn_OperatingLeaseLiabilityAdjustments', window );">Lease liability</a></td>
<td class="num">(400)<span></span>
</td>
<td class="num">(361)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventory</a></td>
<td class="num">(1,367)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="nump">746<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="num">(2,952)<span></span>
</td>
<td class="num">(518)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable and accrued expenses</a></td>
<td class="nump">535<span></span>
</td>
<td class="num">(2,498)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities', window );">Employee related accrued expenses</a></td>
<td class="num">(4,842)<span></span>
</td>
<td class="num">(2,636)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(27,401)<span></span>
</td>
<td class="num">(35,635)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash Flows From Investing Activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireMarketableSecurities', window );">Purchase of marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(9,378)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities', window );">Maturities of marketable securities</a></td>
<td class="nump">15,311<span></span>
</td>
<td class="nump">22,499<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(287)<span></span>
</td>
<td class="num">(96)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by investing activities</a></td>
<td class="nump">15,024<span></span>
</td>
<td class="nump">13,025<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash Flows From Financing Activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercise of options into ordinary shares</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">293<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Issuance cost related to at-the-market issuances</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(203)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">90<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Decrease in Cash and Cash Equivalents</a></td>
<td class="num">(12,373)<span></span>
</td>
<td class="num">(22,520)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash, Cash Equivalents and Restricted Cash at Beginning of Period</a></td>
<td class="nump">54,090<span></span>
</td>
<td class="nump">50,211<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash, Cash Equivalents and Restricted Cash at End of Period</a></td>
<td class="nump">41,717<span></span>
</td>
<td class="nump">27,691<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Supplemental Disclosures of Non-Cash Activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_urgn_NonCashNewLeaseLiabilities', window );">Non-cash new lease liabilities</a></td>
<td class="num">$ (20)<span></span>
</td>
<td class="nump">$ 72<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_urgn_NonCashNewLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Non-cash new lease liabilities</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">urgn_NonCashNewLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>urgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_urgn_OperatingLeaseLiabilityAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating lease liability, adjustments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">urgn_OperatingLeaseLiabilityAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>urgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_urgn_OperatingLeaseRightOfUseAssetAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating lease, right-of-use asset, amortization.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">urgn_OperatingLeaseRightOfUseAssetAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>urgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for purchase of marketable security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities  (held-to-maturity or available-for-sale) during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140482547278008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business and Nature of Operations<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization Consolidation And Presentation Of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NatureOfOperations', window );">Business and Nature of Operations</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Note 1 &#8211; Business and Nature of Operations</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Calibri;font-size:10pt;text-transform:none;font-variant: normal;">Nature of Operations</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">UroGen<span style="letter-spacing:0.65pt;"> </span>Pharma<span style="letter-spacing:0.65pt;"> </span>Ltd.<span style="letter-spacing:0.4pt;"> </span>is<span style="letter-spacing:0.15pt;"> </span>an<span style="letter-spacing:0.25pt;"> </span>Israeli<span style="letter-spacing:0.5pt;"> </span>company<span style="letter-spacing:0.75pt;"> </span>incorporated<span style="letter-spacing:1pt;"> </span>in<span style="letter-spacing:0.2pt;"> </span>April<span style="letter-spacing:0.4pt;"> </span>20<span style="letter-spacing:-0.1pt;">0</span>4<span style="letter-spacing:0.45pt;"> </span>(&#8220;UPL&#8221;). </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">UroGen<span style="letter-spacing:0.65pt;"> </span>Pharma<span style="letter-spacing:0.65pt;"> </span>Inc.,<span style="letter-spacing:0.35pt;"> </span>a<span style="letter-spacing:0.15pt;"> wholly owned </span>subsidiary<span style="letter-spacing:0.8pt;"> </span>of<span style="letter-spacing:0.2pt;"> </span>UPL,<span style="letter-spacing:0.45pt;"> </span>was<span style="letter-spacing:0.35pt;"> </span>incorporated<span style="letter-spacing:1pt;"> </span>in<span style="letter-spacing:0.2pt;"> </span>Del<span style="letter-spacing:-0.1pt;">a</span>ware<span style="letter-spacing:0.75pt;"> </span>in<span style="letter-spacing:0.2pt;"> </span>October<span style="letter-spacing:0.65pt;"> </span>2015<span style="letter-spacing:0.45pt;"> </span>and<span style="letter-spacing:0.35pt;"> </span>began<span style="letter-spacing:0.5pt;"> </span>operati<span style="letter-spacing:-0.1pt;">n</span>g<span style="letter-spacing:0.75pt;"> </span>in<span style="letter-spacing:0.2pt;"> </span>February<span style="letter-spacing:0.75pt;"> </span>2016<span style="letter-spacing:0.45pt;"> </span>(&#8220;UPI&#8221;). </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">UPL<span style="letter-spacing:0.4pt;"> </span>and<span style="letter-spacing:0.35pt;"> </span>UPI<span style="letter-spacing:0.35pt;"> </span>(together<span style="letter-spacing:0.75pt;"> </span>the<span style="letter-spacing:0.3pt;"> </span>&#8220;Company&#8221;)<span style="letter-spacing:0.95pt;"> </span>is<span style="letter-spacing:0.15pt;"> </span>a<span style="letter-spacing:0.45pt;"> </span>bi<span style="letter-spacing:-0.1pt;">o</span>pharmaceutical<span style="letter-spacing:1.45pt;"> </span>company<span style="letter-spacing:0.75pt;"> </span>focused<span style="letter-spacing:0.65pt;"> </span>on<span style="letter-spacing:0.25pt;"> </span>deve<span style="letter-spacing:-0.1pt;">l</span>oping and commercializing<span style="letter-spacing:0.85pt;"> </span>novel<span style="letter-spacing:0.45pt;"> </span>therapies<span style="letter-spacing:0.75pt;"> </span>desi<span style="letter-spacing:-0.1pt;">g</span>ned<span style="letter-spacing:0.75pt;"> </span>to change<span style="letter-spacing:0.65pt;"> </span>the<span style="letter-spacing:0.3pt;"> </span>standard<span style="letter-spacing:0.7pt;"> </span>of<span style="letter-spacing:0.2pt;"> </span>care<span style="letter-spacing:0.4pt;"> </span>for<span style="letter-spacing:0.25pt;"> </span>urological<span style="letter-spacing:0.8pt;"> </span>pathologies. Since commencing operations, the Company has devoted substantially all of its efforts to securing intellectual property rights, performing research and development activities, including conducting clinical trials and manufacturing activities, hiring personnel, launching the Company&#8217;s first commercial product, <span style="font-style:italic;">Jelmyto</span> (mitomycin) for pyelocalyceal solution, formerly known as UGN-101, and its product candidate UGN-102, and raising capital to support and expand these activities. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On April 15, 2020, the U.S. Food and Drug Administration (&#8220;FDA&#8221;) granted expedited approval for <span style="font-style:italic;">Jelmyto</span>, a first-in-class treatment indicated for adults with low-grade upper tract urothelial cancer (&#8220;low grade-UTUC&#8221;). <span style="font-style:italic;">Jelmyto</span> consists of mitomycin, an established chemotherapy, and sterile hydrogel, using our proprietary sustained release <span style="font-style:italic;">RTGel</span> technology. It has been designed to enable longer exposure of urinary tract tissue to mitomycin, thereby enabling the treatment of tumors by non-surgical means.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:6pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI http://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140482545962184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization Consolidation And Presentation Of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccounting', window );">Basis of Presentation</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Note 2 &#8211; Basis of Presentation</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (&#8220;GAAP&#8221;) for interim financial information and in accordance with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all the information and footnotes required by GAAP for complete financial statements. In the opinion of the Company&#8217;s management, the accompanying condensed consolidated financial statements contain all adjustments (consisting of normal recurring accruals and adjustments) necessary for fair statement of its financial position, results of operations and cash flows of the Company at the dates and for the periods indicated. Interim results are not necessarily indicative of results for the full fiscal year. The year-end condensed consolidated balance sheet data was derived from audited financial statements but does not include all disclosures required by accounting principles generally accepted in the United States. The unaudited condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and the notes thereto contained in the Company&#8217;s Annual Report on Form 10-K for the year ended December&#160;31, 2020, as filed with the Securities and Exchange Commission (&#8220;SEC&#8221;) on March 18, 2021.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The consolidated financial statements include the accounts of UPL and its wholly owned subsidiary UPI. All material intercompany balances and transactions have been eliminated during consolidation.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has experienced net losses since its inception and has an accumulated deficit of $382.4 million and $356.5 million as of March&#160;31, 2021 and December&#160;31, 2020, respectively. The Company expects to incur losses and have negative net cash flows from operating activities as it executes on its strategy including engaging in further research and development activities, particularly conducting non-clinical studies and clinical trials.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The success of the Company depends on the ability to successfully commercialize its technologies to support its operations and strategic plan. Based on management&#8217;s cash flow projections the Company believes that its cash and cash equivalents and marketable securities after the closing of the transaction with RTW Investments (See Note 17 for further discussion) are sufficient to fund the Company&#8217;s planned operations for at least the next 12 months. The Company anticipates that it may need to raise additional capital in the future. There can be no assurances that the Company will be able to secure such additional financing if at all, or at terms that are satisfactory to the Company, and that it will be sufficient to meet its needs. In the event the Company is not successful in obtaining sufficient funding, this could force us to delay, limit, or reduce our product development, commercialization efforts or other operations.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccounting">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccounting</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140482547876152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Significant Accounting Policies</a></td>
<td class="text">
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Note 3 &#8211; Significant Accounting Policies</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Calibri;font-size:10pt;text-transform:none;font-variant: normal;">Principles of Consolidation</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The condensed consolidated financial statements include the accounts of UPL and its subsidiary, UPI. Intercompany balances and transactions have been eliminated during consolidation.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Calibri;font-size:10pt;text-transform:none;font-variant: normal;">Use of Estimates</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The<span style="letter-spacing:0.35pt;"> </span>preparation<span style="letter-spacing:0.9pt;"> </span>of<span style="letter-spacing:0.2pt;"> </span>financial<span style="letter-spacing:0.65pt;"> </span>statements<span style="letter-spacing:0.9pt;"> </span>in<span style="letter-spacing:0.2pt;"> </span>conformity<span style="letter-spacing:0.85pt;"> </span>with<span style="letter-spacing:0.35pt;"> U.S. </span>GAAP<span style="letter-spacing:0.5pt;"> </span>requires<span style="letter-spacing:0.65pt;"> </span>man<span style="letter-spacing:-0.1pt;">a</span>gement<span style="letter-spacing:1.05pt;"> </span>to<span style="letter-spacing:0.2pt;"> </span>make<span style="letter-spacing:0.45pt;"> </span>estimates<span style="letter-spacing:0.8pt;"> </span>and<span style="letter-spacing:0.35pt;"> </span>assumptions<span style="letter-spacing:1pt;"> </span>that<span style="letter-spacing:0.35pt;"> </span>affect the<span style="letter-spacing:0.05pt;"> </span>reported<span style="letter-spacing:0.7pt;"> </span>amounts<span style="letter-spacing:0.7pt;"> </span>of<span style="letter-spacing:0.2pt;"> </span>assets<span style="letter-spacing:0.6pt;"> </span>and<span style="letter-spacing:0.35pt;"> </span>liabilities,<span style="letter-spacing:0.75pt;"> </span>the<span style="letter-spacing:0.3pt;"> </span>disclosure<span style="letter-spacing:0.8pt;"> </span>of<span style="letter-spacing:0.2pt;"> </span>cont<span style="letter-spacing:-0.1pt;">i</span>ngent<span style="letter-spacing:0.85pt;"> </span>assets<span style="letter-spacing:0.55pt;"> </span>and<span style="letter-spacing:0.35pt;"> </span>liabilities<span style="letter-spacing:0.7pt;"> </span>at<span style="letter-spacing:0.2pt;"> </span>the<span style="letter-spacing:0.3pt;"> </span>date<span style="letter-spacing:0.4pt;"> </span>of<span style="letter-spacing:0.2pt;"> </span>the<span style="letter-spacing:0.3pt;"> </span>financ<span style="letter-spacing:-0.1pt;">i</span>al<span style="letter-spacing:0.65pt;"> </span>statements<span style="letter-spacing:0.9pt;"> </span>and<span style="letter-spacing:0.35pt;"> </span>the reported<span style="letter-spacing:0.7pt;"> </span>amounts<span style="letter-spacing:0.7pt;"> </span>of<span style="letter-spacing:0.2pt;"> </span>revenues<span style="letter-spacing:0.75pt;"> </span>and<span style="letter-spacing:0.35pt;"> </span>expenses<span style="letter-spacing:0.8pt;"> </span>duri<span style="letter-spacing:-0.1pt;">n</span>g<span style="letter-spacing:0.5pt;"> </span>the<span style="letter-spacing:0.3pt;"> </span>reporting<span style="letter-spacing:0.7pt;"> </span>period.<span style="letter-spacing:0.55pt;"> </span>Actual<span style="letter-spacing:0.5pt;"> </span>results<span style="letter-spacing:0.55pt;"> </span>may<span style="letter-spacing:0.35pt;"> </span>differ<span style="letter-spacing:0.45pt;"> </span>from<span style="letter-spacing:0.4pt;"> </span>those<span style="letter-spacing:0.45pt;"> </span>estimates.<span style="letter-spacing:0.8pt;"> </span>As<span style="letter-spacing:0.25pt;"> </span>applicable<span style="letter-spacing:0.9pt;"> </span>to the unaudited condensed<span style="letter-spacing:0.45pt;"> </span>consolidated<span style="letter-spacing:1pt;"> </span>financi<span style="letter-spacing:-0.1pt;">a</span>l<span style="letter-spacing:0.65pt;"> </span>statements,<span style="letter-spacing:0.95pt;"> </span>the<span style="letter-spacing:0.3pt;"> critical </span>accounting<span style="letter-spacing:0.35pt;"> estimates relate </span>to<span style="letter-spacing:0.2pt;"> </span>the<span style="letter-spacing:0.3pt;"> </span>fair<span style="letter-spacing:0.3pt;"> </span>value<span style="letter-spacing:0.45pt;"> </span>of<span style="letter-spacing:0.2pt;"> </span>share-based<span style="letter-spacing:1pt;"> </span>compensat<span style="letter-spacing:-0.1pt;">i</span>on,<span style="letter-spacing:0.55pt;"> </span>measurement<span style="letter-spacing:0.5pt;"> </span>of<span style="letter-spacing:0.2pt;"> </span>revenue and estimate of uncertain tax positions.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Calibri;font-size:10pt;text-transform:none;font-variant: normal;">Functional<span style="letter-spacing:0.9pt;"> </span>Currency</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The<span style="letter-spacing:0.35pt;"> </span>U.S.<span style="letter-spacing:0.4pt;"> </span>dollar<span style="letter-spacing:0.45pt;"> </span>(&#8220;Dollar&#8221;)<span style="letter-spacing:0.7pt;"> </span>is<span style="letter-spacing:0.15pt;"> </span>the<span style="letter-spacing:0.35pt;"> </span>currency<span style="letter-spacing:0.7pt;"> </span>of<span style="letter-spacing:0.2pt;"> </span>the<span style="letter-spacing:0.3pt;"> </span>primary<span style="letter-spacing:0.6pt;"> </span>economic<span style="letter-spacing:0.8pt;"> </span>environment<span style="letter-spacing:1pt;"> </span>in<span style="letter-spacing:0.2pt;"> </span>which<span style="letter-spacing:0.5pt;"> </span>the<span style="letter-spacing:0.3pt;"> </span>operations<span style="letter-spacing:0.85pt;"> </span>of<span style="letter-spacing:0.2pt;"> </span>the<span style="letter-spacing:0.3pt;"> </span>Com<span style="letter-spacing:-0.1pt;">p</span>any<span style="letter-spacing:0.8pt;"> </span>are conducted.<span style="letter-spacing:0.9pt;"> </span>Therefore,<span style="letter-spacing:0.85pt;"> </span>the<span style="letter-spacing:0.3pt;"> </span>functional<span style="letter-spacing:0.8pt;"> </span>currency<span style="letter-spacing:0.7pt;"> </span>of<span style="letter-spacing:0.2pt;"> </span>the<span style="letter-spacing:0.3pt;"> </span>Company<span style="letter-spacing:0.8pt;"> </span>is<span style="letter-spacing:0.15pt;"> </span>the<span style="letter-spacing:0.3pt;"> </span>Dol<span style="letter-spacing:-0.1pt;">l</span>ar.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accordingly,<span style="letter-spacing:1pt;"> </span>transactions<span style="letter-spacing:0.95pt;"> </span>in<span style="letter-spacing:0.2pt;"> </span>currencies<span style="letter-spacing:0.85pt;"> </span>other<span style="letter-spacing:0.45pt;"> </span>than<span style="letter-spacing:0.4pt;"> </span>the<span style="letter-spacing:0.3pt;"> </span>Do<span style="letter-spacing:-0.1pt;">l</span>lar<span style="letter-spacing:0.5pt;"> </span>are<span style="letter-spacing:0.3pt;"> </span>measured<span style="letter-spacing:0.8pt;"> </span>and<span style="letter-spacing:0.35pt;"> </span>recorded<span style="letter-spacing:0.7pt;"> </span>in<span style="letter-spacing:0.2pt;"> </span>the<span style="letter-spacing:0.3pt;"> </span>functional<span style="letter-spacing:0.8pt;"> </span>currency<span style="letter-spacing:0.7pt;"> </span>usi<span style="letter-spacing:-0.1pt;">n</span>g<span style="letter-spacing:0.45pt;"> </span>the<span style="letter-spacing:0.3pt;"> </span>exchange<span style="letter-spacing:0.8pt;"> </span>rate<span style="letter-spacing:0.35pt;"> </span>in effect<span style="letter-spacing:0.45pt;"> </span>at<span style="letter-spacing:0.2pt;"> </span>the<span style="letter-spacing:0.3pt;"> </span>date<span style="letter-spacing:0.4pt;"> </span>of<span style="letter-spacing:0.2pt;"> </span>the<span style="letter-spacing:0.35pt;"> </span>transaction.<span style="letter-spacing:0.95pt;"> </span>At<span style="letter-spacing:0.2pt;"> </span>the<span style="letter-spacing:0.3pt;"> </span>balance<span style="letter-spacing:0.65pt;"> </span>sheet<span style="letter-spacing:0.45pt;"> </span>date,<span style="letter-spacing:0.45pt;"> </span>monetary<span style="letter-spacing:0.75pt;"> </span>assets<span style="letter-spacing:0.55pt;"> </span>and<span style="letter-spacing:0.35pt;"> </span>liab<span style="letter-spacing:-0.1pt;">i</span>lities<span style="letter-spacing:0.7pt;"> </span>that<span style="letter-spacing:0.35pt;"> </span>are<span style="letter-spacing:0.3pt;"> </span>denominated<span style="letter-spacing:1.05pt;"> </span>in<span style="letter-spacing:0.2pt;"> </span>currencies<span style="letter-spacing:0.85pt;"> </span>other<span style="letter-spacing:0.45pt;"> </span>than the<span style="letter-spacing:0.05pt;"> </span>Dollar<span style="letter-spacing:0.5pt;"> </span>are<span style="letter-spacing:0.3pt;"> </span>measured<span style="letter-spacing:0.8pt;"> </span>using<span style="letter-spacing:0.45pt;"> </span>the<span style="letter-spacing:0.3pt;"> </span>official<span style="letter-spacing:0.55pt;"> </span>exch<span style="letter-spacing:-0.1pt;">a</span>nge<span style="letter-spacing:0.8pt;"> </span>rate<span style="letter-spacing:0.35pt;"> </span>at<span style="letter-spacing:0.2pt;"> </span>the<span style="letter-spacing:0.3pt;"> </span>balance<span style="letter-spacing:0.65pt;"> </span>sheet<span style="letter-spacing:0.45pt;"> </span>date.<span style="letter-spacing:0.45pt;"> </span>The<span style="letter-spacing:0.35pt;"> </span>effects<span style="letter-spacing:0.55pt;"> </span>of<span style="letter-spacing:0.2pt;"> </span>foreign<span style="letter-spacing:0.55pt;"> </span>currency<span style="letter-spacing:0.8pt;"> </span>re-measurements<span style="letter-spacing:1.45pt;"> </span>are recorded<span style="letter-spacing:0.7pt;"> </span>in<span style="letter-spacing:0.2pt;"> </span>the<span style="letter-spacing:0.3pt;"> condensed </span>consolidated<span style="letter-spacing:1pt;"> </span>statements<span style="letter-spacing:0.9pt;"> </span>of<span style="letter-spacing:0.2pt;"> </span>operations<span style="letter-spacing:0.85pt;"> </span>as<span style="letter-spacing:0.25pt;"> </span>&#8220;Interest and other income, net.&#8221;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Calibri;font-size:10pt;text-transform:none;font-variant: normal;">Cash and Cash Equivalents; <span style="color:#000000;">Marketable Securities</span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company considers all highly liquid investments with an original maturity of three months or less when purchased to be cash equivalents. Cash and cash equivalents consist primarily of money market funds and bank money market accounts and are stated at cost, which approximates fair value. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash and cash equivalents and marketable securities totaled $75.9 million as of March&#160;31, 2021. The Company classifies its marketable securities as available-for-sale in accordance with the <span style="letter-spacing:-0.2pt;">Financial Accounting Standards Board (&#8220;</span>FASB&#8221;) Accounting Standards Codification (&#8220;ASC&#8221;) Topic 320, &#8220;Investments &#8212; Debt and Equity Securities&#8221;. Available-for-sale debt securities are carried at fair value with unrealized gains and losses reported in other comprehensive income/loss within shareholders&#8217; equity. Realized gains and losses are recorded as a component of interest and other income (expense), net. The cost of securities sold is based on the specific-identification method. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Short-term investments are valued using models or other valuation methodologies that use Level 2 inputs. These models are primarily industry-standard models that consider various assumptions, including time value, yield curve, volatility factors, default rates, current market and contractual prices for the underlying financial instruments, as well as other relevant economic measures. The majority of these assumptions are observable in the marketplace, can be derived from observable data or are supported by observable levels at which transactions are executed in the marketplace.&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For individual debt securities classified as available-for-sale securities where there has been a decline in fair value below amortized cost, the Company determines whether the decline resulted from a credit loss or other factors. The Company records impairment relating to credit losses through an allowance for credit losses, limited by the amount that the fair value is less than the amortized cost basis. Impairment that has not been recorded through an allowance for credit losses is recorded through other comprehensive income, net of applicable taxes.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Calibri;font-size:10pt;text-transform:none;font-variant: normal;">Concentration of Credit Risk</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial instruments, which potentially subject the Company to significant concentrations of credit risk, consist primarily of cash and cash equivalents and marketable securities. The primary objectives for the Company<span style="color:#000000;">&#8217;</span>s investment portfolio are the preservation of capital and the maintenance of liquidity. The Company does not enter into any investment transaction for trading or speculative purposes.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company<span style="color:#000000;">&#8217;</span>s investment policy limits investments to certain types of instruments such as certificates of deposit, money market instruments, obligations issued by the U.S. government and U.S. government agencies as well as corporate debt securities, and places restrictions on maturities and concentration by type and issuer. The Company maintains cash balances in excess of amounts insured by the Federal Deposit Insurance Corporation and concentrated within a limited number of financial institutions. The accounts are monitored by management to mitigate the risk.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s product sales are recognized through the Company's arrangement with a single customer, a third-party national specialty distributor. The Company assesses the need for an allowance for doubtful accounts primarily based on creditworthiness, historical payment experience and general economic conditions. The Company has not experienced any credit losses related to this customer and has not currently recognized any allowance for doubtful accounts.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Calibri;font-size:10pt;text-transform:none;font-variant: normal;">Income Taxes</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company provides for income taxes based on pretax income, if any, and applicable tax rates available in the various jurisdictions in which it operates, including Israel and the U.S. Deferred<span style="letter-spacing:0.6pt;"> </span>taxes<span style="letter-spacing:0.45pt;"> </span>are<span style="letter-spacing:0.3pt;"> </span>computed<span style="letter-spacing:0.8pt;"> </span>using<span style="letter-spacing:0.45pt;"> </span>the<span style="letter-spacing:0.3pt;"> </span>asset<span style="letter-spacing:0.45pt;"> </span>and<span style="letter-spacing:0.35pt;"> </span>liabi<span style="letter-spacing:-0.1pt;">l</span>ity<span style="letter-spacing:0.65pt;"> </span>method.<span style="letter-spacing:0.65pt;"> </span>Under<span style="letter-spacing:0.5pt;"> </span>the<span style="letter-spacing:0.3pt;"> </span>asset<span style="letter-spacing:0.45pt;"> </span>and<span style="letter-spacing:0.35pt;"> </span>liability<span style="letter-spacing:0.55pt;"> </span>method,<span style="letter-spacing:0.65pt;"> </span>deferred<span style="letter-spacing:0.7pt;"> </span>income<span style="letter-spacing:0.6pt;"> </span>tax<span style="letter-spacing:0.3pt;"> </span>assets<span style="letter-spacing:0.55pt;"> </span>and liabilities<span style="letter-spacing:0.7pt;"> </span>are<span style="letter-spacing:0.3pt;"> </span>determined<span style="letter-spacing:0.9pt;"> </span>bas<span style="letter-spacing:-0.1pt;">e</span>d<span style="letter-spacing:0.5pt;"> </span>on<span style="letter-spacing:0.25pt;"> </span>the<span style="letter-spacing:0.3pt;"> </span>differences<span style="letter-spacing:0.9pt;"> </span>between<span style="letter-spacing:0.7pt;"> </span>the<span style="letter-spacing:0.3pt;"> </span>financial<span style="letter-spacing:0.65pt;"> </span>reporti<span style="letter-spacing:-0.1pt;">n</span>g<span style="letter-spacing:0.7pt;"> </span>and<span style="letter-spacing:0.35pt;"> </span>tax bases<span style="letter-spacing:0.5pt;"> </span>of<span style="letter-spacing:0.2pt;"> </span>assets<span style="letter-spacing:0.55pt;"> </span>and<span style="letter-spacing:0.35pt;"> </span>liabilities<span style="letter-spacing:0.7pt;"> </span>and<span style="letter-spacing:0.35pt;"> </span>are<span style="letter-spacing:0.3pt;"> </span>mea<span style="letter-spacing:-0.1pt;">s</span>ured<span style="letter-spacing:0.8pt;"> </span>using<span style="letter-spacing:0.45pt;"> </span>the<span style="letter-spacing:0.3pt;"> </span>currently<span style="letter-spacing:0.7pt;"> </span>enacted<span style="letter-spacing:0.65pt;"> </span>tax<span style="letter-spacing:0.3pt;"> </span>rates<span style="letter-spacing:0.45pt;"> </span>and<span style="letter-spacing:0.35pt;"> </span>laws.<span style="letter-spacing:0.45pt;"> </span>A<span style="letter-spacing:0.15pt;"> </span>valuation<span style="letter-spacing:0.75pt;"> </span><span style="letter-spacing:-0.1pt;">a</span>llowance<span style="letter-spacing:0.8pt;"> </span>is<span style="letter-spacing:0.15pt;"> </span>recognized<span style="letter-spacing:0.9pt;"> </span>to<span style="letter-spacing:0.2pt;"> </span>the extent<span style="letter-spacing:0.5pt;"> </span>that<span style="letter-spacing:0.35pt;"> </span>it<span style="letter-spacing:0.15pt;"> </span>is<span style="letter-spacing:0.15pt;"> </span>more<span style="letter-spacing:0.45pt;"> </span>likely<span style="letter-spacing:0.45pt;"> </span>than<span style="letter-spacing:0.4pt;"> </span>not<span style="letter-spacing:0.3pt;"> </span>that<span style="letter-spacing:0.35pt;"> </span>the<span style="letter-spacing:0.35pt;"> </span>deferred<span style="letter-spacing:0.7pt;"> </span>taxes<span style="letter-spacing:0.45pt;"> </span>will<span style="letter-spacing:0.3pt;"> </span>not<span style="letter-spacing:0.3pt;"> </span>be<span style="letter-spacing:0.25pt;"> </span>realized<span style="letter-spacing:0.65pt;"> </span>in<span style="letter-spacing:0.2pt;"> </span>the<span style="letter-spacing:0.3pt;"> </span>foresee<span style="letter-spacing:-0.1pt;">a</span>ble<span style="letter-spacing:0.95pt;"> </span>future.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The<span style="letter-spacing:0.35pt;"> </span>Company<span style="letter-spacing:0.8pt;"> </span>follows<span style="letter-spacing:0.55pt;"> </span>a<span style="letter-spacing:0.3pt;"> </span>two-step<span style="letter-spacing:0.8pt;"> </span>approach<span style="letter-spacing:0.75pt;"> </span>in<span style="letter-spacing:0.2pt;"> </span>recognizing<span style="letter-spacing:0.9pt;"> </span>a<span style="letter-spacing:-0.1pt;">n</span>d<span style="letter-spacing:0.35pt;"> </span>measuring<span style="letter-spacing:0.85pt;"> </span>uncertain<span style="letter-spacing:0.75pt;"> </span>tax<span style="letter-spacing:0.3pt;"> </span>positions.<span style="letter-spacing:0.75pt;"> </span>After concluding that a particular filing position can be recognized (i.e., has a more-likely-than-not chance of being sustained), ASC 740-10-30-7 requires that the amount of benefit recognized be measured using a methodology based on the concept of cumulative probability. Under this methodology, the amount of benefit recorded represents the largest amount of tax benefit that is greater than 50% likely to be realized upon settlement with a taxing authority that has full knowledge of all relevant information. &#160;See Note 14 for further discussion related to income taxes.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Calibri;font-size:10pt;text-transform:none;font-variant: normal;">Inventory</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company capitalizes inventory costs related to products to be sold in the ordinary course of business. The Company makes a determination of capitalizing inventory costs for a product based on, among other factors, status of regulatory approval, information regarding safety, efficacy and expectations relating to commercial sales and recoverability of costs.&#160;For <span style="font-style:italic;">Jelmyto</span>, the Company commenced capitalization of inventory at the receipt of FDA approval.</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.67%;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company values its inventory at the lower of cost or net realizable value.&#160;The Company measures inventory approximating actual cost under a first-in, first-out basis. The Company assesses recoverability of inventory each reporting period to determine any write down to net realizable value resulting from excess or obsolete inventories<span style="font-style:italic;">.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Calibri;font-size:10pt;text-transform:none;font-variant: normal;">Property and Equipment</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment are recorded at historical cost, net of accumulated depreciation, amortization and, if applicable, impairment charges. The Company reviews its property and equipment assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment are depreciated over the following useful lives (in years):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:60%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.02%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.88%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Useful Lives</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.02%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Computers and software</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000251">3</span></p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.02%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Laboratory equipment</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.88%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3-6.5</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.02%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Furniture</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.88%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5-16.5</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.02%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Manufacturing equipment</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000252">2</span></p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Leasehold improvements are amortized on a straight-line basis over the shorter of their estimated useful lives or lease terms. See Note 8 for further discussion regarding property and equipment.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Calibri;font-size:10pt;text-transform:none;font-variant: normal;">Leases</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is a lessee in several noncancelable operating leases, primarily for office space, office equipment and vehicles. The Company currently has no finance leases.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company accounts for leases in accordance with ASC Topic 842, &#8220;Leases&#8221;<span style="font-style:italic;">.</span> The Company determines if an arrangement is a lease at inception. Right-of-use (&#8220;ROU&#8221;) assets and operating lease liabilities are recognized based on the present value of lease payments over the lease term as of the commencement date. Operating lease ROU assets are presented as operating lease right of use assets on the condensed consolidated balance sheets. The current portion of operating lease liabilities is included in other current liabilities and the long-term portion is presented separately as operating lease liabilities on the condensed consolidated balance sheets.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lease expense is recognized on a straight-line basis for operating leases. Variable lease payments associated with the Company&#8217;s leases are recognized when the event, activity, or circumstance in the lease agreement on which those payments are assessed occurs. Variable lease payments are presented as operating expense on the condensed consolidated statements of operations in the same line item as expense arising from fixed lease payments.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s lease terms may include options to extend the lease. The lease extensions are included in the measurement of the right of use asset and lease liability when it is reasonably certain that it will exercise that option.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Because most of the Company&#8217;s leases do not provide an implicit rate of return, an incremental borrowing rate is used based on the information available at the commencement date in determining the present value of lease payments on an individual lease basis. The Company&#8217;s incremental borrowing rate for a lease is the rate of interest it would have to pay on a collateralized basis to borrow an amount equal to the lease payments under similar terms. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ROU assets for operating leases are periodically reviewed for impairment losses under ASC 360-10, &#8220;Property, Plant, and Equipment&#8221;, to determine whether an ROU asset is impaired, and if so, the amount of the impairment loss to recognize.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Calibri;font-size:10pt;text-transform:none;font-variant: normal;">Revenues</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Product sales from <span style="font-style:italic;">Jelmyto</span> are recognized as revenue under ASC 606 at the point in time that control of the product has been transferred to the customer, generally at the point the product has been delivered to the treating physician. All product sales of <span style="font-style:italic;">Jelmyto</span> are recognized through the Company's arrangement with a single customer, a third-party national specialty distributor. Net revenues recognized include management&#8217;s estimate of returns, consideration paid to the customer, chargebacks relating to differences between the wholesale acquisition cost and the contracted price offered to the end consumer, chargebacks relating to 340b drug pricing programs, Medicaid drug rebate programs, and the Company&#8217;s copay assistance program, which are estimated based on industry benchmarking studies as well as the Company&#8217;s historical experience.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&#160;</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Calibri;font-size:10pt;text-transform:none;font-variant: normal;">Research and Development Expenses </p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development costs are expensed as incurred and consist primarily of the cost of salaries, share-based compensation expenses, payroll taxes and other employee benefits, subcontractors and materials used for research and development activities, including nonclinical studies, clinical trials, manufacturing costs and professional services. The costs of services performed by others in connection with the research and development activities of the Company, including research and development conducted by others on behalf of the Company, shall be included in research and development costs and expensed as the contracted work is performed. The Company accrues for costs incurred as the services are being provided by monitoring the status of the trial or project and the invoices received from its external service providers. The Company adjusts its accrual as actual costs become known. Where contingent milestone payments are due to third parties under research and development arrangements or license agreements, the milestone payment obligations are expensed when the milestone results are achieved.</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Calibri;font-size:10pt;text-transform:none;font-variant: normal;">Selling<span style="font-weight:normal;font-style:normal;"> </span><span style="color:#000000;">General and Administrative Expenses</span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Selling, general and administrative expenses consist primarily of personnel costs (including share-based compensation related to directors, employees and consultants). Other significant costs include commercial, medical affairs, external professional service costs, facility costs, accounting and audit services, legal services, and other consulting fees. Selling, general and administrative costs are expensed as incurred, and the Company accrues for services provided by third parties related to the above expenses by monitoring the status of services provided and receiving estimates from its service providers and adjusting its accruals as actual costs become known.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Calibri;font-size:10pt;text-transform:none;font-variant: normal;">Share-Based Compensation</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Share-based compensation cost is measured at the grant date based on the fair value of the award and is recognized as expense over the required service period, which is equal to the vesting period. The fair value of options is determined using the Black-Scholes option-pricing model. The fair value of a restricted stock unit (&#8220;RSU&#8221;) equaled the closing price of the Company&#8217;s ordinary shares on the grant date. The Company accounts for forfeitures as they occur in accordance with ASC Topic 718, &#8220;Compensation&#8212;Stock Compensation&#8221;.<span style="letter-spacing:0.75pt;"> </span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The<span style="letter-spacing:0.35pt;"> </span>Company<span style="letter-spacing:0.8pt;"> </span>elected<span style="letter-spacing:0.6pt;"> </span>to<span style="letter-spacing:0.2pt;"> </span>recognize<span style="letter-spacing:0.8pt;"> </span>compen<span style="letter-spacing:-0.1pt;">s</span>ation<span style="letter-spacing:1.1pt;"> </span>costs<span style="letter-spacing:0.45pt;"> </span>for<span style="letter-spacing:0.25pt;"> </span>awards<span style="letter-spacing:0.6pt;"> </span>conditioned<span style="letter-spacing:0.9pt;"> </span>only<span style="letter-spacing:0.35pt;"> </span>on<span style="letter-spacing:0.25pt;"> </span>conti<span style="letter-spacing:-0.1pt;">n</span>ued<span style="letter-spacing:0.8pt;"> </span>service<span style="letter-spacing:0.6pt;"> </span>that<span style="letter-spacing:0.35pt;"> </span>have<span style="letter-spacing:0.4pt;"> </span>a<span style="letter-spacing:0.15pt;"> </span>graded<span style="letter-spacing:0.6pt;"> </span>vesting<span style="letter-spacing:0.6pt;"> </span>schedule<span style="letter-spacing:0.05pt;"> </span>using<span style="letter-spacing:0.45pt;"> </span>the<span style="letter-spacing:0.3pt;"> </span>straight-line<span style="letter-spacing:0.95pt;"> </span>method<span style="letter-spacing:0.55pt;"> </span>and<span style="letter-spacing:0.35pt;"> </span>to<span style="letter-spacing:0.2pt;"> </span>value<span style="letter-spacing:0.45pt;"> </span>the<span style="letter-spacing:0.3pt;"> </span>awards<span style="letter-spacing:0.6pt;"> </span>based<span style="letter-spacing:0.5pt;"> </span>on<span style="letter-spacing:0.25pt;"> </span>the<span style="letter-spacing:0.3pt;"> </span>sin<span style="letter-spacing:-0.1pt;">g</span>le-option<span style="letter-spacing:1pt;"> </span>award<span style="letter-spacing:0.5pt;"> </span>approach.<span style="letter-spacing:0.8pt;"> </span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Calibri;font-size:10pt;text-transform:none;font-variant: normal;">Net Loss per Ordinary Share</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Basic net loss per share is computed by dividing the net loss attributable to ordinary shareholders by the weighted-average number of ordinary shares outstanding. Diluted net loss per share is computed similarly to basic net loss per share except that the denominator is increased to include the number of additional ordinary shares that would have been outstanding if the potential ordinary shares had been issued and if the additional ordinary shares were dilutive. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For all periods presented, potentially dilutive securities are excluded from the computation of fully diluted loss per share as their effect is anti-dilutive.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140482547264024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Financial Information<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_urgn_OtherFinancialInformationAbstract', window );"><strong>Other Financial Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_urgn_OtherFinancialInformationTextBlock', window );">Other Financial Information</a></td>
<td class="text">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Note 4 &#8211; Other Financial Information</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Calibri;font-size:10pt;text-transform:none;font-variant: normal;">Accounts Payable and Accrued Expenses</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accounts payable and accrued expenses consist of the following as of March&#160;31, 2021 and December&#160;31, 2020 (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.74%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">March&#160;31, 2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.74%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31, 2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accounts payable</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.74%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,096</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.74%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,271</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued sales reserves</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.74%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">449</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.74%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">382</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued clinical expenses</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.74%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">554</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.74%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,359</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued research and development costs</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.74%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">862</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.74%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,356</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued selling, general and administrative expenses</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.74%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,309</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.74%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,440</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59.22%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued other expense</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.74%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,288</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.74%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,215</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59.22%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total accounts payable and accrued expenses</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.74%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,558</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.74%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,023</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Calibri;font-size:10pt;text-transform:none;font-variant: normal;">Interest and Other Income (Expenses), Net</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest and other income (expenses) consisted of the following as of March&#160;31, 2021 and 2020 (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.12%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended March&#160;31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest income</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.74%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">167</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.74%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">811</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59.22%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other finance income(expenses)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.74%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.74%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(43</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59.22%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total interest and other income</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.74%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">179</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.74%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">768</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_urgn_OtherFinancialInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other financial information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">urgn_OtherFinancialInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>urgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_urgn_OtherFinancialInformationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other financial information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">urgn_OtherFinancialInformationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>urgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140482547597976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventories<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">Inventories</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:4pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Note 5 &#8211; Inventories</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inventories consist of the following as of March&#160;31, 2021 and December&#160;31, 2020 (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:65.18%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.76%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.62%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">March&#160;31, 2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.76%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.62%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31, 2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.18%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Raw materials</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.62%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,443</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.62%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,051</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:65.18%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Finished goods</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.76%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.62%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">888</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.76%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.62%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">913</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:65.18%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total inventories</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.76%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.62%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,331</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.76%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.62%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,964</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI http://asc.fasb.org/topic&amp;trid=2126998<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140482547264024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Note 6 &#8211; Fair Value Measurements</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company follows authoritative accounting guidance, which among other things, defines fair value, establishes a consistent framework for measuring fair value and expands disclosure for each major asset and liability category measured at fair value on either a recurring or nonrecurring basis. Fair value is an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As a basis for considering such assumptions, a three-tier fair value hierarchy has been established, which prioritizes the inputs used in measuring fair value as follows:</p>
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:2.27%;white-space:nowrap" valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:10pt;">&#160;</p></td>
<td style="width:6.67%;white-space:nowrap" valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level 1:</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:10pt;">Observable inputs such as quoted prices (unadjusted) in active markets for identical assets or liabilities.</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:2.27%;white-space:nowrap" valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:10pt;">&#160;</p></td>
<td style="width:6.67%;white-space:nowrap" valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level 2:</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:10pt;">Inputs other than quoted prices that are observable for the asset or liability, either directly or indirectly. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active.</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:2.27%;white-space:nowrap" valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:10pt;">&#160;</p></td>
<td style="width:6.67%;white-space:nowrap" valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level 3:</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:10pt;">Unobservable inputs that reflect the reporting entity<span style="color:#000000;">&#8217;</span>s own assumptions.</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The carrying amounts of the Company<span style="color:#000000;">&#8217;</span>s other current assets, accounts payable and accrued liabilities are generally considered to be representative of their fair value because of the short-term nature of these instruments. No transfers between levels have occurred during the periods presented.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Assets and liabilities measured at fair value on a recurring basis based on Level 1 and Level 2 fair value measurement criteria as of March&#160;31, 2021 are as follows (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.78%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.04%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Fair Value Measurements Using</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Quoted&#160;Prices</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Significant</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">in Active</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Balance&#160;as&#160;of</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Markets for</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Observable</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">March&#160;31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Identical&#160;Assets</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Inputs</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(Level 1)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(Level 2)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Marketable securities:</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US government</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20,572</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20,572</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate bonds</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,845</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,845</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money market funds<sup style="font-size:85%;line-height:120%;vertical-align:top">(1)</sup></p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30,413</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30,413</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total marketable securities</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">65,830</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">50,985</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,845</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:3.33%;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160; </p>
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:3.8%;white-space:nowrap" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%;line-height:120%;vertical-align:top">(1)</sup></span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:10pt;"><span style="color:#000000;">Included within cash and cash equivalents on the condensed consolidated balance sheets.</span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.13%;text-indent:0%;font-family:Times New Roman;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:2pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Assets and liabilities measured at fair value on a recurring basis based on Level 1 and Level 2 fair value measurement criteria as of December&#160;31, 2020 are as follows (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.78%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.04%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Fair&#160;Value&#160;Measurements&#160;Using</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Quoted&#160;Prices</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Significant</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">in Active</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Balance&#160;as&#160;of</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Markets for</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Observable</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Identical&#160;Assets</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Inputs</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(Level 1)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(Level 2)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Marketable securities:</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US government</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29,186</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29,186</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate bonds</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21,861</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21,861</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money market funds<sup style="font-size:85%;line-height:120%;vertical-align:top">(1)</sup></p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">39,744</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">39,744</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total marketable securities</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">90,791</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">68,930</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21,861</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:3.8%;white-space:nowrap" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%;line-height:120%;vertical-align:top">(1)</sup></span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:10pt;"><span style="color:#000000;">Included within cash and cash equivalents on the condensed consolidated balance sheets.</span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company<span style="color:#000000;">&#8217;</span>s in money market funds are valued based on publicly available quoted market prices for identical securities as of March&#160;31, 2021 and December&#160;31, 2020. </p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140482560893064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Marketable Securities<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments Debt And Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_urgn_MarketableSecuritiesDisclosureTextBlock', window );">Marketable Securities</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Note 7 &#8211; Marketable Securities</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes the Company&#8217;s marketable securities as of March&#160;31, 2021 (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:39.4%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.58%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Amortized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Cost Basis</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.58%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Gains</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.58%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Losses</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.58%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Fair Value</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.4%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Marketable securities:</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.58%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.58%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.58%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.58%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.4%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US government</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.58%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20,448</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.58%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">124</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.58%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.58%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20,572</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.4%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate bonds</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.58%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,826</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.58%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.58%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.58%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,845</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:39.4%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money market funds<sup style="font-size:85%;line-height:120%;vertical-align:top">(1)</sup></p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.58%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30,413</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.58%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.58%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.58%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30,413</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:39.4%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total marketable securities</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.58%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">65,687</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.58%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">143</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.58%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.58%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">65,830</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:3.8%;text-indent:-3.8%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:3.8%;white-space:nowrap" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%;line-height:120%;vertical-align:top">(1)</sup></span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:10pt;"><span style="color:#000000;">Included within cash and cash equivalents on the condensed consolidated balance sheets.</span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company classifies its marketable securities as available-for-sale and they consist of all debt securities. The amortized cost basis as of March&#160;31, 2021 includes $0.1 million of accrued interest receivable<span style="color:#000000;">. </span>As of March&#160;31, 2021, marketable securities were in a net unrealized gain position of $0.1 million.&#160;<span style="color:#000000;">Unrealized gains and losses on available-for-sale debt securities are included as a component of comprehensive loss.&#160;&#160;</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of <span style="color:#000000;">March&#160;31, 2021</span>, the Company did not hold any marketable securities in an unrealized loss position. Per the Company&#8217;s general investment strategy, the Company does not intend to sell the investments before maturity. <span style="color:#000000;">As of&#160;March&#160;31, 2021, the Company believes the cost basis for its marketable securities were recoverable in all material aspects and no credit impairments were recognized in the period.</span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s marketable securities as of March&#160;31, 2021 mature at various dates through February 2022. The fair values of marketable securities by contractual maturity consist of the following (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59.6%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.76%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.42%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">March&#160;31, 2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.76%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.42%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31, 2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.6%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Maturities within one year</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">65,830</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">88,898</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59.6%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Maturities after one year through three years</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.76%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.76%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,893</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59.6%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total marketable securities</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.76%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">65,830</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.76%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">90,791</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_urgn_MarketableSecuritiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Marketable securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">urgn_MarketableSecuritiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>urgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140482559463832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property Plant And Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property and Equipment</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Note 8 &#8211; Property and Equipment</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment, consists of the following as of March&#160;31, 2021 and December&#160;31, 2020 (in thousands):</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59.54%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.42%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">March&#160;31, 2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.42%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31, 2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.54%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Laboratory equipment</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">337</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">333</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.54%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Computer equipment and software</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,970</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,676</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.54%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Furniture</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">586</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">597</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.54%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Leasehold improvements</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">609</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">609</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59.54%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Manufacturing equipment</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">226</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">226</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.54%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,728</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,441</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59.54%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less: accumulated depreciation and amortization</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,586</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,395</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59.54%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment, net</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,142</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,046</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Depreciation and amortization expenses were $0.2 million and&#160;$0.1 million&#160;for the three months ended March&#160;31, 2021 and 2020, respectively. </p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI http://asc.fasb.org/topic&amp;trid=2155823<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=SL120174063-112916<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140482547187832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Leases</a></td>
<td class="text">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Note 9 - Leases </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Calibri;font-size:10pt;text-transform:none;font-variant: normal;">Operating Leases</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has the following office and laboratory facility leases:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:6pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:3.33%;white-space:nowrap" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td style="width:2.27%;white-space:nowrap" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Calibri;">In April 2016, UPL signed an addendum to its November 2014 lease agreement for the Company&#8217;s executive offices located in Israel, in order to increase the office space rented and to extend the rent period until 2019. In March 2019, UPL utilized the agreement extension option and extended the rent period for additional three years until August 2022.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:3.33%;white-space:nowrap" valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td style="width:2.27%;white-space:nowrap" valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Calibri;">In September 2017, UPI entered into a new lease agreement for its office space in New York, which the Company previously used as its headquarters. The lease agreement commenced in October 2017 and terminated in February 2021.</span><span style="font-family:Times New Roman;">&#160;&#160;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:3.33%;white-space:nowrap" valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td style="width:2.27%;white-space:nowrap" valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Calibri;">In April 2018, UPI entered into a new lease agreement for an office in Los Angeles, California. The lease commencement date was July 10, 2018 and terminates in March 2024. The landlord provided a tenant allowance for leasehold improvements of $0.2 million that was accounted for as a lease incentive. The Company&#8217;s remaining contractual obligation under this lease is approximately $0.8 million as of March&#160;31, 2021.</span><span style="color:#212529;font-family:Calibri;"> In November 2019, UPI entered into a sublease for this office space, with a lease commencement date of&#160;January 1, 2020 and continuing until the end of the lease term in March 2024. The subtenants exercised their early access clause and moved into the premises the end of November 2019.&#160;The remaining rental payments to be received over the lease term is approximately $0.7&#160;million </span><span style="font-family:Calibri;">as of March&#160;31, 2021</span><span style="color:#212529;font-family:Calibri;">. The Company accounts for the sublease as on operating lease in accordance with ASC 842-10-25-2 and ASC 842-10-25-3. The main lease was considered for impairment and the amount was determined to be immaterial.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:3.33%;white-space:nowrap" valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td style="width:2.27%;white-space:nowrap" valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Calibri;">In November 2019, UPI entered into a new lease agreement for an office in Princeton, New Jersey, which the Company now uses as its headquarters. The lease commencement date was November 29, 2019 and the lease term is 38 months. The Company&#8217;s remaining contractual obligation under this lease is approximately $1.0 million as of March&#160;31, 2021.</span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, the Company has other operating office equipment and vehicle leases. The Company&#8217;s operating leases may require minimum rent payments, contingent rent payments adjusted periodically for inflation, or rent payments equal to the greater of a minimum rent or contingent rent. The Company&#8217;s leases do not contain any residual value guarantees or material restrictive covenants. The Company&#8217;s leases expire at various dates from 2021 through 2024, with varying renewal and termination options. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The components of lease cost for the three months ended March&#160;31, 2021 were as follows <span style="color:#000000;">(in thousands)</span>:</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:77.4%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.58%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended March&#160;31, 2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:77.4%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease cost</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.58%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">267</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:77.4%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sublease income</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.58%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(56</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:77.4%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Variable lease cost</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.58%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:77.4%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.58%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">233</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The amounts recognized as of March&#160;31, 2021 were as follows <span style="color:#000000;">(in thousands):</span> </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.02%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.88%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">March&#160;31, 2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.02%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Right of use asset</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,901</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.02%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Long-term lease liability</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,201</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.02%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other current liabilities</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,077</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of March&#160;31, 2021, no impairment losses have been recognized to date.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Supplemental information related to leases for the periods reported is as follows (in thousands):</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:77.26%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.72%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended March&#160;31, 2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:77.26%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash paid for amounts included in the measurement of lease liabilities:</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.72%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:77.26%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating cash flows from operating leases</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.72%;white-space:nowrap;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,157</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:77.26%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Right-of-use assets obtained in exchange for new operating lease liabilities</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.72%;white-space:nowrap;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">135</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:77.26%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted-average remaining lease term of operating leases</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.72%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.13 years</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:77.26%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted-average discount rate of operating leases</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.72%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.36%</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Calibri;font-size:10pt;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;color:#000000;font-family:Calibri;font-size:10pt;text-transform:none;font-variant: normal;">Subleases</span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of March&#160;31, 2021 undiscounted cash flows to be received under the Company&#8217;s operating sublease on an annual basis was as follows (in thousands):</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:77.54%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.42%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Operating Leases</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:77.54%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Years ending December 31,</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.42%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:77.54%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Remainder of 2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.42%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">176</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:77.54%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.42%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">243</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:77.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2023</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.42%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">251</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:77.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2024</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.42%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">49</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:77.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2025</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.42%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:77.54%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2026 and thereafter</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.42%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:77.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.42%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">719</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sublease income is recognized net within operating expenses. Sublease income for the three months ended March&#160;31, 2021 was as follows (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:77.54%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.42%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended March&#160;31, 2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:77.54%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sublease income from fixed lease payments</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.42%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">56</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:77.54%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sublease income from variable payments</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.42%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:77.54%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.42%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">56</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI http://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140482545986136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue from Product Sales<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue From Contract With Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerTextBlock', window );">Revenue from Product Sales</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Note 10 &#8211; Revenue From Product Sales</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net product sales consist of the following for the three months ended March&#160;31, 2021 (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:77.68%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.28%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended March&#160;31, 2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:77.68%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Jelmyto</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.28%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,485</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI http://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130551-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130556-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130554-203045<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130550-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130554-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130554-203045<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130554-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130558-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130554-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140482559393352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>License and Collaboration Agreements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_urgn_LiscenseAgreementAbstract', window );"><strong>Liscense Agreement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_urgn_LicenseAndCollaborationAgreementsDisclosureTextBlock', window );">License and Collaboration Agreements</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Note 11 &#8211; License and Collaboration Agreements</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Calibri;font-size:10pt;text-transform:none;font-variant: normal;">Allergan/AbbVie Agreement</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In October 2016, the Company entered into the Allergan/AbbVie Agreement and granted Allergan (now part of AbbVie) an exclusive worldwide license to research, develop, manufacture and commercialize pharmaceutical products that contain <span style="font-style:italic;">RTGel</span> and clostridial toxins (including BOTOX<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup>), alone or in combination with certain other active ingredients, referred to as the Licensed Products, which are approved for the treatment of adults with overactive bladder who cannot use or do not adequately respond to anticholinergics. Additionally, the Company granted Allergan a non-exclusive, worldwide license to use certain of the Company&#8217;s trademarks as required for Allergan to practice its exclusive license with respect to the Licensed Products.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the Allergan/AbbVie Agreement, Allergan is solely responsible for costs and development of the Licensed Products and obtaining all regulatory approvals for Licensed Products worldwide, as well as worldwide commercialization of the Licensed Products after receiving the regulatory approval to do so. Allergan is required to use commercially reasonable efforts to develop and commercialize the Licensed Products for overactive bladder in certain major market countries.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Further, the Company is eligible to receive additional material milestone payments of up to an aggregate of $200.0 million upon the successful completion of certain development, regulatory and commercial milestones. As of March&#160;31, 2021, since inception of the Allergan/AbbVie Agreement the Company has received a total of&#160;$25.0 million in milestone payments from Allergan. Allergan will pay the Company a tiered royalty in the low single digits based on worldwide annual net sales of Licensed Products, subject to certain reductions for the market entry of competing products and/or loss of the Company&#8217;s patent coverage of Licensed Products. The Company is responsible for payments to any third party for certain <span style="font-style:italic;">RTGel</span>-related third-party intellectual properties.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the Allergan/AbbVie Agreement, Allergan granted the Company a non-exclusive, sublicensable, fully paid-up, perpetual, worldwide license under any improvements Allergan makes to the composition, formulation, or manufacture of <span style="font-style:italic;">RTGel</span> for the research, development, manufacture and commercialization of any product containing <span style="font-style:italic;">RTGel</span> and any active ingredient (other than a clostridial toxin) for all indications other than indications covered by the agreement and an exclusive, sublicensable, royalty-bearing (in low single digits), perpetual worldwide license under such improvements for use in the prevention or treatment of oncology indications.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In August 2020, the Company announced that the Phase 2 APOLLO trial did not meet the primary endpoint, it is believed to be the result of BOTOX not effectively permeating the urothelium. The Company is continuing to explore the potential use of <span style="font-style:italic;">RTGel</span> in combination with other products in AbbVie&#8217;s portfolio. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Calibri;font-size:10pt;text-transform:none;font-variant: normal;">Agenus Agreement<span style="font-weight:normal;font-style:normal;"> </span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In November 2019, the Company entered into a license agreement with Agenus Inc, pursuant to which Agenus granted to the Company an exclusive, worldwide (not including Argentina, Brazil, Chile, Colombia, Peru, Venezuela and their respective territories and possessions), royalty-bearing, sublicensable license under Agenus&#8217;s intellectual property rights to develop, make, use, sell, import, and otherwise commercialize products incorporating a proprietary antibody of Agenus known as AGEN1884 for the treatment of cancers of the urinary tract via intravesical delivery. AGEN1884 is an anti-CTLA-4 antagonist that is currently being evaluated by Agenus as a monotherapy in PD-1 refractory patients and in combination with Agenus&#8217; anti-PD-1 antibody in solid tumors. Initially, the Company plans to develop AGEN1884 in combination with UGN-201 for the treatment of high-grade NMIBC. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to the license agreement, the Company paid Agenus an upfront fee of $10.0 million and has agreed to pay Agenus up to $115.0 million upon achieving certain clinical development and regulatory milestones, up to $85.0 million upon achieving certain commercial milestones, and royalties on net sales of licensed products in the 14%-20% range. The Company will be responsible for all development and commercialization activities. Under the terms of the license agreement, Agenus has agreed to use commercially reasonable efforts to supply AGEN1884 to the Company for use in preclinical studies or clinical trials.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unless earlier terminated in accordance with the terms of the license agreement, the license agreement will expire on a product-by-product and country-by-country basis at the later of (a) the expiration of the last to expire valid claim of a licensed patent right that covers the licensed product in such country or (b) 15 years after the first commercial sale of the licensed product in such country. The Company may terminate the license agreement for convenience upon 180 days&#8217; written notice to Agenus. Either party may terminate the license agreement upon 60 days&#8217; notice to the other party if, prior to the first commercial sale of a licensed product, the Company substantially ceases to conduct development activities of the licensed products for nine consecutive months (and during such period, Agenus has complied with its obligations under the license agreement) other than in response to a requirement of an applicable regulatory authority or an event outside of the Company&#8217;s control. In addition, either party may terminate the license agreement in the event of an uncured material breach of the other party. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Calibri;font-size:10pt;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-family:Calibri;font-size:10pt;text-transform:none;font-variant: normal;">MD Anderson Agreement</span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">In January 2021, the Company announced that it entered into a three-year strategic research collaboration agreement with MD Anderson focusing on UGN-302 as an investigational treatment for high-grade NMIBC. Under the agreement, MD Anderson and the Company will collaborate on the design and conduct of non-clinical and clinical studies with oversight from a joint steering committee. The Company will provide funding, developmental candidates, and other support. Pursuant to the agreement, the Company makes bi-annual payments to MD Anderson fund the collaboration. As of March 31, 2021, the Company has made payments to MD Anderson of $</span>500,000 recognized evenly over the associated six-month period through research and development expenses<span style="Background-color:#FFFFFF;">.</span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_urgn_LicenseAndCollaborationAgreementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License and collaboration agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">urgn_LicenseAndCollaborationAgreementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>urgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_urgn_LiscenseAgreementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>liscense agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">urgn_LiscenseAgreementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>urgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140482547467608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholders' Equity<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Shareholders' Equity</a></td>
<td class="text">
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Note 12 &#8211; Shareholders&#8217; Equity </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company had 100.0 million ordinary shares authorized for issuance as of March&#160;31, 2021 and December&#160;31, 2020, respectively. The Company had 22.3 million and 22.2 million ordinary shares issued and outstanding as of March&#160;31, 2021 and December&#160;31, 2020, respectively. Each<span style="letter-spacing:0.45pt;"> </span>ordinary<span style="letter-spacing:0.65pt;"> </span>share<span style="letter-spacing:0.45pt;"> </span>is<span style="letter-spacing:0.15pt;"> </span>entitled<span style="letter-spacing:0.6pt;"> </span>to<span style="letter-spacing:0.2pt;"> </span>one<span style="letter-spacing:0.35pt;"> </span>vote.<span style="letter-spacing:0.4pt;"> </span>The<span style="letter-spacing:0.35pt;"> </span>hol<span style="letter-spacing:-0.1pt;">d</span>ers<span style="letter-spacing:0.6pt;"> </span>of<span style="letter-spacing:0.2pt;"> </span>ordinary<span style="letter-spacing:0.65pt;"> </span>shares<span style="letter-spacing:0.55pt;"> </span>are<span style="letter-spacing:0.3pt;"> </span>also<span style="letter-spacing:0.35pt;"> </span>entitled<span style="letter-spacing:0.6pt;"> </span>to<span style="letter-spacing:0.2pt;"> </span>receive<span style="letter-spacing:0.6pt;"> </span>dividends<span style="letter-spacing:0.75pt;"> </span><span style="letter-spacing:-0.1pt;">w</span>henever<span style="letter-spacing:0.8pt;"> </span>funds<span style="letter-spacing:0.45pt;"> </span>are<span style="letter-spacing:0.3pt;"> </span>legally available,<span style="letter-spacing:0.75pt;"> </span>when<span style="letter-spacing:0.45pt;"> </span>and<span style="letter-spacing:0.35pt;"> </span>if<span style="letter-spacing:0.3pt;"> </span>declared<span style="letter-spacing:0.7pt;"> </span>by<span style="letter-spacing:0.25pt;"> </span>the<span style="letter-spacing:0.3pt;"> </span>Board<span style="letter-spacing:0.5pt;"> </span>of<span style="letter-spacing:0.2pt;"> </span>Directors <span style="Background-color:#FFFFFF;color:#000000;">(the &#8220;Board&#8221;)</span>.<span style="letter-spacing:0.8pt;"> </span>Since<span style="letter-spacing:0.45pt;"> </span>its<span style="letter-spacing:0.2pt;"> </span>inception,<span style="letter-spacing:0.8pt;"> </span>the<span style="letter-spacing:0.3pt;"> </span>Board<span style="letter-spacing:0.8pt;"> </span>has<span style="letter-spacing:0.3pt;"> </span>not<span style="letter-spacing:0.3pt;"> </span>declared<span style="letter-spacing:0.7pt;"> </span>any<span style="letter-spacing:0.3pt;"> </span>dividends.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;&#160;&#160;&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140482545669048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Share-Based Compensation</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Note 13 &#8211; Share-Based Compensation</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In<span style="letter-spacing:0.2pt;"> </span>October<span style="letter-spacing:0.65pt;"> </span>2010,<span style="letter-spacing:0.45pt;"> </span>the<span style="letter-spacing:0.9pt;"> </span>Board<span style="letter-spacing:0.7pt;"> </span>approved<span style="letter-spacing:0.75pt;"> </span>a<span style="letter-spacing:0.15pt;"> </span>share<span style="letter-spacing:0.45pt;"> </span>option<span style="letter-spacing:0.5pt;"> </span>plan<span style="letter-spacing:0.35pt;"> </span>(the<span style="letter-spacing:0.35pt;"> </span>&#8220;Pl<span style="letter-spacing:-0.1pt;">a</span>n&#8221;)<span style="letter-spacing:0.55pt;"> </span>for<span style="letter-spacing:0.25pt;"> </span>grants<span style="letter-spacing:0.5pt;"> </span>to<span style="letter-spacing:0.2pt;"> </span>Company<span style="letter-spacing:0.8pt;"> </span>employees,<span style="letter-spacing:0.9pt;"> </span>consultants, directors,<span style="letter-spacing:0.75pt;"> </span>and<span style="letter-spacing:0.35pt;"> </span>other<span style="letter-spacing:0.45pt;"> </span>service<span style="letter-spacing:0.6pt;"> </span>providers.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The<span style="letter-spacing:0.4pt;"> </span>grant<span style="letter-spacing:0.45pt;"> </span>of<span style="letter-spacing:0.2pt;"> </span>options<span style="letter-spacing:0.6pt;"> </span>to<span style="letter-spacing:0.2pt;"> </span>Israeli<span style="letter-spacing:0.5pt;"> </span>employees<span style="letter-spacing:0.85pt;"> </span>under<span style="letter-spacing:0.5pt;"> </span>the<span style="letter-spacing:0.3pt;"> </span>Plan<span style="letter-spacing:0.4pt;"> </span>is<span style="letter-spacing:0.15pt;"> </span>su<span style="letter-spacing:-0.1pt;">b</span>ject<span style="letter-spacing:0.6pt;"> </span>to<span style="letter-spacing:0.2pt;"> </span>the<span style="letter-spacing:0.3pt;"> </span>terms<span style="letter-spacing:0.45pt;"> </span>stipulated<span style="letter-spacing:0.8pt;"> </span>by<span style="letter-spacing:0.25pt;"> </span>Section<span style="letter-spacing:0.6pt;"> </span>102<span style="letter-spacing:0.35pt;"> </span>of<span style="letter-spacing:0.2pt;"> </span>the<span style="letter-spacing:0.3pt;"> </span>Israeli<span style="letter-spacing:0.5pt;"> </span>Income<span style="letter-spacing:0.6pt;"> </span>Tax<span style="letter-spacing:0.35pt;"> </span>Ordinance (&#8220;Section<span style="letter-spacing:0.75pt;"> </span>102&#8221;).<span style="letter-spacing:0.5pt;"> </span>The<span style="letter-spacing:0.35pt;"> </span>option<span style="letter-spacing:0.5pt;"> </span>grants<span style="letter-spacing:0.5pt;"> </span>are<span style="letter-spacing:0.3pt;"> </span>subject<span style="letter-spacing:0.6pt;"> </span>to<span style="letter-spacing:0.2pt;"> </span>the<span style="letter-spacing:0.3pt;"> </span>track<span style="letter-spacing:0.4pt;"> </span>chosen<span style="letter-spacing:0.6pt;"> </span>by<span style="letter-spacing:0.25pt;"> </span>the<span style="letter-spacing:0.3pt;"> </span>Company,<span style="letter-spacing:0.8pt;"> </span>either<span style="letter-spacing:0.45pt;"> </span>the<span style="letter-spacing:0.3pt;"> </span>&#8220;regular<span style="letter-spacing:0.65pt;"> </span>income&#8221;<span style="letter-spacing:0.65pt;"> </span>track<span style="letter-spacing:0.4pt;"> </span>or<span style="letter-spacing:0.2pt;"> </span>the<span style="letter-spacing:0.3pt;"> </span>&#8220;capital<span style="letter-spacing:0.6pt;"> </span>gains&#8221;<span style="letter-spacing:0.5pt;"> </span>track,<span style="letter-spacing:0.05pt;"> </span>as<span style="letter-spacing:0.25pt;"> </span>set<span style="letter-spacing:0.3pt;"> </span>out<span style="letter-spacing:0.3pt;"> </span>in<span style="letter-spacing:0.2pt;"> </span>Section<span style="letter-spacing:0.6pt;"> </span>102.<span style="letter-spacing:0.4pt;"> </span>The<span style="letter-spacing:0.35pt;"> </span>Company<span style="letter-spacing:0.8pt;"> </span>registered<span style="letter-spacing:0.8pt;"> </span>the<span style="letter-spacing:0.3pt;"> </span>Plan<span style="letter-spacing:0.4pt;"> </span>un<span style="letter-spacing:-0.1pt;">d</span>er<span style="letter-spacing:0.5pt;"> </span>the<span style="letter-spacing:0.3pt;"> </span>capital<span style="letter-spacing:0.55pt;"> </span>gains<span style="letter-spacing:0.45pt;"> </span>track,<span style="letter-spacing:0.45pt;"> </span>which<span style="letter-spacing:0.5pt;"> </span>offers<span style="letter-spacing:0.45pt;"> </span>more<span style="letter-spacing:0.45pt;"> </span>favorable<span style="letter-spacing:0.75pt;"> </span>tax<span style="letter-spacing:0.3pt;"> </span>rates<span style="letter-spacing:0.45pt;"> </span>to<span style="letter-spacing:0.2pt;"> </span>the employees.<span style="letter-spacing:0.9pt;"> </span>As<span style="letter-spacing:0.25pt;"> </span>a<span style="letter-spacing:0.15pt;"> </span>result,<span style="letter-spacing:0.5pt;"> </span>and<span style="letter-spacing:0.35pt;"> </span>pursuant<span style="letter-spacing:0.7pt;"> </span>to<span style="letter-spacing:0.2pt;"> </span>the<span style="letter-spacing:0.3pt;"> </span>terms<span style="letter-spacing:0.45pt;"> </span>of<span style="letter-spacing:0.2pt;"> </span>Section<span style="letter-spacing:0.6pt;"> </span>102,<span style="letter-spacing:0.4pt;"> </span>the<span style="letter-spacing:0.3pt;"> </span>Company<span style="letter-spacing:0.8pt;"> </span>is<span style="letter-spacing:0.15pt;"> </span>not<span style="letter-spacing:0.3pt;"> </span>allowed<span style="letter-spacing:0.65pt;"> </span>to<span style="letter-spacing:0.2pt;"> </span>claim<span style="letter-spacing:0.45pt;"> </span>as<span style="letter-spacing:0.25pt;"> </span>an<span style="letter-spacing:0.25pt;"> </span>ex<span style="letter-spacing:-0.1pt;">p</span>ense<span style="letter-spacing:0.7pt;"> </span>for<span style="letter-spacing:0.25pt;"> </span>tax<span style="letter-spacing:0.3pt;"> </span>purposes<span style="letter-spacing:0.75pt;"> </span>the amounts<span style="letter-spacing:0.7pt;"> </span>credited<span style="letter-spacing:0.65pt;"> </span>to<span style="letter-spacing:0.2pt;"> </span>the<span style="letter-spacing:0.3pt;"> </span>employees<span style="letter-spacing:0.85pt;"> </span>in<span style="letter-spacing:0.2pt;"> </span>respect<span style="letter-spacing:0.6pt;"> </span>of<span style="letter-spacing:0.2pt;"> </span>options<span style="letter-spacing:0.6pt;"> </span>granted<span style="letter-spacing:0.65pt;"> </span>to<span style="letter-spacing:0.2pt;"> </span>them<span style="letter-spacing:0.45pt;"> </span>under<span style="letter-spacing:0.5pt;"> </span>the<span style="letter-spacing:0.3pt;"> </span>P<span style="letter-spacing:-0.1pt;">l</span>an,<span style="letter-spacing:0.45pt;"> </span>including<span style="letter-spacing:0.7pt;"> </span>amounts<span style="letter-spacing:0.7pt;"> </span>recorded<span style="letter-spacing:0.7pt;"> </span>as<span style="letter-spacing:0.25pt;"> </span>salary<span style="letter-spacing:0.5pt;"> </span>be<span style="letter-spacing:-0.1pt;">n</span>efits<span style="letter-spacing:0.8pt;"> </span>in<span style="letter-spacing:0.2pt;"> </span>the Company&#8217;s<span style="letter-spacing:0.9pt;"> </span>accounts,<span style="letter-spacing:0.8pt;"> </span>with<span style="letter-spacing:0.35pt;"> </span>the<span style="letter-spacing:0.3pt;"> </span>exception<span style="letter-spacing:0.8pt;"> </span>of<span style="letter-spacing:0.2pt;"> </span>the<span style="letter-spacing:0.3pt;"> </span>work-income<span style="letter-spacing:1pt;"> </span>b<span style="letter-spacing:-0.1pt;">e</span>nefit<span style="letter-spacing:0.55pt;"> </span>component,<span style="letter-spacing:0.95pt;"> </span>if<span style="letter-spacing:0.15pt;"> </span>any,<span style="letter-spacing:0.35pt;"> </span>determined<span style="letter-spacing:0.9pt;"> </span>on<span style="letter-spacing:0.25pt;"> </span>grant<span style="letter-spacing:0.45pt;"> </span>date.<span style="letter-spacing:0.45pt;"> </span>For<span style="letter-spacing:0.4pt;"> </span>non-employees<span style="letter-spacing:1.3pt;"> </span>and<span style="letter-spacing:0.35pt;"> </span>for non-Israeli<span style="letter-spacing:0.95pt;"> </span>employees,<span style="letter-spacing:0.9pt;"> </span>the<span style="letter-spacing:0.3pt;"> </span>Plan<span style="letter-spacing:0.4pt;"> </span>is<span style="letter-spacing:0.15pt;"> </span>subject<span style="letter-spacing:0.6pt;"> </span>to<span style="letter-spacing:0.2pt;"> </span>Section<span style="letter-spacing:0.6pt;"> </span>3(i)<span style="letter-spacing:0.3pt;"> </span>of<span style="letter-spacing:0.2pt;"> </span>the<span style="letter-spacing:0.3pt;"> </span>Israeli<span style="letter-spacing:0.5pt;"> </span>Income<span style="letter-spacing:0.6pt;"> </span>Tax<span style="letter-spacing:0.35pt;"> </span>Ordinance.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Employees are typically granted stock options and/or restricted stock units, or RSUs, upon commencement of employment. Also, eligible employees may receive an annual grant of options or RSUs. Non-employee members of the Board typically receive a grant of RSUs and/or stock options annually. The term of any option granted under the Plan cannot exceed 10 years. Options shall not have an exercise price less than 100% of the fair market value of the Company&#8217;s ordinary shares on the grant date, and generally vest over a period of three years. If the individual possesses more than 10% of the combined voting power of all classes of equity of the Company, the exercise price shall not be less than 110% of the fair market value of an ordinary share of stock on the date of grant.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s RSU and option grants provide for accelerated or continued vesting in certain circumstances as defined in the plans and related grant agreements, including a termination in connection with a change in control. RSUs generally vest in a 33% increment upon the first anniversary of grant, and in either equal quarterly or annual amounts for the two years following the one-year anniversary of the grant date. Options generally vest in a 33% increment upon the first anniversary of the grant date, and in either equal quarterly or annual amounts for the two years following the one-year anniversary of the grant date.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The<span style="letter-spacing:0.35pt;"> </span>expected<span style="letter-spacing:0.75pt;"> </span>volatility<span style="letter-spacing:0.65pt;"> </span>is<span style="letter-spacing:0.15pt;"> </span>based<span style="letter-spacing:0.5pt;"> </span>on<span style="letter-spacing:0.25pt;"> a mix of the Company&#8217;s historical volatility, and </span>the<span style="letter-spacing:0.3pt;"> </span>histori<span style="letter-spacing:-0.1pt;">c</span>al<span style="letter-spacing:0.7pt;"> </span>volatility<span style="letter-spacing:0.65pt;"> </span>of<span style="letter-spacing:0.2pt;"> </span>comparable<span style="letter-spacing:1pt;"> </span>companies with similar attributes to the Company, including industry, stage of life cycle, size and financial leverage.<span style="letter-spacing:0.9pt;"> </span>The<span style="letter-spacing:0.35pt;"> </span>risk-free<span style="letter-spacing:0.65pt;"> </span>interest<span style="letter-spacing:0.6pt;"> </span>rate<span style="letter-spacing:0.35pt;"> </span>assumption<span style="letter-spacing:0.9pt;"> </span>is<span style="letter-spacing:0.15pt;"> </span>based<span style="letter-spacing:0.5pt;"> </span>on observed<span style="letter-spacing:0.75pt;"> </span>interest<span style="letter-spacing:0.6pt;"> </span>rates<span style="letter-spacing:0.45pt;"> </span>appropriate<span style="letter-spacing:0.9pt;"> </span>for<span style="letter-spacing:0.25pt;"> </span>the<span style="letter-spacing:0.3pt;"> </span>expected<span style="letter-spacing:0.75pt;"> </span>term<span style="letter-spacing:0.4pt;"> </span>of<span style="letter-spacing:0.2pt;"> </span>the<span style="letter-spacing:0.3pt;"> </span>options<span style="letter-spacing:0.6pt;"> </span>granted.<span style="letter-spacing:0.5pt;"> </span>The<span style="letter-spacing:0.35pt;"> </span>expected<span style="letter-spacing:0.75pt;"> </span>term<span style="letter-spacing:0.4pt;"> </span>is<span style="letter-spacing:0.15pt;"> </span>the<span style="letter-spacing:0.3pt;"> </span>length<span style="letter-spacing:0.5pt;"> </span>of<span style="letter-spacing:0.2pt;"> </span>time<span style="letter-spacing:0.35pt;"> </span>until the<span style="letter-spacing:0.05pt;"> </span>expected<span style="letter-spacing:0.75pt;"> </span>dates<span style="letter-spacing:0.45pt;"> </span>of<span style="letter-spacing:0.2pt;"> </span>exercising<span style="letter-spacing:0.8pt;"> </span>the<span style="letter-spacing:0.3pt;"> </span>options and<span style="letter-spacing:0.35pt;"> </span>is<span style="letter-spacing:0.15pt;"> </span>estimated<span style="letter-spacing:0.8pt;"> </span>for<span style="letter-spacing:0.25pt;"> </span>employees<span style="letter-spacing:0.85pt;"> </span>using<span style="letter-spacing:0.45pt;"> </span>the<span style="letter-spacing:0.3pt;"> </span>simplified<span style="letter-spacing:0.75pt;"> </span>method<span style="letter-spacing:0.6pt;"> </span>due<span style="letter-spacing:0.35pt;"> </span>to insufficient<span style="letter-spacing:0.85pt;"> </span>specific<span style="letter-spacing:0.6pt;"> </span>historical<span style="letter-spacing:0.7pt;"> </span>information<span style="letter-spacing:0.9pt;"> </span>of<span style="letter-spacing:0.2pt;"> </span>employ<span style="letter-spacing:-0.1pt;">e</span>es&#8217;<span style="letter-spacing:0.9pt;"> </span>exercise<span style="letter-spacing:0.7pt;"> </span>behavior,<span style="letter-spacing:0.75pt;"> </span>and<span style="letter-spacing:0.35pt;"> </span>for<span style="letter-spacing:0.3pt;"> </span>non-employees,<span style="letter-spacing:1.35pt;"> </span>and directors<span style="letter-spacing:0.7pt;"> </span>using<span style="letter-spacing:0.45pt;"> </span>the<span style="letter-spacing:0.05pt;"> </span>contractual<span style="letter-spacing:0.9pt;"> </span>term.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In March 2017, the Board adopted the 2017 Equity Incentive Plan (the "2017 Plan"), which was approved by the shareholders in April 2017. The 2017 Plan provides for the grant of incentive stock options to the Company's employees and for the grant of </p>
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">nonstatutory stock options, stock appreciation rights, restricted stock awards, </span><span style="font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">RSU</span><span style="font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> awards, performance </span><span style="font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">share </span><span style="font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">awards, performance cash awards, and other forms of </span><span style="font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">share </span><span style="font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">awards to the Company's employees, directors and consultants.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The maximum number of ordinary shares that may initially be issued under the 2017 Plan is 1,400,000. In addition, the number of ordinary shares reserved for issuance under the 2017 Plan will automatically increase on January 1st of each calendar year, from January 1, 2018 through January 1, 2026, so that the number of such shares reserved for issuance will equal 12% of the total number of ordinary shares outstanding on the last day of the calendar month prior to the date of each automatic increase, or a lesser number of shares determined by the Board. The maximum number of ordinary shares that may be issued upon the exercise of stock options under the 2017 Plan is 5,600,000. On January 1, 2018, the share reserve increased by 250,167 to 1,650,167. On October 12, 2018, the Company increased the amount of registered ordinary shares of the Company&#8217;s 2017 Plan by 1,900,000 to 3,550,167. On June 8, 2020 the Company increased the amount of registered ordinary shares of the Company&#8217;s 2017 Plan by 400,000 to 3,950,167. On March 17, 2021, the Board approved an increase to the amount of registered ordinary shares of the Company&#8217;s 2017 Plan by 400,000 to 4,350,167, subject to approval by the Company&#8217;s shareholders.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;&#160;&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In May 2019, the Company adopted the UroGen Pharma Ltd. 2019 Inducement Plan (the &#8220;Inducement Plan&#8221;). Under the Inducement Plan, the Company is authorized to issue up to 900,000 ordinary shares pursuant to awards issued under the Inducement Plan. <span style="Background-color:#FFFFFF;color:#000000;">The only persons eligible to receive grants of Awards (as defined below) under the Inducement Plan are individuals who satisfy the standards for inducement grants under Nasdaq Marketplace Rule 5635(c)(4) or 5635(c)(3) and the related guidance under Nasdaq IM&#160;5635-1,&#160;including individuals who were not previously an employee or director of the Company or are following a bona fide period of&#160;non-employment,&#160;in each case as an inducement material to such individual&#8217;s agreement to enter into employment with the Company.&#160;Under the Inducement Plan, an &#8220;Award&#8221; is a nonstatutory stock option, restricted stock unit or other right to receive ordinary shares pursuant to the Inducement Plan.</span> &#160;&#160;&#160;&#160;&#160;&#160;&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The<span style="letter-spacing:0.35pt;"> </span>following<span style="letter-spacing:0.7pt;"> </span>table<span style="letter-spacing:0.4pt;"> </span>illustrates<span style="letter-spacing:0.75pt;"> </span>the<span style="letter-spacing:0.3pt;"> </span>effect<span style="letter-spacing:0.45pt;"> </span>of<span style="letter-spacing:0.2pt;"> </span>share-based<span style="letter-spacing:1pt;"> </span>com<span style="letter-spacing:-0.1pt;">p</span>ensation<span style="letter-spacing:1.1pt;"> </span>on<span style="letter-spacing:0.25pt;"> </span>the<span style="letter-spacing:0.3pt;"> condensed consolidated </span>statements<span style="letter-spacing:0.9pt;"> </span>of<span style="letter-spacing:0.2pt;"> </span>operations (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.54%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended March&#160;31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development expenses</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,107</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,943</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Selling, general and administrative expenses</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,088</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,674</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,195</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,617</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The total unrecognized compensation cost of options and RSUs at March&#160;31, 2021 is&#160;$33.6 million with a weighted average recognition period of 1.86 years. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140482550084984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Note 14 &#8211; Income Taxes </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">UroGen Pharma Ltd.<span style="letter-spacing:0.8pt;"> </span>is<span style="letter-spacing:0.15pt;"> </span>taxed<span style="letter-spacing:0.45pt;"> </span>under<span style="letter-spacing:0.5pt;"> </span>Israeli<span style="letter-spacing:0.5pt;"> </span>tax<span style="letter-spacing:0.3pt;"> </span>laws. As of March&#160;31, 2021, the Company continues to maintain a full valuation allowance against deferred tax assets for all jurisdictions. In evaluating the need for a valuation allowance, the Company considers all sources of taxable income available to realize the deferred tax asset, including the future reversal of existing temporary differences, forecasts of future taxable income, and tax planning strategies. The Company has cumulative global pretax accounting losses for the years ended 2020, 2019 and 2018, and for the three months ended March&#160;31, 2021. The Company will continue to assess the extent to which its deferred tax assets may be realized in the future and will adjust the valuation allowance as needed.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has a liability for uncertain tax positions of $2.7 million as of March 31, 2021 for tax positions relating to transfer pricing between affiliated entities. The Company recognizes interest accrued and penalties related to uncertain tax positions as a component of income tax expense. As of March 31, 2021, the Company&#8217;s liability for uncertain tax positions includes  $0.7 million of interest and penalties accrued during 2020.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company operates on a global basis and is subject to tax laws and regulations in the U.S. and Israel. The estimate of the Company&#8217;s tax liabilities relating to uncertain tax positions requires management to assess uncertainties and to make judgments about the application of complex tax laws and regulations, expectations regarding the outcome of tax authority examinations, as well as the ultimate measurement of potential liabilities. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The uncertain tax positions are reviewed quarterly and adjusted as events occur that could affect potential liabilities for additional taxes, including lapsing of applicable statutes of limitations, correspondence with tax authorities, proposed assessments by tax authorities, identification of new issues, and issuance of new legislation or regulations. </span><span style="font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company believes that adequate amounts of tax have been provided in income tax expense for any adjustments that may result from its uncertain tax positions. Based upon the information currently available, the Company does not reasonably expect changes in its existing uncertain tax positions in the next 12 months and have recorded the gross uncertain tax positions as a long-term liability.</span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140482547249608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Parties<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related Parties</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Note 15 &#8211; Related Parties</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There were no related party transactions for the three months ended March&#160;31, 2021 or the three months ended March&#160;31, 2020. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:12pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -URI http://asc.fasb.org/topic&amp;trid=2122745<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39691-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140482545881096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments And Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Note 16 &#8211; Commitments and Contingencies </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the normal course of business, the Company enters into contracts that contain a variety of indemnifications with its employees, licensors, suppliers and service providers. Further, the Company indemnifies its directors and officers who are, or were, serving at the Company<span style="color:#000000;">&#8217;</span>s request in such capacities. The Company<span style="color:#000000;">&#8217;</span>s maximum exposure under these arrangements is unknown as of March&#160;31, 2021 and December&#160;31, 2020. The Company does not anticipate recognizing any significant losses relating to these arrangements.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Calibri;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Grants from the Israeli Innovation Authority in Israel (&#8220;IIA&#8221;)</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has received grants from the IIA for research and development funding. Up until 2007, the IIA participation in the funding of the Company&#8217;s operations was by grants provided to Granot Ventures, a government supported technology incubator, as part of the Israeli Ministry of Industry and Commerce Director General Directive 8.2. Since 2008, the funding was provided directly to Company.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On January 12, 2020, the IIA Office of Chief Scientist approved the Company's request to unwind its obligation to the IIA regarding grants that were loaned to the Company between January 2004 and September 2016. The total payment under the IIA approval, net of the royalties already paid, $6.6 million, was fully paid during the first quarter of 2020 and recognized as research and development expense. Based on this payment, the Company will have full freedom to transfer IIA-funded technology or manufacture products developed with IIA-funded technology outside of the State of Israel. Other than the commitment to continue at least 75% of its based R&amp;D jobs in Israel (at the time of settlement) for a period of at least three years, all other obligations with the IIA ceased to exist as per the agreement.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Calibri;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Separation Agreement</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On March 20, 2020, the Company entered into a Separation Agreement with Stephen Mullennix, the Company&#8217;s Chief Operating Officer, which sets forth the terms of Mr. Mullennix&#8217;s termination of employment with the Company, effective as of April 30, 2020, or Separation Date. The arrangement includes cash severance, as well as a pro rata portion of the target annual bonus for calendar year 2020, contingent on certain performance conditions. The Company accrued $0.4 million during the quarter ended March 31, 2020 in relation to this arrangement.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On September 7, 2020, the Company entered into a Separation Agreement with Peter Pfreundschuh, the Company&#8217;s Chief Financial Officer, which sets forth the terms of Mr. Pfreundschuh&#8217;s termination of employment with the Company, effective as of October 15, 2020. The arrangement includes cash severance, a pro rata portion of the target annual bonus for calendar year 2020 contingent on certain performance conditions, and partial acceleration of share-based compensation. The Company recognized $0.7 million during the year ended December 31, 2020 in relation to this arrangement, which was paid during March and April 2021.<span style="font-family:Times New Roman;">&#160;&#160;&#160;&#160; </span>&#160;&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Calibri;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Leases</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">See N</span><span style="font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ote </span><span style="font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9</span><span style="font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> for further discussion regarding lease commitments.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559207&amp;loc=d3e25336-109308<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559207&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140482545989464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Note 17 &#8211; Subsequent Events</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In March 2021, the Company announced a transaction with RTW Investments (&#8220;RTW&#8221;) totaling $75.0 million in funding for the Company to support the launch of Jelmyto and the development of UGN-102. RTW will provide the Company with an upfront cash payment of $75.0 million and will receive tiered future payments based on global annual net product sales of Jelmyto and UGN-102, if approved. The Company received the $75.0 million of cash, net of costs in May 2021 following the receipt of necessary regulatory approvals, and recognized an associated long term liability.&#160;&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI http://asc.fasb.org/topic&amp;trid=2122774<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140482551280792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of Consolidation</a></td>
<td class="text">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Calibri;font-size:10pt;text-transform:none;font-variant: normal;">Principles of Consolidation</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The condensed consolidated financial statements include the accounts of UPL and its subsidiary, UPI. Intercompany balances and transactions have been eliminated during consolidation.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Calibri;font-size:10pt;text-transform:none;font-variant: normal;">Use of Estimates</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The<span style="letter-spacing:0.35pt;"> </span>preparation<span style="letter-spacing:0.9pt;"> </span>of<span style="letter-spacing:0.2pt;"> </span>financial<span style="letter-spacing:0.65pt;"> </span>statements<span style="letter-spacing:0.9pt;"> </span>in<span style="letter-spacing:0.2pt;"> </span>conformity<span style="letter-spacing:0.85pt;"> </span>with<span style="letter-spacing:0.35pt;"> U.S. </span>GAAP<span style="letter-spacing:0.5pt;"> </span>requires<span style="letter-spacing:0.65pt;"> </span>man<span style="letter-spacing:-0.1pt;">a</span>gement<span style="letter-spacing:1.05pt;"> </span>to<span style="letter-spacing:0.2pt;"> </span>make<span style="letter-spacing:0.45pt;"> </span>estimates<span style="letter-spacing:0.8pt;"> </span>and<span style="letter-spacing:0.35pt;"> </span>assumptions<span style="letter-spacing:1pt;"> </span>that<span style="letter-spacing:0.35pt;"> </span>affect the<span style="letter-spacing:0.05pt;"> </span>reported<span style="letter-spacing:0.7pt;"> </span>amounts<span style="letter-spacing:0.7pt;"> </span>of<span style="letter-spacing:0.2pt;"> </span>assets<span style="letter-spacing:0.6pt;"> </span>and<span style="letter-spacing:0.35pt;"> </span>liabilities,<span style="letter-spacing:0.75pt;"> </span>the<span style="letter-spacing:0.3pt;"> </span>disclosure<span style="letter-spacing:0.8pt;"> </span>of<span style="letter-spacing:0.2pt;"> </span>cont<span style="letter-spacing:-0.1pt;">i</span>ngent<span style="letter-spacing:0.85pt;"> </span>assets<span style="letter-spacing:0.55pt;"> </span>and<span style="letter-spacing:0.35pt;"> </span>liabilities<span style="letter-spacing:0.7pt;"> </span>at<span style="letter-spacing:0.2pt;"> </span>the<span style="letter-spacing:0.3pt;"> </span>date<span style="letter-spacing:0.4pt;"> </span>of<span style="letter-spacing:0.2pt;"> </span>the<span style="letter-spacing:0.3pt;"> </span>financ<span style="letter-spacing:-0.1pt;">i</span>al<span style="letter-spacing:0.65pt;"> </span>statements<span style="letter-spacing:0.9pt;"> </span>and<span style="letter-spacing:0.35pt;"> </span>the reported<span style="letter-spacing:0.7pt;"> </span>amounts<span style="letter-spacing:0.7pt;"> </span>of<span style="letter-spacing:0.2pt;"> </span>revenues<span style="letter-spacing:0.75pt;"> </span>and<span style="letter-spacing:0.35pt;"> </span>expenses<span style="letter-spacing:0.8pt;"> </span>duri<span style="letter-spacing:-0.1pt;">n</span>g<span style="letter-spacing:0.5pt;"> </span>the<span style="letter-spacing:0.3pt;"> </span>reporting<span style="letter-spacing:0.7pt;"> </span>period.<span style="letter-spacing:0.55pt;"> </span>Actual<span style="letter-spacing:0.5pt;"> </span>results<span style="letter-spacing:0.55pt;"> </span>may<span style="letter-spacing:0.35pt;"> </span>differ<span style="letter-spacing:0.45pt;"> </span>from<span style="letter-spacing:0.4pt;"> </span>those<span style="letter-spacing:0.45pt;"> </span>estimates.<span style="letter-spacing:0.8pt;"> </span>As<span style="letter-spacing:0.25pt;"> </span>applicable<span style="letter-spacing:0.9pt;"> </span>to the unaudited condensed<span style="letter-spacing:0.45pt;"> </span>consolidated<span style="letter-spacing:1pt;"> </span>financi<span style="letter-spacing:-0.1pt;">a</span>l<span style="letter-spacing:0.65pt;"> </span>statements,<span style="letter-spacing:0.95pt;"> </span>the<span style="letter-spacing:0.3pt;"> critical </span>accounting<span style="letter-spacing:0.35pt;"> estimates relate </span>to<span style="letter-spacing:0.2pt;"> </span>the<span style="letter-spacing:0.3pt;"> </span>fair<span style="letter-spacing:0.3pt;"> </span>value<span style="letter-spacing:0.45pt;"> </span>of<span style="letter-spacing:0.2pt;"> </span>share-based<span style="letter-spacing:1pt;"> </span>compensat<span style="letter-spacing:-0.1pt;">i</span>on,<span style="letter-spacing:0.55pt;"> </span>measurement<span style="letter-spacing:0.5pt;"> </span>of<span style="letter-spacing:0.2pt;"> </span>revenue and estimate of uncertain tax positions.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock', window );">Functional Currency</a></td>
<td class="text">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Calibri;font-size:10pt;text-transform:none;font-variant: normal;">Functional<span style="letter-spacing:0.9pt;"> </span>Currency</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The<span style="letter-spacing:0.35pt;"> </span>U.S.<span style="letter-spacing:0.4pt;"> </span>dollar<span style="letter-spacing:0.45pt;"> </span>(&#8220;Dollar&#8221;)<span style="letter-spacing:0.7pt;"> </span>is<span style="letter-spacing:0.15pt;"> </span>the<span style="letter-spacing:0.35pt;"> </span>currency<span style="letter-spacing:0.7pt;"> </span>of<span style="letter-spacing:0.2pt;"> </span>the<span style="letter-spacing:0.3pt;"> </span>primary<span style="letter-spacing:0.6pt;"> </span>economic<span style="letter-spacing:0.8pt;"> </span>environment<span style="letter-spacing:1pt;"> </span>in<span style="letter-spacing:0.2pt;"> </span>which<span style="letter-spacing:0.5pt;"> </span>the<span style="letter-spacing:0.3pt;"> </span>operations<span style="letter-spacing:0.85pt;"> </span>of<span style="letter-spacing:0.2pt;"> </span>the<span style="letter-spacing:0.3pt;"> </span>Com<span style="letter-spacing:-0.1pt;">p</span>any<span style="letter-spacing:0.8pt;"> </span>are conducted.<span style="letter-spacing:0.9pt;"> </span>Therefore,<span style="letter-spacing:0.85pt;"> </span>the<span style="letter-spacing:0.3pt;"> </span>functional<span style="letter-spacing:0.8pt;"> </span>currency<span style="letter-spacing:0.7pt;"> </span>of<span style="letter-spacing:0.2pt;"> </span>the<span style="letter-spacing:0.3pt;"> </span>Company<span style="letter-spacing:0.8pt;"> </span>is<span style="letter-spacing:0.15pt;"> </span>the<span style="letter-spacing:0.3pt;"> </span>Dol<span style="letter-spacing:-0.1pt;">l</span>ar.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accordingly,<span style="letter-spacing:1pt;"> </span>transactions<span style="letter-spacing:0.95pt;"> </span>in<span style="letter-spacing:0.2pt;"> </span>currencies<span style="letter-spacing:0.85pt;"> </span>other<span style="letter-spacing:0.45pt;"> </span>than<span style="letter-spacing:0.4pt;"> </span>the<span style="letter-spacing:0.3pt;"> </span>Do<span style="letter-spacing:-0.1pt;">l</span>lar<span style="letter-spacing:0.5pt;"> </span>are<span style="letter-spacing:0.3pt;"> </span>measured<span style="letter-spacing:0.8pt;"> </span>and<span style="letter-spacing:0.35pt;"> </span>recorded<span style="letter-spacing:0.7pt;"> </span>in<span style="letter-spacing:0.2pt;"> </span>the<span style="letter-spacing:0.3pt;"> </span>functional<span style="letter-spacing:0.8pt;"> </span>currency<span style="letter-spacing:0.7pt;"> </span>usi<span style="letter-spacing:-0.1pt;">n</span>g<span style="letter-spacing:0.45pt;"> </span>the<span style="letter-spacing:0.3pt;"> </span>exchange<span style="letter-spacing:0.8pt;"> </span>rate<span style="letter-spacing:0.35pt;"> </span>in effect<span style="letter-spacing:0.45pt;"> </span>at<span style="letter-spacing:0.2pt;"> </span>the<span style="letter-spacing:0.3pt;"> </span>date<span style="letter-spacing:0.4pt;"> </span>of<span style="letter-spacing:0.2pt;"> </span>the<span style="letter-spacing:0.35pt;"> </span>transaction.<span style="letter-spacing:0.95pt;"> </span>At<span style="letter-spacing:0.2pt;"> </span>the<span style="letter-spacing:0.3pt;"> </span>balance<span style="letter-spacing:0.65pt;"> </span>sheet<span style="letter-spacing:0.45pt;"> </span>date,<span style="letter-spacing:0.45pt;"> </span>monetary<span style="letter-spacing:0.75pt;"> </span>assets<span style="letter-spacing:0.55pt;"> </span>and<span style="letter-spacing:0.35pt;"> </span>liab<span style="letter-spacing:-0.1pt;">i</span>lities<span style="letter-spacing:0.7pt;"> </span>that<span style="letter-spacing:0.35pt;"> </span>are<span style="letter-spacing:0.3pt;"> </span>denominated<span style="letter-spacing:1.05pt;"> </span>in<span style="letter-spacing:0.2pt;"> </span>currencies<span style="letter-spacing:0.85pt;"> </span>other<span style="letter-spacing:0.45pt;"> </span>than the<span style="letter-spacing:0.05pt;"> </span>Dollar<span style="letter-spacing:0.5pt;"> </span>are<span style="letter-spacing:0.3pt;"> </span>measured<span style="letter-spacing:0.8pt;"> </span>using<span style="letter-spacing:0.45pt;"> </span>the<span style="letter-spacing:0.3pt;"> </span>official<span style="letter-spacing:0.55pt;"> </span>exch<span style="letter-spacing:-0.1pt;">a</span>nge<span style="letter-spacing:0.8pt;"> </span>rate<span style="letter-spacing:0.35pt;"> </span>at<span style="letter-spacing:0.2pt;"> </span>the<span style="letter-spacing:0.3pt;"> </span>balance<span style="letter-spacing:0.65pt;"> </span>sheet<span style="letter-spacing:0.45pt;"> </span>date.<span style="letter-spacing:0.45pt;"> </span>The<span style="letter-spacing:0.35pt;"> </span>effects<span style="letter-spacing:0.55pt;"> </span>of<span style="letter-spacing:0.2pt;"> </span>foreign<span style="letter-spacing:0.55pt;"> </span>currency<span style="letter-spacing:0.8pt;"> </span>re-measurements<span style="letter-spacing:1.45pt;"> </span>are recorded<span style="letter-spacing:0.7pt;"> </span>in<span style="letter-spacing:0.2pt;"> </span>the<span style="letter-spacing:0.3pt;"> condensed </span>consolidated<span style="letter-spacing:1pt;"> </span>statements<span style="letter-spacing:0.9pt;"> </span>of<span style="letter-spacing:0.2pt;"> </span>operations<span style="letter-spacing:0.85pt;"> </span>as<span style="letter-spacing:0.25pt;"> </span>&#8220;Interest and other income, net.&#8221;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_urgn_CashAndCashEquivalentsAndMarketableSecuritiesPolicyPolicyTextBlock', window );">Cash and Cash Equivalents; Marketable Securities</a></td>
<td class="text">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Calibri;font-size:10pt;text-transform:none;font-variant: normal;">Cash and Cash Equivalents; <span style="color:#000000;">Marketable Securities</span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company considers all highly liquid investments with an original maturity of three months or less when purchased to be cash equivalents. Cash and cash equivalents consist primarily of money market funds and bank money market accounts and are stated at cost, which approximates fair value. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash and cash equivalents and marketable securities totaled $75.9 million as of March&#160;31, 2021. The Company classifies its marketable securities as available-for-sale in accordance with the <span style="letter-spacing:-0.2pt;">Financial Accounting Standards Board (&#8220;</span>FASB&#8221;) Accounting Standards Codification (&#8220;ASC&#8221;) Topic 320, &#8220;Investments &#8212; Debt and Equity Securities&#8221;. Available-for-sale debt securities are carried at fair value with unrealized gains and losses reported in other comprehensive income/loss within shareholders&#8217; equity. Realized gains and losses are recorded as a component of interest and other income (expense), net. The cost of securities sold is based on the specific-identification method. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Short-term investments are valued using models or other valuation methodologies that use Level 2 inputs. These models are primarily industry-standard models that consider various assumptions, including time value, yield curve, volatility factors, default rates, current market and contractual prices for the underlying financial instruments, as well as other relevant economic measures. The majority of these assumptions are observable in the marketplace, can be derived from observable data or are supported by observable levels at which transactions are executed in the marketplace.&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For individual debt securities classified as available-for-sale securities where there has been a decline in fair value below amortized cost, the Company determines whether the decline resulted from a credit loss or other factors. The Company records impairment relating to credit losses through an allowance for credit losses, limited by the amount that the fair value is less than the amortized cost basis. Impairment that has not been recorded through an allowance for credit losses is recorded through other comprehensive income, net of applicable taxes.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of Credit Risk</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Calibri;font-size:10pt;text-transform:none;font-variant: normal;">Concentration of Credit Risk</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial instruments, which potentially subject the Company to significant concentrations of credit risk, consist primarily of cash and cash equivalents and marketable securities. The primary objectives for the Company<span style="color:#000000;">&#8217;</span>s investment portfolio are the preservation of capital and the maintenance of liquidity. The Company does not enter into any investment transaction for trading or speculative purposes.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company<span style="color:#000000;">&#8217;</span>s investment policy limits investments to certain types of instruments such as certificates of deposit, money market instruments, obligations issued by the U.S. government and U.S. government agencies as well as corporate debt securities, and places restrictions on maturities and concentration by type and issuer. The Company maintains cash balances in excess of amounts insured by the Federal Deposit Insurance Corporation and concentrated within a limited number of financial institutions. The accounts are monitored by management to mitigate the risk.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s product sales are recognized through the Company's arrangement with a single customer, a third-party national specialty distributor. The Company assesses the need for an allowance for doubtful accounts primarily based on creditworthiness, historical payment experience and general economic conditions. The Company has not experienced any credit losses related to this customer and has not currently recognized any allowance for doubtful accounts.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Calibri;font-size:10pt;text-transform:none;font-variant: normal;">Income Taxes</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company provides for income taxes based on pretax income, if any, and applicable tax rates available in the various jurisdictions in which it operates, including Israel and the U.S. Deferred<span style="letter-spacing:0.6pt;"> </span>taxes<span style="letter-spacing:0.45pt;"> </span>are<span style="letter-spacing:0.3pt;"> </span>computed<span style="letter-spacing:0.8pt;"> </span>using<span style="letter-spacing:0.45pt;"> </span>the<span style="letter-spacing:0.3pt;"> </span>asset<span style="letter-spacing:0.45pt;"> </span>and<span style="letter-spacing:0.35pt;"> </span>liabi<span style="letter-spacing:-0.1pt;">l</span>ity<span style="letter-spacing:0.65pt;"> </span>method.<span style="letter-spacing:0.65pt;"> </span>Under<span style="letter-spacing:0.5pt;"> </span>the<span style="letter-spacing:0.3pt;"> </span>asset<span style="letter-spacing:0.45pt;"> </span>and<span style="letter-spacing:0.35pt;"> </span>liability<span style="letter-spacing:0.55pt;"> </span>method,<span style="letter-spacing:0.65pt;"> </span>deferred<span style="letter-spacing:0.7pt;"> </span>income<span style="letter-spacing:0.6pt;"> </span>tax<span style="letter-spacing:0.3pt;"> </span>assets<span style="letter-spacing:0.55pt;"> </span>and liabilities<span style="letter-spacing:0.7pt;"> </span>are<span style="letter-spacing:0.3pt;"> </span>determined<span style="letter-spacing:0.9pt;"> </span>bas<span style="letter-spacing:-0.1pt;">e</span>d<span style="letter-spacing:0.5pt;"> </span>on<span style="letter-spacing:0.25pt;"> </span>the<span style="letter-spacing:0.3pt;"> </span>differences<span style="letter-spacing:0.9pt;"> </span>between<span style="letter-spacing:0.7pt;"> </span>the<span style="letter-spacing:0.3pt;"> </span>financial<span style="letter-spacing:0.65pt;"> </span>reporti<span style="letter-spacing:-0.1pt;">n</span>g<span style="letter-spacing:0.7pt;"> </span>and<span style="letter-spacing:0.35pt;"> </span>tax bases<span style="letter-spacing:0.5pt;"> </span>of<span style="letter-spacing:0.2pt;"> </span>assets<span style="letter-spacing:0.55pt;"> </span>and<span style="letter-spacing:0.35pt;"> </span>liabilities<span style="letter-spacing:0.7pt;"> </span>and<span style="letter-spacing:0.35pt;"> </span>are<span style="letter-spacing:0.3pt;"> </span>mea<span style="letter-spacing:-0.1pt;">s</span>ured<span style="letter-spacing:0.8pt;"> </span>using<span style="letter-spacing:0.45pt;"> </span>the<span style="letter-spacing:0.3pt;"> </span>currently<span style="letter-spacing:0.7pt;"> </span>enacted<span style="letter-spacing:0.65pt;"> </span>tax<span style="letter-spacing:0.3pt;"> </span>rates<span style="letter-spacing:0.45pt;"> </span>and<span style="letter-spacing:0.35pt;"> </span>laws.<span style="letter-spacing:0.45pt;"> </span>A<span style="letter-spacing:0.15pt;"> </span>valuation<span style="letter-spacing:0.75pt;"> </span><span style="letter-spacing:-0.1pt;">a</span>llowance<span style="letter-spacing:0.8pt;"> </span>is<span style="letter-spacing:0.15pt;"> </span>recognized<span style="letter-spacing:0.9pt;"> </span>to<span style="letter-spacing:0.2pt;"> </span>the extent<span style="letter-spacing:0.5pt;"> </span>that<span style="letter-spacing:0.35pt;"> </span>it<span style="letter-spacing:0.15pt;"> </span>is<span style="letter-spacing:0.15pt;"> </span>more<span style="letter-spacing:0.45pt;"> </span>likely<span style="letter-spacing:0.45pt;"> </span>than<span style="letter-spacing:0.4pt;"> </span>not<span style="letter-spacing:0.3pt;"> </span>that<span style="letter-spacing:0.35pt;"> </span>the<span style="letter-spacing:0.35pt;"> </span>deferred<span style="letter-spacing:0.7pt;"> </span>taxes<span style="letter-spacing:0.45pt;"> </span>will<span style="letter-spacing:0.3pt;"> </span>not<span style="letter-spacing:0.3pt;"> </span>be<span style="letter-spacing:0.25pt;"> </span>realized<span style="letter-spacing:0.65pt;"> </span>in<span style="letter-spacing:0.2pt;"> </span>the<span style="letter-spacing:0.3pt;"> </span>foresee<span style="letter-spacing:-0.1pt;">a</span>ble<span style="letter-spacing:0.95pt;"> </span>future.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The<span style="letter-spacing:0.35pt;"> </span>Company<span style="letter-spacing:0.8pt;"> </span>follows<span style="letter-spacing:0.55pt;"> </span>a<span style="letter-spacing:0.3pt;"> </span>two-step<span style="letter-spacing:0.8pt;"> </span>approach<span style="letter-spacing:0.75pt;"> </span>in<span style="letter-spacing:0.2pt;"> </span>recognizing<span style="letter-spacing:0.9pt;"> </span>a<span style="letter-spacing:-0.1pt;">n</span>d<span style="letter-spacing:0.35pt;"> </span>measuring<span style="letter-spacing:0.85pt;"> </span>uncertain<span style="letter-spacing:0.75pt;"> </span>tax<span style="letter-spacing:0.3pt;"> </span>positions.<span style="letter-spacing:0.75pt;"> </span>After concluding that a particular filing position can be recognized (i.e., has a more-likely-than-not chance of being sustained), ASC 740-10-30-7 requires that the amount of benefit recognized be measured using a methodology based on the concept of cumulative probability. Under this methodology, the amount of benefit recorded represents the largest amount of tax benefit that is greater than 50% likely to be realized upon settlement with a taxing authority that has full knowledge of all relevant information. &#160;See Note 14 for further discussion related to income taxes.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryPolicyTextBlock', window );">Inventory</a></td>
<td class="text">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Calibri;font-size:10pt;text-transform:none;font-variant: normal;">Inventory</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company capitalizes inventory costs related to products to be sold in the ordinary course of business. The Company makes a determination of capitalizing inventory costs for a product based on, among other factors, status of regulatory approval, information regarding safety, efficacy and expectations relating to commercial sales and recoverability of costs.&#160;For <span style="font-style:italic;">Jelmyto</span>, the Company commenced capitalization of inventory at the receipt of FDA approval.</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.67%;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company values its inventory at the lower of cost or net realizable value.&#160;The Company measures inventory approximating actual cost under a first-in, first-out basis. The Company assesses recoverability of inventory each reporting period to determine any write down to net realizable value resulting from excess or obsolete inventories<span style="font-style:italic;">.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment</a></td>
<td class="text">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Calibri;font-size:10pt;text-transform:none;font-variant: normal;">Property and Equipment</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment are recorded at historical cost, net of accumulated depreciation, amortization and, if applicable, impairment charges. The Company reviews its property and equipment assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment are depreciated over the following useful lives (in years):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:60%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.02%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.88%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Useful Lives</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.02%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Computers and software</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000251">3</span></p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.02%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Laboratory equipment</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.88%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3-6.5</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.02%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Furniture</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.88%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5-16.5</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.02%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Manufacturing equipment</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000252">2</span></p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Leasehold improvements are amortized on a straight-line basis over the shorter of their estimated useful lives or lease terms. See Note 8 for further discussion regarding property and equipment.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Calibri;font-size:10pt;text-transform:none;font-variant: normal;">Leases</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is a lessee in several noncancelable operating leases, primarily for office space, office equipment and vehicles. The Company currently has no finance leases.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company accounts for leases in accordance with ASC Topic 842, &#8220;Leases&#8221;<span style="font-style:italic;">.</span> The Company determines if an arrangement is a lease at inception. Right-of-use (&#8220;ROU&#8221;) assets and operating lease liabilities are recognized based on the present value of lease payments over the lease term as of the commencement date. Operating lease ROU assets are presented as operating lease right of use assets on the condensed consolidated balance sheets. The current portion of operating lease liabilities is included in other current liabilities and the long-term portion is presented separately as operating lease liabilities on the condensed consolidated balance sheets.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lease expense is recognized on a straight-line basis for operating leases. Variable lease payments associated with the Company&#8217;s leases are recognized when the event, activity, or circumstance in the lease agreement on which those payments are assessed occurs. Variable lease payments are presented as operating expense on the condensed consolidated statements of operations in the same line item as expense arising from fixed lease payments.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s lease terms may include options to extend the lease. The lease extensions are included in the measurement of the right of use asset and lease liability when it is reasonably certain that it will exercise that option.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Because most of the Company&#8217;s leases do not provide an implicit rate of return, an incremental borrowing rate is used based on the information available at the commencement date in determining the present value of lease payments on an individual lease basis. The Company&#8217;s incremental borrowing rate for a lease is the rate of interest it would have to pay on a collateralized basis to borrow an amount equal to the lease payments under similar terms. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ROU assets for operating leases are periodically reviewed for impairment losses under ASC 360-10, &#8220;Property, Plant, and Equipment&#8221;, to determine whether an ROU asset is impaired, and if so, the amount of the impairment loss to recognize.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenues</a></td>
<td class="text">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Calibri;font-size:10pt;text-transform:none;font-variant: normal;">Revenues</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Product sales from <span style="font-style:italic;">Jelmyto</span> are recognized as revenue under ASC 606 at the point in time that control of the product has been transferred to the customer, generally at the point the product has been delivered to the treating physician. All product sales of <span style="font-style:italic;">Jelmyto</span> are recognized through the Company's arrangement with a single customer, a third-party national specialty distributor. Net revenues recognized include management&#8217;s estimate of returns, consideration paid to the customer, chargebacks relating to differences between the wholesale acquisition cost and the contracted price offered to the end consumer, chargebacks relating to 340b drug pricing programs, Medicaid drug rebate programs, and the Company&#8217;s copay assistance program, which are estimated based on industry benchmarking studies as well as the Company&#8217;s historical experience.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Expenses</a></td>
<td class="text">
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Calibri;font-size:10pt;text-transform:none;font-variant: normal;">Research and Development Expenses </p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development costs are expensed as incurred and consist primarily of the cost of salaries, share-based compensation expenses, payroll taxes and other employee benefits, subcontractors and materials used for research and development activities, including nonclinical studies, clinical trials, manufacturing costs and professional services. The costs of services performed by others in connection with the research and development activities of the Company, including research and development conducted by others on behalf of the Company, shall be included in research and development costs and expensed as the contracted work is performed. The Company accrues for costs incurred as the services are being provided by monitoring the status of the trial or project and the invoices received from its external service providers. The Company adjusts its accrual as actual costs become known. Where contingent milestone payments are due to third parties under research and development arrangements or license agreements, the milestone payment obligations are expensed when the milestone results are achieved.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock', window );">Selling General and Administrative Expenses</a></td>
<td class="text">
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Calibri;font-size:10pt;text-transform:none;font-variant: normal;">Selling<span style="font-weight:normal;font-style:normal;"> </span><span style="color:#000000;">General and Administrative Expenses</span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Selling, general and administrative expenses consist primarily of personnel costs (including share-based compensation related to directors, employees and consultants). Other significant costs include commercial, medical affairs, external professional service costs, facility costs, accounting and audit services, legal services, and other consulting fees. Selling, general and administrative costs are expensed as incurred, and the Company accrues for services provided by third parties related to the above expenses by monitoring the status of services provided and receiving estimates from its service providers and adjusting its accruals as actual costs become known.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansDirectorPolicy', window );">Share-Based Compensation</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Calibri;font-size:10pt;text-transform:none;font-variant: normal;">Share-Based Compensation</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Share-based compensation cost is measured at the grant date based on the fair value of the award and is recognized as expense over the required service period, which is equal to the vesting period. The fair value of options is determined using the Black-Scholes option-pricing model. The fair value of a restricted stock unit (&#8220;RSU&#8221;) equaled the closing price of the Company&#8217;s ordinary shares on the grant date. The Company accounts for forfeitures as they occur in accordance with ASC Topic 718, &#8220;Compensation&#8212;Stock Compensation&#8221;.<span style="letter-spacing:0.75pt;"> </span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The<span style="letter-spacing:0.35pt;"> </span>Company<span style="letter-spacing:0.8pt;"> </span>elected<span style="letter-spacing:0.6pt;"> </span>to<span style="letter-spacing:0.2pt;"> </span>recognize<span style="letter-spacing:0.8pt;"> </span>compen<span style="letter-spacing:-0.1pt;">s</span>ation<span style="letter-spacing:1.1pt;"> </span>costs<span style="letter-spacing:0.45pt;"> </span>for<span style="letter-spacing:0.25pt;"> </span>awards<span style="letter-spacing:0.6pt;"> </span>conditioned<span style="letter-spacing:0.9pt;"> </span>only<span style="letter-spacing:0.35pt;"> </span>on<span style="letter-spacing:0.25pt;"> </span>conti<span style="letter-spacing:-0.1pt;">n</span>ued<span style="letter-spacing:0.8pt;"> </span>service<span style="letter-spacing:0.6pt;"> </span>that<span style="letter-spacing:0.35pt;"> </span>have<span style="letter-spacing:0.4pt;"> </span>a<span style="letter-spacing:0.15pt;"> </span>graded<span style="letter-spacing:0.6pt;"> </span>vesting<span style="letter-spacing:0.6pt;"> </span>schedule<span style="letter-spacing:0.05pt;"> </span>using<span style="letter-spacing:0.45pt;"> </span>the<span style="letter-spacing:0.3pt;"> </span>straight-line<span style="letter-spacing:0.95pt;"> </span>method<span style="letter-spacing:0.55pt;"> </span>and<span style="letter-spacing:0.35pt;"> </span>to<span style="letter-spacing:0.2pt;"> </span>value<span style="letter-spacing:0.45pt;"> </span>the<span style="letter-spacing:0.3pt;"> </span>awards<span style="letter-spacing:0.6pt;"> </span>based<span style="letter-spacing:0.5pt;"> </span>on<span style="letter-spacing:0.25pt;"> </span>the<span style="letter-spacing:0.3pt;"> </span>sin<span style="letter-spacing:-0.1pt;">g</span>le-option<span style="letter-spacing:1pt;"> </span>award<span style="letter-spacing:0.5pt;"> </span>approach.<span style="letter-spacing:0.8pt;"> </span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss per Ordinary Share</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Calibri;font-size:10pt;text-transform:none;font-variant: normal;">Net Loss per Ordinary Share</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Basic net loss per share is computed by dividing the net loss attributable to ordinary shareholders by the weighted-average number of ordinary shares outstanding. Diluted net loss per share is computed similarly to basic net loss per share except that the denominator is increased to include the number of additional ordinary shares that would have been outstanding if the potential ordinary shares had been issued and if the additional ordinary shares were dilutive. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For all periods presented, potentially dilutive securities are excluded from the computation of fully diluted loss per share as their effect is anti-dilutive.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_urgn_CashAndCashEquivalentsAndMarketableSecuritiesPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash and cash equivalents and marketable securities policy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">urgn_CashAndCashEquivalentsAndMarketableSecuritiesPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>urgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=108315417&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=d3e5614-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -URI http://asc.fasb.org/topic&amp;trid=2175825<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32847-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 740<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6491622&amp;loc=d3e9504-115650<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32840-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=116657188&amp;loc=SL116659661-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e32280-109318<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4556-108314<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4492-108314<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116846552&amp;loc=d3e543-108305<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI http://asc.fasb.org/topic&amp;trid=2126998<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918666-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18823-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18823-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for inclusion of significant items in the selling, general and administrative (or similar) expense report caption.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 720<br> -SubTopic 35<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6420018&amp;loc=d3e36677-107848<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansDirectorPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award granted to director under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansDirectorPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140482559385992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_urgn_PropertyPlantAndEquipmentUsefulLifeTableTextBlock', window );">Property and Equipment Useful Lives</a></td>
<td class="text">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment are depreciated over the following useful lives (in years):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:60%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.02%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.88%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Useful Lives</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.02%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Computers and software</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000251">3</span></p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.02%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Laboratory equipment</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.88%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3-6.5</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.02%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Furniture</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.88%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5-16.5</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.02%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Manufacturing equipment</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000252">2</span></p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_urgn_PropertyPlantAndEquipmentUsefulLifeTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Property, plant and equipment, useful life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">urgn_PropertyPlantAndEquipmentUsefulLifeTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>urgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140482545987800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Financial Information (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_urgn_OtherFinancialInformationAbstract', window );"><strong>Other Financial Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock', window );">Schedule of Accounts Payable and Accrued Expenses</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accounts payable and accrued expenses consist of the following as of March&#160;31, 2021 and December&#160;31, 2020 (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.74%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">March&#160;31, 2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.74%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31, 2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accounts payable</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.74%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,096</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.74%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,271</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued sales reserves</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.74%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">449</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.74%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">382</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued clinical expenses</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.74%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">554</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.74%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,359</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued research and development costs</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.74%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">862</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.74%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,356</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued selling, general and administrative expenses</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.74%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,309</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.74%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,440</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59.22%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued other expense</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.74%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,288</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.74%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,215</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59.22%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total accounts payable and accrued expenses</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.74%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,558</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.74%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,023</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock', window );">Schedule of Interest and Other Income (Expenses)</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest and other income (expenses) consisted of the following as of March&#160;31, 2021 and 2020 (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.12%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended March&#160;31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest income</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.74%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">167</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.74%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">811</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59.22%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other finance income(expenses)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.74%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.74%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(43</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59.22%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total interest and other income</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.74%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">179</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.74%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">768</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_urgn_OtherFinancialInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other financial information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">urgn_OtherFinancialInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>urgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of interest income and expense, including, but not limited to, interest income and expense from investments, loans, and securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140482547258984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventories (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Summary of Inventories</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inventories consist of the following as of March&#160;31, 2021 and December&#160;31, 2020 (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:65.18%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.76%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.62%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">March&#160;31, 2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.76%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.62%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31, 2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.18%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Raw materials</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.62%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,443</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.62%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,051</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:65.18%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Finished goods</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.76%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.62%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">888</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.76%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.62%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">913</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:65.18%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total inventories</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.76%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.62%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,331</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.76%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.62%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,964</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140482545984296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Schedule of Assets and Liabilities Measured at Fair Value on a Recurring Basis</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Assets and liabilities measured at fair value on a recurring basis based on Level 1 and Level 2 fair value measurement criteria as of March&#160;31, 2021 are as follows (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.78%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.04%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Fair Value Measurements Using</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Quoted&#160;Prices</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Significant</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">in Active</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Balance&#160;as&#160;of</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Markets for</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Observable</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">March&#160;31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Identical&#160;Assets</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Inputs</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(Level 1)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(Level 2)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Marketable securities:</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US government</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20,572</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20,572</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate bonds</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,845</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,845</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money market funds<sup style="font-size:85%;line-height:120%;vertical-align:top">(1)</sup></p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30,413</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30,413</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total marketable securities</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">65,830</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">50,985</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,845</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:3.33%;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160; </p>
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:3.8%;white-space:nowrap" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%;line-height:120%;vertical-align:top">(1)</sup></span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:10pt;"><span style="color:#000000;">Included within cash and cash equivalents on the condensed consolidated balance sheets.</span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.13%;text-indent:0%;font-family:Times New Roman;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:2pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Assets and liabilities measured at fair value on a recurring basis based on Level 1 and Level 2 fair value measurement criteria as of December&#160;31, 2020 are as follows (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.78%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.04%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Fair&#160;Value&#160;Measurements&#160;Using</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Quoted&#160;Prices</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Significant</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">in Active</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Balance&#160;as&#160;of</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Markets for</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Observable</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Identical&#160;Assets</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Inputs</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(Level 1)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(Level 2)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Marketable securities:</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US government</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29,186</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29,186</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate bonds</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21,861</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21,861</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money market funds<sup style="font-size:85%;line-height:120%;vertical-align:top">(1)</sup></p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">39,744</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">39,744</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total marketable securities</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">90,791</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">68,930</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21,861</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:3.8%;white-space:nowrap" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%;line-height:120%;vertical-align:top">(1)</sup></span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:10pt;"><span style="color:#000000;">Included within cash and cash equivalents on the condensed consolidated balance sheets.</span></p></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140482554825560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Marketable Securities (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments Debt And Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesTextBlock', window );">Summary of Marketable Securities</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes the Company&#8217;s marketable securities as of March&#160;31, 2021 (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:39.4%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.58%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Amortized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Cost Basis</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.58%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Gains</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.58%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Losses</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.58%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Fair Value</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.4%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Marketable securities:</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.58%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.58%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.58%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.58%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.4%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US government</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.58%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20,448</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.58%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">124</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.58%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.58%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20,572</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.4%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate bonds</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.58%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,826</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.58%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.58%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.58%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,845</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:39.4%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money market funds<sup style="font-size:85%;line-height:120%;vertical-align:top">(1)</sup></p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.58%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30,413</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.58%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.58%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.58%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30,413</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:39.4%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total marketable securities</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.58%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">65,687</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.58%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">143</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.58%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.58%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">65,830</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:3.8%;text-indent:-3.8%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:3.8%;white-space:nowrap" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%;line-height:120%;vertical-align:top">(1)</sup></span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:10pt;"><span style="color:#000000;">Included within cash and cash equivalents on the condensed consolidated balance sheets.</span></p></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_urgn_SummaryOfFairValuesOfMarketableSecuritiesByContractualMaturityTableTextBlock', window );">Summary of Fair Values of Marketable Securities by Contractual Maturity</a></td>
<td class="text">The fair values of marketable securities by contractual maturity consist of the following (in thousands)
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59.6%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.76%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.42%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">March&#160;31, 2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.76%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.42%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31, 2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.6%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Maturities within one year</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">65,830</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">88,898</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59.6%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Maturities after one year through three years</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.76%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.76%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,893</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59.6%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total marketable securities</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.76%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">65,830</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.76%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">90,791</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_urgn_SummaryOfFairValuesOfMarketableSecuritiesByContractualMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair values of marketable securities by contractual maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">urgn_SummaryOfFairValuesOfMarketableSecuritiesByContractualMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>urgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of marketable securities. This may consist of investments in certain debt and equity securities, short-term investments and other assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140482554871656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property Plant And Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Property and Equipment</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment, consists of the following as of March&#160;31, 2021 and December&#160;31, 2020 (in thousands):</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59.54%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.42%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">March&#160;31, 2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.42%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31, 2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.54%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Laboratory equipment</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">337</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">333</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.54%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Computer equipment and software</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,970</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,676</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.54%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Furniture</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">586</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">597</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.54%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Leasehold improvements</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">609</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">609</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59.54%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Manufacturing equipment</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">226</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">226</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.54%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,728</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,441</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59.54%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less: accumulated depreciation and amortization</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,586</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,395</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59.54%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment, net</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,142</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,046</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140482547297576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Components of Lease Cost</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The components of lease cost for the three months ended March&#160;31, 2021 were as follows <span style="color:#000000;">(in thousands)</span>:</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:77.4%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.58%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended March&#160;31, 2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:77.4%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease cost</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.58%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">267</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:77.4%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sublease income</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.58%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(56</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:77.4%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Variable lease cost</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.58%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:77.4%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.58%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">233</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_urgn_ScheduleOfOperatingLeaseAmountsRecognizedUponAdoptionTableTextBlock', window );">Schedule of Amounts Recognized</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The amounts recognized as of March&#160;31, 2021 were as follows <span style="color:#000000;">(in thousands):</span> </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.02%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.88%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">March&#160;31, 2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.02%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Right of use asset</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,901</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.02%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Long-term lease liability</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,201</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.02%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other current liabilities</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,077</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_urgn_ScheduleOfSupplementalInformationRelatedToLeasesTableTextBlock', window );">Schedule of Supplemental Information Related to Leases</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Supplemental information related to leases for the periods reported is as follows (in thousands):</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:77.26%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.72%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended March&#160;31, 2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:77.26%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash paid for amounts included in the measurement of lease liabilities:</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.72%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:77.26%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating cash flows from operating leases</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.72%;white-space:nowrap;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,157</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:77.26%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Right-of-use assets obtained in exchange for new operating lease liabilities</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.72%;white-space:nowrap;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">135</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:77.26%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted-average remaining lease term of operating leases</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.72%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.13 years</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:77.26%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted-average discount rate of operating leases</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.72%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.36%</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_urgn_LesseeOperatingSubLeasePaymentsToBeReceivedMaturityTableTextBlock', window );">Schedule of Undiscounted Cash Flows to be Received Under Operating Sublease on an Annual Basis</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of March&#160;31, 2021 undiscounted cash flows to be received under the Company&#8217;s operating sublease on an annual basis was as follows (in thousands):</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:77.54%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.42%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Operating Leases</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:77.54%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Years ending December 31,</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.42%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:77.54%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Remainder of 2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.42%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">176</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:77.54%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.42%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">243</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:77.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2023</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.42%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">251</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:77.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2024</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.42%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">49</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:77.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2025</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.42%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:77.54%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2026 and thereafter</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.42%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:77.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.42%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">719</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_urgn_LesseeOperatingSubLeaseIncomeRecognizedNetInOperatingExpensesTableTextBlock', window );">Schedule of Sublease Income Recognized Net within Operating Expenses</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sublease income is recognized net within operating expenses. Sublease income for the three months ended March&#160;31, 2021 was as follows (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:77.54%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.42%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended March&#160;31, 2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:77.54%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sublease income from fixed lease payments</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.42%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">56</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:77.54%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sublease income from variable payments</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.42%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:77.54%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.42%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">56</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_urgn_LesseeOperatingSubLeaseIncomeRecognizedNetInOperatingExpensesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee operating sub lease income recognized net in operating expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">urgn_LesseeOperatingSubLeaseIncomeRecognizedNetInOperatingExpensesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>urgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_urgn_LesseeOperatingSubLeasePaymentsToBeReceivedMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee operating sub lease payments to be received maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">urgn_LesseeOperatingSubLeasePaymentsToBeReceivedMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>urgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_urgn_ScheduleOfOperatingLeaseAmountsRecognizedUponAdoptionTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule of operating lease amounts recognized upon adoption.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">urgn_ScheduleOfOperatingLeaseAmountsRecognizedUponAdoptionTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>urgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_urgn_ScheduleOfSupplementalInformationRelatedToLeasesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule of supplemental information related to leases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">urgn_ScheduleOfSupplementalInformationRelatedToLeasesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>urgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140482563275976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue from Product Sales (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue From Contract With Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueTableTextBlock', window );">Schedule of Net Product Sales</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net product sales consist of the following for the three months ended March&#160;31, 2021 (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:77.68%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.28%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended March&#160;31, 2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:77.68%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Jelmyto</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.28%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,485</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140482546007128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of Effect of Share-Based Compensation on Statements of Operations</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The<span style="letter-spacing:0.35pt;"> </span>following<span style="letter-spacing:0.7pt;"> </span>table<span style="letter-spacing:0.4pt;"> </span>illustrates<span style="letter-spacing:0.75pt;"> </span>the<span style="letter-spacing:0.3pt;"> </span>effect<span style="letter-spacing:0.45pt;"> </span>of<span style="letter-spacing:0.2pt;"> </span>share-based<span style="letter-spacing:1pt;"> </span>com<span style="letter-spacing:-0.1pt;">p</span>ensation<span style="letter-spacing:1.1pt;"> </span>on<span style="letter-spacing:0.25pt;"> </span>the<span style="letter-spacing:0.3pt;"> condensed consolidated </span>statements<span style="letter-spacing:0.9pt;"> </span>of<span style="letter-spacing:0.2pt;"> </span>operations (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.54%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended March&#160;31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development expenses</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,107</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,943</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Selling, general and administrative expenses</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,088</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,674</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,195</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,617</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140482554576776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business and Nature of Operations - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization Consolidation And Presentation Of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_urgn_EntityIncorporationDateOfIncorporationMonthAndYear', window );">Date of incorporation</a></td>
<td class="text">2004-04<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_urgn_OperationsCommencedDateMonthAndYear', window );">Date of operating commencement</a></td>
<td class="text">2016-02<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_urgn_EntityIncorporationDateOfIncorporationMonthAndYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Entity incorporation date of incorporation month and year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">urgn_EntityIncorporationDateOfIncorporationMonthAndYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>urgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearMonthItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_urgn_OperationsCommencedDateMonthAndYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operations commenced date month and year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">urgn_OperationsCommencedDateMonthAndYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>urgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearMonthItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140482563246856">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Basis of Presentation - Addititonal Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization Consolidation And Presentation Of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="nump">$ 382,436<span></span>
</td>
<td class="nump">$ 356,501<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140482563275976">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Significant Accounting Policies - Additional Information (Details)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_urgn_CashCashEquivalentsAndMarketableSecurities', window );">Total cash and cash equivalents and marketable securities</a></td>
<td class="nump">$ 75.9<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_urgn_CashCashEquivalentsAndMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash, cash equivalents and marketable securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">urgn_CashCashEquivalentsAndMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>urgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140482551352680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies - Property and Equipment Useful Lives (Details)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=urgn_ComputersAndSoftwareMember', window );">Computers and Software</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and Equipment, Useful Lives</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=urgn_LaboratoryEquipmentMember', window );">Laboratory Equipment | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and Equipment, Useful Lives</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=urgn_LaboratoryEquipmentMember', window );">Laboratory Equipment | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and Equipment, Useful Lives</a></td>
<td class="text">6 years 6 months<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and Equipment, Useful Lives</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and Equipment, Useful Lives</a></td>
<td class="text">16 years 6 months<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ManufacturingFacilityMember', window );">Manufacturing Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and Equipment, Useful Lives</a></td>
<td class="text">2 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=urgn_ComputersAndSoftwareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=urgn_ComputersAndSoftwareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=urgn_LaboratoryEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=urgn_LaboratoryEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ManufacturingFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ManufacturingFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140482554702712">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Other Financial Information - Schedule of Accounts Payable and Accrued Expenses (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_urgn_OtherFinancialInformationAbstract', window );"><strong>Other Financial Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">$ 6,096<span></span>
</td>
<td class="nump">$ 3,271<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_urgn_AccruedSalesReserves', window );">Accrued sales reserves</a></td>
<td class="nump">449<span></span>
</td>
<td class="nump">382<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_urgn_AccruedClinicalExpensesCurrent', window );">Accrued clinical expenses</a></td>
<td class="nump">554<span></span>
</td>
<td class="nump">1,359<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_urgn_AccruedResearchAndDevelopmentExpenseCurrent', window );">Accrued research and development costs</a></td>
<td class="nump">862<span></span>
</td>
<td class="nump">1,356<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_urgn_AccruedSellingGeneralAndAdministrativeExpenseCurrent', window );">Accrued selling, general and administrative expenses</a></td>
<td class="nump">1,309<span></span>
</td>
<td class="nump">2,440<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Accrued other expense</a></td>
<td class="nump">1,288<span></span>
</td>
<td class="nump">1,215<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Total accounts payable and accrued expenses</a></td>
<td class="nump">$ 10,558<span></span>
</td>
<td class="nump">$ 10,023<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_urgn_AccruedClinicalExpensesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued clinical expenses current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">urgn_AccruedClinicalExpensesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>urgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_urgn_AccruedResearchAndDevelopmentExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued Research and Development Expense, Current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">urgn_AccruedResearchAndDevelopmentExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>urgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_urgn_AccruedSalesReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued sales reserves.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">urgn_AccruedSalesReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>urgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_urgn_AccruedSellingGeneralAndAdministrativeExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued selling general and administrative expense current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">urgn_AccruedSellingGeneralAndAdministrativeExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>urgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_urgn_OtherFinancialInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other financial information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">urgn_OtherFinancialInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>urgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e7018-107765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140482547371080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Financial Information - Schedule of Interest and Other Income (Expenses) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_urgn_OtherFinancialInformationAbstract', window );"><strong>Other Financial Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="nump">$ 167<span></span>
</td>
<td class="nump">$ 811<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_urgn_OtherFinanceExpensesIncome', window );">Other finance income(expenses)</a></td>
<td class="nump">12<span></span>
</td>
<td class="num">(43)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_urgn_FinanceIncomeExpenseNet', window );">Total interest and other income</a></td>
<td class="nump">$ 179<span></span>
</td>
<td class="nump">$ 768<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_urgn_FinanceIncomeExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Finance income expense net.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">urgn_FinanceIncomeExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>urgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_urgn_OtherFinanceExpensesIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other finance expenses (income).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">urgn_OtherFinanceExpensesIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>urgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_urgn_OtherFinancialInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other financial information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">urgn_OtherFinancialInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>urgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140482547354232">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Inventories - Schedule of Inventories (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryRawMaterials', window );">Raw materials</a></td>
<td class="nump">$ 2,443<span></span>
</td>
<td class="nump">$ 1,051<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoods', window );">Finished goods</a></td>
<td class="nump">888<span></span>
</td>
<td class="nump">913<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Total inventories</a></td>
<td class="nump">$ 3,331<span></span>
</td>
<td class="nump">$ 1,964<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterials">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterials</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140482544419416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount', window );">Fair value assets, transfers between level 1 to level 2</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount', window );">Fair value assets, transfers between level 2 to level 1</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesLevel1ToLevel2TransfersAmount', window );">Fair value liabilities, transfers between level 1 to level 2</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesLevel2ToLevel1TransfersAmount', window );">Fair value liabilities, transfers between level 2 to level 1</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3', window );">Fair value assets, transfers into level 3</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3', window );">Fair value assets, transfers out of level 3</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3', window );">Fair value liabilities, transfers into level 3</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3', window );">Fair value liabilities, transfers out of level 3</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transfers of assets measured on a recurring basis out of Level 1 of the fair value hierarchy into Level 2.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transfers of assets measured on a recurring basis out of Level 2 of the fair value hierarchy into Level 1.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesLevel1ToLevel2TransfersAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transfers of liabilities measured on a recurring basis out of Level 1 of the fair value hierarchy into Level 2.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesLevel1ToLevel2TransfersAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesLevel2ToLevel1TransfersAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transfers of liabilities measured on a recurring basis out of Level 2 of the fair value hierarchy into Level 1.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesLevel2ToLevel1TransfersAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transfers of financial instrument classified as a liability into level 3 of the fair value hierarchy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transfers of financial instrument classified as a liability out of level 3 of the fair value hierarchy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transfer of financial instrument classified as an asset into level 3 of the fair value hierarchy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transfers of financial instrument classified as an asset out of level 3 of the fair value hierarchy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140482554877080">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Summary of Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities:</a></td>
<td class="nump">$ 65,830<span></span>
</td>
<td class="nump">$ 90,791<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities:</a></td>
<td class="nump">65,830<span></span>
</td>
<td class="nump">90,791<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Quoted Prices in Active Markets for Identical Assets (Level 1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities:</a></td>
<td class="nump">50,985<span></span>
</td>
<td class="nump">68,930<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Significant Other Observable Inputs (Level 2)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities:</a></td>
<td class="nump">14,845<span></span>
</td>
<td class="nump">21,861<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | US Government</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities:</a></td>
<td class="nump">20,572<span></span>
</td>
<td class="nump">29,186<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | US Government | Quoted Prices in Active Markets for Identical Assets (Level 1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities:</a></td>
<td class="nump">20,572<span></span>
</td>
<td class="nump">29,186<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Corporate Bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities:</a></td>
<td class="nump">14,845<span></span>
</td>
<td class="nump">21,861<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Corporate Bonds | Significant Other Observable Inputs (Level 2)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities:</a></td>
<td class="nump">14,845<span></span>
</td>
<td class="nump">21,861<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Money Market Funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities:</a></td>
<td class="nump">30,413<span></span>
</td>
<td class="nump">39,744<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Money Market Funds | Quoted Prices in Active Markets for Identical Assets (Level 1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities:</a></td>
<td class="nump">$ 30,413<span></span>
</td>
<td class="nump">$ 39,744<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121558606&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140482559340600">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Marketable Securities - Summary of Marketable Securities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesAbstract', window );"><strong>Marketable securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost Basis</a></td>
<td class="nump">$ 65,687<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gains</a></td>
<td class="nump">143<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">65,830<span></span>
</td>
<td class="nump">$ 90,791<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_USTreasuryAndGovernmentMember', window );">US Government</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesAbstract', window );"><strong>Marketable securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost Basis</a></td>
<td class="nump">20,448<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gains</a></td>
<td class="nump">124<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">20,572<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate Bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesAbstract', window );"><strong>Marketable securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost Basis</a></td>
<td class="nump">14,826<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gains</a></td>
<td class="nump">19<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">14,845<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember', window );">Money Market Funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesAbstract', window );"><strong>Marketable securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost Basis</a></td>
<td class="nump">30,413<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">$ 30,413<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121558606&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121558606&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_USTreasuryAndGovernmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_USTreasuryAndGovernmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140482551195016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Marketable Securities - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments Debt And Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestReceivable', window );">Accrued interest receivable</a></td>
<td class="nump">$ 100,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_urgn_DebtSecuritiesAvailableForSaleUnrealizedGainPosition', window );">Available-for-sale debt securities, unrealized gain position</a></td>
<td class="nump">100,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Available-for-sale debt securities, unrealized loss position</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesPortionRecognizedInEarnings', window );">Other-than-temporary impairment Loss, debt securities, portion recognized in earnings</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_urgn_DebtSecuritiesAvailableForSaleUnrealizedGainPosition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt securities available for sale unrealized gain position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">urgn_DebtSecuritiesAvailableForSaleUnrealizedGainPosition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>urgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position without allowance for credit loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27290-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121582814&amp;loc=SL82922888-210455<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121590138&amp;loc=SL82922954-210456<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of interest earned but not received. Also called accrued interest or accrued interest receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesPortionRecognizedInEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of other-than-temporary impairment (OTTI) on investment in debt security, recognized in earnings.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8A<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=SL6284422-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesPortionRecognizedInEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140482547348968">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Marketable Securities - Summary of Fair Values of Marketable Securities by Contractual Maturity (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract', window );"><strong>Available For Sale Securities Debt Maturities Fair Value [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue', window );">Maturities within one year</a></td>
<td class="nump">$ 65,830<span></span>
</td>
<td class="nump">$ 88,898<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_urgn_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughThreeYearsFairValue', window );">Maturities after one year through three years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,893<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total marketable securities</a></td>
<td class="nump">$ 65,830<span></span>
</td>
<td class="nump">$ 90,791<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_urgn_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughThreeYearsFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Available for sale securities debt maturities after one through three years fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">urgn_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughThreeYearsFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>urgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120252992&amp;loc=SL120269850-112803<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27198-111563<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121558606&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140482550442424">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Property and Equipment - Schedule of Property and Equipment (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment</a></td>
<td class="nump">$ 3,728<span></span>
</td>
<td class="nump">$ 3,441<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: accumulated depreciation and amortization</a></td>
<td class="num">(1,586)<span></span>
</td>
<td class="num">(1,395)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">2,142<span></span>
</td>
<td class="nump">2,046<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=urgn_LaboratoryEquipmentMember', window );">Laboratory Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment</a></td>
<td class="nump">337<span></span>
</td>
<td class="nump">333<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=urgn_ComputersAndSoftwareMember', window );">Computers and Software</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment</a></td>
<td class="nump">1,970<span></span>
</td>
<td class="nump">1,676<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment</a></td>
<td class="nump">586<span></span>
</td>
<td class="nump">597<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold Improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment</a></td>
<td class="nump">609<span></span>
</td>
<td class="nump">609<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ManufacturingFacilityMember', window );">Manufacturing Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment</a></td>
<td class="nump">$ 226<span></span>
</td>
<td class="nump">$ 226<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=urgn_LaboratoryEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=urgn_LaboratoryEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=urgn_ComputersAndSoftwareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=urgn_ComputersAndSoftwareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ManufacturingFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ManufacturingFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140482547249608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment - Additional Information (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property Plant And Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization expense</a></td>
<td class="nump">$ 0.2<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140482550387640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Nov. 30, 2019</div></th>
<th class="th"><div>Apr. 30, 2018</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee Lease Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend', window );">Operating leases, existence of option to extend</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseOptionToExtend', window );">Operating leases, options to extend lease term, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">UPL signed an addendum to its November 2014 lease agreement for the Company&#8217;s executive offices located in Israel, in order to increase the office space rented and to extend the rent period until 2019. In March 2019, UPL utilized the agreement extension option and extended the rent period for additional three years until August 2022.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Operating leases, options to extend lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_urgn_LesseeOperatingLeaseExtendedLeaseExpirationDateMonthAndYear', window );">Operating lease extended lease expiration, month and year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2022-08<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubleaseIncome', window );">Remaining rental payments to be received over the lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 56,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseImpairmentLoss', window );">Impairment losses on operating leases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee Lease Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_urgn_LeaseExpirationYear', window );">Lease expiration year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2021<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee Lease Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_urgn_LeaseExpirationYear', window );">Lease expiration year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2024<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=stpr_NY', window );">New York | UroGen Pharma Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee Lease Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_urgn_LeaseCommencementDateMonthAndYear', window );">Lease commencement period, month and year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2017-10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_urgn_LeaseTerminationDateMonthAndYear', window );">Lease termination period, month and year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2021-02<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=stpr_CA', window );">Los Angeles, California | UroGen Pharma Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee Lease Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_urgn_LeaseTerminationDateMonthAndYear', window );">Lease termination period, month and year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2024-03<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_urgn_LeaseCommencementDate', window );">Lease commencement date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jul. 10,  2018<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_urgn_ProceedsFromTenantAllowance', window );">Proceeds from tenant allowance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligation', window );">Remaining contractual obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 800,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_urgn_LesseeOperatingSubleaseCommencementDate', window );">Lessee operating sublease commencement date</a></td>
<td class="text">Jan.  01,  2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_urgn_LesseeOperatingSubleaseTerminationDateMonthAndYear', window );">Lessee operating sublease termination period, month and year</a></td>
<td class="text">2024-03<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubleaseIncome', window );">Remaining rental payments to be received over the lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">700,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=stpr_NJ', window );">Princeton, NJ | UroGen Pharma Inc. | Lease Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee Lease Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_urgn_LeaseCommencementDate', window );">Lease commencement date</a></td>
<td class="text">Nov. 29,  2019<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligation', window );">Remaining contractual obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Lease term</a></td>
<td class="text">38 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_urgn_LeaseCommencementDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lease commencement date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">urgn_LeaseCommencementDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>urgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_urgn_LeaseCommencementDateMonthAndYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lease commencement date month and year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">urgn_LeaseCommencementDateMonthAndYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>urgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearMonthItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_urgn_LeaseExpirationYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lease expiration year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">urgn_LeaseExpirationYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>urgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_urgn_LeaseTerminationDateMonthAndYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lease termination date month and year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">urgn_LeaseTerminationDateMonthAndYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>urgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearMonthItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_urgn_LesseeOperatingLeaseExtendedLeaseExpirationDateMonthAndYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee operating lease extended lease expiration date, month and year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">urgn_LesseeOperatingLeaseExtendedLeaseExpirationDateMonthAndYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>urgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearMonthItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_urgn_LesseeOperatingSubleaseCommencementDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee operating sublease commencement date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">urgn_LesseeOperatingSubleaseCommencementDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>urgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_urgn_LesseeOperatingSubleaseTerminationDateMonthAndYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee operating sublease termination date month and year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">urgn_LesseeOperatingSubleaseTerminationDateMonthAndYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>urgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearMonthItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_urgn_ProceedsFromTenantAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from tenant allowance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">urgn_ProceedsFromTenantAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>urgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractualObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of contractual obligation, including but not limited to, long-term debt, capital lease obligations, operating lease obligations, purchase obligations, and other commitments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractualObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates (true false) whether lessee has option to extend operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseOptionToExtend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of terms and conditions of option to extend lessee's operating lease. Includes, but is not limited to, information about option recognized as part of right-of-use asset and lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseOptionToExtend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from impairment of right-of-use asset from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 25<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121593497&amp;loc=SL77918431-209957<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubleaseIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of sublease income excluding finance and operating lease expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubleaseIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_NY">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_NY</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=srt_SubsidiariesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=srt_SubsidiariesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_CA">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_CA</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_NJ">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_NJ</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LeaseAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LeaseAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140482547317816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Components of Lease Cost (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease cost</a></td>
<td class="nump">$ 267<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubleaseIncome', window );">Sublease income</a></td>
<td class="num">(56)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableLeaseCost', window );">Variable lease cost</a></td>
<td class="nump">22<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Lease, Cost</a></td>
<td class="nump">$ 233<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubleaseIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of sublease income excluding finance and operating lease expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubleaseIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140482576912952">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Schedule of Amounts Recognized (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right of use asset</a></td>
<td class="nump">$ 1,901<span></span>
</td>
<td class="nump">$ 2,158<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList', window );">Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible List]</a></td>
<td class="text">Other non-current assets<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Long-term lease liability</a></td>
<td class="nump">$ 1,201<span></span>
</td>
<td class="nump">$ 1,497<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Other current liabilities</a></td>
<td class="nump">$ 1,077<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList', window );">Operating Lease, Liability, Current, Statement of Financial Position [Extensible List]</a></td>
<td class="text">Other current liabilities<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes current operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918631-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>srt-types:extensibleListItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes operating lease right-of-use asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918631-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>srt-types:extensibleListItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140482551292536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Schedule of Supplemental Information Related to Leases (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_urgn_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract', window );"><strong>Cash paid for amounts included in the measurement of lease liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Operating cash flows from operating leases</a></td>
<td class="nump">$ 2,157<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Right-of-use assets obtained in exchange for new operating lease liabilities</a></td>
<td class="nump">$ 135<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted-average remaining lease term of operating leases</a></td>
<td class="text">2 years 1 month 17 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted-average discount rate of operating leases</a></td>
<td class="nump">5.36%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_urgn_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash paid for amounts included in measurement of lease liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">urgn_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>urgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140482547373304">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Schedule of Undiscounted Cash Flows to be Received Under Operating Sublease on an Annual Basis (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_urgn_LesseeOperatingSubLeasePaymentsToBeReceivedRemainderOfFiscalYear', window );">Remainder of 2021</a></td>
<td class="nump">$ 176<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_urgn_LesseeOperatingSubLeasePaymentsToBeReceivedNextTwelveMonths', window );">2022</a></td>
<td class="nump">243<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_urgn_LesseeOperatingSubLeasePaymentsToBeReceivedTwoYears', window );">2023</a></td>
<td class="nump">251<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_urgn_LesseeOperatingSubLeasePaymentsToBeReceivedThreeYears', window );">2024</a></td>
<td class="nump">49<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_urgn_LesseeOperatingSubLeasePaymentsToBeReceived', window );">Lessee operating sublease payments to be received</a></td>
<td class="nump">$ 719<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_urgn_LesseeOperatingSubLeasePaymentsToBeReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee operating sub lease payments to be received.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">urgn_LesseeOperatingSubLeasePaymentsToBeReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>urgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_urgn_LesseeOperatingSubLeasePaymentsToBeReceivedNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee operating sublease payments to be received next twelve months.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">urgn_LesseeOperatingSubLeasePaymentsToBeReceivedNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>urgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_urgn_LesseeOperatingSubLeasePaymentsToBeReceivedRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee operating sub lease payments to be received remainder of fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">urgn_LesseeOperatingSubLeasePaymentsToBeReceivedRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>urgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_urgn_LesseeOperatingSubLeasePaymentsToBeReceivedThreeYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee operating sub lease payments to be received three years.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">urgn_LesseeOperatingSubLeasePaymentsToBeReceivedThreeYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>urgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_urgn_LesseeOperatingSubLeasePaymentsToBeReceivedTwoYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee operating sub lease payments to be received two years.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">urgn_LesseeOperatingSubLeasePaymentsToBeReceivedTwoYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>urgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140482547417720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Schedule of Sublease Income Recognized Net within Operating Expenses (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_urgn_LesseeOperatingSubLeaseIncomeFromFixedLeasePayments', window );">Sublease income from fixed lease payments</a></td>
<td class="nump">$ 56<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubleaseIncome', window );">Sublease income</a></td>
<td class="nump">$ 56<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_urgn_LesseeOperatingSubLeaseIncomeFromFixedLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee operating sub lease income from fixed lease payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">urgn_LesseeOperatingSubLeaseIncomeFromFixedLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>urgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubleaseIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of sublease income excluding finance and operating lease expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubleaseIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140482547839080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue from Product Sales - Schedule of Net Product Sales (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue From Contract With Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList', window );">Revenue from Contract with Customer Product and Service [Extensible List]</a></td>
<td class="text">urgn:JelmytoMember<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">$ 7,485<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates product and service for revenue from satisfaction of performance obligation by transferring promised product and service to customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121551570&amp;loc=SL49130690-203046-203046<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>srt-types:extensibleListItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140482554715064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>License and Collaboration Agreements - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Nov. 30, 2019</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=us-gaap_LicenseAgreementTermsMember', window );">Agenus Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research And Development Arrangement Contract To Perform For Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_urgn_UpfrontFee', window );">Upfront fee</a></td>
<td class="nump">$ 10,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_urgn_MaximumAmountPayableUponAchievingCertainClinicalDevelopmentAndRegulatoryMilestones', window );">Maximum amount payable upon achieving certain clinical development and regulatory milestones</a></td>
<td class="nump">115,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_urgn_MaximumAmountPayableUponAchievingCertainCommercialMilestones', window );">Maximum amount payable upon achieving certain commercial milestones</a></td>
<td class="nump">$ 85,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=us-gaap_LicenseAgreementTermsMember', window );">Agenus Agreement | After First Commercial Sale of Licensed Product</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research And Development Arrangement Contract To Perform For Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_urgn_LicenseAgreementExpirationTerm', window );">License agreement expiration term</a></td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=urgn_MDAndersonMember', window );">MD Anderson</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research And Development Arrangement Contract To Perform For Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross', window );">Payments recognized through research and development expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Agenus Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research And Development Arrangement Contract To Perform For Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_urgn_RoyaltyRangingOnNetSalesOfLicensedProducts', window );">Royalty ranging on net sales of licensed products</a></td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Agenus Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research And Development Arrangement Contract To Perform For Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_urgn_RoyaltyRangingOnNetSalesOfLicensedProducts', window );">Royalty ranging on net sales of licensed products</a></td>
<td class="nump">14.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=urgn_AllerganPharmaceuticalsInternationalLimitedAndAbbVieIncMember', window );">Allergan/AbbVie | License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research And Development Arrangement Contract To Perform For Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_urgn_MilestonePaymentsReceivedForLicensingAgreement', window );">Milestone payments received for licensing agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000,000.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=urgn_AllerganPharmaceuticalsInternationalLimitedAndAbbVieIncMember', window );">Allergan/AbbVie | License Agreement | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research And Development Arrangement Contract To Perform For Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_urgn_ContractWithCustomerAdditionalMilestonePaymentEligibleToReceive', window );">License agreement additional milestone payments eligible to receive</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000,000.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_urgn_ContractWithCustomerAdditionalMilestonePaymentEligibleToReceive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contract with customer additional milestone payment eligible to receive.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">urgn_ContractWithCustomerAdditionalMilestonePaymentEligibleToReceive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>urgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_urgn_LicenseAgreementExpirationTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License agreement expiration term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">urgn_LicenseAgreementExpirationTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>urgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_urgn_MaximumAmountPayableUponAchievingCertainClinicalDevelopmentAndRegulatoryMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum amount payable upon achieving certain clinical development and regulatory milestones.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">urgn_MaximumAmountPayableUponAchievingCertainClinicalDevelopmentAndRegulatoryMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>urgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_urgn_MaximumAmountPayableUponAchievingCertainCommercialMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum amount payable upon achieving certain commercial milestones.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">urgn_MaximumAmountPayableUponAchievingCertainCommercialMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>urgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_urgn_MilestonePaymentsReceivedForLicensingAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Milestone payment received for licensing agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">urgn_MilestonePaymentsReceivedForLicensingAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>urgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_urgn_RoyaltyRangingOnNetSalesOfLicensedProducts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Royalty ranging on net sales of licensed products.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">urgn_RoyaltyRangingOnNetSalesOfLicensedProducts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>urgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_urgn_UpfrontFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Upfront fee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">urgn_UpfrontFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>urgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of costs incurred under a research and development arrangement accounted for as a contract to perform research and development for others.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6420387&amp;loc=d3e23221-108380<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6420387&amp;loc=d3e23199-108380<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=us-gaap_LicenseAgreementTermsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=us-gaap_LicenseAgreementTermsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=urgn_AfterFirstCommercialSaleOfLicensedProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=urgn_AfterFirstCommercialSaleOfLicensedProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=urgn_MDAndersonMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=urgn_MDAndersonMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=urgn_AllerganPharmaceuticalsInternationalLimitedAndAbbVieIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=urgn_AllerganPharmaceuticalsInternationalLimitedAndAbbVieIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=urgn_LicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=urgn_LicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140482547372232">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Shareholders' Equity - Additional Information (Details) - shares<br></strong></div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Ordinary shares, shares authorized</a></td>
<td class="nump">100,000,000<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Ordinary shares, issued</a></td>
<td class="nump">22,280,394<span></span>
</td>
<td class="nump">22,167,791<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ordinary shares, outstanding</a></td>
<td class="nump">22,280,394<span></span>
</td>
<td class="nump">22,167,791<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140482550535480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation - Additional Information (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 17, 2021</div></th>
<th class="th"><div>Jun. 08, 2020</div></th>
<th class="th"><div>Oct. 12, 2018</div></th>
<th class="th"><div>Jan. 01, 2018</div></th>
<th class="th"><div>Mar. 31, 2017</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>May 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized compensation cost of options and RSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 33.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Expected to be recognized over a weighted average period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year 10 months 9 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Options | Tranche One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Awards vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs) | Tranche One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=urgn_TwoThousandSeventeenEquityIncentivePlanMember', window );">2017 Equity Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSharesApprovedForIssuance', window );">Maximum number of ordinary share issuable under the 2017 incentive plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,400,000<span></span>
</td>
<td class="nump">5,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum', window );">Number of ordinary shares reserved for issuance, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_urgn_ShareBasedGoodsAndNonEmployeeServicesTransactionSharesReserveIncreaseForIssuance', window );">Increase in number of ordinary share issuable under the 2017 incentive plan</a></td>
<td class="nump">400,000<span></span>
</td>
<td class="nump">400,000<span></span>
</td>
<td class="nump">1,900,000<span></span>
</td>
<td class="nump">250,167<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=urgn_PlanMember', window );">Plan | Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Awards vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_urgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardIndividualVotingPowersPercentage', window );">Combined voting power percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Ordinary Shares | 2019 Inducement Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of stock options approved for grants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">900,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Ordinary Shares | 2017 Equity Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSharesApprovedForIssuance', window );">Maximum number of ordinary share issuable under the 2017 incentive plan</a></td>
<td class="nump">4,350,167<span></span>
</td>
<td class="nump">3,950,167<span></span>
</td>
<td class="nump">3,550,167<span></span>
</td>
<td class="nump">1,650,167<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Plan | Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Options granted, expected term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Plan | Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent', window );">Exercise price of stock options as percentage of fair market value of shares on grant date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_urgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfPurchasePriceForIndividualsHavingMoreThanTenPercentOfCombinedVotingPower', window );">Stock options exercise price percentage for individuals possesses more than 10% of the combined voter power</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">110.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_urgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardIndividualVotingPowersPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award individual voting power percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">urgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardIndividualVotingPowersPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>urgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_urgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfPurchasePriceForIndividualsHavingMoreThanTenPercentOfCombinedVotingPower">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award percentage of purchase price for individuals having more than ten percent of combined voting power.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">urgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfPurchasePriceForIndividualsHavingMoreThanTenPercentOfCombinedVotingPower</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>urgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_urgn_ShareBasedGoodsAndNonEmployeeServicesTransactionSharesReserveIncreaseForIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based goods and non-employee services transaction shares reserve increase for issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">urgn_ShareBasedGoodsAndNonEmployeeServicesTransactionSharesReserveIncreaseForIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>urgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum number of shares that may be issued in accordance with the plan as a proportion of outstanding capital stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSharesApprovedForIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of shares (or other type of equity) that have been approved for issuance in the equity-based payment transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSharesApprovedForIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of vesting of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Purchase price of common stock expressed as a percentage of its fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=urgn_TwoThousandSeventeenEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=urgn_TwoThousandSeventeenEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=urgn_PlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=urgn_PlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=urgn_TwoThousandAndNineteenInducementPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=urgn_TwoThousandAndNineteenInducementPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140482547630824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share Based Compensation - Schedule of Effect of Share-Based Compensation on Condensed Consolidated Statements of Operations (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation</a></td>
<td class="nump">$ 6,195<span></span>
</td>
<td class="nump">$ 7,617<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development Expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation</a></td>
<td class="nump">1,107<span></span>
</td>
<td class="nump">1,943<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, General and Administrative Expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation</a></td>
<td class="nump">$ 5,088<span></span>
</td>
<td class="nump">$ 5,674<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140482547417720">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Additional Information (Details)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Liability for uncertain tax positions</a></td>
<td class="nump">$ 2.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued', window );">Accrued interest and penalties included in liability for uncertain tax positions</a></td>
<td class="nump">$ 0.7<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10B<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=SL37586934-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140482551330072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Additional Information (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=srt_ChiefOperatingOfficerMember', window );">Stephen Mullennix</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_urgn_CommitmentsAndContingentLiabilitiesLineItems', window );"><strong>Commitments And Contingent Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedBonusesCurrentAndNoncurrent', window );">Accrued bonus payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=srt_ChiefFinancialOfficerMember', window );">Peter Pfreundschuh</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_urgn_CommitmentsAndContingentLiabilitiesLineItems', window );"><strong>Commitments And Contingent Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SeveranceCosts1', window );">Employee termination cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=urgn_IsraelInnovationAuthorityMember', window );">IIA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_urgn_CommitmentsAndContingentLiabilitiesLineItems', window );"><strong>Commitments And Contingent Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent', window );">Royalty amount payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_urgn_MaximumPercentageOfCommitmentToContinueEmploymentOfResearchAndDevelopmentJobs', window );">Maximum percentage of commitment to continue employment of research and development jobs</a></td>
<td class="nump">75.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_urgn_MaximumTermForCommitmentToContinueEmploymentOfResearchAndDevelopmentJobs', window );">Maximum term for commitment to continue employment of research and development jobs</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_urgn_CommitmentsAndContingentLiabilitiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commitments and contingent liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">urgn_CommitmentsAndContingentLiabilitiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>urgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_urgn_MaximumPercentageOfCommitmentToContinueEmploymentOfResearchAndDevelopmentJobs">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum percentage of commitment to continue employment of research and development jobs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">urgn_MaximumPercentageOfCommitmentToContinueEmploymentOfResearchAndDevelopmentJobs</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>urgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_urgn_MaximumTermForCommitmentToContinueEmploymentOfResearchAndDevelopmentJobs">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum term for commitment to continue employment of research and development jobs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">urgn_MaximumTermForCommitmentToContinueEmploymentOfResearchAndDevelopmentJobs</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>urgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedBonusesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for incentive compensation awarded to employees and directors or earned by them based on the terms of one or more relevant arrangements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.15(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedBonusesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.15(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedRoyaltiesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SeveranceCosts1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140864-122747<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SeveranceCosts1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_ChiefOperatingOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_ChiefOperatingOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_ChiefFinancialOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_ChiefFinancialOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=urgn_IsraelInnovationAuthorityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=urgn_IsraelInnovationAuthorityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140482549216536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events - Additional Information (Details) - RTW Investments - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>May 13, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_urgn_UpfrontFee', window );">Upfront fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=urgn_RTWInvestmentsMember', window );">Subsequent Events</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_urgn_UpfrontCashPaymentReceivedNetOfCosts', window );">Upfront cash payment received net of costs</a></td>
<td class="nump">$ 75.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_urgn_UpfrontCashPaymentReceivedNetOfCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Upfront cash payment received net of costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">urgn_UpfrontCashPaymentReceivedNetOfCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>urgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_urgn_UpfrontFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Upfront fee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">urgn_UpfrontFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>urgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=urgn_RTWInvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=urgn_RTWInvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>79
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0    ( ,P[K5('04UB@0   +$    0    9&]C4')O<',O87!P+GAM
M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG
M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGD<Z,STA)8*O4'J@)I9GF
M3?X.CD:?<@X>K7A.YNJQ<&4GPZ4A!0W_<FW>J=0U[R;UEA_6\#MI7E!+ P04
M    " #,.ZU2*/# H^T    K @  $0   &1O8U!R;W!S+V-O<F4N>&ULS9+!
M2L0P$(9?17)O)VE1(71S43PI""XHWD(RNQMLTI",M/OVIG6WB^@#>,S,GV^^
M@>E,E&9(^)R&B(D<YJO)]R%+$S?L0!0E0#8']#K7)1%*<S<DKZD\TQZB-A]Z
MC]!P?@,>25M-&F9@%5<B4YTUTB34-*03WIH5'S]3O\"L >S18Z ,HA; U#PQ
M'J>^@PM@AA$FG[\+:%?B4OT3NW2 G9)3=FMJ',=Z;)=<V4' V]/CR[)NY4(F
M'0R67]E).D;<L//DU_;N?OO 5,,;4?'K2K1;?BM;+@5_GUU_^%V$_6#=SOUC
MX[.@ZN#77:@O4$L#!!0    ( ,P[K5*97)PC$ 8  )PG   3    >&PO=&AE
M;64O=&AE;64Q+GAM;.U:6W/:.!1^[Z_0>&?V;0O&-H&VM!-S:7;;M)F$[4X?
MA1%8C6QY9)&$?[]'-A#+E@WMDDVZFSP$+.G[SD5'Y^@X>?/N+F+HAHB4\GA@
MV2_;UKNW+][@5S(D$4$P&:>O\, *I4Q>M5II ,,X?<D3$L/<@HL(2W@4R]9<
MX%L:+R/6ZK3;W5:$:6RA&$=D8'U>+&A T%116F]?(+3E'S/X%<M4C66C 1-7
M02:YB+3R^6S%_-K>/F7/Z3H=,H%N,!M8('_.;Z?D3EJ(X53"Q,!J9S]6:\?1
MTDB @LE]E 6Z2?:CTQ4(,@T[.IU8SG9\]L3MGXS*VG0T;1K@X_%X.+;+THMP
M' 3@4;N>PIWT;+^D00FTHVG09-CVVJZ1IJJ-4T_3]WW?ZYMHG J-6T_3:W?=
MTXZ)QJW0> V^\4^'PZZ)QJO0=.MI)B?]KFNDZ19H0D;CZWH2%;7E0-,@ %AP
M=M;,T@.67BGZ=90:V1V[W4%<\%CN.8D1_L;%!-9ITAF6-$9RG9 %#@ WQ-%,
M4'RO0;:*X,*2TER0UL\IM5 :")K(@?5'@B'%W*_]]9>[R:0S>IU].LYKE']I
MJP&G[;N;SY/\<^CDGZ>3UTU"SG"\+ GQ^R-;88<G;CL3<CH<9T)\S_;VD:4E
M,L_O^0KK3CQG'U:6L%W/S^2>C'(CN]WV6'WV3T=N(]>IP+,BUY1&)$6?R"VZ
MY!$XM4D-,A,_")V&F&I0' *D"3&6H8;XM,:L$> 3?;>^",C?C8CWJV^:/5>A
M6$G:A/@01AKBG'/F<]%L^P>E1M'V5;S<HY=8%0&7&-\TJC4LQ=9XE<#QK9P\
M'1,2S90+!D&&ER0F$JDY?DU($_XKI=K^G-- \)0O)/I*D8]ILR.G=";-Z#,:
MP4:O&W6':-(\>OX%^9PU"AR1&QT"9QNS1B&$:;OP'J\DCIJMPA$K0CYB&38:
M<K46@;9QJ81@6A+&T7A.TK01_%FL-9,^8,CLS9%USM:1#A&27C="/F+.BY 1
MOQZ&.$J:[:)Q6 3]GE[#2<'H@LMF_;A^AM4S;"R.]T?4%TKD#R:G/^DR- >C
MFED)O816:I^JAS0^J!XR"@7QN1X^Y7IX"C>6QKQ0KH)[ ?_1VC?"J_B"P#E_
M+GW/I>^Y]#VATK<W(WUGP=.+6]Y&;EO$^ZXQVM<T+BAC5W+-R,=4KY,IV#F?
MP.S]:#Z>\>WZV22$KYI9+2,6D$N!LT$DN/R+RO JQ GH9%LE"<M4TV4WBA*>
M0AMNZ5/U2I77Y:^Y*+@\6^3IKZ%T/BS/^3Q?Y[3-"S-#MW)+ZK:4OK4F.$KT
ML<QP3A[+##MG/)(=MG>@'37[]EUVY".E,%.70[@:0KX#;;J=W#HXGIB1N0K3
M4I!OP_GIQ7@:XCG9!+E]F%=MY]C1T?OGP5&PH^\\EAW'B/*B(>ZAAIC/PT.'
M>7M?F&>5QE T%&ULK"0L1K=@N-?Q+!3@9& MH >#KU$"\E)58#%;Q@,KD*)\
M3(Q%Z'#GEUQ?X]&2X]NF9;5NKREW&6TB4CG":9@39ZO*WF6QP54=SU5;\K"^
M:CVT%4[/_EFMR)\,$4X6"Q)(8Y07IDJB\QE3ON<K2<15.+]%,[82EQB\X^;'
M<4Y3N!)VM@\",KF[.:EZ93%GIO+?+0P)+%N(61+B35WMU>>;G*YZ(G;ZEW?!
M8/+]<,E'#^4[YU_T74.N?O;=X_INDSM(3)QYQ1$!=$4"(Y4<!A87,N10[I*0
M!A,!S93)1/ "@F2F'("8^@N]\@RY*17.K3XY?T4L@X9.7M(E$A2*L P%(1=R
MX^_ODVIWC-?Z+(%MA%0R9-47RD.)P3TS<D/85"7SKMHF"X7;XE3-NQJ^)F!+
MPWING2TG_]M>U#VT%SU&\Z.9X!ZSAW.;>KC"1:S_6-8>^3+?.7#;.MX#7N83
M+$.D?L%]BHJ $:MBOKJO3_DEG#NT>_&!()O\UMND]MW@#'S4JUJE9"L1/TL'
M?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5
MY3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$%     @
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MCIW9#K3[]3MVTHAVH2M<$-LY[^OGG#@GTYU4#[H ,.2QY$+/O,*8ZL+W=59
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M:N/4F T3]BDNC<*[#'4FG4N1XS.!G.!(2\YR:G!R13D5&9"E-=;D9$$5"%.
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M6.#7!)0-P/MK*<WSQ#:L[ON4_@502P,$%     @ S#NM4N(ZC1,.!@   !@
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M6$.+'+&G1C.0-)7"U88)(+YQ*;I0KQRYQ,L#U+91&$ZA3GO4J1?U=ZYH>03
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M=6&WRSZ_4@<VV9,@M<3=918OXV "XR +Q"\+5[RJ"J7[HUUKF_%:%?4#JS/
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MW\4 2]3WDWJA^,Z,^"NNX,)@7C.XTU&A!>#_#>?JN- .VEOB_']02P,$%
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MW=(*B0U:4[5%-[#CZ.//@E8I!Y-/:(I^WE^ACQ\^H0^(%^BOK:@4+5*UG&D
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M"@)K,+XS%>A<WN\G;# ?6+RE<SS.YW>2E92GB+V8BF)U7(7>,@F=@92&3NN
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MR-*@/B0-DK0]%#W0TM@B(I$N2<?)WW=(+7;:Q$B!7B0N;]Z\F2&'XXU4][H
M,/2Q*H6>>(4QJV/?UUD!%=-'<@4"=Q925<S@5"U]O5+ <F=4E7X4! ._8EQX
MT[%;NU;3L5R;D@NX5E2OJXJIIU,HY6;BA5Z[<,.7A;$+_G2\8DNX!?-U=:UP
MYG<L.:] :"X%5;"8>"?A\6EB\0[PC<-&[XRIC60NY;V=S/*)%UA!4$)F+ /#
MWP.<05E:(I3QJ^'T.I?6<'?<LE^XV#&6.=-P)LOO/#?%Q$L]FL."K4MS(S>?
MH8FG;_DR66KWI9L:&X\\FJVUD55CC HJ+NH_>VSRL&.0!J\81(U!Y'37CIS*
M<V;8=*SDABJ+1C8[<*$Z:Q3'A2W*K5&XR]'.3+^8 A2]X(*)C+.2SD1=:,S8
MV#?HP,+\K"$[K<FB5\AB>BF%*33])'+(G]O[**Q3%[7J3J.]A)=,'=$X[-$H
MB,(]?'$7;>SXXG^/EOXXF6NC\)3\W.,HZ1PESE'R?]*ZG^Q*&J )_? NC<+P
M(]T7Q$F6R;4PFEZS)S8O@3*1VT6UAIQ^>L2KK$%O4:L=%&M0T*(RB5=/&RH7
M%#W2A2SQ!G.QI$S;-:Q-5G3%<13GD$$U1W'-:D /N$!CN=:XK0^/R7,C\I<!
M^5,:>4\&O6 TP'_<BX8A:8/1K$2-"C2H!] D248D3J-N.\,D\@RSTX9#^OV$
MA+VX/^HPUMCIL=IS>, .M<)^8S!R;31)!Y$S&&Q]8O/ !/3H$@0H)'=YR_%:
M<GMT;'_9^D/38$2B7I($'8%TI6L@B(C2U'[#/KF3QO*]I3"8BC#H]?MI/0BB
MF,R$ 8S&.'Q]/F8BDQ70@[;HASUZA3W^&;*6PQMDRW_85MX*?G/M7RSW7:$
MGC6%K2EQ)\ 5O1-52[%Q#8;X3<.0U-$LW&F'!K"52L*('"0Q.6P2R%\+SW(.
M1_@=#M*7[K>_TT(K4$OW4-@[@.6HNVFWVKU%)W4+WL+KAPPC7'*A:0D+- V.
MAGV/JOIQJ"=&KEQ#GDN#[=T-"WQ/05D [B\D7OAF8AUT+_3T-U!+ P04
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MTF9YL::G#+5SH/M*T2_9*B[ \#C.?P-02P,$%     @ S#NM4H\17@B4!0
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MQABF$G-/.<>YABWRJNWMT3[KA<UZ;K-^O%Z8]UJ3LWB8X-CBW$Y@BUT4JD4
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M0=Y8IV4')@62J_;/'KH^'  FR3. K -D07>;**A\SQR;3XW>@?'1Q.87H=2
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MAV5%SQ@:'T#[I:8.=X9/T#^,\U]02P,$%     @ S#NM4M.B/6?,"0  81D
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MT&1T=AJ!Z79#ISA=AWE<:4?3'<22UBD:[T#G:TVWWRL^P;"@L]]02P,$%
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MD*YPB> [=S@ATW;\,)T.YVCI86!W'-OPW2%E9QP&Y(JB@G6Q_(Z&\?!LWAS
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M^7RQRB_1=>DR4[B(JU'ZV^ NREX.8'_ET"W#BP38WVZ7_P!02P,$%     @
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M1ABJT2Y#8E*G"HN!8-T3)$\0I'"M%546WJL2RS_Q(0<S1I2<(EHG%PFOA9E
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MNX@[8'HLL6&SEPD8+QQ"ZU[$P7"-O_P?4$L#!!0    ( ,P[K5*ST2LI( ,
M +H&   9    >&PO=V]R:W-H965T<R]S:&5E=#(S+GAM;*55;6_3,!#^*Z>
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M,,2S+BQK_KF@]0YL+PVWP;#Q ;:_J_D/4$L#!!0    ( ,P[K5)61=UM9Q
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M:53@HUKPRFR8AA!/7%*.9^#,K(?*5,QE? .@2BVBAL-F( 1</45R2XLL92;
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MY&;JA5YW\,"7I;$'_FRR8DMX!/-M=:]PY_<L!:]!:"X%5;"8>A?A^65JY9W
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MU97+M3/@<\,PSRX1TN8+2(ZB\51&#[2TY*R@-C-9M^SN+-)7Y,<HP3O(H<Y
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M.RCK@.L+*<UN8A-T_Q<FOP%02P,$%     @ S#NM4I8%P-3+ @  #@8  !D
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MSSU\[GBD9VNE?Y@4P++[/)/FK)=:6YSZOHE2R+GIJP(DSB1*Y]SBIU[YIM#
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MT>TD(+J[(UV :N_;;*O0-JV?5O99 >T2['ZI%!X#U[G#0Y7] U!+ P04
M" #,.ZU2"[DEBQ0"   C!   &0   'AL+W=O<FMS:&5E=',O<VAE970S-BYX
M;6Q]5$UOVS ,_2N"T4,+;/%'EG4M' -)@V$]% B:=3L,.R@V;0N1)5>BD^[?
MCY(=PP.:Y1"3%/GX'DTY/6ESL#4 LK=&*KL,:L3V/@QM7D/#[4RWH.BDU*;A
M2*ZI0ML:X(4O:F281-'GL.%"!5GJ8UN3I;I#*11L#;-=TW#S9PU2GY9!')P#
MSZ*JT07"+&UY!3O EW9KR M'E$(TH*S0BADHE\$JOE_/7;Y/^"'@9"<V<TKV
M6A^<\U@L@\@1 @DY.@1.CR,\@)0.B&B\#IC!V-(53NTS^E>OG;3LN84'+7^*
M NME\"5@!92\D_BL3]]@T+-P>+F6UO^STY ;!2SO+.IF*"8&C5#]D[\-<Y@4
M)/&%@F0H2#SOOI%GN>'(L]3H$S,NF]"<X:7Z:B(GE'LI.S1T*J@.LYVHE"A%
MSA6R59[K3J%0%=MJ*7(!EGUDJZ(0;H!<LD?5;X$;Y_4&D MI;]@5$XH]"2DI
M;-,0B97##O.!P;IGD%Q@\,3-C,WC#RR)DOAEMV'75S?_HH2D:126C,(2#SN_
M /N>F%^KO45#B_#[/PWF8X.Y;_#I0H/O&FDD.;<UXZKH#7CMQ)%+4&A]D/;\
M0&/:2V 6\L[0(.'=$?6M[GPK=X^.V>UB=A=-?G$:'J=LP\D[=]>'QE@)99F$
MDC"BV>TB8*9?R=Y!W?HUV&NDI?)F3;<8C$N@\U)K/#MNL\;O0O874$L#!!0
M   ( ,P[K5+#@8?*[@(  "\,   9    >&PO=V]R:W-H965T<R]S:&5E=#,W
M+GAM;+5776O;,!3]*\)/&W2UY7RV)(&F'ZS00&CH]C#VH-C7B:@EN9*\-+ ?
M/TE.[ 0:91OX)99DW7///9(O)Z.-D*]J#:#1.\NY&@=KK8OK,%3)&AA1EZ(
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MNQQBY;*^*>N&%I6];)9"X]5E'W/\N !I O#]2@C]UC#W5_NY,OT+4$L#!!0
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MGJW_66S)*UN\BZT5ZA]F&WBVP;%LG-$YX_B.P@?,&QP+./2 PT\%/.3@\%C
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MH$]#^,P75*3FF:M 5KQ1> S K,RCYJ& -;=)^,TV?@VLQJRCB>T 9CL <K>
M#P#[G6J+;%= [6,@;N4?18<B'NU'O,;,0=QV!N1N#?L1'W"1<:'+!E=\:T>\
MN2>U:H_](T"&K<IC="!D9:"W5+7&S*&J>&TW[Y;_#R$[8./$5O]Q< R(;5_
M[EW].Q"'^R'>-G,AM@T#NQO&?HCO>4I_EBH+-_D;"],V =PZ!FI6V[%[R_\.
M:NTM'($?HN UM1JS3CL,=U"SHH_=HO]1:K^SA6+;"7#G"+ 'MC\$[G\#[S@G
M\+>. .JPUYG58/?6SJS,@:'.8\;T!&,ZU7[^>5N_-V)U!K>Z43PKCK%&7"F>
M%)=S2B94& /]?,HUV_+&G(Q5)Z']_P!02P,$%     @ S#NM4J-"@>3_ @
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MF$K4(ER9"C['57#=5E2Z?M"B6CD&[K:,1Y;"1_F_B.ZS+PY(91SXPLZ!*^O
ME_$.7#</S_%QB_?CRCUPMWU\L4]1S=B;5.VC-D?WF*I>&W784 QKA7-Z Q4V
M+]JV8B#9+N]\%DRJ/BI_W:I6%[A>H+ZO&9.? ]U,F>9Y_ ]02P,$%     @
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MA#!3)@75?R\PAC TF32/YR*I5>YI NOC=?;KK'A=S".5,.;A3Q:HY=#J62B
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M;HBSX5)_LX P /U\SKE:3TQ77'X%C?X"4$L#!!0    ( ,P[K5*C\#N(20(
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MW3?HXOG@^$HMK?^R7:>;1*S<6-1-!R8/&J'"G^^[/!P!B.<T(.T Z4O Z!5
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MW]")6MA[V> Z)0K]4E1"Q"++3"62N3WG +V<[/%M"KRC,/#Q=&(4^M7HJA9
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MER4-5S#N ITOM<;=Q@&Z<9W]!E!+ P04    " #,.ZU2T=XK_+H"  !8!P
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MC6+4SH'.-TK9O>'&0S_<L[]02P,$%     @ S#NM4A#E+(!& @  #@4  !D
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M:^UH?L*RI@<+C7>@\U)KM]WX .,3F/T&4$L#!!0    ( ,P[K5(0PHZ07 (
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M;G7S"3L]@6"NA0U?:#K?001Y;9V6'9@82*[:/WOJZK '2(:O )(.D 3>;:+
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M-9)-^U#T@9;&$K$4J9*4'1?]^ XE63(:A<X"16$_V!+%N1[.T8RG&VV^VAS
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M\X6Q:Q72QWI][&A0Z#F7ADEWP;?-N\] HC,E_L*#YW*CJRS'I=9A7_G[3(!
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MF&;J;FZ<+NO!=:D=CL'U90X<.P^_ 9^OM':[&V^@^^]C]@]02P,$%     @
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M;-""V4H;F>1@M" 1:?;-GO.%J !(9P^ Y@!Z*"#, >&A@$X.Z!P*Z.: [J&
M7@[H?0>@^P#]'-#_?H9P#V"0 P8NNEDX7"POF6'CD9(;4%8:M=D+EQ .C2$4
MJ<W=B5'X5"#.C"<+IOC[<XQ^!!<RP2VAF4NJ]W 61<)>LA@^I]DNL0_>7'+#
M1*S?HLC#Y!+>O'H+KT"D<"/B& 7TJ&W0,*N^/<N-.,^,H'N,N&'J!$C_'="
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M-)[&#P.V)[WM2=#V!BQHLMEI:&2)5;BI @%=]J27_U'&J][J53"4]Z+FZ@A
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MPS ,0'_%T)XP!] AB#-E\18$^0%6H@_8$@6*19V_K]JE<9 +&7D]/!+<'FE
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M<RB[-!=6EKN7ZG8O!+[[#U!+ P04    " #,.ZU2]4F2S $"  !>)   &@
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M<' N>&UL4$L! A0#%     @ S#NM4BCPP*/M    *P(  !$
M ( !KP   &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#%     @ S#NM4IE<G",0
M!@  G"<  !,              ( !RP$  'AL+W1H96UE+W1H96UE,2YX;6Q0
M2P$"% ,4    " #,.ZU2=(7_U$<%   K%0  &               @($,"
M>&PO=V]R:W-H965T<R]S:&5E=#$N>&UL4$L! A0#%     @ S#NM4G(,_N"!
M @  JP8  !@              ("!B0T  'AL+W=O<FMS:&5E=',O<VAE970R
M+GAM;%!+ 0(4 Q0    ( ,P[K5+B.HT3#@8    8   8              "
M@4 0  !X;"]W;W)K<VAE971S+W-H965T,RYX;6Q02P$"% ,4    " #,.ZU2
M&$91(5$$   Q#@  &               @(&$%@  >&PO=V]R:W-H965T<R]S
M:&5E=#0N>&UL4$L! A0#%     @ S#NM4L&^(4R'!   51(  !@
M     ("!"QL  'AL+W=O<FMS:&5E=',O<VAE970U+GAM;%!+ 0(4 Q0    (
M ,P[K5(.0[ <[@4  $P6   8              " @<@?  !X;"]W;W)K<VAE
M971S+W-H965T-BYX;6Q02P$"% ,4    " #,.ZU2=PF03YD"  "A!0  &
M            @('L)0  >&PO=V]R:W-H965T<R]S:&5E=#<N>&UL4$L! A0#
M%     @ S#NM4D2^_+3D!@  3!   !@              ("!NR@  'AL+W=O
M<FMS:&5E=',O<VAE970X+GAM;%!+ 0(4 Q0    ( ,P[K5*MV53[> \    I
M   8              " @=4O  !X;"]W;W)K<VAE971S+W-H965T.2YX;6Q0
M2P$"% ,4    " #,.ZU2^[8',#<#  "M!P  &0              @(&#/P
M>&PO=V]R:W-H965T<R]S:&5E=#$P+GAM;%!+ 0(4 Q0    ( ,P[K5(4CG2@
M7@(  "@%   9              " @?%"  !X;"]W;W)K<VAE971S+W-H965T
M,3$N>&UL4$L! A0#%     @ S#NM4H\17@B4!0  U X  !D
M ("!AD4  'AL+W=O<FMS:&5E=',O<VAE970Q,BYX;6Q02P$"% ,4    " #,
M.ZU2RM_^]U$$   9"@  &0              @(%12P  >&PO=V]R:W-H965T
M<R]S:&5E=#$S+GAM;%!+ 0(4 Q0    ( ,P[K5)XCEZZ$ ,  ,$&   9
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M970Q."YX;6Q02P$"% ,4    " #,.ZU2V/&:BXX(  !Q%@  &0
M    @(%2:@  >&PO=V]R:W-H965T<R]S:&5E=#$Y+GAM;%!+ 0(4 Q0    (
M ,P[K5+2"\[PMP0  .D*   9              " @1=S  !X;"]W;W)K<VAE
M971S+W-H965T,C N>&UL4$L! A0#%     @ S#NM4@N/91TG @  ]@0  !D
M             ("!!7@  'AL+W=O<FMS:&5E=',O<VAE970R,2YX;6Q02P$"
M% ,4    " #,.ZU2.3(BFX0&  #2#P  &0              @(%C>@  >&PO
M=V]R:W-H965T<R]S:&5E=#(R+GAM;%!+ 0(4 Q0    ( ,P[K5*ST2LI( ,
M +H&   9              " @1Z!  !X;"]W;W)K<VAE971S+W-H965T,C,N
M>&UL4$L! A0#%     @ S#NM4E9%W6UG$   /C   !D              ("!
M=80  'AL+W=O<FMS:&5E=',O<VAE970R-"YX;6Q02P$"% ,4    " #,.ZU2
M7^[33&8"   H!0  &0              @($3E0  >&PO=V]R:W-H965T<R]S
M:&5E=#(U+GAM;%!+ 0(4 Q0    ( ,P[K5*!'*83/ ,  /4'   9
M      " @;"7  !X;"]W;W)K<VAE971S+W-H965T,C8N>&UL4$L! A0#%
M  @ S#NM4LK&!:)= @  (04  !D              ("!(YL  'AL+W=O<FMS
M:&5E=',O<VAE970R-RYX;6Q02P$"% ,4    " #,.ZU2H6X,5*$#  ";"0
M&0              @(&WG0  >&PO=V]R:W-H965T<R]S:&5E=#(X+GAM;%!+
M 0(4 Q0    ( ,P[K5*+]%O:AP,  #L(   9              " @8^A  !X
M;"]W;W)K<VAE971S+W-H965T,CDN>&UL4$L! A0#%     @ S#NM4I8%P-3+
M @  #@8  !D              ("!3:4  'AL+W=O<FMS:&5E=',O<VAE970S
M,"YX;6Q02P$"% ,4    " #,.ZU2K;JLRXL$  "8#   &0
M@(%/J   >&PO=V]R:W-H965T<R]S:&5E=#,Q+GAM;%!+ 0(4 Q0    ( ,P[
MK5(L-%^34 (   4%   9              " @1&M  !X;"]W;W)K<VAE971S
M+W-H965T,S(N>&UL4$L! A0#%     @ S#NM4HN>WTJ/ @  <04  !D
M         ("!F*\  'AL+W=O<FMS:&5E=',O<VAE970S,RYX;6Q02P$"% ,4
M    " #,.ZU21WB7%T\"  !)!0  &0              @(%>L@  >&PO=V]R
M:W-H965T<R]S:&5E=#,T+GAM;%!+ 0(4 Q0    ( ,P[K5+B)73_- (  +0$
M   9              " @>2T  !X;"]W;W)K<VAE971S+W-H965T,S4N>&UL
M4$L! A0#%     @ S#NM4@NY)8L4 @  (P0  !D              ("!3[<
M 'AL+W=O<FMS:&5E=',O<VAE970S-BYX;6Q02P$"% ,4    " #,.ZU2PX&'
MRNX"   O#   &0              @(&:N0  >&PO=V]R:W-H965T<R]S:&5E
M=#,W+GAM;%!+ 0(4 Q0    ( ,P[K5(XAT=Y^ (  +H(   9
M  " @;^\  !X;"]W;W)K<VAE971S+W-H965T,S@N>&UL4$L! A0#%     @
MS#NM4F\BQ!>/ @  EP8  !D              ("![K\  'AL+W=O<FMS:&5E
M=',O<VAE970S.2YX;6Q02P$"% ,4    " #,.ZU2Y,P6DTT"  "H!0  &0
M            @(&TP@  >&PO=V]R:W-H965T<R]S:&5E=#0P+GAM;%!+ 0(4
M Q0    ( ,P[K5(J\ZQ@EP(  +4(   9              " @3C%  !X;"]W
M;W)K<VAE971S+W-H965T-#$N>&UL4$L! A0#%     @ S#NM4AKL_<@<!
M%14  !D              ("!!L@  'AL+W=O<FMS:&5E=',O<VAE970T,BYX
M;6Q02P$"% ,4    " #,.ZU2HT*!Y/\"  !("P  &0              @(%9
MS   >&PO=V]R:W-H965T<R]S:&5E=#0S+GAM;%!+ 0(4 Q0    ( ,P[K5)4
M;I7:J0(  ((&   9              " @8_/  !X;"]W;W)K<VAE971S+W-H
M965T-#0N>&UL4$L! A0#%     @ S#NM4MBL= QX @  '08  !D
M     ("!;](  'AL+W=O<FMS:&5E=',O<VAE970T-2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( ,P[K5+1WBO\N@(  %@'   9              "
M@8GC  !X;"]W;W)K<VAE971S+W-H965T-3 N>&UL4$L! A0#%     @ S#NM
M4@$D@-S, @  Z 8  !D              ("!>N8  'AL+W=O<FMS:&5E=',O
M<VAE970U,2YX;6Q02P$"% ,4    " #,.ZU2]IZ0P7 "  #H!0  &0
M        @(%]Z0  >&PO=V]R:W-H965T<R]S:&5E=#4R+GAM;%!+ 0(4 Q0
M   ( ,P[K5(0Y2R 1@(   X%   9              " @23L  !X;"]W;W)K
M<VAE971S+W-H965T-3,N>&UL4$L! A0#%     @ S#NM4A#"CI!< @  5 4
M !D              ("!H>X  'AL+W=O<FMS:&5E=',O<VAE970U-"YX;6Q0
M2P$"% ,4    " #,.ZU2/4+H DD$   '$0  &0              @($T\0
M>&PO=V]R:W-H965T<R]S:&5E=#4U+GAM;%!+ 0(4 Q0    ( ,P[K5(%'-YP
M/0(  -<%   9              " @;3U  !X;"]W;W)K<VAE971S+W-H965T
M-38N>&UL4$L! A0#%     @ S#NM4O+AEQJ/!0  "AH  !D
M ("!*/@  'AL+W=O<FMS:&5E=',O<VAE970U-RYX;6Q02P$"% ,4    " #,
M.ZU2P.W !@D#   4"0  &0              @('N_0  >&PO=V]R:W-H965T
M<R]S:&5E=#4X+GAM;%!+ 0(4 Q0    ( ,P[K5(<@2!E*0(  *<$   9
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M 0!X;"]S='EL97,N>&UL4$L! A0#%     @ S#NM4I>*NQS     $P(   L
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64$L%!@    !% $4 VA(  !D7 0    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.21.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>112</ContextCount>
  <ElementCount>307</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>43</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>5</UnitCount>
  <MyReports>
    <Report instance="urgn-10q_20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.urogen.com/20210331/taxonomy/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="urgn-10q_20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>100010 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) (unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.urogen.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParentheticalUnaudited</Role>
      <ShortName>Condensed Consolidated Balance Sheets (Parenthetical) (unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="urgn-10q_20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>100020 - Statement - Condensed Consolidated Balance Sheets (unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.urogen.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited</Role>
      <ShortName>Condensed Consolidated Balance Sheets (unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="urgn-10q_20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>100030 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.urogen.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited</Role>
      <ShortName>Condensed Consolidated Statements of Operations and Comprehensive Loss (unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="urgn-10q_20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>100040 - Statement - Condensed Consolidated Statements of Shareholders' Equity (unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.urogen.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfShareholdersEquityUnaudited</Role>
      <ShortName>Condensed Consolidated Statements of Shareholders' Equity (unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="urgn-10q_20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>100050 - Statement - Condensed Consolidated Statements of Cash Flow (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.urogen.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowUnaudited</Role>
      <ShortName>Condensed Consolidated Statements of Cash Flow (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="urgn-10q_20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>100060 - Disclosure - Business and Nature of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.urogen.com/20210331/taxonomy/role/DisclosureBusinessAndNatureOfOperations</Role>
      <ShortName>Business and Nature of Operations</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="urgn-10q_20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>100070 - Disclosure - Basis of Presentation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.urogen.com/20210331/taxonomy/role/DisclosureBasisOfPresentation</Role>
      <ShortName>Basis of Presentation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="urgn-10q_20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>100080 - Disclosure - Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.urogen.com/20210331/taxonomy/role/DisclosureSignificantAccountingPolicies</Role>
      <ShortName>Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="urgn-10q_20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>100090 - Disclosure - Other Financial Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.urogen.com/20210331/taxonomy/role/DisclosureOtherFinancialInformation</Role>
      <ShortName>Other Financial Information</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="urgn-10q_20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>100100 - Disclosure - Inventories</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.urogen.com/20210331/taxonomy/role/DisclosureInventories</Role>
      <ShortName>Inventories</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="urgn-10q_20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>100110 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.urogen.com/20210331/taxonomy/role/DisclosureFairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="urgn-10q_20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>100120 - Disclosure - Marketable Securities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.urogen.com/20210331/taxonomy/role/DisclosureMarketableSecurities</Role>
      <ShortName>Marketable Securities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="urgn-10q_20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>100130 - Disclosure - Property and Equipment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.urogen.com/20210331/taxonomy/role/DisclosurePropertyAndEquipment</Role>
      <ShortName>Property and Equipment</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="urgn-10q_20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>100140 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.urogen.com/20210331/taxonomy/role/DisclosureLeases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="urgn-10q_20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>100150 - Disclosure - Revenue from Product Sales</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.urogen.com/20210331/taxonomy/role/DisclosureRevenueFromProductSales</Role>
      <ShortName>Revenue from Product Sales</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="urgn-10q_20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>100160 - Disclosure - License and Collaboration Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.urogen.com/20210331/taxonomy/role/DisclosureLicenseAndCollaborationAgreements</Role>
      <ShortName>License and Collaboration Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="urgn-10q_20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>100170 - Disclosure - Shareholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.urogen.com/20210331/taxonomy/role/DisclosureShareholdersEquity</Role>
      <ShortName>Shareholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="urgn-10q_20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>100180 - Disclosure - Share-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.urogen.com/20210331/taxonomy/role/DisclosureShareBasedCompensation</Role>
      <ShortName>Share-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="urgn-10q_20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>100190 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.urogen.com/20210331/taxonomy/role/DisclosureIncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="urgn-10q_20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>100200 - Disclosure - Related Parties</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.urogen.com/20210331/taxonomy/role/DisclosureRelatedParties</Role>
      <ShortName>Related Parties</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="urgn-10q_20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>100210 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.urogen.com/20210331/taxonomy/role/DisclosureCommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="urgn-10q_20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>100220 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.urogen.com/20210331/taxonomy/role/DisclosureSubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="urgn-10q_20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>100230 - Disclosure - Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.urogen.com/20210331/taxonomy/role/DisclosureSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.urogen.com/20210331/taxonomy/role/DisclosureSignificantAccountingPolicies</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="urgn-10q_20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>100240 - Disclosure - Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.urogen.com/20210331/taxonomy/role/DisclosureSignificantAccountingPoliciesTables</Role>
      <ShortName>Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.urogen.com/20210331/taxonomy/role/DisclosureSignificantAccountingPolicies</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="urgn-10q_20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>100250 - Disclosure - Other Financial Information (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.urogen.com/20210331/taxonomy/role/DisclosureOtherFinancialInformationTables</Role>
      <ShortName>Other Financial Information (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.urogen.com/20210331/taxonomy/role/DisclosureOtherFinancialInformation</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="urgn-10q_20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>100260 - Disclosure - Inventories (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.urogen.com/20210331/taxonomy/role/DisclosureInventoriesTables</Role>
      <ShortName>Inventories (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.urogen.com/20210331/taxonomy/role/DisclosureInventories</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="urgn-10q_20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>100270 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.urogen.com/20210331/taxonomy/role/DisclosureFairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.urogen.com/20210331/taxonomy/role/DisclosureFairValueMeasurements</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="urgn-10q_20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>100280 - Disclosure - Marketable Securities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.urogen.com/20210331/taxonomy/role/DisclosureMarketableSecuritiesTables</Role>
      <ShortName>Marketable Securities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.urogen.com/20210331/taxonomy/role/DisclosureMarketableSecurities</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="urgn-10q_20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>100290 - Disclosure - Property and Equipment (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.urogen.com/20210331/taxonomy/role/DisclosurePropertyAndEquipmentTables</Role>
      <ShortName>Property and Equipment (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.urogen.com/20210331/taxonomy/role/DisclosurePropertyAndEquipment</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="urgn-10q_20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>100300 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.urogen.com/20210331/taxonomy/role/DisclosureLeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.urogen.com/20210331/taxonomy/role/DisclosureLeases</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="urgn-10q_20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>100310 - Disclosure - Revenue from Product Sales (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.urogen.com/20210331/taxonomy/role/DisclosureRevenueFromProductSalesTables</Role>
      <ShortName>Revenue from Product Sales (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.urogen.com/20210331/taxonomy/role/DisclosureRevenueFromProductSales</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="urgn-10q_20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>100320 - Disclosure - Share-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.urogen.com/20210331/taxonomy/role/DisclosureShareBasedCompensationTables</Role>
      <ShortName>Share-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.urogen.com/20210331/taxonomy/role/DisclosureShareBasedCompensation</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="urgn-10q_20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>100330 - Disclosure - Business and Nature of Operations - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.urogen.com/20210331/taxonomy/role/DisclosureBusinessAndNatureOfOperationsAdditionalInformationDetails</Role>
      <ShortName>Business and Nature of Operations - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="urgn-10q_20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>100340 - Disclosure - Basis of Presentation - Addititonal Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.urogen.com/20210331/taxonomy/role/DisclosureBasisOfPresentationAddititonalInformationDetails</Role>
      <ShortName>Basis of Presentation - Addititonal Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="urgn-10q_20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>100350 - Disclosure - Significant Accounting Policies - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.urogen.com/20210331/taxonomy/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails</Role>
      <ShortName>Significant Accounting Policies - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="urgn-10q_20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>100360 - Disclosure - Significant Accounting Policies - Property and Equipment Useful Lives (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.urogen.com/20210331/taxonomy/role/DisclosureSignificantAccountingPoliciesPropertyAndEquipmentUsefulLivesDetails</Role>
      <ShortName>Significant Accounting Policies - Property and Equipment Useful Lives (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="urgn-10q_20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>100370 - Disclosure - Other Financial Information - Schedule of Accounts Payable and Accrued Expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.urogen.com/20210331/taxonomy/role/DisclosureOtherFinancialInformationScheduleOfAccountsPayableAndAccruedExpensesDetails</Role>
      <ShortName>Other Financial Information - Schedule of Accounts Payable and Accrued Expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="urgn-10q_20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>100380 - Disclosure - Other Financial Information - Schedule of Interest and Other Income (Expenses) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.urogen.com/20210331/taxonomy/role/DisclosureOtherFinancialInformationScheduleOfInterestAndOtherIncomeExpensesDetails</Role>
      <ShortName>Other Financial Information - Schedule of Interest and Other Income (Expenses) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="urgn-10q_20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>100390 - Disclosure - Inventories - Schedule of Inventories (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.urogen.com/20210331/taxonomy/role/DisclosureInventoriesScheduleOfInventoriesDetails</Role>
      <ShortName>Inventories - Schedule of Inventories (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="urgn-10q_20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>100400 - Disclosure - Fair Value Measurements - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.urogen.com/20210331/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails</Role>
      <ShortName>Fair Value Measurements - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="urgn-10q_20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>100410 - Disclosure - Fair Value Measurements - Summary of Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.urogen.com/20210331/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails</Role>
      <ShortName>Fair Value Measurements - Summary of Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="urgn-10q_20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>100420 - Disclosure - Marketable Securities - Summary of Marketable Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.urogen.com/20210331/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfMarketableSecuritiesDetails</Role>
      <ShortName>Marketable Securities - Summary of Marketable Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="urgn-10q_20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>100430 - Disclosure - Marketable Securities - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.urogen.com/20210331/taxonomy/role/DisclosureMarketableSecuritiesAdditionalInformationDetails</Role>
      <ShortName>Marketable Securities - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="urgn-10q_20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>100440 - Disclosure - Marketable Securities - Summary of Fair Values of Marketable Securities by Contractual Maturity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.urogen.com/20210331/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfFairValuesOfMarketableSecuritiesByContractualMaturityDetails</Role>
      <ShortName>Marketable Securities - Summary of Fair Values of Marketable Securities by Contractual Maturity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="urgn-10q_20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>100450 - Disclosure - Property and Equipment - Schedule of Property and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.urogen.com/20210331/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails</Role>
      <ShortName>Property and Equipment - Schedule of Property and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="urgn-10q_20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>100460 - Disclosure - Property and Equipment - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.urogen.com/20210331/taxonomy/role/DisclosurePropertyAndEquipmentAdditionalInformationDetails</Role>
      <ShortName>Property and Equipment - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="urgn-10q_20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>100470 - Disclosure - Leases - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.urogen.com/20210331/taxonomy/role/DisclosureLeasesAdditionalInformationDetails</Role>
      <ShortName>Leases - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="urgn-10q_20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>100480 - Disclosure - Leases - Components of Lease Cost (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.urogen.com/20210331/taxonomy/role/DisclosureLeasesComponentsOfLeaseCostDetails</Role>
      <ShortName>Leases - Components of Lease Cost (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="urgn-10q_20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>100490 - Disclosure - Leases - Schedule of Amounts Recognized (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.urogen.com/20210331/taxonomy/role/DisclosureLeasesScheduleOfAmountsRecognizedDetails</Role>
      <ShortName>Leases - Schedule of Amounts Recognized (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="urgn-10q_20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>100500 - Disclosure - Leases - Schedule of Supplemental Information Related to Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.urogen.com/20210331/taxonomy/role/DisclosureLeasesScheduleOfSupplementalInformationRelatedToLeasesDetails</Role>
      <ShortName>Leases - Schedule of Supplemental Information Related to Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="urgn-10q_20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>100510 - Disclosure - Leases - Schedule of Undiscounted Cash Flows to be Received Under Operating Sublease on an Annual Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.urogen.com/20210331/taxonomy/role/DisclosureLeasesScheduleOfUndiscountedCashFlowsToBeReceivedUnderOperatingSubleaseOnAnnualBasisDetails</Role>
      <ShortName>Leases - Schedule of Undiscounted Cash Flows to be Received Under Operating Sublease on an Annual Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="urgn-10q_20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>100520 - Disclosure - Leases - Schedule of Sublease Income Recognized Net within Operating Expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.urogen.com/20210331/taxonomy/role/DisclosureLeasesScheduleOfSubleaseIncomeRecognizedNetWithinOperatingExpensesDetails</Role>
      <ShortName>Leases - Schedule of Sublease Income Recognized Net within Operating Expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="urgn-10q_20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>100530 - Disclosure - Revenue from Product Sales - Schedule of Net Product Sales (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.urogen.com/20210331/taxonomy/role/DisclosureRevenueFromProductSalesScheduleOfNetProductSalesDetails</Role>
      <ShortName>Revenue from Product Sales - Schedule of Net Product Sales (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="urgn-10q_20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>100540 - Disclosure - License and Collaboration Agreements - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.urogen.com/20210331/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails</Role>
      <ShortName>License and Collaboration Agreements - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="urgn-10q_20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>100550 - Disclosure - Shareholders' Equity - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.urogen.com/20210331/taxonomy/role/DisclosureShareholdersEquityAdditionalInformationDetails</Role>
      <ShortName>Shareholders' Equity - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="urgn-10q_20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>100560 - Disclosure - Share-Based Compensation - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.urogen.com/20210331/taxonomy/role/DisclosureShareBasedCompensationAdditionalInformationDetails</Role>
      <ShortName>Share-Based Compensation - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="urgn-10q_20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>100570 - Disclosure - Share Based Compensation - Schedule of Effect of Share-Based Compensation on Condensed Consolidated Statements of Operations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.urogen.com/20210331/taxonomy/role/DisclosureShareBasedCompensationScheduleOfEffectOfShareBasedCompensationOnCondensedConsolidatedStatementsOfOperationsDetails</Role>
      <ShortName>Share Based Compensation - Schedule of Effect of Share-Based Compensation on Condensed Consolidated Statements of Operations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="urgn-10q_20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>100580 - Disclosure - Income Taxes - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.urogen.com/20210331/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails</Role>
      <ShortName>Income Taxes - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="urgn-10q_20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>100590 - Disclosure - Commitments and Contingencies - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.urogen.com/20210331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails</Role>
      <ShortName>Commitments and Contingencies - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="urgn-10q_20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>100600 - Disclosure - Subsequent Events - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.urogen.com/20210331/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails</Role>
      <ShortName>Subsequent Events - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" original="urgn-10q_20210331.htm">urgn-10q_20210331.htm</File>
    <File>urgn-20210331.xsd</File>
    <File>urgn-20210331_cal.xml</File>
    <File>urgn-20210331_def.xml</File>
    <File>urgn-20210331_lab.xml</File>
    <File>urgn-20210331_pre.xml</File>
    <File>urgn-ex101_102.htm</File>
    <File>urgn-ex102_101.htm</File>
    <File>urgn-ex103_100.htm</File>
    <File>urgn-ex104_98.htm</File>
    <File>urgn-ex105_99.htm</File>
    <File>urgn-ex106_433.htm</File>
    <File>urgn-ex311_11.htm</File>
    <File>urgn-ex312_6.htm</File>
    <File>urgn-ex321_7.htm</File>
    <File>urgn-ex322_9.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/stpr/2018-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/srt/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/us-gaap/2020-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>85
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "urgn-10q_20210331.htm": {
   "axisCustom": 0,
   "axisStandard": 20,
   "contextCount": 112,
   "dts": {
    "calculationLink": {
     "local": [
      "urgn-20210331_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "urgn-20210331_def.xml"
     ],
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-eedm-def-2020-01-31.xml",
      "http://xbrl.fasb.org/srt/2020/elts/srt-eedm1-def-2020-01-31.xml"
     ]
    },
    "inline": {
     "local": [
      "urgn-10q_20210331.htm"
     ]
    },
    "labelLink": {
     "local": [
      "urgn-20210331_lab.xml"
     ],
     "remote": [
      "https://xbrl.sec.gov/dei/2020/dei-doc-2020-01-31.xml",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-doc-2020-01-31.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "urgn-20210331_pre.xml"
     ]
    },
    "referenceLink": {
     "remote": [
      "https://xbrl.sec.gov/dei/2020/dei-ref-2020-01-31.xml",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-ref-2020-01-31.xml"
     ]
    },
    "schema": {
     "local": [
      "urgn-20210331.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd",
      "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "https://xbrl.sec.gov/exch/2020/exch-2020-01-31.xsd",
      "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd",
      "https://xbrl.sec.gov/sic/2020/sic-2020-01-31.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd",
      "https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-parts-codification-2020-01-31.xsd"
     ]
    }
   },
   "elementCount": 386,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2020-01-31": 12,
    "http://xbrl.sec.gov/dei/2020-01-31": 5,
    "total": 17
   },
   "keyCustom": 52,
   "keyStandard": 255,
   "memberCustom": 11,
   "memberStandard": 31,
   "nsprefix": "urgn",
   "nsuri": "http://www.urogen.com/20210331",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "body",
       "html"
      ],
      "baseRef": "urgn-10q_20210331.htm",
      "contextRef": "C_0001668243_20210101_20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "100000 - Document - Document and Entity Information",
     "role": "http://www.urogen.com/20210331/taxonomy/role/DocumentDocumentAndEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "body",
       "html"
      ],
      "baseRef": "urgn-10q_20210331.htm",
      "contextRef": "C_0001668243_20210101_20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "urgn-10q_20210331.htm",
      "contextRef": "C_0001668243_20210101_20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "urgn:OtherFinancialInformationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100090 - Disclosure - Other Financial Information",
     "role": "http://www.urogen.com/20210331/taxonomy/role/DisclosureOtherFinancialInformation",
     "shortName": "Other Financial Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "urgn-10q_20210331.htm",
      "contextRef": "C_0001668243_20210101_20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "urgn:OtherFinancialInformationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "urgn-10q_20210331.htm",
      "contextRef": "C_0001668243_20210101_20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100100 - Disclosure - Inventories",
     "role": "http://www.urogen.com/20210331/taxonomy/role/DisclosureInventories",
     "shortName": "Inventories",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "urgn-10q_20210331.htm",
      "contextRef": "C_0001668243_20210101_20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "urgn-10q_20210331.htm",
      "contextRef": "C_0001668243_20210101_20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100110 - Disclosure - Fair Value Measurements",
     "role": "http://www.urogen.com/20210331/taxonomy/role/DisclosureFairValueMeasurements",
     "shortName": "Fair Value Measurements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "urgn-10q_20210331.htm",
      "contextRef": "C_0001668243_20210101_20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "urgn-10q_20210331.htm",
      "contextRef": "C_0001668243_20210101_20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "urgn:MarketableSecuritiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100120 - Disclosure - Marketable Securities",
     "role": "http://www.urogen.com/20210331/taxonomy/role/DisclosureMarketableSecurities",
     "shortName": "Marketable Securities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "urgn-10q_20210331.htm",
      "contextRef": "C_0001668243_20210101_20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "urgn:MarketableSecuritiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "urgn-10q_20210331.htm",
      "contextRef": "C_0001668243_20210101_20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100130 - Disclosure - Property and Equipment",
     "role": "http://www.urogen.com/20210331/taxonomy/role/DisclosurePropertyAndEquipment",
     "shortName": "Property and Equipment",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "urgn-10q_20210331.htm",
      "contextRef": "C_0001668243_20210101_20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "urgn-10q_20210331.htm",
      "contextRef": "C_0001668243_20210101_20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100140 - Disclosure - Leases",
     "role": "http://www.urogen.com/20210331/taxonomy/role/DisclosureLeases",
     "shortName": "Leases",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "urgn-10q_20210331.htm",
      "contextRef": "C_0001668243_20210101_20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "urgn-10q_20210331.htm",
      "contextRef": "C_0001668243_20210101_20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100150 - Disclosure - Revenue from Product Sales",
     "role": "http://www.urogen.com/20210331/taxonomy/role/DisclosureRevenueFromProductSales",
     "shortName": "Revenue from Product Sales",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "urgn-10q_20210331.htm",
      "contextRef": "C_0001668243_20210101_20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "urgn-10q_20210331.htm",
      "contextRef": "C_0001668243_20210101_20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "urgn:LicenseAndCollaborationAgreementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100160 - Disclosure - License and Collaboration Agreements",
     "role": "http://www.urogen.com/20210331/taxonomy/role/DisclosureLicenseAndCollaborationAgreements",
     "shortName": "License and Collaboration Agreements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "urgn-10q_20210331.htm",
      "contextRef": "C_0001668243_20210101_20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "urgn:LicenseAndCollaborationAgreementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "urgn-10q_20210331.htm",
      "contextRef": "C_0001668243_20210101_20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100170 - Disclosure - Shareholders' Equity",
     "role": "http://www.urogen.com/20210331/taxonomy/role/DisclosureShareholdersEquity",
     "shortName": "Shareholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "urgn-10q_20210331.htm",
      "contextRef": "C_0001668243_20210101_20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "urgn-10q_20210331.htm",
      "contextRef": "C_0001668243_20210101_20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100180 - Disclosure - Share-Based Compensation",
     "role": "http://www.urogen.com/20210331/taxonomy/role/DisclosureShareBasedCompensation",
     "shortName": "Share-Based Compensation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "urgn-10q_20210331.htm",
      "contextRef": "C_0001668243_20210101_20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "urgn-10q_20210331.htm",
      "contextRef": "C_0001668243_20210331",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217ILS_xbrlishares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100010 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) (unaudited)",
     "role": "http://www.urogen.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParentheticalUnaudited",
     "shortName": "Condensed Consolidated Balance Sheets (Parenthetical) (unaudited)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "urgn-10q_20210331.htm",
      "contextRef": "C_0001668243_20210331",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217ILS_xbrlishares",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "urgn-10q_20210331.htm",
      "contextRef": "C_0001668243_20210101_20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100190 - Disclosure - Income Taxes",
     "role": "http://www.urogen.com/20210331/taxonomy/role/DisclosureIncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "urgn-10q_20210331.htm",
      "contextRef": "C_0001668243_20210101_20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "urgn-10q_20210331.htm",
      "contextRef": "C_0001668243_20210101_20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100200 - Disclosure - Related Parties",
     "role": "http://www.urogen.com/20210331/taxonomy/role/DisclosureRelatedParties",
     "shortName": "Related Parties",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "urgn-10q_20210331.htm",
      "contextRef": "C_0001668243_20210101_20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "urgn-10q_20210331.htm",
      "contextRef": "C_0001668243_20210101_20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100210 - Disclosure - Commitments and Contingencies",
     "role": "http://www.urogen.com/20210331/taxonomy/role/DisclosureCommitmentsAndContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "urgn-10q_20210331.htm",
      "contextRef": "C_0001668243_20210101_20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "urgn-10q_20210331.htm",
      "contextRef": "C_0001668243_20210101_20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100220 - Disclosure - Subsequent Events",
     "role": "http://www.urogen.com/20210331/taxonomy/role/DisclosureSubsequentEvents",
     "shortName": "Subsequent Events",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "urgn-10q_20210331.htm",
      "contextRef": "C_0001668243_20210101_20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "urgn-10q_20210331.htm",
      "contextRef": "C_0001668243_20210101_20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConsolidationPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100230 - Disclosure - Significant Accounting Policies (Policies)",
     "role": "http://www.urogen.com/20210331/taxonomy/role/DisclosureSignificantAccountingPoliciesPolicies",
     "shortName": "Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "urgn-10q_20210331.htm",
      "contextRef": "C_0001668243_20210101_20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConsolidationPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "urgn-10q_20210331.htm",
      "contextRef": "C_0001668243_20210101_20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "urgn:PropertyPlantAndEquipmentUsefulLifeTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100240 - Disclosure - Significant Accounting Policies (Tables)",
     "role": "http://www.urogen.com/20210331/taxonomy/role/DisclosureSignificantAccountingPoliciesTables",
     "shortName": "Significant Accounting Policies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "urgn-10q_20210331.htm",
      "contextRef": "C_0001668243_20210101_20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "urgn:PropertyPlantAndEquipmentUsefulLifeTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "urgn:OtherFinancialInformationTextBlock",
       "body",
       "html"
      ],
      "baseRef": "urgn-10q_20210331.htm",
      "contextRef": "C_0001668243_20210101_20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100250 - Disclosure - Other Financial Information (Tables)",
     "role": "http://www.urogen.com/20210331/taxonomy/role/DisclosureOtherFinancialInformationTables",
     "shortName": "Other Financial Information (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "urgn:OtherFinancialInformationTextBlock",
       "body",
       "html"
      ],
      "baseRef": "urgn-10q_20210331.htm",
      "contextRef": "C_0001668243_20210101_20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:InventoryDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "urgn-10q_20210331.htm",
      "contextRef": "C_0001668243_20210101_20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100260 - Disclosure - Inventories (Tables)",
     "role": "http://www.urogen.com/20210331/taxonomy/role/DisclosureInventoriesTables",
     "shortName": "Inventories (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:InventoryDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "urgn-10q_20210331.htm",
      "contextRef": "C_0001668243_20210101_20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "urgn-10q_20210331.htm",
      "contextRef": "C_0001668243_20210101_20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100270 - Disclosure - Fair Value Measurements (Tables)",
     "role": "http://www.urogen.com/20210331/taxonomy/role/DisclosureFairValueMeasurementsTables",
     "shortName": "Fair Value Measurements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "urgn-10q_20210331.htm",
      "contextRef": "C_0001668243_20210101_20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "urgn:MarketableSecuritiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "urgn-10q_20210331.htm",
      "contextRef": "C_0001668243_20210101_20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:MarketableSecuritiesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100280 - Disclosure - Marketable Securities (Tables)",
     "role": "http://www.urogen.com/20210331/taxonomy/role/DisclosureMarketableSecuritiesTables",
     "shortName": "Marketable Securities (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "urgn:MarketableSecuritiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "urgn-10q_20210331.htm",
      "contextRef": "C_0001668243_20210101_20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:MarketableSecuritiesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "urgn-10q_20210331.htm",
      "contextRef": "C_0001668243_20210331",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100020 - Statement - Condensed Consolidated Balance Sheets (unaudited)",
     "role": "http://www.urogen.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited",
     "shortName": "Condensed Consolidated Balance Sheets (unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "urgn-10q_20210331.htm",
      "contextRef": "C_0001668243_20210331",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "urgn-10q_20210331.htm",
      "contextRef": "C_0001668243_20210101_20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100290 - Disclosure - Property and Equipment (Tables)",
     "role": "http://www.urogen.com/20210331/taxonomy/role/DisclosurePropertyAndEquipmentTables",
     "shortName": "Property and Equipment (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "urgn-10q_20210331.htm",
      "contextRef": "C_0001668243_20210101_20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "urgn-10q_20210331.htm",
      "contextRef": "C_0001668243_20210101_20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100300 - Disclosure - Leases (Tables)",
     "role": "http://www.urogen.com/20210331/taxonomy/role/DisclosureLeasesTables",
     "shortName": "Leases (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "urgn-10q_20210331.htm",
      "contextRef": "C_0001668243_20210101_20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:RevenueFromContractWithCustomerTextBlock",
       "body",
       "html"
      ],
      "baseRef": "urgn-10q_20210331.htm",
      "contextRef": "C_0001668243_20210101_20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100310 - Disclosure - Revenue from Product Sales (Tables)",
     "role": "http://www.urogen.com/20210331/taxonomy/role/DisclosureRevenueFromProductSalesTables",
     "shortName": "Revenue from Product Sales (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:RevenueFromContractWithCustomerTextBlock",
       "body",
       "html"
      ],
      "baseRef": "urgn-10q_20210331.htm",
      "contextRef": "C_0001668243_20210101_20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "urgn-10q_20210331.htm",
      "contextRef": "C_0001668243_20210101_20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100320 - Disclosure - Share-Based Compensation (Tables)",
     "role": "http://www.urogen.com/20210331/taxonomy/role/DisclosureShareBasedCompensationTables",
     "shortName": "Share-Based Compensation (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "urgn-10q_20210331.htm",
      "contextRef": "C_0001668243_20210101_20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:NatureOfOperations",
       "body",
       "html"
      ],
      "baseRef": "urgn-10q_20210331.htm",
      "contextRef": "C_0001668243_20210101_20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "urgn:EntityIncorporationDateOfIncorporationMonthAndYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100330 - Disclosure - Business and Nature of Operations - Additional Information (Details)",
     "role": "http://www.urogen.com/20210331/taxonomy/role/DisclosureBusinessAndNatureOfOperationsAdditionalInformationDetails",
     "shortName": "Business and Nature of Operations - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:NatureOfOperations",
       "body",
       "html"
      ],
      "baseRef": "urgn-10q_20210331.htm",
      "contextRef": "C_0001668243_20210101_20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "urgn:EntityIncorporationDateOfIncorporationMonthAndYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "urgn-10q_20210331.htm",
      "contextRef": "C_0001668243_20210331",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RetainedEarningsAccumulatedDeficit",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100340 - Disclosure - Basis of Presentation - Addititonal Information (Details)",
     "role": "http://www.urogen.com/20210331/taxonomy/role/DisclosureBasisOfPresentationAddititonalInformationDetails",
     "shortName": "Basis of Presentation - Addititonal Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "urgn:CashAndCashEquivalentsAndMarketableSecuritiesPolicyPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "urgn-10q_20210331.htm",
      "contextRef": "C_0001668243_20210331",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "urgn:CashCashEquivalentsAndMarketableSecurities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100350 - Disclosure - Significant Accounting Policies - Additional Information (Details)",
     "role": "http://www.urogen.com/20210331/taxonomy/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails",
     "shortName": "Significant Accounting Policies - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "urgn:CashAndCashEquivalentsAndMarketableSecuritiesPolicyPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "urgn-10q_20210331.htm",
      "contextRef": "C_0001668243_20210331",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "urgn:CashCashEquivalentsAndMarketableSecurities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": null,
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100360 - Disclosure - Significant Accounting Policies - Property and Equipment Useful Lives (Details)",
     "role": "http://www.urogen.com/20210331/taxonomy/role/DisclosureSignificantAccountingPoliciesPropertyAndEquipmentUsefulLivesDetails",
     "shortName": "Significant Accounting Policies - Property and Equipment Useful Lives (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "urgn:OtherFinancialInformationTextBlock",
       "body",
       "html"
      ],
      "baseRef": "urgn-10q_20210331.htm",
      "contextRef": "C_0001668243_20210331",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AccountsPayableCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100370 - Disclosure - Other Financial Information - Schedule of Accounts Payable and Accrued Expenses (Details)",
     "role": "http://www.urogen.com/20210331/taxonomy/role/DisclosureOtherFinancialInformationScheduleOfAccountsPayableAndAccruedExpensesDetails",
     "shortName": "Other Financial Information - Schedule of Accounts Payable and Accrued Expenses (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "urgn:OtherFinancialInformationTextBlock",
       "body",
       "html"
      ],
      "baseRef": "urgn-10q_20210331.htm",
      "contextRef": "C_0001668243_20210331",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AccountsPayableCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock",
       "urgn:OtherFinancialInformationTextBlock",
       "body",
       "html"
      ],
      "baseRef": "urgn-10q_20210331.htm",
      "contextRef": "C_0001668243_20210101_20210331",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:InvestmentIncomeInterest",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100380 - Disclosure - Other Financial Information - Schedule of Interest and Other Income (Expenses) (Details)",
     "role": "http://www.urogen.com/20210331/taxonomy/role/DisclosureOtherFinancialInformationScheduleOfInterestAndOtherIncomeExpensesDetails",
     "shortName": "Other Financial Information - Schedule of Interest and Other Income (Expenses) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock",
       "urgn:OtherFinancialInformationTextBlock",
       "body",
       "html"
      ],
      "baseRef": "urgn-10q_20210331.htm",
      "contextRef": "C_0001668243_20210101_20210331",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:InvestmentIncomeInterest",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "urgn-10q_20210331.htm",
      "contextRef": "C_0001668243_20210101_20210331",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100030 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (unaudited)",
     "role": "http://www.urogen.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited",
     "shortName": "Condensed Consolidated Statements of Operations and Comprehensive Loss (unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "urgn-10q_20210331.htm",
      "contextRef": "C_0001668243_20210101_20210331",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:CostOfRevenue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "us-gaap:InventoryDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "urgn-10q_20210331.htm",
      "contextRef": "C_0001668243_20210331",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:InventoryRawMaterials",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100390 - Disclosure - Inventories - Schedule of Inventories (Details)",
     "role": "http://www.urogen.com/20210331/taxonomy/role/DisclosureInventoriesScheduleOfInventoriesDetails",
     "shortName": "Inventories - Schedule of Inventories (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "us-gaap:InventoryDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "urgn-10q_20210331.htm",
      "contextRef": "C_0001668243_20210331",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:InventoryRawMaterials",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "urgn-10q_20210331.htm",
      "contextRef": "C_0001668243_20210331",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:FairValueAssetsLevel1ToLevel2TransfersAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100400 - Disclosure - Fair Value Measurements - Additional Information (Details)",
     "role": "http://www.urogen.com/20210331/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails",
     "shortName": "Fair Value Measurements - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "urgn-10q_20210331.htm",
      "contextRef": "C_0001668243_20210331",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:FairValueAssetsLevel1ToLevel2TransfersAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:MarketableSecuritiesTextBlock",
       "urgn:MarketableSecuritiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "urgn-10q_20210331.htm",
      "contextRef": "C_0001668243_20210331",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100410 - Disclosure - Fair Value Measurements - Summary of Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details)",
     "role": "http://www.urogen.com/20210331/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails",
     "shortName": "Fair Value Measurements - Summary of Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "urgn-10q_20210331.htm",
      "contextRef": "C_0001668243_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20210331",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:MarketableSecuritiesTextBlock",
       "urgn:MarketableSecuritiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "urgn-10q_20210331.htm",
      "contextRef": "C_0001668243_20210331",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100420 - Disclosure - Marketable Securities - Summary of Marketable Securities (Details)",
     "role": "http://www.urogen.com/20210331/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfMarketableSecuritiesDetails",
     "shortName": "Marketable Securities - Summary of Marketable Securities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:MarketableSecuritiesTextBlock",
       "urgn:MarketableSecuritiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "urgn-10q_20210331.htm",
      "contextRef": "C_0001668243_20210331",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "urgn-10q_20210331.htm",
      "contextRef": "C_0001668243_20210331",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:InterestReceivable",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100430 - Disclosure - Marketable Securities - Additional Information (Details)",
     "role": "http://www.urogen.com/20210331/taxonomy/role/DisclosureMarketableSecuritiesAdditionalInformationDetails",
     "shortName": "Marketable Securities - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "urgn-10q_20210331.htm",
      "contextRef": "C_0001668243_20210331",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:InterestReceivable",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "urgn-10q_20210331.htm",
      "contextRef": "C_0001668243_20210331",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100440 - Disclosure - Marketable Securities - Summary of Fair Values of Marketable Securities by Contractual Maturity (Details)",
     "role": "http://www.urogen.com/20210331/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfFairValuesOfMarketableSecuritiesByContractualMaturityDetails",
     "shortName": "Marketable Securities - Summary of Fair Values of Marketable Securities by Contractual Maturity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "urgn-10q_20210331.htm",
      "contextRef": "C_0001668243_20210331",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "urgn-10q_20210331.htm",
      "contextRef": "C_0001668243_20210331",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100450 - Disclosure - Property and Equipment - Schedule of Property and Equipment (Details)",
     "role": "http://www.urogen.com/20210331/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails",
     "shortName": "Property and Equipment - Schedule of Property and Equipment (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "urgn-10q_20210331.htm",
      "contextRef": "C_0001668243_20210331",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "urgn-10q_20210331.htm",
      "contextRef": "C_0001668243_20210101_20210331",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100460 - Disclosure - Property and Equipment - Additional Information (Details)",
     "role": "http://www.urogen.com/20210331/taxonomy/role/DisclosurePropertyAndEquipmentAdditionalInformationDetails",
     "shortName": "Property and Equipment - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "urgn-10q_20210331.htm",
      "contextRef": "C_0001668243_20210101_20210331",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "urgn-10q_20210331.htm",
      "contextRef": "C_0001668243_20210101_20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseOptionToExtend",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100470 - Disclosure - Leases - Additional Information (Details)",
     "role": "http://www.urogen.com/20210331/taxonomy/role/DisclosureLeasesAdditionalInformationDetails",
     "shortName": "Leases - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "urgn-10q_20210331.htm",
      "contextRef": "C_0001668243_20210101_20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseOptionToExtend",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "urgn-10q_20210331.htm",
      "contextRef": "C_0001668243_20210101_20210331",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100480 - Disclosure - Leases - Components of Lease Cost (Details)",
     "role": "http://www.urogen.com/20210331/taxonomy/role/DisclosureLeasesComponentsOfLeaseCostDetails",
     "shortName": "Leases - Components of Lease Cost (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "urgn-10q_20210331.htm",
      "contextRef": "C_0001668243_20210101_20210331",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "urgn-10q_20210331.htm",
      "contextRef": "C_0001668243_20191231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100040 - Statement - Condensed Consolidated Statements of Shareholders' Equity (unaudited)",
     "role": "http://www.urogen.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfShareholdersEquityUnaudited",
     "shortName": "Condensed Consolidated Statements of Shareholders' Equity (unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "urgn-10q_20210331.htm",
      "contextRef": "C_0001668243_20191231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "urgn-10q_20210331.htm",
      "contextRef": "C_0001668243_20210331",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100490 - Disclosure - Leases - Schedule of Amounts Recognized (Details)",
     "role": "http://www.urogen.com/20210331/taxonomy/role/DisclosureLeasesScheduleOfAmountsRecognizedDetails",
     "shortName": "Leases - Schedule of Amounts Recognized (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "urgn:ScheduleOfOperatingLeaseAmountsRecognizedUponAdoptionTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "urgn-10q_20210331.htm",
      "contextRef": "C_0001668243_20210331",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:OperatingLeaseLiabilityCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "urgn:ScheduleOfSupplementalInformationRelatedToLeasesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "urgn-10q_20210331.htm",
      "contextRef": "C_0001668243_20210101_20210331",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeasePayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100500 - Disclosure - Leases - Schedule of Supplemental Information Related to Leases (Details)",
     "role": "http://www.urogen.com/20210331/taxonomy/role/DisclosureLeasesScheduleOfSupplementalInformationRelatedToLeasesDetails",
     "shortName": "Leases - Schedule of Supplemental Information Related to Leases (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "urgn:ScheduleOfSupplementalInformationRelatedToLeasesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "urgn-10q_20210331.htm",
      "contextRef": "C_0001668243_20210101_20210331",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeasePayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "urgn:LesseeOperatingSubLeasePaymentsToBeReceivedMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "urgn-10q_20210331.htm",
      "contextRef": "C_0001668243_20210331",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "urgn:LesseeOperatingSubLeasePaymentsToBeReceivedRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100510 - Disclosure - Leases - Schedule of Undiscounted Cash Flows to be Received Under Operating Sublease on an Annual Basis (Details)",
     "role": "http://www.urogen.com/20210331/taxonomy/role/DisclosureLeasesScheduleOfUndiscountedCashFlowsToBeReceivedUnderOperatingSubleaseOnAnnualBasisDetails",
     "shortName": "Leases - Schedule of Undiscounted Cash Flows to be Received Under Operating Sublease on an Annual Basis (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "urgn:LesseeOperatingSubLeasePaymentsToBeReceivedMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "urgn-10q_20210331.htm",
      "contextRef": "C_0001668243_20210331",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "urgn:LesseeOperatingSubLeasePaymentsToBeReceivedRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "urgn:LesseeOperatingSubLeaseIncomeRecognizedNetInOperatingExpensesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "urgn-10q_20210331.htm",
      "contextRef": "C_0001668243_20210101_20210331",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "urgn:LesseeOperatingSubLeaseIncomeFromFixedLeasePayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100520 - Disclosure - Leases - Schedule of Sublease Income Recognized Net within Operating Expenses (Details)",
     "role": "http://www.urogen.com/20210331/taxonomy/role/DisclosureLeasesScheduleOfSubleaseIncomeRecognizedNetWithinOperatingExpensesDetails",
     "shortName": "Leases - Schedule of Sublease Income Recognized Net within Operating Expenses (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "urgn:LesseeOperatingSubLeaseIncomeRecognizedNetInOperatingExpensesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "urgn-10q_20210331.htm",
      "contextRef": "C_0001668243_20210101_20210331",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "urgn:LesseeOperatingSubLeaseIncomeFromFixedLeasePayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "urgn-10q_20210331.htm",
      "contextRef": "C_0001668243_20210101_20210331",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100530 - Disclosure - Revenue from Product Sales - Schedule of Net Product Sales (Details)",
     "role": "http://www.urogen.com/20210331/taxonomy/role/DisclosureRevenueFromProductSalesScheduleOfNetProductSalesDetails",
     "shortName": "Revenue from Product Sales - Schedule of Net Product Sales (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "urgn-10q_20210331.htm",
      "contextRef": "C_0001668243_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_us-gaapLicenseAgreementTermsMember_20191101_20191130",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "urgn:UpfrontFee",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100540 - Disclosure - License and Collaboration Agreements - Additional Information (Details)",
     "role": "http://www.urogen.com/20210331/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails",
     "shortName": "License and Collaboration Agreements - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "urgn-10q_20210331.htm",
      "contextRef": "C_0001668243_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_us-gaapLicenseAgreementTermsMember_20191101_20191130",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "urgn:UpfrontFee",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "urgn-10q_20210331.htm",
      "contextRef": "C_0001668243_20210331",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockSharesAuthorized",
      "reportCount": 1,
      "unitRef": "U_xbrlishares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100550 - Disclosure - Shareholders' Equity - Additional Information (Details)",
     "role": "http://www.urogen.com/20210331/taxonomy/role/DisclosureShareholdersEquityAdditionalInformationDetails",
     "shortName": "Shareholders' Equity - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "urgn-10q_20210331.htm",
      "contextRef": "C_0001668243_20210331",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100560 - Disclosure - Share-Based Compensation - Additional Information (Details)",
     "role": "http://www.urogen.com/20210331/taxonomy/role/DisclosureShareBasedCompensationAdditionalInformationDetails",
     "shortName": "Share-Based Compensation - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "urgn-10q_20210331.htm",
      "contextRef": "C_0001668243_20210331",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "urgn-10q_20210331.htm",
      "contextRef": "C_0001668243_20210101_20210331",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100570 - Disclosure - Share Based Compensation - Schedule of Effect of Share-Based Compensation on Condensed Consolidated Statements of Operations (Details)",
     "role": "http://www.urogen.com/20210331/taxonomy/role/DisclosureShareBasedCompensationScheduleOfEffectOfShareBasedCompensationOnCondensedConsolidatedStatementsOfOperationsDetails",
     "shortName": "Share Based Compensation - Schedule of Effect of Share-Based Compensation on Condensed Consolidated Statements of Operations (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "urgn-10q_20210331.htm",
      "contextRef": "C_0001668243_20210101_20210331",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R59": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "urgn-10q_20210331.htm",
      "contextRef": "C_0001668243_20210331",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100580 - Disclosure - Income Taxes - Additional Information (Details)",
     "role": "http://www.urogen.com/20210331/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails",
     "shortName": "Income Taxes - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "urgn-10q_20210331.htm",
      "contextRef": "C_0001668243_20210331",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "urgn-10q_20210331.htm",
      "contextRef": "C_0001668243_20210101_20210331",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100050 - Statement - Condensed Consolidated Statements of Cash Flow (Unaudited)",
     "role": "http://www.urogen.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowUnaudited",
     "shortName": "Condensed Consolidated Statements of Cash Flow (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "urgn-10q_20210331.htm",
      "contextRef": "C_0001668243_20210101_20210331",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:DepreciationAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R60": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "urgn-10q_20210331.htm",
      "contextRef": "C_0001668243_srtTitleOfIndividualAxis_srtChiefOperatingOfficerMember_20200331",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:AccruedBonusesCurrentAndNoncurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100590 - Disclosure - Commitments and Contingencies - Additional Information (Details)",
     "role": "http://www.urogen.com/20210331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
     "shortName": "Commitments and Contingencies - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "urgn-10q_20210331.htm",
      "contextRef": "C_0001668243_srtTitleOfIndividualAxis_srtChiefOperatingOfficerMember_20200331",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:AccruedBonusesCurrentAndNoncurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R61": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:SubsequentEventsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "urgn-10q_20210331.htm",
      "contextRef": "C_0001668243_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_urgnRTWInvestmentsMember_20210101_20210331",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "urgn:UpfrontFee",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100600 - Disclosure - Subsequent Events - Additional Information (Details)",
     "role": "http://www.urogen.com/20210331/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails",
     "shortName": "Subsequent Events - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:SubsequentEventsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "urgn-10q_20210331.htm",
      "contextRef": "C_0001668243_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_urgnRTWInvestmentsMember_20210101_20210331",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "urgn:UpfrontFee",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "urgn-10q_20210331.htm",
      "contextRef": "C_0001668243_20210101_20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NatureOfOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100060 - Disclosure - Business and Nature of Operations",
     "role": "http://www.urogen.com/20210331/taxonomy/role/DisclosureBusinessAndNatureOfOperations",
     "shortName": "Business and Nature of Operations",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "urgn-10q_20210331.htm",
      "contextRef": "C_0001668243_20210101_20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NatureOfOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "urgn-10q_20210331.htm",
      "contextRef": "C_0001668243_20210101_20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccounting",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100070 - Disclosure - Basis of Presentation",
     "role": "http://www.urogen.com/20210331/taxonomy/role/DisclosureBasisOfPresentation",
     "shortName": "Basis of Presentation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "urgn-10q_20210331.htm",
      "contextRef": "C_0001668243_20210101_20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccounting",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "urgn-10q_20210331.htm",
      "contextRef": "C_0001668243_20210101_20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100080 - Disclosure - Significant Accounting Policies",
     "role": "http://www.urogen.com/20210331/taxonomy/role/DisclosureSignificantAccountingPolicies",
     "shortName": "Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "urgn-10q_20210331.htm",
      "contextRef": "C_0001668243_20210101_20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 43,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r419"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report",
        "terseLabel": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r420"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "verboseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address Address Line1",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address City Or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address State Or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r421"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock Shares Outstanding",
        "terseLabel": "Entity Common Stock, Ordinary Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r421"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r421"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation State Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r422"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r421"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r421"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r421"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r421"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r417"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Security12b Title",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r418"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "srt_ChiefFinancialOfficerMember": {
     "auth_ref": [
      "r133"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Chief Financial Officer [Member]",
        "terseLabel": "Peter Pfreundschuh"
       }
      }
     },
     "localname": "ChiefFinancialOfficerMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ChiefOperatingOfficerMember": {
     "auth_ref": [
      "r133",
      "r313"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Chief Operating Officer [Member]",
        "terseLabel": "Stephen Mullennix"
       }
      }
     },
     "localname": "ChiefOperatingOfficerMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ConsolidatedEntitiesAxis": {
     "auth_ref": [
      "r264",
      "r265",
      "r268",
      "r269",
      "r415"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidated Entities [Axis]",
        "terseLabel": "Consolidated Entities"
       }
      }
     },
     "localname": "ConsolidatedEntitiesAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ConsolidatedEntitiesDomain": {
     "auth_ref": [
      "r264",
      "r265",
      "r268",
      "r269"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidated Entities [Domain]",
        "terseLabel": "Consolidated Entities"
       }
      }
     },
     "localname": "ConsolidatedEntitiesDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r47",
      "r84"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]",
        "terseLabel": "Counterparty Name"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r213",
      "r215",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r351",
      "r376",
      "r378"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/DisclosureLeasesAdditionalInformationDetails",
      "http://www.urogen.com/20210331/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails",
      "http://www.urogen.com/20210331/taxonomy/role/DisclosureShareBasedCompensationAdditionalInformationDetails",
      "http://www.urogen.com/20210331/taxonomy/role/DisclosureSignificantAccountingPoliciesPropertyAndEquipmentUsefulLivesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r213",
      "r215",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r351",
      "r376",
      "r378"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/DisclosureLeasesAdditionalInformationDetails",
      "http://www.urogen.com/20210331/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails",
      "http://www.urogen.com/20210331/taxonomy/role/DisclosureShareBasedCompensationAdditionalInformationDetails",
      "http://www.urogen.com/20210331/taxonomy/role/DisclosureSignificantAccountingPoliciesPropertyAndEquipmentUsefulLivesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r203",
      "r213",
      "r215",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r351",
      "r376",
      "r378"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Range [Axis]",
        "terseLabel": "Statistical Measurement"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/DisclosureLeasesAdditionalInformationDetails",
      "http://www.urogen.com/20210331/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails",
      "http://www.urogen.com/20210331/taxonomy/role/DisclosureShareBasedCompensationAdditionalInformationDetails",
      "http://www.urogen.com/20210331/taxonomy/role/DisclosureSignificantAccountingPoliciesPropertyAndEquipmentUsefulLivesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r203",
      "r213",
      "r215",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r351",
      "r376",
      "r378"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Range [Member]",
        "terseLabel": "Statistical Measurement"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/DisclosureLeasesAdditionalInformationDetails",
      "http://www.urogen.com/20210331/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails",
      "http://www.urogen.com/20210331/taxonomy/role/DisclosureShareBasedCompensationAdditionalInformationDetails",
      "http://www.urogen.com/20210331/taxonomy/role/DisclosureSignificantAccountingPoliciesPropertyAndEquipmentUsefulLivesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Repurchase Agreement Counterparty Name [Domain]",
        "terseLabel": "Counterparty Name"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioUnspecifiedDomain": {
     "auth_ref": [
      "r214"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario Unspecified [Domain]",
        "terseLabel": "Scenario"
       }
      }
     },
     "localname": "ScenarioUnspecifiedDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [
      "r130",
      "r131",
      "r198",
      "r201",
      "r377",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Geographical [Domain]",
        "terseLabel": "Geographical"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r130",
      "r131",
      "r198",
      "r201",
      "r377",
      "r401",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement Geographical [Axis]",
        "terseLabel": "Geographical"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_StatementScenarioAxis": {
     "auth_ref": [
      "r184",
      "r214",
      "r319"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement Scenario [Axis]",
        "terseLabel": "Scenario"
       }
      }
     },
     "localname": "StatementScenarioAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_SubsidiariesMember": {
     "auth_ref": [
      "r211",
      "r311",
      "r312",
      "r314"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsidiaries [Member]",
        "terseLabel": "UroGen Pharma Inc."
       }
      }
     },
     "localname": "SubsidiariesMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_TitleOfIndividualAxis": {
     "auth_ref": [
      "r133",
      "r313"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title Of Individual [Axis]",
        "terseLabel": "Title of Individual"
       }
      }
     },
     "localname": "TitleOfIndividualAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title Of Individual With Relationship To Entity [Domain]",
        "terseLabel": "Title of Individual"
       }
      }
     },
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "stpr_CA": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CALIFORNIA",
        "terseLabel": "Los Angeles, California"
       }
      }
     },
     "localname": "CA",
     "nsuri": "http://xbrl.sec.gov/stpr/2018-01-31",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "stpr_NJ": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "NEW JERSEY",
        "terseLabel": "Princeton, NJ"
       }
      }
     },
     "localname": "NJ",
     "nsuri": "http://xbrl.sec.gov/stpr/2018-01-31",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "stpr_NY": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "NEW YORK",
        "terseLabel": "New York"
       }
      }
     },
     "localname": "NY",
     "nsuri": "http://xbrl.sec.gov/stpr/2018-01-31",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "urgn_AccruedClinicalExpensesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.urogen.com/20210331/taxonomy/role/DisclosureOtherFinancialInformationScheduleOfAccountsPayableAndAccruedExpensesDetails": {
       "order": 10030.0,
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued clinical expenses current.",
        "label": "Accrued Clinical Expenses Current",
        "terseLabel": "Accrued clinical expenses"
       }
      }
     },
     "localname": "AccruedClinicalExpensesCurrent",
     "nsuri": "http://www.urogen.com/20210331",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/DisclosureOtherFinancialInformationScheduleOfAccountsPayableAndAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "urgn_AccruedResearchAndDevelopmentExpenseCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.urogen.com/20210331/taxonomy/role/DisclosureOtherFinancialInformationScheduleOfAccountsPayableAndAccruedExpensesDetails": {
       "order": 10040.0,
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued Research and Development Expense, Current.",
        "label": "Accrued Research And Development Expense Current",
        "terseLabel": "Accrued research and development costs"
       }
      }
     },
     "localname": "AccruedResearchAndDevelopmentExpenseCurrent",
     "nsuri": "http://www.urogen.com/20210331",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/DisclosureOtherFinancialInformationScheduleOfAccountsPayableAndAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "urgn_AccruedSalesReserves": {
     "auth_ref": [],
     "calculation": {
      "http://www.urogen.com/20210331/taxonomy/role/DisclosureOtherFinancialInformationScheduleOfAccountsPayableAndAccruedExpensesDetails": {
       "order": 10020.0,
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued sales reserves.",
        "label": "Accrued Sales Reserves",
        "terseLabel": "Accrued sales reserves"
       }
      }
     },
     "localname": "AccruedSalesReserves",
     "nsuri": "http://www.urogen.com/20210331",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/DisclosureOtherFinancialInformationScheduleOfAccountsPayableAndAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "urgn_AccruedSellingGeneralAndAdministrativeExpenseCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.urogen.com/20210331/taxonomy/role/DisclosureOtherFinancialInformationScheduleOfAccountsPayableAndAccruedExpensesDetails": {
       "order": 10050.0,
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued selling general and administrative expense current.",
        "label": "Accrued Selling General And Administrative Expense Current",
        "terseLabel": "Accrued selling, general and administrative expenses"
       }
      }
     },
     "localname": "AccruedSellingGeneralAndAdministrativeExpenseCurrent",
     "nsuri": "http://www.urogen.com/20210331",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/DisclosureOtherFinancialInformationScheduleOfAccountsPayableAndAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "urgn_AfterFirstCommercialSaleOfLicensedProductMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "After first commercial sale of licensed product.",
        "label": "After First Commercial Sale Of Licensed Product [Member]",
        "terseLabel": "After First Commercial Sale of Licensed Product"
       }
      }
     },
     "localname": "AfterFirstCommercialSaleOfLicensedProductMember",
     "nsuri": "http://www.urogen.com/20210331",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "urgn_AllerganPharmaceuticalsInternationalLimitedAndAbbVieIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Allergan Pharmaceuticals International Limited and AbbVie Inc..",
        "label": "Allergan Pharmaceuticals International Limited And Abb Vie Inc [Member]",
        "terseLabel": "Allergan/AbbVie"
       }
      }
     },
     "localname": "AllerganPharmaceuticalsInternationalLimitedAndAbbVieIncMember",
     "nsuri": "http://www.urogen.com/20210331",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "urgn_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughThreeYearsFairValue": {
     "auth_ref": [],
     "calculation": {
      "http://www.urogen.com/20210331/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfFairValuesOfMarketableSecuritiesByContractualMaturityDetails": {
       "order": 10020.0,
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Available for sale securities debt maturities after one through three years fair value.",
        "label": "Available For Sale Securities Debt Maturities After One Through Three Years Fair Value",
        "terseLabel": "Maturities after one year through three years"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughThreeYearsFairValue",
     "nsuri": "http://www.urogen.com/20210331",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfFairValuesOfMarketableSecuritiesByContractualMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "urgn_CashAndCashEquivalentsAndMarketableSecuritiesPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash and cash equivalents and marketable securities policy.",
        "label": "Cash And Cash Equivalents And Marketable Securities Policy Policy [Text Block]",
        "terseLabel": "Cash and Cash Equivalents; Marketable Securities"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAndMarketableSecuritiesPolicyPolicyTextBlock",
     "nsuri": "http://www.urogen.com/20210331",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "urgn_CashCashEquivalentsAndMarketableSecurities": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash, cash equivalents and marketable securities.",
        "label": "Cash Cash Equivalents And Marketable Securities",
        "terseLabel": "Total cash and cash equivalents and marketable securities"
       }
      }
     },
     "localname": "CashCashEquivalentsAndMarketableSecurities",
     "nsuri": "http://www.urogen.com/20210331",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "urgn_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash paid for amounts included in measurement of lease liabilities.",
        "label": "Cash Paid For Amounts Included In Measurement Of Lease Liabilities [Abstract]",
        "terseLabel": "Cash paid for amounts included in the measurement of lease liabilities:"
       }
      }
     },
     "localname": "CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract",
     "nsuri": "http://www.urogen.com/20210331",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/DisclosureLeasesScheduleOfSupplementalInformationRelatedToLeasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "urgn_CommitmentsAndContingentLiabilitiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commitments and contingent liabilities.",
        "label": "Commitments And Contingent Liabilities [Line Items]",
        "terseLabel": "Commitments And Contingent Liabilities [Line Items]"
       }
      }
     },
     "localname": "CommitmentsAndContingentLiabilitiesLineItems",
     "nsuri": "http://www.urogen.com/20210331",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "urgn_CommitmentsAndContingentLiabilitiesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commitments and contingent liabilities.",
        "label": "Commitments And Contingent Liabilities [Table]",
        "terseLabel": "Commitments And Contingent Liabilities [Table]"
       }
      }
     },
     "localname": "CommitmentsAndContingentLiabilitiesTable",
     "nsuri": "http://www.urogen.com/20210331",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "urgn_ComputersAndSoftwareMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Computers and software.",
        "label": "Computers And Software [Member]",
        "terseLabel": "Computers and Software"
       }
      }
     },
     "localname": "ComputersAndSoftwareMember",
     "nsuri": "http://www.urogen.com/20210331",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails",
      "http://www.urogen.com/20210331/taxonomy/role/DisclosureSignificantAccountingPoliciesPropertyAndEquipmentUsefulLivesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "urgn_ContractWithCustomerAdditionalMilestonePaymentEligibleToReceive": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contract with customer additional milestone payment eligible to receive.",
        "label": "Contract With Customer Additional Milestone Payment Eligible To Receive",
        "terseLabel": "License agreement additional milestone payments eligible to receive"
       }
      }
     },
     "localname": "ContractWithCustomerAdditionalMilestonePaymentEligibleToReceive",
     "nsuri": "http://www.urogen.com/20210331",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "urgn_DebtSecuritiesAvailableForSaleUnrealizedGainPosition": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt securities available for sale unrealized gain position.",
        "label": "Debt Securities Available For Sale Unrealized Gain Position",
        "verboseLabel": "Available-for-sale debt securities, unrealized gain position"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedGainPosition",
     "nsuri": "http://www.urogen.com/20210331",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/DisclosureMarketableSecuritiesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "urgn_EntityIncorporationDateOfIncorporationMonthAndYear": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Entity incorporation date of incorporation month and year.",
        "label": "Entity Incorporation Date Of Incorporation Month And Year",
        "terseLabel": "Date of incorporation"
       }
      }
     },
     "localname": "EntityIncorporationDateOfIncorporationMonthAndYear",
     "nsuri": "http://www.urogen.com/20210331",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/DisclosureBusinessAndNatureOfOperationsAdditionalInformationDetails"
     ],
     "xbrltype": "gYearMonthItemType"
    },
    "urgn_FinanceIncomeExpenseNet": {
     "auth_ref": [],
     "calculation": {
      "http://www.urogen.com/20210331/taxonomy/role/DisclosureOtherFinancialInformationScheduleOfInterestAndOtherIncomeExpensesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Finance income expense net.",
        "label": "Finance Income Expense Net",
        "totalLabel": "Total interest and other income"
       }
      }
     },
     "localname": "FinanceIncomeExpenseNet",
     "nsuri": "http://www.urogen.com/20210331",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/DisclosureOtherFinancialInformationScheduleOfInterestAndOtherIncomeExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "urgn_InterestAndOtherIncomeExpensesNet": {
     "auth_ref": [],
     "calculation": {
      "http://www.urogen.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited": {
       "order": 10040.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest and other Income (expenses) net.",
        "label": "Interest And Other Income Expenses Net",
        "terseLabel": "Interest and other income, net"
       }
      }
     },
     "localname": "InterestAndOtherIncomeExpensesNet",
     "nsuri": "http://www.urogen.com/20210331",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "urgn_IsraelInnovationAuthorityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Israel Innovation Authority.",
        "label": "Israel Innovation Authority [Member]",
        "terseLabel": "IIA"
       }
      }
     },
     "localname": "IsraelInnovationAuthorityMember",
     "nsuri": "http://www.urogen.com/20210331",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "urgn_LaboratoryEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Laboratory equipment.",
        "label": "Laboratory Equipment [Member]",
        "terseLabel": "Laboratory Equipment"
       }
      }
     },
     "localname": "LaboratoryEquipmentMember",
     "nsuri": "http://www.urogen.com/20210331",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails",
      "http://www.urogen.com/20210331/taxonomy/role/DisclosureSignificantAccountingPoliciesPropertyAndEquipmentUsefulLivesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "urgn_LeaseCommencementDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lease commencement date.",
        "label": "Lease Commencement Date",
        "terseLabel": "Lease commencement date"
       }
      }
     },
     "localname": "LeaseCommencementDate",
     "nsuri": "http://www.urogen.com/20210331",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "dateItemType"
    },
    "urgn_LeaseCommencementDateMonthAndYear": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lease commencement date month and year.",
        "label": "Lease Commencement Date Month And Year",
        "terseLabel": "Lease commencement period, month and year"
       }
      }
     },
     "localname": "LeaseCommencementDateMonthAndYear",
     "nsuri": "http://www.urogen.com/20210331",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "gYearMonthItemType"
    },
    "urgn_LeaseExpirationYear": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lease expiration year.",
        "label": "Lease Expiration Year",
        "terseLabel": "Lease expiration year"
       }
      }
     },
     "localname": "LeaseExpirationYear",
     "nsuri": "http://www.urogen.com/20210331",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "gYearItemType"
    },
    "urgn_LeaseTerminationDateMonthAndYear": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lease termination date month and year.",
        "label": "Lease Termination Date Month And Year",
        "terseLabel": "Lease termination period, month and year"
       }
      }
     },
     "localname": "LeaseTerminationDateMonthAndYear",
     "nsuri": "http://www.urogen.com/20210331",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "gYearMonthItemType"
    },
    "urgn_LesseeOperatingLeaseExtendedLeaseExpirationDateMonthAndYear": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee operating lease extended lease expiration date, month and year.",
        "label": "Lessee Operating Lease Extended Lease Expiration Date Month And Year",
        "terseLabel": "Operating lease extended lease expiration, month and year"
       }
      }
     },
     "localname": "LesseeOperatingLeaseExtendedLeaseExpirationDateMonthAndYear",
     "nsuri": "http://www.urogen.com/20210331",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "gYearMonthItemType"
    },
    "urgn_LesseeOperatingSubLeaseIncomeFromFixedLeasePayments": {
     "auth_ref": [],
     "calculation": {
      "http://www.urogen.com/20210331/taxonomy/role/DisclosureLeasesScheduleOfSubleaseIncomeRecognizedNetWithinOperatingExpensesDetails": {
       "order": 10010.0,
       "parentTag": "us-gaap_SubleaseIncome",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee operating sub lease income from fixed lease payments.",
        "label": "Lessee Operating Sub Lease Income From Fixed Lease Payments",
        "terseLabel": "Sublease income from fixed lease payments"
       }
      }
     },
     "localname": "LesseeOperatingSubLeaseIncomeFromFixedLeasePayments",
     "nsuri": "http://www.urogen.com/20210331",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/DisclosureLeasesScheduleOfSubleaseIncomeRecognizedNetWithinOperatingExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "urgn_LesseeOperatingSubLeaseIncomeFromVariablePayments": {
     "auth_ref": [],
     "calculation": {
      "http://www.urogen.com/20210331/taxonomy/role/DisclosureLeasesScheduleOfSubleaseIncomeRecognizedNetWithinOperatingExpensesDetails": {
       "order": 10020.0,
       "parentTag": "us-gaap_SubleaseIncome",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee operating sub lease income from variable payments.",
        "label": "Lessee Operating Sub Lease Income From Variable Payments",
        "terseLabel": "Sublease income from variable payments"
       }
      }
     },
     "localname": "LesseeOperatingSubLeaseIncomeFromVariablePayments",
     "nsuri": "http://www.urogen.com/20210331",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/DisclosureLeasesScheduleOfSubleaseIncomeRecognizedNetWithinOperatingExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "urgn_LesseeOperatingSubLeaseIncomeRecognizedNetInOperatingExpensesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee operating sub lease income recognized net in operating expenses.",
        "label": "Lessee Operating Sub Lease Income Recognized Net In Operating Expenses Table [Text Block]",
        "terseLabel": "Schedule of Sublease Income Recognized Net within Operating Expenses"
       }
      }
     },
     "localname": "LesseeOperatingSubLeaseIncomeRecognizedNetInOperatingExpensesTableTextBlock",
     "nsuri": "http://www.urogen.com/20210331",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/DisclosureLeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "urgn_LesseeOperatingSubLeasePaymentsToBeReceived": {
     "auth_ref": [],
     "calculation": {
      "http://www.urogen.com/20210331/taxonomy/role/DisclosureLeasesScheduleOfUndiscountedCashFlowsToBeReceivedUnderOperatingSubleaseOnAnnualBasisDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee operating sub lease payments to be received.",
        "label": "Lessee Operating Sub Lease Payments To Be Received",
        "totalLabel": "Lessee operating sublease payments to be received"
       }
      }
     },
     "localname": "LesseeOperatingSubLeasePaymentsToBeReceived",
     "nsuri": "http://www.urogen.com/20210331",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/DisclosureLeasesScheduleOfUndiscountedCashFlowsToBeReceivedUnderOperatingSubleaseOnAnnualBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "urgn_LesseeOperatingSubLeasePaymentsToBeReceivedFourYears": {
     "auth_ref": [],
     "calculation": {
      "http://www.urogen.com/20210331/taxonomy/role/DisclosureLeasesScheduleOfUndiscountedCashFlowsToBeReceivedUnderOperatingSubleaseOnAnnualBasisDetails": {
       "order": 10050.0,
       "parentTag": "urgn_LesseeOperatingSubLeasePaymentsToBeReceived",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee operating sub lease payments to be received four years.",
        "label": "Lessee Operating Sub Lease Payments To Be Received Four Years",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "LesseeOperatingSubLeasePaymentsToBeReceivedFourYears",
     "nsuri": "http://www.urogen.com/20210331",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/DisclosureLeasesScheduleOfUndiscountedCashFlowsToBeReceivedUnderOperatingSubleaseOnAnnualBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "urgn_LesseeOperatingSubLeasePaymentsToBeReceivedFourYearsAndThereafter": {
     "auth_ref": [],
     "calculation": {
      "http://www.urogen.com/20210331/taxonomy/role/DisclosureLeasesScheduleOfUndiscountedCashFlowsToBeReceivedUnderOperatingSubleaseOnAnnualBasisDetails": {
       "order": 10060.0,
       "parentTag": "urgn_LesseeOperatingSubLeasePaymentsToBeReceived",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee operating sublease payments to be received four years and thereafter.",
        "label": "Lessee Operating Sub Lease Payments To Be Received Four Years And Thereafter",
        "terseLabel": "2026 and thereafter"
       }
      }
     },
     "localname": "LesseeOperatingSubLeasePaymentsToBeReceivedFourYearsAndThereafter",
     "nsuri": "http://www.urogen.com/20210331",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/DisclosureLeasesScheduleOfUndiscountedCashFlowsToBeReceivedUnderOperatingSubleaseOnAnnualBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "urgn_LesseeOperatingSubLeasePaymentsToBeReceivedMaturityTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee operating sub lease payments to be received maturity.",
        "label": "Lessee Operating Sub Lease Payments To Be Received Maturity Table [Text Block]",
        "terseLabel": "Schedule of Undiscounted Cash Flows to be Received Under Operating Sublease on an Annual Basis"
       }
      }
     },
     "localname": "LesseeOperatingSubLeasePaymentsToBeReceivedMaturityTableTextBlock",
     "nsuri": "http://www.urogen.com/20210331",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/DisclosureLeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "urgn_LesseeOperatingSubLeasePaymentsToBeReceivedNextTwelveMonths": {
     "auth_ref": [],
     "calculation": {
      "http://www.urogen.com/20210331/taxonomy/role/DisclosureLeasesScheduleOfUndiscountedCashFlowsToBeReceivedUnderOperatingSubleaseOnAnnualBasisDetails": {
       "order": 10020.0,
       "parentTag": "urgn_LesseeOperatingSubLeasePaymentsToBeReceived",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee operating sublease payments to be received next twelve months.",
        "label": "Lessee Operating Sub Lease Payments To Be Received Next Twelve Months",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "LesseeOperatingSubLeasePaymentsToBeReceivedNextTwelveMonths",
     "nsuri": "http://www.urogen.com/20210331",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/DisclosureLeasesScheduleOfUndiscountedCashFlowsToBeReceivedUnderOperatingSubleaseOnAnnualBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "urgn_LesseeOperatingSubLeasePaymentsToBeReceivedRemainderOfFiscalYear": {
     "auth_ref": [],
     "calculation": {
      "http://www.urogen.com/20210331/taxonomy/role/DisclosureLeasesScheduleOfUndiscountedCashFlowsToBeReceivedUnderOperatingSubleaseOnAnnualBasisDetails": {
       "order": 10010.0,
       "parentTag": "urgn_LesseeOperatingSubLeasePaymentsToBeReceived",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee operating sub lease payments to be received remainder of fiscal year.",
        "label": "Lessee Operating Sub Lease Payments To Be Received Remainder Of Fiscal Year",
        "terseLabel": "Remainder of 2021"
       }
      }
     },
     "localname": "LesseeOperatingSubLeasePaymentsToBeReceivedRemainderOfFiscalYear",
     "nsuri": "http://www.urogen.com/20210331",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/DisclosureLeasesScheduleOfUndiscountedCashFlowsToBeReceivedUnderOperatingSubleaseOnAnnualBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "urgn_LesseeOperatingSubLeasePaymentsToBeReceivedThreeYears": {
     "auth_ref": [],
     "calculation": {
      "http://www.urogen.com/20210331/taxonomy/role/DisclosureLeasesScheduleOfUndiscountedCashFlowsToBeReceivedUnderOperatingSubleaseOnAnnualBasisDetails": {
       "order": 10040.0,
       "parentTag": "urgn_LesseeOperatingSubLeasePaymentsToBeReceived",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee operating sub lease payments to be received three years.",
        "label": "Lessee Operating Sub Lease Payments To Be Received Three Years",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LesseeOperatingSubLeasePaymentsToBeReceivedThreeYears",
     "nsuri": "http://www.urogen.com/20210331",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/DisclosureLeasesScheduleOfUndiscountedCashFlowsToBeReceivedUnderOperatingSubleaseOnAnnualBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "urgn_LesseeOperatingSubLeasePaymentsToBeReceivedTwoYears": {
     "auth_ref": [],
     "calculation": {
      "http://www.urogen.com/20210331/taxonomy/role/DisclosureLeasesScheduleOfUndiscountedCashFlowsToBeReceivedUnderOperatingSubleaseOnAnnualBasisDetails": {
       "order": 10030.0,
       "parentTag": "urgn_LesseeOperatingSubLeasePaymentsToBeReceived",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee operating sub lease payments to be received two years.",
        "label": "Lessee Operating Sub Lease Payments To Be Received Two Years",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingSubLeasePaymentsToBeReceivedTwoYears",
     "nsuri": "http://www.urogen.com/20210331",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/DisclosureLeasesScheduleOfUndiscountedCashFlowsToBeReceivedUnderOperatingSubleaseOnAnnualBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "urgn_LesseeOperatingSubleaseCommencementDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee operating sublease commencement date.",
        "label": "Lessee Operating Sublease Commencement Date",
        "terseLabel": "Lessee operating sublease commencement date"
       }
      }
     },
     "localname": "LesseeOperatingSubleaseCommencementDate",
     "nsuri": "http://www.urogen.com/20210331",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "dateItemType"
    },
    "urgn_LesseeOperatingSubleaseTerminationDateMonthAndYear": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee operating sublease termination date month and year.",
        "label": "Lessee Operating Sublease Termination Date Month And Year",
        "terseLabel": "Lessee operating sublease termination period, month and year"
       }
      }
     },
     "localname": "LesseeOperatingSubleaseTerminationDateMonthAndYear",
     "nsuri": "http://www.urogen.com/20210331",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "gYearMonthItemType"
    },
    "urgn_LicenseAgreementExpirationTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License agreement expiration term.",
        "label": "License Agreement Expiration Term",
        "terseLabel": "License agreement expiration term"
       }
      }
     },
     "localname": "LicenseAgreementExpirationTerm",
     "nsuri": "http://www.urogen.com/20210331",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "urgn_LicenseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License agreement.",
        "label": "License Agreement [Member]",
        "terseLabel": "License Agreement"
       }
      }
     },
     "localname": "LicenseAgreementMember",
     "nsuri": "http://www.urogen.com/20210331",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "urgn_LicenseAndCollaborationAgreementsDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License and collaboration agreements.",
        "label": "License And Collaboration Agreements Disclosure [Text Block]",
        "terseLabel": "License and Collaboration Agreements"
       }
      }
     },
     "localname": "LicenseAndCollaborationAgreementsDisclosureTextBlock",
     "nsuri": "http://www.urogen.com/20210331",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/DisclosureLicenseAndCollaborationAgreements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "urgn_LiscenseAgreementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "liscense agreement.",
        "label": "Liscense Agreement [Abstract]"
       }
      }
     },
     "localname": "LiscenseAgreementAbstract",
     "nsuri": "http://www.urogen.com/20210331",
     "xbrltype": "stringItemType"
    },
    "urgn_MDAndersonMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "MD Anderson.",
        "label": "M D Anderson [Member]",
        "terseLabel": "MD Anderson"
       }
      }
     },
     "localname": "MDAndersonMember",
     "nsuri": "http://www.urogen.com/20210331",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "urgn_MarketableSecuritiesDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Marketable securities.",
        "label": "Marketable Securities Disclosure [Text Block]",
        "terseLabel": "Marketable Securities"
       }
      }
     },
     "localname": "MarketableSecuritiesDisclosureTextBlock",
     "nsuri": "http://www.urogen.com/20210331",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/DisclosureMarketableSecurities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "urgn_MaximumAmountPayableUponAchievingCertainClinicalDevelopmentAndRegulatoryMilestones": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum amount payable upon achieving certain clinical development and regulatory milestones.",
        "label": "Maximum Amount Payable Upon Achieving Certain Clinical Development And Regulatory Milestones",
        "terseLabel": "Maximum amount payable upon achieving certain clinical development and regulatory milestones"
       }
      }
     },
     "localname": "MaximumAmountPayableUponAchievingCertainClinicalDevelopmentAndRegulatoryMilestones",
     "nsuri": "http://www.urogen.com/20210331",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "urgn_MaximumAmountPayableUponAchievingCertainCommercialMilestones": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum amount payable upon achieving certain commercial milestones.",
        "label": "Maximum Amount Payable Upon Achieving Certain Commercial Milestones",
        "terseLabel": "Maximum amount payable upon achieving certain commercial milestones"
       }
      }
     },
     "localname": "MaximumAmountPayableUponAchievingCertainCommercialMilestones",
     "nsuri": "http://www.urogen.com/20210331",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "urgn_MaximumPercentageOfCommitmentToContinueEmploymentOfResearchAndDevelopmentJobs": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum percentage of commitment to continue employment of research and development jobs.",
        "label": "Maximum Percentage Of Commitment To Continue Employment Of Research And Development Jobs",
        "terseLabel": "Maximum percentage of commitment to continue employment of research and development jobs"
       }
      }
     },
     "localname": "MaximumPercentageOfCommitmentToContinueEmploymentOfResearchAndDevelopmentJobs",
     "nsuri": "http://www.urogen.com/20210331",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "urgn_MaximumTermForCommitmentToContinueEmploymentOfResearchAndDevelopmentJobs": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum term for commitment to continue employment of research and development jobs.",
        "label": "Maximum Term For Commitment To Continue Employment Of Research And Development Jobs",
        "terseLabel": "Maximum term for commitment to continue employment of research and development jobs"
       }
      }
     },
     "localname": "MaximumTermForCommitmentToContinueEmploymentOfResearchAndDevelopmentJobs",
     "nsuri": "http://www.urogen.com/20210331",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "urgn_MilestonePaymentsReceivedForLicensingAgreement": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone payment received for licensing agreement.",
        "label": "Milestone Payments Received For Licensing Agreement",
        "terseLabel": "Milestone payments received for licensing agreement"
       }
      }
     },
     "localname": "MilestonePaymentsReceivedForLicensingAgreement",
     "nsuri": "http://www.urogen.com/20210331",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "urgn_NonCashNewLeaseLiabilities": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non-cash new lease liabilities",
        "label": "Non Cash New Lease Liabilities",
        "terseLabel": "Non-cash new lease liabilities"
       }
      }
     },
     "localname": "NonCashNewLeaseLiabilities",
     "nsuri": "http://www.urogen.com/20210331",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "urgn_OperatingLeaseLiabilityAdjustments": {
     "auth_ref": [],
     "calculation": {
      "http://www.urogen.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowUnaudited": {
       "order": 10140.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating lease liability, adjustments.",
        "label": "Operating Lease Liability Adjustments",
        "negatedLabel": "Lease liability"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityAdjustments",
     "nsuri": "http://www.urogen.com/20210331",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "urgn_OperatingLeaseRightOfUseAssetAmortization": {
     "auth_ref": [],
     "calculation": {
      "http://www.urogen.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowUnaudited": {
       "order": 10130.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating lease, right-of-use asset, amortization.",
        "label": "Operating Lease Right Of Use Asset Amortization",
        "terseLabel": "Amortization of right of use asset"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAssetAmortization",
     "nsuri": "http://www.urogen.com/20210331",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "urgn_OperationsCommencedDateMonthAndYear": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operations commenced date month and year.",
        "label": "Operations Commenced Date Month And Year",
        "terseLabel": "Date of operating commencement"
       }
      }
     },
     "localname": "OperationsCommencedDateMonthAndYear",
     "nsuri": "http://www.urogen.com/20210331",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/DisclosureBusinessAndNatureOfOperationsAdditionalInformationDetails"
     ],
     "xbrltype": "gYearMonthItemType"
    },
    "urgn_OtherFinanceExpensesIncome": {
     "auth_ref": [],
     "calculation": {
      "http://www.urogen.com/20210331/taxonomy/role/DisclosureOtherFinancialInformationScheduleOfInterestAndOtherIncomeExpensesDetails": {
       "order": 10020.0,
       "parentTag": "urgn_FinanceIncomeExpenseNet",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other finance expenses (income).",
        "label": "Other Finance Expenses Income",
        "terseLabel": "Other finance income(expenses)"
       }
      }
     },
     "localname": "OtherFinanceExpensesIncome",
     "nsuri": "http://www.urogen.com/20210331",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/DisclosureOtherFinancialInformationScheduleOfInterestAndOtherIncomeExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "urgn_OtherFinancialInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other financial information.",
        "label": "Other Financial Information [Abstract]"
       }
      }
     },
     "localname": "OtherFinancialInformationAbstract",
     "nsuri": "http://www.urogen.com/20210331",
     "xbrltype": "stringItemType"
    },
    "urgn_OtherFinancialInformationTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other financial information.",
        "label": "Other Financial Information [Text Block]",
        "terseLabel": "Other Financial Information"
       }
      }
     },
     "localname": "OtherFinancialInformationTextBlock",
     "nsuri": "http://www.urogen.com/20210331",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/DisclosureOtherFinancialInformation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "urgn_PlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan",
        "label": "Plan [Member]",
        "terseLabel": "Plan"
       }
      }
     },
     "localname": "PlanMember",
     "nsuri": "http://www.urogen.com/20210331",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/DisclosureShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "urgn_ProceedsFromTenantAllowance": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from tenant allowance.",
        "label": "Proceeds From Tenant Allowance",
        "terseLabel": "Proceeds from tenant allowance"
       }
      }
     },
     "localname": "ProceedsFromTenantAllowance",
     "nsuri": "http://www.urogen.com/20210331",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "urgn_PropertyPlantAndEquipmentUsefulLifeTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Property, plant and equipment, useful life.",
        "label": "Property Plant And Equipment Useful Life Table [Text Block]",
        "terseLabel": "Property and Equipment Useful Lives"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentUsefulLifeTableTextBlock",
     "nsuri": "http://www.urogen.com/20210331",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/DisclosureSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "urgn_RTWInvestmentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "RTW Investments.",
        "label": "R T W Investments [Member]",
        "terseLabel": "RTW Investments"
       }
      }
     },
     "localname": "RTWInvestmentsMember",
     "nsuri": "http://www.urogen.com/20210331",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "urgn_RoyaltyRangingOnNetSalesOfLicensedProducts": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalty ranging on net sales of licensed products.",
        "label": "Royalty Ranging On Net Sales Of Licensed Products",
        "terseLabel": "Royalty ranging on net sales of licensed products"
       }
      }
     },
     "localname": "RoyaltyRangingOnNetSalesOfLicensedProducts",
     "nsuri": "http://www.urogen.com/20210331",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "urgn_ScheduleOfOperatingLeaseAmountsRecognizedUponAdoptionTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of operating lease amounts recognized upon adoption.",
        "label": "Schedule Of Operating Lease Amounts Recognized Upon Adoption Table [Text Block]",
        "terseLabel": "Schedule of Amounts Recognized"
       }
      }
     },
     "localname": "ScheduleOfOperatingLeaseAmountsRecognizedUponAdoptionTableTextBlock",
     "nsuri": "http://www.urogen.com/20210331",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/DisclosureLeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "urgn_ScheduleOfSupplementalInformationRelatedToLeasesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of supplemental information related to leases.",
        "label": "Schedule Of Supplemental Information Related To Leases Table [Text Block]",
        "terseLabel": "Schedule of Supplemental Information Related to Leases"
       }
      }
     },
     "localname": "ScheduleOfSupplementalInformationRelatedToLeasesTableTextBlock",
     "nsuri": "http://www.urogen.com/20210331",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/DisclosureLeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "urgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardIndividualVotingPowersPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award individual voting power percentage.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Individual Voting Powers Percentage",
        "terseLabel": "Combined voting power percentage"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardIndividualVotingPowersPercentage",
     "nsuri": "http://www.urogen.com/20210331",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/DisclosureShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "urgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfPurchasePriceForIndividualsHavingMoreThanTenPercentOfCombinedVotingPower": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award percentage of purchase price for individuals having more than ten percent of combined voting power.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Percentage Of Purchase Price For Individuals Having More Than Ten Percent Of Combined Voting Power",
        "terseLabel": "Stock options exercise price percentage for individuals possesses more than 10% of the combined voter power"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfPurchasePriceForIndividualsHavingMoreThanTenPercentOfCombinedVotingPower",
     "nsuri": "http://www.urogen.com/20210331",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/DisclosureShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "urgn_ShareBasedGoodsAndNonEmployeeServicesTransactionSharesReserveIncreaseForIssuance": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based goods and non-employee services transaction shares reserve increase for issuance.",
        "label": "Share Based Goods And Non Employee Services Transaction Shares Reserve Increase For Issuance",
        "terseLabel": "Increase in number of ordinary share issuable under the 2017 incentive plan"
       }
      }
     },
     "localname": "ShareBasedGoodsAndNonEmployeeServicesTransactionSharesReserveIncreaseForIssuance",
     "nsuri": "http://www.urogen.com/20210331",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/DisclosureShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "urgn_SummaryOfFairValuesOfMarketableSecuritiesByContractualMaturityTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair values of marketable securities by contractual maturity.",
        "label": "Summary Of Fair Values Of Marketable Securities By Contractual Maturity Table [Text Block]",
        "terseLabel": "Summary of Fair Values of Marketable Securities by Contractual Maturity"
       }
      }
     },
     "localname": "SummaryOfFairValuesOfMarketableSecuritiesByContractualMaturityTableTextBlock",
     "nsuri": "http://www.urogen.com/20210331",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/DisclosureMarketableSecuritiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "urgn_TwoThousandAndNineteenInducementPlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand and nineteen inducement plan.",
        "label": "Two Thousand And Nineteen Inducement Plan [Member]",
        "terseLabel": "2019 Inducement Plan"
       }
      }
     },
     "localname": "TwoThousandAndNineteenInducementPlanMember",
     "nsuri": "http://www.urogen.com/20210331",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/DisclosureShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "urgn_TwoThousandSeventeenEquityIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2017 equity incentive plan.",
        "label": "Two Thousand Seventeen Equity Incentive Plan [Member]",
        "terseLabel": "2017 Equity Incentive Plan"
       }
      }
     },
     "localname": "TwoThousandSeventeenEquityIncentivePlanMember",
     "nsuri": "http://www.urogen.com/20210331",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/DisclosureShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "urgn_UpfrontCashPaymentReceivedNetOfCosts": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Upfront cash payment received net of costs.",
        "label": "Upfront Cash Payment Received Net Of Costs",
        "terseLabel": "Upfront cash payment received net of costs"
       }
      }
     },
     "localname": "UpfrontCashPaymentReceivedNetOfCosts",
     "nsuri": "http://www.urogen.com/20210331",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "urgn_UpfrontFee": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Upfront fee.",
        "label": "Upfront Fee",
        "terseLabel": "Upfront fee"
       }
      }
     },
     "localname": "UpfrontFee",
     "nsuri": "http://www.urogen.com/20210331",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails",
      "http://www.urogen.com/20210331/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r34"
     ],
     "calculation": {
      "http://www.urogen.com/20210331/taxonomy/role/DisclosureOtherFinancialInformationScheduleOfAccountsPayableAndAccruedExpensesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.urogen.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 10110.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.",
        "label": "Accounts Payable And Accrued Liabilities Current",
        "terseLabel": "Accounts payable and accrued expenses",
        "totalLabel": "Total accounts payable and accrued expenses"
       }
      }
     },
     "localname": "AccountsPayableAndAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/DisclosureOtherFinancialInformationScheduleOfAccountsPayableAndAccruedExpensesDetails",
      "http://www.urogen.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r33"
     ],
     "calculation": {
      "http://www.urogen.com/20210331/taxonomy/role/DisclosureOtherFinancialInformationScheduleOfAccountsPayableAndAccruedExpensesDetails": {
       "order": 10010.0,
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/DisclosureOtherFinancialInformationScheduleOfAccountsPayableAndAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r3",
      "r16",
      "r134",
      "r135"
     ],
     "calculation": {
      "http://www.urogen.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 10230.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable Net Current",
        "verboseLabel": "Accounts receivable"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments": {
     "auth_ref": [
      "r76"
     ],
     "calculation": {
      "http://www.urogen.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowUnaudited": {
       "order": 10110.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Accretion Amortization Of Discounts And Premiums Investments",
        "negatedLabel": "Amortization on marketable securities"
       }
      }
     },
     "localname": "AccretionAmortizationOfDiscountsAndPremiumsInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedBonusesCurrentAndNoncurrent": {
     "auth_ref": [
      "r358",
      "r372"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for incentive compensation awarded to employees and directors or earned by them based on the terms of one or more relevant arrangements.",
        "label": "Accrued Bonuses Current And Noncurrent",
        "terseLabel": "Accrued bonus payable"
       }
      }
     },
     "localname": "AccruedBonusesCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedRoyaltiesCurrentAndNoncurrent": {
     "auth_ref": [
      "r358",
      "r372"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties.",
        "label": "Accrued Royalties Current And Noncurrent",
        "terseLabel": "Royalty amount payable"
       }
      }
     },
     "localname": "AccruedRoyaltiesCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r31",
      "r173"
     ],
     "calculation": {
      "http://www.urogen.com/20210331/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails": {
       "order": 10020.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation Depletion And Amortization Property Plant And Equipment",
        "negatedLabel": "Less: accumulated depreciation and amortization"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r19",
      "r50",
      "r51",
      "r52",
      "r367",
      "r383",
      "r384"
     ],
     "calculation": {
      "http://www.urogen.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 10070.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income Loss Net Of Tax",
        "terseLabel": "Accumulated other comprehensive income"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r49",
      "r52",
      "r53",
      "r86",
      "r87",
      "r88",
      "r267",
      "r379",
      "r380"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "Accumulated Other Comprehensive Income [Member]",
        "terseLabel": "Other Comprehensive Income"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfShareholdersEquityUnaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "auth_ref": [
      "r17"
     ],
     "calculation": {
      "http://www.urogen.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 10050.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.",
        "label": "Additional Paid In Capital Common Stock",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r86",
      "r87",
      "r88",
      "r231",
      "r232",
      "r233"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid In Capital [Member]",
        "terseLabel": "Additional Paid-In Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfShareholdersEquityUnaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r216",
      "r218",
      "r236",
      "r237"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value",
        "terseLabel": "Share-based compensation"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfShareholdersEquityUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities [Abstract]",
        "terseLabel": "Adjustment to reconcile net loss to net cash from operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r218",
      "r227",
      "r235"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Allocated Share Based Compensation Expense",
        "terseLabel": "Share-based compensation"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/DisclosureShareBasedCompensationScheduleOfEffectOfShareBasedCompensationOnCondensedConsolidatedStatementsOfOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Arrangements And Nonarrangement Transactions [Member]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r83",
      "r118",
      "r121",
      "r127",
      "r150",
      "r264",
      "r268",
      "r280",
      "r355",
      "r366"
     ],
     "calculation": {
      "http://www.urogen.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total Assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r4",
      "r5",
      "r46",
      "r83",
      "r150",
      "r264",
      "r268",
      "r280"
     ],
     "calculation": {
      "http://www.urogen.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 10140.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsNoncurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets Noncurrent [Abstract]",
        "terseLabel": "Non-current assets:"
       }
      }
     },
     "localname": "AssetsNoncurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [
      "r143"
     ],
     "calculation": {
      "http://www.urogen.com/20210331/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfMarketableSecuritiesDetails": {
       "order": 10010.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax",
        "terseLabel": "Unrealized Gains"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [
      "r144"
     ],
     "calculation": {
      "http://www.urogen.com/20210331/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfMarketableSecuritiesDetails": {
       "order": 10020.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax",
        "negatedLabel": "Unrealized Losses"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "auth_ref": [
      "r141",
      "r157"
     ],
     "calculation": {
      "http://www.urogen.com/20210331/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfMarketableSecuritiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Available For Sale Debt Securities Amortized Cost Basis",
        "totalLabel": "Amortized Cost Basis"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Available For Sale Securities Debt Maturities Fair Value [Abstract]"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue": {
     "auth_ref": [
      "r145",
      "r146",
      "r364"
     ],
     "calculation": {
      "http://www.urogen.com/20210331/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfFairValuesOfMarketableSecuritiesByContractualMaturityDetails": {
       "order": 10010.0,
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Available For Sale Securities Debt Maturities Within One Year Fair Value",
        "terseLabel": "Maturities within one year"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfFairValuesOfMarketableSecuritiesByContractualMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "auth_ref": [
      "r137",
      "r142",
      "r157",
      "r357"
     ],
     "calculation": {
      "http://www.urogen.com/20210331/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfFairValuesOfMarketableSecuritiesByContractualMaturityDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.urogen.com/20210331/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfMarketableSecuritiesDetails": {
       "order": 10030.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Available For Sale Securities Debt Securities",
        "terseLabel": "Marketable securities:",
        "totalLabel": "Total marketable securities",
        "verboseLabel": "Fair Value"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails",
      "http://www.urogen.com/20210331/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfFairValuesOfMarketableSecuritiesByContractualMaturityDetails",
      "http://www.urogen.com/20210331/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent": {
     "auth_ref": [
      "r139",
      "r157"
     ],
     "calculation": {
      "http://www.urogen.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 10210.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.",
        "label": "Available For Sale Securities Debt Securities Current",
        "terseLabel": "Marketable securities"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecuritiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent": {
     "auth_ref": [
      "r139",
      "r157"
     ],
     "calculation": {
      "http://www.urogen.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 10180.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent.",
        "label": "Available For Sale Securities Debt Securities Noncurrent",
        "terseLabel": "Marketable securities"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecuritiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r219",
      "r229"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/DisclosureShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BasisOfAccounting": {
     "auth_ref": [
      "r85"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis Of Accounting",
        "terseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfAccounting",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/DisclosureBasisOfPresentation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r1",
      "r28",
      "r77"
     ],
     "calculation": {
      "http://www.urogen.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 10200.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash And Cash Equivalents At Carrying Value",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": {
     "auth_ref": [
      "r72",
      "r77",
      "r78"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations",
        "periodEndLabel": "Cash, Cash Equivalents and Restricted Cash at End of Period",
        "periodStartLabel": "Cash, Cash Equivalents and Restricted Cash at Beginning of Period"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r72",
      "r281"
     ],
     "calculation": {
      "http://www.urogen.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowUnaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect",
        "totalLabel": "Decrease in Cash and Cash Equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Flow Noncash Investing And Financing Activities Disclosure [Abstract]",
        "terseLabel": "Supplemental Disclosures of Non-Cash Activities"
       }
      }
     },
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r39",
      "r183",
      "r359",
      "r371"
     ],
     "calculation": {
      "http://www.urogen.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 10020.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments And Contingencies",
        "terseLabel": "Commitments and contingencies (Note 14)"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments And Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r180",
      "r181",
      "r182",
      "r185"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments And Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/DisclosureCommitmentsAndContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r86",
      "r87"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Ordinary Shares"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/DisclosureShareBasedCompensationAdditionalInformationDetails",
      "http://www.urogen.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfShareholdersEquityUnaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock Par Or Stated Value Per Share",
        "terseLabel": "Ordinary shares, par value"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParentheticalUnaudited"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock Shares Authorized",
        "terseLabel": "Ordinary shares, shares authorized"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/DisclosureShareholdersEquityAdditionalInformationDetails",
      "http://www.urogen.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParentheticalUnaudited"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock Shares Issued",
        "terseLabel": "Ordinary shares, issued"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/DisclosureShareholdersEquityAdditionalInformationDetails",
      "http://www.urogen.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParentheticalUnaudited"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r15",
      "r186"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock Shares Outstanding",
        "terseLabel": "Ordinary shares, outstanding"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/DisclosureShareholdersEquityAdditionalInformationDetails",
      "http://www.urogen.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParentheticalUnaudited"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r15"
     ],
     "calculation": {
      "http://www.urogen.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 10040.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock Value",
        "terseLabel": "Ordinary shares, NIS 0.01 par value; 100,000,000 shares authorized at March 31, 2021 and December 31, 2020; 22,280,394 and 22,167,791 shares issued and outstanding as of March 31, 2021 and December 31, 2020, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r56",
      "r58",
      "r59",
      "r64",
      "r362",
      "r375"
     ],
     "calculation": {
      "http://www.urogen.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income Net Of Tax",
        "totalLabel": "Comprehensive Loss"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Comprehensive Income Net Of Tax [Abstract]",
        "terseLabel": "Statements of Comprehensive Loss"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTaxAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "auth_ref": [
      "r107",
      "r365"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for credit risk.",
        "label": "Concentration Risk Credit Risk",
        "terseLabel": "Concentration of Credit Risk"
       }
      }
     },
     "localname": "ConcentrationRiskCreditRisk",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "auth_ref": [
      "r79",
      "r266"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.",
        "label": "Consolidation Policy [Text Block]",
        "terseLabel": "Principles of Consolidation"
       }
      }
     },
     "localname": "ConsolidationPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ContractualObligation": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of contractual obligation, including but not limited to, long-term debt, capital lease obligations, operating lease obligations, purchase obligations, and other commitments.",
        "label": "Contractual Obligation",
        "terseLabel": "Remaining contractual obligation"
       }
      }
     },
     "localname": "ContractualObligation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CorporateBondSecuritiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This category includes information about long-term debt securities that are issued by either a domestic or foreign corporate business entity with a date certain promise of repayment and a return to the holder for the time value of money (for example, variable or fixed interest, original issue discount).",
        "label": "Corporate Bond Securities [Member]",
        "terseLabel": "Corporate Bonds"
       }
      }
     },
     "localname": "CorporateBondSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CorporateDebtSecuritiesMember": {
     "auth_ref": [
      "r204",
      "r212",
      "r385"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment.",
        "label": "Corporate Debt Securities [Member]",
        "terseLabel": "Corporate Bonds"
       }
      }
     },
     "localname": "CorporateDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfMarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostOfRevenue": {
     "auth_ref": [
      "r66",
      "r83",
      "r150",
      "r280"
     ],
     "calculation": {
      "http://www.urogen.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited": {
       "order": 10090.0,
       "parentTag": "us-gaap_GrossProfit",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate cost of goods produced and sold and services rendered during the reporting period.",
        "label": "Cost Of Revenue",
        "terseLabel": "Cost of revenues"
       }
      }
     },
     "localname": "CostOfRevenue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition": {
     "auth_ref": [
      "r149",
      "r158",
      "r162"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position without allowance for credit loss.",
        "label": "Debt Securities Available For Sale Unrealized Loss Position",
        "terseLabel": "Available-for-sale debt securities, unrealized loss position"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPosition",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/DisclosureMarketableSecuritiesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationAndAmortization": {
     "auth_ref": [
      "r75",
      "r171"
     ],
     "calculation": {
      "http://www.urogen.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowUnaudited": {
       "order": 10100.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.",
        "label": "Depreciation And Amortization",
        "terseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r75",
      "r117"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation Depletion And Amortization",
        "terseLabel": "Depreciation and amortization expense"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/DisclosurePropertyAndEquipmentAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisaggregationOfRevenueTableTextBlock": {
     "auth_ref": [
      "r198"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation Of Revenue Table [Text Block]",
        "terseLabel": "Schedule of Net Product Sales"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/DisclosureRevenueFromProductSalesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r238"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Disclosure Of Compensation Related Costs Share Based Payments [Text Block]",
        "terseLabel": "Share-Based Compensation"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/DisclosureShareBasedCompensation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasicAndDiluted": {
     "auth_ref": [
      "r99"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share Basic And Diluted",
        "terseLabel": "Net loss per ordinary share basic and diluted"
       }
      }
     },
     "localname": "EarningsPerShareBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r79",
      "r100",
      "r101"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share Policy [Text Block]",
        "terseLabel": "Net Loss per Ordinary Share"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r36"
     ],
     "calculation": {
      "http://www.urogen.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 10120.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee Related Liabilities Current",
        "terseLabel": "Employee related accrued expenses"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]",
        "terseLabel": "Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/DisclosureShareBasedCompensationScheduleOfEffectOfShareBasedCompensationOnCondensedConsolidatedStatementsOfOperationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "auth_ref": [
      "r228"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.",
        "label": "Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized",
        "terseLabel": "Unrecognized compensation cost of options and RSUs"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/DisclosureShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r228"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1",
        "terseLabel": "Expected to be recognized over a weighted average period"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/DisclosureShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [
      "r225"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Employee Stock Option [Member]",
        "terseLabel": "Options"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/DisclosureShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r86",
      "r87",
      "r88",
      "r90",
      "r95",
      "r97",
      "r103",
      "r151",
      "r186",
      "r187",
      "r231",
      "r232",
      "r233",
      "r255",
      "r256",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r288",
      "r379",
      "r380",
      "r381"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/DisclosureShareBasedCompensationAdditionalInformationDetails",
      "http://www.urogen.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfShareholdersEquityUnaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount": {
     "auth_ref": [
      "r272"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of transfers of assets measured on a recurring basis out of Level 1 of the fair value hierarchy into Level 2.",
        "label": "Fair Value Assets Level1 To Level2 Transfers Amount",
        "terseLabel": "Fair value assets, transfers between level 1 to level 2"
       }
      }
     },
     "localname": "FairValueAssetsLevel1ToLevel2TransfersAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount": {
     "auth_ref": [
      "r272"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of transfers of assets measured on a recurring basis out of Level 2 of the fair value hierarchy into Level 1.",
        "label": "Fair Value Assets Level2 To Level1 Transfers Amount",
        "terseLabel": "Fair value assets, transfers between level 2 to level 1"
       }
      }
     },
     "localname": "FairValueAssetsLevel2ToLevel1TransfersAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]",
        "terseLabel": "Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]"
       }
      }
     },
     "localname": "FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByBalanceSheetGroupingTable": {
     "auth_ref": [
      "r270",
      "r278",
      "r279"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities.",
        "label": "Fair Value By Balance Sheet Grouping [Table]",
        "terseLabel": "Fair Value By Balance Sheet Grouping [Table]"
       }
      }
     },
     "localname": "FairValueByBalanceSheetGroupingTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r204",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r210",
      "r212",
      "r271",
      "r324",
      "r325",
      "r326"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value By Fair Value Hierarchy Level [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r270",
      "r271",
      "r273",
      "r274",
      "r277"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Fair Value By Measurement Frequency [Axis]",
        "terseLabel": "Measurement Frequency"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r276"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/DisclosureFairValueMeasurements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r204",
      "r205",
      "r210",
      "r212",
      "r271",
      "r324"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value Inputs Level1 [Member]",
        "terseLabel": "Quoted Prices in Active Markets for Identical Assets (Level 1)"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r204",
      "r205",
      "r210",
      "r212",
      "r271",
      "r325"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value Inputs Level2 [Member]",
        "terseLabel": "Significant Other Observable Inputs (Level 2)"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueLiabilitiesLevel1ToLevel2TransfersAmount": {
     "auth_ref": [
      "r272"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of transfers of liabilities measured on a recurring basis out of Level 1 of the fair value hierarchy into Level 2.",
        "label": "Fair Value Liabilities Level1 To Level2 Transfers Amount",
        "terseLabel": "Fair value liabilities, transfers between level 1 to level 2"
       }
      }
     },
     "localname": "FairValueLiabilitiesLevel1ToLevel2TransfersAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueLiabilitiesLevel2ToLevel1TransfersAmount": {
     "auth_ref": [
      "r272"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of transfers of liabilities measured on a recurring basis out of Level 2 of the fair value hierarchy into Level 1.",
        "label": "Fair Value Liabilities Level2 To Level1 Transfers Amount",
        "terseLabel": "Fair value liabilities, transfers between level 2 to level 1"
       }
      }
     },
     "localname": "FairValueLiabilitiesLevel2ToLevel1TransfersAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement frequency.",
        "label": "Fair Value Measurement Frequency [Domain]",
        "terseLabel": "Measurement Frequency"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3": {
     "auth_ref": [
      "r275"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of transfers of financial instrument classified as a liability into level 3 of the fair value hierarchy.",
        "label": "Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Into Level3",
        "terseLabel": "Fair value liabilities, transfers into level 3"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3": {
     "auth_ref": [
      "r275"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of transfers of financial instrument classified as a liability out of level 3 of the fair value hierarchy.",
        "label": "Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Out Of Level3",
        "terseLabel": "Fair value liabilities, transfers out of level 3"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3": {
     "auth_ref": [
      "r275"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of transfer of financial instrument classified as an asset into level 3 of the fair value hierarchy.",
        "label": "Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Into Level3",
        "terseLabel": "Fair value assets, transfers into level 3"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3": {
     "auth_ref": [
      "r275"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of transfers of financial instrument classified as an asset out of level 3 of the fair value hierarchy.",
        "label": "Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Out Of Level3",
        "terseLabel": "Fair value assets, transfers out of level 3"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r204",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r210",
      "r212",
      "r324",
      "r325",
      "r326"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Measurements Fair Value Hierarchy [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r276",
      "r277"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Fair Value Measurements Recurring [Member]",
        "terseLabel": "Fair Value, Measurements, Recurring"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [
      "r147",
      "r148",
      "r152",
      "r153",
      "r154",
      "r155",
      "r156",
      "r159",
      "r160",
      "r161",
      "r162",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]",
        "terseLabel": "Financial Instrument"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r166",
      "r167",
      "r169",
      "r170",
      "r353",
      "r354"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by major type or class of finite-lived intangible assets.",
        "label": "Finite Lived Intangible Assets By Major Class [Axis]",
        "terseLabel": "Finite-Lived Intangible Assets by Major Class"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r166",
      "r168"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.",
        "label": "Finite Lived Intangible Assets Major Class Name [Domain]",
        "terseLabel": "Finite-Lived Intangible Assets, Major Class Name"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": {
     "auth_ref": [
      "r79",
      "r290"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.",
        "label": "Foreign Currency Transactions And Translations Policy [Text Block]",
        "terseLabel": "Functional Currency"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.",
        "label": "Furniture And Fixtures [Member]",
        "terseLabel": "Furniture"
       }
      }
     },
     "localname": "FurnitureAndFixturesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails",
      "http://www.urogen.com/20210331/taxonomy/role/DisclosureSignificantAccountingPoliciesPropertyAndEquipmentUsefulLivesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GrossProfit": {
     "auth_ref": [
      "r65",
      "r83",
      "r118",
      "r120",
      "r123",
      "r126",
      "r128",
      "r150",
      "r280"
     ],
     "calculation": {
      "http://www.urogen.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited": {
       "order": 10050.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.",
        "label": "Gross Profit",
        "totalLabel": "Gross profit"
       }
      }
     },
     "localname": "GrossProfit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r175"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/DisclosureShareBasedCompensationScheduleOfEffectOfShareBasedCompensationOnCondensedConsolidatedStatementsOfOperationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/DisclosureShareBasedCompensationScheduleOfEffectOfShareBasedCompensationOnCondensedConsolidatedStatementsOfOperationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r247",
      "r250",
      "r253",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/DisclosureIncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r60",
      "r79",
      "r245",
      "r246",
      "r250",
      "r251",
      "r252",
      "r254",
      "r402"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax Policy [Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
     "auth_ref": [
      "r74"
     ],
     "calculation": {
      "http://www.urogen.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowUnaudited": {
       "order": 10180.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.",
        "label": "Increase Decrease In Accounts Payable And Accrued Liabilities",
        "terseLabel": "Accounts payable and accrued expenses"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r74"
     ],
     "calculation": {
      "http://www.urogen.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowUnaudited": {
       "order": 10160.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase Decrease In Accounts Receivable",
        "negatedLabel": "Accounts receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities": {
     "auth_ref": [
      "r74"
     ],
     "calculation": {
      "http://www.urogen.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowUnaudited": {
       "order": 10190.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.",
        "label": "Increase Decrease In Employee Related Liabilities",
        "terseLabel": "Employee related accrued expenses"
       }
      }
     },
     "localname": "IncreaseDecreaseInEmployeeRelatedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "auth_ref": [
      "r74"
     ],
     "calculation": {
      "http://www.urogen.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowUnaudited": {
       "order": 10150.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.",
        "label": "Increase Decrease In Inventories",
        "negatedLabel": "Inventory"
       }
      }
     },
     "localname": "IncreaseDecreaseInInventories",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase Decrease In Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r74"
     ],
     "calculation": {
      "http://www.urogen.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowUnaudited": {
       "order": 10170.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase Decrease In Prepaid Deferred Expense And Other Assets",
        "negatedLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of interest income and expense, including, but not limited to, interest income and expense from investments, loans, and securities.",
        "label": "Interest Income And Interest Expense Disclosure Table [Text Block]",
        "terseLabel": "Schedule of Interest and Other Income (Expenses)"
       }
      }
     },
     "localname": "InterestIncomeAndInterestExpenseDisclosureTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/DisclosureOtherFinancialInformationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InterestReceivable": {
     "auth_ref": [
      "r45"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of interest earned but not received. Also called accrued interest or accrued interest receivable.",
        "label": "Interest Receivable",
        "terseLabel": "Accrued interest receivable"
       }
      }
     },
     "localname": "InterestReceivable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/DisclosureMarketableSecuritiesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory Disclosure [Abstract]"
       }
      }
     },
     "localname": "InventoryDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryDisclosureTextBlock": {
     "auth_ref": [
      "r165"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.",
        "label": "Inventory Disclosure [Text Block]",
        "terseLabel": "Inventories"
       }
      }
     },
     "localname": "InventoryDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/DisclosureInventories"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryFinishedGoods": {
     "auth_ref": [
      "r41"
     ],
     "calculation": {
      "http://www.urogen.com/20210331/taxonomy/role/DisclosureInventoriesScheduleOfInventoriesDetails": {
       "order": 10020.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.",
        "label": "Inventory Finished Goods",
        "terseLabel": "Finished goods"
       }
      }
     },
     "localname": "InventoryFinishedGoods",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/DisclosureInventoriesScheduleOfInventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryNet": {
     "auth_ref": [
      "r2",
      "r43"
     ],
     "calculation": {
      "http://www.urogen.com/20210331/taxonomy/role/DisclosureInventoriesScheduleOfInventoriesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.urogen.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 10240.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory Net",
        "terseLabel": "Inventory",
        "totalLabel": "Total inventories"
       }
      }
     },
     "localname": "InventoryNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/DisclosureInventoriesScheduleOfInventoriesDetails",
      "http://www.urogen.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryPolicyTextBlock": {
     "auth_ref": [
      "r10",
      "r44",
      "r79",
      "r102",
      "r163",
      "r164",
      "r165"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.",
        "label": "Inventory Policy [Text Block]",
        "terseLabel": "Inventory"
       }
      }
     },
     "localname": "InventoryPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryRawMaterials": {
     "auth_ref": [
      "r42"
     ],
     "calculation": {
      "http://www.urogen.com/20210331/taxonomy/role/DisclosureInventoriesScheduleOfInventoriesDetails": {
       "order": 10010.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory Raw Materials",
        "terseLabel": "Raw materials"
       }
      }
     },
     "localname": "InventoryRawMaterials",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/DisclosureInventoriesScheduleOfInventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentIncomeInterest": {
     "auth_ref": [
      "r68",
      "r116"
     ],
     "calculation": {
      "http://www.urogen.com/20210331/taxonomy/role/DisclosureOtherFinancialInformationScheduleOfInterestAndOtherIncomeExpensesDetails": {
       "order": 10010.0,
       "parentTag": "urgn_FinanceIncomeExpenseNet",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.",
        "label": "Investment Income Interest",
        "terseLabel": "Interest income"
       }
      }
     },
     "localname": "InvestmentIncomeInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/DisclosureOtherFinancialInformationScheduleOfInterestAndOtherIncomeExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentTypeAxis": {
     "auth_ref": [
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of investments.",
        "label": "Investment Type [Axis]",
        "terseLabel": "Investment Type"
       }
      }
     },
     "localname": "InvestmentTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfMarketableSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentTypeCategorizationMember": {
     "auth_ref": [
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset obtained to generate income or appreciate in value.",
        "label": "Investment Type Categorization [Member]",
        "terseLabel": "Investments"
       }
      }
     },
     "localname": "InvestmentTypeCategorizationMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfMarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments Debt And Equity Securities [Abstract]"
       }
      }
     },
     "localname": "InvestmentsDebtAndEquitySecuritiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LeaseAgreementsMember": {
     "auth_ref": [
      "r262"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual agreement that stipulates the lessee pay the lessor for use of an asset.",
        "label": "Lease Agreements [Member]",
        "terseLabel": "Lease Agreement"
       }
      }
     },
     "localname": "LeaseAgreementsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeaseCost": {
     "auth_ref": [
      "r306",
      "r307"
     ],
     "calculation": {
      "http://www.urogen.com/20210331/taxonomy/role/DisclosureLeasesComponentsOfLeaseCostDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lease cost recognized by lessee for lease contract.",
        "label": "Lease Cost",
        "totalLabel": "Lease, Cost"
       }
      }
     },
     "localname": "LeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/DisclosureLeasesComponentsOfLeaseCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "auth_ref": [
      "r306"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.",
        "label": "Lease Cost Table [Text Block]",
        "terseLabel": "Components of Lease Cost"
       }
      }
     },
     "localname": "LeaseCostTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/DisclosureLeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "auth_ref": [
      "r172"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additions or improvements to assets held under a lease arrangement.",
        "label": "Leasehold Improvements [Member]",
        "terseLabel": "Leasehold Improvements"
       }
      }
     },
     "localname": "LeaseholdImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]"
       }
      }
     },
     "localname": "LeasesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Lessee Lease Description [Line Items]",
        "terseLabel": "Lessee Lease Description [Line Items]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "auth_ref": [
      "r298"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about lessee's leases.",
        "label": "Lessee Lease Description [Table]",
        "terseLabel": "Lessee Lease Description [Table]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "auth_ref": [
      "r296"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.",
        "label": "Lessee Leases Policy [Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeLeasesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend": {
     "auth_ref": [
      "r297"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates (true false) whether lessee has option to extend operating lease.",
        "label": "Lessee Operating Lease Existence Of Option To Extend",
        "terseLabel": "Operating leases, existence of option to extend"
       }
      }
     },
     "localname": "LesseeOperatingLeaseExistenceOfOptionToExtend",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "booleanItemType"
    },
    "us-gaap_LesseeOperatingLeaseOptionToExtend": {
     "auth_ref": [
      "r297"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of terms and conditions of option to extend lessee's operating lease. Includes, but is not limited to, information about option recognized as part of right-of-use asset and lease liability.",
        "label": "Lessee Operating Lease Option To Extend",
        "terseLabel": "Operating leases, options to extend lease term, description"
       }
      }
     },
     "localname": "LesseeOperatingLeaseOptionToExtend",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeOperatingLeaseRenewalTerm": {
     "auth_ref": [
      "r297"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee Operating Lease Renewal Term",
        "terseLabel": "Operating leases, options to extend lease term"
       }
      }
     },
     "localname": "LesseeOperatingLeaseRenewalTerm",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeaseTermOfContract": {
     "auth_ref": [
      "r297"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee Operating Lease Term Of Contract",
        "terseLabel": "Lease term"
       }
      }
     },
     "localname": "LesseeOperatingLeaseTermOfContract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "auth_ref": [
      "r308"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.",
        "label": "Lessee Operating Leases [Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeOperatingLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/DisclosureLeases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r35",
      "r83",
      "r122",
      "r150",
      "r265",
      "r268",
      "r269",
      "r280"
     ],
     "calculation": {
      "http://www.urogen.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 10010.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total Liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r22",
      "r83",
      "r150",
      "r280",
      "r356",
      "r369"
     ],
     "calculation": {
      "http://www.urogen.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities And Stockholders Equity",
        "totalLabel": "Total Liabilities and Shareholders' Equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities And Stockholders Equity [Abstract]",
        "terseLabel": "Liabilities and Shareholders' Equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r37",
      "r83",
      "r150",
      "r265",
      "r268",
      "r269",
      "r280"
     ],
     "calculation": {
      "http://www.urogen.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 10080.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities Current",
        "totalLabel": "Total current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesNoncurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities Noncurrent [Abstract]",
        "terseLabel": "Non-current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesNoncurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilityForUncertainTaxPositionsNoncurrent": {
     "auth_ref": [
      "r38"
     ],
     "calculation": {
      "http://www.urogen.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 10100.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount recognized for uncertainty in income taxes classified as noncurrent.",
        "label": "Liability For Uncertain Tax Positions Noncurrent",
        "terseLabel": "Uncertain tax positions liability"
       }
      }
     },
     "localname": "LiabilityForUncertainTaxPositionsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LicenseAgreementTermsMember": {
     "auth_ref": [
      "r242",
      "r243"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Terms of the license agreements under research and development arrangements accounted for as a contract to perform research and development for others.",
        "label": "License Agreement Terms [Member]",
        "terseLabel": "Agenus Agreement"
       }
      }
     },
     "localname": "LicenseAgreementTermsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ManufacturingFacilityMember": {
     "auth_ref": [
      "r172"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Structure used in the manufacturing of goods.",
        "label": "Manufacturing Facility [Member]",
        "terseLabel": "Manufacturing Equipment"
       }
      }
     },
     "localname": "ManufacturingFacilityMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails",
      "http://www.urogen.com/20210331/taxonomy/role/DisclosureSignificantAccountingPoliciesPropertyAndEquipmentUsefulLivesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MarketableSecuritiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Marketable Securities [Abstract]",
        "terseLabel": "Marketable securities:"
       }
      }
     },
     "localname": "MarketableSecuritiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfMarketableSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MarketableSecuritiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Marketable Securities [Line Items]",
        "terseLabel": "Marketable Securities [Line Items]"
       }
      }
     },
     "localname": "MarketableSecuritiesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfMarketableSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MarketableSecuritiesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about investment in marketable security.",
        "label": "Marketable Securities [Table]",
        "terseLabel": "Marketable Securities [Table]"
       }
      }
     },
     "localname": "MarketableSecuritiesTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfMarketableSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MarketableSecuritiesTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of marketable securities. This may consist of investments in certain debt and equity securities, short-term investments and other assets.",
        "label": "Marketable Securities [Text Block]",
        "terseLabel": "Summary of Marketable Securities"
       }
      }
     },
     "localname": "MarketableSecuritiesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/DisclosureMarketableSecuritiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_MoneyMarketFundsMember": {
     "auth_ref": [
      "r204"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.",
        "label": "Money Market Funds [Member]",
        "terseLabel": "Money Market Funds"
       }
      }
     },
     "localname": "MoneyMarketFundsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails",
      "http://www.urogen.com/20210331/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfMarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NatureOfOperations": {
     "auth_ref": [
      "r104",
      "r113"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.",
        "label": "Nature Of Operations",
        "terseLabel": "Business and Nature of Operations"
       }
      }
     },
     "localname": "NatureOfOperations",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/DisclosureBusinessAndNatureOfOperations"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r72"
     ],
     "calculation": {
      "http://www.urogen.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowUnaudited": {
       "order": 10030.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided By Used In Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided By Used In Financing Activities [Abstract]",
        "terseLabel": "Cash Flows From Financing Activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r72"
     ],
     "calculation": {
      "http://www.urogen.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowUnaudited": {
       "order": 10020.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided By Used In Investing Activities",
        "totalLabel": "Net cash provided by investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided By Used In Investing Activities [Abstract]",
        "terseLabel": "Cash Flows From Investing Activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r72",
      "r73",
      "r76"
     ],
     "calculation": {
      "http://www.urogen.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowUnaudited": {
       "order": 10010.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided By Used In Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided By Used In Operating Activities [Abstract]",
        "terseLabel": "Cash Flows From Operating Activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r0",
      "r54",
      "r57",
      "r62",
      "r76",
      "r83",
      "r89",
      "r91",
      "r92",
      "r93",
      "r94",
      "r96",
      "r97",
      "r98",
      "r118",
      "r120",
      "r123",
      "r126",
      "r128",
      "r150",
      "r280",
      "r360",
      "r373"
     ],
     "calculation": {
      "http://www.urogen.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowUnaudited": {
       "order": 10090.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.urogen.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited": {
       "order": 10010.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income Loss",
        "terseLabel": "Net loss",
        "totalLabel": "Net Loss",
        "verboseLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowUnaudited",
      "http://www.urogen.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited",
      "http://www.urogen.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfShareholdersEquityUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r118",
      "r120",
      "r123",
      "r126",
      "r128"
     ],
     "calculation": {
      "http://www.urogen.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited": {
       "order": 10030.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income Loss",
        "totalLabel": "Operating loss"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseCost": {
     "auth_ref": [
      "r299",
      "r307"
     ],
     "calculation": {
      "http://www.urogen.com/20210331/taxonomy/role/DisclosureLeasesComponentsOfLeaseCostDetails": {
       "order": 10010.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.",
        "label": "Operating Lease Cost",
        "terseLabel": "Operating lease cost"
       }
      }
     },
     "localname": "OperatingLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/DisclosureLeasesComponentsOfLeaseCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseImpairmentLoss": {
     "auth_ref": [
      "r291"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of loss from impairment of right-of-use asset from operating lease.",
        "label": "Operating Lease Impairment Loss",
        "terseLabel": "Impairment losses on operating leases"
       }
      }
     },
     "localname": "OperatingLeaseImpairmentLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r293"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease Liability Current",
        "terseLabel": "Other current liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/DisclosureLeasesScheduleOfAmountsRecognizedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList": {
     "auth_ref": [
      "r294"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates line item in statement of financial position that includes current operating lease liability.",
        "label": "Operating Lease Liability Current Statement Of Financial Position Extensible List",
        "terseLabel": "Operating Lease, Liability, Current, Statement of Financial Position [Extensible List]"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/DisclosureLeasesScheduleOfAmountsRecognizedDetails"
     ],
     "xbrltype": "extensibleListItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r293"
     ],
     "calculation": {
      "http://www.urogen.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 10090.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease Liability Noncurrent",
        "terseLabel": "Long-term lease liability"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/DisclosureLeasesScheduleOfAmountsRecognizedDetails",
      "http://www.urogen.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasePayments": {
     "auth_ref": [
      "r295",
      "r302"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.",
        "label": "Operating Lease Payments",
        "terseLabel": "Operating cash flows from operating leases"
       }
      }
     },
     "localname": "OperatingLeasePayments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/DisclosureLeasesScheduleOfSupplementalInformationRelatedToLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r292"
     ],
     "calculation": {
      "http://www.urogen.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 10170.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease Right Of Use Asset",
        "terseLabel": "Right of use asset"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/DisclosureLeasesScheduleOfAmountsRecognizedDetails",
      "http://www.urogen.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList": {
     "auth_ref": [
      "r294"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates line item in statement of financial position that includes operating lease right-of-use asset.",
        "label": "Operating Lease Right Of Use Asset Statement Of Financial Position Extensible List",
        "terseLabel": "Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible List]"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/DisclosureLeasesScheduleOfAmountsRecognizedDetails"
     ],
     "xbrltype": "extensibleListItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r305",
      "r307"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Operating Lease Weighted Average Discount Rate Percent",
        "terseLabel": "Weighted-average discount rate of operating leases"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/DisclosureLeasesScheduleOfSupplementalInformationRelatedToLeasesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r304",
      "r307"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease Weighted Average Remaining Lease Term1",
        "terseLabel": "Weighted-average remaining lease term of operating leases"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/DisclosureLeasesScheduleOfSupplementalInformationRelatedToLeasesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization Consolidation And Presentation Of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r7",
      "r8",
      "r9",
      "r36"
     ],
     "calculation": {
      "http://www.urogen.com/20210331/taxonomy/role/DisclosureOtherFinancialInformationScheduleOfAccountsPayableAndAccruedExpensesDetails": {
       "order": 10060.0,
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Accrued Liabilities Current",
        "terseLabel": "Accrued other expense"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/DisclosureOtherFinancialInformationScheduleOfAccountsPayableAndAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r32"
     ],
     "calculation": {
      "http://www.urogen.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 10190.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets Noncurrent",
        "terseLabel": "Other non-current assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r55",
      "r58",
      "r61",
      "r63",
      "r186",
      "r282",
      "r287",
      "r288",
      "r361",
      "r374"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss).",
        "label": "Other Comprehensive Income Loss Net Of Tax",
        "terseLabel": "Other comprehensive income (loss)"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfShareholdersEquityUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent [Abstract]",
        "terseLabel": "Other comprehensive income"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": {
     "auth_ref": [
      "r48",
      "r50"
     ],
     "calculation": {
      "http://www.urogen.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited": {
       "order": 10020.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax",
        "terseLabel": "Unrealized (loss) gain on marketable securities"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesCurrent": {
     "auth_ref": [
      "r6",
      "r7",
      "r36"
     ],
     "calculation": {
      "http://www.urogen.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 10130.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities Current",
        "terseLabel": "Other current liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesPortionRecognizedInEarnings": {
     "auth_ref": [
      "r140"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of other-than-temporary impairment (OTTI) on investment in debt security, recognized in earnings.",
        "label": "Other Than Temporary Impairment Loss Debt Securities Portion Recognized In Earnings",
        "terseLabel": "Other-than-temporary impairment Loss, debt securities, portion recognized in earnings"
       }
      }
     },
     "localname": "OtherThanTemporaryImpairmentLossDebtSecuritiesPortionRecognizedInEarnings",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/DisclosureMarketableSecuritiesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "auth_ref": [
      "r71"
     ],
     "calculation": {
      "http://www.urogen.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowUnaudited": {
       "order": 10050.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security.",
        "label": "Payments Of Stock Issuance Costs",
        "negatedLabel": "Issuance cost related to at-the-market issuances"
       }
      }
     },
     "localname": "PaymentsOfStockIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireMarketableSecurities": {
     "auth_ref": [
      "r138"
     ],
     "calculation": {
      "http://www.urogen.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowUnaudited": {
       "order": 10060.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for purchase of marketable security.",
        "label": "Payments To Acquire Marketable Securities",
        "negatedLabel": "Purchase of marketable securities"
       }
      }
     },
     "localname": "PaymentsToAcquireMarketableSecurities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r69"
     ],
     "calculation": {
      "http://www.urogen.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowUnaudited": {
       "order": 10080.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments To Acquire Property Plant And Equipment",
        "negatedLabel": "Purchases of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r219",
      "r229"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/DisclosureShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/DisclosureShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r4",
      "r26",
      "r27"
     ],
     "calculation": {
      "http://www.urogen.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 10250.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense And Other Assets Current",
        "terseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities": {
     "auth_ref": [],
     "calculation": {
      "http://www.urogen.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowUnaudited": {
       "order": 10070.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities  (held-to-maturity or available-for-sale) during the period.",
        "label": "Proceeds From Sale And Maturity Of Marketable Securities",
        "terseLabel": "Maturities of marketable securities"
       }
      }
     },
     "localname": "ProceedsFromSaleAndMaturityOfMarketableSecurities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r70",
      "r230"
     ],
     "calculation": {
      "http://www.urogen.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowUnaudited": {
       "order": 10040.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "Proceeds From Stock Options Exercised",
        "terseLabel": "Proceeds from exercise of options into ordinary shares"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property Plant And Equipment [Abstract]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r31",
      "r174"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Property Plant And Equipment By Type [Axis]",
        "terseLabel": "Long-Lived Tangible Asset"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails",
      "http://www.urogen.com/20210331/taxonomy/role/DisclosureSignificantAccountingPoliciesPropertyAndEquipmentUsefulLivesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "auth_ref": [
      "r176",
      "r403",
      "r404",
      "r405"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property Plant And Equipment Disclosure [Text Block]",
        "terseLabel": "Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/DisclosurePropertyAndEquipment"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r30",
      "r172"
     ],
     "calculation": {
      "http://www.urogen.com/20210331/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails": {
       "order": 10010.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property Plant And Equipment Gross",
        "terseLabel": "Property and equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property Plant And Equipment [Line Items]",
        "terseLabel": "Property Plant And Equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails",
      "http://www.urogen.com/20210331/taxonomy/role/DisclosureSignificantAccountingPoliciesPropertyAndEquipmentUsefulLivesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r12",
      "r13",
      "r174",
      "r370"
     ],
     "calculation": {
      "http://www.urogen.com/20210331/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.urogen.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 10150.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property Plant And Equipment Net",
        "terseLabel": "Property and equipment, net",
        "totalLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails",
      "http://www.urogen.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "auth_ref": [
      "r29",
      "r79",
      "r174",
      "r403",
      "r404"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property Plant And Equipment Policy [Text Block]",
        "terseLabel": "Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r12",
      "r174"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property Plant And Equipment [Text Block]",
        "terseLabel": "Schedule of Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/DisclosurePropertyAndEquipmentTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r12",
      "r172"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Property Plant And Equipment Type [Domain]",
        "terseLabel": "Long-Lived Tangible Asset"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails",
      "http://www.urogen.com/20210331/taxonomy/role/DisclosureSignificantAccountingPoliciesPropertyAndEquipmentUsefulLivesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.",
        "label": "Property Plant And Equipment Useful Life",
        "terseLabel": "Property and Equipment, Useful Lives"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/DisclosureSignificantAccountingPoliciesPropertyAndEquipmentUsefulLivesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions [Abstract]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "auth_ref": [
      "r309",
      "r310",
      "r312",
      "r315",
      "r316"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Related Party Transactions Disclosure [Text Block]",
        "terseLabel": "Related Parties"
       }
      }
     },
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/DisclosureRelatedParties"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis": {
     "auth_ref": [
      "r242",
      "r243"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by form of arrangement related to research and development.",
        "label": "Research And Development Arrangement Contract To Perform For Others By Type [Axis]",
        "terseLabel": "Research and Development Arrangement, Contract to Perform for Others, Type"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://www.urogen.com/20210331/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails",
      "http://www.urogen.com/20210331/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross": {
     "auth_ref": [
      "r241",
      "r243"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of costs incurred under a research and development arrangement accounted for as a contract to perform research and development for others.",
        "label": "Research And Development Arrangement Contract To Perform For Others Costs Incurred Gross",
        "terseLabel": "Payments recognized through research and development expenses"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Research And Development Arrangement Contract To Perform For Others [Line Items]",
        "terseLabel": "Research And Development Arrangement Contract To Perform For Others [Line Items]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain": {
     "auth_ref": [
      "r242",
      "r243"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of significant agreements under research and development arrangements accounted for as a contract to perform research and development for others.",
        "label": "Research And Development Arrangement Contract To Perform For Others Type [Domain]",
        "terseLabel": "Research and Development Arrangement, Contract to Perform for Others, Type"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://www.urogen.com/20210331/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails",
      "http://www.urogen.com/20210331/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r240",
      "r416"
     ],
     "calculation": {
      "http://www.urogen.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited": {
       "order": 10060.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research And Development Expense",
        "terseLabel": "Research and development expenses"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research And Development Expense [Member]",
        "terseLabel": "Research and Development Expenses"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/DisclosureShareBasedCompensationScheduleOfEffectOfShareBasedCompensationOnCondensedConsolidatedStatementsOfOperationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r79",
      "r240"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research And Development Expense Policy",
        "terseLabel": "Research and Development Expenses"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RestrictedCashCurrent": {
     "auth_ref": [
      "r1",
      "r11",
      "r78"
     ],
     "calculation": {
      "http://www.urogen.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 10220.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.",
        "label": "Restricted Cash Current",
        "terseLabel": "Restricted cash"
       }
      }
     },
     "localname": "RestrictedCashCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedInvestmentsNoncurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.urogen.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 10160.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents the noncurrent portion of investments which are not defined as or included in marketable (debt, equity, or other) securities that are pledged or subject to withdrawal restrictions.",
        "label": "Restricted Investments Noncurrent",
        "terseLabel": "Restricted deposit"
       }
      }
     },
     "localname": "RestrictedInvestmentsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units R S U [Member]",
        "terseLabel": "Restricted Stock Units (RSUs)"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/DisclosureShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r18",
      "r187",
      "r234",
      "r368",
      "r382",
      "r384"
     ],
     "calculation": {
      "http://www.urogen.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 10060.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings Accumulated Deficit",
        "negatedLabel": "Accumulated deficit",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/DisclosureBasisOfPresentationAddititonalInformationDetails",
      "http://www.urogen.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r86",
      "r87",
      "r88",
      "r90",
      "r95",
      "r97",
      "r151",
      "r231",
      "r232",
      "r233",
      "r255",
      "r256",
      "r379",
      "r381"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfShareholdersEquityUnaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue From Contract With Customer [Abstract]"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r114",
      "r115",
      "r119",
      "r124",
      "r125",
      "r129",
      "r130",
      "r132",
      "r197",
      "r198",
      "r352"
     ],
     "calculation": {
      "http://www.urogen.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited": {
       "order": 10080.0,
       "parentTag": "us-gaap_GrossProfit",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue From Contract With Customer Excluding Assessed Tax",
        "terseLabel": "Revenues"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/DisclosureRevenueFromProductSalesScheduleOfNetProductSalesDetails",
      "http://www.urogen.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList": {
     "auth_ref": [
      "r200"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates product and service for revenue from satisfaction of performance obligation by transferring promised product and service to customer.",
        "label": "Revenue From Contract With Customer Product And Service Extensible List",
        "terseLabel": "Revenue from Contract with Customer Product and Service [Extensible List]"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerProductAndServiceExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/DisclosureRevenueFromProductSalesScheduleOfNetProductSalesDetails"
     ],
     "xbrltype": "extensibleListItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerTextBlock": {
     "auth_ref": [
      "r189",
      "r190",
      "r191",
      "r192",
      "r193",
      "r194",
      "r195",
      "r196",
      "r199",
      "r202"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.",
        "label": "Revenue From Contract With Customer [Text Block]",
        "terseLabel": "Revenue from Product Sales"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/DisclosureRevenueFromProductSales"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenueRecognitionPolicyTextBlock": {
     "auth_ref": [
      "r80",
      "r81"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.",
        "label": "Revenue Recognition Policy [Text Block]",
        "terseLabel": "Revenues"
       }
      }
     },
     "localname": "RevenueRecognitionPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "auth_ref": [
      "r303",
      "r307"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.",
        "label": "Right Of Use Asset Obtained In Exchange For Operating Lease Liability",
        "terseLabel": "Right-of-use assets obtained in exchange for new operating lease liabilities"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/DisclosureLeasesScheduleOfSupplementalInformationRelatedToLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.",
        "label": "Schedule Of Accounts Payable And Accrued Liabilities Table [Text Block]",
        "terseLabel": "Schedule of Accounts Payable and Accrued Expenses"
       }
      }
     },
     "localname": "ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/DisclosureOtherFinancialInformationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "auth_ref": [
      "r218",
      "r226",
      "r235"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.",
        "label": "Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]",
        "terseLabel": "Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/DisclosureShareBasedCompensationScheduleOfEffectOfShareBasedCompensationOnCondensedConsolidatedStatementsOfOperationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r218",
      "r226",
      "r235"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Text Block]",
        "terseLabel": "Schedule of Effect of Share-Based Compensation on Statements of Operations"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/DisclosureShareBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "auth_ref": [
      "r270",
      "r271"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Schedule Of Fair Value Assets And Liabilities Measured On Recurring Basis Table [Text Block]",
        "terseLabel": "Schedule of Assets and Liabilities Measured at Fair Value on a Recurring Basis"
       }
      }
     },
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/DisclosureFairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
     "auth_ref": [
      "r10",
      "r23",
      "r24",
      "r25"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.",
        "label": "Schedule Of Inventory Current Table [Text Block]",
        "terseLabel": "Summary of Inventories"
       }
      }
     },
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/DisclosureInventoriesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r31",
      "r174"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Schedule Of Property Plant And Equipment [Table]",
        "terseLabel": "Schedule Of Property Plant And Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails",
      "http://www.urogen.com/20210331/taxonomy/role/DisclosureSignificantAccountingPoliciesPropertyAndEquipmentUsefulLivesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable": {
     "auth_ref": [
      "r242",
      "r243"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A schedule reflecting the terms of significant agreements under research and development arrangements accounted for as a contract to perform research and development for others (including royalty arrangements, purchase provisions, license agreements, and commitments to provide additional funding), aggregated by similar arrangements or individually if necessary to understand the effects on the financial statements.",
        "label": "Schedule Of Research And Development Arrangement Contract To Perform For Others [Table]",
        "terseLabel": "Schedule Of Research And Development Arrangement Contract To Perform For Others [Table]"
       }
      }
     },
     "localname": "ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r219",
      "r229"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]",
        "terseLabel": "Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/DisclosureShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r67"
     ],
     "calculation": {
      "http://www.urogen.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited": {
       "order": 10070.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.",
        "label": "Selling General And Administrative Expense",
        "terseLabel": "Selling, general and administrative expenses"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpensesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing selling, general and administrative expense.",
        "label": "Selling General And Administrative Expenses [Member]",
        "terseLabel": "Selling, General and Administrative Expenses"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpensesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/DisclosureShareBasedCompensationScheduleOfEffectOfShareBasedCompensationOnCondensedConsolidatedStatementsOfOperationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock": {
     "auth_ref": [
      "r79",
      "r239"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for inclusion of significant items in the selling, general and administrative (or similar) expense report caption.",
        "label": "Selling General And Administrative Expenses Policy [Text Block]",
        "terseLabel": "Selling General and Administrative Expenses"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpensesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SeveranceCosts1": {
     "auth_ref": [
      "r75",
      "r177",
      "r178",
      "r179"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation.",
        "label": "Severance Costs1",
        "terseLabel": "Employee termination cost"
       }
      }
     },
     "localname": "SeveranceCosts1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r74"
     ],
     "calculation": {
      "http://www.urogen.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowUnaudited": {
       "order": 10120.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share Based Compensation",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r220"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1",
        "terseLabel": "Awards vesting period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/DisclosureShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award [Line Items]",
        "terseLabel": "Share Based Compensation Arrangement By Share Based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/DisclosureShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "auth_ref": [
      "r222"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized",
        "terseLabel": "Number of stock options approved for grants"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/DisclosureShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum number of shares that may be issued in accordance with the plan as a proportion of outstanding capital stock.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Percentage Of Outstanding Stock Maximum",
        "terseLabel": "Number of ordinary shares reserved for issuance, percentage"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/DisclosureShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r217",
      "r223"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Share Based Compensation Arrangements By Share Based Payment Award Award Type And Plan Name [Domain]",
        "terseLabel": "Award Type"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/DisclosureShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationAwardTrancheOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "First portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.",
        "label": "Share Based Compensation Award Tranche One [Member]",
        "terseLabel": "Tranche One"
       }
      }
     },
     "localname": "ShareBasedCompensationAwardTrancheOneMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/DisclosureShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansDirectorPolicy": {
     "auth_ref": [
      "r79",
      "r219"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for award granted to director under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.",
        "label": "Share Based Compensation Option And Incentive Plans Director Policy",
        "terseLabel": "Share-Based Compensation"
       }
      }
     },
     "localname": "ShareBasedCompensationOptionAndIncentivePlansDirectorPolicy",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSharesApprovedForIssuance": {
     "auth_ref": [
      "r222"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of shares (or other type of equity) that have been approved for issuance in the equity-based payment transaction.",
        "label": "Share Based Goods And Nonemployee Services Transaction Shares Approved For Issuance",
        "terseLabel": "Maximum number of ordinary share issuable under the 2017 incentive plan"
       }
      }
     },
     "localname": "ShareBasedGoodsAndNonemployeeServicesTransactionSharesApprovedForIssuance",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/DisclosureShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": {
     "auth_ref": [
      "r220"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of vesting of award under share-based payment arrangement.",
        "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Award Vesting Rights Percentage",
        "terseLabel": "Vesting percentage"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/DisclosureShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "auth_ref": [
      "r221"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period",
        "terseLabel": "Options granted, expected term"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/DisclosureShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchase price of common stock expressed as a percentage of its fair value.",
        "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Purchase Price Of Common Stock Percent",
        "terseLabel": "Exercise price of stock options as percentage of fair market value of shares on grant date"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/DisclosureShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_SharesIssued": {
     "auth_ref": [
      "r186"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.",
        "label": "Shares Issued",
        "periodEndLabel": "Balance,Share",
        "periodStartLabel": "Balance,Share"
       }
      }
     },
     "localname": "SharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfShareholdersEquityUnaudited"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r85"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Significant Accounting Policies"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/DisclosureSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r40",
      "r86",
      "r87",
      "r88",
      "r90",
      "r95",
      "r97",
      "r103",
      "r151",
      "r186",
      "r187",
      "r231",
      "r232",
      "r233",
      "r255",
      "r256",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r288",
      "r379",
      "r380",
      "r381"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Statement Equity Components [Axis]",
        "terseLabel": "Equity Components"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/DisclosureShareBasedCompensationAdditionalInformationDetails",
      "http://www.urogen.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfShareholdersEquityUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfShareholdersEquityUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement Of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement Of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement Of Stockholders Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r86",
      "r87",
      "r88",
      "r103",
      "r352"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfShareholdersEquityUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r14",
      "r15",
      "r186",
      "r187",
      "r224"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Stock Issued During Period Shares Stock Options Exercised",
        "terseLabel": "Exercise of options into ordinary shares, shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfShareholdersEquityUnaudited"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r40",
      "r186",
      "r187"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Stock Issued During Period Value Stock Options Exercised",
        "terseLabel": "Exercise of options into ordinary shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfShareholdersEquityUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r15",
      "r20",
      "r21",
      "r83",
      "r136",
      "r150",
      "r280"
     ],
     "calculation": {
      "http://www.urogen.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 10030.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders Equity",
        "periodEndLabel": "Balance",
        "periodStartLabel": "Balance",
        "totalLabel": "Total Shareholders' Equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited",
      "http://www.urogen.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfShareholdersEquityUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders Equity [Abstract]",
        "terseLabel": "Shareholders' equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r82",
      "r187",
      "r188"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders Equity Note Disclosure [Text Block]",
        "terseLabel": "Shareholders' Equity"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/DisclosureShareholdersEquity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubleaseIncome": {
     "auth_ref": [
      "r301",
      "r307"
     ],
     "calculation": {
      "http://www.urogen.com/20210331/taxonomy/role/DisclosureLeasesComponentsOfLeaseCostDetails": {
       "order": 10020.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": -1.0
      },
      "http://www.urogen.com/20210331/taxonomy/role/DisclosureLeasesScheduleOfSubleaseIncomeRecognizedNetWithinOperatingExpensesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of sublease income excluding finance and operating lease expense.",
        "label": "Sublease Income",
        "negatedLabel": "Sublease income",
        "totalLabel": "Sublease income",
        "verboseLabel": "Remaining rental payments to be received over the lease term"
       }
      }
     },
     "localname": "SubleaseIncome",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/DisclosureLeasesAdditionalInformationDetails",
      "http://www.urogen.com/20210331/taxonomy/role/DisclosureLeasesComponentsOfLeaseCostDetails",
      "http://www.urogen.com/20210331/taxonomy/role/DisclosureLeasesScheduleOfSubleaseIncomeRecognizedNetWithinOperatingExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SubsequentEventLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.",
        "label": "Subsequent Event [Line Items]",
        "terseLabel": "Subsequent Event [Line Items]"
       }
      }
     },
     "localname": "SubsequentEventLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r289",
      "r318"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Events"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTable": {
     "auth_ref": [
      "r289",
      "r318"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.",
        "label": "Subsequent Event [Table]",
        "terseLabel": "Subsequent Event [Table]"
       }
      }
     },
     "localname": "SubsequentEventTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r289",
      "r318"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]",
        "terseLabel": "Subsequent Event Type"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r289",
      "r318"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]",
        "terseLabel": "Subsequent Event Type"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "localname": "SubsequentEventsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r317",
      "r320"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "Subsequent Events"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/DisclosureSubsequentEvents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r147",
      "r148",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
        "label": "Transfers And Servicing Of Financial Instruments Types Of Financial Instruments [Domain]",
        "terseLabel": "Financial Instruments"
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r263"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Type Of Arrangement [Axis]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_USGovernmentAgenciesDebtSecuritiesMember": {
     "auth_ref": [
      "r204",
      "r363"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debentures, notes, and other debt securities issued by US government agencies, for example, but not limited to, Government National Mortgage Association (GNMA or Ginnie Mae). Excludes US treasury securities and debt issued by government-sponsored Enterprises (GSEs), for example, but is not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB).",
        "label": "U S Government Agencies Debt Securities [Member]",
        "terseLabel": "US Government"
       }
      }
     },
     "localname": "USGovernmentAgenciesDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_USTreasuryAndGovernmentMember": {
     "auth_ref": [
      "r204",
      "r363",
      "r385"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This category includes investments in debt securities issued by the United States Department of the Treasury, US Government Agencies and US Government-sponsored Enterprises. Such securities may include treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years), debt securities issued by the Government National Mortgage Association (Ginnie Mae) and debt securities issued by the Federal National Mortgage Association (Fannie Mae) or the Federal Home Loan Mortgage Corporation (Freddie Mac).",
        "label": "U S Treasury And Government [Member]",
        "terseLabel": "US Government"
       }
      }
     },
     "localname": "USTreasuryAndGovernmentMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfMarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "auth_ref": [
      "r244",
      "r249"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrecognized tax benefits.",
        "label": "Unrecognized Tax Benefits",
        "terseLabel": "Liability for uncertain tax positions"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefits",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued": {
     "auth_ref": [
      "r248"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.",
        "label": "Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued",
        "terseLabel": "Accrued interest and penalties included in liability for uncertain tax positions"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r105",
      "r106",
      "r108",
      "r109",
      "r110",
      "r111",
      "r112"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use Of Estimates",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_VariableLeaseCost": {
     "auth_ref": [
      "r300",
      "r307"
     ],
     "calculation": {
      "http://www.urogen.com/20210331/taxonomy/role/DisclosureLeasesComponentsOfLeaseCostDetails": {
       "order": 10030.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.",
        "label": "Variable Lease Cost",
        "terseLabel": "Variable lease cost"
       }
      }
     },
     "localname": "VariableLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/DisclosureLeasesComponentsOfLeaseCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_VestingAxis": {
     "auth_ref": [
      "r229"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by vesting schedule of award under share-based payment arrangement.",
        "label": "Vesting [Axis]",
        "terseLabel": "Vesting"
       }
      }
     },
     "localname": "VestingAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/DisclosureShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VestingDomain": {
     "auth_ref": [
      "r229"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vesting schedule of award under share-based payment arrangement.",
        "label": "Vesting [Domain]",
        "terseLabel": "Vesting"
       }
      }
     },
     "localname": "VestingDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/DisclosureShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).",
        "label": "Weighted Average Number Of Share Outstanding Basic And Diluted",
        "terseLabel": "Weighted average number of shares outstanding used in computation of basic and diluted loss per ordinary share"
       }
      }
     },
     "localname": "WeightedAverageNumberOfShareOutstandingBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.urogen.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 5
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3630-109257"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "270",
   "URI": "http://asc.fasb.org/extlink&oid=116846552&loc=d3e543-108305"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70191-108054"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "http://asc.fasb.org/topic&trid=2134479"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4647-111522"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4428-111522"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4531-111522"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121553693&loc=d3e26610-111562"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121553693&loc=d3e26853-111562"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121553693&loc=d3e26626-111562"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121553693&loc=SL6284422-111562"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27198-111563"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27232-111563"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=SL120269820-111563"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27290-111563"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919244-210447"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919249-210447"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919253-210447"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919258-210447"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919230-210447"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121558606&loc=SL82898722-210454"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922888-210455"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922888-210455"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922895-210455"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922900-210455"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4492-108314"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4556-108314"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "330",
   "URI": "http://asc.fasb.org/topic&trid=2126998"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "360",
   "URI": "http://asc.fasb.org/topic&trid=2155823"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.3)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(b))",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "http://asc.fasb.org/topic&trid=2144648"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "http://asc.fasb.org/topic&trid=2208762"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130551-203045"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130556-203045"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130558-203045"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130543-203045"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130545-203045"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130550-203045"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "606",
   "URI": "http://asc.fasb.org/topic&trid=49130388"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118257860&loc=d3e4179-114921"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(f)(3)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121326096&loc=d3e4534-113899"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=SL79508275-113901"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120383193&loc=d3e11149-113907"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120383193&loc=d3e11178-113907"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "http://asc.fasb.org/topic&trid=2228938"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "35",
   "Subparagraph": "(a)",
   "Topic": "720",
   "URI": "http://asc.fasb.org/extlink&oid=6420018&loc=d3e36677-107848"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420387&loc=d3e23199-108380"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420387&loc=d3e23199-108380"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420387&loc=d3e23221-108380"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=SL37586934-109318"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e32247-109318"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e32280-109318"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32705-109319"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32718-109319"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32809-109319"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32840-109319"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32847-109319"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32857-109319"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330215-122817"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "http://asc.fasb.org/topic&trid=2144680"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=121598580&loc=d3e5419-128473"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(3)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=SL6742756-110258"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13467-108611"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13476-108611"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "830",
   "URI": "http://asc.fasb.org/topic&trid=2175825"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121593497&loc=SL77918431-209957"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918631-209977"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918643-209977"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918666-209980"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918673-209980"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918673-209980"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(2)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121568110&loc=SL77918982-209971"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/subtopic&trid=77888251"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.14)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "850",
   "URI": "http://asc.fasb.org/topic&trid=2122745"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "http://asc.fasb.org/topic&trid=2122774"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(i)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(ii)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)(i)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(5)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(6)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(7)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(b)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "http://asc.fasb.org/extlink&oid=119991564&loc=SL119991595-234733"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "340",
   "Topic": "928",
   "URI": "http://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(6))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.15(5))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120252992&loc=d3e62557-112803"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(a)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120252992&loc=SL120269850-112803"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=108315417&loc=d3e61044-112788"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.15(a))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(19))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121643868&loc=SL117782755-158439"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117783719-158441"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117819544-158441"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121641442&loc=d3e19393-158473"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 1))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 6))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 7))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 1))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 6))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 7))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 1))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 6))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 7))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13D(Column B)(Footnote 2))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=SL120429264-123010"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13D(Column C)(Footnote 2))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=SL120429264-123010"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column A))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611379-123010"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column B))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611379-123010"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column C))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611379-123010"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column D))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611379-123010"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "http://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "740",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=6491622&loc=d3e9504-115650"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99779-112916"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99893-112916"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=SL120174063-112916"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 4))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r417": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r418": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r419": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r420": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r421": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r422": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.8)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6801-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e637-108580"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e681-108580"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669686-108580"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL34724394-108580"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e557-108580"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6904-107765"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116657188&loc=SL116659661-227067"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121640130&loc=d3e1436-108581"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(21))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.1,2)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7(b))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6911-107765"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3521-108585"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3044-108585"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=SL98516268-108586"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6935-107765"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18823-107790"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18823-107790"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21914-107793"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21930-107793"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21711-107793"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e7018-107765"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1337-109256"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>86
<FILENAME>0001564590-21-027210-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001564590-21-027210-xbrl.zip
M4$L#!!0    ( ,P[K5+S&4(/"9$" (-5'@ 5    =7)G;BTQ,'%?,C R,3 S
M,S$N:'1M[+UI=^,XLC;X>>:<^0\85W>_F6=DI4CMSJI\C\J6L]37:;LMN_OV
M?/&!2<AB)T6J0-*V[J]_ R"I?:-$29 8O53)$A<@MB<B$ C\^K\_>C8A;XQ[
MENO\=J;E"V>$.89K6L[K;V>!WSFOG?WO;__/__WK_WM^3JZN6[>D8?C6&[NR
M/,-VO8"S3^T?GTG+L2V'D?_^_>&&7+E&T&..3\Y)U_?[%U^^O+^_Y\V.Y7BN
M'?CP'B]ON+TOY/P\?O E9U3\0*ZHSXC\SP71"[IV7BB?:_JCKET4M N]EB\5
MJY6:5OC_"H6+0F'L ?\,)T#&_G-!ROE"7LM7M/+8A??4^$E?&6E=C5U8J5"#
M&D6SH[^\E&B-U;6R2<M:C1D=9KZ4]?&1NOT!MUZ[/OED?)9#A/DZ#K-M-B#7
MED,=PZ(V:<<SS0%IC#QIV#9Y$+=YY(%YC+\Q,Q\]M>L#!X +CG?Q\<)MZ[>S
M,:J);_(N?_VB%PK%+T!!'U[ SL:N-T<WC%]<^1+^&%\:\%=GXLD!=U^9(QDA
M9E$H%K7AM=ZY/^@S;WA]AWHO\L'Q+^*6PGE!.Y^XZ972_MQ[Q ]S;O'\/I\<
MO,>,_*O[]D7\ C=HM:D;N+]H9,.?YKV'^W-OF'>I92P8D67,N=RAEN'-OT'^
M).90G;R%?1C=^7>(7^:](^C-%PG3YU_$E+_ %8Q;QO &D,?5][C.^=1])K/.
M/=^</[CHQSGC$[^ MB^_-;I@_NT+;YMSN1%P#O9I,/^>^-=Y-[J!X_-%]X4_
MSKGM ^S:SPE:OA<E);5ZO?Y%_CK4 )\OU-WZ%_@UOG#FD9-:+GY^H=Y0RRW/
M+>E:=9E="*\8CMFSYHT8+M6^_/>/F[;193UZ/FU,K(]%;]"$Y1'V79CWT>7^
M_.M'EW[Q.76\CLM[TKB+)Y7/"_JY7AE[R#GP8.)!,4]6/:<VXM)B_@CC>B:M
M+*.F^'>/^53"TCG[,[#>?CN[=!U?2.<C:,49,<*_?COSV8?_1=Y-OHC[?,NW
M&7P0=O1<*_SY'!O-/%P$OW^)+_CU2_PJ 1>WWP$Q'(!7GW'R)@!)SY=CX'IQ
MS<&W7TWKC7C^P&:_G9F6U[?I0&@P$Z/^OWZU/B[$XQ@7?X5_6J;)'/FG_!NN
MO0WUF%B@@-?/!?$?H(Q#>^*1S+IH !J; I&O;?H:S?'#?V =F+VX7*M4:GJI
M&$X)_CN<V]FW#K4]]NN7B?>L>G=Q_-VQ,W -_@*U_\THOX9OO&2C$)\2#J*T
M>!#W<*UK;C",?R0=1'U\$$T'1&1P"</@U&XY)OOX+S9(-H#1K\D&HA7&!W(I
MC>081YJ.*?RN9&,Y![\,-##10(JE:CR0R"NXN&&>Q]A=GW'0;>?UAH'A:WY8
M'FBAP>XZ=WVA\8]N\P.^,).-T.?!4M&]YM203F?@6.$3GYXC2_K4OCH;HU^U
M,CWL2[?7LWPA4U[#,84-@<'#D"VV4J9"1\NS+AS+!CL#@SS[%@\S'M*FXYPA
M[\;C+&AZTG'.L%LO:]/CN><NL-H?W-O4\6%$33#"?3&\)X]U OO&ZBP3P^@I
M"Q_R^T!8\0:(S[.PTS#Y?@"&5TR][7;\=\K9#]9[87R>N-P7_YU(F/6R?KC9
MA9?^H$[0 4X$'+AZ30W+!@NS9(9ZTAD6TYTA^-P/%.1/S@'^^&$Y5B_H12-.
MR-T;^N*"T7#Y8'A%FLPMJ3KU\-+K@(,U@/ ;+KL&-PH^>4NF7TXZ_?*.IT\_
M]L7YRK\K/Q).?L;<JS+YC7BO):9 L5J8IL D0LM4QET'9M\ ^/;;/K@/8JQW
MG6$*Y-[U+ $1$KD]Z\5F-X#JZX#CM^$[_2[C\@7>K>N$L9V?<"(S%FQR(C<6
M?9%6,W**=CF3^%V O9>;S*4V(Y8/[(TY ;OF;D] NP#E?UE^]S+P?!?N!I$R
M T,(4YOQ-\M@R68P*49"\2[^SNS>P'=#89LW>OG=6(@B)L-9AXFHG'G1!$6
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MY]%81#V/2X?1J/*Y5DRF4>-W;*91OWZQ/BXX\]R &\P37\EONHR:<KZ_?@&
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MR/V=,/_3#\I_DCN'?8Y&#I 6CSWDA"#65^&(_>I3 68A2WX[ [DPF&U[?6H
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M*I]J,L/E<A'V(A"MN6T+GAV38___C'2$^"XYEK'N-0#?B<R(<G7+$ZE9TK$
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M1CISLO;FPI9XN"!L6J6:J];70:MP[,22=)-\<4<#(S03YM+MK&4C<P0HU6=
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M&2(W2OL1F'M,&LJD87DZ:=@P_Q-XOJAF\Q[=!45K,J\ATQJ78UF-!_9G8'E
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M -]S__I,&)N-"^MW1WD)S=E$W@WVFE>QY3PJMDJ'?B&"*4+NC @Z(IA*W-@
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MN6LP9GJBV*)-9?>8R.8-[CK)78\T3E4NYXJ:.A7+J/>*ZCVB'$I[=LB/*)<
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M=TC5Q<9^<CUNY)%<NCUPI UF"F._(^M^S5YXL%)#JS/,KJ1DM5M';K7O;Y)
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M./^'O*G!(?8"LZD5!&,?V&M@AT]LG_]WGC3D\V"(]D#:R $Q75$&$GEC3+J
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MG2!R/:9]"T$3@5MC1),9+%]N& _]4 =X332=R*5.;U(-1>88/#'JCT@"<Q[
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M%M^? ^W//1C#HL8A*_S,$*-&IP^,;41I1PWV//*["_\:-@:(S,UUH_W[L$'
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M=R8SO41#<WS"6QNLD/HW@\*"XNIZ%+&;NB:S%SU5CZ?FTA$_&$5@)(*HCK.
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ME>@C<YBGVV "1*$*'H6BH)0(7?%@'U^GE0E4C)BA8RA'[,&? ,_6,3"D.7J
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M"F8 /]=LK!9+EVT4Q6RVU!I:8K40^X"M$VCX?#?T-31=D?0]-WR<:+=LY(5
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M=,-P0XJ3$3O#%X)3+0?-..N)<43DXW0>F^J6@\<@" %\?JC;FCL"$:D+*%.
M;F+YT0/AV3- S2]8;<" '[9 3.% ^%WR\OOXW15@9?T1>;%G5W)$3G2ZX-!X
MH44O3L7:K7:O?;W09KYZ@Z',=/SU>J%0]S$]!U'#@[%6UJ<%/]8*)C$]%"6W
M.Q:VRE)A-5@5(OPFWBZ#/+]N\2 C_K&1/-<=<L,XGIH+);HPN)%%>"@5 P(8
M@@9<![%"1+F_6N(/-P&B9#I@(WANJ@. 3+G(I],!S[!\'F.W/ V> (($9!A
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M%5CW0@;>.1^$!+QUO24Y4/MI\]/J]%2BDRP$M;E!4IUQ>+8VR?_1HYA9UY^
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MTCGSEQ.%JQ[6JH!&<OP,,PI;X4A&'*G3-6G*9<Y3=_.S:XP8N.-**\.5SI8
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M -/Z6N4Z[1C>&Y0,@GSX9=@AHN;&]S$QRGS0?^T2 \0MZ<$?5]8O@$ X-=U
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M7Q</Z^_"MR4W("RJ4M$2GJBY7^\ANRK!'#S/M)QGP^=V"_XH=6=I7*XUCO<
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M]=D-_L6"I$/5.NL^+TMZL<#H7[WI=!K]8D\_P)N-VZ2&:KK&L80]</FL<4W
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M_@:" 7-A\Y68Y+(T+N0I2HG#)5L_%I:>&F!^SO-PHH^F#3'/25<I6G.), C
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MQD1@%R8XC_8 ,6F%T2FD$)K6+KDH3H.5HK0I0P(.12'RO\S]XU2=\XP&M=E
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M'Y,8Z6A<YL(%7>#A.S(_UC8VOHM/'.4Q]]8YK/3)S[ CH<$5/744VG^4T40
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M.U5)@EEQZ(J#&7]5F"/7/:]T+X;[(,#3V?ZG+(:'0__E[HW%<'\E'NF5Z 5
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M<UT&?!$NIG$XQ2G/ C&4R76-WEG\+YTPO1R=8TP?>12G0;Y@&UICY(F=9K!
M6,$$2< 0!M)$2"[T<HYC_C#<WAYL&S;(PEJ&"7)Y#+8-WW<!OP$NP%$G=\:P
MG<!C,.PW$7= ADN&U[*_.?7>P]EXIUN[9G$@QT'\)N1V5O *TA5,5L#INR-\
MYA]!6N*B=OS+4P,Z;?6_Y9#CROCG-A$G[>C^]K8/PG[I-)$/L![60I@<')A0
M]!$8=JA41'>\'G*LA6;XC%&]L@]@L /.&WT0<"Z8Z(&3YCN"+L98:^(^\+N*
M]D5STT@&8=,]U7S_7J56\OLY\H&O =D5A,B0+ETH"K+&H >[E4MZE0CH-'$
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MC==GC$_BGMTXJ;075;VHZD55+ZH>IZC:V?'W;HX/UHNJ.Q=58@3_1"CS\*F
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M_?[I] NH X6:>;L#[U_87AJ8-#6/1(4)/DC,O]_&.@0]LL0&R8>CK"SPQH-
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M-7K2^[ME4^D\84S?V5W0K@(\6F<;0%V',=2W8#9/T,Y.4$.93-V-JL@GJ@W
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MZ[G8H^1B9*%1F!F8$'I4<W1_*HJB8NK6)$@-W\("(ZJ_,'Y:T"<9 T/\X,C
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M91P]#PG!111Y<K(*IYV\E+VPV]+,]OKWQR;D>9HYDKV#2PTU&@<J8OK<)9S
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M4;$<%8\=Z.21B6%S97+G31DW0TA/%_8]<3,J^?UWY.15I2.E%:#Y?S1;U6#
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M##<)!N1^SYZ['A44:7?Q>JEZBEZ5 -9W.0W"P3%)0MU[X!/P,;M1R S!#70
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M,Z?@V^R_84Z>V8U:7;\6;-IRF<YD('"B=]7!:"+P=XJQAR&@],%;O;(<?JT
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MA'Y[^B8T$&L8S4TUT%#0!R*PXN <$:\B+OBQ^VNB>ST.7"G::O& 7ZFK;UU
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M[D-8L^E#2E9")\.::I7$]UPB$=4Q$[M(XBH6-PK!:B.NTDI:)Q-+YKW##57
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M-DP?TB6;KL*D45TS5C+H,RZ?W9Y'MAC.UN5L73Z$=1'*+90IUSFAUPOJ;X=
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MC;I6'#B&VQO-[R/E*W^%;ZL)8U[D$?'OPE)NY =M\SV/:.MC55'3$;+@+.,
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MK/:$V*Y9RQ1GS!HHSP[)& &16 C&$TZ_=>T:IWC,]$%PJ&0.6E%P(HS@60?
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MC\->5%E3&I>J:NJ#JS5SABPJQY:,5Y\8"HV!^49EHT.#W3-A6>V0XTJJVZD
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MU['O0"ZV03^U7UG6OYW'ZO^\6.>;E9;RA^/,>WT- ^5YY]D<1T15,&?TJ.$
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MHQ5CEWZ6$H%-6Q_L&(_=9LX3)'T3:F OS!I @I4H%2<^1DFZ;G.3MS$5,%:
M>*[QH>56-Q4]%MY1I%[Y'?F>L6%[1#F!L0!A%KEB(^IT)PSC&&32,2*B>\5C
MY!AR.598"?2 L/LF<\PX%Z/3F4JK<TK=,N:^N.(2YE25!=F=Y-HM2Q*5JTKP
MLPZ8R$>924Q?-(&9&,HDEG7R$)M6-U5G(I8 K/0_OI0D]I+' # A1VHP@H#R
M[S"L\8K&UCWH+LT%<?6JV^&;G+TO]/:8%WK++>.590HGAB4E.O(@U.QHY)YI
M%)W%5(#TA2W+YJ:J.>W.1>NRJ:1^:9)?0L.EBFZI@&>8IF%(X*S<=*V>X6N6
M/+)G#+NUXW01?2TGQ9Q$WDKP84-M*#(B#>TT0;@.<4V41ZG#]T%L%QR<&TZ,
MW5 8+&57W3WQAS@&FFJ#S;8I;F+U)6S4BSX=1&OX)1I=3-*:ZQ"4Z_7(NX)[
M\N38[VC);_0IT$W<N6;A*HE=3S/^?A9,E=.C_E9V]_.JKKM]&X)#*12A=('4
MB<S%755OEE!(1:4+H)GZ(%D7U=LSO(\[[)R?2NXL7-7:@#Z2XS>HAAWG8<9I
M:O&4%2CV*7Q3WL80_;.R^TKR?5)1('TO_D>$)D>$NE#V'ZHNLBWBH7;Y)NI&
M*A$>ESFJ1;&$6*I(+3'99B>/7Q>+-QM!K>V*FQ ["HTFTC>QR0K\AF&15H>"
MMI>L/@.-(=*E/2U.+O4PS6F+).G/R]G?1@J/O,SI0^G&@',>*Y69H"DC9YN8
MGYA<9-(.8 F4E(6/MRC;J&3GNP'?.5V5%0YC=D=H7<22G"+CN=?1JTP6C'+N
MSI9&?<SQMH,<ISH.$V1X286[2B@+-1&ZX=H+GZ5#)F14+530[EZFTD8E#:>9
MG?*=E)CI-X5B&CEY8HNS2"ECD%&8>!32YI)V@],TC]\.VV1\YTEXOV5- ["4
M4+WED8-.]_-J!YC!Y#J8'YR3S?ES,;]_#V=,LU3F"M@FWJW.W2"P-/?RM&L%
M:0CAA))R\M4U'+MOX60^U,IZ8-VPJ.3[7AFU4K"BU[\C%Z.H5CVGDOI5)U@!
M;X ][Q.0FE@C;:DJC/$.7(,-LZ"%JZB 8RKZH,TW,5LQ?<N$-)2V8SJ\8V)X
MI@5@& ;2D.#VGOC\W#&KU*C)TT:#[)J'O"+[0;%SSL'BHDA%TH6[F_!Z.Z5=
M;)%V^_D[WI^&U*%'75\%JPU*=<)U.R49[PAJ8:+9] 73_J8[>N*<=1Q<Q)FI
M8B=W<'&X%/N4>GJ1LHOX52YGK[P0)S;'>"E9/-(SU].YY?C<<OP1MQP;B735
M8W7:%NVZ6IXI5![9E)YMQ-E&O&\;P1QLR&9M\H4DV"KI!V%N:_C$P9W:<2<>
M1,L2[^K,<?((Y_YL3,[&Y'T;DR3_[7B=/TJ*D6]BT:I1R1MP>AP(_4@D]4TW
M1VF=ZDI(F&@.2_Y"WZ#"P7@X'5L>)'/8RQY I%&"T$51[EN!<3M.X!'&?TMS
M-#[/T1@C=!H6-_)>@Z?,W.,Y#6G.9H[D.4\QL?F3T)[XHCRYS]H7!?>:Z=(C
MC'*9MWG:[I^6CYR,"&&>-ZL+-SG<>)#2#<0,0Z:T!H(;=A5^W'4,S<F=8WKO
MFMK?L"26MDR4W@RT"PW!QWRB'2RN0M;0*\DC>>Y547H+.F:ULYY@B2\0KJPT
M;RT<F?'0W)7(^;P3J\HIF Y969.\!KLNS *5BY?A%TTK'0::M&.$0:_Q+,**
M#%$OBT(%@[+A^N0J%U?1#<1+2EJRLA,6? ;W#@CU),F;9/(4OCNG\B5Q&!"8
MB'8-DE%&+I1)&^AJ4YK6-,N%=!O)PZ%Z3M"!'O"5(?R52OF.[B\L6%W24F,K
MZZ51'GB$S,28#8?L8Z'Q^>+)1P6)_/![^D.CS+X%>5A.<&S>UM]T5"X.S_3C
M3BGFOODQ0\-TL"G!\>**/U7[20$A/;BL?XT8<)#,7M7YMKBKZC?W@$Z26_]1
MVBB^IHN_C-OJ!W>HA>?ZX]<O?U"4CS;Y$9B13""[2MM@7=8BPO$.!BXQ!V'<
MY*24.O9&[8*(*J#$++0KK)[G"D>* D<-GWM,J,1ELFQT :D*C?4DK<-$4V=N
MOG,J2&%VZ_PB;+6:U%L(I$FR#T7>H)KN.6FX<YNJ_=_\Z( #C'5WE2RI(3\*
MW"/U,73[\+#<5Y_H&P,I8*HHI<C58>W\F(!QPV>$,:!C"L1&?-NH/!U[/^-P
MT(IZ- /Q6)[CI<$8R-N?0 5AZ%35-(%RX:#G&6.O368LG.KA0)_=H'FDAM[4
MR/LNJDU5__[?KO ?A\A//__TJ^NK67CGC=3'/OT-F \WU9Q62E?OR _6J,+I
M%M2&HE$F [4%L@UU#;%/2I",LNZKV2^K026-%M]#'AX.#]! ";F32#0]Y H/
MN@VSKY#$J/A_N)TA&P%\-.]8<2?]6'(\'GLD2Q(^GFGE".2(YASQLL +&8V?
MOIGGOHE9!P>LJ;JV(2B6P!=3I %=[D53Y\4F>)D6S. ^C>(]3<36N9YJC98N
M0HO:?X(S[%%H,D&0L%MM@?OCQRSZ;#-LM)X!D8^C9#PFRX84>A25T3?236QT
MGCYR$*<[^891RM$MPV*Z+:1!CQ61.QUN6GPNIV&C[<OQBGKF+PD<(YDZ8UHX
M:9V][\*8TAJ0'LATB(?S&GT3%UU@R%,HS/^$+X6H#Q]_%2;G'T6]R8DO2Q 0
M8_HM"N8'L!S\-@ ?Q%X 11T/]L"6DE']]2H*S/!KE!VN2F\$-,+_W]ZW/[>-
M'>G^*RAG<\N^1=&BY+?OI$HCRS.:V&/'LC>[/[E \E!$# (,'J(Y?_WMYWF
MH%[Q2*2$;&TB2R1P'GVZ^W1__;4M_<,J;ZV1\\JE&35E&V_KE[&HI&V4(/D4
ML,+&V_ P O(*B.40:V=Q=K_5>!NVASIT<:.'^#L*O>Z^/AE-"T2"'Q_3+P:O
M\5():_L(7+%\86CCT!5.,@S'CODB2!: \90?Q?D]F2985_36>;]REN.2,R+:
M!2>9(5YY9E#BDQ+>7 OBG!YWZ!<V"*=SZU819)+G)>&TF/ ]_ZXQ$$".XQ!4
M&^)'+#&:789#Q%-2T;PMBCB1<!%"K^PE^3#%<UU&#W6Q#@]+6298GY9I@=N
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M]Y]8+R,^B\%^JXX@;V'M.[?19I&@-%%$46X;FON]*.B(V,N!O5201)'G17Z
M7BU$0N##Y/S*]]VW\%12]V7V"#PW)<DF:6W0&QGE!?B&>.JD'&X[[=V''[IP
M0Y,95+IT?X"=(B_3[2 ZT_Z&U15>WL;<*:3I6HY&]+O3=$G^=VD$[<'N-,D]
M;$AP$W/;@U\AY8:-M'&!$>)JZ#/63+);#X,828=NV4C0,P2O5\T&=TP0!2_
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MM,T(52"N&+5VBZ\&FLS)JH5>:JW3%.X)!DP()Z[3-'?];R5H-23(4! )<+
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M%M7XBW[3^TX)[W6[R;G \V>AT_9KEABKF"X%^Z!Q1XI@HQL%GH'>VF*N.V9
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MU(_>4V5ZN;I-E8EGOE\3'N"2T)L(^.C=D4SRB]T[E4F^AZGC2Q@5#G@B5BF
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M^>C]U[VO7W[_=/3+\<GGHT]';[Z>'+P[.OEZ](\OQY__]^O)T>&73\>?L:X
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MZ.>X*$R%T%5R+K2\?/"2R\L[3V&+3TRG2#I/8<..U+9Z"GN=I] =\(WP%/;
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M;ZO.IF^RA"+N?)2?8:E;?&JB29'/_!84!$]__KJ,_E''166*=!E],O.\J)
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M76USVSB2_GY5]Q]P_K"5U*TLRXZSB7<R6XY?YGSEM[*5[.ZG*8B$)-Q0H 8
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M6WC!2?UWF?S)7\_2R@DH&BR4GV]9<,2KA0NFNIR4]T:K%S4;H*/47%J]!-D
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MFQ^Z>(AB/Y+#,6>X1HS)!'F!,L*+T8WCF\QS.,&3 0XED5T?VC2F8P 1.O$
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M(L7!01TOXWL$-HPS:TY4X^V9DRFBB_1T/ \DXQJ(@/-D/8GJ&$[CB>6@6NV
M:R5VXN,6$HF*G/T)2I5'Q)B^'R[3!T-;!M?4CX<J/\C:A"*'?J5[M,]3OQ7T
M8).'5>1(7/SCT2O%C;>I+@SD )79]?AWYF".>G&H\:"^.]0(V8\]I+AGV '&
MBCKMZD:]VO!*M7&E5:GHXNHP3;.0K"@BTUDKD2)G='1BB+R#'+;8ZJ,G7>JU
M;_ZX@PJ02$.C,P"M7!QOJ4ZL"A.E]YXG#+IB1R0L>'^JYZX=X4"5Z2U*207)
M(L_3Z'%/KYMY0+>!;@\K:RP-F^R9B^"L/:*W%=6VS:793]$6)F_$-&+1*F2J
ML0$7#8BR@0<$F'03MO+J4.OG)(5!3(ZP_AN*R6[]QR!*R$LMD^J>HT4:9?A/
MY_C79',+TPBM=(YIN)/!OKF9RN2B_5$A$?B:#%3?@ UIFH-M;>OO+63.S4XB
M@-F!\JV:V'"($PR/"PJ(I"ST+1/Q/C0N+6#B B;O=(=5>C)B2Y,M1_FZ_36%
M&4ZG%*=1#J=/8TZ;QKYI@!\0Q:Y*#V^<!ED4DJW&*-[G<*7B)H.D#+K6]Y-V
M-QL$.QP54:T]"'@DS-D6-F/OAR?)(HD4U>HY:MRKRH/.F!D[A@0H.[:7/823
M$]?Z"9+K?N%J\0S38 -O]J1+RW)-A5M6G5T,/$Z7@SZD>ASM^V<A!PB8(""A
MDI"%0]Y&1^R=LR?%QZ0!" Z]>W8<AWSSP)&[7-X/!S>T)V0'Q7G:3MPP&RX#
M8$*0H9?%#$&.R>-'N1Z.=62I79T409/SP!(,+!\1+DXZ$0@UNZ>-6O:B!"K2
MTNT8AZ-*<1[(NH.6%?(G+9@;I>1P0PK\0CGX9D)UU;?9BJ 8O]1\X+Z#&G9K
MQ<R-R-0,);01ZDND5%HP0,B"\ML(.[A;C47-BHUG)M^+4YL'=*O-:TP._.,
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MS6F I0E'/\U.)]-7]'(7);^L/6=@&0(=QYH]NO=GT[Q5[:A/+3ZIN' [5M+
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M$;=!FK\^I $>.D+:TTVO4&"(ELF^73]MR_MU;."DW(#(SKO(+(T?4M7E.#4
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MA/<P?8Y"V-ZI81%3I^-Z*^+*+4PCM");+IIW++H3PD;%J66AW(:$B_4:XFA
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M:FP5JQZ@H)\MMU.T/[,I[^+>,49^S&(&$$%R>O)3^W%#\<4EZ)R)>=62NVE
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M'/@[Y@Z>"7L04/Y'("]X@D>8?X$P 3&1!9RP2X#)CQ_\" Q:T",3U<\)YEA
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M&">P&'X/)YL\9]@+R?T+^R!>/L;11KDE7 <!_9V!5H+VK>D.DN)&$IW#BB%
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MD"M#VU;0'^9E/T(4/(\#QA2D95%^56S/NN/Z/VHK&$+G>"X+PMQ [\@!"O:
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MJ>)6=,2R;[Z'E%T9;Y/3E*;[7'08FY7==EJ!M-6V8S"W<"6F48T>B-V1R=F
MZOY]AP=6)@.[(X9*(7T&R7/W'H3ZP)-G^ZIJ*)<]$NU [+ #OI@&3]NQ] X^
MPV1/(2QZA_\4Y4]G^RS'PJ2W*5KMPQS/.^YA^AR%4+^ACBDG@W-/1IQ=;!90
M>9BS%A*!+U@D4,@$N%!T-LS%\K5?CB430G8!F[>YQ'5+N:Q9RD^MEK(0+$6W
M#TY7+X\6-2Q6*]IS)X@_13'$GR5%[+^(HPUA_8#X9%8Z,S?FH]N;P8ROFRX>
MM;@0%F@'I5A@6\A5C/, <LG(N@E?-/$AB;=E/L@F7%J3TB;MK%HY3*^QXV&?
M2S:+30II;PAINU<EJVGF:FR<6/6G YL5*GI2$!=2@* 0PP<#UH0=&>B]WSPM
MW?D5/L'5/H;+]1W,(%8&N0'M' \Y,=H1219I2LYADQ\+EWM MS#%2&W)47&R
M2I\]D(Q;)0^TR=7@7BMK4CB8U''92.%$(1T=W@7Y@"!@E1D\(,!E9(?GJ93@
M%RJG)]FB Z-#[F!].P863V1;,I$K2W,A:N'?FA$+?X1'_7V"O607I/GK3;"%
MBY=(:LVW^UEU<+MH.>C-)7 !A,VTWCL( !I2CF_*CCOT#'XA/,8PZ#NXPT(_
M!1DLQ_[FZYXC4D,G:^4*!/70D&;PN_ '=?R0EAIG@56Y8%%P!25;T.)CC+6\
MEW7,QQ9Q#---D-P^!>DV".$^C\(@SJX(.W:U;A!?1]N(=$5(5HO'QQ\CLH[[
M"6X?%4YK&'+1G*T9<74R>2LD @V10$TFP(6B2Y=,++)*_ZT/$SD[]H+L(31?
MVQ"#<R'..\;)?+O)@_>+ZZ\F:?,+9O. &SWXA8DT=AO0!_S:R[60QLLFRP,$
M]*=#K01=I DQ9HS(-N$SK,UC:#02?F>WC^1/&-K:0W[,DOL!1%)Z]1(L[E:$
M YF"BHC82+R5/440@%1]WF!OKCYYP#]E>.Z+?3Q3R!ET2>L#ILCJ/_RNR^]T
MS0$98C$SZ(O!4>!-A[XZ=R"R5Q\*NPH#Z8IY-:M13.:['M<M^&HEYZ:.C['R
M:VMD  TDH28/-5^[J)RKO61DH9K*H>AQA]13I:(&J]^GKR1-4$U=+3$TJ1^Q
M(("+JB.^VA]TK_8?5<O]>;7<ORZ7^X\ D<^/H=JN82$G^+T)(XH;]F.P6W3Z
M2@UHFE3?9!\."RV_%F^9X21&5 GP'Y'(821J,2P[D:B)WYLP(HN1B(4AU6T(
M.X&HF?Z1AN<:ZPN]9 SNAN\FZV#E> .3?2:;6X_ET#( (06->0Q&YW2!<K(T
M:9#:#B_O]KS'H@1IA%0*/#H>UMLZ;27FHLR+49]^)[M?]6A0*]ZIN2AV*J^+
M+5B,5]U1</R<9#L81NL(KM2J.7H(:.J[B^";-NU!&)"4=KQ4>5S7-A#8V"NQ
M()TF+J,TPWG>=@M3<N'R?4#J&OF8L>('4%2+*E3IZFZ5J_%Q4SA!9 !K(@0(
M2RE AL6@5VIR0<".2>+#NJXN[,A$[7."N);%4GRI!* 2 =QS? LIBJ-:%NHC
MIGCC>/AEEX<O:VW?Y]/Y@G03S%"B&&D.']0]/],@Y.:$S#DHN/@0!SJUCGJ5
MXI6&15<5U&ONAF[$Y7[V"52BSG#SYCI*X!7.OL?:NQ'X3;+65?)WN%YJ<DZ#
MR >H@)X<!+)J6W8631L8O@4[LKAD*F]"LSESW;;/7Y97])ZUSMH.6[\1K<1%
M35=KOX%*'%"=YN4"@4(B8D)WMI0RQ;GE6LYP"/[0J>5YOG3<?-^R.:'0C#(%
M)7N9=7NYY/[S#@\.27X)Y9M%B(]HIIL5"2>I/"</UM"+-@PM.D8=BM!KCA"\
M1-O]=K$EQWVPY9"#H9]W*%F$3Q%\QN9R!E-RR_<9)D5JZ,61,5G=P<T^)EB_
MEN8GW]+/!6O=*8QU4=Q,,YF8(*!RDL!&.V?ML:0@*$0%(9,5A%Q8L!)2![)[
MGY;R5D.D%XT#'1HC<HRT6^<K5VQ<NEDK$]<.U<+4!]>IELAFZB%]%J/L"YT@
M:5G]'7H-XOSU#EL0YK%,;F!.UB&S@W50>1M7(:EIT?(LG-@O9P]2QA]@LTU@
M3G<CLK;M""^L50-II*EN3Y))<08B9)+F,PO;@L9U&2]MR.AK%E6;%CI,H=ZN
M!N.Z\IA\@ L(B(2@%!%P&4$A9'WI*B&73)7*^S2%\ISE' :&UI9PO 65Z%E.
MI0V;!C+V$%[;#E =O^?WNG']33E?L$P YDRWFK.VO>:>-]4[6WCQLHM2FC:1
M<DCI''*(C*43;W6RXYPY!+!D"K!1;GW(#251ZSJ+V*9&CQ'JW[-HP&/_K**+
M5XKK;U,5(5?,:#WR?':_SU"69U=)N$]3N/J8HFRL;? VQI/L8QX*8M_\;X7M
M&+1)HG]"<G58BO:;)_R1<,A(S+FQAQ K&Q@59[ +WF-C=K;#NR!\4_9D<8.<
MB@@*&0$5TC0CN7\*4G@:X"0'9[+$<&DT%(0Z?:V^POUA\25(5U?)*GJ.5OL@
M_A&1.S-NT1<L(Y8Z)*/[1GZ?S:$$FJ.L,XF<I%!4%/!(9"%SLU)>(';*>'P%
MF?"]HCEV0*0&42DV>*9R@QT1'.Q*P7W(PMQ;*AH'?ZV5:&V9*N[+]2WOG7B;
MXDP(!Y9*WNS? C*M_812^/ 4X-0KX<\MUYC?8Y3 E?!*[GW;C=1CQP,7;^%I
M#*EB!5DB*)MT[LC;TB*6*LADX(F^,-CB-V:=FG*8%!3(XR%_[5HXFG4,<NJ%
MQG'+G9V.>\W H *R+@T8W#)@S-1&#WA#(=S>,<"B"^4,1/'$W)?V[A"_6%3\
M42%]O6+ EL&UWC!@!=,W8USQ-'8EEYW=8G4JGAH2']',2RH23I("0MZ#,;=%
MMZA# 9[HL;:$-*C$*22,*^&F.OK#XH-&_[7&@P:=+45"#@YMT@#C3Q>A=H6C
M7GUXI=RXJ==IVGSICX:53I(5<3VU&SC<\C?($QS(\_:]T:D5H3'0>8L64R29
MYHFE$*7(BC\=:?6N)K$3M2ZVNQB]0GB?H_"WY8Z\C7I'L!XB^M;02=1^$&#4
M/=F9&T8$22O)6^USARJX ,H&,#X3'CK/TRC,X8I*\SF)\NSN_K.Z.PP0,MK&
M[";LY/PW9\?QH0S!UYAE]HT?SB*'&5)2H=?XQ+W0W(%[\'DJ__D1RT3.ABK.
MVVJ/Z>M>(&/?$SAQ/VR^3<^H1Q$>Z32NJ7.:>1IGKC[!:CQHK%974QH?C;5[
M(M*B#*\TVS39:=+TCJD1G?;@J4?X!)<)5,]4E,A:G]BUL;'O#IP#P"S\< D=
M+(=G[MW*G!%N@_-L-GNN$+76Y>WA"WIX0OLL2%;W\!G/UR%,+OZQC_+7JX3L
M94?/4&,S1Y&JYCZ%$A<G6T(?WI_\"X"4)8@*GF"'F?I0G:&'+=+7[GQP% ,E
M!9'Q R5#8&>C:H)7X[$$<P8%:U#R;G_/J69.Q9*EZM2I_IQ^G!?IN-GJ].#J
M[%YEHSYE^*38N*'3:>90^KM4]O:77.\,>6JVW3,INYLQ#K=1##8]AK,W<A=E
ME$ 2Y*^2U3ZDFS)FJ=L@2?/Q?H"%DZ2-C(QY,3*2_R5< E*3RT7P,8>31;@E
M@9-2\TS0;*1NWX.*E?VD;90W:LO8Z.VNA5TVWG"J=$V[GOI:IS>Q#6X.]^0'
MN3NH(9;8AA\H[[SVK2NQ19M2J?*01&_^]J-0P6'#=-S%G<=A73XV=5D=9[^%
M:816RN''#E-#*[(AA+/:$;#!LN1P=43/>=.-V>$^"*,&%ZN&TXPQ]K!Y,T8B
M1IQ'N8#SV!)OA%843+JY!)W:@3%Z%&R+$EJLP(^'C1*%)*28P.(&I;(?IRY>
M2#NJ\N@E6H.,%HX@'K^"K'%6<QU$*=@&Z6\P!\]!O&?/D-?)2.LG&N_ *L@]
M61\9P4YM!#U)Y-^N35H*BX6T@(I+3GTQ@7DY%!=Y+A-#^G^\Q(!%^9-1IHBM
M?"=(]EOD<%3JGX%G7LFQ&QA-9S'[ZS,<&_/ 3F#>DI%8FQNR_R]*A;B,YNMP
MGO>=$7WLK*U#@Y!8O'EE6+.E2ES Y 5,8'#K@S+][6!26RBL9;BPG@$+V6ZS
M#\D.91DD_Q5:D9R\_V\D <Z?8*T-";%N(OQ_8.'2&:I7))E>(_<CG="$]P3L
M10%Y4T!>%>!W+2CP1)'!)_K57&;5XB!X%VV><M76:FX%F&#>TB>0L^)JZ2'-
M^^FOE$'9F/D.X_0FC<?2?+>>6C)1I5(!U39R'Q%:962[%R7E&4"8/N- FY&Z
MVRP(B=ST^QEI7ID^PZLD3"%^EHPW6;8/DE N%+EA;-S,S8X@SONQ;8B8K&X#
M)<>P.$F9<5%!7LE:+-NE3%I2HDO%98D/%]B'*@]G9GC8"LTFRJ-T,VN3' Y)
MOMCM4L0N;U1R3?M,;2P8& KA[H:,9$_J4,C\ *6K* G2HB4B=2YZ:0:Y49O.
M'FB9=;U(WJ,4PJJ%M:Y 60'QS5A3RQ2)RL4*GRK)0"$:$&1CZ0+^+I>.386X
M?'-9^Q:GK\M]GN5X2,,Y#IV[<_\:92U<2HX)ECTEY+(?V&XZ EJ90ZQJN<.1
MG_,AU^9H8X5=&MZW;'J.%HH$F?F^()?:YFJ=3],%T84+)CC7<)N?S%==0X,O
MN) 9?;F4H%3X'$=A%O!Y3]=LL<^?4$KN-1EEZ.UF/D'0ZQ+&Y2#;*,4ITCDR
MQ-(Z&T]:4[FS+ALC:3]P;\Z2K(V9W R+QLDX^I62CAV]RM;2C:&A X*8QB/\
MTW)]5][$Q+;=Z9TX!MW;K0I@H]FV18'<=G5OCID][;A+:<ESE;R\<H+?:^1I
MBW<7%MK:[MTZ\&_2&F,/#-%)3,19)=K"^SS(:2B_YH*JM@KH):-O$3UDG<QH
M,#-0<@,%.S]B@PQ22$%U'J,2#P R35>"CM=6;U(P0,@Z,*Y:&,S38;H['$BH
MSVMLAMUFFNYR[==C7K +2[7ZWPZ3LWV99XV\DUZXU;6NXCV=%S.XUK4=R<'+
M6EM4.@/4X@9@S8M5.<O)F@? &-/<?(0)3(,8"[=8;:,DRG)RR.\9%N:DT<M1
MC;#!+$"%D8.Y)F-_!+@ U"/K(GCFE'J0(R.-SPK>N(9L">RB&]BIO-?.O/=:
MIP^(==86+@>P(XJ#PZZVI_[7OO4+<66(;7=+V$3YC1E=/*6]N;E_C0D(5^T*
MY@%8)7#)4C2X5$R*@Z-&1,>L'#<4&/H1(A211'KZG =JW$]+EMT.RMGZF%?<
MH(0<7H;LU$+V@/(@%O].8L<-RG^&>157K&<8>D(X#OLZ0MD/!Y^3M(KG8CS
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MBJVOUG!R.DB5R@MH;88,Q7*@2I0339X\JAQ;!6^4KUF)ZL[:H_-@=G<VK?/
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M>ECM9L[^A?P_4BOGW_\_4$L#!!0    ( ,P[K5(^*Q6.4Q(  $?X   2
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MM=V[X#5-28A EZBM 'NKG0_N>(*=>43IE)2(D\& ]*GUHM9DK+8FN .EXO_
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MTG:8C=ZL;0_9UJ(">-X0@IJC!++KC@C/"$10EDNB1\;8<F ($9VYZ)WQJY+
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M:@ 4!,@3<,&_8)1 .@/M!G!;SF$##&8 1CX8(#9%* +=$'^'_(\1> \IY1
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MC\8@YO:3,7AM<ZN/<+N- =N56^O:VT.:QVSFS/F'&;"['IQ@QDVM[TAFY=,
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MM?.0\-KWLW_<LN]G_R'F_U!+ P04    " #,.ZU2A/X$50WB  #JU@< $@
M '5R9VXM97@Q,#9?-#,S+FAT;>R]^U/;R+8O_ONMNO^#;O:C8+[&P;P)<Z;*
M 9(P.R$<(),[WUV[3K6EMJV)+'GTL/'\]7<]NJ66+#\@$ ST/G4FV-:C>W7W
M>J_/^OG_G'P^OO[]XM3Y</WIHW/QY>W'LV/GU<;KUU^WCU^_/KD^X1]VFILM
MYSH68>*G?A2*X/7KT_-7SJM^F@[?O'X]'H^;X^UF%/=>7U^^[J>#8.=U$$6)
M;'JI]^J7__V_?L;OZ%\I//PW]=- PA]9W LWY$UK<^]_=K:WFW 9_/A:__KS
M:WW]_]G8<,[?.\=1.))Q*F-GM-O<;&XU=S>=C0V\H!-Y$_CW?_T\=))T$LC_
M>I7*FW1#!'XO?!/[O7YZ]%:XWWIQE(7>AAL%4?SF;^_H?T<#$??\<*,3I6DT
M>+,Y3/4W:32DC_0H/_1DF+[9_,=1-PK3C;'$A[[I1(''7R3^7_)-"R^GCUTQ
M\(/)FVM_(!/G7(Z=RV@@0G4ICO!-&,4#$?##4Z1M%[Z ;T/)5XU$[ MXHZ,N
M?/7+Z4W?[_BIT]IL[OW\>OB+,=O[G5PQEU>__#/L),.C'_2ZA:139%<D^2YJ
M'I]>7K?/SIWCS^?OSDY.SZ_/VA^=L_-WGR\_M:_//M,/>,'I"7SK7'\XNW+@
MM'SY!%<VG$_MRW_!#V]_=_[]TT\__:?A?&A?.6]/3\^=SY_.KJ_QI]/C]I>K
M4^?LVH$[WWZ^_N"LG:T[YY^OX>;KTTM\6_O\!+Z$;^&*ZP^G#AW%ZP_M:^?+
MY>?W\+"+#VT8C?/Q^J3I7%^>MJ^O''C/Q>79;_ (Y_-E:? +UTAD:72W%9J[
MFXW-\K-P0C& E__/A^#;[FYK=VNKM05?OQ:5GW8.=G?WMP[K?H*[MO>VZ^[:
MV]O<V=S?WN:?EMR8#S_IVH$8[">0W3KN4S.PK9WO'YG)F*:_J9R/;#B4L2L2
MN?Q!IV$;LW-A8#*^XT1JCG-^4!/X*MAPQ3"9/6IC+;9NS7E?_7)Q>;IQT3X[
M<>#0?VU?GM"1OVP?7S\F%1:S,(,RWTF MQ-'A)[S5J9C*</96UA-;ZE-W-J]
MU[7_KAG6T?+5+U_BZ+T,G8N^@(N<CZG7?"GK#8O]4J9Z>?W5.0-U,4D',*#$
M.3MN_^; :QW\X1W,U]EZ*:0X$:GT')$X4=?Y)&*W[[0.&L[6YE;K+M*3AG!O
MXG-*0MU.$/UXP6X\GRAQ"U5XMNZ[U*K>H^X[9SZ!'\J-/K^*Z' ?$]ROS*\-
M PKN?59;N["EMPZW]IQ1=6=/S>KNADIU+M6U,O=-\1<:O[$>S5#TY$8GEN+;
MAN@"1WDC@K&8)$=CWTO[,#YXWZL9DGB6+7OWT_ X.]#Y&7_0$ZSA F5C%R_X
MY9[TDR7YUPP+_WZ4D!E4*<R=]NG9YR\?19)>2AA6++T+V#-O<<O0+]H\FDO$
M'S7JZ_;;CV"-OB/U&6S1J_KU>OJ;MD1NNL^3;A0+=(J]R7"=D,^@80&+52*"
MYX\<VJK BL <Q-.=BDX@G4X4PVW_]6KSE>/*($B&PO7#7OYY*#Q/?]8OYEN0
MA@$H!_*-_N/(J?"/-,;_>,Y(O1D(^DH_A"_=:[9V_W$T[ONIW,!7(U'&L1C.
MDA![MY,'ZO=-&-'FYOU9<8M6=)G56ZVAM2^OSX[A#+7TIIG::(\X..?D]-W9
M^1GZQ,R3_?/KU)O>7S]^X]QI5DOJ@5OLU:K;./0_^+%5)0G\)\;_X/&&?^'D
M/_'S?W=G;WD9[Y<;FRMX#!/LQ+ZY<JV*!E^_6\O4:!TT#WXP.6YO)-V['%N9
M45U)%P6ITVI.G:FY;.8)[\^ZA2"E"-6[&9*@5N6XE5U[(KM^2)&\I.XMMWK6
MXJ6JG+'FX=8+XCA6&*SLTEAA\#2$P985!@\I#(YEG H_=,[0@S*,92KN1S!L
M;5K)\*(D@W43_# WP=9*N@G>7[;/K]$-B*DLEZ>_G9Y_.74N:,QG%YQ2<WGV
M_L.U]2%4?0A;UHGP=!BWU1N?@MZX99T(#ZLWOH?AI]^O)5K_P<O2$I_/TE@Y
M\#3D@/4?/*@<N(CEQH7P/>==%(]%[#D7L>]**QBL8+""P0J&518,VU8P/*1@
M.(^<=I)D ^DYGSM 4_8K-YS3U&U:\6#%@_4NKZAW>7LEO<O''S]?G9V_M\[C
M*>?QE('S[ [_\^'+5C=\"KKAMG4>/W#201 EP%2^7PU<[-RQ:J"5!*NX-%82
M/ U)8-W'#^L^%A.LS\;2Y(?R)%L9\;)DA'45_#!7P<Y*N@HN3R\N3Z].SZ\I
MZ>R*8):^MB\Q/>WLU):P60_"4V;75F]\"GKCCO4@/+ '(1H,13CYY]\.MEK[
M1XES*8>Q3$"3Y# 3P5I]%3$FJ?GR'JH9K!+YLI3(Y[,T5F \#8%A'0T/[6B0
M\0\3%WM67%AQ\227QHJ+IR$N;/;:0V>OG0V&@2^]!Y<5^U96O"A98?W3/\P_
MO;N2_NGCS^<G#*?F7'^VB6TSW=('UBW]9+BT51N?@MJX:]W2#^V6#CU&5G/2
MR$G[TBG['8Q*B.]7'*?XHU4<G[7B^'R6QDJ+IR$MK$_Z!TN+:ECS7N7%H947
M+TI>6$?##W,T[*VHH^&WT_-VN2&#=2Z0<V';0JX]'<YLU<6GH"[N6>?"PZJ+
MEW(8Q>E]U,U-<S^K"CYK5?#Y+(V5!4]#%EC7P0/+@I$,,W(O4W_3(Z?X!F2$
MZP_I\92L4+G6.9&I\(/O=RA8*6*ER!-=&BM%GH84L5EN#]L)RD_<($JR^![R
MV+9MB8R5!D]S::PT>!K28,=*@X>4!F=A,F1:<Y)S._/\-$%H#B,T^?UR8K%,
MMW+"RHE57!HK)YZ&G-BU<N)AY40*K 6HG8G N8BCH8S3B?-)I*F,O]^.:%H!
M807$$UT:*R">AH!87)[]3/;G8PF(C8^^*\/D/MQ*BXT^*PVL-%C%I;'2X&E(
M@\4%V,]D?SZ.-/B<I?<G#IK;BXT[*P^L/%C%I;'RX&G(@\5UE<]D?SX2M(K$
MBJ:1="X"Z?4DA1K0I12[L?3\-(J==B^6$E.5OM]ZL$!<5EH\S:6QTN)I2(O%
M597/9'\^6E Z"D8R="?.Z<B*!"L2K$BP(F'%14)KT\J$AY0)7Q+)#8,B5THO
M.7).?* LR(CO[Q;4M.+!BH<GNC16/#P1\6#KI!_69#AK?[^58%%YK1AXFDMC
MQ< 3$0.V1/I!Q<!I%\:>$K3:<10FV6 @4NE<XZ2$>S^0:E9*6"GQ1)?&2HDG
M(B5L"?2#2HEW69SV9>RTDR2#F;CWD;)JI8*5"D]S::Q4>")2P99"/VRWP#CR
M,C<%PP$X1RIC$5BI8*6"E0I6*JRT5+"%SP_K44K<.!I;26 E@94$5A*LM"2P
M%<X/V[E%QJGP0^=:W-PC\(5MZ/6RY()!;]N@Y6&&UE8-6O9G,H/';-!R=GYR
M^NG\[-W9<1O[P=HV+7IH]#]4E:>J*YX=$W@^_-DJAT]!.=RW;5H>5C=\+T-T
M&#MG</L@]--[@,RTG?M>EF+X?);&RH2G(1-L+N+#8AY$J>]2T=)Q(/S!/>28
M6)%@1<+37!HK$IZ&2+")AP\J$C[Z S_EUMX.T/NC+SI^8*T%*QJL:+"B8<5%
M@\T^?-@\DQLWR!*$2+N4 ^E]OTC860Q(846"%0FKN#16)#P-D6!3#Q]4)&"B
MR74L14H=?*.NCBYT?9<;_>I&P%966%EALU!6- OE8"6S4(X_G[\[.SD]OSYK
M?SR[_MUFH52S4*99XK-C L^'/UN%\2DHC <V"^6!,Y2CL.M[H!'ZXEZ\RE8M
M?&%JX?-9&BL1GH9$L#DH#RH1VEG:CV+XPG-._,0-HB2+OQ\P=V>Q'+=RX3G)
M!>LN^&'N@L.5=!=<GUY^.CNW!2OUKH(I(?;L&,#SX<U6,7P*BN&A=14\K&+X
M*4LS$3C7,A[X(3WI^[7"Q;J\U0JM4%C%I;%"X6D(!>LM>&AO ?R0^JZ5"X\M
M%X:EI252O7$E=DRM,:)H9QBS)*,%EW^CSQ-K&60P"$//]D.,&+P!T7#?QN0M
MCOB:__-K\<LZTN1>UGAU9F9,9VI%'F!^^Y7IM6$\P;U/:FMW<ZNU=;BUYXQ:
ME35;8MO==2[5I3)/4O'7__Y?/_=C/9JAZ,F-3BS%MPW1A</S1@1C,4F.*@I1
MW6F+<0H+#MM3V(#.-.=63^]$@4>9QWV_XZ=.:[-I(DA9W70UQ(/539^&;OIR
M2N>$$XH!S.%_VJ=GG[]\%$EZ*5'AE-X%L-NWR&WIEVU45L5W:(YUJN</4X:O
MLGCDC^X!!-KJOR_,+V*C93\L6E9TW9WB (\9+OMT=G5\^O%C^_ST\Y<K&S"S
M ;,GS)ZM_OD4]$\PWFS$[$'UP0]2(%>YAV(KJP^^+'WP^2R-E05/1!;80-D/
M@':SHL"* BL*K"A8;5'P<OS2CR(*3F^&,DSN0Q8L7B@K"ZPL6,6EL;+@B<@"
MB^'VL/ES20*$1$@>*PVL-+#2P$J#E98&%K[M8:4!" */H-M$Z#E?A3^2\?<W
M#-Q9+,.M8+""8167Q@J&)R(8;"/9AW49A:D?2Z?=BZ6\'V/!R@0K$Y[FTEB9
M\$1DPKZ5"0\;47:N^W[L;5R(.)TX;V4HN[[KPP3N([1@Y8.5#T]S::Q\>"+R
MX<#*AX>4#^^CD8Q#X"O.1S'^?H&PV/5G!8(5"*NX-%8@/!&!L+@CX3/9H(\C
M$'[-8C_Q?"+WD?.;#+/OQW5M6KE@Y<(371HK%YZ(7&@M;BKP3';H(^$62+ 4
M[JNO\,[B4) 5"%8@K.+26('P5 2"+5Q^6($PE"[VC'0N9(RS$*%[#RT@K&"P
M@N%I+HT5#$]%,-@JY@=N%Y<AH.Q0Q/?10M@*!"L0GN;26('P5 2"K65^4(%P
M*0.Z/^G[0^PWG_:E@_E(]Y*#9.7#[>7#G'G>'89ZV14K!OA  WD</.REX6MW
M%'QM)W9>_U(APTM!Y?<M)/]WS\]"\EM(_ON"Y/]N/OR8C'?NI&>K,*]^.8._
M;U A471)&LZ5VY=>%L" L;BR'8;RIE!2'DYD6=FI9.>'X-O>[MY6:V?OD,6D
MWK+M-Z5U5E-!Z_;-WC;1YAT\#1?S.!H,13AQ/@_]$)7.AU^]QR&:ILS;A93Y
M3009[7[G(HY<V-_QB]K3WS40^T;[1OM&^\:5>N.C21USJON;S>U_/.,IW)\M
M[KB!%#'HHVE_U>URVR_/&N?/W3@WS</;[LCO5=;9\OXN/J,F2^.=/]O*^'Y\
MHY]E7:*[-1V]'GOP%Y>G&Q?MLQ/GW>?+K^W+$^?X\_GU9?OX^CLLIT5KMM_<
M.UP10_SPV^7VU^MX:V]OY^#XZO/HYN;L7YN3Y-OF?GO__.O'@_:OK>V=B6[%
M5G?;X:E[^&[K<N_//;[HNN\GSG)+O)CZ#<<3J?0<D:#)_TG$;M]I'32<+6"(
MSEJ*K_KGWPZVMC:/E@QHO?JEBIM"][>.UAL./&P@/$DN(3JA\&(_3".G,Z'O
M.C(=2QG6N-]R"B= WV##%<,$XV'77YVS<"23%%^7.&?'[=_TKKK; C1@',Y9
M["=]YS@* @QMCJ333A*9;L ^@<-&@&&_R;X/NH@3RYZ?Z'G ?3+ :0AT>CG9
M /AT$ BG"\1QQG[:=Q()I.D1O0-?I8#GDTZRS@9>FB#9Y:VI?B$F!7S9,MNH
M6!;8-$3^*(3!]$70Q:W@ SWUD!H.4OH=SF.K09<NNT)?XN@]S.VB+^!@.!]3
MKYGO.R1T$@L9.#"?H9H2T\E5GB<FK_HE!(+*V-EM;>]N[^_Q[KP]F913J[(U
MF\LQH6D)\_1$R;*$@I/E7#OGSJES!?]W"G]_6":R34SQU2]OGC-S__KA]/*T
M?=6@^+OVD@)O Q: WW2R!$B8($.%73Z(PIX#!@ML7>"F82\!CBM',HB&6"R.
M9PEV^P V >BU_E_X'47UX\C+7#B":\!,/-F%!R)[#*+Q^A'>]'+HBA3B/ ?@
M;T"*!*&Y0&30^6/I(9QA+#>&PO>0E8U%C#0-X9UN"K]$(Q]SL8C+&0_&H]_:
M/TJ<'HPMQ2<6;U&I%:0QXR^Q="7* 3BH?6<H)BQMD,T[F)SGN_Z0>13L@&Z6
M9C%*AA&6?";Z67HZ:1^6J=>G[R[Y&D[AR)]Q26^=7G=\N+QQ^R+L29J,&DB>
M" (TN$ :O%,TN(A]5]8\J)'35 ^*J9K@5!4U%HRN1*WJN/)?<A(O-=(&/4B
M_H'\$(417@N+/$C4,0D]G[)?0(ZF^":0%'3DX.CE.L>2G/R)G8SSSU^=:SP=
MH,6=$J& &HD/W)I716]8"0<A@1%SEE## >KB>OH2_G8C6$]!&Q=U%$TPDYK
MI"0\&W_'A>Q%D4<?1ACWP+3'TEL;ZIUP-H:,H0JZW9^9<"<XGC%H2'U'P%'
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MX6^4H^ +,:(-S_0'&$FA/\UG1EU@ AIZAPMC=/X9/TY!T3 /T,=^&"7IQG1
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M739(*,P7HMR!T@\1,S^1JY9%UYDXK>;N/U9L5,Z:V8"!"Y)37\;).DI?JC>
M$RYGJP\DL"FU ;G"JA'=IBX^M=1%9PT/^AV3D[5F>"(#@5AZ$R-#:54FJ*M?
M&RIG"35:+#C&M")B8!U).KGG^;IXE=,Q4EGPMFKE;*WENV(3MV?QJ9U%;8Z2
MU;=B8WM32G'V_)'.P$#_XZN[9' LF;)Q>-@\.)R3LK&[UVSMSLG9V-EN[MN<
MC=5-")B"X-[:V]LY_-#_;S_9GP'2C5?L'YX=CW>2;U_.XLW33R?^]=[H_]YL
MM>?<47JFDE7.->I>MW]!X1$J9RI,G];R$2R2#0UGH(U=K-)^7&#SM$OJ^REF
MPA57XFY:&"VT2_N(5GC=2=\]/C=/NKR8['^\_M=0G&S)G3G\9/%M[:8S*Y&)
M<X=Q"_U]:W.SL<G_;WG!JFT8O7!XLIV6BAW8 [ZRZV6>U$\?WN_^_ENZ<W"P
M=_CV7Z>3O6SP]5_IUOO/[[[]=G#S__^U<SQ]NI>]Y^V<H\V0:QAF,<\V.6T"
M1+"BOA*81OTGWH\L8-NR@-7=4MO-S7_8,[_""S3C_.Z?7ICGMW>Y>7C^VZ?8
M?5<CU&]QV_&<DX\5+3<$\@?BW9[J5=XTK;I3;=.3'N7,GGU8]O#=-@ODCJ_1
M)UM;?LI;4)NXTS!*HG16!PCV."7LVU#730W%1!N-18ELK@%0Z@E?6&3^&(S%
MRV*"=LYJWN)0^SJP2HLZWODV++8"S7W@2P7ZLH1[U\&K7:Q@E*6;JE3B5N!.
MSX>O'8_]Z&;.BQXW5I=J#WPIP\8(@_5ZL>P1]N0LGMN!)V@TM5'DNPI(F7)H
M2EDV"MN+]+ "$91(ZE$C1@WB-1 3')+G=[LREJKFK?@TE+$?>0O6Q)-#R1E!
M:DX:>XX),FN6T]-S8X*3507.O%-"V/&XH;C(&RR3IO-VXHP9=53>B,$0T>[\
M[I*OR.DF2&XAXF9[&/N!T]J:04K>MW]O'>QJ ==@[&-UW_;\^[9:F\5]NICT
MURR4SO;F@CL/C3?"5>$RNS>':?UW=9G^XR1]P1NP=!1KK+XI(,3IE]9O,$U*
MGBDJDTL\BJ*\.3'K'ZP(5JFC-;!1NUG,';R\/[*$*Y85?ZB-V[WT1,/M[TLT
M+'D(IL6$<]C<_8>S9BS/,$($0:P6SX9C$7NE==+L$$.1M:N5U&8-EN.2]YLL
MN3XG#[&KJ[7AK9PX2/]MJ ]P /F/-=RHV!G@WM.3UY=)GD#P30JN57,]YU<E
MUK":,F<PTV#@B&WC4B<IL)BB$Z3&FR0ZU$C@@D$/Q(T_R :S@\\%Q+"?T+NH
M*2SLH$!9'B0CLD&'>[XB_TRJ$N>>*=1TSN:DO"*..J*SAVDP,0'IEWY\ :Y<
M(N,RZP+[J;PN:YP&D'\_CC)X <'3*Z#G*GN>ED;%.,QWF[7O,. "(F71Y(#L
M;M^'\^2M(R$1UY[S>D,O/U"-F=-$O.H.-F+4&\;+YZIE*1^^\APZDC"U>2'F
M&+1\;U^,).42\_*I!5PPL7*JT])+%DO"-IZ:SM%+SC ^M!G&-L-X]EQLAK'-
M,%Z13*$Y2N(2"@C+E\3Y^XKE/]ELNJ>636>8)*ANK-CH['YZ<OM)NV%6;%QV
M)SVYG52RQ));F;$K-A4PS59L1& IKMB(5J\&Z4XND!6;A65["]G>JBU9V6VV
M8H.S^^G)[:?<R4K1/6LQV@WUG0-*39\\HY?GGGG59(]<TR+E+1>K6+[JO_JL
MVT#<.F*G>G_/;,FFFX,WN/]XPQG'?HK1[#^R4+7B=/-6UX(BI)B'@4J+U-T+
M0X'8[L\S<GU;@NN^<PM[X)E=$ZG];]CU/16*]K$Q\D 1'?'=-_H1MPK@9I4)
MDA_;+!9Y"*JOL>1,*$0XEPUG$'DRX+YXJ73[H8_-F9VU3D81)'6GV4TS 4O(
MI3@V/*_'+3%%T$/X_S[ADXM4\'\5V#G^Z6"Q('?QA6_<OAP0"#F^M>/#RO?H
M(T*GHZM?#:>//<B3+$@33I?!?![<APS,SB-.,')K>[26]M6R+1;SZV>UN30Q
MBF:UNL0?N&_O=*>)F?=PVW5.W\+6ZPXV<!]S2]:(&U0X:B"W:>W96-S;LT3,
MF:&K9]XHZ"X;*Y!>3VH7K5K@V>!<W 7M6_4^(( _\KT,CWB 37@I=6;I<5P!
MX_"R0#JM9DN]6S_YQ$_<($JP?XB^JK'<6JM/>3ZU5G48M@/M[BBDR+B7X03^
MS/QXTG0J^Z)F RR*BSZ+G?&1#VEM(M7<EL286G3=]V-L((-]\JA3C4(XJ["/
MG&]4=A_E4^B^.*+FW*O!57)X!.Z5-/9!PF&Z(:458KX$)I)B.QY/=>/)4Y_T
M')MJ=I8ET,++<*: &41QVA,]X,>!C\T_AL0$L&4V]I+QA[P\!$D' KRA6@/!
MTG@C&2<2U\H?-(I&2<65,G2S02=&Y"-J)")Q)5VS3?8WH*BI]' S*^.R$).D
MJ:4WD(7;3\L;W#A)KJQR7VN1\BZAKU%$QDG?'YKO*?+L*'#:R 64&$6^QX/L
M.EZ4=>"W"QD/_!3WZD<MV9;:?#*T&)WFQHN2Q9J--FE(^QS 3J2V[:SZTN;"
M?Z,$?P?.0EW2L*$=WHYJ9D@7%GO($ )XB1?!)I3$=KI2W19EZ4;4W1A&[C>9
MY@_!Y7=AA1+Y3'M8U>,WO/V_O[6B$?RO]:=LW^SLW+$F!)<:*<AHF,XIFB,)
MZ ^I5CQN_W;8+7SH<,\T*&]72Z2-SF1#MQ[#%<5U2^,)?JW^Q&1?GX- #G4F
MP\,:N<"D8)1%PW%8?#\6)O)H(!(@:+1!OTCG-X&%7,>X#Y5N:K0HA_<"$\SK
M%?2(P-SB^@4>RE&ID3D]E_1LG-HEM^[#SFH&R9#_4#5$GF0_X]$O:*,>O!=O
MP\E@W!J/?KTZV]LZ.?C0WCUMO_?$IU_OMF6G@5OG;=4EWU\H5")TSD_:F*X)
MSRYLM'<G;=1KC)=G:1\,<J4'*20,MIHKMYY^:BOSC9)G8:UB5*#@@M,,>QB+
MD-T&GC:OD,V6D701H_!+\ZJ)O^+?^$A1O))RGO,>7^3'P)9RW?SGPKZ+#'U[
M@F*ZFU&EQX 90'Y4IV91'I!Q !0A4.\S_2"^RZH!^@G]02<#I8.R^85:M 24
M4= XX%=4]Z5742%!8J-JFZ2"7UAIEY9$@0PF4]HOKN7FWM$5NT&<O>960TOY
MZ6U3YE:H(O#XY3*C?^Y'>%&!R!WES2?E?G+:2@\]I1CKS(:+6#.HKE316)7(
MI/U8^>JKTK+4'] &@<.4'X:BF!"OJ%;H-8C'B^*)E1?",[ *3+SDA.O6ILVX
MMAG7L^=B,ZYOOU(VX_I!QI$[OZ@&U\AY/0/N3 $2=)M>H.*%3C'VXYNJB^'^
MH@ZL^T>)$9R)8NUEF_\\>+MZ?4VC =-;[NA.NB2X.( :=?$!([8\ MF#;8\Z
M$4)E>&AGH#\%8U.N9,-ZHCTFY"M)<K/(3XI>V7FD@!POUTA+P5K2B;*UX9WJ
ME<9336<@UFG*&%? C#E$'3B4JHVY5G-O_V*?WZP(35HJME*0>0T?@P3<]05P
M";Q#O:0#]EIHE <:SM#IP OW]KVE%E+H&*8W3N^-^E;?#;T3\C[G>OC)C$C)
M2_6(?_)#*@J]E&D6PRK/JC+F\M)G2K1Z:_>#^W[\]5-[\\/'_9W)GW^TVGO'
M=U/4P0:>:U;/?U'A,20*G,19KV0B)UE'.6I5/B5V7%%UK5]"'W^X2CF,"0?-
MA1&RJY?L/;[^GV(P/#IVVC4)FF)6(V[%*$0H@J@798EI0SODLX%A)<0_Z9EX
M<9VEBZ[(!"MW% ,I#?EY6H:WWC_S^CO5A*V*H!42M(= ']INTY <#0/>A'C]
M&.,),;[?4T GB8:3+'G?8!G9U^ ;D"KHU\ 'A4Y']D70K0B#1D44Y(X9':JJ
M$1Z&LE%5( R90F7_4QW@T7>81!I!9YC%PRC1PD\W&_/9F9/#=+APO4_&^1U
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M;$E2QB3SG"!";:N8*4M-YMH^'(^>#%TTZ0QJY:,?X DNPB0A;#_MN8?C2Z-
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M;[$89N1B+"GE:_/F#/Y=FC/L-%MKW];7_/6U]OH1+;ONJ$#0L6@C9HI'FY^
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MER@:55,1)<I4K CUU2H)Q#X+M0>$2@'KD?*.6F?0_G&%$]O,%VEZ$",FA$:
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M<?$!Q^Q7?SPHLUOQ\]/[3(S-?_GCR6OQHYT6915 K4,,1A[&%1I?##3EY0"
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MJGJ5)W04O7#'>QV.0VNN[^VVC[J=_<.:&_P8J&!_J6ZN(^!AEV=\?<3#GU9
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M&+ICLWK@2K?J5%</A%_@!SD]DM/C48'#C[1G3)KP2'LXIP.)?Y6W4J4)RYA
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M:>*9S"Z%'ZQ%D<N2"E(@H.W'8KT'4P::L65<6;DM<Q6QFYU40#:5O+DB2(=
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M/89)F)CU:!YN.J[ )?5NSLUY8T B,[><^ $PW67,Z\3%R:))883.B%D1T3(
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MUB498>%=]W;$!]R0>K5<._:2=ZM%\X%9IAZ7K5I[<<*UN[W^V>E9N]4_N[P
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MCCO\V^'?!N*?_^/C7Q>836VLA.# PI#YAH_!K?6*$M"O>IVHSS57UX,LT,%
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M40]Y1\^:VV)//]-4#@_UVNMF)ENN5WLJ2RKEWPX3V#C0&/%H-#;-50:_WKW
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M   1              "  3R1 @!U<F=N+3(P,C$P,S,Q+GAS9%!+ 0(4 Q0
M   ( ,P[K5)W4%>MH T  ->]   5              "  9BD @!U<F=N+3(P
M,C$P,S,Q7V-A;"YX;6Q02P$"% ,4    " #,.ZU25ZB'*849  #!F0$ %0
M            @ %KL@( =7)G;BTR,#(Q,#,S,5]D968N>&UL4$L! A0#%
M  @ S#NM4GYJ2A"Q7   4WP% !4              ( !(\P" '5R9VXM,C R
M,3 S,S%?;&%B+GAM;%!+ 0(4 Q0    ( ,P[K5(5R.C&<C8  %'X P 5
M          "  0<I P!U<F=N+3(P,C$P,S,Q7W!R92YX;6Q02P$"% ,4
M" #,.ZU2/BL5CE,2  !'^   $@              @ &L7P, =7)G;BUE>#$P
M,5\Q,#(N:'1M4$L! A0#%     @ S#NM4BTU[R7R"P  87L  !(
M     ( !+W(# '5R9VXM97@Q,#)?,3 Q+FAT;5!+ 0(4 Q0    ( ,P[K5*-
MOU1^H@L  +5H   2              "  5%^ P!U<F=N+65X,3 S7S$P,"YH
M=&U02P$"% ,4    " #,.ZU2VP:<Z@8+  !75@  $0              @ $C
MB@, =7)G;BUE>#$P-%\Y."YH=&U02P$"% ,4    " #,.ZU230X$$T\*  "2
M1@  $0              @ %8E0, =7)G;BUE>#$P-5\Y.2YH=&U02P$"% ,4
M    " #,.ZU2A/X$50WB  #JU@< $@              @ '6GP, =7)G;BUE
M>#$P-E\T,S,N:'1M4$L! A0#%     @ S#NM4E<<X6K5"   HD@  !$
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- !  !00  /^>!     $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
